PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Berens, C; Schnappinger, D; Hillen, W				Berens, C; Schnappinger, D; Hillen, W			The role of the variable region in Tet repressor for inducibility by tetracycline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DNA-BINDING MOTIF; CRYSTAL-STRUCTURE; ANTIBIOTIC-RESISTANCE; OPERATOR; COMPLEX; TN10; MECHANISM; MUTANTS; GENE	A set of deletions and substitutions to alanine was introduced into the loop separating helices alpha 8 and alpha 9 of Tn10 Tet repressor (TetR). This region appears as an unstructured loop in the crystal structure of the TetR(D).([Mg-tc](+))(2) complex and is the only internal segment of variable length in an alignment of Tet repressors from seven different resistance determinants. In vivo analysis of 10 mutants shows that this loop is important for inducibility by tetracycline (tc), whereas DNA binding is not or only marginally affected, All deletions have an induction-deficient TetR(S) phenotype, but the corresponding substitutions do not or only slightly affect inducibility. The purified mutant TetR proteins have a reduced affinity for tc in vitro that correlates with their lack of inducibility. The association rate of [Mg-tc](+) to the TetR mutants is enhanced. Since none of the mutated residues contacts tc directly in the crystal structure, we propose that the length of the loop is important for the structural transition between a closed, tc binding and an open, operator binding conformation of TetR. We propose that the deletions in the loop shift the equilibrium between both forms toward the open, operator binding conformation.	UNIV ERLANGEN NURNBERG,INST MIKROBIOL BIOCHEM & GENET,LEHRSTUHL MIKROBIOL,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; BAUMEISTER R, 1992, PROTEINS, V14, P168, DOI 10.1002/prot.340140204; BAUMEISTER R, 1992, J MOL BIOL, V226, P1257, DOI 10.1016/0022-2836(92)91065-W; BERENS C, 1992, J BIOL CHEM, V267, P1945; BERENS C, 1995, MOL MICROBIOL, V18, P437, DOI 10.1111/j.1365-2958.1995.mmi_18030437.x; Brandon C., 1991, INTRO PROTEIN STRUCT, p18e19; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P5; DEGENKOLB J, 1991, ANTIMICROB AGENTS CH, V35, P1591, DOI 10.1128/AAC.35.8.1591; EBRIGHT RH, 1986, P NATL ACAD SCI USA, V83, P303, DOI 10.1073/pnas.83.2.303; Ettner N, 1996, J CHROMATOGR A, V742, P95, DOI 10.1016/0021-9673(96)00232-4; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GIBCO BRL, 1986, FOCUS, V8, P9; HECHT B, 1993, J BACTERIOL, V175, P1206, DOI 10.1128/JB.175.4.1206-1210.1993; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lederer T, 1996, BIOCHEMISTRY-US, V35, P7439, DOI 10.1021/bi952683e; LEVY SB, 1989, ANTIMICROB AGENTS CH, V33, P1373, DOI 10.1128/AAC.33.8.1373; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Miller JH., 1992, SHORT COURSE BACTERI, P72; MULLER G, 1995, NAT STRUCT BIOL, V2, P693, DOI 10.1038/nsb0895-693; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Perrin D. D., 2012, BUFFERS PH METAL ION; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SMITH LD, 1988, J MOL BIOL, V203, P949, DOI 10.1016/0022-2836(88)90120-9; SU TZ, 1988, GENE, V69, P81, DOI 10.1016/0378-1119(88)90380-0; TAKAHASHI M, 1991, ANAL BIOCHEM, V199, P197, DOI 10.1016/0003-2697(91)90089-C; TAKAHASHI M, 1986, J MOL BIOL, V187, P341, DOI 10.1016/0022-2836(86)90437-7; TOVAR K, 1989, THESIS F ALEXANDER U; VERMERSCH PS, 1990, J BIOL CHEM, V265, P16592; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WISSMANN A, 1991, EMBO J, V10, P4145, DOI 10.1002/j.1460-2075.1991.tb04992.x; WISSMANN A, 1991, GENETICS, V128, P225; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	42	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6936	6942		10.1074/jbc.272.11.6936	http://dx.doi.org/10.1074/jbc.272.11.6936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054381	hybrid			2022-12-25	WOS:A1997WN14700020
J	Herbst, R; Schafer, U; Seckler, R				Herbst, R; Schafer, U; Seckler, R			Equilibrium intermediates in the reversible unfolding of firefly (Photinus pyralis) luciferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RETICULOCYTE LYSATE; LUCIOLA-MINGRELICA; PROTEIN; AGGREGATION; MECHANISM; CLONING; SYSTEM; CHAINS; CDNA	Firefly luciferase has been used as a model protein to study cotranslational and chaperone-assisted protein folding, We found conditions for reversible unfolding of luciferase in the absence of cellular factors, and we characterized denaturant-induced equilibrium unfolding transitions and refolding kinetics of the enzyme. Luciferase unfolding induced by guanidinium chloride at 10 degrees C can be described as a four-state equilibrium with two inactive intermediates highly populated around 1 and 3 M denaturant, The transitions occur around 0.3, 1.7, and 3.8 M denaturant, The fi ee energy of denaturation to the first inactive intermediate (Delta G(N=11)(0) = 15 +/- 3 kJ . mol(-1)) is small for a protein of 60 kDa, Fluorescence and circular dichroism spectra of the intermediates indicate that I-1 has a compact conformation, whereas aromatic side chains are highly exposed in the second intermediate, I-2, despite its high content of secondary structure. In the presence of a hydrophilic detergent, significant reactivation of luciferase is observed up to temperatures at which the native protein is unstable, Reactivation kinetics of luciferase are exceedingly slow and probably not limited by proline isomerization, as suggested by their independence from the time spent in the unfolded state.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY	University of Regensburg								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baldwin TO, 1996, STRUCTURE, V4, P223, DOI 10.1016/S0969-2126(96)00026-3; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; DEVINE JH, 1993, BIOCHIM BIOPHYS ACTA, V1173, P121, DOI 10.1016/0167-4781(93)90172-A; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Goldberg, 1995, Fold Des, V1, P21; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIEFHABER T, 1992, J MOL BIOL, V224, P231, DOI 10.1016/0022-2836(92)90586-9; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KRICKA LJ, 1982, ARCH BIOCHEM BIOPHYS, V217, P674, DOI 10.1016/0003-9861(82)90549-5; LEACH FR, 1986, METHOD ENZYMOL, V133, P51; MCELROY WD, 1955, METHOD ENZYMOL, V2, P851, DOI 10.1016/S0076-6879(55)02314-8; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MIKI T, 1985, ANAL BIOCHEM, V146, P28, DOI 10.1016/0003-2697(85)90390-2; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rozema D, 1996, J BIOL CHEM, V271, P3478; Schmid F X, 1986, Methods Enzymol, V131, P70; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SELIGER HH, 1960, ARCH BIOCHEM BIOPHYS, V88, P136, DOI 10.1016/0003-9861(60)90208-3; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; UGAROVA NN, 1989, J BIOLUM CHEMILUM, V4, P406, DOI 10.1002/bio.1170040155; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; WOOD KV, 1995, PHOTOCHEM PHOTOBIOL, V62, P662, DOI 10.1111/j.1751-1097.1995.tb08714.x; ZARDENETA G, 1994, ANAL BIOCHEM, V223, P1, DOI 10.1006/abio.1994.1537	34	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7099	7105		10.1074/jbc.272.11.7099	http://dx.doi.org/10.1074/jbc.272.11.7099			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054403	hybrid			2022-12-25	WOS:A1997WN14700042
J	Pappan, K; Qin, WS; Dyer, JH; Zheng, L; Wang, XM				Pappan, K; Qin, WS; Dyer, JH; Zheng, L; Wang, XM			Molecular cloning and functional analysis of polyphosphoinositide-dependent phospholipase D, PLD beta, from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN; FAMILY; CDNA; PURIFICATION; EXPRESSION; NEOMYCIN; BINDING; CALCIUM	A novel plant phospholipase D (PLD; EC 3.1.4.4) activity, which is dependent on phosphatidylinositol 4,5-bisphosphate (PIP2) and nanomolar concentrations of calcium, has been identified in Arabidopsis, This report describes the cloning, expression, and characterization of an Arabidopsis cDNA that encodes this PLD, We have designated names of PLD beta for this PIP2-dependent PLD and PLD alpha for the previously characterized PIP2-independent PLD that requires millimolar Ca2+ for optimal activity, The PLD beta cDNA contains an open reading frame of 2904 nucleotides coding for a 968-amino acid protein of 108,575 daltons, Expression of this PLD beta cDNA clone in Escherichia coli results in the accumulation of a functional PLD having PLD beta, but not PLD alpha, activity, The activity of the expressed PLD beta is dependent on PIP2 and submicromolar amounts of Ca2+, inhibited by neomycin, and stimulated by a soluble factor hom plant extracts, Sequence analysis reveals that PLD beta is evolutionarily divergent from PLD alpha and that its N terminus contains a regulatory Ca2+-dependent phospholipid-binding (C2) domain that is found in a number of signal transducing and membrane trafficking proteins.	KANSAS STATE UNIV, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Kansas State University			Pappan, Kirk/AAV-5946-2021; Wang, Xuemin/M-2853-2013	Pappan, Kirk/0000-0002-2341-8798; wang, xuemin/0000-0002-6251-6745				BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DYER JH, 1994, PLANT PHYSIOL, V105, P715, DOI 10.1104/pp.105.2.715; Dyer JH, 1996, BIOCHEM BIOPH RES CO, V221, P31, DOI 10.1006/bbrc.1996.0558; Dyer JH, 1995, PLANT PHYSIOL, V109, P1497; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Heller M, 1978, Adv Lipid Res, V16, P267; KATES M, 1954, CAN J BIOCHEM PHYS, V32, P571; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; NIVISON HT, 1987, PLANT MOL BIOL REP, V5, P295; PALIYATH G, 1987, PHYSIOL PLANTARUM, V71, P503, DOI 10.1111/j.1399-3054.1987.tb02891.x; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; Ponting CP, 1996, PROTEIN SCI, V5, P914; Ponting CP, 1996, PROTEIN SCI, V5, P162; REGAD F, 1993, FEBS LETT, V316, P133, DOI 10.1016/0014-5793(93)81201-A; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; RYU SB, 1995, PLANT PHYSIOL, V108, P713, DOI 10.1104/pp.108.2.713; SCHACHT J, 1978, J LIPID RES, V19, P1063; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TREWAVAS A, 1994, PLANT MOL BIOL, V26, P1329, DOI 10.1007/BF00016478; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; UEKI J, 1995, PLANT CELL PHYSIOL, V36, P903, DOI 10.1093/oxfordjournals.pcp.a078837; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WANG X, 1993, ARCH BIOCHEM BIOPHYS, V306, P496; WANG X, 1993, LIPID METABOLISM PLA, P499; WANG XM, 1994, J BIOL CHEM, V269, P20312; Young SA, 1996, PLANT CELL, V8, P1079, DOI 10.1105/tpc.8.6.1079	34	97	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7055	7061		10.1074/jbc.272.11.7055	http://dx.doi.org/10.1074/jbc.272.11.7055			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054397	hybrid			2022-12-25	WOS:A1997WN14700036
J	Valtavaara, M; Papponen, H; Pirttila, AM; Hiltunen, K; Helander, H; Myllyla, R				Valtavaara, M; Papponen, H; Pirttila, AM; Hiltunen, K; Helander, H; Myllyla, R			Cloning and characterization of a novel human lysyl hydroxylase isoform highly expressed in pancreas and muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; SYNDROME TYPE-VI; HUMAN SKIN FIBROBLASTS; PROLYL 4-HYDROXYLASE; HISTIDINE-RESIDUES; 2 SIBLINGS; GENE PLOD; COLLAGEN; CDNA; RECOMBINATION	me report the isolation and characterization of cDNA clones for a novel isoform of lysyl hydroxylase (lysyl hydroxylase 2), a posttranslational enzyme of collagen biosynthesis. The open reading frame predicted a protein of 737 amino acids, including an amino-terminal signal peptide. The amino acid sequence has overall similarity of over 75% to the lysyl hydroxylase (lysyl hydroxylase 1) characterized earlier. This similarity is even higher in the carboxyl-terminal end of the molecules. Lysyl hydroxylase 2 contains nine cysteine residues, which are conserved in lysyl hydroxylase 1. Furthermore, the conserved histidines and aspartate residues required for lysyl hydroxylase activity are present in the sequence. Northern analysis identified a transcript of 4.2 kilobases, which was highly expressed in pancreas and muscle tissues. Expression of cDNA in insect cells using a baculovirus vector yielded proteins with lysyl hydroxylase activity and an antiserum against a synthetic peptide of the deduced amino acid sequence recognized proteins with molecular weights of 88 and 97 kDa in homogenates of the transfected cells.	UNIV OULU,DEPT BIOCHEM,FIN-90570 OULU,FINLAND; UNIV OULU,BIOCTR,FIN-90570 OULU,FINLAND	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu				Helander, Heli/0000-0002-7319-3531; Pirttila, Anna Maria/0000-0002-2455-6375				AMSTRONG LC, 1995, BIOCHIM BIOPHYS ACTA, V1264, P93; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARNES MJ, 1974, BIOCHEM J, V139, P461, DOI 10.1042/bj1390461; HA VT, 1994, J CLIN INVEST, V93, P1716, DOI 10.1172/JCI117155; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HAUTALA T, 1993, GENOMICS, V15, P399, DOI 10.1006/geno.1993.1074; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; Heikkinen J, 1997, AM J HUM GENET, V60, P48; HYLAND J, 1992, NAT GENET, V2, P228, DOI 10.1038/ng1192-228; IHME A, 1984, J INVEST DERMATOL, V83, P161, DOI 10.1111/1523-1747.ep12263502; Kielty Cay M., 1993, P103; Kivirikko K. I., 1991, POST TRANSLATIONAL M, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1988, BIOCHEM J, V253, P489, DOI 10.1042/bj2530489; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; POUSI B, 1994, AM J HUM GENET, V55, P899; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RISTELI L, 1980, BIOCHEM BIOPH RES CO, V96, P1778, DOI 10.1016/0006-291X(80)91380-7; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; ROBINS SP, 1982, COLLAGEN HLTH DISEAS, P160; ROYCE PM, 1985, BIOCHEM J, V230, P475, DOI 10.1042/bj2300475; YEOWELL HN, 1992, J INVEST DERMATOL, V99, P864, DOI 10.1111/1523-1747.ep12614840; YEOWELL HN, 1994, J INVEST DERMATOL, V102, P382, DOI 10.1111/1523-1747.ep12371799	28	102	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6831	6834		10.1074/jbc.272.11.6831	http://dx.doi.org/10.1074/jbc.272.11.6831			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054364	hybrid			2022-12-25	WOS:A1997WN14700003
J	Chan, KW; Sui, JL; Vivaudou, M; Logothetis, DE				Chan, KW; Sui, JL; Vivaudou, M; Logothetis, DE			Specific regions of heteromeric subunits involved in enhancement of G protein-gated K+ channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC POTASSIUM CHANNEL; BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; FUNCTIONAL EXPRESSION; MOLECULAR-PROPERTIES; XENOPUS OOCYTES; GATING CHARGE; I-KACH; GIRK1; CLONING	Heterologous coexpression of recombinant, G proteingated, inwardly rectifying K+ (GIRK) channel subunits has yielded large currents, severalfold greater than those obtained from expression of the individual sub units, Such current enhancement has been obtained from coexpression of the inactive GIRK1 subunit with the low activity GIRK2-5 subunits in Xenopus oocytes, Using deletion and chimeric constructs, we now report the identification of a C-terminal region unique to GIRK1 and a larger central region of GIRK4 highly homologous to GIRK1, both of which are critical for production of large currents, Chimeras containing these two regions produced homomeric channels, exhibiting currents severalfold greater than those from either wild-type subunit alone. G protein regulation of such chimeric channel currents resembled that of wild-type currents, Green fluorescent protein-tagged channels showed that the amount of chimeric channel expressed on the oocyte cell surface was similar to its wild-type counterpart, suggesting that the enhanced activity was not due to differences in relative levels of expression but rather to the coexistence of the chimeric regions, Single-channel recordings of the active chimeras exhibited patterns of activities with open-time kinetics and conductance characteristics representative of those of GLRK4, indicating that the presence of the GIRK1 C-terminal region caused an increase in the frequency of channel openings without affecting their duration.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Vivaudou, Michel/C-5338-2008	Vivaudou, Michel/0000-0002-9777-3127	NHLBI NIH HHS [HL54185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KOBAYASHI T, 1995, BIOCHEM BIOPH RES CO, V208, P1166, DOI 10.1006/bbrc.1995.1456; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOGOTHETIS DE, 1993, NEURON, V10, P1121, DOI 10.1016/0896-6273(93)90060-5; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MIYAKE M, 1989, P NATL ACAD SCI USA, V86, P3419, DOI 10.1073/pnas.86.9.3419; Ponce A, 1996, J NEUROSCI, V16, P1990; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Spauschus A, 1996, J NEUROSCI, V16, P930; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9	37	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6548	6555		10.1074/jbc.272.10.6548	http://dx.doi.org/10.1074/jbc.272.10.6548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045681	hybrid			2022-12-25	WOS:A1997WM64700065
J	Zambrano, N; Buxbaum, JD; Minopoli, G; Fiore, F; DeCandia, P; DeRenzis, S; Faraonio, R; Sabo, S; Cheetham, J; Sudol, M; Russon, T				Zambrano, N; Buxbaum, JD; Minopoli, G; Fiore, F; DeCandia, P; DeRenzis, S; Faraonio, R; Sabo, S; Cheetham, J; Sudol, M; Russon, T			Interaction of the phosphotyrosine interaction/phosphotyrosine binding-related domains of Fe65 with wild-type and mutant Alzheimer's beta-amyloid precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHC; RECEPTOR; MOTIF; MUTATION	The two tandem phosphotyrosine interaction/phosphotyrosine binding (PID/PTB) domains of the Fe65 protein interact with the intracellular region of the Alzheimer's beta-amyloid precursor protein (APP). This interaction, previously demonstrated in vitro and in the yeast two hybrid system, also takes place in vivo in mammalian cells, as demonstrated here by anti-Fe65 co-immunoprecipitation experiments, This interaction differs from that occurring between other PID/PTB domain-containing proteins, such as She and insulin receptor substrate 1, and activated growth factor receptors as follows: (i) the Fe65-APP interaction is phosphorylation-independent; (ii) the region of the APP intracellular domain involved in the binding is larger than that of the growth factor receptor necessary for the formation of the complex with She; and (iii) despite a significant similarity the carboxyl-terminal regions of PID/PTB of Fe65 and of She are not functionally interchangeable in terms of binding cognate ligands, A role for Fe65 in the pathogenesis of familial Alzheimer's disease is suggested by the finding that mutant APP, responsible for some cases of familial Alzheimer's disease, shows an altered in vivo interaction with Fe65.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,CEINGE BIOTECNOL AVANZATE SCRL,I-80131 NAPLES,ITALY; ROCKEFELLER UNIV,MOL & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	CEINGE Biotecnologie Avanzate; University of Naples Federico II; Rockefeller University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			de Candia, Paola/Z-1498-2019; Russo, Tommaso/K-1331-2016; de Candia, Paola/HGC-8826-2022; Zambrano, Nicola/B-9352-2014; faraonio, raffaella/K-3802-2018; Buxbaum, Joseph D/G-6001-2010	de Candia, Paola/0000-0003-4767-446X; Russo, Tommaso/0000-0003-4426-0106; de Candia, Paola/0000-0003-4767-446X; Zambrano, Nicola/0000-0001-9395-3481; Faraonio, Raffaella/0000-0002-7040-6781; Buxbaum, Joseph/0000-0001-8898-8313; De Renzis, Stefano/0000-0003-4764-2070; Sabo, Shasta/0000-0001-6386-7443				ALLINQUANT B, 1994, J NEUROSCI, V14, P6842; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Busfield Frances, 1995, P59, DOI 10.1016/B978-012286965-5/50006-6; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OBRIAN JP, 1996, P NATL ACAD SCI USA, V93, P2729; Okamoto T, 1996, EMBO J, V15, P3769, DOI 10.1002/j.1460-2075.1996.tb00750.x; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	33	144	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6399	6405		10.1074/jbc.272.10.6399	http://dx.doi.org/10.1074/jbc.272.10.6399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045663	hybrid			2022-12-25	WOS:A1997WM64700047
J	Cohen, S; Regev, A; Lavi, S				Cohen, S; Regev, A; Lavi, S			Small polydispersed circular DNA (spcDNA) in human cells: Association with genomic instability	ONCOGENE			English	Article						genomic instability; spcDNA; two dimensional electrophoresis gene amplification; cancer; mutator phenotype	HAMSTER EMBRYO CELLS; GENE AMPLIFICATION; MITOCHONDRIAL-DNA; EXTRACHROMOSOMAL DNA; MOUSE 3T6-CELLS; HELA-CELLS; SEQUENCES; ELEMENT; MECHANISMS; SATELLITE	Small Polydispersed Circular DNA (spcDNA) was suggested to be associated with genetically unstable cells. However, until now, qualitative and quantitative research has been limited due to the lack of efficient methods for detection and analysis. We developed a two-dimensional (2-D) neutral-neutral gel electrophoresis assay for the identification, characterisation and quantitation of spcDNA. Using this method, we established the relation of spcDNA to genetic and induced genomic instability in human cells, both in vitro and in vivo. Enhanced amounts of spcDNA were found in genetically unstable cells and tissues. spcDNA was detected in a tumor cell-line (HeLa) and in tumor tissue (colon carcinoma) as well as in fibroblasts derived from patients suffering from the genomic instability disease, Fanconi's Anemia. We failed to detect spcDNA in the genetically stable normal human fibroblasts. However, following treatment with the initiating carcinogen MNNG, an induction of spcDNA was observed. The level of spcDNA was quantified according to mitochondrial DNA (mtDNA) standards. In light of these findings, we discuss the possible role of spcDNA as a marker and an enhancer of genomic instability.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ASSUM G, 1993, HUM GENET, V91, P489; BERKOFLINT Y, 1990, MOL CELL BIOL, V10, P75, DOI 10.1128/MCB.10.1.75; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen S, 1996, MOL CELL BIOL, V16, P2002; DELAP RJ, 1978, PLASMID, V1, P508, DOI 10.1016/0147-619X(78)90008-2; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FLORES SC, 1988, NUCLEIC ACIDS RES, V16, P3889, DOI 10.1093/nar/16.9.3889; FRIEDBERG EC, 1995, DNA REPAIR; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GAUBATZ JW, 1990, MUTAT RES, V237, P29, DOI 10.1016/0921-8734(90)90029-Q; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; GOLDSTEIN S, 1984, MOL CELL BIOCHEM, V64, P15, DOI 10.1007/BF00420924; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLIS M, 1986, GENE, V46, P153, DOI 10.1016/0378-1119(86)90399-9; JONES RS, 1985, NUCLEIC ACIDS RES, V13, P1027, DOI 10.1093/nar/13.3.1027; KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; KOWALD A, 1993, MUTAT RES, V295, P93, DOI 10.1016/0921-8734(93)90011-Q; KRYSAN PJ, 1991, MOL CELL BIOL, V11, P1464, DOI 10.1128/MCB.11.3.1464; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; KUNISADA T, 1984, GENE, V31, P213, DOI 10.1016/0378-1119(84)90212-9; KUNISADA T, 1987, J MOL BIOL, V198, P557, DOI 10.1016/0022-2836(87)90199-9; KUNISADA T, 1985, MECH AGEING DEV, V29, P89, DOI 10.1016/0047-6374(85)90050-8; KUNISADA T, 1983, PLASMID, V9, P8, DOI 10.1016/0147-619X(83)90027-6; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LAVI S, 1981, CARCINOGENESIS, V2, P417, DOI 10.1093/carcin/2.5.417; LAVI S, 1982, GENE AMPLIFICATION, P225; LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6; LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732; MISRA R, 1989, NUCLEIC ACIDS RES, V17, P8327, DOI 10.1093/nar/17.20.8327; MISRA R, 1987, J MOL BIOL, V196, P233, DOI 10.1016/0022-2836(87)90687-5; MOTEJLEK K, 1993, MUTAT RES, V293, P205, DOI 10.1016/0921-8777(93)90071-N; NEIDLINGER C, 1988, HUM GENET, V79, P286, DOI 10.1007/BF00366254; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; RIABOWOL K, 1985, NUCLEIC ACIDS RES, V3, P5563; RIO DC, 1990, ANNU REV GENET, V24, P543; RUIZ JC, 1989, MOL CELL BIOL, V9, P109, DOI 10.1128/MCB.9.1.109; RUSH MG, 1985, PLASMID, V14, P177, DOI 10.1016/0147-619X(85)90001-0; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SMITH CA, 1972, J MOL BIOL, V69, P163, DOI 10.1016/0022-2836(72)90222-7; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SUNNERHAGEN P, 1986, NUCLEIC ACIDS RES, V14, P7823, DOI 10.1093/nar/14.20.7823; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; TLSTY T, 1982, GENE AMPLIFICATION, P231; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; WAHL GM, 1989, CANCER RES, V49, P1333; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YAMAGISHI H, 1985, MECH AGEING DEV, V29, P101, DOI 10.1016/0047-6374(85)90051-X; YAMAGISHI H, 1986, BIOESSAYS, V4, P218, DOI 10.1002/bies.950040508	56	80	85	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					977	985		10.1038/sj.onc.1200917	http://dx.doi.org/10.1038/sj.onc.1200917			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050997				2022-12-25	WOS:A1997WK34400011
J	Pollegioni, L; Blodig, W; Ghisla, S				Pollegioni, L; Blodig, W; Ghisla, S			On the mechanism of D-amino acid oxidase - Structure/linear free energy correlations and deuterium kinetic isotope effects using substituted phenylglycines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-REACTIVITY CORRELATIONS; REDUCTIVE HALF-REACTION; TRIGONOPSIS-VARIABILIS; RHODOTORULA-GRACILIS; DEHYDROGENASE; SECONDARY; OXIDATION; SUBSTRATE; ANALOGS; PH	The kinetic mechanism of the reaction of D-amino acid oxidase (EC 1.4.3.3) from Trigonopsis variabilis with [alpha-H-1]- and [alpha-H-2]phenylglycine has been determined. The pH dependence of V-max is compatible with pK(a) values of approximate to 8.1 and >9.5, the former of which is attributed to a base which should be deprotonated for efficient catalysis. The deuterium isotope effect on turnover is approximate to 3.9, and the solvent isotope effect approximate to 1.6. The reductive half-reaction is biphasic, the first, fast phase, k(2), corresponding to substrate dehydrogenation/enzyme flavin reduction and the second to conversion/release of product. Enzyme flavin reduction consists in an approach to equilibrium involving a finite rate for k(-2), the reversal of k(2). k(2) is 28.8 and 4.6 s(-1) for [alpha-H-1]- and [alpha-H-2]phenylglycine, respectively, yielding a primary deuterium iso tope effect approximate to 6. The solvent deuterium isotope effect on the apparent rate of reduction for [alpha-H-1]- and [alpha-H-2]phenylglycine is approximate to 2.8 and approximate to 5. The rates for k(-2), are 4.2 and 0.9 s(-1) for [alpha-H-1]- and [alpha-H-2]phenylglycine, respectively, and the corresponding isotope effect is approximate to 4.7. The isotope effect on alpha-H and the solvent one thus behave multiplicatively consistent with a highly concerted process and a symmetric transition state. The k(2) and k(-2) values for phenylglycines carrying the para substituents F, Cl, Br, CH3, OH, NO2 and OCH3 have been determined. There is a Linear correlation of k(2) with the substituent volume V-M and with sigma(+); k(-2) correlates best with sigma or sigma(+) while steric parameters have little influence. This is consistent with the transition state being structurally similar to the product. The Bronsted plot of Delta G(double dagger) versus Delta G(0) allows the estimation of the intrinsic Delta G(0)(double dagger) as approximate to 58 kJ . M(-1). From the linear free energy correlations, the relation of Delta G(double dagger) versus Delta G(0) and according to the theory of Marcus it is concluded that there is little if any development of charge in the transition state. This, together with the recently solved three-dimensional structure of D amino acid oxidase from pig kidney (Mattevi, A., Vanoni, M.A., Todone, F., Rizzi, M., Teplyakov, A., Coda, A., Bolognesi, M., and Curti, B. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7496-7501), argues against a carbanion mechanism in its classical formulation. Our data are compatible with transfer of a hydride from the substrate alpha C-H to the oxidized flavin N(5) position, although, clearly, they cannot prove it.	UNIV KONSTANZ,FAK BIOL,D-78434 CONSTANCE,GERMANY; UNIV MILAN,FAC SCI 3,I-21100 VARESE,ITALY	University of Konstanz; University of Milan				POLLEGIONI, LOREDANO/0000-0003-1733-7243				AVERILL BA, 1975, J BIOL CHEM, V250, P1603; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; Bright H.B., 1975, ENZYMES, V12B, P421; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; DALZIEL K, 1969, BIOCHEM J, V114, P547, DOI 10.1042/bj1140547; DENU JM, 1994, BIOCHEMISTRY-US, V33, P4001, DOI 10.1021/bi00179a029; DENU JM, 1994, J BIOL CHEM, V269, P15054; DENU JM, 1992, BIOCHEMISTRY-US, V31, P8207, DOI 10.1021/bi00150a013; ECKSTEIN JW, 1993, BIOCHEMISTRY-US, V32, P404, DOI 10.1021/bi00053a004; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P2916; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Ghisla S., 1982, FLAVINS FLAVOPROTEIN, P133; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GOTTHARDT H, 1976, CHEM BER-RECL, V109, P740, DOI 10.1002/cber.19761090235; GREENSTEIN JP, 1966, CHEM AMICO ACIDS, VB, P698; Hammett L.P., 1940, PHYS ORGANIC CHEM, P184; Hansch C, 1979, SUBSTITUENT CONSTANT; HERSH LB, 1975, J BIOL CHEM, V250, P8728; KLINMAN JP, 1976, BIOCHEMISTRY-US, V15, P2018, DOI 10.1021/bi00654a032; KUBICEKPRANZ EM, 1985, CAN J MICROBIOL, V31, P625, DOI 10.1139/m85-118; LANGKAU B, 1993, THESIS U KONSTANZ; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; March J., 1992, ADV ORG CHEM, P273; MARCUS RA, 1968, J PHYS CHEM-US, V72, P891, DOI 10.1021/j100849a019; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MATSUO H, 1967, CHEM PHARM BULL, V15, P391; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; MELANDER L, 1980, REACTION RATES ISOTO, P276; MILLER SM, 1985, BIOCHEMISTRY-US, V24, P2114, DOI 10.1021/bi00330a004; MIURA R, 1988, BIOORG CHEM, V16, P97, DOI 10.1016/0045-2068(88)90039-9; NEIMS AH, 1966, BIOCHEMISTRY-US, V5, P203, DOI 10.1021/bi00865a027; POHL B, 1986, EUR J BIOCHEM, V160, P109, DOI 10.1111/j.1432-1033.1986.tb09946.x; POLLEGIONI L, 1993, BIOCHEM MOL BIOL INT, V31, P709; POLLEGIONI L, 1994, J BIOL CHEM, V269, P31666; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13580; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SIMONETTA MP, 1987, BIOCHIM BIOPHYS ACTA, V914, P136, DOI 10.1016/0167-4838(87)90056-2; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; TSUNEMATSU H, 1980, J BIOCHEM-TOKYO, V88, P1773, DOI 10.1093/oxfordjournals.jbchem.a133152; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011	45	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4924	4934		10.1074/jbc.272.8.4924	http://dx.doi.org/10.1074/jbc.272.8.4924			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030552	hybrid, Green Published			2022-12-25	WOS:A1997WJ85500040
J	Wearsch, PA; Nicchitta, CV				Wearsch, PA; Nicchitta, CV			Interaction of endoplasmic reticulum chaperone GRP94 with peptide substrates is adenine nucleotide-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CASEIN KINASE-II; MOLECULAR CHAPERONES; STRESS PROTEINS; BINDING; CELLS; ATP; TRANSLOCATION; CATALYSTS; VESICLES	GRP94, the endoplasmic reticulum paralog of hsp90, has recently been identified as a peptide and adenine nucleotide-binding protein. To determine if adenine nucleotides directly contribute to the regulation of GRP94 peptide binding activity, an in vitro peptide binding assay was developed. Using purified GRP94, we observed specific, saturable, temperature-sensitive binding of the peptide VSV8, a known in vivo ligand. ATP was without effect on VSV8 binding to GRP94, whether present during or subsequent to peptide binding. To evaluate the interaction of GRP94 with adenine nucleotides, the ATP binding and hydrolysis activities were directly assayed. Only negligible binding of ATP to GRP94 was observed. In addition, analysis of the GRP94 adenine nucleotide content indicated that GRP94 did not copurify with bound adenine nucleotides. GRP94 preparations exhibited low ATPase and apparent autophosphorylation activities. Further purification, combined with inhibitor studies, indicated that both activities were the result of trace contamination (<0.1%) with casein kinase II. On the basis of these data, we propose that the peptide binding activity of GRP94 is adenine nucleotide-independent and that ATP binding and hydrolysis are not inherent properties of GRP94.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University			Wearsch, Pamela/K-8505-2014	Wearsch, Pamela/0000-0002-9569-3852	NIDDK NIH HHS [DK47897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; CALA SE, 1994, J BIOL CHEM, V269, P5926; Chen NQ, 1996, BIOCHEMISTRY-US, V35, P8299, DOI 10.1021/bi960296e; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0	39	99	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5152	5156		10.1074/jbc.272.8.5152	http://dx.doi.org/10.1074/jbc.272.8.5152			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030582	hybrid			2022-12-25	WOS:A1997WJ85500070
J	Olshan, AF; Weissler, MC; Pei, H; Conway, K; Anderson, S; Fried, DB; Yarbrough, WG				Olshan, AF; Weissler, MC; Pei, H; Conway, K; Anderson, S; Fried, DB; Yarbrough, WG			Alterations of the p16 gene in head and neck cancer: Frequency and association with p53, PRAD-1 and HPV	ONCOGENE			English	Article						head and neck neoplasms; mutation; p53; p16INK44; HPV; PRAD-1	SQUAMOUS-CELL CARCINOMA; CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA-PROTEIN; HOMOZYGOUS DELETIONS; ALTERED EXPRESSION; FAMILIAL MELANOMA; SUPPRESSOR GENES; INHIBITOR GENE; MTS1 GENE; TUMORS	Alterations, especially homozygous deletions, of the putative tumor suppressor gene, p16 (p16(INK4A), MTS1, CDKN2) have been found in tumor cell lines from a variety of neoplasms. Recent studies have reported frequent p16 gene deletions in cell lines from squamous cell carcinomas of the head and neck (SCCHN), although the prevalence of alterations was variable in primary tumors. This study determined the prevalence of point mutations and deletions of the p16 gene in 33 SCCHN. In addition, the association of p16 gene alterations and abnormalities of p53, PRAD-1 (cyclin D1), and the presence of human papillomavirus (HPV) was examined. We found an overall prevalence of p16 alterations of 36% (nine deletions, three single base substitutions, including one polymorphism). Seven tumors (of 29, 24%) had an alteration of p16 and p53; five (of 33, 15%) had alterations of p16 and PRAD-1; three (of 29, 10%) had alterations of all three genes. In addition, of the five tumors with human papillomavirus detected, only one also had a p16 gene alteration. The results indicate a potentially important role for the p16 gene in head and neck tumorigenesis. In addition, the presence of tumors with multiple somatic gene alterations suggest a possible interaction in the dysregulation of the cell cycle.	UNIV N CAROLINA,SCH MED,DIV OTOLARYNGOL HEAD & NECK SURG,CHAPEL HILL,NC 27599; LAB CORP AMER,DEPT MOL BIOL & PATHOL,RES TRIANGLE PK,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Olshan, AF (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CHAPEL HILL,NC, USA.							AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Bauer HM, 1992, DIAGNOSTIC MOL PATHO, V2, P131; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; GRANA X, 1995, ONCOGENE, V11, P211; GRUIS NA, 1995, AM J PATHOL, V146, P1199; HANNON GJ, 1994, NATURE, V371, P357; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIU ET, 1993, SEMIN CANCER BIOL, V4, P47; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAWROZ H, 1994, CANCER RES, V54, P1152; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Yeudall WA, 1995, ORAL ONCOL, V31B, P291, DOI 10.1016/0964-1955(95)00028-3; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; YOO GH, 1994, CANCER RES, V54, P4603; ZHANG SY, 1994, CANCER RES, V54, P50; ZHOU XL, 1994, ONCOGENE, V9, P3737	49	79	79	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					811	818		10.1038/sj.onc.1200892	http://dx.doi.org/10.1038/sj.onc.1200892			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047388				2022-12-25	WOS:A1997WJ11200007
J	Nagarajan, L; Storms, RK				Nagarajan, L; Storms, RK			Molecular characterization of GCV3 the Saccharomyces cerevisiae gene coding for the glycine cleavage system hydrogen carrier protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-PROTEIN; C1-TETRAHYDROFOLATE SYNTHASE; NUCLEOTIDE-SEQUENCE; DECARBOXYLASE COMPLEX; THYMIDYLATE SYNTHASE; LEAF MITOCHONDRIA; ESCHERICHIA-COLI; CDNA CLONING; YEAST; SERINE	YAL044, a gene on the left arm of Saccharomyces cerevisiae chromosome one, is shown to code for the H-protein subunit of the multienzyme glycine cleavage system. The gene designation has therefore been changed to GCV3, reflecting its role in the glycine cleavage system. GCV3 encodes a 177-residue protein with a putative mitochondrial targeting signal at its amino terminus. Targeted gene replacement shows that GCV3 is not required for growth on minimal medium; however, it is essential when glycine serves as the sole nitrogen source. Studies of GCV3 expression revealed that it is highly regulated. Supplementation of minimal medium with glycine, the glycine cleavage system's substrate, induced expression at least 30-fold. In contrast, and consistent with the cleavage of glycine providing activated single-carbon units, the addition of the metabolic end products that require activated single-carbon units repressed expression about 10-fold. Finally, like many amino acid biosynthetic genes, GCV3 is subject to regulation by the general amino acid control system.	CONCORDIA UNIV, DEPT BIOL, MONTREAL, PQ H3G 1M8, CANADA; CONCORDIA UNIV, DEPT CHEM & BIOCHEM, MONTREAL, PQ H3G 1M8, CANADA	Concordia University - Canada; Concordia University - Canada			Storms, Reginald/B-2405-2013					ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; FUJIWARA K, 1991, BIOCHEM BIOPH RES CO, V176, P711, DOI 10.1016/S0006-291X(05)80242-6; FUJIWARA K, 1991, FEBS LETT, V293, P115, DOI 10.1016/0014-5793(91)81164-4; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; KIM YH, 1990, J BIOL CHEM, V265, P848; KNAPPE J, 1987, ESCHERICHIA COLI SAL, V1, P151; MACHEREL D, 1990, BIOCHEM J, V268, P783, DOI 10.1042/bj2680783; MCKENZIE KQ, 1977, GENETICS, V86, P85; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; McNeil JB, 1996, GENETICS, V142, P371; MEEDEL TH, 1974, J BACTERIOL, V118, P905, DOI 10.1128/JB.118.3.905-910.1974; MELCHER K, 1995, CURR GENET, V27, P501, DOI 10.1007/BF00314439; MELCHER K, 1992, CURR GENET, V21, P295, DOI 10.1007/BF00351686; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MORTIMER RK, 1966, GENETICS, V53, P1165; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; Mudd S. H., 1964, COMPR BIOCHEM, V15, P1; ODELL BL, 1947, J AM CHEM SOC, V69, P250, DOI 10.1021/ja01194a023; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; OLIVER DJ, 1994, ANNU REV PLANT PHYS, V45, P323, DOI 10.1146/annurev.pp.45.060194.001543; ORD RW, 1988, CURR GENET, V14, P363, DOI 10.1007/BF00419994; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; REBEILLE F, 1994, BIOCHEM J, V302, P223, DOI 10.1042/bj3020223; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P1; Sinclair DA, 1996, MOL MICROBIOL, V19, P611, DOI 10.1046/j.1365-2958.1996.419947.x; SINCLAIR DA, 1995, GENETICS, V140, P213; SRINIVASAN R, 1992, PLANT PHYSIOL, V98, P1518, DOI 10.1104/pp.98.4.1518; STABEN C, 1986, J BIOL CHEM, V261, P4629; STORMS RK, 1984, MOL CELL BIOL, V4, P2858, DOI 10.1128/MCB.4.12.2858; STRUHL K, 1981, J MOL BIOL, V152, P553, DOI 10.1016/0022-2836(81)90268-0; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; YAMAMOTO M, 1991, J BIOL CHEM, V266, P3317	50	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4444	4450		10.1074/jbc.272.7.4444	http://dx.doi.org/10.1074/jbc.272.7.4444			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020168	hybrid			2022-12-25	WOS:A1997WH01900084
J	Nelson, DA; Krucher, NA; Ludlow, JW				Nelson, DA; Krucher, NA; Ludlow, JW			High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE-PRODUCT; SERINE THREONINE PHOSPHATASES; CELL-CYCLE CONTROL; SV40 LARGE-T; PHOSPHOPROTEIN PHOSPHATASE; SUBUNIT STRUCTURE; TUMOR-SUPPRESSOR; SKELETAL-MUSCLE; PHOSPHORYLATION; IDENTIFICATION	pRb controls cell proliferation by restricting inappropriate entry of cells into the cell division cycle, As dephosphorylation of pRb during mitotic exit activates its growth suppressive function, identification of the protein phosphatase that dephosphorylates pRb, and characterization of the mechanism of its regulation, are essential to elucidating the mechanisms of cell growth control. By fractionating mitotic CV-1P cell extracts, we identify the protein phosphatase which dephosphorylates pRb as a type 1 serine/threonine phosphoprotein phosphatase (PP1). Molecular sizing analyses indicate that the catalytic enzyme (PP1c) is present in a high molecular weight complex, with a predicted molecular mass of 166 kDa. PP1-interacting proteins in the mitotic cell extracts are identified. Two PP1-interacting proteins (41 and 110 kDa) are shown to form distinct complexes with PP1c from fractions of separated mitotic cell extracts containing phosphorylase phosphatase activity. However, only the 110-kDa PP1-interacting protein is present in fractions containing pRb directed phosphatase activity, identifying this protein as a putative activator of PP1 function toward pRb during mitosis.	UNIV ROCHESTER, CTR CANC, DIV DEV THERAPEUT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Nelson, Deirdre/0000-0001-5527-2570	NCI NIH HHS [CA11198, CA56940] Funding Source: Medline; NIDCR NIH HHS [DE07202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA056940, P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1989, ADV PROTEIN PHOSPHAT, V5, P1; Cohn EJ, 1934, J AM CHEM SOC, V56, P784, DOI 10.1021/ja01319a006; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRATECOS D, 1977, BIOCHEMISTRY-US, V16, P4812, DOI 10.1021/bi00641a009; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KATO J, 1993, GENE DEV, V7, P331; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4850; KHATRA BS, 1986, J BIOL CHEM, V261, P8944; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KRANENBURG O, 1995, FEBS LETT, V367, P103, DOI 10.1016/0014-5793(95)00587-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LI HC, 1988, METHOD ENZYMOL, V159, P346; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 1968, HDB BIOCH SELECTED D, pC1; THOMAS NSB, 1991, ONCOGENE, V6, P317; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817	59	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4528	4535		10.1074/jbc.272.7.4528	http://dx.doi.org/10.1074/jbc.272.7.4528			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020179	hybrid			2022-12-25	WOS:A1997WH01900095
J	Cosgaya, JM; Perona, R; Aranda, A				Cosgaya, JM; Perona, R; Aranda, A			Retinoic acid induces secretion of transforming growth factors by PC12 pheochromocytoma cells	ONCOGENE			English	Article						retinoic acid; PC12 conditioned medium; TGF-beta 1	FACTOR-BETA; EXPRESSION; FACTOR-BETA-1; GROWTH-FACTOR-BETA-1; DIFFERENTIATION; INDUCTION; RECEPTORS; PROMOTER; LINES; SUPERFAMILY	Conditioned medium from PC12 cells incubated with retinoic acid (RA) increases [H-3]thymidine incorporation in normal rat kidney (NRK) fibroblasts and 3D9 epithelial cells. The medium also causes anchorage-independent growth of NRK cells, which is strongly potentiated either in the presence of EGF or after activation of latent forms of transforming growth factors (TGFs) by acidification. These results suggest that RA regulates the release of more than one growth factor by PC12 cells. Conditioned media from control or NGF-treated PC12 cells causes growth of NRK cells in soft agar only after acidification. An increase in expression of the TGF-beta 1 gene is coincident with NGF-induced neuronal differentiation of PC12 cells. In addition, RA also causes a dose- and time-dependent increase in content of TGF-beta 1 transcripts. This increase is, at least in part, secondary to transcriptional activation. Sequences responsible for the effect of RA and NGF are located in the 5'-flanking region of the TGF-beta 1 gene. The TFG-beta 1 gene has two promoters and in transient transfection assays RA and NGF significantly enhance the activity of constructs containing the second promoter, High-affinity TGF-beta 1 receptors were undetectable in PC12 cells both before and after NGF or RA treatment. RA and NGF decrease PC12 cell proliferation and a neutralizing anti-TGF-beta 1 antibody does not reverse this inhibition. In summary, an increase in expression and secretion of TGF-beta 1 accompanies RA and NGF-induced PC12 cell growth arrest, but TGF-beta 1 does not play an autocrine role in this inhibition.	CSIC, INST INVEST BIOMED, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916				ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN PS, 1995, CANCER RES, V55, P2380; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cosgaya JM, 1996, J NEUROCHEM, V66, P89; COSGAYA JM, 1995, J NEUROCHEM, V65, P2484; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; FALK LA, 1991, BLOOD, V77, P1248; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUSUHARA M, 1992, CANCER RES, V52, P3011; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; MONIER S, 1994, CLIN EXP RHEUMATOL, V12, P595; PETERSON EP, 1994, J CELL PHYSIOL, V159, P551, DOI 10.1002/jcp.1041590319; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANZOELEN EJJ, 1993, GROWTH FACTORS, V9, P329, DOI 10.3109/08977199308991593; VANZOELEN EJJ, 1986, J BIOL CHEM, V261, P5003	35	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					579	587		10.1038/sj.onc.1200865	http://dx.doi.org/10.1038/sj.onc.1200865			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053856				2022-12-25	WOS:A1997WF52400009
J	Crouch, MF; Simson, L				Crouch, MF; Simson, L			The G-protein G(i) regulates mitosis but not DNA synthesis in growth factor-activated fibroblasts: A role for the nuclear translocation of G(i)	FASEB JOURNAL			English	Article						immunoprecipitation; nuclear fraction; EGF; cellular proliferation; beta-subunit	GTP-BINDING PROTEIN; RECEPTOR TYROSINE KINASES; ADENYLATE-CYCLASE; BALB/C3T3 CELLS; SUBCELLULAR-DISTRIBUTION; MAP-KINASE; ALPHA; COMPONENT; PURIFICATION; SUBSTRATE	GTP binding proteins, heterotrimeric molecules composed of alpha-, beta-, and gamma-subunits, are known to serve as transducers of information from seven-transmembrane receptors, Activation of G-proteins has been generally considered to involve subunit dissociation, with G(alpha) separating from G(beta gamma). However, we have found a receptor activation of G(i) in proliferating cells that differs from these models and involves the subcellular translocation of the alpha-subunit from the cell periphery to the nucleus where G(i alpha) binds to chromatin for the duration of mitosis, This report describes the mechanism of G(i) activation in Swiss 3T3 cells in response to serum, thrombin, and epidermal growth factor, and describes a role for G(i2) in the cell cycle, Agonists were found to be unable to induce the physical dissociation of G(i2) subunits, The alpha- and beta-subunits of G(i2) could be coimmunoprecipitated with a G(i alpha) antibody from both the membrane and nuclear fractions of long-term activated cultures, showing that G(i alpha 2) and G(i beta) are induced to comigrate to the nucleus in response to growth factor receptor activation, G(i2) appears to be activated in part by a postreceptor signal that carl be mimicked by protein kinase C activation; this signal may be responsible for the convergence of the signaling mechanisms of these distinct seven-transmembrane and tyrosine kinase receptors, mie suggest that translocation of G(i alpha) to the nucleus induced by either thrombin or EGF may occur without subunit dissociation, Functional studies of the role of G(i) showed that pertussis toxin does riot block DNA synthesis in Swiss 3T3 fibroblasts induced by serum or thrombin, but that cell proliferation is retarded to each, These results provide direct evidence for a novel mechanism of GTP binding protein activation and for an essential role of G(i) in the induction of cell division by a variety of growth factor receptors, G(i) can carry out this role in control of cellular proliferation through its translocation to the nucleus of mitotic cells.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV NEUROSCI, CANBERRA, ACT 2600, AUSTRALIA	Australian National University; John Curtin School of Medical Research			Simson, Ljubov/C-2954-2009					BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CROUCH MF, 1993, MED RES REV, V13, P105, DOI 10.1002/med.2610130105; CROUCH MF, 1989, P NATL ACAD SCI USA, V86, P1776, DOI 10.1073/pnas.86.6.1776; CROUCH MF, 1993, CELL SIGNAL, V5, P41, DOI 10.1016/0898-6568(93)90006-8; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; CROUCH MF, 1990, BIOCHEM BIOPH RES CO, V167, P1369, DOI 10.1016/0006-291X(90)90674-C; CROUCH MF, 1994, CELL SIGNAL, V6, P695, DOI 10.1016/0898-6568(94)90051-5; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HANSKI E, 1981, J BIOL CHEM, V256, P2911; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KATADA T, 1984, J BIOL CHEM, V259, P3578; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEVITZKI A, 1993, INT ENCYCL PHARM TH, P47; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN CT, 1992, LAB INVEST, V67, P770; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RODBELL M, 1985, TRENDS BIOCHEM SCI, V10, P461, DOI 10.1016/0968-0004(85)90032-5; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SARNDAHL E, 1993, P NATL ACAD SCI USA, V90, P6552, DOI 10.1073/pnas.90.14.6552; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0	41	55	55	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					189	198		10.1096/fasebj.11.2.9039962	http://dx.doi.org/10.1096/fasebj.11.2.9039962			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039962				2022-12-25	WOS:A1997WK50900012
J	Leverrier, Y; Thomas, J; Perkins, GR; Mangeney, M; Collins, MKL; Marvel, J				Leverrier, Y; Thomas, J; Perkins, GR; Mangeney, M; Collins, MKL; Marvel, J			In bone marrow derived Baf-3 cells, inhibition of apoptosis by IL-3 is mediated by two independent pathways	ONCOGENE			English	Article						apoptosis; Bcl-X; survival; IL-3; MAP-kinase	HEMATOPOIETIC-CELLS; CALCIUM IONOPHORES; BCL-2 PROTECTION; C-MYC; DEATH; GROWTH; INTERLEUKIN-3; SUPPRESSION; ACTIVATION; EXPRESSION	The inhibition of cell death by growth factors plays a key role in the maintenance of the haematopoietic system homeostasis. However the mechanisms involved in this inhibition are still poorly understood. In order to determine if inhibition of apoptosis by growth factors is dependent only on the expression of survival genes, we have studied that process in the bone marrow derived IL-3 dependent cell line Baf-3. We show that, following IL-3 starvation, mRNA and protein levels of Bcl-X but not Bcl-2 decrease rapidly preceeding the onset of death. The death of IL-3 starved cells is asynchronous, starting between 6 to 8 h with 50% death being reached after 10 to 12 h. At any time point, apoptosis can be rapidly inhibited by growth factor re-addition, This has allowed us to determine that the inhibition of apoptosis by growth factor takes place at two levels. The first one, which we have called short term inhibition, is independent of mRNA and protein synthesis i.e. it takes place in the absence of survival gene neosynthesis and can be demonstrated during the first 6 h following growth factor re-addition. The second one corresponds to long-term survival-more than 24 h survival-and is strongly correlated with the induction of Bcl-X but not Bcl-2 gene expression. This induction of Bcl-X by IL3 is shown to be dependent on MAP-kinase activation.	ECOLE NORMALE SUPER LYON,LBMC,CNRS UMR49,INRA LA 913,F-69364 LYON 07,FRANCE; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			LEVERRIER, Yann/M-3767-2014; marvel, jacqueline/H-8638-2014	LEVERRIER, Yann/0000-0002-4227-5446; marvel, jacqueline/0000-0001-6241-459X; Mangeney, Marianne/0000-0002-9102-191X; Thomas, Joelle/0000-0002-0461-6131				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LIENHARD GE, 1994, NATURE, V372, P128, DOI 10.1038/372128a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAY WS, 1994, J BIOL CHEM, V269, P26865; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTANI H, 1993, J BIOL CHEM, V268, P22733; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	35	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					425	430		10.1038/sj.onc.1200845	http://dx.doi.org/10.1038/sj.onc.1200845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053839				2022-12-25	WOS:A1997WE36400005
J	Nishida, HI; Nishida, T				Nishida, HI; Nishida, T			Phospholipid transfer protein mediates transfer of not only phosphatidylcholine but also cholesterol from phosphatidylcholine cholesterol vesicles to high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; EXCHANGE PROTEIN; ESTER; MECHANISM; ACYLTRANSFERASE; LIPOLYSIS; CONVERSION; TRANSPORT; LIPOSOMES; INVITRO	Phospholipid transfer protein (PLTP) purified from human plasma was found to enhance the transfer of cholesterol from single bilayer vesicles containing phosphatidylcholine and cholesterol to high density lipoprotein-3. The rate of cholesterol transfer was greatly influenced by the cholesterol content of the donor vesicles. The maximal rate was observed with the vesicles containing 20-25 mol % cholesterol. This was in contrast to a progressive decline in the rate of phosphatidylcholine transfer with an increase in the cholesterol content. To determine the binding of cholesterol and phosphatidylcholine to PLTP, the mixtures of PLTP and the vesicles containing H-3-labeled phosphatidylcholine and C-14-labeled cholesterol were incubated and subjected to sucrose density gradient centrifugation. Determination of the label profiles showed that cholesterol as well as phosphatidylcholine were transferred from the vesicles to PLTP. The reversible nature of the binding was shown by the transfer of labeled cholesterol and phosphatidylcholine bound to PLTP to the acceptor vesicles or low density lipoprotein. Isothermal equilibrium binding of PLTP for cholesterol and phosphatidylcholine showed that PLTP possessed a considerably higher affinity and binding capacity for phosphatidylcholine than for cholesterol. The phosphatidylcholine binding affinity and capacity were greater when PLTP was incubated with phosphatidylcholine vesicles without cholesterol. A possible importance of PLTP-mediated cholesterol transfer in the circulation was described.	UNIV ILLINOIS,BURNSIDES RES LAB,DEPT FOOD SCI & HUMAN NUTR,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F31HL117597, R37HL017597, R01HL017597] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BREWSTER ME, 1978, BIOCHIM BIOPHYS ACTA, V529, P147, DOI 10.1016/0005-2760(78)90113-3; CHAJEK T, 1978, J CLIN INVEST, V62, P1654; COGAN U, 1973, BIOCHEMISTRY-US, V12, P521, DOI 10.1021/bi00727a026; DAMEN J, 1981, BIOCHIM BIOPHYS ACTA, V665, P538, DOI 10.1016/0005-2760(81)90268-X; DEMEL R A, 1976, Biochimica et Biophysica Acta, V457, P109, DOI 10.1016/0304-4157(76)90008-3; EDELSTEIN C, 1979, J LIPID RES, V20, P143; EISENBERG S, 1979, J LIPID RES, V20, P614; FURUKAWA Y, 1979, J BIOL CHEM, V254, P7213; GAMBLE W, 1978, J LIPID RES, V19, P1068; IHM J, 1980, BIOCHEM BIOPH RES CO, V93, P1114, DOI 10.1016/0006-291X(80)90604-X; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JONAS A, 1979, BIOCHEMISTRY-US, V18, P1722, DOI 10.1021/bi00576a014; LANGE Y, 1983, J BIOL CHEM, V258, P6920; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MORTON RE, 1982, J LIPID RES, V23, P1058; MUESING RA, 1971, BIOCHEMISTRY-US, V10, P2952; NEWMAN GC, 1975, BIOCHEMISTRY-US, V14, P3863; NISHIDA HI, 1986, J BIOL CHEM, V261, P2028; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; PATSCH JR, 1978, P NATL ACAD SCI USA, V75, P4519, DOI 10.1073/pnas.75.9.4519; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; SIMARD G, 1989, BIOCHIM BIOPHYS ACTA, V1005, P245, DOI 10.1016/0005-2760(89)90044-1; SWEENY SA, 1985, BIOCHIM BIOPHYS ACTA, V835, P279, DOI 10.1016/0005-2760(85)90283-8; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; TALL AR, 1981, J BIOL CHEM, V256, P2035; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; YAMAZAKI S, 1983, J BIOL CHEM, V258, P5847; YEN FT, 1990, J LIPID RES, V31, P349	38	71	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6959	6964		10.1074/jbc.272.11.6959	http://dx.doi.org/10.1074/jbc.272.11.6959			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054384	hybrid			2022-12-25	WOS:A1997WN14700023
J	Baouz, S; Jacquet, E; Bernardi, A; Parmeggiani, A				Baouz, S; Jacquet, E; Bernardi, A; Parmeggiani, A			The N-terminal moiety of CDC25(Mm), a GDP/GTP exchange factor of Ras proteins, controls the activity of the catalytic domain - Modulation by calmodulin and calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SACCHAROMYCES-CEREVISIAE; PH DOMAIN; ACTIVATION; CLONING; CDNAS; GRB2; IDENTIFICATION; INACTIVATION; PRODUCT	This work describes the in vitro properties of full-length CDC25(Mm) (1262 amino acid residues), a GDP/GTP exchange factor (GEF) of H-ras p21. CDC25(Mm), isolated as a recombinant protein in Escherichia coli and purified by various chromatographic methods, could stimulate the H-ras p21 . GDP dissociation rate; however, its specific activity was 25 times lower than that of the isolated catalytic domain comprising the last C-terminal 285 residues (C-CDC25(Mm285)) and 5 times lower than the activity of the C-terminal half-molecule (631 residues). This reveals a negative regulation of the catalytic domain by other domains of the molecule, Accordingly, the GEF activity of CDC25(Mm) was increased severalfold by the Ca2+ dependent protease calpain that cleaves around a PEST-like region (residues 798-853), producing C terminal fragments of 43-56 kDa. In agreement with the presence of an IQ motif on CDC25(Mm) (residues 202-229), calmodulin interacted functionally with the exchange factor, Depending on the calmodulin concentration an inhibition up to 50% of the CDC25(Mm)-induced nucleotide exchange activity on H-ras p21 was observed, an effect requiring Ca2+ ions. Calmodulin also inhibited C-CDC25(Mm285) but With a similar to 100 times higher IC50 than in the case of CDC25(Mm) (similar to 10 mu M versus 0.1 mu M, respectively), Together, these results emphasize the role of the other domains of CDC25(Mm) in controlling the activity of the catalytic domain and support the involvement of calmodulin and calpain in the in vivo regulation of the CDC25(Mm) activity.	ECOLE POLYTECH, GRP BIOPHYS, EQUIPE 2, F-91128 PALAISEAU, FRANCE; CNRS, ENZYMOL LAB, F-91198 GIF SUR YVETTE, FRANCE; UNIV PARIS 07, INST JACQUES MONOD, F-75251 PARIS 05, FRANCE	Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite				JACQUET, Eric/0000-0001-6366-8436				Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cheney R. E., 1994, Molecular Biology of the Cell, V5, p21A; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Guerrero C, 1996, ONCOGENE, V12, P1097; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; ISHIDA A, 1994, J BIOCHEM-TOKYO, V115, P1075, DOI 10.1093/oxfordjournals.jbchem.a124460; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAPLON T, 1995, J BIOL CHEM, V270, P20742, DOI 10.1074/jbc.270.35.20742; KITANI T, 1995, J BIOCHEM-TOKYO, V117, P1070, DOI 10.1093/oxfordjournals.jbchem.a124808; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTEGANI E, 1993, EUR J HISTHCEM, V37, P73; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MOLINARI M, 1995, J BIOL CHEM, V270, P14576, DOI 10.1074/jbc.270.24.14576; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PARRINI MC, 1995, BIOCHEMISTRY-US, V34, P13776, DOI 10.1021/bi00042a008; REICHSTEINER M, 1990, CELL BIOL, V1, P433; REICHSTEINER M, 1996, TRENDS BIOCHEM SCI, V21, P267; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; ZIPPEL R, 1994, INT J ONCOL, V4, P175; Zippel R, 1996, ONCOGENE, V12, P2697	39	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6671	6676		10.1074/jbc.272.10.6671	http://dx.doi.org/10.1074/jbc.272.10.6671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045698	hybrid			2022-12-25	WOS:A1997WM64700082
J	Kumar, CK; Moyer, MP; Dudeja, PK; Said, HM				Kumar, CK; Moyer, MP; Dudeja, PK; Said, HM			A protein-tyrosine kinase-regulated, pH-dependent, carrier-mediated uptake system for folate in human normal colonic epithelial cell line NCM460	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; INTESTINAL RESECTION; CALCIUM-ABSORPTION; NA+/H+ EXCHANGER; TRANSPORT; RAT; PHOSPHORYLATION; 5-METHYLTETRAHYDROFOLATE; COTRANSPORT; MECHANISM	A significant proportion of the bacterially synthesized folate in the large intestine exists in the form of folate monoglutamate. Recent studies in our laboratory using human colonic apical membrane vesicles have shown the existence of an efficient carrier-mediated system for folate uptake, Nothing, however, is known about the cellular regulation of the colonic uptake process, In this study, we used a recently established human normal colonic epithelial cell line NCM460 to address this issue, Uptake of folic acid by NCM460 cells was: 1) linear with time for 4 min of incubation and occurred with minimal metabolic alterations, 2) temperature- and pH- (but not Na+) dependent, 3) saturable as a function of concentration (apparent K-m of 1.4 mu M), 4) inhibited by structural analogs and anion transport inhibitors, and 5) energy-dependent, These characteristics of folic acid uptake by NCM460 cells are similar to those seen with apical membrane vesicles derived from human native colonic tissue, Using these cells, we found that protein kinase C- and Ca2+/calmodulin-mediated pathways have no role in regulating folic acid uptake, On the other hand, cAMP (through a mechanism independent of protein kinase A) and protein-tyrosine kinase-mediated pathways were found to play a role in the regulation of folic acid uptake by these cells, These results establish the suitability of NCM460 cells as an in vitro model system for investigating the details of the mechanism of colonic folate uptake and its regulation, Folic acid uptake by these cells appears to involve a carrier-mediated system, which is temperature-, pH-, and energy dependent and appears to be under the regulation of cAMP and protein tyrosine kinase.	VET ADM MED CTR,LONG BEACH VA MED PROGRAM,LONG BEACH,CA 90822; UNIV CALIF IRVINE,SCH MED,IRVINE,CA 92717; UNIV TEXAS,HLTH SCI CTR,CTR HUMAN CELL BIOTECHNOL,SAN ANTONIO,TX 78284; UNIV ILLINOIS,CHICAGO,IL 60612; W SIDE VET ADM MED CTR,CHICAGO,IL 60612	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047203] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48497] Funding Source: Medline; NIDDK NIH HHS [DK47203] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGUIN P, 1994, J BIOL CHEM, V269, P24437; Blakley R.L., 1984, FOLATES PTERINS CHEM, V1; Blakley R.L., 1969, N HOLLAND RES MONOGR, P1; Blakley RL, 1985, FOLATES PTERINS CHEM, V2; BLAKLEY RL, 1986, FOLATES PTERINS NUTR, V3; BRANDSCH M, 1993, AM J PHYSIOL, V264, pG936; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; CRAVO ML, 1991, AM J CLIN NUTR, V53, P1450, DOI 10.1093/ajcn/53.6.1450; DEJONGE HR, 1990, TXB SECRETORY DIARRH, P191; DIXON KH, 1994, J BIOL CHEM, V269, P17; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; DONOWITZ M, 1987, PHYSL GASTROINTESTIN, P1351; ELSBORG L, 1981, FOLIC ACID FOLIC ACI; ELSHARYDAH A, 1994, GASTROENTEROLOGY, V106, pA230; FLIEGEL L, 1992, BIOCHEM J, V282, P139, DOI 10.1042/bj2820139; GINSTEAD WC, 1984, AM J PHYSIOL, V247, pG189; HAYES G, 1995, PFLUG ARCH EUR J PHY, V430, P819, DOI 10.1007/BF00386181; HYLANDER E, 1980, SCAND J GASTROENTERO, V15, P55, DOI 10.3109/00365528009181432; HYLANDER E, 1990, SCAND J GASTROENTERO, V25, P705, DOI 10.3109/00365529008997596; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; Mason Joel B., 1994, P1979; Moyer M. P., 1990, COLON CANCER CELLS, P85; MOYER MP, 1997, IN PRESS IN VITRO CE; MOYER MP, 1991, J TISSUE CULT METHOD, V13, P107; Muller U, 1996, BIOCHEM BIOPH RES CO, V218, P461, DOI 10.1006/bbrc.1996.0082; NGUYEN TT, 1997, IN PRESS GASTROENTER; PIPER RC, 1993, J BIOL CHEM, V268, P16557; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; RONG N, 1991, J NUTR, V121, P1955, DOI 10.1093/jn/121.12.1955; ROOD RP, 1988, J CLIN INVEST, V82, P1091, DOI 10.1172/JCI113665; SAHI J, 1995, GASTROENTEROLOGY, V108, pA321; SAID HM, 1985, AM J PHYSIOL, V249, pG567, DOI 10.1152/ajpgi.1985.249.5.G567; SAID HM, 1994, AM J PHYSIOL, V266, pG15, DOI 10.1152/ajpgi.1994.266.1.G15; Said HM, 1996, BBA-BIOMEMBRANES, V1281, P164, DOI 10.1016/0005-2736(96)00005-3; SAID HM, 1983, J PHARMACOL EXP THER, V226, P95; SAID HM, 1987, AM J PHYSIOL, V252, pG229, DOI 10.1152/ajpgi.1987.252.2.G229; SAID HM, 1987, BIOCHEM J, V247, P141, DOI 10.1042/bj2470141; SCHRON CM, 1985, J CLIN INVEST, V76, P2030, DOI 10.1172/JCI112205; STAUFFER JS, 1995, AM J SURG, V169, P190, DOI 10.1016/S0002-9610(99)80135-4; TORANIA SA, 1995, GASTROENTEROLOGY, V108, pA757, DOI 10.1016/0016-5085(95)27340-9; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WRONG OM, 1980, LARGE INTESTINE ITS, P113; ZIMMERMAN J, 1990, GASTROENTEROLOGY, V99, P964, DOI 10.1016/0016-5085(90)90614-7	45	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6226	6231		10.1074/jbc.272.10.6226	http://dx.doi.org/10.1074/jbc.272.10.6226			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045638	hybrid			2022-12-25	WOS:A1997WM64700022
J	LopezNieto, CE; You, GF; Bush, KT; Barros, EJG; Beier, DR; Nigam, SK				LopezNieto, CE; You, GF; Bush, KT; Barros, EJG; Beier, DR; Nigam, SK			Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SEQUENCES; SYSTEMS; ANION; IDENTIFICATION; SUBSTANCES; INTERACT; MEMBRANE	We have identified a gene product (NKT) encoding an apparently novel transcript that appears to be related to the organic ion transporter family and is expressed al most exclusively in the kidney, Analysis of the deduced 546-amino acid protein sequence indicates that NKT is a unique gene product which shares a similar transmembrane domain hydropathy profile as well as transporter-specific amino acid motifs with a variety of bacterial and mammalian nutrient transporters, Nevertheless, the overall homology of NKT to two recently cloned organic ion transport proteins (NLT and OCT-1) is significantly greater; together these three gene products may represent a new subgroup of transporters, The NKT was characterized further with respect to its tissue distribution and its expression during kidney development. A 2.5-kilobase transcript was found in kidney and at much lower levels in brain, but not in a number of other tissues, Studies on the embryonic kidney indicate that the NKT transcript is developmentally regulated with significant expression beginning at mouse gestational day 18 and rising just before birth, consistent with a role in differentiated kidney function, Moreover, in situ hybridization detected specific signals in mouse renal proximal tubules. NKT was mapped by linkage disequilibrium to mouse chromosome 19, the same site to which several mouse mutations localize, including that for osteochondrodystrophy (ocd). Although initial experiments in a Xenopus oocyte expression system failed to demonstrate transport of known substrates for OCT-1, the homology to OCT-1 and other transporters, along with the proximal tubule localization, raise the possibility that this gene may play a role in organic solute transport or drug elimination by the kidney.	BRIGHAM & WOMENS HOSP,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,DIV GENET,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Barros, Elvino José Guardão/M-8612-2014		NHGRI NIH HHS [R01 HG00951] Funding Source: Medline; NICHD NIH HHS [HD29028] Funding Source: Medline; NIDDK NIH HHS [DK44503] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029028] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044503] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANZLER WH, 1995, J PHARMACOL EXP THER, V272, P663; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HOHAGE H, 1994, J PHARMACOL EXP THER, V268, P897; HOHAGE H, 1994, J PHARMACOL EXP THER, V269, P659; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LopezNieto CE, 1996, NAT BIOTECHNOL, V14, P857, DOI 10.1038/nbt0796-857; MANLEY KF, 1991, MAMM GENOME, V4, P303; ROCHELLE JM, 1992, GENOMICS, V14, P26, DOI 10.1016/S0888-7543(05)80278-2; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SIMONSON GD, 1994, J CELL SCI, V107, P1065; ULLRICH KJ, 1992, PFLUG ARCH EUR J PHY, V421, P286, DOI 10.1007/BF00374841; ULLRICH KJ, 1993, PFLUG ARCH EUR J PHY, V425, P300, DOI 10.1007/BF00374180; ULLRICH KJ, 1993, CLIN INVESTIGATOR, V71, P843; ULLRICH KJ, 1993, PFLUG ARCH EUR J PHY, V425, P280, DOI 10.1007/BF00374179; WEDDEN SE, 1989, DEVELOPMENT, V105, P639; WOLFF NA, 1992, MOL CELL BIOCHEM, V114, P35; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0; YOU GF, 1995, J BIOL CHEM, V270, P29365, DOI 10.1074/jbc.270.49.29365; ZIMMERMAN WB, 1991, J BIOL CHEM, V266, P5459; [No title captured]	30	211	221	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6471	6478		10.1074/jbc.272.10.6471	http://dx.doi.org/10.1074/jbc.272.10.6471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045672	hybrid			2022-12-25	WOS:A1997WM64700056
J	Perego, C; Bulbarelli, A; Longhi, R; Caimi, M; Villa, A; Caplan, MJ; Pietrini, G				Perego, C; Bulbarelli, A; Longhi, R; Caimi, M; Villa, A; Caplan, MJ; Pietrini, G			Sorting of two polytopic proteins, the gamma-aminobutyric acid and betaine transporters, in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; GROWTH-FACTOR RECEPTOR; MDCK CELLS; ENDOPLASMIC-RETICULUM; HIPPOCAMPAL-NEURONS; CYTOPLASMIC DOMAIN; RAT-BRAIN; APICAL LOCALIZATION; GABA TRANSPORTER; SIGNALS	The gamma-aminobutyric acid transporter (GAT-1) isoform of the gamma-aminobutyric acid and the betaine (BGT) transporters exhibit distinct apical and basolateral distributions when introduced into Madin-Darby canine kidney cells (Pietrini, G., Suh, Y. J., Edelman, L., Rudnick, G., and Caplan, M. J. (1994) J. Biol. Chem. 269, 4668-4674), We have investigated the presence of sorting signals in their COOH-terminal cytosolic domains by expression in Madin-Darby canine kidney cells of mutated and chimeric transporters, Whereas truncated GAT-1 (Delta C-GAT) maintained the original functional activity and apical localization, either the removal (Delta C-myc BGT) or the substitution (BGS chimera) of the cytosolic tail of BGT generated proteins that accumulated in the endoplasmic reticulum, Moreover, we have found that the cytosolic tail of BGT redirected apical proteins, the polytopic GAT-1 (GBS chimera) and the monotopic human nerve growth factor receptor, to the basolateral surface, These results suggest the presence of basolateral sorting information in the cytosolic tail of BGT. We have further shown that information necessary for the exit of BGT from the endoplasmic reticulum and for the basolateral localization of the GBS chimera is contained in a short segment, rich in basic residues, within the cytosolic tail of BGT.	UNIV MILAN,CELLULAR & MOL PHARMACOL CTR,CNR,DEPT PHARMACOL,I-20129 MILAN,ITALY; CNR,INST HORMONE CHEM,I-20129 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY; CECCARELLI CTR,I-20132 MILAN,ITALY; YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Yale University			Perego, Carla/L-6147-2015; Villa, Antonello/B-4781-2012	Perego, Carla/0000-0003-3027-1779; Villa, Antonello/0000-0002-3820-8072; Caplan, Michael/0000-0001-5768-4405				Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; Amara S G, 1993, Curr Opin Neurobiol, V3, P337, DOI 10.1016/0959-4388(93)90126-J; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTI C, 1993, J RECEPTOR RES, V13, P453, DOI 10.3109/10799899309073672; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RADIAN R, 1990, J NEUROSCI, V10, P1319; RASOLA A, 1995, FEBS LETT, V373, P229, DOI 10.1016/0014-5793(95)01052-G; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197	44	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6584	6592		10.1074/jbc.272.10.6584	http://dx.doi.org/10.1074/jbc.272.10.6584			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045687	hybrid			2022-12-25	WOS:A1997WM64700071
J	Cuervo, AM; Dice, JF; Knecht, E				Cuervo, AM; Dice, JF; Knecht, E			A population of rat liver lysosomes responsible for the selective uptake and degradation of cytosolic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; POLYACRYLAMIDE GELS; PEPTIDE SEQUENCES; RIBONUCLEASE-A; CATHEPSIN-D; TRANSLOCATION; PROTEOLYSIS; IDENTIFICATION; HETEROGENEITY	Two populations of rat liver lysosomes can be distinguished on the basis of their density. A major difference between these populations is that one contains the heat shock cognate protein of 73 kDa (hsc73) within the lysosomal lumen. The lysosomal fraction containing hsc73 exhibits much higher efficiencies in the in vitro uptake and degradation of glyceraldehyde-3-phosphate dehydrogenase and ribonuclease A, two well established substrates of the selective lysosomal pathway of intracellular protein degradation. Preloading of the lysosomal population that is devoid of lumenal hsc73 with hsc73 isolated from cytosol activated the selective transport of substrate proteins into these lysosomes. Furthermore, treatment of animals with leupeptin, an inhibitor of lysosomal cathepsins, or 88 h of starvation also increased the amount of hsc73 within their lysosomal lumen, and these in vivo treatments also activated the selective transport of substrate proteins in vitro. Thus, the hsc73 located within lysosomes appears to be required for efficient uptake of cytosolic proteins by these organelles. The difference in hsc73 content between the lysosomal populations appears to be due to differences in their ability to take up hsc73 combined with differences in the intralysosomal degradation rates of hsc73. The increased stability of hsc73 in one population of lysosomes is primarily a consequence of this lysosomal population's more acidic pH.	INST INVEST CITOLOGICAL CAJA AHORROS VALENCIA, VALENCIA 46010, SPAIN		Cuervo, AM (corresponding author), TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA.		Knecht, Erwin/K-2432-2014; Knecht, Erwin/A-9366-2014	Knecht, Erwin/0000-0002-7208-3832; Cuervo, Ana Maria/0000-0002-0771-700X	NIA NIH HHS [AG06116] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006116, R01AG006116] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANIENTO F, 1993, J BIOL CHEM, V268, P10463; ARAKI N, 1995, EXP CELL RES, V217, P469, DOI 10.1006/excr.1995.1111; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DICE JF, 1986, J BIOL CHEM, V261, P6853; DICE JF, 1994, BIOL HEAT SHOCK PROT, P137; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; GROH V, 1981, CELL TISSUE RES, V214, P613, DOI 10.1007/BF00233500; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KELLY BM, 1989, MOL CELL BIOCHEM, V87, P171, DOI 10.1007/BF00219260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; OHSUMI Y, 1983, J BIOCHEM, V93, P547; OLSON TS, 1992, INVIVO PATHWAYS DEGR, P89; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SMITH R, 1974, EUR J BIOCHEM, V48, P245, DOI 10.1111/j.1432-1033.1974.tb03762.x; TACK BF, 1980, J BIOL CHEM, V255, P8842; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TERLECKY SR, 1994, EXPERIENTIA, V50, P1021, DOI 10.1007/BF01923456; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165	41	220	226	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5606	5615		10.1074/jbc.272.9.5606	http://dx.doi.org/10.1074/jbc.272.9.5606			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038169	hybrid			2022-12-25	WOS:A1997WK74700037
J	Roberts, T; Cowell, JK				Roberts, T; Cowell, JK			Cloning of the human Gfi-1 gene and its mapping to chromosome region 1p22	ONCOGENE			English	Article						human Gfi gene; cDNA sequence; chromosome 1p22	TRANSLOCATION; PROTEIN	Recently the rat and mouse Growth Factor Independence (Gfi-1) genes have been cloned (Gilks et al., 1993; Zoring ed al; 1996), This gene allows cells in culture to overcome the depletion of growth factors in the culture medium and maintain their proliferative potential, As part of a cloning strategy to isolated genes from human chromosome 1p22 which are associated with a constitutional chromosome translocation from a patient with stage 4S neuroblastoma, we have identified the human homologue of the Gfi gene and defined a 50 Kb map position within a well characterised YAC contig from the region, The full length cDNA sequence is 81% homologous with the rodent counterparts and, at the protein level, is even more highly conserved.	CLEVELAND CLIN FDN,DEPT NEUROSCI,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Roberts, Terry/A-8211-2014	Cowell, John/0000-0002-2079-5950				BICKMORE WA, 1992, METHOD ENZYMOL, V216, P224; BRODEUR GM, 1983, CANCER GENET CYTOGEN, V8, P93, DOI 10.1016/0165-4608(83)90041-9; CARBONE P, 1988, CANCER GENET CYTOGEN, V32, P143, DOI 10.1016/0165-4608(88)90321-4; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308; KOOLS PFJ, 1995, CANCER GENET CYTOGEN, V79, P1, DOI 10.1016/0165-4608(94)00137-Z; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MEAD RS, 1995, CANCER GENET CYTOGEN, V81, P151; Zornig M, 1996, ONCOGENE, V12, P1789	10	19	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					1003	1005		10.1038/sj.onc.1200910	http://dx.doi.org/10.1038/sj.onc.1200910			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9051000				2022-12-25	WOS:A1997WK34400014
J	Bagu, JR; Sykes, BD; Craig, MM; Holmes, CFB				Bagu, JR; Sykes, BD; Craig, MM; Holmes, CFB			A molecular basis for different interactions of marine toxins with protein phosphatase-1 - Molecular models for bound motuporin, microcystins, okadaic acid, and calyculin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-REGULATION; POTENT INHIBITOR; BINDING; LIVER; LR; CYANOBACTERIA; CONFORMATION; NODULARIN; COMPLEX; WATER	The hepatotoxic cyclic heptapeptide microcystins and cyclic pentapeptide nodularins are powerful liver tumor promoters and potent inhibitors of the catalytic sub units of protein phosphatase-1 and -2A (PP-1c and PP-2Ac), In marked contrast to microcystins, which interact covalently with PP-1 and PP-2A, the nodularins do not bind covalently to PP-1 and PP-2A and may additionally possess unique carcinogenic properties, The conformation of microcystin-LR has been determined in solution and bound to PP lc. We show here that the free NMR solution structures of two distinct microcystin structural congeners (microcystin-LR and -LL) are remarkably similar to the bound crystal structure of microcystin-LR, We have exploited this finding by using Metropolis Monte Carlo modeling to dock the solution structures of microcystin-LL and the marine toxin motuporin (nodularin-V) onto the crystal structure of PP-1c. Both of these toxins occupy a position similar to that of microcystin-LR when bound to PP-1c, However, al though there are relatively minor differences in the structural orientation of microcystin-LL compared with microcystin-LR, there is a striking difference in the position of the N-methyldehydrobutyrine residue in motuporin relative to the comparable N-methyldehydroalanine residue in microcystin-LR. We propose that this difference in orientation provides a molecular explanation for why nodularins are incapable of forming a covalent linkage with PP-1c. Furthermore, the predicted position of N-methyldehydrobutyrine in motuporin is at the surface of the PP-1c-toxin complex, which may thus facilitate chemical interaction with a further macromolecule(s) possibly relating to its carcinogenic properties, PP-1c and PP-2Ac are also targets for other marine toxins such as okadaic acid and calyculin A. It was therefore of interest to use Metropolis Monte Carlo modeling to dock the known free crystal structures of okadaic acid and calyculin A to the crystal structure of PP-1c, These experiments predict that both okadaic acid and calyculin A are strikingly similar to microcystins and motuporin in their tertiary structure and relative PP-1c binding position.	UNIV ALBERTA, MRC, CANADA GRP PROT STRUCT & FUNCT, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta								ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; ALTSCHUH D, 1992, SCIENCE, V256, P92, DOI 10.1126/science.1566062; CARMICHAEL WW, 1994, SCI AM, V270, P78, DOI 10.1038/scientificamerican0194-78; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRAIG M, 1993, TOXICON, V31, P1541, DOI 10.1016/0041-0101(93)90338-J; Craig M, 1996, BIOCHEM CELL BIOL, V74, P569, DOI 10.1139/o96-061; DESILVA ED, 1992, TETRAHEDRON LETT, V33, P1561, DOI 10.1016/S0040-4039(00)91674-5; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; ELTAYAR N, 1993, J MED CHEM, V36, P3757, DOI 10.1021/jm00076a002; ERIKSSON JE, 1990, BIOCHEM BIOPH RES CO, V173, P1347, DOI 10.1016/S0006-291X(05)80936-2; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; GAGU JR, 1995, NAT STRUCT BIOL, V2, P114; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HOLMES CFB, 1990, FEBS LETT, V221, P142; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; NI F, 1992, BIOCHEMISTRY-US, V31, P2545, DOI 10.1021/bi00124a015; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIWAKIMATSUSHIMA R, 1991, JPN J CANCER RES, V82, P993, DOI 10.1111/j.1349-7006.1991.tb01933.x; OHTA T, 1994, CANCER RES, V54, P6402; OHTA T, 1992, CARCINOGENESIS, V13, P2443, DOI 10.1093/carcin/13.12.2443; QUINN RJ, 1993, BIOORG MED CHEM LETT, V3, P1029, DOI 10.1016/S0960-894X(00)80281-4; RINEHART KL, 1988, J AM CHEM SOC, V110, P8557, DOI 10.1021/ja00233a049; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; RUDOLPHBOHNER S, 1994, FEBS LETT, V349, P319, DOI 10.1016/0014-5793(94)00680-6; RUNNEGAR M, 1995, BIOCHEM BIOPH RES CO, V216, P162, DOI 10.1006/bbrc.1995.2605; STOTTS RR, 1993, TOXICON, V31, P783, DOI 10.1016/0041-0101(93)90384-U; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; Trogen GB, 1996, BIOCHEMISTRY-US, V35, P3197, DOI 10.1021/bi952368s; WANG JJ, 1995, J AM CHEM SOC, V117, P8627, DOI 10.1021/ja00138a019; WENGER RM, 1994, FEBS LETT, V340, P255, DOI 10.1016/0014-5793(94)80149-5; YOSHIZAWA S, 1990, J CANCER RES CLIN, V116, P609, DOI 10.1007/BF01637082; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997	37	132	137	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5087	5097		10.1074/jbc.272.8.5087	http://dx.doi.org/10.1074/jbc.272.8.5087			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030574	hybrid			2022-12-25	WOS:A1997WJ85500062
J	Chauvin, MF; MegninChanet, F; Martin, G; Mispelter, J; Baverel, G				Chauvin, MF; MegninChanet, F; Martin, G; Mispelter, J; Baverel, G			The rabbit kidney tubule simultaneously degrades and synthesizes glutamate - A C-13 NMR STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRIC-ACID-CYCLE; NUCLEAR MAGNETIC-RESONANCE; RAT-BRAIN INVIVO; CORTICAL TUBULES; METABOLISM; GLUCOSE; FLUX; SPECTROSCOPY; PYRUVATE; HEART	The rabbit kidney does not readily metabolize but synthesizes glutamine at high rates by pathways that remain poorly defined, Therefore, the metabolism of variously labeled [C-13]- and [C-14]glutamates has been studied in isolated rabbit kidney tubules with and without acetate, CO2, glutamine, and alanine were the main carbon and nitrogenous end products of glutamate metabolism but no ammonia accumulated, Absolute fluxes through enzymes involved in glutamate metabolism, including enzymes of four different cycles operating simultaneously, were assessed by combining mainly the C-13 NMR data with a new model of glutamate metabolism, In contrast to a previous conclusion of Klahr et al, (Klahr, S., Schoolwerth, A. C., and Bourgoignie, J. J. (1972) Am, J. Physiol, 222, 813-820), glutamate metabolism was found to be initiated by glutamate dehydrogenase at high rates, Glutamate dehydrogenase also operated at high rates in the reverse direction; this, together with the operation of the glutamine synthetase reaction; masked the release of ammonia, Addition of acetate stimulated the operation of the ''glutamate --> alpha-ketoglutarate --> glutamate'' cycle and the accumulation of glucose but reduced both the net oxidative deamination of glutamate and glutamine synthesis, Acetate considerably increased flux through alpha-ketoglutarate dehydrogenase and citrate synthase at the expense of flux through phosphoenolpyruvate carboxykinase; acetate also caused a large decrease in flux through alanine aminotransferase, pyruvate dehydrogenase, and the ''substrate cycle'' involving oxaloacetate, phosphoenolpyruvate, and pyruvate.	HOP EDOUARD HERRIOT, CTR ETUD METAB SPECT RESONANCE MAGNET, INSERM CRI950201, F-69374 LYON 03, FRANCE; INSERM U350, UNITE BIOPHYS MOL, F-91405 ORSAY, FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Chanet, Frédérique Megnin/M-1983-2018					BAVEREL G, 1979, BIOCHEM J, V184, P599, DOI 10.1042/bj1840599; BAVEREL G, 1978, KIDNEY INT, V14, P567, DOI 10.1038/ki.1978.165; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; BURCH HB, 1978, BIOCHEM BIOPH RES CO, V82, P498, DOI 10.1016/0006-291X(78)90902-6; CANIONI P, 1983, BIOCHEMISTRY-US, V22, P4974, DOI 10.1021/bi00290a015; CERDAN S, 1990, J BIOL CHEM, V265, P12916; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; CHAUVIN MF, 1994, J BIOL CHEM, V269, P26025; COHEN SM, 1981, P NATL ACAD SCI-BIOL, V78, P60, DOI 10.1073/pnas.78.1.60; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; COHEN SM, 1981, J BIOL CHEM, V256, P3428; COHEN SM, 1979, P NATL ACAD SCI USA, V76, P4808, DOI 10.1073/pnas.76.10.4808; DUGELAY S, 1991, BIOCHIM BIOPHYS ACTA, V1075, P191, DOI 10.1016/0304-4165(91)90251-B; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; GOLDSTEIN L, 1966, AM J PHYSIOL, V210, P661, DOI 10.1152/ajplegacy.1966.210.3.661; GULLANS SR, 1984, J MEMBRANE BIOL, V78, P257, DOI 10.1007/BF01925973; HOWARTH OW, 1978, PROG NUCL MAG RES SP, V12, P1, DOI 10.1016/0079-6565(78)80001-6; JANS AWH, 1989, BIOCHEM J, V263, P231, DOI 10.1042/bj2630231; JUE T, 1989, P NATL ACAD SCI USA, V86, P4489, DOI 10.1073/pnas.86.12.4489; KALDERON B, 1987, FEBS LETT, V213, P209, DOI 10.1016/0014-5793(87)81493-X; KLAHR S, 1971, AM J PHYSIOL, V221, P69, DOI 10.1152/ajplegacy.1971.221.1.69; KLAHR S, 1972, AM J PHYSIOL, V222, P813, DOI 10.1152/ajplegacy.1972.222.4.813; Kleinzeller A, 1943, BIOCHEM J, V37, P674, DOI 10.1042/bj0370674; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; LAPIDOT A, 1994, J BIOL CHEM, V269, P27198; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LOWRY M, 1986, AM J PHYSIOL, V250, pF649, DOI 10.1152/ajprenal.1986.250.4.F649; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; Martin G, 1997, J BIOL CHEM, V272, P4717, DOI 10.1074/jbc.272.8.4717; MARTIN G, 1994, J BIOL CHEM, V269, P26034; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; MICHOUDET C, 1987, FEBS LETT, V216, P113, DOI 10.1016/0014-5793(87)80767-6; MICHOUDET C, 1987, BIOCHEM PHARMACOL, V36, P3987, DOI 10.1016/0006-2952(87)90468-0; RICHTERICH RW, 1958, AM J PHYSIOL, V195, P316, DOI 10.1152/ajplegacy.1958.195.2.316; ROTHMAN DL, 1992, P NATL ACAD SCI USA, V89, P9603, DOI 10.1073/pnas.89.20.9603; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; SHIMADA H, 1982, JPN J PHARMACOL, V32, P121, DOI 10.1254/jjp.32.121; SQUIRES EJ, 1978, ANAL BIOCHEM, V84, P473, DOI 10.1016/0003-2697(78)90065-9; VANDEWALLE A, 1981, AM J PHYSIOL, V240, pF492, DOI 10.1152/ajprenal.1981.240.6.F492; WATFORD M, 1980, BIOCHEM J, V188, P741, DOI 10.1042/bj1880741	44	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4705	4716		10.1074/jbc.272.8.4705	http://dx.doi.org/10.1074/jbc.272.8.4705			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030522	hybrid			2022-12-25	WOS:A1997WJ85500010
J	Gaudu, P; Moon, N; Weiss, B				Gaudu, P; Moon, N; Weiss, B			Regulation of the soxRS oxidative stress regulon - Reversible oxidation of the Fe-S centers of SoxR in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE RESPONSE REGULON; IRON-SULFUR CLUSTER; ESCHERICHIA-COLI; PROTEIN; EXPRESSION; PARAQUAT; ACTIVATION; GENES	SoxR protein, a transcriptional activator of the soxRS (superoxide response) regulon of Escherichia coli, contains autooxidizable [2Fe-2S] centers that are presumed to serve as redox sensors. In vitro transcription experiments previously demonstrated that only the oxidized form is active. Reduced SoxR was detected in overproducing strains by EPR spectroscopy of suspensions of intact cells. Oxidized Fe-S centers were determined by lysing the cells and treating them with the reducing agent sodium dithionite prior to EPR measurements. in uninduced cells, 90% of the SoxR was in the reduced form. Treatment with the redox cycling agents phenazine methosulfate or plumbagin was accompanied by reversible oxidation of the Fe-S centers. Mutant SoxR derivatives that were constitutively activated existed constitutively in an oxidized state. The results indicate the presence of a cellular pathway for countering the autooxidation of SoxR and confirm the hypothesis that induction of the regulon is mediated by a shift in the redox equilibrium of SoxR rather than by assembly of its Fe-S clusters.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			GAUDU, Philippe/AAE-9696-2022; GAUDU, Philippe/AFE-8376-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032785, R55GM032785] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32785] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; FU WG, 1992, J BIOL CHEM, V267, P16135; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HIDALGO E, 1996, REGULATION GENE EXPR, P434; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; JOHNSON MK, 1985, BIOCHEM BIOPH RES CO, V131, P653, DOI 10.1016/0006-291X(85)91287-2; KAO SM, 1985, J BIOL CHEM, V260, P478; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Miller J. H., 1992, LAB MANUAL HDB ESCHE; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; NUNOSHIBA T, 1994, NUCLEIC ACIDS RES, V22, P2958, DOI 10.1093/nar/22.15.2958; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; WEISS B, 1994, INT CONGR SER, V1058, P241; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991	31	120	128	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5082	5086		10.1074/jbc.272.8.5082	http://dx.doi.org/10.1074/jbc.272.8.5082			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030573	hybrid			2022-12-25	WOS:A1997WJ85500061
J	Honke, K; Tsuda, M; Hirahara, Y; Ishii, A; Makita, A; Wada, Y				Honke, K; Tsuda, M; Hirahara, Y; Ishii, A; Makita, A; Wada, Y			Molecular cloning and expression of cDNA encoding human 3'-phosphoadenylylsulfate:galactosylceramide 3'-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL-CARCINOMA; GLYCOLIPID SULFOTRANSFERASES; BINDING-SITE; PURIFICATION; HEPARIN	We have isolated a cDNA clone encoding human 3'-phosphoadenylylsulfate:galactosylceramide 3'-sulfotransferase (EC 2.8.2.11). Degenerate oligonucleotides, based on amino acid sequence data for the purified enzyme, were used as primers to amplify fragments of the gene from human renal cancer cell cDNA by the polymerase chain reaction method. The amplified cDNA fragment was then used as probe to screen a human renal cancer cell cDNA library. The isolated cDNA clone contained an open reading frame encoding 423 amino acids including all of the peptides that were sequenced. The deduced amino acid sequence predicts a type II transmembrane topology and contains two potential N-glycosylation sites. There is no significant homology between this sequence and either the sulfotransferases cloned to date or other known proteins. Northern blot analysis demonstrated that a 1.9-kilobase mRNA was unique to renal cancer cells. When the cDNA was inserted into the expression vector pSVK3 and transfected into COS-l cells, galactosylceramide sulfotransferase activity in the transfected cells increased from 8- to 16-fold over that of controls, and the enzyme product, sulfatide, was expressed on the transformed cells.	HOKKAIDO UNIV,SCH MED,INST CANC,BIOCHEM LAB,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO BUNKYO JR COLL,ENIWA 06114,JAPAN	Hokkaido University	Honke, K (corresponding author), OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,DEPT MOL MED,840 MURODO CHO,IZUMI,OSAKA 59002,JAPAN.							Balbaa M, 1996, BBA-LIPID LIPID MET, V1299, P141, DOI 10.1016/0005-2760(95)00193-X; CHIBA H, 1995, P NATL ACAD SCI USA, V92, P8176, DOI 10.1073/pnas.92.18.8176; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Her CT, 1996, GENOMICS, V33, P409, DOI 10.1006/geno.1996.0216; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; KAMIO K, 1995, GLYCOCONJUGATE J, V12, P762, DOI 10.1007/BF00731236; KAWANO M, 1989, ANAL BIOCHEM, V182, P9, DOI 10.1016/0003-2697(89)90709-4; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; KOBAYASHI T, 1994, EUR J BIOCHEM, V219, P407, DOI 10.1111/j.1432-1033.1994.tb19953.x; KOBAYASHI T, 1993, INT J CANCER, V55, P448, DOI 10.1002/ijc.2910550321; KOBAYASHI T, 1993, CANCER RES, V53, P5638; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAKITA A, 1985, NEW COMPREHENSIVE BI, V10, P1; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; MIYAO N, 1989, UROL RES, V17, P317; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; SAKAC D, 1992, J BIOL CHEM, V267, P1655; SAKAKIBARA N, 1989, CANCER RES, V49, P335; SUNDARAM KS, 1992, J BIOL CHEM, V267, P24041; TENNEKOON G, 1985, ARCH BIOCHEM BIOPHYS, V240, P932, DOI 10.1016/0003-9861(85)90102-X; Thudichum J.L.W., 1962, TREATISE CHEM CONSTI; VOS JP, 1994, BBA-LIPID LIPID MET, V1211, P125, DOI 10.1016/0005-2760(94)90262-3; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	27	100	106	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4864	4868		10.1074/jbc.272.8.4864	http://dx.doi.org/10.1074/jbc.272.8.4864			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030544	hybrid			2022-12-25	WOS:A1997WJ85500032
J	Stechschulte, DJ; Wu, JJ; Eyre, DR				Stechschulte, DJ; Wu, JJ; Eyre, DR			Fibronectin lacking the ED-B domain is a major structural component of tracheal cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; CROSS-LINKING; MESSENGER-RNAS; RHEUMATOID-ARTHRITIS; PLASMA FIBRONECTIN; FACTOR-XIIIA; II COLLAGEN; GENE; IDENTIFICATION; EXPRESSION	Fibronectin is a highly conserved dimeric glycoprotein found in high concentrations in plasma and widely distributed in low concentrations in the extracellular matrix of tissues. The protein is the product of a single gene, but multiple splicing variants are expressed that show tissue specificity. Three exons (IIIA, IIIB, and V) can be alternatively spliced to produce different fibronectin isoforms, We report here that fibronectin is a remarkably abundant component of the extracellular matrix of bovine tracheal cartilage, increasing with age to more than 20% of the tissue, dry weight, This matrix form of fibronectin is inextractable by 4 M guanidine HCl, indicating that it is a covalently cross-linked structural component, By protein sequence analysis, the main molecular form of fibronectin in bovine tracheal cartilage was shown to lack the ED-B domain encoded by exon IIIB.	UNIV WASHINGTON,DEPT ORTHOPED,ORTHOPED RES LABS,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR037318, R37AR036794, R01AR037318, R01AR036794] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36794, R01 AR036794, R37 AR037318, AR37318] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BOGAERT R, 1994, AM J HUM GENET, V55, P1128; BURTONWURSTER N, 1984, BIOCHIM BIOPHYS ACTA, V800, P52; CARSONS S, 1989, FIBRONECTIN, P327; CHEVALIER X, 1993, SEMIN ARTHRITIS RHEU, V22, P307, DOI 10.1016/S0049-0172(05)80010-1; EYRE D, 1987, METHOD ENZYMOL, V144, P115; EYRE DR, 1975, BIOCHEM J, V151, P595, DOI 10.1042/bj1510595; HEINEGARD DK, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P95; HIRANO H, 1983, P NATL ACAD SCI-BIOL, V80, P46, DOI 10.1073/pnas.80.1.46; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; Hynes R.O., 1990, FIBRONECTINS, P113, DOI DOI 10.1007/978-1-4612-3264-3_6; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON T, 1989, THESIS U LUND; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MILLER DR, 1984, CONNECT TISSUE RES, V12, P267, DOI 10.3109/03008208409013689; Mosher, 1989, FIBRONECTIN, P1; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1984, BIOCHEM J, V221, P623, DOI 10.1042/bj2210623; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SCOTT DL, 1981, ANN RHEUM DIS, V40, P142, DOI 10.1136/ard.40.2.142; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TAMKUN JW, 1984, P NATL ACAD SCI-BIOL, V81, P5140, DOI 10.1073/pnas.81.16.5140; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARTIO T, 1981, EUR J CLIN INVEST, V11, P207, DOI 10.1111/j.1365-2362.1981.tb01842.x; VIBEPEDERSEN K, 1984, EMBO J, V3, P2511, DOI 10.1002/j.1460-2075.1984.tb02165.x; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; ZHANG DW, 1995, J BIOL CHEM, V270, P1817, DOI 10.1074/jbc.270.4.1817	38	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4783	4786		10.1074/jbc.272.8.4783	http://dx.doi.org/10.1074/jbc.272.8.4783			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030533	hybrid			2022-12-25	WOS:A1997WJ85500021
J	Jiang, HP; Lin, JJ; Tao, J; Fisher, PB				Jiang, HP; Lin, JJ; Tao, J; Fisher, PB			Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta	ONCOGENE			English	Article						interferon-beta; melanoma differentiation associated gene-20 (mda-20); ribosomal protein L23a; cell growth inhibition; antisense transcripts	BOVINE SEMINAL RIBONUCLEASE; DOUBLE-STRANDED-RNA; C-MYC GENE; MESSENGER-RNAS; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; 2-5A-DEPENDENT RNASE; DIFFERENTIATION; CLEAVAGE; SITE	Interferons inhibit cell growth in normal and tumor-derived cells. The molecular basis of interferons antiproliferative activity remains to be defined. Using subtraction hybridization, a human melanoma differentiation associated gene, mda-20, has been identified that is down-regulated by treatment with interferon. Sequence analysis indicates that mda-20 is human ribosomal protein L23a (rp L23a). The mRNA levels of rp L23a and growth are diminished in a variety of human tumor cell lines following treatment with human fibroblast interferon, interferon-beta (IFN-beta). Expression of rp L23a is also reduced in human melanoma cells treated with human leukocyte (IFN-alpha) and immune (IFN-gamma) interferons, but not by growth inhibition resulting from serum starvation. These findings suggest that growth suppression alone is not sufficient to reduce rp L23a expression. Instead, reduced rp L23a mRNA results from biochemical changes mediated by interferons. Ectopic expression of an antisense rp L23a sequence in human HeLa cervical carcinoma cells results in a reduction in colony formation indicating a direct antiproliferative effect by inhibiting rp L23a expression. The mechanism underlying inhibition in rp L23a expression in IFN-beta-treated cells may involve antisense rp L23a RNA. These results suggest that rp L23a may be one of the target molecules involved in mediating growth inhibition by interferon.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN MED CTR,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN MED CTR,DEPT UROL,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital					NCI NIH HHS [CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BIRNBAUM M, 1990, DIFFERENTIATION, V45, P138, DOI 10.1111/j.1432-0436.1990.tb00467.x; CAFFARELLI E, 1984, EMBO J, V6, P3493; CELANO P, 1992, J BIOL CHEM, V267, P15092; CHAN YL, 1995, BBA-GENE STRUCT EXPR, V1260, P113, DOI 10.1016/0167-4781(94)00193-7; CHATTERJEE D, 1992, CANCER CHEMOTH PHARM, V30, P12, DOI 10.1007/BF00686479; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELBARADI TTAL, 1985, EMBO J, V4, P2101, DOI 10.1002/j.1460-2075.1985.tb03898.x; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARBE C, 1993, J INVEST DERMATOL, V100, pS239; *GEN COMP GROUP, 1991, PROGR MAN; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GREINER JW, 1985, PHARMACOL THERAPEUT, V31, P209, DOI 10.1016/0163-7258(85)90023-3; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; JACOBS FA, 1985, EUR J BIOCHEM, V150, P255, DOI 10.1111/j.1432-1033.1985.tb09015.x; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LEGHA SS, 1989, SEMIN ONCOL, V16, P34; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; OVERMAN PF, 1993, SOMAT CELL MOLEC GEN, V19, P347, DOI 10.1007/BF01232747; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; ROMEO G, 1989, TRENDS GENET, V5, P19, DOI 10.1016/0168-9525(89)90007-3; SCHEIN CH, 1995, BIOCHEM J, V307, P123, DOI 10.1042/bj3070123; SCHEIN CH, 1990, FEBS LETT, V270, P229, DOI 10.1016/0014-5793(90)81275-S; SEKAR V, 1983, BIOCHEM BIOPH RES CO, V114, P950, DOI 10.1016/0006-291X(83)90652-6; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SILVERMAN RH, 1994, J INTERFERON RES, V14, P101, DOI 10.1089/jir.1994.14.101; SREEVALSAN T, 1980, J CELL PHYSIOL, V104, P1, DOI 10.1002/jcp.1041040102; SUZUKI K, 1993, J BIOL CHEM, V268, P2755; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; VESTER B, 1984, J MOL BIOL, V179, P431, DOI 10.1016/0022-2836(84)90074-3; WAGNER M, 1985, MOL CELL BIOL, V5, P3560, DOI 10.1128/MCB.5.12.3560; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZOON KC, 1986, P NATL ACAD SCI USA, V83, P8226, DOI 10.1073/pnas.83.21.8226	55	31	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					473	480		10.1038/sj.onc.1200858	http://dx.doi.org/10.1038/sj.onc.1200858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053844				2022-12-25	WOS:A1997WE36400010
J	Millard, SS; Yan, JS; Nguyen, HA; Pagano, M; Kiyokawa, H; Koff, A				Millard, SS; Yan, JS; Nguyen, HA; Pagano, M; Kiyokawa, H; Koff, A			Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; DIFFERENTIATION; G1; EXPRESSION; UBIQUITIN; P21; TRANSLATION; PATHWAY; BETA	p27(Kip1) regulates the decision to enter into S-phase or withdraw from the cell cycle by establishing an inhibitory threshold above which G(1) cyclin-dependent kinases accumulate before activation. We have used the HL-60 cell line to study regulation of p27 as cells withdraw from the cell cycle following treatment with 12-O-tetra-decanoylphorbol-13-acetate (TPA). We found that the amount of p27 is maximal in G(0) cells, lower in G(1) cells, and undetectable in S-phase cells, In contrast to the protein, the amount of p27 mRNA was the same in these populations, suggesting tliat accumulation of p27 during the cell cycle and as cells withdraw hom the cell cycle is controlled by post-transcriptional mechanisms, In S-phase cells, the degradation of p27 appears to predominate as a regulatory mechanism, In G(0) cells, there was an increase in the synthesis rate of p27, Our data demonstrate that, in G(0) cells, accumulation of p27 is due to an increase in the amount of p27 mRNA in polyribosomes.	MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; New York University			Millard, Sean/A-8522-2013	Millard, Sean/0000-0001-8573-4625; Koff, Andrew/0000-0003-3271-3067; pagano, michele/0000-0003-3210-2442; Kiyokawa, Hiroaki/0000-0002-7942-6455				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKHOVICH K, 1989, CELL, V58, P1097; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLLINS SJ, 1987, BLOOD, V70, P1233; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knapp D, 1996, MOL CELL BIOL, V16, P5701; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koff A, 1995, Prog Cell Cycle Res, V1, P141; KOFF A, 1995, FRONTIERS ENDOCRINOL, V14, P207; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACDONALD PM, 1992, SEMIN DEV BIOL, V3, P413; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8	42	168	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7093	7098		10.1074/jbc.272.11.7093	http://dx.doi.org/10.1074/jbc.272.11.7093			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054402	hybrid			2022-12-25	WOS:A1997WN14700041
J	Gerber, NC; RodriguezCrespo, I; Nishida, CR; deMontellano, PRO				Gerber, NC; RodriguezCrespo, I; Nishida, CR; deMontellano, PRO			Active site topologies and cofactor-mediated conformational changes of nitric-oxide synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU REARRANGEMENT; IRON COMPLEXES; CALMODULIN; TETRAHYDROBIOPTERIN; SPECIFICITY; EXPRESSION; ENZYME	The active site topologies of neuronal (nNOS), endothelial (eNOS), and inducible (iNOS) nitric-oxide synthases heterologously expressed in Escherichia coli have been examined using three aryldiazene (Ar-N=NH) probes, The topological information derives from (a) the rate and extent of aryl iron complex formation in the presence and absence of tetrahydrobiopterin (H4B), Ca2+ dependent calmodulin (CaM), and L-arginine, and (b) the N-phenylprotoporphyrin M regioisomer ratios obtained upon migration of the phenyl of the phenyl-iron complex to the heme nitrogen atoms, The N-phenylprotoporphyrin ratios indicate that the three NOS isoforms have related active site topologies with unencumbered space above all four pyrrole rings but particularly above pyrrole ring D. H4B binds directly above the heme pyrrole ring D or causes a conformational change that constricts that region, because H4B markedly decreases phenyl migration to pyrrole ring D. Small CaM-dependent changes in the nNOS N-phenylporphyrin isomer pattern are consistent with a conformational link between the CaM and heme sites in this protein, The ceiling height directly above the heme iron atom differs among the isoforms and is lower than in the P450 enzymes because only nNOS and iNOS react with 2-naphthyldiazene, and none of the isoforms reacts with p-biphenyldiazene. L-Arg blocks access to the heme iron atom in all three NOS isoforms and nearly suppresses the phenyldiazene reaction, The data indicate that topological differences, including differences in the size of the active site, are superimposed on the structural similarities among the NOS active sites.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Rodriguez-Crespo, J. Ignacio/M-1966-2018	Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X	NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DEMONTELLANO PRO, 1995, BIOCHIMIE, V77, P581, DOI 10.1016/0300-9084(96)88174-0; Fossetta JD, 1996, FEBS LETT, V379, P135, DOI 10.1016/0014-5793(95)01496-9; FRUETEL JA, 1994, J BIOL CHEM, V269, P28815; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HUANG PKC, 1968, J AM CHEM SOC, V90, P2354, DOI 10.1021/ja01011a027; KLATT P, 1994, J BIOL CHEM, V269, P13861; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LIU JW, 1994, J BIOL CHEM, V269, P11691; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; TUCK SF, 1992, BIOCHEMISTRY-US, V31, P6911, DOI 10.1021/bi00145a007; TUCK SF, 1993, J BIOL CHEM, V268, P269; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763	33	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6285	6290		10.1074/jbc.272.10.6285	http://dx.doi.org/10.1074/jbc.272.10.6285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045646	hybrid			2022-12-25	WOS:A1997WM64700030
J	Karnam, P; Standaert, ML; Galloway, L; Farese, RV				Karnam, P; Standaert, ML; Galloway, L; Farese, RV			Activation and translocation of Rho (and ADP ribosylation factor) by insulin in rat adipocytes - Apparent involvement of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; STIMULATED PHOSPHATIDYLCHOLINE HYDROLYSIS; NEUTROPHIL PHOSPHOLIPASE-D; KINASE-C; PERTUSSIS TOXIN; BC3H-1 MYOCYTES; HL-60 CELLS; 4,5-BISPHOSPHATE; 3,4,5-TRISPHOSPHATE; DIACYLGLYCEROL	Insulin reportedly (Standaert, M. L., Avignon, A., Yamada, K., Bandyopadhyay, G., and Farese, R. V. (1996) Biochem. J. 313, 1039-1046) activates phospholipase D (PLD) dependent hydrolysis of phosphatidylcholine (PC) in plasma membranes of rat adipocytes by a mechanism that may involve wortmannin-sensitive phosphatidylinositol (PI) 3 kinase. Because Rho and ADP ribosylation factor (ARF) activate PC-PLD, we questioned whether these small G-proteins are regulated by insulin and PI 3-kinase. We found that insulin provoked a rapid translocation of both Rho and ARF to the plasma membrane and increased GTP loading of Rho. Wortmannin and LY294002 inhibited Rho translocation in intact adipocytes, and the polyphosphoinositide, PI 4,5-(PO4)(2), stimulated Rho translocation in adipocyte homogenates. On the other hand, wortmannin did not block GTP loading of Rho. Guanosine 5'-3-O-(thio)triphosphate stimulated both Rho and ARF translocation and activated PC-PLD in homogenates. C3 transferase, which inhibits and depletes Rho, inhibited PC-PLD activation by insulin in intact adipocytes. C3 transferase also inhibited insulin stimulation of [H-3]2-deoxyglucose uptake. Our findings suggest that: (a) insulin translocates Rho by a PI 3-kinase dependent mechanism, but another factor is responsible for GTP loading of Rho; (b) both Rho and ARF may contribute to PC PLD activation during insulin action; and (c) Rho may be required for insulin stimulation of glucose transport.	JAMES A HALEY VET HOSP,RES SERV VAR151,TAMPA,FL 33612; UNIV S FLORIDA,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM MOL BIOL,TAMPA,FL 33612	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida			Farese, Robert/B-3605-2015					AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BALDINI PM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P208, DOI 10.1016/0167-4889(92)90203-N; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOPER DR, 1992, BIOCHEM BIOPH RES CO, V188, P142, DOI 10.1016/0006-291X(92)92361-Z; DONCHENKO V, 1994, BBA-MOL CELL RES, V1222, P492, DOI 10.1016/0167-4889(94)90059-0; FARESE RV, 1982, J BIOL CHEM, V257, P4042; FARESE RV, 1985, BIOCHEM J, V231, P269, DOI 10.1042/bj2310269; HOFFMAN JM, 1991, BIOCHEMISTRY-US, V30, P3315, DOI 10.1021/bi00227a021; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; STANDAERT ML, 1994, CELL SIGNAL, V6, P707, DOI 10.1016/0898-6568(94)90052-3; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TERUI T, 1994, J BIOL CHEM, V269, P28130; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	37	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6136	6140		10.1074/jbc.272.10.6136	http://dx.doi.org/10.1074/jbc.272.10.6136			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045624	hybrid			2022-12-25	WOS:A1997WM64700008
J	Nagelhus, TA; Haug, T; Singh, KK; Keshav, KF; Skorpen, F; Otterlei, M; Bharati, S; Lindmo, T; Benichou, S; Benarous, R; Krokan, HE				Nagelhus, TA; Haug, T; Singh, KK; Keshav, KF; Skorpen, F; Otterlei, M; Bharati, S; Lindmo, T; Benichou, S; Benarous, R; Krokan, HE			A sequence in the N-terminal region of human uracil-DNA glycosylase with homology to XPA interacts with the c-terminal part of the 34-kDa subunit of replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; EXCISION-REPAIR; BINDING-PROTEIN; 2-HYBRID SYSTEM; HELA-CELLS; GENE; PHOSPHORYLATION; PURIFICATION	Uracil-DNA glycosylase releases free uracil from DNA and initiates base excision repair for removal of this potentially mutagenic DNA lesion, Using the yeast two-hybrid system, human uracil-DNA glycosylase encoded by the UNG gene (UNG) was found to interact with the C-terminal part of the 34-kDa subunit of replication protein A (RPA2). No interaction with RPA4 (a homolog of RPA2), RPA1, or RPA3 was observed, A sandwich enzyme-linked immunosorbent assay with trimeric RPA and the two-hybrid system both demonstrated that the interaction depends on a region in UNG localized between amino acids 28 and 79 in the open reading frame. In this part of UNG a 23-amino acid sequence has a significant homology to the RPA2-binding region of XPA, a protein involved in damage recognition in nucleotide excision repair, Trimeric RPA did not enhance the activity of UNG in vitro on single- or double-stranded DNA, A part of the N-terminal region of UNG corresponding in size to the complete presequence was efficiently removed by proteinase K, leaving the proteinase K-resistant compact catalytic domain intact and fully active. These results indicate that the N-terminal part constitutes a separate structural domain required for RPA binding and suggest a possible function for RPA in base excision repair.	NORWEGIAN UNIV SCI & TECHNOL, FAC MED, UNIGEN, CTR MOL BIOL, N-7005 TRONDHEIM, NORWAY; JOHNS HOPKINS UNIV, CTR ONCOL, RADIOBIOL LAB, BALTIMORE, MD 21287 USA; NORWEGIAN UNIV SCI & TECHNOL, DEPT PHYS, N-7005 TRONDHEIM, NORWAY; INSERM U332, F-75014 PARIS, FRANCE; DREXEL UNIV, DEPT BIOSCI & BIOTECHNOL, PHILADELPHIA, PA 19104 USA	Norwegian University of Science & Technology (NTNU); Johns Hopkins University; Johns Hopkins Medicine; Norwegian University of Science & Technology (NTNU); Institut National de la Sante et de la Recherche Medicale (Inserm); Drexel University				Benichou, Serge/0000-0003-3602-3530; Skorpen, Frank/0000-0001-7093-8000; Otterlei, Marit/0000-0002-5232-1186				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P147; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HARPER JW, 1993, CELL, V75, P805; Haug T, 1996, GENOMICS, V36, P408, DOI 10.1006/geno.1996.0485; HAUG T, 1994, FEBS LETT, V353, P180, DOI 10.1016/0014-5793(94)01042-0; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; KESHAV KF, 1995, MOL CELL BIOL, V15, P3119; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KROKAN H, 1981, FEBS LETT, V133, P89, DOI 10.1016/0014-5793(81)80477-2; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LI L, 1995, MOL CELL BIOL, V15, P5396; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MILLNS AK, 1994, VIROLOGY, V198, P504, DOI 10.1006/viro.1994.1061; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; MYRNES B, 1988, EUR J BIOCHEM, V173, P383, DOI 10.1111/j.1432-1033.1988.tb14010.x; NAGELHUS TA, 1995, EXP CELL RES, V220, P292, DOI 10.1006/excr.1995.1318; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEAL G, 1987, BIOCHIM BIOPHYS ACTA, V925, P226, DOI 10.1016/0304-4165(87)90113-9; SINGH KK, 1995, P NATL ACAD SCI USA, V92, P4907, DOI 10.1073/pnas.92.11.4907; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; TALPAERTBORLE M, 1982, J BIOL CHEM, V257, P1208	44	127	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6561	6566		10.1074/jbc.272.10.6561	http://dx.doi.org/10.1074/jbc.272.10.6561			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045683	hybrid			2022-12-25	WOS:A1997WM64700067
J	Rao, E; Dang, W; Tian, G; Sen, RJ				Rao, E; Dang, W; Tian, G; Sen, RJ			A three-protein-DNA complex on a B cell-specific domain of the immunoglobulin mu heavy chain gene enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSGENIC MICE; TRANSCRIPTION FACTOR; V(D)J RECOMBINATION; B/HLH/Z DOMAIN; BINDING SITES; ETS-DOMAIN; EXPRESSION; MOTIF; REPRESSION	The lymphoid-specific immunoglobulin mu heavy chain gene intron enhancer (mu E) contains multiple binding sites for trans acting nuclear factors, We have used a combination of in vitro and in vivo assays to reconstruct protein-DNA interactions on a minimal B cell-specific mu enhancer that contains three motifs, mu A, mu B, and mu E3. Using ETS-domain proteins that transactivate the minimal enhancer in non-lymphoid cells, we show that (i) PU.1 binds coordinately to both mu A and mu B sites in vitro and (ii) in the presence of Ets-1, this factor binds to the mu A site and PU.1 to the mu B site, Two factors, TFE3 and USF, bind to the mu E3 element, When the ETS proteins are present together with mu E3 binding proteins, a three-protein-DNA complex is generated. Furthermore, we provide evidence for protein-protein interactions between Ets-1 and PU.1 proteins that bind to mu A and mu B sites, and between Ets-1 and TFE3 bound to the mu A and mu E3 sites, We propose that this domain of the mu enhancer is assembled into a nucleoprotein complex that contains two tissue-restricted ETS domain proteins that recognize DNA from the same side of the helix and one ubiquitously expressed bHLH-leucine zipper protein that binds between them, recognizing its site from a different side of the helix.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038925, R29GM038925] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38925] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GYURIS J, 1993, CELL, V74, P205; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; JAMIESON C, 1990, DNA PROT ENG TECH, V2, P80; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LIBERMANN TA, 1990, MOL ASPECTS CELL REG, V6, P399; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; NELSEN B, 1992, INT REV CYTOL, V133, P121, DOI 10.1016/S0074-7696(08)61859-8; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OLTZ EM, 1993, MOL CELL BIOL, V13, P6223, DOI 10.1128/MCB.13.10.6223; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; ROSE MD, 1990, GENETICS, P155; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SEIBENLIST U, 1980, P NATL ACAD SCI USA, V77, P122; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SHEN LY, 1993, MOL CELL BIOL, V13, P3530, DOI 10.1128/MCB.13.6.3530; SMITH CL, 1988, GENOME ANAL PRACTICA, P31; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	50	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6722	6732		10.1074/jbc.272.10.6722	http://dx.doi.org/10.1074/jbc.272.10.6722			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045705	hybrid			2022-12-25	WOS:A1997WM64700089
J	Walker, DC; Christodoulou, J; Craig, HJ; Simard, LR; Ploder, L; Howell, PL; McInnes, RR				Walker, DC; Christodoulou, J; Craig, HJ; Simard, LR; Ploder, L; Howell, PL; McInnes, RR			Intragenic complementation at the human argininosuccinate lyase focus - Identification of the major complementing alleles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-CRYSTALLIN; SEQUENCE-ANALYSIS; PLASMID DNA; HUMAN-LIVER; GENE; EXPRESSION; PURIFICATION; FUMARASE; SITE; CDNA	To determine the molecular and biochemical basis of intragenic complementation observed at the human argininosuccinate lyase (ASL) locus, we identified the ASL alleles in ASL-deficient cell strains with two unique complementation phenotypes: (i) frequent complementers, strains that participated in the majority of complementation events, and (ii) high activity complementers, strains in which complementation was associated with a relatively high level of restoration of ASL activity, Four mutations (Q286R, D87G, A398D, and a deletion of exon 13) were identified in the four strains examined, One of the two frequent complementers was homozygous, and the other heterozygous, for the Q286R allele, Similarly, one of the two high activity complementers was homozygous, and the other heterozygous, for the D87G allele, When the Q286R and D87G mutations were introduced by site-directed mutagenesis into wild type ASL cDNA, each conferred loss of ASL activity in COS cell transfection assays, To test directly the hypothesis that intragenic complementation occurs at the ASL locus, one of the major complementation events observed previously, between strains carrying the Q286R and D87G alleles, was reconstructed in COS cell transfection assays, A partial restoration of ASL activity, comparable with the increase seen in the fibroblast complementation analysis, was observed on joint cotransfection of these two alleles, The results provide molecular confirmation of the major features of the ASL mutant complementation map, identify the Q286R and D87D alleles as the frequent and high activity complementing alleles, respectively, and provide direct proof of intragenic complementation at the ASL locus.	HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,PROGRAM DEV BIOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DIV BIOCHEM RES,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,FAC MED,DEPT MED & MOL GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,FAC MED,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Christodoulou, John/E-5866-2015; Christodoulou, John/M-3628-2019	Christodoulou, John/0000-0002-8431-0641; Simard, Louise/0000-0003-0391-8821				ABRAMSON RD, 1991, GENOMICS, V10, P126, DOI 10.1016/0888-7543(91)90492-W; BARBOSA P, 1991, J BIOL CHEM, V266, P22319; BARBOSA P, 1991, J BIOL CHEM, V266, P5286; BASCOM RA, 1995, HUM MOL GENET, V4, P1895, DOI 10.1093/hmg/4.10.1895; BRUSILOW SW, 1995, METABOLIC BASIS INHE, V1, P1187; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRICK FHC, 1964, J MOL BIOL, V8, P161, DOI 10.1016/S0022-2836(64)80156-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fincham J.R.S., 1966, GENETIC COMPLEMENTAT; GLYNIAS MJ, 1992, GENEWORKS VERSION 2; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; KONDOH H, 1991, GENE, V99, P267, DOI 10.1016/0378-1119(91)90137-Z; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; LEE HJ, 1992, BIOCHEM J, V283, P597, DOI 10.1042/bj2830597; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTY CJ, 1972, J BIOL CHEM, V247, P7010; MATSUBASA T, 1989, P NATL ACAD SCI USA, V86, P592, DOI 10.1073/pnas.86.2.592; MCINNES RR, 1984, P NATL ACAD SCI-BIOL, V81, P4480, DOI 10.1073/pnas.81.14.4480; OBRIEN WE, 1981, BIOCHEMISTRY-US, V20, P2056, DOI 10.1021/bi00510a049; OBRIEN WE, 1986, P NATL ACAD SCI USA, V83, P7211, DOI 10.1073/pnas.83.19.7211; PALEKAR AG, 1981, J BIOL CHEM, V256, P9192; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Sambrook J., 2002, MOL CLONING LAB MANU; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHYAM E, 1986, GENE ANAL TECH, V3, P41, DOI 10.1016/0735-0651(86)90004-X; SIMARD L, 1986, AM J HUM GENET, V39, P38; SIMPSON A, 1994, NAT STRUCT BIOL, V1, P724, DOI 10.1038/nsb1094-724; STONE RL, 1993, J BIOL CHEM, V268, P19710; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TODD S, 1989, GENOMICS, V4, P53, DOI 10.1016/0888-7543(89)90314-5; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER DC, 1990, P NATL ACAD SCI USA, V87, P9625, DOI 10.1073/pnas.87.24.9625; WEAVER TM, 1995, NAT STRUCT BIOL, V2, P654, DOI 10.1038/nsb0895-654; WILLIAMS SE, 1992, BIOCHEMISTRY-US, V31, P9768, DOI 10.1021/bi00155a033; WOODS SA, 1988, FEMS MICROBIOL LETT, V51, P181, DOI 10.1111/j.1574-6968.1988.tb02994.x; ZABIN I, 1975, ANNU REV BIOCHEM, V44, P295, DOI 10.1146/annurev.bi.44.070175.001455	37	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6777	6783		10.1074/jbc.272.10.6777	http://dx.doi.org/10.1074/jbc.272.10.6777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045711	hybrid			2022-12-25	WOS:A1997WM64700095
J	Harhaj, EW; Sun, SC				Harhaj, EW; Sun, SC			The serine/threonine phosphatase inhibitor calyculin A induces rapid degradation of I kappa B beta - Requirement of both the N- and C-terminal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; UBIQUITIN-PROTEASOME PATHWAY; TRANS-ACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; ALPHA PROTEOLYSIS; T-CELLS; SIGNAL; NUCLEAR; GENE; EXPRESSION	Signal-initiated activation of the transcription factor NF-kappa B is mediated through proteolysis of its cytoplasmic inhibitory proteins I kappa B alpha and I kappa B beta. While most NF-kappa B inducers trigger the degradation of I kappa B alpha, only certain stimuli are able to induce the degradation of I kappa B beta. The degradation of I kappa B alpha is targeted by its site-specific phosphorylations, although the mechanism underlying the degradation of I kappa B beta remains elusive. In the present study, we have analyzed the effect of phosphatase inhibitors on the proteolysis of I kappa B beta. We show that the serine/threonine phosphatase inhibitor calyculin A induces the hyperphosphorylation and subsequent degradation of I kappa B beta in both human Jurkat T cells and the murine 70Z-3 preB cells, which is associated with the nuclear expression of active NF-kappa B. The calyculin A-mediated degradation of I kappa B beta is further enhanced by the cytokine tumor necrosis factor-alpha (TNF-alpha), although TNF-alpha alone is unable to induce the degradation of I kappa B beta. Mutational analyses have revealed that the inducible degradation of I kappa B beta induced by calyculin A, and TNF-alpha requires two N-terminal serines (serines 19 and 23) that are homologous to the inducible phosphorylation sites present in I kappa B alpha. Furthermore, the C-terminal 51 amino acid residues, which are rich in serines and aspartic acids, are also required for the inducible degradation of I kappa B beta. These results suggest that the degradation signal of I kappa B beta may be controlled by the opposing actions of protein kinases and phosphatases and that both the N- and C-terminal sequences of I kappa B beta are required for the inducible degradation of this NF-kappa B inhibitor.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [1 R01 CA68471-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD D W, 1989, New Biologist, V1, P83; BAUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Harhaj EW, 1996, ONCOGENE, V12, P2385; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	45	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5409	5412		10.1074/jbc.272.9.5409	http://dx.doi.org/10.1074/jbc.272.9.5409			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038140	hybrid			2022-12-25	WOS:A1997WK74700008
J	Norbeck, J; Blomberg, A				Norbeck, J; Blomberg, A			Metabolic and regulatory changes associated with growth of Saccharomyces cerevisiae in 1.4 m NaCl - Evidence for osmotic induction of glycerol dissimilation via the dihydroxyacetone pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ENOLASE GENE ENO1; 3-PHOSPHATE DEHYDROGENASE; GEL-ELECTROPHORESIS; SCHIZOSACCHAROMYCES-POMBE; STRESS-RESPONSE; KINASE-A; YEAST; PURIFICATION; TRANSCRIPTION	The salt-instigated protein expression of Saccharomyces cerevisiae during growth in either 0.7 or 1.4 M NaCl was studied by two-dimensional polyacrylamide gel electrophoresis. The 73 protein spots that were identified as more than 3-fold responsive in 1.4 M NaCl were further grouped by response class (halometric, low-salt, and high-salt regulation). Roughly 40% of these responsive proteins were found to decrease in expression, while at higher magnitudes of change (>8-fold) only induction was recorded. Enolase 1 (Eno1p) was the most increasing protein by absolute numbers per cell, but not by -fold change, and the enzymes involved in glycerol synthesis, Gpd1p and Gpp2p, were also induced to a similar degree as Eno1p. We furthermore present evidence for salt induction of glycerol dissimilation via dihydroxyacetone and also identify genes putatively encoding the two enzymes involved; dihydroxyacetone kinase (DAK1 and DAK2) and glycerol dehydrogenase (YPR1 and GCY1). The GPD1, GPP2, GCY1, DAK1, and ENO1 genes all displayed a halometric increase in the amount of transcript, This increase was closely Linked to the gait-induced rate of protein synthesis of the corresponding proteins, indicating mainly transcriptional regulation of expression for these genes. A consensus element with homology to the URS sequence of the ENO1 promoter was found in the promoters of the GPD1, GPP2, GCY1, and DAK1 genes.			Norbeck, J (corresponding author), GOTHENBURG UNIV,DEPT GEN & MARINE MICROBIOL,MED AREGATAN 9 C,S-41390 GOTHENBURG,SWEDEN.			Norbeck, Joakim/0000-0001-6017-2689				ADLER L, 1985, J BACTERIOL, V162, P300, DOI 10.1128/JB.162.1.300-306.1985; ALBERTYN J, 1994, CURR GENET, V25, P12, DOI 10.1007/BF00712960; BATAILLE N, 1991, YEAST, V7, P367, DOI 10.1002/yea.320070407; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; BLOMBERG A, 1995, J BACTERIOL, V177, P3563, DOI 10.1128/jb.177.12.3563-3572.1995; BLOMBERG A, 1995, ELECTROPHORESIS, V16, P1935, DOI 10.1002/elps.11501601320; BLOMBERG A, 1992, ADV MICROB PHYSIOL, V33, P145, DOI 10.1016/S0065-2911(08)60217-9; BLOMBERG A, 1996, IN PRESS YEAST; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CARMEN AA, 1995, YEAST, V11, P1031, DOI 10.1002/yea.320111105; COHEN R, 1987, MOL CELL BIOL, V7, P2753, DOI 10.1128/MCB.7.8.2753; DANIEL R, 1995, J BACTERIOL, V177, P4392, DOI 10.1128/jb.177.15.4392-4401.1995; Demianova M, 1996, J BIOL CHEM, V271, P11383, DOI 10.1074/jbc.271.19.11383; ERIKSSON P, 1995, MOL MICROBIOL, V17, P95, DOI 10.1111/j.1365-2958.1995.mmi_17010095.x; EVANS TC, 1985, ARCH BIOCHEM BIOPHYS, V243, P492, DOI 10.1016/0003-9861(85)90526-0; FUGE EK, 1994, J BACTERIOL, V176, P5802, DOI 10.1128/JB.176.18.5802-5813.1994; GANCEDO C, 1986, EUR J BIOCHEM, V159, P171, DOI 10.1111/j.1432-1033.1986.tb09848.x; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1994, ELECTROPHORESIS, V15, P1; HIRATA D, 1995, MOL GEN GENET, V249, P257, DOI 10.1007/BF00290525; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; IIDA H, 1984, J CELL BIOL, V99, P199, DOI 10.1083/jcb.99.1.199; IIDA H, 1984, J CELL BIOL, V99, P1441, DOI 10.1083/jcb.99.4.1441; IIDA H, 1988, MOL CELL BIOL, V8, P5555, DOI 10.1128/MCB.8.12.5555; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; LERNER HR, 1980, BIOCHIM BIOPHYS ACTA, V615, P1, DOI 10.1016/0005-2744(80)90002-9; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MARSHALL JH, 1989, J GEN MICROBIOL, V135, P697; MARSHALL JH, 1985, J GEN MICROBIOL, V131, P1581; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; MIRALLES VJ, 1995, MOL MICROBIOL, V17, P653, DOI 10.1111/j.1365-2958.1995.mmi_17040653.x; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Norbeck J, 1996, FEMS MICROBIOL LETT, V137, P1; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; NORBECK J, 1995, ELECTROPHORESIS, V16, P149, DOI 10.1002/elps.1150160124; OECHSNER U, 1988, FEBS LETT, V238, P123, DOI 10.1016/0014-5793(88)80240-0; OLZ R, 1993, J BACTERIOL, V175, P2205, DOI 10.1128/JB.175.8.2205-2213.1993; PAVLIK P, 1993, CURR GENET, V24, P21, DOI 10.1007/BF00324660; RONNOW B, 1993, YEAST, V9, P1121, DOI 10.1002/yea.320091013; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SCHUURINK R, 1990, J GEN MICROBIOL, V136, P1043, DOI 10.1099/00221287-136-6-1043; VANZYL PJ, 1991, APPL MICROBIOL BIOT, V36, P369, DOI 10.1007/BF00208158; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232	50	164	201	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5544	5554		10.1074/jbc.272.9.5544	http://dx.doi.org/10.1074/jbc.272.9.5544			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038161	hybrid			2022-12-25	WOS:A1997WK74700029
J	Witt, H; Ludwig, B				Witt, H; Ludwig, B			Isolation, analysis, and deletion of the gene coding for subunit IV of cytochrome c oxidase in Paracoccus denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL OXIDASES; PURIFICATION; 2-SUBUNIT; CHAIN	The gene coding for subunit IV of the cytochrome c oxidase in Paracoccus denitrificans has been cloned and sequenced. The derived amino acid sequence shows no significant homology to any known protein. Gene deletion has no consequences for the integrity of the complex and its spectral and enzymatic properties. Complementation of the deletion mutant in trans results in expression of subunit IV; sequence analysis of the 5'-noncoding region leads to the identification of a putative promoter sequence.	UNIV FRANKFURT,INST BIOCHEM,D-60439 FRANKFURT,GERMANY	Goethe University Frankfurt								CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DEGIER JWL, 1994, MOL MICROBIOL, V13, P183, DOI 10.1111/j.1365-2958.1994.tb00414.x; DEVRIES GE, 1989, ARCH MICROBIOL, V152, P52, DOI 10.1007/BF00447011; GENNIS RB, 1994, ANNU REV BIOCHEM, V63, P675; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HALTIA T, 1992, FINN SOC SCI LETT, V136, P1; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KITA K, 1984, J BIOL CHEM, V259, P3368; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RICHTER OMH, 1994, J BIOL CHEM, V269, P23079; Saiki K, 1996, J BIOL CHEM, V271, P15336, DOI 10.1074/jbc.271.26.15336; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEINRUCKE P, 1993, FEMS MICROBIOL LETT, V104, P83, DOI 10.1111/j.1574-6968.1993.tb05865.x; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; VANSPANNING RJM, 1991, J BACTERIOL, V173, P6962, DOI 10.1128/jb.173.21.6962-6970.1991; WITT H, 1995, BBA-BIOENERGETICS, V1230, P74, DOI 10.1016/0005-2728(95)00050-S	22	37	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5514	5517		10.1074/jbc.272.9.5514	http://dx.doi.org/10.1074/jbc.272.9.5514			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038156	hybrid			2022-12-25	WOS:A1997WK74700024
J	DiPaolo, G; Lutjens, R; Pellier, V; Stimpson, SA; Beuchat, MH; Catsicas, S; Grenningloh, G				DiPaolo, G; Lutjens, R; Pellier, V; Stimpson, SA; Beuchat, MH; Catsicas, S; Grenningloh, G			Targeting of SCG10 to the area of the Golgi complex is mediated by its NH2-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATED PHOSPHORYLATION; NERVE GROWTH-FACTOR; BREFELDIN-A; T-ANTIGEN; PROTEIN; PHOSPHOPROTEIN; CELLS; STATHMIN; GENE; ONCOPROTEIN-18	SCG10 is a neuronal growth-associated protein that is concentrated in the growth cones of developing neurons. SCG10 shows a high degree of sequence homology to the ubiquitous phosphoprotein stathmin, which has been recently identified as a factor that destabilizes microtubules by increasing their catastrophe rate. Whereas stathmin is a soluble cytosolic protein, SCG10 is membrane-associated, indicating that the protein acts in a distinct subcellular compartment. Identifying the precise intracellular distribution of SCG10 as well as the mechanisms responsible for its specific targeting will contribute to elucidating its function. The main structural feature distinguishing the two proteins is that SCG10 contains an NH2-terminal extension of 34 amino acids. In this study, we have examined the intracellular distribution of SCG10 in PC12 cells and in transfected COS-7 cells and the role of the NH2-terminal domain in membrane-binding and intracellular targeting, SCG10 was found to be localized to the Golgi complex region. We show that the NH2-terminal region (residues 1-34) was necessary for membrane targeting and Golgi localization. Fusion proteins consisting of the NH2-terminal 34 amino acids of SCG10 and the related protein stathmin or the unrelated protein, beta-galactosidase, accumulated in the Golgi, demonstrating that this sequence was sufficient for Golgi localization. Biosynthetic labeling of transfected COS-7 cells with [H-3]palmitic acid revealed that two cysteine residues contained within the NH2-terminal domain were sites of palmitoylation.	GENEVA BIOMED RES INST, CH-1228 PLAN LES OUATES, GENEVA, SWITZERLAND; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA; DEPT BIOCHEM, CH-1211 GENEVA, SWITZERLAND	GlaxoSmithKline; University of Geneva			Pellier-Monnin, Veronique/I-7962-2017	pellier-monnin, veronique/0000-0002-5027-235X				ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HESS DT, 1992, J NEUROSCI, V12, P4634; JAMES G, 1993, METHODS COMPANION ME, P270; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LUO XN, 1994, J BIOL CHEM, V269, P10312; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SOLIMENA M, 1994, J CELL BIOL, V126, P331, DOI 10.1083/jcb.126.2.331; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	34	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5175	5182		10.1074/jbc.272.8.5175	http://dx.doi.org/10.1074/jbc.272.8.5175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030585	hybrid			2022-12-25	WOS:A1997WJ85500073
J	Girgis, S; Suh, JR; Jolivet, J; Stover, PJ				Girgis, S; Suh, JR; Jolivet, J; Stover, PJ			5-formyltetrahydrofolate regulates homocysteine remethylation in human neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; SERINE HYDROXYMETHYLTRANSFERASE; 5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE; FOLATE METABOLISM; CELLS; ACID; COMPARTMENTATION	The metabolic role of 5-formyltetrahydrofolate is not known; however, it is an inhibitor of several folate-dependent enzymes including serine hydroxymethyltransferase, Methenyltetrahydrofolate synthetase (MTHFS) is the only enzyme known to metabolize 5-formyltetrahydrofolate and catalyzes the conversion of 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate. In order to address the function of 5-formyltetrahydrofolate in mammalian cells, intracellular 5-formyltetrahydrofolate levels were depleted in human 5Y neuroblastoma by overexpressing the human cDNA encoding MTHFS (5YMTHFS cells), When cultured with 2 mM exogenous glycine, the intracellular serine and glycine concentrations in 5YMTHFS cells are elevated approximately 3-fold relative to 5Y cells; 5YMTHFS cells do not contain measurable levels of free methionine and display a 30-40% decrease in cell proliferation rates compared with 5Y cells. Medium supplemented with pharmacological levels of exogenous folinate or methionine ameliorated the glycine induced growth inhibition. Analysis of the folate derivatives demonstrated that 5-methyltetrahydrofolate accounts for 30% of total cellular folate in 5Y cells when cultured with 5 mm exogenous glycine. 5YMTHFS cells do not contain detectable levels of 5-methyltetrahydrofolate under the same culture conditions. These results suggest that 5-formyltetrahydrofolate inhibits serine hydroxymethyltransferase activity in vivo and that serine synthesis and homocysteine remethylation compete for one-carbon units in the cytoplasm.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853; HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ H2W 1T8,CANADA	Cornell University; Universite de Montreal					NIDDK NIH HHS [DK07158-21, DK49621] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158, R29DK049621] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BERTRAND R, 1995, BBA-MOL CELL RES, V1266, P245, DOI 10.1016/0167-4889(95)00020-S; Cowin GJ, 1996, BBA-MOL CELL RES, V1310, P32, DOI 10.1016/0167-4889(95)00142-5; DAYAN A, 1995, GENE, V165, P307, DOI 10.1016/0378-1119(95)00321-V; HASHIMOTO A, 1992, J CHROMATOGR-BIOMED, V582, P41, DOI 10.1016/0378-4347(92)80300-F; HORNE DW, 1981, ANAL BIOCHEM, V116, P393, DOI 10.1016/0003-2697(81)90378-X; KOHL RL, 1980, J NEUROSCI RES, V5, P271, DOI 10.1002/jnr.490050403; MARAS B, 1994, J BIOL CHEM, V269, P18429; Narkewicz MR, 1996, BIOCHEM J, V313, P991, DOI 10.1042/bj3130991; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCOTT JM, 1995, FOLATE HLTH DIS, P329; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1990, J BIOL CHEM, V265, P14227; STOVER P, 1991, J BIOL CHEM, V266, P1543; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; WEGNER C, 1992, NEUROLOGY, V42, P17	19	90	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4729	4734		10.1074/jbc.272.8.4729	http://dx.doi.org/10.1074/jbc.272.8.4729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030524	hybrid			2022-12-25	WOS:A1997WJ85500012
J	Lee, MR; Li, L; Kitazawa, T				Lee, MR; Li, L; Kitazawa, T			Cyclic GMP causes Ca2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CONTRACTILE ELEMENTS; 2ND MESSENGERS; PHOSPHORYLATION; INHIBITION; DEPHOSPHORYLATION; SENSITIVITY; MECHANISM; FIBERS; SITE	Using permeabilized, arterial smooth muscle strips where membrane-associated pathways remain intact but intracellular Ca2+ stores are depleted, we investigated mechanism(s) for the Ca2+ desensitization of contractile force by cGMP. The nonhydrolyzable analog 8-bromo-cGMP, when applied to these strips with submaximal Ca2+ levels clamped, dramatically and reversibly reduced the steady state levels of phosphorylation at 20-kDa myosin light chain and contractile force, with a nanomolar concentration required to obtain 50% reduction, Supramaximal concentrations of 8-bromo-cGMP (10 mu M), however, did not change the steady state relationship between phosphorylation and force, When light chain phosphatase activity was blocked at pCa 6.7, 10 mu M 8-bromo-cGMP did not affect the rates of rise of light chain phosphorylation and contractile force, When light chain kinase activity was blocked, 10 mu M 8-bromo-cGMP significantly accelerated light chain dephosphorylation and force relaxation from the maximal contraction steady state, The light chain phosphorylation time course of a pCa 6.0-induced contraction in the presence of 8-bromo-cGMP exhibited kinetics that are predictable from a mathematical model in which only light chain phosphatase activity is increased, The results of this study strongly suggest that cGMP indirectly activates light chain phosphatase, the first proposed mechanism for cGMP-induced Ca2+ desensitization in vasodilatation.	GEORGETOWN UNIV,MED CTR,DEPT PHYSIOL & BIOPHYS,WASHINGTON,DC 20007	Georgetown University					NHLBI NIH HHS [HL51824] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051824] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barany K., 1996, BIOCH SMOOTH MUSCLE, P21; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; CHATTERJEE M, 1983, SCIENCE, V221, P464, DOI 10.1126/science.6867722; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GONG MC, 1992, J BIOL CHEM, V267, P14662; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; Hartshorne DJ, 1987, PHYSL GASTROINTESTIN, P423; HATHAWAY DR, 1985, J MOL CELL CARDIOL, V17, P841, DOI 10.1016/S0022-2828(85)80098-5; HOFMANN F, 1994, AIRWAYS SMOOTH MUSCL, P253; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; IKEBE M, 1986, J BIOL CHEM, V261, P36; ITOH T, 1995, J BIOL CHEM, V270, P20400, DOI 10.1074/jbc.270.35.20400; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KARAKI H, 1988, EUR J PHARMACOL, V156, P259, DOI 10.1016/0014-2999(88)90329-9; Khromov A, 1995, BIOPHYS J, V69, P2611, DOI 10.1016/S0006-3495(95)80132-3; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1996, BIOPHYS J, V70, P383; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MITSUI T, 1994, J BIOL CHEM, V269, P5842; MORGAN JP, 1984, J PHYSIOL-LONDON, V357, P539, DOI 10.1113/jphysiol.1984.sp015516; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; PFITZER G, 1986, PFLUG ARCH EUR J PHY, V407, P87, DOI 10.1007/BF00580726; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SELLERS JR, 1996, BIOCH SMOOTH MUSCLE, P181; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STULL JT, 1990, J BIOL CHEM, V265, P16683; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WINDER SJ, 1993, CELL SIGNAL, V5, P667; YANAGISHAWA T, 1988, BRIT J PHARMACOL, V98, P469	37	192	198	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5063	5068		10.1074/jbc.272.8.5063	http://dx.doi.org/10.1074/jbc.272.8.5063			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030570	hybrid			2022-12-25	WOS:A1997WJ85500058
J	Burke, CL; Lemmon, MA; Coren, BA; Engelman, DM; Stern, DF				Burke, CL; Lemmon, MA; Coren, BA; Engelman, DM; Stern, DF			Dimerization of the p185(neu) transmembrane domain is necessary but not sufficient for transformation	ONCOGENE			English	Article						receptor tyrosine kinase; dimerization; transmembrane domain; neu/HERZ/erbB-2	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; NEU-ONCOGENE; POINT MUTATION; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; PROTO-ONCOGENE; CROSS-LINKING	The neu proto-oncogene encodes a receptor tyrosine kinase (RTK). The oncogenic allele neu* (p185*) bears a glutamic acid for valine substitution at position 664 within the predicted transmembrane domain. We have used this mutant to explore the role of the transmembrane domain in signal transduction by RTKs. Analysis of a panel of neu* proteins with second-site mutations in the transmembrane domain revealed a strong correlation of dimerization with transformation. Both dimerization and transformation are dependent on a domain formed by the amino acids Val663-Glu664-Gly665 (VEG). However, movement of the VEG elsewhere within the transmembrane domain promoted weak dimerization but not transformation, Epidermal growth factor receptor (EGFR)/neu chimeras were used to determine if mutations that disrupt activation by Glu664 affect hormone-regulated signal transduction as well. These mutations (of Val663 and Gly665) did not affect regulation by EGF, Introduction of the known transmembrane dimerization domain from Glycophorin A (GpA) stimulated dimerization, but was not sufficient for transformation. These results indicate that dimerization is necessary but not sufficient for transforming activity. The homologous wild-type domain, VVG, is not required for hormone-regulated signaling.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; UNIV PENN, SCH MED, DEPT BIOPHYS & BIOCHEM, PHILADELPHIA, PA 19104 USA	Yale University; Yale University; Yale University; University of Pennsylvania				Lemmon, Mark/0000-0002-3379-5319	NCI NIH HHS [R01CA45708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, IN PRESS; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; CAO HN, 1992, J BIOL CHEM, V267, P20489; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LONGO N, 1992, J BIOL CHEM, V267, P12416; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKAHSHI M, 1987, J BIOL CHEM, V263, P3400; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	72	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					687	696		10.1038/sj.onc.1200873	http://dx.doi.org/10.1038/sj.onc.1200873			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038376				2022-12-25	WOS:A1997WG43000007
J	Nordstrom, T; Shrode, LD; Rotstein, OD; Romanek, R; Goto, T; Heersche, JNM; Manolson, MF; Brisseau, GF; Grinstein, S				Nordstrom, T; Shrode, LD; Rotstein, OD; Romanek, R; Goto, T; Heersche, JNM; Manolson, MF; Brisseau, GF; Grinstein, S			Chronic extracellular acidosis induces plasmalemmal vacuolar type H+ ATPase activity in osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-RESORPTION; INTRACELLULAR PH; RAT OSTEOCLASTS; BICARBONATE CONCENTRATIONS; ADENOSINE-TRIPHOSPHATASE; INDIVIDUAL OSTEOCLASTS; METABOLIC-ACIDOSIS; PROTON CONDUCTANCE; CYTOPLASMIC PH; SOLUBLE FACTOR	Proton extrusion into an extracellular resorption compartment is an essential component of bone degradation by osteoclasts. Chronic metabolic acidosis is known to induce negative calcium balance and bone loss by stimulating osteoclastic bone resorption, but the underlying mechanism is not known. The present studies were undertaken to evaluate whether chronic acidosis affects proton extrusion mechanisms in osteoclasts cultured on glass coverslips. Acidosis, mimicked experimentally by maintaining the cells at extracellular pH 6.5, rapidly lowered intracellular pH to 6.8. However, after 2 hours, a proportion of cells demonstrated the capacity to restore intracellular pH to near normal levels, To define the mechanism responsible for this recovery, the activity of individual H+ transport pathways was analyzed. We found that chronic acid treatment for up to 6 h did not significantly affect the cellular buffering power or Na+/H+ antiport activity, In contrast, chronic acidosis activated vacuolar H+ pumps in the osteoclasts. Although only similar to 5% of the control cells displayed proton pump activity, about 40% of cells kept at extracellular pH 6.5 for 4-6 h were able to recover from the acute acid load by means of bafilomycin A(1)-sensitive proton extrusion, Conversely, the H+-selective conductance recently described in the plasma membrane of osteoclasts was clearly inhibited in the cells exposed to chronic acidosis, Following acid treatment, the activation threshold of the H+ conductance was shifted to more positive potentials, and the current density was significantly reduced. Considered together, these results suggest that induction of plasmalemmal vacuolar type ATPase activity by chronic acidosis, generated either systemically due to metabolic disease or locally at sites of inflammation, is likely to stimulate osteoclastic bone resorption and thus to promote bone loss.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; TORONTO HOSP,DEPT SURG,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,FAC DENT,TORONTO,ON M5G 1G6,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Nordström, Tommy/H-9111-2016	Nordström, Tommy/0000-0002-2153-5819; Shrode, Lamara/0000-0003-4737-431X; Manolson, Morris/0000-0001-8755-5460				ARKETT SA, 1992, J PHYSIOL-LONDON, V458, P633, DOI 10.1113/jphysiol.1992.sp019438; ARNETT TR, 1994, J BONE MINER RES, V9, P375; ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; ASOTRA S, 1994, J BONE MINER RES, V9, P1115; BASTANI B, 1994, EXP NEPHROL, V2, P171; BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Boyarsky G, 1996, AM J PHYSIOL-CELL PH, V271, pC1131, DOI 10.1152/ajpcell.1996.271.4.C1131; CARANO A, 1993, AM J PHYSIOL, V264, pC694, DOI 10.1152/ajpcell.1993.264.3.C694; CHAMBREY R, 1994, J BIOL CHEM, V269, P3243; DOMINGUEZ JH, 1979, CALCIFIED TISSUE INT, V29, P7, DOI 10.1007/BF02408049; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; Goto K, 1918, J BIOL CHEM, V36, P355; GOTO T, 1995, J BONE MINER RES, V10, pS428; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HORIE S, 1990, P NATL ACAD SCI USA, V87, P4742, DOI 10.1073/pnas.87.12.4742; KALLIO DM, 1971, J ULTRA MOL STRUCT R, V37, P169, DOI 10.1016/S0022-5320(71)80048-5; KANEHISA J, 1989, BONE, V10, P125, DOI 10.1016/8756-3282(89)90010-0; KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756-3282(88)90106-8; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KRIEGER NS, 1992, AM J PHYSIOL, V262, pF442, DOI 10.1152/ajprenal.1992.262.3.F442; LORENZO JA, 1991, CRIT REV IMMUNOL, V11, P195; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; MAHAUTSMITH MP, 1989, J EXP BIOL, V145, P455; MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo-119-4-1654; MCSHEEHY PMJ, 1987, J CLIN INVEST, V80, P425, DOI 10.1172/JCI113089; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; MURER H, 1994, KIDNEY INT, V45, pS23; MURRILLS RJ, 1993, J CELL PHYSIOL, V154, P511, DOI 10.1002/jcp.1041540309; MYERS M, 1993, J BIOL CHEM, V268, P9184; NORDSTROM T, 1995, J BIOL CHEM, V270, P2203, DOI 10.1074/jbc.270.5.2203; QUEDNAU B, 1994, AM J PHYSIOL, V266, pC480, DOI 10.1152/ajpcell.1994.266.2.C480; RAVESLOOT JH, 1995, J GEN PHYSIOL, V105, P177, DOI 10.1085/jgp.105.2.177; ROMANEK R, 1994, CELL BIOL LAB HDB, P404; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SHIBUTANI T, 1993, J BONE MINER RES, V8, P331; Sims Stephen M., 1992, P223; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; SUNDQUIST KT, 1994, J BONE MINER RES, V9, P1575; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; WALSH CA, 1990, J BONE MINER RES, V5, P1243	49	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6354	6360		10.1074/jbc.272.10.6354	http://dx.doi.org/10.1074/jbc.272.10.6354			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045656	hybrid			2022-12-25	WOS:A1997WM64700040
J	Qiu, WQ; Ye, Z; Kholodenko, D; Seubert, P; Selkoe, DJ				Qiu, WQ; Ye, Z; Kholodenko, D; Seubert, P; Selkoe, DJ			Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; SENILE PLAQUES; PEPTIDE; GENE; A-BETA-42(43)	Amyloid beta-protein (A beta) is the major component of neuritic (amyloid) plaques in Alzheimer's disease, and its deposition is an early and constant event in the complex pathogenetic cascade of the disease. Although many studies have focused on the biosynthetic processing of the beta-amyloid precursor protein and on the production and polymerization of A beta, understanding the degradation and clearance of A beta has received very little attention, By incubating the conditioned medium of metabolically labeled A beta-secreting cells with media of various cultured cell lines, we observed a time dependent decrease in the amount of A beta in the mixed media, The factor principally responsible for this decrease was a secreted metalloprotease released by both neural and non-neural cells, Among the cells examined, the microglial cell line, BV-2, produced the most A beta-degrading activity, The protease was completely blocked by the metalloprotease inhibitor, 1,10-phenanthroline, and partially inhibited by EDTA, whereas inhibitors of other protease classes produced little or no inhibition, Substrate analysis suggests that the enzyme was a non-matrix metalloprotease. The protease cleaved both A beta(1-40) and A beta(1-42) peptides secreted by beta-amyloid precursor protein-transfected cells but failed to degrade low molecular weight oligomers of A beta that form in the culture medium, Lipopolysaccharide, a stimulator of macrophages/microglia, activated BV-2 cells to increase their A beta-degrading metalloprotease activity, We conclude that secreted A beta(1-40) and A beta(1-42) peptides are constitutively degraded by a metalloprotease released by microglia and other neural cells, providing a potential mechanism for the clearance of A beta in brain tissue.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080	Harvard University; Brigham & Women's Hospital; Harvard Medical School				Qiu, Wei Qiao (Wendy)/0000-0002-2082-2410	NATIONAL INSTITUTE ON AGING [R01AG006173, R37AG006173, R01AG012749, RF1AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06173, AG 12749] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ATANASSOV CL, 1994, RES IMMUNOL, V145, P277, DOI 10.1016/S0923-2494(94)80016-2; BEYNON RJ, 1993, PROTEOLYTIC ENZYMES, P241; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MANN DMA, 1989, NEUROPATH APPL NEURO, V15, P317, DOI 10.1111/j.1365-2990.1989.tb01232.x; Masliah E, 1996, J NEUROSCI, V16, P5795; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0	25	149	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6641	6646		10.1074/jbc.272.10.6641	http://dx.doi.org/10.1074/jbc.272.10.6641			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045694	hybrid			2022-12-25	WOS:A1997WM64700078
J	Tellam, JT; Macaulay, SL; McIntosh, S; Hewish, DR; Ward, CW; James, DE				Tellam, JT; Macaulay, SL; McIntosh, S; Hewish, DR; Ward, CW; James, DE			Characterization of Munc-18c and syntaxin-4 in 3T3-L1 adipocytes - Putative role in insulin-dependent movement of GLUT-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLE PROTEINS; RAT ADIPOSE CELL; PLASMA-MEMBRANE; BINDING PROTEIN; TRANSLOCATION; COMPLEX; CELLUBREVIN; EXPRESSION	We have previously identified three mammalian Seel/Munc-18 homologues in adipocytes (Tellam, J. T., McIntosh, S., and James, D. E. (1995) J. Biol, Chem, 270, 5857-5863). These proteins are thought to modulate the interaction between vesicle membrane and target membrane soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) and thus regulate intracellular vesicular transport, This study aimed to further characterize these Munc-18 isoforms and to define their potential role in the trafficking of GLUT-4 in adipocytes, a process reported to involve the vesicle membrane SNARE, VAMP-8, Using an in vitro binding assay with recombinant fusion proteins, we show that Munc-18a and Munc-18b bind to syntaxin-1A, -2, and -3, while Munc-18c binds only to syntaxin-2 and -4, The specific interaction between Munc-18c and syntaxin 4 is of interest because aside from syntaxin-1A, which is not expressed in adipocytes, syntaxin-4 is the only syntaxin that binds to VAMP S. Using a three-way binding assay, it was shown that Munc-18c inhibits the binding of syntaxin-4 to VAMP-S, The subcellular distribution of syntaxin-4 and Munc-18c was almost identical, both being enriched in the plasma membrane, and both exhibiting an insulin-dependent movement out of an intracellular membrane fraction similar to that observed for GLUT-4, Munc-18b had a similar distribution to Munc-18c and so may also be involved in vesicle transport to the cell surface, whereas Munc-18a was undetectable by immunoblotting; in adipocytes, Microinjection of a syntaxin-4 antibody into 3T3-L1 adipocytes blocked the insulin-dependent recruitment of GLUT 4 to the cell surface, These data suggest that syntaxin-4/Munc-18c/VAMP-2 may play a role in the docking/fusion of intracellular GLUT-4-containing vesicles with the cell surface in adipocytes.	UNIV QUEENSLAND,CTR MOL & CELLULAR BIOL,BRISBANE,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA; CSIRO,DIV BIOMOL ENGN,PARKVILLE,VIC 3052,AUSTRALIA	University of Queensland; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Macaulay, Stuart Lance/A-6086-2008; mcintosh, shane/AAL-4279-2021	Macaulay, Stuart Lance/0000-0001-5069-9516; mcintosh, shane/0000-0003-2835-7936; James, David/0000-0001-5946-5257				BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HODEL A, 1994, J BIOL CHEM, V269, P8623; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; Jagadish MN, 1996, BIOCHEM J, V317, P945, DOI 10.1042/bj3170945; Jagadish MN, 1997, BIOCHEM J, V321, P151, DOI 10.1042/bj3210151; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; RALSTON E, 1994, J BIOL CHEM, V269, P15403; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SLOT JW, 1990, NATURE, V346, P369, DOI 10.1038/346369a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233	48	186	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6179	6186		10.1074/jbc.272.10.6179	http://dx.doi.org/10.1074/jbc.272.10.6179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045631	hybrid			2022-12-25	WOS:A1997WM64700015
J	Bernstein, HS; Coughlin, SR				Bernstein, HS; Coughlin, SR			Pombe Cdc5-related protein - A putative human transcription factor implicated in mitogen-activated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; SCHIZOSACCHAROMYCES-POMBE; NUCLEAR-LOCALIZATION; TRANSDUCTION PATHWAY; NUCLEOTIDE-SEQUENCE; C-MYB; KINASE; ONCOPROTEIN; YEAST; CDNA	The Schizosaccharomyces pombe cdc5 gene product is a cell cycle regulator that exerts its effects at the G(2)/M transition in fission yeast. We describe the cloning of a putative human transcription factor, pombe Cdc5-related protein (PCDC5RP), which bears significant homology to S. pombe Cdc5 and to expressed sequences in mouse, nematode, and budding yeast. PCDC5RP is expressed widely in normal adult human tissues and thus may have an important general function that has been preserved evolutionarily. PCDC5RP contains two tandem repeats of a helix-turn-helix DNA binding motif, four consensus nuclear localization signals, and a hydrophilic, proline-rich central region similar to the transcriptional activating domain in Myb family members, Remarkably, PCDC5RP moved rapidly from cytoplasm to nucleus upon serum stimulation of cultured cells, This movement correlated temporally with an increase in PCDC5RP phosphorylation, Thus, PCDC5RP is a presumed transcription factor that appears to transduce cytoplasmic signals to the nucleus upon serum stimulation.	UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL44907, HL03228] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL103228, R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSABEL F, 1995, SHORT PROTOCOLS MOL; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	32	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5833	5837		10.1074/jbc.272.9.5833	http://dx.doi.org/10.1074/jbc.272.9.5833			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038199	hybrid			2022-12-25	WOS:A1997WK74700067
J	Smith, ER; Jones, PL; Boss, JM; Merrill, AH				Smith, ER; Jones, PL; Boss, JM; Merrill, AH			Changing J774A.1 cells to new medium perturbs multiple signaling pathways, including the modulation of protein kinase C by endogenous sphingoid bases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PHOSPHATIDIC-ACID PHOSPHOHYDROLASE; MANGANOUS SUPEROXIDE-DISMUTASE; D-ERYTHRO-SPHINGOSINE; LONG-CHAIN BASES; PHORBOL ESTERS; HUMAN-NEUTROPHILS; PHOSPHOLIPASE-D; 2ND MESSENGER; OLEIC-ACID	Sphingosine, sphinganine, and other long-chain (sphingoid) bases are highly bioactive intermediates of sphingolipid metabolism that have diverse effects when added to cells, including the inhibition of protein kinase C (PRC) as evaluated by both enzymatic activity and [H-3]phorbol dibutyrate ([H-3]PDBu) binding. Nonetheless, changes in endogenous sphingoid bases have not been proven to affect PKC or other signal transduction pathways. We have discovered recently that changing J774A.1 cells to new medium results in up to 10-fold increases in sphingoid bases (Smith, E, R., and Merrill, A. H., Jr, (1995) J. Biol. Chem. 270, 18749-18758); therefore, this system was used to elevate sphingosine and sphinganine and determine if PEC was affected. Incubation of J774A.1 cells in new medium for 30 min increased the levels of these endogenous sphingoid bases to approximately 0.5 nmol/mg of protein and decreased [H-3]PDBu binding by 40-60%. Addition of NH4Cl, which suppresses the change in sphingosine, restored [3H]PDBu binding. Elevation of endogenous sphinganine by a second method (addition of fumonisin B-1, an inhibitor of ceramide synthase) also reduced [H-3]PDBu binding; therefore, elevations in sphingosine and sphinganine can both affect PKC. The elevation in sphingoid bases was also associated with an increase in the amount of PRC-delta (the major PKC isozyme in J774A.1 cells) in the cytosol, as determined by activity assays and immunoblot analyses, Changing the culture medium affected other PKC isozymes, increased cellular levels of diacylglycerol, dihydroceramide, and ceramide, and altered the expression of two genes (the expression of JE was increased, and the induction of MnSOD by TNF-alpha was potentiated). Thus, changing the culture medium has numerous effects on J774A.1 cells, including the modulation of PKC by endogenous sphingoid bases.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ROLLINS RES CTR 4113,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,ATLANTA,GA 30322	Emory University; Emory University				Merrill, Alfred/0000-0002-6673-968X	NCI NIH HHS [CA47953] Funding Source: Medline; NIGMS NIH HHS [GM46368, GM08367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R01GM046368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BAZZI MD, 1987, BIOCHEM BIOPH RES CO, V146, P203, DOI 10.1016/0006-291X(87)90711-X; BORNER C, 1992, J BIOL CHEM, V267, P12892; BOSS JM, 1991, IMMUNOLOGY, V73, P309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAO R, 1992, J BIOL CHEM, V267, P23459; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLATTA F, 1992, J IMMUNOL, V148, P760; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GOODING LR, 1979, J IMMUNOL, V122, P1002; GORDON HM, 1992, J IMMUNOL, V148, P4021; HA KS, 1993, J BIOL CHEM, V268, P10534; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HUANG CX, 1995, CANCER RES, V55, P1655; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KISS Z, 1992, BIOCHEM J, V288, P853, DOI 10.1042/bj2880853; KIYOTAKI C, 1984, J IMMUNOL, V132, P857; KOBAYASHI T, 1988, EUR J BIOCHEM, V172, P747, DOI 10.1111/j.1432-1033.1988.tb13952.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1994, BBA-MOL CELL RES, V1220, P323, DOI 10.1016/0167-4889(94)90156-2; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LI WQ, 1994, J BIOL CHEM, V269, P2349; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1992, NESTLE NUTR WORKS SE, V28, P41; MERRILL AH, 1988, ANAL BICOH, V171, P372; MERRILL AH, 1996, HANDB LIP R, V8, P205; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOVOTNEY M, 1991, BIOCHEMISTRY-US, V30, P5597, DOI 10.1021/bi00236a037; OHNO S, 1994, J BIOL CHEM, V269, P17495; OISHI K, 1990, J BIOL CHEM, V265, P70; PERRY DK, 1992, J IMMUNOL, V149, P2749; PRIESS J, 1986, J BIOL CHEM, V261, P8597; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; STEVENS VL, 1989, CANCER RES, V49, P3229; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WANG E, 1991, J BIOL CHEM, V266, P14486; WERTZ PW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P213, DOI 10.1016/0005-2760(89)90289-0; WILSON E, 1988, J BIOL CHEM, V263, P9304; WILSON E, 1986, J BIOL CHEM, V261, P2616; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	66	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5640	5646		10.1074/jbc.272.9.5640	http://dx.doi.org/10.1074/jbc.272.9.5640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038174	hybrid			2022-12-25	WOS:A1997WK74700042
J	Zharkov, DO; Rieger, RA; Iden, CR; Grollman, AP				Zharkov, DO; Rieger, RA; Iden, CR; Grollman, AP			NH2-terminal proline acts as a nucleophile in the glycosylase/AP-lyase reaction catalyzed by Escherichia coli formamidopyrimidine-DNA glycosylase (Fpg) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; SUBSTRATE-SPECIFICITY; AMINO-TERMINUS; DAMAGED DNA; ZINC-FINGER; MECHANISM; RESIDUES; REPAIR; 8-OXOGUANINE; RECOGNITION	Formamidopyrimidine-DNA glycosylase (Fpg) protein plays a prominent role in the repair of oxidatively damaged DNA in Escherichia coli, The protein possesses three enzymatic activities, hydrolysis of the N-glycosidic bond (DNA glycosylase), beta-elimination (AP lyase), and delta-elimination; these functions act in a concerted manner to excise oxidized deoxynucleosides from duplex DNA, Schiff base formation between the enzyme and substrate has been demonstrated (Tchou, J., and Grollman, A. P. (1995) J. Biol. Chem. 270, 11671-11677); this protein-DNA complex can be trapped by reduction with sodium borohydride, By digesting the stable, co-valently linked intermediate with proteases and determining the accurate mass of the products by negative electrospray ionization-mass spectrometry, we show that the N-terminal proline of Fpg protein is linked to DNA and, therefore, is identified as the nucleophile that initiates the catalytic excision of oxidized bases from DNA, This experimental approach may be applicable to the analysis of other protein-DNA complexes.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Zharkov, Dmitry/K-2158-2012	Zharkov, Dmitry/0000-0001-5013-0194	NATIONAL CANCER INSTITUTE [R37CA017395, R01CA017395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NCI NIH HHS [CA17395] Funding Source: Medline; NIEHS NIH HHS [ES04068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8384; DUWAT P, 1995, MICROBIOL-UK, V141, P411, DOI 10.1099/13500872-141-2-411; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FERSHT A, ENZYME STRUCTURE MEC, P69; FRIEDBERG EC, 1995, DNA REPAIR; GROLLMAN AP, 1994, ANN NY ACAD SCI, V726, P208, DOI 10.1111/j.1749-6632.1994.tb52816.x; KARAKAYA A, 1996, IN PRESS NUCL ACIDS; KOW YW, 1985, P NATL ACAD SCI USA, V82, P8354, DOI 10.1073/pnas.82.24.8354; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P803, DOI 10.1021/bi951077g; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1993, J BIOL CHEM, V268, P26738; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1	28	170	177	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5335	5341		10.1074/jbc.272.8.5335	http://dx.doi.org/10.1074/jbc.272.8.5335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030608	hybrid			2022-12-25	WOS:A1997WJ85500096
J	Francastel, C; AugeryBourget, Y; Prenant, M; Walters, M; Martin, DIK; RobertLezenes, J				Francastel, C; AugeryBourget, Y; Prenant, M; Walters, M; Martin, DIK; RobertLezenes, J			c-Jun inhibits NF-E2 transcriptional activity in association with p18/maf in Friend erythroleukemia cells	ONCOGENE			English	Article						c-Jun; NF-E2; transactivation; globin regulation; erythroleukemia	PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; SMALL MAF PROTEINS; ERYTHROID-CELLS; TRANSGENIC MICE; DIFFERENTIATION; EXPRESSION; FOS; ENHANCER	We have reported previously that antisense c-jun overcomes a block of Friend erythroleukemia cells to differentiation suggesting that the factor c-Jun may be an important negative regulator of erythroid differentiation, The recently described erythroid transcription factor NF-E2 plays an important role in the regulation of the transcription of globin genes and recognizes a sequence containing an AP-1 site, NF-E2 is a complex of two bZip proteins, p45 and p18/Maf. In order to determine whether c-Jun can interact with NF-E2/AP-1 sites to regulate transcriptional activation from them, we have compared the activity of AP-1 and NF-E2 in transient transcriptional assays, in erythroid and nonerythroid cells in the presence of c-jan sense and antisense expression vectors. In non-erythroid cells, c-Jun activates and NF-E2p18 inhibits both AP-1 and NF-E2 activities, suggesting that NF-E2/AP-1 sites function as AP-1 binding sites in these cells, In contrast, NF-E2p18 is a positive regulator of NF-E2 activity in erythroid cells. c-Jun alone is also a positive regulator of NF-E2 activity in erythroid cells but in association with NF-E2p18 inhibits this activity, Moreover antisense c-jun increases endogenous NF-E2 activity in erythroid cells. These results suggest that c-Jun could act as a repressor of NF-E2 transcriptional activity by forming inactive c-Jun/NF-E2p18 heterocomplexes which interfer with the transcription of globin genes in Friend erythroleukemia cells.	HOP PAUL BROUSSE,INSERM U268,F-94800 VILLEJUIF,FRANCE; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Fred Hutchinson Cancer Center			Francastel, Claire/AAI-4798-2021	Francastel, Claire/0000-0002-6353-4320				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHARNAY P, 1984, CELL, V55, P17; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; FRANCASTEL C, 1992, LEUKEMIA, V6, P935; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PROFOUSJUCHELKA HR, 1983, MOL CELL BIOL, V3, P229, DOI 10.1128/MCB.3.2.229; ROBERTLEZENES J, 1988, CANCER RES, V48, P3972; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444	26	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					873	877		10.1038/sj.onc.1200902	http://dx.doi.org/10.1038/sj.onc.1200902			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047395				2022-12-25	WOS:A1997WJ11200014
J	Douglas, AM; Goss, GA; Sutherland, RL; Hilton, DJ; Berndt, MC; Nicola, NA; Begley, CG				Douglas, AM; Goss, GA; Sutherland, RL; Hilton, DJ; Berndt, MC; Nicola, NA; Begley, CG			Expression and function of members of the cytokine receptor superfamily on breast cancer cells	ONCOGENE			English	Article						breast cancer; cytokines; receptors; cell growth; growth factors	LEUKEMIA INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; MAMMARY EPITHELIAL-CELLS; IL-6 SIGNAL TRANSDUCER; CARCINOMA CELLS; PROLACTIN RECEPTORS; MESSENGER-RNAS; EGF RECEPTOR; GM-CSF; INTERLEUKIN-6	Receptors for the cytokines leukemia inhibitory factor (LIF), interleukin-6 (IL-6), oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and interleukin-11 (IL-11) are members of the structurally conserved hemopoietin receptor superfamily, In addition, they all share the transmembrane signalling protein gp130, In this paper the expression and function of this family of receptors in breast cancer cells was examined, RT-PCR analyses demonstrated that gp130 was expressed in 12/12 breast cell lines and the specific receptor alpha-chains for IL-6, LIF, IL-11 and CNTF were expressed in the majority of these cell lines, This was in contrast to other hemopoitin receptors, Examination of 50 clinical samples of malignant breast tissue by RT-PCR showed a similar pattern of expression of gp130 associated receptors, Treatment of breast cancer cell lines with OSM resulted in changes in cellular morphology. Cellular proliferation was inhibited following exposure to OSM (3/4 cell lines), IL-11 (2/4 cell lines), and by IL-6 and LIF (1/4 cell lines), Cell surface binding of LIF and OSM was also documented, The expression of these receptors in 12/12 cell lines and greater than 95% of clinical samples suggests that these molecules may be important in regulating the growth of breast cells.	ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA; BAKER MED RES INST, PRAHRAN, VIC 3181, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, COOPERAT RES CTR GROWTH FACTORS, PARKVILLE, VIC 3050, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Baker Heart and Diabetes Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Douglas, AM (corresponding author), ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LABS, PARKVILLE, VIC 3050, AUSTRALIA.		Sutherland, Robert L/A-8378-2008; Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013; Berndt, Michael C/D-5580-2012	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; 				ABE O, 1992, LANCET, V339, P71; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BONNETERRE J, 1986, EUR J CANCER CLIN ON, V22, P1331, DOI 10.1016/0277-5379(86)90141-0; BONNETERRE J, 1987, CANCER RES, V47, P4724; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DANFORTH DN, 1993, CANCER RES, V53, P1538; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DICKSON RB, 1992, SEMIN ONCOL, V19, P286; EMERMAN JT, 1994, BONE MARROW TRANSPL, V13, P285; ETHIER SP, 1993, CANCER RES, V53, P627; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARRIS AL, 1994, BREAST CANCER RES TR, V29, P1, DOI 10.1007/BF00666176; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KACINSKI BM, 1991, ONCOGENE, V6, P941; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOEHORST SGA, 1993, J STEROID BIOCHEM, V45, P227, DOI 10.1016/0960-0760(93)90336-U; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; LASFARGUES EY, 1958, J NATL CANCER I, V21, P1131; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MCQUIRE WL, 1986, CANC SURVEYS, V5, P527; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURPHY LJ, 1984, J CLIN ENDOCR METAB, V58, P149, DOI 10.1210/jcem-58-1-149; MURPHY LJ, 1984, CANCER RES, V44, P1963; Nandurkar HH, 1996, ONCOGENE, V12, P585; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STAMPFER MR, 1993, CANCER SURV, V18, P7; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAMM I, 1991, P NATL ACAD SCI USA, V88, P4414, DOI 10.1073/pnas.88.10.4414; TAMM I, 1994, P NATL ACAD SCI USA, V91, P3329, DOI 10.1073/pnas.91.8.3329; TAMM I, 1994, P NATL ACAD SCI USA, V91, P4338, DOI 10.1073/pnas.91.10.4338; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TANIGAWA T, 1995, BLOOD, V85, P379; TREMPE G, 1973, IN VITRO CELL DEV B, V8, P433; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	65	89	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					661	669		10.1038/sj.onc.1200882	http://dx.doi.org/10.1038/sj.onc.1200882			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038373				2022-12-25	WOS:A1997WG43000004
J	BeerRomero, P; Glass, S; Rolfe, M				BeerRomero, P; Glass, S; Rolfe, M			Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells	ONCOGENE			English	Article						E6; p53; E6AP; papillomavirus; antisense	HUMAN PAPILLOMAVIRUS TYPE-16; UBIQUITIN-CONJUGATING ENZYME; TUMOR-SUPPRESSOR GENE; P53-DEPENDENT APOPTOSIS; IN-VIVO; PROTEIN; ASSOCIATION; ONCOPROTEIN; E6-AP; DEFICIENCY	Invasive cervical cancer is very highly correlated with the presence of high-risk human papillomavirus (HPV) types 16 and 18, Two viral proteins, E6 and E7, act in concert to subvert growth control of infected cells by inactivating the tumor suppressor proteins, p53 and Rb, respectively. E6 is thought to abrogate p53 function by stimulating its degradation via ubiquitin-mediated proteolysis in reaction requiring E6AP (EB-Associated Protein), Here we evaluate the in vivo role of E6AP in p53 degradation in normal and HPV-infected cell types using antisense phosphorothioate oligodeoxynucleotides (S-ODNs). This study shows that reduction of E6AP in viva in high-risk HPV-infected cells leads to an elevation of p53, confirming the function of E6AP predicted by in vitro experiments. Further, we demonstrate that reduction of E6AP in normal cells has no effect on p53 levels, indicative of an E6AP-indpendent mechanism for p53 degradation. These experiments show that inhibition of intermediate proteins in the ubiquitin-mediated proteolysis pathway (ubiquitin-conjugating enzymes or associated recognition proteins) can result in specific inhibition of substrate degradation. We propose that modulation of p53 levels by elimination of E6AP function may have therapeutic potential for cervical cancer.			BeerRomero, P (corresponding author), MITOTIX INC,1 KENDALL SQ,BLDG 600,CAMBRIDGE,MA 02139, USA.							Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LANDANYI M, 1993, CANCER RES, V53, P16; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maki CG, 1996, CANCER RES, V56, P2649; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENES DEV, V9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1993, ONCOGENE, V8, P1407; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STREMLAU A, 1985, NATURE, V314, P111; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEE C, 1985, AM J PATHOL, V119, P361; zur Hausen H, 1987, Appl Pathol, V5, P19	40	92	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					595	602		10.1038/sj.onc.1200872	http://dx.doi.org/10.1038/sj.onc.1200872			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053858				2022-12-25	WOS:A1997WF52400011
J	GarciaMartinez, LF; Ivanov, D; Gaynor, RB				GarciaMartinez, LF; Ivanov, D; Gaynor, RB			Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; ACTIVATION-RESPONSIVE REGION; TRANS-ACTIVATION; BINDING-PROTEIN; IN-VITRO; INITIATOR ELEMENT; MESSENGER-RNA; ELONGATION	The HIV-1 (human immunodeficiency virus type 1) and HIV-2 Tat proteins increase the level of transcription from their corresponding long terminal repeats. Tat activates transcription likely by interaction with components of the transcriptional initiation and elongation complexes during different stages of the transcription reaction. In the current study, two approaches were used to address the sites at which Tat becomes stably associated with the HIV transcription complex. First, we isolated column purified HIV-1 and HIV-2 transcription complexes that were competent for in vitro transcription and found that wild-type but not mutant Tat protein was specifically associated with this complex. An intact HIV TATA element and the presence of functional TATA-binding protein were necessary for Tat association. In contrast, the HIV-1 and HIV-2 TAR bulge sequences which serve as binding sites for Tat were not required for its association with the HIV preinitiation complex. A second complementary approach using immobilized HIV-1 and HIV-2 templates also demonstrated a functional association of Tat with HIV-1 and HIV-2 preinitiation complexes. Wild-type but not mutant Tat proteins associated with transcription complexes assembled on immobilized HIV-1 and HIV-2 templates and the association of Tat correlated with increases in the level of in vitro transcription. These results indicate that Tat can associate with HIV-1 and HIV-2 transcription complexes prior to the initiation of transcription by RNA polymerase II.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOL VIROL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV HEMATOL ONCOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Ivanov, Dmitri/0000-0002-4806-1369				ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Blau J, 1996, MOL CELL BIOL, V16, P2044; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CHURCHER MJ, 1995, P NATL ACAD SCI USA, V92, P2408, DOI 10.1073/pnas.92.6.2408; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; ELANGOVAN B, 1992, J VIROL, V66, P2031, DOI 10.1128/JVI.66.4.2031-2036.1992; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIAMARTINEZ LF, 1995, J MOL BIOL, V254, P350; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GRAEBLE MA, 1993, P NATL ACAD SCI USA, V90, P6184, DOI 10.1073/pnas.90.13.6184; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SUNE C, 1995, J VIROL, V69, P3098; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128; WUBAER F, 1995, EMBO J, V14, P5995, DOI 10.1002/j.1460-2075.1995.tb00288.x; WUBAER F, 1995, P NATL ACAD SCI USA, V92, P6213; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	64	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6951	6958		10.1074/jbc.272.11.6951	http://dx.doi.org/10.1074/jbc.272.11.6951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054383	hybrid			2022-12-25	WOS:A1997WN14700022
J	Guo, SY; Ma, N; Ives, DH				Guo, SY; Ma, N; Ives, DH			cis-active ras G2-like sequence implicated in the heterotropic activation of the deoxyadenosine kinase of Lactobacillus acidophilus R-26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE KINASE; GTP HYDROLYSIS; CRYSTAL-STRUCTURE; LIMITED PROTEOLYSIS; SUBUNIT INTERFACE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; MECHANISM; BINDING; DEOXYGUANOSINE	Deoxyadenosine kinase (dAK) forms a heterodimer with either deoxyguanosine kinase (dGK) or deoxycytidine kinase (dCK), and is heterotropically activated 3-5 times by dGuo or dCyd. Expressed alone, dAK is inactive and exhibits no response to dGuo or dCyd; activity and heterotropic response are fully restored upon reassociation with dGK or dCK. However, turnover of independently expressed dGK or dCK: is nearly maximal, being further activated only 50-100% upon reassociation with dAK, In neither case is the heterotropic activation due to ligand-induced heterodimer formation. A proline/alanine substitution within a dAK segment homologous to loop G2 of Has proteins yielded a heterodimer with dAK permanently cis-activated a-fold, with a corresponding reduction in heterotropic activation by dGuo, A chimeric dAK, with 25% of its C terminus substituted by the homologous sequence from dGK, was inactive alone, and its characteristics were unchanged in the reconstituted heterodimer, Superimposing the Pro/Ala substitution on this chimera also reduced heterotropic activation by half, Cross-linking the dimer by 1,5-difluoro-2,4-dinitrobenzene was inhibited by ATP, dATP, dGTP, and dAdo, suggesting the proximity of the active site(s) to the interface, These data suggest that dAK depends on dGK or dCK in a manner resembling the reliance of Has upon GTPase activating protein.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	Ohio State University					NIGMS NIH HHS [GM49635] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049635] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CHAKRAVARTY R, 1984, BIOCHEMISTRY-US, V23, P6235, DOI 10.1021/bi00320a053; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COLLINS RA, 1995, BIOCHEM J, V310, P117, DOI 10.1042/bj3100117; Deibel M R Jr, 1978, Methods Enzymol, V51, P346, DOI 10.1016/S0076-6879(78)51046-X; DEIBEL MR, 1977, J BIOL CHEM, V252, P8240; DEIBEL MR, 1977, J BIOL CHEM, V252, P8235; DURHAM JP, 1971, BIOCHIM BIOPHYS ACTA, V228, P9, DOI 10.1016/0005-2787(71)90542-9; ECCLESTON JF, 1985, J BIOL CHEM, V260, P6237; Goldsmith EJ, 1996, FASEB J, V10, P702, DOI 10.1096/fasebj.10.7.8635687; IKEDA S, 1986, J BIOL CHEM, V261, P5836; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P13373, DOI 10.1021/bi00249a025; IVES DH, 1984, ANAL BIOCHEM, V136, P416, DOI 10.1016/0003-2697(84)90237-9; KORNBLATT JA, 1980, CAN J BIOCHEM CELL B, V58, P219, DOI 10.1139/o80-030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levitzki A., 1978, QUANTITATIVE ASPECTS, P3; MA GT, 1995, J BIOL CHEM, V270, P6595, DOI 10.1074/jbc.270.12.6602; Ma N, 1996, P NATL ACAD SCI USA, V93, P14385, DOI 10.1073/pnas.93.25.14385; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; SCRUTTON NS, 1992, SCIENCE, V258, P1140, DOI 10.1126/science.1439821; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Wold F, 1967, METHOD ENZYMOL, V11, P617	40	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6890	6897		10.1074/jbc.272.11.6890	http://dx.doi.org/10.1074/jbc.272.11.6890			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054375	hybrid			2022-12-25	WOS:A1997WN14700014
J	Jackson, DE; Ward, CM; Wang, RG; Newman, PJ				Jackson, DE; Ward, CM; Wang, RG; Newman, PJ			The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation - Evidence for a mechanistic link between PECAM-1- and integrin-mediated cellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GUANINE-NUCLEOTIDE EXCHANGE; IN-VIVO; CYTOPLASMIC DOMAIN; ADAPTER PROTEIN; P-SELECTIN; CD31; GRB2; RAS	Platelet/endothelial cell adhesion molecule-1 (PECAM-1) is a homophilic adhesion receptor that mediates leukocyte/endothelial cell interactions that take place during transendothelial migration, Recent reports have shown that the binding of certain anti-PECAM-1 antibodies results in up-regulation of integrin function on the surface of leukocytes and platelets, suggesting that PECAM-1 may be capable of transmitting information into the cell following its engagement, PECAM-1 isolated from resting or activated but nonaggregated platelets was phosphorylated predominantly on serine residues; however, PECAM 1 derived from activated, aggregated platelets was strongly phosphorylated on tyrosine, Synthetic tyrosine phosphorylated peptides derived from five different regions within the cytoplasmic domain of PECAM 1 were screened for their ability to associate with cytoplasmic signaling molecules. The protein-tyrosine phosphatase SHP-2 was found to interact specifically with two different PECAM-1 phosphopeptides containing highly conserved phosphatase-binding motifs on PECAM-1 with the sequences VQpY(663)TEV and TVpY(686)SEV. More important, SHP-2 bound not only PECAM-1 phosphopeptides, but also became associated with full-length cellular PECAM-1 during the platelet aggregation process, and this interaction was mediated by the amino-terminal Src homology 2 domains of the phosphatase. Since SHP-2 normally serves as a positive regulator of signal transduction, its association with activated PECAM-1 suggests a number of potential mechanisms by which PECAM-1 engagement might be coupled to integrin activation in vascular cells.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; MED COLL WISCONSIN, DEPT CELLULAR BIOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT PHARMACOL, MILWAUKEE, WI 53226 USA	Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040926, P01HL044612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40926, HL-44612] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 1996, CELL, V85, P15; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERMAN ME, 1995, J IMMUNOL, V154, P299; Berman ME, 1996, J IMMUNOL, V156, P1515; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; BOGEN SA, 1992, AM J PATHOL, V141, P843; Buckley CD, 1996, J CELL SCI, V109, P437; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; Jackson DE, 1996, EUR J BIOCHEM, V240, P280, DOI 10.1111/j.1432-1033.1996.0280h.x; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MODDERMAN PW, 1994, BIOCHEM J, V299, P613, DOI 10.1042/bj2990613; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NEWMAN PJ, 1994, PLATELET DEPENDENT V, P165; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Varon D, 1996, TISSUE ANTIGENS, V48, pPL402; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAN HC, 1995, J BIOL CHEM, V270, P23672, DOI 10.1074/jbc.270.40.23672; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	65	198	200	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6986	6993		10.1074/jbc.272.11.6986	http://dx.doi.org/10.1074/jbc.272.11.6986			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054388	hybrid			2022-12-25	WOS:A1997WN14700027
J	Maddox, JF; Hachicha, M; Takano, T; Petasis, NA; Fokin, VV; Serhan, CN				Maddox, JF; Hachicha, M; Takano, T; Petasis, NA; Fokin, VV; Serhan, CN			Lipoxin A(4) stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A(4) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; ARACHIDONIC-ACID; LIGAND-BINDING; HL-60 CELLS; IDENTIFICATION; ADHESION; LEUKOTRIENE-B4; TRANSMIGRATION; CONVERSION	Lipoxins (LX) are bioactive eicosanoids that activate human monocytes and inhibit neutrophils. LXA(4) is rap idly converted by monocytes to inactive products, and to resist metabolism, synthetic analogs of LXA(4) were designed, Here, we examined the bioactivity of several LXA(4),analogs in monocytes and found, for chemotaxis, 15(R/S)-methyl-LXA(4) and 15-epi-LXA(4) were equal in activity, and 16-phenoxy-LXA(4) was more potent than native LXA(4). Both 15(R/S)-methyl-LXA(4) and 16-phenoxy-LXA(4) were similar to 1 log molar more potent than LXA(4) in stimulating THP-1 cell adherence (EC(50) approximate to 1 x 10(-10) M), Dimethylamide derivatives of the LXA(4) analogs also possessed agonist rather than antagonist properties for monocytes. Neither LXA(4) nor 16-phenoxy-LXA(4) affected monocyte-mediated cytotoxicity. We cloned an LXA(4) receptor from THP-1 cells identical to that found in PMN. Evidence of receptor-mediated function of LXA(4) and the stable analogs in monocytes included desensitization of intracellular calcium mobilization to a second challenge by equimolar concentrations of these analogs, but not to LTB(4). Increases in [Ca2+](i) by LXA(4) and the analogs were specifically inhibited by an antipeptide antibody to the LXA(4) receptor; and both LXA(4-) and analog-induced adherence and increments in Ca2+ were sensitive to pertussis toxin. Together, these results indicate that the LXA(4) stable analogs are potent monocyte chemoattractants and are more potent than native LXA(4) in stimulating THP-1 cell adherence, at subnanomolar concentrations, Moreover, they provide additional evidence that the LXA(4) stable analogs retain selective bioactivity in monocytes and are valuable instruments for examining the functions and modes of action of LXA(4).	BRIGHAM & WOMENS HOSP,DEPT ANESTHESIA,CTR EXPT THERAPEUT & REPERFUS INJURY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV SO CALIF,DEPT CHEM,LOKER HYDROCARBON INST 219,LOS ANGELES,CA 90089	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Southern California			Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK50305] Funding Source: Medline; NIGMS NIH HHS [R01-GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; COLGAN SP, 1993, J CLIN INVEST, V92, P75, DOI 10.1172/JCI116601; DENHOLM EM, 1991, J IMMUNOL METHODS, V144, P247, DOI 10.1016/0022-1759(91)90092-T; Elsner J, 1996, EUR J IMMUNOL, V26, P1560, DOI 10.1002/eji.1830260723; FALCONE RC, 1990, J PHARMACOL EXP THER, V255, P565; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Fiore S, 1995, BIOCHEMISTRY-US, V34, P16678, DOI 10.1021/bi00051a016; FIORE S, 1993, BLOOD, V81, P3395; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; HAINES KA, 1993, J IMMUNOL, V151, P1491; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MADDOX YT, 1978, NATURE, V273, P549, DOI 10.1038/273549a0; MULLER E, 1993, P NATL ACAD SCI USA, V90, P5818, DOI 10.1073/pnas.90.12.5818; NIGAM S, 1990, J CELL PHYSIOL, V143, P512, DOI 10.1002/jcp.1041430316; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Papayianni A, 1996, J IMMUNOL, V156, P2264; PAPAYIANNI A, 1995, KIDNEY INT, V47, P1295, DOI 10.1038/ki.1995.184; PEREZ HD, 1992, GENE, V118, P303, DOI 10.1016/0378-1119(92)90208-7; RAUD J, 1991, ADV EXP MED BIOL, V314, P185; Romano M, 1996, J IMMUNOL, V157, P2149; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; THIERAUCH KH, 1994, J HYPERTENS, V12, P1; THOMAS E, 1995, INFLAMM RES, V44, P121, DOI 10.1007/BF01782022; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325	29	230	245	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6972	6978		10.1074/jbc.272.11.6972	http://dx.doi.org/10.1074/jbc.272.11.6972			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054386	hybrid, Green Published			2022-12-25	WOS:A1997WN14700025
J	Piotrowicz, RS; Martin, JL; Dillman, WH; Levin, EG				Piotrowicz, RS; Martin, JL; Dillman, WH; Levin, EG			The 27-kDa heat shock protein facilitates basic fibroblast growth factor release from endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; MOLECULAR CHAPERONES; MODULATION; PHOSPHORYLATION; RECEPTOR; ESTROGEN; ANGIOGENESIS; ORGANIZATION; TRANSLATION; BINDING	Basic fibroblast growth factor is an important mitogenic and angiogenic factor that stimulates endothelial cell growth and migration. This hormone is not secreted via the classical vesicular pathway, and the identification of intracellular proteins that facilitate its release remains lacking, Transfection and expression of the 27-kDa human heat shock protein in bovine arterial endothelial cells doubles the rate of estrogen-induced basic fibroblast growth factor secretion, preferentially inducing the release of high molecular weight forms of the hormone. The secreted basic fibroblast growth factor is mitogenic to breast adenocarcinoma cells cultured in the conditioned medium obtained from the transfected endothelial cells, In contrast, decreasing the level of the endogenous heat shock protein homolog with an antisense vector markedly decreases basic fibroblast growth factor release, Anti-heat shock protein or anti-basic fibroblast growth factor antibodies co-precipitate both proteins from endothelial cell extracts, demonstrating a direct association between the two proteins. This interaction is likely to be an important step in the mechanism of basic fibroblast growth factor secretion.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40435] Funding Source: Medline; NIDDK NIH HHS [DK07202] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CaulinGlaser T, 1996, J CLIN INVEST, V98, P36, DOI 10.1172/JCI118774; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; Edwards D P, 1981, Breast Cancer Res Treat, V1, P209, DOI 10.1007/BF01806261; EDWARDS DP, 1980, BIOCHEM BIOPH RES CO, V93, P804, DOI 10.1016/0006-291X(80)91148-1; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1987, SCIENCE, V235, P291; Gagliardi AR, 1996, ANTICANCER RES, V16, P1101; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRADY LH, 1991, ENDOCRINOLOGY, V129, P3321, DOI 10.1210/endo-129-6-3321; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; INGARTROWBRIDGE DM, 1996, ENDOCRINOLOGY, V137, P1735; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KLAGSBRUN M, 1988, ENDOTHELIAL CELLS, P38; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TORRY RJ, 1992, AM J REPROD IMMUNOL, V27, P171, DOI 10.1111/j.1600-0897.1992.tb00746.x; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; Vickers AEM, 1996, CARCINOGENESIS, V17, P1235, DOI 10.1093/carcin/17.6.1235	38	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7042	7047		10.1074/jbc.272.11.7042	http://dx.doi.org/10.1074/jbc.272.11.7042			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054395	Green Published, hybrid			2022-12-25	WOS:A1997WN14700034
J	Xu, XM; Tang, JL; Chen, XM; Wang, LH; Wu, KK				Xu, XM; Tang, JL; Chen, XM; Wang, LH; Wu, KK			Involvement of two Sp1 elements in basal endothelial prostaglandin H synthase-1 promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; BOX-BINDING-PROTEINS; SYNERGISTIC ACTIVATION; ENDOPEROXIDE SYNTHASE; RECEPTOR GENE; CLONING; CELLS; SITES; EXPRESSION; FAMILY	Prostaglandin H synthase-1 (PGHS-1) is a constitutively expressed key enzyme in the biosynthesis of physiologically important prostanoids. The promoter of the human PGHS-1 gene lacks a TATA box, has a very GC-rich region, and contains multiple transcription start sites, To identify the elements involved in the constitutive expression of the PGHS-1 gene, we constructed a 2075-base pair fragment (-2095 to -21 relative to the translation start codon) and a series of 5'-deletion mutants into a promoterless luciferase expression vector, which was transfected in HUVEC. Two important regions were identified. DNase I footprinting identified a protected segment, which contains an Sp1 binding site proximal to the transcription start sites. Band shift assays confirmed specific binding of Sp1 to this segment, Band shift assays further revealed specific binding of Sp1 to a distal region containing a canonical Sp1 site, Mutation of either Sp1 binding site significantly reduced the promoter activity. When both sites were mutated, the activity was reduced to 29% of that of the wild type, Mutation of Sp1 sites did not abrogate promoter activity stimulated by phorbol ester. These results indicate that binding of Sp1 or its related proteins to two widely separated Sp1 sites on the promoter region activates the basal PGHS-1 gene transcription.	UNIV TEXAS, HLTH SCI CTR, VASC BIOL RES CTR, DIV HEMATOL, HOUSTON, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston			Wu, Kenneth Kun-Yu/B-1070-2010	TANG, JIH-LUH/0000-0003-4021-3281	NHLBI NIH HHS [HL-32727, HL-50675] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032727, R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; Felgner P L, 1991, Methods Mol Biol, V7, P81, DOI 10.1385/0-89603-178-0:81; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JOHNSON MR, 1992, J BIOL CHEM, V267, P12202; JONES DA, 1993, J BIOL CHEM, V268, P9049; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LANS MS, 1994, J BIOL CHEM, V269, P14170; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MASHANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shiffman D, 1996, J BIOL CHEM, V271, P12199, DOI 10.1074/jbc.271.21.12199; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; WU KK, 1988, J BIOL CHEM, V263, P19043; WU RL, 1994, J BIOL CHEM, V269, P28450; Xu XM, 1996, AM J PHYSIOL-CELL PH, V270, pC259, DOI 10.1152/ajpcell.1996.270.1.C259; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	42	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6943	6950		10.1074/jbc.272.11.6943	http://dx.doi.org/10.1074/jbc.272.11.6943			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054382	hybrid			2022-12-25	WOS:A1997WN14700021
J	Bartsevich, VV; Pakrasi, HB				Bartsevich, VV; Pakrasi, HB			Molecular identification of a novel protein that regulates biogenesis of photosystem .1. A membrane protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; ANABAENA-VARIABILIS ATCC-29413; GENE-EXPRESSION; CHLAMYDOMONAS-REINHARDTII; TRANSFORMATION; MUTAGENESIS; STABILITY; MUTANT; PSAA; RNA	Photosystem I (PSI) is a multisubunit pigment-protein complex in the thylakoid membranes of cyanobacteria and chloroplasts. BP26, a random photosynthesis-deficient mutant strain of the cyanobacterium Synechocystis 6803 has a severely reduced PSI content, whereas its photosystem II is present in normal amount. The BP26 mutant is complemented by a novel gene, btpA, that encodes a 30-kDa protein. In this strain, a missense mutation in the btpA gene, resulting in the replacement of a valine by a glycine residue, significantly affects the accumulation of the PSI reaction center proteins, PsaA and PsaB. Northern blot analysis revealed that the steady-state levels of the transcripts from the psaAB operon, encoding these proteins, remain unaltered in the mutant strain. Hence the BtpA protein regulates a post-transcriptional process during the life cycle of the PSI protein complex such as 1) translation of the psaAB mRNA, 2) assembly of the PsaA/PsaB polypeptides and their associated cofactors into a functional complex, or 3) degradation of the protein complex. Close relatives of the BtpA protein have been found in nonphotosynthetic organisms, viz. the archaebacterium Methanococcus jannaschii, the eubacterium Escherichia coli, and the nematode, Caenorhabditis elegans, suggesting that these proteins may regulate biogenesis of other protein complexes in these evolutionarily distant organisms.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)								ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; Golden S. S., 1994, MOL BIOL CYANOBACTER, P693; GRIGORIEVA G, 1982, FEMS MICROBIOL LETT, V13, P367, DOI 10.1111/j.1574-6968.1982.tb08289.x; GRUISSEM W, 1989, CELL, V56, P161, DOI 10.1016/0092-8674(89)90889-1; KIM JM, 1991, J BIOL CHEM, V266, P14931; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNAN RM, 1993, PLANT PHYSIOL, V103, P971, DOI 10.1104/pp.103.3.971; MANNAN RM, 1991, P NATL ACAD SCI USA, V88, P10168, DOI 10.1073/pnas.88.22.10168; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; NYHUS KJ, 1993, MOL MICROBIOL, V9, P979, DOI 10.1111/j.1365-2958.1993.tb01227.x; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; REDDY KJ, 1990, BIOTECHNIQUES, V8, P250; REY L, 1993, MOL MICROBIOL, V8, P471, DOI 10.1111/j.1365-2958.1993.tb01591.x; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUBERT WD, 1995, PHOTOSYNTHESIS LIGHT, V2, P3; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	39	31	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6382	6387		10.1074/jbc.272.10.6382	http://dx.doi.org/10.1074/jbc.272.10.6382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045660	hybrid			2022-12-25	WOS:A1997WM64700044
J	Chen, PF; Tsai, AL; Berka, V; Wu, KK				Chen, PF; Tsai, AL; Berka, V; Wu, KK			Mutation of Glu-361 in human endothelial nitric-oxide synthase selectively abolishes L-arginine binding without perturbing the behavior of heme and other redox centers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; ISOLATED OXYGENASE; REDUCTASE DOMAINS; L-THIOCITRULLINE; BRAIN; CALMODULIN; EXPRESSION; POTENT; IDENTIFICATION; COORDINATION	Nitric oxide (NO) and L citrulline are formed from the oxidation of L-arginine by three different isoforms of NO synthase (NOS). Defining amino acid residues responsible for L arginine binding and oxidation is a primary step toward a detailed understanding of the NOS reaction mechanisms and designing strategies for the selective inhibition of the individual isoform. We have altered Glu-361 in human endothelial NOS to Gin or Leu by site-directed mutagenesis and found that these mutations resulted in a complete loss of L citrulline formation without disruption of the cytochrome c reductase and NADPH oxidase activities. Optical and EPR spectroscopic studies demonstrated that the Glu-361 mutants had similar spectra either in resting state or reduced GO-complex as the wild type. The heme ligand, imidazole, could induce a low spin state in both wild-type and Glu-361 mutants. However, unlike the wild-type enzyme, the low spin imidazole complex of Glu-361 mutants was not reversed to a high spin state by addition of either L-arginine, acetylguanidine, or a-aminothiazole. Direct L-arginine binding could not be detected in the mutants either. These results strongly indicate that Glu-361 in human endothelial NOS is specifically involved in the interaction with L arginine. Mutation of this residue abolished the L-arginine binding without disruption of other functional characteristics.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston	Chen, PF (corresponding author), UNIV TEXAS,SCH MED,DIV HEMATOL,HLTH SCI CTR,6431 FANNIN,MSB 5-284,HOUSTON,TX 77030, USA.		Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50675] Funding Source: Medline; NIGMS NIH HHS [R01 GM044911-08, GM-44911, R01 GM044911] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; FREY C, 1994, J BIOL CHEM, V269, P26083; FUKUTO JM, 1990, BIOCHEM BIOPH RES CO, V168, P458, DOI 10.1016/0006-291X(90)92343-X; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLATT P, 1994, J BIOL CHEM, V269, P1674; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3683; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sari MA, 1996, BIOCHEMISTRY-US, V35, P7204, DOI 10.1021/bi960087u; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TSAI AL, 1993, J BIOL CHEM, V268, P8554; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563	36	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6114	6118		10.1074/jbc.272.10.6114	http://dx.doi.org/10.1074/jbc.272.10.6114			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045621	hybrid, Green Accepted			2022-12-25	WOS:A1997WM64700005
J	Chen, XH; Patel, BKR; Wang, LM; Frankel, M; Ellmore, N; Flavell, RA; LaRochelle, WJ; Pierce, JH				Chen, XH; Patel, BKR; Wang, LM; Frankel, M; Ellmore, N; Flavell, RA; LaRochelle, WJ; Pierce, JH			Jak1 expression is required for mediating interleukin-4 induced tyrosine phosphorylation of insulin receptor substrate and state signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID CELLS; HEMATOPOIETIC-CELLS; IL-4 RECEPTOR; GAMMA-CHAIN; FACTOR-I; PROTEIN; MITOGENESIS; INTERFERON; CLONING; KINASE	The Jak1, Jak2, Jak8, and Fes tyrosine kinases have been demonstrated to undergo tyrosine phosphorylation in response to interleukin (IL)-4 stimulation in different cell systems. However, it is not clear which, if any, of these kinases are responsible for initiating IL-4-induced tyrosine phosphorylation of intracellular substrates in vivo, In the present study, we have utilized a mutant Jak1-deficient HeLa cell line, E1C3, and its parental Jakl-expressing counterpart, 1D4, to analyze the role of Jak1 in mediating IL-8-induced tyrosine phosphorylation events, IL-4 treatment rapidly induced tyrosine phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 in 1D4 but not in E1C3 cells. IL-4-mediated tyrosine phosphorylation of State was pronounced in 1D4 cells, while no IL-4-induced State phosphorylation was detected in E1C3 cells. IL-4 also induced State DNA binding activity from lysates of 1D4 but not E1C3 cells utilizing a radiolabeled immunoglobulin heavy chain germline epsilon promotor sequence (I epsilon) in an electrophoretic mobility shift assay, Reconstitution of Jak1 expression in E1C3 cells restored the ability of IL-4 to induce IRS and Stat6 tyrosine phosphorylation, These results provide evidence that Jak1 expression is required for mediating tyrosine phosphorylation and activation of crucial molecules involved in IL-4 signal transduction.	NCI,MOL & CELLULAR BIOL LAB,NIH,BETHESDA,MD 20892; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT BIOL,NEW HAVEN,CT 06510	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University								FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE W, 1996, J BIOL CHEM, V271, P1164; HE YW, 1995, J IMMUNOL, V154, P1596; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, TRENDS GENET, V11, P3951; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAPLAN MH, 1996, IMMUNITY, V4, P1; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; LOH JE, 1992, EMBO J, V11, P1351, DOI 10.1002/j.1460-2075.1992.tb05180.x; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MATTHEWS DJ, 1995, BLOOD, V85, P1; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; PAUL WE, 1991, BLOOD, V77, P1859; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RUSSEL SM, 1993, SCIENCE, V262, P1874; RUSSEL SM, 1995, SCIENCE, V266, P1042; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Wang HY, 1997, J IMMUNOL, V158, P1037; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, J BIOL CHEM, V269, P26614	43	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6556	6560		10.1074/jbc.272.10.6556	http://dx.doi.org/10.1074/jbc.272.10.6556			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045682	hybrid			2022-12-25	WOS:A1997WM64700066
J	Fusaki, N; Iwamatsu, A; Iwashima, M; Fujisawa, J				Fusaki, N; Iwamatsu, A; Iwashima, M; Fujisawa, J			Interaction between Sam68 and Src family tyrosine kinases, Fyn and Lck, in T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL PROTOONCOGENE; JAK-3 JANUS KINASE; ANTIGEN RECEPTOR; SH3 DOMAINS; HTLV-I; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; BINDING-PROTEIN; NUCLEIC-ACID; PROLINE-RICH	The Src family protein-tyrosine kinase, Fyn, is associated with the T cell receptor (TCR) and plays an important role in TCR-mediated signaling. We found that a human T cell leukemia virus type 1-infected T cell line, Hayai, overexpressed Fyn. To identify the molecules downstream of Fyn, we analyzed the tyrosine phosphorylation of cellular proteins in the cells. In Hayai, a 68-kDa protein was constitutively tyrosine-phosphorylated. The 68-kDa protein was coimmunoprecipitated with various signaling proteins such as phospholipase C gamma 1, the phosphatidylinositol 3-kinase p85 subunit, Grb(2), SHP-1, Cb1, and Jak3, implying that the protein might function as an adapter. Purification and microsequencing of this protein revealed that it was the RNA-binding protein, Sam68 (Src associated in mitosis, 68 kDa). Sam68 was associated with the Src homology 2 and 3 domains of Fyn and also those of another Src family kinase, Lck. CD3 cross linking induced tyrosine phosphorylation of Sam68 in uninfected T cells. These data suggest that Sam68 participates in the signal transduction pathway downstream of TCR-coupled Src family kinases Fyn and Lck in lymphocytes, that is not only in the mitotic pathway downstream of c-Src in fibroblasts.	KANSAI MED UNIV,DEPT MICROBIOL,MORIGUCHI,OSAKA 570,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; MITSUBISHI KASEI INST LIFE SCI,DIV CELL & INFORMAT PRECURSORY RES EMBRYON SCI,RES DEV CORP JAPAN,MACHIDA,TOKYO 194,JAPAN	Kansai Medical University; Kirin Brewery Company Limited; Japan Science & Technology Agency (JST)			Fusaki, Noemi/U-1628-2019					APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BLAKE TJ, 1991, ONCOGENE, V6, P653; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; Fusaki N, 1996, J IMMUNOL, V156, P1369; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GILES O, 1995, J EXP MED, V182, P611; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KOGA Y, 1989, J IMMUNOL, V142, P4493; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATSUOKA M, 1986, BLOOD, V4, P1070; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Ribon V, 1996, MOL CELL BIOL, V16, P45; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Sattler M, 1996, ONCOGENE, V12, P839; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Xu X, 1996, ONCOGENE, V13, P135; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D	60	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6214	6219		10.1074/jbc.272.10.6214	http://dx.doi.org/10.1074/jbc.272.10.6214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045636	hybrid			2022-12-25	WOS:A1997WM64700020
J	Grima, J; Zhu, LJ; Cheng, CY				Grima, J; Zhu, LJ; Cheng, CY			Testin is tightly associated with testicular cell membrane upon its secretion by sertoli cells whose steady state mRNA level in the testis correlates with the turnover and integrity of inter-testicular cell junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE INT-1; RAT TESTIS; GERM-CELLS; 3-DIMENSIONAL RECONSTRUCTION; EXTRACELLULAR-MATRIX; SPERMATID BINDING; MEDIUM CONTAINS; CULTURE-MEDIUM; ACTIN BUNDLES; IDENTIFICATION	Testin, a Sertoli cell secretory protein whose mRNA is predominantly expressed in the testis, was shown to become tightly associated with Sertoli cell membrane upon its secretion whose solubilization requires the use of a detergent such as SDS. In the in vitro studies using Sertoli cells cultured at high cell density, where specialized junctions were being formed, the concentration of ''soluble'' testin in the spent media was greatly reduced versus monolayer cultures at low cell density, where specialized junctions were absent. Conversely, the concentration of ''membrane-bound'' testin from detergent-solubilized Sertoli cell membrane extract was positively correlated to the existence of specialized junctions in these cultures. In normal rat testes, the level of radioimmunoassayable soluble testin in the cytosol was low. However, when the inter-testicular cell junctions were disrupted either by a drug treatment such as lonidamine in vivo or by a physical treatment in vitro such as exposing Sertoli-germ cell co cultures where specialized junctions were formed to a hypotonic treatment, a drastic surge in the testin gene expression was noted. Thus, testin can become tightly associated with Sertoli cell membrane upon its secretion when intercellular junctions are formed. It is also a marker to monitor the integrity of inter testicular cell junctions.	POPULAT COUNCIL,NEW YORK,NY 10021	Population Council				Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [HD-13541] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARAVINDAN GR, 1993, J ENDOCRINOL, V137, P485, DOI 10.1677/joe.0.1370485; Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; BARDIN CW, 1988, PHYSL REPRODUCTION, V1, P933; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BYERS S, 1991, AM J ANAT, V191, P35, DOI 10.1002/aja.1001910104; Byers S., 1993, SERTOLI CELL, P461; BYERS SW, 1994, ENDOCRINOLOGY, V134, P630, DOI 10.1210/en.134.2.630; CAMERON DF, 1991, J CELL SCI, V100, P623; CHAN YL, 1990, FEBS LETT, V263, P85, DOI 10.1016/0014-5793(90)80711-Q; CHENG CY, 1989, J BIOL CHEM, V264, P21386; CHENG CY, 1987, J BIOL CHEM, V262, P12768; CORSI G, 1976, J MED CHEM, V19, P778, DOI 10.1021/jm00228a008; CYR DG, 1992, ENDOCRINOLOGY, V131, P139, DOI 10.1210/en.131.1.139; DEKRETSER DM, 1988, PHYSL REPROD, P933; DEMARTINO C, 1981, CHEMOTHERAPY, V27, P27, DOI 10.1159/000238043; ENDERS GC, 1988, J CELL SCI, V90, P105; Enders GC, 1993, SERTOLI CELL, P448; Galdieri M, 1981, J ANDROL, V5, P249; GRIMA J, 1992, MOL CELL ENDOCRINOL, V89, P127, DOI 10.1016/0303-7207(92)90219-V; Grima J, 1996, J ANDROL, V17, P263; GRIMA J, 1995, BIOL REPROD, V52, P340, DOI 10.1095/biolreprod52.2.340; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HIKIM APS, 1994, ENDOCRINOLOGY, V134, P1627, DOI 10.1210/en.134.4.1627; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; HOWARDS SS, 1975, FERTIL STERIL, V26, P13; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; Long J. A., 1922, Memoirs of the University of California, V6, P1; MALORNI W, 1992, ANTICANCER RES, V12, P2037; MANDL AM, 1951, J EXP BIOL, V28, P585; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ONODA M, 1990, MOL CELL ENDOCRINOL, V73, P35, DOI 10.1016/0303-7207(90)90042-7; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PFEIFFER DC, 1991, ANAT RECORD, V231, P89, DOI 10.1002/ar.1092310110; PINEAU C, 1993, J ANDROL, V14, P87; ROSS MH, 1976, ANAT REC, V186, P79, DOI 10.1002/ar.1091860107; ROSSI V, 1989, J ANDROL, V10, P466; RUSSELL LD, 1983, AM J ANAT, V167, P181, DOI 10.1002/aja.1001670204; Russell LD, 1980, TESTICULAR DEV STRUC, P55; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; Silvestrini B., 1984, PROG MED CHEM, V21, P111; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SKINNER MK, 1985, P NATL ACAD SCI USA, V82, P114, DOI 10.1073/pnas.82.1.114; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRES LL, 1983, P NATL ACAD SCI-BIOL, V80, P3377, DOI 10.1073/pnas.80.11.3377; WEBER JE, 1983, AM J ANAT, V167, P163, DOI 10.1002/aja.1001670203; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG TY, 1982, AM J ANAT, V165, P13; ZHU LJ, 1994, J ANDROL, V15, P575; ZONG SD, 1992, BIOL REPROD, V47, P568, DOI 10.1095/biolreprod47.4.568; ZONG SD, 1994, BIOL REPROD, V51, P843, DOI 10.1095/biolreprod51.5.843; ZWAIN IH, 1994, MOL CELL ENDOCRINOL, V104, P213, DOI 10.1016/0303-7207(94)90124-4	57	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6499	6509		10.1074/jbc.272.10.6499	http://dx.doi.org/10.1074/jbc.272.10.6499			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045675	hybrid			2022-12-25	WOS:A1997WM64700059
J	Sun, TX; Das, BK; Liang, JJN				Sun, TX; Das, BK; Liang, JJN			Conformational and functional differences between recombinant human lens alpha A- and alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEIN; CIRCULAR-DICHROISM; EXPRESSION; AGGREGATION; FIBERS; SYSTEM	Human and other mammalian lens proteins are composed of three major crystallins: alpha-, beta-, and gamma-crystallin. alpha-Crystallin plays a prominent role in the supramolecular assembly required 60 maintain lens transparency. With age, the crystallins, especially alpha-crystallin, undergo posttranslational modifications that may disrupt the supramolecular assembly, and the lens becomes susceptible to other stresses resulting in cataract formation. Because these modifications occur even at a relatively young age, it is difficult to obtain pure, unmodified crystallins for in vitro experiments. alpha-Crystallin is composed of two subunits, alpha A and alpha B. Before the application of recombinant DNA technology, these two alpha-crystallin subunits were separated from calf lens in the denatured state and reconstituted by the removal of the denaturant, but they were not refolded properly. In the present studies, we applied the recombinant DNA technology to prepare native, unmodified alpha A- and alpha B-crystallins for conformational and functional studies. The expressed proteins from Escherichia coli are in the native state and can be studied directly. First, alpha A and alpha B cDNAs were isolated from a human lens epithelial cell cDNA library. The cDNAs were cloned into a pAED4 expression vector and then expressed in E. coli strain BL21(DE3). Pure recombinant alpha A- and alpha B-crystallins were obtained after purification by gel filtration and DEAE liquid chromatography. They were subjected to conformational studies involving various spectroscopic measurements and an assessment of chaperone-like activity. alpha A- and alpha B-crystallins have not only different secondary structure, but also tertiary structure. 1-Anilino-8-naphthalene sulfonate fluorescence indicates that alpha B-crystallin is more hydrophobic than alpha A-crystallin. The chaperone-like activity, as measured by the ability to protect insulin aggregation, is about 4 times greater for alpha B- than for alpha A-crystallin. The resulting data provide a base line for further studies of human lens alpha-crystallin.	BRIGHAM & WOMENS HOSP, CTR OPHTHALM RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NEI NIH HHS [EY 05803] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Cantor C. R., 1982, PROTEINS, VV, P145; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DATILES MB, 1992, CURR EYE RES, V11, P669, DOI 10.3109/02713689209000740; DERETIC D, 1994, J BIOL CHEM, V269, P16853; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harding J. J., 1991, CATARACT BIOCH EPIDE, P1; Hitotsumatsu T, 1996, CANCER, V77, P352, DOI 10.1002/(SICI)1097-0142(19960115)77:2<352::AID-CNCR19>3.0.CO;2-0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1993, ACTA NEUROPATHOL, V85, P475; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1991, KIDNEY INT, V40, P52, DOI 10.1038/ki.1991.178; JIN JP, 1995, J BIOL CHEM, V270, P6908; JOHNSON JD, 1979, BIOCHEMISTRY-US, V18, P1292, DOI 10.1021/bi00574a027; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LK, 1973, EXP EYE RES, V15, P179, DOI 10.1016/0014-4835(73)90117-6; LIANG J, 1989, INVEST OPHTH VIS SCI, V30, P2065; LIANG JN, 1982, BIOCHEMISTRY-US, V21, P1847, DOI 10.1021/bi00537a022; LIANG JN, 1991, EXP EYE RES, V53, P61, DOI 10.1016/0014-4835(91)90145-5; LIANG JN, 1985, BIOCHIM BIOPHYS ACTA, V832, P197, DOI 10.1016/0167-4838(85)90332-2; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMULDERS RHPH, 1995, J BIOL CHEM, V270, P13916, DOI 10.1074/jbc.270.23.13916; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; THOMSON JA, 1989, BIOCHIM BIOPHYS ACTA, V994, P246, DOI 10.1016/0167-4838(89)90300-2; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WANG KY, 1995, EXP EYE RES, V61, P115; WANG KY, 1994, J BIOL CHEM, V269, P13601	40	170	180	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6220	6225		10.1074/jbc.272.10.6220	http://dx.doi.org/10.1074/jbc.272.10.6220			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045637	hybrid			2022-12-25	WOS:A1997WM64700021
J	Fukuyama, K; Sato, K; Itakura, H; Takahashi, S; Hosoya, T				Fukuyama, K; Sato, K; Itakura, H; Takahashi, S; Hosoya, T			Binding of iodide to Arthromyces ramosus peroxidase investigated with X-ray crystallographic analysis, H-1 and I-127 NMR spectroscopy, and steady-state kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; COPRINUS-CINEREUS PEROXIDASE; AROMATIC DONOR MOLECULES; HEME-LINKED IONIZATION; HORSERADISH-PEROXIDASE; ACTIVE-SITE; MACRORHIZUS PEROXIDASE; THYROID PEROXIDASE; CRYSTAL-STRUCTURE; COMPOUND-II	The site and characteristics of iodide binding to Arthromyces ramosus peroxidase were examined by x-ray crystallographic analysis, H-1 and I-127 NMR and kinetic studies. X-ray analysis of an A. ramosus peroxidase crystal soaked in a KI solution at pH 5.5 showed that a single iodide ion is located at the entrance of the access channel to the distal side of the heme and Lies between the two peptide segments, Phe(90)-Pro(91)-Ala(92) and Ser(151)-Leu(152)-Ile(153), 12.8 Angstrom from the heme iron, The distances between the iodide ion and heme peripheral methyl groups were all more than 10 Angstrom. The findings agree with the results obtained with H-1 NMR in which the chemical shift and intensity of the methyl groups in the hyperfine shift region of A. ramosus peroxidase were hardly affected by the addition of iodide, unlike the case of horseradish peroxidase. Moreover, I-127 NMR and steady-state kinetics showed that the binding of iodide depends on protonation of an amino acid residue with a pK(a) of about 5.3, which presumably is the distal histidine (His(56)), 7.8 Angstrom away from the iodide ion. The mechanism of electron transfer from the iodide ion to the heme iron is discussed on the basis of these findings.	OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN; KUMAMOTO UNIV,SCH MED,KUMAMOTO 860,JAPAN; JAPAN WOMENS UNIV,FAC SCI,BUNKYO KU,TOKYO 112,JAPAN; SCI UNIV TOKYO,FAC SCI & TECHNOL,NODA,CHIBA 278,JAPAN	Osaka University; Kumamoto University; Japan Womens University; Tokyo University of Science								ANDERSEN MB, 1991, ACTA CHEM SCAND, V45, P1080, DOI 10.3891/acta.chem.scand.45-1080; ARAISO T, 1981, J BIOL CHEM, V256, P99; BAUNSGAARD L, 1993, EUR J BIOCHEM, V213, P605, DOI 10.1111/j.1432-1033.1993.tb17800.x; BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BHATTACHARYYA DK, 1993, J BIOL CHEM, V268, P22292; BJORKSTEN F, 1970, BIOCHIM BIOPHYS ACTA, V212, P396, DOI 10.1016/0005-2744(70)90245-7; BRUNGER AT, 1992, XPLOR VERSION 3 0; CRITCHLOW JE, 1972, J BIOL CHEM, V247, P3714; DEVAULT D, 1984, QUANTUM MECHANICAL T; DUGAD LB, 1992, BIOCHIM BIOPHYS ACTA, V1122, P63, DOI 10.1016/0167-4838(92)90128-Z; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1987, BIOCHEMISTRY-US, V26, P1503, DOI 10.1021/bi00380a002; Everse J., 1991, PEROXIDASES CHEM BIO, V2; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FUKUYAMA K, 1995, J BIOL CHEM, V270, P21884, DOI 10.1074/jbc.270.37.21884; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HIGASHI T, 1990, PROCESS PROGRAM INDE; HOSOYA T, 1963, J BIOCHEM-TOKYO, V53, P381, DOI 10.1093/oxfordjournals.jbchem.a127712; HOSOYA T, 1989, BIOCHEMISTRY-US, V28, P2639, DOI 10.1021/bi00432a042; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KIMURA S, 1978, ARCH BIOCHEM BIOPHYS, V189, P14, DOI 10.1016/0003-9861(78)90108-X; KJALKE M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P248, DOI 10.1016/0167-4838(92)90244-8; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LAMAR GN, 1980, J BIOL CHEM, V255, P6646; LUKAT GS, 1989, BIOCHEMISTRY-US, V28, P3338, DOI 10.1021/bi00434a032; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P197; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1992, CHEM REV, V92, P481, DOI 10.1021/cr00011a007; MODI S, 1989, J BIOL CHEM, V264, P19677; MODI S, 1989, BIOCHIM BIOPHYS ACTA, V996, P214, DOI 10.1016/0167-4838(89)90250-1; MODI S, 1989, BIOCHEMISTRY-US, V28, P4689, DOI 10.1021/bi00437a027; MORITA Y, 1988, J BIOCHEM-TOKYO, V103, P693, DOI 10.1093/oxfordjournals.jbchem.a122331; NAGAOKA S, 1992, J PHYS CHEM-US, V96, P2754, DOI 10.1021/j100185a065; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OHTAKI S, 1981, J BIOL CHEM, V256, P805; POMMIER J, 1973, EUR J BIOCHEM, V38, P497, DOI 10.1111/j.1432-1033.1973.tb03085.x; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAKURADA J, 1985, CHEM LETT, P211, DOI 10.1246/cl.1985.211; SAKURADA J, 1987, J BIOL CHEM, V262, P4007; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SAKURADA J, 1987, BIOCHEMISTRY-US, V26, P6478, DOI 10.1021/bi00394a028; SAWAIHATANAKA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1221, DOI 10.1271/bbb.59.1221; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SMULEVICH G, 1994, BIOCHEMISTRY-US, V33, P15425, DOI 10.1021/bi00255a024; TAKAHASHI S, 1988, J MAGN RESON, V76, P347, DOI 10.1016/0022-2364(88)90119-9; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; UGAROVA NN, 1981, BIOCHIM BIOPHYS ACTA, V662, P210, DOI 10.1016/0005-2744(81)90032-2; VEITCH NC, 1994, EUR J BIOCHEM, V222, P909, DOI 10.1111/j.1432-1033.1994.tb18939.x; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; [No title captured]	55	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5752	5756		10.1074/jbc.272.9.5752	http://dx.doi.org/10.1074/jbc.272.9.5752			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038188	hybrid			2022-12-25	WOS:A1997WK74700056
J	Liu, HL; Force, T; Bloch, KD				Liu, HL; Force, T; Bloch, KD			Nerve growth factor decreases soluble guanylate cyclase in rat pheochromocytoma PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GENE-EXPRESSION; PROTEIN-KINASE; MESSENGER-RNA; HIGH-AFFINITY; RECEPTOR; DIFFERENTIATION; ASSOCIATION; CGMP; LUNG	Nitric oxide (NO) modulates neurotransmission in the central and peripheral nervous systems. NO acts, ill part, by stimulating cGMP production by soluble guanylate cyclase (sGC), an obligate heterodimer composed of alpha and beta subunits. To investigate mechanisms that regulate responsiveness to NO in the nervous system, sGC regulation was examined in a rat pheochromocytoma cell line (PC12) exposed to nerve growth factor (NGF). NGF decreased sGC alpha 1 and beta 1 subunit mRNA and protein levels as well as NO-stimulated sGC enzyme activity, The NGF-mediated decrease in sGC subunit mRNA levels was blocked by 5'-deoxy-5'-methylthioadenosine (an inhibitor of NGF-induced tyrosine phosphorylation), NGF did not decrease sGC subunit mRNA levels in PC12 cells containing a mutant Ras protein that blocks Ras-dependent intracellular signaling, Incubation of PC12 cells with a transcription inhibitor (actinomycin D) or protein synthesis inhibitors (anisomycin or cycloheximide) attenuated the ability of NGF to decrease sGC subunit mRNA levels. Moreover, sGC subunit mRNA levels decreased more rapidly in NGF-treated cells than in actinomycin D-treated cells, suggesting that NGF decreases sGC subunit mRNA stability. Thus, NGF decreases sGC subunit mRNA levels via mechanisms that are dependent on protein tyrosine phosphorylation and Ras activation. The effect of NGF on sGC subunit mRNA stability appears to be transcription- and translation-dependent. Modulation of sGC subunit levels and enzyme activity in PC12 cells suggests that NO responsiveness may be regulated in the nervous system by NGF.	MASSACHUSETTS GEN HOSP,GEN MED SERV,CARDIAC UNIT,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University	Liu, HL (corresponding author), MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CNY 4,149 13TH ST,CHARLESTOWN,MA 02129, USA.			Force, Thomas/0000-0002-0450-8659	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055377, T32HL007208] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55377, T32 HL07208] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; BERND P, 1984, J BIOL CHEM, V259, P5509; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUSKIRK R, 1985, MOL CELL BIOL, V5, P1984; DAWSON TM, 1994, J NEUROSCI, V14, P5147; Farinelli SE, 1996, J NEUROSCI, V16, P2325; HATANAKA H, 1978, FEBS LETT, V92, P313, DOI 10.1016/0014-5793(78)80777-7; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEAKIN SO, 1991, P NATL ACAD SCI USA, V88, P5862, DOI 10.1073/pnas.88.13.5862; Mittal C K, 1986, Methods Enzymol, V132, P422; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PAPAPETROPOULOS A, 1995, HYPERTENSION, V26, P696, DOI 10.1161/01.HYP.26.4.696; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RAIFIONI S, 1993, ANN REV BIOCH, V62, P823; Sambrook J., 2002, MOL CLONING LAB MANU; SANDBERG K, 1989, J NEUROSCI, V9, P3946; SHIMOUCHI A, 1993, AM J PHYSIOL, V265, pL456, DOI 10.1152/ajplung.1993.265.5.L456; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; UJIIE K, 1994, J PHARMACOL EXP THER, V270, P761; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; ZHUO M, 1994, NEUROREPORT, V5, P1033, DOI 10.1097/00001756-199405000-00004	30	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6038	6043		10.1074/jbc.272.9.6038	http://dx.doi.org/10.1074/jbc.272.9.6038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038227	hybrid			2022-12-25	WOS:A1997WK74700095
J	McCormick, TS; McColl, KS; Distelhorst, CW				McCormick, TS; McColl, KS; Distelhorst, CW			Mouse lymphoma cells destined to undergo apoptosis in response to thapsigargin treatment fail to generate a calcium-mediated grp78/grp94 stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; CHAIN-BINDING-PROTEIN; MESSENGER-RNA LEVELS; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; MALFOLDED PROTEINS; MAMMALIAN-CELLS; GRP78 PROMOTER; INDUCTION; GRP94	grp78/grp94 induction is critical for maintaining the viability of epithelial cells and fibroblasts following treatment with thapsigargin (TG), an inhibitor of Ca2+ uptake into the endoplasmic reticulum, In contrast to these cell types, WEHI7.2 mouse lymphoma cells undergo apoptosis when treated with TG, prompting us to examine the grp78/grp94 stress response in WEHI7.2 cells, TG treatment failed to induce grp78/grp94 transcription in WEHI7.2 cells, measured by Northern hybridization and nuclear run-on assays, even if the cells were protected from apoptosis by overexpressing bcl-2. However, grp78/grp94 transcription was induced by the glycosylation inhibitor tunicamycin, suggesting that there are at least two grp78/grp94 signaling pathways, one in response to TG-induced endoplasmic reticulum Ca2+ pool depletion, which is inoperable in WEHI7.2 cells, and one in response to glycosylatian inhibition, which is operable in WEHI7.2 cells. Studies of additional lymphoid lines, as well as several nonlymphoid lines, suggested a correlation between grp78/grp94 induction and resistance to apoptosis following TG treatment, In conclusion, the vulnerability of TG-treated WEHI7.2 cells to apoptosis may be due to failure to signal a grp78/grp94 stress response.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,IRELAND CANC CTR,CLEVELAND,OH 44106	Case Western Reserve University; University Hospitals of Cleveland				McCormick, Thomas/0000-0002-3294-0326	NATIONAL CANCER INSTITUTE [T32CA059366, R01CA042755] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA42755, T32 CA59366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Distelhorst CW, 1996, CELL CALCIUM, V19, P473, DOI 10.1016/S0143-4160(96)90056-1; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FEI HH, 1993, BIOTECHNIQUES, V15, P838; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOMER CJ, 1991, CANCER RES, V51, P6574; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HUGHES CS, 1989, CANCER RES, V49, P4452; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; KIM YK, 1987, J CELL PHYSL, V133, P533; KOCH G, 1986, J CELL SCI, V86, P217; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LENNY N, 1991, J BIOL CHEM, V266, P20532; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI WWF, 1993, J BIOL CHEM, V268, P12003; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LODISCH HF, 1992, J BIOL CHEM, V267, P12763; LOFQUIST AK, 1995, MOL CELL BIOL, V15, P1737; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MORI K, 1993, CELL, V7, P473; PRICE BD, 1992, CANCER RES, V52, P3814; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; ULATOWSKI LM, 1993, J BIOL CHEM, V268, P7482; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612	44	90	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6087	6092		10.1074/jbc.272.9.6087	http://dx.doi.org/10.1074/jbc.272.9.6087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038234	hybrid			2022-12-25	WOS:A1997WK74700102
J	Mullin, NP; Hitchen, PG; Taylor, ME				Mullin, NP; Hitchen, PG; Taylor, ME			Mechanism of Ca2+ and monosaccharide binding to a C-type carbohydrate-recognition domain of the macrophage mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CA2+-DEPENDENT ANIMAL LECTINS; SITE-DIRECTED MUTAGENESIS; WHEAT-GERM-AGGLUTININ; CRYSTAL-STRUCTURE; LIGAND-BINDING; SUGAR LIGANDS; PROTEIN; EXPRESSION; RESOLUTION	Site-directed mutagenesis has been used to identify residues that ligate Ca2+ and sugar to the fourth C-type carbohydrate-recognition domain (CRD) of the macrophage mannose receptor. CRD-4 is the only one of the eight CRDs of the mannose receptor to exhibit detectable monosaccharide binding when expressed in isolation, and it is central to ligand binding by the receptor. CRD-4 requires two Ca2+ for sugar binding, like the CRD of rat serum mannose-binding protein (MBP-A). Sequence comparisons between the two CRDs suggest that the binding site for one Ca2+, which ligates directly to the bound sugar in MBP-A, is conserved in CRD-4 but that the auxiliary Ca2+ binding site is not. Mutation of the four residues at positions in CRD-4 equivalent to the auxiliary Ca2+ binding site in MBP-A indicates that only one, Asn(728), is involved in ligation of Ca2+, Alanine-scanning mutagenesis was used to identify two other asparagine residues and one glutamic acid residue that are probably involved in ligation of the auxiliary Ca2+ to CRD-4. Sequence comparisons with other C-type CRDs suggest that the proposed, binding site for the auxiliary Ca2+ in CRD-4 of the mannose receptor is unique. Evidence that the conserved Ca2+ in CRD-4 bridges between the protein and bound sugar in a manner analogous to MBP-A was obtained by mutation of one of the amino acid side chains at this site. Ring current shifts seen in the H-1 NMR spectra of methyl glycosides of mannose, GlcNAc, and fucose in the presence of CRD-4 and site-directed mutagenesis indicate that a stacking interaction with Tyr(729) is also involved in binding of sugars to CRD-4. This interaction contributes about 25% of the total free energy of binding to mannose. C-5 and C-6 of mannose interact with Tyr(729), whereas C-2 of GlcNAc is closest to this residue, indicating that these two sugars bind to CRD-4 in opposite orientations. Sequence comparisons with other mannose/GlcNAc-specific C-type CRDs suggest that use of a stacking interaction in the binding of these sugars is probably unique to CRD-4 of the mannose receptor.	UNIV OXFORD,DEPT BIOCHEM,GLYCOBIOL INST,OXFORD OX1 3QU,ENGLAND	University of Oxford				Mullin, Nicholas/0000-0003-4802-440X				ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; ANOSTARIO M, 1995, J BIOL CHEM, V270, P8138, DOI 10.1074/jbc.270.14.8138; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DEREWENDA Z, 1989, EMBO J, V8, P2198; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; Ewart KV, 1996, J BIOL CHEM, V271, P16627, DOI 10.1074/jbc.271.28.16627; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GENG JG, 1991, J BIOL CHEM, V266, P22313; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HARRIS N, 1992, BLOOD, V80, P2363; HESTER G, 1995, NAT STRUCT BIOL, V2, P472, DOI 10.1038/nsb0695-472; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; IOBST ST, 1994, J BIOL CHEM, V269, P15512; IOBST ST, 1994, J BIOL CHEM, V269, P15505; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JERNIGAN R, 1994, CURR OPIN STRUC BIOL, V4, P256, DOI 10.1016/S0959-440X(94)90317-4; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LIM BL, 1994, J BIOL CHEM, V269, P11820; LOEB JA, 1988, J BIOL CHEM, V263, P9752; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; PERKINS SJ, 1980, BIOCHEMISTRY-US, V19, P245, DOI 10.1021/bi00543a001; RINI JM, 1993, J BIOL CHEM, V268, P10126; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WRIGHT CS, 1984, J MOL BIOL, V178, P91, DOI 10.1016/0022-2836(84)90232-8; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13	44	80	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5668	5681		10.1074/jbc.272.9.5668	http://dx.doi.org/10.1074/jbc.272.9.5668			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038177	hybrid			2022-12-25	WOS:A1997WK74700045
J	NagamotoCombs, K; Piech, KM; Best, JA; Sun, BY; Tank, AW				NagamotoCombs, K; Piech, KM; Best, JA; Sun, BY; Tank, AW			Tyrosine hydroxylase gene promoter activity is regulated by both cyclic AMP-responsive element and AP1 sites following calcium influx - Evidence for cyclic AMP-responsive element binding protein-independent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELL-LINE; C-FOS TRANSCRIPTION; IMMEDIATE-EARLY GENES; RAT ADRENAL-MEDULLA; MEMBRANE DEPOLARIZATION; MESSENGER-RNA; DEPENDENT TRANSCRIPTION; EXPRESSION; INDUCTION; KINASE	Membrane depolarization of PC12 cells using 50 mM KCI leads to induction of tyrosine hydroxylase (TH) mRNA, This induction of TH mRNA is apparently due to increased TH gene promoter activity mediated by the influx of Ca2+. In PC12 cells transiently transfected with a chimeric gene expressing chloramphenicol acetyltransferase (CAT) driven by the proximal TH gene 5'-flanking region, 50 mM KCl increases TH gene promoter activity 3-4-fold, Promoter analysis utilizing TH-CAT constructs containing mutagenized sequences indicates that this response to the depolarization-mediated influx of Ca2+ is primarily dependent on both the TH cAMP-responsive element (CRE) and TH activating protein-1 (AP1) site. Minimal promoter constructs that contain a single copy of either the TH CRE or TH AP1 site fused upstream of the TH gene basal promoter are only modestly responsive or nonresponsive, respectively, to depolarization. However, both these constructs are strongly responsive to the calcium ionophore, A23187, Gel shift assays indicate that TH AP1 complex formation is dramatically increased after treatment with either 50 mM KCl or A23187. Using antibodies to transcription factors of the Fos and Jun families, we show that the nuclear proteins comprising the inducible TH AP1 complex include c-Fos, c-Jun, JunB, and JunD. In cAMP-responsive element binding protein (CREB)-deficient cell lines that express antisense RNA complementary to CREB mRNA, the response of the TH gene promoter to cyclic AMP is dramatically inhibited, but the response to A23187 remains robust, This result indicates that transcription factors other than CREB can participate in the Ca2+-mediated regulation of the TH gene. In summary, our results support the hypothesis that regulation of the TH gene by Ca2+ is mediated by mechanisms involving both the TH CRE and TH AP1 sites and that transcription factors other than or in addition to CREB participate in this response.	UNIV ROCHESTER, MED CTR, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, PROGRAM NEUROSCI, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester			Nagamoto-Combs, Kumi/AAN-6697-2021		NIDA NIH HHS [DA07232] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007232] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BEST JA, 1995, J NEUROCHEM, V65, P1934; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FAUCONBIGUET N, 1986, EMBO J, V5, P287; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1992, J PHYSIOLOGY-PARIS, V86, P99, DOI 10.1016/S0928-4257(05)80013-0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KVETANSK.R, 1971, AM J PHYSIOL, V220, P928, DOI 10.1152/ajplegacy.1971.220.4.928; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIU F, 1993, J BIOL CHEM, V268, P6714; MALLET J, 1983, COLD SPRING HARB SYM, V48, P305, DOI 10.1101/SQB.1983.048.01.033; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; Nankova B, 1996, MOL BRAIN RES, V35, P164, DOI 10.1016/0169-328X(95)00201-3; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; RICHARD F, 1988, J NEUROSCI RES, V20, P32, DOI 10.1002/jnr.490200106; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STACHOWIAK MK, 1994, MOL BRAIN RES, V22, P309, DOI 10.1016/0169-328X(94)90059-0; TANK AW, 1986, MOL PHARMACOL, V30, P497; TANK AW, 1985, J NEUROCHEM, V45, P1030, DOI 10.1111/j.1471-4159.1985.tb05519.x; TANK AW, 1986, MOL PHARMACOL, V30, P486; THOENEN H, 1970, NATURE, V228, P861, DOI 10.1038/228861a0; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	43	94	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6051	6058		10.1074/jbc.272.9.6051	http://dx.doi.org/10.1074/jbc.272.9.6051			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038229	hybrid			2022-12-25	WOS:A1997WK74700097
J	Nielsen, MS; Brejning, J; Garcia, R; Zhang, HF; Hayden, MR; Vilaro, S; Gliemann, J				Nielsen, MS; Brejning, J; Garcia, R; Zhang, HF; Hayden, MR; Vilaro, S; Gliemann, J			Segments in the C-terminal folding domain of lipoprotein lipase important for binding to the low density lipoprotein receptor-related protein and to heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; CELL-SURFACE PROTEOGLYCANS; HEPATIC LIPASE; PANCREATIC LIPASE; LIGAND-BINDING; HIGH-AFFINITY; IN-VITRO; IDENTIFICATION; DEGRADATION; EXPRESSION	Lipoprotein lipase (LpL) can mediate cellular uptake of chylomicron and VLDL remnants via binding to heparan sulfate proteoglycans (HSPG) and the endocytic alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha(2)MR/LRP). Whereas it is established that the C-terminal folding domain binds to alpha(2)MR/LRP, it remains uncertain whether it binds to heparin and to HSPG. To identify segments important for binding to alpha(2)MR/LRP and to clarify possible binding to heparin, we produced constructs of the human C-terminal folding domain, LpL-(313-448), and of the fragment LpL-(347-448) in Escherichia coli. In addition to binding to alpha(2)MR/LRP, LpL-(313-448) displayed binding to heparin with an affinity similar to that of the LpL monomer, whereas it bound poorly to lipoprotein particles. Moreover, LpL-(313-448) displayed heparin sensitive binding to normal, but not to HSPG deficient Chinese hamster ovary cells, LpL-(313-448) and LpL-(347-448) showed similar affinities for binding to both purified alpha(2)MR/LRP and to heparin. Deletion of LpL residues 380-384 abolished the binding to LRP, whereas binding to heparin was unperturbed. The binding to both heparin and alpha(2)MR/LRP was essentially abolished following deletion of residues 404-430, and pretreatment of CHO cells with the peptide comprising aa 402-423 inhibited the binding of LpL-(313-448). We conclude that the C-terminal folding domain of human LPL has a site for binding to heparin and to HSPG, presumably involving amino acids within residues 404-430. Two segments of the domain are necessary for efficient binding to alpha(2)MR/LRP, one comprising residues 380-384 and another overlapping the segment important for binding to heparin.	UNIV BARCELONA, DEPT CELLULAR BIOL, E-08028 BARCELONA, SPAIN; UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER, BC V6T 1Z4, CANADA	University of Barcelona; University of British Columbia	Nielsen, MS (corresponding author), AARHUS UNIV, DEPT BIOCHEM MED, OLE WORMS ALLE, BLDG 170, DK-8000 AARHUS, DENMARK.		Hayden, Michael R/D-8581-2011; Nielsen, Morten Schallburg/G-9498-2016	Hayden, Michael R/0000-0001-5159-1419; Nielsen, Morten Schallburg/0000-0001-9863-9694				BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FERNANDEZBORJA M, 1995, CELL MOTIL CYTOSKEL, V30, P89, DOI 10.1002/cm.970300202; HATA A, 1993, J BIOL CHEM, V268, P8447; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KRAPP A, 1995, J LIPID RES, V36, P2362; Krapp A, 1996, J LIPID RES, V37, P926; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LARNKJAER A, 1995, BIOCHEM J, V307, P205, DOI 10.1042/bj3070205; LIU MS, 1992, BIOCHIM BIOPHYS ACTA, V1128, P113, DOI 10.1016/0005-2760(92)90264-V; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MA YH, 1994, J LIPID RES, V35, P2049; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Pagan R, 1996, EXP CELL RES, V222, P333, DOI 10.1006/excr.1996.0043; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SKARLATOS SI, 1993, J CLIN ENDOCR METAB, V76, P793, DOI 10.1210/jc.76.3.793; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TORNVALL P, 1995, ARTERIOSCL THROM VAS, V15, P1086, DOI 10.1161/01.ATV.15.8.1086; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	39	45	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5821	5827		10.1074/jbc.272.9.5821	http://dx.doi.org/10.1074/jbc.272.9.5821			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038197	hybrid			2022-12-25	WOS:A1997WK74700065
J	Poon, RYC; Lew, J; Hunter, T				Poon, RYC; Lew, J; Hunter, T			Identification of functional domains in the neuronal Cdk5 activator protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; BRAIN-SPECIFIC ACTIVATOR; TAU-PROTEIN; CELL-CYCLE; CDC2-LIKE KINASE; ULTRAVIOLET-IRRADIATION; CRYSTAL-STRUCTURE; BOVINE BRAIN; KDA SUBUNIT; PHOSPHORYLATION	Cyclin-dependent kinase 5 (Cdk5) is activated by the neuronal-specific activator protein, p35, In contrast to the activation of typical CDKs by cyclin subunits, p35 . Cdk5 was not further activated by the CDK-activating kinase (CAK) and was neither phosphorylated nor inhibited by the Tyr-15-specific Wee1 kinase. The previously identified proteolytic active fragment of p35, p25 (residues 91-307) as well as the slightly smaller fragment containing residues 109-291, was found to be sufficient to bind and activate Cdk5, Other CDKs, including Cdk2, associated weakly with p25. However, their kinase activity was only activated to the low level observed for cyclin A . Cdk2 without Thr-160 phosphorylation, and phosphorylation of Thr-160 in Cdk2 did not activate the p25 . Cdk2 complex further, We have identified distinct regions in p35 required for binding to CdkB or activation of Cdk5. Residues similar to 150-200 of p35 were sufficient for binding to Cdk5, but residues similar to 279-291 were needed in addition for activation of CdkB in vitro.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego				Poon, Randy/0000-0001-5571-6231	NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; Matsuura I, 1996, J BIOL CHEM, V271, P5443, DOI 10.1074/jbc.271.10.5443; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY A, 1993, CELL CYCLE; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; POON RYC, 1995, CURR BIOL, V5, P1243; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHAPEK SX, 1995, SCIENCE, V267, P1022; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; vanGrunsven LA, 1996, ONCOGENE, V12, P855; XIONG Y, 1992, CELL, V71, P504; YAN GZ, 1995, J NEUROSCI, V15, P6200	60	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5703	5708		10.1074/jbc.272.9.5703	http://dx.doi.org/10.1074/jbc.272.9.5703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038181	hybrid			2022-12-25	WOS:A1997WK74700049
J	Roe, JL; Durfee, T; Zupan, JR; Repetti, PP; McLean, BG; Zambryski, PC				Roe, JL; Durfee, T; Zupan, JR; Repetti, PP; McLean, BG; Zambryski, PC			TOUSLED is a nuclear serine/threonine protein kinase that requires a coiled-coil region for oligomerization and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SIGNAL-TRANSDUCTION; DROSOPHILA; SUBUNIT; DNA; IDENTIFICATION; EXPRESSION; RECEPTORS; FUSIONS; DOMAINS	The TOUSLED (TSL) gene is essential for the proper morphogenesis of leaves and flowers in Arabidopsis thaliana. Protein sequence analysis predicts TSL is composed of a carboxyl-terminal protein kinase catalytic domain and a large amino-terminal regulatory domain. TSL fusion proteins, expressed in and purified from yeast, were used to demonstrate TSL protein kinase activity in vitro. TSL trans-autophosphorylates on serine and threonine residues, and phosphorylates exogenous substrates. Using the yeast two-hybrid system, TSL was found to oligomerize via its NH2-terminal domain, A deletion series indicates that a region containing two alpha-helical segments predicted to participate in a coiled-coil structure is essential for oligomerization. TSL localizes to the nucleus in plant cells through an essential NH2-terminal nuclear localization signal; however, this signal is not necessary for protein kinase activity. Finally, deletion mutants demonstrate a strict correlation between catalytic activity and the ability to oligomerize, arguing that activation of the protein kinase requires interaction between TSL molecules.			Roe, JL (corresponding author), UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA.							ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; Bai C, 1996, METHOD ENZYMOL, V273, P331; BOWMAN S, 1990, Technique (Philadelphia), V2, P254; BUCK V, 1991, MOL GEN GENET, V227, P452, DOI 10.1007/BF00273937; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS L I, 1992, Current Opinion in Cell Biology, V4, P424, DOI 10.1016/0955-0674(92)90007-Y; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LIU ZC, 1995, DEVELOPMENT, V121, P975; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; McLean BG, 1995, PLANT CELL, V7, P2101, DOI 10.1105/tpc.7.12.2101; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Rose MD., 1990, METHODS YEAST GENETI; Running MP, 1996, DEVELOPMENT, V122, P1261; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SESSIONS RA, 1995, DEVELOPMENT, V121, P1519; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIMON MA, 1994, DEV BIOL, V166, P431, DOI 10.1006/dbio.1994.1327; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756	47	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5838	5845		10.1074/jbc.272.9.5838	http://dx.doi.org/10.1074/jbc.272.9.5838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038200	hybrid			2022-12-25	WOS:A1997WK74700068
J	Skerka, C; Hellwage, J; Weber, W; Tilkorn, A; Buck, F; Marti, T; Kampen, E; Beisiegel, U; Zipfel, PF				Skerka, C; Hellwage, J; Weber, W; Tilkorn, A; Buck, F; Marti, T; Kampen, E; Beisiegel, U; Zipfel, PF			The human factor H-related protein 4 (FHR-4) - A novel short consensus repeat-containing protein is associated with human triglyceride-rich lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; APOLIPOPROTEIN-A-I; CHOLESTEROL ACYLTRANSFERASE; REGULATORY DOMAINS; HUMAN PLASMA; C-II; METABOLISM; FAMILY; GENE; IDENTIFICATION	A novel apoprotein of an apparent molecular mass of 86 kDa in its unreduced form was identified in human triglyceride-rich lipoproteins. This protein was purified and the amino acid sequence of six proteolytic fragments was found to overlap with that of the factor H-related proteins. In parallel we identified the cDNA encoding a new complement factor H-related protein, termed FHR-4. The sequences of the new apoprotein overlapped with that of the FHR-4 protein, Similar to the previously described factor II-related proteins, FHR-4 contains a hydrophobic signal sequence followed by a stretch of five repetitive elements termed short consensus repeats, Recombinant FHR-4 protein was expressed in the baculovirus system and has an apparent molecular mass of 42 kDa, In addition a 84-kDa dimeric form of the recombinant FHR-4 was detected, Using an immunoaffinity column with antibodies raised against the recombinant FHR-4, we isolated a 86-kDa protein from human plasma, The different molecular mass of the recombinant FHR-4 and the dimeric FHR-4 in plasma is due to different carbohydrate moieties. The 86-kDa plasma protein and the novel apolipoprotein had identical mobility on SDS-polyacrylamide gel electrophoresis analysis and reacted with antisera raised against the reFHR-4 and the purified apoprotein. In conclusion, we have identified a novel factor H-related protein, FHR-4, in human plasma and demonstrate that this protein is present in triglyceride-rich lipoproteins in a dimeric form, This observation provides an intriguing new aspect on possible function(s) of this novel protein and the other factor II-related proteins.	BERNHARD NOCHT INST TROP MED,D-20359 HAMBURG,GERMANY; UNIV HAMBURG,HOSP EPPENDORF,MED CLIN,D-20246 HAMBURG,GERMANY; UNIV HAMBURG,INST CELL BIOL & CLIN NEUROBIOL,D-20246 HAMBURG,GERMANY	Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; University of Hamburg								BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; CHEN CH, 1983, BIOCHIM BIOPHYS ACTA, V753, P40, DOI 10.1016/0005-2760(83)90095-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ESTALLER C, 1991, J IMMUNOL, V146, P3190; FEIFEL E, 1992, IMMUNOGENETICS, V36, P104, DOI 10.1007/BF00215286; FUNAKOSHI M, 1988, BIOCHIM BIOPHYS ACTA, V963, P98, DOI 10.1016/0005-2760(88)90342-6; GORDON DL, 1995, J IMMUNOL, V155, P348; GROOT PHE, 1978, BIOCHIM BIOPHYS ACTA, V530, P91, DOI 10.1016/0005-2760(78)90129-7; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; INNERARITY TL, 1991, ENCY HUMAN BIOL, V6, P23; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUHN S, 1995, J IMMUNOL, V155, P5663; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Meri S, 1994, IMMUNOLOGIST, V2, P149; MEYER CG, 1995, IMMUNOGENETICS, V41, P335; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFER EJ, 1978, J LIPID RES, V19, P667; SCHAEFER EJ, 1978, BIOCHEM BIOPH RES CO, V80, P405, DOI 10.1016/0006-291X(78)90691-5; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SKERKA C, 1991, J BIOL CHEM, V266, P12015; SKERKA C, 1992, J IMMUNOL, V148, P3313; SKERKA C, 1995, IMMUNOGENETICS, V42, P268; SKERKA C, 1993, J BIOL CHEM, V268, P2904; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; TIMMANN C, 1991, J IMMUNOL, V146, P1265; VAKEVA A, 1994, IMMUNOLOGY, V82, P28; VIK DP, 1988, J BIOL CHEM, V263, P16720; VIK DP, 1990, J BIOL CHEM, V265, P3193; VIK DP, 1989, CURR TOP MICROBIOL I, V153, P148; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	40	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5627	5634		10.1074/jbc.272.9.5627	http://dx.doi.org/10.1074/jbc.272.9.5627			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038172	hybrid			2022-12-25	WOS:A1997WK74700040
J	Torgersen, KM; Vaage, JT; Levy, FO; Hansson, V; Rolstad, B; Tasken, K				Torgersen, KM; Vaage, JT; Levy, FO; Hansson, V; Rolstad, B; Tasken, K			Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; CYCLIC-AMP; BINDING-SITES; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; RECEPTORS; COMPLEX; ANALOGS; MODULATION; RECOGNITION	The present study examines the expression and involvement of cAMP-dependent protein kinase (PKA) isozymes in cAMP-induced inhibition of natural killer (NK) cell-mediated cytotoxicity. Rat interleukin-a-activated NK cells express the PKA alpha-isoforms RI alpha, RII alpha, and C alpha and contain both PKA type I and type II. Prostaglandin E(2), forskolin, and cAMP analogs all inhibit NK cell lysis of major histocompatibility complex class I mismatched allogeneic lymphocytes as well as of standard tumor target cells, Specific involvement of PKA in the cAMP-induced inhibition of NK cell cytotoxicity is demonstrated by the ability of a cAMP antagonist, (R(p))-8-Br-adenosine 3',5'-cyclic monophosphorothioate, to reverse the inhibitory effect of complementary cAMP agonist (S-p)-8-Br-adenosine 3',5'-cyclic monophosphorothioate. Furthermore, the use of cAMP analog pairs selective for either PKA isozyme (PKA type I or PKA type II), shows a preferential involvement of the PKA type I isozyme, indicating that PKA type I is necessary and sufficient to completely abolish killer activatory signaling leading to NK cell cytotoxicity. Finally, combined treatment with phorbol ester and ionomycin maintains NK cell cytotoxicity and eliminates the cAMP-mediated inhibition, demonstrating that protein kinase C and Ca2+-dependent events stimulate the cytolytic activity of NK cells at a site distal to the site of cAMP/PKA action.	UNIV OSLO, INST BASIC MED SCI, DEPT BIOCHEM MED, N-0317 OSLO, NORWAY	University of Oslo	Torgersen, KM (corresponding author), UNIV OSLO, INST BASIC MED SCI, DEPT ANAT, POB 1105, N-0317 OSLO, NORWAY.			Tasken, Kjetil/0000-0003-2841-4697; Vaage, John T./0000-0003-0988-5768				BANCROFT GJ, 1993, CURR OPIN IMMUNOL, V5, P503, DOI 10.1016/0952-7915(93)90030-V; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1986, ENZYMES, V17, P43; BENNETT M, 1987, ADV IMMUNOL, V41, P333, DOI 10.1016/S0065-2776(08)60034-6; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; DOSKELAND SO, 1991, METH SURV I, V21, P103; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; GOTO T, 1983, J IMMUNOL, V130, P1350; HALL TJ, 1983, CLIN EXP IMMUNOL, V54, P493; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LANG P, 1992, J BIOL CHEM, V267, P11677; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; Levy FO, 1996, EUR J IMMUNOL, V26, P1290, DOI 10.1002/eji.1830260617; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Maghazachi AA, 1996, J IMMUNOL, V157, P5308; MCKNIGHT AJ, 1992, IMMUNOLOGY, V75, P286; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; MURAGUCHI A, 1984, J IMMUNOL, V133, P1283; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; Naper C, 1996, INT IMMUNOL, V8, P1779, DOI 10.1093/intimm/8.11.1779; NAPER C, 1995, EUR J IMMUNOL, V25, P1249, DOI 10.1002/eji.1830250518; NICOLLS MR, 1993, TRANSPLANTATION, V55, P459, DOI 10.1097/00007890-199303000-00001; OGREID D, 1989, EUR J BIOCHEM, V181, P19; Olcese L, 1996, J IMMUNOL, V156, P4531; PRYZWANSKY KB, 1981, SCIENCE, V211, P407, DOI 10.1126/science.6261328; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; RHEE SG, 1993, ADV SEC MESS PHOSPH, V28, P57; RODER JC, 1979, J IMMUNOL, V123, P2785; ROLSTAD B, 1994, NATURAL IMMUNITY NOR, P99; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RYAN JC, 1995, J EXP MED, V181, P1911, DOI 10.1084/jem.181.5.1911; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; TASKEN K, 1994, ENDOCRINOLOGY, V135, P2109, DOI 10.1210/en.135.5.2109; TASKEN K, 1995, PROTEIN KINASE FACTS, P58; TING AT, 1992, J BIOL CHEM, V267, P23957; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VAAGE JT, 1994, J EXP MED, V180, P641, DOI 10.1084/jem.180.2.641; WINDEBANK KP, 1988, J IMMUNOL, V141, P3951; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	52	66	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5495	5500		10.1074/jbc.272.9.5495	http://dx.doi.org/10.1074/jbc.272.9.5495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038153	hybrid			2022-12-25	WOS:A1997WK74700021
J	Hart, KC; Donoghue, DJ				Hart, KC; Donoghue, DJ			Derivatives of activated H-ras lacking C-terminal lipid modifications retain transforming ability if targeted to the correct subcellular location	ONCOGENE			English	Article						ras; subcellular localization; transformation	GUANINE-NUCLEOTIDE-BINDING; MURINE SARCOMA-VIRUS; SRC-GENE-PRODUCT; PLASMA-MEMBRANE; POSTTRANSLATIONAL MODIFICATION; ONCOGENE PROTEIN; GOLGI-COMPLEX; P21; DOMAIN; SIGNAL	To examine the ability of uas to activate signal transduction pathways in the absence of lipid modifications, fusion proteins were constructed that target ras(WT) or activated ras(61L) to cellular membranes as integral membrane proteins, using the first transmembrane domain of the El protein of avian infectious bronchitis virus (IBV), which contains a cis-Golgi targeting signal. Golgi-targeted derivatives of activated ras were completely inactive in transformation assays. However, when examined in focus formation assays, transformation of NIH3T3 cells were seen with derivatives of vas(61L) containing a mutated El targeting sequence that results in plasma membrane localization. Removal of the lipid modification sites in and upstream of the CAAX motif did not abrogate the transforming activity of plasma membrane-localized ras(61L) derivatives, indicating that these lipid modifications are not essential for ras activity, as long as the protein is correctly localized to the plasma membrane. Interestingly, the activity of integral membrane versions of vas(61L) was strictly dependent on a minimum distance between the transmembrane domain anchor region and the coding sequence of vas. Derivatives with only a 3-amino acid linker were inactive, while linkers of either 11- or 22-amino acids were sufficient to restore transforming activity. These results demonstrate that: (1) activated ras targeted to Golgi membranes is unable to cause transformation; (2) lipid modifications at the C-terminus are not required for the transforming activity of plasma membrane-anchored ras(61L) derivatives, and serve primarily a targeting function; (3) a transmembrane domain can effectively substitute for C-terminal modifications that would normally target uas to the inner surface of the plasma membrane, indicating that ras(61L) does not need to reversibly dissociate from the membrane as might be allowed by the normal lipidation; and (4) in order to function properly, there exists a critical distance that the ras protein must reside from the plasma membrane.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,CTR GENET MOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,MOL PATHOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDTRAUF PW, 1990, J PROTEIN CHEM, V9, P137, DOI 10.1007/BF01025304; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hart K C, 1995, Genet Eng (N Y), V17, P181; HART KC, 1994, J CELL BIOL, V127, P1843, DOI 10.1083/jcb.127.6.1843; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOHN J, 1989, J BIOL CHEM, V264, P13086; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LACAL PM, 1988, ONCOGENE, V2, P533; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1986, CANCER SURV, V5, P275; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; Okada T, 1996, J BIOL CHEM, V271, P4671; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIH TY, 1984, CANCER INVEST, V2, P109, DOI 10.3109/07357908409020294; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; XU YF, 1993, J CELL BIOL, V123, P549, DOI 10.1083/jcb.123.3.549; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	50	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					945	953		10.1038/sj.onc.1200908	http://dx.doi.org/10.1038/sj.onc.1200908			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050994	Green Published, Bronze			2022-12-25	WOS:A1997WK34400008
J	Lutterbach, B; Hann, SR				Lutterbach, B; Hann, SR			Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation	ONCOGENE			English	Article						c-Myc; phosphorylation; immortalization; transactivation	CASEIN KINASE-II; TRANSFORMING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; NEOPLASTIC-CELLS; POINT MUTATIONS; GENE-EXPRESSION; PROTEIN; SITE; VIRUS	Using an extensive series of deletion and site-specific mutation constructs, we have identified five new phosphorylation sites in c-Myc in the N-terminal transactivation domain and near the C-terminal DNA binding/heterodimerization domain. We have also found that Thr-58 phosphorylation is regulated by specific cellular events. When c-Myc is overexpressed in cells Thr-58 phosphorylation was greatly enhanced in the overexpressed, exogenous c-Myc as compared with the endogenous protein. In contrast, an inhibition of Thr-58 phosphorylation and an enhancement of Serine 62 phosphorylation was observed in c-Myc from immortalized cells compared with primary cells. No significant changes in c-Myc phosphorylation were found when transformed and nontransformed cells were compared. Finally, mutations at these phosphorylation sites, either individually or in combination with previously described sites, did not affect the ability of c-Myc to transactivate through the CACGTG Myc/Max DNA binding sites. These results further suggest that either the molecular role for c-Myc phosphorylation does not involve modulating transcriptional activity of c-Myc or that the CACGTG site does not represent a physiological promoter element.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NCI NIH HHS [CA-47399, CA-48799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047399, P01CA048799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FILARDO EJ, 1991, J VIROL, V65, P6621, DOI 10.1128/JVI.65.12.6621-6629.1991; FRYKBERG L, 1987, ONCOGENE, V1, P415; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PULVERER BJ, 1994, ONCOGENE, V9, P59; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SYMONDS G, 1989, ONCOGENE, V4, P285; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	46	29	29	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					967	975		10.1038/sj.onc.1200920	http://dx.doi.org/10.1038/sj.onc.1200920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050996				2022-12-25	WOS:A1997WK34400010
J	MarcosGutierrez, CV; Wilson, SW; Holder, N; Pachnis, V				MarcosGutierrez, CV; Wilson, SW; Holder, N; Pachnis, V			The zebrafish homologue of the ret receptor and its pattern of expression during embryogenesis	ONCOGENE			English	Article						tyrosine kinase receptor; zebrafish; c-ret proto-oncogene; nervous system; excretory system	TYROSINE KINASE; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; RETICULOSPINAL NEURONS; AXONAL OUTGROWTH; PROTOONCOGENE; MUTATIONS; ACTIVATION; CADHERIN; EMBRYOS	The c-ret proto-oncogene, a member of the receptor tyrosine kinase gene superfamily, plays a critical role in the development of the excretory system and the enteric and autonomic nervous systems of mammalian embryos. To study the potential function of the c-vet locus in lower vertebrates, we have isolated its zebrafish homologue, ret1 and established its expression pattern during embryogenesis. Ret1 mRNA first appears during early somitogenesis in the presumptive brain, spinal cord and excretory system. Within the CNS, expression of ret1 is detected in primary motor and sensory (Rohon-Beard) neurons. Ret1 transcripts are also expressed in subsets of neural crest cells and cranial ganglia as well as in the enteric nervous system. In the excretory system, expression is detected in the developing nephric duct and the pronephros. Our findings reveal a remarkable similarity in the expression pattern of c-ret between higher and lower vertebrates, suggesting that the function of this locus has been conserved throughout vertebrate evolution. Furthermore, the conservation of ret1 expression in cell types which remain unaffected by the mammalian c-vet mutations, such as motor and sensory neurons, suggests a function of this receptor in these cell lineages.	NATL INST MED RES, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND; UNIV LONDON KINGS COLL, RANDALL INST, DIV BIOMED SCI, RES CTR, LONDON WC2B 5RL, ENGLAND	MRC National Institute for Medical Research; University of London; King's College London			Wilson, Stephen W/B-9404-2008	Wilson, Stephen W/0000-0002-8557-5940; Pachnis, Vassilis/0000-0001-9733-7686				Appel B, 1995, DEVELOPMENT, V121, P4117; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EISEN JS, 1990, J NEUROSCI, V10, P34; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Green MC., 1989, GENETIC VARIANTS STR, P12; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUNTER T, 1990, ADV SEC MESS PHOSPH, V24, P260; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KORZH V, 1993, DEVELOPMENT, V118, P417; MASLAND RH, 1993, J NEUROSCI, V13, P5194, DOI 10.1523/JNEUROSCI.13-12-05194.1993; MENDELSON B, 1986, J COMP NEUROL, V251, P160, DOI 10.1002/cne.902510203; MENDELSON B, 1986, J COMP NEUROL, V251, P172, DOI 10.1002/cne.902510204; METCALFE WK, 1990, DEVELOPMENT, V110, P491; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS PZ, 1986, J NEUROSCI, V6, P2278; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; ROBERTSON K, 1995, MECH DEVELOP, V53, P329, DOI 10.1016/0925-4773(95)00449-1; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weinberg E.S., 1992, Results and Problems in Cell Differentiation, V18, P91; Westerfield M, 1994, ZEBRAFISH BOOK; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XU QL, 1994, DEVELOPMENT, V120, P287	52	54	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					879	889		10.1038/sj.onc.1201048	http://dx.doi.org/10.1038/sj.onc.1201048			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050987				2022-12-25	WOS:A1997WK34400001
J	Baldassare, JJ; Jarpe, MB; Alferes, L; Raben, DM				Baldassare, JJ; Jarpe, MB; Alferes, L; Raben, DM			Nuclear translocation of RhoA mediates the mitogen-induced activation of phospholipase D involved in nuclear envelope signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL-GROWTH-FACTOR; CANINE KIDNEY-CELLS; MOLECULAR-SPECIES ANALYSIS; GTP-BINDING PROTEIN; ALPHA-THROMBIN; LYSOPHOSPHATIDIC ACID; CULTURED FIBROBLASTS; PHOSPHATIDYLCHOLINE HYDROLYSIS; 1,2-DIACYLGLYCEROL LEVELS	In this paper we demonstrate for the first time a mitogen;induced activation of a nuclear acting phosphatidylcholine-phospholipase D (PLD) which is mediated, at least in part, by the translocation of RhoA to the nucleus, Addition of alpha-thrombin to quiescent IIC9 cells results in an increase in PLD activity in IIC9 nuclei, This is indicated by an increase in the alpha-thrombin-induced production of nuclear phosphatidylethanol in quiescent cells incubated in the presence of ethanol as well as an increase in PLD activity in isolated nuclei, Consistent with our previous report (Wright, T. M., Willenberger, S., and Raben, D, M. (1992) Biochem. J. 285, 395-400), the presence of ethanol decreases the alpha-thrombin-induced production of phosphatidic acid without affecting the induced increase in nuclear diglyceride, indicating that the increase in nuclear PLD activity is responsible for the effect on phosphatidic acid, but not that on diglyceride. Our data further demonstrate that RhoA mediates the activation of nuclear PLD, RhoA translocates to the nucleus in response to alpha-thrombin, Additionally, PLD activity in nuclei isolated from alpha-thrombin-treated cells is reduced in a concentration-dependent fashion by incubation with RhoGDI and restored by the addition of prenylated RhoA in the presence of guanosine 5'-3-O-(thio)triphosphate, Western blot analysis indicates that this RhoGDI treatment results in the extraction of RhoA from the nuclear envelope, These data support a role for a RhoA-mediated activation of PLD in our recently described hypothesis, which proposes that a signal transduction cascade exists in the nuclear envelope and represents a novel signal transduction cascade that we have termed NEST (nuclear envelope Signal transduction).	JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; ST LOUIS UNIV, SCH MED, DEPT PHARMACOL & PHYSIOL SCI, ST LOUIS, MO 63104 USA	Johns Hopkins University; Saint Louis University					NHLBI NIH HHS [HL40901] Funding Source: Medline; NIGMS NIH HHS [GM51593] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG TH, 1993, J BIOL CHEM, V268, P775; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; EXTON JH, 1992, CIBA F SYMP, V164, P36; EXTON JH, 1991, MOL CELL BIOCHEM, V104, P81; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HUANG CF, 1992, J BIOL CHEM, V267, P16859; INUI H, 1994, J BIOL CHEM, V269, P30546; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P526, DOI 10.1021/bi00168a018; KENNERLY DA, 1991, METHOD ENZYMOL, V197, P191; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1993, BIOCHEM SOC T, V21, P879, DOI 10.1042/bst0210879; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LISCOVITCH M, 1993, J LIPID MEDIATOR, V8, P177; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; RABEN DM, 1994, J MEMBRANE BIOL, V142, P1; RANGAN LA, 1991, CELL REGUL, V2, P311, DOI 10.1091/mbc.2.4.311; Thompson N T, 1993, Adv Pharmacol, V24, P199, DOI 10.1016/S1054-3589(08)60938-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; Zhang Wei, 1992, Neurological Research, V14, P397	41	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4911	4914		10.1074/jbc.272.8.4911	http://dx.doi.org/10.1074/jbc.272.8.4911			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030550	hybrid			2022-12-25	WOS:A1997WJ85500038
J	Barbone, FP; Middleton, SA; Johnson, DL; McMahon, FJ; Tullai, J; Gruninger, RH; Schilling, AE; Jolliffe, LK; Mulcahy, LS				Barbone, FP; Middleton, SA; Johnson, DL; McMahon, FJ; Tullai, J; Gruninger, RH; Schilling, AE; Jolliffe, LK; Mulcahy, LS			Mutagenesis studies of the human erythropoietin receptor - Establishment of structure-function relationships	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; HUMAN GROWTH-HORMONE; HUMAN TISSUE FACTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; SURFACE EXPRESSION; LIGAND-BINDING; GM-CSF; COMPLEX; RESIDUES	Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding. We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR, Residues were chosen for site specific alanine substitution based on the results of the random mutagenesis or on their homology to residues that are conserved or have been reported to be involved in ligand binding in other receptors of the cytokine receptor family, Site-specific mutants were expressed in Escherichia coli as soluble EBP and analyzed for EPO binding in several different assay formats, In addition, selected mutant proteins were expressed as full-length EPOR on the surface of COS cells and analyzed for I-125-EPO binding in receptor binding assays. Using these methods, we have identified residues that appear to be involved in EPO binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the EPOR, We present correlations between these mutagenesis data and the recently solved crystal structure of the EBP with a peptide ligand.			Barbone, FP (corresponding author), RW JOHNSON PHARMACEUT RES INST, DRUG DISCOVERY RES, 1000 ROUTE 202, POB 300, RARITAN, NJ 08869 USA.		McMahon, Francis J/A-7290-2009	McMahon, Francis J/0000-0002-9469-305X				BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOSHI PD, 1994, BLOOD, V84, P2539, DOI 10.1182/blood.V84.8.2539.bloodjournal8482539; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JOLLIFFE LK, 1995, NEPHROL DIAL TRANSPL, V10, P28, DOI 10.1093/ndt/10.supp2.28; JONES SS, 1990, BLOOD, V76, P31; KRANTZ SB, 1991, BLOOD, V77, P419; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LYNE PD, 1995, PROTEIN SCI, V4, P2223, DOI 10.1002/pro.5560041027; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619	28	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4985	4992		10.1074/jbc.272.8.4985	http://dx.doi.org/10.1074/jbc.272.8.4985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030560	hybrid			2022-12-25	WOS:A1997WJ85500048
J	Hawkins, M; Angelov, I; Liu, R; Barzilai, N; Rossetti, L				Hawkins, M; Angelov, I; Liu, R; Barzilai, N; Rossetti, L			The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE ACTIVITY; TRANSPORT SYSTEM; DIABETIC RATS; HEXOSAMINE BIOSYNTHESIS; CHRONIC HYPERGLYCEMIA; RESPONSIVE TISSUES; RESISTANCE; CELLS; URIDINE; GLUT4	To delineate the biochemical mechanism by which increased availability of GlcN impairs insulin action on skeletal muscle glucose uptake, we replenished the uridine pool during GlcN administration, Go-infusion of uridine with GlcN prevented the GlcN-induced fall in skeletal muscle UDP-glucose levels (24.9 +/- 5.3 versus 10.1 +/- 2.9 nmol/g; p < 0.01) and further increased the skeletal muscle UDP-GlcNAc levels (198.4 +/- 26.3 versus 96.0 +/- 8.4 nmol/g; p < 0.01). Greater reductions in the rates of glucose infusion (similar to 53%), glucose uptake (similar to 43%), and glycogen synthesis (similar to 60%) were observed with the addition of uridine, Similarly, the infusion of uridine alone markedly increased the skeletal muscle levels of both UDP-glucose (55.2 +/- 14.2 versus 17.8 +/- 6.1 nmol/g; p < 0.01) and UDP-GlcNAc (86.8 +/- 8.8 versus 35.9 +/- 8.4 nmol/g; p < 0.05) and induced marked insulin resistance, The decrease in insulin action on peripheral glucose uptake was highly correlated with the increase in skeletal muscle UDP-GlcNAc levels, Finally, immunoisolation of GLUT4-containing vesicles revealed that the rate of labeled GlcN incorporation was similar to 100-fold greater following GlcN compared with saline infusions (p < 0.01). We suggest that the marked reduction in insulin action induced by GlcN and uridine is mediated by increased accumulation of muscle UDP-N-acetylhexosamines, perhaps via altered glycosylation of protein(s) in GLUT4-containing vesicles.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV ENDOCRINOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048321, P60DK020541, R29DK045024, R01DK045024, P30DK020541, R37DK048321] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48321, DK 45024, DK 20541] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1991, ANAL BIOCHEM, V197, P113, DOI 10.1016/0003-2697(91)90365-Z; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BONADONNA RC, 1993, J CLIN INVEST, V92, P486, DOI 10.1172/JCI116592; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; CALVARUSO G, 1986, LIFE SCI, V39, P2221, DOI 10.1016/0024-3205(86)90400-5; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CROOK ED, 1993, DIABETES, V42, P1289, DOI 10.2337/diabetes.42.9.1289; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ERICHSEN C, 1987, ANTICANCER RES, V7, P77; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1993, DIABETES, V42, P1773, DOI 10.2337/diabetes.42.12.1773; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; HAWKINS M, 1996, DIABETES, V46, P1734; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOLSTEGE A, 1986, J NATL CANCER I, V76, P485; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HOSTETLE.KY, 1967, BIOCHEMISTRY-US, V6, P2961, DOI 10.1021/bi00862a001; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KARLANDER S, 1986, AM J PHYSIOL, V251, pE530, DOI 10.1152/ajpendo.1986.251.5.E530; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MICHAL G, 1984, METHOD ENZYMAT AN, V6, P191; PEDERSON NV, 1992, CANCER RES, V52, P3782; RIJCKEN WRP, 1995, BIOCHEM J, V305, P865, DOI 10.1042/bj3050865; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROSSETTI L, 1995, CLIN INVEST MED, V18, P255; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; ROSSETTI L, 1989, J CLIN INVEST, V84, P892, DOI 10.1172/JCI114250; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; YKIJARVINEN H, 1992, J CLIN ENDOCR METAB, V75, P795, DOI 10.1210/jc.75.3.795	42	104	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4889	4895		10.1074/jbc.272.8.4889	http://dx.doi.org/10.1074/jbc.272.8.4889			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030547	hybrid			2022-12-25	WOS:A1997WJ85500035
J	Kanzaki, M; Nie, L; Shibata, H; Kojima, I				Kanzaki, M; Nie, L; Shibata, H; Kojima, I			Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; SURFACE-ANTIGEN; PERTUSSIS TOXIN; PROTEIN; TYROSINE; RECEPTOR; LYMPHOCYTES; ASSOCIATION; INVOLVEMENT; ONCOGENES	CD20 functions as a calcium-permeable cation channel. When expressed in Balb/c 3T3 cells, CD20 accelerates the G(1) progression induced by insulin-like growth factor-I (IGF-I). To further characterize how CD20 modulates the action of IGF-I, we investigated whether the activity of CD20 channel was affected by IGF-I. In quiescent cells expressing CD20, IGF-I increased cytoplasmic free calcium concentration, [Ca2+](c), which was reversed by the removal of extracellular calcium. In contrast, IGF-I did not increase [Ca2+](c) in cells that did not express CD20. In perforated patch clamp recordings, addition of IGF-I to the bath solution augmented the Ca2+ permeability, which was reversed by anti CD20 antibody. In cell-attached patch, calcium-permeable channel activity with unitary conductance of 7 picosiemens was detected, which was abolished by anti-CD20 antibody. The single channel activities were markedly enhanced when IGF-I was included in the pipette solution, whereas IGF-I added to the bath solution was ineffective. When cells were first exposed to pertussis toxin, activation of the channel by IGF-I was blocked. Transfection of cDNA for Gip2, a constitutive active form of alpha(i2), activated the CD20 channel. These results indicate that the CD20 channel is regulated by the IGF-I receptor by a mechanism involving pertussis toxin-sensitive G protein.	GUNMA UNIV, INST MOL & CELLULAR REGULAT, DEPT CELL BIOL, MAEBASHI, GUMMA 371, JAPAN	Gunma University			Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955				BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; KOJIMA I, 1989, FEBS LETT, V258, P150, DOI 10.1016/0014-5793(89)81637-0; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUNAGA H, 1988, AM J PHYSIOL, V255, pC442, DOI 10.1152/ajpcell.1988.255.4.C442; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NISSLEY SP, 1985, J CELL SCI, P39; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; ROSENTHAL P, 1983, J IMMUNOL, V131, P232; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; STASHENKO P, 1980, J IMMUNOL, V125, P1678; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1995, STEM CELLS, V13, P360, DOI 10.1002/stem.5530130407	32	35	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4964	4969		10.1074/jbc.272.8.4964	http://dx.doi.org/10.1074/jbc.272.8.4964			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030557	hybrid			2022-12-25	WOS:A1997WJ85500045
J	Lochter, A; Srebrow, A; Sympson, CJ; Terracio, N; Werb, Z; Bissell, MJ				Lochter, A; Srebrow, A; Sympson, CJ; Terracio, N; Werb, Z; Bissell, MJ			Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN GENE-EXPRESSION; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; BASEMENT-MEMBRANE; IV COLLAGENASE; SYNOVIAL FIBROBLASTS; ENZYMATIC-PROPERTIES; TISSUE INHIBITOR; TRANSGENIC MICE; METALLOPROTEINASES	Stromelysin-1 is a member of the metalloproteinase family of extracellular matrix-degrading enzymes that regulates tissue remodeling, We previously established a transgenic mouse model in which rat stromelysin-1 targeted to the mammary gland augmented expression of endogenous stromelysin-l, disrupted functional differentiation, and induced mammary tumors. A cell line generated from an adenocarcinoma in one of these animals and a previously described mammary tumor cell line generated in culture readily invaded both a reconstituted basement membrane and type I collagen gels, whereas a nonmalignant, functionally normal epithelial cell line did not. Invasion of Matrigel by tumor cells was largely abolished by metalloproteinase inhibitors, but not by inhibitors of other proteinase families. Inhibition experiments with antisense oligodeoxynucleotides revealed that Matrigel invasion of both cell lines was critically dependent on stromelysin-l expression. Invasion of collagen, on the other hand, was reduced by only 40-50%. Stromelysin-l was expressed in both malignant and nonmalignant cells grown on plastic substrata. Its expression was completely inhibited in nonmalignant cells, but up-regulated in tumor cells, in response to Matrigel. Thus misregulation of stromelysin-1 expression appears to be an important aspect of mammary tumor cell progression to an invasive phenotype.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Lochter, A (corresponding author), UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA.				NCI NIH HHS [CA 58207, CA 57621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, R01CA057621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG DM, 1993, PROTEIN METHODS, P74; BONFIL RD, 1994, INT J CANCER, V58, P233; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; CHIN JR, 1985, J BIOL CHEM, V260, P2367; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DECLERCK YA, 1992, CANCER RES, V52, P701; Desprez Pierre-Yves, 1993, Molecular and Cellular Differentiation, V1, P99; DJONOV V, 1995, INT J ONCOL, V7, P311; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; HOYHTYA M, 1990, INT J CANCER, V46, P282, DOI 10.1002/ijc.2910460224; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; ITO A, 1991, COMP BIOCHEM PHYS B, V99, P381, DOI 10.1016/0305-0491(91)90058-L; JOUANNEAU J, 1991, CANCER CELL-MON REV, V3, P525; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIN CQ, 1995, J CELL BIOL, V129, P1115, DOI 10.1083/jcb.129.4.1115; LIOTTA LA, 1984, AM J PATHOL, V117, P339; Lund LR, 1996, DEVELOPMENT, V122, P181; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEIKLE MC, 1980, CALCIFIED TISSUE INT, V30, P77, DOI 10.1007/BF02408610; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PORTELLA G, 1994, INVAS METAST, V14, P7; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; SYMPSON C, 1994, PERSPECT DRUG DISCOV, V2, P401; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; WITTY JP, 1994, CANCER RES, V54, P4805	43	121	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5007	5015		10.1074/jbc.272.8.5007	http://dx.doi.org/10.1074/jbc.272.8.5007			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030563	hybrid, Green Submitted			2022-12-25	WOS:A1997WJ85500051
J	Lutsenko, S; Daoud, S; Kaplan, JH				Lutsenko, S; Daoud, S; Kaplan, JH			Identification of two conformationally sensitive cysteine residues at the extracellular surface of the Na,K-ATPase alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CATION-BINDING; PHOSPHORYLATION; NA+,K+-ATPASE; ATPASE; DISPOSITION; SEPARATION; DIGESTION; OCCLUSION; SITE	Na,K-ATPase in right side-out oriented vesicles was stabilized in different conformations, and the location of intramembrane Cys residues of the alpha-subunit was assessed with membrane-permeable and membrane-impermeable Cys-directed reagents, In the presence of Mg2+ and P-i, Cys(964) was the most accessible for both membrane-impermeable 4-acetamido-4'-maleimidylstilbene-2,2'disulfonic acid (or stilbene disulfonate maleimide, SDSM) and membrane-permeable 7-diethylamino-3-(4'-maleimidyl)-4-methylcoumarin (CPM). In the presence of K+, Cys(964) was modified only by hydrophobic CPM, indicating that the environment around Cys(964) was dif ferent in these two conformations, Cys(964) seems to mark the extracellular border of transmembrane segment Me, Cys(911) in transmembrane segment M8 showed similar behavior; however, it was not so readily modified. Complete modification of Cys(964) and Cys(911) causes only partial (about 50%) inactivation of both ATPase activity and Rb+ (or K+) occlusion, indicating that the effect on cation occlusion is indirect and not within the occlusion cavity, The ATP binding capacity remains unaltered by the modifications. Treatment of the K+-stabilized post-tryptic preparation of purified Na,K-ATPase revealed labeling of several cysteines by CPM, none of which were labeled with SDSM, Removal of K+ ions from the preparation, which we have previously shown is accompanied by release of the M5M6 hairpin to the supernatant (1), causes changes in the organization of the C-terminal 21-kDa fragment, In particular Cys(983) in M10 became labeled by both CPM and SDSM, pointing to a tight association between the C terminus and the M5M6 hairpin of the alpha-subunit.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Oregon Health & Science University				Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERBERG SJ, 1995, BIOCHEMISTRY-US, V34, P9508, DOI 10.1021/bi00029a027; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; GODSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LINGREL JB, 1994, J BIOL CHEM, V269, P19569; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; NAGAI M, 1986, J BIOL CHEM, V261, P3197; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; ROBINSON JD, 1980, J BIOENERG BIOMEMBR, V12, P165, DOI 10.1007/BF00744681; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497	24	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5249	5255		10.1074/jbc.272.8.5249	http://dx.doi.org/10.1074/jbc.272.8.5249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030596	hybrid			2022-12-25	WOS:A1997WJ85500084
J	Ohnuma, S; Hirooka, K; Ohto, C; Nishino, T				Ohnuma, S; Hirooka, K; Ohto, C; Nishino, T			Conversion from archaeal geranylgeranyl diphosphate synthase to farnesyl diphosphate synthase - Two amino acids before the first aspartate-rich motif solely determine eukaryotic farnesyl diphosphate synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE PRODUCT SPECIFICITY; MOLECULAR-CLONING; ESCHERICHIA-COLI; PYROPHOSPHATE SYNTHETASE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; SACCHAROMYCES-CEREVISIAE; BIOSYNTHETIC-PATHWAY; GENE; SEQUENCE; ENZYME	Farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) are precursors for a variety of important natural products, such as sterols, carotenoids, and prenyl quinones, Although FPP synthase and GGPP synthase catalyze similar consecutive condensations of isopentenyl diphosphate with allylic diphosphates and have several homologous regions in their amino acid sequences, nothing is known about how these enzymes form the specific products. To locate the region that causes the difference of final products between GGPP synthase and FPP synthase, we constructed six mutated archaeal GGPP synthases whose regions around the first aspartate-rich motif were replaced with the corresponding regions of FPP synthases from human, rat, Arabidopsis thaliana, Saccharomyces cerevisiae, Escherichia coli, Bacillus stearothermophilus, and from some other related mutated enzymes. From the analysis of these mutated enzymes, we revealed that the region around the first aspartate-rich motif is essential for the product specificity of all FPP synthases and that the mechanism of the chain termination in eukaryotic FPP synthases (type I) is different from those of prokaryotic FPP synthases (type II). In FPP synthases of type I, two amino acids situated at the fourth and the fifth positions before the motif solely determine their product chain length, while the product specificity of the type II enzymes is determined by one aromatic amino acid at the fifth position before the motif, two amino acids inserted in the motif, and other modifications, These data indicate that FPP synthases have evolved from the progenitor corresponding to the archaeal GGPP synthase in two ways.	TOHOKU UNIV,DEPT BIOCHEM & ENGN,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOYOTA MOTOR CO LTD,BIORES LAB,TOYOTA 47171,JAPAN	Tohoku University; Toyota Motor Corporation			Hirooka, Kazutake/K-9827-2017; Ohto, Chikara/GQB-4702-2022	Hirooka, Kazutake/0000-0001-5879-936X; Ohnuma, Shin-ichi/0000-0002-3305-5126				ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CHEN AJ, 1993, J BIOL CHEM, V268, P11002; CHEN AJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P399, DOI 10.1006/abbi.1994.1459; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; FUJII H, 1980, BIOCHEM BIOPH RES CO, V96, P1648, DOI 10.1016/0006-291X(80)91363-7; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; HUNDLE B, 1994, MOL GEN GENET, V245, P406, DOI 10.1007/BF00302252; JIANG Y, 1995, J BIOL CHEM, V270, P21793, DOI 10.1074/jbc.270.37.21793; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNTZ M, 1992, PLANT J, V2, P25; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MICHALOWSKI CB, 1991, J BIOL CHEM, V266, P11866; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; Sambrook J., 2002, MOL CLONING LAB MANU; TACHIBANA A, 1993, BIOSCI BIOTECH BIOCH, V57, P1129, DOI 10.1271/bbb.57.1129; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	29	84	91	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5192	5198		10.1074/jbc.272.8.5192	http://dx.doi.org/10.1074/jbc.272.8.5192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030588	hybrid			2022-12-25	WOS:A1997WJ85500076
J	Robledo, O; Fourcin, M; Chevalier, S; Guillet, C; Auguste, P; PouplardBarthelaix, A; Pennica, D; Gascan, H				Robledo, O; Fourcin, M; Chevalier, S; Guillet, C; Auguste, P; PouplardBarthelaix, A; Pennica, D; Gascan, H			Signaling of the cardiotrophin-1 receptor - Evidence for a third receptor component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; CNTF RECEPTOR; ONCOSTATIN-M; HUMAN INTERLEUKIN; TRANSDUCER GP130; KINASE JAK1; STEM-CELLS; CYTOKINE; DIFFERENTIATION	Cardiotrophin-1 (CT-1) is a recently isolated cytokine belonging to the interleukin-6 cytokine family. In the present study we show that CT-1 activates its receptor expressed at the surface of a human neural cell line by recruiting gp130 and gp190/leukemia inhibitory factor receptor beta, as shown by analyzing their tyrosine phosphorylation level. Neutralizing antibody directed against gp130 and reconstitution experiments performed in the COS-7 cell line demonstrate that gp130-gp190 heterocomplex formation is essential for CT-1 signaling. Analysis of the subsequent activation events revealed that CT-1 induces and utilizes Jak1-, Jak2-, and Tyk2-associated tyrosine kinases, which are in turn relayed by STAT 3 transcription factor. Cross-linking of iodinated CT-1 to the cell surface led to the identification of a third alpha component in addition to gp130 and gp190, with an apparent molecular mass of 80 kDa. Removal of N-linked carbohydrates from the protein backbone of the alpha component resulted in a protein of 45 kDa. Our results provide evidence that the CT-1 receptor is composed of a tripartite complex, a situation similar to the high affinity receptor for ciliary neurotrophic factor.	CHU ANGERS,BIOL CELLULAIRE LAB,F-49033 ANGERS,FRANCE; GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Roche Holding; Genentech				Auguste, Patrick/0000-0003-1485-0295				BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GASCAN H, 1990, J IMMUNOL, V144, P2592; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P465; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LEARY AG, 1990, BLOOD, V75, P1960; LIU L, 1994, J BIOL CHEM, V269, P16774; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MUSASHI M, 1991, BLOOD, V78, P1448; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Pennica D, 1996, CYTOKINE, V8, P183, DOI 10.1006/cyto.1996.0026; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Robledo O, 1996, J NEUROCHEM, V66, P1391; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THOMA B, 1994, J BIOL CHEM, V269, P6215; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	103	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4855	4863		10.1074/jbc.272.8.4855	http://dx.doi.org/10.1074/jbc.272.8.4855			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030543	hybrid			2022-12-25	WOS:A1997WJ85500031
J	White, AL; Guerra, B; Lanford, RE				White, AL; Guerra, B; Lanford, RE			Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATIONS; PRIMARY BABOON HEPATOCYTES; DISULFIDE BOND FORMATION; APO(A) MESSENGER-RNA; SIZE POLYMORPHISM; PRIMARY CULTURES; MOLECULAR-BASIS; ISOFORM SIZE; GENE FAMILY; LP(A)	Plasma levels of lipoprotein(a) (Lp(a)) vary over 1000-fold between individuals and are determined by the gene for its unique apolipoprotein, apo(a), which has greater than 100 alleles. Using primary baboon hepatocyte cultures, we previously demonstrated that differences in the ability of apo(a) allelic variants to escape the endoplasmic reticulum (ER) are a major determinant of Lp(a) production rate. To examine the reason for these differences, the folding of newly synthesized apo(a) was analyzed in pulse-chase experiments. Samples were harvested in the presence of N-ethylmaleimide to preserve disulfide-bonded folding intermediates, and apo(a) was analyzed by immunoprecipitation and SDS-polyacrylamide gel electrophoresis. Apo(a) required a prolonged period (30-60 min) to reach its fully oxidized form. Multiple folding intermediates were resolved, including a disulfide-linked, apo(a)-containing complex. Unexpectedly, all allelic variants examined showed similar patterns and kinetics of folding. Even ''null'' apo(a) proteins, which are unable to exit the ER, appeared to fold normally. The ER glucosidase inhibitor, castanospermine, prevented apo(a) secretion, but did not inhibit folding. This suggests that an event which is dependent on trimming of N-linked glucoses, and which occurs after the folding events detectable in our assay, is required for apo(a) secretion. Differences in the ability to undergo this event may explain the variable efficiency with which apo(a) allelic variants exit the ER.			White, AL (corresponding author), SW FDN BIOMED RES,DEPT VIROL & IMMUNOL,POB 28147,SAN ANTONIO,TX 78227, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BERG K, 1990, CLIN GENET, V37, P473; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; COHEN JC, 1993, J CLIN INVEST, V91, P1630, DOI 10.1172/JCI116370; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GAUBATZ JW, 1990, J LIPID RES, V31, P603; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; GAW A, 1994, J CLIN INVEST, V93, P2526, DOI 10.1172/JCI117263; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; ICHINOSE A, 1995, BIOCHEM BIOPH RES CO, V209, P372, DOI 10.1006/bbrc.1995.1513; ICHINOSE A, 1992, BIOCHEMISTRY-US, V31, P3113, DOI 10.1021/bi00127a011; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KRAFT HG, 1995, HUM GENET, V95, P275; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LAWN RM, 1995, J BIOL CHEM, V270, P24004, DOI 10.1074/jbc.270.41.24004; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MAKINO K, 1991, LIPIDS, V26, P679, DOI 10.1007/BF02535613; MANCINI FP, 1995, HUM MOL GENET, V4, P1535, DOI 10.1093/hmg/4.9.1535; MARCOVINA SM, 1993, BIOCHEM BIOPH RES CO, V191, P1192, DOI 10.1006/bbrc.1993.1343; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MOSSER V, 1995, HUM MOL GENET, V4, P173; PEROMBELON YFN, 1994, J CLIN INVEST, V93, P1481, DOI 10.1172/JCI117126; PHILLIPS ML, 1994, CHEM PHYS LIPIDS, V67-8, P91, DOI 10.1016/0009-3084(94)90127-9; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; RAINWATER DL, 1989, BIOCHIM BIOPHYS ACTA, V1003, P30, DOI 10.1016/0005-2760(89)90094-5; RAINWATER DL, 1986, BIOCHIM BIOPHYS ACTA, V877, P75, DOI 10.1016/0005-2760(86)90120-7; RAINWATER DL, 1989, J LIPID RES, V30, P549; SCANU AM, 1994, BBA-MOL BASIS DIS, V1227, P41, DOI 10.1016/0925-4439(94)90104-X; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TROMMSDORFF M, 1995, J CLIN INVEST, V96, P150, DOI 10.1172/JCI118015; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; WADE DP, 1993, P NATL ACAD SCI USA, V90, P1369, DOI 10.1073/pnas.90.4.1369; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, J BIOL CHEM, V269, P28716; WHITE AL, 1994, CHEM PHYS LIPIDS, V67-8, P123, DOI 10.1016/0009-3084(94)90131-7; ZYSOW BR, 1995, ARTERIOSCL THROM VAS, V15, P58, DOI 10.1161/01.ATV.15.1.58	60	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5048	5055		10.1074/jbc.272.8.5048	http://dx.doi.org/10.1074/jbc.272.8.5048			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030568	hybrid			2022-12-25	WOS:A1997WJ85500056
J	Seimiya, H; Mashima, T; Toho, M; Tsuruo, T				Seimiya, H; Mashima, T; Toho, M; Tsuruo, T			c-Jun NH2-terminal kinase-mediated activation of interleukin-1 beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; LEUKEMIA U937 CELLS; AGENT-INDUCED APOPTOSIS; DNA-DAMAGING AGENTS; BCL-2 HOMOLOG BAK; INDUCED-DIFFERENTIATION; HL-60 CELLS; IL-1-BETA-CONVERTING ENZYME; MULTIDRUG RESISTANCE; MAMMALIAN HOMOLOG	Upon treatment with various anticancer drugs, myeloid leukemia U937 cells undergo apoptosis. In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1 beta converting enzyme)/CED-3-like proteases in U937 cells. Phorbol ester-resistant U937 variant, UT16 cells, displayed a decreased susceptibility to apoptosis induced by these drugs. The drugs did not cause JNK1 activation, c-jun expression, nor activation of ICE/CED-3-like proteases in UT16 cells. As reported previously, benzyloxycarbonyl-Asp-CH2OC(O)-2,6-dichlorobenzene (Z-Asp), a preferential inhibitor of ICE/CED-3-like proteases, blocked the apoptosis of U937 cells. Interestingly, however, Z-Asp did not inhibit JNK1 activation in either VP-16- or CPT-treated U937 cells. The JNK1 antisense oligonucleotides diminished protein expression of JNK1 and inhibited drug-induced apoptosis of U937 cells, whereas sense control oligonucleotides did not. Consistent with this observation, the antisense oligonucleotide-treated cells did not respond to VP-16 or CPT with Z-Asp-sensitive proteases. These results indicate that JNK1 triggers the DNA damaging drug-induced apoptosis of U937 cells by activating Z-Asp-sensitive ICE/CED-3-like proteases.	JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN; UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	Japanese Foundation for Cancer Research; University of Tokyo				Seimiya, Hiroyuki/0000-0003-3314-9736				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; EVANS DL, 1993, CANCER RES, V53, P2133; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Grant S, 1996, CELL GROWTH DIFFER, V7, P603; GUNJI H, 1991, CANCER RES, V51, P741; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HASS R, 1989, EUR J CELL BIOL, V48, P282; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MA LD, 1992, ONCOL RES, V4, P291; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NISHIO K, 1990, BRIT J CANCER, V62, P415, DOI 10.1038/bjc.1990.309; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; SEIMIYA H, 1995, ONCOGENE, V11, P2047; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TAKEDA Y, 1991, INT J CANCER, V48, P931, DOI 10.1002/ijc.2910480622; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSURUO T, 1988, JPN J CANCER RES, V79, P285, DOI 10.1111/j.1349-7006.1988.tb01588.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	64	210	215	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4631	4636		10.1074/jbc.272.7.4631	http://dx.doi.org/10.1074/jbc.272.7.4631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020192	hybrid			2022-12-25	WOS:A1997WH01900108
J	vantVeer, C; Mann, KG				vantVeer, C; Mann, KG			Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR-XA; BLOOD-COAGULATION; FACTOR-IXA; NATURAL ANTICOAGULANT; ANTI-THROMBIN; FACTOR-XI; ACTIVATION; CLEAVAGE	The effects of the stoichiometric inhibitors tissue factor pathway inhibitor (TFPI), antithrombin-III (AT-III) and heparin cofactor-II (HC-II) on thrombin generation were evaluated in a reaction system composed of coagulation factors VIIa, X, IX, VIII, and V and prothrombin initiated by tissue factor (TF) and phospholipids. Initiation of the reaction in the absence of inhibitors resulted in explosive thrombin generation for factor VIIa-TF concentrations varying from 100 to 0.25 pM with the lag time or initiation phase of thrombin generation increasing from 0 to 180 s with decreasing factor VIIa-TF concentrations, During the propagation phase, prothrombin is quantitatively activated to 1.4 mu M alpha-thrombin. At normal plasma concentration (2.5 nM) full-length recombinant TFPI prolonged the initiation phase of thrombin generation 2-fold, and the rate of thrombin generation in the propagation phase of the reaction was 25-50% that of the uninhibited reaction when the reaction was initiated with 1.25-20 pM factor VIIa-TF. Inhibition of the reaction by TFPI is associated with a delay in factor V activation, In the presence of TFPI no explosive thrombin generation was observed when factor VIII was omitted from reactions initiated by factor VIIa-TF concentrations less than or equal to 20 pM. This indicates that in the presence of TFPI the factor Ma factor VIIIa pathway becomes essential at low factor VIIa-TF concentrations. In the reconstituted system, AT-III (3.4 mu M) did not prolong the initiation phase of thrombin generation when the reaction was initiated with 1.25 pM factor VIIa-TF, nor did AT-III delay factor V activation. The rate of thrombin formation in the presence of AT-III was reduced to 30% that of the uninhibited reaction, and the cu-thrombin formed was rapidly inhibited subsequent to its generation, The addition of HC-II alone at its physiological concentration (1.38 mu M) to the procoagulant mixture did not alter the rate or extent of thrombin generation. Subsequently, the thrombin formed was slowly inhibited by HC-II. The slow inactivation of thrombin by HC-II does not contribute to thrombin inhibition in the presence of AT-III. In contrast, the combination of physiological levels of AT-III and TFPI inhibited explosive thrombin generation initiated by 1.25 pM factor Wa TF completely, The absence of prothrombin consumption indicated that the combination of TFPI and AT-III is able to prevent the formation of prothrombinase activity at low factor VIIa-TF concentrations, The data indicate that TFPI potentiates the action of AT-III by decreasing the rate of formation and thus the amount of catalyst formed in the reaction, enabling AT-III to effectively scavenge the limited traces of factor IXa and factor Xa formed in the presence of TFPI, The initiation of thrombin generation by increasing factor VIIa-TF concentrations in the presence of physiological concentrations of TFPI and AT-III showed dramatic changes in the maximal rates of thrombin generation over small changes in initiator concentration, These data demonstrate that significant thrombin generation becomes a ''threshold-limited'' event with regard to the initiating factor VIIa-TF concentration in the presence of TFPI and AT-III.	UNIV VERMONT, DEPT BIOCHEM, BURLINGTON, VT 05405 USA	University of Vermont					NHLBI NIH HHS [P01HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1981, FEBS LETT, V126, P257, DOI 10.1016/0014-5793(81)80255-4; BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BROZE GJ, 1988, BLOOD, V71, P335; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; JONES KC, 1994, J BIOL CHEM, V269, P23367; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LINDHOUT T, 1994, BIOCHEM J, V297, P131, DOI 10.1042/bj2970131; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MARCINIAK E, 1973, BRIT J HAEMATOL, V24, P391, DOI 10.1111/j.1365-2141.1973.tb01662.x; MORRISSEY JH, 1993, BLOOD, V81, P734; NAITO K, 1991, J BIOL CHEM, V266, P7353; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; RAPAPORT SI, 1991, THROMB HAEMOSTASIS, V66, P6; REPKE D, 1990, P NATL ACAD SCI USA, V87, P7623, DOI 10.1073/pnas.87.19.7623; ROSENBERG RD, 1984, J CLIN INVEST, V74, P1, DOI 10.1172/JCI111389; SANDSET PM, 1991, P NATL ACAD SCI USA, V88, P708, DOI 10.1073/pnas.88.3.708; TANS G, 1991, J BIOL CHEM, V266, P21864; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1985, BLOOD, V66, P769; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van 'T Veer Cornelis, 1995, Blood, V86, p448A; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001	44	153	171	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4367	4377		10.1074/jbc.272.7.4367	http://dx.doi.org/10.1074/jbc.272.7.4367			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020158	hybrid			2022-12-25	WOS:A1997WH01900074
J	Saito, H; Nakatsuru, S; Inazawa, J; Nishihira, T; Park, JG; Nakamura, Y				Saito, H; Nakatsuru, S; Inazawa, J; Nishihira, T; Park, JG; Nakamura, Y			Frequent association of alternative splicing of NER, a nuclear hormone receptor gene in cancer tissues	ONCOGENE			English	Article						nuclear hormone receptor; alternative splicing; cancer cell lines and primary cancers; NER	ACTIVATION	We have detected frequent alternative splicing of a gene that encodes NER, a protein homologous to the retinoic acid receptors, in cancer cells, Western and immunohistochemical analyses disclosed accumulation of a large amount of the aberrant NER product, generated by alternative splicing that caused skipping of an exon corresponding to the DNA-binding domain, in the nucleoli of cells of cancer cell lines and primary cancer tissues, The aberrant protein was detected in 116 of 228 primary cancers developed in various tissues including breast and colon, but was absent in the corresponding normal tissues; it was also detected in 31 of 39 cancer cell lines, This observation may imply that the aberrant NER product has some relation to the development and/or progression of cancers in a variety of human tissues.	JAPANESE FDN CANC RES,INST CANC,DEPT HUMAN GENOME ANAL,TOSHIMA KU,TOKYO 170,JAPAN; UNIV TOKYO,INST MED SCI,MOL MED LAB,MINATO KU,TOKYO 108,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN; TOHOKU UNIV,DEPT SURG 2,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; SEOUL NATL UNIV,SCH MED,SEOUL 110744,SOUTH KOREA	Japanese Foundation for Cancer Research; University of Tokyo; Kyoto Prefectural University of Medicine; Tohoku University; Seoul National University (SNU)			Park, Jae-Gahb/J-5494-2012					BANIAHMAD A, 1993, J CELL BIOCHEM, V51, P151, DOI 10.1002/jcb.240510206; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GRIFFIOEN AW, 1994, CELL ADHES COMMUN, V2, P195, DOI 10.3109/15419069409004437; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ragsdale CW, 1991, CURR OPIN CELL BIOL, V3, P928, DOI 10.1016/0955-0674(91)90109-C; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SUDO K, 1994, GENOMICS, V24, P276, DOI 10.1006/geno.1994.1616; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3	11	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					617	621		10.1038/sj.onc.1200859	http://dx.doi.org/10.1038/sj.onc.1200859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053861				2022-12-25	WOS:A1997WF52400014
J	Fischer, Y; Thomas, J; Sevilla, L; Munoz, P; Becker, C; Holman, G; Kozka, IJ; Palacin, M; Testar, X; Kammermeier, H; Zorzano, A				Fischer, Y; Thomas, J; Sevilla, L; Munoz, P; Becker, C; Holman, G; Kozka, IJ; Palacin, M; Testar, X; Kammermeier, H; Zorzano, A			Insulin-induced recruitment of glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac myocytes - Evidence of the existence of different intracellular GLUT4 vesicle populations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; HEART-MUSCLE-CELLS; SKELETAL-MUSCLE; DEVELOPMENTAL REGULATION; SUBCELLULAR TRAFFICKING; INDUCED TRANSLOCATION; HUMAN ERYTHROCYTE; XENOPUS OOCYTES; PLASMA-MEMBRANE; DIABETIC RATS	Using isolated rat cardiomyocytes we have examined: 1) the effect of insulin on the cellular distribution of glucose transporter 4 (GLUT4) and GLUT1, 2) the total amount of these transporters, and 3) the co-localization of GLUT4, GLUT1, and secretory carrier membrane proteins (SCAMPs) in intracellular membranes. Insulin induced 5.7- and 2.7-fold increases in GLUT4 and GLUT1 at the cell surface, respectively, as determined by the nonpermeant photoaffinity label [H-3]2-N-[4(1-azi-2,2,2-trifluoroethyl)benzoyl] -1,3-bis-(D-mannos-4-yloxy)propyl-2-amine. The total amount of GLUT1, as determined by quantitative Western blot analysis of cell homogenates, was found to represent a substantial fraction (similar to 30%) of the total glucose transporter content. Intracellular GLUT4-containing vesicles were immunoisolated from low density microsomes by using monoclonal anti-GLUT4 (1F8) or anti-SCAMP antibodies (3FS) coupled to either agarose or acrylamide. With these different immunoisolation conditions two GLUT4 membrane pools were found in nonstimulated cells: one pool with a high proportion of GLUT4 and a low content in GLUT1 and SCAMP 39 (pool 1) and a second GLUT4 pool with a high content of GLUT1 and SCAMP 39 (pool 2). The existence of pool 1 was confirmed by immunotitration of intracellular GLUT4 membranes with 1F8-acrylamide. Acute insulin treatment caused the depletion of GLUT4 in both pools and of GLUT1 and SCAMP 39 in pool 2. In conclusion: 1) GLUT4 is the major glucose transporter to be recruited to the surface of cardiomyocytes in response to insulin; 2) these cells express a high level of GLUT1; and 3) intracellular GLUT4-containing vesicles consist of at least two populations, which is compatible with recently proposed models of GLUT4 trafficking in adipocytes.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & BIOL MOL,E-08028 BARCELONA,SPAIN; UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	University of Barcelona; University of Bath	Fischer, Y (corresponding author), RHEIN WESTFAL TH AACHEN,FAC MED,INST PHYSIOL,PAUWELSSTR 30,D-52057 AACHEN,GERMANY.		Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015	Palacin, Manuel/0000-0002-8670-293X				ALEDO JC, 1995, BIOCHEM BIOPH RES CO, V215, P321, DOI 10.1006/bbrc.1995.2469; BELL GI, 1993, J BIOL CHEM, V268, P19161; BERS DM, 1979, BIOCHIM BIOPHYS ACTA, V555, P131, DOI 10.1016/0005-2736(79)90078-6; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; BROZINICK JT, 1994, BIOCHEM J, V297, P539, DOI 10.1042/bj2970539; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; DORIAMEDINA CL, 1993, AM J PHYSIOL, V265, pE454, DOI 10.1152/ajpendo.1993.265.3.E454; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FISCHER Y, 1991, LIFE SCI, V49, P1679, DOI 10.1016/0024-3205(91)90310-8; FISCHER Y, 1995, ENDOCRINOLOGY, V136, P412, DOI 10.1210/en.136.2.412; Fischer Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1204, DOI 10.1152/ajpcell.1996.270.4.C1204; FISCHER Y, 1995, BIOCHEM J, V311, P575, DOI 10.1042/bj3110575; GOULD GW, 1994, J BIOL CHEM, V269, P26622; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; HOPKINS JCA, 1995, J MOL CELL CARDIOL, V27, pA182; JONES LR, 1979, J BIOL CHEM, V254, P530; KAINULAINEN H, 1994, BBA-MOL BASIS DIS, V1225, P275, DOI 10.1016/0925-4439(94)90007-8; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KOLTER T, 1992, BIOCHEM BIOPH RES CO, V189, P1207, DOI 10.1016/0006-291X(92)92333-S; KRAEGEN EW, 1993, BIOCHEM J, V295, P287, DOI 10.1042/bj2950287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; OKA Y, 1988, J BIOL CHEM, V263, P13432; PALFREYMAN RW, 1992, BIOCHEM J, V284, P275, DOI 10.1042/bj2840275; PUJADES C, 1992, J CELL SCI, V102, P815; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SATOH S, 1993, J BIOL CHEM, V268, P17820; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; STUDELSKA DR, 1992, AM J PHYSIOL, V263, pE102, DOI 10.1152/ajpendo.1992.263.1.E102; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; WANG C, 1991, BIOCHEM BIOPH RES CO, V177, P1095, DOI 10.1016/0006-291X(91)90651-M; WEINSTEIN SP, 1992, BIOCHIM BIOPHYS ACTA, V1136, P302, DOI 10.1016/0167-4889(92)90121-Q; WHEELER TJ, 1994, BBA-BIOMEMBRANES, V1196, P191, DOI 10.1016/0005-2736(94)00211-8; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YANG J, 1992, J BIOL CHEM, V267, P10393; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; ZOCCOLI MA, 1978, J BIOL CHEM, V253, P6923; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	53	137	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7085	7092		10.1074/jbc.272.11.7085	http://dx.doi.org/10.1074/jbc.272.11.7085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054401	hybrid, Green Published			2022-12-25	WOS:A1997WN14700040
J	Acharya, S; Saad, Y; Karnik, SS				Acharya, S; Saad, Y; Karnik, SS			Transducin-alpha C-terminal peptide binding site consists of C-D and E-F loops of rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; BOVINE RHODOPSIN; ACTIVATION; INTERACT; RECEPTOR; SUBUNIT; PROTEINS; CYCLASE; CASCADE; VISION	The binding of heterotrimeric GTP-binding proteins (G-proteins) to serpentine receptors involves dependent contacts. We have deduced the points of interaction between mutant bovine rhodopsins and alpha(t)-(340350), a peptide corresponding to the C terminus of the cu subunit (cu,) of bovine retinal G-protein, transducin , Direct binding of alpha(t)-(340350) to rhodopsin stabilizes the activated metarhodopsin II state (M II), consequently uncoupling the rhodopsin-transducin interaction, This peptide action requires two segments on the cytoplasmic domain of rhodopsin: the Tyr(136)-Val(137) Val(138)-Val(139) sequence on the C-D loop and the Glu(247) Lys(248)-Glu(249)-Val(250)-Thr(251) sequence on the E-F loop, We propose that a tertiary interaction of these two loop regions forms a pocket for binding the cu, C terminus of the transducin during light transduction in vivo. In most G-proteins, the C termini of alpha subunits are important for interaction with receptors, and, in several serpentine receptors, regions similar to those in rhodopsin are essential for G-protein activation, indicating that the interaction described here may be a generally applicable mode of G-protein binding in signal transduction.	CLEVELAND CLIN FDN,DEPT MOL CARDIOL,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NEI NIH HHS [P30 EY025585] Funding Source: Medline; NHLBI NIH HHS [R01 HL057470] Funding Source: Medline; PHS HHS [9704] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHARYA S, 1996, J BIOL CHEM, V271, P25408; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CONKLIN BR, 1993, NATUE, V363, P224; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, EUR J BIOCHEM, V127, P97; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; NAKANISHI K, 1995, BIOPHYS CHEM, V56, P13, DOI 10.1016/0301-4622(95)00010-U; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Taylor JM, 1996, J BIOL CHEM, V271, P3336; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697	31	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6519	6524		10.1074/jbc.272.10.6519	http://dx.doi.org/10.1074/jbc.272.10.6519			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045677	hybrid			2022-12-25	WOS:A1997WM64700061
J	Gowda, DC; Gupta, P; Davidson, EA				Gowda, DC; Gupta, P; Davidson, EA			Glycosylphosphatidylinositol anchors represent the major carbohydrate modification in proteins of intraerythrocytic stage Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINIDASE; MEROZOITE SURFACE-ANTIGEN; CYTOPLASMIC GLYCOPROTEINS; ERYTHROCYTIC STAGES; SYNTHETIC PEPTIDES; MALARIA PARASITES; O-GLCNAC; GLYCOSYLATION; BIOSYNTHESIS; MANNOSAMINE	The nature and extent of carbohydrate modification in intraerythrocytic stage Plasmodium falciparum proteins have been controversial. This study describes the characterization of the carbohydrates in intraerythrocytic P. falciparum proteins and provides an overall picture of the nature of carbohydrate modification in the parasite proteins. P. falciparum strains were metabolically labeled with radioactive sugar precursors and ethanolamine at different developmental stages. The individual parasite proteins separated on SDS-polyacrylamide gels and whole parasite cell lysates were analyzed for the carbohydrate moieties. The results established the following: 1) glycosylphosphatidylinositol (GPI) anchors represent the major carbohydrate modification in the intraerythrocytic stage P. falciparum proteins; 2) in contrast to previous reports, O-linked carbohydrates are either absent or present only at very low levels in the parasite; and 3) P. falciparum contains low levels of N-glycosylation capability. The amount of N-linked carbohydrates in whole parasite proteins is approximately 6% compared with the GPI anchors attached to proteins based on radioactive GlcN incorporated into the proteins. The glycan cores of multiple parasite protein GPI anchors are all similar, consisting of protein-ethanolamine-phosphate-(Man-alpha-1-2)6Man-alpha-1-2Man-alpha-1-6Man-alpha-1-4GlcN. The fourth Man residues distal to GlcN of the GPI anchor glycan cores contain unidentified substituents that are susceptible to conditions of nitrous acid deamination. This unusual structural feature may contribute to the reported pathogenic properties of the P. falciparum GPI anchors.			Gowda, DC (corresponding author), GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.			Gowda, Channe/0000-0002-6860-5108				BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; BRETON CB, 1990, RES IMMUNOL, V141, P743, DOI 10.1016/0923-2494(90)90005-J; CARLSON DM, 1966, J BIOL CHEM, V241, P2984; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Chang SP, 1996, INFECT IMMUN, V64, P253, DOI 10.1128/IAI.64.1.253-261.1996; CHEUNG A, 1986, P NATL ACAD SCI USA, V83, P8328, DOI 10.1073/pnas.83.21.8328; CHOU CF, 1992, J BIOL CHEM, V267, P3901; COOPER JA, 1992, MOL BIOCHEM PARASIT, V51, P301, DOI 10.1016/0166-6851(92)90080-4; DAYALDRAGER R, 1991, CARBOHYD RES, V209, pC5, DOI 10.1016/0008-6215(91)80172-J; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; DIECKMANNSCHUPPERT A, 1993, EUR J BIOCHEM, V216, P779, DOI 10.1111/j.1432-1033.1993.tb18198.x; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; ETLINGER HM, 1991, INFECT IMMUN, V59, P3498, DOI 10.1128/IAI.59.10.3498-3503.1991; FENTON B, 1989, MOL BIOCHEM PARASIT, V34, P79, DOI 10.1016/0166-6851(89)90022-4; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; Field M. C., 1992, LIPID MODIFICATION P, P155; GEROLD P, 1994, J BIOL CHEM, V269, P2597; Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9; HALDAR K, 1986, P NATL ACAD SCI USA, V83, P8565, DOI 10.1073/pnas.83.22.8565; HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HEIDRICH HG, 1984, Z PARASITENKD, V70, P747, DOI 10.1007/BF00927127; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; HOLDER AA, 1988, PROG ALLERGY, V41, P72; HOLDER AA, 1988, PARASITE IMMUNOL, V10, P607, DOI 10.1111/j.1365-3024.1988.tb00248.x; HOLT GD, 1987, J BIOL CHEM, V262, P14847; JAKOBSEN PH, 1987, J CLIN MICROBIOL, V25, P2075, DOI 10.1128/JCM.25.11.2075-2079.1987; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Kimura EA, 1996, J BIOL CHEM, V271, P14452, DOI 10.1074/jbc.271.24.14452; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; MAURICE J, 1995, SCIENCE, V267, P320, DOI 10.1126/science.7824925; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCILHINNEY RAJ, 1992, LIPID MODIFICATION P, P15; MENON AK, 1994, METHOD ENZYMOL, V230, P418; Nasir-ud-Din, 1992, Biochemical Society Transactions, V20, p388S; NASIRUDDIN, 1992, BIOCHEM INT, V27, P55; NASIRUDDIN, 1990, J CHEM SOC PAKISTAN, V12, P344; ODUOLA AMJ, 1988, EXP PARASITOL, V66, P86, DOI 10.1016/0014-4894(88)90053-7; PAN YT, 1992, J BIOL CHEM, V267, P21250; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; PONNUDURAI T, 1986, PARASITOLOGY, V93, P263, DOI 10.1017/S003118200005143X; RALTON JE, 1993, J BIOL CHEM, V268, P24183; RAMASAMY R, 1986, MOL BIOCHEM PARASIT, V19, P91, DOI 10.1016/0166-6851(86)90113-1; RAMASAMY R, 1987, IMMUNOL CELL BIOL, V65, P147, DOI 10.1038/icb.1987.16; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SCHMIDT KF, 1995, SCIENCE, V269, P1670, DOI 10.1126/science.7569890; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; Schofield L, 1996, J IMMUNOL, V156, P1886; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tachado SD, 1996, J IMMUNOL, V156, P1897; UDEINYA IJ, 1980, B WORLD HEALTH ORGAN, V58, P445; UMEMOTO J, 1978, ANAL BIOCHEM, V91, P186, DOI 10.1016/0003-2697(78)90830-8; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VERMEULEN AN, 1986, MOL BIOCHEM PARASIT, V20, P155, DOI 10.1016/0166-6851(86)90027-7; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; YANG YF, 1987, MOL BIOCHEM PARASIT, V26, P61, DOI 10.1016/0166-6851(87)90130-7	66	113	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6428	6439		10.1074/jbc.272.10.6428	http://dx.doi.org/10.1074/jbc.272.10.6428			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045667	hybrid			2022-12-25	WOS:A1997WM64700051
J	Nikolakaki, E; Meier, J; Simos, G; Georgatos, SD; Giannakouros, T				Nikolakaki, E; Meier, J; Simos, G; Georgatos, SD; Giannakouros, T			Mitotic phosphorylation of the lamin B receptor by a serine/arginine kinase and p34(cdc2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE INNER MEMBRANE; NUCLEAR-ENVELOPE; SPLICING FACTORS; CELL-CYCLE; PROTEIN-KINASE; CDC2 KINASE; SERINE-RICH; BINDING; MITOSIS; CHROMOSOMES	The lamin B receptor (LBR) is an integral protein of the inner nuclear membrane that is modified at interphase by a nuclear envelope-bound protein kinase. This enzyme (RS kinase) specifically phosphorylates arginine-serine dipeptide motifs located at the NH2-terminal domain of LBR and regulates its interactions with other nuclear envelope proteins. To compare the phosphorylation state of LBR during interphase and mitosis, we performed phosphopeptide mapping of in vitro and in vivo P-32-labeled LBR and analyzed a series of recombinant proteins and synthetic peptides. Our results show that LBR undergoes two types of mitotic phosphorylation mediated by the RS and the p34(cdc2) protein kinases, respectively. The RS kinase modifies similar sites at interphase and mitosis (i.e. Ser(76), Ser(78), Ser(80), Ser(82), Ser(84)), whereas p34(cdc2) mainly phosphorylates Ser(71), These findings clarify the phosphorylation state of LBR during the cell cycle and provide new information for understanding the mechanisms responsible for nuclear envelope assembly and disassembly.	ARISTOTELIAN UNIV THESSALONIKI, SCH CHEM, BIOCHEM LAB, GR-54006 THESSALONIKI, GREECE; EUROPEAN MOL BIOL LAB, CELL BIOL PROGRAMME, D-69017 HEIDELBERG, GERMANY; UNIV CRETE, FAC MED, DEPT BASIC SCI, GR-71110 IRAKLION, CRETE, GREECE	Aristotle University of Thessaloniki; European Molecular Biology Laboratory (EMBL); University of Crete			GIANNAKOUROS, THOMAS/R-3204-2019; Simos, George/AAH-2596-2021	Georgatos, Spyros/0000-0002-2078-7467; Simos, George/0000-0001-5453-3185				AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE B, 1990, EXP CELL RES, V186, P169, DOI 10.1016/0014-4827(90)90223-W; CARLOS S, 1993, J BIOL CHEM, V268, P185; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; Delius H, 1994, Curr Top Microbiol Immunol, V186, P13; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MAISON C, 1995, EMBO J, V14, P3311, DOI 10.1002/j.1460-2075.1995.tb07338.x; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; OELLIG C, 1987, J VIROL, V61, P3048, DOI 10.1128/JVI.61.10.3048-3057.1987; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; Simos G, 1996, J BIOL CHEM, V271, P12617, DOI 10.1074/jbc.271.21.12617; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; YE Q, 1994, J BIOL CHEM, V269, P11306; YUAN J, 1991, J BIOL CHEM, V266, P9211	46	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6208	6213		10.1074/jbc.272.10.6208	http://dx.doi.org/10.1074/jbc.272.10.6208			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045635	hybrid			2022-12-25	WOS:A1997WM64700019
J	Rasnick, D				Rasnick, D			Kinetics analysis of consecutive HIV proteolytic cleavages of the Gag-Pol polyprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEASE INHIBITORS; VIRAL INFECTIVITY; IN-VITRO; PARTICLE FORMATION; PROTEINASE DIMER; MATURATION; IDENTIFICATION; RESISTANCE; SUSCEPTIBILITY	The ordered, sequential cleavages of the Gag-Pol polyprotein by human immunodeficiency virus (HIV) protease present the virus with severe limitations on viable mutations of the enzyme, An extension of the method of Kuchel et al, (Kuchel, P. W., Nichol, L. W., and Jeffrey, P. D. (1974) J. Theor, Biol, 48, 39-49) for the analysis of consecutive enzyme reactions leads to a simple description of the catalytic efficiency of mutant and wild type HIV protease in the presence or absence of inhibitors, The overall catalytic efficiency of a mutant HIV protease relative to the wild type enzyme is given by the product of the ratios of their respective efficiencies for the 8 obligatory cleavages, Under no conditions is HIV viable when the geometric mean efficiency of a mutant HIV protease is less than 61% of the wild type activity for each cleavage, The lower catalytic efficiencies of the mutant enzymes coupled with the exponential dependence on 1/(1 + [1]/K-i) more than offset the inhibitor resistance acquired by HIV protease, The conclusion of this analysis is that inhibitor-resistant mutant HIV proteases are very unlikely to contribute to viral viability in vivo. The results strongly suggest that future protease inhibitor clinical trials should measure the infectivity of the virions in blood plasma instead of relying on viral RNA levels.	ARRIS PHARMACEUT CORP,S SAN FRANCISCO,CA 94080									ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BABE LM, 1995, P NATL ACAD SCI USA, V92, P10069, DOI 10.1073/pnas.92.22.10069; Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; GOWDA SD, 1989, J BIOL CHEM, V264, P8459; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; HOSUR MV, 1994, J AM CHEM SOC, V116, P847, DOI 10.1021/ja00082a004; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379; JAMES JS, 1995, AIDS TREATMENT NEWS, V235, P8; KAGEYAMA S, 1994, AIDS RES HUM RETROV, V10, P735, DOI 10.1089/aid.1994.10.735; KAPLAN AH, 1991, P NATL ACAD SCI USA, V88, P4528, DOI 10.1073/pnas.88.10.4528; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KEMPF DJ, 1991, ANTIMICROB AGENTS CH, V35, P2209, DOI 10.1128/AAC.35.11.2209; KING RW, 1995, ANTIVIR RES, V28, P13, DOI 10.1016/0166-3542(95)00033-I; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KONVALINKA J, 1995, EUR J BIOCHEM, V228, P191, DOI 10.1111/j.1432-1033.1995.tb20249.x; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; KRAUSSLICH HG, 1992, J VIROL, V66, P567; KUCHEL PW, 1974, J THEOR BIOL, V48, P39, DOI 10.1016/0022-5193(74)90178-7; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; LIN YZ, 1995, BIOCHEMISTRY-US, V34, P1143, DOI 10.1021/bi00004a007; MASCHERA B, 1995, J VIROL, V69, P5431, DOI 10.1128/JVI.69.9.5431-5436.1995; MERGENER K, 1992, VIROLOGY, V186, P25, DOI 10.1016/0042-6822(92)90058-W; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106; Pazhanisamy S, 1996, J BIOL CHEM, V271, P17979, DOI 10.1074/jbc.271.30.17979; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLLARD RB, 1994, PHARMACOTHERAPY, V14, pS21; ROSE JR, 1995, J VIROL, V69, P2751; Rose RE, 1996, P NATL ACAD SCI USA, V93, P1648, DOI 10.1073/pnas.93.4.1648; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; SHEPPARD HW, 1993, NATURE, V364, P291, DOI 10.1038/364291a0; SHIH CYT, 1981, J VIROL, V40, P942, DOI 10.1128/JVI.40.3.942-945.1981; STEWART L, 1994, VIROLOGY, V204, P45, DOI 10.1006/viro.1994.1509; TANG J, 1995, FEBS LETT, V367, P112, DOI 10.1016/0014-5793(95)00547-M; VELLA S, 1994, AIDS, V8, pS25, DOI 10.1097/00002030-199409001-00006; WINSLOW DL, 1995, AIDS RES HUM RETROV, V11, P107, DOI 10.1089/aid.1995.11.107	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6348	6353						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045655				2022-12-25	WOS:A1997WM64700039
J	Lee, PJ; Jiang, BH; Chin, BY; Iyer, NV; Alam, J; Semenza, GL; Choi, AMK				Lee, PJ; Jiang, BH; Chin, BY; Iyer, NV; Alam, J; Semenza, GL; Choi, AMK			Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CARBON-MONOXIDE; MONOLAYER PERMEABILITY; OXIDATIVE STRESS; HEAVY-METALS; BASAL LEVEL; FACTOR-I; INDUCTION; EXPRESSION; ERYTHROPOIETIN	Exposure of rats to hypoxia (7% O-2) markedly increased the level of heme oxygenase-1 (HO-1) mRNA in several tissues. Accumulation of HO-1 transcripts was also observed after exposure of rat aortic vascular smooth muscle (VSM) cells to 1% O-2, and this induction was dependent on gene transcription, Activation of the mouse HO-1 gene by all agents thus far tested is mediated by two 5'-enhancer sequences, SX2 and AB1, but neither fragment was responsive to hypoxia in VSM cells. Hypoxia-dependent induction of the chloramphenicol acetyltransferase (CAT) reporter gene was mediated by a 163-bp fragment located approximately 9.5 kilobases upstream of the transcription start site. This fragment contains two potential binding sites for hypoxia-inducible factor 1 (HIF-1), A role for HIF-1 in HO-1 gene regulation was established by the following observations: 1) HIF-1 specifically bound to an oligonucleotide spanning these sequences, 2) mutation of these sequences abolished HIF-1 binding and hypoxia-dependent gene activation in VSM cells, 3) hypoxia increased HIF-1 alpha and HIF-1 beta protein levels in VSM cells, and 4) hypoxia-dependent HO-1 mRNA accumulation was not observed in mutant hepatoma cells lacking HIF-1 DNA-binding activity, Taken together, these data demonstrate that hypoxia induces HO-1 expression in animal tissues and cell cultures and implicate HIF-1 in this response.	ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT MOL GENET,NEW ORLEANS,LA 70121; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV PULM & CRIT CARE,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,CTR GENET MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Ochsner Health System; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X; Jiang, Bing-Hua/0000-0003-4526-2031	NHLBI NIH HHS [R01-HL55338] Funding Source: Medline; NIA NIH HHS [K11AG00516] Funding Source: Medline; NIDDK NIH HHS [DK43135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K11AG000516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1992, J BIOL CHEM, V267, P21894; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; BARKER SGE, 1993, ARTERIOSCLER THROMB, V13, P70, DOI 10.1161/01.ATV.13.1.70; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Maines MD, 1992, HEME OXYGENASE CLIN, P145; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; NUNN JF, 1989, APPL RESP PHYSL, P471; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; SANTILLI SM, 1993, J VASC SURG, V18, P227, DOI 10.1016/0741-5214(93)90602-I; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, HEMATOL ONCOL CLIN N, V8, P863, DOI 10.1016/S0889-8588(18)30134-5; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P2685; SHREENIWAS R, 1991, J CELL PHYSIOL, V146, P8, DOI 10.1002/jcp.1041460103; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SILVERSTEIN JL, 1988, ARCH DERMATOL, V124, P1379, DOI 10.1001/archderm.124.9.1379; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	48	615	635	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5375	5381		10.1074/jbc.272.9.5375	http://dx.doi.org/10.1074/jbc.272.9.5375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038135	hybrid			2022-12-25	WOS:A1997WK74700003
J	Sangawa, H; Himeda, T; Shibata, H; Higuti, T				Sangawa, H; Himeda, T; Shibata, H; Higuti, T			Gene expression of subunit c(P1), subunit c(P2), and oligomycin sensitivity-conferring protein may play a key role in biogenesis of H+-ATP synthase in various rat tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOVINE HEART-MITOCHONDRIA; ESCHERICHIA-COLI; LIVER MITOCHONDRIA; CDNA CLONING; COORDINATE INDUCTION; COUPLING FACTOR-6; MOLECULAR-CLONING; IMPORT PRECURSOR; THYROID-HORMONES	Mammalian H+-ATP synthase is a supramolecule composed of at least 14 subunits that have a constant stoichiometry. Nevertheless the coordinate regulation of the gene expressions of various subunits remains obscure. To clarify the coordinate transcriptional regulatory system of mammalian H+-ATP synthase, we determined the absolute amount of nine species of mRNAs for eight nuclear-encoded subunits of HC-ATP synthase in different tissues of 8-week-old rats by use of the synthetic mRNAs and P-32-labeled DNA probes for each mRNA. Our quantitative analyses of the transcripts of H+-ATP synthase revealed that nine species of the subunits in different tissues of 8-week-old rats were divisible into two groups: a high transcript gene (HTG) group (beta-subunit, subunit b, subunit d, subunit e, and Factor 6) and a low transcript gene (LTG) group (subunit c(P1), subunit c(P2), IF1, and oligomycin sensitivity-conferring protein). The transcription step of LTG could constitute a bottleneck in the biogenesis of H+-ATP synthase. Thus, the transcriptional regulatory system of the LTG may play a hey role in the biogenesis of mammalian H+-ATP synthase. The HTG were transcribed in a tissue-specific manner that corresponds with energy demand in the tissues. However, there was no tissue specificity in subunit c(P2), Furthermore, the tissue specificity of the transcript of IF1 differed substantially from that of HTG, suggesting that it could be crucial in the protection of mitochondrial membrane under abnormal conditions.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN	Tokushima University								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANGOV E, 1991, J BACTERIOL, V173, P407, DOI 10.1128/jb.173.1.407-411.1991; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRUSILOW WSA, 1982, J BACTERIOL, V151, P1363, DOI 10.1128/JB.151.3.1363-1371.1982; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HARRIS DA, 1991, BIOCHEM J, V280, P561, DOI 10.1042/bj2800561; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HENGERER B, 1993, BIOTECHNIQUES, V14, P522; HIGUTI T, 1992, J BIOL CHEM, V267, P22658; HIGUTI T, 1993, BIOCHIM BIOPHYS ACTA, V1172, P311, DOI 10.1016/0167-4781(93)90219-4; HIGUTI T, 1990, BIOCHEM BIOPH RES CO, V171, P1079, DOI 10.1016/0006-291X(90)90794-N; HIGUTI T, 1992, BIOCHEMISTRY-US, V31, P12451, DOI 10.1021/bi00164a022; HIGUTI T, 1993, J BIOCHEM-TOKYO, V114, P714, DOI 10.1093/oxfordjournals.jbchem.a124242; HIGUTI T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P87, DOI 10.1016/0167-4781(93)90249-D; HOUSTEK J, 1995, J BIOL CHEM, V270, P7689, DOI 10.1074/jbc.270.13.7689; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; IZQUIERDO JM, 1993, FEBS LETT, V323, P109, DOI 10.1016/0014-5793(93)81459-D; IZQUIERDO JM, 1993, BIOCHEM BIOPH RES CO, V196, P55, DOI 10.1006/bbrc.1993.2215; IZQUIERDO JM, 1995, J BIOL CHEM, V270, P10342, DOI 10.1074/jbc.270.17.10342; LAHRACH HD, 1977, BIOCHEMISTRY-US, V16, P4743; MORRISSEY DV, 1989, ANAL BIOCHEM, V181, P345, DOI 10.1016/0003-2697(89)90255-8; MURAGUCHI M, 1990, BIOCHEM BIOPH RES CO, V168, P226, DOI 10.1016/0006-291X(90)91697-Q; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; PATI S, 1991, BIOCHEMISTRY-US, V30, P4710, DOI 10.1021/bi00233a011; SCARPULLA RC, 1986, J BIOL CHEM, V261, P4660; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TSURUMI C, 1990, BIOCHEM BIOPH RES CO, V169, P136, DOI 10.1016/0006-291X(90)91444-W; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; YOSHIHARA Y, 1991, BIOCHEMISTRY-US, V30, P6854, DOI 10.1021/bi00242a008	36	25	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6034	6037		10.1074/jbc.272.9.6034	http://dx.doi.org/10.1074/jbc.272.9.6034			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038226	hybrid			2022-12-25	WOS:A1997WK74700094
J	Sheng, ZL; Knowlton, K; Chen, J; Hoshijima, M; Brown, JH; Chien, KR				Sheng, ZL; Knowlton, K; Chen, J; Hoshijima, M; Brown, JH; Chien, KR			Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway - Divergence from downstream CT-1 signals for myocardial cell hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; GENE-EXPRESSION; EMBRYONIC MOTONEURONS; GROWTH-FACTOR; IN-VITRO; CYTOKINES; RECEPTOR; GP130; MICE; DIFFERENTIATION	Cardiac myocyte survival is of central importance in the maintenance of the function of heart, as well as in the development of a variety of cardiac diseases, To understand the molecular mechanisms that govern this function, we characterized apoptosis in cardiac muscle cells following serum deprivation, Cardiotrophin 1 (CT-1), a potent cardiac survival factor (Sheng, Z., Pennica, D., Wood, W. I., and Chien, K. R. (1996) Development (Camb.) 122, 419-428), is capable of inhibiting apoptosis in cardiac myocytes, To explore the potential downstream pathways that might be responsible for this effect, we documented that CT-1 activated both signal transducer and activator of transcription 3 (STAT3)-and mitogen-activated protein (MAP) kinase-dependent pathways, The transfection of a MAP kinase kinase 1 (MEK1) dominant negative mutant cDNA into myocardial cells blocked the antiapoptotic effects of CT-1, indicating a requirement of the MAP kinase pathway for the survival effect of CT-1, A MEK-specific inhibitor (PD098059) (Dudley, D. T., Pang, L., Decker, S.-J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl, Acad. Sci. USA 92, 7686-7689) is capable of blocking the activation of MAP kinase, as well as the survival effect of CT-1. In contrast, this inhibitor did not block the activation of STAT3, nor did it have any effect on the hypertrophic response elicited following stimulation of CT-1, Therefore, CT-1 promotes cardiac myocyte survival via the activation of an antiapoptotic signaling pathway that requires MAP kinases, whereas the hypertrophy induced by CT-1 may be mediated by alternative pathways, e.g. Janus kinase/STAT or MEK kinase/c-Jun NH2-terminal protein kinase.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,CTR GENET MOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,AMER HEART ASSOC BUGHER FDN,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,CTR BIOL MOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Chen, Ju/E-5579-2011		NHLBI NIH HHS [HL53773, 1 RO1 HL51549, P01 HL46345] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773, P01HL046345, R01HL051549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; Barunwald E, 1996, HEART DIS TXB CARDIO, P1626; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COLUCCI WS, 1996, HEART DIS TXB CARDIO, P394; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LINDSAY RM, 1995, NATURE, V373, P289, DOI 10.1038/373289a0; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Reed JC, 1996, J CLIN INVEST, V97, P2403, DOI 10.1172/JCI118684; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; Sheng ZL, 1996, DEVELOPMENT, V122, P419; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	45	335	347	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5783	5791		10.1074/jbc.272.9.5783	http://dx.doi.org/10.1074/jbc.272.9.5783			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038192	hybrid			2022-12-25	WOS:A1997WK74700060
J	Brazil, BT; Cleland, JL; McDowell, RS; Skelton, NJ; Paris, K; Horowitz, PM				Brazil, BT; Cleland, JL; McDowell, RS; Skelton, NJ; Paris, K; Horowitz, PM			Model peptide studies demonstrate that amphipathic secondary structures can be recognized by the chaperonin GroEL (cpn60)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; MITOCHONDRIAL RHODANESE; COHERENCE-TRANSFER; ESCHERICHIA-COLI; PROTEIN; SEQUENCE; CONFORMATION; SPECTROSCOPY; CARBOXYLASE; POLYPEPTIDE	The molecular chaperone cpn60 binds many unfolded proteins and facilitates their proper folding. Synthetic peptides have been used to probe the question of how cpn60 might recognize such a diverse set of unfolded proteins, Three hybrid peptides were synthesized encompassing portions of the bee venom peptide, apamin, and the sequence KWLAESVRAGK from an amphipathic helix in the NH2-terminal region of bovine rhodanese, Two disulfides connecting cysteine residues hold the peptides in stable helical conformations with unobstructed faces oriented away from the disulfides, Peptides were designed to present either a hydrophobic or hydrophilic face of the amphipathic helix that is similar to the one near the amino terminus of rhodanese, Aggregation of these peptides was detected by measuring 1,1'-bis(4-anilino)napthalene-5,5'-disulfonic acid (bisANS) fluorescence at increasing peptide concentrations, and aggregation was not apparent below 2 mu M. Thus, all experiments with the peptides were performed at a concentration of 1 mu M. Reducing agents cause these helical peptides to form random coils, Fluorescence anisotropy measurements of fluorescein-labeled peptide with the exposed hydrophobic face yielded a K-d = similar to 106 mu M for binding to cpn60, whereas there was no detectable binding of the reduced form, The peptide with the exposed hydrophilic face did not bind to cpn60 in either the oxidized or reduced states, Fluorescence experiments utilizing bisANS as a probe showed that binding of the helical hydrophobic peptide could induce the exposure of hydrophobic surfaces on cpn60, whereas the same peptide in its random coil form had no effect, Thus, binding to cpn60 is favored by a secondary structure that organizes and exposes a hydrophobic surface, a feature found in amphipathic helices, Further, the binding of a hydrophobic surface to cpn60 can induce further exposure of complementary surfaces on cpn60 complexes, thus amplifying interactions available for target proteins.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; GENENTECH INC,S SAN FRANCISCO,CA 94080	University of Texas System; University of Texas Health San Antonio; Roche Holding; Genentech					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKKE M, 1991, TECHNIQUES PROTEIN C, V2, P401; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CALLEWAERT G L, 1968, Febs Letters, V1, P111, DOI 10.1016/0014-5793(68)80033-X; CAVANAGH J, 1992, J MAGN RESON, V96, P670, DOI 10.1016/0022-2364(92)90357-D; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER G, 1990, BIOCHEMISTRY-US, V29, P2205; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROWITZ P, 1986, J BIOL CHEM, V261, P5652; HOROWITZ P, 1977, J COLLOID INTERF SCI, V61, P197, DOI 10.1016/0021-9797(77)90428-3; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LIMINET AA, 1990, EMBO J, V99, P2315; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; PEASE JHB, 1988, BIOCHEMISTRY-US, V27, P8491, DOI 10.1021/bi00422a029; PEASE JHB, 1990, P NATL ACAD SCI USA, V87, P5643, DOI 10.1073/pnas.87.15.5643; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHOLZER M, 1992, INT J PEPT PROT RES, V40, P180; TANDON S, 1986, J BIOL CHEM, V261, P5615; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEMMER D, 1983, BIOCHEMISTRY-US, V22, P1901; Wuthrich K, 1986, NMR PROTEINS NUCL AC	39	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5105	5111		10.1074/jbc.272.8.5105	http://dx.doi.org/10.1074/jbc.272.8.5105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030576	hybrid			2022-12-25	WOS:A1997WJ85500064
J	Liu, F; Tokeson, J; Persengiev, SP; Ebert, K; Kilpatrick, DL				Liu, F; Tokeson, J; Persengiev, SP; Ebert, K; Kilpatrick, DL			Novel repeat elements direct rat proenkephalin transcription during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-3',5'-MONOPHOSPHATE RESPONSE ELEMENT; ANGIOTENSIN-CONVERTING ENZYME; MOUSE PROTAMINE-1 PROMOTER; GERM-CELL DIFFERENTIATION; TRANS-ACTING FACTOR; SOMATIC-CELLS; MESSENGER-RNA; TESTIS; GENE; EXPRESSION	The developmental program controlling sperm formation occurs in multiple stages that sequentially involve mitosis, meiosis, and spermiogenesis. The transcriptional mechanisms regulating these distinct phases are poorly understood. In particular, while a required role for the germ cell transcription factor cyclic AMP response element modulator-tau during spermiogenesis has recently been demonstrated, the transcriptional mechanisms leading to early haploid cell formation are unknown. The rat and mouse proenkephalin genes are selectively expressed from an alternate, germ cell-specific promoter in meiotic and early haploid cells. In this study, the minimal rat proenkephalin germ line promoter was localized to a 116-bp region encompassing the transcriptional start site region. Further, a proximal 51-bp sequence located in the 5'-flanking region is absolutely required for germ line promoter activity. This 51 bp sequence corresponds to a previously characterized binding element (GCP1) that forms cell-specific complexes with rat spermatogenic cell nuclear factors distinct from cyclic AMP response element binding proteins. Further, GCP1 contains novel direct repeat sequences required for factor binding and transgene expression in spermatogenic cells. These repeat elements are highly similar to sequences within the active regions of other male germ line promoters expressed during meiosis. GCP1 may therefore contain transcriptional elements that participate more generally during meiosis in the differentiation of spermatocytes and early haploid spermatids.	WORCESTER FDN BIOMED RES, NEUROBIOL GRP, SHREWSBURY, MA 01545 USA; TUFTS UNIV, SCH VET MED, DEPT ANAT & CELL BIOL, NORTH GRAFTON, MA 01536 USA	Worcester Foundation for Biomedical Research; Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468, F32DK009006] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK09006, DK36468] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLVE AR, 1977, J HISTOCHEM CYTOCHEM; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELMAS V, 1994, MOL CELL ENDOCRINOL, V100, P121, DOI 10.1016/0303-7207(94)90290-9; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FABBRI A, 1985, ENDOCRINOLOGY, V117, P2544, DOI 10.1210/endo-117-6-2544; GALCHEVAGARGOVA Z, 1993, MOL ENDOCRINOL, V7, P979, DOI 10.1210/me.7.8.979; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOTO M, 1993, NUCLEIC ACIDS RES, V21, P209, DOI 10.1093/nar/21.2.209; Gu W, 1996, MOL CELL BIOL, V16, P4535; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; KILPATRICK DL, 1986, P NATL ACAD SCI USA, V83, P5015, DOI 10.1073/pnas.83.14.5015; KISTLER MK, 1994, BIOL REPROD, V51, P1322, DOI 10.1095/biolreprod51.6.1322; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LIM K, 1992, J BIOL CHEM, V267, P15271; MORRIS PL, 1987, BIOCHEM BIOPH RES CO, V148, P1513, DOI 10.1016/S0006-291X(87)80303-0; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NAYERNIA K, 1994, J BIOL CHEM, V269, P32181; ONEILL MJ, 1995, DEVELOPMENT, V121, P561; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUN ZM, 1995, J BIOL CHEM, V270, P20962, DOI 10.1074/jbc.270.36.20962; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; THOMAS K, 1990, DEVELOPMENT, V109, P483; TORRY DS, 1992, AM J REPROD IMMUNOL, V27, P167, DOI 10.1111/j.1600-0897.1992.tb00745.x; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; VANWERT JM, 1995, BIOCHEMISTRY-US, V34, P8733, DOI 10.1021/bi00027a024; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; Walter C A, 1989, Biotechniques, V7, P1065; WILLIAMS M, 1992, NUCLEIC ACIDS RES, V20, P4935, DOI 10.1093/nar/20.18.4935; WOLFE SA, 1995, BIOCHEMISTRY-US, V34, P12461, DOI 10.1021/bi00038a045; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; Zhou WT, 1996, BIOL REPROD, V54, P84, DOI 10.1095/biolreprod54.1.84; ZHOU WT, 1994, BIOL REPROD, V51, P425, DOI 10.1095/biolreprod51.3.425; ZINKEL SS, 1992, MOL CELL BIOL, V12, P2029, DOI 10.1128/MCB.12.5.2029; ZINN SA, 1991, J BIOL CHEM, V266, P23850	49	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5056	5062		10.1074/jbc.272.8.5056	http://dx.doi.org/10.1074/jbc.272.8.5056			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030569	hybrid			2022-12-25	WOS:A1997WJ85500057
J	Suehiro, K; Gailit, J; Plow, EF				Suehiro, K; Gailit, J; Plow, EF			Fibrinogen is a ligand for integrin alpha(5)beta(1) on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CROSS-LINKING; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; EXTRACELLULAR-MATRIX; ADHESIVE PROTEINS; HUMAN-PLATELETS; VITRONECTIN RECEPTOR; PLASMA FIBRONECTIN; DIVALENT-CATIONS; BINDING DOMAIN	Previous studies have shown that fibrinogen can associate with endothelial cells via an Arg-Gly-Asp (RGD) recognition specificity. In the present study, we have characterized the specificity of fibrinogen binding to endothelial cells under different cation conditions. Fibrinogen binding to suspended endothelial cells was selectively supported by Mn2+ and was suppressed by Ca2+. The Mn2+-supported interaction was completely inhibited by RGD peptides but not by alpha(v) beta(3) blocking monoclonal antibodies. In contrast, the interaction was completely blocked by two alpha(5) beta(1) monoclonal antibodies. This interaction was not mediated by fibronectin bound to the integrin; could be demonstrated with purified alpha(5) beta(1); and also was observed with a second alpha(5) beta(1)-bearing cell type, platelets. The binding of fibrinogen to alpha(5) beta(1) On endothelial cells in the presence of Mn2+ was time-dependent, specific, saturable, and of high affinity (K-d = 65 nM). By employing anti-peptide monoclonal antibodies, the carboxyl-terminal RGD sequence at A alpha 572-574 was implicated in fibrinogen recognition by alpha(5) beta(1) Two circumstances were identified in which alpha(5) beta(1) interacted with fibrinogen in the presence of Ca2+: when the receptor was activated with monoclonal antibody (8A2) or when the fibrinogen was presented as an immobilized substratum. These results identify fibrinogen as a ligand for alpha(5) beta(1) on endothelial and other cells, an interaction which may have broad biological implications.	CLEVELAND CLIN FDN, CTR THROMBOSIS & VASC BIOL FF20, DEPT MOL CARDIOL, CLEVELAND, OH 44195 USA; SUNY STONY BROOK, DEPT DERMATOL, STONY BROOK, NY 11794 USA	Cleveland Clinic Foundation; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NHLBI NIH HHS [HL-54924, HL-38292] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292, R01HL054924] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; BARUTHIO F, 1988, CLIN CHEM, V34, P227; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BUCHANAN MR, 1993, BLOOD, V81, P3303; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CHANG MC, 1995, THROMB HAEMOSTASIS, V74, P764; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHEN CS, 1991, BLOOD, V77, P2200; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CONFORTI G, 1989, BLOOD, V73, P1576; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DEJANA E, 1987, J CELL BIOL, V104, P1403, DOI 10.1083/jcb.104.5.1403; DEJANA E, 1990, BLOOD, V75, P1509; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ERBAN JK, 1992, J BIOL CHEM, V267, P2451; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GAILIT J, 1988, J BIOL CHEM, V263, P12927; HORMANN H, 1985, PLASMA FIBRONECTIN S, P99; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LANGUINO LR, 1989, BLOOD, V73, P734; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MARGUERIE G, 1977, BIOCHIM BIOPHYS ACTA, V490, P94, DOI 10.1016/0005-2795(77)90109-X; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; NIEUWENHUIZEN W, 1981, THROMB RES, V22, P653, DOI 10.1016/0049-3848(81)90063-3; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1994, J BIOL CHEM, V269, P960; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEI A, 1995, IN VITRO CELL DEV-AN, V31, P467; TAUBENFELD SM, 1995, THROMB HAEMOSTASIS, V74, P923; TRANQUI L, 1989, J CELL BIOL, V108, P2519, DOI 10.1083/jcb.108.6.2519; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Ugarova TP, 1996, BIOCHEMISTRY-US, V35, P10913, DOI 10.1021/bi960717s; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada KM, 1989, FIBRONECTIN, P47; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116	58	138	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5360	5366		10.1074/jbc.272.8.5360	http://dx.doi.org/10.1074/jbc.272.8.5360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030612	hybrid			2022-12-25	WOS:A1997WJ85500100
J	Tirone, E; DAlessandris, C; Hascall, VC; Siracusa, G; Salustri, A				Tirone, E; DAlessandris, C; Hascall, VC; Siracusa, G; Salustri, A			Hyaluronan synthesis by mouse cumulus cells is regulated by interactions between follicle-stimulating hormone (or epidermal growth factor) and a soluble oocyte factor (or transforming growth factor beta(1))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-MONOPHOSPHATE; TRYPSIN INHIBITOR FAMILY; PROTEIN-KINASE PATHWAY; MURAL GRANULOSA-CELLS; MEIOTIC MATURATION; EXTRACELLULAR-MATRIX; SPERM MOTILITY; ACID SYNTHESIS; INVITRO; EXPANSION	Expansion of the cumulus cell oocyte complex (COC) in the preovulatory mammalian follicle requires a transient induction of hyaluronan (HA) synthesis by the cumulus cells. We studied the interactions of known factors that regulate this process by isolating compact COCs from mice and inducing their expansion in vitro. Maximum HA synthesis requires either follicle-stimulating hormone (FSH) or epidermal growth factor (EGF) in combination with either a soluble factor(s) produced by the oocyte or transforming growth factor beta(1). FSH (or EGF) exerts its effects during the first 2 h of incubation, before HA synthesis actually beans, The oocyte factor(s) (or transforming growth factor beta(1)) exerts its effects from 2 h onwards and must be continuously present throughout the subsequent similar to 10 h to achieve a maximum level of HA synthesis, FSH stimulates intra cellular cAMP synthesis, which correlates with net HA production up to similar to 14 fmol/COC at 5 ng/ml FSH; however, higher concentrations of FSH increase cAMP levels similar to 10-fold higher with no additional effect on HA synthesis, EGF at saturating concentrations for HA synthesis does not stimulate cAMP above basal levels, Tyrosine kinase inhibitors genistein and tyrphostin AG18 nearly abolish the HA synthesis response to EGF and inhibit the response to FSH by similar to 60%, suggesting that a tyrosine kinase activity is involved for both factors, whereas FSH also operates partially through another signaling pathway, Actinomycin D abolishes HA synthesis if added at the beginning of culture and reduces HA synthesis by similar to 50% if added between 6-12 h when HA synthesis is normally maximal, The results suggest that regulation of HA synthesis is primarily controlled at the transcriptional level.	UNIV ROME, DIPARTIMENTO SANITA PUBBL & BIOL CELLULARE, FAC MED, I-00173 ROME, ITALY; CLEVELAND CLIN FDN, DEPT BIOMED ENGN, CLEVELAND, OH 44195 USA	Sapienza University Rome; Cleveland Clinic Foundation				SALUSTRI, ANTONIETTA/0000-0002-8731-1041				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Camaioni A, 1996, ARCH BIOCHEM BIOPHYS, V325, P190, DOI 10.1006/abbi.1996.0024; CANIPARI R, 1995, DEV BIOL, V167, P371, DOI 10.1006/dbio.1995.1031; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; COSKUN S, 1995, MOL REPROD DEV, V42, P311, DOI 10.1002/mrd.1080420308; DEFELICI M, 1985, GAMETE RES, V12, P227, DOI 10.1002/mrd.1120120302; DOWNS SM, 1988, J EXP ZOOL, V245, P86, DOI 10.1002/jez.1402450113; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; EPPIG JJ, 1993, MOL REPROD DEV, V34, P450, DOI 10.1002/mrd.1080340415; EPPIG JJ, 1988, GAMETE RES, V20, P125, DOI 10.1002/mrd.1120200203; EPPIG JJ, 1980, BIOL REPROD, V23, P545, DOI 10.1095/biolreprod23.3.545; FAURE M, 1994, J BIOL CHEM, V269, P7851; FENG P, 1988, ENDOCRINOLOGY, V122, P181, DOI 10.1210/endo-122-1-181; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GOMBERGMALOOL S, 1993, ENDOCRINOLOGY, V132, P362, DOI 10.1210/en.132.1.362; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HSU C, 1987, BIOCHEM BIOPH RES CO, V17, P242; HUSZAR G, 1990, FERTIL STERIL, V54, P1127; KEEL BA, 1995, ENDOCRINOLOGY, V136, P1197, DOI 10.1210/en.136.3.1197; KORNOVSKI BS, 1994, FERTIL STERIL, V61, P935; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; MEIZEL S, 1985, AM J ANAT, V174, P285, DOI 10.1002/aja.1001740309; MORRIS JK, 1993, ENDOCRINOLOGY, V133, P770, DOI 10.1210/en.133.2.770; MOSCATELLI D, 1976, J CELL PHYSL, V91, P79; Mulheron G.W., 1993, OVARY, P337; ORLY J, 1994, ENDOCRINOLOGY, V134, P2336, DOI 10.1210/en.134.6.2336; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SALUSTRI A, 1990, J BIOL CHEM, V265, P19517; SALUSTRI A, 1990, DEV BIOL, V138, P26, DOI 10.1016/0012-1606(90)90173-G; SALUSTRI A, 1992, DEV BIOL, V151, P541, DOI 10.1016/0012-1606(92)90192-J; SALUSTRI A, 1985, BIOL REPROD, V33, P797, DOI 10.1095/biolreprod33.4.797; SCHULTZ RM, 1983, DEV BIOL, V97, P264, DOI 10.1016/0012-1606(83)90085-4; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; STEINER AL, 1972, J BIOL CHEM, V247, P1106; TOMIDA M, 1977, BIOCHEM J, V162, P539, DOI 10.1042/bj1620539; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	46	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4787	4794		10.1074/jbc.272.8.4787	http://dx.doi.org/10.1074/jbc.272.8.4787			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030534	hybrid			2022-12-25	WOS:A1997WJ85500022
J	Zhu, XY; Rebello, J; Matsumura, P; Volz, K				Zhu, XY; Rebello, J; Matsumura, P; Volz, K			Crystal structures of CheY mutants Y106W and T871/Y106W - CheY activation correlates with movement of residue 106	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSIGNALING PROTEIN CHEY; LEAST-SQUARES REFINEMENT; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; RESPONSE REGULATOR; CONSERVED ASPARTATE; GENE-PRODUCTS; F-19 NMR; PHOSPHORYLATION	Position 106 in CheY is highly conserved as an aromatic residue in the response regulator superfamily. In the structure of the wild-type, apo-CheY, Tyr(106) is a rotamer whose electron density is observed in both the inside and the outside positions. In the structure of the T87I mutant of CheY, the threonine to isoleucine change at position 87 causes the side chain of Tyr(106) to be elusively restricted to the outside position. In this report we demonstrate that the T87I mutation causes cells to be smooth swimming and non chemotactic. We also show that another CheY mutant, Y106W, causes cells to be more tumbly than wild-type CheY, and impairs chemotaxis. In the structure of Y106W, the side chain of Trp(106) stays exclusively in the inside position. Furthermore, a T87I/Y106W double mutant, which confers the same phenotype as T87I, restricts the side chain of Trp(106) to the outside position. The results from these behavioral and structural studies indicate that the rotameric nature of the Tyr(106) residue is involved in activation of the CheY molecule. Specifically, Chefs signaling ability correlates with the conformational heterogeneity of the Tyr(106) Side chain. Our data also suggest that these mutations affect the signal at an event subsequent to phosphorylation.	UNIV ILLINOIS,DEPT MICROBIOL & IMMUNOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047522] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18985] Funding Source: Medline; NIGMS NIH HHS [GM47522] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSLER CD, 1993, J BACTERIOL, V175, P6238, DOI 10.1128/JB.175.19.6238-6244.1993; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BORKAKOTI N, 1982, ACTA CRYSTALLOGR B, V38, P2210, DOI 10.1107/S0567740882008346; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; *CCP4, 1979, SERC UK COLL COMP PR; DEMEL VSJ, 1994, FEBS LETT, V349, P155, DOI 10.1016/0014-5793(94)00664-4; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HALL SR, 1988, XTAL 2 4 USERS MANUA; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KREBS JF, 1991, BIOCHEMISTRY-US, V30, P9153, DOI 10.1021/bi00102a005; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; MARTINEZOYANEDEL J, 1991, J MOL BIOL, V222, P335, DOI 10.1016/0022-2836(91)90215-R; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; *MOL SIM INC, 1994, QUANTA 4 1 1; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; Rossmann M. G., 1972, MOL REPLACEMENT METH; RUSSELL CB, 1989, J BACTERIOL, V171, P2614, DOI 10.1128/jb.171.5.2614-2618.1989; Sambrook J., 2002, MOL CLONING LAB MANU; SANATINIA H, 1995, J BACTERIOL, V177, P2713, DOI 10.1128/jb.177.10.2713-2720.1995; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SHUKLA D, 1995, J BIOL CHEM, V270, P24414, DOI 10.1074/jbc.270.41.24414; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P12275; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; Wang H, 1996, MOL MICROBIOL, V19, P695, DOI 10.1046/j.1365-2958.1996.393934.x; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10270; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; ZHULIN IB, 1991, CURR MICROBIOL, V22, P307, DOI 10.1007/BF02091959	45	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5000	5006		10.1074/jbc.272.8.5000	http://dx.doi.org/10.1074/jbc.272.8.5000			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030562	hybrid			2022-12-25	WOS:A1997WJ85500050
J	Varley, JM; Thorncroft, M; McGown, G; Appleby, J; Kelsey, AM; Tricker, KJ; Evans, DGR; Birch, JM				Varley, JM; Thorncroft, M; McGown, G; Appleby, J; Kelsey, AM; Tricker, KJ; Evans, DGR; Birch, JM			A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene	ONCOGENE			English	Article						chromosome 17; LOH; Li-Fraumeni; tumours	GERMLINE P53 MUTATIONS; CANCER FAMILY SYNDROME; BREAST-OVARIAN CANCER; WILD-TYPE CHROMOSOME; SUPPRESSOR GENE; SPLICING MUTATION; BRAIN-TUMORS; YOUNG-ADULTS; PRONE FAMILY; ALLELE LOSS	We have studied a total of 36 tumours from 28 patients with germline mutations to the TP53 gene for loss of heterozygosity at TP53 using techniques of both direct sequencing and restriction fragment length polymorphism analysis. All patients were from families conforming to the definition of classical Li-Fraumeni syndrome (LFS) or were Li-Frammeni-like (LFL). The data we have obtained show that loss of the wild-type TP53 gene is observed in under half (44%) of all tumours, and that the pattern of LOH at TP53 may be mutation specific, LOH has been observed in premalignant as web as invasive tumours. Two tumours (6%) show loss of the mutant allele and retention of the wild-type, To confirm that TP53 is indeed the target for LOH events on chromosome 17, we have used additional microsatellite repeats to examine patterns of allelic imbalance along the length of chromosome 17. Data from this analysis indicate that TP53 is the target of loss, but reveal some other interesting patterns of allelic imbalance at other loci on chromosome 17.	ROYAL MANCHESTER CHILDRENS HOSP,CRC,PAEDIAT & FAMILIAL CANC RES GRP,MANCHESTER M27 4HA,LANCS,ENGLAND	Royal Manchester Children's Hospital	Varley, JM (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784				BIRCH JM, 1994, CANCER RES, V54, P1298; BIRCH JM, 1990, J PATHOL, V161, P1, DOI 10.1002/path.1711610102; BORRESEN AL, 1992, CANCER RES, V52, P3234; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; BRUGIERES L, 1993, CANCER RES, V53, P452; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1990, GENETIC BASIS FOR CARCINOGENESIS, P33; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EELES RA, 1993, ONCOGENE, V8, P1269; FELIX CA, 1995, MED PEDIATR ONCOL, V25, P431, DOI 10.1002/mpo.2950250603; FELIX CA, 1993, ONCOGENE, V8, P1203; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FREBOURG T, 1995, AM J HUM GENET, V56, P608; GARBER JE, 1991, CANCER RES, V51, P6094; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GRAYSON GH, 1994, AM J PEDIAT HEMATOL, V16, P341; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; GUTIERREZ MI, 1994, HUM MOL GENET, V3, P2247, DOI 10.1093/hmg/3.12.2247; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMELIN R, 1994, HUM GENET, V94, P88, DOI 10.1007/BF02272849; Heim S, 1995, CANC CYTOGENETICS; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORIO Y, 1994, ONCOGENE, V9, P1231; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JOLLY KW, 1994, ONCOGENE, V9, P97; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOVAR H, 1992, ONCOGENE, V7, P2169; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Li YJ, 1995, INT J CANCER, V64, P383, DOI 10.1002/ijc.2910640606; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SCOTT RJ, 1993, SCHWEIZ MED WSCHR, V123, P1287; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; Varley JM, 1996, ONCOGENE, V12, P2437; VARLEY JM, 1997, UNPUB MANUSCRIPT; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WILLIAMS KJ, 1996, IN PRESS ONCOGENE; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	66	84	85	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					865	871		10.1038/sj.onc.1201041	http://dx.doi.org/10.1038/sj.onc.1201041			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047394				2022-12-25	WOS:A1997WJ11200013
J	Venkatachalam, S; Denissenko, M; Wani, AA				Venkatachalam, S; Denissenko, M; Wani, AA			Modulation of (+/-)-anti-BPDE mediated p53 accumulation by inhibitors of protein kinase C and poly(ADP-ribose) polymerase	ONCOGENE			English	Article						DNA damage; p53 induction; apoptosis; cell cycle arrest	PERIPHERAL-BLOOD LYMPHOCYTES; DNA-DAMAGING AGENTS; ATAXIA-TELANGIECTASIA; HUMAN-CELLS; IONIZING-RADIATION; MOLECULAR CONTROLS; HUMAN FIBROBLASTS; SUPPRESSOR GENES; STRAND BREAKS; G(1) ARREST	The rapid accumulation of the p53 gene product is considered to be an important component of the cellular response to a variety of genotoxins, In order to gain insights on the biochemical pathways leading to p53 stabilization, the effect of (+/-) 7,8-dihydroxy-anti-9, 10-epoxy-7,8,9,10-tetrahydrobenzo(a)-pyrene [(+/-)-anti-BPDE] induced DNA damage on p53 protein levels was investigated in various repair-proficient and repair-deficient human cells, Brief exposure of normal human fibroblasts to 0.05-1 mu M (+/-)-anti-BPDE resulted in elevated p53 protein levels as compared to the constitutive levels of control sells, The rapid induction response, detectable within a few hours, was sustained up to a period of at least 24 h, Repair-proficient and repair-deficient (XPA) human lymphoblastoid cells showed a similar response, The poly(ADP-ribose) polymerase inhibitor, 3-aminobenzamide (3-AB), diminished the p53 induction response by concomitantly decreasing the extent of (+/-)-anti-BPDE induced DNA damage in cells pretreated with the inhibitor, However, the direct involvement of poly ADP-ribosylation was also apparent as 3-AB was able to attenuate (similar to 50%) the p53 response by post-damage inhibitor treatment of the cells, Inhibition:of cellular DNA replication by hydroxyurea and AraC, in the presence or absence of DNA damage, also resulted in rapid p53 accumulation in repair-deficient cells, On the contrary, inhibition of protein kinase C (PKC) by calphostin-C led to an abrogation of (+/-)-anti-BPDE mediated p53 induction, Analysis of the downstream effects of carcinogen treatment showed that the lymphoblastoid cells undergo DNA fragmentation indicative of apoptosis while fibroblasts exhibit cell cycle arrest at the G(1)-S boundary.	OHIO STATE UNIV,DEPT RADIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,BIOCHEM PROGRAM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006074, R01ES002388] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES6074, ES2388] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BAE IS, 1995, CANCER RES, V55, P2387; BERGER NA, 1981, BIOCHEMISTRY-US, V20, P3610, DOI 10.1021/bi00515a047; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BJELOGRLIC NM, 1994, CARCINOGENESIS, V15, P771, DOI 10.1093/carcin/15.4.771; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHATTERJEE S, 1994, MOL CELL BIOCHEM, V138, P61, DOI 10.1007/BF00928444; CONNEY AH, 1982, CANCER RES, V42, P4875; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAN SJ, 1994, CANCER RES, V54, P5824; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GIBSONDAMBROSIO RE, 1986, IN VITRO CELL DEV B, V22, P529; GRANA X, 1995, ONCOGENE, V11, P211; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUENGERICH FP, 1988, CANCER RES, V48, P2946; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1991, CANCER RES, V51, pS5023; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASPIN LC, 1996, IN PRESS PAH; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUMAR M, 1995, BIOCHEM BIOPH RES CO, V214, P744, DOI 10.1006/bbrc.1995.2348; KURIAN P, 1992, CARCINOGENESIS, V13, P489, DOI 10.1093/carcin/13.3.489; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIU M, 1995, ONCOGENE, V10, P1955; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MOLINARI M, 1995, ONCOGENE, V10, P1849; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OSBORNE MR, 1981, CARCINOGENESIS, V2, P553, DOI 10.1093/carcin/2.6.553; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Price BD, 1996, CANCER RES, V56, P246; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1993, ONCOGENE, V8, P3055; PRICE BD, 1993, ONCOGENE, V8, P305; Sancar A, 1995, ANNU REV GENET, V29, P69, DOI 10.1146/annurev.ge.29.120195.000441; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STIERUM RH, 1995, CARCINOGENESIS, V16, P2765, DOI 10.1093/carcin/16.11.2765; STIERUM RH, 1994, CARCINOGENESIS, V15, P745, DOI 10.1093/carcin/15.4.745; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VENKATACHALAM S, 1993, BIOCHEM BIOPH RES CO, V197, P722, DOI 10.1006/bbrc.1993.2539; VENKATACHALAM S, 1994, CARCINOGENESIS, V15, P565, DOI 10.1093/carcin/15.4.565; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; WHITACRE CM, 1995, CANCER RES, V55, P3697; ZHANG W, 1994, CANCER RES, V54, P4448	60	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					801	809		10.1038/sj.onc.1200890	http://dx.doi.org/10.1038/sj.onc.1200890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047387				2022-12-25	WOS:A1997WJ11200006
J	Seitz, S; Rohde, K; Bender, E; Nothnagel, A; Kolble, K; Schlag, PM; Scherneck, S				Seitz, S; Rohde, K; Bender, E; Nothnagel, A; Kolble, K; Schlag, PM; Scherneck, S			Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: Linkage analysis in German breast cancer families	ONCOGENE			English	Article						breast cancer gene; loss of heterozygosity; linkage analysis; chromosome 8p	HETEROZYGOSITY; CARCINOMA; ALLELOTYPE; DISEASE; ONSET; LOCI; 8P	Chromosomal losses involving the short arm of chromosome 8 are frequent in a variety of tumor types, including breast cancer, suggesting the presence of one or more tumor suppressor genes in this region, Previous linkage analysis and studies of loss of heterozygosity (LOH) have suggested the presence of a putative third breast cancer susceptibility gene around D8S505 at 8p12-p22, We have performed linkage analysis in two German breast cancer families, showing negative lod scores with 17q and 13q markers, using seven adjacent microsatellite markers from 8p12-p22, Incorporating LOH data from tumors of the affected family members a maximum cumulative three-point lod score of 3.30 at Theta = 0.00 was obtained with D8S137 and D8S131, Our findings considerably strengthen the evidence for a third breast cancer susceptibility locus (BRCA3) mapping to the short arm of human chromosome 8.	MAX DELBRUCK CTR MOL MED,DEPT TUMOR GENET,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT BIOINFORMAT,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,DEPT PATHOL,D-10117 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,ROBERT ROESSLE CLIN,DEPT SURG ONCOL,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Humboldt University of Berlin								CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLIBY W, 1993, CANCER RES, V53, P2393; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DEVILEE P, 1991, ONCOGENE, V6, P1705; EMI M, 1992, CANCER RES, V52, P5368; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KNOWLES MA, 1993, ONCOGENE, V8, P1357; MACOSKA JA, 1995, CANCER RES, V55, P5390; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; ROHDE K, 1995, HUM HERED, V45, P337, DOI 10.1159/000154302; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; WASYLYSHYN ML, 1991, SURGERY, V110, P268; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZIMMERMANN W, 1993, AM J HUM GENET, V52, P789; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	21	99	101	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					741	743		10.1038/sj.onc.1200881	http://dx.doi.org/10.1038/sj.onc.1200881			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038382				2022-12-25	WOS:A1997WG43000013
J	Zhong, WX; Oberley, LW; Oberley, TD; StClair, DK				Zhong, WX; Oberley, LW; Oberley, TD; StClair, DK			Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase	ONCOGENE			English	Article						MnSOD; tumor suppressor gene; gene transfection; glioma; antioxidant enzymes; reactive oxygen species	GLUTATHIONE-PEROXIDASE-ACTIVITY; ANTIOXIDANT ENZYMES; EXPRESSION VECTOR; MAMMALIAN-CELLS; GENE; MELANOMA; DIFFERENTIATION; CHROMOSOME-6; METASTASIS; INDUCTION	Manganese superoxide dismutase (MnSOD) has been previously shown to suppress the malignant phenotype of human melanoma and breast cancer cells, To test the possible role of MnSOD in glioma malignancy, MnSOD was overexpressed in wild type human glioma U118 cells and subcloned U118-9 cells by transfection of human MnSOD cDNA, The MnSOD-transfected cell lines demonstrated expression of exogenous (plasmid) MnSOD mRNA, increase in MnSOD immunoreactive protein, and a three- to eightfold increase in MnSOD enzymatic activity, The MnSOD overexpressing cell lines became less malignant as demonstrated by requiring a higher serum concentration to grow in vitro and much slower tumor growth in nude mice than the parental and neo control cell lines, These findings further support the hypothesis that MnSOD may be a tumor suppressor gene in a aide variety of human tumors.	UNIV IOWA, RADIAT RES LAB, MED LABS 77, IOWA CITY, IA 52242 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, PATHOL SERV, MADISON, WI 53705 USA; UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53705 USA; UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40536 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Kentucky					NATIONAL CANCER INSTITUTE [R29CA049797, R01CA041267, R01CA049797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010758] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BECKMAN BS, 1989, J CELL PHYSIOL, V139, P370, DOI 10.1002/jcp.1041390220; BULLARD DE, 1981, J NEUROPATH EXP NEUR, V40, P410, DOI 10.1097/00005072-198107000-00005; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG737, DOI 10.1152/ajpgi.1994.266.4.G737; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LI JJ, 1995, ONCOGENE, V10, P1989; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miele ME, 1995, ANTICANCER RES, V15, P2065; MILLIKIN D, 1991, CANCER RES, V51, P5449; MURAMATSU H, 1995, CANCER RES, V55, P6210; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; Oberley LW, 1986, FREE RADICALS AGING, P352; OBERLEY TD, 1990, AM J PATHOL, V137, P199; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI DOI 10.1074/jbc.RA117.001068; SAFFORD SE, 1994, CANCER RES, V54, P4261; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; SUN Y, 1993, CARCINOGENESIS, V14, P1457, DOI 10.1093/carcin/14.7.1457; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YOSHIZAKI N, 1994, INT J CANCER, V57, P287, DOI 10.1002/ijc.2910570226; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	38	203	217	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					481	490		10.1038/sj.onc.1200852	http://dx.doi.org/10.1038/sj.onc.1200852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053845				2022-12-25	WOS:A1997WE36400011
J	Bork, P; Hofmann, K; Bucher, P; Neuwald, AF; Altschul, SF; Koonin, EV				Bork, P; Hofmann, K; Bucher, P; Neuwald, AF; Altschul, SF; Koonin, EV			A superfamily of conserved domains in DNA damage responsive cell cycle checkpoint proteins	FASEB JOURNAL			English	Article						BRCT domain; database search; PARP; profile; motif	REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; POLY(ADP-RIBOSE) POLYMERASE; FISSION YEAST; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; SEQUENCE SIMILARITY; SECONDARY STRUCTURE; MULTIPLE ALIGNMENT; FEEDBACK CONTROLS	Computer analysis of a conserved domain, BRCT, first described at the carboxyl terminus of the breast cancer protein BRCA1, a p53 binding protein (53BP1), and the yeast cell cycle checkpoint protein RAD9 revealed a large superfamily of domains that occur predominantly in proteins involved in cell cycle checkpoint functions responsive to DNA damage. The BRCT domain consists of similar to 95 amino acid residues and occurs as a tandem repeat at the carboxyl terminus of numerous proteins, but has been observed also as a tandem repeat at the amino terminus or as a single copy. The BRCT superfamily presently includes similar to 40 nonorthologous proteins, namely, BRCA1, 53BP1, and RAD9; a protein family that consists of the fission yeast replication checkpoint protein Rad4, the oncoprotein ECT2, the DNA repair protein XRCC1, and yeast DNA polymerase subunit DPB11; DNA binding enzymes such as terminal deoxynucleotidyltransferases, deoxycytidyl transferase involved in DNA repair, and DNA-ligases III and IV; yeast multifunctional transcription factor RAP1; and several uncharacterized gene products. Another previously described domain that is shared by bacterial NAD-dependent DNA-ligases, the large subunits of eukaryotic replication factor C, and poly(ADP-ribose) polymerases appears to be a distinct version of the BRCT domain. The retinoblastoma protein (a universal tumor suppressor) and related proteins may contain a distant relative of the BRCT domain. Despite the functional diversity of all these proteins, participation in DNA damage-responsive checkpoints appears to be a unifying theme. Thus, the BRCT domain is likely to perform critical, yet uncharacterized, functions in the cell cycle control of organisms from bacteria to humans. The carboxyterminal BRCT domain of BRCA1 corresponds precisely to the recently identified minimal transcription activation domain of this protein, indicating one such, function.	EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Swiss Institute Experimental Cancer Research	Bork, P (corresponding author), NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, NIH, BETHESDA, MD 20894 USA.		Bork, Peer/F-1813-2013; Altschul, Stephen/R-4000-2019	Bork, Peer/0000-0002-2627-833X; 				Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Birney E, 1996, NUCLEIC ACIDS RES, V24, P2730, DOI 10.1093/nar/24.14.2730; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Bork P, 1996, METHOD ENZYMOL, V266, P162; BRIDGES BA, 1995, BIOESSAYS, V17, P63, DOI 10.1002/bies.950170112; Brown M, 1993, Proc Int Conf Intell Syst Mol Biol, V1, P47; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Eddy S R, 1995, J Comput Biol, V2, P9, DOI 10.1089/cmb.1995.2.9; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KHANNA KK, 1995, ONCOGENE, V11, P609; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Koonin EV, 1996, METHOD ENZYMOL, V266, P295; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEE EYHP, 1995, SEMIN CANCER BIOL, V6, P119, DOI 10.1006/scbi.1995.0019; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEHMANN AR, 1993, NUCLEIC ACIDS RES, V21, P5274, DOI 10.1093/nar/21.22.5274; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUTHY R, 1994, PROTEIN SCI, V3, P139; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MONTEIRO ANA, 1996, IN PRESS P NATL ACAD; MULLER T, 1994, J STRUCT BIOL, V113, P1, DOI 10.1006/jsbi.1994.1027; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NEFF MW, 1992, MOL CELL BIOL, V12, P3857, DOI 10.1128/MCB.12.9.3857; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIBBALD PR, 1990, J MOL BIOL, V216, P813, DOI 10.1016/S0022-2836(99)80003-5; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SUBLER MA, 1994, ONCOGENE, V9, P1351; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; YODER BL, 1991, J BIOL CHEM, V266, P22689	95	637	655	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1997	11	1					68	76		10.1096/fasebj.11.1.9034168	http://dx.doi.org/10.1096/fasebj.11.1.9034168			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034168				2022-12-25	WOS:A1997WK14700010
J	BenMenahem, D; Kudo, M; Pixley, MB; Sato, A; Suganuma, N; Perlas, E; Hsueh, AJW; Boime, I				BenMenahem, D; Kudo, M; Pixley, MB; Sato, A; Suganuma, N; Perlas, E; Hsueh, AJW; Boime, I			The biologic action of single-chain choriogonadotropin is not dependent on the individual disulfide bonds of the beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN LUTEINIZING-HORMONE; GLYCOPROTEIN HORMONES; RECEPTOR; EXPRESSION; CELLS; SUPERFAMILY; CONVERSION; PROTEIN; BINDING	Disrupting disulfide loops in the human chorionic gonadotropin beta subunit (CG beta) inhibits combination with the alpha subunit. Because the bioactivity requires a heterodimer, studies on the role of disulfide bonds on receptor binding/signal transduction have previously been precluded. To address this problem, we bypassed the assembly step and genetically fused CGP subunits bearing paired cysteine mutations to a wild-type a (WT alpha) subunit. The changes altered secretion of the single-chain mutants which parallel that seen for the CGP monomeric subunit. Despite conformational changes in CG disulfide bond mutants (assayed by gel electrophoresis and conformationally sensitive monoclonal antibodies), the variants bind to the lutropin/CG receptor and activated adenylate cyclase in vitro. The data show that the structural requirements for secretion and bioactivity are not the same. The results also suggest that the extensive native subunit interactions determined by the cystine bonds are not required for signal transduction. Moreover, these studies demonstrate that the single-chain model is an effective approach to structure-activity relationships of residues and structural domains associated with assembly of multisubunit ligands.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,DEPT OBSTET GYNECOL,DIV REPROD BIOL,STANFORD,CA 94305	Washington University (WUSTL); Stanford University				Ben-Menahem, David/0000-0002-8985-0591	NICHD NIH HHS [N01-HD67922] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEDOWS E, 1993, J BIOL CHEM, V268, P11655; Birken S, 1996, ENDOCRINOLOGY, V137, P1402, DOI 10.1210/en.137.4.1402; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1991, J BIOL CHEM, V266, P19357; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KRICHEVSKY A, 1994, ENDOCRINE, V2, P511; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Liu C, 1996, ARCH BIOCHEM BIOPHYS, V329, P127, DOI 10.1006/abbi.1996.0200; LUSTBADER J, 1987, J BIOL CHEM, V262, P14204; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Ward D.N., 1979, ANIMAL MODELS RES FE, P151; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YOO J, 1991, J BIOL CHEM, V266, P17741	29	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6827	6830		10.1074/jbc.272.11.6827	http://dx.doi.org/10.1074/jbc.272.11.6827			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054363	hybrid			2022-12-25	WOS:A1997WN14700002
J	Grant, RP; Spitzfaden, C; Altroff, H; Campbell, ID; Mardon, HJ				Grant, RP; Spitzfaden, C; Altroff, H; Campbell, ID; Mardon, HJ			Structural requirements for biological activity of the ninth and tenth FIII domains of human fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; SITE-DIRECTED MUTAGENESIS; ADHESIVE FUNCTION; TYROSINE PHOSPHORYLATION; PLASMA FIBRONECTIN; RECEPTOR; PROTEINS; IDENTIFICATION; ATTACHMENT; INTEGRINS	The ninth and tenth type III domains of fibronectin each contain specific cell binding sequences, RGD in FIII10 and PHSRN in FIII9, that act synergistically in mediating cell adhesion, We investigated the relationship between domain-domain orientation and synergistic adhesive activity of the FIII9 and FIII10 pair of domains. The interdomain interaction of the FIII9-10 pair was perturbed by introduction of short flexible linkers between the FIII9 and FIII10 domains. Incremental extensions of the interdomain link between FIII9 and FIII10 reduced the initial cell attachment, but had a much more pronounced effect on the downstream cell adhesion events of spreading and phosphorylation of focal adhesion kinase. The extent of disruption of cell adhesion depended upon the length of the interdomain linker, Nuclear magnetic resonance spectroscopy of the wild type and mutant FIII9-10 proteins demonstrated that the structure of the RGD-containing loop is unaffected by domain-domain interactions, We conclude that integrin-mediated cell adhesion to the central cell binding domain of fibronectin depends not only upon specific interaction sites, but also on the relative orientation of these sites. These data have implications for the molecular mechanisms by which integrin-ligand interactions are achieved.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,WOMENS CTR,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford; University of Oxford			Altroff, Harri/B-3544-2011; Grant, Richard/E-3276-2010	Grant, Richard/0000-0003-2386-8876	Wellcome Trust [073028] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSK M, 1992, J BIOL CHEM, V267, P5790; CAMPBELL ID, 1994, STRUCTURE, V2, P333, DOI 10.1016/S0969-2126(00)00034-4; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; FERNANDEZSHAW S, 1992, HUM REPROD, V7, P156, DOI 10.1093/oxfordjournals.humrep.a137609; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; HYNES RO, 1984, CIBA F SYMP, V108, P75; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1985, BLOOD, V66, P724; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SMITH JW, 1990, J BIOL CHEM, V265, P11008; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; TAKADA Y, 1987, NATURE, V326, P607, DOI 10.1038/326607a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	45	134	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6159	6166		10.1074/jbc.272.10.6159	http://dx.doi.org/10.1074/jbc.272.10.6159			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045628	Green Accepted, hybrid			2022-12-25	WOS:A1997WM64700012
J	Hardy, MM; Feder, J; Wolfe, RA; Bu, GJ				Hardy, MM; Feder, J; Wolfe, RA; Bu, GJ			Low density lipoprotein receptor-related protein modulates the expression of tissue-type plasminogen activator in human colon fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; RIBONUCLEIC-ACID; GRANULOSA-CELLS; BINDING-PROTEIN; RAT-LIVER; INHIBITOR; LOCALIZATION	Human colon fibroblasts (HCF) produce tissue type plasminogen activator (t-PA) in culture, but after 24-48 h, t-PA ceases to accumulate in the medium, Here, we report negative feedback regulation of t-PA expression, exerted by t-PA or complexes of t-PA with its physiological inhibitor, plasminogen activator inhibitor type 1 (PAI-1), Inhibition of t-PA expression could be induced by addition of exogenous t-PA or t-PA . PAI-1 complexes and reversed by monoclonal antibody directed against the active site of t-PA. Analysis of metabolically radiolabeled protein and cellular mRNA showed that both t-PA protein and mRNA levels declined considerably after 24 h, When I-125-labeled t-PA or t-PA . PAI-1 complexes were incubated with HCF, monensin-inhibitable endocytosis and catabolism were observed, The low density lipoprotein receptor-related protein (LRP) was found to be expressed by HCF and to mediate these events, Addition of the 39-kDa receptor associated protein (RAP), an antagonist for ligand interactions with LRP, removed the block to t-PA expression and restored its accumulation in the medium, Moreover, RAP completely prevented the degradation of exogenous I-125-labeled t-PA by HCF, suggesting that LRP is the endocytic receptor for t-PA in these cells, These results demonstrate that cellular modulation of t-PA expression in HCF involves LRP receptor-mediated clearance of t-PA This LRP receptor-mediated event results in down-regulation of t-PA expression at the mRNA level.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL)	Hardy, MM (corresponding author), MONSANTO CO,DEPT CELL CULTURE & BIOCHEM,800 N LINDBERGH BLVD,T3P,ST LOUIS,MO 63167, USA.							BAKHIT C, 1987, J BIOL CHEM, V262, pS716; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1994, BLOOD, V83, P3427; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CATHERWOOD BD, 1994, ENDOCRINOLOGY, V134, P1429, DOI 10.1210/en.134.3.1429; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; DAVIS LG, 1986, BASIC METHODS MOL BI, P147; DUBEAU L, 1988, CANCER RES, V47, P5552; EINARSSON M, 1988, THROMB HAEMOSTASIS, V59, P474; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; HOAL EG, 1983, CELL, V34, P273, DOI 10.1016/0092-8674(83)90158-7; KADOURI A, 1983, BIO-TECHNOL, V1, P354, DOI 10.1038/nbt0683-354; KRAUSE J, 1988, Fibrinolysis, V2, P133, DOI 10.1016/0268-9499(88)90026-4; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUROSE I, 1992, DIGEST DIS SCI, V37, P307, DOI 10.1007/BF01308189; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEE LS, 1978, NATURE, V274, P696, DOI 10.1038/274696a0; LEWIS JB, 1985, VIROLOGY, V143, P452, DOI 10.1016/0042-6822(85)90385-X; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; OCONNELL ML, 1987, J BIOL CHEM, V262, P2339; OHLSSON M, 1993, MOL CELL BIOL, V13, P266, DOI 10.1128/MCB.13.1.266; ORTH K, 1994, J BIOL CHEM, V269, P21117; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; STRICKLAND S, 1976, J BIOL CHEM, V251, P5694; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	36	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6812	6817		10.1074/jbc.272.10.6812	http://dx.doi.org/10.1074/jbc.272.10.6812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045716	hybrid			2022-12-25	WOS:A1997WM64700100
J	Montague, JW; Hughes, FM; Cidlowski, JA				Montague, JW; Hughes, FM; Cidlowski, JA			Native recombinant cyclophilins A, B, and C degrade DNA independently of peptidylprolyl cis-trans-isomerase activity - Potential roles of cyclophilins in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN CYCLOPHILIN; CALCIUM-DEPENDENT ENDONUCLEASE; HIGH-MOLECULAR-WEIGHT; ESCHERICHIA-COLI; CYCLOSPORINE-A; THYMOCYTE APOPTOSIS; CARBONIC-ANHYDRASE; PROLYL ISOMERASE; RAT THYMOCYTES; HIV-1 VIRIONS	Previous work in our laboratory (Montague, J., Gaido, M., Frye, C., and Cidlowski, J. (1994) J. Biol. Chem. 269, 18877-18880) has shown that human recombinant cyclophilins A, B, and C have sequence homology with the apoptotic nuclease NCTC18 and that denatured cyclophilins can degrade DNA. We have now evaluated the nucleolytic activity of recombinant cyclophilins under native conditions. We show that nuclease activity inherent to cyclophilins is distinct from cis-trans-peptidylprolyl isomerase activity and is similar to that described for apoptotic nucleases. Cyclophilin nucleolytic activity is stimulated by Ca2+ and/or Mg2+, with a combination of the two being optimal for cyclophilins A and B. Mg2+ alone is sufficient for cyclophilin C nuclease activity. pH optimums are in the range of pH 7.5-9.5. Cyclophilins can degrade both single-stranded and double-stranded DNA, Additionally, cyclophilins produce 3'-OH termini in linear double-stranded substrates, suggesting the cuts produced are similar to those of apoptotic cells. Cyclophilins also display endonucleolytic activity, demonstrated by their ability to degrade supercoiled DNA. In the absence of ions, cyclophilins bind linearized DNA. When added to nuclei from nonapoptotic cells, cyclophilin C induces 50-kilobase pair DNA fragmentation but not internucleosomal fragmentation. Together, these data suggest that cyclophilins are involved in degradation of the genome during apoptosis.	NIEHS,NIH,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill			Hughes, Francis M/G-8036-2017; Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516; Hughes, Francis/0000-0003-3776-3653				ALBERTS B, 1989, MOL BIOL CELL, P388; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Birren BW, 1993, PULSED FIELD GEL ELE, DOI [10.1016/B978-0-12-101290-8.50002-X, DOI 10.1016/B978-0-12-101290-8.50002-X]; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BORTNER CD, 1996, IN PRESS AM J PHYSL; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CHATELLARDGRUAZ D, 1994, BIOCHEM J, V303, P863, DOI 10.1042/bj3030863; COHEN JJ, 1984, J IMMUNOL, V132, P38; DENG GE, 1995, FASEB J, V9, P665, DOI 10.1096/fasebj.9.8.7768359; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HORNBOGEN T, 1995, BIOCHEM MOL BIOL INT, V36, P169; JAIN J, 1993, NATURE, V365, P325; JOHNSON EK, 1994, COMP BIOCHEM PHYS C, V107, P359, DOI 10.1016/1367-8280(94)90062-0; KERN G, 1995, J BIOL CHEM, V270, P740, DOI 10.1074/jbc.270.2.740; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KOK RG, 1994, BBA-GENE STRUCT EXPR, V1219, P601, DOI 10.1016/0167-4781(94)90218-6; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KRUMMREI U, 1995, FEBS LETT, V371, P47, DOI 10.1016/0014-5793(95)00815-Q; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LIU J, 1991, CELL, V66, P1; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MARIVET J, 1994, PLANT MOL BIOL, V26, P1181, DOI 10.1007/BF00040698; MATSUBARA K, 1994, EXP CELL RES, V213, P412, DOI 10.1006/excr.1994.1217; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCDONALD ML, 1992, TRANSPLANTATION, V53, P460, DOI 10.1097/00007890-199202010-00037; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; RYFFEL B, 1991, IMMUNOLOGY, V72, P399; SCHNEIDER H, 1994, BIOCHEMISTRY-US, V33, P8218, DOI 10.1021/bi00193a007; SCHWARTZMAN RA, 1993, ENDOCRINOLOGY, V133, P591, DOI 10.1210/en.133.2.591; SERPESU E, 1986, BIOCHEMISTRY-US, V26, P1289; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; SUN XM, 1994, J BIOL CHEM, V269, P14857; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WEIGEL NL, 1989, ENDOCRINOLOGY, V125, P2494, DOI 10.1210/endo-125-5-2494; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XU Q, 1992, J BIOL CHEM, V267, P11968; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901	62	141	157	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6677	6684		10.1074/jbc.272.10.6677	http://dx.doi.org/10.1074/jbc.272.10.6677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045699	hybrid			2022-12-25	WOS:A1997WM64700083
J	Naslavsky, N; Stein, R; Yanai, A; Friedlander, G; Taraboulos, A				Naslavsky, N; Stein, R; Yanai, A; Friedlander, G; Taraboulos, A			Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED CULTURED-CELLS; GPI-ANCHORED PROTEINS; NEURO-BLASTOMA CELLS; TRANS-GOLGI-NETWORK; EPITHELIAL-CELLS; ULTRASTRUCTURAL-LOCALIZATION; NEUROBLASTOMA-CELLS; SECONDARY STRUCTURE; PRP 27-30; CAVEOLAE	Cells infected with prions contain both prion protein isoforms cellular prion protein (PrPC) and scrapie prion protein (PrPSc). PrPSc is formed posttranslationally through the pathological refolding of PrPC. In scrapie-infected ScN2a cells, the metabolism of both PrP isoforms involves cholesterol-dependent pathways. We show here that both PrPC and PrPSc are attached to Triton X-100-insoluble, low density complexes or ''rafts.'' These complexes are sensitive to saponin and thus probably contain cholesterol. This finding suggests that the transformation PrPC --> PrPSc occurs within rafts. It also reveals the existence of rafts in late compartments of the endocytic pathway, where most PrPSc resides. When Triton X-100 lysates of cells were incubated at 37 degrees C prior to density analysis, PrPC was still found in buoyant complexes, although it now failed to sediment at high speed. This property was shared by another glycophosphatidyl inositol protein, Thy-1, and also by the raft resident GM1. In one ScN2a clone and in the brain of a Syrian hamster with scrapie, Triton X-100 extraction at 37 degrees C permitted resolution of PrPC and PrPSc into two distinct peaks of different densities. This suggests that there are two populations of PrP-containing rafts and may permit isolation of PrPC-specific rafts from those containing PrPSc. Our findings reinforce the contention that rafts are involved in various aspects of PrP metabolism and in the ''life cycle'' of prions.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOL BIOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem				Friedlander, Gerard/0000-0002-6854-4261; Yanai, Anat/0000-0002-0792-6901				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HARMEY JH, 1995, BIOCHEM BIOPH RES CO, V210, P753, DOI 10.1006/bbrc.1995.1723; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KRISTENSSON K, 1993, NEUROLOGY, V43, P2335, DOI 10.1212/WNL.43.11.2335; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LASZLO L, 1992, J PATHOL, V166, P333, DOI 10.1002/path.1711660404; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35; ROGERS M, 1991, J IMMUNOL, V147, P3568; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Taraboulos A., 1992, PRION DIS HUMANS ANI, P434; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065	70	346	351	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6324	6331		10.1074/jbc.272.10.6324	http://dx.doi.org/10.1074/jbc.272.10.6324			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045652	hybrid			2022-12-25	WOS:A1997WM64700036
J	Popova, JS; Garrison, JC; Rhee, SG; Rasenick, MM				Popova, JS; Garrison, JC; Rhee, SG; Rasenick, MM			Tubulin, G(q), and phosphatidylinositol 4,5-bisphosphate interact to regulate phospholipase C beta(1) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; C ISOZYMES; GQ CLASS; ACTIVATION; RECEPTOR; TRANSDUCTION; PURIFICATION	The cytoskeletal protein, tubulin, has been shown to regulate adenylyl cyclase activity through its interaction with the specific G protein alpha subunits, G alpha(s) or G alpha(11). Tubulin activates these G proteins by transferring GTP and stabilizing the active nucleotide-bound G alpha conformation. To study the possibility of tubulin involvement in G alpha(q)-mediated phospholipase C beta(1) (PLC beta(1)) signaling, the m(1) muscarinic receptor, G alpha(q), and PLC beta(1) were expressed in Sf9 cells. A unique ability of tubulin to regulate PLC beta(1) was observed. Low concentrations of tubulin, with guanine nucleotide bound, activated PLC beta(1), whereas higher concentrations inhibited the enzyme. Interaction of tubulin with both G alpha(q) and PLC beta(1), accompanied by guanine nucleotide transfer from tubulin to G alpha(q), is suggested as a mechanism for the enzyme activation. The PLC beta(1) substrate, phosphatidylinositol 4,5-bisphosphate, bound to tubulin and prevented microtubule assembly. This observation suggested a mechanism for the inhibition of PLC beta(1) by tubulin, since high tubulin concentrations might prevent the access of PLC beta(1) to its substrate. Activation of m(1) muscarinic receptors by carbachol relaxed this inhibition, probably by increasing the affinity of G alpha(q) for tubulin. Involvement of tubulin in the articulation between PLC beta(1) signaling and microtubule assembly might prove important for the intracellular governing of a broad range of cellular events.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, COLL MED, CHICAGO, IL 60612 USA; UNIV ILLINOIS, COMM NEUROSCI, COLL MED, CHICAGO, IL 60612 USA; UNIV ILLINOIS, DEPT PSYCHIAT, COLL MED, CHICAGO, IL 60612 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; NHLBI, LAB CELL SIGNALING, NIH, BETHESDA, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NCI NIH HHS [CA 40042] Funding Source: Medline; NIMH NIH HHS [MH 339595] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDRADE R, 1993, NEURON, V10, P83, DOI 10.1016/0896-6273(93)90244-L; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANCOCK JF, 1988, ONCOGENE, V3, P187; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1986, ANN NY ACAD SCI, V466, P519, DOI 10.1111/j.1749-6632.1986.tb38429.x; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; LUTHIN GR, 1984, MOL PHARMACOL, V26, P164; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARKER EM, 1991, J BIOL CHEM, V266, P519; POPOVA JS, 1995, J NEUROCHEM, V64, P130; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; RASENICK MM, 1988, J NEUROCHEM, V51, P300, DOI 10.1111/j.1471-4159.1988.tb04870.x; RASENICK MM, 1995, BEHAV BRAIN SCI, V18, P484, DOI 10.1017/S0140525X00039418; RASENICK MM, 1994, METHOD ENZYMOL, V237, P100; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUGIURA Y, 1981, BIOCHIM BIOPHYS ACTA, V641, P148, DOI 10.1016/0005-2736(81)90578-2; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VAZIRI C, 1992, J BIOL CHEM, V267, P22973; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239; Yan K, 1996, J NEUROCHEM, V66, P1489	44	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6760	6765		10.1074/jbc.272.10.6760	http://dx.doi.org/10.1074/jbc.272.10.6760			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045709	hybrid			2022-12-25	WOS:A1997WM64700093
J	Slater, SJ; Kelly, MB; Larkin, JD; Ho, CJ; Mazurek, A; Taddeo, FJ; Yeager, MD; Stubbs, CD				Slater, SJ; Kelly, MB; Larkin, JD; Ho, CJ; Mazurek, A; Taddeo, FJ; Yeager, MD; Stubbs, CD			Interaction of alcohols and anesthetics with protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; RANA-PIPIENS TADPOLES; GENERAL-ANESTHETICS; PHOSPHOLIPID-VESICLES; MOLECULAR-BASIS; SHORT CHAIN; ACTIVATION; RECEPTOR; GAMMA; ETHANOL	The key signal transduction enzyme protein kinase C (PKC) contains a hydrophobic binding site for alcohols and anesthetics (Slater, S. J., Cox, K. J. A., Lombardi, J. V., Ho, C., Kelly, M. B., Rubin, E., and Stubbs, C. D. (1993) Nature 864, 82-84). In this study, we show that interaction of n-alkanols and general anesthetics with PKC alpha results in dramatically different effects on membrane-associated compared with lipid-independent enzyme ac activity. Furthermore, the effects on membrane-associated PKC alpha differ markedly depending on whether activity is induced by diacylglycerol or phorbol ester and also on n-alkanol chain length. PKC alpha contains two distinct phorbol ester binding regions of low and high affinity for the activator, respectively (Slater, S. J., Ho, C., Kelly, M. B., Larkin, J. D., Taddeo, F. J., Yeager, M. D., and Stubbs, C. D. (1996) J. Biol. Chem. 271, 4627-4631). Short chain n-alkanols competed for low affinity phorbol ester binding to the enzyme, resulting in reduced enzyme activity, whereas high affinity phorbol ester binding was unaffected. Long chain n-alkanols not only competed for low affinity phorbol ester binding but also enhanced high affinity phorbol ester binding. Furthermore, long chain n-alkanols enhanced phorbol ester induced PKC alpha activity. This effect of long chain n-alkanols was similar to that of diacylglycerol, although the n-alkanols alone were weak activators of the enzyme. The cellular effects of n-alkanols and general anesthetics on PKC-mediated processes will therefore depend in a complex manner on the locality of the enzyme (e.g. cytoskeletal or membrane-associated) and activator type, apart from any isoform-specific differences. Furthermore, effects mediated by interaction with the region on the enzyme possessing low affinity for phorbol esters represent a novel mechanism for the regulation of PKC activity.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,JAH,PHILADELPHIA,PA 19107	Jefferson University				Larkin, Jonathan/0000-0002-1202-9287	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, R01AA008022, R29AA008022] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08022, AA07215, AA07186] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BELL RM, 1991, J BIOL CHEM, V266, P4661; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BONI LT, 1985, J BIOL CHEM, V260, P819; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; DILDYMAYFIELD JE, 1994, J NEUROCHEM, V62, P1639; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; EPAND RM, 1994, ANAL BIOCHEM, V218, P241, DOI 10.1006/abio.1994.1173; FIRESTONE LL, 1996, MOL CELLULAR MECH AN, P455; FIRESTONE S, 1995, ALCOHOL CLIN EXP RES, V19, P416, DOI 10.1111/j.1530-0277.1995.tb01524.x; FIRESTONE S, 1993, ANESTH ANALG, V77, P1026; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FRASER DM, 1990, BIOCHEMISTRY-US, V29, P2664, DOI 10.1021/bi00463a007; HEMMINGS HC, 1994, ANESTHESIOLOGY, V81, P147, DOI 10.1097/00000542-199407000-00021; HUIDOBROTORO JP, 1987, J PHARMACOL EXP THER, V242, P963; JAIN MK, 1978, BIOCHIM BIOPHYS ACTA, V509, P1, DOI 10.1016/0005-2736(78)90002-0; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MARQUEZ C, 1992, J IMMUNOL, V149, P2560; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MEYER H, 1989, ARCH EXP PATHOL PH, V42, P109; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Overton E., 1901, STUDIEN NARKOSE; PREKERIS R, 1996, CELL, V132, P77; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; ROIVAINEN R, 1994, EXS, V71, P29; ROONEY TA, 1989, J BIOL CHEM, V264, P6817; SANNA E, 1994, MOL PHARMACOL, V45, P1004; SHIEH HL, 1995, MOL CARCINOGEN, V12, P166, DOI 10.1002/mc.2940120308; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; WOOD SC, 1991, MOL PHARMACOL, V39, P332	47	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6167	6173		10.1074/jbc.272.10.6167	http://dx.doi.org/10.1074/jbc.272.10.6167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045629	hybrid			2022-12-25	WOS:A1997WM64700013
J	Stempka, L; Girod, A; Muller, HJ; Rincke, G; Marks, F; Gschwendt, M; Bossemeyer, D				Stempka, L; Girod, A; Muller, HJ; Rincke, G; Marks, F; Gschwendt, M; Bossemeyer, D			Phosphorylation of protein kinase C delta (PKC delta) at threonine 505 is not a prerequisite for enzymatic activity - Expression of rat PKC delta and an alanine 505 mutant in bacteria in a functional form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; TYROSINE PHOSPHORYLATION; CATALYTIC SUBUNIT; IN-VIVO; PERMISSIVE ACTIVATION; CRYSTAL-STRUCTURE; PORCINE SPLEEN; CELLS; ALPHA; FAMILY	A structural feature shared by many protein kinases is the requirement for phosphorylation of threonine or tyrosine in the so called activation loop for full enzyme activity, Previous studies by several groups have indicated that the isotypes alpha, beta(I), and beta(II) of protein kinase C (PKC) are synthesized as inactive precursors and require phosphorylation by a putative ''PKC kinase'' for permissive activation, Expression of PKC alpha in bacteria resulted in a nonfunctional enzyme, apparently due to lack of this kinase, The phosphorylation sites for the PKC kinase in the activation loop of PKC alpha and PKC beta(II) could be identified as Thr(497) and Thr(500), respectively, We report here that PKC delta, contrary to PKC alpha, can be expressed in bacteria in a functional form, The activity of the recombinant enzyme regarding substrate phosphorylation, autophosphorylation, and dependence an activation by 12-O-tetradecanoylphorbol-13-acetate as well as the K-m values for two substrates are comparable to those of recombinant PKC delta expressed in baculovirus infected insect cells. By site directed mutagenesis we were able to show that Thr(505), corresponding to Thr(497) and Thr(500) of PKC alpha and PKC beta(II), respectively, is not essential for obtaining a catalytically competent conformation of PKC delta, The mutant Ala(505) can be activated and does not differ from the wild type regarding activity and several other features, Ser(504) can not take over the role of Thr(505) and is not prerequisite for the kinase to become activated, as proven by the unaffected enzyme activity of respective mutants (Ala(504) and Ala(504)/Ala(505)), These results indicate that phosphorylation of Thr(505) is not required for the formation of functional PKC delta and that at least this PKC isoenzyme differs from the isotypes alpha, beta(I), and beta(II) regarding the permissive activation by a PKC kinase.	GERMAN CANC RES CTR, DIV BIOCHEM TISSUE SPECIF REGULAT, D-69120 HEIDELBERG, GERMANY; GERMAN CANC RES CTR, DIV PATHOCHEM, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)								AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; BORNER C, 1989, J BIOL CHEM, V264, P13902; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Bossemeyer Dirk, 1996, P37, DOI 10.1002/9783527615032.ch2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONANCIN F, 1996, CURR BIOL, V6, P1114; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON S, 1990, EUR J BIOCHEM, V194, P799, DOI 10.1111/j.1432-1033.1990.tb19472.x; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FILIPUZZI I, 1993, J CELL BIOCHEM, V52, P78, DOI 10.1002/jcb.240520111; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Girod A, 1996, FEBS LETT, V391, P121, DOI 10.1016/0014-5793(96)00717-X; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GSCHWENDT M, 1995, CARCINOGENESIS, V16, P107, DOI 10.1093/carcin/16.1.107; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GSCHWENDT M, 1995, BIOCHEM BIOPH RES CO, V206, P614, DOI 10.1006/bbrc.1995.1087; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; LI WQ, 1994, J BIOL CHEM, V269, P2349; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Marks Friedrich, 1996, P81, DOI 10.1002/9783527615032.ch3; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ORNELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726; ORR JW, 1994, J BIOL CHEM, V269, P27715; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Stabel S., 1993, INTRACELLULAR MESSEN, P167; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641; ZHANG J, 1994, J BIOL CHEM, V269, P19578	53	97	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6805	6811		10.1074/jbc.272.10.6805	http://dx.doi.org/10.1074/jbc.272.10.6805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045715	hybrid			2022-12-25	WOS:A1997WM64700099
J	Bradbury, FA; Kawate, N; Foster, CM; Menon, KMJ				Bradbury, FA; Kawate, N; Foster, CM; Menon, KMJ			Post-translational processing in the Golgi plays a critical role in the trafficking of the luteinizing hormone/human chorionic gonadotropin receptor to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITED PRECOCIOUS PUBERTY; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; CONSTITUTIVELY ACTIVATING MUTATION; LIGAND-BINDING; IDENTIFICATION; GLYCOSYLATION; FAMILY; ENZYME; GENE	Point mutations in the luteinizing hormone/human chorionic gonadotropin (LH/hCG) receptor have been shown to cause constitutive activation which results in precocious puberty in affected males, We introduced one of these mutations, Asp-556 --> Gly, into the rat LH/hCG receptor and demonstrated that the mutant receptor constitutively activated adenylate cyclase in transfected 293 T cells. The cell surface expression of the mutant receptor was lower than that of the wild type receptor, Pulse-chase studies showed that the 73-kDa precursor of both the mutant and wild type receptors was synthesized at comparable efficiencies. However, post-translational processing of the mutant receptor to the mature 92-kDa form, which has N-linked complex type oligosaccharide chains, was impaired. Sensitivity of the mutant receptor to peptide-N-glycanase F and endoglycosidase H, and insensitivity to sialidase indicated that the 73-kDa species represents the high mannose form that has not yet been trafficked through the medial and trans Golgi. Additionally, although time wild type receptor was palmitoylated, the mutant receptor was not. Although the high mannose 73-kDa species is capable of binding LH/hCG, our results show that post-translational processing in the Golgi is required for the mature 92-kDa receptor to reach the cell surface.	UNIV MICHIGAN, DEPT OBSTET & GYNECOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NICHD NIH HHS [HD 06656, I-P 30 HD 18258, PR5-T32-HD-07048] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD006656] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007048, P30HD018258, R37HD006656] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AZHAR S, 1981, J BIOL CHEM, V256, P6548; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; Fernandez LM, 1996, BIOCHEMISTRY-US, V35, P3986, DOI 10.1021/bi952421c; Gilman A G, 1974, Methods Enzymol, V38, P49; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; HUNZICKERDUNN M, 1985, LUTEINIZING HORMONE, P57; KAWATE N, 1995, J MED GENET, V32, P553, DOI 10.1136/jmg.32.7.553; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MENON KMJ, 1974, FERTIL STERIL, V25, P732; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PETAJAREPO UE, 1994, BIOCHEM J, V298, P361, DOI 10.1042/bj2980361; ROCHE PC, 1985, ENDOCRINOLOGY, V117, P790, DOI 10.1210/endo-117-2-790; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHAUER I, 1985, J CELL BIOL, V100, P1664, DOI 10.1083/jcb.100.5.1664; SCHEDEWIE HK, 1981, J CLIN ENDOCR METAB, V52, P271, DOI 10.1210/jcem-52-2-271; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; Yano K, 1996, BIOCHEM BIOPH RES CO, V220, P1036, DOI 10.1006/bbrc.1996.0528; ZHANG QY, 1989, P NATL ACAD SCI USA, V86, P8294, DOI 10.1073/pnas.86.21.8294; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	30	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5921	5926		10.1074/jbc.272.9.5921	http://dx.doi.org/10.1074/jbc.272.9.5921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038211	hybrid			2022-12-25	WOS:A1997WK74700079
J	Gleixner, G; Schmidt, HL				Gleixner, G; Schmidt, HL			Carbon isotope effects on the fructose-1,6-bisphosphate aldolase reaction, origin for non-statistical C-13 distributions in carbohydrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE BISPHOSPHATE ALDOLASE; RABBIT MUSCLE ALDOLASE; FRACTIONATION; DISCRIMINATION; DEPENDENCE; MECHANISM; PRODUCTS; GLUCOSE; ACID; FOOD	The kinetic and equilibrium isotope effects on the fructose-1,6-bisphosphate aldolase reaction have been determined using the rabbit muscle enzyme, The natural C-13 abundance for both atoms participating in the bond splitting were measured in position C-1 of dihydroxyacetone phosphate and glyceraldehyde 3-P after irreversible conversion to glycerol-3-P and 3-phosphoglycerate, respectively, and chemical degradation, The carbon isotope effects were determined comparing the C-13 content of the corresponding positions after partial and complete turnover, and after complete equilibration of the reactants. (13)(V-max/K-m) on C-3 was 1.016 +/- 0.007 and 0.997 +/- 0.009 on position C-4, and the equilibrium isotope effects K-12/K-13 on these positions were 1.0036 +/- 0.0002 and 1.0049 +/- 0.0001. The observed kinetic isotope effect on C-3 is discussed to originate from the formation of the enamine, which comes to equilibrium before the rate determining release of glyceraldehyde 3-P from the ternary complex. The equilibrium isotope effect is seen as the reason for an earlier-found relative C-13 enrichment in position C-3 and C-4 of glucose and for varying enrichments in C-13 of carbohydrates from different compartments of cells. The kinetic isotope effect is suggested to cause C-13 discriminations in the C-3 pool in context with the hexose formation in competition with other dihydroxyacetone phosphate turnover reactions.			Gleixner, G (corresponding author), TECH UNIV MUNICH,LEHRSTUHL ALLGEMEINE CHEM & BIOCHEM,VOTTINGERSTR 40,D-85350 FREISING,GERMANY.		Gleixner, Gerd/M-8519-2017; Gleixner, Gerd/O-4215-2019	Gleixner, Gerd/0000-0002-4616-0953; Gleixner, Gerd/0000-0002-4616-0953				ABELSON PH, 1961, P NATL ACAD SCI USA, V47, P623, DOI 10.1073/pnas.47.5.623; BEDNARSKI MD, 1989, J AM CHEM SOC, V111, P627, DOI 10.1021/ja00184a034; BERGMEYER HU, 1974, METHODEN ENZYMATISCH; BIELLMANN JF, 1969, J AM CHEM SOC, V91, P6484, DOI 10.1021/ja01051a053; BOYER PD, 1972, ENZYMES, V7; CLELAND WW, 1980, METHOD ENZYMOL, V64, P108; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; DENIRO MJ, 1977, SCIENCE, V197, P261, DOI 10.1126/science.327543; FARQUHAR GD, 1983, AUST J PLANT PHYSIOL, V10, P205, DOI 10.1071/PP9830205; Galimov E.M, 1985, BIOL FRACTIONATION I; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; GLEIXNER G, 1993, PLANT PHYSIOL, V102, P1287, DOI 10.1104/pp.102.4.1287; HATZFELD WD, 1990, PLANTA, V180, P198, DOI 10.1007/BF00193996; HOGG JL, 1980, J AM CHEM SOC, V102, P49; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; LITTLECHILD JA, 1993, TRENDS BIOCHEM SCI, V18, P36, DOI 10.1016/0968-0004(93)90048-R; LITTLECHILD JA, 1990, BFE, V7, P158; MARSH JJ, 1992, TRENDS BIOCHEM SCI, V17, P110, DOI 10.1016/0968-0004(92)90247-7; MEINSCHEIN WG, 1974, BIOMED MASS SPECTROM, V1, P172, DOI 10.1002/bms.1200010306; MELZER E, 1987, J BIOL CHEM, V262, P8159; METGES C, 1990, BRIT J NUTR, V63, P187, DOI 10.1079/BJN19900106; MONSON KD, 1982, GEOCHIM COSMOCHIM AC, V46, P139, DOI 10.1016/0016-7037(82)90241-1; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; O'Leary M H, 1980, Methods Enzymol, V64, P83; OLEARY MH, 1981, PHYTOCHEMISTRY, V20, P553, DOI 10.1016/0031-9422(81)85134-5; PARK R, 1960, GEOCHIM COSMOCHIM AC, V36, P110; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4391, DOI 10.1021/bi00839a025; RAUSCHENBACH P, 1966, Z PHYSL CHEM, V346, P290; RINALDI G, 1974, BIOMED MASS SPECTROM, V1, P415, DOI 10.1002/bms.1200010609; ROSE IA, 1987, J BIOL CHEM, V262, P692; ROSSMANN A, 1991, PLANT PHYSIOL, V96, P609, DOI 10.1104/pp.96.2.609; Schmidt H-L, 1995, STABLE ISOTOPES BIOS, P17; SCHMIDT K, 1970, ANAL BIOCHEM, V34, P170, DOI 10.1016/0003-2697(70)90098-9; SCHNARRENBERGER C, 1983, ISOZYMES-CURR T BIOL, V8, P23; SIMON H, 1967, ANWENDUNG ISOTOPEN O, V1; VOET D, 1992, BIOCHIMIE, P329; WHELAN T, 1970, BIOCHEM BIOPH RES CO, V41, P1205, DOI 10.1016/0006-291X(70)90214-7; WINKLER FJ, 1983, PHYSIOL VEG, V21, P889; WINKLER FJ, 1980, Z LEBENSM UNTERS FOR, V171, P85, DOI 10.1007/BF01140746; Winkler FJ, 1982, STABLE ISOTOPES, P83	42	96	98	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5382	5387		10.1074/jbc.272.9.5382	http://dx.doi.org/10.1074/jbc.272.9.5382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038136	hybrid			2022-12-25	WOS:A1997WK74700004
J	Jagle, U; Muller, AM; Kohler, H; Bonifer, C				Jagle, U; Muller, AM; Kohler, H; Bonifer, C			Role of positive and negative cis-regulatory elements in the transcriptional activation of the lysozyme locus in developing-macrophages of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN LYSOZYME; GENE DOMAIN; HYPERSENSITIVE SITES; PRECURSOR CHARACTERIZATION; MONOCLONAL-ANTIBODIES; MOUSE MACROPHAGES; CONTROL REGION; CHROMATIN; ENHANCER; DIFFERENTIATION	Expression of the chicken lysozyme locus in macrophages is regulated by at least six different positive and negative cis-regulatory elements. Chromatin of the chicken lysozyme locus is gradually reorganized during macrophage differentiation, indicating tl-tat each cis-regulatory element is activated at a different developmental stage, Irrespective of their differential developmental activation, individual cis-regulatory regions are capable of driving transcription of the lysozyme gene in mature macrophages of transgenic mice. In order to examine the role of different cis-regulatory regions in lysozyme locus activation, we analyzed the time course of transcriptional up-regulation of deletion mutants of the lysozyme locus in a new in vitro differentiation system based on enriched primary macrophage precursor cells from the bone marrow of transgenic mice. We show that constructs carrying cis-regulatory elements which are structurally reorganized early in development are also transcriptionally active at an early stage. A construct in which the early enhancer has been deleted shows a delay in transcriptional activation. The presence or absence of a negative regulatory element has no influence on the time course of transcriptional activation of the lysozyme locus.	UNIV FREIBURG,INST BIOL 3,D-79104 FREIBURG,GERMANY; MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY	University of Freiburg; Max Planck Society			Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825				ALTSCHMIED J, 1989, NUCLEIC ACIDS RES, V17, P4975, DOI 10.1093/nar/17.13.4975; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1990, CELL, V61, P729; BONIFER C, 1994, EUR J BIOCHEM, V226, P227, DOI 10.1111/j.1432-1033.1994.tb20045.x; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BONIFER C, 1994, NUCLEIC ACIDS RES, V22, P4202, DOI 10.1093/nar/22.20.4202; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DEBRUIJN MFTR, 1994, EUR J IMMUNOL, V24, P2279, DOI 10.1002/eji.1830241003; FAUST N, 1994, DNA CELL BIOL, V13, P901, DOI 10.1089/dna.1994.13.901; FAUST N, 1997, IN PRESS EXP HEMATOL; FORD AM, 1992, P NATL ACAD SCI USA, V89, P3424, DOI 10.1073/pnas.89.8.3424; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FRITTON HP, 1984, NATURE, V311, P163, DOI 10.1038/311163a0; FRITTON HP, 1983, NUCLEIC ACIDS RES, V11, P3467, DOI 10.1093/nar/11.11.3467; GOETHE R, 1994, J BIOL CHEM, V269, P31302; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; HECHT A, 1988, EMBO J, V7, P2063, DOI 10.1002/j.1460-2075.1988.tb03046.x; Huber MC, 1996, NUCLEIC ACIDS RES, V24, P1443, DOI 10.1093/nar/24.8.1443; HUBER MC, 1995, DNA CELL BIOL, V14, P397, DOI 10.1089/dna.1995.14.397; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618; KINCADE PW, 1982, J IMMUNOL METHODS, V42, P17; LEE MS, 1992, P NATL ACAD SCI USA, V89, P9166, DOI 10.1073/pnas.89.19.9166; LEENEN PJM, 1990, EUR J IMMUNOL, V20, P15, DOI 10.1002/eji.1830200104; LEENEN PJM, 1990, EUR J IMMUNOL, V20, P27, DOI 10.1002/eji.1830200105; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; MOLLERS B, 1992, NUCLEIC ACIDS RES, V20, P1917, DOI 10.1093/nar/20.8.1917; MULLER A, 1990, BONE MARROW TRANSPL, V5, P13; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; Sippel A E, 1987, Results Probl Cell Differ, V14, P255; SIPPEL AE, 1988, ARCHITECTURE EUKARYO, P355; SLIEKER WAT, 1993, INT IMMUNOL, V5, P1099, DOI 10.1093/intimm/5.9.1099; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; VANDERLOO JCM, 1995, BLOOD, V85, P952, DOI 10.1182/blood.V85.4.952.bloodjournal854952	39	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5871	5879		10.1074/jbc.272.9.5871	http://dx.doi.org/10.1074/jbc.272.9.5871			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038204	hybrid			2022-12-25	WOS:A1997WK74700072
J	Patel, JR; McDonald, KS; Wolff, MR; Moss, RL				Patel, JR; McDonald, KS; Wolff, MR; Moss, RL			Ca2+ binding to troponin C in skinned skeletal muscle fibers assessed with cased Ca2+ and a Ca2+ fluorophore - Invariance of Ca2+ binding as a function of sarcomere length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-BRIDGE ATTACHMENT; OSMOTIC COMPRESSION; FORCE PRODUCTION; TENSION; SENSITIVITY; CALCIUM; CA-2+; RAT; TEMPERATURE; ACTIVATION	Ca2+ sensitivity of tension varies with sarcomere length in both skeletal and cardiac muscles, One possible explanation for this effect is that the Ca2+ affinity of the regulatory protein troponin C decreases when sarcomere length is reduced. To examine length dependence of Ca2+ binding to troponin C: in skeletal muscle, we developed a protocol to simultaneously monitor changes in sarcomere length, tension, and Ca2+ concentration following sash photolysis of caged Ca2+. In this protocol, [Ca2+] was rapidly increased by flash photolysis of caged Ca2+, and changes in [Ca2+] due to photolysis and the subsequent binding to troponin C were assessed using a Ca2+ fluorophore. Small bundles of fibers from rabbit skinned psoas muscles were loaded with Ca2+ fluorophore (Fluo-3) and caged Ca2+ (dimethoxynitrophenamine or o-nitrophenyl-EGTA). The bundles were then transferred to silicone oil, where [Ca2+](free), tension, and sarcomere length were monitored before and after photolysis of caged Ca2+. Upon photolysis of caged Ca2+, fluorescence increased and then decayed to a new steady-state level within similar to 1 s, while tension increased to a new steady-state level within similar to 1.5 s, After extracting troponin C, fibers did not generate tension following the flash, but steady-state post-flash fluorescence was significantly greater than when troponin C was present, The difference in [Ca2+](free) represents the amount of Ca2+ bound to troponin C. In fibers that were troponin C-replete, Ca2+ binding to troponin C did not differ at short (similar to 1.97 mu m) and long (similar to 2.51 mu m) sarcomere length, yet tension was similar to 50% greater at the long sarcomere length, These results show that the affinity of troponin C for Ca2+ is not altered by changes in sarcomere length, indicating that length-dependent changes in Ca2+ sensitivity of tension in skeletal muscle are not related to length-dependent changes in Ca2+ binding affinity of troponin C.	UNIV WISCONSIN, SCH MED, DEPT PHYSIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison				McDonald, Kerry/0000-0002-1588-1782	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-25861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN JD, 1987, J PHYSIOL-LONDON, V390, P119, DOI 10.1113/jphysiol.1987.sp016689; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; DONALDSON SKB, 1975, J GEN PHYSIOL, V66, P427, DOI 10.1085/jgp.66.4.427; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUCHS F, 1977, BIOCHIM BIOPHYS ACTA, V491, P523, DOI 10.1016/0005-2795(77)90297-5; FUCHS F, 1991, AM J PHYSIOL, V261, pC787, DOI 10.1152/ajpcell.1991.261.5.C787; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; HIBBERD MG, 1982, J PHYSIOL-LONDON, V329, P527, DOI 10.1113/jphysiol.1982.sp014317; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; HOFMANN PA, 1987, AM J PHYSIOL, V253, pC90; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; MCDONALD KS, 1995, CIRC RES, V77, P199, DOI 10.1161/01.RES.77.1.199; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOSS RL, 1983, BIOPHYS J, V43, P115, DOI 10.1016/S0006-3495(83)84329-X; MOSS RL, 1983, J CELL BIOL, V96, P970, DOI 10.1083/jcb.96.4.970; POTTER JD, 1975, J BIOL CHEM, V250, P4628; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; STEPHENSON DG, 1982, J PHYSIOL-LONDON, V333, P637, DOI 10.1113/jphysiol.1982.sp014473; SWEITZER NK, 1990, J GEN PHYSIOL, V96, P1221, DOI 10.1085/jgp.96.6.1221; WANG YP, 1995, J MOL CELL CARDIOL, V27, P1235, DOI 10.1016/S0022-2828(05)82385-5; YATES LD, 1983, J BIOL CHEM, V258, P5770; ZOT HG, 1987, J MUSCLE RES CELL M, V8, P428, DOI 10.1007/BF01578432	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6018	6027		10.1074/jbc.272.9.6018	http://dx.doi.org/10.1074/jbc.272.9.6018			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038224	hybrid			2022-12-25	WOS:A1997WK74700092
J	Rivas, CI; Vera, JC; Guaiquil, VH; Velasquez, FV; BorquezOjeda, OA; Carcamo, JG; Concha, II; Golde, DW				Rivas, CI; Vera, JC; Guaiquil, VH; Velasquez, FV; BorquezOjeda, OA; Carcamo, JG; Concha, II; Golde, DW			Increased uptake and accumulation of vitamin C in human immunodeficiency virus 1-infected hematopoietic cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACETYL-L-CYSTEINE; ASCORBIC-ACID; DEHYDROASCORBIC ACID; INFECTED-CELLS; GLUCOSE TRANSPORTERS; N-ACETYLCYSTEINE; HTLV-III; EXPRESSION; REPLICATION	Vitamin C (ascorbic acid) is required for normal host defense and functions importantly in cellular redox systems. To define the interrelationship between human immunodeficiency virus (EW) infection and vitamin C flux at the cellular level, we analyzed vitamin C uptake and its effects on virus production and cellular proliferation in HIV-infected and uninfected human lymphoid, myeloid, and mononuclear phagocyte cell lines. Chronic or acute infection of these cell lines by HIV-1 led to increased expression of glucose transporter 1, associated with increased transport and accumulation of vitamin C. Infected cells also showed increased transport of glucose analogs. Exposure to vitamin C had a complex effect on cell proliferation and viral production. Low concentrations of vitamin C increased or decreased cell proliferation depending on the cell line and either had no effect or caused increased viral production. Exposure to high concentrations of vitamin C preferentially decreased the proliferation and survival of the HIV-infected cells and caused decreased viral production. These findings indicate that EW infection in lymphocytic, monocytic, and myeloid cell lines leads to increased expression of glucose transporter 1 and consequent increased cellular vitamin C uptake. High concentrations of vitamin C were preferentially toxic to HIV-infected host defense cell Lines in vitro.	UNIV AUSTRAL CHILE, FAC CIENCIAS, INST BIOQUIM, VALDIVIA, CHILE	Universidad Austral de Chile	Rivas, CI (corresponding author), MEM SLOAN KETTERING CANC CTR, PROGRAM MOL PHARMACOL & THERAPEUT, BOX 451, 1275 YORK AVE, NEW YORK, NY 10021 USA.			Carcamo, Juan Guillermo/0000-0002-2595-4375	NATIONAL CANCER INSTITUTE [P30CA008748, R01CA030388] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748, R01 CA30388] Funding Source: Medline; NHLBI NIH HHS [R01 HL421076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON R, 1981, VITAMIN C ASCORBIC A, P249; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BIGLEY R, 1981, BIOCHIM BIOPHYS ACTA, V659, P15, DOI 10.1016/0005-2744(81)90266-7; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BODE AM, 1993, CURR EYE RES, V12, P593, DOI 10.3109/02713689309001838; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CLOUSE KA, 1989, J IMMUNOL, V142, P431; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; Cunningham-Rundles Ward F., 1993, P91; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GARTNER S, 1990, TECHNIQUES HIV RES, P53; HARAKEH S, 1991, AM J CLIN NUTR, V54, pS1231, DOI 10.1093/ajcn/54.6.1231s; HARAKEH S, 1994, CHEM-BIOL INTERACT, V91, P207, DOI 10.1016/0009-2797(94)90041-8; HARAKEH S, 1990, P NATL ACAD SCI USA, V87, P7245, DOI 10.1073/pnas.87.18.7245; HODGES RE, 1971, AM J CLIN NUTR, V24, P432; JARIWALLA RJ, 1996, SUBCELL BIOCH, V25, P215; KITANO K, 1990, BLOOD, V76, P1980; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; MARTENSSON J, 1993, P NATL ACAD SCI USA, V90, P317, DOI 10.1073/pnas.90.1.317; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; NOTTET HSLM, 1994, J LEUKOCYTE BIOL, V56, P702, DOI 10.1002/jlb.56.6.702; POPOVIC M, 1984, LANCET, V2, P1472; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROEDERER M, 1991, AIDS RES HUM RETROV, V7, P563, DOI 10.1089/aid.1991.7.563; ROEDERER M, 1991, INT IMMUNOL, V3, P933, DOI 10.1093/intimm/3.9.933; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; ROEDERER M, 1993, PHARMACOLOGY, V46, P121, DOI 10.1159/000139037; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; SCHNITTMAN SM, 1994, ADV INTERNAL MED, V39, P305; SILBER R, 1992, BLOOD, V80, P2038; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; STAHL RL, 1985, CANCER RES, V45, P6507; THOMAS WR, 1978, CLIN EXP IMMUNOL, V32, P370; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; VERA JC, 1988, ANAL BIOCHEM, V174, P187, DOI 10.1016/0003-2697(88)90534-9; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WINKLER BS, 1992, BIOCHIM BIOPHYS ACTA, V1117, P287, DOI 10.1016/0304-4165(92)90026-Q	46	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5814	5820		10.1074/jbc.272.9.5814	http://dx.doi.org/10.1074/jbc.272.9.5814			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038196	hybrid			2022-12-25	WOS:A1997WK74700064
J	Ono, Y; Fukuhara, N; Yoshie, O				Ono, Y; Fukuhara, N; Yoshie, O			Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; ZINC-FINGER PROTEIN; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; RECEPTOR-ALPHA; SCL GENE; EXPRESSION; FAMILY; TRANSLOCATION; ASSOCIATION	TAL1, which is frequently activated in T cell acute lymphoblastic leukemia (T-ALL), encodes lineage-specific basic helix-loop-helix (bHLH) proteins that bind specifically to E-box DNA motif upon dimerization with ubiquitous basic helix-loop-helix proteins E47 or E12, RBTN1 and RBTN2, also frequently activated in T-ALL, encode proteins only with tandem cysteine-rich LIM domains, We found that aberrant expression of TAL1 detected in 11 out of 14 T-ALL cell lines was invariably accompanied by that of either RBTN1 or RBTN2, Forced expression of TAL1 together with RBTN1 or RBTN2, but not TAL1 alone, strongly induced artificial reporter genes in a TAL1/RBTN-negative T-ALL cell Line, HPB-ALL, Such collaborative transcriptional activity of TAL1 and RBTN was not, however, observed in non-T cell lines, suggesting further involvement of some T cell-specific cofactors. In this context, we carried out preliminary evaluation of a potential role of the T cell-specific GATA-binding protein, GATA3, in the transcriptional activity of TAL1 and RBTN. We also showed that coexpression of TAL1 and RBTN1 in HPB-ALL strongly induced TALLA1, a highly specific T-ALL marker whose positivity correlated 100% with ectopic expression of TAL1 among various T-ALL cell lines, Collectively, ectopic TAL1 and RBTN1 or -2, together with some endogenous T cell-specific cofactors like GATA3, constitute a highly collaborative set of transcription factors whose aberrant activity in T cells may lead to leukemogenesis by modulating expression of downstream genes such as TALLA1.	SHIONOGI INST MED SCI,SETTSU,OSAKA 566,JAPAN	Shionogi & Company Limited				Yoshie, Osamu/0000-0003-4353-5809				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BERNARD O, 1991, ONCOGENE, V6, P1477; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; ELWOOD NJ, 1995, CELL GROWTH DIFFER, V6, P19; ELWOOD NJ, 1993, ONCOGENE, V8, P3093; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; ROBB L, 1995, ONCOGENE, V10, P205; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	40	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4576	4581		10.1074/jbc.272.7.4576	http://dx.doi.org/10.1074/jbc.272.7.4576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020185	hybrid			2022-12-25	WOS:A1997WH01900101
J	Roder, HM; Fracasso, RP; Hoffman, FJ; Witowsky, JA; Davis, G; Pellegrino, CB				Roder, HM; Fracasso, RP; Hoffman, FJ; Witowsky, JA; Davis, G; Pellegrino, CB			Phosphorylation-dependent monoclonal tau antibodies do not reliably report phosphorylation by extracellular signal-regulated kinase 2 at specific sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE STATE; ABNORMAL PHOSPHORYLATION; PROTEIN-KINASES; DISEASE; IDENTIFICATION; RECOGNITION; PK40(ERK); ISOFORMS; EPITOPE	Analysis of phosphorylation of tau, the microtubule-associated proteins hyperphosphorylated in Alzheimer's disease, is often performed using phosphorylation-sensitive monoclonal antibodies thought to report the presence or absence of one or two specific phosphorylations (cognate sites). Using several such antibodies we found a much more complicated relationship between phosphorylation at specific sites, as monitored by two-dimensional phosphopeptide mapping, and antibody recognition of these sites. Multiple phosphorylation of tau in several stages by the brain extracellular signal-regulated kinase 2 isoform PR40 suggested that phosphorylation at cognate sites is sometimes necessary (but not sufficient) to induce a change of antibody reactivity and in some cases is not even necessary in the background of multiple phosphorylation at other sites. No single phosphorylation site was found to be responsible for any level of gel mobility shift associated with phosphorylation. Tau acquired its maximal gel mobility retardation and final immunochemical profile at substoichiometric phosphorylation of most sites, This suggests that many alternate phosphorylation patterns can produce the same conformational and immunochemical presentation on sodium dodecyl sulfate-gel electrophoresis. Although PK40(erk2) prefers some phosphorylation sites, most notably Ser(235), followed by Ser(199) or Ser(202) and Thr(205), the phosphorylation of multiple Ser/Thr-Pro sites is not highly sequential. Ser(396) is one of the least preferred sites and seems to require prior phosphorylation at Ser(404).	BAYER CORP, INST RES TECHNOL, W HAVEN, CT 06516 USA	Bayer AG	Roder, HM (corresponding author), BAYER CORP, INST DEMENTIA RES, 400 MORGAN LA, W HAVEN, CT 06516 USA.							BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BLANCHARD BJ, 1994, BIOCHEM BIOPH RES CO, V200, P187, DOI 10.1006/bbrc.1994.1432; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; DOLORESLEDESMA M, 1995, NEUROBIOL AGING, V16, P515; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1995, NEUROBIOL AGING, V16, P325, DOI 10.1016/0197-4580(95)00017-9; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Hasegawa M, 1996, FEBS LETT, V384, P25, DOI 10.1016/0014-5793(96)00271-2; KOPKE E, 1993, J BIOL CHEM, V268, P24374; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; RODER HM, 1991, J NEUROSCI, V11, P3325; RODER HM, 1993, BIOCHEM BIOPH RES CO, V193, P639, DOI 10.1006/bbrc.1993.1672; RODER HM, 1995, J NEUROCHEM, V64, P2203; Singh TJ, 1996, MOL CELL BIOCHEM, V154, P143, DOI 10.1007/BF00226782; SINGH TJ, 1995, FEBS LETT, V358, P267, DOI 10.1016/0014-5793(94)01445-7; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836	27	15	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4509	4515		10.1074/jbc.272.7.4509	http://dx.doi.org/10.1074/jbc.272.7.4509			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020176	hybrid			2022-12-25	WOS:A1997WH01900092
J	Bartholomew, C; Kilbey, A; Clark, AM; Walker, M				Bartholomew, C; Kilbey, A; Clark, AM; Walker, M			The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation	ONCOGENE			English	Article						Evi-1; repression; leukaemogenesis; development	ZINC-FINGER PROTEIN; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; MYELODYSPLASTIC SYNDROMES; RETROVIRAL INSERTIONS; CONSENSUS SEQUENCE; MAMMALIAN-CELLS; GENE-EXPRESSION; ACTIVATION; IDENTIFICATION	The myeloid transforming gene Evi-1 encodes a protein with two zinc finger domains, designated ZF1 and ZF2, with distinct DNA binding specificities. For the first time we demonstrate that Evi-1 has transcriptional repressor activity which is directly proportional to the amount of Evi-1 protein in cells. Repression has been observed with two distinct promoters: the minimal HSV-1 tk promoter and a VP16 inducible adenovirus E1b minimal promoter. Optimal repression is DNA binding dependent and is mediated by either ZF1 or a heterologous GAL4 DNA binding domain (GAL4DBD) but is significantly less efficient through the ZF2 binding site. Both GAL4DBD/Evi-1 fusion and non-fusion proteins have been used to map the repressor activity to a proline-rich region located within amino acids 514-724 between the ZF1 and ZF2 domains. Constitutive expression of mutant proteins lacking the repressor domain are defective for transformation of Rat1 fibroblasts demonstrating that this region is required for the oncogenic activity of the Evi-1 protein. These studies show that the Evi-1 gene encodes a transcriptional repressor and has important implications for the mechanism of action of the Evi-1 protein both in development and in the progression of some myeloid leukaemias.			Bartholomew, C (corresponding author), BEATSON INST CANC RES, CANC RES CAMPAIGN, BEATSON LABS, GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, LANARK, SCOTLAND.							BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DREYFUS F, 1995, LEUKEMIA, V9, P203; FUNABIKI T, 1994, ONCOGENE, V9, P1575; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAMA T, 1995, BLOOD, V86, P841; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LEVY ER, 1994, BLOOD, V83, P1348; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUGI T, 1995, ONCOGENE, V11, P191; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERKINS AS, 1991, DEVELOPMENT, V111, P479; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	46	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					569	577		10.1038/sj.onc.1200864	http://dx.doi.org/10.1038/sj.onc.1200864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053855				2022-12-25	WOS:A1997WF52400008
J	Huang, DCS; Cory, S; Strasser, A				Huang, DCS; Cory, S; Strasser, A			Bcl-2, Bcl-x(L) and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death	ONCOGENE			English	Article						apoptosis; Bcl-2; Bcl-x(L); E1B19kD adenovirus protein; Fas/APO-1 (CD95); TNF	TUMOR-NECROSIS-FACTOR; ANTI-FAS ANTIBODY; TRANSGENIC MICE; CAENORHABDITIS-ELEGANS; PROTOONCOGENE BCL-2; NEGATIVE SELECTION; INDUCED APOPTOSIS; MULTIPLE FORMS; LYMPHOID-CELLS; T-CELLS	Apoptosis is the physiological process by which unwanted cells in an organism are killed. Bcl-2, a membrane-bound cytoplasmic protein, is an effective inhibitor of apoptotic cell death induced by many cytotoxic agents. Survival-promoting homologues of Bcl-2 include its close relative, Bcl-x(L) and the 19 kD protein encoded by the E1B gene of adenoviruses. Whether these proteins are functionally equivalent and whether they can antagonise all or only some pathways to apoptosis is unresolved. We have carried out a systematic comparison of Bcl-2, Bcl-x(L) and adenovirus E1B19kD activity, using several cell lines and a range of cytotoxic conditions. High levels of expression of each of these proteins inhibited apoptosis induced by growth factor deprivation or treatment with gamma-radiation, glucocorticoid and various cytotoxic drugs. In contrast, none of them could effectively counter apoptosis induced via the TNF receptor or Fas/APO-1 (CD95). Biochemical analysis revealed that all three proteins can associate with Bar and Bah, members of the Bcl-2 protein subfamily that can facilitate apoptosis. The results provide evidence that Bcl-2, Bcl-x(L), and adenovirus protein E1B19kD are indistinguishable in their ability to regulate the cell death effector machinery.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Huang, David C. S./C-7586-2013; Strasser, Andreas/C-7581-2013	Cory, Suzanne/0000-0002-6818-3451; Huang, David C. S./0000-0002-3101-4873; Strasser, Andreas/0000-0002-5020-4891				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gibson L, 1996, ONCOGENE, V13, P665; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEBRUN DP, 1993, AM J PATHOL, V142, P743; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REAP EA, 1995, J IMMUNOL, V154, P936; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7; STRASSER A, 1995, CELL GROWTH DIFFER, V6, P799; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	81	227	235	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					405	414		10.1038/sj.onc.1200848	http://dx.doi.org/10.1038/sj.onc.1200848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053837				2022-12-25	WOS:A1997WE36400003
J	Horrevoets, AJG; Pannekoek, H; Nesheim, ME				Horrevoets, AJG; Pannekoek, H; Nesheim, ME			A steady-state template model that describes the kinetics of fibrin-stimulated [Glu(1)]- and [Lys(78)]plasminogen activation by native tissue-type plasminogen activator and variants that lack either the finger or kringle-2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYS-PLASMINOGEN; CONFORMATION; FRAGMENT; BINDING	The kinetics of activation of both [Glu(1)]- and [Lys(78)]Plg(S741C-fIuorescein) by native (recombinant) tissue-type plasminogen activator and its deletion variants lacking either the finger or kringle-2 domain were measured by fluorescence within fully polymerized fibrin clots. The kinetics conform to the Michaelis-Menten equation at any fixed fibrin concentration so long as the plasminogen concentration is expressed as either the free or fibrin-bound, but not the total. The apparent k(cat) and K-m values both vary systematically with the concentration of fibrin. Competition kinetics disclosed an active site-dependent interaction between t-PA and [Glu(1)]Plg(S741C-fluorescein) in the presence, but not the absence, of fibrin. A steady-state template model having the rate equation upsilon/[A](o) = k(cat(app)).[PIg]/(K-m(app) + [Plg]) was derived and used to interpret the data. The model indicates that catalytic efficiency is determined by the stability of the ternary activator-fibrin-plasminogen complex rather than the binding of the activator or plasminogen to fibrin. This implies that efforts to improve the enzymatic properties of t-PA might be more fruitfully directed at enhancing the stability of the ternary complex rather than fibrin binding.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,NL-1105 AZ AMSTERDAM,NETHERLANDS	Queens University - Canada; University of Amsterdam; Academic Medical Center Amsterdam								BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEVRIES C, 1991, THROMB HAEMOSTASIS, V65, P280; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; HIGGINS DL, 1990, ANNU REV PHARMACOL, V30, P91; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HORREVOETS AJG, 1995, J BIOL CHEM, V270, P15770, DOI 10.1074/jbc.270.26.15770; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LOSCALZO J, 1988, J CLIN INVEST, V82, P1391, DOI 10.1172/JCI113743; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MULLERTZ S, 1984, BIOCHEM J, V223, P169; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1993, THROMB HAEMOSTASIS, V70, P80; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1985, BIOCHIM BIOPHYS ACTA, V870, P510; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395	25	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	1997	272	4					2183	2191						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD679	9036151				2022-12-25	WOS:A1997WD67900027
J	Goin, JC; Leiros, CP; Borda, E; SterinBorda, L				Goin, JC; Leiros, CP; Borda, E; SterinBorda, L			Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: Functional and pathological implications	FASEB JOURNAL			English	Article						chagasic cardiomyopathy; mAChRs; 24-mer peptide; heart contractility; cAMP; cGMP; immunoblot; ELISA assay	TRYPANOSOMA-CRUZI; ANTIBODIES; DISEASE; CONTRACTILITY; LOCALIZATION; CARDIOPATHY; SYSTEM; SERA	Circulating antibodies from human and murine chagasic sera are able to interact with myocardium-activating neurotransmitter receptors. Here we reported the presence of autoantibodies against the second extracellular loop of the human heart muscarinic acetylcholine receptors (mAChR) in patients with Chagas' disease by using a synthetic 24-mer peptide in immunoblotting and enzyme immunoassay. Affinity-purified antipeptide IgG from chagasic patients, similar to monoclonal antihuman M-2 mAChR, recognized bands with a molecular weight corresponding to the cardiac mAChR. The binding was inhibited by the peptide, assessing the specificity of the interaction. The antipeptide autoantibody also displayed an ''agonist-like'' activity modifying the intracellular events associated with mAChR activation, i.e., decreased contractility, increased cGMP, and decreased cAMP production. All of these effects on rat atria by chagasic antipeptide autoantibodies resemble the effects of the authentic agonist and those of the total polyclonal chagasic IgG, being selectively blunted by atropine and neutralized by the synthetic peptide corresponding in amino acid sequence to the second extracellular loop of the human M-2 mAChR. A clinical relevance of these findings is demonstrated by a strong association between the existence of circulating antipeptide antoantibodies in chagasic patients and the presence of dysautonomic symptoms, making these antoantibodies a proper early marker of heart autonomic dysfunction.	CONSEJO NACL INVEST CIENT & TECN, CTR ESTUDIOS FARMACOL & BOT, RA-1414 BUENOS AIRES, DF, ARGENTINA; UNIV BUENOS AIRES, SCH MED & DENT, DEPT PHARMACOL, BUENOS AIRES, DF, ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires								ACOSTA AM, 1985, CIRCULATION, V71, P1255, DOI 10.1161/01.CIR.71.6.1255; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; COSSIO PM, 1977, AM J PATHOL, V86, P533; COSSIO PM, 1974, CIRCULATION, V49, P13, DOI 10.1161/01.CIR.49.1.13; CUNNINGHAM DS, 1980, INFECT IMMUN, V30, P496; DEBRACCO MMD, 1984, CLIN EXP IMMUNOL, V55, P405; ECHAGUE AV, 1994, ACTA PHYSL PHARM LAT, V44, P100; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; FU M, 1994, J HISTOCHEM CYTOCHEM, V42, P337, DOI 10.1177/42.3.8308250; FU MLX, 1994, CLIN IMMUNOL IMMUNOP, V72, P15, DOI 10.1006/clin.1994.1101; GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7; GOIN JC, 1991, P SOC EXP BIOL MED, V197, P186, DOI 10.3181/00379727-197-43244; Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284; Goin Juan Carlos, 1994, Molecular Neuropharmacology, V3, P189; GORELIK G, 1992, J MOL CELL CARDIOL, V24, P9, DOI 10.1016/0022-2828(92)91155-X; IOSA D, 1990, J AUTONOM NERV SYST, V30, pS83, DOI 10.1016/0165-1838(90)90107-T; KOBERLE F, 1961, Bol Oficina Sanit Panam, V51, P404; Koberle F., 1974, CIBA F SYMP, P137; LIANGXIONG F, 1995, J MOL CELL CARDIOL, V27, P427; MIRKIN GA, 1994, CLIN IMMUNOL IMMUNOP, V73, P69, DOI 10.1006/clin.1994.1171; PASCUAL J, 1986, BIOCHEM PHARMACOL, V35, P3839, DOI 10.1016/0006-2952(86)90673-8; Sterin-Borda Leonor J., 1994, Acta Physiologica Pharmacologica et Therapeutica Latinoamericana, V44, P109; STERINBORDA L, 1981, ARCH INT PHARMACOD T, V250, P93; STERINBORDA L, 1995, BRIT J PHARMACOL, V115, P1525, DOI 10.1111/j.1476-5381.1995.tb16646.x; STERINBORDA L, 1976, CARDIOVASC RES, V10, P613, DOI 10.1093/cvr/10.6.613; STERINBORDA L, 1981, EUR J PHARMACOL, V69, P1, DOI 10.1016/0014-2999(81)90596-3; STERINBORDA L, 1990, FASEB J, V4, P1661, DOI 10.1096/fasebj.4.6.2156743; STERINBORDA L, 1986, INT J IMMUNOPHARMACO, V8, P581, DOI 10.1016/0192-0561(86)90029-9; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8; STORINO R, 1986, MIOCARDIOPATIA CHAGA, P121; SZARFMAN A, 1982, J EXP MED, V155, P1161, DOI 10.1084/jem.155.4.1161	32	66	68	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1997	11	1					77	83		10.1096/fasebj.11.1.9034169	http://dx.doi.org/10.1096/fasebj.11.1.9034169			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034169				2022-12-25	WOS:A1997WK14700011
J	Roy, K; Egan, MG; Sirlin, S; Sirotnak, FM				Roy, K; Egan, MG; Sirlin, S; Sirotnak, FM			Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell - Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENT INHIBITOR; CYTO-TOXICITY; CCRF-CEM; METHOTREXATE; RNA; INVITRO; TUMOR; POLYGLUTAMYLATION; NITROCELLULOSE; PURIFICATION	L1210 cell variants resistant to edatrexate (EDX) were isolated by selection in vivo during therapy with this folate analogue. Among the variants selected, seven (L1210/EDX-4 to -7 and L1210/EDX-12 to -14) were found to exhibit 2-23-fold lower levels of folylpolyglutamate synthetase (FPGS) activity compared with parental L1210 cells. Lower levels of FPGS activity in cell-free extract from these variants using EDX as substrate were characterized by the same relative decrease in value for V-max with no change in apparent K-m. The results of an analysis of FPGS activity in mixtures of variant and parental cell extract suggested that no endogenous inhibitors in the variant cells or stimulatory factors in parental cells accounted for the differences observed. Also, FPGS hom variant and parental cells showed no difference in thermostability. Decreases in a 60-61-kDa protein as shown by immunoblotting with anti-FPGS peptide antibody were found to occur commensurately with the decrease in FPGS activity in cell extract from the variants compared with parental cells. However, no evidence was obtained for a difference in turnover of FPGS protein during measurement of the decay of FPGS activity in cycloheximide-treated variant and parental cells. In addition, Northern blotting of poly(A)(+) RNA did not reveal any difference in the size or level of FPGS mRNA among these various cell types, Studies of in vitro translation of hybridization-selected FPGS mRNA from L1210 cells showed that both mitochondrial and cytosolic forms of FPGS were generated during the reaction. Moreover, FPGS mRNA from the variant cells was significantly less effective in mediating formation of the FPGS peptide product in a manner correlating with FPGS activity and protein found in the cytosol of the various cell types, These results suggest that FPGS gene expression in these variants is posttranscriptionally altered at the level of the cognate mRNA itself and that this alteration constitutively down-regulates the steady-state level of FPGS in these variants.	MEM SLOAN KETTERING CANC CTR, LAB MOL THERAPEUT, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA; CORNELL UNIV, GRAD SCH MED SCI, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA56517, CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R35CA056517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; FABRE I, 1984, CANCER RES, V44, P3190; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Harlow E, 1988, ANTIBODIES LABORATOR, P471; JACKMAN AL, 1991, CANCER RES, V51, P5579; KISLIUK RL, 1981, MOL CELL BIOCHEM, V39, P331, DOI 10.1007/BF00232583; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PIZZORNO G, 1995, CANCER RES, V55, P566; POSER RG, 1981, CANCER RES, V41, P4441; RHEE MS, 1993, CANCER RES, V53, P2227; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; ROY K, 1995, J BIOL CHEM, V270, P26918, DOI 10.1074/jbc.270.45.26918; Roy K., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P306; RUMBERGER BG, 1990, CANCER COMMUN, V2, P305; SAMUELS LL, 1986, CANCER RES, V46, P2230; SAMUELS LL, 1985, CANCER RES, V45, P1488; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SHANE B, 1989, VITAM HORM, V45, P263; SHEEHAN JC, 1965, J AM CHEM SOC, V87, P2492, DOI 10.1021/ja01089a034; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1987, NATL CANCER I MONOGR, V5, P127; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	39	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6903	6908		10.1074/jbc.272.11.6903	http://dx.doi.org/10.1074/jbc.272.11.6903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054377	hybrid			2022-12-25	WOS:A1997WN14700016
J	Fertala, A; AlaKokko, L; Wiaderkiewicz, R; Prockop, DJ				Fertala, A; AlaKokko, L; Wiaderkiewicz, R; Prockop, DJ			Collagen II containing a Cys substitution for Arg-alpha 1-519 - Homotrimeric monomers containing the mutation do not assemble into fibrils but alter the self-assembly of the normal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN GENE COL2A1; TRANSGENIC MICE; SPONDYLOEPIPHYSEAL DYSPLASIA; PRECOCIOUS OSTEOARTHRITIS; MILD CHONDRODYSPLASIA; GEL-ELECTROPHORESIS; TRIPLE-HELIX; N-PROTEINASE; CYSTEINE; CLEAVAGE	A recombinant system was used to prepare human type II procollagen containing the substitution of Cys for Arg at alpha 1-519 found in three unrelated families with early onset generalized osteoarthritis together with features of a mild chondrodysplasia probably best classified as spondyloepiphyseal dysplasia. In contrast to mutated procollagens containing Cys substitutions for obligatory Gly residues, the Cys substitution at alpha 1-519 did not generate any intramolecular disulfide bonds. The results were consistent with computer modeling experiments that demonstrated that the alpha carbon distances were shorter with Cys substitutions for obligatory Gly residues than with Cys substitutions in the Y position residues in repeating -G1S-X-Y- sequences of the collagen triple helix. The mutated collagen did not assemble into fibrils under conditions in which the normal monomers polymerized. However, the presence of the mutated monomer in mixtures with normal collagen II increased the lag time for fibril assembly and altered the morphology of the fibrils formed.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOL MED, DEPT BIOCHEM & MOL BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University								ALAKOKKO L, 1990, MATRIX, V10, P279, DOI 10.1016/S0934-8832(11)80182-4; ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BLEASEL JF, 1995, J RHEUMATOL, V22, P255; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Byers Peter H., 1993, P317; CHAN D, 1993, J BIOL CHEM, V268, P15238; CHAN D, 1995, J RHEUMATOL, V22, P37; CHEN JM, 1995, J BIOMOL STRUCT DYN, V12, P1129, DOI 10.1080/07391102.1995.10508804; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; EYRE DR, 1991, J CLIN INVEST, V87, P357, DOI 10.1172/JCI114994; EYRE DR, 1986, AM J HUM GENET, V39, P52; Fertala A, 1996, J BIOL CHEM, V271, P14864, DOI 10.1074/jbc.271.25.14864; FERTALA A, 1994, J BIOL CHEM, V269, P11584; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLDERBAUM D, 1996, IN PRESS MATRIX BIOL; Horton William A., 1993, P641; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; KUIVANIEMI H, 1996, IN PRESS HUM MUTAT; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; LIGHTFOOT SJ, 1994, J BIOL CHEM, V269, P30352; METSARANTA M, 1992, J CELL BIOL, V118, P203, DOI 10.1083/jcb.118.1.203; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PIHLAJANIEMI T, 1981, BIOCHEMISTRY-US, V20, P7409, DOI 10.1021/bi00529a014; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; SIERON AL, 1993, J BIOL CHEM, V268, P21232; SOKOLOV B P, 1989, Medical Science Research, V17, P911; SOKOLOV BP, 1987, BIOKHIMIYA, V53, P1828; STRAUSS WM, 1989, CURRENT PROTOCOLS MO, V1; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; TRYGGVASON K, 1980, BIOCHEMISTRY-US, V19, P1284, DOI 10.1021/bi00548a003; VANDENBERG P, 1991, P NATL ACAD SCI USA, V88, P7640, DOI 10.1073/pnas.88.17.7640; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILLIAMS CJ, 1995, HUM MOL GENET, V4, P309, DOI 10.1093/hmg/4.2.309; WILLIAMS CJ, 1993, HUM GENET, V92, P499, DOI 10.1007/BF00216458; WU JJ, 1992, J BIOL CHEM, V267, P23007	45	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6457	6464		10.1074/jbc.272.10.6457	http://dx.doi.org/10.1074/jbc.272.10.6457			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045670	hybrid			2022-12-25	WOS:A1997WM64700054
J	IslasTrejo, A; Land, M; Tcherepanova, I; Freedman, JH; Rubin, CS				IslasTrejo, A; Land, M; Tcherepanova, I; Freedman, JH; Rubin, CS			Structure and expression of the Caenorhabditis elegans protein kinase C2 gene - Origins and regulated expression of a family of Ca2+-activated protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; SIGNAL-TRANSDUCTION; PHORBOL ESTERS; RBL-2H3 CELLS; BETA-GENE; II-BETA; CLONING; ISOZYMES; SEQUENCE; SUBUNIT	The molecular and cellular basis for concerted Ca2+/lipid signaling in Caenorhabditis elegans was investigated, A unique gene (pkc-2) and cognate cDNAs that encode six Ca2+/diacylglycerol-stimulated PKC2 isoenzymes were characterized, PKC2 polypeptides (680-717 amino acid residues) share identical catalytic, Ca2+-binding, diacylglycerol-activation and pseudosubstrate domains, However, sequences of the N- and C-terminal regions of the kinases diverge, PKC2 diversity is partly due to differential activation of transcription by distinct promoters, Each promoter precedes an adjacent exon that encodes 5'-untranslated RNA, an initiator AUG codon and a unique open reading frame. PKC2 mRNAs also incorporate one of two 3'-terminal exons via alternative splicing. Cells that are capable of receiving and propagating signals carried by Ca2+/diacylglycerol were identified by assessing activities of pkc-2 gene promoters in transgenic C. elegans and visualizing the distribution of PKC2 polypeptides via immunofluorescence. Highly-selective expression of certain PKC2 isoforms was observed in distinct subsets of neurons, intestinal and muscle cells, A low level of PKC2 isoforms is observed in embryos, When L1 larvae hatch and interact with the external environment PKC2 content increases 10-fold. Although 77- and 78-kDa PKC2 isoforms are evident throughout post-embryonic development, an 81-kDa isoform appears to be adapted for function in L1 and L2 larvae.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,ATRAN LABS,DEPT MOL PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIDDK NIH HHS [DK07513, DK44957] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513, R01DK044957] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAIER G, 1993, J BIOL CHEM, V268, P4997; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CHEN KH, 1990, J BIOL CHEM, V265, P19961; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; FIRE A, 1991, DEVELOPMENT, V113, P503; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOUSE C, 1987, SCIENCE, V238, P1426; HU ED, 1990, J BIOL CHEM, V265, P5072; HUBBARD SR, 1991, SCIENCE, V254, P1776; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1988, J BIOL CHEM, V263, P6927; ORR JW, 1994, J BIOL CHEM, V269, P27715; OSADA S, 1990, J BIOL CHEM, V265, P22434; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO T, 1995, J MOL BIOL, V251, P477, DOI 10.1006/jmbi.1995.0449; SASSA T, 1992, BIOCHEM J, V282, P219, DOI 10.1042/bj2820219; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Sulston J., 1988, NEMATODE CAENORHABDI, P603; TABUSE Y, 1995, BIOCHEM J, V312, P69, DOI 10.1042/bj3120069; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; [No title captured]	69	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6629	6640		10.1074/jbc.272.10.6629	http://dx.doi.org/10.1074/jbc.272.10.6629			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045693	hybrid			2022-12-25	WOS:A1997WM64700077
J	Steinert, K; Wagner, V; KrothPancic, PG; BickelSandkotter, S				Steinert, K; Wagner, V; KrothPancic, PG; BickelSandkotter, S			Characterization and subunit structure of the ATP synthase of the halophilic archaeon Haloferax volcanii and organization of the ATP synthase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; ARCHAEBACTERIUM HALOBACTERIUM-SACCHAROVORUM; SULFOLOBUS-ACIDOCALDARIUS; NUCLEOTIDE-SEQUENCE; TRANSLOCATING ATPASE; ENTEROCOCCUS-HIRAE; ACIDOTHERMOPHILIC ARCHAEBACTERIUM; PROTEOLIPID SUBUNIT; CHROMAFFIN GRANULES; MOLECULAR-CLONING	The archaeal ATPase of the halophile Haloferax vol canii synthesizes ATP at the expense of a proton gradient, as shown by sensitivity to the uncoupler carboxyl cyanide p-trifluoromethoxyphenylhydrazone, to the ionophore nigericin, and to the proton channel-modifying reagent N,N'-dicyclohexylcarbodiimide. The conditions for an optimally active ATP synthase have been determined, We were able to purify the enzyme complex and to identify the larger subunits with antisera raised against synthetic peptides, To identify additional subunits of this enzyme complex, we cloned and sequenced a gene cluster encoding five hydrophilic subunits of the A(1) part of the proton-translocating archaeal ATP synthase, Initiation, termination, and ribosome-binding sequences as well as the result of a single transcript suggest that the ATPase genes are organized in an operon, The calculated molecular masses of the deduced gene products are 22.0 kDa (subunit D), 38.7 kDa (subunit C), 11.6 kDa (subunit E), 52.0 kDa (subunit B), and 64.5 kDa (subunit A), The described operon contains genes in the order D, C, E, B, and A; it contains no gene for the hydrophobic, so-called proteolipid (subunit c, the proton conducting subunit of the A(0) part), This subunit has been isolated and purified; its molecular mass as deduced by SDS-polyacrylamide gel electrophoresis is 9.7 kDa.	UNIV DUSSELDORF,INST BIOCHEM PFLANZEN,D-40225 DUSSELDORF,GERMANY	Heinrich Heine University Dusseldorf			Kroth, Peter G/A-9728-2008	Kroth, Peter G/0000-0003-4734-8955				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLINE SW, 1989, CAN J MICROBIOL, V35, P148, DOI 10.1139/m89-022; DANE M, 1992, Z NATURFORSCH C, V47, P835; DENDA K, 1990, J BIOL CHEM, V265, P21509; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; DENDA K, 1989, J BIOL CHEM, V264, P7119; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FOURY F, 1990, J BIOL CHEM, V265, P18554; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRAF R, 1994, J BIOL CHEM, V269, P3767; GUPTA R, 1983, SCIENCE, V221, P656, DOI 10.1126/science.221.4611.656; HERMANS J, 1988, PLANT MOL BIOL, V10, P323, DOI 10.1007/BF00029882; HEUKESHOVEN J, 1986, PHARM BIOTECH RE 034; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HOCHSTEIN LI, 1987, BIOCHEM BIOPH RES CO, V147, P295, DOI 10.1016/S0006-291X(87)80120-1; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KONISHI J, 1990, J BIOCHEM, V108, P554, DOI 10.1093/oxfordjournals.jbchem.a123241; KRISTJANSSON H, 1985, ARCH BIOCHEM BIOPHYS, V241, P590, DOI 10.1016/0003-9861(85)90584-3; LEICHT W, 1981, ANAL BIOCHEM, V114, P186, DOI 10.1016/0003-2697(81)90472-3; LUBBEN M, 1988, BIOL CHEM H-S, V369, P1259, DOI 10.1515/bchm3.1988.369.2.1259; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, J EXP BIOL, V172, P149; PANCIC PG, 1991, FEBS LETT, V280, P387, DOI 10.1016/0014-5793(91)80338-4; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEEL E, 1990, EUR J BIOCHEM, V187, P727, DOI 10.1111/j.1432-1033.1990.tb15360.x; SCHOBERT B, 1991, J BIOL CHEM, V266, P8008; STEINERT K, 1995, BBA-PROTEIN STRUCT M, V1249, P137, DOI 10.1016/0167-4838(95)00033-Q; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wilms R, 1996, J BIOL CHEM, V271, P18843, DOI 10.1074/jbc.271.31.18843; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4574	47	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6261	6269		10.1074/jbc.272.10.6261	http://dx.doi.org/10.1074/jbc.272.10.6261			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045643	hybrid			2022-12-25	WOS:A1997WM64700027
J	Behrooz, A; IsmailBeigi, F				Behrooz, A; IsmailBeigi, F			Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ERYTHROPOIETIN 3' ENHANCER; INDUCIBLE FACTOR-I; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; PROTEIN-BINDING; CLONE-9 CELLS; FOS GENE; SERUM; MOUSE	glut1 gene expression and glucose transport are stimulated in a variety of cells and tissues in response to hypoxia, glut1 is also up-regulated by inhibitors of oxidative phosphorylation (such as azide) in the presence of oxygen, Here, we test the hypothesis that hypoxia stimulates glut1 gene expression independent of its inhibitory effect on oxidative phosphorylation, We examined the effect of cobalt chloride, a known stimulator of genes responsive to reduced oxygen concentration per se, on GLUT1 expression under normoxic conditions and compared the results with the response to azide. Exposure of a rat liver cell line (Clone 9) to 250 mu M cobalt chloride increases GLUT1 mRNA content, which becomes evident at 2 h, reaches a maximal value of similar to 12-fold at 8 h, and remains elevated at similar to 8-fold at 24 h, GLUT1 mRNA was the only GLUT isoform expressed in control cells and in cells exposed to cobalt chloride or azide, The induction of GLUT1 mRNA by cobalt chloride is associated with a similar to 10-fold stimulation of cytochalasin B-inhibitable 3-O-methyl-D-glucose transport at 24 h, I, contrast to the rapid decrease in cell ATP levels and the stimulation of glucose transport in response to azide, cell ATP content and glucose transport remained unaltered during the initial l-h period of exposure to cobalt chloride. The effect of cobalt chloride on GLUT1 mRNA content is mimicked by Ni(II) or Mn(II) but not by Fe(II), Employing actinomycin D, we found no increase in the similar to 1.5-h half-life of GLUT1 mRNA in cobalt chloride-treated cells, suggesting that the effect of cobalt chloride on GLUT1 mRNA content is largely mediated at the transcriptional level; in contrast, GLUT1 mRNA half-life increased to 28 h in azide-treated cells, In transient transfections we found that similar to 6 kilobase pairs (kbp) of 5'-flanking region of the rat glut1 promoter confers both cobalt chloride- and azide-inducibility to a reporter gene. Deletion of similar to 2,500 base pairs (bp) from the 5' end of the similar to 6-kbp DNA fragment results in a reduction of the response to cobalt chloride and a complete loss of the response to azide, A 666-bp DNA segment located similar to 6.0 kbp upstream of the transcription start site was found to be necessary for the increase in reporter gene expression in response to azide, whereas a 480-bp segment located at approximately -3.5 kbp mediated the response to cobalt chloride, The 480-bp segment is highly homologous to the previously reported mouse glut1 enhancer and contains several potential regulatory elements, including a hypoxia-inducible element; an additional hypoxia-inducible element is present in the 666-bp segment, Our results suggest that glut1 gene expression is regulated in a dual fashion by hypoxia per se and in response to inhibition of oxidative phosphorylation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOL BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NIDDK NIH HHS [DK45945] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045945] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; BEHROOZ A, 1996, 10 INT C END JUN 12, P427; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; ELBRINK J, 1975, SCIENCE, V188, P1177, DOI 10.1126/science.1096301; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FISHER JW, 1992, CANCER-AM CANCER SOC, V70, P928; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IMAGAWA S, 1991, BLOOD, V77, P278; ISMAILBEIGI F, 1993, J MEMBRANE BIOL, V135, P1; KAHN SE, 1994, DIABETES, V43, P587, DOI 10.2337/diabetes.43.4.587; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MERCADO CL, 1989, AM J PHYSIOL, V257, pC19, DOI 10.1152/ajpcell.1989.257.1.C19; Mitani Y, 1996, AM J PHYSIOL-CELL PH, V270, pC235, DOI 10.1152/ajpcell.1996.270.1.C235; MORGAN HE, 1959, BIOCHEM J, V73, P573, DOI 10.1042/bj0730573; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SHETTY M, 1993, AM J PHYSIOL, V265, pC1224, DOI 10.1152/ajpcell.1993.265.5.C1224; Snedecor G W, 1976, STAT METHODS; STEIN I, 1995, MOL CELL BIOL, V15, P5363; TAN CC, 1991, AM J PHYSIOL, V261, pF982, DOI 10.1152/ajprenal.1991.261.6.F982; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	53	149	157	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5555	5562		10.1074/jbc.272.9.5555	http://dx.doi.org/10.1074/jbc.272.9.5555			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038162	hybrid			2022-12-25	WOS:A1997WK74700030
J	Chen, G; Duran, GE; Steger, KA; Lacayo, NJ; Jaffrezou, JP; Dumontet, C; Sikic, BI				Chen, G; Duran, GE; Steger, KA; Lacayo, NJ; Jaffrezou, JP; Dumontet, C; Sikic, BI			Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; DRUG-RESISTANCE; MDR1 GENE; TRANSMEMBRANE DOMAIN; TUMOR-CELLS; SDZ PSC-833; MES-SA; DOXORUBICIN; EXPRESSION; MUTATIONS	A variant of the multidrug-resistant human sarcoma cell line Dx5 was derived by co-selection with doxorubicin and the cyclosporin D analogue PSC 833, a potent inhibitor of the multidrug transporter P-glycoprotein, The variant DxP cells manifest an altered phenotype compared with Dx5, with decreased cross-resistance to Vinca alkaloids and no resistance to dactinomycin. Resistance to doxorubicin and paclitaxel is retained. The multidrug resistance phenotype of DxP cells is not modulated by 2 mu M PSC 833 or cyclosporine, DxP cells manifest a decreased ability to transport [H-3]cyclosporine. DNA heteroduplex analysis and sequencing reveal a mutant mdr1 gene (deletion of a phenylalanine at amino acid residue 335) in the DxP cell line. The mutant P-glycoprotein has a decreased affinity for PSC 833 and vinblastine and a decreased ability to transport rhodamine 123, Transfection of the mutant mdr1 gene into drug-sensitive MES-SA sarcoma cells confers resistance to both doxorubicin and PSC 833. Our study demonstrates that survival of cells exposed to doxorubicin and PSC 833 in a multistep selection occurred as a result of a P-glycoprotein mutation in transmembrane region 6. These data suggest that Phe(335) is an important binding site on P-glycoprotein for substrates such as dactinomycin and vinblastine and for inhibitors such as cyclosporine and PSC 833.	STANFORD UNIV,SCH MED,DEPT MED,DIV ONCOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MED,DIV CLIN PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University			Chen, Kevin G/D-6769-2011; Chen, Kevin/GYU-8963-2022	Chen, Kevin G/0000-0003-2983-6330; Dumontet, Charles/0000-0003-1875-134X	NATIONAL CANCER INSTITUTE [R01CA052168] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbaszadegan M. R., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P330; ARCECI RJ, 1993, BLOOD, V81, P2215; BAUM C, 1994, BIOTECHNIQUES, V17, P1058; BECK WT, 1990, CANCER TREAT REV, V17, P11, DOI 10.1016/0305-7372(90)90011-4; BEKETICORESKOVIC L, 1995, J NATL CANCER I, V87, P1593, DOI 10.1093/jnci/87.21.1593; BOESCH D, 1991, EXP CELL RES, V196, P26, DOI 10.1016/0014-4827(91)90452-Z; BOESCH D, 1991, CANCER RES, V51, P4226; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHEN G, 1994, CANCER RES, V54, P4980; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; FISHER GA, 1995, HEMATOL ONCOL CLIN N, V9, P363, DOI 10.1016/S0889-8588(18)30099-6; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, CANCER RES, V53, P747; Greenberger L M, 1994, Cancer Treat Res, V73, P69; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HARKER WG, 1985, CANCER RES, V45, P4091; HARKER WG, 1983, CANCER RES, V43, P4943; HOLZMAYER TA, 1992, J NATL CANCER I, V84, P1486, DOI 10.1093/jnci/84.19.1486; JAFFREZOU JP, 1995, BBA-MOL CELL RES, V1266, P1, DOI 10.1016/0167-4889(94)00219-5; KAJIJI S, 1994, BIOCHEMISTRY-US, V33, P5041, DOI 10.1021/bi00183a006; KASAHARA K, 1992, J NATL CANCER I, V84, P113, DOI 10.1093/jnci/84.2.113; LING V, 1992, CANCER-AM CANCER SOC, V69, P2603, DOI 10.1002/1097-0142(19920515)69:10<2603::AID-CNCR2820691034>3.0.CO;2-E; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOO TW, 1993, J BIOL CHEM, V268, P19965; MARIE JP, 1991, BLOOD, V78, P586; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SASAI K, 1994, INT J RADIAT ONCOL, V30, P1127, DOI 10.1016/0360-3016(94)90319-0; SCHEPER RJ, 1993, CANCER RES, V53, P1475; SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629; SONNEVELD P, 1990, BRIT J HAEMATOL, V75, P208, DOI 10.1111/j.1365-2141.1990.tb02650.x; TAMAI I, 1991, J BIOL CHEM, V266, P16796; YAHANDA AM, 1992, J CLIN ONCOL, V10, P1624, DOI 10.1200/JCO.1992.10.10.1624; ZAMAN GJR, 1993, CANCER RES, V53, P1747	38	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5974	5982		10.1074/jbc.272.9.5974	http://dx.doi.org/10.1074/jbc.272.9.5974			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038218	hybrid			2022-12-25	WOS:A1997WK74700086
J	Potter, D; Wojnar, JM; Narasimhan, C; Miziorko, HM				Potter, D; Wojnar, JM; Narasimhan, C; Miziorko, HM			Identification and functional characterization of an active-site lysine in mevalonate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PEROXISOMES; PROTEINS; NUCLEOTIDE; ACIDURIA; BINDING; IMPORT; SIGNAL	We report the construction of an expression plasmid for rat mevalonate kinase and the overexpression of recombinant enzyme in Escherichia coli, The homogeneous enzyme had a specific activity of 30 units/mg and an observed subunit molecular mass of 42 kDa. The Michaelis constants (K-m) for DL-potassium mevalonate (288 mu m) and for ATP (1.24 mM) were in agreement with values reported for enzymes isolated from rat liver (Tanaka, R. D., Schafer, B. L., Lee, L. Y., Freudenberger, J. S., and Mosley, S. T. (1990) J. Biol. Chem, 265, 2391-2398), Recombinant rat mevalonate kinase was inactivated by the lysine-specific reagent, pyridoxal phosphate (PLP), ATP (5 mM) afforded protection against inactivation, suggesting reaction of PLP with an active-site lysine, Mapping, isolation, and Edman degradation of the ATP-protectable peptide from [H-3]PLP-inactivated borohydride-reduced mevalonate kinase allow assignment of lysine 13, a residue invariant in known mevalonate kinase sequences, as the modification site, These results represent the first identification of an active-site residue in mevalonate kinase. The function of lysine 13 was evaluated by replacing this residue with methionine, V-m of the mutant protein is diminished by 56-fold, suggesting that lysine 13 facilitates catalysis, K-d values of wild-type and mutant proteins for ATP were determined in electron spin resonance competition experiments, The observed 56-fold diminution in affinity for the mutant enzyme supports an additional role for lysine 13 in stabilization of ATP binding.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin					NCRR NIH HHS [RR-01008] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEYTIA E, 1970, J BIOL CHEM, V245, P5450; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; DORSEY JK, 1979, J BIOL CHEM, V10, P931; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GRAEF E, 1994, ONCOGENE, V9, P81; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; KOTEICHE HA, 1995, BIOCHEMISTRY-US, V34, P15068, DOI 10.1021/bi00046a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1992, ENZFITTER VERSION 1; MILDVAN AS, 1965, J BIOL CHEM, V240, P238; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; PORTER JW, 1985, METHOD ENZYMOL, V110, P71; POTTER D, 1996, FASEB J, V10, pA1100; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Runquist JA, 1996, BIOCHEMISTRY-US, V35, P15049, DOI 10.1021/bi9619334; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; Schneider D. J., 1989, BIOL MAGN RESON, V8, P1; SOLER M, 1979, INT J BIOCHEM, V10, P931, DOI 10.1016/0020-711X(79)90126-5; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; STOCK A, 1966, BIOCHEM Z, V344, P353; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TCHEN TT, 1958, J BIOL CHEM, V233, P1100; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; Wanders RJA, 1996, J INHERIT METAB DIS, V19, P193, DOI 10.1007/BF01799427; [No title captured]	31	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5741	5746		10.1074/jbc.272.9.5741	http://dx.doi.org/10.1074/jbc.272.9.5741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038186	hybrid			2022-12-25	WOS:A1997WK74700054
J	Roy, K; Mitsugi, K; Sirotnak, FM				Roy, K; Mitsugi, K; Sirotnak, FM			Additional organizational features of the murine folylpolyglutamate synthetase gene - Two remotely situated exons encoding an alternate 5' end and proximal open reading frame under the control of a second promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; MULTIPLE TRANSCRIPTS; EXPRESSION; CELLS; MOUSE; PURIFICATION; SEQUENCES	Nucleotide sequence analysis of independently isolated clones from a mouse liver cDNA library identified two additional splice variants of folylpolyglutamate synthetase (FPGS) mRNA with novel sequence at the 5' end, These variants incorporate two new alternatives (exons Ala and Alb) of exon 1 in the murine FPGS gene which are also spliced to exon 2, Exon Ala encodes most of the 5'-untranslated region, Exon Alb encodes a downstream segment of the 5'-untranslated region, two ATG start codons, and a unique mitochondrial leader peptide as well as 15 additional amino acids of cytosolic FPGS not encoded by all previously identified (Roy, K,, Mitsugi, K,, and Sirotnak, F. M, (1996) J, Biol, Chem,, 271, 23820-23827) splice variants, It was also found by direct sequencing of genomic fragments that although exon Alb is spliced to exon 2, these new alternatives (i.e. exons Ala and Alb) to exon 1 are found approximately 9.5 kilobases upstream from exons Bla, Bib, and B1c, Exons Ala and Alb are separated from each other by a 124-nucleotide intron, Sequencing of the region 5' to exon Ala revealed a nucleotide sequence that was promoter-like and different from the downstream promoter region in the content of putative cis-acting elements, Primer extension analysis identified a number of potential transcription start sites within the more 3' end of this region, FPGS RNA transcripts incorporating exons Ala and Alb were detected in both normal mouse tissues, particularly, liver and kidney, and also to a varying extent in tumors; FPGS RNA transcripts incorporating exons Bla, Bib, and B1c were detected mainly in tumors, Thus, transcription of the FPGS gene in this tissue-specific manner appears to reflect the different usage of alternates to exon 1 under the control of different promoters, An unusual splice variant identified infrequently in a mouse liver cDNA library was 2.67 kilobases in size and incorporated exons Ala and Alb and a segment of the downstream promoter region along with exons B1c and B1b and exons 2-15.	MEM SLOAN KETTERING CANC CTR, LAB MOL THERAPEUT, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA; CORNELL UNIV, GRAD SCH MED SCI, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA08748, CA56417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BARREDO J, 1992, MOL PHARMACOL, V42, P687; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; EGAN MG, 1995, J BIOL CHEM, V270, P5462, DOI 10.1074/jbc.270.10.5462; FABRE I, 1984, CANCER RES, V44, P3190; FRASER P, 1989, MOL CELL BIOL, V9, P3308, DOI 10.1128/MCB.9.8.3308; Freemantle S. J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P384; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENDRICK SM, 1984, NATURE, V308, P149; KISLIUK RL, 1981, MOL CELL BIOCHEM, V39, P331, DOI 10.1007/BF00232583; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; ROY K, 1995, J BIOL CHEM, V270, P26918, DOI 10.1074/jbc.270.45.26918; SAMUELS LL, 1985, CANCER RES, V45, P1488; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANE B, 1989, VITAM HORM, V45, P263; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SIROTNAK FM, 1984, FOLATE ANTAGONISTS T, V2, P43; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; TAYLOR SM, 1995, CANCER RES, V55, P6030; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YAMASAKI T, 1991, GENE, V104, P277, DOI 10.1016/0378-1119(91)90262-A	35	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5587	5593		10.1074/jbc.272.9.5587	http://dx.doi.org/10.1074/jbc.272.9.5587			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038166	hybrid			2022-12-25	WOS:A1997WK74700034
J	Wada, J; Kanwar, YS				Wada, J; Kanwar, YS			Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GROWTH-FACTOR; MUSCLE LECTIN; PROTEIN; EXPRESSION; CLONING; LAMININ; FAMILY; GENE; IGE	A 36-kDa beta-galactoside mammalian lectin protein, designated as galectin-9, was isolated from mouse embryonic kidney by using a degenerate primer polymerase chain reaction and cloning strategy. Its deduced amino acid sequence had the characteristic conserved sequence motif of galectins. Endogenous galectin-9, extracted from liver and thymus, as well as recombinant galectin-9 exhibited specific binding activity for the lactosyl group. It had two distinct N- and C-terminal carbohydrate-binding domains connected by a link peptide, with no homology to any other protein. Galectin-9 had an alternate splicing isoform, exclusively expressed in the small intestine with a 31-amino acid insertion between the N-terminal domain and link peptide. Sequence homology analysis revealed that the C-terminal carbohydrate-binding domain of mouse galectin-9 had extensive similarity to that of monomeric rat galectin-5. The presence of galectin-5 in the mouse could not be demonstrated by polymerase chain reaction or by Northern or Southern blot genomic DNA analyses. Sequence comparison of rat galectin-5 and rat galectin-9 cDNA did not reveal identical nucleotide sequences in the overlapping C-terminal carbohydrate-binding domain, indicating that galectin-9 is not an alternative splicing isoform of galectin-5. However, galectin-9 had a sequence identical with that of its intestinal isoform in the overlapping regions in both species. Southern blot genomic DNA analyses, using the galectin-9 specific probe derived from the N-terminal carbohydrate-binding domain, indicated the presence of a novel gene encoding galectin-9 in both mice and rats. In contrast to galectin-5, which is mainly expressed in erythrocytes, galectin-9 was found to be widely distributed, i.e. in Liver, small intestine, thymus > kidney, spleen, lung cardiac and skeletal muscle > reticulocyte, brain. Collectively, these data indicate that galectin-9 is a new member of the galectin gene family and has a unique intestinal isoform.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA	Northwestern University			WADA, Jun/B-2023-2011	WADA, Jun/0000-0003-1468-5170	NIDDK NIH HHS [DK28492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028492, R01DK028492] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Borson N D, 1992, PCR Methods Appl, V2, P144; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHUI DHK, 1980, BRIT J HAEMATOL, V44, P431, DOI 10.1111/j.1365-2141.1980.tb05913.x; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; EKBLOM P, 1995, MOL CELLULAR ASPECTS, P359; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GU MJ, 1994, J CELL SCI, V107, P175; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; JUNG SK, 1994, J BIOCHEM-TOKYO, V116, P547, DOI 10.1093/oxfordjournals.jbchem.a124560; KANWAR YS, 1995, KIDNEY INT, V48, P1646, DOI 10.1038/ki.1995.460; KEREN DF, 1992, DIAGN IMMUNOL, P291; Kuwabara I, 1996, J IMMUNOL, V156, P3939; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU ZZ, 1993, KIDNEY INT, V44, P1242, DOI 10.1038/ki.1993.375; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; ODA Y, 1993, J BIOL CHEM, V268, P5929; POIRIER F, 1992, DEVELOPMENT, V115, P143; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; SATO S, 1992, J BIOL CHEM, V267, P6983; Saxen L., 1987, ORGANOGENESIS KIDNEY; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wada J, 1996, J CELL BIOL, V132, P1161, DOI 10.1083/jcb.132.6.1161; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683	50	272	300	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6078	6086		10.1074/jbc.272.9.6078	http://dx.doi.org/10.1074/jbc.272.9.6078			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038233	hybrid			2022-12-25	WOS:A1997WK74700101
J	Dittmer, J; PiseMasison, CA; Clemens, KE; Choi, KS; Brady, JN				Dittmer, J; PiseMasison, CA; Clemens, KE; Choi, KS; Brady, JN			Interaction of human T-cell lymphotropic virus type I Tax, Ets1, and Sp1 in transactivation of the PTHrP P2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; NF-KAPPA-B; RECEPTOR GENE-EXPRESSION; LONG TERMINAL REPEAT; TROPICAL SPASTIC PARAPARESIS; BOX-BINDING-PROTEINS; HTLV-I; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; NUCLEAR TRANSLOCATION	We have previously shown that the parathyroid hormone-related protein (PTHrP) promoter contains binding sites for transcription factors Ets1 and Spl and that human T-cell lymphotropic virus type I (HTLV I) Tax cooperates with Ets1 to transactivate the PTHrP P2 promoter. Using the yeast two-hybrid interaction system, we now provide evidence that Tax interacts with Ets1. Moreover, a double mutation (D22A,C23S) in the Tax protein that abrogated the Tax/Ets1 interaction also inhibited the Tax/Ets1 cooperative effect, suggesting that the interaction between Tax and Ets1 is important for transactivation of the PTHrP promoter. In coimmunoprecipitation assays, we find that Tax facilitates the interaction between Ets1 and Spl, forming a ternary complex. When the Spl site in the PTHrP promoter was mutated, the Tax/Ets1 cooperative effect was dramatically decreased. This suggests that Spl plays an important role in the Ets1-dependent Tax transactivation of the PTHrP P2 promoter, Finally, we demonstrate that Gal4-Tax is a strong activator of the Gal PTHrP promoter, implying that Tax contributes directly to the transcriptional activation of the promoter. We propose a model in which the Tax/Ets1 cooperative effect on the PTHrP P2 promoter is based on the ability of Tax, Ets1, and Sp1 to form a ternary complex on the template DNA, Tax facilitates the interaction of Ets1/Sp1 and participates directly in the transcription initiation process.	NCI,NIH,VIRUS TUMOR BIOL SECT,MOL VIROL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Dittmer, Juergen/G-1160-2011	Choi, Kyeong Sook/0000-0003-2331-0856				ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Akino K, 1996, CANCER RES, V56, P77; ALEXANDRE C, 1991, ONCOGENE, V6, P543; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BURTON PBJ, 1990, BIOCHEM BIOPH RES CO, V167, P1134, DOI 10.1016/0006-291X(90)90641-Y; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; EJIMA E, 1993, BLOOD, V81, P1017; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; Fuks F, 1996, J VIROL, V70, P1331, DOI 10.1128/JVI.70.3.1331-1339.1996; FUKUMOTO S, 1988, ARCH INTERN MED, V148, P921, DOI 10.1001/archinte.148.4.921; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GESSAIN A, 1985, LANCET, V2, P407; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAHN SL, 1994, ONCOGENE, V9, P2499; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; INOUE D, 1993, J BIOL CHEM, V268, P16730; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI X, 1993, CANCER RES, V53, P2980; LUPARELLO C, 1995, MOL CELL ENDOCRINOL, V111, P225, DOI 10.1016/0303-7207(95)03577-T; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MCKNIGHT RA, 1995, MOL ENDOCRINOL, V9, P717, DOI 10.1210/me.9.6.717; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MOTOKURA T, 1989, ANN INTERN MED, V111, P484, DOI 10.7326/0003-4819-111-6-484; MURATA Y, 1994, J BIOL CHEM, V269, P20674; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSAME M, 1986, LANCET, V1, P1031; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RABBANI SA, 1995, ENDOCRINOLOGY, V136, P5416, DOI 10.1210/en.136.12.5416; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; RODGERSJOHNSON P, 1985, LANCET, V2, P1247; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1995, ONCOGENE, V10, P1199; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUCHIYA H, 1994, ONCOGENE, V9, P337; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WAKE A, 1995, BLOOD, V86, P2257, DOI 10.1182/blood.V86.6.2257.bloodjournal8662257; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; Whitfield JF, 1996, J CELL PHYSIOL, V166, P1, DOI 10.1002/(SICI)1097-4652(199601)166:1<1::AID-JCP1>3.0.CO;2-T; YAMAGUCHI K, 1994, LEUKEMIA, V8, P1708; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	84	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4953	4958		10.1074/jbc.272.8.4953	http://dx.doi.org/10.1074/jbc.272.8.4953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030555	hybrid			2022-12-25	WOS:A1997WJ85500043
J	Manzella, SM; Dharmesh, SM; Cohick, CB; Soares, MJ; Baenziger, JU				Manzella, SM; Dharmesh, SM; Cohick, CB; Soares, MJ; Baenziger, JU			Developmental regulation of a pregnancy-specific oligosaccharide structure, NeuAc alpha 2,6GalNAc beta 1,4GlcNAc, on select members of the rat placental prolactin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGALACTOSAMINE-TRANSFERASE; PITUITARY GLYCOPROTEIN HORMONES; CIRCULATORY HALF-LIFE; SIALYLATED OLIGOSACCHARIDES; BOVINE PROOPIOMELANOCORTIN; SULFATED OLIGOSACCHARIDES; CELL-DIFFERENTIATION; GALNAC-TRANSFERASE; PROTEIN-C	Successful pregnancy is dependent upon an array of signaling proteins secreted by the trophoblast cells of the placenta, Among these is a group of proteins related to pituitary prolactin, known as the prolactin/growth hormone family, These proteins are expressed at specific times during gestation and synthesized in distinct trophoblast cell types in the rat placenta, We report here that select members of this family, prolactin-like protein (PLP-A), PLP-B, PLP-C, decidual/trophoblast PRP, and placental lactogen I variant, only which are expressed in the spongiotrophoblast, late in rat placental development bear Asn-linked oligosaccharides terminating with NeuAc alpha 2,6GalNAc beta 1,4GlcNAc beta-R. This reflects the concurrent expression of these prolactin/growth hormone family members with the peptide specific beta 1,4GalNAc-transferase and an alpha 2,6-sialyltransferase, which can add sialic acid to terminal beta 1,4-linked GalNAc, We have determined that at least one of the prolactin like proteins, PLP-A, is recognized by the protein specific GalNAc-transferase. The presence of NeuAc alpha 2,6GalNAc beta 1,4GlcNAc beta-R on only a limited number of glycoproteins synthesized by the spongiotrophoblasts between mid gestation and birth reflects the need for both the GalNAc-transferase and the peptide recognition determinant for efficient addition of GalNAc. Thus, expression of the GalNAc-transferase and specific members of the prolactin/growth hormone family is developmentally regulated in the rat placenta, suggesting a physiological role for the terminal NeuAc alpha 2,6GalNAc beta 1,4GlcNAc beta-R sequence on Asn-linked oligosaccharides of these proteins.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; UNIV KANSAS,MED CTR,DEPT PHYSIOL,KANSAS CITY,KS 66103	Washington University (WUSTL); University of Kansas; University of Kansas Medical Center			Baenziger, Jacques U/E-9430-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020676] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD29797, R01-HD20676] Funding Source: Medline; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; COHICK CB, 1997, IN PRESS J ENDOCRINO; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROWLEY WF, 1985, EPISODIC SECRETION H, P121; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DEB S, 1991, ENDOCRINOLOGY, V128, P3066, DOI 10.1210/endo-128-6-3066; DEB S, 1991, J BIOL CHEM, V266, P1605; DEB S, 1993, J BIOL CHEM, V268, P3298; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; EVANS WS, 1992, ENDOCR REV, V13, P81, DOI 10.1210/er.13.1.81; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895, DOI 10.1210/endo-129-6-2895; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GU Y, 1994, ENDOCRINOLOGY, V135, P1422, DOI 10.1210/en.135.4.1422; HAMLIN GP, 1994, ENDOCRINOLOGY, V134, P2390, DOI 10.1210/en.134.6.2390; HOOPER LV, 1993, ANAL BIOCHEM, V212, P128, DOI 10.1006/abio.1993.1301; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; JUNKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; NAKATA N, 1993, BIOCHEMISTRY-US, V32, P4369, DOI 10.1021/bi00067a029; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; OKAMOTO N, 1991, AM J REPROD IMMUNOL, V26, P137, DOI 10.1111/j.1600-0897.1991.tb00713.x; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Rasmussen CA, 1996, ENDOCRINOLOGY, V137, P5558, DOI 10.1210/en.137.12.5558; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; Soares MJ, 1996, PLACENTA, V17, P277, DOI 10.1016/S0143-4004(96)90051-X; SOUTHARD JN, 1991, MOL CELL ENDOCRINOL, V79, pC133, DOI 10.1016/0303-7207(91)90084-6; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; SZKUDLINSKI MW, 1995, ENDOCRINOLOGY, V136, P3325, DOI 10.1210/en.136.8.3325; TOMIYA N, 1993, J BIOL CHEM, V268, P113; VELDHUIS JD, 1987, P NATL ACAD SCI USA, V84, P7686, DOI 10.1073/pnas.84.21.7686; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	54	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4775	4782		10.1074/jbc.272.8.4775	http://dx.doi.org/10.1074/jbc.272.8.4775			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030532	hybrid			2022-12-25	WOS:A1997WJ85500020
J	Muthukumaran, G; Kotenko, S; Donnelly, R; Ihle, JN; Pestka, S				Muthukumaran, G; Kotenko, S; Donnelly, R; Ihle, JN; Pestka, S			Chimeric erythropoietin-interferon gamma receptors reveal differences in functional architecture of intracellular domains for signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; EXTRACELLULAR DOMAIN; ACCESSORY FACTOR; CRYSTAL-STRUCTURE; GROWTH-HORMONE; HUMAN-CELLS; EXPRESSION; ACTIVATION; CLONING; COMPLEX	Binding of interferon gamma (IFN-gamma) causes oligomerization of the two interferon gamma receptor (IFN-gamma) subunits, receptor chain 1 (IFN-gamma R1, the ligand-binding chain) and the second chain of the receptor (IFN-gamma R2), and causes activation of two Jak kinases (Jak1 and Jak2). In contrast, the erythropoietin receptor (EpoR) requires only one receptor chain and one Jak kinase (Jak2). Chimeras between the EpoR and the IFN-gamma R1 and IFN-gamma R2 chains demonstrate that the architecture of the EpoR and the IFN-gamma R complexes differ significantly. Although IFN-gamma R1 alone cannot initiate signal transduction, the chimera EpoR/gamma R1 (extracellular/intracellular) generates slight responses characteristic of IFN-gamma in response to Epo and the EpoR/gamma R1 . EpoR/gamma R2 heterodimer is a fully functional receptor complex. The results demonstrate that the configuration of the extra cellular domains influences the architecture of the intracellular domains.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital	Muthukumaran, G (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MOL GENET & MICROBIOL, PISCATAWAY, NJ 08854 USA.				NCI NIH HHS [R01 CA46465, R01 CA52363] Funding Source: Medline; NIAID NIH HHS [R01 AI36450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465, R01CA052363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BACK EA, 1995, SCIENCE, V269, P1215; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRISCOE J, 1995, J INTERFERON CYTOKIN, V15, pS56; COFANO F, 1990, J BIOL CHEM, V265, P4064; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JONES SS, 1990, BLOOD, V76, P31; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; Muthukumaran G, 1996, J INTERF CYTOK RES, V16, P1039, DOI 10.1089/jir.1996.16.1039; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; POLLACK BP, 1996, EUR CYTOKINE NETW, V7, P478; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SKRENTA H, 1996, EUR CYTOKINE NETW, V7, P622; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657	57	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4993	4999		10.1074/jbc.272.8.4993	http://dx.doi.org/10.1074/jbc.272.8.4993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030561	hybrid			2022-12-25	WOS:A1997WJ85500049
J	Villafuerte, BC; Zhao, WD; Herington, AC; Saffery, R; Phillips, LS				Villafuerte, BC; Zhao, WD; Herington, AC; Saffery, R; Phillips, LS			Identification of an insulin-responsive element in the rat insulin-like growth factor-binding protein-3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-3; IGF-I; TRANSCRIPTION FACTORS; PROMOTER; CELLS; EXPRESSION; COMPLEX; SEQUENCE; SERUM; LIVER	The hepatic expression and serum levels of insulinlike growth factor-binding protein-3 (IGFBP-3) are decreased in insulin-dependent and insulin-resistant diabetes. Insulin increases hepatic IGFBP-3 expression by enhancing gene transcription. This report identifies sequences within the IGFBP-3 promoter that are necessary and sufficient for the response to insulin in hepatic nonparenchymal cells. By transient transfection, we mapped the insulin response element to the -1150 to -1124 base pair (bp) region of the rat IGFBP-3 promoter. Three tandem repeats of the -1150 to -1117 bp region conferred insulin responses in a heterologous promoter. Gel shift analyses revealed a 3-fold increase in DNA-protein complex formation with nuclear extracts obtained from insulin-stimulated nonparenchymal cells compared with cells incubated without insulin and revealed 3-4-fold decrease in complex formation with nuclear extracts obtained from the livers of streptozotocin-diabetic rats compared with control rats. Mutational analysis of this 34-bp region showed a core sequence of 10 bp (-1148 to -1139) that is critical for interaction with insulin-induced trans-acting factors. Southwestern blotting revealed a similar to 90-kDa protein that was increased 23-fold by the addition of insulin. Thus, we have identified cis-acting DNA sequences that are responsible for regulation of IGFBP-3 transcription by insulin and essential for binding of insulin-responsive nuclear factors.	QUEENSLAND UNIV TECHNOL,SCH LIFE SCI,BRISBANE,QLD 4001,AUSTRALIA; ROYAL CHILDRENS HOSP,MURDOCH INST,MELBOURNE,VIC 3052,AUSTRALIA	Queensland University of Technology (QUT); Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Villafuerte, BC (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,1639 PIERCE DR,1301 WMRB,W WING,ATLANTA,GA 30322, USA.		Saffery, Richard/GLS-1976-2022	Saffery, Richard/0000-0002-9510-4181; Herington, Adrian/0000-0002-7736-887X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048124, R01DK033475, K08DK002215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33475, DK-48124, DK-02215] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBISTON AL, 1995, ENDOCRINOLOGY, V136, P696, DOI 10.1210/en.136.2.696; ALBISTON AL, 1992, ENDOCRINOLOGY, V130, P497, DOI 10.1210/en.130.1.497; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BINOUX M, 1984, J CLIN ENDOCR METAB, V59, P453, DOI 10.1210/jcem-59-3-453; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; COVERLEY JA, 1995, ENDOCRINOLOGY, V136, P5778, DOI 10.1210/en.136.12.5778; DAUGHADA.WH, 1966, J LAB CLIN MED, V68, P357; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EHRENBORG E, 1992, GENOMICS, V12, P497, DOI 10.1016/0888-7543(92)90440-4; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRIMES RW, 1994, ENDOCRINOLOGY, V134, P337, DOI 10.1210/en.134.1.337; HOECK WG, 1994, J CELL BIOCHEM, V56, P262, DOI 10.1002/jcb.240560220; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOB KK, 1994, J BIOL CHEM, V269, P25515; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; LASSARRE C, 1994, GROWTH REGULAT, V4, P48; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OH Y, 1992, ENDOCRINOLOGY, V131, P3123, DOI 10.1210/en.131.6.3123; PAN L, 1995, ARCH BIOCHEM BIOPHYS, V316, P886, DOI 10.1006/abbi.1995.1119; PAO CI, 1995, J BIOL CHEM, V270, P24917, DOI 10.1074/jbc.270.42.24917; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; ROBERTSON DG, 1994, BIOCHEM BIOPH RES CO, V200, P226, DOI 10.1006/bbrc.1994.1438; ROMANUS JA, 1986, ENDOCRINOLOGY, V118, P1743, DOI 10.1210/endo-118-5-1743; SHIMASAKI S, 1990, J BIOL CHEM, V265, P2198; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SUH DS, 1994, MOL ENDOCRINOL, V8, P794, DOI 10.1210/me.8.6.794; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622; VILLAFUERTE BC, 1995, ENDOCRINOLOGY, V136, P1928, DOI 10.1210/en.136.5.1928; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; YOUNG CL, 1995, ENDOCRINOLOGY, V136, P668	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5024	5030		10.1074/jbc.272.8.5024	http://dx.doi.org/10.1074/jbc.272.8.5024			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030565	hybrid			2022-12-25	WOS:A1997WJ85500053
J	Trecca, D; Guerrini, L; Fracchiolla, NS; Pomati, M; Baldini, L; Maiolo, AT; Neri, A				Trecca, D; Guerrini, L; Fracchiolla, NS; Pomati, M; Baldini, L; Maiolo, AT; Neri, A			Identification of a tumor-associated mutant form of the NF-kappa B RelA gene with reduced DNA-binding and transactivating activities	ONCOGENE			English	Article						NF-kappa B; RelA; transcriptional activity; lymphoid malignancies	P65 SUBUNIT; TRANSCRIPTION FACTOR; LYMPHOID MALIGNANCIES; ANTISENSE INHIBITION; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; C-REL; ACTIVATION; EXPRESSION; PROTEINS	Alterations of NF-kappa B family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus amplification, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this specific mutation (called RelA(494D)) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower affinity for kappa B binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Ga14-RelA(494D) fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of ReLA. Furthermore, in vitro translated RelA(494D) is able to dimerize efficiently with other NF-kappa B members, such as p50, cREL and I kappa B alpha. Our data therefore suggest that this mutation may alter the specific structural conformation needed for the DNA interaction of RelA, and provide insights into the amino acid sequences involved in mediating the biological activities of RelA.	UNIV MILAN,OSPED MAGGIORE,SERV EMATOL,IST SCI MED,IRCCS,LAB EMATOL SPERIMENTALE & GENET MOL,I-20122 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan			Neri, Antonino/I-9690-2014; Fracchiolla, Nicola Stefano/K-1915-2015	Neri, Antonino/0000-0001-9047-5912; Fracchiolla, Nicola Stefano/0000-0002-5356-8690; Critelli, Salvatore/0000-0001-7325-0228; Baldini, Luca/0000-0003-2964-9981; Fracchiolla, Nicola/0000-0002-8982-8079				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHANG CC, 1994, ONCOGENE, V9, P923; DELOUKAS P, 1993, HUM MOL GENET, V2, P1895, DOI 10.1093/hmg/2.11.1895; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GRECO A, 1992, ONCOGENE, V7, P237; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1994, ONCOGENE, V9, P2391; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Houldsworth J, 1996, BLOOD, V87, P25; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LAI JL, 1995, BLOOD, V85, P2490, DOI 10.1182/blood.V85.9.2490.bloodjournal8592490; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; LU D, 1991, ONCOGENE, V6, P1235; MATHEW S, 1993, ONCOGENE, V8, P191; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERI A, 1993, BLOOD, V81, P128; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOKOLOSKI JA, 1993, BLOOD, V82, P625; VANDENBERGHE H, 1979, CANCER, V44, P179; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	45	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					791	799		10.1038/sj.onc.1200895	http://dx.doi.org/10.1038/sj.onc.1200895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047386				2022-12-25	WOS:A1997WJ11200005
J	LeGall, AH; Powell, SK; Yeaman, CA; RodriguezBoulan, E				LeGall, AH; Powell, SK; Yeaman, CA; RodriguezBoulan, E			The neural cell adhesion molecule expresses a tyrosine-independent basolateral sorting signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; RETINAL-PIGMENT EPITHELIUM; LYSOSOMAL ACID-PHOSPHATASE; CANINE KIDNEY-CELLS; DI-LEUCINE MOTIF; N-CAM; MDCK CELLS; CYTOPLASMIC DOMAIN; INTERNALIZATION SIGNAL; TRANSFERRIN RECEPTOR	Transmembrane isoforms of the neural cell adhesion molecule, N-CAM (N-CAM-140 and N-CAM-180), are vectorially targeted from the trans-Golgi network to the basolateral domain upon expression in transfected Madin-Darby canine kidney cells (Powell, S. K., Cunningham, B. A. Edelman, G. M., and Rodriguez-Boulan, E. (1991) Nature 353, 76-77), To localize basolateral targeting information, mutant forms of N-CAM-140 were constructed and their surface distribution analyzed in Madin-Darby canine kidney cells. N-CAM-140 deleted of its cytoplasmic domain shows a non-polar steady state distribution, resulting from delivery from the trans-Golgi network to both the apical and basolateral surfaces. This result suggests that entrance into the basolateral pathway may occur without cytoplasmic signals, implying that apical targeting from the trans-Golgi network is not a default mechanism but, rather, requires positive sorting information. Subsequent construction and analysis of a nested set of C-terminal deletion mutants identified a region of 40 amino acids (amino acids 749-788) lacking tyrosine residues required for basolateral targeting. Addition of these 40 amino acids is sufficient to restore basolateral targeting to both the non-polar cytoplasmic deletion mutant of N-CAM as well as to the apically expressed cytoplasmic deletion mutant of the p75 low affinity neurotrophin receptor (p75(NTR)), indicating that this tyrosine-fi ee sequence is capable of functioning independently as a basolateral sorting signal. Deletion of both cytoplasmic and transmembrane domains resulted in apical secretion of N-CAM, demonstrating that the ectodomain of this molecule carries recessive apical sorting information.	CORNELL UNIV,COLL MED,DYSON VIS RES INST,DEPT OPHTHALMOL,NEW YORK,NY 10021; NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892	Cornell University; Dyson; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Yeaman, Charles A/A-1624-2009	Yeaman, Charles/0000-0001-6149-628X	NEI NIH HHS [R01 EY008538, EY08538-02] Funding Source: Medline; NIGMS NIH HHS [GM34107-11, R01 GM034107, GM41771-05] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041771, R01GM034107] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOK D, 1992, EXP EYE RES, V55, P853, DOI 10.1016/0014-4835(92)90011-G; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHUONG CM, 1985, J CELL BIOL, V101, P1009, DOI 10.1083/jcb.101.3.1009; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COVAULT J, 1986, J CELL BIOL, V102, P731, DOI 10.1083/jcb.102.3.731; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KUNDU A, 1994, J VIROL, V68, P1812, DOI 10.1128/JVI.68.3.1812-1818.1994; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LEGALL AH, 1995, SEMIN NEPHROL, V15, P272; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MURRAY BA, 1986, J CELL BIOL, V103, P1431, DOI 10.1083/jcb.103.4.1431; MUSTO NA, 1993, EXP CELL RES, V209, P271, DOI 10.1006/excr.1993.1311; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NAIM HY, 1995, J CELL BIOL, V129, P1241, DOI 10.1083/jcb.129.5.1241; OGATA S, 1994, J BIOL CHEM, V269, P5210; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PENG I, 1990, DEV BIOL, V141, P164, DOI 10.1016/0012-1606(90)90111-U; PERSOHN E, 1990, J NEUROCYTOL, V19, P807, DOI 10.1007/BF01186812; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RIEGER F, 1985, J CELL BIOL, V101, P285, DOI 10.1083/jcb.101.1.285; RIEGER F, 1988, J CELL BIOL, V107, P707, DOI 10.1083/jcb.107.2.707; RINDLER MJ, 1988, J CELL BIOL, V107, P471, DOI 10.1083/jcb.107.2.471; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; THIERY JP, 1977, J BIOL CHEM, V252, P6841; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WILDE A, 1994, J BIOL CHEM, V269, P7131	65	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4559	4567		10.1074/jbc.272.7.4559	http://dx.doi.org/10.1074/jbc.272.7.4559			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020183	hybrid			2022-12-25	WOS:A1997WH01900099
J	Song, QS; Gilbert, LI				Song, QS; Gilbert, LI			Molecular cloning, developmental expression, and phosphorylation of ribosomal protein SE in the endocrine gland responsible for insect molting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 PHOSPHORYLATION; MANDUCA-SEXTA; PROTHORACIC GLANDS; ECDYSTEROID BIOSYNTHESIS; MESSENGER-RNA; CLONED CDNA; KINASE; STIMULATION; SITES; STEROIDOGENESIS	Phosphorylation of ribosomal protein S6 is requisite for prothoracicotropic hormone (PTTH)-stimulated specific protein synthesis and subsequent ecdysteroidogenesis in the prothoracic glands of the tobacco hornworm, Manduca sexta, To better understand the role of S6 in regulating ecdysteroidogenesis, S6 cDNA was isolated from a Manduca prothoracic gland cDNA library and sequenced. The deduced protein is comprised of 253 amino acids, has a molecular weight of 29,038, and contains four copies of a 10-amino acid motif defining potential DNA-binding sites. This Manduca S6 possesses a consensus recognition sequence for the p70(s6k) binding domain as well as six seryl residues at the carboxyl-terminal sequence of 17 amino acids. Phosphoamino acid analysis revealed that the phosphorylation of Manduca prothoracic gland S6 is limited exclusively to serine residues, Although alterations in the quantity of S6 mRNA throughout the last larval instar and early pupal-adult development were not well correlated with the hemolymph ecdysteroid titer, developmental expression and phosphorylation of S6 were temporally correlated with PTTH release and the hemolymph ecdysteroid titer. These data provide additional evidence that S6 phosphorylation is a critical element in the transduction pathway leading to PTTH-stimulated ecdysteroidogenesis.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIDDK NIH HHS [DK-30118] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030118, R01DK030118] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANDI HR, 1993, J BIOL CHEM, V268, P4530; BOLLENBACHER WE, 1975, DEV BIOL, V44, P46, DOI 10.1016/0012-1606(75)90375-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKHARD SJ, 1983, J BIOL CHEM, V258, P4003; CHAN YL, 1988, J BIOL CHEM, V263, P2891; FERRARI S, 1991, J BIOL CHEM, V266, P2270; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; Gilbert L. I., 1996, METAMORPHOSIS POSTEM, P60; GILBERT LI, 1988, BIOESSAYS, V8, P153, DOI 10.1002/bies.950080506; GRIENEISEN ML, 1993, INSECT BIOCHEM MOLEC, V23, P13, DOI 10.1016/0965-1748(93)90077-6; HEINZE H, 1988, J BIOL CHEM, V263, P4139; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; Jowett T., 1986, DROSOPHILA, P275; KEIGHTLEY DA, 1990, MOL CELL ENDOCRINOL, V74, P229, DOI 10.1016/0303-7207(90)90228-Z; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAWEN A, 1989, EUR J BIOCHEM, V183, P245, DOI 10.1111/j.1432-1033.1989.tb14920.x; LEER RJ, 1992, NUCLEIC ACIDS RES, V10, P5869; LOTT JB, 1988, GENE, V65, P31, DOI 10.1016/0378-1119(88)90414-3; NIELSEN PJ, 1981, EUR J BIOCHEM, V120, P523, DOI 10.1111/j.1432-1033.1981.tb05731.x; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RYBCZYNSKI R, 1995, MOL CELL ENDOCRINOL, V115, P73, DOI 10.1016/0303-7207(95)03672-T; RYBCZYNSKI R, 1994, INSECT BIOCHEM MOLEC, V24, P175, DOI 10.1016/0965-1748(94)90084-1; SMITH WA, PROGR INSECT NEUROCH, P319; SMITH WA, 1989, J EXP ZOOL, V252, P262; SONG QS, 1995, INSECT BIOCHEM MOLEC, V25, P591, DOI 10.1016/0965-1748(94)00100-V; SONG QS, 1994, DEV GENET, V15, P332, DOI 10.1002/dvg.1020150404; Song QS, 1996, ARCH INSECT BIOCHEM, V31, P465, DOI 10.1002/(SICI)1520-6327(1996)31:4&lt;465::AID-ARCH8&gt;3.0.CO;2-U; SPENCER TA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P332, DOI 10.1016/0167-4781(93)90225-3; STEWART MJ, 1993, MOL BIOL EVOL, V10, P1041; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARREN JT, 1986, INSECT BIOCHEM, V16, P65, DOI 10.1016/0020-1790(86)90080-6; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WHITEHOUSE BJ, 1992, J ENDOCRINOL, V134, P1, DOI 10.1677/joe.0.1340001	42	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4429	4435		10.1074/jbc.272.7.4429	http://dx.doi.org/10.1074/jbc.272.7.4429			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020166	hybrid			2022-12-25	WOS:A1997WH01900082
J	Koreth, J; Bakkenist, CJ; McGee, JO				Koreth, J; Bakkenist, CJ; McGee, JO			Allelic deletions at chromosome 11q22-q23.1 and 11q25-qterm are frequent in sporadic breast but not colorectal cancers	ONCOGENE			English	Article						LOH; breast; colorectal; cancer; microsatellites; chromosome 11q	ATAXIA-TELANGIECTASIA; GENETIC ALTERATIONS; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; OVARIAN-CANCER; LONG ARM; HETEROZYGOSITY; TUMORS; REGION; 11Q23	We identified the chromosome 11q23 region as containing a putative tumour suppressor gene(s) frequently deleted in nonfamilial breast and other cancers. To define this region(s) further, we performed a systematic genetic analysis at chromosome 11q14-qterm in sporadic breast and colorectal cancer, Tumour and constitutional DNA from a panel of 81 cases (51 breast and 30 colorectal cancers) were analysed with multiple microsatellite markers distal to 11q13. Of 51 breast cancers, 31 of 49 informative cases (63%) showed LOH at the 11q22-q23.1 region (similar to 8 Mb). Furthermore, 23 of 45 informative cases (51%) had a deletion at 11q25 (similar to 2 Mb), Overall, LOH on 11q occurred in 37 of 51 breast cancers (72%). Colorectal cancers had LOH at 11q22 in two of 18 informative cases (11%), LOH at 11q23.3 in two of 17 informative cases (12%) and LOH at 11q25 in three of 20 informative cases (15%). Overall, LOH at 11q occurred in five of 30 colorectal cancers (16%), This data shows that chromosome 11q contains at least two independent regions (one novel) frequently deleted in breast cancers. Contrary to previous reports, LOH at distal 11q is not frequent in colorectal cancer. Chromosome 11q22-q23.1 and 11q25-qterm contain putative tumour suppressor genes with a significant role in breast but not colorectal carcinogenesis.	UNIV OXFORD, NUFFIELD DEPT PATHOL & BACTERIOL, JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND	University of Oxford								Baffa R, 1996, CANCER RES, V56, P268; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARTER SL, 1994, CANCER RES, V54, P6270; CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; Coleman A., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P196; Davis M, 1996, CANCER RES, V56, P741; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; LASKEY RA, 1990, RADIOISOTOPES BIOL P, P87; LITT M, 1995, GENOMICS, V27, P101, DOI 10.1006/geno.1995.1011; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; PARSHAD R, 1992, HUM GENET, V88, P524, DOI 10.1007/BF00219338; RASIO D, 1995, CANCER RES, V55, P3988; SATO T, 1990, CANCER RES, V50, P7184; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; STICKLAND JE, 1992, BR J CANCER S17, V66, P3; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Tomlinson IPM, 1996, J CLIN PATHOL, V49, P386, DOI 10.1136/jcp.49.5.386; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; WINQVIST R, 1995, CANCER RES, V55, P2660	36	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					431	437		10.1038/sj.onc.1200847	http://dx.doi.org/10.1038/sj.onc.1200847			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053840				2022-12-25	WOS:A1997WE36400006
J	IidaKlein, A; Guo, J; Takemura, M; Drakes, MT; Potts, JT; AbouSamra, A; Bringhurst, FR; Segre, GV				IidaKlein, A; Guo, J; Takemura, M; Drakes, MT; Potts, JT; AbouSamra, A; Bringhurst, FR; Segre, GV			Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; GLUCAGON-LIKE PEPTIDE-1; SITE-DIRECTED MUTAGENESIS; 2 SIGNALING PATHWAYS; EXPRESSION CLONING; FUNCTIONAL EXPRESSION; CALCITONIN RECEPTOR; ADENYLYL-CYCLASE; BETA-GAMMA; ADENOSINE-MONOPHOSPHATE	To define the structural requirements of the parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor necessary for activation of phospholipase C (PLC), receptors with random mutations in their second cytoplasmic loop were synthesized, and their properties were assessed. A mutant in which the wild type (WT) rat PTH/PTHrP receptor sequence EKKY (amino acids 317-320) was replaced with DSEL had little or no PTH-stimulated PLC activity when expressed transiently in COS-7 cells, but it retained full capacity to bind ligand and to generate cAMP. This phenotype was confirmed in LLC-PK1 cells stably expressing the DSEL mutant receptor, where both PTH-stimulated PLC activity and sodium-dependent phosphate co-transport were essentially abolished. Individual mutations of these four residues point to a critical role for Lys-319 in receptor-G protein coupling. PTH-generated IPs were reduced to 27 +/- 13% when K319E, compared with the WT receptor, and PLC activation was fully recovered in a receptor revertant in which Glu-319 in the DSEL mutant cassette was restored to the WT residue, Lys. Moreover, the WT receptor and a mutant receptor in which K319R had indistinguishable properties, thus suggesting that a basic amino acid at this position may be important for PLC activation. All of these receptors had unimpaired capacity to bind ligand and to generate cAMP. To ensure adequacy of G alpha(p)-subunits for transducing the receptor signal, G alpha(p) was expressed in HER293 and in LLC-PK1 cells together with either WT receptors or receptors with the DSEL mutant cassette. PTH generated no inositol phosphates (LPs) in either HEK293 or LLC-PK1 cells, when they expressed DSEL mutant receptors together with G alpha(p). In contrast, PTH generated 2- and 2.5-fold increases in IPs, respectively, when these cells co expressed both the WT receptor and GLYB Thus, generation of IPs by the activated PTR/PTHrP receptor can be selectively abolished without affecting its capacity to generate cAMP, and Lys-319 in the second intracellular loop is critical for activating the PLC pathway, Moreover, alpha-subunits of the G(q), family, rather than py-subunits, transduce the signal from the activated receptor to PLC, and the PLC, rather than the adenylyl cyclase, pathway mediates sodium-dependent phosphate cotransport in LLC-PK1 cells.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			xu, tao/K-6631-2016; Abou-Samra, Abdul/ABE-8723-2020	Abou-Samra, Abdul/0000-0001-8735-1142	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK008751] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32-DK08751, DK11794, DK47034] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; BERGWITZ C, 1996, 10 INT C END SAN FRA; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; DELPORTE C, 1995, MOL CELL ENDOCRINOL, V107, P71, DOI 10.1016/0303-7207(94)03424-R; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; GUDERMANN T, 1992, MOL ENDOCRINOL, V6, P272, DOI 10.1210/me.6.2.272; GUO J, 1995, ENDOCRINOLOGY, V136, P3884, DOI 10.1210/en.136.9.3884; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CH, 1992, J BIOL CHEM, V267, P16044; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P22273; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NISSENSON RA, 1993, RECEPTOR, V3, P193; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; REAGAN JD, 1994, J BIOL CHEM, V269, P9; Sambrook J., 2002, MOL CLONING LAB MANU; Sande J.V, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMPSON EB, 1991, MOL ENDOCRINOL, V6, P501; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WANK SA, 1993, P NATIONAL ACADEMY S, V90, P6345; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Yu JX, 1996, ENDOCRINOLOGY, V137, P192, DOI 10.1210/en.137.1.192	53	99	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6882	6889		10.1074/jbc.272.11.6882	http://dx.doi.org/10.1074/jbc.272.11.6882			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054374	hybrid			2022-12-25	WOS:A1997WN14700013
J	Vincent, V; Goffin, V; RozakisAdcock, M; Mornon, JP; Kelly, PA				Vincent, V; Goffin, V; RozakisAdcock, M; Mornon, JP; Kelly, PA			Identification of cytoplasmic motifs required for short prolactin receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED ENDOCYTOSIS; SIGNAL TRANSDUCER GP130; GROWTH-HORMONE RECEPTOR; TRANSFERRIN RECEPTOR; MAMMARY-GLAND; MEDIATED INTERNALIZATION; MONOCLONAL-ANTIBODIES; GENE-TRANSCRIPTION; DOWN-REGULATION; LDL RECEPTOR	Cloning of rat prolactin receptor (PRLR) cDNAs revealed the existence of two isoforms, termed short and long according to the length of their cytoplasmic domain, Internalization studies show, first, that PRLR internalization is hormone-dependent and, second, that ligand-receptor complexes of the short PRLR are internalized to a larger extent compared to the long form. In order to identify regions within the cytoplasmic domain of the short PRLR required for efficient internalization, serial truncations of the cytoplasmic tail were performed by inserting a stop codon in place of those encoding residues 282, 273, 262, 253, 244, or 237 (wild type short PRLR contains 291 amino acids), Our data show that two motifs, lying within residues 253-261 and 273-281, are involved in internalization. Both regions contain a consensus feature identified within other receptors as internalization signals, namely a di-leucine peptide (amino acids 259-260) and a tetrapeptide predicted to adopt a beta-turn structure (amino acids 276-279). We propose these two motifs are involved in PRLR endocytosis, Finally, we show that alpha-adaptin, a component of adaptor protein AP-2, coprecipitates with short PRLR complexes upon PRL stimulation, which strongly suggests that PRLR internalization is mediated by the clathrin-coated pits endocytotic pathway.	FAC MED NECKER ENFANTS MALAD, INSERM U344, F-75730 PARIS 15, FRANCE; UNIV PARIS 06, LAB MINERAL CRISTALLOG, F-75252 PARIS 05, FRANCE; UNIV PARIS 07, CNRS URA 09, F-75252 PARIS 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			GOFFIN, Vincent/G-3322-2013	GOFFIN, Vincent/0000-0002-8021-3086				ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAS R, 1995, MOL ENDOCRINOL, V9, P1750, DOI 10.1210/me.9.12.1750; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; DJIANE J, 1979, BIOCHEM BIOPH RES CO, V90, P1371, DOI 10.1016/0006-291X(79)91187-2; DJIANE J, 1981, P NATL ACAD SCI-BIOL, V78, P7445, DOI 10.1073/pnas.78.12.7445; DJIANE J, 1982, MOL CELL ENDOCRINOL, V25, P163, DOI 10.1016/0303-7207(82)90049-1; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; GARNIER J, 1978, J MOL BIOL, V88, P873; GENTY N, 1994, MOL CELL ENDOCRINOL, V99, P221, DOI 10.1016/0303-7207(94)90011-6; Goffin V, 1996, CLIN ENDOCRINOL, V45, P247, DOI 10.1046/j.1365-2265.1996.00799.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KELLY PA, 1979, ENDOCRINOLOGY, V104, P1631, DOI 10.1210/endo-104-6-1631; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LESUEUR L, 1990, MOL CELL ENDOCRINOL, V71, pR7, DOI 10.1016/0303-7207(90)90079-N; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROUPAS P, 1986, MOL CELL ENDOCRINOL, V47, P81, DOI 10.1016/0303-7207(86)90018-3; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WATTS C, 1992, J CELL SCI, V103, P1	55	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7062	7068		10.1074/jbc.272.11.7062	http://dx.doi.org/10.1074/jbc.272.11.7062			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054398	hybrid			2022-12-25	WOS:A1997WN14700037
J	Korte, JJ; Salo, WL; Cabrera, VM; Wright, PA; Felskie, AK; Anderson, PM				Korte, JJ; Salo, WL; Cabrera, VM; Wright, PA; Felskie, AK; Anderson, PM			Expression of carbamoyl-phosphate synthetase III mRNA during the early stages of development and in muscle of adult rainbow trout (Oncorhynchus mykiss)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN-CAD; ORNITHINE-UREA CYCLE; SQUALUS-ACANTHIAS; MICROPTERUS-SALMOIDES; SUBCELLULAR-LOCALIZATION; NITROGEN-METABOLISM; FRESH-WATER; GENE; LIVER; SEQUENCE	It has been reported that the activities of the urea cycle related enzymes ornithine carbamoyltransferase and carbamoyl-phosphate synthetase III (CPSase III) are induced during early life stages of ammonotelic rainbow trout (Oncorhynchus mykiss), suggesting that the urea cycle may play a physiological role in early development in teleost fish (Wright, P. A., Felskie, A., and Anderson, P. M. (1995) J. Exp. Biol. 198, 127-135). CPSase III cDNA prepared from embryo mRNA was sequenced, confirming the existence of the CPSase III gene in trout and its expression. The deduced amino acid sequence of the CPSase III is homologous to other CPSases. Supporting evidence for the expression of CPSase III activity in trout embryos was obtained by demonstrating expression of CPSase III mRNA as early as day 3 post-fertilization, reaching a maximum at 10-14 days, declining to a minimum at day 70, and then increasing to a relatively constant level from days 90 to 110 (relative to total RNA). Unexpectedly, in tissues of adult and fingerling trout, CPSase III mRNA was found to be present in muscle but not in other tissues, including liver. This finding was confirmed by assay of extracts, which showed CPSase III and ornithine carbamoyltransferase activity in muscle but not in other tissues. The pyrimidine nucleotide pathway-related CPSase II mRNA was expressed in all tissues.	UNIV MINNESOTA,DEPT BIOCHEM & MOL BIOL,DULUTH,MN 55812; UNIV GUELPH,DEPT ZOOL,GUELPH,ON N1G 2W1,CANADA	University of Minnesota System; University of Minnesota Duluth; University of Guelph								Anderson P. M., 1970, METHODS ENZYMOL    A, V17A, P235; ANDERSON PM, 1980, SCIENCE, V208, P291, DOI 10.1126/science.6245445; ANDERSON PM, 1984, J BIOL CHEM, V259, P456; ANDERSON PM, 1991, BIOCHEM CELL BIOL, V69, P317, DOI 10.1139/o91-049; ANDERSON PM, 1981, J BIOL CHEM, V256, P2228; ANDERSON PM, 1976, COMP BIOCHEM PHYS B, V54, P261, DOI 10.1016/0305-0491(76)90154-1; ANDERSON PM, 1995, J EXP BIOL, V198, P755; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; [Anonymous], 1995, FISH PHYSL, DOI DOI 10.1016/S1546-5098(01)20004-1; BEIN K, 1991, J BIOL CHEM, V266, P3791; Borson N D, 1992, PCR Methods Appl, V2, P144; Campbell J., 1991, EXPT METABOLIC ANIMA, V4th ed., P277; CAMPBELL JW, 1991, BIOCH MOL BIOL FISHE, P43; CAO XY, 1991, J EXP ZOOL, V258, P24, DOI 10.1002/jez.1402580104; CASEY CA, 1983, J BIOL CHEM, V258, P8723; CHIU YN, 1986, J NUTR, V116, P1640, DOI 10.1093/jn/116.9.1640; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; DEPECHE J, 1979, COMP BIOCHEM PHYS A, V63, P51, DOI 10.1016/0300-9629(79)90626-1; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EVANS DR, 1993, BIOCHEM SOC T, V21, P186, DOI 10.1042/bst0210186; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HARAGUCHI Y, 1991, GENE, V107, P335; HELBING CC, 1994, J BIOL CHEM, V269, P11743; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; JOHNSON WV, 1990, ARCH BIOCHEM BIOPHYS, V280, P376, DOI 10.1016/0003-9861(90)90345-Y; JONES ME, 1961, ARCH BIOCHEM BIOPHYS, V95, P499, DOI 10.1016/0003-9861(61)90182-5; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MOMMSEN TP, 1989, SCIENCE, V243, P72, DOI 10.1126/science.2563172; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; Perlman D.F., 1988, P253; RAIJMAN L, 1974, BIOCHEM J, V138, P225, DOI 10.1042/bj1380225; RANDALL DJ, 1989, NATURE, V337, P165, DOI 10.1038/337165a0; SAHA N, 1994, COMP BIOCHEM PHYS B, V108, P315, DOI 10.1016/0305-0491(94)90083-3; SAHA N, 1989, J EXP ZOOL, V252, P1, DOI 10.1002/jez.1402520102; SAHA N, 1997, IN PRESS COMP BIOCH; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; THURSTON RV, 1984, T AM FISH SOC, V113, P56, DOI 10.1577/1548-8659(1984)113<56:CTOATR>2.0.CO;2; THURSTON RV, 1983, T AM FISH SOC, V112, P696, DOI 10.1577/1548-8659(1983)112<696:ATOATR>2.0.CO;2; TRAMELL PR, 1971, COMP BIOCHEM PHYSIOL, V40, P395, DOI 10.1016/0305-0491(71)90224-0; TRAMELL PR, 1970, J BIOL CHEM, V245, P6634; WINDMUELLER HG, 1981, ENDOCRINOL METAB, V4, pE473; Wood Chris M., 1993, P379; WRIGHT PA, 1995, J EXP BIOL, V198, P127; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	49	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6270	6277		10.1074/jbc.272.10.6270	http://dx.doi.org/10.1074/jbc.272.10.6270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045644	hybrid			2022-12-25	WOS:A1997WM64700028
J	Ventura, C; Pintus, G; Tadolini, B				Ventura, C; Pintus, G; Tadolini, B			Opioid peptide gene expression in the primary hereditary cardiomyopathy of the Syrian hamster .2. Role of intracellular calcium loading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT CARDIAC MYOCYTES; CHROMAFFIN CELLS; CALPHOSTIN-C; HEART; RECEPTOR; CHANNEL; CA2+; HYPERTROPHY; STIMULATION	We have previously shown that prodynorphin gene expression was markedly increased in adult myocytes of BIO 14.6 cardiomyopathic hamsters and that nuclear protein kinase C (PKC) may be involved in the induction of this opioid gene, Here we report that the cytosolic Ca2+ concentration was significantly increased in resting and in KCl-depolarized cardiomyopathic myocytes compared with normal cells, In normal and in cardiomyopathic cells, KCl significantly increased prodynorphin mRNA levels and prodynorphin gene transcription, These effects were abolished by the Ca2+ channel blocker verapamil. In control myocytes, the KCl-induced increase in prodynorphin mRNA expression was in part attenuated by chelerythrine or calphostin C, two selective PKC inhibitors, In these cells, KCL induced the translocation of PKC-alpha into the nucleus, increasing nuclear PKC activity, In resting cardiomyopathic myocytes, the increase in prodynorphin mRNA levels and gene transcription were significantly attenuated by the intracellular Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetraacetoxymethylester being completely abolished when the chelating agent was administered in the presence of PKC inhibitors, KCI and the PKC activator 1,2-dioctanoyl-sn-glycerol additively stimulated prodynorphin gene expression both in normal and in cardiomyopathic cells, Therefore, we conclude that PKC activation and intracellular Ca2+ overload may represent the two major signaling mechanisms involved in the induction of the prodynorphin gene in cardiomyopathic cells.	NATL INST BIOSTRUCT & BIOSYST, NATL LAB, OSILO, ITALY		Ventura, C (corresponding author), UNIV SASSARI, SCH MED, INST BIOL CHEM A BONSIGNORE, VIALE SAN PIETRO 43-B, I-07100 SASSARI, ITALY.				Telethon [593] Funding Source: Medline	Telethon(Fondazione Telethon)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BALKE CW, 1994, J PHYSIOL-LONDON, V474, P447, DOI 10.1113/jphysiol.1994.sp020036; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHIAMVIMONVAT N, 1995, J PHYSIOL-LONDON, V483, P307, DOI 10.1113/jphysiol.1995.sp020587; FINKEL MS, 1993, LIFE SCI, V52, P1109, DOI 10.1016/0024-3205(93)90432-3; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P546, DOI 10.1097/00005344-199204000-00011; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P610, DOI 10.1097/00005344-199204000-00019; FORMAN R, 1972, J MOL CELL CARDIOL, V4, P203, DOI 10.1016/0022-2828(72)90058-2; FOSTER KA, 1990, AM J PHYSIOL, V259, pH432, DOI 10.1152/ajpheart.1990.259.2.H432; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HA KS, 1993, J BIOL CHEM, V268, P10534; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; JASMIN G, 1982, MUSCLE NERVE, V5, P20, DOI 10.1002/mus.880050105; Jasmin G, 1979, Ann N Y Acad Sci, V317, P46, DOI 10.1111/j.1749-6632.1979.tb56509.x; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUO TH, 1987, BIOCHEM BIOPH RES CO, V148, P926, DOI 10.1016/S0006-291X(87)80221-8; KUO TH, 1992, BIOCHIM BIOPHYS ACTA, V1138, P343, DOI 10.1016/0925-4439(92)90013-D; KUO TH, 1987, BIOCHIM BIOPHYS ACTA, V900, P10, DOI 10.1016/0005-2736(87)90272-0; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; MACARTHUR L, 1993, MOL PHARMACOL, V44, P545; MARBAN E, 1990, HYPERTENSION, V15, P652, DOI 10.1161/01.HYP.15.6.652; PATEL J, 1987, J BIOL CHEM, V262, P16686; PROSCHEK L, 1982, MUSCLE NERVE, V5, P26, DOI 10.1002/mus.880050106; ROKAEUS A, 1990, ENDOCRINOLOGY, V127, P3096, DOI 10.1210/endo-127-6-3096; SEN L, 1994, CIRC RES, V75, P149, DOI 10.1161/01.RES.75.1.149; SEN L, 1990, CIRC RES, V67, P599, DOI 10.1161/01.RES.67.3.599; SEN L, 1990, AM J PHYSIOL, V259, pH1533, DOI 10.1152/ajpheart.1990.259.5.H1533; SONNENBLICK EH, 1985, AM J CARDIOL, V55, pB179, DOI 10.1016/0002-9149(85)90629-0; Strobeck J E, 1979, Ann N Y Acad Sci, V317, P59, DOI 10.1111/j.1749-6632.1979.tb37326.x; SUH HW, 1995, J NEUROCHEM, V64, P608; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; VENTURA C, 1994, J BIOL CHEM, V269, P5384; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330; WEISMAN HF, 1987, J AM COLL CARDIOL, V10, P1135, DOI 10.1016/S0735-1097(87)80357-1; XIAO RP, 1993, J MOL CELL CARDIOL, V25, P661, DOI 10.1006/jmcc.1993.1079; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034	44	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6693	6698		10.1074/jbc.272.10.6693	http://dx.doi.org/10.1074/jbc.272.10.6693			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045701	hybrid			2022-12-25	WOS:A1997WM64700085
J	Castellino, AM; Parker, GJ; Boronenkov, IV; Anderson, RA; Chao, MV				Castellino, AM; Parker, GJ; Boronenkov, IV; Anderson, RA; Chao, MV			A novel interaction between the juxtamembrane region of the p55 tumor necrosis factor receptor and phosphatidylinositol-4-phosphate 5-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C; 4-PHOSPHATE 5-KINASE; CYTOPLASMIC DOMAIN; SH3 DOMAIN; PROTEIN; KINASE; EXPRESSION; DEATH; IDENTIFICATION	Tumor necrosis factor-alpha (TNF-alpha) binding to its receptors leads to a diversity of biological responses. The actions of TNF are the result of the interaction of cytoplasmic proteins that bind directly to the intracellular domains of the two TNF receptors, p55 and p75. Here we report a novel interaction between the juxtamembrane region of the p55 TNF receptor and a newly discovered 47-kDa isoform of phosphatidylinositol-4-phosphate 5-kinase (PIP5K), a member of the enzyme family that generates the key signaling messenger, phosphatidylinositol 4,5-bisphosphate. The interaction was found to be specific for the p55 TNF receptor and was not observed with the p75 TNF receptor, the Fas antigen, or the p75 neurotrophin receptor, which are other members of the TNF receptor superfamily. In vitro experiments using recombinant fusion proteins verify the authenticity of the interaction between the p55 receptor and PIP5KII beta, a new isoform of PIP5K, but not the previously identified 53-kDa PIP5KII alpha. Treatment of HeLa cells with TNF-alpha resulted in an increased PIP5K activity. These results indicate that phosphatidylinositol turnover may be linked to stimulation of the p55 TNF receptor and suggest that a subset of TNF responses may result from the direct association of PIP5KII beta with the p55 TNF receptor.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,PROGRAM MOL & CELLULAR BIOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT BIOMOL CHEM,MADISON,WI 53706; CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Cornell University				Anderson, Richard/0000-0001-6265-8359; Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038906, R01GM051968, R01GM038906] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NIGMS NIH HHS [GM51968, GM38906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROOKSBANK CEL, 1993, BIOCHEM J, V291, P77, DOI 10.1042/bj2910077; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COCHET C, 1991, J BIOL CHEM, V266, P637; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1992, BIOCHEM J, V288, P637, DOI 10.1042/bj2880637; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HSU KC, 1993, J BIOL CHEM, V268, P16430; ITOH N, 1993, J BIOL CHEM, V268, P10932; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; LING LE, 1989, J BIOL CHEM, V264, P5080; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Orlinick JR, 1996, J BIOL CHEM, V271, P8627, DOI 10.1074/jbc.271.15.8627; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RON D, 1992, BIOTECHNIQUES, V13, P866; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SINGHAL RL, 1994, CANCER RES, V54, P5574; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	55	85	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5861	5870		10.1074/jbc.272.9.5861	http://dx.doi.org/10.1074/jbc.272.9.5861			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038203	hybrid			2022-12-25	WOS:A1997WK74700071
J	Hu, DL; Fiedler, HR; Golan, T; Edelman, M; Strotmann, H; Shavit, N; Leu, S				Hu, DL; Fiedler, HR; Golan, T; Edelman, M; Strotmann, H; Shavit, N; Leu, S			Catalytic properties and sensitivity to tentoxin of Chlamydomonas reinhardtii ATP synthases changed in codon 83 of atpB by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; CHLOROPLAST TRANSFORMATION; ADENINE-NUCLEOTIDES; SUBUNIT; GENE; CF1; PHOTOPHOSPHORYLATION; BETA	The participation of the amino acid beta 83 in determining the sensitivity of chloroplast ATP synthases to tentoxin was reported previously, We have changed codon 83 of the Chlamydomonas reinhardtii atpB gene by site-directed mutagenesis to further examine the role of this amino acid in the response of the ATP synthase to tentoxin and in the mechanism of ATP synthesis and hydrolysis, Amino acid beta 83 was changed from Glu to Asp (beta E83D) and to Lys (beta E83K), and the highly conserved tetrapeptide beta T82-E83-G84-L85 (Delta TEGL) was deleted, Mutant strains were produced by particle gun transformation of atpB deletion mutants cw15 Delta atpB and FUD50 with the mutated atpB genes, The transformants containing the beta E83D and beta E83K mutant genes grew well photoautotrophically. The Delta TEGL transformant did not grow photoautotrophically, and no CF1 subunits were detected by immunostaining of Western blots using CF1 specific antibodies, The rates of ATP synthesis at clamped Delta pH with thylakoids isolated from cw15 and the two mutants, beta E83D and beta E83K, were similar, However, only the phosphorylation activity of the mutant beta E83D was inhibited by tentoxin with 50% inhibition attained at 4 mu M. These results confirm that amino acid beta 83 is critical in determining the response of ATP synthase to tentoxin, The rates of the latent Mg-ATPase activity of the CF(1)s isolated from cw15, beta E83D, and beta E83K were similar and could be enhanced by heat, alcohols, and octylglucoside, As in the case of the membrane-bound enzyme, only CF1 from the beta E83D mutant was sensitive to tentoxin, A lower alcohol concentration was required for optimal stimulation of the ATPase of the beta E83K-CF1 than that of CF1 from the other two strains, Moreover, the optimal activity of the beta E83K-CF1 was also lower, These results suggest that introduction of an amino acid with a positively charged side chain in position 83 in the ''crown'' domain affects the active conformation of the CF1-ATPase.	BEN GURION UNIV NEGEV,DORIS & BERTIE BLACK CTR BIOENERGET LIFE SCI,IL-84105 BEER SHEVA,ISRAEL; UNIV DUSSELDORF,INST BIOCHEM,D-4000 DUSSELDORF,GERMANY; WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL	Ben Gurion University; Heinrich Heine University Dusseldorf; Weizmann Institute of Science								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANTHON GE, 1984, BIOCHIM BIOPHYS ACTA, V766, P354, DOI 10.1016/0005-2728(84)90251-2; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BARZVI D, 1983, FEBS LETT, V160, P233, DOI 10.1016/0014-5793(83)80973-9; BARZVI D, 1996, J BIOENERG BIOMEMBR, V28, P473; BOUDREAU E, 1994, PLANT MOL BIOL, V24, P585, DOI 10.1007/BF00023556; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; CHEN ZG, 1995, J BIOL CHEM, V270, P17124, DOI 10.1074/jbc.270.29.17124; DAHSE I, 1994, J PLANT PHYSIOL, V143, P615, DOI 10.1016/S0176-1617(11)81147-8; FIEDLER HR, 1996, PHOTOSYNTHESIS LIGHT, V3, P35; FIEDLER HR, 1997, IN PRESS BIOCH BIOPH; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Hase B, 1996, FEBS LETT, V382, P171, DOI 10.1016/0014-5793(96)00167-6; HU NM, 1993, J BIOL CHEM, V268, P8536; KINDLE KL, 1991, P NATL ACAD SCI USA, V88, P1721, DOI 10.1073/pnas.88.5.1721; KNEUSEL RE, 1982, BIOCHIM BIOPHYS ACTA, V681, P337, DOI 10.1016/0005-2728(82)90173-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEU S, 1990, FEBS LETT, V269, P41, DOI 10.1016/0014-5793(90)81114-4; LEU S, 1996, PHOTOSYNTHESIS LIGHT, V3, P179; NEWMAN SM, 1990, GENETICS, V126, P875; OHTA Y, 1993, PLANT CELL PHYSIOL, V34, P523; PICK U, 1983, EUR J BIOCHEM, V133, P289, DOI 10.1111/j.1432-1033.1983.tb07461.x; PICK U, 1982, BIOCHEMISTRY-US, V21, P6144, DOI 10.1021/bi00267a019; REIMER S, 1978, J BIOL CHEM, V253, P7249; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; SELMANREIMER S, 1981, BIOCHEMISTRY-US, V20, P5476, DOI 10.1021/bi00522a020; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V504, P136, DOI 10.1016/0005-2728(78)90012-9; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; STROTMANN H, 1990, EUR J BIOCHEM, V193, P879, DOI 10.1111/j.1432-1033.1990.tb19412.x; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WOESSNER JP, 1986, GENE, V44, P17; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065	36	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5457	5463		10.1074/jbc.272.9.5457	http://dx.doi.org/10.1074/jbc.272.9.5457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038147	hybrid			2022-12-25	WOS:A1997WK74700015
J	Miller, MJ; Prigent, S; Kupperman, E; Rioux, L; Park, SH; Feramisco, JR; White, MA; Rutkowski, JL; Meinkoth, JL				Miller, MJ; Prigent, S; Kupperman, E; Rioux, L; Park, SH; Feramisco, JR; White, MA; Rutkowski, JL; Meinkoth, JL			RalGDS functions in Ras- and cAMP-mediated growth stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; CYCLIC-AMP; DNA-SYNTHESIS; CELLULAR RAS; R-RAS; CELLS; INHIBITION; PATHWAY; RAF-1	Thyroid-stimulating hormone stimulates proliferation through both the cAMP-dependent protein kinase and Ras but not through Raf-l and mitogen-activated and extracellular signal-related kinase kinase. We now report that thyroid-stimulating hormone represses mitogen-activated protein kinase activity and that microinjection of an effector domain mutant Ha-Ras protein, Ras(12V,37G), defective in Raf-l binding and mitogen-activated protein kinase activation, stimulates DNA synthesis in quiescent and thyroid-stimulating hormone-treated thyrocytes. A yeast two-hybrid screen identified RalGDS as a Ras(12V,37G) binding protein and therefore a potential effector of nas in these cells. Associations between Ras and RalGDS were observed in extracts prepared from thyroid cells. Microinjection of a mutant Ra1A(28N) protein thought to sequester RaIGDS family members reduced DNA synthesis stimulated by Ras as well as cAMP-mediated DNA synthesis in two cell lines which respond to cAMP with mitogenesis. These results support the idea that RalGDS may be an effector of Ras in cAMP-mediated growth stimulation.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Diego; University of California System; University of California San Diego; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Meinkoth, Judy L/G-2900-2010		NATIONAL CANCER INSTITUTE [P01CA058689, P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50528, CA 58689] Funding Source: Medline; NIDDK NIH HHS [DK45696] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Harlow E., 1988, ANTIBODIES LAB MANUA; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULIENFLORES V, 1995, J BIOL CHEM, V270, P22473; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; KURIYAMA M, 1996, J BIOL CHEM, V271, P307; LAMY F, 1993, J BIOL CHEM, V268, P8398; LopezBarahona M, 1996, ONCOGENE, V12, P463; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; Okazaki M, 1996, CANCER RES, V56, P2387; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; RAFF MC, 1978, CELL, V15, P813, DOI 10.1016/0092-8674(78)90266-0; RAFF MC, 1978, NATURE, V273, P672, DOI 10.1038/273672a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; RUTKOWSKI JL, 1995, NAT MED, V1, P24; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; SPARK SH, 1995, ONCOGENE, V11, P2349; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P208; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	44	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5600	5605		10.1074/jbc.272.9.5600	http://dx.doi.org/10.1074/jbc.272.9.5600			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038168	hybrid			2022-12-25	WOS:A1997WK74700036
J	Royer, WE; Fox, RA; Smith, FR; Zhu, D; Braswell, EH				Royer, WE; Fox, RA; Smith, FR; Zhu, D; Braswell, EH			Ligand linked assembly of Scapharca dimeric hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY ENHANCEMENT; TETRAMERIC HEMOGLOBINS; OXYGEN BINDING; INAEQUIVALVIS; MODEL; COOPERATIVITY; INTERMEDIATE; EQUILIBRIUM; RESOLUTION; REPRESSOR	The assembly of Scapharca dimeric hemoglobin as a function of ligation has been explored by analytical gel chromatography, sedimentation equilibrium, and oxygen binding experiments to test the proposal that its cooperativity is based on quaternary enhancement. This hypothesis predicts that the liganded form would be assembled more tightly into a dimer than the unliganded form and that dissociation would lead to lower oxygen affinity. Our experiments demonstrate that although the dimeric interface is quite tight in this hemoglobin, dissociation can be clearly detected in the liganded states with monomer to dimer association constants in the range of 10(8) M(-1) for the CO-liganded state and lower association constants measured in the oxygenated state. In contrast, the deoxy dimer shows no detectable dissociation by analytical ultracentrifugation. Thus, the more highly hydrated deoxy interface of this dimer is also the more tightly assembled. Equilibrium oxygen binding experiments reveal an increase in oxygen affinity and decrease in cooperativity as the concentration is lowered (in the mu M range), These experiments unambiguously refute the hypothesis of quaternary enhancement and indicate that, as in the case of human hemoglobin and other allosteric proteins, quaternary constraint underlies cooperativity in Scapharca dimeric hemoglobin.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOL BIOL,WORCESTER,MA 01605; UNIV CONNECTICUT,DEPT MOL & CELL BIOL,STORRS,CT 06260	University of Massachusetts System; University of Massachusetts Worcester; University of Connecticut	Royer, WE (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOL MED,378 PLANTAT ST,WORCESTER,MA 01605, USA.				NIDDK NIH HHS [DK 43323] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERS GK, 1990, BIOPHYS CHEM, V37, P265, DOI 10.1016/0301-4622(90)88026-O; ACKERS GK, 1980, BIOPHYS J, V32, P331, DOI 10.1016/S0006-3495(80)84960-5; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P11182, DOI 10.1021/bi00160a032; DOYLE ML, 1992, PROTEINS, V14, P351, DOI 10.1002/prot.340140304; GIBSON QH, 1987, J BIOL CHEM, V262, P516; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; IKEDASAITO M, 1983, J MOL BIOL, V170, P1009, DOI 10.1016/S0022-2836(83)80200-9; JOHNSON AD, 1981, NATURE, V294, P217, DOI 10.1038/294217a0; JOHNSON ML, 1976, BIOCHEMISTRY-US, V15, P5363, DOI 10.1021/bi00669a024; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KELLETT GL, 1971, J MOL BIOL, V59, P401, DOI 10.1016/0022-2836(71)90307-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLS FC, 1979, P NATL ACAD SCI USA, V76, P273, DOI 10.1073/pnas.76.1.273; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PETRUZZELLI R, 1985, FEBS LETT, V184, P328, DOI 10.1016/0014-5793(85)80632-3; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; PHILO JS, 1990, J BIOL CHEM, V265, P139; ROSSIFANELLI A, 1958, ARCH BIOCHEM BIOPHYS, V77, P478, DOI 10.1016/0003-9861(58)90094-8; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SPAGNUOLO C, 1983, J MOL BIOL, V164, P627, DOI 10.1016/0022-2836(83)90054-2; SUMMERFORD CM, 1995, PROTEIN ENG, V8, P593, DOI 10.1093/protein/8.6.593; VALDES R, 1979, METHODS ENZMOL, V61, P74; WYMAN J, 1948, ADV PROTEIN CHEM, V4, P407, DOI 10.1016/S0065-3233(08)60011-X	32	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5689	5694		10.1074/jbc.272.9.5689	http://dx.doi.org/10.1074/jbc.272.9.5689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038179	hybrid			2022-12-25	WOS:A1997WK74700047
J	Tenev, T; Keilhack, H; Tomic, S; Stoyanov, B; SteinGerlach, M; Lammers, R; Krivtsov, AV; Ullrich, A; Bohmer, FD				Tenev, T; Keilhack, H; Tomic, S; Stoyanov, B; SteinGerlach, M; Lammers, R; Krivtsov, AV; Ullrich, A; Bohmer, FD			Both SH2 domains are involved in interaction of SHP-1 with the epidermal growth factor receptor but cannot confer receptor-directed activity to SHP-1/SHP-2 chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; HEMATOPOIETIC-CELL PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; SH-PTP2; PHOSPHORYLATION; ACTIVATION; INSULIN; BETA	The previously demonstrated functional and physical interaction of the SH2 domain protein-tyrosine phosphatase SHP-1 with the epidermal growth factor (EGF) receptor (Tomic, S,, Greiser, U,, Lammers, R,, Kharitonenkov, A, Imyanitov, E,, Ullrich, A, and Bohmer, F. D, (1995) J, Biol, Chem 270, 21277-21284) was investigated with respect to the involved structural elements of SHP-1, Various mutants of SHP-1 were transiently expressed in 293 or COS-7 cells and analyzed for their capacity to associate with immobilized autophosphorylated EGF receptor in vitro and to dephosphorylate coexpressed EGF receptor in intact cells, inactivating point mutation of the C-terminal SH2 domain reduced the association weakly, point mutation of the N-terminal SH2 domain reduced association strongly and the respective double mutation abolished association totally. The capacity of SHP-1 to dephosphorylate coexpressed EGF receptor was impaired by all point mutations, Truncation of the N-terminal or of both SH2 domains strongly reduced or abolished association, respectively, but the truncated SHP-1 derivatives still dephosphorylated coexpressed EGF receptor effectively. Various chimeric protein-tyrosine phosphatases constructed from SHP-1 and the closely homologous SHP-2 dephosphorylated the EGF receptor when they contained the catalytic domain of SHP-1, As native SHP-2, the chimera lacked activity toward the receptor when they contained the catalytic domain of SHP-2, despite their capacity to associate with the receptor and to dephosphorylate an artificial phosphopeptide. We conclude that the differential interaction of SHP-1 and SHP-2 with the EGF receptor is due to the specificity of the respective catalytic domains rather than to the specificity of the SH2 domains, Functional interaction of native SHP-1 with the EGF receptor requires association mediated by both SH2 domains.	UNIV JENA, MAX PLANCK SOC, FAC MED, RES UNIT MOL CELL BIOL, D-07747 JENA, GERMANY; MAX PLANCK INST BIOCHEM, DEPT MOL BIOL, D-82152 MARTINSRIED, GERMANY	Friedrich Schiller University of Jena; Max Planck Society; Max Planck Society			Krivtsov, Andrei/AAJ-9966-2021	Tenev, Tencho/0000-0001-8762-1069				Adachi M, 1996, CELL, V85, P15; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Pregel MJ, 1995, PROTEIN ENG, V8, P1309, DOI 10.1093/protein/8.12.1309; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	38	79	83	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5966	5973		10.1074/jbc.272.9.5966	http://dx.doi.org/10.1074/jbc.272.9.5966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038217	hybrid			2022-12-25	WOS:A1997WK74700085
J	Lallemand, D; Spyrou, G; Yaniv, M; Pfarr, CM				Lallemand, D; Spyrou, G; Yaniv, M; Pfarr, CM			Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts	ONCOGENE			English	Article						Jun; Fos; AP-1; NIH3T3; cell cycle	TRANSCRIPTION FACTOR AP-1; PROGRAMMED CELL-DEATH; LACKING C-FOS; DNA-BINDING; MOUSE FIBROBLASTS; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; G0-TO-G1 TRANSITION; EMBRYO FIBROBLASTS; NEGATIVE REGULATOR	We have analysed the different Jun and Fos proteins as NIH3T3 fibroblasts pass from exponential growth to quiescence and during the first 24 h after their re-entry into the cell cycle following serum stimulation, We show that these proteins can be divided into 3 subgroups based on their pattern of expression. The first contains c-Jun, Jun-D and Fra-2 which are expressed at high level in cycling cells and are only mildly induced by serum. The second contains Jun-B, c-Fos, Fos-B and Delta Fos-B whose levels are low in cycling cells but increase strongly and rapidly after stimulation by serum. The third group contains only Fra-1, which is absent from cycling cells and behaves as a delayed early response protein after serum stimulation, AP-I binding activity is low both in cycling and quiescent fibroblasts but increases after stimulation by serum with kinetics matching the induction of the various Jun and Fos proteins. Antibody supershift analyses demonstrate that the composition of AP-I binding activity reflects the relative abundance of each Jun and Fos protein. Furthermore, the state of post-translational modification varies continuously for all of the AP-1 proteins as growth conditions change. These data indicate that AP-1 activity during the G(0)-G(1) transition is finely regulated and complex, involving changes both in protein expression and in posttranslational modification.	INST PASTEUR, UNITE VIRUS ONCOGENES, UA 1149 CNRS, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE; KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Karolinska Institutet			Pfarr, Curt/HHD-1410-2022; lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CARILLO S, 1996, BIOCHEM J, V270, P623; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHATTON B, 1994, ONCOGENE, V9, P375; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HERBER, 1994, ONCOGENE, V9, P2105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	73	132	133	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					819	830		10.1038/sj.onc.1200901	http://dx.doi.org/10.1038/sj.onc.1200901			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047389				2022-12-25	WOS:A1997WJ11200008
J	Boekhoff, I; Touhara, K; Danner, S; Inglese, J; Lohse, MJ; Breer, H; Lefkowitz, RJ				Boekhoff, I; Touhara, K; Danner, S; Inglese, J; Lohse, MJ; Breer, H; Lefkowitz, RJ			Phosducin, potential role in modulation of olfactory signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; MUSCARINIC ACETYLCHOLINE-RECEPTORS; G-PROTEIN; DEPENDENT PHOSPHORYLATION; BINDING; ACTIVATION; CILIA; DESENSITIZATION; TRANSDUCTION	Phosducin, which tightly binds beta gamma-subunits of heterotrimeric G-proteins, has been conjectured to play a role in regulating second messenger signaling cascades, but to date its specific function has not been elucidated. Here we demonstrate a potential role for phosducin in regulating olfactory signal transduction. In isolated olfactory cilia certain odorants elicit a rapid and transient cAMP response, terminated by a concerted process which requires the action of two protein kinases, protein kinase A (PKA) and a receptor-specific kinase (GRK3) (Schleicher, S., Boekhoff, I. Arriza, J., Lefkowitz, R. J., and Breer, H. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 1420-1424). The mechanism of action of GRK3 involves a G beta gamma-mediated translocation of the kinase to the plasma membrane bound receptors (Pitcher, J. A. Inglese, J., Higgins, J. B., Arriza, J. L., Casey, P. J., Rim, C., Benovic, J. L., Kwatra, M. M., Caron, M. G., and Lefkowitz, R. J. (1992) Science 257, 1264-1267). A protein with a molecular mass of 33 kDa that comigrates on SDS gels with recombinant phosducin and which is immunoreactive with phosducin antibodies is present in olfactory cilia. Recombinant phosducin added to permeabilized olfactory cilia preparations strongly inhibits termination of odorant-induced cAMP response and odorant-induced membrane translocation of GRK3. In addition, the cAMP analogue dibutyryl cAMP stimulates membrane targeting of the receptor kinase. This effect is presumably due to PKA-mediated phosphorylation of phosducin, which diminishes its affinity for binding to the G beta gamma-subunit, thereby making G beta gamma available to function as a membrane anchor for GRK3. A specific PKA inhibitor blocks the odorant-induced translocation of the receptor kinase. Consistent with this formulation, a non-phosphorylatable mutant of phosducin (phosducin Ser-73 --> Ala) is an even more effective inhibitor of desensitization and membrane targeting of GRK3 than the wild-type protein. A phosducin mutant that mimics phosphorylated phosducin (phosducin Ser-73 --> Asp) lacks this property and in fact recruits GRK3 to the membrane and potentiates desensitization. These results suggest that phosducin may act as a phosphorylation-dependent switch in second messenger signaling cascades, regulating the kinetics of desensitization processes by controlling the activity of G beta gamma-dependent GRKs.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV STUTTGART HOHENHEIM,INST ZOOPHYSIOL,D-70599 STUTTGART,GERMANY; UNIV WURZBURG,INST PHARMACOL,D-97078 WURZBURG,GERMANY	Duke University; Howard Hughes Medical Institute; University Hohenheim; University of Wurzburg			Lohse, Martin J/A-7160-2012; Lefkowitz, Robert/AAW-2649-2021	Lohse, Martin J/0000-0002-0599-3510; 	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANHOLT RRH, 1986, J NEUROSCI, V6, P1403; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; CHEN Z, 1986, J NEUROSCI, V6, P2146; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P541, DOI 10.1113/jphysiol.1978.sp012480; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KRIEGER J, 1994, EUR J BIOCHEM, V219, P829, DOI 10.1111/j.1432-1033.1994.tb18564.x; KUO CH, 1989, MOL BRAIN RES, V6, P1, DOI 10.1016/0169-328X(89)90022-3; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LOLLEY RN, 1977, BIOCHEM BIOPH RES CO, V78, P572, DOI 10.1016/0006-291X(77)90217-0; MCGINNIS JF, 1985, CURR EYE RES, V4, P1127, DOI 10.3109/02713688509003359; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086	32	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4606	4612		10.1074/jbc.272.7.4606	http://dx.doi.org/10.1074/jbc.272.7.4606			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020189	hybrid			2022-12-25	WOS:A1997WH01900105
J	Brendeford, EM; Myrset, AH; Hegvold, AB; Lundin, M; Gabrielsen, OS				Brendeford, EM; Myrset, AH; Hegvold, AB; Lundin, M; Gabrielsen, OS			Oncogenic point mutations induce altered conformation, redox sensitivity, and DNA binding in the minimal DNA binding domain of avian myeloblastosis virus v-Myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-RELATED MOTIF; C-MYB; TRANSCRIPTIONAL ACTIVATION; ONCOPROTEIN; TRANSFORMATION; PROTEINS; DIFFERENTIATION; RECOGNITION; EXPRESSION; YEAST	c-Myb is the founder member of a class of transcription factors with tryptophan-rich repeats responsible for DNA binding, Activated oncogenic forms of Myb are encoded by the avian retroviruses, avian myeloblastosis virus (AMV) and E26. AMV v-Myb encodes a truncated protein with 11 point mutations relative to c-Myb, The mutations in the DNA binding domain (DBD) were reported to impose distinct phenotypes of differentiation on transformed myeloid cells (Introna, M., Golay, J., Frampton, J., Nakano, T., Ness, S. A., and Graf, T. (1990) Cell 63, 1287-1297), The molecular mechanism operating has remained elusive since no change in sequence specificity has been found, We introduced AMV-specific point mutations in the minimal DBD of chicken c-Myb and studied their effect on structure and function of the purified protein. Fluorescence emission spectra and fluorescence quenching experiments showed that the AMV-specific point mutations had a significant effect on the conformation of the DBD, giving rise to a more compact structure, a change that was accompanied by a reduced sensitivity toward cysteine-specific alkylation and oxidation, The DNA binding properties were also altered by the AMV-specific point mutations, leading to protein-DNA complexes with highly reduced stability, This reduction in stability was, however, more severe with certain subtypes of binding sequences than with others. This differential behavior was also observed in an in vivo model system where DBD-VP16 fusions were coexpressed with various reporters, These findings imply that different subsets of Myb-responsive promoters may react differentially toward the AMV-specific mutations, a phenomenon that could contribute to the altered patterns of gene expression induced by the AMV v-Myb relative to wild type c-Myb.	UNIV OSLO,DEPT BIOCHEM,N-0316 OSLO,NORWAY	University of Oslo								BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN RH, 1995, ONCOGENE, V11, P1771; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Miller JH., 1972, EXPT MOL GENETICS; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; Ording E, 1996, ONCOGENE, V13, P1043; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; SARAI A, 1993, BIOCHEMISTRY-US, V32, P7759, DOI 10.1021/bi00081a022; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; VALTIERI M, 1991, BLOOD, V77, P1181; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	39	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4436	4443		10.1074/jbc.272.7.4436	http://dx.doi.org/10.1074/jbc.272.7.4436			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020167	hybrid			2022-12-25	WOS:A1997WH01900083
J	Savelieva, E; Belair, CD; Newton, MA; DeVries, S; Gray, JW; Waldman, F; Reznikoff, CA				Savelieva, E; Belair, CD; Newton, MA; DeVries, S; Gray, JW; Waldman, F; Reznikoff, CA			20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells	ONCOGENE			English	Article						HPV16 E7; human uroepithelial cells; immortalization; 20q amplification; genome instability	RETINOBLASTOMA GENE-PRODUCT; BREAST CARCINOMAS; BLADDER-CANCER; DNA-SEQUENCES; SOLID TUMORS; COPY NUMBER; HPV16 E7; HYBRIDIZATION; KINASE; LOSSES	Breast, bladder, colon, and ovarian carcinomas show frequent low level 20q gain and less frequently high level 20q13.2 amplification, but the significance of these 20q amplifications in transformation has not been defined, Using karyotypic and comparative genomic hybridization (CGH) analyses, chromosome losses and gains were analysed in six newly immortalized human uroepithelial cell (HUC) lines transformed by Human Papillomavirus 16 (HPV16) E7. Results showed clonal chromosomes with 20q11->qter gain in all six lines. CGH revealed a peak of 20q13.2 amplification in two cell lines. FISH with whole chromosome 20 paint showed expanded chromosome regions (ECRs) and double minute chromosomes (DMs) that contained chromosome 20 material in cell lines with 20q13.2 amplification. FISH with probes from the center of the 20q13.2 human breast cancer amplicon showed as many as 24 signals in cells with 20q13.2 amplification. The acquisition of genome instability in these E7-HUCs did not correlate with TP53 mutation, as all E7-HUCs contained only wildtype TP53. These results suggest that low level 20q gain is associated with overcoming cellular senescence in E7 transformed cells (P-value=2x10(-7)), but does not confer genome instability, while high level 20q13.2 amplification is associated with chromosome instability. Loss of 10p (P-value=3x10(-5) was also important in immortalization of E7-transformed HUCs. Thus, these results have profound implications for interpreting the significance of high versus low level 20q gains in human cancers.	UNIV WISCONSIN,SCH MED,DEPT HUMAN ONCOL,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,DEPT BIOSTAT,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,CTR ENVIRONM TOXICOL,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,COMPREHENS CLIN CANC CTR,MADISON,WI 53792; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC GENET LAB,SAN FRANCISCO,CA 94143; DIV MOL CYTOMETRY,SAN FRANCISCO,CA 94143	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [R01 CA29525-16, R01 CA7158-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELAIR CD, 1996, RADIAT ONCOL INVEST, V3, P368; Brinkmann U, 1996, GENOME RES, V6, P187, DOI 10.1101/gr.6.3.187; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EYFJORD JE, 1995, CANCER RES, V55, P646; GRAY JW, 1992, CANCER, V69, P1536, DOI 10.1002/1097-0142(19920315)69:6+<1536::AID-CNCR2820691306>3.0.CO;2-J; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Holt SE, 1996, MOL CELL BIOL, V16, P2932; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; Reznikoff CA, 1996, CANCER RES, V56, P2886; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Scherf U, 1996, P NATL ACAD SCI USA, V93, P2670, DOI 10.1073/pnas.93.7.2670; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHLEGEL J, 1995, CANCER RES, V55, P6002; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; TOMMASINO M, 1993, ONCOGENE, V8, P195; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YEAGER T, 1995, CANCER RES, V55, P493; YUNIS JJ, 1982, GENE AMPLIFICATION, P297	36	120	130	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					551	560		10.1038/sj.onc.1200868	http://dx.doi.org/10.1038/sj.onc.1200868			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053853				2022-12-25	WOS:A1997WF52400006
J	Desmet, J; Wilson, IA; Joniau, M; DeMaeyer, M; Lasters, I				Desmet, J; Wilson, IA; Joniau, M; DeMaeyer, M; Lasters, I			Computation of the binding of fully flexible peptides to proteins with flexible side chains	FASEB JOURNAL			English	Article						docking; peptide binding; MHC structures; dead-end elimination; rotamer library	DEAD-END ELIMINATION; MOLECULAR RECOGNITION; DOCKING; COMPLEX; COMPLEMENTARITY; CALMODULIN; ALGORITHM; THEOREM; DESIGN; SEARCH	Docking algorithms play an important role in the process of rational drug design and in understanding the mechanism of molecular recognition, Au important determinant for successful docking is the extent to which the configurational space (including conformational changes) of the ligand/receptor system is searched, Here we describe a new, combinatorial method for flexible docking of peptides to proteins that allows full rotation around all single bonds of the peptide Ligand and around those of a large set of receptor side chains, We have simulated the binding of several viral peptides to murine major histocompatibility complex class I H-2K(b). In addition, we have explored the Limits of our by simulating a complex between calmodulin and an 18-residue long helical peptide from calmodulin-dependent protein kinase II alpha. The calculated peptide conformations generally matched well with the X-ray structures, Essential information about local flexibility and about residues that are responsible for strong binding was obtained, We have frequently observed considerable side-chain flexibility during the simulations, showing the need for a flexible treatment of the receptor, Our method may also be useful whenever the receptor side-chain conformation is not available or uncertain, as illustrated by the docking of an H-SKb binding nonapeptide to the receptor structure taken from an octapeptide/H-2K(b) complex.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; FLANDERS INTERUNIV INST BIOTECHNOL, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM	Scripps Research Institute	Desmet, J (corresponding author), KATHOLIEKE UNIV LEUVEN, INTERDISCIPLINARY RES CTR, CAMPUS KORTRIJK, UNIV CAMPUS, B-8500 KORTRIJK, BELGIUM.							BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1994, PROTEIN FOLDING PROB, P125; CAFLISCH A, 1992, PROTEINS, V13, P223, DOI 10.1002/prot.340130305; CHAMBERS JL, 1979, ACTA CRYSTALLOGR B, V35, P1861, DOI 10.1107/S0567740879007925; CRAIG JJ, 1986, INTRO ROBOTICS, P15; DELHAISE P, 1984, J MOL GRAPHICS, V2, P103, DOI 10.1016/0263-7855(84)80002-8; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DESMET J, 1994, PROTEIN FOLDING PROB, P307; DUNBRACK RL, 1994, NAT STRUCT BIOL, V1, P334, DOI 10.1038/nsb0594-334; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FISCHER D, 1995, J MOL BIOL, V248, P459, DOI 10.1006/jmbi.1995.0234; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GOLDSTEIN RF, 1994, BIOPHYS J, V66, P1335, DOI 10.1016/S0006-3495(94)80923-3; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KOSHLAND D E JR, 1971, Pure and Applied Chemistry, V25, P119, DOI 10.1351/pac197125010119; KUNTZ ID, 1994, ACCOUNTS CHEM RES, V27, P117, DOI 10.1021/ar00041a001; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; LASTERS I, 1993, PROTEIN ENG, V6, P717, DOI 10.1093/protein/6.7.717; LASTERS I, 1995, PROTEIN ENG, V8, P815, DOI 10.1093/protein/8.8.815; LEACH AR, 1994, J MOL BIOL, V235, P345, DOI 10.1016/S0022-2836(05)80038-5; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOON JB, 1991, PROTEINS, V11, P314, DOI 10.1002/prot.340110409; PEARL J, 1987, ANNU REV COMPUT SCI, V2, P451, DOI 10.1146/annurev.cs.02.060187.002315; PELLEGRINI M, 1993, PROTEINS, V15, P436, DOI 10.1002/prot.340150410; ROSENFELD R, 1995, ANNU REV BIOPH BIOM, V24, P677, DOI 10.1146/annurev.bb.24.060195.003333; Rosenfeld R, 1995, GENET ANAL-BIOMOL E, V12, P1, DOI 10.1016/1050-3862(95)00107-7; ROSENFELD R, 1993, J MOL BIOL, V234, P515, DOI 10.1006/jmbi.1993.1607; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SANDAK B, 1995, COMPUT APPL BIOSCI, V11, P87; SAWYER TK, 1992, INT J PEPT PROT RES, V40, P274; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SEZERMAN U, 1993, PROTEIN SCI, V2, P1827, DOI 10.1002/pro.5560021105; SHOICHET BK, 1991, J MOL BIOL, V221, P327, DOI 10.1016/0022-2836(91)80222-G; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; WODAK SJ, 1978, J MOL BIOL, V124, P323, DOI 10.1016/0022-2836(78)90302-9	41	49	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					164	172		10.1096/fasebj.11.2.9039959	http://dx.doi.org/10.1096/fasebj.11.2.9039959			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039959				2022-12-25	WOS:A1997WK50900009
J	Madsen, CS; Hershey, JC; Hautmann, MB; White, SL; Owens, GK				Madsen, CS; Hershey, JC; Hautmann, MB; White, SL; Owens, GK			Expression of the smooth muscle myosin heavy chain gene is regulated by a negative-acting GC-rich element located between two positive-acting serum response factor-binding elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; LONG TERMINAL REPEAT; ISOFORM DIVERSITY; CARDIAC-MUSCLE; DNA-BINDING; CARG BOXES; CELLS; PROMOTER; ATHEROSCLEROSIS; IDENTIFICATION	To identify cis- and trans-acting factors that regulate smooth muscle-specific gene expression, we studied the smooth muscle myosin heavy chain gene, a rigorous marker of differentiated smooth muscle. A comparison of smooth muscle myosin heavy chain promoter sequences from multiple species revealed the presence of a highly conserved 227-base pair domain (nucleotides -1321 to -1095 in rat). Results of a deletion analysis of a 4.3-kilobase pair segment of the rat promoter (nucleotides -4220 to +88) demonstrated that this domain was necessary for maximal transcriptional activity in smooth muscle cells. Gel-shift analysis and site-directed mutagenesis demonstrated that one true CArG and another CArG-like element contained within this domain were both recognized by the serum response factor and were both required for the positive activity attributable to this domain. Additional studies demonstrated that mutation of a GC-rich sequence within the 227-base pair conserved domain resulted in a nearly 100% increase in transcriptional activity. Gel-shift analysis showed that this GC rich repressor element was recognized by both Spl and Sp3. These data demonstrate that transcriptional control of the smooth muscle myosin heavy chain gene is highly complex, involving both negative and positive regulatory elements, including CArG sequences found in the promoters of multiple smooth muscle differentiation marker genes.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MOL PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; UNIV VERMONT,DEPT MOL PHYSIOL & BIOPHYS,BURLINGTON,VT 05405	University of Virginia; University of Vermont					NHLBI NIH HHS [P01-HL19242, 5T32-HL07284, R01-HL38854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854, P01HL019242, T32HL007284] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BORRIONE AC, 1989, EUR J BIOCHEM, V183, P413, DOI 10.1111/j.1432-1033.1989.tb14943.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DARBY I, 1990, LAB INVEST, V63, P21; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRID MG, 1993, J VASC RES, V30, P279, DOI 10.1159/000159007; GABBIANI G, 1981, P NATL ACAD SCI-BIOL, V78, P298, DOI 10.1073/pnas.78.1.298; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; Hungerford JE, 1996, DEV BIOL, V178, P375, DOI 10.1006/dbio.1996.0225; Kallmeier RC, 1995, J BIOL CHEM, V270, P30949, DOI 10.1074/jbc.270.52.30949; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KELLEY CA, 1994, CAN J PHYSIOL PHARM, V72, P1351, DOI 10.1139/y94-195; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LIAU G, 1993, J VASC RES, V30, P327, DOI 10.1159/000159014; MADSEN CS, 1993, MOL CELL BIOL, V13, P2162, DOI 10.1128/MCB.13.4.2162; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OWENS GK, 1995, PHYSIOL REV, V75, P487; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; REIN T, 1995, J BIOL CHEM, V270, P19643, DOI 10.1074/jbc.270.33.19643; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ SM, 1984, PROG CARDIOVASC DIS, V26, P355, DOI 10.1016/0033-0620(84)90010-0; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; Watanabe M, 1996, CIRC RES, V78, P978, DOI 10.1161/01.RES.78.6.978; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	52	95	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6332	6340		10.1074/jbc.272.10.6332	http://dx.doi.org/10.1074/jbc.272.10.6332			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045653	hybrid			2022-12-25	WOS:A1997WM64700037
J	Schedin, S; Sindelar, PJ; Pentchev, P; Brunk, U; Dallner, G				Schedin, S; Sindelar, PJ; Pentchev, P; Brunk, U; Dallner, G			Peroxisomal impairment in Niemann-Pick type C disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RAT-LIVER PEROXISOMES; STEROL CARRIER; MURINE MODEL; CHOLESTEROL-BIOSYNTHESIS; ISOPRENOID BIOSYNTHESIS; PRENYLTRANSFERASE; SEPARATION; ACTIVATION; DOLICHOL	Niemann-Pick type C disease (NPC) belongs to the group of lysosomal storage diseases characterized by an accumulation of cholesterol and sphingomyelin. Using a mutant mouse strain, enzymatic markers for lysosomes, mitochondria, microsomes, and peroxisomes were in vestigated in the liver and brain, Aside from lysosomal changes, we found a sizable decrease of peroxisomal beta-oxidation of fatty acids and catalase activity in the brain and liver, Isolated peroxisomes displayed a significant decrease of these enzyme activities, Furthermore, the only phospholipid change in brain was a decreased content of the plasmalogen form of phosphatidylethanolamine, and the dimethylacetal pattern was also modified. The electron microscopical appearance of peroxisomes did not display any large changes, The defect of peroxisomal enzymes was already present 18 days before the onset of the disease, In contrast, the lysosomal marker enzyme increased in activity only 6 days after appearance of the symptoms, The events of the studied process have previously been considered to be elicited by a lysosomal deficiency, but this study demonstrates disturbances similar to those in a number of peroxisomal diseases, It appears that the peroxisomal impair ment is an early event in the process and could be a factor in the development of Niemann-Pick type C disease.	KAROLINSKA INST,NOVUM,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; LINKOPING UNIV,DEPT PATHOL,S-58185 LINKOPING,SWEDEN; NINCDS,NIH,BETHESDA,MD 20892	Karolinska Institutet; Linkoping University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Schedin, S (corresponding author), UNIV STOCKHOLM,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.			Schedin Weiss, Sophia/0000-0003-2143-7052				ANGERMULLER S, 1981, HISTOCHEMISTRY, V71, P33, DOI 10.1007/BF00592568; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; BERGMEYER HU, 1955, BIOCHEM Z, V327, P255; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CARSTEA ED, 1993, P NATL ACAD SCI USA, V90, P2002, DOI 10.1073/pnas.90.5.2002; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DUGAN LL, 1986, J CHROMATOGR, V378, P317, DOI 10.1016/S0378-4347(00)80728-8; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; ERICSSON J, 1993, J BIOL CHEM, V268, P832; GANOZA MC, 1964, THESIS DUKE U ANN AR; GOLDFISCHER S, 1988, LIVER BIOL PATHOBIOL, P255; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P303, DOI 10.1016/0005-2760(92)90236-O; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON WR, 1964, J LIPID RES, V5, P600; NAKAGAWA Y, 1983, J LIPID RES, V24, P1268; OSSENDORP BC, 1993, BIOCHIMIE, V75, P191, DOI 10.1016/0300-9084(93)90077-6; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; PENTCHEV PG, 1980, BIOCHIM BIOPHYS ACTA, V619, P669, DOI 10.1016/0005-2760(80)90116-2; POOSCH MS, 1986, BIOCHIM BIOPHYS ACTA, V884, P585, DOI 10.1016/0304-4165(86)90211-4; RODRIGUEZLAFRASSE C, 1994, BBA-MOL BASIS DIS, V1226, P138, DOI 10.1016/0925-4439(94)90021-3; ROFF CF, 1992, J BIOL CHEM, V267, P15902; RUNQUIST M, 1994, J BIOL CHEM, V269, P5804; SCALLEN TJ, 1985, CHEM PHYS LIPIDS, V38, P239, DOI 10.1016/0009-3084(85)90019-2; SCALLEN TJ, 1971, J BIOL CHEM, V246, P224; SCHEDIN S, 1995, J NEUROCHEM, V65, P670; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; VALTERSSON C, 1982, J LIPID RES, V23, P868; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANIER MT, 1991, J INHERIT METAB DIS, V14, P580, DOI 10.1007/BF01797928	38	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6245	6251		10.1074/jbc.272.10.6245	http://dx.doi.org/10.1074/jbc.272.10.6245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045641	hybrid			2022-12-25	WOS:A1997WM64700025
J	Yang, DQ; Song, JS; Wagenknecht, T; Roche, TE				Yang, DQ; Song, JS; Wagenknecht, T; Roche, TE			Assembly and full functionality of recombinantly expressed dihydrolipoyl acetyltransferase component of the human pyruvate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BILIARY-CIRRHOSIS; SUBUNIT-BINDING DOMAIN; PROTEIN-X COMPONENT; ESCHERICHIA-COLI; MULTIENZYME COMPLEX; LIPOYL DOMAIN; SACCHAROMYCES-CEREVISIAE; TRANSACETYLASE COMPONENT; BOVINE KIDNEY; BACILLUS-STEAROTHERMOPHILUS	The dihydrolipoyl acetyltransferase (E2) component of mammalian pyruvate dehydrogenase complex (PDC) consists of 60 COOH-terminal domains as an inner assemblage and sequentially via linker regions an exterior pyruvate dehydrogenase (E1) binding domain and two lipoyl domains, Mature human E2, expressed in a protease-deficient Escherichia coli strain at 27 degrees, was prepared in a highly purified form, Purified E2 had a high acetyltransferase activity, was well lipoylated based on its acetylation, and bound a large complement of bovine E1. Electron micrographs demonstrated that the inner core was assembled in the expected pentagonal dodecahedron shape with El binding around the inner core periphery, With saturating E1 and excess dihydrolipoyl dehydrogenase (E3) but no E3-binding protein (E3BP), the recombinant E2 supported the overall PDC reaction at 4% of the rate of bovine E2 E3BP subcomplex, The lipoates of assembled human E2 or its free bilipoyl domain region were reduced by E3 at rates proportional to the lipoyl domain concentration, but those of the E2 E3BP were rapidly used in a concentration-independent manner consistent with bound E3 rapidly using a set of lipoyl domains localized nearby, Given this restriction and the need for E3BP for high PDC activity, directed channeling of reducing equivalents to bound E3 must be very efficient in the complex, The recombinant E2 oligomer increased E1 kinase activity by up to 4-fold and, in a Ca2+-dependent process, increased phospho-E1 phosphatase activity more than 15-fold. Thus the E2 assemblage fully provides the molecular intervention whereby a single E2-bound kinase or phosphatase molecule rapidly phosphorylate or dephosphorylate, respectively, many E2-bound E1. Thus, we prepared properly assembled, fully functional human E2 that mediated enhanced regulatory enzyme activities but, lacking E3BP, supported low PDC activity.	KANSAS STATE UNIV, DEPT BIOCHEM, MANHATTAN, KS 66506 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	Kansas State University; State University of New York (SUNY) System; Wadsworth Center				Song, Jiasheng/0000-0003-3053-0929	NIDDK NIH HHS [DK18320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHAL RH, 1994, J BIOL CHEM, V269, P31372; BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; BLEILE DM, 1981, J BIOL CHEM, V256, P514; BUTTERWORTH PJ, 1975, J BIOL CHEM, V250, P1921; CATE RL, 1979, J BIOL CHEM, V254, P1659; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; DAMMUNI Z, 1984, BIOCHEM BIOPH RES CO, V65, P575; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; DEMARCUCCI OL, 1995, ARCH BIOCHEM BIOPHYS, V323, P169, DOI 10.1006/abbi.1995.0023; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; HANEMAAIJER R, 1989, EUR J BIOCHEM, V181, P47, DOI 10.1111/j.1432-1033.1989.tb14692.x; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; HARRIS RA, 1996, ALPHA KETO ACID DEHY, P139; HIPPS DS, 1994, BIOCHEM J, V297, P137, DOI 10.1042/bj2970137; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; JAMES AG, 1995, FEBS LETT, V373, P111, DOI 10.1016/0014-5793(95)01020-F; JILKA JM, 1986, J BIOL CHEM, V261, P1858; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P11249, DOI 10.1021/bi00111a009; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LESSARD IAD, 1995, BIOCHEM J, V306, P727, DOI 10.1042/bj3060727; LI L, 1992, ARCH BIOCHEM BIOPHYS, V296, P497, DOI 10.1016/0003-9861(92)90603-T; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; MACHADO RS, 1993, FEBS LETT, V323, P243, DOI 10.1016/0014-5793(93)81349-5; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; MILES JS, 1987, BIOCHIM BIOPHYS ACTA, V913, P117, DOI 10.1016/0167-4838(87)90319-0; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OCONNOR TP, 1982, J BIOL CHEM, V257, P3110; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; ONO K, 1993, J BIOL CHEM, V268, P26135; PACKMAN LC, 1986, FEBS LETT, V206, P193, DOI 10.1016/0014-5793(86)80979-6; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERHAM RN, 1996, ALPHA KETO ACID DEHY, P1; PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; Roche T. E., 1996, CHANNELING INTERMEDI, P115; ROCHE TE, 1993, BIOCHEMISTRY-US, V32, P5629, DOI 10.1021/bi00072a019; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; SCHULZE E, 1991, EUR J BIOCHEM, V202, P841, DOI 10.1111/j.1432-1033.1991.tb16441.x; STOFFLERMEILICKE M, 1988, METHOD ENZYMOL, V164, P503; SURH CD, 1989, HEPATOLOGY, V10, P127, DOI 10.1002/hep.1840100202; SURH CD, 1990, J IMMUNOL, V144, P3367; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WU TL, 1984, BIOCHEMISTRY-US, V23, P221, DOI 10.1021/bi00297a008; YANG YS, 1986, BIOCHEMISTRY-US, V25, P8173, DOI 10.1021/bi00373a008	72	30	31	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6361	6369		10.1074/jbc.272.10.6361	http://dx.doi.org/10.1074/jbc.272.10.6361			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045657	hybrid			2022-12-25	WOS:A1997WM64700041
J	Booth, AA; Khalifah, RG; Todd, P; Hudson, BG				Booth, AA; Khalifah, RG; Todd, P; Hudson, BG			In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs) - Novel inhibition of post-Amadori glycation pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	ASBMB / ASIP / AAI Meeting	JUN 02-06, 1996	NEW ORLEANS, LA	ASBMB, ASIP, AAI			MAILLARD REACTION-PRODUCTS; ADVANCED GLYCOSYLATION; DIABETES-MELLITUS; CROSS-LINKING; ALZHEIMERS-DISEASE; NONENZYMATIC GLYCOSYLATION; AUTOXIDATIVE GLYCOSYLATION; PHYSIOLOGICAL CONDITIONS; PROTEIN GLYCOSYLATION; GLUCOSE AUTOXIDATION	Nonenzymatic protein glycation (Maillard reaction) leads to heterogeneous, toxic, and antigenic advanced glycation end products (''AGEs'') and reactive precursors that have been implicated in the pathogenesis of diabetes, Alzheimer's disease, and normal aging, In vitro inhibition studies of AGE formation in the presence of high sugar concentrations are difficult to interpret, since AGE-forming intermediates may oxidatively arise from free sugar or from Schiff base condensation products with protein amino groups, rather than from just their classical Amadori rearrangement products. We recently succeeded in isolating an Amadori intermediate in the reaction of ribonuclease A (RNase) with ribose (Khalifah, R. G., Todd, P., Booth, A. A., Yang, S. X., Mott, J. D., and Hudson, B. G. (1996) Biochemistry 35, 4645-4654) for rapid studies of post-Amadori AGE formation in absence of free sugar or reversibly formed Schiff base precursors to Amadori products. This provides a new strategy for a better understanding of the mechanism of AGE inhibition by established inhibitors, such as aminoguanidine, and for searching for novel inhibitors specifically acting on post-Amadori pathways of AGE formation, Aminoguanidine shows little inhibition of post-Amadori AGE formation in RNase and bovine serum albumin, in contrast to its apparently effective inhibition of initial (although not late) stages of glycation in the presence of high concentrations of sugar, Of several derivatives of vitamins B-1 and B-6 recently studied for possible AGE inhibition in the presence of glucose (Booth, A. A., Khalifah, R. G., and Hudson, B. G. (1996) Biochem. Biophys. Res. Commun. 220, 113-119), pyridoxamine and, to a lesser extent, thiamine pyrophosphate proved to be novel and effective post-Amadori inhibitors that decrease the final levels of AGEs formed, Our mechanism-based approach to the study of AGE inhibition appears promising for the design and discovery of novel post-Amadori AGE inhibitors of therapeutic potential that may complement others, such as aminoguanidine, known to either prevent initial sugar attachment or to scavenge highly reactive dicarbonyl intermediates.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOL BIOL, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center				Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [DK 43507] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043507] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGYAL SJ, 1984, ADV CARBOHYD CHEM BI, V42, P15, DOI 10.1016/S0065-2318(08)60122-5; ARAKI N, 1992, J BIOL CHEM, V267, P10211; Baynes J. W., 1989, MAILLARD REACTION AG, P43; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Booth AA, 1996, BIOCHEM BIOPH RES CO, V220, P113, DOI 10.1006/bbrc.1996.0366; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1981, ANNU REV BIOCHEM, V50, P385, DOI 10.1146/annurev.bi.50.070181.002125; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1992, DIABETES, V41, P57, DOI 10.2337/diab.41.2.S57; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Bruice TC., 1966, BIOORGANIC MECH, VII; BUNN HF, 1981, SCIENCE, V213, P222, DOI 10.1126/science.12192669; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; CHEN HJC, 1993, J CARBOHYD CHEM, V12, P731; Cohen MP, 1996, J AM SOC NEPHROL, V7, P183; COHEN MP, 1994, KIDNEY INT, V45, P1673, DOI 10.1038/ki.1994.219; COLACO CALS, 1994, NEUROREPORT, V5, P859, DOI 10.1097/00001756-199404000-00001; DANIELS BS, 1992, DIABETES, V41, P1415, DOI 10.2337/diabetes.41.11.1415; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; EDELSTEIN D, 1992, DIABETES, V41, P26, DOI 10.2337/diabetes.41.1.26; Engvall E, 1980, Methods Enzymol, V70, P419; Finot P.A., 1990, MAILLARD REACTION FO; FU MX, 1992, DIABETES, V41, P42, DOI 10.2337/diab.41.2.S42; FUJIMORI E, 1989, BIOCHIM BIOPHYS ACTA, V998, P105, DOI 10.1016/0167-4838(89)90260-4; GANEA E, 1994, BBA-MOL BASIS DIS, V1226, P286, DOI 10.1016/0925-4439(94)90039-6; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; HARDING JJ, 1985, ADV PROTEIN CHEM, V37, P248; HARRINGTON CR, 1994, NATURE, V370, P247, DOI 10.1038/370247a0; HAYAKAWA M, 1991, J NUTR SCI VITAMINOL, V37, P149; HIRSCH J, 1991, CARBOHYD RES, V220, pC5, DOI 10.1016/0008-6215(91)80024-H; HIRSCH J, 1992, CARBOHYD RES, V232, P125, DOI 10.1016/S0008-6215(00)90999-6; HIRSCH J, 1995, CARBOHYD RES, V267, P17, DOI 10.1016/0008-6215(94)00285-N; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Kemeny D.M., 1988, ELISA OTHER SOLID PH; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; KHATAMI M, 1988, LIFE SCI, V43, P1725, DOI 10.1016/0024-3205(88)90484-5; KIMURA T, 1995, NEUROREPORT, V6, P866, DOI 10.1097/00001756-199504190-00010; LEDL F, 1990, ADV LIF SCI, P19; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MEANS GE, 1982, DIABETES S3, V31, P1; MONNIER VM, 1990, ADV LIF SCI, P393; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MONNIER VM, 1989, MAILLARD REACTION AG, P1; NAKAYAMA H, 1989, BIOCHEM BIOPH RES CO, V162, P740, DOI 10.1016/0006-291X(89)92372-3; NAKAYAMA H, 1991, J IMMUNOL METHODS, V140, P119; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; OU PM, 1993, BIOCHEM PHARMACOL, V46, P1139, DOI 10.1016/0006-2952(93)90461-5; RAETZ CRH, 1972, BIOCHEMISTRY-US, V11, P2229, DOI 10.1021/bi00762a004; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; REISER KM, 1991, P SOC EXP BIOL MED, V196, P17; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; VLASSARA H, 1994, LAB INVEST, V70, P138; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; ZYZAK DV, 1995, ARCH BIOCHEM BIOPHYS, V316, P547, DOI 10.1006/abbi.1995.1073	76	243	253	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5430	5437		10.1074/jbc.272.9.5430	http://dx.doi.org/10.1074/jbc.272.9.5430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	WK747	9038143	hybrid			2022-12-25	WOS:A1997WK74700011
J	Kanoh, H; Williger, BT; Exton, JH				Kanoh, H; Williger, BT; Exton, JH			Arfaptin 1, a putative cytosolic target protein of ADP-ribosylation factor, is recruited to Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BREFELDIN-A; PHOSPHOLIPASE-D; GUANINE-NUCLEOTIDE; AMINO-TERMINUS; ENDOPLASMIC-RETICULUM; ORGANELLE STRUCTURE; BINDING PROTEINS; COATED VESICLES; MESSENGER-RNAS	ADP-ribosylation factors (ARFs) have been implicated in vesicle transport in the Golgi complex. Employing yeast two-hybrid screening of an HL60 cDNA library using a constitutively active mutant of ARF3 (ARF3 . Q71L), as a probe, we have identified a cDNA encoding a novel protein with a calculated molecular mass of 38.6 kDa, which we have named arfaptin 1. The mRNA of arfaptin 1 was ubiquitously expressed, and recombinant arfaptin 1 bound preferentially to class I ARFs, especially ARF1, but only in the GTP-bound form, The interactions were independent of myristoylation of ARF. Arfaptin 1 in cytosol was recruited to Golgi membranes by ARF in a guanosine 5'-O-(3-thiotriphosphate)-dependent and brefeldin A-sensitive manner, When expressed in COS cells, arfaptin 1 was localized to the Golgi complex. The yeast two-hybrid system yielded another clone, which encoded a putative protein, which we have named arfaptin 2. This consisted of the same number of amino acids as arfaptin 1 and was 60% identical to it, Arfaptin 2 was also ubiquitously expressed and bound to the GTP-, but not GDP-liganded form of class I ARFs, especially ARF1, These results suggest that arfaptins 1 and 2 may be direct target proteins of class 1 ARFs, Arfaptin 1 may be involved in Golgi function along with ARF1.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOL BIOPHYS & PHARMACOL,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAYHOFF MO, 1987, ATLAS PROTEIN SEQ S3, V5; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Sambrook J., 2002, MOL CLONING LAB MANU; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	55	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5421	5429		10.1074/jbc.272.9.5421	http://dx.doi.org/10.1074/jbc.272.9.5421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038142	hybrid			2022-12-25	WOS:A1997WK74700010
J	Shaikh, AC; Sadowski, PD				Shaikh, AC; Sadowski, PD			The Cre recombinase cleaves the lox site in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-DELTA-RESOLVASE; FLP RECOMBINASE; ACTIVE-SITE; INTEGRASE FAMILY; CATALYTIC PARTY; DNA CLEAVAGE; PROTEIN; MECHANISM; PLASMID; BINDING	The Cre protein is a conservative site-specific recombinase that is encoded by bacteriophage P1. Its function in vivo is to resolve dimeric lysogenic P1 plasmids that arise by general recombination. In this way Cre facilitates effective partition of the P1 prophage. Cre is a member of the integrase family of conservative site-specific recombinases. Cleavage of the DNA by the integrases involves covalent attachment of a conserved nucleophilic tyrosine to the S'-phosphoryl end at the site of the break. We have used in vitro complementation tests to show that the Cre protein, like the Flp protein of the 2-mu m plasmid of Saccharomyces cerevisiae, cleaves its target lox site in trans. Moreover, the data are compatible with two modes of cleavage; one requires the reconstitution of a pseudo full-site from half-sites and the other requires the assembly of a higher order complex that resembles a synaptic complex.	UNIV TORONTO,DEPT MED GENET & MICROBIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto								ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; Blakely GW, 1996, MOL MICROBIOL, V20, P234, DOI 10.1111/j.1365-2958.1996.tb02505.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DIXON JE, 1995, MOL MICROBIOL, V18, P449, DOI 10.1111/j.1365-2958.1995.mmi_18030449.x; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; GRINDLEY NDF, 1993, SCIENCE, V262, P738, DOI 10.1126/science.8235593; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PAN GH, 1993, J BIOL CHEM, V268, P3683; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; Sambrook J., 2002, MOL CLONING LAB MANU; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; STARK WM, 1995, TRENDS GENET, V11, P121; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VETTER D, 1983, P NATL ACAD SCI-BIOL, V80, P7284, DOI 10.1073/pnas.80.23.7284; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Yang JY, 1996, CELL, V85, P447, DOI 10.1016/S0092-8674(00)81122-8; YANG SH, 1994, J BIOL CHEM, V269, P12789	37	40	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5695	5702		10.1074/jbc.272.9.5695	http://dx.doi.org/10.1074/jbc.272.9.5695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038180	hybrid			2022-12-25	WOS:A1997WK74700048
J	Wang, DG; Landick, R				Wang, DG; Landick, R			Nuclease cleavage of the upstream half of the nontemplate strand DNA in an Escherichia coli transcription elongation complex causes upstream translocation and transcriptional arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TERNARY COMPLEXES; STAPHYLOCOCCAL NUCLEASE; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; GREA; SITE; ION; TERMINATION; INITIATION	We tested the susceptibility of nucleic acid strands in a halted transcription elongation complex to digestion by micrococcal nuclease (MN). The 16-nucleotide nascent RNA was protected within RNA polymerase. A 27-28-nucleotide template strand DNA fragment also was resistant to MN digestion. However, the upstream half of the nontemplate DNA within this region was digested rapidly by MN, suggesting that the nontemplate strand emerges from the RNA polymerase near the middle of the melted transcription bubble with the bases oriented away from the enzyme surface. MN cleavage of the exposed nontemplate DNA shifted polymerase backward, making it unable to extend the RNA chain, However, the MN-trimmed G16 complexes could be reactivated by GreB-stimulated cleavage of the nascent RNA. These results favor a model of transcriptional arrest involving upstream slippage of RNA polymerase along the RNA and DNA chains. They also suggest that the exposed segment of nontemplate DNA may directly or indirectly stabilize the lateral position of the transcription complex along the DNA.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; WASHINGTON UNIV,DIV BIOL & BIOMED SCI,ST LOUIS,MO 63130	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL)					NIGMS NIH HHS [GM38660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038660, R01GM038660, R29GM038660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN MJ, 1995, HARVEY LECT, P1; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FENG GH, 1994, J BIOL CHEM, V269, P22282; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1993, J BIOL CHEM, V268, P25604; HEUMANN H, 1986, EUR J BIOCHEM, V158, P575, DOI 10.1111/j.1432-1033.1986.tb09793.x; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KOMISSAROVA N, 1997, IN PRESS P NATL ACAD; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LEE DN, 1994, J BIOL CHEM, V269, P22295; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; Maxam A M, 1980, Methods Enzymol, V65, P499; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Perrin DM, 1996, BIOCHEMISTRY-US, V35, P5318, DOI 10.1021/bi952197r; REEDER C, 1996, CELL, V87, P767; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; ROHRER H, 1977, EUR J BIOCHEM, V79, P401, DOI 10.1111/j.1432-1033.1977.tb11822.x; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P8050, DOI 10.1021/bi00348a032; THEDERAHN T, 1990, BIOCHEM BIOPH RES CO, V168, P756, DOI 10.1016/0006-291X(90)92386-E; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	39	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5989	5994		10.1074/jbc.272.9.5989	http://dx.doi.org/10.1074/jbc.272.9.5989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038220	hybrid			2022-12-25	WOS:A1997WK74700088
J	ONeill, FJ; Hu, Y; Chen, T; Carney, H				ONeill, FJ; Hu, Y; Chen, T; Carney, H			Identification of p53 unbound to T-antigen in human cells transformed by simian virus 40 T-antigen	ONCOGENE			English	Article						p53; T-antigen; human cells; transformation; immortalization	TUMOR-SUPPRESSOR P53; MOUSE EMBRYO FIBROBLASTS; MONOCLONAL-ANTIBODIES; CELLULAR-TRANSFORMATION; IMMUNOCHEMICAL ANALYSIS; SV40-TRANSFORMED CELLS; PROTEIN P53; SV40; MUTATIONS; EXPRESSION	In several clones of SV40-transformed human cells, we investigated the relative amounts of large T-Antigen (T-Ag) and p53 proteins, both unbound and associated within complexes, with the goal of identifying changes associated with transformation and immortalization, Cells were transformed by wild type (wt) T-Ag, a functionally temperature sensitive T-Ag (tsA58) and other T-Ag variants, Western analysis showed that while most of the T-Ag was ultimately bound by p53, most of the p53 remained unbound to T-Ag, Unbound p53 remained in the supernatant after a T-Ag immunoprecipitation and p53 was present in two to fourfold excess of T-Ag, In one transformant there was five to tenfold more p53 than T-Ag, p53 was present in transformants in amounts at least 200-fold greater than in untransformed human cells, In wt and variant T-Ag transformants, including those generated with tsA58 T-Ag, large amounts of unbound p53 were present in both pre-crisis and immortal cells and when the cells were grown at permissive or non-permissive temperatures, We also found that in transformants produced by tsA58, an SV40/JCV chimeric T-Ag and other variants, T-Ag appeared to form a complex with p53 slowly perhaps because one or both proteins matured slowly, The presence in transformed human cells of large amounts of unbound p53 and in excesss of T-Ag suggests that sequestration of p53 by T-Ag, resulting from complex formation, is required neither for morphological transformation nor immortalization of human cells, Rather, these results support the proposal that high levels of p53, the T-Ag/p53 complexes, or other biochemical event(s), lead to transformation and immortalization of human cells by T-Ag.	UNIV UTAH, HUNTSMAN CANC INST, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA; VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84148 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ONeill, FJ (corresponding author), UNIV UTAH, HUNTSMAN CANC INST, DEPT ONCOL SCI, DIV MOL BIOL & GENET, SALT LAKE CITY, UT 84132 USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARTEK J, 1990, ONCOGENE, V5, P893; BENCHIMOL S, 1982, EMBO J, V1, P1053; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1989, NATO ASI SERIES; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEE AP, 1981, ANAL BIOCHEM, V116, P524, DOI 10.1016/0003-2697(81)90397-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; Hansen R, 1995, ONCOGENE, V11, P2535; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P5304; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1980, PROC R SOC SER B-BIO, V210, P451, DOI 10.1098/rspb.1980.0146; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; ONEILL FJ, 1990, INTERVIROLOGY, V31, P175, DOI 10.1159/000150152; ONEILL FJ, 1988, VIRUS RES, V11, P109, DOI 10.1016/0168-1702(88)90037-8; ONEILL FJ, 1993, VIRUS RES, V30, P171, DOI 10.1016/0168-1702(93)90005-8; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1994, VIRUS RES, V34, P237, DOI 10.1016/0168-1702(94)90126-0; ONEILL FJ, 1982, J VIROL, V43, P18, DOI 10.1128/JVI.43.1.18-25.1982; ONEILL FJ, 1995, ONCOGENE, V90, P1131; PRIVES C, 1991, COLD SPRING HARB SYM, V56, P227; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TIEMANN F, 1994, ONCOGENE, V9, P1907; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOLKEN RH, 1981, J IMMUNOL METHODS, V54, P209; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZERRAHN J, 1993, J VIROL, V67, P1555, DOI 10.1128/JVI.67.3.1555-1563.1993; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	59	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					955	965		10.1038/sj.onc.1200913	http://dx.doi.org/10.1038/sj.onc.1200913			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050995				2022-12-25	WOS:A1997WK34400009
J	Adeli, K; Wettesten, M; Asp, L; Mohammadi, A; Macri, J; Olofsson, SO				Adeli, K; Wettesten, M; Asp, L; Mohammadi, A; Macri, J; Olofsson, SO			Intracellular assembly and degradation of apolipoprotein B-100-containing lipoproteins in digitonin-permeabilized HEP G2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; APO-B-100-CONTAINING LIPOPROTEINS; MCA-RH7777 CELLS; PULSE-CHASE; OLEIC-ACID; APO-B; SECRETION; TRANSLOCATION; HEPATOCYTES	Permeabilized Hep G2 cells have been used to investigate the turnover of apolipoprotein B-100 (apoB-100). When such cells were chased in the presence of buffer, there was no biosynthesis of apoB-100, nor was the protein secreted from the cells, Thus the turnover of apoB-100 in these cells reflected the posttranslational degradation of the protein, Pulse-chase studies indicated that apoB-100 was degraded both when associated with the membrane and when present as lipoproteins in the secretory pathway, Neither albumin nor alpha(1)-antitrypsin showed any significant posttranslational intracellular degradation under the same condition, The kinetics for the turnover of apoB-100 in the luminal content differed from that of apoB-100 that was associated with the microsomal membrane. Moreover, while the degradation of the luminal apoB-100 was inhibited by N-acetyl-leucyl-leucyl-norleucinal (ALLN), this was not the case for the membrane-associated protein, Together these results suggest the existence of different pathways for the degradation of luminal apoB-100 and membrane-associated apoB-100, This was further supported by results from pulse-chase studies in intact cells, showing that ALLN increased the amount of radioactive apoB-100 that associated with the microsomal membrane during the pulse-labeling of the cells. However, ALLN did not influence the rate of turnover of the membrane-associated apoB-100. The presence of an ATP-generating system during the chase of the permeabilized cells prevented the disappearance of pulse labeled apoB-100 from the luminal lipoprotein associated pool. The ATP-generating system combined with cytosol protected the total apoB-100 in the system from being degraded, The cells cultured in the presence of oleic acid and chased after permeabilization in the presence of cytosol and the ATP-generating system showed an increase in the amount of apoB-100 present on dense (''high density lipoprotein-like'') particles, This increase was linear during the time investigated (i.e. from 0 to 2 h chase) and independent of protein biosynthesis, Our results indicate that the dense particle was generated by a redistribution of apoB-100 within the secretory pathway and that it most likely was assembled from the membrane-associated form of apoB-100, These results indicate that the release of apoB-100 from this membrane-associated form to the microsomal lumen is dependent on cytosolic factors and a source of metabolic energy.	GOTHENBURG UNIV,DEPT BIOCHEM MED,S-41390 GOTHENBURG,SWEDEN; UNIV WINDSOR,DEPT CHEM & BIOCHEM,WINDSOR,ON N9B 3P4,CANADA	University of Gothenburg; University of Windsor				Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1994, J BIOL CHEM, V269, P9166; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DU EZ, 1994, J BIOL CHEM, V269, P24169; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; PIND S, 1993, METHOD ENZYMOL, V221, P222, DOI 10.1016/0076-6879(93)21019-5; PULLINGER CR, 1989, J LIPID RES, V30, P1065; ROPOSO SM, 1995, J CELL BIOL, V131, P1403; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; RUSTAEUS S, 1995, ATHEROSCLEROSIS, V10, P958; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; Sjoberg A, 1996, J LIPID RES, V37, P275; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WU XJ, 1994, J BIOL CHEM, V269, P12375; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	37	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5031	5039		10.1074/jbc.272.8.5031	http://dx.doi.org/10.1074/jbc.272.8.5031			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030566	hybrid			2022-12-25	WOS:A1997WJ85500054
J	Ekena, K; Weis, KE; Katzenellenbogen, JA; Katzenellenbogen, BS				Ekena, K; Weis, KE; Katzenellenbogen, JA; Katzenellenbogen, BS			Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; BREAST-CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; PROMOTER-CONTEXT; LIGAND-BINDING; IDENTIFICATION; ACID; DNA; MUTAGENESIS; CYSTEINES	We have previously examined, by alanine scanning mutagenesis, amino acids 515-535 of the estrogen receptor (ER) ligand binding domain to determine which of these residues are important in estradiol binding, Mutation at four sites that potentially lie along one face of an alpha-helix, Gly(521), His(524), Leu(525), and Met(528), all significantly impaired estradiol binding by the ER (Ekena, K., Weis, K. E., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. (1996) J. Biol. Chem. 271, 20053-20059), In this report, we compare the pattern of residues that are important in the recognition of several structurally diverse estrogen agonists and antagonists (the synthetic nonsteroidal agonist hexestrol, an agonist derived from the mold metabolite zearalenone, P1496, and the partial agonist antagonist trans-hydroxytamoxifen) with those that are predicted to contact estradiol in the receptor-ligand complex, Although there are some similarities in the pattern of residue recognition among all four ligands, each ligand showed distinct differences as well, Interestingly, alanine substitution at only one residue, the leucine at position 525, was found to inhibit binding of all the ligands tested, Another residue, His(524), was found to be important in the recognition of three different agonists but not trans-hydroxytamoxifen (the only ligand lacking a second hydroxyl group), The recognition of estradiol and another agonist, P1496, was impaired by the G521A mutation, whereas ligand-induced activity by the two compounds that lack B- and C-rings, hexestrol and trans-hydroxytamoxifen, was unaffected, Our findings demonstrate that these ligands fit into the ER ligand binding pocket differently and that each contacts a distinct set of amino acids, The smaller ligands (estradiol and hexestrol) have a narrower footprint of interacting residues than the larger ligands (P1496 and trans hydroxytamoxifen). This pattern of interaction is most consistent with the amino acids within this region being in contact with the portion of these ligands that corresponds to the D-ring end of estradiol, The interplay between the shape of an ER ligand and the residues that support its binding to ER may potentially underlie the selective actions of different ER ligands in various cell and promoter contexts.	UNIV ILLINOIS,DEPT MOL & INTEGRAT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL CANCER INSTITUTE [F32CA068653, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015556] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA68653, 2R37CA18119] Funding Source: Medline; NIDDK NIH HHS [2R37DK15556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; ECKERT RL, 1982, J BIOL CHEM, V257, P8840; Ekena K, 1996, J BIOL CHEM, V271, P20053, DOI 10.1074/jbc.271.33.20053; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; KATZENELLENBOGEN BS, 1979, ENDOCRINOLOGY, V105, P33, DOI 10.1210/endo-105-1-33; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; KATZENELLENBOGEN BS, 1991, J NATL CANCER I, V83, P1434, DOI 10.1093/jnci/83.20.1434; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KATZENELLENBOGEN JA, 1975, BIOCHEMISTRY-US, V14, P1742, DOI 10.1021/bi00679a029; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; PAKDEL F, 1993, MOL ENDOCRINOL, V7, P1408, DOI 10.1210/me.7.11.1408; READ LD, 1991, GENES ONCOGENES HORM, P277; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; REESE JC, 1991, J BIOL CHEM, V266, P10880; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sambrook J., 2002, MOL CLONING LAB MANU; Sarrel P.M., 1994, SCI MED, V1, P44; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WAKELING AE, 1995, BIOCHEM PHARMACOL, V49, P1545, DOI 10.1016/0006-2952(94)00528-T; WAKELING AE, 1996, HORMONE DEPENDENT CA, P107; WRENN CK, 1993, J BIOL CHEM, V268, P24089	34	65	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5069	5075		10.1074/jbc.272.8.5069	http://dx.doi.org/10.1074/jbc.272.8.5069			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030571	hybrid			2022-12-25	WOS:A1997WJ85500059
J	Zhou, ZH; Zuber, ME; Burrus, LW; Olwin, BB				Zhou, ZH; Zuber, ME; Burrus, LW; Olwin, BB			Identification and characterization of a fibroblast growth factor (FGF) binding domain in the cysteine-rich FGF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL ECTODERMAL RIDGE; HEPARIN-BINDING; NUCLEAR TRANSLOCATION; MITOGENIC ACTIVITY; ENDOTHELIAL-CELLS; LIMB DEVELOPMENT; INNER-EAR; FACTOR-I; SULFATE; SEQUENCE	Three distinct transmembrane glycoproteins bind fibroblast growth factor (FGF) family members. These include heparan sulfate proteoglycans, the tyrosine kinase-containing FGF receptors (FGFRs), and a cysteine-rich FGF receptor (CFR), The four FGFRs are thought to mediate FGF-signaling events but require the participation of the heparan sulfate proteoglycans to bind FGFs and transduce intracellular signals. However, a number of groups have proposed that FGF action requires events independent of FGFR activation, CFR, a high affinity FGF binding protein, was first isolated from chicken embryos. To better understand the interactions between CFR and FGFs, we have constructed a series of CFR deletion mutants and CFR fragments, Analysis of these has identified a similar to 200-amino acid domain that constitutes a CFR FGF binding site, A CFR fragment of 450 residues, CFR(290-740), binds FGF-2 with an affinity indistinguishable from the full-length molecule, whereas smaller fragments display greatly reduced FGF binding. Although CFR binds heparin with high affinity, an analysis of the heparin CFR interaction failed to identify a linear sequence containing a heparin binding site, Two types of FGF binding sites were identified: an ionic strength and heparin-independent site that represents FGF binding to CFR(290-740), and an additional FGF binding site that is heparan sulfate-dependent and sensitive to high ionic strength, This latter site is likely to bind FGF indirectly via heparan sulfate binding to CFR. FGF-2 peptides that encompass a sequence implicated in FGF-2 binding to FGFRs also block FGF-S binding to CFR, Our data suggest that binding of FGFs to CFR and FGFRs is mutually exclusive, since the CFR FGF binding site does not require heparan sulfate, and similar regions on FGF-2 interact with both FGFRs and CFR.	UNIV COLORADO,DEPT MOL CELLULAR & DEV BIOL,BOULDER,CO 80309; WALTHER CANC INST,INDIANAPOLIS,IN 46208	University of Colorado System; University of Colorado Boulder; Walther Cancer Institute			Olwin, Bradley B/A-1333-2014					BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GONATAS JO, 1995, J CELL SCI, V108, P457; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Patstone G, 1996, J BIOL CHEM, V271, P3343; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOULET L, 1994, MOL REPROD DEV, V39, P49, DOI 10.1002/mrd.1080390109; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WALKER A, 1994, J BIOL CHEM, V269, P931; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILKIE AOM, 1995, CURR BIOL, V5, P500; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WU DQ, 1991, J BIOL CHEM, V266, P16778; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZUBER ME, 1996, IN PRESS J CELL PHYS	53	23	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5167	5174		10.1074/jbc.272.8.5167	http://dx.doi.org/10.1074/jbc.272.8.5167			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030584	hybrid			2022-12-25	WOS:A1997WJ85500072
J	Park, WM; Mosteller, RD; Broek, D				Park, WM; Mosteller, RD; Broek, D			Identification of a dominant-negative mutation in the yeast CDC25 guanine nucleotide exchange factor for Ras	ONCOGENE			English	Article						Ras; CDC25 dominant-negative mutant; yeast; signal transduction	ADENYLYL CYCLASE GENE; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; PROTEINS; ACTIVATION; MUTANT; RESIDUES; TRANSFORMATION; COMPLEX; CELLS	In previous studies we changed five conserved amino acid residues in the catalytic domain of the yeast Ras-specific guanine nucleotide exchange factor CDC25(GEF) (Park et al., 1994). One of the substitutions (R1489E) resulted in a molecule which could bind Ras but was catalytically inactive. These observations suggested that CDC25(R1489E) might be a dominant-negative mutant. Here we report further experiments which confirm the dominant-negative phenotype of CDC25(R1489E). Two lines of evidence indicate that the CDC25(R1489E) mutant exhibits Ras-specific binding in vivo. First, expression of CDC25(R1489E) in a wild-type yeast strain caused a partial inhibition of growth which was reversed by overexpression of the wildtype yeast RAS2 protein. Second, expression of CDC25(R1489E) in yeast strain containing a temperature-sensitive, dominant-negative RAS2 mutation (RAS2(vall9ala22)) suppressed the temperature-sensitive phenotype. The latter findings suggest that the CDC25(R1489E) protein bound the mutant RAS2 protein thereby releasing the wild-type CDC25 protein for activation of the wild-type RAS1 protein. Further, using a protein-protein binding assay and guanine nucleotide exchange assay (release of [H-3]-GDP) in vitro, we demonstrate that the CDC25(R1489E) protein can bind wild-type Ras protein but is unable to catalyze GDP-GTP exchange. Thus, the results of genetic and biochemical experiments demonstrate that CDC25(R1489E) encodes a dominant-negative GEF which blocks the Ras signaling pathway by binding wild-type Ras in a catalytically inactive complex.	UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, DEPT BIOCHEM & MOL BIOL, LOS ANGELES, CA 90033 USA	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CHEN SY, 1994, ONCOGENE, V9, P2691; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; HANEY SA, 1994, J BIOL CHEM, V269, P16541; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MACARA IG, 1996, FASEB J, V10, P624; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman F, 1986, LAB COURSE MANUAL ME; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	26	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					831	836		10.1038/sj.onc.1200893	http://dx.doi.org/10.1038/sj.onc.1200893			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047390				2022-12-25	WOS:A1997WJ11200009
J	Chao, JR; Chen, CS; Wang, TF; Tseng, LH; Tsai, JJ; Kuo, ML; Yen, JJY; Yen, HFY				Chao, JR; Chen, CS; Wang, TF; Tseng, LH; Tsai, JJ; Kuo, ML; Yen, JJY; Yen, HFY			Characterization of factor-independent variants derived from TF-1 hematopoietic progenitor cells: The role of the Raf/MAP kinase pathway in the anti-apoptotic effect of GM-CSF	ONCOGENE			English	Article						apoptosis; GM-CSF signalling; Raf-1; MAP; kinase	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; RAPID PHOSPHORYLATION; PROTOONCOGENE RAF-1; MYELOID-LEUKEMIA; GROWTH-FACTORS; ACTIVATION; INTERLEUKIN-3	Human hematopoietic progenitor cells (TF-I) undergo apoptosis upon deprivation of their dependent cytokine, In this report, we have isolated and characterized some spontaneously derived cytokine-independent variants from TF-1 cells, Analysis of several signaling molecules known to be activated by the GM-CSF pathway revealed that two non-autocrine variants were still responsive to GM-CSF stimulation, However, both variants, without ligand stimulation, already had some activated forms of Raf and MAP kinases, Given current knowledge, the activated Raf/MAP kinase pathway was likely to be responsible for the survival of both variants in the cytokine-free medium, However, the growth of hybrids between wild type and either variant was unexpectedly dependent on GM-CSF, Both variants like the wild type cells were still susceptible to apoptosis induced by other stimuli, These results suggest that either the activated Raf/MAP kinase pathway in both variants fs not sufficient to repress the 'two-fold' death signals generated from the hybrids or that there is another mechanism that is responsible for the factor-independent growth of both variants.	ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN; CATHAY GEN HOSP,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,TAIPEI,TAIWAN; NATL TAIWAN UNIV HOSP,DEPT MED GENET,TAIPEI,TAIWAN; CHINESE CULTURE UNIV,INST BIOTECHNOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,SCH MED,INST TOXICOL,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; Academia Sinica - Taiwan; Cathay General Hospital; National Taiwan University; National Taiwan University Hospital; Chinese Culture University; National Taiwan University			Yen, Jeffrey Jong-Young/Q-5134-2018; Kuo, Min-Liang/C-4872-2009	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; KUO, MIN-LIANG/0000-0002-7139-0144; TSENG, LI-HUI/0000-0002-8308-6772				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; KANAKURA Y, 1991, BLOOD, V77, P243; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWENBERG B, 1993, NEW ENGL J MED, V328, P614, DOI 10.1056/NEJM199303043280904; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKUDA K, 1994, EXP HEMATOL, V22, P1111; OKUDA K, 1992, BLOOD, V79, P2880; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TOMPSON CB, 1995, SCIENCE, V267, P1456, DOI DOI 10.1126/SCIENCE.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; YEN JJY, 1995, J IMMUNOL, V154, P2144	29	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					721	728		10.1038/sj.onc.1200884	http://dx.doi.org/10.1038/sj.onc.1200884			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038380	Bronze			2022-12-25	WOS:A1997WG43000011
J	Chi, NC; Adam, EJH; Adam, SA				Chi, NC; Adam, EJH; Adam, SA			Different binding domains for Ran-GTP and Ran-GDP/RanBP1 on nuclear import factor p97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; RAN/TC4 GTPASE; CYTOSOLIC FACTORS; PORE COMPLEX; IDENTIFICATION; TRANSPORT; NUCLEOPORINS; SUBSTRATE; SEQUENCE; DISSOCIATION	Several proteins are required for the transport of nuclear proteins from the cytoplasm to the nucleus, including the nuclear location sequence receptor (NLS receptor), p97, the small nuclear GTPase Ran/TC4, and several nucleoporins. The interaction of Ran with p97 is thought to regulate the interaction of these transport components. Ran-GTP alone binds p97, but Ran-GDP binds p97 only in conjunction with RanBP1. Using site-directed mutagenesis and deletion analysis, we have identified two distinct but overlapping binding domains for Ran-GTP and Ran-GDP/RanBP1 on p97. A short acidic sequence in p97 is part of the Ran-GDP/RanBP1 binding domain, possibly functioning in a similar manner as the C-terminal acidic sequence in Ran. A conserved cysteine residue in p97, Cys-158, is required for binding Ran-GDP/RanBP1, but not for binding of Ran-GTP to p97. In a permeabilized cell protein import assay, a mutant p97 with alanine substituted for Cys-158 is unable to support import in the presence of NLS receptor and Ran. These results support a direct active role for Ran-GDP in the receptor complex and provide evidence that the activity of downstream effecters of small GTPases may be regulated by both GTP- and GDP-bound forms of the protein.	NORTHWESTERN UNIV, SCH MED, DEPT MOL & CELL BIOL, CHICAGO, IL 60611 USA	Northwestern University				Adam, Stephen/0000-0003-3444-7655	NIGMS NIH HHS [5-T32-GM08152-10, 2RO1GM47866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047866, T32GM008152] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; REN MD, 1995, MOL CELL BIOL, V15, P2117; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	43	81	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6818	6822		10.1074/jbc.272.10.6818	http://dx.doi.org/10.1074/jbc.272.10.6818			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045717	hybrid			2022-12-25	WOS:A1997WM64700101
J	Mittl, PRE; DiMarco, S; Krebs, JF; Bai, X; Karanewsky, DS; Priestle, JP; Tomaselli, KJ; Grutter, MG				Mittl, PRE; DiMarco, S; Krebs, JF; Bai, X; Karanewsky, DS; Priestle, JP; Tomaselli, KJ; Grutter, MG			Structure of recombinant human CPP32 in complex with the tetrapeptide Acetyl-Asp-Val-Ala-Asp fluoromethyl ketone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; PROTEASE; INHIBITORS; EXPRESSION; PROTEINASE; CLEAVAGE; CED-3; GENE	The cysteine protease CPP32 has been expressed in a soluble form in Escherichia coli and purified to >95% purity. The three-dimensional structure of human CPP32 in complex with the irreversible tetrapeptide inhibitor acetyl Asp Val-Ala-Asp fluoromethyl ketone was determined by x-ray crystallography at a resolution of 2.3 Angstrom. The asymmetric unit contains a (p17/p12)(2) tetramer, in agreement with the tetrameric structure of the protein in solution as determined by dynamic light scattering and size exclusion chromatography. The overall topology of CPP32 is very similar to that of interleukin-1 beta-converting enzyme (ICE); however, differences exist at the N terminus of the p17 subunit, where the first helix found in ICE is missing in CPP32. A deletion/insertion pattern is responsible for the striking differences observed in the loops around the active site. In addition, the P1 carbonyl of the ketone inhibitor is pointing into the oxyanion hole and forms a hydrogen bond with the peptidic nitrogen of Gly-122, resulting in a different state compared with the tetrahedral intermediate observed in the structure of ICE and CPP32 in complex with an aldehyde inhibitor, The topology of the interface formed by the two p17/p12 heterodimers of CPP32 is different from that of ICE. This results in different orientations of CPP32 heterodimers compared with ICE heterodimers, which could affect substrate recognition. This structural information will be invaluable for the design of small synthetic inhibitors of CPP32 as well as for the design of CPP32 mutants.	CIBA GEIGY AG, CORE DRUG DISCOVERY TECHNOL, CH-4002 BASEL, SWITZERLAND; IDUN PHARMACEUT INC, LA JOLLA, CA 92037 USA	Novartis			Mittl, Peer/E-5352-2017; Di Marco, Stefania -/C-3859-2009					Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BORNSEN KO, 1990, CHIMIA, V44, P412; Boulakia CA, 1996, ONCOGENE, V12, P529; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; MCPHERSON A, 1989, PREPARATION ANAL PRO, P94; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; NAZAVA J, 1994, ACTA CRYSTALLOGR D, V50, P157; NEUHOFF V, 1985, ELECTROPHORESIS, V6, P427, DOI 10.1002/elps.1150060905; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; REVESZ L, 1994, TETRAHEDRON LETT, V35, P9693, DOI 10.1016/0040-4039(94)88361-0; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZULAUF M, 1992, J CRYST GROWTH, V122, P102, DOI 10.1016/0022-0248(92)90232-8	45	212	230	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6539	6547		10.1074/jbc.272.10.6539	http://dx.doi.org/10.1074/jbc.272.10.6539			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045680	hybrid			2022-12-25	WOS:A1997WM64700064
J	Basu, A; Lenka, N; Mullick, J; Avadhani, NG				Basu, A; Lenka, N; Mullick, J; Avadhani, NG			Regulation of murine cytochrome oxidase Vb gene expression in different tissues and during myogenesis - Role of a YY-1 factor-binding negative enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-IV GENE; SERUM RESPONSE FACTOR; C-OXIDASE; TRANSCRIPTION FACTOR; PROMOTER ELEMENTS; POLYMERASE-II; NF-E1 YY-1; YY1; REPRESSION; PROTEIN	The mouse cytochrome oxidase (COX) Vb promoter contains three sequence motifs with partial or full consensus for YY-1 and GTG factor binding and a CArG box, located between positions -480 and -390, Individually, all three motifs stimulated transcription of the TKCAT promoter, and bound distinctly different proteins from the liver and differentiated C2C12 nuclear extracts, Collectively, these motifs, together with the downstream flanking sequence, -378 to -320, suppressed the transcription activity of heterologous promoters, thymidine kinase-chloramphenicol acetyltransferase (TKCAT) and COXIV/CAT, The transcription activities of both TKCAT and COXIV/CAT constructs were induced 3-4-fold during induced myogenesis of C2C12 cells, The downstream CArG-like motif binds transcription factor YY-1, while the upstream YY-1-like motif binds to a yet unidentified factor. Go-expression with intact YY-1, but not that lacking the DNA binding domain suppressed the transcriptional activity. Mutations targeted to the CArG-like motif abolished the suppressive effect of the negative enhancer and the inducibility of the promoter during myogenic differentiation. Our results suggest that the activity of the negative enhancer may determine the level of expression of the COX Vb gene in different tissues.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, BIOCHEM LAB, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Lenka, Nibedita/ABX-3824-2022		NIGMS NIH HHS [GM-49683] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049683] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; BASU A, 1993, J BIOL CHEM, V268, P4188; BASU A, 1991, J BIOL CHEM, V266, P15450; BAUKNECHT T, 1995, J VIROL, V69, P1; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CAO X, 1988, ANN NY ACAD SCI, V550, P337, DOI 10.1111/j.1749-6632.1988.tb35348.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHOU JL, 1991, J BIOL CHEM, V266, P24471; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; Lenka N, 1996, J BIOL CHEM, V271, P30281, DOI 10.1074/jbc.271.47.30281; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATYAMOORTHY K, 1993, MOL CELL BIOL, V13, P6621, DOI 10.1128/MCB.13.11.6621; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SUCHAROV C, 1996, GENE EXP, V5, P93; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	47	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5899	5908		10.1074/jbc.272.9.5899	http://dx.doi.org/10.1074/jbc.272.9.5899			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038208	hybrid			2022-12-25	WOS:A1997WK74700076
J	Cabrita, G; Iqbal, M; Reddy, H; Kemp, G				Cabrita, G; Iqbal, M; Reddy, H; Kemp, G			Activation of the adenovirus protease requires sequence elements from both ends of the activating peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE; TYPE-2; DNA; INHIBITORS; HEAD	The adenovirus protease requires activation by an 11-residue peptide, GVQSLKRRRCF, to achieve maximum proteolytic activity. Derived from the C terminus of the viral protein pVI, the activating peptide (pVI-CT) forms a disulfide bond with cysteine 104 of the protease and causes a conformational change that accompanies the development of proteolytic activity, Results presented here show that the interaction of pVI-CT with the protease is dependent not only on the cysteine 10 but also on glycine 1 and valine 2, Removal of these residues, acetylation of the N-terminal glycine, or mutation of the valine to alanine or threonine significantly reduces or abolishes activation, Peptides lacking Gly-l and Val-2 still form a disulfide bond with the protease but do not cause a conformational change in the protease also they are not effective inhibitors of activation as the interaction is readily reversed by full-length pVI-CT. These results suggest that pVI-CT causes activation by binding to two distinct regions of the protease and in doing so stabilizes the catalytic site, The reversible nature of the activation, suggested by the results presented here, may well reflect an in vivo regulatory mechanism.	UNIV ST ANDREWS,DIV CELL & MOL BIOL,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	University of St Andrews				Cabrita, Goncalo/0000-0002-6511-539X; Iqbal, Munir/0000-0001-5165-5339	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKUSJARVI G, 1981, J VIROL, V38, P469; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; Chiocca S, 1996, J VIROL, V70, P2939, DOI 10.1128/JVI.70.5.2939-2949.1996; CHROBOCZEK J, 1992, VIROLOGY, V186, P280, DOI 10.1016/0042-6822(92)90082-Z; CORNISH JA, 1995, BIOORG MED CHEM LETT, V5, P25, DOI 10.1016/0960-894X(94)00452-L; DAVISON AJ, 1993, J MOL BIOL, V234, P1308, DOI 10.1006/jmbi.1993.1687; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; FREIMUTH P, 1993, VIROLOGY, V193, P349; GRIERSON AW, 1994, J GEN VIROL, V75, P2761, DOI 10.1099/0022-1317-75-10-2761; Jones SJ, 1996, J GEN VIROL, V77, P1821, DOI 10.1099/0022-1317-77-8-1821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; SONG BW, 1995, GENE, V152, P279, DOI 10.1016/0378-1119(94)00657-E; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WEBSTER A, 1993, J GEN VIROL, V74, P1415, DOI 10.1099/0022-1317-74-7-1415; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215	25	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5635	5639		10.1074/jbc.272.9.5635	http://dx.doi.org/10.1074/jbc.272.9.5635			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038173	hybrid			2022-12-25	WOS:A1997WK74700041
J	Freije, JMP; Blay, P; MacDonald, NJ; Manrow, RE; Steeg, PS				Freije, JMP; Blay, P; MacDonald, NJ; Manrow, RE; Steeg, PS			Site-directed mutation of nm23-H1 - Mutations lacking motility suppressive capacity upon transfection are deficient in histidine-dependent protein phosphotransferase pathways in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE-KINASE; GTP-BINDING PROTEINS; TUMOR-METASTASIS; DROSOPHILA DEVELOPMENT; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MYXOCOCCUS-XANTHUS; MELANOMA-CELLS; GENE; PHOSPHORYLATION	We previously compared the structure and motility suppressive capacity of nm23-H1 by transfection of wild type and site-directed mutant forms into breast carcinoma cells, Wild type nm23-H1 and an nm23-H1(S44A) (serine 44 to alanine) mutant suppressed motility, whereas the nm23-H1(P96S), nm23-H1(S120G), and to a lesser extent, nm23-H1(S120A) mutant forms failed to do so, In the present study wild type and mutant recombinant Nm23-H1 proteins have been produced, purified, and assayed for phosphorylation and phosphotransfer activities, We report the first association of Nm23-H1 mutations lacking motility suppressive capacity with decreased in vitro activity in histidine-dependent protein phosphotransferase assays. Nm23-H1(P96S), a Drosophila developmental mutation homolog, exhibited normal autophosphorylation and nucleoside-diphosphate kinase (NDPK) characteristics but deficient phosphotransfer activity in three histidine protein kinase assays, using succinic thiokinase, Nm23-H2, and GST-Nm23-H1 as substrates. Nm23-H1(S120G), found in advanced human neuroblastomas, exhibited deficient activity in several histidine-dependent protein phosphotransfer reactions, including histidine autophosphorylation, downstream phosphorylation on serines, and slightly decreased histidine protein kinase activity; significant NDPK activity was observed. The Nm23-H1(S120A) mutant was deficient in only histidine-dependent serine autophosphorylation. Nm23-H1 and Nm23-H1(S44A) exhibited normal activity in all assays conducted. Based on this correlation, we hypothesize that a histidine-dependent protein phosphotransfer activity of Nm23-H1 may be responsible for its biological suppressive effects.	NCI, WOMENS CANC SECT, PATHOL LAB, DIV CLIN SCI, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Freije, José M.P./A-6535-2008; Blay, Pilar/ABG-8432-2020	Freije, José M.P./0000-0002-4688-8266; Blay, Pilar/0000-0002-1772-2216				ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; BABA H, 1995, CANCER RES, V55, P1977; BERBERICH S, 1995, ONCOGENE, P2343; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; FREIJE JMP, 1996, ATTEMPTS UNDERSTAND, V2, P215; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; HEIDBUCHEL H, 1993, PFLUG ARCH EUR J PHY, V422, P316, DOI 10.1007/BF00374286; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; KANTOR JD, 1993, CANCER RES, V53, P1971; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P90; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LOMBARDI D, 1995, EXP CELL RES, V217, P267, DOI 10.1006/excr.1995.1086; MACDONALD NJ, 1993, CANCER SURV, V16, P175; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; MELKI R, 1992, BIOCHEM BIOPH RES CO, V187, P65, DOI 10.1016/S0006-291X(05)81459-7; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; PARHAR RS, 1995, INT J CANCER, V60, P204; PARKS RE, 1973, NUCLEOSIDE DIPHOSPHO; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TIMMONS L, 1996, IN PRESS ADV GENET; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; XU J, 1996, IN PRESS GENES DEV; Zhang Dechang, 1995, Chinese Medical Sciences Journal, V10, P25	61	121	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5525	5532		10.1074/jbc.272.9.5525	http://dx.doi.org/10.1074/jbc.272.9.5525			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038158	hybrid			2022-12-25	WOS:A1997WK74700026
J	Araujo, JC; Doniger, J; Stoppler, H; Sadie, MR; Rosenthal, LJ				Araujo, JC; Doniger, J; Stoppler, H; Sadie, MR; Rosenthal, LJ			Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation	ONCOGENE			English	Article						transformation suppression; cellular oncogene promoter suppressor; viral oncogene promoter suppressor; retroviral mediated gene transfer	IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; BOVINE PAPILLOMAVIRUS; BINDING PROTEIN; REGION; DNA; INHIBITION; ELEMENTS; RNA; REPLICATION	Human herpesvirus 6A (HHV-6A) strain U1102 was previously shown to contain a 1473 bp transformation suppressor gene (ts) (Araujo et al,, 1995), Ts inhibited transformation of NIH3T3 cells by H-vas and transcription of the H-uas and human immunodeficiency type 1 (HIV-1) promoters in transient transfection experiments. In the current study, stable NIH3T3 cell lines expressing ts protein were established by transfection with pRc-ts containing the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and a neomycin selectable marker. Selected cell lines contained approximately one to two copies per cell of intact ts sequences, expressed ts protein and grew at approximately the same rate as parental NIH3T3 cells. These cell lines were protected from H-ras transformation while parental and NIH3T3 cells containing the ts gene cloned in the antisense orientation were not. Expression of the chloramphenicol acetyl transferase (CAT) gene under the control of the EJ-H-ras promoter was also suppressed in the ts cell lines but not when the CAT gene was under the control of the murine osteosarcoma virus LTR or human cytomegalovirus immediate early promoter. When NIH3T3 cell lines expressing ts protein were established by infection with the retrovirus, LNCts, the cells expressed ts protein and were protected from H-ras transformation, Furthermore, bovine papillomavirus type 1 (BPV-1) transformation was also suppressed in cells cotransfected with BPV-1 plus ts and in ts expressing cell lines transfected with BPV-1. The BPV-1 p89 and p2443 promoters were down-regulated in 3T3-ts lines. Because the human papillomavirus type 16 (HPV-16) p97 promoter has similarity to the BPV-1 p89 promoter, the ability of ts to suppress p97 was also tested. Like the H-ras and BPV-1 promoters, HPV-16 p97 was downregulated in 3T3-ts lines. The data indicate the utility of ts against H-ras, BPV-1 and HPV-16 promoters and their respective oncogenes.	GEORGETOWN UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PATHOL, WASHINGTON, DC 20007 USA; US FDA, CTR BIOL EVALUAT & RES, DIV TRANSFUS TRANSMITTED DIS, ROCKVILLE, MD 20852 USA	Georgetown University; Georgetown University; Georgetown University; US Food & Drug Administration (FDA)								ANTONI BA, 1991, J VIROL, V65, P396, DOI 10.1128/JVI.65.1.396-404.1991; ARAUJO JC, 1995, J VIROL, V69, P4933, DOI 10.1128/JVI.69.8.4933-4940.1995; BATCHU RB, 1994, CANCER LETT, V86, P23, DOI 10.1016/0304-3835(94)90176-7; BATCHU RB, 1995, FEBS LETT, V367, P267, DOI 10.1016/0014-5793(95)00584-V; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIORINI JA, 1994, J VIROL, V68, P797, DOI 10.1128/JVI.68.2.797-804.1994; DONIGER J, 1987, J BIOL CHEM, V262, P3813; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; HERMONAT PL, 1991, CANCER RES, V51, P3373; HERMONAT PL, 1989, VIROLOGY, V172, P253, DOI 10.1016/0042-6822(89)90127-X; HERMONAT PL, 1994, CANCER RES, V54, P2278; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LANS MS, 1994, J BIOL CHEM, V269, P14170; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OELZE I, 1994, J VIROL, V68, P1229, DOI 10.1128/JVI.68.2.1229-1233.1994; RITTNER K, 1992, J GEN VIROL, V73, P2977, DOI 10.1099/0022-1317-73-11-2977; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; THOMSON BJ, 1994, VIROLOGY, V204, P304, DOI 10.1006/viro.1994.1535; THOMSON BJ, 1991, NATURE, V351, P78, DOI 10.1038/351078a0; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128	28	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					937	943		10.1038/sj.onc.1200899	http://dx.doi.org/10.1038/sj.onc.1200899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050993				2022-12-25	WOS:A1997WK34400007
J	Frank, S; Munz, B; Werner, S				Frank, S; Munz, B; Werner, S			The human homologue of a bovine non-selenium glutathione peroxidase is a novel keratinocyte growth factor-regulated gene	ONCOGENE			English	Article						KGF; keratinocyte; skin; oxidative stress; peroxidase; psoriasis	FACTOR EXPRESSION; MESSENGER-RNA; TRANSFERASE; INDUCTION; CLONING; SKIN; PURIFICATION; SEQUENCE; FAMILY; CELLS	Keratinocyte growth factor is a potent and specific mitogen for different types of epithelial cells, including keratinocytes of the skin. Furthermore, it has been implicated in morphogenetic processes of several organs. To further define the mechanisms of KGF action in the skin, we attempted to identify genes which are regulated by KGF in keratinocytes. Using the differential display RT-PCR technology, a gene was identified which was strongly induced in these cells by treatment with KGF but not with serum growth factors or pro-inflammatory cytokines. Molecular cloning of the full-length cDNA revealed a strong homology of the corresponding gene product with a bovine non-selenium glutathione peroxidase. Upon transfection of COS cells with the full-length cDNA, a 27 kD cytoplasmic protein was obtained which had the expected size of glutathione peroxidase. Expression of the novel gene was detected in normal human skin and at particularly high levels in psoriatic skin, indicating a possible in vivo function of the protein in this tissue. Identification of a peroxidase as a KGF-regulated gene suggests that prevention from oxygen toxicity is a novel and specific mechanism of KGF action.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ACETO A, 1992, BIOCHEM MED METAB B, V48, P212, DOI 10.1016/0885-4505(92)90067-9; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Ames B.N., 1993, DNA FREE RADICALS, P1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUER D, 1994, PCR METH APPL, V4, P97; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOPHERS E, 1987, DERMATOLOGY GENERAL, P461; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; CUNHA GR, 1994, INT CONGR SER, V1064, P45; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; KANO T, 1987, CANCER RES, V47, P5626; LONTZ W, 1995, FREE RADICAL BIO MED, V18, P349, DOI 10.1016/0891-5849(94)E0124-2; Maniatis T., 1982, MOL CLONING; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MATHIEU M, 1996, BIOL CHEM, V270, P24197; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PENTLAND AP, 1994, ADV EXP MED BIOL, V366, P87; PETERS K, 1994, EMBO J, V13, P3269; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHOPF RE, 1992, MOLECULAR BASIS OF OXIDATIVE DAMAGE BY LEUKOCYTES, P333; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Wendel A, 1981, Methods Enzymol, V77, P325; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	39	108	112	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					915	921		10.1038/sj.onc.1200905	http://dx.doi.org/10.1038/sj.onc.1200905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050990	Bronze			2022-12-25	WOS:A1997WK34400004
J	Craig, AG; Jimenez, EC; Dykert, J; Nielsen, DB; Gulyas, J; Abogadie, FC; Porter, J; Rivier, JE; Cruz, LJ; Olivera, BM; McIntosh, JM				Craig, AG; Jimenez, EC; Dykert, J; Nielsen, DB; Gulyas, J; Abogadie, FC; Porter, J; Rivier, JE; Cruz, LJ; Olivera, BM; McIntosh, JM			A novel post translational modification involving bromination of tryptophan - Identification of the residue, L-6-bromotryptophan, in peptides from Conus imperialis and Conus radiatus venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUNICATE EUDISTOMA-OLIVACEUM; WATER MARINE SPONGE; MASS-SPECTROMETRY; DEEP-WATER; GAMMA-CARBOXYGLUTAMATE; INDOLE ALKALOIDS; CONANTOKIN-G; ANTAGONIST; TOXIN; PURIFICATION	We report a novel post-translational modification involving halogenation of tryptophan in peptides recovered from the venom of carnivorous marine cone snails (Conus). The residue, L-6-bromotryptophan, was identified in the sequence of a heptapeptide, isolated from Conus imperialis, a worm-hunting cone, This peptide does not elicit gross behavioral symptoms when injected centrally or peripherally in mice, L-6-Bromotryptophan was also identified in a 33-amino acid peptide from Conus radiatus; this peptide has been shown to induce a sleep-like state in mice of all ages and is referred to as bromosleeper peptide, The sequences of the two peptides Pca-Cys-Gly-Gln-Ala-Trp*-Cys-NH2 [GRAPHICS] were determined using a combination of mass spectrometry, amino acid, and chemical sequence analyses, where Pca = pyroglutamic acid, Hyp = hydroxyproline, Gla = gamma-carboxyglutamate, and Trp* = L-6-bromotryptophan, The precise structure and stereo chemistry of the modified residue were determined as L-6-bromotryptophan by synthesis, co elution, and enzymatic hydrolysis experiments, To our knowledge this is the first documentation of tryptophan residues in peptides/proteins being modified in a eukaryotic system and the first report of halogenation of tryptophan in vivo.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PSYCHIAT, SALT LAKE CITY, UT 84112 USA; SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA; UNIV PHILIPPINES, INST MARINE SCI, Quezon City 1101, PHILIPPINES	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Salk Institute; University of the Philippines System; University of the Philippines Diliman			Jimenez, Elsie/AAA-7347-2019		NIGMS NIH HHS [GM 48677] Funding Source: Medline; NIMH NIH HHS [K20 MH00929, MH53631] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631, K20MH000929] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABDERHALDEN E, 1907, Z PHYSL CHEM, V52, P207; ANDERSEN SO, 1972, ACTA CHEM SCAND, V26, P3097, DOI 10.3891/acta.chem.scand.26-3097; AZUMI K, 1990, BIOCHEMISTRY-US, V29, P159, DOI 10.1021/bi00453a021; BARBER M, 1982, ANAL CHEM, V54, pA645; BARRETT GC, 1985, CHEM BIOCH AMINO ACI, P11; BIEMANN K, 1990, METHOD ENZYMOL, V193, P351, DOI 10.1016/0076-6879(90)93426-L; BIFULCO G, 1994, J NAT PROD, V57, P1294, DOI 10.1021/np50111a020; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CARLE JS, 1979, J AM CHEM SOC, V101, P4012, DOI 10.1021/ja00508a073; CARLE JS, 1980, J ORG CHEM, V45, P1586, DOI 10.1021/jo01297a007; CARTER GT, 1978, TETRAHEDRON LETT, P4479; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; COTTER RJ, 1989, BIOMED ENVIRON MASS, V18, P513, DOI 10.1002/bms.1200180803; CRAIG AG, 1994, TRECHNIQUES PROTEIN, V6, P31; DEBITUS C, 1988, J NAT PROD, V51, P799, DOI 10.1021/np50058a029; DELLAR G, 1981, J CHEM SOC PERK T 1, P1679, DOI 10.1039/p19810001679; DJURA P, 1980, J ORG CHEM, V45, P1435, DOI 10.1021/jo01296a019; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; FAHY E, 1991, J NAT PROD, V54, P564, DOI 10.1021/np50074a032; FALICK AM, 1989, ANAL BIOCHEM, V182, P165, DOI 10.1016/0003-2697(89)90736-7; Faulkner DJ, 1996, NAT PROD REP, V13, P75, DOI 10.1039/np9961300075; FAULKNER DJ, 1988, BROMINE COMPOUNDS CH, P121; FINK K, 1948, SCIENCE, V108, P358, DOI 10.1126/science.108.2805.358; Friedlander P, 1909, BER DTSCH CHEM GES, V42, P765, DOI 10.1002/cber.190904201122; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P3; GUNASEKERA SP, 1994, J NAT PROD, V57, P1437, DOI 10.1021/np50112a014; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HAMMERLAND LG, 1992, EUR J PHARM-MOLEC PH, V226, P239, DOI 10.1016/0922-4106(92)90067-6; Harington CR, 1931, BIOCHEM J, V25, P1032, DOI 10.1042/bj0251032; Henze M, 1907, Z PHYSL CHEM, V51, P64; HIGA T, 1975, NATURWISSENSCHAFTEN, V62, P395, DOI 10.1007/BF00625356; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOLST PB, 1994, J NAT PROD, V57, P1310, DOI 10.1021/np50111a024; HUNT S, 1972, FEBS LETT, V24, P109, DOI 10.1016/0014-5793(72)80838-X; INOUE S, 1994, TETRAHEDRON, V50, P2753, DOI 10.1016/S0040-4020(01)86990-8; INOUE S, 1994, TETRAHEDRON, V50, P2729, DOI 10.1016/S0040-4020(01)86989-1; KOBAYASHI J, 1986, TETRAHEDRON LETT, V27, P1191, DOI 10.1016/S0040-4039(00)84213-6; KOBAYASHI J, 1984, J AM CHEM SOC, V106, P1526, DOI 10.1021/ja00317a080; KOHMOTO S, 1988, J ORG CHEM, V53, P3116, DOI 10.1021/jo00248a040; KONDO K, 1994, J NAT PROD, V57, P1008, DOI 10.1021/np50109a023; Konig Gabriele M., 1994, Natural Product Letters, V5, P141, DOI 10.1080/10575639408044048; LAKE RJ, 1988, TETRAHEDRON LETT, V29, P2255, DOI 10.1016/S0040-4039(00)86725-8; LOW EM, 1951, MARINE RES, V10, P239; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MENA EE, 1990, NEUROSCI LETT, V118, P241, DOI 10.1016/0304-3940(90)90637-O; MORNER CT, 1913, Z PHYSL CHEM, V88, P138; MORRIS HR, 1976, BIOCHEM J, V153, P663, DOI 10.1042/bj1530663; MORRIS SA, 1990, TETRAHEDRON, V46, P715, DOI 10.1016/S0040-4020(01)81355-7; MURATA O, 1991, TETRAHEDRON LETT, V32, P3539, DOI 10.1016/0040-4039(91)80827-S; Nakamura T, 1996, PROTEIN SCI, V5, P524; Neidleman S L, 1983, Biochem Soc Symp, V48, P39; OHMIYA Y, 1989, EUR J BIOCHEM, V182, P11, DOI 10.1111/j.1432-1033.1989.tb14794.x; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PORTER J, 1987, INT J PEPT PROT RES, V30, P13; Powell JFF, 1996, P NATL ACAD SCI USA, V93, P10461, DOI 10.1073/pnas.93.19.10461; RAVERTY WD, 1977, J CHEM SOC PERK T 1, P1204, DOI 10.1039/p19770001204; RINEHART KL, 1984, J AM CHEM SOC, V106, P1524, DOI 10.1021/ja00317a079; ROCHE J, 1963, COMP BIOCH, P493; SEARLE PA, 1994, J ORG CHEM, V59, P6600, DOI 10.1021/jo00101a018; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; SWERSEY JC, 1994, J NAT PROD, V57, P842, DOI 10.1021/np50108a027; TAKAI K, 1987, METHOD ENZYMOL, V142, P195; TSCHIERSCH B, 1963, COMP BIOCH, P1; TYMIAK AA, 1985, TETRAHEDRON, V41, P1039, DOI 10.1016/S0040-4020(01)96471-3; Vickery HB, 1931, CHEM REV, V9, P169, DOI 10.1021/cr60033a001; WELINDER BS, 1972, BIOCHIM BIOPHYS ACTA, V279, P491, DOI 10.1016/0304-4165(72)90171-7; Wheeler HL, 1909, J BIOL CHEM, V7, P1; WOLFF J, 1969, EUR J BIOCHEM, V9, P371, DOI 10.1111/j.1432-1033.1969.tb00618.x; WOLFF P, 1981, J CHEM SOC P1, P2895; ZABRISKIE TM, 1986, J AM CHEM SOC, V108, P3123, DOI 10.1021/ja00271a062	76	92	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4689	4698		10.1074/jbc.272.8.4689	http://dx.doi.org/10.1074/jbc.272.8.4689			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030520	hybrid			2022-12-25	WOS:A1997WJ85500008
J	Mukai, H; Toshimori, M; Shibata, H; Takanaga, H; Kitagawa, M; Miyahara, M; Shimakawa, M; Ono, Y				Mukai, H; Toshimori, M; Shibata, H; Takanaga, H; Kitagawa, M; Miyahara, M; Shimakawa, M; Ono, Y			Interaction of PKN with alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ZIPPER-LIKE SEQUENCES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; LEUCINE ZIPPER; BINDING PROTEINS; PLASMA-MEMBRANE; SMOOTH-MUSCLE; SPECTRIN; PURIFICATION; CLONING	PKN is a fatty acid- and Rho-activated serine/threonine protein kinase, having a catalytic domain homologous to protein kinase C family. To identify components of the PKN-signaling pathway such as substrates and regulatory proteins of PKN, the yeast two-hybrid strategy was employed. Using the N-terminal region of PKN as a bait, cDNAs encoding actin cross-linking protein alpha-actinin, which lacked the N-terminal actin-binding domain, were isolated from human brain cDNA library. The responsible region for interaction between PKN and alpha-actinin was determined by in vitro binding analysis using the various truncated mutants of these proteins. The N-terminal region of PKN outside the RhoA-binding domain was sufficiently shown to associate with alpha-actinin. PKN bound to the third spectrin-like repeats of both skeletal and non-skeletal muscle type alpha-actinin. PKN also bound to the region containing EF-hand-like motifs of non-skeletal muscle type a actinin in a Ca2+-sensitive manner and bound to that of skeletal muscle type alpha-actinin in a Ca2+-insensitive manner. alpha-Actinin was co-immunoprecipitated with PKN from the lysate of COS7 cells transfected with both expression constructs for PKN and alpha-actinin lacking the actin-binding domain, In vitro translated full length alpha-actinin containing the actin-binding site hardly bound to PKN, but the addition of phosphatidylinositol 4,5-bisphosphate, which is implicated in actin reorganization, stimulated the binding activity of the full-length cu actinin with PKN. We therefore propose that PKN is linked to the cytoskeletal network via a direct association between PKN and alpha-actinin.	KOBE UNIV,FAC SCI,DEPT BIOL,NADA KU,KOBE 657,JAPAN; KOBE UNIV,RADIOISOTOPE RES CTR,KOBE 657,JAPAN; KOBE UNIV,GRAD SCH SCI & TECHNOL,KOBE 657,JAPAN	Kobe University; Kobe University; Kobe University			Kitagawa, Michinori/B-1792-2013	Kitagawa, Michinori/0000-0003-1660-6421; Toshimori, Masanao/0000-0003-3869-7790; Mukai, Hideyuki/0000-0002-0167-8695				ABE M, 1990, J BIOCHEM-TOKYO, V107, P507, DOI 10.1093/oxfordjournals.jbchem.a123075; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; DUHAIMAN AS, 1984, BIOCHEMISTRY-US, V23, P1600, DOI 10.1021/bi00303a003; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; HONG WJ, 1989, J BIOL CHEM, V264, P12758; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KOBAYASHI R, 1990, J MUSCLE RES CELL M, V11, P465, DOI 10.1007/BF01745214; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MOMMAERTS WFHM, 1951, J BIOL CHEM, V188, P559; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; ONO Y, 1988, J BIOL CHEM, V263, P6927; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	46	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4740	4746		10.1074/jbc.272.8.4740	http://dx.doi.org/10.1074/jbc.272.8.4740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030526	hybrid			2022-12-25	WOS:A1997WJ85500014
J	Rayanade, RJ; Patel, K; Ndubuisi, M; Sharma, S; Omura, S; Etlinger, JD; Pine, R; Sehgal, PB				Rayanade, RJ; Patel, K; Ndubuisi, M; Sharma, S; Omura, S; Etlinger, JD; Pine, R; Sehgal, PB			Proteasome- and p53-dependent masking of signal transducer and activator of transcription (STAT) factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; KAPPA-B-ALPHA; PROTEIN; INTERLEUKIN-6; CELLS; INHIBITION; SUPPRESSION; DEGRADATION; LACTACYSTIN; MODULATION	Hepatoma Hep3B cell lines stably expressing a temperature-sensitive p53 species (p53-Val-135) displayed a reduced response to interleukin-6 (IL-6) when cultured at the wild-type (wt) p53 temperature (Wang, L., Ray anade, R., Garcia, D., Patel, K., Pan, H., and Sehgal, P. B. (1995) J. Biol. Chem, 270, 23159-23165). We now report that in such cultures IL-6 caused a rapid (20-30 min) and marked loss of cellular immunostaining for STAT3 and STAT5, but not for STAT1, The loss of STAT3 and STAT5 immunostaining was transient (lasted 120 min) and tyrosine kinase dependent, and even though the loss was blocked by the proteasome inhibitors MG132 and lactacystin it was not accompanied by changes in cellular levels of STAT3 and STAT5 proteins suggesting that IL-6 triggered a rapid masking but not degradation of these transcription factors, STAT3 and STAT5 masking was accompanied by a reduction in IL-B-induced nuclear DNA-binding activity, The data suggest that p53 may influence Jak-STAT signaling through a novel indirect mechanism involving a wt p53-dependent gene product which upon cytokine addition is activated into a ''STAT-masking factor'' in a proteasome dependent step.	NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT OPHTHALMOL,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT MED,VALHALLA,NY 10595; KITASATO INST,MINATO KU,TOKYO 108,JAPAN; PUBL HLTH RES INST,NEW YORK,NY 10016	New York Medical College; New York Medical College; New York Medical College								CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARPER JW, 1993, CELL, V75, P805; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Lai CF, 1995, ANN NY ACAD SCI, V762, P189; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLINER JD, 1993, BIOESSAYS, V15, P703, DOI 10.1002/bies.950151102; OMURA S, 1991, J ANTIBIOT TOKYO, V44, P1183; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	31	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4659	4662		10.1074/jbc.272.8.4659	http://dx.doi.org/10.1074/jbc.272.8.4659			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030516	hybrid			2022-12-25	WOS:A1997WJ85500004
J	Trummler, K; Wajant, H				Trummler, K; Wajant, H			Molecular cloning of acetone cyanohydrin lyase from flax (Linum usitatissimum) - Definition of a novel class of hydroxynitrile lyases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORGHUM-BICOLOR L; POLYACRYLAMIDE GELS; PRUNUS-SEROTINA; PURIFICATION; PROTEINS; FOLD; RNA; DNA	Acetone cyanohydrin lyase from Linum usitatissimum is a hydroxynitrile lyase (HNL) which is involved in the catabolism of cyanogenic glycosides in young seedlings of flax. We have isolated a full-length cDNA clone encoding L. usitatissimum HNL (LuHNL) from a cDNA expression library by immunoscreening, LuHNL cDNA was expressed in Escherichia coli and isolated from the respective soluble fraction in an active form which was biochemically indistinguishable from the natural enzyme, An open reading frame of 1266 base pairs encodes for a protein of 45,780 kDa, The derived amino acid sequence shows no overall homologies to the to date cloned HNLs, but has significant similarities to members of the alcohol dehydrogenase (ADH) family of enzymes, In particular, the cysteine and histidine residues responsible for coordination of an active site Zn2+ and a second structurally important Zn2+ in alcohol dehydrogenases are conserved, Nevertheless, we found neither alcohol dehydrogenase activity in LuHNL nor HNL activity in ADH. Moreover, well known inhibitors of ADHs, which interfere with the coordination of the active site Zn2+, fail to affect HNL activity of LuHNL, suggesting principally different mechanisms of cyanohydrin cleavage and alcohol oxidation, Interestingly, LuHNL like ADH and Prunus serotina (PsHNL) possesses an ADP-binding beta alpha beta unit motif, pointing to the possibility that the non-flavoprotein PsHNL and the flavoprotein LuHNL have developed from two independent lines of evolution of a common ancestor with an ADP-binding beta alpha beta unit.	UNIV STUTTGART,INST CELL BIOL & IMMUNOL,D-70569 STUTTGART,GERMANY	University of Stuttgart			Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				ALBRECHT J, 1993, BIOTECHNOL APPL BIOC, V17, P191; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Branden C.-I., 1975, ENZYMES, V11, P103; CHENG IP, 1993, PLANT CELL PHYSIOL, V34, P1139; Conn EE, 1981, BIOCH PLANTS COMPREH, P479; DRUM DE, 1970, BIOCHEMISTRY-US, V9, P4078, DOI 10.1021/bi00823a008; DUNN MF, 1971, BIOCHEMISTRY-US, V10, P4569, DOI 10.1021/bi00800a035; Hasslacher M, 1996, J BIOL CHEM, V271, P5884, DOI 10.1074/jbc.271.10.5884; HUGHES J, 1994, ARCH BIOCHEM BIOPHYS, V311, P496, DOI 10.1006/abbi.1994.1267; KUROKI GW, 1989, P NATL ACAD SCI USA, V86, P6978, DOI 10.1073/pnas.86.18.6978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBEREI R, 1985, PLANT SYST EVOL, V150, P49, DOI 10.1007/BF00985567; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELMAR D, 1988, PLANT PHYSIOL, V86, P711, DOI 10.1104/pp.86.3.711; SELMAR D, 1987, ANAL BIOCHEM, V166, P208, DOI 10.1016/0003-2697(87)90565-3; SWAIN E, 1994, PLANT PHYSIOL, V106, P437, DOI 10.1104/pp.106.2.437; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758; Wajant H, 1996, BIOL CHEM, V377, P611; Wajant H, 1996, J BIOL CHEM, V271, P25830, DOI 10.1074/jbc.271.42.25830; WAJANT H, 1995, PLANT PHYSIOL, V109, P1231, DOI 10.1104/pp.109.4.1231; WAJANT H, 1994, PLANT SCI, V103, P145, DOI 10.1016/0168-9452(94)90202-X; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XU LL, 1988, ARCH BIOCHEM BIOPHYS, V263, P256, DOI 10.1016/0003-9861(88)90634-0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	27	45	47	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4770	4774		10.1074/jbc.272.8.4770	http://dx.doi.org/10.1074/jbc.272.8.4770			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030531	hybrid			2022-12-25	WOS:A1997WJ85500019
J	Yaoita, Y; Nakajima, K				Yaoita, Y; Nakajima, K			Induction of apoptosis and CPP32 expression by thyroid hormone in a myoblastic cell line derived from tadpole tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; AMPHIBIAN METAMORPHOSIS; ENDONUCLEASE ACTIVITY; ICE/CED-3 PROTEASE; MAMMALIAN HOMOLOG; ACTIVATION; XENOPUS; ICE; FIBROBLASTS	During amphibian metamorphosis, the tail and gills that are useful in aquatic life but inappropriate for terrestrial activity are induced to degenerate completely in several days by endogenous thyroid hormone (TH). The dramatic resorption of the tadpole tail has attracted a good deal of attention as an experimental system of cell death, but the mechanism has not been well characterized. To facilitate in vitro analysis, we have established a myoblast cell line (XLT-15) derived from the Xenopus laevis tadpole tail. This cultured cell line died in response to TH and exhibited positive TUNEL reaction and internucleosomal DNA cleavage. Simultaneously, expression of the Xenopus CPP32/apopain/Yama gene was up-regulated by TH in the cell line as it is in regressing tadpole tail, whereas interleukin-1 beta converting enzyme (ICE) mRNA is around 1 copy/cell in tail and undetectable in XLT-15 cells, A CPP32/apopain/Yama inhibitor (acetyl-Asp-Glu-Val-Asp-aldehyde) prevented TH-induced apoptosis of XLT-15 cells, but an ICE inhibitor (acetyl-Tyr-Val-Ala-Asp-aldehyde) did not. These results suggested that an increase of CPP32/apopain/Yama gene expression is involved in TH-dependent apoptosis of XLT-15 and tadpole tail resorption during metamorphosis.			Yaoita, Y (corresponding author), TOKYO METROPOLITAN INST NEUROSCI,DEPT MOL NEUROBIOL,2-6 MUSASHIDAI,FUCHU,TOKYO 183,JAPAN.							BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRANDHORST BP, 1974, J MOL BIOL, V85, P451, DOI 10.1016/0022-2836(74)90444-6; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; COHEN JJ, 1984, J IMMUNOL, V132, P38; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLAWS JA, 1995, ENDOCRINOLOGY, V136, P5042, DOI 10.1210/en.136.11.5042; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NIKI K, 1982, DEV BIOL, V94, P116, DOI 10.1016/0012-1606(82)90074-4; NISHIKAWA A, 1994, DEV BIOL, V165, P89; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OHSHIMA S, 1988, COMP BIOCHEM PHYS B, V90, P779, DOI 10.1016/0305-0491(88)90334-3; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; SAITOH O, 1988, CELL TISSUE RES, V252, P263; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WANG Z, 1993, J BIOL CHEM, V268, P16270; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YOSHIHAR.K, 1974, BIOCHEM BIOPH RES CO, V59, P658, DOI 10.1016/S0006-291X(74)80030-6; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	36	89	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5122	5127		10.1074/jbc.272.8.5122	http://dx.doi.org/10.1074/jbc.272.8.5122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030578	hybrid			2022-12-25	WOS:A1997WJ85500066
J	Luttrell, LM; DellaRocca, GJ; vanBiesen, T; Luttrell, DK; Lefkowitz, RJ				Luttrell, LM; DellaRocca, GJ; vanBiesen, T; Luttrell, DK; Lefkowitz, RJ			G beta gamma subunits Src-dependent phosphorylation of the epidermal growth factor receptor - A scaffold for G protein-coupled receptor-mediated Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SHC ADAPTER PROTEIN; TYROSINE-KINASE; ANGIOTENSIN-II; MAP KINASE; PHOSPHOINOSITIDE-3 KINASE; PHOSPHOLIPASE C-GAMMA-1; LYSOPHOSPHATIDIC ACID; PATHWAY; FIBROBLASTS	In many cells, stimulation of mitogen-activated protein kinases by both receptor tyrosine kinases and receptors that couple to pertussis toxin-sensitive heterotrimeric G proteins proceed via convergent signaling pathways. Both signals are sensitive to inhibitors of tyrosine protein kinases and require Res activation via phosphotyrosine-dependent recruitment of Ras guanine nucleotide exchange factors. Receptor tyrosine kinase stimulation mediates ligand-induced receptor autophosphorylation, which creates the initial binding sites for SH2 domain-containing docking proteins. However, the mechanism whereby G protein-coupled receptors mediate the phosphotyrosine-dependent assembly of a mitogenic signaling complex is poorly understood. We have studied the role of Src family nonreceptor tyrosine kinases in G protein-coupled receptor-mediated tyrosine phosphorylation in a transiently transfected COS-7 cell system. Stimulation of G(i)-coupled lysophosphatidic acid and alpha 2A adrenergic receptors or overexpression of G beta 1 gamma 2 subunits leads to tyrosine phosphorylation of the She adapter protein, which then associates with tyrosine phosphoproteins of approximately 130 and 180 kDa, as well as Grb2. The 180-kDa She-associated tyrosine phosphoprotein band contains both epidermal growth factor (EGF) receptor and p185(neu). 3-5-fold increases in EGF receptor but not p185(neu) tyrosine phosphorylation occur following G(i)-coupled receptor stimulation. Inhibition of endogenous Src family kinase activity by cellular expression of a dominant negative kinase-inactive mutant of c-Src inhibits G beta 1 gamma 2 subunit-mediated and G(i)-coupled receptor-mediated phosphorylation of both EGF receptor and She. Expression of Csk, which inactivates Src family kinases by phosphorylating the regulatory carboxyl-terminal tyrosine residue, has the same effect. The G(i)-coupled receptor-mediated increase in EGF receptor phosphorylation does not reflect increased EGF receptor autophosphorylation, assayed using an autophosphorylation-specific EGF receptor monoclonal antibody. Lysophosphatidic acid stimulates binding of EGF receptor to a GST fusion protein containing the c-Src SH2 domain, and this too is blocked by Csk expression. These data suggest that G beta gamma subunit-mediated activation of Src family nonreceptor tyrosine kinases can account for the G(i)-coupled receptor-mediated tyrosine phosphorylation events that direct recruitment of the She and Grb2 adapter proteins to the membrane.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; GLAXO WELLCOME INC,RES & DEV,DEPT MOL BIOCHEM,RES TRIANGLE PK,NC 27709	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; GlaxoSmithKline			Lefkowitz, Robert/AAW-2649-2021; Della Rocca, Gregory/AAM-5281-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [T32GM-07171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FAURE M, 1994, J BIOL CHEM, V269, P7851; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0	48	429	435	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4637	4644		10.1074/jbc.272.7.4637	http://dx.doi.org/10.1074/jbc.272.7.4637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020193	hybrid			2022-12-25	WOS:A1997WH01900109
J	Weyman, CM; Ramocki, MB; Taparowsky, EJ; Wolfman, A				Weyman, CM; Ramocki, MB; Taparowsky, EJ; Wolfman, A			Distinct signaling pathways regulate transformation and inhibition of skeletal muscle differentiation by oncogenic Ras	ONCOGENE			English	Article						skeletal muscle; differentiation; oncogenic Ras; MAP kinase	FIBROBLAST GROWTH-FACTOR; NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE CASCADE; MYOGENIC DIFFERENTIATION; H-RAS; B-RAF; TERMINAL DIFFERENTIATION; MYOBLAST DIFFERENTIATION; FACTOR-BETA; CELL-CYCLE	Expression of oncogenic Ras in 23A2 skeletal myoblasts is sufficient to induce both a transformed phenotype and a differentiation-defective phenotype, but the signaling pathways activated by oncogenic Ras in these cells and their respective contribution to each phenotype have not been explored, In this study, we investigated MAP kinase activity in control 23A2 myoblasts and in 23A2 myoblasts rendered differentiation-defective by the stable expression of an oncogenic (G12V)Ha-ras gene (Ras9 cells), The MAP kinase immunoprecipitated from Ras9 cells was 30-40% more active than that from control 23A2 cells, To establish if this elevated MAP kinase activity is essential to the maintenance of the onccogenic Ras-induced phenotype, we utilized the selective MAP kinase kinase 1 (MEK1) inhibitor, PD 098059. PD 098059 decreased the MAP kinase activity in Ras9 cells to the level found in 23A2 cells. PD 098059 did not affect the ability of 23A2 myoblasts to differentiate, PD 098059 reverted the transformed morphology of Ras9 cells but did not restore the ability of these cells to express the muscle-specific myosin heavy chain gene or to form muscle fibers, Treatment with PD 098059 also did not affect the ability of oncogenic Ha-Ras to establish a non-myogenic phenotype in C3H10T1/2 cells co-expressing MyoD. These results demonstrate that the activation of MAP kinase is necessary for the transformed morphology of Ras9 cells but is not required by oncogenic Ras to establish or to maintain a differentiation-defective phenotype. While these data do not rule out the possibility that constitutive signaling by MEK1 or MAP kinase could inhibit myoblast differentiation, they clearly demonstrate that other pathways activated by oncogenic Ras are sufficient to inhibit differentiation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weyman, CM (corresponding author), CLEVELAND CLIN FDN,DEPT CELL BIOL,CLEVELAND,OH 44195, USA.				NCI NIH HHS [T32 CA09634] Funding Source: Medline; NIGMS NIH HHS [GM 49652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049652, R55GM049652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FOX PL, 1994, ONCOGENE, V9, P3519; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	54	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					697	704		10.1038/sj.onc.1200874	http://dx.doi.org/10.1038/sj.onc.1200874			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038377				2022-12-25	WOS:A1997WG43000008
J	Daly, SE; Blostein, R; Lane, LK				Daly, SE; Blostein, R; Lane, LK			Functional consequences of a posttransfection mutation in the H2-H3 cytoplasmic loop of the alpha subunit of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; 4TH TRANSMEMBRANE SEGMENT; RAT-ALPHA-1 NA,K-ATPASE; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CATALYTIC SUBUNIT; ACTIVE-TRANSPORT; CATION-BINDING; POTASSIUM-IONS	During kinetic studies of mutant rat Na,K-ATPases, we identified a spontaneous mutation in the first cytoplasmic loop between transmembrane helices 2 and 3 (H2-H3 loop) which results in a functional enzyme with distinct Na,K-ATPase kinetics. The mutant cDNA contained a single G(950) to, A substitution, which resulted in the replacement of glutamate at 233 with a lysine (E233K). E233K and alpha 1 cDNAs were transfected into HeLa cells and their kinetic behavior was compared. Transport studies carried out under physiological conditions with intact cells indicate that the E233K mutant and alpha 1 have similar apparent affinities for cytoplasmic Na+ and extracellular K+. In contrast, distinct kinetic properties are observed when ATPase activity is assayed under conditions (low ATP concentration) in which the K+ deocclusion pathway of the reaction is rate-limiting. At 1 mu M ATP K+ inhibits Na+-ATPase of alpha 1, but activates Na+-ATPase of E233K, This distinctive behavior of E233K is due to its faster rate of formation of dephosphoenzyme (E(1)) from K+-occluded enzyme (E(2)(K)), as well as 6-fold higher affinity for ATP at the low affinity ATP binding site. A lower ratio of V-max to maximal level of phosphoenzyme indicates that E233K has a lower catalytic turnover than alpha 1. These distinct kinetics of E233K suggest a shift in its E(1)/E(2) conformational equilibrium toward E(1). Furthermore, the importance of the H2-H3 loop in coupling conformational changes to ATP hydrolysis is underscored by a marked (2 orders of magnitude) reduction in vanadate sensitivity effected by this Glu(233) --> LyS mutation.	MCGILL UNIV, DEPT MED, MONTREAL, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA	McGill University; University of Cincinnati					NHLBI NIH HHS [HL 49204] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049204] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Bandell M, 1996, BBA-BIOMEMBRANES, V1280, P81, DOI 10.1016/0005-2736(95)00280-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DUX L, 1983, J BIOL CHEM, V258, P111; EISNER DA, 1981, J PHYSIOL-LONDON, V319, P403, DOI 10.1113/jphysiol.1981.sp013917; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FAHN S, 1966, J BIOL CHEM, V241, P1882; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; FORBUSH B, 1991, SOC GEN PHY, V46, P211; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1988, PROG CLIN BIOL RES, V268, P85; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LANE LK, 1993, J BIOL CHEM, V268, P17930; LANE LK, 1993, BIOCHEM MOL BIOL INT, V31, P817; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; POST RL, 1972, J BIOL CHEM, V247, P6530; SACHS JR, 1987, J GEN PHYSIOL, V90, P291, DOI 10.1085/jgp.90.2.291; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	43	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6341	6347		10.1074/jbc.272.10.6341	http://dx.doi.org/10.1074/jbc.272.10.6341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045654	hybrid			2022-12-25	WOS:A1997WM64700038
J	Hilbert, TP; Chaung, WR; Boorstein, RJ; Cunningham, RP; Teebor, GW				Hilbert, TP; Chaung, WR; Boorstein, RJ; Cunningham, RP; Teebor, GW			Cloning and expression of the cDNA encoding the human homologue of the DNA repair enzyme, Escherichia coli endonuclease III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRRADIATED DNA; INSITU HYBRIDIZATION; CATALYTIC MECHANISM; PURIFICATION; GLYCOSYLASES; INTERMEDIATE; CELLS; GENES	We previously purified a bovine pyrimidine hydratethymine glycol DNA glycosylase/AP lyase, The amino acid sequence of tryptic bovine peptides was homologous to Escherichia coli endonuclease III, theoretical proteins of Saccharomyces cerevisiae and Caenorhabditis elegans, and the translated sequences of rat and hu man 3'-expressed sequence tags (3'-ESTs) (Hilbert, T. P., Boorstein, R, J., Kung, H, C., Bolton, P. H., Xing, D., Cunningham, R. P., Teebor, G. W. (1996) Biochemistry 35, 2505-2511). Now the human 3'-EST was used to isolate the cDNA clone encoding the human enzyme, which, when expressed as a GST-fusion protein, demonstrated thymine glycol-DNA glycosylase activity and, after incubation with NaCNBH3, became irreversibly cross linked to a thymine glycol-containing oligodeoxynucleotide, a reaction characteristic of DNA glycosylase/AP lyases. Amino acids within the active site, DNA binding do mains, and [4Fe-4S] cluster of endonuclease III are con served in the human enzyme. The gene for the human enzyme was localized to chromosome 16p13.2-.3. Genomic sequences encoding putative endonuclease III homologues are present in bacteria, archeons, and eukaryotes. The ubiquitous distribution of endonuclease III-like proteins suggests that the 5,6-double bond of pyrimidines is subject to oxidation, reduction, and/or hydration in the DNA of organisms of all biologic domains and that the resulting modified pyrimidines are deleterious to the organism.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	New York University; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Teebor, George/0000-0002-7397-2500	NCI NIH HHS [CA 49689, CA 16669, CA 16087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA016669, R01CA016669, P30CA016087] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BACCHETTI S, 1975, BIOCHIM BIOPHYS ACTA, V390, P285, DOI 10.1016/0005-2787(75)90349-4; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BOORSTEIN RJ, 1989, BIOCHEMISTRY-US, V28, P6164, DOI 10.1021/bi00441a007; BRENT TP, 1973, BIOPHYS J, V13, P399, DOI 10.1016/S0006-3495(73)85993-4; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DUKER NJ, 1975, NATURE, V255, P82, DOI 10.1038/255082a0; Heng Henry H. Q., 1994, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HIGGINS SA, 1987, BIOCHEMISTRY-US, V26, P1683, DOI 10.1021/bi00380a029; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; KAO JY, 1993, J BIOL CHEM, V268, P17787; KIM J, 1989, J BIOL CHEM, V264, P2739; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NESS IF, 1978, BIOCHIM BIOPHYS ACTA, V520, P111; OUELLETTE BFF, 1993, GENOME, V36, P32, DOI 10.1139/g93-005; RADMAN M, 1976, J BIOL CHEM, V251, P1438; SAKAI K, 1992, J GASTROEN HEPATOL, V7, P288, DOI 10.1111/j.1440-1746.1992.tb00982.x; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; Teebor G.W., 1995, DNA REPAIR MECH IMPA, P99; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197	32	130	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6733	6740		10.1074/jbc.272.10.6733	http://dx.doi.org/10.1074/jbc.272.10.6733			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045706	hybrid			2022-12-25	WOS:A1997WM64700090
J	Harlow, GR; Halpert, JR				Harlow, GR; Halpert, JR			Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4 - Role of residues 210 and 211 in flavonoid activation and substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER-MICROSOMES; DIRECTED MUTAGENESIS; AMINO-ACID; NIFEDIPINE OXIDASE; ESCHERICHIA-COLI; OXIDATION; BINDING; CDNA; EXPRESSION; MECHANISM	Alanine-scanning mutagenesis was performed on amino acid residues 210-216 of cytochrome P450 3A4, the major drug-metabolizing enzyme of human liver. Mutagenesis of this region, which has been proposed to align with the C-terminal ends of F-helices from cytochromes P450(BM-3), P450(terp), and P450(cam), served as a test of the applicability of the substrate recognition site model of Gotoh (Gotoh, O. (1992) J. Biol. Chem. 267, 83-90) to P450 3A4. The results, using two steroid substrates, indicated that substitution of Ala for Leu(210) altered the responsiveness to the effector alpha-naphthoflavone and the regioselectivity of testosterone hydroxylation, Replacement of Leu(211) by Ala also decreased the stimulation by alpha-naphthoflavone, whereas mutations at residues 212-216 had little effect, The diminished flavonoid responses of the 210 and 211 mutants were observed over a wide range of progesterone and alpha-naphthoflavone concentrations. Further characterization was performed with the additional effectors beta-naphthoflavone, flavone, and 4-chromanone. The finding that P450 3A4 with one altered residue, Leu(210) --> Ala, can have both an altered testosterone hydroxylation profile and response to flavonoid stimulation provides evidence that the substrate binding and effector sites are at least partially overlapping.			Harlow, GR (corresponding author), UNIV ARIZONA, COLL PHARM, DEPT PHARMACOL & TOXICOL, TUCSON, AZ 85721 USA.				NIEHS NIH HHS [ES06694] Funding Source: Medline; NIGMS NIH HHS [GM17860] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017860] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1989, J BIOL CHEM, V264, P10388; BEAUNE PH, 1986, P NATL ACAD SCI USA, V83, P8064, DOI 10.1073/pnas.83.21.8064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GONZALEZ FJ, 1988, DNA-J MOLEC CELL BIO, V7, P79, DOI 10.1089/dna.1988.7.79; GOTOH O, 1992, J BIOL CHEM, V267, P83; Guengerich F. P., 1995, CYTOCHROME P, P473; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; Harlow GR, 1996, ARCH BIOCHEM BIOPHYS, V326, P85, DOI 10.1006/abbi.1996.0050; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASLER JA, 1994, MOL PHARMACOL, V46, P338; HE YA, 1992, BIOCHEMISTRY-US, V31, P9220, DOI 10.1021/bi00153a015; HE YA, 1994, BIOCHEMISTRY-US, V33, P4419, DOI 10.1021/bi00180a040; HSU MH, 1993, J BIOL CHEM, V268, P6939; HUANG MT, 1981, J BIOL CHEM, V256, P897; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; IWASAKI M, 1993, J BIOL CHEM, V268, P759; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; IWASAKI M, 1993, BIOCHEM J, V291, P569, DOI 10.1042/bj2910569; JOHN GH, 1994, ARCH BIOCHEM BIOPHYS, V314, P367, DOI 10.1006/abbi.1994.1455; JUVONEN RO, 1991, J BIOL CHEM, V266, P16431; JUVONEN RO, 1992, BIOCHEMISTRY-US, V31, P11519, DOI 10.1021/bi00161a033; KAMINSKY LS, 1993, MOL PHARMACOL, V43, P234; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; KORZEKWA KR, 1993, PHARMACOGENETICS, V3, P1, DOI 10.1097/00008571-199302000-00001; KRONBACH T, 1989, MOL PHARMACOL, V36, P89; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Liu JP, 1996, ARCH BIOCHEM BIOPHYS, V327, P167, DOI 10.1006/abbi.1996.0105; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; RANEY KD, 1992, CHEM RES TOXICOL, V5, P202, DOI 10.1021/tx00026a009; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; UENG YF, 1995, CHEM RES TOXICOL, V8, P218, DOI 10.1021/tx00044a006; Von Wachenfeldt Claes, 1995, P183; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P462; WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F; WHITE RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P493, DOI 10.1016/0003-9861(84)90015-8; YEOM H, 1995, BIOCHEMISTRY-US, V34, P14733, DOI 10.1021/bi00045a014; YUN CH, 1993, DRUG METAB DISPOS, V21, P403	49	135	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5396	5402		10.1074/jbc.272.9.5396	http://dx.doi.org/10.1074/jbc.272.9.5396			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038138	hybrid			2022-12-25	WOS:A1997WK74700006
J	Karki, S; Tokito, MK; Holzbaur, ELF				Karki, S; Tokito, MK; Holzbaur, ELF			Casein kinase II binds to and phosphorylates cytoplasmic dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CELLULAR-REGULATION; DYNACTIN COMPLEX; SUBUNIT; PURIFICATION; ASSOCIATION; COMPONENT; CLONING; CELLS; ALPHA	We have isolated a 27-kDa protein that hinds to cytoplasmic dynein. Microsequencing of a 17-amino acid peptide of this polypeptide yielded a sequence which completely matched the predicted sequence of the beta subunit of casein kinase II, a highly conserved serine/threonine kinase. Affinity chromatography using a dynein column indicates that both the alpha and beta subunits of casein kinase II are retained by the column from rat brain cytosol, Although dynactin is also bound to the column, casein kinase II is not a dynactin subunit, Casein kinase II does not co-immunoprecipitate with dynactin, and it binds to a dynein intermediate chain column which has been preblocked with excess p150(Glued), a treatment that inhibits the binding of dynactin from cytosol. Bacterially expressed and purified rat dynein intermediate chain can be phosphorylated by casein kinase II in vitro. Further, native cytoplasmic dynein purified from rat brain can also be phosphorylated by casein kinase II in vitro. We propose that CKII may be involved in the regulation of dynein function possibly by altering its cargo specificity or its ability to interact with dynactin.	UNIV PENN, SCH MED, CELL & MOL BIOL GRAD GRP, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NIGMS NIH HHS [GM48661] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048661] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED K, 1993, CELL MOL BIOL RES, V39, P451; ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139, DOI 10.1016/0167-4781(91)90230-J; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; OSPINA B, 1992, MOL CELL BIOCHEM, V118, P49, DOI 10.1007/BF00249694; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; Sweeney HL, 1996, ANNU REV PHYSIOL, V58, P751, DOI 10.1146/annurev.ph.58.030196.003535; Thaler C D, 1996, Int Rev Cytol, V164, P269; Tokito MK, 1996, MOL BIOL CELL, V7, P1167, DOI 10.1091/mbc.7.8.1167; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; VANCUROVA I, 1995, J CELL SCI, V108, P779; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	37	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5887	5891		10.1074/jbc.272.9.5887	http://dx.doi.org/10.1074/jbc.272.9.5887			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038206	hybrid			2022-12-25	WOS:A1997WK74700074
J	Kaur, KJ; Khurana, S; Salunke, DM				Kaur, KJ; Khurana, S; Salunke, DM			Topological analysis of the functional mimicry between a peptide and a carbohydrate moiety	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMYLASE INHIBITOR; CONCANAVALIN-A; MOLECULAR MIMICRY; BINDING-SITE; DRUG DESIGN; PEPTIDOMIMETICS; PROTEIN; LIBRARY; FAMILY	The shared surface topology of two chemically dissimilar but functionally equivalent molecular structures has been analyzed. A carbohydrate moiety (alpha-D-mannopyranoside) and a peptide molecule (DVFYPYPYASGS) bind to concanavalin A at a common binding site. The cross-reactivity of the polyclonal antibodies (pAbs) was used for understanding the topological relationship between these two independent ligands. The anti-alpha-D-mannopyranoside pAbs recognized various peptide ligands of concanavalin A, and the anti-DVFYPYPYASGS pAbs recognized the carbohydrate ligands, providing direct evidence of molecular mimicry. On the basis of differential binding of various rationally designed peptide analogs to the anti-alpha-D-mannopyranoside pAbs, it was possible to identify different peptide residues critical for the mimicry. The comparison of circular dichroism profiles of the designed analogs suggests that the carbohydrate mimicking conformation of the peptide ligand incorporates a polyproline type II structural fold. The concanavalin A binding activity off these analogs was found to have a direct correlation with the topological relationship between peptide and carbohydrate ligands.	NATL INST IMMUNOL, STRUCT BIOL UNIT, NEW DELHI 110067, INDIA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				BAUM H, 1993, TRENDS BIOCHEM SCI, V18, P140, DOI 10.1016/0968-0004(93)90022-F; BEELEY N, 1994, TRENDS BIOTECHNOL, V12, P213, DOI 10.1016/0167-7799(94)90117-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FROUDE J, 1989, CURR TOP MICROBIOL, V145, P5; GANTE J, 1994, ANGEW CHEM INT EDIT, V33, P1699, DOI 10.1002/anie.199416991; GRAY RD, 1973, J BIOL CHEM, V248, P7547; GREWAL N, 1994, PROTEIN ENG, V7, P205, DOI 10.1093/protein/7.2.205; HOFMANN O, 1985, BIOL CHEM H-S, V366, P1161, DOI 10.1515/bchm3.1985.366.2.1161; Kim K. H., 1995, MOL SIMILARITY DRUG; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LISKAMP RMJ, 1994, ANGEW CHEM INT EDIT, V33, P305, DOI 10.1002/anie.199403051; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MASEK BB, 1993, PROTEINS, V17, P193, DOI 10.1002/prot.340170208; MOORE GJ, 1994, TRENDS PHARMACOL SCI, V15, P124, DOI 10.1016/0165-6147(94)90049-3; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NAKANISHI H, 1993, GENE, V137, P51, DOI 10.1016/0378-1119(93)90250-7; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SO LL, 1969, CARBOHYD RES, V10, P231, DOI 10.1016/S0008-6215(00)80465-6; VERTESY L, 1984, EUR J BIOCHEM, V141, P505, DOI 10.1111/j.1432-1033.1984.tb08221.x; VLATAKIS G, 1993, NATURE, V361, P645, DOI 10.1038/361645a0; WAINER BH, 1979, J PHARMACOL EXP THER, V208, P498; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907; YAO J, 1994, J MOL BIOL, V243, P754, DOI 10.1016/0022-2836(94)90045-0	28	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5539	5543		10.1074/jbc.272.9.5539	http://dx.doi.org/10.1074/jbc.272.9.5539			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038160	hybrid			2022-12-25	WOS:A1997WK74700028
J	Puech, A; Dupressoir, A; Loireau, MP; Mattei, MG; Heidmann, T				Puech, A; Dupressoir, A; Loireau, MP; Mattei, MG; Heidmann, T			Characterization of two age-induced intracisternal A-particle-related transcripts in the mouse liver - Transcriptional read-through into an open reading frame with similarities to the yeast CCR4 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOGENOUS RETROVIRUS; MESSENGER-RNAS; SACCHAROMYCES-CEREVISIAE; INDUCED ERYTHROBLASTOSIS; DEPENDENT EXPRESSION; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; ACTIVATION; VIRUS; METHYLATION	Intracisternal A-particle (IAP) sequences are endogenous retrovirus-like elements present at 1,000 copies in the mouse genome, We had previously identified IAP-related transcripts of unusual size (6 and 10 kilobases (kb)), which are observed exclusively in the liver of the aging mouse. In this report, using cDNA libraries that we have constructed from the liver mRNAs of an aged DBA/2 mouse, we have cloned and entirely sequenced the corresponding cDNAs, Both are initiated within the 5' long terminal repeat of a type I Delta 1 IAP sequence, and correspond to a read-through into a unique flanking cellular sequence containing a 966-nucleotide open reading frame, located 3' to the IAP sequence, The 6-kb IAP-related transcript corresponds to a post-transcriptional modification of the 10-kb mRNA, and is generated by a splicing event with the donor site in the IAP sequence, and the acceptor site 5' to the open reading frame. This open reading frame is located on chromosome 3, is evolutionarily conserved, and discloses significant similarity to the yeast CCR4 transcription factor at the amino acid level, The specific expression of these age-induced transcripts, which account for more than 50% of the IAP-related transcripts in the liver of old mice, is therefore entirely consistent with the induction of a single genomic locus, thus strengthening the importance of position effects for the expression of transposable elements, Characterization of this locus should now allow studies on its chromatin and methylation status, and on the ''molecular factors of senescence'' possibly involved in its induction.	INST GUSTAVE ROUSSY,UNITE PHYSICOCHIM & PHARMACOL MACROMOL BIOL,CNRS URA 147,F-94805 VILLEJUIF,FRANCE; FAC MED MARSEILLE,INSERM U406,UNITE GENET MED & DEV,F-13385 MARSEILLE,FRANCE	UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Dupressoir, Anne/M-5280-2018; PUECH, Anne/A-7470-2013	Dupressoir, Anne/0000-0002-3464-8513; 				BENSON S A, 1984, Biotechniques, V2, P66; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Coffin J.M, 1992, RETROVIRIDAE, P19; DEAN RG, 1985, ARCH GERONTOL GERIAT, V4, P43, DOI 10.1016/0167-4943(85)90017-2; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; Dupressoir A, 1995, BBA-GENE STRUCT EXPR, V1264, P397, DOI 10.1016/0167-4781(95)00181-6; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; FLORINE DL, 1980, CANCER RES, V40, P519; GAUBATZ JW, 1991, MECH AGEING DEV, V57, P71, DOI 10.1016/0047-6374(91)90025-U; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KATO N, 1990, MOL CELL BIOL, V10, P4401, DOI 10.1128/MCB.10.8.4401; KATO N, 1987, J VIROL, V61, P2182, DOI 10.1128/JVI.61.7.2182-2191.1987; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LESLIE KB, 1991, MOL CELL BIOL, V11, P5562, DOI 10.1128/MCB.11.11.5562; LIU AY, 1991, CANCER RES, V51, P4107; LUEDERS KK, 1986, NUCLEIC ACIDS RES, V14, P1495, DOI 10.1093/nar/14.3.1495; LUEDERS KK, 1993, MOL CELL BIOL, V13, P7439, DOI 10.1128/MCB.13.12.7439; LUEDERS KK, 1987, GENE, V52, P139, DOI 10.1016/0378-1119(87)90040-0; MALVAR T, 1992, GENETICS, V132, P951; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MAYSHOOPES L, 1986, DEV GENET, V7, P65, DOI 10.1002/dvg.1020070202; MAYSHOOPES LL, 1983, MOL CELL BIOL, V3, P1371, DOI 10.1128/MCB.3.8.1371; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MOUNTZ JD, 1993, IMMUNOL TODAY, V14, P532, DOI 10.1016/0167-5699(93)90182-K; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; REUSS FU, 1991, J VIROL, V65, P5702, DOI 10.1128/JVI.65.11.5702-5709.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SHENONG GLC, 1982, J VIROL, V42, P411, DOI 10.1128/JVI.42.2.411-421.1982; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SUPAKAR PC, 1993, J BIOL CHEM, V268, P26400; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901	45	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5995	6003		10.1074/jbc.272.9.5995	http://dx.doi.org/10.1074/jbc.272.9.5995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038221	hybrid			2022-12-25	WOS:A1997WK74700089
J	Wang, SB; Yan, L; Wesley, RA; Danner, RL				Wang, SB; Yan, L; Wesley, RA; Danner, RL			Nitric oxide increases tumor necrosis factor production in differentiated U937 cells by decreasing cyclic AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED GUANYLATE-CYCLASE; BLOOD MONONUCLEAR-CELLS; TNF-ALPHA PRODUCTION; ADENYLYL-CYCLASE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; HUMAN-NEUTROPHILS; S-NITROSYLATION; GENE-EXPRESSION; LINE U937	Nitric oxide (NO) increases tumor necrosis factor (TNF) synthesis in human peripheral blood mononuclear cells by a cGMP-independent mechanism, NO has been shown to inhibit adenylate cyclase in cell membranes, Since cAMP down-regulates TNF transcription, we examined the possibility that NO enhances TNF synthesis by decreasing cAMP. U937 cells were induced to differentiate using phorbol myristate acetate (100 nM for 48 h) and then were incubated for 24 h with sodium nitroprusside (SNP) or S-nitroso-N-acetylpenicillamine (SNAP). These NO donors increased TNF production (7.0- and 15.6-fold, respectively, at 500 mu M) in a dose-dependent manner (p = 0.002), However, SNP and SNAP did not elevate cGMP levels in U937 cell cultures, and the cGMP analog, 8-bromo-cGMP, had no effect on TNF production, In contrast, SNP (p = 0.001) and SNAP (p = 0.009) decreased intracellular cAMP levels by up to 51.5% over 24 h and, in the presence of a phosphodiesterase inhibitor, blunted isoproterenol-stimulated increases in cAMP by 21.8% (p = 0.004) and 27.6% (p = 0.008), respectively. H89, an inhibitor of cAMP-dependent protein kinase, dose dependently increased TNF production in phorbol myristate acetate-differentiated U937 cells in the absence (6.5-fold at 30 mu M;p = 0.035), but not in the presence (p = 0.77) of SNAP, Conversely, the cAMP analog dibutyryl cAMP (Bt(2)cAMP) blocked SNAP-induced TNF production (p = 0.001), SNP and SNAP (500 mu M) increased relative TNF mRNA levels by 57.5% (p = 0.045) and 66.2% (p = 0.001), respectively, This effect was prevented by Bt(2)cAMP. These results indicate that NO up-regulates TNF production by decreasing intracellular cAMP.	NIH,DEPT CRIT CARE MED,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BARNES PJ, 1995, EUR RESPIR J, V8, P457, DOI 10.1183/09031936.95.08030457; BARNETTE M S, 1992, American Review of Respiratory Disease, V145, pA282; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOWEN R, 1991, J CARDIOVASC PHARM, V17, P424, DOI 10.1097/00005344-199103000-00011; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; DANNER RL, 1987, J CLIN INVEST, V80, P605, DOI 10.1172/JCI113112; DOOPER MWSM, 1994, BIOCHEM PHARMACOL, V47, P289, DOI 10.1016/0006-2952(94)90019-1; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; EVANS CH, 1995, AGENT ACTION SUPPL, V47, P107; Forstermann U, 1995, Adv Pharmacol, V34, P171; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Gill G N, 1979, Adv Cyclic Nucleotide Res, V10, P93; HASS R, 1991, LEUKEMIA RES, V15, P327, DOI 10.1016/0145-2126(91)90008-H; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P205; IANNONE MA, 1991, BIOCHEM PHARMACOL, V42, pS105, DOI 10.1016/0006-2952(91)90399-P; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; ISHITOYA J, 1987, J IMMUNOL, V138, P1201; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; KUO PC, 1995, ANN SURG, V221, P220, DOI 10.1097/00000658-199503000-00003; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MAGRINAT G, 1992, BLOOD, V80, P1880; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MELLION BT, 1981, BLOOD, V57, P946; MILLER R, 1986, ANOVA BASICS APPL ST, P74; MOILANEN E, 1995, ANN MED, V27, P359, DOI 10.3109/07853899509002589; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Posternak T, 1974, Methods Enzymol, V38, P399; PRABHAKAR U, 1994, INT J IMMUNOPHARMACO, V16, P805, DOI 10.1016/0192-0561(94)90054-X; Righi M, 1993, Funct Neurol, V8, P359; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SELDON PM, 1995, MOL PHARMACOL, V48, P747; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; Sonnenburg W K, 1994, Adv Pharmacol, V26, P87, DOI 10.1016/S1054-3589(08)60052-6; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STEWART AG, 1994, MICROSURG, V15, P693, DOI 10.1002/micr.1920151006; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAIMI M, 1993, IMMUNOLOGY, V79, P229; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TURNER NC, 1994, BRIT J PHARMACOL, V111, P1047, DOI 10.1111/j.1476-5381.1994.tb14850.x; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; ZHONG WW, 1995, IMMUNOLOGY, V84, P446	60	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5959	5965		10.1074/jbc.272.9.5959	http://dx.doi.org/10.1074/jbc.272.9.5959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038216	hybrid			2022-12-25	WOS:A1997WK74700084
J	Gorospe, M; Cirielli, C; Wang, XT; Seth, P; Capogrossi, MC; Holbrook, NJ				Gorospe, M; Cirielli, C; Wang, XT; Seth, P; Capogrossi, MC; Holbrook, NJ			p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells	ONCOGENE			English	Article						melanoma; p53; p21; apoptosis	CYCLE CONTROL; G(1) ARREST; P53; EXPRESSION; ADENOVIRUS; CANCER; P21	The tumor suppressive effect of p53 is believed to be rooted in its two primary functions: the implementation of cellular growth arrest and the execution of apoptotic cell death, While p53-regulated expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) appears to be central for the implementation of G(1) arrest, the participation of p21(Waf1/Cip1) in p53-triggered cell death remains controversial, In the present study, overexpression of p53 in human melanoma SK-MEL-110 cells through use of an adenoviral expression vector (AdCMV,p53) was found to result in apoptosis, while similar infection of primary vascular smooth muscle cells (VSMC) instead resulted in a moderate inhibition of growth, Expression of p21(Waf1/Cip1) was strongly elevated in VSMC, but showed little change in SK-MEL-110 cells, although expression of another p53-regulated gene (GADD45) was comparable in both AdCMV.p53-infected cell types, Evidence that p21(Waf1/Cip1) expression may be required for surviving p53-induced cell death was further supported by the finding that p53 overexpression was highly toxic for p21-deficient mouse embryonal fibroblasts (p21(-/-) MEFs), In both SK-MEL-110 and p21(-/-) MEFs, adenovirus-driven ectopic expression of p21(Waf1/Cip1) resulted in a substantial protection against p53-induced apoptosis, indicating that p21(Waf1/Cip1) rescued cells from a path of programmed cell death to one of enhanced survival.	NIA,NIH,CELLULAR & MOL BIOL LAB,BALTIMORE,MD 21224; NIA,NIH,CARDIOVASC SCI LAB,BALTIMORE,MD 21224; NCI,MED BRANCH,MED BREAST CANC SECT,NIH,BETHESDA,MD 20892; IST DERMOPAT IMMACOLATA,LAB PATOL VASCOLARE,I-00167 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Istituto Dermopatico dell'Immacolata (IDI)				Cirielli, Corrado/0000-0003-2524-7889				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIRIELLI C, 1995, INT J CANCER, V63, P1; CLAYMAN GL, 1995, CANCER RES, V55, P1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DRAZAN KE, 1994, SURGERY, V116, P197; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; GOROSPE M, 1996, IN PRESS MOL CELL BI; GOROSPE M, 1996, CANCER RES, V56, P457; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KIM YH, 1992, J IMMUNOL, V149, P17; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210	35	292	298	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					929	935		10.1038/sj.onc.1200897	http://dx.doi.org/10.1038/sj.onc.1200897			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050992				2022-12-25	WOS:A1997WK34400006
J	Gibson, A; Baburaj, K; Day, DE; Verhamme, I; Shore, JD; Peterson, CB				Gibson, A; Baburaj, K; Day, DE; Verhamme, I; Shore, JD; Peterson, CB			The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM SPREADING FACTOR; HEPARIN-BINDING DOMAIN; SOMATOMEDIN-B DOMAIN; ANTITHROMBIN-III; REACTIVE CENTER; TISSUE-TYPE; S-PROTEIN; STRUCTURAL REQUIREMENTS; ESCHERICHIA-COLI; ALPHA-THROMBIN	Plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tissue-type plasminogen activator and urokinase, is known to convert readily to a latent form by insertion of the reactive center loop into a central P-sheet. Interaction with vitronectin stabilizes PAI-1 and decreases the rate of conversion to the latent form, but conformational effects of vitronectin on the reactive center loop of PAI-1 have not been documented. Mutant forms of PAI-1 were designed with a cysteine substitution at either position P1' or P9 of the reactive center loop. Labeling of the unique cysteine with a sulfhydryl-reactive fluorophore provides a probe that is sensitive to vitronectin binding. Results indicate that the scissile P1-P1' bond of PAI-1 is more solvent exposed upon interaction with vitronectin, whereas the N-terminal portion of the reactive loop does not experience a significant change in its environment. These results were complemented by labeling vitronectin with an arginine-specific coumarin probe which compromises heparin binding but does not interfere with PAI-1 binding to the protein. Dissociation constants of approximately 100 nM are calculated for the vitronectin/PAI-1 interaction from titrations using both fluorescent probes. Furthermore, experiments in which PAI-1 failed to compete with heparin for binding to vitronectin argue for separate binding sites for the two ligands on vitronectin.	UNIV TENNESSEE,DEPT BIOCHEM & CELLULAR & MOL BIOL,KNOXVILLE,TN 37996; HENRY FORD HLTH SYST,DEPT BIOCHEM RES,DETROIT,MI 48202	University of Tennessee System; University of Tennessee Knoxville; Henry Ford Health System; Henry Ford Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050676, R29HL050676, R01HL045930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45930, HL50676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABURAJ K, 1994, BBA-GEN SUBJECTS, V1199, P253, DOI 10.1016/0304-4165(94)90004-3; BARNES DW, 1983, J BIOL CHEM, V258, P2548; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P3899; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; KEIJER J, 1991, J BIOL CHEM, V266, P10700; KOST C, 1992, J BIOL CHEM, V267, P12098; KRUITHOF EKO, 1984, BLOOD, V64, P907; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P258; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1995, MOL BASIS THROMBOSIS, P517; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1993, BIOCHEMISTRY-US, V33, P2315; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PITT WG, 1989, J COLLOID INTERF SCI, V129, P231, DOI 10.1016/0021-9797(89)90435-9; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHERMAN PM, 1995, J BIOL CHEM, V270, P9301, DOI 10.1074/jbc.270.16.9301; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SHORE JD, 1992, FIBRINOLYSIS S2, V6, P292; SIGURDARDOTTIR O, 1992, FIBRINOLYSIS, V6, P27, DOI 10.1016/0268-9499(92)90044-I; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; SOBEL M, 1992, J BIOL CHEM, V267, P8857; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; THORSEN S, 1988, EUR J BIOCHEM, V175, P33, DOI 10.1111/j.1432-1033.1988.tb14162.x; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WUN TC, 1989, J BIOL CHEM, V264, P7862; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	68	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5112	5121		10.1074/jbc.272.8.5112	http://dx.doi.org/10.1074/jbc.272.8.5112			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030577	hybrid, Green Published			2022-12-25	WOS:A1997WJ85500065
J	Mitsui, H; Takuwa, N; Kurokawa, K; Exton, JH; Takuwa, Y				Mitsui, H; Takuwa, N; Kurokawa, K; Exton, JH; Takuwa, Y			Dependence of activated G alpha 12-induced G(1) to S phase cell cycle progression on both Ras/mitogen-activated protein kinase and Ras/Ras1/Jun N-terminal kinase cascades in NIH3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC SIGNAL TRANSDUCTION; MUTANT ALPHA-SUBUNITS; MAP KINASE; NEOPLASTIC TRANSFORMATION; RAS TRANSFORMATION; ASTROCYTOMA-CELLS; MAMMALIAN-CELLS; DNA-SYNTHESIS; 3T3 CELLS; HA-RAS	We evaluated the roles of mitogen-activated protein kinase (MAPK) and Jun N-terminal kinase (JNK) signaling cascades in G alpha 12-induced G(1) to S phase cell cycle progression in NIH3T3(M17) fibroblasts. Transient expression of a constitutively active mutant of G alpha 12, G alpha 12(R203C), resulted in a a-fold increase in the number of bromodeoxyuridine-positive S phase cells over vector control level under serum-deprived conditions. Consistent with the ability of G alpha 12(R203C) to induce G(1)/S transition, its expression led to a a-fold increase in cyclin A promoter activity, which showed a marked synergism with a low concentration of serum, resulting in up to a 15-fold elevation over the basal level. In addition, G alpha 12(R203C) caused a a-fold stimulation in E2F-mediated transactivation. Wild type G alpha 12 showed similar stimulatory effects on cyclin A promoter activity and E2F-mediated transactivation, although of lesser magnitude. We observed a modest but constitutive activation of MAPK in cells transfected with G alpha 12(R203C), which was abolished by a dominant negative form of Ras, G alpha 12(R203C) also induced a 3-fold increase in JNK activity, which was abolished by dominant negative forms of either Rad or Ras. The expression of dominant negative forms of Ras, MAPK, Rac1, or JNK inhibited G alpha 12(R203C)-induced increases in bromodeoxyuridine-positive cells. Also, the dominant negative forms of Ras, MAPK, and JNK strongly inhibited G alpha 12(R203C)-induced stimulation of cyclin A promoter activity. These results demonstrate that both the Ras/MAPK and Ras/Rac1/JNK pathways convey necessary, if not sufficient, mitogenic signals induced by G alpha 12 activation.	UNIV TOKYO,FAC MED,DEPT CARDIOVASC BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED,BUNKYO KU,TOKYO 113,JAPAN; VANDERBILT UNIV,SCH MED,DEPT MOL PHYSIOL & BIOPHYS,HOWARD HUGHES MED INST,NASHVILLE,TN 37232	University of Tokyo; University of Tokyo; University of Tokyo; Howard Hughes Medical Institute; Vanderbilt University				TAKUWA, Noriko/0000-0002-4278-2704				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEVINS JR, 1992, SCIENCE, V258, P424; OFFERMANNS S, 1994, MOL CELL ENDOCRINOL, V100, P71, DOI 10.1016/0303-7207(94)90281-X; OKAZAKI K, 1995, ONCOGENE, V10, P1149; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKUWA N, 1987, J BIOL CHEM, V262, P182; Takuwa Y, 1989, Prog Growth Factor Res, V1, P195, DOI 10.1016/0955-2235(89)90011-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	60	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4904	4910		10.1074/jbc.272.8.4904	http://dx.doi.org/10.1074/jbc.272.8.4904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030549	hybrid			2022-12-25	WOS:A1997WJ85500037
J	Lorenzo, MJ; Gish, GD; Houghton, C; Stonehouse, TJ; Pawson, T; Ponder, BAJ; Smith, DP				Lorenzo, MJ; Gish, GD; Houghton, C; Stonehouse, TJ; Pawson, T; Ponder, BAJ; Smith, DP			RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2	ONCOGENE			English	Article						RET; multiple endocrine neoplasia type 2; Hirschsprung disease; Shc; Grb2	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; SIGNAL-TRANSDUCTION; HIRSCHSPRUNG DISEASE; NUCLEOTIDE EXCHANGE; POINT MUTATION; PROTOONCOGENE; RECEPTOR; PROTEIN	Activating germline mutations of the RET receptor tyrosine kinase are found in the majority of cases of inherited cancer syndrome MEN 2, and inactivating mutations in some cases of dominantly inherited Hirschsprung disease. Using RET activated by a MEN 2 mutation, we show that both the SH2 and PTB domains of the adaptor protein Shc interact with RET, and we identify the PTB domain interaction site. Interaction with both the SH2 and PTB domains of She contributes to the transcriptional activation of a serum response element. RET alternate splicing affects the strength of interaction with both the She SH2 and PTB domains. In addition, a splice isoform-specific HSCR missense mutation, which does not inactivate the RET kinase activity, decreases the strength of the PTB domain interaction and the level of RET-dependent She phosphorylation.	UNIV CAMBRIDGE, ADDENBROOKES HOSP,DEPT PATHOL,CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1TN, ENGLAND; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Lorenzo, Maria Jesus/0000-0003-4416-0615				ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CROWE AJ, 1994, ONCOGENE, V9, P537; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gotoh N, 1995, ONCOGENE, V11, P2525; GUITON M, 1994, J BIOL CHEM, V269, P30370; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JOHANSEN FE, 1996, BIOCHIM BIOPHYS ACTA, V1242, P1; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1995, J INTERN MED, V238, P343, DOI 10.1111/j.1365-2796.1995.tb01208.x; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS SM, 1995, ONCOGENE, V11, P2039; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PONDER BAJ, 1996, IN PRESS ADV CAN RES; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	111	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					763	771		10.1038/sj.onc.1200894	http://dx.doi.org/10.1038/sj.onc.1200894			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047383	Bronze			2022-12-25	WOS:A1997WJ11200002
J	Probst, MR; Fan, CM; TessierLavigne, M; Hankinson, O				Probst, MR; Fan, CM; TessierLavigne, M; Hankinson, O			Two murine homologs of the Drosophila single-minded protein that interact with the mouse aryl hydrocarbon receptor nuclear translocator protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; DIOXIN-RESPONSIVE ENHANCER; LIGANDED AH RECEPTOR; HEAT-SHOCK PROTEIN; TRANSCRIPTION FACTORS; DOWN-SYNDROME; DEVELOPMENTAL EXPRESSION; FUNCTIONAL DOMAINS; DNA INTERACTIONS; CRITICAL REGION	Drosophila single-minded, which acts as a positive master gene regulator in central nervous system midline formation in Drosophila, its two mouse homologs SIM1 and SIM2, and the mammalian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) proteins are members of the basic-helix-loop-helix PAS family of transcription factors. In the yeast two-hybrid system, we demonstrate strong constitutive interaction of ARNT with SIM1 and SIM2 and fully ligand-dependent interaction of ARNT with AHR. Both the helix-loop-helix and the PAS regions of SIM1 and of ARNT are required for efficient heterodimerization. SIM1 and SIM2 do not form homodimers, and they do not interact with AHB We also failed to detect homodimerization of ARNT. The interaction of ARNT with SIM1 was confirmed with in vitro synthesized proteins. Like AHR, in vitro synthesized SIM1 associates with the 90-kDa heat shock protein. SIM1 inhibits binding of the AHR . ARNT dimer to the xenobiotic response element in vitro. Introduction of SIM1 into hepatoma cells inhibits transcriptional transactivation by the endogenous AHR . ARNT dimer. The mouse SIM1 . ARNT dimer binds only weakly to a proposed DNA target for the Drosophila SIM . ARNT dimer. In adult mice mRNA for SIM1 was expressed in lung skeletal muscle, and kidney, whereas the mRNA for SIM2 was found in the latter two. ARNT is also expressed in these organs. Thus mouse SIM1 and SIM2 are novel heterodimerization partners for ARNT in vitro, and they may function both as positive and negative transcriptional regulators in vivo, during embryogenesis and in the adult organism.	UNIV CALIF LOS ANGELES, MED CTR,CTR HLTH SCI,DEPT PATHOL & LAB MED,SCH MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOL BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90095 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT ANAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco					NCI NIH HHS [CA 28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT BD, 1995, DEV DYNAM, V204, P144, DOI 10.1002/aja.1002040205; ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BURBACH KM, 1992, P NATL ACAD SCI USA, V92, P5510; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN H, 1995, NAT GENET, V10, P9, DOI 10.1038/ng0595-9; CHEN HS, 1994, J BIOL CHEM, V269, P27554; DAHMANE N, 1995, P NATL ACAD SCI USA, V92, P9191, DOI 10.1073/pnas.92.20.9191; Ema M, 1996, BIOCHEM BIOPH RES CO, V218, P588, DOI 10.1006/bbrc.1996.0104; Fan CM, 1996, MOL CELL NEUROSCI, V7, P519, DOI 10.1006/mcne.1996.0037; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; FRANKS RG, 1994, MECH DEVELOP, V45, P269, DOI 10.1016/0925-4773(94)90013-2; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; MUENKE M, 1995, AM J HUM GENET, V57, P1074; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	45	77	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4451	4457		10.1074/jbc.272.7.4451	http://dx.doi.org/10.1074/jbc.272.7.4451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020169	hybrid			2022-12-25	WOS:A1997WH01900085
J	JacobsHelber, SM; Penta, K; Sun, ZH; Lawson, A; Sawyer, ST				JacobsHelber, SM; Penta, K; Sun, ZH; Lawson, A; Sawyer, ST			Distinct signaling from stem cell factor and erythropoietin in HCD57 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID PROGENITOR CELLS; TYROSINE PHOSPHORYLATION; DNA-BINDING; MOUSE-LIVER; RECEPTOR; PROTEIN; JAK2; ACTIVATION; KINASE; ASSOCIATION	A recent report (Wu, H,, Klingmuller, U., Besmer, P., and Lodish, H, F. (1995) Nature 377, 242-246) documents the interaction of the erythropoietin (EPO) receptor (EPOR) with the stem cell factor (SCF) receptor (c-KIT) and suggests that SCF acts through the EPOR. To elucidate the ability of SCF to affect the erythropoietin signaling pathway, we studied the effect of SCF on EPOR phosphorylation, SHC/ERK-1 activity, and cell proliferation and apoptosis in EPO-dependent HCD57 cells, Treatment of these cells with SCF resulted in phosphorylation of the EPOR, However, SCF-dependent phosphorylation of the EPOR did not initiate an EPO-like intracellular signal. SCF induced proliferation, SHC phosphorylation, and activation of ERK-1 but did not activate the JAK/STAT pathway. SCF stimulated SHC phosphorylation and ERK-1 activation independent of the EPOR in cells where the EPOR was down-regulated; the presence of the EPOR appeared to facilitate SCF activation of SHC and ERK-1. Furthermore, treatment of HCD57 cells with SCF increased cell number over a 3-day treatment, but apoptosis was observed in these cells. These data may illustrate two distinct pathways for erythroid cell proliferation and prevention of apoptosis in response to EPO, thereby providing a system to discriminate these intracellular signals.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL TOXICOL,RICHMOND,VA 23298; VANDERBILT UNIV,MED CTR,DEPT MED,DIV CARDIOL,NASHVILLE,TN 37232	Virginia Commonwealth University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039781] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK39781] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; DAMEN JE, 1993, BLOOD, V82, P2296; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; HE TC, 1994, J BIOL CHEM, V269, P18291; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; Maniatis T, 1989, DECONTAMINATION DILU; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MIURA O, 1994, BLOOD, V84, P1501; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; SAWYER ST, 1994, HEMATOL ONCOL CLIN N, V8, P895, DOI 10.1016/S0889-8588(18)30136-9; SAWYER ST, 1993, P NATL ACAD SCI USA, V90, P6849, DOI 10.1073/pnas.90.14.6849; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; ZHNANG H, 1995, J BIOL CHEM, V270, P14500	23	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6850	6853		10.1074/jbc.272.11.6850	http://dx.doi.org/10.1074/jbc.272.11.6850			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054369	hybrid			2022-12-25	WOS:A1997WN14700008
J	Ohkura, T; Fukushima, K; Kurisaki, A; Sagami, H; Ogura, K; Ohno, K; HaraKuge, S; Yamashita, K				Ohkura, T; Fukushima, K; Kurisaki, A; Sagami, H; Ogura, K; Ohno, K; HaraKuge, S; Yamashita, K			A partial deficiency of dehydrodolichol reduction is a cause of carbohydrate-deficient glycoprotein syndrome type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM TRANSFERRIN; DOLICHYL-PHOSPHATE; LINKED OLIGOSACCHARIDES; RAT-LIVER; GLYCOSYLATION; BIOSYNTHESIS; POLYPRENOL; DISORDERS; DEFECT; MUTANT	Carbohydrate deficient glycoprotein (CDG) syndrome type I is a congenital disorder that involves the underglycosylation of N-glycosylated glycoproteins (Yamashita, K., Ideo, H., Ohkura, T., Fukushima, K., Yuasa, I., Ohno, K., and Takeshita, K. (1993) J. Biol. Chen. 268, 5783-5789). In an effort to further elucidate the biochemical basis of CDG syndrome type I in our patients, we investigated the defect in the multi-step pathway for biosynthesis of lipid-linked oligosaccharides (LLO) by the metabolic labeling method using [H-3]glucosamine , [3H]mannose, and [H-3]mevalonate. The LLO levels in synchronized cultures of fibroblasts from these patients were severalfold lower than those in control fibroblasts in the S phase, and the oligosaccharides released from LLO showed the same structural composition, Glc1 similar to 3 Man(9) GlcNAc GlcNAc, in the case of both the patients and controls. The amount of [H-3]mannose incorporated into mannose 6-phosphate, mannose l-phosphate , and GDP-mannose was greater in fibroblasts from these patients than in the control fibroblasts in the G(1) period, although the ratios of these acidic mannose derivatives as indicated by the relative levels of radioactivity were the same for the two types of fibroblasts. Furthermore, upon metabolic labeling with [H-3]mevalonate, the level of [H-3]dehydrodolichol in fibroblasts from these patients increased in the S phase, and the levels of [H-3]dolichol and [H-3]dolichol-PP oligosaccharides concomitantly decreased, although the chain length distribution of the respective dolichols and dehydrodolichols was the same in the two types of fibroblasts. These results indicate that the conversion of dehydrodolichol to dolichol is partially defective in our patients and that the resulting loss of dolichol leads directly to underglycosylation.	SASAKI INST,DEPT BIOCHEM,CHIYODA KU,TOKYO 101,JAPAN; TOHOKU UNIV,INST CHEM REACT SCI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT NEUROBIOL,YONAGO,TOTTORI 683,JAPAN	Tohoku University; Tottori University								Barnard E A, 1975, Methods Enzymol, V42, P6; BUTTERWORTH PH, 1968, ARCH BIOCHEM BIOPHYS, V128, P503, DOI 10.1016/0003-9861(68)90057-X; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GLASER L, 1959, BIOCHIM BIOPHYS ACTA, V33, P522, DOI 10.1016/0006-3002(59)90143-X; GU JG, 1995, J BIOCHEM-TOKYO, V117, P1276, DOI 10.1093/oxfordjournals.jbchem.a124855; GUHA SK, 1985, ARCH BIOCHEM BIOPHYS, V243, P168, DOI 10.1016/0003-9861(85)90785-4; HAGBERG BA, 1993, PEDIATR NEUROL, V9, P255, DOI 10.1016/0887-8994(93)90060-P; Jaeken J., 1996, Journal of Inherited Metabolic Disease, V19, P6; JAEKEN J, 1993, GLYCOBIOLOGY, V3, P423, DOI 10.1093/glycob/3.5.423; JAEKEN J, 1984, CLIN CHIM ACTA, V144, P245, DOI 10.1016/0009-8981(84)90059-7; JAEKEN J, 1980, PEDIATR RES, V14, P179, DOI 10.1203/00006450-198002000-00117; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KRASNEWICH DM, 1995, GLYCOBIOLOGY, V5, P503, DOI 10.1093/glycob/5.5.503; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; OHNO K, 1992, BRAIN DEV-JPN, V14, P30, DOI 10.1016/S0387-7604(12)80276-2; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; POWELL LD, 1994, J CLIN INVEST, V94, P1901, DOI 10.1172/JCI117540; PREISS J, 1972, METHOD ENZYMOL, V28, P281; RIPKA J, 1986, MOL CELL BIOL, V6, P1268, DOI 10.1128/MCB.6.4.1268; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROSENWALD AG, 1993, GLYCOBIOLOGY, V3, P481, DOI 10.1093/glycob/3.5.481; RUSH JS, 1995, ANAL BIOCHEM, V224, P494, DOI 10.1006/abio.1995.1078; SAGAMI H, 1993, J BIOL CHEM, V268, P10109; Sagami H, 1996, J BIOL CHEM, V271, P9560, DOI 10.1074/jbc.271.16.9560; SCHMITT JW, 1979, J BIOL CHEM, V254, P2291; SMALL DM, 1979, PHYTOCHEMISTRY, V18, P1147, DOI 10.1016/0031-9422(79)80123-5; Snider MD, 1984, BIOL CARBOHYDRATES, V2, P163; STIBLER H, 1990, ARCH DIS CHILD, V65, P107, DOI 10.1136/adc.65.1.107; STIBLER H, 1991, ACTA PAEDIATR SC   S, V375, P21; STOLL J, 1988, J BIOL CHEM, V263, P10766; STOLL J, 1988, J BIOL CHEM, V263, P10774; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; WADA Y, 1992, BIOCHEM BIOPH RES CO, V189, P832, DOI 10.1016/0006-291X(92)92278-6; YAMADA K, 1985, ANAL BIOCHEM, V150, P26, DOI 10.1016/0003-2697(85)90437-3; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; YAMASHITA K, 1993, J BIOL CHEM, V268, P5783; YAMASHITA K, 1993, J BIOCHEM-TOKYO, V114, P766, DOI 10.1093/oxfordjournals.jbchem.a124253; YAMASHITA K, 1996, GLYCOPROTEINS DIS, P443; YASUGI E, 1994, BIOCHEM BIOPH RES CO, V200, P816, DOI 10.1006/bbrc.1994.1524	41	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6868	6875		10.1074/jbc.272.11.6868	http://dx.doi.org/10.1074/jbc.272.11.6868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054372	hybrid			2022-12-25	WOS:A1997WN14700011
J	Polverino, AJ; Patterson, SD				Polverino, AJ; Patterson, SD			Selective activation of caspases during apoptotic induction in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; DEATH GENE CED-3; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASE; MAMMALIAN HOMOLOG; INHIBITION; MECHANISM; KINETICS	Apoptosis is a highly regulated biochemical process that results in the selective death of cells, Members of the caspase family of cysteine proteases play a pivotal role in the effector phase of apoptosis, We show that, in HL-60 cells, the addition of either anisomycin, a protein synthesis inhibitor, or geranylgeraniol, an intermediate in the cholesterol biosynthetic pathway, results in a rapid and en masse induction of apoptosis, The levels of actin, p42 and p44 MAPK, JNK1, JNK2, p38, and PCNA were not substantially altered during this process. Although these treatments appear to function by diverse pathways, they both result in the processing and activation of caspase-3 (CPP32 beta/Yama/Apopain). In contrast, no activation of caspase-1 (interleukin-1 beta converting enzyme (ICE)) was observed, Furthermore, we obtained ambiguous results regarding the activation of caspase-2 (Ich-1) depending on the antibody used, Pretreatment of the cells with benzyloxycarbonyl-val-Ala-Asp-(OMe)-fluoromethylketone (zVAD.fmk), a tetrapeptide inhibitor of caspases, prevented the induction of apoptosis for 24 h, Even after 72 h of treatment, some cells were still alive and progressing through the cell. cycle, suggesting that blockage of caspase activity is able to protect cells. These results suggest that selective activation of some caspases is necessary to induce apoptosis in HL-60 cells.	AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Amgen			Patterson, Scott/A-7404-2009					Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AYALA JM, 1994, J IMMUNOL, V153, P2592; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Dustin P., 1984, MICROTUBULES; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAZITT Y, 1994, CANCER RES, V54, P950; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GORCZYCA W, 1993, INT J ONCOL, V3, P627; GROLLMAN AP, 1967, J BIOL CHEM, V242, P3226; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hasegawa J, 1996, CANCER RES, V56, P1713; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krajewski S, 1996, ANAL BIOCHEM, V236, P221, DOI 10.1006/abio.1996.0160; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OHIZUMI H, 1995, J BIOCHEM-TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1993, MOL CELL BIOL, V13, P7000, DOI 10.1128/MCB.13.11.7000; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	45	134	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7013	7021		10.1074/jbc.272.11.7013	http://dx.doi.org/10.1074/jbc.272.11.7013			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054391	hybrid			2022-12-25	WOS:A1997WN14700030
J	Brandt, TL; Fraser, DJ; Leal, S; Halandras, PM; Kroll, AR; Kroll, DJ				Brandt, TL; Fraser, DJ; Leal, S; Halandras, PM; Kroll, AR; Kroll, DJ			c-Myb trans-activates the human DNA topoisomerase II alpha gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY DOMAIN; ETS PROTEINS COOPERATE; B-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE EXPRESSION; PROTOONCOGENE PRODUCT; CELLULAR PROGENITOR; 5'-FLANKING REGION; BINDING DOMAIN	DNA topoisomerase II alpha (topo II alpha) is an essential proliferation-dependent nuclear enzyme which has been exploited as an anti-tumor drug target. Since the proliferative status of human leukemia cells is associated with expression of the c-myb proto oncogene, c-Myb was investigated as a trans-activator of the topo II alpha gene, Using topo II alpha promoter-luciferase reporter plasmids, c-myb expression caused trans-activation of the topo II alpha promoter a maximum of similar to 4.5-fold over basal levels in HL-60 human promyelocytic leukemia cells. Trans-activation was submaximal with higher levels of c-myb expression plasmid but a Myb protein lacking its negative regulatory domain resulted in similar to 19-fold trans-activation. Mutagenesis and 5'-deletion studies revealed that Myb trans-activation was mediated via a Myb-binding site at positions -16 to -11 and that this region governed the bulk of basal topo II alpha promoter activity in human leukemia cells, Trans activation of topo II alpha by c-Myb was lymphoid- or myeloid-dependent, However, B-Myb, a more widely-expressed Myb family member, caused topo II alpha trans-activation in both HL-60 cells and HeLa epithelial cervical carcinoma cells. These data provide evidence for a new Myb-responsive gene which is directly linked to and required for cellular proliferation.	UNIV COLORADO,SCH PHARM,DEPT PHARMACEUT SCI,DENVER,CO 80262; UNIV COLORADO,CTR CANC,DENVER,CO 80262; AMGEN INC,DNA TECHNOL GRP,BOULDER,CO 80301	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver; Amgen					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM050381] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50381] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FAVIER D, 1994, ONCOGENE, V9, P305; FRASER DJ, 1995, MOL PHARMACOL, V47, P696; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HSIANG YH, 1988, CANCER RES, V48, P3230; HU YL, 1991, ONCOGENE, V6, P1549; ISSACS RJ, 1996, J BIOL CHEM, V271, P16741; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KAUFMANN SH, 1991, CANCER RES, V51, P3534; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KROLL DJ, 1993, MOL ENDOCRINOL, V7, P305, DOI 10.1210/me.7.3.305; KROLL DJ, 1989, THESIS U FLORIDA; KU DH, 1993, J BIOL CHEM, V268, P2255; KUBO T, 1995, CANCER RES, V55, P3860; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NELSON WG, 1987, CANCER RES, V47, P3246; NELSON WG, 1986, NATURE, V322, P187, DOI 10.1038/322187a0; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NITISS JL, 1992, CANCER RES, V52, P4467; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; QUEVA C, 1992, DEVELOPMENT, V114, P125; RABIZADEH E, 1993, FEBS LETT, V328, P225, DOI 10.1016/0014-5793(93)80932-K; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; SUDO T, 1992, ONCOGENE, V7, P1999; SULLIVAN DM, 1987, CANCER RES, V47, P3973; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TASHIRO S, 1995, ONCOGENE, V10, P1699; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Watt PM, 1996, CURR BIOL, V6, P265, DOI 10.1016/S0960-9822(02)00474-8; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9	74	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6278	6284		10.1074/jbc.272.10.6278	http://dx.doi.org/10.1074/jbc.272.10.6278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045645	hybrid			2022-12-25	WOS:A1997WM64700029
J	Chen, DD; Schnell, DJ				Chen, DD; Schnell, DJ			Insertion of the 34-kDa chloroplast protein import component, IAP34, into the chloroplast outer membrane is dependent on its intrinsic GTP-binding capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-ANCHOR SEQUENCE; ENVELOPE MEMBRANE; MACHINERY; PATHWAY; IDENTIFICATION	IAP34 is a 34-kDa component of the outer membrane complex that mediates the initial stages of protein import into chloroplasts (Seedorf, M., Waegemann, K., and Sell, J. (1995) Plant J. 7, 401-411; Kessler, F., Blobel, G., Patel, H. A., and Schnell, D. J. (1994) Science 266, 1035-1039), We have investigated the targeting and insertion of IAP34 at the outer envelope membrane, The analyses of IAP34 deletion mutants and hybrid proteins (consisting of regions of IAP34 fused to the soluble IgG-binding domain of staphylococcal protein A) suggest that the transmembrane domain and C-terminal tail of IAP34 contain information essential but not sufficient for targeting to the outer membrane, Treatment of chloroplasts with exogenous proteases does not affect IAP34 insertion, indicating that targeting does not require surface-exposed receptors at the envelope. GTP or GDP is required for maximal integration of IAP34 into the outer membrane, The GTP/GDP requirement is attributed to the intrinsic GTP binding activity of IAP34 because GTP/GDP binding-deficient mutants are defective in outer membrane insertion, On the basis of these observations, we propose that IAP34 is targeted to the chloroplast by a C-terminal signal and efficiently integrated into the outer membrane by conformation-induced insertion upon GTP/GDP binding.	RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102	Rutgers State University Newark; Rutgers State University New Brunswick								BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MA Y, 1996, J CELL BIOL, V134, P1; Marston F. A. O., 1987, DNA CLONING, P59; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Muckel E, 1996, J BIOL CHEM, V271, P23846, DOI 10.1074/jbc.271.39.23846; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SHORE GC, 1992, MEMBRANE BIOGENESIS, P253; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x	24	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6614	6620		10.1074/jbc.272.10.6614	http://dx.doi.org/10.1074/jbc.272.10.6614			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045691	hybrid			2022-12-25	WOS:A1997WM64700075
J	Holmberg, CI; Leppa, S; Eriksson, JE; Sistonen, L				Holmberg, CI; Leppa, S; Eriksson, JE; Sistonen, L			The phorbol ester 12-O-tetradecanoylphorbol 13-acetate enhances the heat-induced stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; PROTEIN-KINASE-C; DNA-BINDING ACTIVITY; HUMAN HSP70 PROMOTER; GENE-TRANSCRIPTION; MAP KINASE; THERMOTOLERANCE DEVELOPMENT; AP-1 ACTIVITY; HT-29 CELLS; IN-VIVO	Induction of heat shock: gene expression is mediated by specific heat shock transcription factors (HSFs), but the signaling pathways leading to activation of HSFs are poorly understood. To elucidate whether protein kinase C-responsive signaling pathways could be involved in the regulation of heat shock gene expression, we have examined the effects of the protein kinase C activator 12-O-tetradecanoylphorbol 13-acetate (TPA) on the heat-induced stress response in K562 cells. We demonstrate that TPA treatment markedly enhances heat shock gene expression during heat stress, although TPA alone does not induce the heat shock response. This TPA-mediated enhancement can initially be detected as an accelerated acquisition of DNA binding and transcriptional activity of HSF1 resulting in elevated Hsp70 protein concentrations. In the presence of TPA, the attenuation of HSF1 DNA binding activity during continuous exposure to heat shock occurs more rapidly and in concert with the appearance of newly synthesized Hsp70, which supports earlier studies on the autoregulatory role of Hsp70 in deactivation of HSF1. During heat stress, a correlation between the hyperphosphorylation of HSF1 and its transcriptional activity was observed, in both the presence and the absence of TPA. Our results show that the heat-induced stress response can be significantly modulated by activation of protein kinase C-responsive signaling pathways.	UNIV TURKU,TURKU CTR BIOTECHNOL,ABO AKAD UNIV,FIN-20520 TURKU,FINLAND; ABO AKAD UNIV,DEPT BIOCHEM & PHARM,FIN-20521 TURKU,FINLAND	Abo Akademi University; University of Turku; Abo Akademi University				Holmberg-Still, Carina/0000-0001-9645-2009; Leppa, Sirpa/0000-0002-8265-511X; Sistonen, Lea/0000-0003-1341-2867				ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; BRUCE JL, 1993, CANCER RES, V53, P12; CARTER T, 1987, CANCER RES, V47, P803; CHANG NT, 1993, J BIOL CHEM, V268, P1436; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLAZER RI, 1994, PROTEIN KINASE C, P171; GREEN M, 1995, MOL CELL BIOL, V15, P3354; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOJ A, 1994, EMBO J, V13, P2617; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KIM DH, 1995, P NATL ACAD SCI USA, V92, P2126, DOI 10.1073/pnas.92.6.2126; KIM SH, 1993, BIOCHEM BIOPH RES CO, V193, P759, DOI 10.1006/bbrc.1993.1690; KUO JF, 1994, PROTEIN KINASE C; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LEE YJ, 1994, BIOCHEM PHARMACOL, V48, P2057, DOI 10.1016/0006-2952(94)90505-3; LEE YJ, 1994, BIOCHEM BIOPH RES CO, V199, P714, DOI 10.1006/bbrc.1994.1287; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MATHUR SK, 1994, P NATL ACAD SCI USA, V91, P8695, DOI 10.1073/pnas.91.18.8695; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MORGAN WD, 1989, MOL CELL BIOL, V9, P4099, DOI 10.1128/MCB.9.9.4099; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RITZ MF, 1993, RECEPTOR, V3, P311; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WATOWICH SS, 1990, THESIS NW U EVANSTON; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; WOOTEN MW, 1991, EXP CELL RES, V193, P274, DOI 10.1016/0014-4827(91)90096-D; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	71	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6792	6798		10.1074/jbc.272.10.6792	http://dx.doi.org/10.1074/jbc.272.10.6792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045713	hybrid			2022-12-25	WOS:A1997WM64700097
J	Kashiwagi, K; Shibuya, S; Tomitori, H; Kuraishi, A; Igarashi, K				Kashiwagi, K; Shibuya, S; Tomitori, H; Kuraishi, A; Igarashi, K			Excretion and uptake of putrescine by the PotE protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL UPTAKE SYSTEM; SITE-DIRECTED MUTAGENESIS; ORNITHINE DECARBOXYLASE; TRANSPORT PROTEIN; CELL-GROWTH; POLYAMINE METABOLISM; SPERMIDINE; INHIBITION; MEMBRANE; CHROMOSOME	The structure and function of the polyamine transport protein PotE was studied. Uptake of putrescine by PotE was dependent on the membrane potential. In contrast, the putrescine-ornithine antiporter activity of PotE studied with inside-out membrane vesicles was not dependent on the membrane potential (Kashiwagi, K., Miyamoto, S., Suzuki, F., Kobayashi, H., and Igarashi, K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4529-4533). The K-m values for putrescine uptake and for putrescine-ornithine antiporter activity were 1.8 and 73 mu M, respectively. Uptake of putrescine was inhibited by high concentrations of ornithine. This effect of ornithine appears to be due to putrescine-ornithine antiporter activity because it occurs only after accumulation of putrescine within cells and because ornithine causes excretion of putrescine. Thus, PotE can function not only as a putrescine-ornithine antiporter to excrete putrescine but also as a putrescine uptake protein. Both the NH2 and COOH termini of PotE were located in the cytoplasm, as determined by the activation of alkaline phosphatase and beta-galactosidase by various PotE-fusion proteins. The activities of putrescine uptake and excretion were studied using mutated PotE proteins. It was found that glutamic acid 207 was essential for both the uptake and excretion of putrescine by the PotE protein and that glutamic acids 77 and 433 were also involved in both activities. These three glutamic acids are located on the cytoplasmic side of PotE, and the function of these three residues could not be replaced by other amino acids. Putrescine transport activities did not change significantly with mutations at the other 13 glutamic acid or aspartic acid residues in PotE.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN	Chiba University				Igarashi, Kazuei/0000-0003-3751-3187				CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; ECKERT B, 1989, J BIOL CHEM, V264, P11663; FUKUCHI J, 1992, EUR J BIOCHEM, V209, P689, DOI 10.1111/j.1432-1033.1992.tb17337.x; FUKUCHI JI, 1995, J BIOL CHEM, V270, P18831, DOI 10.1074/jbc.270.32.18831; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GUTNICK D, 1969, J BACTERIOL, V100, P215, DOI 10.1128/JB.100.1.215-219.1969; HE Y, 1993, EUR J BIOCHEM, V217, P89, DOI 10.1111/j.1432-1033.1993.tb18222.x; IGARASHI K, 1995, CANCER RES, V55, P2615; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; IGARASHI K, 1990, BIOCHEM BIOPH RES CO, V172, P715, DOI 10.1016/0006-291X(90)90733-4; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KAMEJI T, 1993, BIOCHEM J, V289, P581, DOI 10.1042/bj2890581; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P591, DOI 10.1006/bbrc.1994.1489; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1995, J BIOL CHEM, V270, P25377, DOI 10.1074/jbc.270.43.25377; KIMMICH GA, 1975, ANAL BIOCHEM, V69, P187, DOI 10.1016/0003-2697(75)90580-1; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LEE JI, 1992, J BIOL CHEM, V267, P20758; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MENG SY, 1992, J BACTERIOL, V174, P2659, DOI 10.1128/jb.174.8.2659-2669.1992; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller JH., 1972, EXPT MOL GENETICS; MOLENAAR D, 1993, J BACTERIOL, V175, P2864, DOI 10.1128/JB.175.10.2864-2870.1993; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; PEGG AE, 1988, CANCER RES, V48, P759; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; PORTER CW, 1987, BIOCHEM J, V45, P2050; PORTER CW, 1990, BIOCHEM J, V268, P331; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; Rottenberg H, 1979, Methods Enzymol, V55, P547; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAKAYAMA M, 1994, MOL MICROBIOL, V8, P5; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	53	80	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6318	6323		10.1074/jbc.272.10.6318	http://dx.doi.org/10.1074/jbc.272.10.6318			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045651	hybrid			2022-12-25	WOS:A1997WM64700035
J	Ventura, C; Pintus, G				Ventura, C; Pintus, G			Opioid peptide gene expression in the primary hereditary cardiomyopathy of the Syrian hamster .3. Autocrine stimulation of prodynorphin gene expression by dynorphin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CARDIAC MYOCYTES; ADULT-RAT; ENKEPHALIN IMMUNOREACTIVITY; CULTURED CARDIOMYOCYTES; ANTAGONIST MODULATION; NEURO-BLASTOMA; GROWTH-FACTORS; CALPHOSTIN-C; CANCER CELLS	Prodynorphin mRNA and dynorphin B expression have been previously shown to be greatly increased in cardiac myocytes of BIO 14.6 cardiomyopathic hamsters. Here we report that exogenous dynorphin B in duced a dose-dependent increase in prodynorphin mRNA levels and stimulated prodynorphin gene transcription in normal hamster myocytes. Similar responses were elicited by the synthetic selective kappa opioid receptor agonist U-50,488H. These effects were counteracted by the kappa opioid receptor antagonist Mr-1452 and were not observed in the presence of chelerythrine or calphostin C, two specific protein kinase C (PKC) inhibitors, Treatment of cardiomyopathic cells with Mr-1452 significantly decreased both prodynorphin mRNA levels and prodynorphin gene transcription. In control myocytes, dynorphin B induced the translocation of PKC-alpha to the nucleus and increased nuclear PKC activity without affecting the expression of PKC-delta, -epsilon, or -zeta. Acute release of either U-50,488H or dyn B over single normal or cardiomyopathic cells transiently increased the cytosolic Ca2+ concentration. A sustained treatment with each opioid agonist increased the cytosolic Ca2+ level for a more prolonged period in cardiomyopathic than in control myocytes and led to a depletion of Ca2+ from the sarcoplasmic reticulum in both groups of cells, The possibility that prodynorphin gene expression may affect the function of the cardiomyopathic cell through an autocrine mechanism is discussed.	NATL INST BIOSTRUCT & BIOSYST, NATL LAB, OSILO, ITALY		Ventura, C (corresponding author), UNIV SASSARI, SCH MED, INST BIOL CHEM A BONSIGNORE, VIALE SAN PIETRO 43-B, I-07100 SASSARI, ITALY.				Telethon [593] Funding Source: Medline	Telethon(Fondazione Telethon)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; ALLO SN, 1991, J BIOL CHEM, V266, P22003; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; FEDIDA D, 1993, PHYSIOL REV, V73, P469, DOI 10.1152/physrev.1993.73.2.469; FINKEL MS, 1993, LIFE SCI, V52, P1109, DOI 10.1016/0024-3205(93)90432-3; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P610, DOI 10.1097/00005344-199204000-00019; FLEISCHER S, 1985, P NATL ACAD SCI USA, V832, P7356; GOLDSTEIN A, 1983, PEPTIDES ANAL SYNTHE, V7, P95; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; KASPER E, 1992, LIFE SCI, V50, P2029, DOI 10.1016/0024-3205(92)90568-A; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUO TH, 1992, BIOCHIM BIOPHYS ACTA, V1138, P343, DOI 10.1016/0925-4439(92)90013-D; LAW PY, 1995, J PHARMACOL EXP THER, V272, P322; LEGSSYER A, 1988, J PHYSIOL-LONDON, V401, P185, DOI 10.1113/jphysiol.1988.sp017157; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; MANECKJEE R, 1992, P NATL ACAD SCI USA, V89, P1169, DOI 10.1073/pnas.89.4.1169; MANECKJEE R, 1990, CANCER RES, V50, P2234; MCLAUGHLIN PJ, 1994, LIFE SCI, V54, P1423, DOI 10.1016/0024-3205(94)00597-4; MERINEY SD, 1991, J NEUROSCI, V11, P3705; PANERAI AE, 1984, BRAIN RES, V304, P153, DOI 10.1016/0006-8993(84)90872-2; PATEL J, 1987, J BIOL CHEM, V262, P16686; PILCHER CWT, 1983, LIFE SCI, V33, P697, DOI 10.1016/0024-3205(83)90598-2; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TERZIC A, 1993, PHARMACOL REV, V45, P147; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; VENTURA C, 1995, J BIOL CHEM, V270, P30115; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; Ventura C, 1997, J BIOL CHEM, V272, P6693, DOI 10.1074/jbc.272.10.6693; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; VENTURA C, 1994, J BIOL CHEM, V269, P5384; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; ZAGON IS, 1985, SCIENCE, V227, P1049, DOI 10.1126/science.3883485; ZAGON IS, 1995, AM J PHYSIOL-REG I, V268, pR942, DOI 10.1152/ajpregu.1995.268.4.R942; ZAGON IS, 1983, SCIENCE, V221, P671, DOI 10.1126/science.6867737; ZAGON IS, 1989, BRAIN RES, V480, P16, DOI 10.1016/0006-8993(89)91562-X; ZAGON IS, 1994, MOL BRAIN RES, V21, P85, DOI 10.1016/0169-328X(94)90381-6; ZAGON IS, 1986, CELL TISSUE RES, V246, P561, DOI 10.1007/BF00215197; ZAGON IS, 1993, RECEPTORS DEV NERVOU, V1, P39	51	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6699	6705		10.1074/jbc.272.10.6699	http://dx.doi.org/10.1074/jbc.272.10.6699			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045702	hybrid			2022-12-25	WOS:A1997WM64700086
J	Xie, ZJ; Bikle, DD				Xie, ZJ; Bikle, DD			Cloning of the human phospholipase C-gamma 1 promoter and identification of a DR6-type vitamin D-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOCALCIN GENE; HUMAN EPIDERMAL-KERATINOCYTES; FACTOR RECEPTOR GENE; SIGNAL TRANSDUCTION; ELEVATED CONTENT; DIFFERENTIATION; SEQUENCE; GROWTH; REGION; CELLS	The 5'-flanking region of the human phospholipase C-gamma 1 gene was isolated from a human P1 genomic DNA library. The S1-nuclease mapping and primer extension analysis revealed that there is a single transcriptional start site located at 135 bases upstream from the translation start codon in the human phospholipase C-gamma 1 gene, DNA sequence analysis showed that the sequence around the transcriptional start site is very GC rich and has no TATA box, The fragment +135 to -877 in the 5'-flanking region of the human phospholipase C-gamma 1 gene was subcloned into a luciferase reporter vector, The chimeric gene produced a high level of luciferase activity and responded to 1,25-(OH)(2)D-3 in transiently transfected human keratinocytes, Deletion and mutation studies of the fragment +135 to -877 demonstrated a vitamin D-responsive element that contains a motif arranged as two direct repeats separated by 6 bases (DR6), AGGTCAgaccacTGGACA, located between -786 and -803 base pairs, Incubation of the oligonucleotide containing the DR6 with keratinocyte nuclear extracts produced a specific protein-DNA complex that shifted to a higher molecular weight form upon the addition of an antibody specific to the 1,25-(OH)(2)D-3 receptor, Therefore, the 5'-flanking region of the human phospholipase C-gamma 1 gene confers promoter activity and contains a DR6-type vitamin D-responsive element that mediates, at least in part, the enhanced expression of this gene in human keratinocytes by 1,25-(OH)(2)D-3.	UNIV CALIF SAN FRANCISCO, VET AFFAIRS MED CTR, ENDOCRINE UNIT, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)			xie, zhongjian/K-7858-2016	xie, zhongjian/0000-0002-4328-1303				ABMAYR SM, 1994, CURRENT PROTOCOL MOL; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARROLL JM, 1992, J CELL SCI, V103, P925; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KAHLEN JP, 1994, BIOCHEM BIOPH RES CO, V202, P1366, DOI 10.1006/bbrc.1994.2081; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KIM SJ, 1989, J BIOL CHEM, V264, P402; LIU M, 1994, MOL ENDOCRINOL, V8, P1593, DOI 10.1210/me.8.12.1593; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NANNEY LB, 1992, CELL GROWTH DIFFER, V3, P233; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; OZONO K, 1990, J BIOL CHEM, V265, P21881; PARK JG, 1994, CANCER RES, V54, P2240; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; PILLAI S, 1991, J CELL PHYSIOL, V146, P94, DOI 10.1002/jcp.1041460113; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; PUNNONEN K, 1994, MOL CARCINOGEN, V10, P216, DOI 10.1002/mc.2940100406; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; SREEKUMAR P, 1995, J CLIN INVEST, V96, P602, DOI 10.1172/JCI118075; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; THANGUE NBL, 1988, TRANSCRIPTION SPLICI, P1	38	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6573	6577		10.1074/jbc.272.10.6573	http://dx.doi.org/10.1074/jbc.272.10.6573			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045685	hybrid			2022-12-25	WOS:A1997WM64700069
J	Takai, D; Inoue, K; Goto, Y; Nonaka, I; Hayashi, JI				Takai, D; Inoue, K; Goto, Y; Nonaka, I; Hayashi, JI			The interorganellar interaction between distinct human mitochondria with deletion mutant mtDNA from a patient with mitochondrial disease and with HeLa mtDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; CELLS; GENOME; TUMORIGENICITY; RECOMBINATION; DYSFUNCTION; SEGREGATION; ASSIGNMENT; ORGANELLES; EXPRESSION	For the examination of possible intermitochondrial interaction of human mitochondria from different cells, cybrids were constructed by introducing HeLa mitochondria into cells with respiration-deficient (rho(-)) mitochondria, Respiration deficiency was due to the predominance of mutant mtDNA with a 5,196-base pair deletion including five tRNA genes (Delta mtDNA(5196)). The HeLa mtDNA and Delta mtDNA(5196) encoded chloramphenicol-resistant (CAP(r)) and chloramphenicol-sensitive (CAPS) 16 S rRNA, respectively. The first evidence for the interaction was that polypeptides exclusively encoded by Delta mtDNA(5196) were translated on the introduction of HeLa mitochondria, suggesting supplementation of the missing tRNAs by rho(-) mitochondria from HeLa mitochondria. Second, the exchange of mitochondrial rRNAs was observed; even in the presence of CAP, CAP(s) Delta mtDNA(5196)-specific polypeptides as well as those encoded by CAP(r) HeLa mtDNA were translated in the cybrids, These phenomena can be explained assuming that the translation in rho(-) mitochondria was restored by tRNAs and CAP(r) 16 S rRNA supplied from HeLa mitochondria, unambiguously indicating interorganellar interaction, These observations introduce a new concept of the dynamics of the mitochondrial genetic system and help in understanding the relationship among mtDNA mutations and expression of human mitochondrial diseases and aging.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV ULTRASTRUCT RES,KODAIRA,TOKYO 187,JAPAN	University of Tsukuba; National Center for Neurology & Psychiatry - Japan								ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BELLIARD G, 1979, NATURE, V281, P401, DOI 10.1038/281401a0; BIRKY CW, 1983, SCIENCE, V222, P468, DOI 10.1126/science.6353578; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; DUJON B, 1974, GENETICS, V78, P415; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GURGO C, 1969, J MOL BIOL, V45, P205, DOI 10.1016/0022-2836(69)90100-4; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1983, EXP CELL RES, V148, P258, DOI 10.1016/0014-4827(83)90206-9; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HAYASHI JI, 1985, EXP CELL RES, V160, P387, DOI 10.1016/0014-4827(85)90185-5; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HAYASHI JI, 1984, CANCER RES, V44, P3957; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; MIYAKAWA I, 1984, J CELL SCI, V66, P21; MONNAT RJ, 1986, GENE, V43, P205, DOI 10.1016/0378-1119(86)90208-8; NONAKA I, 1989, J NEUROL SCI, V9, P193; OLIVER NA, 1982, MOL CELL BIOL, V2, P30, DOI 10.1128/MCB.2.1.30; OLIVER NA, 1983, J BIOL CHEM, V258, P5834; POSAKONY JW, 1975, J CELL SCI, V19, P315; PREISS T, 1995, TRENDS GENET, V11, P211, DOI 10.1016/S0168-9525(00)89048-4; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Takai D, 1995, BIOCHEM BIOPH RES CO, V217, P668, DOI 10.1006/bbrc.1995.2826; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YATSCOFF RW, 1978, SOMAT CELL GENET, V4, P633, DOI 10.1007/BF01543155; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	30	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6028	6033		10.1074/jbc.272.9.6028	http://dx.doi.org/10.1074/jbc.272.9.6028			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038225	hybrid			2022-12-25	WOS:A1997WK74700093
J	Behrmann, I; Janzen, C; Gerhartz, C; SchmitzVandeLeur, H; Hermanns, H; Heesel, B; Graeve, L; Horn, F; Tavernier, J; Heinrich, PC				Behrmann, I; Janzen, C; Gerhartz, C; SchmitzVandeLeur, H; Hermanns, H; Heesel, B; Graeve, L; Horn, F; Tavernier, J; Heinrich, PC			A single STAT recruitment module in a chimeric cytokine receptor complex is sufficient for STAT activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA RECEPTOR; BETA-SUBUNIT; SIGNAL-TRANSDUCTION; HUMAN INTERLEUKIN-5; CYTOPLASMIC DOMAIN; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; GM-CSF; BINDING; CELLS	We established a system of receptor chimeras that enabled us to induce heterodimerization of different cytoplasmic tails, Fusion constructs were created that are composed of the extracellular parts of the interleukin-5 receptor alpha and beta chains, respectively, and the transmembrane and intracellular parts of gp130, the signal transducing chain of the interleukin-6 receptor complex, In COS-7 transfectants we observed a dose-dependent interleukin-5-inducible STAT1 activation for which the presence of both the alpha and the beta chain chimera was needed, No STAT activity was detected if one of the cytoplasmic tails of the receptor complex was deleted, indicating that STAT activity resulted from a receptor dimer rather than from higher receptor aggregates. We further investigated whether dimerization of STAT1 depends on the juxtaposition of two STAT recruitment modules in a receptor complex, We show that a receptor dimer with only a single STAT1 docking site was still able to lead to STAT1 activation, This indicates that the formation of a paired set of STAT binding sites in a receptor complex is not the prerequisite for STAT factor dimerization, Our findings are discussed in view of alternative STAT dimerization models.	STATE UNIV GHENT VIB, DEPT MED PROT CHEM, MOL BIOL UNIT, B-9000 GHENT, BELGIUM	Flanders Institute for Biotechnology (VIB); Ghent University	Behrmann, I (corresponding author), RHEIN WESTFAL TH AACHEN, INST BIOCHEM, PAUWELSSTR, D-52057 AACHEN, GERMANY.		Tavernier, Jan/AAG-3636-2019; Janzen, Christian J/A-4771-2011	Behrmann, Iris/0000-0003-3688-3645				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; Chang WP, 1996, P NATL ACAD SCI USA, V93, P5947, DOI 10.1073/pnas.93.12.5947; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DAndrea RJ, 1996, BLOOD, V87, P2641, DOI 10.1182/blood.V87.7.2641.bloodjournal8772641; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HOU J, 1994, SCIENCE, V365, P1701; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURAKAMI M, 1993, SCIENCE, V241, P825; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; TAVERNIER J, 1996, BLOOD CEL B, V7, P321; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x	50	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5269	5274		10.1074/jbc.272.8.5269	http://dx.doi.org/10.1074/jbc.272.8.5269			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030599	hybrid			2022-12-25	WOS:A1997WJ85500087
J	Fukui, K; Sasaki, T; Imazumi, K; Matsuura, Y; Nakanishi, H; Takai, Y				Fukui, K; Sasaki, T; Imazumi, K; Matsuura, Y; Nakanishi, H; Takai, Y			Isolation and characterization of a GTPase activating protein specific for the Rab3 subfamily of small G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; BINDING PROTEIN; TARGET PROTEIN; SMG P25A; RAS; RABPHILIN-3A; FAMILY; YEAST	The Rab small G protein family, consisting of nearly 30 members, is implicated in intracellular vesicle trafficking. They cycle between the GDP-bound and GTP-bound forms, and the latter is converted to the former by the action of a GTPase activating protein (GAP). No GAP specific for each Rab family member or Rab subfamily has been isolated in mammal. Here we purified a GAP with Rab3A as a substrate from rat brain. The purified protein was specifically active on the Rab3 subfamily members (Rab3A, -B, -C, and D). Of this subfamily, Rab3A and -C are implicated in Ca2+-dependent exocytosis, particularly in neurotransmitter release. This GAP, named Rab3 GAP, was active on the lipid-modified form, but not on the lipid-unmodified form. Rab3 GAP showed a minimum molecular mass of about 130 kDa on SDS-polyacrylamide gel electrophoresis. We cloned its cDNA from a human brain cDNA library, and the isolated cDNA encoded a protein with a M(r) of 110,521 and 981 amino acids, which showed no homology to any known protein. The recombinant protein exhibited GAP activity toward the Rab3 subfamily members, and the catalytic domain was located at the C-terminal region. Northern blot analysis indicated that Rab3 GAP was ubiquitously expressed.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,SUITA,OSAKA 565,JAPAN; NATL INST HLTH,DEPT VIROL 2,TOKYO 162,JAPAN	Osaka University				Nakanishi, Hiroyuki/0000-0002-9765-0266				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSER E, 1992, J BIOL CHEM, V267, P16025; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; ORITA S, 1993, J BIOL CHEM, V268, P25542; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X	24	132	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4655	4658		10.1074/jbc.272.8.4655	http://dx.doi.org/10.1074/jbc.272.8.4655			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030515	hybrid			2022-12-25	WOS:A1997WJ85500003
J	Lu, GQ; Giroux, EL; Kantrowitz, ER				Lu, GQ; Giroux, EL; Kantrowitz, ER			Importance of the dimer-dimer interface for allosteric signal transduction and AMP cooperativity of pig kidney fructose-1,6-bisphosphatase - Site-specific mutagenesis studies of Glu-192 and Asp-187 residues on the 190's loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; CRYSTAL-STRUCTURE; PHENOTYPIC SELECTION; SUBSTRATE-ANALOG; ESCHERICHIA-COLI; NEUTRAL FORM; 1,6-BISPHOSPHATASE; BISPHOSPHATASE; INHIBITION	The role of the 190's loop of fructose-1,6-bisphosphatase (Fru-1,6-P(2)ase) in the allosteric regulation of Fru-1,6-P(2)ase has been investigated through kinetic studies on three mutant enzymes, Glu-192 --> Ala, Glu-192 --> Gln, and Asp-187 --> Ala. AMP is an allosteric inhibitor, which binds to the regulatory sites and induces the R- to T-state transition; for wild-type Fru-1,6-P(2)ase AMP inhibition is cooperative with a Hill coefficient of 2.0. The replacement of Asp-187, which forms an interaction across the C1:C2 monomer-monomer interface, with alanine did not change the catalytic efficiency, and it had no effect on the cooperativity of AMP inhibition; however, the apparent dissociation constant for AMP increased more than 4-fold as compared to the value for the wild-type enzyme. The replacement of Glu-192, which forms interactions across the C1:C4 dimer-dimer interface, with Ala and Gln lowered k(cat) from 21 s(-1) for wild type enzyme to 15 s(-1) and 13 s(-1), respectively, for the mutant enzymes, while their respective K-m values were not changed, However, these replacements did have dramatic effects on AMP inhibition; first, cooperative AMP inhibition was lost; second, the AMP inhibition was biphasic, which can be interpreted as due to AMP binding to two classes of binding sites. The high affinity class of sites corresponds to the regulatory sites, while the low affinity class of sites may be the active sites. The results reported here, combined with the structural and kinetic results from the Lys-42 --> Ala enzyme, strongly suggest that the C1:C4 dimer-dimer interface, rather than the C1:C2 monomer-monomer interface, is critical for the propagation of the allosteric signal between the AMP sites on different subunits; in addition, cooperative AMP inhibition is essential for the enzyme to be fully inhibited by the binding of AMP to the allosteric site.	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College								BENKOVIC PA, 1978, ARCH BIOCHEM BIOPHYS, V191, P719, DOI 10.1016/0003-9861(78)90412-5; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; ELMAGHRABI MR, 1991, BIOCHEM BIOPH RES CO, V176, P137, DOI 10.1016/0006-291X(91)90900-R; GIROUX E, 1994, J BIOL CHEM, V269, P31404; GRAZI E, 1973, BIOCHEM BIOPH RES CO, V54, P1321, DOI 10.1016/0006-291X(73)91131-5; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JY, 1992, P NATL ACAD SCI USA, V89, P2404, DOI 10.1073/pnas.89.6.2404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; LU GQ, 1995, BIOCHEMISTRY-US, V34, P13272, DOI 10.1021/bi00041a002; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; PONTREMOLI S, 1979, ARCH BIOCHEM BIOPHYS, V194, P481, DOI 10.1016/0003-9861(79)90642-8; RICARD J, 1987, EUR J BIOCHEM, V166, P255, DOI 10.1111/j.1432-1033.1987.tb13510.x; RIOU JP, 1977, P NATL ACAD SCI USA, V74, P4615, DOI 10.1073/pnas.74.10.4615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDIVY JM, 1984, J BACTERIOL, V158, P1048, DOI 10.1128/JB.158.3.1048-1053.1984; Stec B, 1996, PROTEIN SCI, V5, P1541, DOI 10.1002/pro.5560050810; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4307, DOI 10.1021/bi00013a020; WILLIAMS MK, 1992, P NATL ACAD SCI USA, V89, P3080, DOI 10.1073/pnas.89.7.3080; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	29	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5076	5081		10.1074/jbc.272.8.5076	http://dx.doi.org/10.1074/jbc.272.8.5076			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030572	hybrid			2022-12-25	WOS:A1997WJ85500060
J	Mounier, CE; Shi, J; Sirimanne, SR; Chen, BH; Moore, AB; GillWoznichak, MM; Ping, DS; May, SW				Mounier, CE; Shi, J; Sirimanne, SR; Chen, BH; Moore, AB; GillWoznichak, MM; Ping, DS; May, SW			Pyruvate-extended amino acid derivatives as highly potent inhibitors of carboxyl-terminal peptide amidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLGLYCINE ALPHA-MONOOXYGENASE; TRYPTOPHAN INDOLE-LYASE; PEPTIDYLAMIDOGLYCOLATE LYASE; HYDROXYGLYCINE DERIVATIVES; MECHANISM; ENZYME; DEALKYLATION; SUBSTRATE; GLYCINE; INTERMEDIATE	Carboxyl-terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymatic action by pep tidylglycine monooxygenase (PAM, EC 1.14.17.3) and peptidylamidoglycolate lyase (PGL, EC 4.3.2.5). The mo nooxygenase, PAM, first catalyzes conversion of a glycine-extended pro-peptide to the corresponding alpha-hydroxyglycine derivative, and the lyase, PGL, then catalyzes breakdown of this alpha-hydroxyglycine derivative to the amidated peptide plus glyoxylate. We now introduce the first potent inhibitors for peptidylamidoglycolate lyase. These inhibitors, which can be viewed as pyruvate extended N-acetyl amino acids, constitute a novel class of compounds. They were designed to resemble likely transient species along the reaction pathway of PGL catalysis. A general synthetic procedure for preparation of pyruvate-extended N-acetyl amino acids or peptides is described. Since these compounds possess the 2,4-dioxo-carboxylate moiety, their solution tautomerization was investigated using both NMR and high performance liquid chromatography analyses. The results establish that freshly prepared solutions of N-Ac-Phe-pyruvate consist predominantly of the enol tautomer, which then slowly tautomerizes to the diketo form when left standing for several days in an aqueous medium; upon acidification, formation of the hydrate tautomer occurs. Kinetic experiments established that these novel compounds are highly potent, pure competitive inhibitors of PGL. Kinetic experiments with the ascorbate dependent copper monooxygenases, PAM and dopamine-beta-monooxygenase, established that these compounds also bind competitively with respect to ascorbate; however, pyruvate-extended N-acyl-amino acid derivatives possessing hydrophobic side chains are much more potent inhibitors of PGL than of PAM. Selective targeting of N-Ac-Phe-pyruvate so as to inhibit the lyase, but not the monooxygenase, domain was demonstrated with the bifunctional amidating enzyme of Xenopus laevis. The availability of potent inhibitors of PGL should facilitate studies regarding the possible biological role of alpha-hydroxyglycine-extended peptides.	GEORGIA INST TECHNOL,SCH CHEM & BIOCHEM,ATLANTA,GA 30332	University System of Georgia; Georgia Institute of Technology					NIGMS NIH HHS [GM 40540] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040540] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTESTI P, 1974, B SOC CHIM FR, V9, P2214; BECKER M, 1960, Z ELEKTROCHEM, V64, P813; BECKER M, 1964, BERICH BUNSEN GESELL, V68, P669, DOI 10.1002/bbpc.19640680713; BRADBURY AF, 1990, EUR J BIOCHEM, V189, P363, DOI 10.1111/j.1432-1033.1990.tb15497.x; BRADBURY AF, 1987, BIOSCIENCE REP, V7, P907, DOI 10.1007/BF01122123; BUNDGAARD H, 1991, PEPTIDES, V12, P745, DOI 10.1016/0196-9781(91)90127-B; Dakin HD, 1928, J BIOL CHEM, V78, P745; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; ERION MD, 1994, J MED CHEM, V37, P4430, DOI 10.1021/jm00052a002; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GUTHRIE JP, 1972, J AM CHEM SOC, V94, P7020, DOI 10.1021/ja00775a026; IWASAKI Y, 1993, Patent No. 5196316; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; LI CZ, 1994, BIOCHEM J, V300, P31, DOI 10.1042/bj3000031; Marvel C. S., 1941, ORG SYNTH, V1, P238; MAY SW, 1981, J BIOL CHEM, V256, P2258; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PHILLIPS RS, 1990, BIOCHEMISTRY-US, V29, P8608, DOI 10.1021/bi00489a016; PHILLIPS RS, 1989, J AM CHEM SOC, V111, P727, DOI 10.1021/ja00184a051; PING DS, 1992, J AM CHEM SOC, V114, P3998, DOI 10.1021/ja00036a071; PING DS, 1995, J BIOL CHEM, V270, P29250, DOI 10.1074/jbc.270.49.29250; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TODISCO A, 1995, J BIOL CHEM, V270, P28337; TOWNES S, 1990, BIOCHIM BIOPHYS ACTA, V1037, P240, DOI 10.1016/0167-4838(90)90174-E; WIMALASENA K, 1987, J AM CHEM SOC, V109, P4036, DOI 10.1021/ja00247a033; ZABRISKIE TM, 1992, J AM CHEM SOC, V114, P2270, DOI 10.1021/ja00032a058; ZABRISKIE TM, 1991, J CHEM SOC CHEM COMM, P571, DOI 10.1039/c39910000571	33	31	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5016	5023		10.1074/jbc.272.8.5016	http://dx.doi.org/10.1074/jbc.272.8.5016			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030564	hybrid			2022-12-25	WOS:A1997WJ85500052
J	Yatomi, Y; Yamamura, S; Ruan, FQ; Igarashi, Y				Yatomi, Y; Yamamura, S; Ruan, FQ; Igarashi, Y			Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; 2ND MESSENGER; SIGNAL-TRANSDUCTION; SPHINGOSINE-1-PHOSPHATE; CALCIUM; CELLS; PATHWAY; PROLIFERATION; MOBILIZATION; DERIVATIVES	Sphingosine 1-phosphate (Sph-1-P) has been implicated as an intracellular second messenger in many studies. We investigated the metabolism of Sph-1-P and the mechanism by which Sph-1-P induces activation in enucleated and highly differentiated platelets. Platelets lack Sph-1-P lyase activity, possess persistently active sphingosine (Sph) kinase, and abundantly store Sph-1-P. Although exogenous Sph-1-P activated platelets, intracellular Sph-1-P, formed from exogenously added Sph by cytosolic Sph kinase, failed to do so. To support the notion that exogenous Sph-1-P stimulates platelets from outside, contact of platelet surfaces with immobilized Sph-1-P covalently linked to glass particles resulted in platelet activation. Furthermore, we detected the specific binding sites for radiolabeled Sph-1-P on the platelet surface, suggesting extracellular effects of Sph-1-P on plasma membrane receptors. This specific Sph-1-P binding was inhibited not by other sphingolipids but by lysophosphatidic acid (LPA), and platelet aggregation response to LPA was specifically desensitized by prior addition of Sph-1-P. Finally, internally stored Sph-1-P is released extracellularly upon stimulation, and the release correlated well with protein kinase C activation in intact platelets. These results suggest that Sph-1-P acts not intracellularly but intercellularly, following discharge from activated platelets, and shares a platelet surface receptor with LPA.	BIOMEMBRANE INST, SEATTLE, WA 98119 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle				Yatomi, Yutaka/0000-0003-1719-4297				BENTON AM, 1982, BLOOD, V60, P642; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; CHENG T, 1994, J BIOL CHEM, V269, P30848; Choi OH, 1996, NATURE, V380, P634; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAWIGER J, 1989, METHOD ENZYMOL, V169, P191; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Mao CG, 1996, P NATL ACAD SCI USA, V93, P1993, DOI 10.1073/pnas.93.5.1993; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHTA H, 1994, ANAL BIOCHEM, V222, P489, DOI 10.1006/abio.1994.1522; Okajima F, 1996, FEBS LETT, V379, P260, DOI 10.1016/0014-5793(95)01526-4; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RUAN FQ, 1995, TETRAHEDRON LETT, V36, P6615, DOI 10.1016/00404-0399(50)1368-R; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P169, DOI 10.1515/bchm2.1973.354.1.169; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P635, DOI 10.1515/bchm2.1970.351.1.635; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; VUNNAM RR, 1979, BIOCHIM BIOPHYS ACTA, V573, P73, DOI 10.1016/0005-2760(79)90174-7; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZUCKER MB, 1989, METHOD ENZYMOL, V169, P117	54	192	202	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5291	5297		10.1074/jbc.272.8.5291	http://dx.doi.org/10.1074/jbc.272.8.5291			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030602	hybrid			2022-12-25	WOS:A1997WJ85500090
J	Gu, JJ; Spychala, J; Mitchell, BS				Gu, JJ; Spychala, J; Mitchell, BS			Regulation of the human inosine monophosphate dehydrogenase type I gene - Utilization of alternative promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; HUMAN IMP DEHYDROGENASE; TISSUE-DIFFERENTIAL EXPRESSION; HUMAN NORMAL LYMPHOCYTES; SYNTHETASE SUBUNIT-I; OPEN READING FRAMES; 2 DISTINCT GENES; PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; MYCOPHENOLIC-ACID; MESSENGER-RNA	Catalysis of guanine nucleotide formation from IMP in the de novo purine synthetic pathway is carried out by two isoforms of the enzyme inosine monophosphate dehydrogenase (IMPDH) that are catalytically indistinguishable but are encoded by separate genes, In order to assess the potential for cell type-specific expression of IMPDH activity, we have characterized the IMPDH type I gene and identified three major RNA transcripts that are differentially expressed from three different promoters, A 4.O-kilobase pair (kb) mRNA containing 1.3 kb of 5'-untranslated region is expressed in activated peripheral blood lymphocytes and to a far lesser extent in cultured tumor cell lines, The Pi promoter that regulates the transcription of this mRNA has a high degree of sequence identity to an Alu repetitive sequence, A transcript of 2.7 kb is found in a subset of the tumor cell lines examined, whereas a 2.5-kb mRNA species is universally expressed and is the prevalent mRNA in most cell lines and tissues. The relative strengths of the three promoter regions and the effects of variable extents of 5'-flanking sequence on the P3 promoter differ in Jurkat T, as compared with Raji B lymphoid cell lines, demonstrating a complex cell type-specific transcriptional regulation of IMPDH type I gene expression.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT INTERNAL MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [R01-CA64192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON AC, 1991, TRANSPL P, V23, P10; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECKER MA, 1995, METABOLIC MOL BASES, V2, P1655; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; CALIGO MA, 1995, INT J CANCER, V60, P837, DOI 10.1002/ijc.2910600619; CARR SF, 1993, J BIOL CHEM, V268, P27286; CATAPANO CV, 1995, MOL PHARMACOL, V47, P948; Coligan J.E., 1994, CURRENT PROTOCOLS IM, V2; COLLART FR, 1990, BLOOD, V75, P570; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; DAYTON JS, 1994, J IMMUNOL, V152, P984; DAYTON JS, 1993, BIOCHEM BIOPH RES CO, V195, P897, DOI 10.1006/bbrc.1993.2129; DAYTON JS, 1992, MOL PHARMACOL, V41, P671; DONZE O, 1992, EMBO J, V11, P3747, DOI 10.1002/j.1460-2075.1992.tb05460.x; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; GLESNE D, 1993, GENOMICS, V16, P274, DOI 10.1006/geno.1993.1177; GOFFEAU A, 1967, J BIOL CHEM, V242, P1845; GU JJ, 1994, GENOMICS, V24, P179, DOI 10.1006/geno.1994.1597; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; ISHIZUKA T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P139, DOI 10.1016/0167-4781(92)90521-Z; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; KIGUCHI K, 1990, EXP CELL RES, V187, P47, DOI 10.1016/0014-4827(90)90114-P; KOKADO Y, 1989, TRANSPLANT P, V21, P1575; KONNO Y, 1991, J BIOL CHEM, V266, P506; LUCAS DL, 1983, BIOCHEM BIOPH RES CO, V115, P971, DOI 10.1016/S0006-291X(83)80030-8; MahnkeZizelman DK, 1996, BBA-GENE STRUCT EXPR, V1306, P75, DOI 10.1016/0167-4781(95)00231-6; MITA K, 1990, TRANSPLANT P, V22, P1679; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; SABINA RL, 1995, METABOLIC MOL BASES, V2, P1769; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SHEN MR, 1991, J MOL EVOL, V33, P311; SIDI Y, 1988, BRIT J CANCER, V58, P61, DOI 10.1038/bjc.1988.162; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TAIRA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P203, DOI 10.1016/0167-4781(89)90040-7; TAIRA M, 1989, SOMAT CELL MOLEC GEN, V15, P29, DOI 10.1007/BF01534667; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; VANDENBERGH F, 1995, BIOCHEM J, V312, P401, DOI 10.1042/bj3120401; YU J, 1989, CANCER RES, V49, P5555; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111; ZIMMERMANN AG, 1995, J BIOL CHEM, V270, P6808, DOI 10.1074/jbc.270.12.6808	54	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4458	4466		10.1074/jbc.272.7.4458	http://dx.doi.org/10.1074/jbc.272.7.4458			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020170	hybrid			2022-12-25	WOS:A1997WH01900086
J	Ogretmen, B; Safa, AR				Ogretmen, B; Safa, AR			Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells	ONCOGENE			English	Article						deleted p53; multidrug resistance; MCF-7/Adr	ADRIAMYCIN-RESISTANT; GROWTH SUPPRESSION; P-GLYCOPROTEIN; GENE; MUTATIONS; BCL-2; TRANSACTIVATION; MECHANISMS; PROMOTER; MUTANTS	Multidrug resistance in MCF-7/Adr human breast cancer cells is mediated by several mechanisms including overexpression of the MDR1 gene product, P-glycoprotein and glutathion-related detoxifying enzymes. Mutations in the p53 tumor suppressor protein have been reported to play a role in the development of resistance to DNA damaging agents in several human cancer cells, In the present study we have assessed the mutational status of the p53 protein and its expression levels, degree of stability and cellular localization to investigate whether it is involved in modulating multidrug resistance in MCF-7/Adr cells compared to sensitive MCF-7 cells, As revealed by immunofluorescence microscopy using the anti-p53 mouse monoclonal antibody DO-1, wild-type p53 is sequestered in the cytoplasm of MCF-7 cells, whereas in MCF-7/Adr cells, the protein is localized in the nucleus, The sequencing of full-length p53 cDNA revealed a 21 bp deletion in its one of the four conserved regions within the conformational domain, spanning codons 126-133 at exon five, in MCF-7/Adr cells, Moreover, detection of ThaI polymorphism of codon 72 showed that MCF-7 cells predominantly express wild-type p53 with proline, while mutated p53 in MCF-7/Adr cells contains an arginine residue at codon 72, In addition, we demonstrate that the half-life of p53 in MCF-7 cells is less than 30 min while the mutated protein is more stable; its half-life is about 4 h in MCF-7/Adr cells, Thus, this study demonstrates that the deletion of codons 126-133 in p53 causes increased stability, overexpression and nuclear localization of the protein in multidrug resistant MCF-7/Adr cells, and further suggests that mutated p53 might be involved in the development of multidrug resistance in this cell line.	MED UNIV S CAROLINA,HOLLINGS CANC CTR,DEPT EXPT ONCOL,CHARLESTON,SC 29424	Medical University of South Carolina					NATIONAL CANCER INSTITUTE [R01CA056078] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FUCHS B, 1995, ONCOGENE, V10, P789; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P1894, DOI 10.1074/jbc.270.4.1894; HALDAR S, 1994, CANCER RES, V54, P2095; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANDESMAN Y, 1994, ONCOGENE, V9, P1241; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NEGRINI M, 1994, CANCER RES, V54, P1818; NGUYEN KT, 1994, ONCOL RES, V6, P71; OCONNOR PM, 1993, CANCER RES, V53, P4776; OGRETMEN B, 1995, BIOTECHNIQUES, V19, P374; OGRETMEN B, 1996, INT J CANCER, V67, P1; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROUBY SE, 1993, BLOOD, V82, P3452; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SAFA AR, 1994, BIOCHEMISTRY-US, V33, P256, DOI 10.1021/bi00167a034; SEGAWA K, 1993, FEBS LETT, V329, P283, DOI 10.1016/0014-5793(93)80238-P; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; TAKAHASHI T, 1991, BIOTECHNIQUES, V11, P166; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WELLS WW, 1995, FREE RADICAL BIO MED, V18, P699, DOI 10.1016/0891-5849(94)00188-P; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	39	86	88	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					499	506		10.1038/sj.onc.1200855	http://dx.doi.org/10.1038/sj.onc.1200855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053847				2022-12-25	WOS:A1997WE36400013
J	Chen, HJ; Yuan, J; Lobel, P				Chen, HJ; Yuan, J; Lobel, P			Systematic mutational analysis of the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor cytoplasmic domain - An acidic cluster containing a key aspartate is important for function in lysosomal enzyme sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; DI-LEUCINE MOTIF; GLUT4 GLUCOSE-TRANSPORTER; LEU-LEU SEQUENCE; 6-PHOSPHATE RECEPTOR; CELL-SURFACE; RAPID INTERNALIZATION; CARBOXYL-TERMINUS; ENDOCYTIC PATHWAY; FC-RECEPTORS	We have used systematic mutational analysis to identify signals in the 166-residue murine cation-independent mannose 6-phosphate/insulin-like growth factor II receptor cytoplasmic domain required for efficient sorting of lysosomal enzymes. Alanine cluster mutagenesis on all conserved residues apart from the endocytosis signal demonstrates that the major sorting determinant is a conserved casein kinase II site followed by a dileucine motif ((157)DDSDEDLL(164)). Small deletions or additions outside this region have severe to mild effects, indicating that context is important. Single residue mutagenesis indicates that cycles of serine phosphorylation/dephosphorylation are not obligatory for sorting. In addition, the two leucine residues and four of the five negatively charged residues can readily tolerate conservative substitutions. In contrast, aspartate 160 could not tolerate isoelectric or isosteric substitutions, implicating it as a critical component of the sorting signal.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,GRAD PROGRAM MICROBIOL & MOL GENET,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45992] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREMNES B, 1994, J CELL SCI, V107, P2021; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CHEN HJ, 1995, THESIS RUTGERS U NEW; CONIBEAR E, 1994, J CELL SCI, V107, P923; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; Dahms NM, 1996, BBA-BIOMEMBRANES, V1279, P84, DOI 10.1016/0005-2736(95)00234-0; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HOFLACK B, 1993, ADV CELL MOL BIOL M, V1, P51; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; OGATA S, 1994, J BIOL CHEM, V269, P5210; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRYDZ K, 1990, J BIOL CHEM, V265, P12629; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; SABATINI DD, 1995, METABOLIC BASIS INHE, V1, P459; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; STOCK JB, 1992, J BIOL CHEM, V267, P19753; TAIT JF, 1981, J BIOL CHEM, V256, P1086; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WESTCOTT KR, 1988, J CELL BIOCHEM, V38, P23, DOI 10.1002/jcb.240380104	50	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7003	7012		10.1074/jbc.272.11.7003	http://dx.doi.org/10.1074/jbc.272.11.7003			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054390	hybrid			2022-12-25	WOS:A1997WN14700029
J	Gorovits, BM; Ybarra, J; Horowitz, PM				Gorovits, BM; Ybarra, J; Horowitz, PM			ATP hydrolysis is critical for induction of conformational changes in GroEL that expose hydrophobic surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMODYNAMIC PARTITIONING MODEL; CHAPERONIN CPN60; BETA-LACTAMASE; BINDING; POLYPEPTIDES; RECOGNIZES; RHODANESE; PROTEINS; MONOMERS	The degree of hydrophobic exposure in the molecular chaperone GroEL during its cycle of ATP hydrolysis was analyzed using 1,1'-bis(4-anilino)naphthalene-5,5'disulfonic acid (bisANS), a hydrophobic probe, whose fluorescence is highly sensitive to the environment, In the presence of 10 mM MgCl, and 10 mM KCI the addition of ATP, but not ADP or AMP-PNP, resulted in a time-dependent, linear increase in the bisANS fluorescence, The rate of the increase in the bisANS fluorescence depended on the concentrations of both GroEL and the probe, The effect could be substantially inhibited by addition of excess ADP or by converting ATP to ADP using hexokinase, showing that the increase in the bisANS fluorescence was correlated with ATP hydrolysis. The rate of ATP hydrolysis catalyzed by GroEL was uncompetitively inhibited in the presence of bisANS, This uncompetitive inhibition suggests that the probe can interact with the GroEL-ATP complex, The inability of the nonhydrolyzable ATP analog, AMP-PNP, to cause a similar effect is explained by the interaction of bisANS with a transient conformational state of GroEL formed consequent to ATP hydrolysis, It is suggested that this short lived hydrophobic exposure reflects a conformational shift in GroEL that results from electrostatic repulsion between the bound products of ATP hydrolysis, and it plays an important role in the mechanism of the chaperonin cycle.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio								Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; GOROVITS BM, 1995, J BIOL CHEM, V270, P13057, DOI 10.1074/jbc.270.22.13057; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LLORCA O, 1997, IN PRESS J STRUCT BI; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	21	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6842	6845		10.1074/jbc.272.11.6842	http://dx.doi.org/10.1074/jbc.272.11.6842			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054367	hybrid			2022-12-25	WOS:A1997WN14700006
J	Verrall, S; Ishii, M; Chen, M; Wang, L; Tram, T; Coughlin, SR				Verrall, S; Ishii, M; Chen, M; Wang, L; Tram, T; Coughlin, SR			The thrombin receptor second cytoplasmic loop confers coupling to G(q)-like G proteins in chimeric receptors - Additional evidence for a common transmembrane signaling and G protein coupling mechanism in G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTORS; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; PROTEOLYTIC MECHANISM; ADRENERGIC-RECEPTORS; MOLECULAR-CLONING; HUMAN PLATELETS; AMINO-ACIDS; SPECIFICITY	Thrombin activates human platelets and other cells in part by cleaving an unusual G protein-coupled receptor, Thrombin cleavage of this receptor's amino-terminal exodomain unmasks a new amino terminus, This then binds intramolecularly to the body of the receptor to trigger transmembrane signaling and activation of G(i)-and G(q)-like G proteins, Toward identifying the domains responsible for thrombin receptor-G protein interactions, we examined the signaling properties of chimeric receptors in which thrombin receptor cytoplasmic sequences replaced the cognate sequences in the G(s)-coupled beta(2)-adrenergic receptor (beta(2)AR) or the G(i)-coupled dopamine D-2 receptor (D(2)R). In Xenopus oocytes, a chimeric beta(2)AR bearing the thrombin receptor second cytoplasmic (C2) loop gained the ability to trigger intracellular Ca2+ release in response to adrenergic agonist, whereas a beta(2)AR bearing the cognate C2 loop from the D(2)R did not. Similarly, in COS-7 cells, a chimeric D(2)R bearing the thrombin receptor C2 loop gained the ability to trigger phosphoinositide hydrolysis in response to dopaminergic agonist, apparently by coupling to a G(q)-like G protein. No detectable G(s) coupling was seen. Thus, the thrombin receptor C2 loop was able to confer G(q)-like coupling in several different receptor contexts. These observations suggest that the thrombin receptor C2 loop specifies G(q) coupling by directly contacting G(q) or by contributing to a structure required for G(q) coupling. The ability of the thrombin receptor C2 loop to function in the context of the D(2)R and beta(2)AR strongly suggests that the transmembrane switching and G protein activation strategies used by the thrombin receptor must be very similar to those used by the D(2)R and beta(2)AR despite the thrombin receptor's strikingly different liganding mechanism.	UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BAHOU WF, 1994, BLOOD, V84, P4195, DOI 10.1182/blood.V84.12.4195.bloodjournal84124195; BENKA ML, 1995, FEBS LETT, V363, P49, DOI 10.1016/0014-5793(95)00278-H; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLANK JL, 1993, J BIOL CHEM, V268, P25184; BOURNE HR, 1997, IN PRESS CURR OPIN C; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; ENGLAND BP, 1991, FEBS LETT, V279, P87, DOI 10.1016/0014-5793(91)80257-4; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; HIRONO C, 1987, J PHYSIOL-LONDON, V382, P523, DOI 10.1113/jphysiol.1987.sp016382; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; ISHII K, 1993, J BIOL CHEM, V268, P9780; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MALEK D, 1993, FEBS LETT, V325, P215; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VARRAULT A, 1994, J BIOL CHEM, V269, P16720; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; YAMADA M, 1994, MOL PHARMACOL, V46, P470	51	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6898	6902		10.1074/jbc.272.11.6898	http://dx.doi.org/10.1074/jbc.272.11.6898			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054376	hybrid			2022-12-25	WOS:A1997WN14700015
J	Beauvais, A; Monod, M; Debeaupuis, JP; Diaquin, M; Kobayashi, H; Latge, JP				Beauvais, A; Monod, M; Debeaupuis, JP; Diaquin, M; Kobayashi, H; Latge, JP			Biochemical and antigenic characterization of a new dipeptidyl-peptidase isolated from Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ALKALINE PROTEASE; IV; METALLOPROTEASE; PURIFICATION; SEQUENCE; BINDING; ENTRY; GENE; CD26	A novel dipeptidyl-peptidase (DPP V) was purified from the culture medium of Aspergillus fumgatus. This is the first report of a secreted dipeptidyl-peptidase. The enzyme had a molecular mass of 88 kDa and contained approximately 9 kDa of N-linked carbohydrate, The expression and secretion of dipeptidyl-peptidase varied with the growth conditions; maximal intra- and extracellular levels were detected when the culture medium contained only proteins or protein hydrolysates in the absence of sugars. The gene of DPP V was cloned and showed significant sequence homology to other eukaryotic dipeptidyl-peptidase genes. Unlike the other dipeptidyl-peptidases, which are all intracellular, DPP V contained a signal peptide. Like the genes of other dipeptidyl-peptidases, that of DPP V displayed the consensus sequences of the catalytic site of the nonclassical serine proteases, The biochemical properties of native and recombinant DPP V obtained in Pichia pastoris were unique and were characterized by a substrate specificity limited to the hydrolysis of X-Ala, Ris-Ser, and Ser-Tyr dipeptides at a neutral pH optimum. In addition, we showed that DPP V is identical to one of the two major antigens used for the diagnosis of aspergillosis.	CHU VAUDOIS, DERMATOL SERV, LAUSANNE, SWITZERLAND; TOHOKU COLL PHARMACEUT SCI, DEPT HYG CHEM, AOBA KU, SENDAI, MIYAGI, JAPAN	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Tohoku Medical & Pharmaceutical University	Beauvais, A (corresponding author), INST PASTEUR, LAB ASPERGILLUS, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		latge, jean paul/F-3581-2011; Debeaupuis, Jean-Paul/A-2035-2012; Latge, Jean Paul/C-9846-2014; Beauvais, Anne/A-6358-2012					BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BOUT D, 1973, CR ACAD SCI D NAT, V276, P2341; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CASADEVALL A, 1995, CAN J BOT, V73, pS1180, DOI 10.1139/b95-376; CASSONE A, 1995, CAN J BOT, V73, pS1192; CENCI E, 1997, IN PRESS INFECT IMMU; DEEPE GS, 1995, CAN J BOT, V73, pS1178; DEREPENTIGNY L, 1989, EUR J CLIN MICROBIOL, V8, P362, DOI 10.1007/BF01963470; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIRARDIN H, 1993, J CLIN MICROBIOL, V31, P1547, DOI 10.1128/JCM.31.6.1547-1554.1993; HAMILTON AJ, 1995, J CLIN MICROBIOL, V33, P495, DOI 10.1128/JCM.33.2.495-496.1995; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HARVEY C, 1987, CLIN EXP IMMUNOL, V70, P247; HEARN VM, 1992, J MED MICROBIOL, V36, P61, DOI 10.1099/00222615-36-1-61; JATONOGAY K, 1994, MOL MICROBIOL, V14, P917, DOI 10.1111/j.1365-2958.1994.tb01327.x; JATONOGAY K, 1992, FEMS MICROBIOL LETT, V92, P163, DOI 10.1111/j.1574-6968.1992.tb05253.x; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KOBAYASHI H, 1993, INFECT IMMUN, V61, P4767, DOI 10.1128/IAI.61.11.4767-4771.1993; LAMY B, 1991, MOL MICROBIOL, V5, P1811, DOI 10.1111/j.1365-2958.1991.tb01930.x; LATGE JP, 1994, FEMS SYMP, P321; LATGE JP, 1984, J GEN APPL MICROBIOL, V30, P135, DOI 10.2323/jgam.30.135; LATGE JP, 1991, INFECT IMMUN, V59, P2586; LOPEZMEDRANO R, 1995, INFECT IMMUN, V63, P4774; Mackenzie D. W. R., 1989, Medical mycology. A practical approach., P201; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MCDONALD JK, 1980, BIOCHIM BIOPHYS ACTA, V616, P68; MCDONALD JK, 1968, J BIOL CHEM, V243, P4143; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; MONOD M, 1991, J MED MICROBIOL, V35, P23, DOI 10.1099/00222615-35-1-23; MONOD M, 1993, INFECT IMMUN, V61, P4099, DOI 10.1128/IAI.61.10.4099-4104.1993; MONOD M, 1994, MOL BIOL PATHOGENIC, P33; ORAVECZ T, 1995, NAT MED, V1, P919, DOI 10.1038/nm0995-919; PANNEERSELVAM M, 1980, ITAL J BIOCHEM, V29, P102; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; Tran Van Ky P, 1966, Rev Immunol Ther Antimicrob, V30, P13	39	92	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6238	6244		10.1074/jbc.272.10.6238	http://dx.doi.org/10.1074/jbc.272.10.6238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045640	hybrid			2022-12-25	WOS:A1997WM64700024
J	Couet, J; Li, SW; Okamoto, T; Ikezu, T; Lisanti, MP				Couet, J; Li, SW; Okamoto, T; Ikezu, T; Lisanti, MP			Identification of peptide and protein ligands for the caveolin-scaffolding domain - Implications for the interaction of caveolin with caveolae-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; PLASMA-MEMBRANE; CELLS; TYROSINE; PURIFICATION; SEQUENCE; PALMITOYLATION; VIP21-CAVEOLIN; EXPRESSION; TRANSPORT	Caveolin, a 21-24-kDa integral membrane protein, is a principal component of caveolae membranes, We have suggested that caveolin functions as a scaffolding protein to organize and concentrate certain caveolin-interacting proteins within caveolae membranes, In this regard, caveolin co purifies with a variety of lipid-modified signaling molecules, including G-proteins, Src-like kinases, Ha-Ras, and eNOS, Using several independent approaches, it has been shown that a 20-amino acid membrane proximal region of the cytosolic amino-terminal domain of caveolin is sufficient to mediate these interactions, For example, this domain interacts with G-protein cu subunits and Src-like kinases and can functionally suppress their activity, This caveolin-derived protein domain has been termed the caveolin scaffolding domain, However, it remains unknown how the caveolin-scaffolding domain recognizes these molecules. Here, we have used the caveolin-scaffolding domain as a receptor to select random peptide ligands from phage display libraries, These caveolin selected peptide ligands are rich in aromatic amino acids and have a characteristic spacing in many cases, A known caveolin-interacting protein, G(i2 alpha), was used as a ligand to further investigate the nature of this interaction. G(i2 alpha), and other G-protein alpha subunits contain a single region that generally resembles the sequences derived from phage display. We show that this short peptide sequence derived from G(i2 alpha) interacts directly with the caveolin-scaffolding domain and competitively inhibits the interaction of the caveolin-scaffolding domain with the appropriate region of G(i2 alpha). This interaction is strictly dependent on the presence of aromatic residues within the peptide ligand, as replacement of these residues with alanine or glycine prevents their interaction with the caveolin-scaffolding domain, In addition, we have used this interaction to define which residues within the caveolin-scaffolding domain are critical for recognizing these peptide and protein ligands, Also, we find that the scaffolding domains of caveolins 1 and 3 both recognize the same peptide ligands, whereas the corresponding domain within caveolin-2 fails to recognize these ligands under the same conditions, These results serve to further demonstrate the specificity of this interaction, The implications of our current findings are discussed regarding other caveolin- and caveolae-associated proteins.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE CTR 9, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED, SHRINERS HOSP CRIPPLED CHILDREN,DEPT ANESTHESIA, BOSTON, MA 02114 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital			Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382; Li, PhD,EIC,FRSM,FRSB, Shengwen Calvin/0000-0002-9699-9204; Ikezu, Tsuneya/0000-0002-3979-8596; Couet, Jacques/0000-0001-5409-8689	NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA071326, CA-71326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; ROBBINS S, 1995, J CELL BIOCH A S, V19, P27; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646	48	776	839	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6525	6533		10.1074/jbc.272.10.6525	http://dx.doi.org/10.1074/jbc.272.10.6525			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045678	hybrid			2022-12-25	WOS:A1997WM64700062
J	Gaudino, RJ; Pikaard, CS				Gaudino, RJ; Pikaard, CS			Cytokinin induction of RNA polymerase I transcription in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TIF-IA; RIBOSOMAL-RNA; HORMONAL-REGULATION; DEPENDENT REGULATION; ESCHERICHIA-COLI; PROCESSING EVENT; GENE-EXPRESSION; GROWTH-RATE; INITIATION; RDNA	RNA polymerase I (pol I) transcribes the repeated genes that encode the precursor of 17-18, 5.8, and 25-28 S ribosomal RNA (rRNA), Pol I transcription is up-regulated in growing cells and down-regulated in quiescent cells, presumably reflecting the demand for ribosomes and protein synthesis, However, the signal transduction pathways responsible for pol I regulation are poorly understood, We tested the effects of exogenously applied plant hormones on promoter-dependent rRNA transcription in Arabidopsis thaliana. Gibberellic acid, abscisic acid, auxin, and ethylene had no detectable effect on rRNA transcription, but kinetin (a cytokinin) stimulated rRNA transcription within 1 h of treatment, Increased steady-state levels of accurately initiated rRNA transcripts, detected by S1 nuclease protection, were paralleled by increased levels of nascent rRNA transcripts in isolated nuclei, Therefore, the primary effect of cytokinin appears to be at the level of transcription initiation rather than rRNA stability, Pol I accounts for similar to 34% of total nuclear transcription in untreated plants and similar to 60% following cytokinin treatment, The specific responsiveness of pol I transcription to kinetin suggests that cytokinins may act as general regulators of protein synthetic capacity and growth status in plant cells.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)			Pikaard, Craig S/K-8772-2012	Pikaard, Craig S/0000-0001-8204-7459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077590] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANIEV ED, 1987, PLANTA, V170, P370, DOI 10.1007/BF00395029; BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BRZOBOHATY B, 1994, PLANT MOL BIOL, V26, P1483, DOI 10.1007/BF00016486; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1985, NUCLEIC ACIDS RES, V13, P3357, DOI 10.1093/nar/13.9.3357; CHAUDHURY AM, 1993, PLANT J, V4, P907, DOI 10.1046/j.1365-313X.1993.04060907.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P8294; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; COPENHAVER GP, 1995, PLANT J, V7, P273, DOI 10.1046/j.1365-313X.1995.7020273.x; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; COTTON JLS, 1990, PLANT MOL BIOL, V14, P707, DOI 10.1007/BF00016503; CRAIG N, 1987, P NATL ACAD SCI USA, V84, P629, DOI 10.1073/pnas.84.3.629; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; DOELLING JH, 1995, PLANT J, V8, P683, DOI 10.1046/j.1365-313X.1995.08050683.x; DOELLING JH, 1993, P NATL ACAD SCI USA, V90, P7528, DOI 10.1073/pnas.90.16.7528; FEINBAUM RL, 1988, MOL CELL BIOL, V8, P1985, DOI 10.1128/MCB.8.5.1985; FILIPOWICZ W, 1990, MOL BIOL REP, V14, P125, DOI 10.1007/BF00360443; GOKAL PK, 1990, J BIOL CHEM, V265, P16234; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GRUMMT I, 1976, CELL, V7, P439, DOI 10.1016/0092-8674(76)90174-4; GRUMMT I, 1981, P NATL ACAD SCI-BIOL, V78, P727, DOI 10.1073/pnas.78.2.727; GUILFOYLE TJ, 1980, BIOCHEMISTRY-US, V19, P6112, DOI 10.1021/bi00567a025; Guilfoyle TJ, 1995, METHOD CELL BIOL, V50, P101, DOI 10.1016/S0091-679X(08)61025-0; GUILFOYLE TJ, 1983, ENZYMES NUCLEIC ACID, V2, P1; HOBBIE L, 1994, PLANT MOL BIOL, V26, P1499, DOI 10.1007/BF00016487; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KASSAVETIS GA, 1994, RAV S MOL C, V3, P107; KINOSHITA I, 1979, PLANT CELL PHYSIOL, V20, P707; KREBBERS E, 1988, PLANT MOL BIOL, V11, P745, DOI 10.1007/BF00019515; LOBO SM, 1994, TRANSCRIPTION MECH R, V3, P127; MAGER WH, 1991, MOL CELL BIOCHEM, V104, P181; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16244; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MARZLUFF WF, 1990, METHOD ENZYMOL, V181, P30; MIKULOVICH TP, 1978, BIOCHEM PHYSIOL PFL, V172, P101; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Paule Marvin R., 1993, Gene Expression, V3, P1; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PAULE MR, 1991, MOL CELL BIOCHEM, V104, P119, DOI 10.1007/BF00229811; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PLANTA RJ, 1988, TRENDS GENET, V4, P64, DOI 10.1016/0168-9525(88)90042-X; RAUE HA, 1991, PROG NUCLEIC ACID RE, V41, P89; REEDER RH, 1974, RIBOSOMES, P489; REEDER RH, 1992, REGULATION TRANSCRIP, V1; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNEIDER J, 1981, PHYSL PFLANZ, V176, P614; SERIZAWA H, 1994, RAV S MOL C, V3, P27; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WEBER HW, 1991, MOL CELL BIOCHEM, V104, P201; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	61	49	54	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6799	6804		10.1074/jbc.272.10.6799	http://dx.doi.org/10.1074/jbc.272.10.6799			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045714	hybrid			2022-12-25	WOS:A1997WM64700098
J	Kambampati, R; Chakraburtty, K				Kambampati, R; Chakraburtty, K			Functional subdomains of yeast elongation factor 3 - Localization of ribosome-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-III; SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; SEQUENCE-ANALYSIS; CANDIDA-ALBICANS; RNA-BINDING; GENE; SUBUNITS; GTPASE; ATPASE	Elongation factor 3 (EF-3) is an essential requirement of the fungi for translational elongation, EF-3 is an ATPase, and the hydrolytic activity is stimulated 2 orders of magnitude by yeast ribosomes. Limited trypsinolysis of EF-3 results in the cleavage of a single peptide bond between residues 774 (Arg) and 775 (Gin), generating polypeptides of approximate molecular mass 90 and 30 kDa. The 90-kDa fragment is relatively resistant to proteolysis and retains ribosome-independent ATPase activity. The 30-kDa fragment is further proteolyzed into smaller fragments and retains the specificity for binding to yeast ribosomes. Both the intact EF-3 and the 30-kDa fragment are protected from proteolysis by yeast ribosomes, EF-3 is NH2 terminally blocked, and so is the 90-kDa fragment. The COOH terminally derived 30-kDa fragment contains glutamine (residue 775) at the NH2-terminal end. A construct was designed representing the COOH terminal domain of EF-3 (30-kDa fragment), subcloned, and expressed as a glutathione S-transferase fusion in yeast. The glutathione S-transferase-30-kDa peptide remains stringently associated with ribosomes. Isolated fusion peptide rebinds to yeast ribosomes with high affinity, Eased on these results, we propose that at least one of the ribosome-binding sites of EF-3 resides at the COOH-terminal end of the protein.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin								BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; CHAKRABURTTY K, 1988, INT J BIOCHEM, V20, P581, DOI 10.1016/0020-711X(88)90096-1; Chakraburtty K., 1992, New approaches for antifungal drugs., P114; COLTHURST DR, 1992, MOL MICROBIOL, V6, P1025, DOI 10.1111/j.1365-2958.1992.tb02168.x; DASMAHAPATRA B, 1981, J BIOL CHEM, V256, P9999; DIDOMENICO BJ, 1992, YEAST, V8, P337, DOI 10.1002/yea.320080502; FEINBERG B, 1982, J BIOL CHEM, V257, P846; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; KAMATH A, 1986, J BIOL CHEM, V261, P2596; KOVALCHUKE O, 1995, INDIAN J BIOCHEM BIO, V32, P336; Kovalchuke O, 1995, BIOCHIMIE, V77, P713, DOI 10.1016/0300-9084(96)88187-9; KOVALCHUKE O, 1994, EUR J BIOCHEM, V226, P133, DOI 10.1111/j.1432-1033.1994.tb20034.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MINKS MA, 1978, EUR J BIOCHEM, V82, P271, DOI 10.1111/j.1432-1033.1978.tb12020.x; MITCHELL DA, 1995, METHOD ENZYMOL, V250, P68; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MYERS KK, 1992, NUCLEIC ACIDS RES, V20, P1705, DOI 10.1093/nar/20.7.1705; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; QIN SL, 1990, J BIOL CHEM, V265, P1903; SANDBAKEN M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P230, DOI 10.1016/0167-4781(90)90172-X; SANDBAKEN MG, 1990, J BIOL CHEM, V265, P15838; SKOGERSON L, 1976, P NATL ACAD SCI USA, V73, P73, DOI 10.1073/pnas.73.1.73; SNYDER S, 1989, COLD SPRING HARB S T, P43; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIANA F, 1994, BIOCHEM MOL BIOL INT, V33, P909; TRIANA FJ, 1993, TRANSLATIONAL APPARATUS, P327; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; URITANI M, 1988, J BIOCHEM-TOKYO, V103, P522, DOI 10.1093/oxfordjournals.jbchem.a122302; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YEH LCC, 1995, J MOL BIOL, V246, P295, DOI 10.1006/jmbi.1994.0085; YPMAWONG MF, 1992, INFECT IMMUN, V60, P4140, DOI 10.1128/IAI.60.10.4140-4145.1992	34	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6377	6381		10.1074/jbc.272.10.6377	http://dx.doi.org/10.1074/jbc.272.10.6377			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045659	hybrid			2022-12-25	WOS:A1997WM64700043
J	Saleh, A; Lang, V; Cook, R; Brandl, CJ				Saleh, A; Lang, V; Cook, R; Brandl, CJ			Identification of native complexes containing the yeast coactivator/repressor proteins NGG1/ADA3 and ADA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; PUTATIVE TRANSCRIPTIONAL ADAPTER; ACIDIC ACTIVATION DOMAINS; POLYMERASE-II HOLOENZYME; SACCHAROMYCES-CEREVISIAE; GENETIC-EVIDENCE; GCN5; INTERACTS; PURIFICATION; RESISTANCE	NGG1p/ADA3p and ADA2p are dual function regulators that stimulate or inhibit a set of yeast transcriptional activator proteins, In vitro, NGG1p and ADA2p associate in a complex that also contains GCN5p (Horiuchi, J., Silverman, N., Marcus, G, A., and Guarente, L, (1995) Mel. Cell, Biol, 15, 1203-1209), We have found that NGG1p and ADA2p are coimmunoprecipitated from yeast whole cell extracts, In fact, <2% of cellular ADA2p was not associated with NGG1p, Also in agreement with their association in vivo, the stability of ADA2p and NGG1p depended on the presence of each other, In addition, three NGG1p- and ADA2p-containing peak fractions were resolved by Q-Sepharose Fast Flow ion-exchange chromatography of whole cell extract, The presence of another high molecular mass complex was supported by the separation of one of the NGG1p- and ADA2p-containing peak fractions by gel-filtration chromatography, Together, the combination of ion-exchange and gel-filtration chromatography suggests a total of four complexes, two with sizes of >2 MDa and single complexes of similar to 900 and 200 kDa, At least one of these complexes was found to associate with the TATA-binding protein (TBP) since TBP was present in immunoprecipitates with NGG1p, The association of TBP with the ADA proteins required amino acids 274-307 of NGG1p, a region of NGG1p required for activity, This supports a role for NGG1P in the interaction with TBP and suggests that the interaction with TBP is functionally relevant.	UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON N6A 5C1, CANADA	Western University (University of Western Ontario)				Saleh, Ayman M/0000-0003-1126-6018				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BADARACCO G, 1983, J BIOL CHEM, V258, P2022; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRANDL CJ, 1993, EMBO J, V12, P5255, DOI 10.1002/j.1460-2075.1993.tb06221.x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1996, J BIOL CHEM, V271, P5237; Candau R, 1996, MOL CELL BIOL, V16, P593; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; Shi XM, 1996, MOL CELL BIOL, V16, P669; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Song WJ, 1996, MOL CELL BIOL, V16, P115; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	43	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5571	5578		10.1074/jbc.272.9.5571	http://dx.doi.org/10.1074/jbc.272.9.5571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038164	hybrid			2022-12-25	WOS:A1997WK74700032
J	Sexl, V; Mancusi, G; Holler, C; GloriaMaercker, E; Schutz, W; Freissmuth, M				Sexl, V; Mancusi, G; Holler, C; GloriaMaercker, E; Schutz, W; Freissmuth, M			Stimulation of the mitogen-activated protein kinase via the A(2A)-adenosine receptor in primary human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NA-H EXCHANGE; ADENOSINE RECEPTOR; MAP KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; TYROSINE-KINASE; PHOSPHOLIPASE-C; ANGIOTENSIN-II; ALPHA-SUBUNIT	Adenosine exerts a mitogenic effect on human endothelial cells via stimulation of the A(2A)-adenosine receptor. This effect can also be elicited by the beta(2)-adrenergic receptor but is not mimicked by elevation of intracellular cAMP levels, In the present work, we report that stimulation of the A(2A)-adenosine receptor and of the beta(2)-adrenergic receptor activates mitogen-activated protein kinase (MAP kinase) in human endothelial cells based on the following criteria: adenosine analogues and beta-adrenergic agonists cause an (i) increase in tyrosine phosphorylation of the p42 isoform and to a lesser extent of the p44 isoform of MAP kinase and (ii) stimulate the phosphorylation of myelin basic protein by MAP kinase; (iii) this is accompanied by a redistribution of the enzyme to the perinuclear region. Pretreatment of the cells with cholera toxin (to down-regulate G(s) alpha) abolishes activation of MAP kinase by isoproterenol but not that induced by adenosine analogues. In addition, MAP kinase stimulation via the A(2A)-adenosine receptor is neither impaired following pretreatment of the cells with pertussis toxin (to block G(i)-dependent pathways) nor affected by GF109203X (1 mu M; to inhibit typical protein kinase C isoforms) nor by a monoclonal antibody, which blocks epidermal growth factor-dependent signaling. In contrast, MAP kinase activation is blocked by PD 098059, an inhibitor of MAP kinase kinase 1 (MEK1) activation, which also blunts the A(2A)-adenosine receptor-mediated increase in [H-3]thymidine incorporation. Activation of the Az,-adenosine receptor is associated with increased levels of GTP-bound p21(ras). Thus, our experiments define stimulation of MAP kinase as the candidate cellular target mediating the mitogenic action of the A(2A)-adenosine receptor on primary human endothelial cells; the signaling pathway operates via p21(ras) and MEK1 but is independent of G(i), G(s), and the typical protein kinase C isoforms. This implies an additional G protein which links this prototypical G(s)-coupled receptor to the MAP kinase cascade.	UNIV VIENNA, INST PHARMACOL, A-1090 VIENNA, AUSTRIA	University of Vienna			Sexl, Veronika/B-8657-2016	Sexl, Veronika/0000-0001-9363-0412; Freissmuth, Michael/0000-0001-9398-1765				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARBER DL, 1992, J BIOL CHEM, V267, P20607; Boehm S, 1996, J NEUROCHEM, V66, P1019; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUSSEAU JW, 1986, CIRC RES, V59, P163, DOI 10.1161/01.RES.59.2.163; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ETHIER MF, 1993, AM J PHYSIOL, V265, pH131, DOI 10.1152/ajpheart.1993.265.1.H131; FAURE M, 1994, J BIOL CHEM, V269, P7851; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREISSMUTH M, 1986, N-S ARCH PHARMACOL, V334, P56, DOI 10.1007/BF00498740; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FRODIN M, 1994, J BIOL CHEM, V269, P6207; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEITMAN DC, 1986, J CELL PHYSIOL, V127, P237, DOI 10.1002/jcp.1041270208; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MEININGER CJ, 1990, AM J PHYSIOL, V258, pH198, DOI 10.1152/ajpheart.1990.258.1.H198; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MOODIE SA, 1991, BRIT J PHARMACOL, V102, P101, DOI 10.1111/j.1476-5381.1991.tb12139.x; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NANOFF C, 1994, J BIOL CHEM, V269, P31999; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SADOSHIMA J, 1995, CIRC RES, V76, P1; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDAELE P, 1992, CIRC RES, V70, P82, DOI 10.1161/01.RES.70.1.82; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432; ZIADA AMAR, 1984, CARDIOVASC RES, V18, P724, DOI 10.1093/cvr/18.12.724	48	154	157	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5792	5799		10.1074/jbc.272.9.5792	http://dx.doi.org/10.1074/jbc.272.9.5792			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038193	hybrid			2022-12-25	WOS:A1997WK74700061
J	Stenfors, C; Hellman, U; Silberring, J				Stenfors, C; Hellman, U; Silberring, J			Characterization of endogenous neuropeptide Y in rat hippocampus and its metabolism by nanospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; RECEPTORS; NPY; BRAIN; IDENTIFICATION; ELECTROSPRAY	Neuropeptide Y (NPY) is a 36-residue-long neuropeptide which has been implicated in the regulation of feeding behavior and modulation of the circadian rhythm, We identified the primary structure of the endogenous NPY-immunoreactive material in the rat hippocampus using a combination of chromatographic techniques and nanospray mass spectrometry, The major component in the brain tissue corresponded to the authentic amidated form of NPY(1-36). The fate of NPY in the central nervous system was studied by subjecting pure peptide to the protease(s) present in hippocampal synaptosomes to reveal potential cleavage site(s). NPY was efficiently metabolized with a single cleavage between Leu(30)-Ile(31). Thus, processing of NPY resulted in formation of the C-terminally truncated fragment NPY(1-30) and its counterpart NPY(31-36), The enzyme revealed properties of aspartic protease, being blocked by pepstatin and having a pH optimum between 4 and 5. The data clarify the structure of NPY and its inactivation pathway in the brain, which is different from that found in the periphery, and may have important consequences in vivo.	KAROLINSKA INST, DEPT LAB MED, STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT CLIN NEUROSCI, EXPT DRUG ADDICT SECT, STOCKHOLM, SWEDEN; LUDWIG INST CANC RES, S-75124 UPPSALA, SWEDEN	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research			Silberring, Jerzy/AGA-5631-2022	Silberring, Jerzy/0000-0002-4362-8362				ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; CASTEL MN, 1994, BIOCHEM PHARMACOL, V47, P53, DOI 10.1016/0006-2952(94)90437-5; DeLorenzo R J, 1980, Ann N Y Acad Sci, V356, P92, DOI 10.1111/j.1749-6632.1980.tb29603.x; GEHLERT DR, 1994, LIFE SCI, V55, P551, DOI 10.1016/0024-3205(94)00481-1; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GRUNDEMAR L, 1994, TRENDS PHARMACOL SCI, V15, P153, DOI 10.1016/0165-6147(94)90076-0; HEILIG M, 1989, ACTA PHYSIOL SCAND, V137, P243, DOI 10.1111/j.1748-1716.1989.tb08745.x; HEILIG M, 1990, ACTA PSYCHIAT SCAND, V82, P95, DOI 10.1111/j.1600-0447.1990.tb01366.x; JAMES P, 1994, PROTEIN SCI, V3, P1347, DOI 10.1002/pro.5560030822; KALRA SP, 1990, ANN NY ACAD SCI, V611, P273; Ludwig R, 1995, BIOCHIMIE, V77, P739, DOI 10.1016/0300-9084(96)88191-0; Ludwig R, 1996, MOL BRAIN RES, V37, P181, DOI 10.1016/0169-328X(95)00312-G; MEDEIROS MS, 1994, BIOCHIMIE, V76, P283, DOI 10.1016/0300-9084(94)90159-7; MENTLEIN R, 1993, REGUL PEPTIDES, V49, P133, DOI 10.1016/0167-0115(93)90435-B; MOORE RY, 1990, ANN NY ACAD SCI, V611, P247; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; NYLANDER I, 1995, LIFE SCI, V57, P123, DOI 10.1016/0024-3205(95)00253-3; PRICE JS, 1991, BRIT J PHARMACOL, V104, P321, DOI 10.1111/j.1476-5381.1991.tb12429.x; ROEPSTORFF P, 1992, ANALYST, V117, P299, DOI 10.1039/an9921700299; SCHWARTZ TW, 1989, NEUROPEPTIDE Y, P143; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHEIKH SP, 1990, J BIOL CHEM, V265, P8304; STENFORS C, 1995, J NEUROSCI RES, V41, P206, DOI 10.1002/jnr.490410208; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WAHLESTEDT C, 1987, BRAIN RES, V417, P33, DOI 10.1016/0006-8993(87)90176-4; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	29	25	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5747	5751		10.1074/jbc.272.9.5747	http://dx.doi.org/10.1074/jbc.272.9.5747			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038187	hybrid			2022-12-25	WOS:A1997WK74700055
J	Terada, T; Kitajima, K; Inoue, S; Wilson, JC; Norton, AK; Kong, DCM; Thomson, RJ; vonItzstein, M; Inoue, Y				Terada, T; Kitajima, K; Inoue, S; Wilson, JC; Norton, AK; Kong, DCM; Thomson, RJ; vonItzstein, M; Inoue, Y			Catalysis by a new sialidase, deaminoneuraminic acid residue-cleaving enzyme (KDNase Sm), initially forms a less stable alpha-anomer of 3-deoxy-D-glycero-D-galacto-nonulosonic acid and is strongly inhibited by the transition state analogue, 2-deoxy-2,3-didehydro-D-glycero-D-galacto-2-nonulopyranosonic acid, but not by 2-deoxy-2,3-didehydro-N-acetylneuraminic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; RAINBOW-TROUT EGGS; INFLUENZA-VIRUS; VITELLINE ENVELOPE; RICH GLYCOPROTEIN; BACTERIAL; CHAINS; IDENTIFICATION; ARTHROBACTER; H-1-NMR	Deaminoneuraminic acid residue-cleaving enzyme (KDNase Sm) is a new sialidase that has been induced and purified from Sphingobacterium multivorum. Catalysis by this new sialidase has been studied by enzyme kinetics and H-1 NMR spectroscopy. V-max/K-m values determined for synthetic and natural substrates of KDNase Sm reveal that 4-methylumbelliferyl-KDN (KDN alpha 2MeUmb, V-max/K-m = 0.033 min(-1)) is the best substrate for this sialidase, presumably because of its good leaving group properties. The transition state analogue, 2,3-didehydro-2,3-dideoxy-D-galacto-D-glycero-nonulosonic acid, is a strong competitive inhibitor of KDNase Sm (K-i = 7.7 mu M versus K-m = 42 mu M for KDN alpha 2MeUmb). 2-Deoxy-2,3-didehydro-N-acetylneuraminic acid and 2-deoxy-2,3-didehydro-N-glycolylneuraminic acid are known to be strong competitive inhibitors for bacterial sialidases such as Arthrobacter ureafaciens sialidase; however, KDNase Sm activity is not significantly inhibited by these compounds. This observation suggests that the hydroxyl group at C-5 is important for recognition of the inhibitor by the enzyme. Reversible addition of water molecule (or hydroxide ion) to the reactive sialosyl cation, presumably formed at the catalytic site of KDNase Sm, eventually gives rise to two different adducts, the alpha- and beta-anomers of free 3-deoxy-D-glycero-D-galacto-nonulosonic acid. H-1 NMR spectroscopic studies clearly demonstrate that the thermodynamically less stable alpha-form is preferentially formed as the first product of the cleavage reaction and that isomerization rapidly follows, leading to an equilibrium mixture of the two isomers, the beta-isomer being the major species at equilibrium. Therefore, we propose that KDNase Sm catalysis proceeds via a mechanism common to the known exosialidases, but the recognition of the substituent at C-5 by the enzyme differs.	ACAD SINICA, INST BIOL CHEM, TAIPEI 115, TAIWAN; UNIV TOKYO, GRAD SCH SCI, DEPT BIOCHEM & BIOPHYS, TOKYO 113, JAPAN; MONASH UNIV, VICTORIAN COLL PHARM, DEPT MED CHEM, PARKVILLE, VIC 3052, AUSTRALIA	Academia Sinica - Taiwan; University of Tokyo; Monash University			von Itzstein, Mark/E-4823-2010; Kong, David/AAX-2897-2021; Wilson, Jennifer/H-5297-2013	Kong, David/0000-0002-5022-9060; Thomson, Robin/0000-0002-1014-2614				AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANGATA T, 1994, GLYCOBIOLOGY, V4, P517, DOI 10.1093/glycob/4.4.517; CASSIDY JT, 1965, J BIOL CHEM, V240, P3501; CHONG AKJ, 1992, EUR J BIOCHEM, V207, P335, DOI 10.1111/j.1432-1033.1992.tb17055.x; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; HINE J, 1956, PHYSICAL ORGANIC CHE, P178; HOLZER CT, 1993, GLYCOCONJUGATE J, V10, P40, DOI 10.1007/BF00731185; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KANAMORI A, 1994, HISTOCHEMISTRY, V93, P2759; KIMURA M, 1994, J BIOL CHEM, V269, P32138; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; LEE YC, 1969, BIOCHEM BIOPH RES CO, V35, P161, DOI 10.1016/0006-291X(69)90499-9; LI YT, 1993, ARCH BIOCHEM BIOPHYS, V310, P234; MILLER CA, 1978, BIOCHEM BIOPH RES CO, V83, P1479, DOI 10.1016/0006-291X(78)91388-8; NADANO D, 1986, J BIOL CHEM, V261, P1550; Nishino S, 1996, J BIOL CHEM, V271, P2909, DOI 10.1074/jbc.271.6.2909; NOHLE U, 1985, EUR J BIOCHEM, V152, P459, DOI 10.1111/j.1432-1033.1985.tb09219.x; SATO C, 1993, J BIOL CHEM, V268, P23675; SONG Y, 1993, BIOCHEMISTRY-US, V32, P9221, DOI 10.1021/bi00086a030; SONG Y, 1995, GLYCOBIOLOGY, V5, P207, DOI 10.1093/glycob/5.2.207; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, BIOCHEM J, V287, P905, DOI 10.1042/bj2870905; TERADA T, 1993, J BIOL CHEM, V268, P2640; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; VONITZSTEIN M, 1991, CHEM ABSTR 49151, V117; WARNER TG, 1979, BIOCHEMISTRY-US, V18, P2783, DOI 10.1021/bi00580a014; WILSON JC, 1995, J AM CHEM SOC, V117, P4214, DOI 10.1021/ja00120a002; ZIAK M, 1996, P NATL ACAD SCI USA, V101, P333	34	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5452	5456		10.1074/jbc.272.9.5452	http://dx.doi.org/10.1074/jbc.272.9.5452			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038146	hybrid, Green Published			2022-12-25	WOS:A1997WK74700014
J	VecseySemjen, B; Lesieur, C; Mollby, R; vanderGoot, FG				VecseySemjen, B; Lesieur, C; Mollby, R; vanderGoot, FG			Conformational changes due to membrane binding and channel formation by staphylococcal alpha-toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING PROTEIN; COLICIN-A; ANGSTROM RESOLUTION; BACTERIAL PORIN; ANNEXIN-V; AUREUS; INSERTION; DOMAIN; OLIGOMERIZATION; FLUORESCENCE	Conformational changes occurring upon membrane binding and subsequent insertion of staphylococcal ol-toxin were studied using complementary spectroscopic techniques. Experimental conditions were established where binding could be uncoupled from membrane insertion but insertion and channel formation seemed to be concomitant. Binding led to changes in tertiary structure as witnessed by an increase in tryptophan fluorescence, a red shift of the tryptophan maximum emission wavelength, and a change in the near UV CD spectrum, In contrast to what was observed for the soluble form of the toxin, 78% of the tryptophan residues in the membrane-bound form were accessible to the hydrophilic quencher KI, At this stage, the tryptophan residues were not in the immediate vicinity of the lipid bilayer, Upon membrane insertion, a second conformational change occurred resulting in a dramatic drop of the near UV CD signal but an increase of the far UV signal, Tryptophan residues were no longer accessible to KI but could be quenched by brominated lipids. In the light of the available data on channel formation by cytoxin, our results suggest that the tryptophan residues might be dipping into the membrane in order to anchor the extramembranous part of the channel to the lipid bilayer.	UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA,SWITZERLAND; KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-17177 STOCKHOLM,SWEDEN	University of Geneva; Karolinska Institutet			van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X				BAYLEY H, 1994, J CELL BIOCHEM, V56, P177, DOI 10.1002/jcb.240560210; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BLOMQVIST L, 1987, FEBS LETT, V211, P127, DOI 10.1016/0014-5793(87)81422-9; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; Bychkova VE, 1996, BIOCHEMISTRY-US, V35, P6058, DOI 10.1021/bi9522460; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; EISELE JL, 1990, J BIOL CHEM, V265, P10217; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GONZALEZMANAS JM, 1993, EUR J BIOCHEM, V211, P625, DOI 10.1111/j.1432-1033.1993.tb17590.x; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; Gouaux J. E., 1996, Medical Microbiology and Immunology, V185, P109; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LALA AK, 1995, J BIOL CHEM, V270, P11348, DOI 10.1074/jbc.270.19.11348; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LIND I, 1987, ANAL BIOCHEM, V164, P84, DOI 10.1016/0003-2697(87)90371-X; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; MEERS P, 1994, BIOCHEMISTRY-US, V33, P5829, DOI 10.1021/bi00185a022; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Ostermeier C, 1996, CURR OPIN STRUC BIOL, V6, P460, DOI 10.1016/S0959-440X(96)80110-2; PALMER M, 1993, J BIOL CHEM, V268, P11963; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; SOPKOVA J, 1994, BIOCHEMISTRY-US, V33, P4490, DOI 10.1021/bi00181a008; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; VecseySemjen B, 1996, J BIOL CHEM, V271, P8655, DOI 10.1074/jbc.271.15.8655; WALEV I, 1995, INFECT IMMUN, V63, P118; WALKER B, 1993, J BIOL CHEM, V268, P5285; WALKER B, 1994, PROTEIN ENG, V7, P91, DOI 10.1093/protein/7.1.91; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WINISKI AP, 1988, BIOCHEMISTRY-US, V27, P386, DOI 10.1021/bi00401a058	50	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5709	5717		10.1074/jbc.272.9.5709	http://dx.doi.org/10.1074/jbc.272.9.5709			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038182	hybrid			2022-12-25	WOS:A1997WK74700050
J	Dear, TN; Hainzl, T; Follo, M; Nehls, M; Wilmore, H; Matena, K; Boehm, T				Dear, TN; Hainzl, T; Follo, M; Nehls, M; Wilmore, H; Matena, K; Boehm, T			Identification of interaction partners for the basic-helix-loop-helix protein E47	ONCOGENE			English	Article						E47; helix-loop-helix; eip1	REPLICATION FACTOR-C; DNA-BINDING; DROSOPHILA-MELANOGASTER; IMMUNOGLOBULIN ENHANCER; DEVELOPING SOMITES; EXPRESSION VECTOR; HLH PROTEINS; GENE; E2A; CLONING	Helix-loop-helix proteins constitute a family of transcription factors with the potential to form homo- and hetero-dimers mediated by the helix-loop-helix domain, Oncogenic mutations in such genes can disrupt the equilibrium of protein-protein interactions in the affected cell, In order to assess the biological consequences of such mutations, the full complement of interacting proteins must be known, To identify proteins interacting with the basic-helix-loop-helix domain of the ubiquitously expressed E47 protein, a 'sandwich'-screening procedure was developed which distinguishes between homo- and hetero-oligomers, and specifically excludes the detection of complexes which cannot bind DNA, Nine distinct cDNAs were identified which encode proteins with apparent basic-helix-loop-helix domains, including a novel clone termed eip1 which is distantly related in the basic-helix-loop-helix domain to the Drosophila enhancer-of-split m7 protein, Using epitope-tagging, interaction of E47 basic-helix-loop-helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells, Interaction was also observed in the yeast two-hybrid system, Three cDNAs encoding proteins without basic-helix-loop-helix domains were also found to interact in the sandwich-expression screen, Interactions with human PARP and mouse replication factor la were confirmed using glutathione transferase-tagged cDNAs, A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic-helix-loop-helix only when fused to a beta-galactosidase tag.	DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; INNERE MED ABT 1,D-79106 FREIBURG,GERMANY; UNIV FRANKFURT,MED KLIN 4,ZENTRUM INNERE MED,D-60590 FRANKFURT,GERMANY; UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); MRC Laboratory Molecular Biology; Goethe University Frankfurt; University of Bath				Follo, Marie/0000-0002-3090-7442				APERLO C, 1996, IN PRESS GENOMICS; BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLINE TW, 1976, GENETICS, V84, P723; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HAINZL T, 1994, ONCOGENE, V9, P885; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU JS, 1992, MOL CELL BIOL, V12, P1031; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VASTRIK I, 1993, ONCOGENE, V8, P503; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	41	39	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					891	898		10.1038/sj.onc.1200912	http://dx.doi.org/10.1038/sj.onc.1200912			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050988				2022-12-25	WOS:A1997WK34400002
J	Glombitza, GJ; Becker, E; Kaiser, HW; Sandhoff, K				Glombitza, GJ; Becker, E; Kaiser, HW; Sandhoff, K			Biosynthesis, processing, and intracellular transport of G(M2) activator protein in human epidermal keratinocytes - The lysosomal targeting of the G(M2) activator is independent of a mannose-6-phosphate signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D; BETA-HEXOSAMINIDASE; GANGLIOSIDE GM2; DICTYOSTELIUM-DISCOIDEUM; SULFATIDE ACTIVATOR; SKIN FIBROBLASTS; HEPG2 CELLS; BREFELDIN-A; ENZYMES; MANNOSE	The processing, intracellular transport, and endocytosis of the G(M2) activator protein (G(M2)AP), an essential cofactor of beta-hexosaminidase A for the degradation of ganglioside G(M2), was investigated in human epidermal keratinocytes. The G(M2)AP precursor is synthesized as an 18-kDa peptide, which is singly glycosylated, resulting in 22-kDa high mannose and 24-27-kDa complex glycoforms. A small portion of the 22-kDa form bears phosphomannosyl residues, About 30% of the G(M2)AP precursor is secreted during 12 h after synthesis, consisting almost exclusively of complex glycoforms. in a post-Golgi compartment, the intracellular remainder is converted to a 20-kDa mature form within 24 h, bearing a heavily trimmed N-glycan on a 17-kDa backbone, Interestingly, even nonglycosylated G(M2)AP is delivered to the lysosome, as shown by tunicamycin treatment and subcellular fractionation, Also, its endocytosis is independent of carbohydrate-linked signals and is even more effective for nonglycosylated G(M2)AP. We conclude that a mannose-6-phosphate-independent pathway for the lysosomal delivery of G(M2)AP exists in cultured human keratinocytes.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; UNIV KLINIKEN BONN,HAUTKLIN,D-53127 BONN,GERMANY	University of Bonn; University of Bonn								AERTS JMFG, 1988, BIOCHIM BIOPHYS ACTA, V964, P303, DOI 10.1016/0304-4165(88)90030-X; AOYAGI T, 1975, COLD SPRING HARBOR C, V2, P429; BURG J, 1983, H-S Z PHYSIOL CHEM, V364, P821, DOI 10.1515/bchm2.1983.364.2.821; BURG J, 1985, BIOL CHEM H-S, V366, P887, DOI 10.1515/bchm3.1985.366.2.887; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CAPONY F, 1994, EXP CELL RES, V215, P154, DOI 10.1006/excr.1994.1327; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; DIMENT S, 1988, J BIOL CHEM, V263, P6901; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; FURST W, 1990, EUR J BIOCHEM, V192, P709, DOI 10.1111/j.1432-1033.1990.tb19280.x; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GOLDBERG D, 1984, LYSOSOM BIOL PATHOL, P45; GONZALEZNORIEGA A, 1982, J CELL BIOL, V95, P536; Graham JM, 1993, BIOMEMBRANE PROTOCOL, P1; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASILIK A, 1981, EUR J BIOCHEM, V121, P125, DOI 10.1111/j.1432-1033.1981.tb06440.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; IMAI K, 1985, J BIOCHEM, V98, P1405, DOI 10.1093/oxfordjournals.jbchem.a135408; IMORT M, 1983, BIOCHEM J, V214, P671, DOI 10.1042/bj2140671; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLIMA H, 1993, BIOCHEM J, V294, P227; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSTER A, 1994, EUR J BIOCHEM, V224, P685, DOI 10.1111/j.1432-1033.1994.00685.x; LI SC, 1995, J BIOL CHEM, V270, P24246, DOI 10.1074/jbc.270.41.24246; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; RODRIGUEZPARIS JM, 1993, J BIOL CHEM, V268, P9110; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; SALMINEN A, 1990, BIOCHEM J, V272, P39, DOI 10.1042/bj2720039; SANDHOFF K, 1995, METABOLIC MOL BASES, V2, P2427; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRODER M, 1993, HUM GENET, V92, P437, DOI 10.1007/BF00216446; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TIKKANEN R, 1995, DNA CELL BIOL, V14, P305, DOI 10.1089/dna.1995.14.305; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; VIELHABER G, 1997, J BIOL CHEM, V272, P32438; VONFIGURA K, 1979, EUR J BIOCHEM, V101, P103; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Wu YY, 1996, J BIOL CHEM, V271, P10611, DOI 10.1074/jbc.271.18.10611; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZHU Y, 1994, J BIOL CHEM, V269, P3846	62	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5199	5207		10.1074/jbc.272.8.5199	http://dx.doi.org/10.1074/jbc.272.8.5199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030589	hybrid			2022-12-25	WOS:A1997WJ85500077
J	Hiraga, K; Yutani, K				Hiraga, K; Yutani, K			Roles of hydrogen bonding residues in the interaction between the alpha and beta subunits in the tryptophan synthase complex - Asn-104 of the alpha subunit is especially important	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SWITCH; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; CONFORMATIONAL STABILITY; ALPHA(2)BETA(2) COMPLEX; HINGE REGION; PROTEIN; GENES; SYNTHETASE	The interaction of the a subunit with the beta(2) subunit of tryptophan synthase is known to be necessary for the activation of each subunit and for the catalytic efficiency of the alpha(2) beta(2) complex, To elucidate the roles of hydrogen bonds in the interaction site between the alpha and beta subunits for subunit association, eight mutant alpha subunits at five hydrogen bonding residues (N104D, N104A, N108D, N108A, E134A, E135A, N157D, and N157A) were constructed, and the thermodynamic parameters of association with the beta subunit were obtained using a titration calorimeter, The N104D and N104A mutations remarkably decreased the stimulation activities, the association constants, and the association enthalpies, Although the association constant and the stimulation activities of E134A were reduced in the absence of salt, the change in the association enthalpy was relatively small, and the addition of salt could repair its defects, The substitutions at positions 135 and 157 did not affect the stimulation activity and decreased the Gibbs energy of association corresponding to the defect in 1 mol of hydrogen bond, The present results suggest that the alpha subunit which has a mutation at position 104 cannot fold into an intact conformation upon complex formation, resulting in reduced stimulation activities, The hydrogen bond with Asn-104, which is a conserved residue among 16 microorganisms, was especially important for alpha/beta interaction and mutual activation.	OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	Osaka University								ADACHI O, 1974, J BIOL CHEM, V249, P7756; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BONAFE CFS, 1991, J BIOL CHEM, V266, P13210; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; Crawford I P, 1991, DNA Seq, V1, P189, DOI 10.3109/10425179109020770; CRAWFORD IP, 1989, BIOCHIMIE, V71, P521, DOI 10.1016/0300-9084(89)90183-1; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DUNN MF, 1994, ADV LIF SCI-SERIES, P119; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; GUEGUEN J, 1988, J SCI FOOD AGR, V44, P167, DOI 10.1002/jsfa.2740440208; HADERO A, 1986, MOL BIOL EVOL, V3, P191; HATHAWAY GM, 1970, BIOCHEMISTRY-US, V9, P1801, DOI 10.1021/bi00810a020; HENNER DJ, 1985, GENE, V4, P169; HIGGINS W, 1979, BIOCHEMISTRY-US, V18, P4827, DOI 10.1021/bi00589a010; Hiraga K, 1996, EUR J BIOCHEM, V240, P63, DOI 10.1111/j.1432-1033.1996.0063h.x; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HONIG B, 1993, J PHYS CHEM-US, V97, P1101, DOI 10.1021/j100108a002; HYDE CC, 1988, J BIOL CHEM, V263, P17857; ISHIWATA K, 1989, AGR BIOL CHEM TOKYO, V53, P2941, DOI 10.1080/00021369.1989.10869796; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; KAUFMANN M, 1991, BIOCHEMISTRY-US, V30, P4173, DOI 10.1021/bi00231a010; KOSHIYAMA I, 1971, AGR BIOL CHEM TOKYO, V35, P385, DOI 10.1080/00021369.1971.10859931; KOYAMA Y, 1990, J BACTERIOL, V172, P3490, DOI 10.1128/jb.172.6.3490-3495.1990; LAM WL, 1990, P NATL ACAD SCI USA, V87, P6614, DOI 10.1073/pnas.87.17.6614; LIM WK, 1991, J BIOL CHEM, V266, P20205; LINKENS HJ, 1993, FEBS LETT, V320, P224, DOI 10.1016/0014-5793(93)80591-H; MATSUI K, 1986, NUCLEIC ACIDS RES, V14, P10113, DOI 10.1093/nar/14.24.10113; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; NATORI Y, 1990, J BIOCHEM, V107, P248, DOI 10.1093/oxfordjournals.jbchem.a123034; NICHOLS BP, 1981, NUCLEIC ACIDS RES, V9, P1743, DOI 10.1093/nar/9.7.1743; OGASAHARA K, 1980, J BIOCHEM-TOKYO, V88, P1733, DOI 10.1093/oxfordjournals.jbchem.a133148; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; PEDROSA C, 1994, BIOCHEMISTRY-US, V33, P4046, DOI 10.1021/bi00179a033; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; PERACCHI A, 1994, ADV LIF SCI-SERIES, P125; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; ROSS CM, 1988, J BACTERIOL, V170, P757, DOI 10.1128/jb.170.2.757-768.1988; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; RUAN KC, 1988, BIOCHEMISTRY-US, V27, P3295, DOI 10.1021/bi00409a026; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; SCHWENKE K D, 1975, Nahrung, V19, P425, DOI 10.1002/food.19750190506; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SIBOLD L, 1988, MOL GEN GENET, V214, P439, DOI 10.1007/BF00330478; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; WARWICKER J, 1989, J MOL BIOL, V206, P381, DOI 10.1016/0022-2836(89)90487-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441; ZALKIN H, 1982, J BIOL CHEM, V257, P1491; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; ZHAO GP, 1992, J BIOL CHEM, V267, P526	58	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4935	4940		10.1074/jbc.272.8.4935	http://dx.doi.org/10.1074/jbc.272.8.4935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030553	hybrid			2022-12-25	WOS:A1997WJ85500041
J	MacrezLepretre, N; Kalkbrenner, F; Schultz, G; Mironneau, J				MacrezLepretre, N; Kalkbrenner, F; Schultz, G; Mironneau, J			Distinct functions of G(q) and G(11) proteins in coupling alpha(1)-adrenoreceptors to Ca2+ release and Ca2+ entry in rat portal vein myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HETEROTRIMERIC G-PROTEINS; CAPACITATIVE CALCIUM-ENTRY; GAMMA-SUBUNIT; ANTISENSE OLIGONUCLEOTIDES; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; EXPRESSION; SUBTYPES; INFLUX	In this study, we identified the subunit composition of G(q) and G(11) proteins coupling alpha(1)-adrenoreceptors to increase in cytoplasmic Ca2+ concentration ([Ca2+](i)) in rat portal vein myocytes maintained in short-term primary culture, We used intranuclear antisense oligonucleotide injection to inhibit selectively the expression of subunits of G protein. Increases in [Ca2+](i) were measured in response to activation of alpha(1)-adrenoreceptors, angiotensin AT(1) receptors, and caffeine. Antisense oligonucleotides directed against the mRNAs coding for alpha(q), alpha(11), beta(1), beta(3), gamma(2), and gamma(3) subunits selectively inhibited the increase in [Ca2+](i) activated by alpha(1)-adrenoreceptors. A corresponding reduction of the expression of these G protein subunits was immunochemically confirmed. In experiments performed in Ca2+-free solution only cells injected with anti-alpha(q) antisense oligonucleotides displayed a reduction of the alpha(1)-adrenoreceptor-induced Ca2+ release, In contrast, in Ca2+-containing solution, injection of anti-alpha(11) antisense oligonucleotides suppressed the alpha(1)-adrenoreceptor-induced stimulation of the store-operated Ca2+ influx, Agents that specifically bound G beta gamma subunits (anti-beta(com) antibody and overexpression of a beta-adrenergic receptor kinase carboxyl-terminal fragment) had no effect on the alpha(1)-adrenoreceptor induced signal transduction, Taken together, these results suggest that alpha(1)-adrenoreceptors utilize two different G alpha subunits to increase [Ca2+](i). G alpha(q) may activate phosphatidylinositol 4,5-bisphosphate hydrolysis and induce release of Ca2+ from intracellular stores, G alpha(11) may enhance the Ca2+-activated Ca2+ influx that replenishes intracellular Ca2+ stores.	UNIV BORDEAUX 2,FAC PHARM,CNRS ESA 5017,LAB PHYSIOL CELLULAIRE & PHARMACOL MOL,F-33076 BORDEAUX,FRANCE; FREE UNIV BERLIN,INST PHARMAKOL,D-14195 BERLIN,GERMANY	UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin				MACREZ, Nathalie/0000-0002-3844-4403				ALBERT PR, 1994, TRENDS PHARMACOL SCI, V15, P250, DOI 10.1016/0165-6147(94)90320-4; Arnaudeau S, 1996, BIOCHEM BIOPH RES CO, V222, P809, DOI 10.1006/bbrc.1996.0808; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CAMPBELL V, 1993, J PHYSIOL-LONDON, V470, P1; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GUDERMANN T, 1996, ANN REV PHARM TOXICO, V36, P428; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; KALKBRENNER F, 1995, EMBO J, V14, P101; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; LEPRETRE N, 1994, J PHARMACOL EXP THER, V268, P167; LOIRAND G, 1991, J PHYSIOL-LONDON, V437, P461, DOI 10.1113/jphysiol.1991.sp018606; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; Morel JL, 1996, BRIT J PHARMACOL, V118, P73, DOI 10.1111/j.1476-5381.1996.tb15368.x; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; MURRAY RK, 1991, J PHYSIOL-LONDON, V435, P123, DOI 10.1113/jphysiol.1991.sp018501; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; OFFERMANNS S, 1994, N-S ARCH PHARMACOL, V350, P329; PACAUD P, 1993, J BIOL CHEM, V268, P3866; PELET C, 1995, EUR J PHARMACOL, V279, P15, DOI 10.1016/0014-2999(95)00125-5; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SIMPSON AWM, 1990, BIOCHEM J, V267, P277, DOI 10.1042/bj2670277; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169	38	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5261	5268		10.1074/jbc.272.8.5261	http://dx.doi.org/10.1074/jbc.272.8.5261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030598	hybrid			2022-12-25	WOS:A1997WJ85500086
J	Mazurek, S; Michel, A; Eigenbrodt, E				Mazurek, S; Michel, A; Eigenbrodt, E			Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; ROUS-SARCOMA VIRUS; HUMAN-DIPLOID FIBROBLASTS; MALATE-ASPARTATE SHUTTLE; EPIDERMAL-GROWTH-FACTOR; GLUCOSE-FREE MEDIUM; KINASE TYPE-K; LACTATE-DEHYDROGENASE; MALIC ENZYME; FRUCTOSE 2,6-BISPHOSPHATE	In differentiated tissues, such as muscle and brain, increased adenosine monophosphate (AMP) levels stimulate glycolytic flux rates, In the breast cancer cell line MCF-7, which characteristically has a constantly high glycolytic flux rate, AMP induces a strong inhibition of glycolysis, The human breast cancer cell line MDA-MB-453, on the other hand, is characterized by a more differentiated metabolic phenotype, MDA-MB-453 cells have a lower glycolytic flux rate and higher pyruvate consumption than MCF-7 cells, In addition, they have an active glycerol 3-phosphate shuttle, AMP inhibits cell proliferation as well as NAD and NADH synthesis in both MCF-7 and MDA-MB-453 cells, However, in MDA-MB-453 cells glycolysis is slightly activated by AMP, This disparate response of glycolytic flux rate to AMP treatment is presumably caused by the fact that the reduced NAD and NADH levels in AMP-treated MDA-MB-453 cells reduce lactate dehydrogenase but not cytosolic glycerol-3-phosphate dehydrogenase reaction, Due to the different enzymatic complement in MCF-7 cells, proliferation is inhibited under glucose starvation, whereas MDA-MB-453 cells grow under these conditions, The inhibition of cell proliferation correlates with a reduction in glycolytic carbon flow to synthetic processes and a decrease in phosphotyrosine content of several proteins in both cell lines.	SCHEBO TECH GMBH, D-35435 WETTENBERG, GERMANY		Mazurek, S (corresponding author), UNIV GIESSEN, FAC VET, INST BIOCHEM & ENDOCRINOL, FRANKFURTER STR 100, D-35392 GIESSEN, GERMANY.		Mazurek, Sybille/ABH-2089-2020					ARGAUD D, 1995, J BIOL CHEM, V270, P24229, DOI 10.1074/jbc.270.41.24229; ARORA KK, 1988, J BIOL CHEM, V263, P17422; ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842; BERGMEYER HU, 1974, VERLAG CHEM, V2; BERGMEYER HU, 1974, VERLAG CHEM, V1; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BOSCA L, 1988, EUR J BIOCHEM, V175, P317, DOI 10.1111/j.1432-1033.1988.tb14199.x; CARNEY DN, 1982, LANCET, V1, P583; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DENIS C, 1984, INT J BIOCHEM, V16, P87, DOI 10.1016/0020-711X(84)90055-7; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; EIGENBRODT E, 1983, EMBO J, V2, P1565, DOI 10.1002/j.1460-2075.1983.tb01625.x; Eigenbrodt E, 1994, BIOCH MOL ASPECTS SE, V2, P311; EPNER DE, 1993, CANCER RES, V53, P1995; FREITAS I, 1991, ANTICANCER RES, V11, P1293; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; GAUTHIER T, 1989, INT J BIOCHEM, V21, P191, DOI 10.1016/0020-711X(89)90108-0; GHOSE AK, 1989, P NATL ACAD SCI USA, V86, P8242, DOI 10.1073/pnas.86.21.8242; GLASER G, 1980, BIOCHEM J, V192, P793, DOI 10.1042/bj1920793; GLOSSMANN H, 1981, MOL CELL ENDOCRINOL, V23, P49, DOI 10.1016/0303-7207(81)90116-7; GONZALEZMATEOS F, 1993, J BIOL CHEM, V268, P7809; GREGORY SH, 1976, ARCH BIOCHEM BIOPHYS, V175, P644, DOI 10.1016/0003-9861(76)90555-5; GREGORY SH, 1977, EXP CELL RES, V110, P387, DOI 10.1016/0014-4827(77)90305-6; GREINER EF, 1994, J BIOL CHEM, V269, P31484; GROELKE J, 1984, J CELL PHYSIOL, V119, P133, DOI 10.1002/jcp.1041190121; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; GUTIERREZJUAREZ R, 1993, INT J BIOCHEM, V25, P725, DOI 10.1016/0020-711X(93)90360-Q; HENDERSO.JF, 1965, J BIOL CHEM, V240, P2349; HENDERSO.JF, 1965, J BIOL CHEM, V240, P2363; HENDERSON JF, 1980, PHARMACOL THERAPEUT, V8, P539; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUGO F, 1992, J CELL PHYSIOL, V153, P539, DOI 10.1002/jcp.1041530315; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; ISBEN KH, 1971, ARCH BIOCHEM BIOPHYS, V143, P187, DOI 10.1016/0003-9861(71)90199-8; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; LANKS KW, 1986, J CELL PHYSIOL, V126, P319, DOI 10.1002/jcp.1041260224; LANKS KW, 1987, J BIOL CHEM, V262, P10093; LOPEZALARCON L, 1979, ARCH BIOCHEM BIOPHYS, V192, P391, DOI 10.1016/0003-9861(79)90107-3; LOPEZALARCON L, 1986, CANCER RES, V46, P5589; MARCHOK AC, 1984, CARCINOGENESIS, V5, P789, DOI 10.1093/carcin/5.6.789; Mazurek S, 1996, J CELL PHYSIOL, V167, P238, DOI 10.1002/(SICI)1097-4652(199605)167:2<238::AID-JCP7>3.0.CO;2-Q; MCKEEHAN WL, 1981, J BIOL CHEM, V256, P2973; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; MOREADITH RW, 1984, J BIOL CHEM, V259, P6222; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAVAS P, 1986, BIOCHEM BIOPH RES CO, V135, P110, DOI 10.1016/0006-291X(86)90949-6; OHNO K, 1994, J CELL PHYSIOL, V160, P358, DOI 10.1002/jcp.1041600217; PRESEK P, 1980, CANCER RES, V40, P1733; PRESEK P, 1988, FEBS LETT, V242, P194, DOI 10.1016/0014-5793(88)81014-7; RAPAPORT E, 1980, J CELL PHYSIOL, V105, P267, DOI 10.1002/jcp.1041050210; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; RENNER ED, 1972, J BIOL CHEM, V247, P5765; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; ROBINSON EA, 1966, J BIOL CHEM, V241, P2737; SANCHEZJIMENEZ F, 1985, BIOCHIMIE, V67, P259, DOI 10.1016/S0300-9084(85)80055-9; SAUER LA, 1980, J BIOL CHEM, V255, P3844; SCHULTZ V, 1978, J BIOL CHEM, V253, P1938; SCHWARTZ JP, 1974, J BIOL CHEM, V249, P4138; SCHWARTZ MK, 1990, CLIN BIOCHEM, V23, P395, DOI 10.1016/0009-9120(90)90119-F; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SENER A, 1988, J BIOL CHEM, V263, P1904; SINGER S, 1995, CANCER RES, V55, P5140; SKALA H, 1987, EUR J BIOCHEM, V163, P513, DOI 10.1111/j.1432-1033.1987.tb10898.x; SKOG S, 1982, EXP CELL RES, V141, P23, DOI 10.1016/0014-4827(82)90063-5; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SMITH ML, 1979, J CELL PHYSIOL, V101, P293, DOI 10.1002/jcp.1041010210; SRERE PA, 1993, BIOL CHEM H-S, V374, P833; STAAL GEJ, 1987, CANCER RES, V47, P5047; STEINBERG P, 1994, CARCINOGENESIS, V15, P125, DOI 10.1093/carcin/15.1.125; TALHA S, 1983, EXP CELL RES, V149, P471, DOI 10.1016/0014-4827(83)90359-2; TEJWANI GA, 1978, TRENDS BIOCHEM SCI, V3, P31; TELLER JK, 1990, J BIOL CHEM, V265, P19486; VICARIO PP, 1989, BIOCHEM SOC T, V17, P1110, DOI 10.1042/bst0171110; VORA S, 1985, CANCER RES, V45, P2993; WARBURG O, 1956, SCIENCE, V124, P269; WEBER G, 1971, CANCER RES, V31, P2177; WEERNINK PAO, 1992, BIOCHIM BIOPHYS ACTA, V1121, P61; WEERNINK PAO, 1990, CANCER RES, V50, P4604; WEISMAN GA, 1988, J BIOL CHEM, V263, P12367; WEISMAN GA, 1984, J CELL PHYSIOL, V119, P211, DOI 10.1002/jcp.1041190211; WENZEL A, 1989, BIOL CHEM H-S, V370, P205, DOI 10.1515/bchm3.1989.370.1.205; WHITFIELD CD, 1981, J BIOL CHEM, V256, P6651; WICE BM, 1981, J BIOL CHEM, V256, P7812; WOLFROM C, 1989, EXP CELL RES, V183, P303, DOI 10.1016/0014-4827(89)90391-1; YOSHIMOTO K, 1983, J BIOL CHEM, V258, P2355; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311; ZHANG ZY, 1995, J BIOL CHEM, V270, P16052; ZIELKE HR, 1980, J CELL PHYSIOL, V104, P433, DOI 10.1002/jcp.1041040316; ZIELKE HR, 1978, J CELL PHYSIOL, V95, P41	92	96	100	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4941	4952		10.1074/jbc.272.8.4941	http://dx.doi.org/10.1074/jbc.272.8.4941			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030554	hybrid			2022-12-25	WOS:A1997WJ85500042
J	Marais, R; Light, Y; Paterson, HF; Mason, CS; Marshall, CJ				Marais, R; Light, Y; Paterson, HF; Mason, CS; Marshall, CJ			Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; PLASMA-MEMBRANE; EXPRESSION; CELLS; TRANSFORMATION; IDENTIFICATION; SPECIFICITY; STIMULATION; ANTIBODIES	It has previously been shown that maximal activation of Raf-1 is produced by synergistic signals from oncogenic Ras and activated tyrosine kinases, This synergy arises because Ras-GTP translocates Raf-1 to the plasma membrane where it becomes phosphorylated on tyrosine residues 340 and 341 by membrane bound tyrosine kinases (Marais, R,, Light, Y,, Paterson, H, F,, and Marshall, C. J. (1995) EMBO J. 14, 3136-3145), We have examined whether the other two members of the Raf family, A-Raf and B-Raf, are regulated in a similar way to Raf-1. A-Raf behaves like Raf-1, being weakly activated by oncogenic Ras more strongly activated by oncogenic Src, and these signals synergize to give maximal activation, B-Raf by contrast is strongly activated by oncogenic Ras alone and is not activated by oncogenic Src, These results show that maximal activation of B-Raf merely requires signals that generate Ras-GTP whereas activation of Raf-1 and A-Raf requires Ras GTP together with signals that lead to their tyrosine phosphorylation, B-Raf may therefore be the primary target of oncogenic Ras.	INST CANC RES, CHESTER BEATTY LABS, CANC RES CAMPAIGN, DEPT CELL & MOL BIOL, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Marais, Richard/0000-0001-7484-4183; Mason, Clive/0000-0003-3179-6622				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; COX AD, 1994, ONCOGENE, V9, P3281; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EYCHENE A, 1995, ONCOGENE, V10, P1159; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RAPP UR, 1988, ONCOGENE HDB; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	39	352	375	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4378	4383		10.1074/jbc.272.7.4378	http://dx.doi.org/10.1074/jbc.272.7.4378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020159	hybrid			2022-12-25	WOS:A1997WH01900075
J	Milner, CM; Smith, SV; Carrillo, MB; Taylor, GL; Hollinshead, M; Campbell, RD				Milner, CM; Smith, SV; Carrillo, MB; Taylor, GL; Hollinshead, M; Campbell, RD			Identification of a sialidase encoded in the human major histocompatibility complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEURAMINIDASE DEFICIENCY; VIBRIO-CHOLERAE NEURAMINIDASE; CLASS-III REGION; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; BACTERIAL SIALIDASES; CYTOSOLIC SIALIDASE; BETA-GALACTOSIDASE; MOUSE H-2-COMPLEX; CRYSTAL-STRUCTURE	Mammalian sialidases are important in modulating the sialic acid content of cell-surface and intracellular glycoproteins. However, the full extent of this enzyme family and the physical and biochemical properties of its individual members are unclear. We have identified a novel gene, G9, in the human major histocompatibility complex (MHC), that encodes a 415-amino acid protein sharing 21-28% sequence identity with the bacterial sialidases and containing three copies of the Asp-block motif characteristic of these enzymes. The level of sequence identity between human G9 and a cytosolic sialidase identified in rat and hamster (28-29%) is much less than would be expected for analogous proteins in these species, suggesting that G9 is distinct from the cytosolic enzyme. Expression of G9 in insect cells has confirmed that it encodes a sialidase, which shows optimal activity at pH 4.6, but appears to have limited substrate specificity. The G9 protein carries an N-terminal signal sequence and immunofluorescence staining of COS7 cells expressing recombinant G9 shows localization of this sialidase exclusively to the endoplasmic reticulum. The location of the G9 gene, within the human MHC, corresponds to that of the murine Neu-1 locus, suggesting that these are analogous genes. One of the functions attributed to Neu-1 is the up-regulation of sialidase activity during T cell activation.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND; UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	University of Oxford; University of Bath; University of Oxford			Milner, Caroline M/P-5526-2015; Taylor, Garry/G-3017-2014	Milner, Caroline M/0000-0001-7355-9655; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguado B, 1996, HLA MHC GENES MOL FU, P39; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; CAMPBELL RD, 1997, IMMUNOL TODAY, V18; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; FIGUEROA F, 1982, J IMMUNOL, V129, P2089; GALEN JE, 1992, INFECT IMMUN, V60, P406, DOI 10.1128/IAI.60.2.406-415.1992; GREFFARD A, 1994, INT J BIOCHEM, V26, P769, DOI 10.1016/0020-711X(94)90106-6; HARADA F, 1987, HUM GENET, V75, P91; HIRAIWA M, 1988, J BIOCHEM-TOKYO, V103, P86, DOI 10.1093/oxfordjournals.jbchem.a122245; HOOGEVEEN AT, 1980, NATURE, V285, P500, DOI 10.1038/285500a0; HOYER LL, 1992, MOL MICROBIOL, V6, P873, DOI 10.1111/j.1365-2958.1992.tb01538.x; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KISHORE GS, 1975, J BIOL CHEM, V250, P2655; KITTS PA, 1992, CLONTECHNIQUES, V7, P1; KLEIN D, 1982, IMMUNOGENETICS, V16, P181, DOI 10.1007/BF00364405; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAFUSE WP, 1992, IMMUNOGENETICS, V36, P110, DOI 10.1007/BF00215287; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LANDOLFI NF, 1985, IMMUNOGENETICS, V22, P159, DOI 10.1007/BF00563513; LIVINGSTONE C, 1989, NUCLEIC ACIDS RES, V17, P2366, DOI 10.1093/nar/17.6.2366; LOWDEN JA, 1979, AM J HUM GENET, V31, P1; LUND T, 1993, DIABETOLOGIA, V36, P727, DOI 10.1007/BF00401143; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P794, DOI 10.1093/oxfordjournals.jbchem.a123127; MIYAGI T, 1984, EUR J BIOCHEM, V141, P75, DOI 10.1111/j.1432-1033.1984.tb08159.x; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MORREAU H, 1992, J BIOL CHEM, V267, P17949; MUELLER OT, 1986, P NATL ACAD SCI USA, V83, P1817, DOI 10.1073/pnas.83.6.1817; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS J, 1981, GENET RES, V38, P47, DOI 10.1017/S0016672300020395; PILATTE Y, 1992, FASEB J, V6, pA1615; POTIER M, 1979, FEBS LETT, V108, P345, DOI 10.1016/0014-5793(79)80560-8; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROGGENTIN P, 1988, FEBS LETT, V238, P31, DOI 10.1016/0014-5793(88)80219-9; ROTHE B, 1989, J GEN MICROBIOL, V135, P3087; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SARGENT CA, 1989, EMBO J, V8, P2305, DOI 10.1002/j.1460-2075.1989.tb08357.x; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNOEK M, 1993, GENOMICS, V15, P350, DOI 10.1006/geno.1993.1067; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; TAIRA S, 1988, J IMMUNOL, V141, P440; USUKI S, 1988, J BIOL CHEM, V263, P6847; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARNER TG, 1979, BIOCHEMISTRY-US, V18, P2783, DOI 10.1021/bi00580a014; WARREN L, 1959, J BIOL CHEM, V234, P1971; WINTER RM, 1980, CLIN GENET, V18, P203	69	99	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4549	4558		10.1074/jbc.272.7.4549	http://dx.doi.org/10.1074/jbc.272.7.4549			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020182	hybrid			2022-12-25	WOS:A1997WH01900098
J	Terada, K; Kaziro, Y; Satoh, T				Terada, K; Kaziro, Y; Satoh, T			Ras-dependent activation of c-Jun N-terminal kinase/stress-activated protein kinase in response to interleukin-3 stimulation in hematopoietic BaF3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; CDC42 GTPASES; GM-CSF; PATHWAY; RECEPTOR; RHO; PROLIFERATION; REQUIRES	Activation of the c-Jun N-terminal kinase (JNK)/stress-activated protein kinase pathway in response to stimulation of the interleukin (IL)-3 or granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor was examined in mouse hematopoietic BaF3-derived cell lines (BaF3-N6 and -V2 cells). Significant increase in the activity of JNK1 was observed within 30 min following IL-3 or GM-CSF stimulation at physiological concentrations. Dominant-negative Ras(S17N), which is conditionally expressed in the presence of isopropyl-1-thio-beta-D-galactoside in BaF3-N6 cells, prevented the IL -3 stimulation of JNK1, whereas anisomycin-induced JNK1 activation was unaffected. Furthermore, a deletion mutant of the common beta subunit for IL-3 and GM-CSF receptors that consists of only the membrane-proximal region, including box 1 and box 2 motifs, was incapable of facilitating JNK1 activity as well as Ras activation. These results provide evidence that Ras is required for IL-3-stimulated JNK1 activation. We also examined if constitutively active Ras(G12V) alone could stimulate JNK1 activity by using the inducible expression system. Isopropyl-1-thio-beta-D-galactoside induction of Ras(G12V) in the BaF3-V2 cell line caused no significant increase in JNK1 activity, which could be activated by IL-3 or anisomycin. On the contrary, the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway was fully activated following Ras(G12V) induction. Together with these results, it seems likely that the Ras protein is indispensable for the IL-3 stimulation of JNK1 although Ras activation by itself is insufficient for JNK1 activation.			Terada, K (corresponding author), TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,4259 NAGATSUTA CHO,YOKOHAMA,KANAGAWA 226,JAPAN.		Satoh, Takaya/K-2628-2014; Terada, Koji/G-3049-2012					AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Heasley LE, 1996, MOL CELL BIOL, V16, P648; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKUDA K, 1994, J BIOL CHEM, V269, P24602; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	48	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4544	4548		10.1074/jbc.272.7.4544	http://dx.doi.org/10.1074/jbc.272.7.4544			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020181	hybrid			2022-12-25	WOS:A1997WH01900097
J	Simantov, R; Tauber, M				Simantov, R; Tauber, M			The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells	FASEB JOURNAL			English	Article						apoptosis; drug abuse; transporter; psychosis; nitric oxide; neurodegeneration	3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; NITRIC-OXIDE; RAT-BRAIN; METHYLENEDIOXYMETHAMPHETAMINE MDMA; CHORIOCARCINOMA CELLS; NEUROTOXICITY; DOPAMINE; TRANSPORTER; NEURONS; RELEASE	The widely abused amphetamine analog 3,4-methylenedioxymethamphetamine (MDMA, also called ''ecstasy'') induces hallucination and psychostimulation, as well as long-term neuropsychiatric behaviors such as panic and psychosis, In rodents and monkeys, MDMA is cytotoxic to serotonergic neurons, but this is less clear with humans. Herein, MDMA was cytotoxic to human serotonergic JAR cells; it altered the cell cycle, increased G2/M phase arrest, and induced DNA fragmentation in a cycloheximide-sensitive way. Tills apoptosis was not observed in nonserotonergic human NMB cells, The stereospecific effect of amphetamines in JAR cells, and the key role of NO and dopamine in MDMA-induced apoptosis were determined. The relevancy of MDMA-induced cell death to drug users is discussed.			Simantov, R (corresponding author), WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL.							AZMITIA EC, 1990, BRAIN RES, V510, P97, DOI 10.1016/0006-8993(90)90732-Q; BENAZZI F, 1991, LANCET, V338, P1520, DOI 10.1016/0140-6736(91)92332-V; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BRODKIN J, 1993, PHARMACOL BIOCHEM BE, V45, P647, DOI 10.1016/0091-3057(93)90520-4; CALDWELL J, 1972, BIOCHEM J, V129, P11, DOI 10.1042/bj1290011; COMMINS DL, 1987, J PHARMACOL EXP THER, V241, P338; COOL DR, 1991, J BIOL CHEM, V266, P15750; CREIGHTON FJ, 1991, BRIT J PSYCHIAT, V159, P713, DOI 10.1192/bjp.159.5.713; FULLER RW, 1965, BIOCHEM PHARMACOL, V14, P483, DOI 10.1016/0006-2952(65)90221-2; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; GUDELSKY GA, 1994, EUR J PHARMACOL, V264, P325, DOI 10.1016/0014-2999(94)90669-6; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUANG XM, 1993, EUR J PHARMACOL, V238, P291, DOI 10.1016/0014-2999(93)90859-G; INSEL TR, 1989, J PHARMACOL EXP THER, V249, P713; JOHNSON MP, 1986, EUR J PHARMACOL, V132, P268; KELLAND MD, 1989, EUR J PHARMACOL, V169, P11, DOI 10.1016/0014-2999(89)90812-1; KING SC, 1992, BIOCHEM BIOPH RES CO, V183, P487, DOI 10.1016/0006-291X(92)90508-I; LEONARDI ETK, 1994, NEUROPSYCHOPHARMACOL, V10, P231, DOI 10.1038/npp.1994.26; LORRAIN DS, 1993, NEUROREPORT, V5, P87, DOI 10.1097/00001756-199310000-00024; MCCANN UD, 1993, J CLIN PSYCHOPHARM, V13, P214; MCCANN UD, 1991, J CLIN PSYCHOPHARM, V11, P302; MCGUIRE P, 1991, BRIT MED J, V302, P697, DOI 10.1136/bmj.302.6778.697; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OHEARN E, 1988, J NEUROSCI, V8, P2788; POGUN S, 1994, BRAIN RES, V641, P83, DOI 10.1016/0006-8993(94)91818-X; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RIAD M, 1994, J NEUROCHEM, V62, P2224; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; RICAURTE GA, 1988, JAMA-J AM MED ASSOC, V260, P51, DOI 10.1001/jama.260.1.51; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; RUDNICK G, 1993, MOL PHARMACOL, V43, P271; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; SCHIFANO F, 1991, LANCET, V338, P1335, DOI 10.1016/0140-6736(91)92633-D; SCHMIDT CJ, 1994, J NEUROCHEM, V62, P1382; SCHMIDT CJ, 1987, J PHARMACOL EXP THER, V240, P1; SCHMIDT CJ, 1992, EUR J PHARMACOL, V220, P151, DOI 10.1016/0014-2999(92)90743-N; SEIDEN LS, 1984, PHARMACOL BIOCHEM BE, V21, P29, DOI 10.1016/0091-3057(84)90125-4; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; SIMANTOV R, 1995, BIOCHEM PHARMACOL, V50, P435, DOI 10.1016/0006-2952(95)00068-B; SLIKKER W, 1988, TOXICOL APPL PHARM, V94, P448, DOI 10.1016/0041-008X(88)90285-2; SPRAGUE JE, 1994, LIFE SCI, V55, P1193, DOI 10.1016/0024-3205(94)00658-X; STEELE TD, 1994, ADDICTION, V89, P539, DOI 10.1111/j.1360-0443.1994.tb03330.x; STONE DM, 1986, EUR J PHARMACOL, V128, P41, DOI 10.1016/0014-2999(86)90555-8; WHITE SR, 1994, NEUROSCIENCE, V62, P41, DOI 10.1016/0306-4522(94)90313-1; WILSON MA, 1989, NEUROSCIENCE, V28, P121, DOI 10.1016/0306-4522(89)90237-6	49	74	78	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					141	146		10.1096/fasebj.11.2.9039956	http://dx.doi.org/10.1096/fasebj.11.2.9039956			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039956				2022-12-25	WOS:A1997WK50900006
J	Liu, Y; MoenneLoccoz, P; Loehr, TM; deMontellano, PRO				Liu, Y; MoenneLoccoz, P; Loehr, TM; deMontellano, PRO			Heme oxygenase-1, intermediates in verdoheme formation and the requirement for reduction equivalents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; RESONANCE RAMAN; CATALYTIC SITE; IX-ALPHA; HYPERBILIRUBINEMIA; PROTOPORPHYRIN; OXIDATION; COMPLEX; LIGAND; IRON	Conversion of heme to verdoheme by heme oxygenase-1 (HO-1) is thought to involve alpha-meso-hydroxylation and elimination of the meso-carbon as CO, a reaction supported by both H2O2 and NADPH-cytochrome P450 reductase/O-2. Anaerobic reaction of the heme-HO-1 complex with 1 eq of H2O2 produces an enzyme-bound intermediate identified by spectroscopic methods as alpha-meso-hydroxyheme, This is the first direct evidence for HO-1-catalyzed formation of alpha-meso-hydroxyheme. alpha-meso-Hydroxyheme exists as a mixture of Fe(III) phenolate, Fe(III) keto anion, and Fe(II) keto pi neutral radical resonance structures. EPR shows that complexation with CO enhances the Fe(II) pi neutral radical component. Reaction of the alpha-meso-hydroxyheme-HO-1 complex with O-2 generates Fe(III) verdoheme, which can be reduced in the presence of CO to the Fe(II) verdoheme-CO complex, Thus, conversion of alpha-meso-hydroxyheme to Fe(III) verdoheme, in contrast to a previous report (Matera, K. M., Takahashi, S., Fujii, H., Zhou, H., Ishikawa, K., Yoshimura, T., Rousseau, D. L., Yoshida, T., and Ikeda-Saito, M. (1996) J. Biol. Chem. 271, 6618-6624), does not require a reducing equivalent, An electron is only required to reduce ferric to ferrous verdoheme in the first step of its conversion to biliverdin.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOL BIOL,PORTLAND,OR 97291	University of California System; University of California San Francisco				MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM34468] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; BALCH AL, 1993, J AM CHEM SOC, V115, P1422, DOI 10.1021/ja00057a027; BOGUMIL R, 1995, BIOCHEMISTRY-US, V34, P10483, DOI 10.1021/bi00033a021; BONNETT R, 1987, J CHEM SOC PERK T 1, P1063, DOI 10.1039/p19870001063; Dolphin, 1979, PORPHYRINS, VVI, P257; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; JACKSON AH, 1968, J CHEM SOC C, P302, DOI 10.1039/j39680000302; KAPPAS A, 1988, PEDIATRICS, V81, P485; KITAGAWA T, 1994, COORDIN CHEM REV, V135, P685, DOI 10.1016/0010-8545(94)80081-2; Lipscomb J. D., 1983, Computer Enhanced Spectroscopy, V1, P11; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; MAINES MD, 1992, BIOCHIM BIOPHYS ACTA, V1131, P166, DOI 10.1016/0167-4781(92)90072-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P109; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MARKS GS, 1994, CELL MOL BIOL, V40, P863; MASUOKA N, 1987, BIOCHEMISTRY-US, V26, P3672, DOI 10.1021/bi00386a062; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MORISHIMA I, 1995, INORG CHEM, V34, P1528, DOI 10.1021/ic00110a035; RAMETTES RW, 1965, J AM CHEM SOC, V82, P5001; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SANO S, 1981, J AM CHEM SOC, V103, P2888, DOI 10.1021/ja00400a077; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TENHUNEN R, 1972, BIOCHEMISTRY-US, V11, P1716, DOI 10.1021/bi00759a029; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Torpey J, 1996, J AM CHEM SOC, V118, P9172, DOI 10.1021/ja9623469; Torpey J, 1996, J BIOL CHEM, V271, P26067, DOI 10.1074/jbc.271.42.26067; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; YONETANI T, 1987, J BIOL CHEM, V262, P9547; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHIDA T, 1980, J BIOCHEM-TOKYO, V88, P557, DOI 10.1093/oxfordjournals.jbchem.a133003; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	50	112	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6909	6917		10.1074/jbc.272.11.6909	http://dx.doi.org/10.1074/jbc.272.11.6909			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054378	hybrid			2022-12-25	WOS:A1997WN14700017
J	Baum, CL; Reschly, EJ; Gayen, AK; Groh, ME; Schadick, K				Baum, CL; Reschly, EJ; Gayen, AK; Groh, ME; Schadick, K			Sterol carrier protein-2 overexpression enhances sterol cycling and inhibits cholesterol ester synthesis and high density lipoprotein cholesterol secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEIN; APOLIPOPROTEIN-A-I; RAT-LIVER PEROXISOMES; PLASMA-MEMBRANE; HUMAN FIBROBLASTS; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; INTRACELLULAR CHOLESTEROL; NUCLEOTIDE-SEQUENCE	Recent data indicate that sterol carrier protein-a (SCP-S) functions in the rapid movement of newly synthesized cholesterol to the plasma membrane (Puglielli, L., Rigotti, A, Greco, A. V., Santos, M, J., and Nervi, F. (1995) J. Biol, Chem. 270, 18723-18726), In order to further characterize the cellular function of SCP-2, we transfected McA-RH7777 rat hepatoma cells with a preSCP-8 cDNA expression construct. In stable transfectants, pre-SCP-a processing resulted in an 8 fold increase in peroxisomal levels of SCP-S, SCP-2 overexpression increased the rates of newly synthesized cholesterol transfer to the plasma membrane and plasma membrane cholesterol internalization by 4-fold, There was no effect of SCP-2 overexpression on the microsomal levels of acyl-CoA:cholesterol acyltransferase and neutral cholesterol ester (CE) hydrolase; however, in the intact cell, CE synthesis and mass were reduced by 50% SCP 8 overexpression also reduced high density lipoprotein-cholesterol secretion and apoA-I gene expression by 70% and doubled the rate of plasma membrane desmosterol conversion to cholesterol, We conclude that SCP-2 overexpression enhances the rate of cholesterol cycling, which reduces the availability of cholesterol for CE synthesis and alters the activity of a cellular cholesterol pool involved in regulating apoA-I-mediated high density lipoprotein cholesterol secretion, The net result of these changes in cholesterol metabolism is a 46% increase in plasma membrane cholesterol content, the implications of which are discussed.	UNIV CHICAGO,GASTROENTEROL SECT,CHICAGO,IL 60637	University of Chicago	Baum, CL (corresponding author), UNIV CHICAGO,DEPT MED MC4080,CLIN NUTR RES UNIT,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.			Groh, Margaret/0000-0002-7473-597X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002118, P30DK026678, P30DK042086] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42086, DK26678, DK02118] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BAUM CL, 1993, J LIPID RES, V34, P729; BAUM CL, 1990, J BIOL CHEM, V265, P19263; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BILLHEIMER JT, 1990, DNA CELL BIOL, V9, P159, DOI 10.1089/dna.1990.9.159; BILLHEIMER JT, 1990, SUBCELLULAR BIOCH, P301; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOGUSKI MS, 1985, P NATL ACAD SCI USA, V82, P992, DOI 10.1073/pnas.82.4.992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHANDERBAHN R, 1993, BIOCHEM BIOPH RES CO, V117, P702; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDERBHAN RF, 1986, ENDOCR RES, V12, P351, DOI 10.3109/07435808609035445; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; GASIC GP, 1994, CELL, V7, P17; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GORGAS K, 1984, ANAT EMBRYOL, V169, P9, DOI 10.1007/BF00300582; GROH M, 1993, FASEB J, V7, pA566; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAMILTON RL, 1991, J LIPID RES, V32, P529; HENSLER ME, 1992, AM J PATHOL, V141, P707; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; Ito T, 1996, GASTROENTEROLOGY, V110, P1619, DOI 10.1053/gast.1996.v110.pm8613070; JOHNSON WJ, 1994, J LIPID RES, V35, P563; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; KALMBACH P, 1978, CELL BIOL INT REP, V2, P389, DOI 10.1016/0309-1651(78)90025-5; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KESAV S, 1992, BIOCHEM SOC T, V20, P818, DOI 10.1042/bst0200818; Kraemer R, 1995, J LIPID RES, V36, P2630; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; LYONS HT, 1991, ARCH BIOCHEM BIOPHYS, V285, P238, DOI 10.1016/0003-9861(91)90355-M; MANDEL H, 1995, J LIPID RES, V36, P1385; MANFRA DJ, 1995, PROTEIN EXPRES PURIF, V6, P196, DOI 10.1006/prep.1995.1025; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZZONE T, 1991, J LIPID RES, V32, P507; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; MCLEAN JW, 1983, J BIOL CHEM, V258, P8993; MCLEAN MP, 1995, ENDOCRINOLOGY, V136, P3360, DOI 10.1210/en.136.8.3360; MCNAMARA BC, 1989, ARCH BIOCHEM BIOPHYS, V275, P53, DOI 10.1016/0003-9861(89)90349-4; MENDISHANDAGAMA SMLC, 1990, ENDOCRINOLOGY, V127, P2947, DOI 10.1210/endo-127-6-2947; MENDISHANDAGAMA SMLC, 1995, TISSUE CELL, V27, P483, DOI 10.1016/S0040-8166(05)80056-4; MONGE JC, 1989, FEBS LETT, V243, P213, DOI 10.1016/0014-5793(89)80132-2; OSSENDORP BC, 1994, BIOCHEM BIOPH RES CO, V205, P1581, DOI 10.1006/bbrc.1994.2847; PASTUSZYN A, 1987, J BIOL CHEM, V262, P13219; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SEEDORF U, 1991, J BIOL CHEM, V266, P630; SELTMAN H, 1985, BIOCHEM J, V230, P19, DOI 10.1042/bj2300019; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; TANIMOTO Y, 1990, CARCINOGENESIS, V11, P1647, DOI 10.1093/carcin/11.9.1647; Thurberg BL, 1996, J BIOL CHEM, V271, P6062, DOI 10.1074/jbc.271.11.6062; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; Underwood KW, 1996, J LIPID RES, V37, P1556; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; VAHOUNY GV, 1985, CHEM PHYS LIPIDS, V38, P1; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1001, P243, DOI 10.1016/0005-2760(89)90106-9; VANHAREN L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P288; VANHEUSDEN GPH, 1985, BIOCHIM BIOPHYS ACTA, V846, P21, DOI 10.1016/0167-4889(85)90105-3; VANNOORT M, 1988, BIOCHEM BIOPH RES CO, V154, P60, DOI 10.1016/0006-291X(88)90649-3; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	80	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6490	6498		10.1074/jbc.272.10.6490	http://dx.doi.org/10.1074/jbc.272.10.6490			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045674	hybrid			2022-12-25	WOS:A1997WM64700058
J	Lemmon, MA; Pinchasi, D; Zhou, M; Lax, I; Schlessinger, J				Lemmon, MA; Pinchasi, D; Zhou, M; Lax, I; Schlessinger, J			Kit receptor dimerization is driven by bivalent binding of stem cell factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; LIGAND-BINDING; ACTIVATION; COMPLEX; OLIGOMERIZATION; PROTEINS; SITE	Most growth factors and cytokines activate their receptors by inducing dimerization upon binding. We have studied binding of the dimeric cytokine stem cell factor (SCF) to the extracellular domain of its receptor Kit, which is a receptor tyrosine kinase similar to the receptors for platelet derived growth factor and colony-stimulating factor-1. Calorimetric studies show that one SCF dimer binds simultaneously to two molecules of the Kit extracellular domain. Gel filtration and other methods show that this results in Kit dimerization. It has been proposed that SCF-induced Kit dimerization proceeds via a conformational change that exposes a key receptor dimerization site in the fourth of the five immunoglobulin (Ig)-like domains in Kit. We show that a form of Kit containing just the first three Ig domains (Kit-123) binds to SCF with precisely the same thermodynamic parameters as does Kit-12345. Analytical ultracentrifugation, light scattering, and gel filtration show that Kit-123 dimerizes upon SCF binding in a manner indistinguishable from that seen with Kit-12345. These data argue that the fourth Ig-like domain of Kit is not required for SCF-induced receptor dimerization and provide additional support for a model in which bivalent binding of the SCF dimer provides the driving force for Kit dimerization.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University				Lemmon, Mark/0000-0002-3379-5319				ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1992, J BIOL CHEM, V267, P10866; PHILO J, 1994, J BIOL CHEM, V269, P27840; Philo JS, 1996, J BIOL CHEM, V271, P6895, DOI 10.1074/jbc.271.12.6895; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P104; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; ZIERLER K, 1989, TRENDS BIOCHEM SCI, V14, P314, DOI 10.1016/0968-0004(89)90157-6	30	91	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6311	6317		10.1074/jbc.272.10.6311	http://dx.doi.org/10.1074/jbc.272.10.6311			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045650	hybrid			2022-12-25	WOS:A1997WM64700034
J	Mikhailenko, I; Krylov, D; Argraves, KM; Roberts, DD; Liau, G; Strickland, DK				Mikhailenko, I; Krylov, D; Argraves, KM; Roberts, DD; Liau, G; Strickland, DK			Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD) - High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; LDL RECEPTOR; PLATELET THROMBOSPONDIN; SURFACE PROTEOGLYCANS; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; MULTILIGAND RECEPTOR; APOLIPOPROTEIN-E; GENE FAMILY; 2 MEMBERS	Thrombospondin-1 (TSP-1) is a large modular trimeric protein that has been proposed to play a diverse role in biological processes. Newly synthesized TSP-1 either is incorporated into the matrix or binds to the cell surface where it is rapidly internalized and degraded. TSP-1 catabolism is mediated by the low density lipoprotein receptor-related protein (LRP), a large endocytic receptor that is a member of the low density lipoprotein receptor family. Using adenovirus-mediated gene transfer experiments, we demonstrate that the very low density lipoprotein receptor can also bind and internalize TSP 1. An objective of the current investigation was to identify the portion of TSP-1 that binds to these endocytic receptors. The current studies found that the amino terminal heparin binding domain (HBD, residues 1-214) of mouse TSP-1, when prepared as a fusion protein with glutathione S-transferase (GST), bound to purified LRP with an apparent K-D ranging from 10 to 25 nM. Recombinant HBD (rHBD) purified following proteolytic cleavage of GST-HBD, also bound to purified LRP, but with an apparent K-D of 830 nM. The difference in affinity was attributed to the fact that GST-HBD exists in solution as a dimer, whereas rHBD is a monomer. Like TSP-1, I-125-labeled GST-HBD or I-125-labeled rHBD were internalized and degraded by wild type fibroblasts that express LRP, but not by fibroblasts that are genetically deficient in LRP. The catabolism of both I-125-labeled GST-HBD and rHBD in wild type fibroblast was blocked by the 39-kDa receptor-associated protein, an inhibitor of LRP function. GST-HBD and rHBD both completely blocked catabolism of I-125-labeled TSP-1 in a dose dependent manner, as did antibodies prepared against the HBD. Taken together, these data provide compelling evidence that the amino-terminal domain of TSP-1 binds to LRP and thus the recognition determinants on TSP-1 for both LRP and for cell surface proteoglycans reside within the same TSP-1 domain. Further, high affinity binding of TSP-1 to LRP likely results from the trimeric structure of TSP-1.	AMER RED CROSS,HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855; AMER RED CROSS,HOLLAND LAB,DEPT MOL BIOL,ROCKVILLE,MD 20855; NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892; NCI,PATHOL LAB,NIH,BETHESDA,MD 20892	American Red Cross; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981	NHLBI NIH HHS [HL37510, HL50787] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037510] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BALE MD, 1986, J BIOL CHEM, V261, P862; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; DARDIK R, 1987, EUR J BIOCHEM, V168, P347, DOI 10.1111/j.1432-1033.1987.tb13426.x; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; ISAACS IJ, 1988, J BIOL CHEM, V263, P6709; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KREIGER M, 1994, ANNU REV BIOCHEM, V63, P601; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; OSHEA KS, 1990, J CELL BIOL, V111, P2713, DOI 10.1083/jcb.111.6.2713; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SCHAFER BM, 1994, AM J PATHOL, V144, P1269; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	59	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6784	6791		10.1074/jbc.272.10.6784	http://dx.doi.org/10.1074/jbc.272.10.6784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045712	hybrid			2022-12-25	WOS:A1997WM64700096
J	KamathLoeb, AS; Hizi, A; Kasai, H; Loeb, LA				KamathLoeb, AS; Hizi, A; Kasai, H; Loeb, LA			Incorporation of the guanosine triphosphate analogs 8-oxo-dGTP and 8-NH2-dGTP by reverse transcriptases and mammalian DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; MUTATIONAL SPECIFICITY; EXTENSION KINETICS; FIDELITY; HIV-1; BETA; INSERTION; INVITRO; 8-HYDROXYDEOXYGUANOSINE; 8-HYDROXYGUANINE	We have measured the efficiencies of utilization of 8-oxo-dGTP and 8-NH2-dGTP by human immunodeficiency virus type 1 and murine leukemia virus reverse transcriptases and compared them to those of DNA polymerases alpha and beta. Initially, we carried out primer extension reactions in the presence of dGTP or a dGTP analog and the remaining three dNTPs using synthetic DNA and RNA templates. These assays revealed that, in general, 8-NH2-dGTP is incorporated and extended more efficiently than 8-oxo-dGTP by all enzymes tested, Second, we determined rate constants for the incorporation of each analog opposite a template cytidine residue using steady state single nucleotide extension kinetics. Our results demonstrated the following. 1) Both reverse transcriptases incorporate the nucleotide analogs; discrimination against their incorporation is a function primarily of K-m or V-max depending on the analog and the enzyme, 2) Discrimination against the analogs is more stringent with the DNA template than with a homologous RNA template, 3) Polymerase or exhibits a mixed kinetic phenotype, with a large discrimination against 8-oxo-dGTP but a comparatively higher preference for 8-NH2-dGTP. 4) Polymerase beta incorporates both analogs efficiently; there is no discrimination with respect to K-m and a significantly lower discrimination with respect to V-max when compared with the other polymerases.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; TEL AVIV UNIV,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL; INST IND ECOL SCI,KITAKYUSHU,FUKUOKA 807,JAPAN	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Tel Aviv University					NATIONAL CANCER INSTITUTE [R35CA039903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038180] Funding Source: NIH RePORTER; NCI NIH HHS [CA39903] Funding Source: Medline; NIAID NIH HHS [AI38180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CHENG KC, 1992, J BIOL CHEM, V267, P166; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FRY M, 1986, ANIMAL CELL DNA POLY, P75; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LIN TS, 1985, J MED CHEM, V28, P1194, DOI 10.1021/jm00147a012; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; Poltev V I, 1990, J Mol Recognit, V3, P45, DOI 10.1002/jmr.300030105; POLTEV VI, 1993, J BIOMOL STRUCT DYN, V11, P293, DOI 10.1080/07391102.1993.10508727; PRESTON BD, 1986, P NATL ACAD SCI USA, V83, P8501, DOI 10.1073/pnas.83.22.8501; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sambrook J., 1989, MOL CLONING LAB REFE; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SINGER B, 1989, BIOCHEMISTRY-US, V28, P1478, DOI 10.1021/bi00430a008; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SODUM RS, 1993, CHEM RES TOXICOL, V6, P269, DOI 10.1021/tx00033a004; STALKER DM, 1976, BIOCHEMISTRY-US, V15, P3114, DOI 10.1021/bi00659a027; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TOPAL MD, 1982, P NATL ACAD SCI-BIOL, V79, P2211, DOI 10.1073/pnas.79.7.2211; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; YU H, 1992, J BIOL CHEM, V267, P10888	37	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5892	5898		10.1074/jbc.272.9.5892	http://dx.doi.org/10.1074/jbc.272.9.5892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038207	hybrid			2022-12-25	WOS:A1997WK74700075
J	Lee, KY; Helbing, CC; Choi, KS; Johnston, RN; Wang, JH				Lee, KY; Helbing, CC; Choi, KS; Johnston, RN; Wang, JH			Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; TUMOR-SUPPRESSOR PROTEIN; BRAIN-SPECIFIC ACTIVATOR; LARGE T-ANTIGEN; GENE-PRODUCT; TRANSGENIC MICE; TRANSCRIPTION FACTOR; NERVOUS-SYSTEM; CDC2 KINASE; RB PROTEIN	The tumor suppressor retinoblastoma protein (RE) plays a central role in cellular growth regulation, differentiation, and apoptosis. Phosphorylation of RR results in a consequent loss of its ability to inhibit cell cycle progression However, how RE: phosphorylation might be regulated in apoptotic or postmitotic cells, such as neurons, remains unclear. Here we report that neuronal Cdc2-like kinase (Nclk), composed of Cdk5 and a neuronal Cdk5 activator (p25(nck5a)), can bind and phosphorylate RE. Since RE has been shown recently to associate with D-type G(1) cyclins and viral oncoproteins through a common peptide sequence motif of LXCXE, Nclk binding may be mediated by a related sequence motif (LXCXXE) found in p25(nck5a). We demonstrate (i) in vitro binding of bacterially expressed p25(nck5a) to a GST-RB fusion protein, (ii) coprecipitation of GST-RB and reconstituted Cdk5 . p25(nck5a), and (iii) phosphorylation of GST-RB by bacterially expressed Cdk5 . p25(nck5a) kinase and by Cdk5 . p25(nck5a) kinase purified from bovine brain. Finally, we show that immunoprecipitation of RE from embryonic mouse brain homogenate results in the coprecipitation of Cdk5 and that Cdk5 kinase activity is maximal during late embryonic development, a period when programmed cell death of developing neurons is greatest, Taken together, these results suggest that NcIk can bind to and phosphorylate RE in vitro and in vivo. We infer that Nclk may play an important role in regulating the activity of RE in the brain, including perhaps in apoptosing neurons.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA; HONG KONG UNIV SCI & TECHNOL,DEPT BIOCHEM,HONG KONG,HONG KONG	University of Calgary; Hong Kong University of Science & Technology	Lee, KY (corresponding author), UNIV CALGARY,DEPT ANAT,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.		Johnston, Randal/B-9247-2009	Helbing, Caren/0000-0002-8861-1070				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAGO J, 1991, J NEUROSCI METH, V37, P251, DOI 10.1016/0165-0270(91)90031-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEEMH, 1996, P NATL ACAD SCI USA, V93, P3259; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN BTY, 1992, CIBA F SYMP, V170, P227; MATSUBARA M, 1996, J BIOL CHEM, V271, P21105; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; NEVINS JR, 1992, SCIENCE, V258, P424; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OKANO HJ, 1993, J NEUROSCI, V13, P2930; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; RADULESCU RT, 1995, MED HYPOTHESES, V44, P28, DOI 10.1016/0306-9877(95)90297-X; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SLARK RS, 1993, ONCOGENE, V8, P1585; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1996, COLD SPRING HARB C C, P13; TSAI LH, 1993, DEVELOPMENT, V119, P1029; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU X, 1995, THESIS U CALGARY	60	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5622	5626		10.1074/jbc.272.9.5622	http://dx.doi.org/10.1074/jbc.272.9.5622			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038171	hybrid			2022-12-25	WOS:A1997WK74700039
J	Proweller, A; Butler, JS				Proweller, A; Butler, JS			Ribosome concentration contributes to discrimination against poly(A)(-) mRNA during translation initiation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSTABLE MESSENGER-RNAS; XENOPUS-OOCYTES; POSSIBLE INVOLVEMENT; PROTEIN-SYNTHESIS; YEAST; STABILITY; POLYADENYLATION; DEADENYLATION; MATURATION; SUBUNITS	Inactivation of Saccharomyces cerevisiae poly(A) polymerase in a strain bearing the temperature-sensitive lethal pap1-1 mutation results in the synthesis of poly(A)(-) mRNAs that initiate translation with surprising efficiency. Translation of poly(A)(-) mRNAs after polyadenylation shut-off might result from an increase in the ratio of ribosomes and associated translation factors to mRNA, caused by the inability of poly(A)(-) mRNAs to accumulate to normal levels, To test this hypothesis, we used ribosomal subunit protein gene mutations to decrease either 40 or 60 S ribosomal subunit concentrations in strains carrying the pap1-1 mutation, Polyadenylation shut-off in such cells results in a nearly normal ratio of ribosomes to mRNA as revealed by polyribosome sedimentation analysis. Ribonuclease protection and Northern blot analyses showed that a significant percentage of poly(A)-deficient and poly(A)(-) mRNA associate with smaller polyribosomes compared with cells with normal ribosome levels, Analysis of the ratio of poly(A)-deficient and poly(A)(-) forms of a specific mRNA showed relatively more poly(A)- mRNA sedimenting with 20-60 S complexes than do poly(A)i forms, suggesting a block in an early step of the translation initiation of the poly(A)(-) transcripts. These findings support models featuring the poly(A) tail as an enhancer of translation and suggest that the full effect of a poly(A) tail on the initiation strength of a mRNA may require competition for a limited number of free ribosomes or translation factors.	UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA	University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356] Funding Source: NIH RePORTER; NIAID NIH HHS [5-T32-AI070362] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07356] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; ABOVICH N, 1985, MOL CELL BIOL, V5, P3429, DOI 10.1128/MCB.5.12.3429; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; DESHPANDE AK, 1979, J BIOL CHEM, V254, P8937; DOEL MT, 1976, CELL, V8, P51, DOI 10.1016/0092-8674(76)90184-7; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; DWORKIN MB, 1985, DEV BIOL, V112, P451, DOI 10.1016/0012-1606(85)90417-8; GALILI G, 1988, J BIOL CHEM, V263, P5764; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Hatfield L, 1996, MOL CELL BIOL, V16, P5830; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HUEZ G, 1981, P NATL ACAD SCI-BIOL, V78, P908, DOI 10.1073/pnas.78.2.908; JACOBSON A, 1983, NUCLEIC ACIDS RES, V11, P6353, DOI 10.1093/nar/11.18.6353; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LASKEY RA, 1977, CELL, V11, P345, DOI 10.1016/0092-8674(77)90051-4; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; NAM HG, 1986, MOL CELL BIOL, V6, P1535, DOI 10.1128/MCB.6.5.1535; NEMER M, 1975, CELL, V6, P559, DOI 10.1016/0092-8674(75)90046-X; NUDEL U, 1976, EUR J BIOCHEM, V64, P115, DOI 10.1111/j.1432-1033.1976.tb10279.x; OHTAKE Y, 1995, MOL CELL BIOL, V15, P2772; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PALATNIK CM, 1984, CELL, V36, P1017, DOI 10.1016/0092-8674(84)90051-5; Proweller A, 1996, J BIOL CHEM, V271, P10859, DOI 10.1074/jbc.271.18.10859; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SIMON R, 1992, GENE DEV, V6, P2580, DOI 10.1101/gad.6.12b.2580; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; VARUM SM, 1992, GENE DEV, V4, P2270; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VIND J, 1993, J MOL BIOL, V231, P678, DOI 10.1006/jmbi.1993.1319; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	47	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6004	6010		10.1074/jbc.272.9.6004	http://dx.doi.org/10.1074/jbc.272.9.6004			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038222	hybrid			2022-12-25	WOS:A1997WK74700090
J	Garland, JM; Halestrap, A				Garland, JM; Halestrap, A			Energy metabolism during apoptosis - bcl-2 promotes survival in hematopoietic cells induced to apoptose by growth factor withdrawal by stabilizing a form of metabolic arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; HEAT-SHOCK; DEATH; PROTECTS; AGENTS; PHOSPHORYLATION; INTERLEUKIN-3; ACTIVATION; MEMBRANE; STRESS	We have investigated cell metabolism during apoptosis in the murine interleukin-3 (IL-3) dependent cell line Po and two derivative clones (B14 and B15) overexpressing human bcl-2a. On removal of IL-3, Bo cells underwent apoptosis within 8 h, whereas B14 and B15 cells were resistant for at least 24 h. Metabolically, Bo, B14, and B15 cells were indistinguishable from each other. All were insensitive to mitochondrial poisons, derived ATP entirely by glycolysis, and maintained similar mitochondrial membrane potentials measured by rhodamine-123 fluorescence with or without IL-3. All virtually ceased glycolysis and production of lactic acid on IL-3 withdrawal but maintained intracellular [ATP] until in Po cultures the cells began to apoptose. B14 and B15 cells became glycolytically arrested but maintained stable ATP levels during protection from apoptosis. Depletion of intracellular ATP by uncoupling the mitochondrial ATPase with 2,4-dinitrophenol or carbonyl cyanide p-trifluoromethoxyphenylhydrazone induced apoptosis in Eo cells with or without IL-3, but not in B14 or B15 cells. bcl-2-overexpressing cells were recoverable with high plating efficiency even after prolonged exposure to 2,4-dinitrophenol. We conclude that IL-3 withdrawal leads to arrest of energy metabolism in which ATP levels are maintained. In Bo cells this is followed by apoptosis, whereas in bcl-2-overexpressing cells this state is stably prolonged. ATP depletion is a strong apoptotic signal which overrides IL-3 signaling in normal cells but is ineffective in bcl-2-overexpressing cells. Prolonged metabolic arrest and resistance to ATP depletion facilitated by bcl-2 are both reversible, Persistent reversible meta belie dormancy would provide cells with a survival advantage in nonsustainable environments (e.g. hypoxia or substrate lack) and suggests a mechanism for the survival advantage displayed by cells overexpressing bcl-2.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	Garland, JM (corresponding author), UNIV EXETER,FORCE,CANC RES LABS,ROYAL DEVON & EXETER HOSP,CLIN SCI INST,EXETER EX2 5DW,DEVON,ENGLAND.		Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778				ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bucher T, 1963, METHOD ENZYMAT AN, P253; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COLLINS M, 1993, TRENDS BIOCHEM SCI, V318, P307; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DARZYNKIEWICZ Z, 1981, P NATL ACAD SCI-BIOL, V78, P2383, DOI 10.1073/pnas.78.4.2383; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FOLKMAN J, 1993, CANC MED, P153; FREEMAN KB, 1983, EUR J BIOCHEM, V134, P215, DOI 10.1111/j.1432-1033.1983.tb07553.x; GARLAND JM, 1988, LEUKEMIA, V2, P476; GARLAND JM, 1984, LYMPHOKINES, V9, P153; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JAIN RK, 1987, CANCER METAST REV, V6, P559, DOI 10.1007/BF00047468; JAIN RK, 1988, CANCER RES, V48, P2641; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LIZARD G, 1995, CYTOMETRY, V21, P275, DOI 10.1002/cyto.990210308; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marchetti P, 1996, CANCER RES, V56, P2033; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENS CWI, 1965, BIOCHEM J, V94, P705, DOI 10.1042/bj0940705; PALACIOS R, 1984, P NATL ACAD SCI-BIOL, V81, P1208, DOI 10.1073/pnas.81.4.1208; QUINLAN PT, 1986, BIOCHEM J, V236, P789, DOI 10.1042/bj2360789; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	47	135	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4680	4688		10.1074/jbc.272.8.4680	http://dx.doi.org/10.1074/jbc.272.8.4680			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030519	hybrid			2022-12-25	WOS:A1997WJ85500007
J	Hasegawa, T; Takeuchi, A; Miyaishi, O; Isobe, K; deCrombrugghe, B				Hasegawa, T; Takeuchi, A; Miyaishi, O; Isobe, K; deCrombrugghe, B			Cloning and characterization of a transcription factor that binds to the proximal promoters of the two mouse type I collagen genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; DNA-BINDING; REGULATORY FACTORS; TRANSGENIC MICE; EXPRESSION; ALPHA-2(I); YEAST; SITE; RECOGNITION; ALPHA-1(I)	We have used the yeast one-hybrid system to clone transcription factors that bind to specific sequences in the proximal promoters of the type I collagen genes. We utilized as bait the sequence between -180 and -136 in the pro-alpha 2(I) collagen promoter because it acts as a functional promoter element and binds several DNA-binding proteins. Three cDNA clones were isolated that encoded portions of the mouse SPR2 transcription factor, whereas a fourth cDNA contained a potential open reading frame for a polypeptide of 775 amino acids and was designated BFCOL1. Recombinant BFCOL1 was shown to bind to the -180 to -152 segment of the mouse pro-cua(I) collagen proximal promoter and to two discrete sites in the proximal promoter of the mouse pro-alpha 1(I) gene. The N-terminal portion of BFCOL1 contains its DNA-binding domain. DNA transfection experiments using fusion polypeptides with the yeast GAL4 DNA-binding segment indicated that the C-terminal part of BFCOL1 contained a potential transcriptional activation domain. We speculate that BBCOL1 participates in the transcriptional control of the two type I collagen genes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030; NATL INST LONGEV SCI,DEPT BASIC GERONTOL,OBU,AICHI 474,JAPAN	University of Texas System; UTMD Anderson Cancer Center			Takeuchi, Akihide/AAT-4675-2020; isobe, ken-ichi/A-6685-2011	Takeuchi, Akihide/0000-0002-2781-0180; isobe, ken-ichi/0000-0002-8150-2496	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041264, R01HL141264] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NHLBI NIH HHS [HL41264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HARPER JW, 1993, CELL, V75, P805; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PAVLIN D, 1992, J CELL BIOL, V116, P226; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMIDT A, 1986, MOL CELL BIOL, V6, P347, DOI 10.1128/MCB.6.2.347; SIKORSKI RS, 1989, GENETICS, V122, P19; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	30	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4915	4923		10.1074/jbc.272.8.4915	http://dx.doi.org/10.1074/jbc.272.8.4915			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030551	hybrid			2022-12-25	WOS:A1997WJ85500039
J	Muda, M; Boschert, U; Smith, A; Antonsson, B; Gillieron, C; Chabert, C; Camps, M; Martinou, I; Ashworth, A; Arkinstall, S				Muda, M; Boschert, U; Smith, A; Antonsson, B; Gillieron, C; Chabert, C; Camps, M; Martinou, I; Ashworth, A; Arkinstall, S			Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; MAP KINASE; TYROSINE-PHOSPHATASE; GROWTH-FACTOR; HEAT-SHOCK; CHROMOSOMAL LOCALIZATION; MAMMALIAN-CELLS; STRESS; EXPRESSION	Extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and p38/RK/CSBP (p38) mitogen-activated protein (MAP) kinases are target enzymes activated by a wide range of cell-surface stimuli, Recently, a distinct class of dual specificity phosphatase has been shown to reverse activation of MAP kinases by dephosphorylating critical tyrosine and threonine residues, By searching the expressed sequence tag data base (dbEST) for homologues of known dual specificity phosphatases, we identified a novel partial human sequence for which we isolated a full-length cDNA (termed MKP-4). The deduced amino acid sequence of MKP-4 is most similar to MKP-X/PYST2 (61% identity) and MKP-3/PYST1 (57% identity), includes two N-terminal CH2 domains homologous to the cell cycle regulator Cdc25 phosphatase, and contains the extended active site sequence motif VXVHCXAGXSRSXTX(3)AYLM (where X is any amino acid) conserved in dual specificity phosphatases, MKP-4 produced in Escherichia coli catalyzes vanadate-sensitive breakdown of p-nitrophenyl phosphate as well as in vitro inactivation of purified ERK2. When expressed in COS-7 cells, MKP-4 blocks activation of MAP kinases with the selectivity ERK > p38 = JNK/SAPK. This cellular specificity is similar to MKP-3/PYST1, although distinct from hVH-5/M3-6 (JNK/SAPK = p38 >>> ERK). Northern analysis reveals a highly restricted tissue distribution with a single MKP-4 mRNA species of approximately 2.5 kilobases detected only in placenta, kidney, and embryonic liver, Immunocytochemical analysis showed MKP-4 to be present within cytosol although punctate nuclear staining co-localizing with promyelocytic protein was also observed in a subpopulation (10-20%) of cells. Chromosomal localization by analysis of DNAs from human/rodent somatic cell hybrids and a panel of radiation hybrids assign the human gene for MKP-4 to Xq28., The identification and characterization of MKP-4 highlights the emergence of an expanding family of structurally homologous dual specificity phosphatases possessing distinct MAP kinase specificity and subcellular localization as well as diverse patterns of tissue expression.	GLAXO WELLCOME RES & DEV LTD, GENEVA BIOMED RES INST, CH-1228 PLAN LES OUATES, GENEVA, SWITZERLAND; INST CANC RES, CHESTER BEATTY LABS, CTR CELL & MOL BIOL, CANC RES CAMPAIGN, LONDON SW3 6JB, ENGLAND	GlaxoSmithKline; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Camps, Montserrat/0000-0002-9849-8657				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE MS, 1995, BIOCHIM BIOPHYS ACTA, V1265, P152; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS S, 1992, EMBO J, V1, P569; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA A, 1996, SCIENCE, V270, P1326; XIAOZONG W, 1996, SCIENCE, V272, P1347; YI HF, 1995, GENOMICS, V28, P92, DOI 10.1006/geno.1995.1110; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	69	132	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5141	5151		10.1074/jbc.272.8.5141	http://dx.doi.org/10.1074/jbc.272.8.5141			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030581	hybrid			2022-12-25	WOS:A1997WJ85500069
J	OMalley, KM; Nair, SA; Rubin, H; Cooperman, BS				OMalley, KM; Nair, SA; Rubin, H; Cooperman, BS			The kinetic mechanism of serpin proteinase complex formation - An intermediate between the Michaelis complex and the inhibited complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; PROMOTING FACTOR; ACTIVE-SITE; CENTER LOOP; THROMBIN; BINDING	Serine proteinase inhibitors (serpins) form enzymatically inactive, 1:1 complexes (denoted E*I*) with their target proteinases that release free enzyme and cleaved inhibitor only very slowly. The mechanism of E*I* formation is incompletely understood and continues to be a source of controversy. Kinetic evidence exists that formation of E*I* proceeds via a Michaelis complex (E . I) and so involves at least two steps. In this paper, we determine the rate of E*I* formation from alpha-chymotrypsin and alpha(1)-antichymotrypsin using two approaches: first, by stopped-flow spectrofluorometric monitoring of the fluorescent change resulting from reaction of alpha-chymotrypsin with a fluorescent derivative of alpha(1)-antichymotrypsin (derivatized at position P7 of the reactive center loop); and second, by a rapid mixing/quench approach and SDS-polyacrylamide gel electrophoresis analysis. In some cases, serpins are both substrates and inhibitors of the same enzyme. Our results indicate the presence of an intermediate between E . I and E*I* and suggest that the partitioning step between inhibitor and substrate pathways precedes P1-P1' cleavage.	UNIV PENN, SCH MED, DEPT CHEM, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL 50523] Funding Source: Medline; NIA NIH HHS [AG 10599] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS PA, 1977, BIOCHEM J, V161, P83, DOI 10.1042/bj1610083; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1982, J BIOL CHEM, V257, P9487; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCH M, 1989, BIOCHEM J, V259, P929, DOI 10.1042/bj2590929; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; FARINOTTI R, 1983, J CHROMATOGR, V269, P81, DOI 10.1016/S0021-9673(01)90788-5; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P168; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIEBERMAN J, 1995, NEUROBIOL AGING, V16, P747, DOI 10.1016/0197-4580(95)00056-K; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PEEHL DM, 1995, CANCER-AM CANCER SOC, V75, P2021, DOI 10.1002/1097-0142(19950401)75:7+<2021::AID-CNCR2820751644>3.0.CO;2-R; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCALIA R, 1995, SHOCK, V4, P251, DOI 10.1097/00024382-199510000-00004; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Song HK, 1995, FEBS LETT, V377, P150; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652	50	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5354	5359		10.1074/jbc.272.8.5354	http://dx.doi.org/10.1074/jbc.272.8.5354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030611	hybrid			2022-12-25	WOS:A1997WJ85500099
J	Wong, VV; Glass, DJ; Arriaga, R; Yancopoulos, GD; Lindsay, RM; Conn, G				Wong, VV; Glass, DJ; Arriaga, R; Yancopoulos, GD; Lindsay, RM; Conn, G			Hepatocyte growth factor promotes motor neuron survival and synergizes with ciliary neurotrophic factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; SCATTER FACTOR; C-MET; POSTMITOTIC NEURONS; TYROSINE KINASE; FACTOR RECEPTOR; MAH CELLS; LIMB BUD; VINCRISTINE; EXPRESSION	Hepatocyte growth factor (HGF) has been shown to function as a potent mitogen for a variety of cells, transducing its signal through the c-met tyrosine kinase receptor. Ciliary neurotrophic factor (CNTF) is a cytokine that has been shown to promote survival of motor neurons. We show here that c-met mRNA is present in the embryonic rat spinal cord. Peak expression of c-met (at E14) coincides with the period of naturally occurring cell death in motor neurons, suggesting a possible role of HGF in the regulation of this process. Utilizing a neuron-enriched culture system, we established that HGF, like CNTF, stimulates choline acetyltransferase (CAT) activity in motor neurons. When co administered to motor neuron cultures, saturating concentrations of HGF and CNTF produced a synergistic increase in CAT levels. We show that this synergy reflects enhanced motor neuron survival. Exposure of motor neuron cultures to the cytostatic agent vincristine markedly decreased CAT levels; co treatment with HGF and CNTF (but not either factor alone) restored CAT activity to control levels. Our findings indicate that HGF is a survival factor for motor neurons, that it acts synergistically with CNTF, and that HGF and CNTF can together be neuroprotective in the face of vincristine toxicity.			Wong, VV (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Glass, David/AAI-3910-2021; Lindsay, Ronald/GQP-8001-2022; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				APFEL SC, 1993, ANN NY ACAD SCI, V692, P243; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADLEY WG, 1970, J NEUROL SCI, V10, P107, DOI 10.1016/0022-510X(70)90013-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGREGORIO F, 1989, MUSCLE NERVE, V12, P1017, DOI 10.1002/mus.880121210; DIRENZO MF, 1993, ONCOGENE, V8, P219; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FALETTO DL, 1993, HEPATOCYTE GROWTH FA, P107; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; Hamanoue M, 1996, J NEUROSCI RES, V43, P554, DOI 10.1002/(SICI)1097-4547(19960301)43:5<554::AID-JNR5>3.0.CO;2-H; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JENNISCHE E, 1993, AM J PHYSIOL, V265, pC122, DOI 10.1152/ajpcell.1993.265.1.C122; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KMIECIK TE, 1992, BLOOD, V80, P2454; KRASNOSELSKY A, 1994, J NEUROSCI, V14, P7284; LEGHA SS, 1986, MED TOXICOL ADV DRUG, V1, P421, DOI 10.1007/BF03259853; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MCLEOD JG, 1969, J NEUROL NEUROSUR PS, V32, P297, DOI 10.1136/jnnp.32.4.297; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; NAKAYAMA H, 1989, BIOCHEM BIOPH RES CO, V163, P967; NALDINI L, 1991, ONCOGENE, V6, P501; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; OPPENHEIM RW, 1993, J NEUROBIOL, V24, P1965; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STENR CD, 1993, HEPATOCYTE GROWTH FA, P369; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; UAHARA Y, 1995, NATURE, V373, P702; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; VERDI JM, 1994, P NATL ACAD SCI USA, V91, P3949, DOI 10.1073/pnas.91.9.3949; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; Wong V., 1994, Molecular Biology of the Cell, V5, p465A; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	43	81	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5187	5191		10.1074/jbc.272.8.5187	http://dx.doi.org/10.1074/jbc.272.8.5187			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030587	hybrid			2022-12-25	WOS:A1997WJ85500075
J	Ho, GY; Chisholm, RL				Ho, GY; Chisholm, RL			Substitution mutations in the myosin essential light chain lead to reduced actin-activated ATPase activity despite stoichiometric binding to the heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; DICTYOSTELIUM-DISCOIDEUM MYOSIN; SCANNING MUTAGENESIS; ANGSTROM RESOLUTION; SCALLOP MYOSIN; MOTOR DOMAIN; GENE; EXPRESSION; INVITRO; PHOSPHORYLATION	Myosin essential light chain (ELC) wraps around an alpha-helix that extends from the myosin head, where it is believed to play a structural support role. To identify other role(s) of the ELC in myosin function, we have used an alanine scanning mutagenesis approach to convert charged residues in loops I, II, III, and helix G of the Dictyostelium ELC into uncharged alanines, Dictyostelium was used as a host system to study the phenotypic and biochemical consequences associated with the mutations, The ELC carrying loop mutations bound with normal stoichiometry to the myosin heavy chain when expressed in ELC-minus cells. When expressed in wild type cells these mutants competed efficiently with the endogenous ELC for binding, suggesting that the affinity of their interaction with the heavy chain is comparable to that of wild type, However, despite apparently normal association of ELC the cells still exhibited a reduced efficiency to undergo cytokinesis in suspension. Myosin purified from these cells exhibited 4-5-fold reduction in actin-activated ATPase activity and a decrease in motor function as assessed by an in vitro motility assay, These results suggest that the ELC contributes to myosin's enzymatic activity in addition to providing structural support for the Lu-helical neck region of myosin heavy chain.	NORTHWESTERN UNIV, SCH MED, DEPT MOL & CELL BIOL, CHICAGO, IL 60611 USA	Northwestern University			Chisholm, Rex L/B-3418-2009	Chisholm, Rex L/0000-0002-5638-3990	NIGMS NIH HHS [GM-39264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039264] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHEN TLL, 1995, J CELL SCI, V108, P3207; CHISHOLM RL, 1988, MOL CELL BIOL, V8, P794, DOI 10.1128/MCB.8.2.794; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIFFARD RG, 1983, J MUSCLE RES CELL M, V4, P115, DOI 10.1007/BF00711962; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HO GY, 1995, J BIOL CHEM, V270, P27977, DOI 10.1074/jbc.270.46.27977; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; HYNES TR, 1987, CELL, V48, P953, DOI 10.1016/0092-8674(87)90704-5; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KING SM, 1986, METHOD ENZYMOL, V134, P291; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; POLLENZ RS, 1991, CELL MOTIL CYTOSKEL, V20, P83, DOI 10.1002/cm.970200202; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SIVARAMAKRISHNAN M, 1982, J BIOL CHEM, V257, P1102; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAN JL, 1991, J BIOL CHEM, V266, P16044; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WERTMAN KF, 1992, GENETICS, V132, P337; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	55	27	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4522	4527		10.1074/jbc.272.7.4522	http://dx.doi.org/10.1074/jbc.272.7.4522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020178	hybrid			2022-12-25	WOS:A1997WH01900094
J	Chang, JY; Xia, WY; Shao, RP; Sorgi, F; Hortobagyi, GN; Huang, L; Hung, MC				Chang, JY; Xia, WY; Shao, RP; Sorgi, F; Hortobagyi, GN; Huang, L; Hung, MC			The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer	ONCOGENE			English	Article						HER-2/neu; E1A; gene therapy; adenoviral vector; cationic liposome	PROTEINS INDUCE APOPTOSIS; GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-PRODUCTS; NONHUMAN-PRIMATES; OVARIAN-CANCER; POOR SURVIVAL; EXPRESSION; METASTASIS; CELLS	The HER-2/neu proto-oncogene is frequently amplified or overexpressed in human breast and ovarian cancers, and is significantly correlated with shorter survival, We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can repress HER-2/neu overexpression by repressing HER-2/neu promoter activity, and suppress the tumorigenic potential of HER-2/neu-overexpressing ovarian cancer cells, To examine E1A tumor suppressor function in breast cancer, we transduced E1A in vitro by adenovirus into both HER-2/neu-overexpressing and low expressing human breast cancer cell lines, In HER-2/neu-overexpressing cells, E1A greatly inhibited tumor cell growth in vitro, However, in HER-2/neu low expressing cancer cell lines, E1A had no significant effect on cell growth in culture medium, To test the therapeutic efficacy of E1A, we used both adenovirus-mediated and cationic liposome-mediated E1A gene delivery systems in an orthotopic breast cancer animal model, An advanced breast cancer model was established by inoculation of HER-2/neu-overexpressing human breast cancer cells in mammary fat pad and treated by local injections of either replication-deficient adenovirus expressing EIA, Ad.E1A(+) or a liposome-E1A DNA complex, As controls, mice bearing tumors were also treated with Ad.E1A(-) which is virtually the same adenovirus as Ad.E1A(+) except that EIA is deleted, a liposome-E1A frame-shift mutant DNA complex, or just PBS, In mice bearing a HER-2/neu-overexpressing breast cancer cell line, EIA delivered either by adenovirus or liposome significantly inhibited tumor growth and prolonged mouse survival compared with the controls, In fact, 60-80% of E1A-treated mice lived longer than 2 years versus only 0-20% of control mice (P<0.05), Western blot analysis showed that E1A protein was expressed in tumor tissue and immunohistochemical analysis showed that HER-2/neu p185 protein expression was suppressed, Taken together, our results indicated that both adenovirus and cationic liposome delivery systems were effective in transfering EIA gene for tumor suppression in a HER-2/neu-overexpressing breast cancer model.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BREAST & GYNECOL MED ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, P01CA059327] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, CA59327, R01-CA60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHANG JY, 1996, IN PRESS ONCOGENE; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KERN JA, 1990, CANCER RES, V50, P5284; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PARKER SE, 1995, HUM GENE THER, V6, P575, DOI 10.1089/hum.1995.6.5-575; PATERSON MC, 1991, CANCER RES, V51, P556; PRESS MF, 1993, CANCER RES, V53, P5675; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TEODORO JG, 1995, ONCOGENE, V11, P467; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YONEMURA Y, 1991, CANCER RES, V51, P1034; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P1947	38	80	83	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					561	568		10.1038/sj.onc.1200861	http://dx.doi.org/10.1038/sj.onc.1200861			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053854				2022-12-25	WOS:A1997WF52400007
J	Terradillos, O; Billet, O; Renard, CA; Levy, R; Molina, T; Briand, P; Buendia, MA				Terradillos, O; Billet, O; Renard, CA; Levy, R; Molina, T; Briand, P; Buendia, MA			The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice	ONCOGENE			English	Article						hepatitis B virus; hepatocellular carcinoma; transactivation; oncogene; apoptosis	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; HBX GENE; IN-VIVO; PROTEIN; ACTIVATION; EXPRESSION	The hepatitis B virus X protein (HBx) is thought to be implicated in the development of hepatocellular carcinoma, but its exact function remains controversial, Transgenic mice from PEX7 and AX16 lineages that express HBx in the liver under control of different viral regulatory elements develop no liver pathology (Billet ed al., 1995), We have crossed these two mouse lineages with WHV/c-myc oncomice in which liver-specific expression of c-myc driven by woodchuck hepatitis virus (WHV) regulatory sequences causes liver cancer in all animals, The average tumor latency was shortened by 2 to 3 months in bitransgenic animals from all populations compared with simple c-myc transgenic littermates, At preneoplastic stages, adult bitransgenic mice showed four to fivefold enhanced expression of the c-myc transgene, increased hepatocyte proliferation and more extensive liver lesions compared with simple WHV/c-myc transgenics, Thus in this model, HBx alone has no direct pathological effect but it is shown to accelerate tumor development induced by c-myc. The data presented here firmly establish the oncogenic potential of HBx, apparently acting as a tumor promoter, This model offers unique opportunities to investigate the mechanisms by which HBx trans-activates the expression of target genes and deregulates the hepatocyte growth control in vivo.	INST PASTEUR,DEPT RETROVIRUS,INSERM U163,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS 15,FRANCE; INST COCHIN GENET MOL,INSERM U380,UNITE GENET & PATHOL EXPT,F-75014 PARIS,FRANCE; UNIV PARIS,HOTEL DIEU,FAC BROUSSAIS,LAB RECH HISTOPATHOL,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BALSANO C, 1993, ARCH VIROL         S, V8, P63; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DUFLOT A, 1995, HEPATOLOGY, V21, P1483, DOI 10.1016/0270-9139(95)90448-4; ETIEMBLE J, 1994, ONCOGENE, V9, P727; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1990, ONCOGENE, V5, P867; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GU JR, 1986, J CELL PHYSL S, V4, P13; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HIMENO Y, 1988, LIVER, V8, P208; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KAY A, 1991, J MED VIROL, V33, P228, DOI 10.1002/jmv.1890330404; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOSHY R, 1991, ADV AP BIOT, V13, P159; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MURAKAMI H, 1993, CANCER RES, V53, P1719; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1994, ONCOGENE, V9, P2837; OGSTON CW, 1982, CELL, V29, P385, DOI 10.1016/0092-8674(82)90155-6; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PERFUMO S, 1992, J VIROL, V66, P6819, DOI 10.1128/JVI.66.11.6819-6823.1992; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TRUANT R, 1995, J VIROL, V69, P1951; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wei Y, 1996, J GEN VIROL, V77, P177, DOI 10.1099/0022-1317-77-2-177; WEI Y, 1995, J MED VIROL, V45, P82, DOI 10.1002/jmv.1890450116; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; Yen BTS, 1996, J BIOMED SCI, V3, P20; ZHANG XK, 1990, ONCOGENE, V5, P909; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	71	239	259	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					395	404		10.1038/sj.onc.1200850	http://dx.doi.org/10.1038/sj.onc.1200850			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053836				2022-12-25	WOS:A1997WE36400002
J	Svistunenko, DA; Patel, RP; Voloshchenko, SV; Wilson, MT				Svistunenko, DA; Patel, RP; Voloshchenko, SV; Wilson, MT			The globin-based free radical of ferryl hemoglobin is detected in normal human blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; HYDROGEN-PEROXIDE; COVALENT BINDING; RAT-HEART; MYOGLOBIN; OXIDATION; METMYOGLOBIN; CHLORPROMAZINE; METHEMOGLOBIN; OXYHEMOGLOBIN	Normal human venous blood was studied by electron paramagnetic resonance (EPR) spectroscopy at -196 degrees C. The EPR signal of free radicals in frozen blood is shown to have the same radiospectroscopic parameters and properties as the signal of the globin based free radical, 'Hb(Fe(IV)=O), formed in the reaction of purified methemoglobin (metHb) with H2O2 and therefore has been assigned as such. The globin-based radicals and metHb exhibited significant variation (fluctuations) in different frozen samples taken from the same liquid blood sample. In any given sample a high concentration of free radicals was associated with a low concentration of metHb and vice versa, i.e. the fluctuations were always of opposite sense. No such fluctuations were observed in the concentration of two other paramagnetic components of blood, transferrin and ceruloplasmin. The time course of free radical formation and decay upon the addition of H2O2 to purified metHb was studied at three different molar ratios H2O2/metHb. This kinetic study together with the results of an annealing experiment allow us to propose a mechanism for the formation and decay of the globin-based radical in blood. Within this mechanism, the source of H2O2 in blood is considered to be dismutation of O-2(radical anion) radicals produced via autoxidation of Db. We postulate that the dismutation is intensified on the phase separation surfaces during cooling and freezing of a blood sample. The fluctuations are explained within this hypothesis.	UNIV ESSEX, DEPT CHEM & BIOL SCI, COLCHESTER CO4 3SQ, ESSEX, ENGLAND; RUSSIAN ACAD SCI, INST CHEM PHYS, CHIMBIO DEPT, MOSCOW 117977, RUSSIA	University of Essex; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences				Patel, Rakesh/0000-0002-1526-4303; Svistunenko, Dimitri/0000-0001-8060-2738	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASA R, 1972, BIOCHEM BIOPH RES CO, V49, P806, DOI 10.1016/0006-291X(72)90482-2; ARDUINI A, 1990, FREE RADICAL BIO MED, V9, P511, DOI 10.1016/0891-5849(90)90130-B; Balagopalakrishna C, 1996, BIOCHEMISTRY-US, V35, P6393, DOI 10.1021/bi952875+; BENNETT JE, 1957, PROC R SOC LON SER-A, V240, P67, DOI 10.1098/rspa.1957.0067; BLUMENFELD LA, 1964, MECH KINETICS FERMEN, P83; BLUMENFELD LA, 1968, STUD BIOPHYS, V10, P101; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BUTCHER GP, 1995, FREE RADICAL RES, V22, P99, DOI 10.3109/10715769509147532; CANNISTRARO S, 1981, STUD BIOPHYS, V86, P163; CHAMULITRAT W, 1995, ARCH BIOCHEM BIOPHYS, V316, P30, DOI 10.1006/abbi.1995.1006; CHERNOV GA, 1994, IZV AN SSSR BIOL+, V1, P20; CHETVERIKOV A G, 1964, Biofizika, V9, P678; COMMONER B, 1954, NATURE, V174, P689, DOI 10.1038/174689a0; COMMONER B, 1961, P NATL ACAD SCI USA, V47, P1374, DOI 10.1073/pnas.47.9.1374; COOPER CE, 1994, FREE RADICAL RES, V20, P219, DOI 10.3109/10715769409147518; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; FREIDEN E, 1981, MET IONS BIOL SYST, P117; GALARIS D, 1988, ARCH BIOCHEM BIOPHYS, V262, P221, DOI 10.1016/0003-9861(88)90184-1; GIBSON JF, 1956, NATURE, V178, P871, DOI 10.1038/178871b0; GIULIVI C, 1994, FREE RADICAL BIO MED, V16, P123, DOI 10.1016/0891-5849(94)90249-6; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; GUNTHER MR, 1995, OX 95 ANN M OX SOC P; HARADA K, 1987, J BIOCHEM, V101, P283, DOI 10.1093/oxfordjournals.jbchem.a121903; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P39, DOI 10.1006/abbi.1994.1409; KELDER PP, 1991, ARCH BIOCHEM BIOPHYS, V284, P313, DOI 10.1016/0003-9861(91)90301-X; KELDER PP, 1989, BIOCHEM PHARMACOL, V38, P3593, DOI 10.1016/0006-2952(89)90132-9; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; KOPYLOVSKY SA, 1989, BIOFIZIKA+, V34, P1068; MAUPOIL V, 1990, CARDIOVASC DRUG THER, V4, P791, DOI 10.1007/BF00051276; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; NEUBERGER A, 1994, FREE RADICAL DAMAGE, V28, P67; Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916; PULATOVA MK, 1989, ELECT PARAMAGNETIC R; RICE RH, 1983, ARCH BIOCHEM BIOPHYS, V221, P417, DOI 10.1016/0003-9861(83)90160-1; RICEEVANS C, 1993, FREE RADICALS BASIC, P323; SARTI P, 1994, BBA-PROTEIN STRUCT M, V1208, P38, DOI 10.1016/0167-4838(94)90157-0; SHIGA T, 1975, ARCH BIOCHEM BIOPHYS, V167, P469, DOI 10.1016/0003-9861(75)90489-0; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SOLOMON EI, 1983, COPPER COORDINATION, P1; Stolc S, 1996, FREE RADICAL BIO MED, V20, P89; SVISTUNEKO DA, 1992, INT J RADIAT BIOL, V62, P327, DOI 10.1080/09553009214552181; SVISTUNENKO D A, 1986, Radiobiologiya, V26, P28; Svistunenko DA, 1996, FREE RADICAL RES, V24, P269, DOI 10.3109/10715769609088024; SVISTUNENKO DA, 1991, B BULL ACAD SCI USSR, V18, P358; SVISTUNENKO DA, 1990, BIOL B ACAD SCI USSR, V17, P530; TEW D, 1988, J BIOL CHEM, V263, P17880; TOMODA A, 1978, BIOCHEM J, V171, P329, DOI 10.1042/bj1710329; WAZAWA T, 1992, BIOPHYS J, V63, P544, DOI 10.1016/S0006-3495(92)81608-9; XU Y, 1990, J AGR FOOD CHEM, V38, P1494, DOI 10.1021/jf00097a014; YONETANI T, 1967, J BIOL CHEM, V242, P1974; YOSHIDA Y, 1994, BBA-GEN SUBJECTS, V1201, P165, DOI 10.1016/0304-4165(94)90037-X	58	106	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7114	7121		10.1074/jbc.272.11.7114	http://dx.doi.org/10.1074/jbc.272.11.7114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054405	hybrid			2022-12-25	WOS:A1997WN14700044
J	Podust, VN; Fanning, E				Podust, VN; Fanning, E			Assembly of functional replication factor C expressed using recombinant baculoviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; DOUBLE-STRANDED DNA; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; ESCHERICHIA-COLI; 37-KDA SUBUNIT; HELA-CELLS; RF-C; ACTIVATOR-1	Replication factor C (RF-C), a complex of five subunits, is an essential eukaryotic protein involved in both DNA replication and DNA repair. To generate an easily accessible source of human RF-G for biochemical and genetic studies, we cloned the cDNAs of all five subunits into baculoviruses so that each subunit could be expressed both as a non-fused polypeptide and as an N-terminal His-tagged fusion (-his). Go-infection of insect cells with five baculoviruses encoding individual RF-C subunits (p140, p40, p38, p37, and p36) yielded a protein preparation active in two assays characteristic for authentic RF-C: stimulation of DNA polymerase delta DNA synthesis on singly primed single stranded DNA template and formation of a complex of proliferating cell nuclear antigen with circular double-stranded DNA. Functional recombinant RF-C containing p40-his, p37-his, or p36-his was isolated using affinity resin. Active RF-C was reconstituted only by co-expression of all five subunits. A model for assembly of RF-C from individual subunits was derived from co-purification experiments performed with various combinations of His-tagged and non-fused subunits expressed by co-infection of insect cells with recombinant baculoviruses. p37 and p36 are proposed to form the first intermediate, which, upon addition of either p40 or p38, generates stable tertiary complexes: p40 . p37 . p36 and p38 . p37 . p36. The remaining fourth small subunit binds to the tertiary complex to form a quaternary complex p40 . p38 . p37 . p36. Large subunit p140 binds last to form the five-subunit protein.	VANDERBILT UNIV,DEPT MOL BIOL,NASHVILLE,TN 37235	Vanderbilt University								ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MEYER TF, 1979, J BIOL CHEM, V254, P2642; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; WAGA S, 1994, J BIOL CHEM, V269, P10923; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YODER BL, 1991, J BIOL CHEM, V266, P22689	41	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6303	6310		10.1074/jbc.272.10.6303	http://dx.doi.org/10.1074/jbc.272.10.6303			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045649	hybrid			2022-12-25	WOS:A1997WM64700033
J	Presotto, C; Agnolucci, L; Biral, D; Dainese, P; Bernardi, P; Salviati, G				Presotto, C; Agnolucci, L; Biral, D; Dainese, P; Bernardi, P; Salviati, G			A novel muscle protein located inside the terminal cisternae of the sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MYOTENDINOUS JUNCTIONS; INTEGRIN; DYSTROPHIN; AFFINITY; CELLS; DIFFERENTIATION; 53,000-DALTON; PURIFICATION; FIBRONECTIN	An immunofluorescence study of adult rat muscle tissues with a polyclonal antibody against the RGD-directed fibronectin receptor of Friend's erythroleukemia cells (alpha(5) beta(1)-integrin) unexpectedly revealed a pattern of intracellular antigen distribution, Western blotting analysis of rat and rabbit membrane fractions indicated that the antibody recognizes a 167-kDa protein expressed both in heart and in skeletal muscle (relative abundance: heart > slow muscle > fast muscle), but not in liver and kidney. The 167-kDa protein did not show altered electrophoretic mobility upon reduction and failed to bind several lectins, including wheat germ agglutinin, A study of its subcellular distribution in rabbit skeletal muscle revealed that the 167-kDa protein is mostly associated with the terminal cisternae of the sarcoplasmic reticulum (SR) and, to a smaller extent, with the sarcolemma, while it is absent in the longitudinal tubules of the SR, The 167-kDa protein is not an integral membrane protein since it can be extracted at pH greater than or equal to 10. This protein can be proteolytically cleaved only in the presence of detergent, indicating that it resides on the luminal side of the SR, The 167-kDa protein could be resolved from the closely spaced sarcalumenin and histidine-rich protein by column chromatography followed by detergent dialysis and two-dimensional gel electrophoresis, The N terminus and the internal sequences did not match any known sequence in protein and DNA data bases, indicating that the 167-kDa protein is a novel muscle protein selectively localized to the SR, Integrins from rat kidney fibroblasts were not recognized by either (i) a polyclonal antiserum against the purified 167kDa protein or (ii) the anti-alpha(5) beta(1)-integrin antiserum after affinity purification onto the 167-kDa protein, These data indicate that the 167-kDa protein is not immunologically cross-reactive with integrins, despite its reaction with a polyclonal anti-integrin antibody.	UNIV PADUA,DIPT SCI BIOMED SPERIMENTALI,SCH MED,I-35121 PADUA,ITALY; CNR,UNIT MUSCLE BIOL & PHYSIOPATHOL,I-35121 PADUA,ITALY; CNR,UNIT BIOMEMBRANES,I-35121 PADUA,ITALY; ETH ZENTRUM,ZURICH,SWITZERLAND	University of Padua; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Swiss Federal Institutes of Technology Domain; ETH Zurich			Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736	Telethon [179] Funding Source: Medline	Telethon(Fondazione Telethon)		BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; BLASCHUK KL, 1994, DEV BIOL, V164, P475, DOI 10.1006/dbio.1994.1217; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; Cala S E, 1990, Semin Cell Biol, V1, P265; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; ENOMOTO MI, 1993, DEV BIOL, V155, P180, DOI 10.1006/dbio.1993.1017; GU MJ, 1994, J CELL SCI, V107, P175; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LUISE M, 1993, BIOCHEM J, V293, P243, DOI 10.1042/bj2930243; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PICELLO E, 1992, BIOCHEM BIOPH RES CO, V186, P659, DOI 10.1016/0006-291X(92)90797-O; PORATH J, 1983, BIOCHEMISTRY-US, V22, P1621, DOI 10.1021/bi00276a015; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; SWADISON S, 1989, CELL TISSUE RES, V257, P537; TERRACIO L, 1990, J CELL PHYSIOL, V145, P78, DOI 10.1002/jcp.1041450112; TIDBALL JG, 1986, J CELL BIOL, V103, P1465, DOI 10.1083/jcb.103.4.1465; TIDBALL JG, 1991, AM J PATHOL, V138, P17; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; WATERMAN-STORER C M, 1991, Medicine and Science in Sports and Exercise, V23, P1240; ZOLKIEWSKA A, 1995, J BIOL CHEM, V270, P9227, DOI 10.1074/jbc.270.16.9227	28	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6534	6538		10.1074/jbc.272.10.6534	http://dx.doi.org/10.1074/jbc.272.10.6534			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045679	hybrid			2022-12-25	WOS:A1997WM64700063
J	Ventura, C; Pintus, G; Fiori, MG; Bennardini, F; Pinna, G; Gaspa, L				Ventura, C; Pintus, G; Fiori, MG; Bennardini, F; Pinna, G; Gaspa, L			Opioid peptide gene expression in the primary hereditary cardiomyopathy of the Syrian hamster .1. Regulation of prodynorphin gene expression by nuclear protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CARDIAC MYOCYTES; RAT-BRAIN; ENKEPHALIN IMMUNOREACTIVITY; CALPHOSTIN-C; SPINAL-CORD; HEART; CELLS; DYNORPHIN; POTENT	Prodynorphin gene expression was investigated in adult ventricular myocytes isolated from normal (F1B) or cardiomyopathic (BIG 14.6) hamsters, Prodynorphin mRNA levels were higher in cardiomyopathic than in control myocytes and were stimulated by treatment of control cells with the protein kinase C (PKC) activator 1,2-dioctanoyl-sn-glycerol. Both chelerythrine and calphostin C, two PKC inhibitors, abolished the stimulatory effect of the diglyceride and significantly reduced prodynorphin gene expression in cardiomyopathic myocytes, Nuclear run-off experiments indicated that the prodynorphin gene was regulated at the transcriptional level and that treatment of nuclei isolated from control cells with 1,2 dioctanoyl-sn-glycerol increased prodynorphin gene transcription, whereas chelerythrine or calphostin C abolished this transcriptional effect, Direct exposure of nuclei isolated from cardiomyopathic myocytes to these inhibitors markedly down-regulated the rate of gene transcription, The expression of PKC-alpha, -delta, and -epsilon, as well as PKC activity, were increased in nuclei of cardiomyopathic myocytes compared with nuclei from control cells, The levels of both intracellular and secreted dynorphin B, a biologically active product of the gene, were higher in cardiomyopathic than in control cells and were stimulated or inhibited by cell treatment with 1,2-dioctanoyl-sn-glycerol or PKC inhibitors, respectively.	NATL INST BIOSTRUCT & BIOSYST, NATL LAB, OSILO, ITALY; UNIV SASSARI, SCH PHARM, INST BIOL CHEM, I-07100 SASSARI, ITALY	University of Sassari	Ventura, C (corresponding author), UNIV SASSARI, SCH MED, INST BIOL CHEM A BONSIGNORE, VIALE SAN PIETRO 43-B, I-07100 SASSARI, ITALY.		Pintus, Gianfranco/C-2975-2009	Pintus, Gianfranco/0000-0002-3031-7733	Telethon [593] Funding Source: Medline	Telethon(Fondazione Telethon)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALLEN BG, 1991, BIOCHEMISTRY-US, V30, P4334, DOI 10.1021/bi00231a032; AZARI J, 1980, J MOL CELL CARDIOL, V12, P1353, DOI 10.1016/0022-2828(80)90121-2; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLUM M, 1989, METHOD ENZYMOL, V168, P618; CAPOGROSSI MC, 1986, J GEN PHYSIOL, V88, P589, DOI 10.1085/jgp.88.5.589; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONE RI, 1983, J NEUROSCI, V3, P2146; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; EDWARDS MJ, 1970, MOL PHARMACOL, V6, P641; ELSTEIN E, 1992, J MOL CELL CARDIOL, V24, P1471, DOI 10.1016/0022-2828(92)91087-L; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P3, DOI 10.1006/jmcc.1994.1002; HENGSTENBERG C, 1994, HERZ, V19, P84; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JACOBSON SL, 1986, J MOL CELL CARDIOL, V18, P661, DOI 10.1016/S0022-2828(86)80939-7; JAMIESON JD, 1964, J CELL BIOL, V23, P151, DOI 10.1083/jcb.23.1.151; KASPER E, 1992, LIFE SCI, V50, P2029, DOI 10.1016/0024-3205(92)90568-A; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOHOUT TA, 1993, AM J PHYSIOL, V264, pC1350, DOI 10.1152/ajpcell.1993.264.5.C1350; KRAUSE JE, 1989, METHOD ENZYMOL, V168, P634; LAMERS JMJ, 1981, BIOCHIM BIOPHYS ACTA, V640, P521, DOI 10.1016/0005-2736(81)90476-4; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCILROY BK, 1991, ANAL BIOCHEM, V195, P148, DOI 10.1016/0003-2697(91)90310-P; PATEL J, 1987, J BIOL CHEM, V262, P16686; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; PIPER HM, 1988, J MOL CELL CARDIOL, V20, P825, DOI 10.1016/S0022-2828(88)80007-5; PROSCHEK L, 1982, MUSCLE NERVE, V5, P26, DOI 10.1002/mus.880050106; SCHOLTE HR, 1973, BIOCHIM BIOPHYS ACTA, V305, P413, DOI 10.1016/0005-2728(73)90187-4; SEN L, 1990, CIRC RES, V67, P599, DOI 10.1161/01.RES.67.3.599; SEN L, 1990, AM J PHYSIOL, V259, pH1533, DOI 10.1152/ajpheart.1990.259.5.H1533; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPAMPINATO S, 1992, BRAIN RES, V580, P225, DOI 10.1016/0006-8993(92)90948-9; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; VENTURA C, 1995, J BIOL CHEM, V270, P30115; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; VENTURA C, 1994, J BIOL CHEM, V269, P5384; VENTURA C, 1991, CIRC RES, V261, pH1671; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330; WEISMAN HF, 1987, J AM COLL CARDIOL, V10, P1135, DOI 10.1016/S0735-1097(87)80357-1; XIE GX, 1987, J NEUROSCI, V7, P2049; ZAGON IS, 1985, SCIENCE, V227, P1049, DOI 10.1126/science.3883485; ZAGON IS, 1986, CELL TISSUE RES, V246, P561, DOI 10.1007/BF00215197	54	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6685	6692		10.1074/jbc.272.10.6685	http://dx.doi.org/10.1074/jbc.272.10.6685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045700	hybrid			2022-12-25	WOS:A1997WM64700084
J	Glavy, JS; Horwitz, SB; Orr, GA				Glavy, JS; Horwitz, SB; Orr, GA			Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; CELLS; RESISTANT; GENE; PRECURSORS; HOMOLOGY; DOMAIN	P-glycoprotein, the multidrug resistance transporter, is phosphorylated in vivo and the major phosphorylation domain has been identified as the linker region (amino acids 629-686), The linker region is a highly charged segment of the transporter in which the negative and positive amino acid side chains are spatially segregated. Both of these charged domains contain several consensus phosphorylation sites for protein kinases, Three of the consensus phosphorylation sites for basic-directed kinases in murine mdr1b P-glycoprotein are utilized in vivo and have been identified as serines 665, 669, and 681, Mutagenesis of all the consensus basic-directed kinase phosphorylation sites in the linker region of human MDR1 P-glycoprotein did not alter the ability of the mutated transporter to confer the multidrug resistance phenotype in stably transfected cell lines, These studies would suggest that phosphorylation/dephosphorylation within the basic domain of the linker region is not directly involved in regulation of drug transporter activity. We now report that the linker region of mdr1b P-glycoprotein is also phosphorylated in vivo within the acidic domain (amino acids 631-658), These sites have been mapped using casein kinase II, a prototypic acidic-directed kinase, and a recombinant mdr1b linker region peptide (amino acids 621-687), Electrospray mass spectrometry demonstrated that casein kinase II could introduce up to five phosphates into the recombinant peptide. Two-dimensional phosphopeptide mapping indicated that all the phosphates were contained in a tryptic peptide consisting of amino acids 631-658. Phosphopeptide mapping of in vivo labeled P-glycoprotein, isolated from either J7.V1-1, a murine vinblastine-resistant cell line, or HeLa cells stably transfected with mdr1b P-glycoprotein cDNA, revealed that this tryptic peptide was phosphorylated in both proteins.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				Glavy, Joseph/0000-0003-3716-3965	NCI NIH HHS [CA56677, 5P30 CA13330, CA39821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039821, R01CA056677, P30CA013330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COHEN D, 1990, LIFE SCI, V46, P489, DOI 10.1016/0024-3205(90)90004-B; COHEN P, 1991, METHOD ENZYMOL, V201, P153; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GLAVY JS, 1997, IN PRESS METHODS ENZ; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1993, SOC GEN PHY, V48, P95; HAMADA H, 1987, CANCER RES, V47, P2860; HSU SIH, 1989, J BIOL CHEM, V264, P12053; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; MA LD, 1991, J BIOL CHEM, V266, P5593; MARSH W, 1985, BIOCHEM PHARMACOL, V34, P4180, DOI 10.1016/0006-2952(85)90216-3; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; ORR GA, 1993, J BIOL CHEM, V268, P25054; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROY SN, 1985, CANCER RES, V45, P3856; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4	25	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5909	5914		10.1074/jbc.272.9.5909	http://dx.doi.org/10.1074/jbc.272.9.5909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038209	hybrid			2022-12-25	WOS:A1997WK74700077
J	MacKenzie, CR; Hirama, T; Lee, KK; Altman, E; Young, NM				MacKenzie, CR; Hirama, T; Lee, KK; Altman, E; Young, NM			Quantitative analysis of bacterial toxin affinity and specificity for glycolipid receptors by surface plasmon resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ESCHERICHIA-COLI; CHOLERA-TOXIN; CRYSTAL-STRUCTURE; BINDING SPECIFICITIES; VIBRIO-CHOLERAE; VEROTOXIN-1; RECOGNITION; ANTIBODIES; TECHNOLOGY	The primary virulence factors of many pathogenic bacteria are secreted protein toxins which bind to glycolipid receptors on host cell surfaces, The binding specificities of three such toxins for different glycolipids, mainly from the ganglioside series, were determined by surface plasmon resonance (SPR) using a liposome capture method, Unlike microtiter plate and thin layer chromatography overlay assays, the SPR/liposome methodology allows for real time analysis of toxin binding under conditions that mimic the natural cell surface venue of these interactions and without any requirement for labeling of toxin or receptor. Compared to conventional assays, the liposome technique showed more restricted oligosaccharide specificities for toxin binding, Cholera toxin demonstrated an absolute requirement for terminal galactose and internal sialic acid residues (as in G(M1)) with tolerance for substitution with a second internal sialic acid (as in G(D1b)), Escherichia coli heat-labile enterotoxin bound to G(M1) and tolerated removal or extension of the internal sialic acid residue (as in asialo-G(M1) and G(D1b), respectively) but not substitution of the terminal galactose of G(M1). Tetanus toxin showed a requirement for two internal sialic acid residues as in G(D1b). Extension of terminal galactose with a single sialic acid was tolerated to some extent, The SPR analyses also yielded rate and affinity constants which are not attainable by conventional assays, Complex binding profiles were observed in that the association and dissociation rate constants varied with toxin:receptor ratios, The sub-nanomolar affinities of cholera toxin and heat-labile enterotoxin for liposome-anchored gangliosides were attributable largely to very slow dissociation rate constants, The SPR/liposome technology should have general applicability in the study of glycolipid-protein interactions and in the evaluation of reagents designed to interfere with these interactions.			MacKenzie, CR (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,100 SUSSEX DR,OTTAWA,ON K1A 0R6,CANADA.							ALTMAN E, 1994, METHOD ENZYMOL, V247, P243; ANGSTROM J, 1994, P NATL ACAD SCI USA, V91, P11859, DOI 10.1073/pnas.91.25.11859; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5172, DOI 10.1021/bi00183a022; CUATRECASAS P, 1973, BIOCHEMISTRY-US, V12, P3547, DOI 10.1021/bi00742a031; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; GRIFFITHS SL, 1986, BIOCHEM J, V238, P313, DOI 10.1042/bj2380313; HOLMGREN J, 1980, EUR J BIOCHEM, V106, P371, DOI 10.1111/j.1432-1033.1980.tb04583.x; JOHNSON KG, 1976, CAN J MICROBIOL, V22, P29, DOI 10.1139/m76-004; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i; Lingwood CA, 1996, GLYCOCONJUGATE J, V13, P495, DOI 10.1007/BF00731435; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; MASSERINI M, 1992, BIOCHEMISTRY-US, V31, P2422, DOI 10.1021/bi00123a030; MASSON L, 1994, ANAL BIOCHEM, V218, P405, DOI 10.1006/abio.1994.1199; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Nishiki T, 1996, FEBS LETT, V378, P253, DOI 10.1016/0014-5793(95)01471-3; ORLANDI PA, 1994, BIOCHEMISTRY-US, V33, P12886, DOI 10.1021/bi00209a021; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PELLEQUER JL, 1993, J IMMUNOL METHODS, V166, P133, DOI 10.1016/0022-1759(93)90337-7; PLANT AL, 1995, ANAL BIOCHEM, V226, P342, DOI 10.1006/abio.1995.1234; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SIXMA TK, 1993, BIOCHEMISTRY-US, V32, P191, DOI 10.1021/bi00052a025; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STEIN PE, 1994, NAT STRUCT BIOL, V1, P591, DOI 10.1038/nsb0994-591; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STHILAIRE PM, 1994, BIOCHEMISTRY-US, V33, P14452, DOI 10.1021/bi00252a011; TENEBERG S, 1994, GLYCOCONJUGATE J, V11, P533, DOI 10.1007/BF00731304; YIU SCK, 1992, ANAL BIOCHEM, V202, P188, DOI 10.1016/0003-2697(92)90226-W	34	193	197	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5533	5538		10.1074/jbc.272.9.5533	http://dx.doi.org/10.1074/jbc.272.9.5533			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038159	hybrid			2022-12-25	WOS:A1997WK74700027
J	Molino, M; Bainton, DF; Hoxie, JA; Coughlin, SR; Brass, LF				Molino, M; Bainton, DF; Hoxie, JA; Coughlin, SR; Brass, LF			Thrombin receptors on human platelets - Initial localization and subsequent redistribution during platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; VEIN ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIB-IIIA; MICROPARTICLE FORMATION; STIMULATED PLATELETS; AGONIST PEPTIDES; TETHERED LIGAND; ALPHA-GRANULES; MECHANISM; INTERNALIZATION	Platelet responses to thrombin are at least partly mediated by a G-protein-coupled receptor whose NH2 terminus is a substrate for thrombin, In the present studies we have examined the location of thrombin receptors in resting platelets and followed their redistribution during platelet activation, The results reveal several new aspects of thrombin receptor biology, 1) On resting platelets, approximately two-thirds of the receptors were located in the plasma membrane, The remainder were present in the membranes of the surface connecting system, 2) When platelets were activated by ADP or a thromboxane analog, thrombin receptors that were initially in the surface connecting system were exposed on the platelet surface, increasing the number of detectable receptors by 40% and presumably making them available for subsequent activation by thrombin, 3) Platelet activation by thrombin rapidly abolished the binding of the antibodies whose epitopes are sensitive to receptor cleavage and left the platelets in a state refractory to both thrombin and the agonist peptide, SFLLRN, This was accompanied by a 60% decrease in the binding of receptor antibodies directed COOH-terminal to the cleavage site irrespective of whether the receptors were activated proteolytically by thrombin or nonproteolytically by SFLLRN, 4) The loss of antibody binding sites caused by thrombin was due in part to receptor internalization and in part to the shedding of thrombin receptors into membrane microparticles, especially under conditions in which aggregation was allowed to occur, However, at least 40% of the cleaved receptors remained on the platelet surface, 5) Lacking the ability to synthesize new receptors and lacking an intracellular reserve of preformed receptors comparable to that found in endothelial cells, platelets were unable to repopulate their surface with intact receptors following exposure to thrombin, This difference underlies the ability of endothelial cells to recover responsiveness to thrombin rapidly while platelets do not, despite the presence on both of the same receptor for thrombin.	UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,CTR EXPT THERAPEUT,PHILADELPHIA,PA 19104; IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL031610, R37HL031610, R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31610, HL44907, HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAINTON DF, 1987, J EXP MED, V166, P1641, DOI 10.1084/jem.166.6.1641; BEDNAR B, 1995, THROMB RES, V77, P453, DOI 10.1016/0049-3848(95)93881-Y; BEHNKE O, 1989, THROMB HAEMOSTASIS, V62, P718; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1995, TRENDS CARDIOVAS MED, V5, P123, DOI 10.1016/1050-1738(95)00051-A; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; ESCOLAR G, 1994, J LAB CLIN MED, V123, P536; GEMMELL CH, 1993, J BIOL CHEM, V268, P14586; GEORGE JN, 1982, BLOOD, V60, P834; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; HOURDILLE P, 1985, BRIT J HAEMATOL, V59, P171, DOI 10.1111/j.1365-2141.1985.tb02977.x; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; JAMIESON GA, 1988, PLATELET MEMBRANE RE, P137; MCGOWAN EB, 1983, J BIOL CHEM, V258, P1243; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MORGENSTERN E, 1982, EUR J CELL BIOL, V26, P315; NIEWIARO.S, 1966, NATURE, V212, P1544, DOI 10.1038/2121544a0; NORTON KJ, 1993, BLOOD, V82, P2125; NURDEN P, 1994, SEMIN HEMATOL, V31, P240; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; STENBERG PE, 1984, HISTOCHEM J, V16, P983, DOI 10.1007/BF01003853; STENBERG PE, 1984, J CELL BIOL, V98, P748, DOI 10.1083/jcb.98.2.748; TANS G, 1991, BLOOD, V77, P2641; TOKUYASU KT, 1983, J HISTOCHEM CYTOCHEM, V31, P164, DOI 10.1177/31.1A_Suppl.6186722; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WOODS VL, 1986, J BIOL CHEM, V261, P5242; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; ZACHARIAS U, 1995, EXP CELL RES, V216, P371, DOI 10.1006/excr.1995.1047	47	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6011	6017		10.1074/jbc.272.9.6011	http://dx.doi.org/10.1074/jbc.272.9.6011			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038223	hybrid			2022-12-25	WOS:A1997WK74700091
J	Morell, MK; Wilkin, JM; Kane, HJ; Andrews, TJ				Morell, MK; Wilkin, JM; Kane, HJ; Andrews, TJ			Side reactions catalyzed by ribulose-bisphosphate carboxylase in the presence and absence of small subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTANT; RIBULOSEBISPHOSPHATE CARBOXYLASE; 1,5-BISPHOSPHATE CARBOXYLASE; SLOW INACTIVATION; ACTIVE-SITE; XYLULOSE 1,5-BISPHOSPHATE; DIPHOSPHATE OXYGENASE; BETA-ELIMINATION; INTERMEDIATE; MECHANISM	The large subunit core of ribulose-bisphosphate carboxylase from Synechococcus PCC 6301 expressed in Escherichia coli in the absence of its small subunits retains a trace of carboxylase activity (about 1% of the k(cat) of the holoenzyme) (Andrews, T. J (1988) J. Biol. Chem. 263, 12213-12219), During steady-state catalysis at substrate saturation, this residual activity diverted approximately 10% of the reaction flux to 1-deoxy-D-glycero-2,3-pentodiulose-5-phosphate as a result of beta elimination of inorganic phosphate from the first reaction intermediate, the 2,3-enediol form of ribulose bisphosphate. This indicates that the active site's ability to stabilize and/or retain this intermediate is compromised by the absence of small subunits, Epimerization and isomerization of the substrate resulting from misprotonation of the enediol intermediate were not significantly exacerbated by lack of small subunits, The residual carboxylating activity partitioned product between pyruvate and 3-phosphoglycerate in a ratio similar to that of the holoenzyme, indicating that stabilization of the penultimate three-carbon aci-acid intermediate is not perturbed by lack of small subunits. The underlying instability of the five-carbon enediol intermediate was revealed, even with the holoenzyme, under conditions designed to lead to exhaustion of substrate CO2 (and O-2), When carboxylation (and oxygenation) stalled upon exhaustion of gaseous substrate, both spinach and Synechococcus holoenzymes continued slowly to beta eliminate inorganic phosphate from and to misprotonate the enediol intermediate. With carboxylation and oxygenation blocked, the products of these side reactions of the enediol intermediate accumulated to readily detectable levels, illustrating the difficulties attendant upon ribulose-P-2 carboxylase's use of this reactive species as a catalytic intermediate.	AUSTRALIAN NATL UNIV,RES SCH BIOL SCI,MOL PLANT PHYSIOL GRP,CANBERRA,ACT 2601,AUSTRALIA	Australian National University			Morell, Matthew/AAQ-5368-2021	Morell, Matthew/0000-0003-4467-1626				Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ANDREWS TJ, 1991, J BIOL CHEM, V266, P9447; ANDREWS TJ, 1983, J BIOL CHEM, V258, P7514; ANDREWS TJ, 1973, BIOCHEMISTRY-US, V12, P11, DOI 10.1021/bi00725a003; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; ANDREWS TJ, 1986, J BIOL CHEM, V261, P2184; BOWES G, 1971, BIOCHEM BIOPH RES CO, V45, P716, DOI 10.1016/0006-291X(71)90475-X; CHEN YR, 1995, J BIOL CHEM, V270, P11741, DOI 10.1074/jbc.270.20.11741; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Collatz GJ, 1979, CARNEGIE I WASH YR B, V78, P171; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1383, DOI 10.1104/pp.93.4.1383; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; GATENBY AA, 1985, NATURE, V314, P617, DOI 10.1038/314617a0; GUTTERIDGE S, 1995, PLANT CELL, V7, P809, DOI 10.1105/tpc.7.7.809; GUTTERIDGE S, 1991, J BIOL CHEM, V266, P7359; HARPEL MR, 1995, BIOCHEMISTRY-US, V34, P11296, DOI 10.1021/bi00035a039; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; KANE HJ, 1994, AUST J PLANT PHYSIOL, V21, P449, DOI 10.1071/PP9940449; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LARIMER FW, 1994, J BIOL CHEM, V269, P11114; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; LEE EH, 1993, J BIOL CHEM, V268, P26583; LI RS, 1995, ANAL BIOCHEM, V230, P37, DOI 10.1006/abio.1995.1434; LORIMER GH, 1973, BIOCHEMISTRY-US, V12, P18, DOI 10.1021/bi00725a004; MORELL MK, 1994, J BIOL CHEM, V269, P8091; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; PAECH C, 1978, BIOCHEM BIOPH RES CO, V83, P1084, DOI 10.1016/0006-291X(78)91506-1; PAUL K, 1991, BIOCHEMISTRY-US, V30, P10019, DOI 10.1021/bi00105a029; PAULSEN JM, 1966, BIOCHEMISTRY-US, V5, P2350, DOI 10.1021/bi00871a025; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; YOKOTA A, 1991, PLANT CELL PHYSIOL, V32, P755; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5445	5451		10.1074/jbc.272.9.5445	http://dx.doi.org/10.1074/jbc.272.9.5445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038145	hybrid			2022-12-25	WOS:A1997WK74700013
J	Stiegler, P; Schuchner, S; Lestou, V; Wintersberger, E				Stiegler, P; Schuchner, S; Lestou, V; Wintersberger, E			Polyomavirus large T antigen-dependent DNA amplification	ONCOGENE			English	Article						DNA amplification; tumor viruses; cell cycle; checkpoint; tumorsuppressors	CELL-CYCLE CONTROL; SV40-TRANSFORMED HUMAN-CELLS; CHINESE-HAMSTER CELLS; WILD-TYPE P53; GENE AMPLIFICATION; GROWTH ARREST; RETINOBLASTOMA PROTEIN; GENOMIC INSTABILITY; HUMAN FIBROBLASTS; ADENOVIRUS E1A	DNA amplification is a readily measurable indicator for genome destabilization. Contrary to normal senescing cells, those of most immortal or transformed cell lines are karyotypically unstable and permissive for amplification. Permissivity for amplification can be generated by gene products of several DNA tumor viruses whereby their interaction with the tumorsuppressor protein p53 is important. p53 is the major protein involved in check point control of DNA damage. Polyomavirus large T antigen is also involved in immortalization and transformation of cells but it does not interact with p53. We, therefore, examined whether this protein could still make the non-permissive cell line REF52 permissive for gene amplification. To this end REF52 cell lines were constructed which conditionally expressed the wild type polyomavirus large T antigen or a mutant form unable to bind the retinoblastoma protein. Using the inhibitor of de novo pyrimidine biosynthesis, phosphonoacetyl-L-aspartate (PALA), as selective agent we found that PALA resistant cells arise with a frequency of about 5x10(-5) and that the interaction of polyomavirus large T protein with the retinoblastoma protein or another related pocket protein is important for this to occur. PALA resistant cells have an increased number of chromosomes and dicentric chromosomes which are considered as starting point for DNA structures characteristic for amplified DNA. Such structures were indeed found with the help of fluorescence in situ hybridization. PALA resistant cells appear normal with respect to p53. Our data indicate that PALA induces a G(1) block which can be partially overcome by polyomavirus large T protein by its interaction with E2F-pocket protein complexes providing further evidence that these complexes are downstream targets of p53.	UNIV VIENNA, VIENNA BIOCTR, INST MOL BIOL, VIENNA, AUSTRIA; ST ANNA CHILDRENS HOSP, A-1090 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Saint Anna Children's Hospital								ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; GANNON JV, 1991, NATURE, V349, P802; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HICKMAN ES, 1994, ONCOGENE, V9, P2177; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; OTTO E, 1989, J BIOL CHEM, V264, P3390; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; SZEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320; Thomas RC, 1996, EXP CELL RES, V223, P227, DOI 10.1006/excr.1996.0076; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINTERSBERGER E, 1994, CHROMOSOMA, V103, P73, DOI 10.1007/BF00352315; WOODS C, 1994, ONCOGENE, V9, P2943; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZERFASS K, 1995, J GEN VIROL, V76, P1815, DOI 10.1099/0022-1317-76-7-1815; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	59	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					987	995		10.1038/sj.onc.1200904	http://dx.doi.org/10.1038/sj.onc.1200904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050998				2022-12-25	WOS:A1997WK34400012
J	AvidorReiss, T; Nevo, I; Saya, D; Bayewitch, M; Vogel, Z				AvidorReiss, T; Nevo, I; Saya, D; Bayewitch, M; Vogel, Z			Opiate-induced adenylyl cyclase superactivation is isozyme-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MU-OPIOID RECEPTOR; NUCLEOTIDE-BINDING-PROTEINS; IN-SITU HYBRIDIZATION; CYCLIC-AMP PRODUCTION; MOUSE LYMPHOMA-CELLS; GLIOMA HYBRID-CELLS; RAT-BRAIN; MOLECULAR-CLONING; MESSENGER-RNA	While acute activation of inhibitory G(i/o)-coupled receptors leads to inhibition of adenylyl cyclase, chronic activation of such receptors leads to an increase in cAMP accumulation. This phenomenon, observed in many cell types, has been referred to as adenylyl cyclase superactivation, At this stage, the mechanism leading to adenylyl cyclase superactivation and the nature of the isozyme(s) responsible for this phenomenon are largely unknown. Here we show that transfection of adenylyl cyclase isozymes into COS-7 cells results in an isozyme-specific increase in AC activity upon stimulation (e.g. with forskolin, ionomycin, or stimulatory receptor ligands). However, independently of the method used to activate specific adenylyl cyclase isozymes, acute activation of the mu-opioid receptor inhibited the activity of adenylyl cyclases I, V, VI, and VIII, while types II, IV, and VII were stimulated and type III was not affected. Chronic mu-opioid receptor activation followed by removal of the agonist was previously shown, in transfected COS-7 cells, to induce superactivation of adenylyl cyclase type V. Here we show that it also leads to superactivation of adenylyl cyclase types I, VI, and VIII, but not of type II, III, IV, or VII, demonstrating that the superactivation is isozyme-specific. Not only were isozymes II, IV, and VII not superactivated, but a reduction in the activities of these isozymes was actually observed upon chronic opiate exposure. These results suggest that the phenomena of tolerance and withdrawal involve specific adenylyl cyclase isozymes.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science			Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NIDA NIH HHS [DA-06265] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; AMMER H, 1993, MOL PHARMACOL, V43, P556; AvidorReiss T, 1996, J BIOL CHEM, V271, P21309, DOI 10.1074/jbc.271.35.21309; AVIDORREISS T, 1995, FEBS LETT, V361, P70, DOI 10.1016/0014-5793(95)00154-2; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; CRUCIANI RA, 1993, P NATL ACAD SCI USA, V90, P3019, DOI 10.1073/pnas.90.7.3019; DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GRIFFIN MT, 1985, J NEUROCHEM, V45, P1585, DOI 10.1111/j.1471-4159.1985.tb07230.x; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES SB, 1987, P NATL ACAD SCI USA, V84, P1294, DOI 10.1073/pnas.84.5.1294; JONES SB, 1988, J BIOL CHEM, V263, P14236; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LIM K, 1989, BIOTECHNIQUES, V7, P576; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; MATSUOKA I, 1994, EUR J PHARM-MOLEC PH, V268, P215, DOI 10.1016/0922-4106(94)90191-0; MCDERMOTT AM, 1995, CELL SIGNAL, V7, P277, DOI 10.1016/0898-6568(94)00086-Q; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PUTTFARCKEN PS, 1989, LIFE SCI, V45, P1937, DOI 10.1016/0024-3205(89)90548-1; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; SABOL SL, 1979, J BIOL CHEM, V254, P1921; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; THOMAS JM, 1989, MOL PHARMACOL, V35, P116; THOMAS JM, 1987, TRENDS PHARMACOL SCI, V8, P308, DOI 10.1016/0165-6147(87)90124-6; Thomas JM, 1996, MOL PHARMACOL, V49, P907; THOMAS JM, 1992, CELL SIGNAL, V4, P417, DOI 10.1016/0898-6568(92)90036-8; THOMAS JM, 1992, CELL SIGNAL, V4, P571, DOI 10.1016/0898-6568(92)90026-5; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TRABER J, 1975, LIFE SCI, V16, P1863, DOI 10.1016/0024-3205(75)90292-1; TSU RC, 1995, J NEUROCHEM, V64, P2700; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WANG L, 1994, J NEUROCHEM, V63, P1726; WANG Z, 1994, LIFE SCI, V54, pPL339, DOI 10.1016/0024-3205(94)90022-1; WATSON PA, 1994, J BIOL CHEM, V269, P28893; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	74	139	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5040	5047		10.1074/jbc.272.8.5040	http://dx.doi.org/10.1074/jbc.272.8.5040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030567	hybrid			2022-12-25	WOS:A1997WJ85500055
J	Beau, I; Misrahi, M; Gross, B; Vannier, B; Loosfelt, H; Hai, MTV; Pichon, C; Milgrom, E				Beau, I; Misrahi, M; Gross, B; Vannier, B; Loosfelt, H; Hai, MTV; Pichon, C; Milgrom, E			Basolateral localization and transcytosis of gonadotropin and thyrotropin receptors expressed in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; LUTEINIZING-HORMONE RECEPTOR; HETEROTRIMERIC G-PROTEIN; GTP-BINDING PROTEINS; LUTROPIN CHORIOGONADOTROPIN RECEPTOR; FOLLICLE-STIMULATING-HORMONE; POLARIZED EPITHELIAL-CELLS; TRANSFECTED L-CELLS; MDCK CELLS; BREFELDIN-A	The thyrotropin (TSH) and follicle stimulating hormone (FSH) receptors are present mainly on the basolateral cell surface in the thyroid gland and in Sertoli cells, whereas in ovarian and in testicular cells, the luteinizing hormone (LH) receptors are distributed throughout the cell surface, When expressed in Madin-Darby canine kidney (MDCK) cells, all three receptors accumulated at the basolateral cell surface showing that they carry the corresponding targeting signals, The receptors were directly delivered to the basolateral surface of the MDCK cells, A minor fraction of the gonadotropin receptors but not of TSH receptors was secondarily targeted to the apical surface through transcytosis, The mechanisms of basolateral targeting and transcytosis were analyzed using the FSH receptor as a model, Both were insensitive to brefeldin A and pertussis toxin, G(s) activation by AlF4- and cholera toxin provoked a marked enhancement of FSH receptor transcytosis, The population of G(s) proteins involved in this mechanism was different from that involved in signal transduction since neither FSH nor forskolin mimicked the effects of AlF4- and cholera toxin, G(s) activation provoked a similar effect on LH receptor distribution in MDCK cells, whereas it did not modify the compartmentalization of the TSH receptor, Hormone-specific transcytosis was observed in MDCK cells expressing the gonadotropin (FSH and LH) receptors and was increased after cholera toxin administration.	HOP BICETRE, INSERM U135, UNITE RECH HORMONES & REPROD, F-94275 LE KREMLIN BICETRE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay			Beau, Isabelle/M-4423-2017	Beau, Isabelle/0000-0002-3352-6813; Vannier, Brigitte/0000-0002-6870-507X				AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; APODACA G, 1993, J BIOL CHEM, V268, P20380; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BUTOR C, 1991, EUR J CELL BIOL, V56, P269; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Couet J, 1996, J BIOL CHEM, V271, P4545; GHINEA N, 1994, J CELL BIOL, V125, P87, DOI 10.1083/jcb.125.1.87; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; HAI MTV, 1990, ENDOCRINOLOGY, V127, P2090; HAI MTV, 1992, BIOCHEMISTRY-US, V31, P8377; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MEDURI G, 1992, ENDOCRINOLOGY, V131, P366, DOI 10.1210/en.131.1.366; Meduri G, 1996, J ENDOCRINOL, V148, P435, DOI 10.1677/joe.0.1480435; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; MISRAHI M, 1994, CURR OPIN ENDOCRINOL, V1, P175; MISRAHI M, 1993, OVARY, P57; MOHR H, 1980, BIOCHEM J, V188, P649, DOI 10.1042/bj1880649; MOSTOV K, 1993, J CELL SCI, P21; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PIMPLIKAR SW, 1993, J CELL SCI, P27; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SETCHELL BP, 1972, J ENDOCRINOL, V54, P67, DOI 10.1677/joe.0.0540067; SHLATZ LJ, 1975, J MEMBRANE BIOL, V24, P131, DOI 10.1007/BF01868619; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1993, J CELL SCI, P33; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Vannier B, 1996, BIOCHEMISTRY-US, V35, P1358, DOI 10.1021/bi952290f; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WAN JS, 1992, J BIOL CHEM, V267, P13446; Wozniak M, 1996, J BIOL CHEM, V271, P5017; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZHOU J, 1990, P NATL ACAD SCI USA, V87, P7532, DOI 10.1073/pnas.87.19.7532	72	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5241	5248		10.1074/jbc.272.8.5241	http://dx.doi.org/10.1074/jbc.272.8.5241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030595	hybrid			2022-12-25	WOS:A1997WJ85500083
J	HernandezSanchez, C; Werner, H; Roberts, CT; Woo, EJ; Hum, DW; Rosenthal, SM; LeRoith, D				HernandezSanchez, C; Werner, H; Roberts, CT; Woo, EJ; Hum, DW; Rosenthal, SM; LeRoith, D			Differential regulation of insulin-like growth factor-I (IGF-I) receptor gene expression by IGF-I and basic fibroblastic growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING-PROTEINS; BC3H-1 MUSCLE-CELLS; RIBONUCLEIC-ACID; RESPONSE ELEMENT; CYCLIC-AMP; INDUCTION; SERUM; INHIBITION; INCREASES; PROMOTER	Insulin-like growth factor-I receptor (IGF-IR) gene expression is regulated by various stimuli, including hormones, growth factors, and nutritional status. We have investigated the molecular mechanism by which two growth factors, insulin-like growth factor-I (IGF-I) and basic fibroblast growth factor (bFGF) regulate IGF-IR gene expression. bFGF increases the endogenous IGF-IR mRNA levels and IGF-IR promoter activity. This effect is mediated by a region of the IGF-IR promoter located between nucleotides -476 and -188 in the 5'-flanking region. In contrast, IGF-I decreases the IGF-IR mRNA levels. IGF-I down-regulates IGF-IR transcriptional activity as deduced from experiments in which the levels of pre-mRNA and mRNA were measured. IGF-I reduced pre-mRNA and mRNA levels in parallel, while the mRNA stability was found to be unchanged by IGF-I treatment. While these results strongly suggest an effect of IGF-I on IGF-IR transcriptional activity, no specific IGF-I response element was demonstrated in the 5'-untranslated region or 5'-flanking region studied, Thus, bFGF and IGF-I have differential effects on IGF-IR gene transcription, with the IGF-I response region as yet unidentified.	UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	HernandezSanchez, C (corresponding author), NIDDK, SECT MOL & CELLULAR PHYSIOL,DIABET BRANCH,NIH, RM 8S235A, BLDG 10, BETHESDA, MD 20892 USA.		Roberts, Charles/K-6953-2017; Hernández-Sánchez, Catalina/N-1737-2014	Roberts, Charles/0000-0003-1756-5772; Hernández-Sánchez, Catalina/0000-0002-0846-5019				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V24, P5244; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Du J, 1996, ENDOCRINOLOGY, V137, P1378, DOI 10.1210/en.137.4.1378; ESHET R, 1993, J MOL ENDOCRINOL, V10, P115, DOI 10.1677/jme.0.0100115; FRODIN M, 1994, P NATL ACAD SCI USA, V91, P1771, DOI 10.1073/pnas.91.5.1771; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LOWE WL, 1989, J CLIN INVEST, V84, P619, DOI 10.1172/JCI114207; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OTA A, 1989, MOL BRAIN RES, V6, P69, DOI 10.1016/0169-328X(89)90030-2; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PFEIFLE B, 1987, ENDOCRINOLOGY, V120, P2251, DOI 10.1210/endo-120-6-2251; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PONS S, 1992, ENDOCRINOLOGY, V131, P2271, DOI 10.1210/en.131.5.2271; Quinn LS, 1996, J CELL PHYSIOL, V168, P34, DOI 10.1002/(SICI)1097-4652(199607)168:1<34::AID-JCP5>3.0.CO;2-9; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENFELD RG, 1980, ENDOCRINOLOGY, V107, P1841, DOI 10.1210/endo-107-6-1841; ROSENFELD RG, 1982, J CLIN ENDOCR METAB, V55, P434, DOI 10.1210/jcem-55-3-434; ROSENTHAL SM, 1991, MOL ENDOCRINOL, V5, P678, DOI 10.1210/mend-5-5-678; ROSENTHAL SM, 1994, J ENDOCRINOL, V141, P69, DOI 10.1677/joe.0.1410069; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; RUSSO VC, 1994, ENDOCRINOLOGY, V135, P1437, DOI 10.1210/en.135.4.1437; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1990, DIABETES, V39, P1490, DOI 10.2337/diabetes.39.12.1490; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; YAMAMOTO H, 1993, ENDOCRINOLOGY, V133, P1420, DOI 10.1210/en.133.3.1420	38	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4663	4670		10.1074/jbc.272.8.4663	http://dx.doi.org/10.1074/jbc.272.8.4663			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030517	hybrid			2022-12-25	WOS:A1997WJ85500005
J	Kilic, F; Dalton, MB; Burrell, SK; Mayer, JP; Patterson, SD; Sinensky, M				Kilic, F; Dalton, MB; Burrell, SK; Mayer, JP; Patterson, SD; Sinensky, M			In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPRENYLATED PROTEIN ENDOPROTEASE; INTERMEDIATE FILAMENT PROTEINS; LAMIN-A PRECURSOR; NUCLEAR-ENVELOPE; CARBOXYL METHYLTRANSFERASE; LOCALIZATION; IDENTIFICATION; RECOGNITION; MEVALONATE; INHIBITORS	The 72-kDa nuclear lamina protein lamin A is synthesized as a 74-kDa farnesylated precursor. Conversion of this precursor to mature lamin A appears to be mediated by a specific endoprotease. Prior studies of overexpressed wild-type and mutant lamin A proteins in cultured cells have indicated that the precursor possesses the typical carboxyl-terminal S-farnesylated, cysteine methyl ester and that farnesylation is required for endoproteolysis to occur. In this report, we describe the synthesis of an S-farnesyl, cysteinyl methyl ester peptide corresponding to the carboxyl-terminal 18 amino acid residues of human prelamin A. This peptide acts as a substrate for the prelamin A endoprotease in vitro, with cleavage of the synthetic peptide at the expected site between Tyr(657) and Leu(658). Endoproteolytic cleavage requires the S-prenylated cysteine methyl ester and, in agreement with transfection studies, is more active with the farnesylated than geranylgeranylated cysteinyl substrate. N-Acetyl farnesyl methyl cysteine is shown to be a noncompetitive inhibitor of the enzyme. Taken together, these observations suggest that there is a specific farnesyl binding site on the enzyme which is not at the active site.	E TENNESSEE STATE UNIV,JAMES H QUILLEN COLL MED,DEPT BIOCHEM & MOL BIOL,JOHNSON CITY,TN 37614; UNIV COLORADO,HLTH SCI CTR,DEPT PHYSIOL,DENVER,CO 80262; AMGEN INC,THOUSAND OAKS,CA 91320	East Tennessee State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Amgen			Patterson, Scott/A-7404-2009					BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; CALDWELL GA, 1994, P NATL ACAD SCI USA, V91, P1275, DOI 10.1073/pnas.91.4.1275; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLARKE S, 1992, ANN REV BIOCH, V61, P855; COX AD, 1992, MOL CELL BIOL, V12, P2605; DALTON MB, 1995, CANCER RES, V55, P3295; FAUST J, 1987, J BIOL CHEM, V262, P1996; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; HENNEKES H, 1994, J CELL SCI, V107, P1019; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KIM CM, 1992, J BIOL CHEM, V267, P23113; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MA YT, 1993, BIOCHEMISTRY-US, V32, P2386, DOI 10.1021/bi00060a033; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MA YT, 1992, BIOCHEMISTRY-US, V31, P11772, DOI 10.1021/bi00162a014; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; OKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SINENSKY M, 1994, CANCER RES, V54, P3229; SINENSKY M, 1994, J CELL SCI, V107, P61; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; TAN EW, 1991, J BIOL CHEM, V266, P10719; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; ZHANG LL, 1995, J BIOL CHEM, V270, P22859, DOI 10.1074/jbc.270.39.22859; ZHENG FL, 1996, ANN REV BIOCH, V65, P241	38	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5298	5304		10.1074/jbc.272.8.5298	http://dx.doi.org/10.1074/jbc.272.8.5298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030603	hybrid, Green Published			2022-12-25	WOS:A1997WJ85500091
J	Kim, DS; Jung, HH; Park, SH; Chin, H				Kim, DS; Jung, HH; Park, SH; Chin, H			Isolation and characterization of the 5'-upstream region of the human N-type calcium channel alpha(1B) subunit gene - Chromosomal localization and promoter analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM REGULATORY ELEMENTS; NEURON-SPECIFIC EXPRESSION; FUNCTIONAL EXPRESSION; TRANSCRIPTION INVITRO; NEGATIVE REGULATION; ALPHA-1 SUBUNIT; MOLECULAR-BASIS; CORE PROMOTER; DIVERSITY; PROTEIN	omega-Conotoxin-sensitive N-type Ca2+ channels, unlike dihydropyridine-sensitive L-type channels, are exclusively expressed in nervous tissues. To understand the molecular basis for neuron-specific expression of the N-type channel, we have isolated genomic clones encoding the human alpha(1B) subunit gene, localized to the long arm of chromosome 9 (9q34) by fluorescence in. situ hybridization, and characterized its 5'-upstream region. The proximal promoter of the alpha(1B) subunit gene lacks a typical TATA box, is highly GC-rich, and contains several sequences for transcription factor binding. Primer extension experiments revealed the presence of two transcription start sites. In vitro transfection study of the alpha(1B) subunit-luciferase fusion gene showed that the 4.0-kb 5'-flanking region of the alpha(1B) gene functions as an efficient promoter in neuronal cells but not in glioma or nonneuronal cells, consistent with the patterns of the endogenous alpha(1B) gene expression in these cells. Deletion analysis of alpha(1B) subunit-luciferase fusion gene constructs further revealed the presence of several cis-acting regulatory elements, including a potential repressor located in the distal upstream region (-3992 to -1788) that may be important for the neuron-specific expression of the N-type Ca2+ channel alpha(1B) subunit gene.	NINCDS,NEUROCHEM LAB,NIH,BETHESDA,MD 20892; KOREA UNIV,COLL MED,DEPT ANAT,SEOUL 136701,SOUTH KOREA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Korea University; Korea University Medicine (KU Medicine)								AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CHIN H, 1992, FEBS LETT, V299, P69, DOI 10.1016/0014-5793(92)80103-N; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Gottschalk W., 1995, Society for Neuroscience Abstracts, V21, P1573; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAMP TJ, 1995, CELL MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02089942; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI Y, 1993, J BIOL CHEM, V268, P26482; NEDIVI E, 1992, J NEUROSCI, V12, P691; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; TAKIMOTO K, 1994, CIRC RES, V75, P1006, DOI 10.1161/01.RES.75.6.1006; TAKIMOTO K, 1993, NEURON, V11, P45; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501	43	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5098	5104		10.1074/jbc.272.8.5098	http://dx.doi.org/10.1074/jbc.272.8.5098			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030575	hybrid			2022-12-25	WOS:A1997WJ85500063
J	Martin, G; Chauvin, MF; Baverel, G				Martin, G; Chauvin, MF; Baverel, G			Model applicable to NMR studies for calculating flux rates in five cycles involved in glutamate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRIC-ACID-CYCLE; ISOTOPOMER ANALYSIS; KIDNEY-CORTEX; KREBS CYCLE; GLUCONEOGENESIS; SPECTROSCOPY; PYRUVATE; GLUCOSE; HEART; PATHWAYS	Based on the same principles as those utilized in a recent study for modeling glucose metabolism (Martin, G., Chauvin, M. F., Dugelay, S., and Baverel, G. (1994) J. Biol. Chem. 269, 26034-26039), a method is presented for determining metabolic fluxes involved in glutamate metabolism in mammalian cells. This model consists of five different cycles that operate simultaneously. It includes not only the tricarboxylic acid cycle, the ''oxaloacetate --> phosphoenolpyruvate --> pyruvate --> oxaloacetate'' cycle and the ''oxaloacetate --> phosphoenolpyruvate --> pyruvate --> acetyl-CoA --> citrate --> oxaloacetate'' cycle but also the ''glutamate --> alpha-ketoglutarate --> glutamate'' and the ''glutamate --> glutamine --> glutamate'' cycles, The fates of each carbon of glutamate, expressed as ratios of integrated transfer of this carbon to corresponding carbons in subsequent metabolites, are described by a set of equations, Since the data introduced in the model are micrograms of atom of traced carbon incorporated into each carbon of end products, the calculation strategy was determined on the basis of the most reliable parameters determined experimentally. This model, whose calculation routes offer a large degree of flexibility, is applicable to data obtained by C-13 NMR spectroscopy, gas chromatography - mass spectrometry, or C-14 counting in a great variety of mammalian cells.			Martin, G (corresponding author), HOP EDOUARD HERRIOT,CTR ETUD METAB SPECT RESONANCE MAGNET,INSERM CRI950102,PAVILLON P,F-69374 LYON 03,FRANCE.							CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; Chauvin MF, 1997, J BIOL CHEM, V272, P4705, DOI 10.1074/jbc.272.8.4705; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; LAPIDOT A, 1994, J BIOL CHEM, V269, P27198; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MARTIN G, 1994, J BIOL CHEM, V269, P26034; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; ROGNSTAD R, 1972, J BIOL CHEM, V247, P6047; WATFORD M, 1980, BIOCHEM J, V188, P741, DOI 10.1042/bj1880741	16	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4717	4728		10.1074/jbc.272.8.4717	http://dx.doi.org/10.1074/jbc.272.8.4717			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030523	hybrid			2022-12-25	WOS:A1997WJ85500011
J	GravesWoodward, KL; Gottlieb, J; Challberg, MD; Weller, SK				GravesWoodward, KL; Gottlieb, J; Challberg, MD; Weller, SK			Biochemical analyses of mutations in the HSV-1 helicase-primase that alter ATP hydrolysis, DNA unwinding, and coupling between hydrolysis and unwinding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; NUCLEOTIDE-BINDING SITE; SINGLE-STRANDED-DNA; ELONGATION-FACTOR TU; BOX RNA HELICASE; ESCHERICHIA-COLI; GENE-PRODUCT; NUCLEOSIDE TRIPHOSPHATE; CONFORMATIONAL-CHANGES; TRANSCRIPTION FACTOR	Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase composed of the products of the UL5, UL52, and UL8 genes. UL5 possesses six motifs conserved among superfamily 1 of helicase proteins. Substitutions of conserved residues in each moth abolishes DNA replication in vivo (Zhu, L., and Weller, S. K. (1992) J. Virol. 66, 469-479). Purified UL5-52 harboring a Gay to Ala change in motif V retains primase and helicase activities in vitro but exhibits a higher K-M for single-stranded DNA and lower DNA-dependent ATPase activity (Graves-Woodward, K. L., and Weller, S. K. (1996) J. Biol. Chem. 272, 13629-13635). We have purified and characterized six other subcomplexes with residue changes in the UL5 helicase motifs. Each variant subcomplex displays at least wild type or greater levels of primase and DNA binding activities, but all are defective in helicase activity. Mutations in motifs I and II exhibit profound decreases in DNA-dependent ATPase activity. Mutations in motifs III-VI decrease DNA-dependent ATPase activity 3-6-fold. Since mutations in motifs III, IV, V, and VI do not eliminate ATP hydrolysis or DNA binding, we propose that they may be involved in the coupling of these two activities to the process of DNA unwinding. This analysis represents the first comprehensive structure-function analysis of the conserved motifs in helicase superfamily 1.	UNIV CONNECTICUT, CTR HLTH, DEPT MICROBIOL, FARMINGTON, CT 06030 USA; NIAID, VIRAL DIS LAB, NIH, BETHESDA, MD 20892 USA	University of Connecticut; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Weller, Sandra/N-3979-2013	Weller, Sandra/0000-0002-4519-6276	PHS HHS [A121747] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARAI K, 1981, J BIOL CHEM, V256, P5247; BAILIS AM, 1995, MOL CELL BIOL, V15, P3998; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DESBIEZ C, 1995, P NATL ACAD SCI USA, V92, P5640, DOI 10.1073/pnas.92.12.5640; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NUCLEIC ACIDS RES, V16, P7734, DOI 10.1093/nar/16.15.7734; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; GravesWoodward KL, 1996, J BIOL CHEM, V271, P13629, DOI 10.1074/jbc.271.23.13629; JINDAL HK, 1994, J BIOL CHEM, V269, P3283; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LI J, 1995, NUCLEIC ACIDS RES, V23, P1590, DOI 10.1093/nar/23.9.1590; LI J, 1993, J BIOL CHEM, V268, P20016; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LONDONOVALLEJO JA, 1994, J BACTERIOL, V176, P4642; Lukonis CJ, 1996, J VIROL, V70, P1751, DOI 10.1128/JVI.70.3.1751-1758.1996; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; OLIVO PD, 1990, HERPESVIRUS TRANSCRI, P137; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAI EF, 1990, EMBO J, V9, P2353; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEO YS, 1991, J BIOL CHEM, V266, P13161; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; SHRIMANKAR P, 1992, J BACTERIOL, V174, P7689, DOI 10.1128/JB.174.23.7689-7696.1992; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; WELLER SK, 1990, HERPESVIRUS TRANSCRI, P105; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YARRANTON GT, 1979, J BIOL CHEM, V254, P2002; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	71	73	74	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4623	4630		10.1074/jbc.272.7.4623	http://dx.doi.org/10.1074/jbc.272.7.4623			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020191	hybrid			2022-12-25	WOS:A1997WH01900107
J	Kakhniashvili, D; Mayor, JA; Gremse, DA; Xu, Y; Kaplan, RS				Kakhniashvili, D; Mayor, JA; Gremse, DA; Xu, Y; Kaplan, RS			Identification of a novel gene encoding the yeast mitochondrial dicarboxylate transport protein via overexpression, purification, and characterization of its protein product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ANION-EXCHANGE REACTIONS; BOVINE HEART-MITOCHONDRIA; BROWN FAT MITOCHONDRIA; ADP ATP TRANSLOCASE; AMINO-ACID-SEQUENCE; UNCOUPLING PROTEIN; SACCHAROMYCES-CEREVISIAE; AFFINITY-CHROMATOGRAPHY; STRUCTURAL RELATIONSHIP	A gene encoding the mitochondrial dicarboxylate transport protein (DTP) has been identified for the first time from any organism, Our strategy involved overexpression of putative mitochondrial transporter genes, selected based on analysis of the yeast genome, followed by purification and functional reconstitution of the resulting protein products. The DTP gene from the yeast Saccharomyces cerevisiae encodes a 298-residue basic protein which, in common with other mitochondrial an. ion transporters of known sequence and function, displays the mitochondrial transporter signature motif, three homologous 100-amino acid sequence domains, and six predicted membrane-spanning regions, The product of this gene has been abundantly expressed in Escherichia coli where it accumulates in inclusion bodies, Upon solubilization of the overexpressed DTP from isolated inclusion bodies with Sarkosyl, 28 mg of DTP was obtained per liter of E. coli culture at a purity of 75%. The purified, overexpressed DTP was then reconstituted in phospholipid vesicles where both its kinetic properties (i.e. K-m = 1.55 mM and V-max = 3.0 mu mol/min/mg protein) and its substrate specificity were determined. The intraliposomal substrates malonate, malate, succinate, and phosphate effectively supported [C-14]malonate uptake, whereas other anions tested did not. External substrate competition studies revealed a similar specificity profile, Inhibitor studies indicated that the reconstituted transporter was sensitive to inhibition by n-butylmalonate, p-chloromercuribenzoate, mersalyl, and to a lesser extent pyridoxal 5'-phosphate but was insensitive to N-ethylmaleimide and selective inhibitors of other mitochondrial anion transporters, In combination, the above findings indicate that the identified gene encodes a mitochondrial transport protein which upon overexpression and reconstitution displays functional properties that are virtually identical to those of the native mitochondrial dicarboxylate transport system. In conclusion, the present investigation has resulted in identification of a gene encoding the mitochondrial DTP and thus eliminates a major impediment to molecular studies with this metabolically important transporter, Based on both structural and functional considerations, the yeast DTP is assignable to the mitochondrial carrier family. Additionally, the development of a procedure that enables the expression and isolation of large quantities of functional DTP provides the foundation for comprehensive investigations into the structure/function relationships within this transporter via site-directed mutagenesis, as well as for the initiation of crystallization trials.	UNIV S ALABAMA,COLL MED,DEPT PHARMACOL,MOBILE,AL 36688; UNIV S ALABAMA,COLL MED,DEPT PEDIAT,MOBILE,AL 36688	University of South Alabama; University of South Alabama			Mayor, June/AAP-1544-2021		NIDDK NIH HHS [DK-44993] Funding Source: Medline; NIGMS NIH HHS [GM-54642] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; CHATEAUBODEAU GD, 1974, FEBS LETT, V46, P184, DOI 10.1016/0014-5793(74)80364-9; COTY WA, 1975, MOL CELL BIOCHEM, V9, P109, DOI 10.1007/BF01732202; CROMPTON M, 1974, FEBS LETT, V46, P247, DOI 10.1016/0014-5793(74)80379-0; CROMPTON M, 1974, BIOCHEM J, V142, P127, DOI 10.1042/bj1420127; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GRIBSKOV M, 1991, SEQUENCE ANAL PRIMER, P233; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; INDIVERI C, 1993, BIOCHIM BIOPHYS ACTA, V1143, P310, DOI 10.1016/0005-2728(93)90202-Q; INDIVERI C, 1989, BIOCHIM BIOPHYS ACTA, V977, P187, DOI 10.1016/S0005-2728(89)80070-2; JOHNSON RN, 1973, BIOCHEM J, V134, P769, DOI 10.1042/bj1340769; KAPLAN RS, 1990, ARCH BIOCHEM BIOPHYS, V280, P181, DOI 10.1016/0003-9861(90)90534-6; KAPLAN RS, 1991, ARCH BIOCHEM BIOPHYS, V287, P305, DOI 10.1016/0003-9861(91)90483-Y; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1985, J BIOL CHEM, V260, P293; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KAPLAN RS, 1996, MOL BIOL MEMBRANE TR, P277; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOLAROV J, 1972, BIOCHIM BIOPHYS ACTA, V267, P457, DOI 10.1016/0005-2728(72)90173-9; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LancarBenba J, 1996, BIOCHIMIE, V78, P195, DOI 10.1016/0300-9084(96)89505-8; LANCARBENBA J, 1994, BBA-BIOMEMBRANES, V1190, P213, DOI 10.1016/0005-2736(94)90076-0; MEIJER AJ, 1970, FEBS LETT, V8, P41, DOI 10.1016/0014-5793(70)80220-4; PALMIERI F, 1974, BIOCHIM BIOPHYS ACTA, V333, P195, DOI 10.1016/0005-2728(74)90004-8; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PALMIERI F, 1971, EUR J BIOCHEM, V22, P66, DOI 10.1111/j.1432-1033.1971.tb01515.x; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PERKINS M, 1973, BIOCHEM J, V134, P923, DOI 10.1042/bj1340923; PERKINS M, 1972, FEBS LETT, V25, P271, DOI 10.1016/0014-5793(72)80501-5; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; QUAGLIARIELLO E, 1972, BIOCH BIOPHYSICS MIT, P659; ROBINSON BH, 1970, FEBS LETT, V11, P200, DOI 10.1016/0014-5793(70)80528-2; ROBINSON BH, 1970, BIOCHIM BIOPHYS ACTA, V216, P63, DOI 10.1016/0005-2728(70)90159-3; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SOLING HD, 1976, GLUCONEOGENESIS ITS, P369; SZEWCZYK A, 1987, BIOCHIM BIOPHYS ACTA, V894, P252, DOI 10.1016/0005-2728(87)90194-0; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; VINAS O, 1990, BIOCHEM J, V265, P321, DOI 10.1042/bj2650321; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255	51	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4516	4521		10.1074/jbc.272.7.4516	http://dx.doi.org/10.1074/jbc.272.7.4516			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020177	hybrid			2022-12-25	WOS:A1997WH01900093
J	Kuppuswamy, D; Kerr, C; Narishige, T; Sasi, VS; Menick, DR; Cooper, G				Kuppuswamy, D; Kerr, C; Narishige, T; Sasi, VS; Menick, DR; Cooper, G			Association of tyrosine-phosphorylated c-Src with the cytoskeleton of hypertrophying myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; ANNEXIN-II TETRAMER; SIGNAL-TRANSDUCTION; CONTRACTILE DYSFUNCTION; EXTRACELLULAR-MATRIX; PLATELET-AGGREGATION; MEMBRANE SKELETON; CELL-CELL; INTEGRIN	Given the central position of the focal adhesion complex, both physically in coupling integrins to the interstitium and biochemically in providing an upstream site for anabolic signal generation, we asked whether the recruitment of non-receptor tyrosine kinases to the cytoskeleton might be a mechanism whereby cellular loading could activate growth regulatory signals responsible for cardiac hypertrophy. Analysis revealed cytoskeletal association of c-Src, FAX, and beta 3-integrin, but no Fyn, in the pressure-overloaded right ventricle, This association was seen as early as 4 h after right ventricular pressure overloading, increased through 48 h, and reverted to normal in 1 week, Cytoskeletal binding of nonreceptor tyrosine kinases was synchronous with tyro sine phosphorylation of several cytoskeletal proteins, including c-Src. Examination of cytoskeleton-bound c. Src revealed that a significant portion of the tyrosine phosphorylation was not at the Tyr-527 site and therefore presumably was at the Tyr-416 site, Thus, these studies strongly suggest that non-receptor tyrosine kinases, in particular c-Src, may play a critical role in hypertrophic growth regulation by their association with cytoskeletal structures, possibly via load activation of integrin-mediated signaling,	MED UNIV S CAROLINA,DEPT CELL BIOL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT BIOCHEM,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT PHYSIOL,GAZES CARDIAC RES INST,CHARLESTON,SC 29425; MED UNIV S CAROLINA,VET ADM HOSP,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Kuppuswamy, D (corresponding author), MED UNIV S CAROLINA,DIV CARDIOL,DEPT MED,CARDIOL SECT,CHARLESTON,SC 29425, USA.				NHLBI NIH HHS [HL-48788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; COOPER G, 1973, CIRC RES, V33, P213, DOI 10.1161/01.RES.33.2.213; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FEDER D, 1990, J BIOL CHEM, V265, P8205; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HESKETH JE, 1991, BIOCHEM J, V277, P1; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; INGBER DE, 1991, CHEST, V99, P34; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; ODA A, 1992, J BIOL CHEM, V267, P20075; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; ROZICH JD, 1995, J MOL CELL CARDIOL, V27, P485, DOI 10.1016/S0022-2828(08)80044-2; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Tagawa H, 1996, CIRCULATION, V93, P1230, DOI 10.1161/01.CIR.93.6.1230; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; TURNER CE, 1991, CURR OPIN CELL BIOL, V3, P869; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHIDKOVA NI, 1995, BIOCHEM BIOPH RES CO, V214, P279, DOI 10.1006/bbrc.1995.2285	44	98	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4500	4508		10.1074/jbc.272.7.4500	http://dx.doi.org/10.1074/jbc.272.7.4500			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020175	hybrid			2022-12-25	WOS:A1997WH01900091
J	Papkoff, J				Papkoff, J			Regulation of complexed and free catenin pools by distinct mechanisms - Differential effects of Wnt-1 and v-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CELL-CELL-ADHESION; TYROSINE KINASE SUBSTRATE; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; E-CADHERIN; ALPHA-CATENIN; SIGNAL-TRANSDUCTION; GENE-PRODUCT; CARCINOMA-CELLS	Cadherins are transmembrane receptors with an extracellular domain that participates in homophilic cell to cell adhesion and a cytoplasmic domain that associates with proteins called catenins. Cadherin-mediated adhesion as well as adhesion-independent functions for catenins play important roles in differentiation, development, and malignant transformation. Mechanisms that regulate steady-state catenin levels and cadherin-catenin complex stability are poorly understood, but activities of both the Wnt-1 proto-oncogene and tyrosine kinases are implicated. Here I define, at the biochemical level, distinct mechanisms that modulate steady-state catenin levels. Increased cadherin expression, providing more catenin binding sites, leads to selective stabilization of the cadherin-associated population of alpha- and beta-catenin, but not p120(cas). In contrast, expression of Wnt-1 leads primarily to increased stability of the uncomplexed pool of beta-catenin without effect on p120(cas), Significantly, the Wnt-1-induced stabilization of uncomplexed beta-catenin is independent of cadherin expression. Transformation by v-Src does not disrupt the catenin-cadherin complex despite the phosphorylation of E-cadherin and beta-catenin on tyrosine. In contrast to the effects of Wnt-1, v-Src does not modulate the uncomplexed population of beta-catenin. p120(cas) is phosphorylated on tyrosine by v-Src, and this is accompanied by a significant decrease in the level of uncomplexed p120(cas) as well as a change in behavior of p120(cas) upon biochemical fractionation. Taken together these data suggest that p120(cas) and beta-catenin are regulated independently.	SUGEN INC, REDWOOD CITY, CA 94063 USA									ABERLE H, 1994, J CELL SCI, V107, P3655; AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNK U, 1976, EXP CELL RES, V103, P295, DOI 10.1016/0014-4827(76)90266-4; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; CHINKERS M, 1981, J CELL BIOL, V88, P422, DOI 10.1083/jcb.88.2.422; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; DOWNING JR, 1991, ONCOGENE, V6, P607; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; FINNEMANN S, 1995, MOL CELL BIOL, V15, P5082; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Kemler R, 1992, Semin Cell Biol, V3, P149; KIM L, 1995, MOL CELL BIOL, V15, P4553; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nathke Inke S., 1995, Seminars in Developmental Biology, V6, P89, DOI 10.1016/S1044-5781(06)80018-6; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158	69	128	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4536	4543						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020180				2022-12-25	WOS:A1997WH01900096
J	Wang, JF; Sirenko, O; Needleman, R				Wang, JF; Sirenko, O; Needleman, R			Genomic footprinting of Mig1p in the MAL62 promoter - Binding is dependent upon carbon source and competitive with the Mal63p activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; IN-VIVO; YEAST; PROTEIN; COMPLEX; DNA; TRANSFORMATION	Mig1p inhibits gene expression in glucose by binding the Cyc8p (Ssn6p)-Tup1p repressor to the promoter of glucose-repressible genes. While the binding properties of Mig1p have been studied in vitro and the ability of Mig1p-Cyc8p (Ssn6p)-Tup1p to repress has been studied in vivo, no experiments have measured the effect of a carbon source on the in vivo binding of Mig1p or the effect of bound MIg1p on activator occupancy of the upstream activation sequence (UAS). To obtain this information, we used genomic footprinting to investigate glucose repression of MAL62, a gene that is also regulated by the Mal63p activator. These experiments show that two interrelated mechanisms are involved in the glucose repression of MAL62: 1) competition between the Mal63p activator and Mig1p for DNA binding and 2) modulation of Mig1p binding by the carbon source. Mig1p affects basal MAL62 expression in the absence of Mal63p by binding to a site in the MAL62 promoter and affects Mal63p-dependent synthesis by also inhibiting the access of Mal63p to site 1 in the UAS(MAL). The binding of Mig1p is increased in glucose and decreased in non-repressing sugars, but the increased binding in glucose is not due to an increase in the levels of Mig1p.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; CHANG M, 1994, THESIS WAYNE STATE U; COOPER TG, 1976, J BIOL CHEM, V251, P7278; DECKERT J, 1995, MOL CELL BIOL, V15, P6109; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HU Z, 1995, CURR GENET, V28, P258, DOI 10.1007/BF00309785; HUIBREGTSE JM, 1991, METHOD ENZYMOL, V194, P550; HULL MW, 1991, METHOD CELL BIOL, V35, P383; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; LEVINE J, 1992, CURR GENET, V22, P181, DOI 10.1007/BF00351724; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MATHIEU M, 1994, EMBO J, V13, P4022, DOI 10.1002/j.1460-2075.1994.tb06718.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NEEDLEMAN RB, 1984, P NATL ACAD SCI-BIOL, V81, P2811, DOI 10.1073/pnas.81.9.2811; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NI B, 1990, MOL CELL BIOL, V10, P3797, DOI 10.1128/MCB.10.7.3797; NI B, 1992, THESIS WAYNE STATE U; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIRENKO OI, 1995, CURR GENET, V27, P509, DOI 10.1007/BF00314440; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; VALLIER LG, 1994, GENETICS, V137, P49; Wang JF, 1996, GENETICS, V142, P51; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; YAO B, 1994, MOL GEN GENET, V243, P622, DOI 10.1007/BF00279571	33	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4613	4622		10.1074/jbc.272.7.4613	http://dx.doi.org/10.1074/jbc.272.7.4613			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020190	hybrid			2022-12-25	WOS:A1997WH01900106
J	Arap, W; Knudsen, ES; Wang, JYJ; Cavenee, WK; Huang, HJS				Arap, W; Knudsen, ES; Wang, JYJ; Cavenee, WK; Huang, HJS			Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma	ONCOGENE			English	Article						tumor suppressor gene; CDKN2A; p16(INK4a); RB; mutation; glioma	CELL-CYCLE INHIBITION; HOMOZYGOUS DELETIONS; CDK4 AMPLIFICATION; HUMAN ASTROCYTOMAS; GENE-MUTATIONS; P16; RETINOBLASTOMA; P16(INK4); PROTEIN; LINES	Deletions of chromosomal region 9p21 are among the most common genetic alterations observed during the clonal evolution of high grade malignant gliomas. Structural and functional evidence has suggested that homozygous deletion involving CDKN2A (the genetic locus encoding the cyclin-dependent kinase inhibitor p16(INK4a)) is mechanism of inactivation of this gene and that it can be a growth suppressor in human gliomas. However, the presence of other potential suppressor genes in the 9p21 region and the relatively large sizes of the deletions has made it difficult to be certain that the CDKN2A gene is their actual target. Here, we tested this hypothesis by determining the growth suppressive effects, cell cycle inhibitions, and the activities of seven naturally occurring glioma-derived CDKN2A alleles carrying point mutations and found that two of them were functionally compromised. To resolve discrepancies among the different existing functional assays, we developed an assay for p16(INK4a) function that allowed us to demonstrate that the expression of wild-type CDKN2A, but not alleles with inactivating mutations, prevents pRB phosphorylation in vivo in human glioma cells. These data suggest that CDKN2A is a critical target for mutational inactivation in human malignant gliomas.	UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; STANFORD UNIV,CAN BIOL PROGRAM,STANFORD,CA 94305	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Costello JF, 1996, CANCER RES, V56, P2405; DURO D, 1995, ONCOGENE, V11, P21; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GIANI C, 1994, CANCER RES, V54, P6338; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GURNARI GB, 1995, CANCER SURV, V25, P233; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; JAMES CD, 1993, CANCER RES, V53, P3674; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kyritsis A. P., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P582; Kyritsis AP, 1996, ONCOGENE, V12, P63; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOULTON T, 1995, AM J PATHOL, V146, P613; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLOPADE OI, 1992, CANCER RES, V52, P2523; Parry D, 1996, MOL CELL BIOL, V16, P3844; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STONE S, 1995, CANCER RES, V55, P2988; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DG, 1995, CANCER RES, V55, P20; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YANG R, 1995, CANCER RES, V55, P2503	45	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					603	609		10.1038/sj.onc.1200870	http://dx.doi.org/10.1038/sj.onc.1200870			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053859				2022-12-25	WOS:A1997WF52400012
J	deRooij, J; Bos, JL				deRooij, J; Bos, JL			Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras	ONCOGENE			English	Article						Ras; small GTPases; activation-specific probes	KINASE; IDENTIFICATION; STIMULATION; ONCOGENES; P21(RAS); COMPLEX; P21RAS; CELLS	Ras is a small GTPase that cycles between an inactive GDP-bound and an active GTP-bound form. A large variety of ligands that stimulate cell surface receptors induce the activation of Ras. Thus far, this activation could only be measured by the increase of GTP bound to Ras, which was precipitated from radio-labelled cell extract. We have used the minimal Ras-binding domain (RED) of Ran (aa 51-131) to identify in vivo activated Ras. This novel method is based on the observation that RED binds RasGTP in vitro with a Kd of 20 nM whereas the affinity between RED and RasGDP is three orders of magnitude lower. Here we show that the Gst-RBD fusion protein precipitates transfected RasL61 (RasGTP) but not RasN17 (RasGDP) from cell lysates. In addition, we demonstrate for two different cell lines that the increase in RasGTP is reflected by an increase in Ras bound to Gst-RBD. From these results we conclude that the minimal Ras-binding domain of Raf1 is an excellent activation specific-probe for Ras.	UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3584 CG UTRECHT,NETHERLANDS	Utrecht University			de rooij, johan/C-1325-2019					BOS JL, 1989, CANCER RES, V49, P4682; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FRANKE B, 1997, IN PRESS EMBO J; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOODIE SA, 1993, SCIENCE, V260; PONTING CP, 1996, TRENDS BIOCHEM SCI, V21, P423; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; VANWEERING DHJ, 1997, IN RPESS J BIOL CHEM; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wolthuis RMF, 1996, ONCOGENE, V13, P353; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	22	405	408	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					623	625		10.1038/sj.onc.1201005	http://dx.doi.org/10.1038/sj.onc.1201005			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053862				2022-12-25	WOS:A1997WF52400015
J	Sun, Y; Bian, JH; Wang, YL; Jacobs, C				Sun, Y; Bian, JH; Wang, YL; Jacobs, C			Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound	ONCOGENE			English	Article						phenanthroline; p53; transcriptional activation; apoptosis; redox regulation	WILD-TYPE P53; CELL-CYCLE CHECKPOINT; DNA-BINDING; ANTICANCER AGENTS; APOPTOSIS; SEQUENCE; CONFORMATION; INDUCTION; PROTEIN; GENE	p53, a tumor suppressor gene, functioning as transcription factor, has been recently shown in a cell free system to be subject to redox (reduction/oxidation) regulation. Oxidants or metal chelating reagents disrupt wildtype p53 conformation and decrease or abolish its DNA binding activity, while reductants restore wildtype conformation and increase DNA binding. We have extended these observations to intact cell systems by using luciferase transactivation assay in two murine tumor cell lines, both harboring endogenous wildtype p53. The results showed that none of these in vitro active reagents, except 1,10-phenanthroline (OF) has a significant effect on p53 transactivation activity. OF, a metal chelator and p53 inactivator in cell free systems, however, induces p53 transactivation activity as well as sequence-specific DNA binding in a dose dependent manner. OP also differentially induces endogenous expression of several known p53 target genes such as Waf-1 and Mdm-2, but not Bar, Gadd45, and PCNA. Increased p53 activity induced by OP is not due to elevated p53 mRNA nor to protein levels. Furthermore, the OP-induced p53 transcriptional activation is not due to its potential DNA intercalating activity, but mainly due to its metal chelating activity. OF was also found to induce dramatically apoptotic cell death in these tumor cells harboring wildtype p53, to a less extent in MEF cells from p53 knockout mice and not at all in Saos-2 cells without p53 or Rb. We concluded from this study that (a) unlike what has been seen in vitro, OP induces p53 activity in intact cells (b) OP activates p53 transcriptional activity without increasing p53 protein; and (c) activation of p53 may contribute to apoptosis, but is not required.			Sun, Y (corresponding author), WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT MOL BIOL, 2800 PLYMOUTH RD, ANN ARBOR, MI 48105 USA.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ADEBODUN F, 1995, J CELL PHYSIOL, V163, P80, DOI 10.1002/jcp.1041630109; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRY DW, 1985, BIOCHEM PHARMACOL, V34, P3499, DOI 10.1016/0006-2952(85)90724-5; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUGHES FM, 1994, J STEROID BIOCHEM, V49, P303, DOI 10.1016/0960-0760(94)90272-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; SEBOLT JS, 1987, CANCER RES, V47, P4299; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SRINIVASAN R, 1993, CANCER RES, V53, P5361; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; SUN Y, 1995, INT J ONCOL, V6, P465; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; WHITACRE CM, 1995, CANCER RES, V55, P3697; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YI S, 1993, INT J CANCER, V55, P952, DOI 10.1002/ijc.2910550613; ZALEWSKI PD, 1991, BIOCHEM INT, V24, P1093; ZHAN QM, 1994, ONCOGENE, V9, P3743	55	75	79	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					385	393		10.1038/sj.onc.1200834	http://dx.doi.org/10.1038/sj.onc.1200834			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053835				2022-12-25	WOS:A1997WE36400001
J	Cote, GP; Luo, X; Murphy, MB; Egelhoff, TT				Cote, GP; Luo, X; Murphy, MB; Egelhoff, TT			Mapping of the novel protein kinase catalytic domain of Dictyostelium myosin II heavy chain kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE KINASE; PHOSPHORYLATION; FAMILY; HISTIDINE	Myosin heavy chain kinase A (MHCK A) in Dictyostelium was identified as a biochemical activity that phosphorylates threonine residues in the myosin II tail domain and regulates myosin filament assembly. The catalytic domain of MHCK A has now been mapped through the functional characterization of a series of MHCK A truncation mutants expressed in Escherichia coli, A recombinant protein comprising the central nonrepetitive domain of MHCK A (residues 552-841) was isolated in a soluble form and shown to phosphorylate Dictyostelium myosin II, myelin basic protein, and a synthetic peptide substrate, The functionally mapped catalytic domain of MHCK A shows no detectable sequence similarity to known classes of eukaryotic protein kinases but shares substantial sequence similarity with a transcribed Caenorhabditis elegans gene and with the mammalian elongation factor-a kinase (calcium/ calmodulin dependent protein kinase III). We suggest that MHCK A represents the prototype for a novel, widely occurring protein kinase family.	CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA	Case Western Reserve University; Queens University - Canada					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050009, R29GM050009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COTE GP, 1987, J BIOL CHEM, V262, P13033; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Kolman MF, 1996, J CELL BIOL, V132, P101, DOI 10.1083/jcb.132.1.101; MEDLEY QG, 1991, METHOD ENZYMOL, V196, P23; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; POPOV KM, 1993, J BIOL CHEM, V268, P26602; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VELASCO MA, 1993, PROTEIN EXPRES PURIF, V4, P328	16	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6846	6849		10.1074/jbc.272.11.6846	http://dx.doi.org/10.1074/jbc.272.11.6846			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054368	hybrid			2022-12-25	WOS:A1997WN14700007
J	Sobieszek, A; Babiychuk, EB; Ortner, B; Borkowski, J				Sobieszek, A; Babiychuk, EB; Ortner, B; Borkowski, J			Purification and characterization of a kinase-associated, myofibrillar smooth muscle myosin light chain phosphatase possessing a calmodulin-targeting subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; VERTEBRATE NON-MUSCLE; PROTEIN PHOSPHATASES; REACTION-MECHANISM; PHOSPHORYLATION; BINDING; CONTRACTILE; ACTIVATION; DEPHOSPHORYLATION; CALCIUM	A myofibrillar form of smooth muscle myosin light chain phosphatase (MLCPase) was purified hom turkey gizzard myofibrils, and it was found to be closely associated with the myosin light chain kinase (MLCHase). For this reason we have named this phosphatase the kinase- and myosin-associated protein phosphatase (HAMPPase). Subunits of the KAMPPase could be identified during the first ion exchange chromatography step. After further purification on calmodulin (CaM) and on thiophosphorylated regulatory myosin light chain affinity columns we obtained either a homogenous preparation of a 37-kDa catalytic (PC) subunit or a mixture of the PC subunit and variable amounts of a 67-kDa targeting (PT) subunit. The PT subunit bound the PC subunit to CaM affinity columns in a Ca2+-independent manner; thus, elution of the subunits required only high salt concentration. Specificity of interaction between these subunits was shown by the following observations: 1) activity of isolated PC subunit, but not of the PTC holoenzyme, was stimulated 10-20-fold after preincubation with 5-50 mu M Of CoCl2; 2) the pH activity profile of the PC subunit was modified by the PT subunit (the specific activity of the PTC holoenzyme was higher at neutral pH and lower at alkaline pH); and 3) affinity of the holoenzyme for unphosphorylated myosin was 3-fold higher, and for phosphorylated myosin it was 2-fold lower, in comparison with that of the purified PC subunit. KAMPPase was inhibited by okadaic acid (K-i = 250 nM), microcystin-LR (50 nM) and calyculin A (1.5 mu M) but not by arachidonic acid or the heat-stable inhibitor (I-2), which suggested that this is a type PP1 or PP2A protein phosphatase.			Sobieszek, A (corresponding author), AUSTRIAN ACAD SCI, INST MOL BIOL, BILLROTHSTR 11, A-5020 SALZBURG, AUSTRIA.		Sobieszek, Apolinary/AAD-8985-2022; Babiychuk, Eduard/AAV-7223-2021	Sobieszek, Apolinary/0000-0003-4915-9621; Borkowski, Jacek/0000-0002-5535-5955; Babiychuk, Eduard/0000-0003-1786-0085				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; CONTI MA, 1991, METHOD ENZYMOL, V196, P34; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CROSS RA, 1985, FEBS LETT, V188, P367, DOI 10.1016/0014-5793(85)80404-X; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; DISALVO J, 1988, ADV PROTEIN PHOSPHAT, V1, P327; GONG MC, 1992, J BIOL CHEM, V267, P21492; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; JOHNSON JD, 1995, ADV SEC MESS PHOSPH, V30, P153; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KENDRICKJONES J, 1987, J MOL BIOL, V198, P241, DOI 10.1016/0022-2836(87)90310-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MITSUI T, 1992, J BIOL CHEM, V267, P16727; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; OKUBO S, 1993, ADV PROTEIN PHOSPHAT, V7, P295; ONISHI H, 1982, J BIOCHEM, V91, P265, DOI 10.1093/oxfordjournals.jbchem.a133684; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATO MD, 1980, J BIOL CHEM, V255, P6535; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOBIESZEK A, 1994, ELECTROPHORESIS, V15, P1014, DOI 10.1002/elps.11501501151; SOBIESZEK A, 1988, ANAL BIOCHEM, V172, P43, DOI 10.1016/0003-2697(88)90409-5; SOBIESZEK A, 1975, EUR J BIOCHEM, V55, P49, DOI 10.1111/j.1432-1033.1975.tb02137.x; SOBIESZEK A, 1995, BIOCHEMISTRY-US, V34, P11855, DOI 10.1021/bi00037a025; Sobieszek A, 1997, J BIOL CHEM, V272, P7034, DOI 10.1074/jbc.272.11.7034; SOBIESZEK A, 1991, J MOL BIOL, V220, P947, DOI 10.1016/0022-2836(91)90365-D; SOBIESZEK A, 1990, J MUSCLE RES CELL M, V11, P114, DOI 10.1007/BF01766490; SOBIESZEK A, 1977, J MOL BIOL, V112, P559, DOI 10.1016/S0022-2836(77)80164-2; SOBIESZEK A, 1991, EUR J BIOCHEM, V199, P735, DOI 10.1111/j.1432-1033.1991.tb16178.x; Sobieszek A., 1977, BIOCH SMOOTH MUSCLE, P413; Sobieszek A., 1994, AIRWAYS SMOOTH MUSCL, P1; SOBIESZEK A, 1984, SMOOTH MUSCLE CONTRA, P283; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WERTH DK, 1982, J BIOL CHEM, V257, P7306	44	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7027	7033		10.1074/jbc.272.11.7027	http://dx.doi.org/10.1074/jbc.272.11.7027			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054393	hybrid			2022-12-25	WOS:A1997WN14700032
J	Hsu, YR; Wu, GM; Mendiaz, EA; Syed, R; Wypych, J; Toso, R; Mann, MB; Boone, TC; Narhi, LO; Lu, HS; Langley, KE				Hsu, YR; Wu, GM; Mendiaz, EA; Syed, R; Wypych, J; Toso, R; Mann, MB; Boone, TC; Narhi, LO; Lu, HS; Langley, KE			The majority of stem cell factor exists as monomer under physiological conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; GROWTH-FACTOR; KIT RECEPTOR; HUMAN SERUM; BINDING; LIGAND; RAT; DIMERIZATION	Soluble Escherichia coli-derived recombinant human stem cell factor (rhSCF) forms a non-covalently associated dimer. We have determined a dimer association constant (K-a) of 2-4 x 10(8) M(-1), using sedimentation equilibrium and size exclusion chromatography. SCF has been shown previously to be present at concentrations of approximately 3.3 ng/ml in human serum, Based on the dimerization K-a, greater than 90% of the circulating SCF would be in the monomeric form. When I-125-rhSCF was added to human serum and the serum analyzed by size exclusion chromatography, 72-49% of rhSCF was monomer when the total SCF concentration was in the range of 10-100 ng/ml, consistent with the K-a determination. Three SCF variants, SCF(F63C), SCF (V49L,F63L), and SCF(A165C), were recombinantly expressed in Escherichia coli, purified, and characterized. The dimer K-a values, biophysical properties, and biological activities of these variants were studied. Dimerization-defective variants SCF(F63C)S-CH2CONH2 and SCF(V49L,F63L) showed substantially reduced mitogenic activity, while the activity of the Cys(165)-Cys(165) disulfide-linked SCF(A165C) dimer was 10-fold higher than that of wild type rhSCF. The results suggest a correlation between dimerization affinity and biological activity, consistent with a model in which SCF dimerization mediates dimerization of its receptor, Kit, and subsequent signal transduction.			Hsu, YR (corresponding author), AMGEN INC, AMGEN CTR, 14-2-E, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.							ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; DAS SK, 1982, J BIOL CHEM, V257, P13679; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; ERLICH HA, 1989, PCR TECHNOLOGY, P61; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hsu YR, 1996, PROTEIN SCI, V5, P1165; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; LANGLEY KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P55, DOI 10.1006/abbi.1994.1208; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LANGLEY KE, 1993, BLOOD, V81, P656; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1992, J BIOL CHEM, V267, P10866; LU HS, 1995, BIOCHEM J, V305, P563, DOI 10.1042/bj3050563; LU HS, 1991, J BIOL CHEM, V266, P8102; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; McClanahan T, 1996, BLOOD, V88, P3371, DOI 10.1182/blood.V88.9.3371.bloodjournal8893371; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PHILO J, 1994, J BIOL CHEM, V269, P27840; Philo JS, 1996, J BIOL CHEM, V271, P6895, DOI 10.1074/jbc.271.12.6895; SMITH KA, 1992, CURRENT PROTOCOLS IM; Timasheff S. N., 1970, ENZYMES, VII, P371; TURNER AM, 1995, BLOOD, V85, P2052, DOI 10.1182/blood.V85.8.2052.bloodjournal8582052; ULLICH A, 1990, CELL, V61, P203; WILKS AF, 1993, ADV CANCER RES, V60, P43; WYPYCH J, 1995, BLOOD, V85, P66, DOI 10.1182/blood.V85.1.66.bloodjournal85166	33	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6406	6415		10.1074/jbc.272.10.6406	http://dx.doi.org/10.1074/jbc.272.10.6406			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045664	hybrid			2022-12-25	WOS:A1997WM64700048
J	Kanai, M; Goke, M; Tsunekawa, S; Podolsky, DK				Kanai, M; Goke, M; Tsunekawa, S; Podolsky, DK			Signal transduction pathway of human fibroblast growth factor receptor 3 - Identification of a novel 66-kDa phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; TYROSINE PHOSPHORYLATION; LIGAND-BINDING; AUTOPHOSPHORYLATION SITES; FACTORS STIMULATE; SOS-GRB2 COMPLEX; DOMAIN-III; FACTOR-I; PROTEIN; KINASE	Stimulation of fibroblast growth factor receptor 3 (FGFR3) results in a variety of functional effects, including regulation of epithelial cell growth and differentiation, In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain, Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb expressing cells responded only to FGF-1, Activation of FGFR3 upon ligand binding resulted in activation of mitogen-activated protein kinase pathway, FGFR3 utilizes two different pools of adapter protein GRB2 to link to Pas, Activated FGFR3 predominantly interacts with GRB2 . Sos in complex with a previously identified 90-kDa protein and designated protein 80K-H, In addition, 80K-H . GRB2 . Sos complex was found to con tain a novel 66-kDa protein, Tyrosine phophorylation of the 66-kDa protein was dependent on ligand activation of FGFR3, suggesting that the 66-kDa protein may play an important role in FGFR3-specific signaling, In addition to this unique pathway, FGFR3 also links to GRB2 . Sos complex via the adapter protein Shc. Furthermore, activated FGFR3 was not able to induce dissociation of GRB2 . Sos complex following Sos phosphorylation, In summary, FGFR3 signaling pathway utilizes two GRB2-containing complexes; Shc . GRB2 . Sos and 80K-H . pp66 . GRB2 . Sos; these two complexes may alternatively link FGFG3 to mitogen-activated protein kinase, Finally, activated FGFR3 was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of c-Src.	MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR STUDY INFLAMMATORY BOWEL DIS, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041557, P30DK043351, R37DK041557] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43351, DK41557] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CREUZET C, 1995, J NEUROCHEM, V64, P1541; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Holt KH, 1996, MOL CELL BIOL, V16, P577; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KANAI M, 1997, IN PRESS AM J PHYSL; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LANDGREN E, 1995, ONCOGENE, V10, P2027; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MURGUE B, 1994, CANCER RES, V54, P5206; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS KG, 1992, DEVELOPMENT, V114, P233; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SantosOcampo S, 1996, J BIOL CHEM, V271, P1726, DOI 10.1074/jbc.271.3.1726; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAOUL E, 1995, ONCOGENE, V10, P1553; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOLER C, 1994, ONCOGENE, V9, P2207; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221	60	123	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6621	6628		10.1074/jbc.272.10.6621	http://dx.doi.org/10.1074/jbc.272.10.6621			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045692	hybrid			2022-12-25	WOS:A1997WM64700076
J	Liao, DF; Monia, B; Dean, N; Berk, BC				Liao, DF; Monia, B; Dean, N; Berk, BC			Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SELECTIVE-INHIBITION; MESANGIAL CELLS; PHORBOL ESTERS; MESSENGER-RNA; MAP KINASE; IN-VITRO; GROWTH; EXPRESSION	Activation of 44 and 42 kDa extracellular signal-regulated kinases (ERK)1/2 by angiotensin II (angII) plays an important role in vascular smooth muscle cell (VSMC) function, The dual specificity mitogen-actived protein (MAP) kinase/ERK kinase (MEK) activates ERK1/S in response to angII, but the MEK activating kinases remain undefined, Raf is a candidate MEK kinase, However, a kinase other than Raf appears responsible for angII-mediated signal transduction because we showed previously that treatment with 1 mu M phorbol 12,13-dibutyrate (PDBU) for 24 h completely blocked Raf-Ras association in VSMC but did not inhibit activation of MEK and ERK1/2 by angII. We hypothesized that an atypical protein kinase C (PKC) isoform, which lacks a phorbol ester binding domain, mediated ERK1/2 activation by angII, Western blot analysis of rat aortic VSMC with PKC isoform-specific antibodies showed PKC-alpha, -beta 1, delta, -epsilon, and -zeta in relative abundance. All isoforms except PKC-zeta were down regulated by 1 mu M PDBU for 24 h suggesting that PKC zeta was responsible for angII-mediated ERK1/2 activation. In response to angII, PKC-zeta associated with Pas as shown by co precipitation of PKC-zeta with anti H-Ras antibody, To characterize further the role of PKC-zeta, PKC-zeta protein was depleted specifically by transfection with antisense PKC-zeta oligonucleotides. Antisense PKC-zeta oligonucleotide treatment significantly decreased PKC-zeta protein expression (without effect on other PKC isoforms) and angII-mediated ERK1/2 activation in a concentration dependent manner. In contrast, ERK1/2 activation by platelet-derived growth factor and phorbol ester was not significantly inhibited, These results demonstrate an important difference in signal transduction by angII compared with PDGF and phorbol ester in VSMC, and suggest a critical role for PKC-zeta and Ras in angII stimulation of ERK1/2.	UNIV WASHINGTON,DIV CARDIOL,DEPT MED,SEATTLE,WA 98195; ISIS PHARMACEUT,CARLSBAD,CA 92008	University of Washington; University of Washington Seattle; Isis Pharmaceuticals Inc				Berk, Bradford/0000-0002-2767-4115				ALLEN BG, 1994, J BIOL CHEM, V269, P29288; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1993, J CELL PHYSIOL, V154, P368, DOI 10.1002/jcp.1041540221; BERK BC, 1996, NA PLUS H PLUS EXCHA, P47; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHOUDHURY GG, 1994, KIDNEY INT, V46, P37, DOI 10.1038/ki.1994.242; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DIXON BS, 1994, AM J PHYSIOL, V266, pC1406, DOI 10.1152/ajpcell.1994.266.5.C1406; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FORCE T, 1991, J BIOL CHEM, V266, P6650; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GSCHWENDT M, 1992, FEBS LETT, V307, P151, DOI 10.1016/0014-5793(92)80756-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Liao DF, 1996, CIRC RES, V79, P1007, DOI 10.1161/01.RES.79.5.1007; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MONIA BP, 1992, J BIOL CHEM, V267, P19954; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; STEPHENS EV, 1993, ONCOGENE, V8, P19; STOKEO D, 1994, SCIENCE, V364, P1463; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TOKER A, 1994, J BIOL CHEM, V269, P32358; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	46	198	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6146	6150		10.1074/jbc.272.10.6146	http://dx.doi.org/10.1074/jbc.272.10.6146			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045626	hybrid			2022-12-25	WOS:A1997WM64700010
J	SeguraAguilar, J; Baez, S; Widersten, M; Welch, CJ; Mannervik, B				SeguraAguilar, J; Baez, S; Widersten, M; Welch, CJ; Mannervik, B			Human class mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; ONE-ELECTRON REDUCTION; SUPEROXIDE-DISMUTASE; DT-DIAPHORASE; S-TRANSFERASES; ORTHO-QUINONE; CATALASE; NEUROTOXICITY; TOXICITY; KIDNEY	Human glutathione transferases (GSTs) were shown to catalyze the reductive glutathione conjugation of aminochrome (2,3-dihydroindole-5,6-dione), The class Mu enzyme GST M2-2 displayed the highest specific activity (148 mu mol/min/mg), whereas GSTs A1-1, A2-2, M1-1, M3-3, and P1-1 had markedly lower activities (<1 mu mol/min/mg), The product of the conjugation, with a UV spectrum exhibiting absorption peaks at 277 and 295 nm, was 4-S-glutathionyl-5,6-dihydroxyindoline as determined by NMR spectroscopy, In contrast to reduced forms of aminochrome (leucoaminochrome and o-semiquinone), 4-S-glutathionyl-5,6-dihydroxyindoline was stable in the presence of molecular oxygen, superoxide radicals, and hydrogen peroxide. However, the strongly oxidizing complex of Mn3+ and pyrophosphate oxidizes 4-S-glutathionyl-5,6-dihydroxyindoline to 4-S-glutathionylaminochrome, a new quinone derivative with an absorption peak at 620 nm, GST M2-2 (and to a lower degree, GST M1-1) prevents the formation of reactive oxygen species linked to one-electron reduction of aminochrome catalyzed by NADPH-cytochrome P450 reductase. The results suggest that the reductive conjugation of aminochrome catalyzed by GSTs, in particular GST M2-2, is an important cellular antioxidant activity preventing the formation of o-semiquinone and thereby the generation of reactive oxygen species.	UNIV UPPSALA,CTR BIOMED,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN; UNIV UPPSALA,CTR BIOMED,DIV ORGAN PHARMACEUT CHEM,S-75123 UPPSALA,SWEDEN; UNIV STOCKHOLM,WALLENBERG LAB,BIOCHEM TOXICOL UNIT,S-10691 STOCKHOLM,SWEDEN	Uppsala University; Uppsala University; Stockholm University	SeguraAguilar, J (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT PHARMACEUT BIOSCI,DIV BIOCHEM,BOX 575,S-75123 UPPSALA,SWEDEN.		Segura-Aguilar, Juan/H-8839-2013; Widersten, Mikael/O-2565-2015	Segura-Aguilar, Juan/0000-0002-1018-673X; 				ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; BAEZ S, 1995, BIOCHEM MOL MED, V56, P37, DOI 10.1006/bmme.1995.1054; BAEZ S, 1994, CHEM-BIOL INTERACT, V93, P103, DOI 10.1016/0009-2797(94)90090-6; BAEZ S, 1994, REDOX REP, V1, P65, DOI 10.1080/13510002.1994.11746958; BAEZ S, 1995, BIOCHEM MOL MED, V54, P12, DOI 10.1006/bmme.1995.1002; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; BEYER RE, 1992, BIOCHEM CELL BIOL, V70, P390, DOI 10.1139/o92-061; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADET JL, 1994, NEUROSCI BIOBEHAV R, V18, P457, DOI 10.1016/0149-7634(94)90001-9; DISCHIA M, 1987, TETRAHEDRON, V43, P5351, DOI 10.1016/S0040-4020(01)87713-9; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GRAHAM DG, 1984, NEUROTOXICOLOGY, V5, P83; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARRISON WH, 1968, BIOCHEMISTRY-US, V7, P3089, DOI 10.1021/bi00849a010; HAWLEY MD, 1967, J AM CHEM SOC, V89, P447, DOI 10.1021/ja00978a051; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; LINDERSON Y, 1994, BBA-GEN SUBJECTS, V1200, P197, DOI 10.1016/0304-4165(94)90136-8; M PG, 1995, ADV DRUG METABOLISM, P407; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; Mannervik B, 1981, Methods Enzymol, V77, P231; MASON HS, 1948, J BIOL CHEM, V172, P83; SEGURAAGUILAR J, 1990, CARCINOGENESIS, V11, P1727, DOI 10.1093/carcin/11.10.1727; SEGURAAGUILAR J, 1994, CARCINOGENESIS, V15, P1631, DOI 10.1093/carcin/15.8.1631; SEGURAAGUILAR J, 1989, CHEM-BIOL INTERACT, V72, P309, DOI 10.1016/0009-2797(89)90006-9; SEGURAAGUILAR J, 1992, LEUKEMIA RES, V16, P631, DOI 10.1016/0145-2126(92)90013-W; Smythies J, 1996, P ROY SOC B-BIOL SCI, V263, P487, DOI 10.1098/rspb.1996.0073; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P8893; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	29	102	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5727	5731		10.1074/jbc.272.9.5727	http://dx.doi.org/10.1074/jbc.272.9.5727			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038184	hybrid			2022-12-25	WOS:A1997WK74700052
J	Chen, CM; Brinkworth, R; Waters, MJ				Chen, CM; Brinkworth, R; Waters, MJ			The role of receptor dimerization domain residues in growth hormone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGE REVERSAL MUTAGENESIS; ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; BINDING; ACTIVATION; PROTEIN; HOMODIMERIZATION; TRANSDUCTION; COMPLEXES; DESIGN	While there is a considerable amount of evidence that signal transduction by the growth hormone (GH) receptor requires receptor homodimerization, there has been no systematic study of the role of receptor dimerization domain residues in this process, In conjunction with the distances derived from the crystal structure of the hGH-hGH receptor (extracellular domain) complex, we have used a luciferase based c-fos promoter reporter assay in transiently transfected Chinese hamster ovary (CHO) cells, and stable receptor expressing CHO cell populations to define the dimerization domain residues needed for effective signaling, In addition to alanine substitution, we have used both aspartate and lysine substitutions to allow us to provide evidence for proximity relations through charge complementation. Introduced cysteine substitutions were also used, but unlike the erythropoietin receptor, these were unable to generate constitutively active receptor, We conclude that serine 145, histidine 150, aspartate 152, tyrosine 200, and serine 201, but not leucine 146 or threonine 147 are required for effective signal transduction through the dimerization domain, This information may be valuable in designing small molecule antagonists of GH and other cytokines that block dimerization by binding to the dimerization domain.	UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,CTR CELLULAR & MOL BIOL,BRISBANE,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,DRUG DESIGN CTR,BRISBANE,QLD 4072,AUSTRALIA	University of Queensland; University of Queensland; University of Queensland			waters, michael j/C-9582-2014					Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BARNARD R, 1993, PROTEIN ENG, V6, P455, DOI 10.1093/protein/6.4.455; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4502; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOBIUS KS, 1992, J MOL ENDOCRINOL, V9, P213, DOI 10.1677/jme.0.0090213; HORTON N, 1992, PROTEIN SCI, V1, P169; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MADISON EL, 1990, J BIOL CHEM, V265, P21423; Mamdouh Z, 1996, BBA-BIOMEMBRANES, V1282, P171, DOI 10.1016/0005-2736(96)00077-6; ROWLINSON SW, 1994, BIOCHEMISTRY-US, V33, P11724, DOI 10.1021/bi00205a008; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5	27	46	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5133	5140		10.1074/jbc.272.8.5133	http://dx.doi.org/10.1074/jbc.272.8.5133			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030580	hybrid			2022-12-25	WOS:A1997WJ85500068
J	Shibata, T; Shimoyama, Y; Gotoh, M; Hirohashi, S				Shibata, T; Shimoyama, Y; Gotoh, M; Hirohashi, S			Identification of human cadherin-14, a novel neurally specific type II cadherin, by protein interaction cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; TYROSINE KINASE SUBSTRATE; N-CADHERIN; R-CADHERIN; NEURITE OUTGROWTH; EPITHELIAL-CELLS; NERVOUS-SYSTEM; GENE-PRODUCT; T-CADHERIN; EXPRESSION	Cadherins, a family of Ca2+-dependent cell-cell adhesion molecules, mediate neural cell-cell interactions and may play important roles in neural development. By searching for molecules that interact with beta-catenin, a cytoplasmic regulator of cadherins, we have identified a new member of the cadherin family, which we named human cadherin-14. Cadherin-14 had high amino acid sequence homology with the type II subgroup of cadherins and was broadly expressed in the central nervous system. Cadherin-14 is a novel neurally specific cell-cell adhesion molecule and may regulate neural morphogenesis.	NATL CANC CTR,RES INST,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN; RES DEV CORP,HIROHASHI CELL CONFIGURAT PROJECT,EXPLATORY RES ADV TECHNOL,TSUKUBA,IBARAKI 30026,JAPAN	National Cancer Center - Japan; Japan Science & Technology Agency (JST)								ABERLE H, 1994, J CELL SCI, V107, P3655; BARAMI K, 1994, NEURON, V13, P567, DOI 10.1016/0896-6273(94)90026-4; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; ESPESETH A, 1995, MOL CELL NEUROSCI, V6, P199, DOI 10.1006/mcne.1995.1017; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; GANZLER SII, 1995, J NEUROSCI, V15, P4157; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; Kemler R, 1992, Semin Cell Biol, V3, P149; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Muller Ulrich, 1995, Current Opinion in Neurobiology, V5, P36, DOI 10.1016/0959-4388(95)80084-0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; REDIES C, 1992, J NEUROSCI, V12, P3525; REDIES C, 1995, EXP CELL RES, V220, P243, DOI 10.1006/excr.1995.1313; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; SHIMAMURA K, 1992, DEVELOPMENT, V116, P1011; SHIMOSATO Y, 1986, CANCER LETT, V33, P241, DOI 10.1016/0304-3835(86)90064-9; SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787; SHIMOYAMA Y, 1995, CANCER RES, V55, P2206; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; TANIHARA H, 1994, J CELL SCI, V107, P1697; WHITESIDES JG, 1995, DEV BIOL, V169, P229, DOI 10.1006/dbio.1995.1140; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2	40	32	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5236	5240		10.1074/jbc.272.8.5236	http://dx.doi.org/10.1074/jbc.272.8.5236			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030594	hybrid			2022-12-25	WOS:A1997WJ85500082
J	Song, KS; Tang, ZL; Li, SW; Lisanti, MP				Song, KS; Tang, ZL; Li, SW; Lisanti, MP			Mutational analysis of the properties of caveolin-1 - A novel role for the C-terminal domain in mediating homo-typic caveolin-caveolin interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; TRANS-GOLGI-NETWORK; PLASMA-MEMBRANE; PROTEIN-COMPONENT; EPITHELIAL-CELLS; LINKED PROTEIN; IN-VITRO; VESICLES; SEQUENCE; VIP21-CAVEOLIN	Caveolin is a principal structural component of caveolae membranes in vivo, Recently, a family of caveolin-related proteins has been identified; caveolin has been retermed caveolin-1. Caveolin family members share three characteristic properties: (i) detergent insolubility at low temperatures; (ii) self-oligomerization; and (iii) incorporation into low density Triton-insoluble fractions enriched in caveolae membranes. Here, we have used a deletion mutagenesis approach as a first step toward understanding which regions of caveolin-1 contribute to its unusual properties, Two caveolin-1 deletion mutants were created that lack either the C-terminal domain (Cav-1 Delta C) or the N-terminal domain (Cav-1 Delta N); these mutants were compared with the behavior of full-length caveolin-1 (Cav-1FL) expressed in parallel, Our results show that the N-terminal domain and membrane spanning segment are sufficient to form high molecular mass oligomers of caveolin-1. However, a complete caveolin-1 molecule is required for conveying detergent insolubility and incorporation into low density Triton-insoluble complexes, These data indicate that homo-oligomerization and an intact transmembrane are not sufficient to confer detergent insolubility, suggesting an unknown role for the C-terminal domain in this process, To better understand the role of the C-terminal domain, this region of caveolin-1 (residues 135-178) was expressed as a glutathione S-transferase fusion protein in Escherichia coli, Purified recombinant glutathione S-transferase-C-Cav-1 was found to stably interact with full-length caveolin-1 but not with the two caveolin-1 deletion mutants, These results suggest that the C-terminal domain interacts with both the N-terminal and C-terminal domains of an adjacent caveolin-1 homo-oligomer, This appears to be a specific homo-typic interaction, because the C-terminal domain of caveolin-1 failed to interact with full-length forms of caveolin-2 and caveolin-3, Homo-typic interaction of the C-terminal domain with an adjacent homo-oligomer could provide a mechanism for clustering caveolin-1 homooligomers while excluding other caveolin family members. This type of lateral segregation event could promote caveolae membrane formation and contribute to the detergent insolubility of caveolins-1, -2, and -3.	WHITEHEAD INST BIOMED RES, CAMBRIDGE CTR 9, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael/B-6131-2018; Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Li, Shengwen Calvin/0000-0002-9699-9204; 	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	46	151	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4398	4403		10.1074/jbc.272.7.4398	http://dx.doi.org/10.1074/jbc.272.7.4398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020162	hybrid			2022-12-25	WOS:A1997WH01900078
J	Okumura, K; Kaneko, Y; Nonoguchi, K; Nishiyama, H; Yokoi, H; Higuchi, T; Itoh, K; Yoshida, O; Miki, T; Fujita, J				Okumura, K; Kaneko, Y; Nonoguchi, K; Nishiyama, H; Yokoi, H; Higuchi, T; Itoh, K; Yoshida, O; Miki, T; Fujita, J			Expression of a novel isoform of Vav, Vav-T, containing a single Src homology 3 domain in murine testicular germ cells	ONCOGENE			English	Article						testis; vav; vav-T; Src homology 3	TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; EXCHANGE FACTOR; STEEL FACTOR; SH2 DOMAIN; B-CELLS; PROTEIN; KINASE; FIBROBLASTS	Vav is a signal transducing molecule containing C-terminal Src homology 3 (SH3)-SH2-SH3 domains, and has been thought to be expressed exclusively in hematopoietic and trophoblastic cells, By Northern blot analysis, vav transcripts of unique sizes, 4.8 kb and 1.0 kb, were detected in the testis among various tissues examined, From a mouse spermatocyte cDNA library, a novel isoform of vav (vav-T) was cloned, which corresponded to a part of the 4.8 kb transcript, Vav-T had an alternative 5' sequence up to the middle of SH2-coding region, and encoded 163 amino acids with a single SH3 domain, Northern blot analysis of fractionated testicular cells and in situ hybridization histochemistry demonstrated that vav-T transcripts were expressed in the differentiating germ cells, especially spermatocytes. A 24 kD protein was detected by anti-Vav antibodies in the testis, but not in the spleen or bone marrow, Transcripts of heterogeneous nuclear ribonucleoprotein K, known to associate with the most C-terminal SH3 domain of Vav, were also detected in the differentiating male germ cells, These results demonstrate expression of previously nondescribed Vav-isoform in the testicular germ cells, and suggest that it interacts with RNA-binding proteins and plays an important role in spermatogenesis.	KYOTO UNIV,FAC MED,DEPT CLIN MOL BIOL,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT UROL,KYOTO 60601,JAPAN; NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	Kyoto University; Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GOLDBERG E, 1977, ISOZYMES CURRENT TOP, P79; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; HIGUCHI T, 1995, BIOL REPROD, V53, P840, DOI 10.1095/biolreprod53.4.840; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Romero F, 1996, MOL CELL BIOL, V16, P37; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	40	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					713	720		10.1038/sj.onc.1200878	http://dx.doi.org/10.1038/sj.onc.1200878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038379	Green Submitted			2022-12-25	WOS:A1997WG43000010
J	Guerrin, M; Scotet, E; Malecaze, F; Houssaint, E; Plouet, J				Guerrin, M; Scotet, E; Malecaze, F; Houssaint, E; Plouet, J			Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2	ONCOGENE			English	Article						VEGF; FGF-2; retinal pigment epithelial cells; transformation	PIGMENT EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; ANGIOGENESIS; RECEPTOR; MITOGEN; VASCULOTROPIN; EXPRESSION	Vascular endothelial growth factor (VEGF) is a family of homodimeric proteins produced from a single gene by alternative splicing of the VEGF transcript. VEGF induces irt vivo angiogenesis and vascular permeability. We have recently demonstrated that VEGF is an autocrine growth factor for retinal pigment epithelial (RPE) cells. To further understand the role of VEGF, we overexpressed VEGF in rat RPE cells. The transfected cells exhibited a growth advantage in vitro and an increased response to the mitogenic effect of fibroblasts growth factor-2 (FGF-2), and formed colonies in soft agar upon FGF-2 addition. Moreover, analysis of FGF-receptors evidenced a dramatic increase in FGFR-1 mRNA and protein level, supporting the hypothesis that this receptor mediates the transforming effect of FGF-2. These results reveal that the oncogenic role of VEGF is exerted through a cross regulation between VEGF and FGF signal transduction pathways.	UPR 9006 CNRS, LAB BIOL MOL EUCARYOTE, F-31062 TOULOUSE, FRANCE; INST BIOL, INSERM U211, F-44035 NANTES, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			SCOTET, Emmanuel/AAC-9971-2019; SCOTET, Emmanuel/L-2576-2015	SCOTET, Emmanuel/0000-0001-8010-9556; SCOTET, Emmanuel/0000-0001-8010-9556				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; Ferrara N, 1991, NEUROENDOCRINE PERSP, P127; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; GOTO F, 1993, LAB INVEST, V69, P508; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Lachgar S, 1996, J INVEST DERMATOL, V106, P17, DOI 10.1111/1523-1747.ep12326964; LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MOUKADIRI H, 1992, GROWTH FACTORS OF THE VASCULAR AND NERVOUS SYSTEMS, P123; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PLOUET J, 1992, GENETIC HYPERTENSION, V218, P207; PRALORAN V, 1991, CR ACAD SCI III-VIE, V313, P21; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P934, DOI 10.1016/0006-291X(87)90340-8; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816	58	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					463	471		10.1038/sj.onc.1200846	http://dx.doi.org/10.1038/sj.onc.1200846			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053843				2022-12-25	WOS:A1997WE36400009
J	Baler, R; Covington, S; Klein, DC				Baler, R; Covington, S; Klein, DC			The rat arylalkylamine N-acetyltransferase gene promoter - cAMP activation via a cAMP-responsive element-CCAAT complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ENHANCER ELEMENTS; TRANSCRIPTION FACTOR; ADRENERGIC REGULATION; BINDING FACTOR; PINEAL-GLAND; CYCLIC-AMP; EXPRESSION; INITIATOR; PROTEINS; RNA	A 10-100-fold rhythm in the activity of arylalkylamine N-acetyltransferase (AA-NAT; EC 2.3.1.87) controls the rhythm in melatonin synthesis in the pineal gland. In some mammals, including the rat, the high nocturnal level of AA-NAT activity is preceded by an similar to 100-fold increase in AA-NAT mRNA The increase in AA-NAT mRNA is generated by norepinephrine acting through a cAMP mechanism. Indirect evidence has suggested that cAMP enhances AA-NAT gene expression by stimulating phosphorylation of a DNA-binding protein (cAMP-responsive element (CRE)-binding protein) bound to a CRE. The nature of the sites involved in cAMP activation was investigated in this report by analysing the AA-NAT promoter. An similar to 3700-base pair fragment of the 5'-flanking region of the rat AA-NAT gene was isolated, and the major transcription start points were mapped. The results of deletion analysis and site-directed mutagenesis indicate that cAMP activation requires a CRE-CCAAT complex consisting of a near-perfect CRE and an inverted CCAAT box located within two helical turns.	NICHHD, SECT NEUROENDOCRINOL, DEV NEUROBIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Klein, David/0000-0002-1792-5806				Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALER R, 1995, J BIOL CHEM, V270, P27319, DOI 10.1074/jbc.270.45.27319; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUDA M, 1978, ENDOCRINOLOGY, V103, P1483, DOI 10.1210/endo-103-4-1483; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; EVERED D, 1985, CIBA FOUND S, V117, P38; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KLEIN DC, 1985, CIBA F SYMP, V117, P38; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; KWASTWELFELD J, 1993, J BIOL CHEM, V268, P19581; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; MURO AF, 1992, J BIOL CHEM, V267, P12767; OLIVA D, 1995, EUR J BIOCHEM, V232, P141, DOI 10.1111/j.1432-1033.1995.tb20792.x; PARFITT A, 1976, NEUROPHARMACOLOGY, V15, P353, DOI 10.1016/0028-3908(76)90083-6; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; ROSEBOOM PH, 1995, MOL PHARMACOL, V47, P439; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SREBROW A, 1993, FEBS LETT, V327, P25, DOI 10.1016/0014-5793(93)81031-T; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; SUGDEN AL, 1986, J BIOL CHEM, V261, P1608; SUGDEN LA, 1987, J BIOL CHEM, V262, P741; VANECEK J, 1985, ENDOCRINOLOGY, V116, P2167, DOI 10.1210/endo-116-6-2167; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIMURA K, 1993, J BIOL CHEM, V268, P2300; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	44	155	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6979	6985		10.1074/jbc.272.11.6979	http://dx.doi.org/10.1074/jbc.272.11.6979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054387	hybrid			2022-12-25	WOS:A1997WN14700026
J	Derman, MP; Toker, A; Hartwig, JH; Spokes, K; Falck, JR; Chen, CS; Cantley, LC; Cantley, LG				Derman, MP; Toker, A; Hartwig, JH; Spokes, K; Falck, JR; Chen, CS; Cantley, LC; Cantley, LG			The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SCATTER FACTOR; FACTOR RECEPTOR; PEPTIDE MODULATION; ACTIVATION; RAC; CHEMOTAXIS; 3,4,5-TRISPHOSPHATE	Phosphoinositide 3-kinase has been implicated as an activator of cell motility in a variety of recent studies, yet the role of its lipid product, phosphatidylinositol 1,4,5-trisphosphate (PtdIns-3,4,5-P-3), has yet to be elucidated. In this study, three independent preparations of PtdIns-3,4,5 P-3 were found to increase the motility of NIH 3T3 cells when examined utilizing a microchemotaxis chamber. Dipalmitoyl L-alpha-phosphatidyl-D-myo-inositol 3,4,5-triphosphate (Di-C-16-PtdIns-3,4,5-P-3) also produced actin reorganization and membrane ruffling. Cells pretreated with 12-O-tetradecanoylphorbol-13-acetate to cause down-regulation of protein kinase C (PKC) exhibited complete inhibition of cell motility induced by Di-C-16-PtdInaqs-3,4,5-P-3. These results are consistent with previous observations that PtdIns-3,4,5-P-3 activates Ca2+ independent PKC isoforms in vitro and in vivo and provide the first demonstration of an in. vivo role for the lipid products of the phosphoinositide 3-kinase. PtdIns-3,4,5-P-3 appears to directly initiate cellular motility via activation of a PKC family member.	BETH ISRAEL DEACONESS MED CTR,DEPT MED,DIV NEPHROL,BOSTON,MA 02215; BETH ISRAEL DEACONESS MED CTR,DEPT MED,DIV SIGNAL TRANSDUCT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,DIV EXPT MED,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75325; UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40506	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Kentucky			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Falck, John/0000-0002-9219-7845	NIDDK NIH HHS [DK48871] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMANNGRILL BC, 1989, EUR J CELL BIOL, V50, P128; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTLEY LG, 1995, J AM SOC NEPHROL, V5, P1872; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; DELAFUENTE M, 1994, PEPTIDES, V15, P1157, DOI 10.1016/0196-9781(94)90137-6; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Derman MP, 1996, J BIOL CHEM, V271, P4251; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOU DM, 1994, J CHEM SOC CHEM COMM, P2125, DOI 10.1039/c39940002125; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NOBES CD, 1995, J CELL SCI, V108, P225; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTENBERG SA, 1995, P ANN M AM ASS CANC, V36, P2589; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TOKER A, 1994, J BIOL CHEM, V269, P32358; VEMURI GS, 1994, BIOCHEM BIOPH RES CO, V202, P1619, DOI 10.1006/bbrc.1994.2118; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; YENUSH L, 1994, J BIOL CHEM, V269, P100	43	119	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6465	6470		10.1074/jbc.272.10.6465	http://dx.doi.org/10.1074/jbc.272.10.6465			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045671	hybrid, Green Published			2022-12-25	WOS:A1997WM64700055
J	Gebe, JA; Kiener, PA; Ring, HJZ; Li, X; Francke, U; Aruffo, A				Gebe, JA; Kiener, PA; Ring, HJZ; Li, X; Francke, U; Aruffo, A			Molecular cloning, mapping to human chromosome 1 q21-q23, and cell binding characteristics of Sp alpha, a new member of the scavenger receptor cysteine-rich (SRCR) family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; DELTA T-CELLS; DIFFERENTIATION ANTIGEN; LYMPHOCYTES-T; SURFACE; GENES; CD5; SUPERFAMILY; RESPONSES; CONTAINS	CD5 and CD6, two type I cell surface antigens predominantly expressed by T cells and a subset of B cells, have been shown to function as accessory molecules capable of modulating T cell activation, Here we report the cloning of a cDNA encoding Sp alpha, a secreted protein that is highly homologous to CD5 and CD6, Sp alpha has the same domain organization as the extracellular region of CD5 and CD6 and is composed of three SRCR (scavenger receptor cysteine rich) domains, Chromosomal mapping by fluorescence in situ hybridization and radiation hybrid panel analysis indicated that the gene encoding Sp alpha is located on the long arm of human chromosome 1 at q21-q23 within contig WC1.17. RNA transcripts encoding Sp alpha were found in human bone marrow, spleen, lymph node, thymus, and fetal liver but not in non-lymphoid tissues, Cell binding studies with an Sp alpha immunoglobulin (Sp alpha-mIg) fusion protein indicated that Sp alpha is capable of binding to peripheral monocytes but not to T or B cells. Sp alpha-mig was also found to bind to the monocyte precursor cell lines K-562 and weakly to THP-1 but not to U937, Sp alpha-mig also bound to the B cell line Raji and weakly to the T cell line HUT-78. These findings indicate that Sp alpha, a novel secreted protein produced in lymphoid tissues, may regulate monocyte activation, function, and/or survival.	STANFORD UNIV,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	Gebe, JA (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00298] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALAKAPEE U, 1989, CYTOGENET CELL GENET, V5; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; Bowen MA, 1996, J BIOL CHEM, V271, P17390, DOI 10.1074/jbc.271.29.17390; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; BOWEN MA, 1997, IN PRESS J IMMUNOL; BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; GANGEMI RMR, 1989, J IMMUNOL, V143, P2439; HECHT BK, 1989, CYTOGENET CELL GENET, V51; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; LI X, 1995, MAMM GENOME, V6, P42, DOI 10.1007/BF00350892; OKEEFFE MA, 1994, INT IMMUNOL, V6, P1687, DOI 10.1093/intimm/6.11.1687; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TARAKHOVSKY A, 1994, EUR J IMMUNOL, V24, P1678, DOI 10.1002/eji.1830240733; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; TSUGE I, 1985, SOMAT CELL MOLEC GEN, V11, P217, DOI 10.1007/BF01534678; VAN DE VELDE H, 1991, NATURE, V351, P662; WALKER ID, 1994, IMMUNOLOGY, V83, P517; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEE SF, 1994, CELL IMMUNOL, V158, P353, DOI 10.1006/cimm.1994.1282; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; WIJNGAARD PLJ, 1994, J IMMUNOL, V152, P3476; WIJNGAARD PLJ, 1992, J IMMUNOL, V149, P3273	33	83	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6151	6158		10.1074/jbc.272.10.6151	http://dx.doi.org/10.1074/jbc.272.10.6151			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045627	hybrid			2022-12-25	WOS:A1997WM64700011
J	Koli, KM; Arteaga, CL				Koli, KM; Arteaga, CL			Processing of the transforming growth factor beta type I and II receptors - Biosynthesis and ligand-induced regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EXPRESSION CLONING; CANCER CELLS; COMPLEX; PROTEIN; BINDING; KINASE; LINES	Three cell surface transforming growth factor beta (TGF beta) receptor (R) proteins regulate the effects of TGF beta isoforms on growth and differentiation. TGF beta-IR and -IIR are transmembrane serine/threonine kinases directly mediating the signaling across the plasma membrane. Both TGF beta and its receptors are ubiquitously expressed, hence the fine regulation of the multiplicity of responses most likely involves several levels of control including the regulation of expression, complex formation, and down-regulation of the receptor proteins. In mink lung epithelial cells, TGF beta-IIR was first synthesized as a similar to 60-kDa endoglycosidase II-sensitive precursor protein, which was converted to a mature similar to 70-kDa protein. The half-life of metabolically labeled mature TGF beta-IIR was estimated to be 60 min and was further reduced to similar to 45 min in the presence of exogenous TGF beta 1. Minimal internalization of I-125-TGF beta 1 at 37 degrees C was detected suggesting that the rapid turnover was not due to endocytosis and degradation of the ligand-receptor complexes. TGF beta-IR was synthesized as a similar to 53-kDa precursor protein, which was processed to a mature similar to 55-kDa receptor protein. The half-life of TGF beta-IR was >12 h. A fraction of tunicamycin treated type I and II receptors that reach the cell surface was able to associate in the presence of ligand suggesting that heteromeric complexes can form in a post-endoplasmic reticulum compartment before full glycosylation is achieved. These results show differential processing and turnover of TGF beta-IR and TGF beta-IIR providing a potential additional mechanism for modulation of cellular responses to TGF beta s.	VANDERBILT UNIV, DIV MED ONCOL, DEPT MED, SCH MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; VANDERBILT CANC CTR, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System					NATIONAL CANCER INSTITUTE [R01CA062212] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA62212] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Centrella M, 1996, J BIOL CHEM, V271, P18616, DOI 10.1074/jbc.271.31.18616; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KeskiOja J, 1995, TRENDS GLYCOSCI GLYC, V7, P277, DOI 10.4052/tigg.7.277; Koli K, 1996, ADV CANCER RES, V70, P63, DOI 10.1016/S0065-230X(08)60872-6; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MOSES HL, 1990, KAR INS NCS, P141; MOSES HL, 1985, CANCER CELL, V3, P65; NORGAARD P, 1995, CANCER TREAT REV, V21, P367, DOI 10.1016/0305-7372(95)90038-1; NORGAARD P, 1994, BRIT J CANCER, V69, P802, DOI 10.1038/bjc.1994.158; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHAO J, 1995, CANCER RES, V55, P6181	29	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6423	6427		10.1074/jbc.272.10.6423	http://dx.doi.org/10.1074/jbc.272.10.6423			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045666	hybrid			2022-12-25	WOS:A1997WM64700050
J	Jeyaseelan, R; Poizat, C; Wu, HY; Kedes, L				Jeyaseelan, R; Poizat, C; Wu, HY; Kedes, L			Molecular mechanisms of doxorubicin-induced cardiomyopathy - Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C GENE; KINASE-C; MYOGENIC DIFFERENTIATION; PHOSPHOLIPID DEGRADATION; MITOCHONDRIAL-MEMBRANE; FUNCTIONAL EXPRESSION; ELECTRON-TRANSPORT; LIPID-PEROXIDATION; BOVINE HEART; COMPLEX-III	Doxorubicin, a cardiotoxic antineoplastic, disrupts the cardiac-specific program of gene expression (Kurabayashi, M., Dutta, S. Jeyaseelan, R., and Kedes, L. (1995) Mol. Cell, Biol, 15, 6356-6897), We have now identified neonatal rat cardiomyocyte mRNAs rapidly sensitive to doxorubicin, or its congener daunomycin, including transcripts of nuclear genes encoding enzymes critical in production of energy in cardiomyocytes: ADP/ATP translocase, a heart- and muscle-specific isoform; Reiske iron-sulfur protein (RISP), a ubiquitously expressed electron transport chain component; and a muscle isozyme of phosphofructokinase, Loss of these mRNAs following doxorubicin or daunomycin is evident as early as 2 h and precedes significant reduction of intracellular ATP, ATP levels in control cardiomyocytes (17.9 +/- 2.9 nM/mg of protein) fall only after 14 h and reach residual levels of 10.4 +/- 0.9 nM (doxorubicin; p = <0.006) and 6.7 +/- 1.9 nM (daunomycin; p = <0.001) by 24 h, Loss of mRNAs generating ATP was highly selective since mRNAs for other energy production enzymes, (cytochrome c, cytochrome b, and malate dehydrogenase), and genes important in glycolysis (pyruvate kinase and glyceraldehyde-3-phosphate dehydrogenase) wore unaffected even at 24 and 48 h, The drugs had no effect on levels of ubiquitously expressed RISP mRNA in fibroblasts, These findings could link doxorubicin-induced damage to membranes and signaling pathways with 1) suppression of transcripts encoding myofibrillar proteins and proteins of energy production pathways and 2) depletion of intracellular ATP stores, myofibrillar degeneration, and related cardiotoxic effects.	UNIV SO CALIF,MED CTR,HMR 413,INST MED GENET,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of Southern California								ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AZUMA J, 1981, J MOL CELL CARDIOL, V13, P381, DOI 10.1016/0022-2828(81)90281-9; BAGCHI D, 1995, TOXICOLOGY, V95, P1, DOI 10.1016/0300-483X(94)02867-T; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIANCHI C, 1987, EXP MOL PATHOL, V46, P123, DOI 10.1016/0014-4800(87)90036-0; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; CHU TW, 1987, J BIOL CHEM, V262, P12806; DEPRE C, 1993, ACTA CARDIOL, V48, P147; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; DUNAWAY GA, 1985, J MOL CELL CARDIOL, V17, P947, DOI 10.1016/S0022-2828(85)80075-4; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; ETO K, 1994, BIOCHEM BIOPH RES CO, V198, P990, DOI 10.1006/bbrc.1994.1141; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; GEKAKIS N, 1994, J BIOL CHEM, V269, P3348; GEKAKIS N, 1994, BIOCHEMISTRY-US, V33, P1771, DOI 10.1021/bi00173a021; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Kapelko V I, 1990, Biomed Sci, V1, P77; KAPELKO VI, 1991, AM J PHYSIOL, V261, P39, DOI 10.1152/ajplung.1991.261.4.L39; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOIKE K, 1982, GENE, V20, P177; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; KURABAYASHI M, 1994, J BIOL CHEM, V269, P31162; KURABAYASHI M, 1995, MOL CELL BIOL, V15, P6386; LI YL, 1994, J BIOL CHEM, V269, P5781; LIANG P, 1992, CANCER RES, V52, P6966; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; MORRE DJ, 1994, J BIOENERG BIOMEMBR, V26, P137, DOI 10.1007/BF00763225; NAKAJIMA H, 1987, FEBS LETT, V223, P113, DOI 10.1016/0014-5793(87)80519-7; NICOLAY K, 1987, BIOCHIM BIOPHYS ACTA, V892, P320, DOI 10.1016/0005-2728(87)90236-2; NICOLAY K, 1987, BIOCHIM BIOPHYS ACTA, V929, P5, DOI 10.1016/0167-4889(87)90234-5; NISHIKIMI M, 1989, BIOCHEM BIOPH RES CO, V159, P19, DOI 10.1016/0006-291X(89)92398-X; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1992, NEUROSCI RES, V15, P3, DOI 10.1016/0168-0102(92)90013-3; OHNISHI T, 1994, BIOCHEM SOC T, V22, P191, DOI 10.1042/bst0220191; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PRAET M, 1993, BIOCHIM BIOPHYS ACTA, V1149, P79, DOI 10.1016/0005-2736(93)90027-W; RABEN N, 1995, AM J HUM GENET, V56, P131; RABEN N, 1995, HUM MUTAT, V6, P1, DOI 10.1002/humu.1380060102; RAJAGOPALAN S, 1988, CANCER RES, V48, P4766; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SHINOHARA Y, 1993, BIOCHIM BIOPHYS ACTA, V1152, P192, DOI 10.1016/0005-2736(93)90248-X; SINGAL PK, 1995, J MOL CELL CARDIOL, V27, P1055, DOI 10.1016/0022-2828(95)90074-8; SINGAL PK, 1984, CAN J PHYSIOL PHARM, V62, P1239, DOI 10.1139/y84-207; SINGAL PK, 1986, AM J PHYSIOL, V250, pH419, DOI 10.1152/ajpheart.1986.250.3.H419; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; Sussman MA, 1997, CIRC RES, V80, P52, DOI 10.1161/01.RES.80.1.52; THOMSON AJ, 1991, BIOCHEM SOC T, V19, P594, DOI 10.1042/bst0190594; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; VIDAL H, 1993, FEBS LETT, V330, P329, DOI 10.1016/0014-5793(93)80898-5; YU CA, 1993, J BIOENERG BIOMEMBR, V25, P259, DOI 10.1007/BF00762587	58	106	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5828	5832		10.1074/jbc.272.9.5828	http://dx.doi.org/10.1074/jbc.272.9.5828			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038198	hybrid			2022-12-25	WOS:A1997WK74700066
J	Merickel, A; Kaback, HR; Edwards, RH				Merickel, A; Kaback, HR; Edwards, RH			Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; AMINE TRANSPORTER; RESERPINE BINDING; LACTOSE PERMEASE; ACETYLCHOLINE TRANSPORTER; TETRACYCLINE-RESISTANCE; GENE; EXPRESSION; NEUROTRANSMITTERS; IDENTIFICATION	Vesicular monoamine transporters package monoamine neurotransmitters into secretory vesicles for regulated exocytotic release, Both vesicular monoamine transporter 1 and 2 contain several charged residues predicted to reside within transmembrane domains (TMDs), and conservation of these residues in multiple species and in other members of the gene family suggest important roles in transporter structure and function, To determine the role of these residues, we have used site-directed mutagenesis, Replacement of Asp-263 in TMD6 with Asn (D263N) had no effect on transport activity, However, replacement of Lys-139 in TMD2 with Ala (K139A), Asp-400 in TMD10 with Asn (D400N), or Asp-427 in TMD11 with Asn (D427N) eliminated transport activity despite normal levels of protein expression, Remarkably, the double mutant K139A/D427N showed substantial transport activity, suggesting that Lys-139 and Asp-427 interact to form an ion pair in the native protein and hence that TMD2 occurs next to TMD11. Nonetheless, the double mutant showed reduced apparent affinity for serotonin and reduced ability of serotonin to inhibit reserpine binding, suggesting that although not required for activity, the ion pair promotes high affinity interaction with the substrate, In addition, a double mutant in which the polarity of the charged residues was reversed (K139D/D427K) showed no active transport, Remarkably, however, this mutant displayed normal reserpine binding that remained coupled to <Delta(mu)over tilde (H+)>, but serotonin failed to inhibit reserpine binding, suggesting that the charge reversal specifically disrupts substrate recognition.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, SCH MED,HOWARD HUGHES MED INST, INTERDEPT PROGRAM NEUROSCI,MOL BIOL INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED,HOWARD HUGHES MED INST, DEPT PHYSIOL & MICROBIOL,MOL BIOL INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED,HOWARD HUGHES MED INST,DEPT MOL GENET, MOL BIOL INST, LOS ANGELES, CA 90095 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; PETER D, 1995, J NEUROSCI, V15, P6179; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SteinerMordoch S, 1996, J BIOL CHEM, V271, P13048, DOI 10.1074/jbc.271.22.13048; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	28	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5403	5408		10.1074/jbc.272.9.5403	http://dx.doi.org/10.1074/jbc.272.9.5403			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038139	hybrid			2022-12-25	WOS:A1997WK74700007
J	Kupke, T; Gotz, F				Kupke, T; Gotz, F			The enethiolate anion reaction products of EpiD - p kappa(alpha) value of the enethiol side chain is lower than that of the thiol side chain of peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; L-TRYPTOPHAN 2',3'-OXIDASE; ACTIVE-SITE; POSTTRANSLATIONAL MODIFICATIONS; OXIDATIVE DECARBOXYLATION; CHROMOBACTERIUM-VIOLACEUM; BACKBONE MODIFICATIONS; SUBSTRATE-SPECIFICITY; CYSTEINE RESIDUES; BIOSYNTHESIS	One of the steps involved in the biosynthesis of the lantibiotic epidermin is the oxidative decarboxylation reaction of peptides catalyzed by the flavoenzyme EpiD. EpiD catalyzes the formation of a (Z)-enethiol derivative from the C-terminal cysteine residue of the precursor peptide of epidermin and related peptides. The UV-visible spectra of the reaction products of EpiD are pH-dependent, indicating that the enethiol side chain is converted to an enethiolate anion. The pK(alpha), value of the enethiol group was determined to be 6.0 and is substantially lower than the pK(alpha) value of the thiol side chain of cysteine residues. The increased acid strength of the enethiol side chain compared with that of the thiol group is attributed to the resonance stabilization of the negative charge of the anion.			Kupke, T (corresponding author), UNIV TUBINGEN,WALDHAUSERSTR 70-8,D-72076 TUBINGEN,GERMANY.			Kupke, Thomas/0000-0003-2341-1710				ALLGAIER H, 1985, ANGEW CHEM INT EDIT, V24, P1051, DOI 10.1002/anie.198510511; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BAYER A, 1993, ANGEW CHEM INT EDIT, V32, P1336, DOI 10.1002/anie.199313361; BAYER A, 1995, EUR J BIOCHEM, V234, P414, DOI 10.1111/j.1432-1033.1995.414_b.x; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; Crampton MR., 1974, CHEM THIOL GROUP, P379; GENET R, 1995, J BIOL CHEM, V270, P23540, DOI 10.1074/jbc.270.40.23540; GENET R, 1994, J BIOL CHEM, V269, P18177; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Keeffe J. R., 1990, CHEM ENOLS, P399; Kempter C, 1996, ANGEW CHEM INT EDIT, V35, P2104, DOI 10.1002/anie.199621041; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KUPKE T, 1993, FEMS MICROBIOL LETT, V112, P43, DOI 10.1016/0378-1097(93)90535-A; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; KUPKE T, 1994, J BIOL CHEM, V269, P5653; Kupke T, 1996, ANTON LEEUW INT J G, V69, P139, DOI 10.1007/BF00399419; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; Lundblad R.L., 1984, CHEM REAGENTS PROTEI; MAIER GD, 1957, J AM CHEM SOC, V79, P4386, DOI 10.1021/ja01573a040; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; NODA LH, 1953, J AM CHEM SOC, V75, P913, DOI 10.1021/ja01100a041; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; TEE OS, 1986, J ORG CHEM, V51, P2150, DOI 10.1021/jo00361a050; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	27	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4759	4762		10.1074/jbc.272.8.4759	http://dx.doi.org/10.1074/jbc.272.8.4759			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030529	hybrid			2022-12-25	WOS:A1997WJ85500017
J	Zhao, LY; Chang, LS				Zhao, LY; Chang, LS			The human POLD1 gene - Identification of an upstream activator sequence, activation by Sp1 and Sp3, and cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; 5' EXONUCLEASE ACTIVITY; BOX-BINDING-PROTEINS; TRANSCRIPTION FACTOR; CATALYTIC SUBUNIT; NUCLEAR ANTIGEN; DIHYDROFOLATE-REDUCTASE; AUXILIARY PROTEIN; CALF THYMUS; SACCHAROMYCES-CEREVISIAE	The promoter of the human POLD1 gene encoding the catalytic subunit of DNA polymerase delta is G/C-rich and does not contain a TATA box. Transient transfection analysis in HeLa cells employing POLD1-luciferase chimeric plasmids revealed a core promoter region extending 328 base pairs (bp) from the major transcription initiation site. Multiple elements in this region including two Il-bp direct repeats located between nucleotide positions -92 and -22, play an important role in POLD1 promoter activity. Deletion or linker-replacement mutations of the repeats drastically reduced the promoter activity. A 70-bp DNA fragment containing the two repeats could stimulate the expression of the POLD1 or a heterologous promoter in an orientation-independent manner. DNase I footprinting and band-shift assays showed that HeLa nuclear extracts contained proteins specifically binding to the repeat sequences. Southwestern blot and UV cross linking analyses identified Spl and two 85-kDa proteins that bound to the repeats. Additionally, screening of HeLa cDNA expression libraries for the sequence specific DNA-binding protein using the 11-bp repeat sequences as the probe, identified a cDNA that corresponds to Sp3, a member of the Spl family. Cotransfection studies in Drosophila SL2 cells showed that both Spl and Sp3, but not Sp2, could activate the POLD1 promoter through the repeat sequences. The POLD1 promoter activity was induced about 4-fold at the late G(1)/S boundary in serum-stimulated cells. The 11-bp repeats together with an E2F-like sequence, located adjacent to the major transcription initiation site, were important for the stimulation. Taken together, this study provides a direct evidence for transcriptional regulation of the human POLD1 gene.	OHIO STATE UNIV, CHILDRENS HOSP, OHIO STATE BIOCHEM PROGRAM, COLUMBUS, OH 43205 USA; OHIO STATE UNIV, CHILDRENS HOSP, DEPT BIOCHEM MED, COLUMBUS, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Zhao, LY (corresponding author), OHIO STATE UNIV, CHILDRENS HOSP, DEPT PEDIAT, 700 CHILDRENS DR, COLUMBUS, OH 43205 USA.		Chang, Long-sheng/E-2871-2011					Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHANG LS, 1995, GENOMICS, V28, P411, DOI 10.1006/geno.1995.1169; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FOX BA, 1991, MOL BIOCHEM PARASIT, V49, P289, DOI 10.1016/0166-6851(91)90072-E; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HIROSE F, 1993, J BIOL CHEM, V268, P2092; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JOHNSON L F, 1992, Current Opinion in Cell Biology, V4, P149, DOI 10.1016/0955-0674(92)90025-8; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUWAHARA J, 1993, BIOCHEMISTRY-US, V32, P5994, DOI 10.1021/bi00074a010; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PIGNEDE G, 1991, J MOL BIOL, V222, P209, DOI 10.1016/0022-2836(91)90207-M; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; RIDLEY RG, 1991, NUCLEIC ACIDS RES, V19, P6731, DOI 10.1093/nar/19.24.6731; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; Sjottem E, 1996, J VIROL, V70, P188; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TAN CK, 1986, J BIOL CHEM, V261, P2310; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	76	60	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4869	4882		10.1074/jbc.272.8.4869	http://dx.doi.org/10.1074/jbc.272.8.4869			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030545	hybrid			2022-12-25	WOS:A1997WJ85500033
J	Bernardin, F; CollyndHooghe, M; Quief, S; Bastard, C; Leprince, D; Kerckaert, JP				Bernardin, F; CollyndHooghe, M; Quief, S; Bastard, C; Leprince, D; Kerckaert, JP			Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation	ONCOGENE			English	Article						LAZ3/BCL6; lymphoma; major translocation cluster	PROTEIN INTERACTION MOTIF; FINGER ENCODING GENE; CENTER B-CELLS; PROMOTER REGION; DNA-BINDING; BCL-6 GENE; CHROMOSOMAL TRANSLOCATIONS; BTB/POZ DOMAIN; SEQUENCE; MOUSE	The LAZ3/BCL6 gene encoding a Zinc-finger nuclear protein is altered in Non-Hodgkin's Lymphomas (NHLs) by translocations, mutations and/or deletions clustered in its 5' non coding region, in a 3.3 Kbp EcoRI fragment which thus defines the Major Translocation Cluster (MTC). In the present study, we describe at the molecular level the deletions found in the MTC of two (NHL) cases using, (i) DNA obtained from a patient (GUI) with a monosomy 3 and three microdeletions of 101, 22, 25 bp in its unique untranslocated 3q27 allele; (ii) a cell line derived from a patient (VAL) carrying a t(3;4) (q27;pll) translocation and a 2.4 Kbp deletion in the untranslocated allele. As the MTC is recurrently subject to alterations, me have cloned and sequenced the murine equivalent of the human MTC and promoter region in an attempt to identify sequences well conserved in mammals that may be thus important for the LAZ3/BCL6 gene regulation. We show that the human and mouse 5' upstream regions of the LAZ3/BCL6 gene although mainly intronic share a particularly high homology of 79% on the overall sequence. Strikingly, the small sequences which are deleted in patient (GUI) are highly conserved (81%, 100% and 92% respectively). Furthermore, they may play a role in the pathogenesis since proteins prepared from B cell lines and HeLa nuclear extracts bind to these sequences in gel retardation assays. Although a large part of this region is intronic, the high conservation of its sequence and the frequency of alterations in NHLs suggest that they are likely to be significant for the regulation of the LAZ3/BCL6 gene.	INST RECH CANC LILLE,U124 INSERM,F-59045 LILLE,FRANCE; CTR TRANSFUS SANGUINE,DEPT CYTOGENET,F-76232 BOIS GUILLAUME,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Leprince, Dominique/0000-0002-1999-0775				Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DALLERY E, 1995, ONCOGENE, V10, P2171; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FLENGHI L, 1995, AM J PATHOL, V147, P405; FOLEY J, 1994, GENOMICS, V22, P456, DOI 10.1006/geno.1994.1410; FUKUDA T, 1995, ONCOGENE, V11, P1657; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; GALSON DL, 1993, BLOOD, V82, P3321; GWYNN B, 1990, MOL CELL BIOL, V10, P5244, DOI 10.1128/MCB.10.10.5244; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 1996, LEUKEMIA, V10, P658; NAKAMURA Y, 1995, BRIT J HAEMATOL, V90, P404, DOI 10.1111/j.1365-2141.1995.tb05166.x; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	39	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					849	855		10.1038/sj.onc.1200903	http://dx.doi.org/10.1038/sj.onc.1200903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047392				2022-12-25	WOS:A1997WJ11200011
J	Alvaro, V; Prevostel, C; Joubert, D; Slosberg, E; Weinstein, BI				Alvaro, V; Prevostel, C; Joubert, D; Slosberg, E; Weinstein, BI			Ectopic expression of a mutant form of PKC alpha originally found in human tumors: Aberrant subcellular translocation and effects on growth control	ONCOGENE			English	Article						protein kinase c; somatic mutation; transformation; fibroblast	PROTEIN-KINASE-C; RAT FIBROBLASTS; EPSILON ISOFORM; DOWN-REGULATION; PHORBOL ESTERS; FOCAL CONTACTS; GENE-TRANSFER; CELL-LINES; RECEPTOR; OVEREXPRESSION	A point mutation in PKC alpha was originally discovered in a subpopulation of human pituitary tumors characterized by their invasive phenotype, and the same mutation was also seen in some thyroid neoplasms, To investigate the role of this mutation in tumorigenesis, normal and mutant human PKC alpha cDNAs were overexpressed in Rat6 embryo fibroblasts (R6), When extracts of R6 cells that expressed either the normal or mutant PKC alpha were assayed in the presence of calcium, phosphatidylserine and the phorbol ester TPA, for phosphorylation of either histone IIIS or the EGF-receptor peptide, both extracts gave similar results, However, the subcellular localization of the two proteins differed. Immunohistochemistry studies indicated that after treatment with TPA normal PKC alpha mainly translocated to the plasma membrane, but mutant PKC alpha translocated mainly to the perinuclear region and slightly to the nucleus, Furthermore, the cells that expressed the mutant PKC alpha displayed a decreased requirement for serum when compared to the cells expressing the normal human PKC alpha, and they formed small colonies in soft agar, By contrast, the cells expressing the normal human PKC alpha failed to form colonies in soft-agar, Thus, ectopic expression in rat fibroblasts of this mutant human PKC alpha sequence alters the growth properties of these cells and, when activated, the mutant PKC alpha displays aberrant intracellular translocation, Therefore, this mutation in PKC alpha could contribute to the process of tumor progression in certain human tumors.	CCIPE,INSERM U401,F-34094 MONTPELLIER 5,FRANCE; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CANC RES INST,NEW YORK,NY 10032	Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University; Columbia University			Prevostel, Corinne/AAO-1433-2020	PREVOSTEL, Corinne/0000-0002-7553-087X				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; AHMAD S, 1993, MOL PHARMACOL, V43, P858; ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; BENZIL DL, 1992, CANCER RES, V52, P2951; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CACACE AM, 1993, ONCOGENE, V8, P2095; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; DONG LQ, 1993, CELL GROWTH DIFFER, V4, P793; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES CLA, 1994, PKC M TAOS NEW MEX; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LELI U, 1992, FEBS LETT, V297, P91, DOI 10.1016/0014-5793(92)80334-D; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; LIU B, 1994, J NATL CANCER I, V86, P1145, DOI 10.1093/jnci/86.15.1145; MAPPELI E, 1994, INT J CANCER, V57, P281; MARKOWITZ D, 1990, ANN NY ACAD SCI, V612, P407; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PREVOSTEL C, 1995, ONCOGENE, V11, P669; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	47	26	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					677	685		10.1038/sj.onc.1200880	http://dx.doi.org/10.1038/sj.onc.1200880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038375				2022-12-25	WOS:A1997WG43000006
J	Sakai, M; Imaki, J; Yoshida, K; Ogata, A; MatsushimaHibiya, Y; Kuboki, Y; Nishizawa, M; Nishi, S				Sakai, M; Imaki, J; Yoshida, K; Ogata, A; MatsushimaHibiya, Y; Kuboki, Y; Nishizawa, M; Nishi, S			Rat maf related genes: Specific expression in chondrocytes, lens and spinal cord	ONCOGENE			English	Article						maf; transcription factor; chondrocyte; lens; spinal cord	TRANSFERASE-P EXPRESSION; TRANSCRIPTION FACTOR; FACTOR NF-E2; V-MAF; FOS; JUN; ONCOGENE; PROTEINS; ENCODES; DOMAIN	maf is a family of oncogenes originally identified from avian oncogenic retrovirus, AS42, encoding a nuclear bZip transcription factor, We have isolated two maf related cDNA clones, maf-1 and maf-2, from a rat liver cDNA library, Comparison of the sequence homologies of the proteins encoded by maf-1 and maf-2 with those of c-maf and chicken mafB indicated that maf-1 and maf-2 are the rat homologues of mafB and c-maf, respectively, Both genes are expressed at low levels in a wide variety of rat tissues, including spleen, kidney, muscle and liver. Immunohistochemical studies and ill situ hybridization analyses show that maf-2 and maf-2 are strongly expressed in the late stages of chondrocyte development in the femur epiphysis and the rib and limb cartilage of 15 day old (E15) embryo in rat, Cartilage cells, induced by subcutaneous implantation of bone morphogenic protein, also expressed maf-1 and maf-2. In situ hybridization analyses of E15 embryos show that both genes are expressed in the eye lens and the spinal cord as well as the cartilage, However, the expression patterns of maf-1 and maf-2 in lens and spinal cord are different.	HOKKAIDO UNIV,SCH DENT,DEPT BIOCHEM,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; NIPPON MED COLL,DEPT ANAT,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC MED,DEPT MOL ONCOL,SAKYO KU,KYOTO 606,JAPAN	Hokkaido University; Nippon Medical School; Kyoto University	Sakai, M (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,KITA KU,N15 W7,SAPPORO,HOKKAIDO 060,JAPAN.		Sakai, Masaharu/A-4773-2012					ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KUBOKI Y, 1995, CONNECTIVE TISSUE RE, V12, P207; Liu Q, 1996, ONCOGENE, V12, P207; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SAKAI M, 1992, BIOCHEM BIOPH RES CO, V187, P976, DOI 10.1016/0006-291X(92)91293-Y; SAKAI M, 1995, CANCER RES, V55, P5370; SENBA E, 1982, J COMP NEUROL, V208, P54, DOI 10.1002/cne.902080105; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; URIST MR, 1984, P NATL ACAD SCI-BIOL, V81, P371, DOI 10.1073/pnas.81.2.371	21	83	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					745	750		10.1038/sj.onc.1200869	http://dx.doi.org/10.1038/sj.onc.1200869			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038383				2022-12-25	WOS:A1997WG43000014
J	Agostinho, P; Duarte, CB; Oliveira, CR				Agostinho, P; Duarte, CB; Oliveira, CR			Impairment of excitatory amino acid transporter activity by oxidative stress conditions in retinal cells: Effect of antioxidants	FASEB JOURNAL			English	Article						D-[H-3]aspartate uptake; lipid peroxidation; antioxidants; melatonin; oxidation of proteins	OXYGEN-FREE RADICALS; HIGH-AFFINITY UPTAKE; ARACHIDONIC-ACID; GLUTAMATE TRANSPORTER; LIPID-PEROXIDATION; NEUROTRANSMITTER TRANSPORTERS; ASPARTATE TRANSPORTER; NERVOUS-SYSTEM; CYTO-TOXICITY; GLIAL-CELLS	In the present study we analyzed how oxidative stress conditions induced by ascorbate/Fe2+ affect the excitatory amino acid (EAA) transport systems in cultured chick retina cells, The uptake of D-[H-3]aspartate, which is transported by the same carrier as glutamate, was determined in control cells and in cells subjected to ascorbate/Fe2+. The uptake of this EAA was Na+ dependent and was inhibited by about 40% under oxidative stress conditions. To clarify the molecular mechanisms involved in the inhibition of D-[H-3]aspartate uptake by ascorbate/Fe2+, we investigated the effect of vitamin E (Vit E), melatonin, reduced glutathione (GSH), and dithiothreitol (DTT) on the uptake of D-[H-3]aspartate and on the extent of lipid peroxidation in control and in peroxidized cells, Preincubation with Vit E (100 mu M) abolished lipid peroxidation, but had no significant effect on the inhibition of D-[H-3]aspartate uptake evoked by ascorbate/Fe2+ Melatonin was more effective in reducing the formation of TEARS and conjugated dienes than in preventing the D-[H-3]aspartate uptake inhibition evoked by the oxidant pair, Conversely, GSH (4 mM) and DTT (41 mM) completely prevented the inhibition of D-[H-3]aspartate uptake in cells subjected to oxidative stress, but were without effect on the extent of peroxidation., Free fatty acids, such as arachidonic acid, seem not to be involved in reducing the activity of the D-[H-3]aspartate uptake system, whereas the reduction of the Na+ electrochemical gradient that occurs under oxidative stress was in part involved in the reduction of D-[H-3]aspartate uptake by the cells, The inhibition of D-[H-3]aspartate uptake by ascorbate/Fe2+ persisted for at least 1 h, but could be partially reverted by disulfide reducing agents, It is concluded that oxidative stress causes long-lasting modifications of the glutamate/D-[H-3]aspartate transport system (or systems), such as oxidation of protein sulfhydryl (SR) groups, which cll he recovered by some antioxidants.	UNIV COIMBRA, DEPT ZOOL, P-3000 COIMBRA, PORTUGAL; UNIV COIMBRA, FAC MED, P-3000 COIMBRA, PORTUGAL	Universidade de Coimbra; Universidade de Coimbra	Agostinho, P (corresponding author), UNIV COIMBRA, CTR NEUROSCI COIMBRA, P-3000 COIMBRA, PORTUGAL.		Oliveira, Catarina R./F-3685-2010; Agostinho, Paula/F-3748-2010; Duarte, Carlos B/K-6358-2013	Agostinho, Paula/0000-0001-5523-4945; Duarte, Carlos B/0000-0002-1474-0208; Oliveira, Catarina/0000-0001-6942-4328				Agostinho P, 1996, NEUROSCI RES, V25, P343; AGOSTINHO P, 1994, BRAIN RES, V655, P213, DOI 10.1016/0006-8993(94)91616-0; Agostinho P, 1996, J NEUROCHEM, V67, P1153; AGOSTINHO P, 1995, NEUROSCI LETT, V198, P193, DOI 10.1016/0304-3940(95)11996-A; ATTWELL D, 1993, SEMIN NEUROSCI, V5, P159, DOI 10.1016/S1044-5765(05)80049-1; BALEAR VJ, 1972, J NEUROCHEM, V19, P2657; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; Buege J A, 1978, Methods Enzymol, V52, P302; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CHAN PH, 1988, J NEUROCHEM, V50, P1185, DOI 10.1111/j.1471-4159.1988.tb10591.x; CHEN LD, 1995, NEUROSCI RES COMMUN, V17, P151; CHOI DW, 1987, J NEUROSCI, V7, P369; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; Duarte CB, 1996, J NEUROSCI RES, V44, P363; FACCI L, 1990, J NEUROSCI RES, V27, P202, DOI 10.1002/jnr.490270210; Ferreira IL, 1996, EUR J PHARMACOL, V302, P153, DOI 10.1016/0014-2999(96)00044-1; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HANDELMAN GJ, 1986, ADV FREE RADICAL BIO, V2, P1, DOI 10.1016/S8755-9668(86)80024-2; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HUBA R, 1990, NEUROSCI LETT, V117, P37, DOI 10.1016/0304-3940(90)90116-Q; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KELLEY EE, 1995, ARCH BIOCHEM BIOPHYS, V319, P102, DOI 10.1006/abbi.1995.1271; LITTLEFIELD LG, 1988, INT J RADIAT BIOL, V53, P875, DOI 10.1080/09553008814551241; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEAL MJ, 1994, J NEUROCHEM, V62, P1025; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; RAUEN T, 1994, NEUROSCI LETT, V169, P137, DOI 10.1016/0304-3940(94)90375-1; REED CF, 1960, J LAB CLIN MED, V56, P281; Reed D.J., 1984, PHARMACOL REV, V36, p25S; Rego AC, 1996, J NEUROCHEM, V66, P2506; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; ROMANO C, 1995, J NEUROCHEM, V65, P59; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TROTTI D, 1995, J BIOL CHEM, V270, P9890, DOI 10.1074/jbc.270.17.9890; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; VOLTERRA A, 1994, RENAL PHYSIOL BIOCH, V17, P165; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WITTING LA, 1980, FREE RADICAL BIO MED, V4, P295; Yang CS, 1996, FREE RADICAL BIO MED, V20, P245, DOI 10.1016/0891-5849(95)02042-X; YIM MB, 1994, J BIOL CHEM, V269, P1621	56	57	58	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					154	163		10.1096/fasebj.11.2.9039958	http://dx.doi.org/10.1096/fasebj.11.2.9039958			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039958	Green Submitted			2022-12-25	WOS:A1997WK50900008
J	Sangfelt, O; Erickson, S; Einhorn, S; Grander, D				Sangfelt, O; Erickson, S; Einhorn, S; Grander, D			Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines	ONCOGENE			English	Article						interferon; cell cycle; cyclin-dependent kinase; cyclin-dependent kinase inhibitors	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; MUTANT P53; TGF-BETA; ARREST; EXPRESSION; LYMPHOMA; PROTEIN; P21; E2F	One prominent effect of IFNs is their cell growth inhibitory activity. The exact molecular mechanism behind this inhibition of proliferation remains to be elucidated. Possible effecters for IFN-induced growth inhibition are the recently discovered cyclin-dependent kinase inhibitors. The effect of IFN-alpha treatment on the members of the Ink4 and Cip/Kip families of Cdk inhibitors was investigated in three hematopoietic cell lines Daudi, U-266 and H9. Two of these cell lines, Daudi and U-266, respond to IFN-alpha by G(1) arrest, whereas the H9 cell line is not growth arrested by IFN-alpha. We show that a p53-independent upregulation of p21 mRNA occurs following IFN-alpha treatment in all three cell lines. In Daudi and U-266 cells, the mRNA induction is accompanied by an increase in p21 protein, followed by an increased binding of p21 to Cdk2 and a subsequent decrease in Cdk2 activity, temporally coinciding with G(1) arrest. In both these cell lines, there was also an increased binding of p21 to Cdk4. In contrast, p21 protein was not expressed in H9 cells, despite high levels of p21 mRNA following IFN-alpha treatment. In U-266 cells, IFN-alpha increased not only p21 but also p15 mRNA and protein levels, followed by an increased association of p15 with Cdk4, Furthermore, IFN-alpha treatment caused a four- to sixfold induction of the p16 E1 beta transcript in U-266 cells. Expression levels of the other Ink4 and Cip/Kip Cdk inhibitors mere not induced by IFN treatment in any of the cell lines. We conclude that IFN-alpha can act as a potent regulator of Cdk-inhibitor expression, correlating with decreased Cdk activity and cell growth inhibition, One mechanism for resistance to IFN may be loss of the ability of cells to upregulate these proteins.	KAROLINSKA HOSP & INST,RADIUMHEMMET,DEPT ONCOL PATHOL,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital								Brandter LB, 1996, EUR J HAEMATOL, V56, P313; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CORRADINI P, 1994, LEUKEMIA, V8, P758; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEMAYER EM, 1988, INTERFERONS OTHER RE; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; GRANA X, 1995, ONCOGENE, V11, P211; GRANDER D, 1990, LANCET, V336, P337, DOI 10.1016/0140-6736(90)91879-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, CANCER RES, V56, P722; HEYMAN M, 1994, LEUKEMIA, V8, P425; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KUNLIANG G, 1994, GENE DEV, V8, P2939; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUOKA MKJ, 1994, CELL, V79, P487; MAZARS GR, 1992, ONCOGENE, V7, P1015; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1995, CELL, V83, P993; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROOS G, 1984, CANCER RES, V44, P5358; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIYANOV P, 1996, MOL CELL BIOL, V16, P734; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; TAYLORPAPADIMIT.J, 1985, INTERFERONS THEIR IM, P81; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIMAN KG, 1991, ONCOGENE, V6, P1633; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	49	98	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					415	423		10.1038/sj.onc.1200832	http://dx.doi.org/10.1038/sj.onc.1200832			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053838				2022-12-25	WOS:A1997WE36400004
J	Wang, WY; Gorrell, A; Honzatko, RB; Fromm, HJ				Wang, WY; Gorrell, A; Honzatko, RB; Fromm, HJ			A study of Escherichia coli adenylosuccinate synthetase association states and the interface residues of the homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL MODIFICATION; SUBUNIT ASSOCIATION; SEQUENCE; BINDING; CLONING; SITE; PURIFICATION; PROTEINS; PURA; GENE	The state of aggregation of adenylosuccinate synthetase from Escherichia coli is a point of controversy, with crystal structures indicating a dimer and some solution studies indicating a monomer, Crystal structures implicate Arg(143) and Asp(231) in stabilizing the dimer, with Arg(143) interacting directly with bound IMP of the a fold related subunit, Residue Arg(143) was changed to Lys and Leu, and residue Asp(231) was changed to Ala. Matrix-assisted laser desorption ionization mass spectroscopy and analytical ultracentrifugation of the wild-type and the mutant enzymes indicate a mixture of monomers and dimers, with a majority of the enzyme in the monomeric state, In the presence of active site ligands, the wild-type enzyme exists almost exclusively as a dimer, whereas the mutant enzymes show only slightly decreased dissociation constants for the dimerization, Initial rate kinetic studies of the wild-type and mutant enzymes show similar K-cat and K-m values for aspartate, However, increases in the K-m values of GTP and IMP are observed for the mutant, Changes in dissociation constants for IMP are comparable with changes in K-m, values, Our results suggest that IMP binding induces enzyme dimerization and that two residues in the interface region, Arg(143) and Asp(231), play significant roles in IMP and GTP binding.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NINDS NIH HHS [NS10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; ANDREICHUK IV, 1995, MOL GENET MIKROBIOL, V1, P21; ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; DEABREU RA, 1995, PURINE PYRIMIDINE ME, V8, P195; DONG Q, 1991, J BIOL CHEM, V266, P12228; DONG Q, 1990, J BIOL CHEM, V265, P6235; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22532; HEIM DR, 1995, PESTIC BIOCHEM PHYS, V53, P138, DOI 10.1006/pest.1995.1061; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MS, 1986, J BIOL CHEM, V261, P1571; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P5055, DOI 10.1021/bi00590a005; MANTSALA P, 1992, J BACTERIOL, V174, P1883; MARKHAM GD, 1977, ARCH BIOCHEM BIOPHYS, V181, P24; MARKHAM GD, 1975, FEBS LETT, V52, P266; McRorie D. K., 1993, SELF ASSOCIATING SYS; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; POLAND BP, 1996, IN PRESS J MOL BIOL; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; RUDOLPH FB, 1971, THESIS IOWA STATE U; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; STAYTON MM, 1976, 172ND ANN M AM CHEM, P155; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	40	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7078	7084		10.1074/jbc.272.11.7078	http://dx.doi.org/10.1074/jbc.272.11.7078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054400	hybrid			2022-12-25	WOS:A1997WN14700039
J	Armstrong, LC; Komiya, T; Bergman, BE; Mihara, K; Bornstein, P				Armstrong, LC; Komiya, T; Bergman, BE; Mihara, K; Bornstein, P			Metaxin is a component of a preprotein import complex in the outer membrane of the mammalian mitochondrion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; THROMBOSPONDIN-3 THBS3; GAUCHER-DISEASE; RAT-LIVER; RECEPTOR; YEAST; GENE; TERMINUS; SIGNAL; SEARCH	Metaxin, a novel gene located between the glucocerebrosidase and thrombospondin 3 genes in the mouse, is essential for survival of the postimplantation mouse embryo, In this study, the subcellular location, domain structure, and biochemical function of metaxin mere investigated, Anti-recombinant metaxin antibodies recognized 35 and 70-kDa proteins in mitochondria from various tissues; the 35-kDa protein is consistent in size with the predicted translation product of metaxin cDNA When metaxin cDNA was transfected into COS cells, immunofluorescence staining demonstrated that the protein is located in mitochondria. Metaxin contains a putative mitochondrial outer membrane signal anchor domain at its C terminus, and a truncated form of metaxin lacking this signal anchor domain had a reduced association with mitochondria. In addition, metaxin was highly susceptible to proteases in intact mitochondria, We there fore conclude that metaxin is a mitochondrial protein that extends into the cytosol while anchored into the outer membrane at its C terminus, In its N-terminal region, metaxin shows significant sequence identity to Tom37, a component of the outer membrane portion of the mitochondrial preprotein translocation apparatus in Saccharomyces cerevisiae, but important structural differ ences, including apparently different mechanisms of targeting to membranes, also exist between the two proteins, Given the similar subcellular locations of metaxin and Tom37, the possible role of metaxin in mitochondrial preprotein import was investigated, Antibodies against metaxin, when preincubated with mitochondria, partially inhibited the uptake of radiolabeled preadrenodoxin into mitochondria, Metaxin is therefore the second mammalian component of the protein translocation apparatus of the mitochondrial outer membrane to be characterized at the molecular level and the first for which an inherited mutation has been described. The early embryonic lethal phenotype of mice lacking metaxin demonstrates that efficient import of proteins into mitochondria is crucial for cellular survival. The characterization of metaxin provides an opportunity to elucidate similarities and possible differences in the mechanisms of protein import between fungi and mammals and in the phenotypes of fungi and mammals lacking mitochondrial import receptors.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOL BIOL,FUKUOKA 812,JAPAN	University of Washington; University of Washington Seattle; Kyushu University					NIA NIH HHS [AG051361] Funding Source: Medline; NIGMS NIH HHS [5F32GM17395-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017395] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG LC, 1995, MOL BIOL CELL, V6, P434; BEUTLER E, 1995, ADV GENET, V32, P17; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Bomer U, 1996, J MOL BIOL, V262, P389, DOI 10.1006/jmbi.1996.0522; BORNSTEIN P, 1993, GENOMICS, V15, P607, DOI 10.1006/geno.1993.1114; BORNSTEIN P, 1995, P NATL ACAD SCI USA, V92, P4547, DOI 10.1073/pnas.92.10.4547; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Collins M, 1996, NUCLEIC ACIDS RES, V24, P3661, DOI 10.1093/nar/24.19.3661; Court DA, 1996, FEBS LETT, V390, P73, DOI 10.1016/0014-5793(96)00629-1; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Fleischer S, 1974, Methods Enzymol, V31, P6; GOPING IS, 1995, FEBS LETT, V373, P45; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HILL KK, 1995, GENETICS, V141, P595; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; JARAUSCH J, 1985, EUR J BIOCHEM, V146, P219, DOI 10.1111/j.1432-1033.1985.tb08641.x; Komiya T, 1996, J BIOL CHEM, V271, P22105, DOI 10.1074/jbc.271.36.22105; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; Nakai M, 1995, J BIOL CHEM, V270, P30571, DOI 10.1074/jbc.270.51.30571; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; QABAR AN, 1994, J BIOL CHEM, V269, P1262; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROST B, 1995, PROTEIN SCI, V4, P521; SCHIMMEL SD, 1973, P NATL ACAD SCI USA, V70, P3195, DOI 10.1073/pnas.70.11.3195; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; STOLZENBACH F, 1966, METHOD ENZYMOL, V9, P278; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; Trouet A, 1974, Methods Enzymol, V31, P323; VOS HL, 1992, J BIOL CHEM, V267, P12192	38	101	104	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6510	6518		10.1074/jbc.272.10.6510	http://dx.doi.org/10.1074/jbc.272.10.6510			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045676	hybrid			2022-12-25	WOS:A1997WM64700060
J	Goldberg, DE; Sharma, V; Oksman, A; Gluzman, IY; Wellems, TE; PiwnicaWorms, D				Goldberg, DE; Sharma, V; Oksman, A; Gluzman, IY; Wellems, TE; PiwnicaWorms, D			Probing the chloroquine resistance locus of Plasmodium falciparum with a novel class of multidentate metal(III) coordination complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; MALARIA PARASITES; IRON CHELATORS; HEME POLYMERIZATION; DIGESTIVE VACUOLE; RELAXATION AGENTS; MECHANISM; GENE; INVITRO; GALLIUM	The malaria organism Plasmodium falciparum detoxifies heme released during degradation of host erythrocyte hemoglobin by sequestering it within the parasite digestive vacuole as a polymer called hemozoin, Antimalarial agents such as chloroquine appear to work by interrupting the heme polymerization process, but their efficacy has been impaired by the emergence of drug-resistant organisms, We report here the identification of a new class of antimalarial compounds, hexadentate ethylene diamine-N,N'-bis[propyl(2-hydroxy-(R)-benzylimino)]-metal(III) complexes [(R)-ENBPI-M(III)] and a corresponding ((R)-benzylamino)] analog [(R)-ENBPA-M(III)], a group of lipophilic monocationic leads amenable to metallopharmaceutical development, Racemic mixtures of Al(III), Fe(III), or Ga(III) but not In(III) (R)-ENBPI metallo-complexes killed intraerythrocytic malaria parasites in a stage-specific manner, the R = 4,6-dimethoxy-substituted ENBPI Fe(III) complex being most potent (IC50 similar to 1 mu M), Inhibiting both chloroquine sensitive and -resistant parasites, potency of these imino complexes correlated in a free metal-independent manner with their ability to inhibit heme polymerization in vitro, In contrast, the reduced (amino) 3-MeO-ENBPA Ga(III) complex (MR045) was found to be selectively toxic to chloroquine-resistant parasites in a verapamil-insensitive manner. In 21 independent recombinant progeny of a genetic cross, susceptibility to this agent mapped in perfect linkage with the chloroquine resistance phenotype suggesting that a locus for 3-MeO-ENBPA Ga(III) susceptibility was located on the same 36-kilobase segment of chromosome 7 as the chloroquine resistance determinant, These compounds may be useful as novel probes of chloroquine resistance mechanisms and for antimalarial drug development.	WASHINGTON UNIV,SCH MED,MALLINCKRODT INST RADIOL,DEPT RADIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; NIAID,NIH,BETHESDA,MD 20892	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NATIONAL CANCER INSTITUTE [R01CA065735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER; NCI NIH HHS [CA65735] Funding Source: Medline; NIAID NIH HHS [AI31615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS MJ, 1993, SCIENCE, V261, P725, DOI 10.1126/science.8102010; BENDRAT K, 1995, NATURE, V378, P138, DOI 10.1038/378138a0; BRYCESMITH D, 1986, CHEM SOC REV, V15, P93, DOI 10.1039/cs9861500093; CHERNOFF DM, 1993, BIOCHIM BIOPHYS ACTA, V1147, P262, DOI 10.1016/0005-2736(93)90011-N; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DEUTSCH E, 1983, PROG INORG CHEM, V30, P75, DOI 10.1002/9780470166314.ch2; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; FOOTE SJ, 1994, ACTA TROP, V56, P157, DOI 10.1016/0001-706X(94)90061-2; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FORD JM, 1990, PHARMACOL REV, V42, P155; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GORDEUK VR, 1993, AM J TROP MED HYG, V48, P193, DOI 10.4269/ajtmh.1993.48.193; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREEN MA, 1984, J AM CHEM SOC, V106, P3689, DOI 10.1021/ja00324a058; HERSHKO C, 1992, J INORG BIOCHEM, V47, P267, DOI 10.1016/0162-0134(92)84072-U; Ito T., 1983, CHEM LETT, V12, P121; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; KUMAR K, 1993, PURE APPL CHEM, V65, P515, DOI 10.1351/pac199365030515; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; LICHTSTEIN D, 1979, P NATL ACAD SCI USA, V76, P650, DOI 10.1073/pnas.76.2.650; LYTTON SD, 1993, AM J HEMATOL, V43, P217, DOI 10.1002/ajh.2830430311; LYTTON SD, 1991, MOL PHARMACOL, V40, P584; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; MAY PM, 1983, PROGR MED CHEM, V20, P225, DOI 10.1016/S0079-6468(08)70220-0; Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441; PIWNICAWORMS D, 1995, BIOCHEMISTRY-US, V34, P12210, DOI 10.1021/bi00038a015; RITCHIE RJ, 1984, PROG BIOPHYS MOL BIO, V43, P1, DOI 10.1016/0079-6107(84)90002-6; Sarma B. D., 1955, J AM CHEM SOC, V77, P5476; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Sharma V, 1996, J MED CHEM, V39, P3483, DOI 10.1021/jm950823c; SHARMA V, 1996, J NUCL MED, V37, P71; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; STAHEL E, 1988, AM J TROP MED HYG, V39, P236, DOI 10.4269/ajtmh.1988.39.236; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TSANG BW, 1993, J NUCL MED, V34, P1127; TSANG BW, 1994, J MED CHEM, V37, P4400, DOI 10.1021/jm00051a018; VANDERJAGT DL, 1992, BIOCHIM BIOPHYS ACTA, V1122, P256, DOI 10.1016/0167-4838(92)90401-X; VANES HHG, 1994, MOL CELL BIOL, V14, P2419, DOI 10.1128/MCB.14.4.2419; VEIGNIE E, 1991, ANN TROP MED PARASIT, V85, P229, DOI 10.1080/00034983.1991.11812550; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WELLHONER HH, 1991, J BIOL CHEM, V266, P4309; Wernsdorfer Walther H., 1988, MALARIA PRINCIPLES P; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; WONG E, 1995, INORG CHEM, V34, P93, DOI 10.1021/ic00105a018; XU J, 1995, J AM CHEM SOC, V117, P7245, DOI 10.1021/ja00132a025; YINNON AM, 1989, BLOOD, V74, P2166	57	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6567	6572		10.1074/jbc.272.10.6567	http://dx.doi.org/10.1074/jbc.272.10.6567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045684	hybrid			2022-12-25	WOS:A1997WM64700068
J	Jiang, RF; Greener, T; Barouch, W; Greene, L; Eisenberg, E				Jiang, RF; Greener, T; Barouch, W; Greene, L; Eisenberg, E			Interaction of auxilin with the molecular chaperone, Hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; EUKARYOTIC DNAJ HOMOLOG; UNCOATING ATPASE; COATED VESICLES; SUBSTRATE-BINDING; BOVINE BRAIN; HSP70; CLATHRIN; TRANSLOCATION; NUCLEOTIDE	We have studied the direct interaction of the constitutive isoform of Hsp70 (Hsc70) with the DnaJ homolog, auxilin, a cofactor that binds to clathrin-coated vesicles and is required for their uncoating by Hsc70. Auxilin caused a 5 fold increase in Hsc70 ATPase activity and a corresponding increase in steady-state levels of bound ADP; the dissociation constant for this effect was 0.6 mu M. Auxilin also induced polymerization of Hsc7O and bound to the resulting polymer at a 1:1 molar ratio; here too the dissociation constant was 0.6 mu M. Both this binding and polymerization required ATP; the Hsc70 depolymerized with a 4-min half-life when ATP was completely hydrolyzed to ADP. Although auxilin induces polymerization stoichiometrically and other DnaJ homologs induce polymerization catalytically, these data show that auxilin is similar to other DnaJ homologs in its ability to activate the Hsc70 ATPase activity, to polymerize Hsc70, and in the nucleotide dependence of this polymerization. Furthermore, the 70-amino acid J-domain of auxilin polymerized Hsc76 with the same nucleotide dependence as intact auxilin. Therefore, although only auxilin and not other DnaJ homologs support uncoating, our data suggest that various DnaJ homologs share a common mechanism of interaction with Hsc70, perhaps be cause their J-domains interact similarly with Hsc70.	NHLBI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BAROUCH W, 1997, IN PRESS BIOCHEMISTR; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CHOCK SP, 1979, J BIOL CHEM, V254, P3229; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GAO BC, 1993, J BIOL CHEM, V268, P8507; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P21; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLSTEIN S, 1996, J CELL BIOL, V4, P925; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; KING C, 1997, IN PRESS BIOCHEMISTR; KING C, 1995, MOL BIOL CELL, V6, P69; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1994, J BIOL CHEM, V269, P6931; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RASSOW J, 1995, REV PHYSIOL BIOCH P, V126, P199, DOI 10.1007/BFb0049777; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307	31	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6141	6145		10.1074/jbc.272.10.6141	http://dx.doi.org/10.1074/jbc.272.10.6141			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045625	hybrid			2022-12-25	WOS:A1997WM64700009
J	Reuber, BE; Karl, C; Reimann, SA; Mihalik, SJ; Dodt, G				Reuber, BE; Karl, C; Reimann, SA; Mihalik, SJ; Dodt, G			Cloning and functional expression of a mammalian gene for a peroxisomal sarcosine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIPECOLIC ACID OXIDATION; RAT-LIVER MITOCHONDRIA; DIMETHYLGLYCINE DEHYDROGENASE; BIOGENESIS DISORDERS; NUCLEOTIDE-SEQUENCE; BINDING-PROTEINS; ESCHERICHIA-COLI; PURIFICATION; DNA; IDENTIFICATION	Sarcosine oxidation in mammals occurs via a mitochondrial dehydrogenase closely linked to the electron transport chain, An additional H2O2-producing sarcosine oxidase has now been purified from rabbit kidney, A corresponding cDNA was cloned from rabbit liver and the gene designated sox, This rabbit sox gene encodes a protein of 390 amino acids and a molecular mass of 44 kDa identical to the molecular mass estimated for the purified enzyme, Sequence analysis revealed an N-terminal ADP-beta alpha beta-binding fold, a motif highly conserved in tightly bound flavoproteins, and a C-terminal peroxiso mal targeting signal 1. Sarcosine oxidase from rabbit liver exhibits high sequence homology (25-28% identity) to monomeric bacterial sarcosine oxidases, Both purified sarcosine oxidase and a recombinant fusion protein synthesized in Escherichia coli contain a covalently bound flavin, metabolize sarcosine, L-pipecolic acid, and L-proline, and cross-react with antibodies raised against L-pipecolic acid oxidase from monkey liver, Subcellular fractionation demonstrated that sarcosine oxidase is a peroxisomal enzyme in rabbit kidney, Transfection of human fibroblast cell lines and CV-1 cells (monkey kidney epithelial cells) with the sox cDNA resulted in a peroxisomal localization of sarcosine oxidase and revealed that the import into the peroxisomes is mediated by the peroxisomal targeting signal 1 pathway.	RUHR UNIV BOCHUM,INST PHYSIOL CHEM,D-44780 BOCHUM,GERMANY; JOHNS HOPKINS UNIV,SCH MED,KENNEDY KRIEGER RES INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Ruhr University Bochum; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARBER MJ, 1987, BIOCHEM J, V242, P89, DOI 10.1042/bj2420089; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHLUMSKY LJ, 1995, J BIOL CHEM, V270, P18252, DOI 10.1074/jbc.270.31.18252; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK RJ, 1985, J BIOL CHEM, V260, P2998; Cornish-Bowden A., 1979, FUNDAMENTALS ENZYME, P82; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; EDMONDSON DE, 1991, CHEM BIOCH FLAVOENZY, V1, P73; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISELL WR, 1962, J BIOL CHEM, V237, P94; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HAYASHI S, 1980, BIOCHEM BIOPH RES CO, V96, P924, DOI 10.1016/0006-291X(80)91443-6; HOHFELD J, 1991, J CELL BIOL, V114, P1168; HUBL P, 1964, H-S Z PHYSIOL CHEM, V335, P146, DOI 10.1515/bchm2.1964.335.1.146; INOUYE Y, 1987, CHEM PHARM BULL, V35, P4194; KOYAMA Y, 1991, AGR BIOL CHEM TOKYO, V55, P1259, DOI 10.1080/00021369.1991.10870758; KVALNESKRICK K, 1987, BIOCHEMISTRY-US, V26, P7391, DOI 10.1021/bi00397a029; KVALNESKRICK K, 1986, BIOCHEMISTRY-US, V25, P6061, DOI 10.1021/bi00368a034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; MACKENZIE CG, 1956, J BIOL CHEM, V222, P145; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MANNAERTS GP, 1992, CELL BIOCHEM FUNCT, V10, P141, DOI 10.1002/cbf.290100303; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MASSAD G, 1995, J BACTERIOL, V177, P5878, DOI 10.1128/jb.177.20.5878-5883.1995; MATSUDA Y, 1987, CHEM PHARM BULL, V35, P711; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MIHALIK SJ, 1991, J BIOL CHEM, V266, P4822; MIHALIK SJ, 1989, PEDIATR RES, V25, P548, DOI 10.1203/00006450-198905000-00024; MIHALIK SJ, 1991, J COMP PHYSIOL B, V160, P671, DOI 10.1007/BF00571266; MIHALIK SJ, 1989, J BIOL CHEM, V264, P2509; MORI N, 1980, AGR BIOL CHEM TOKYO, V44, P1391, DOI 10.1080/00021369.1980.10864124; MOSER HW, 1993, ADV HUM GENET, V21, P1; MOSER HW, 1980, ANN NEUROL, V7, P542, DOI 10.1002/ana.410070607; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; NEGRI A, 1987, J BIOL CHEM, V262, P10026; NISHIYA Y, 1993, J FERMENT BIOENG, V75, P239, DOI 10.1016/0922-338X(93)90145-X; OGUSHI S, 1988, CHEM PHARM BULL, V36, P1445; OHLSSON I, 1974, J MOL BIOL, V89, P339, DOI 10.1016/0022-2836(74)90523-3; PARKES JG, 1970, BIOCHIM BIOPHYS ACTA, V196, P162, DOI 10.1016/0005-2736(70)90003-9; POOSCH MS, 1986, BIOCHIM BIOPHYS ACTA, V884, P585, DOI 10.1016/0304-4165(86)90211-4; PORTER DH, 1985, ARCH BIOCHEM BIOPHYS, V243, P396, DOI 10.1016/0003-9861(85)90516-8; RAIKHINSTEIN M, 1992, Methods in Molecular and Cellular Biology, V3, P108; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1982, J MOL BIOL, V160, P287, DOI 10.1016/0022-2836(82)90177-2; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; STEENKAMP DJ, 1982, BIOCHEM J, V203, P707, DOI 10.1042/bj2030707; SUZUKI H, 1991, J BIOCHEM-TOKYO, V109, P909, DOI 10.1093/oxfordjournals.jbchem.a123479; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; Willie A, 1996, BIOCHEMISTRY-US, V35, P5292, DOI 10.1021/bi952995h; Willie A, 1995, BIOCHEMISTRY-US, V34, P16703, DOI 10.1021/bi00051a019; WITTWER AJ, 1981, J BIOL CHEM, V256, P4102; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZELLER HD, 1989, BIOCHEMISTRY-US, V28, P5145, DOI 10.1021/bi00438a035	60	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6766	6776		10.1074/jbc.272.10.6766	http://dx.doi.org/10.1074/jbc.272.10.6766			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045710	hybrid			2022-12-25	WOS:A1997WM64700094
J	Tellam, JT; James, DE; Stevens, TH; Piper, RC				Tellam, JT; James, DE; Stevens, TH; Piper, RC			A mammalian Golgi Sec1p-like protein, mVps45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SYNAPTIC VESICLE DOCKING; SYNTAXIN-BINDING PROTEIN; UNC-18 GENE ENCODES; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SEC1 HOMOLOG; C-ELEGANS; VACUOLE; CELLS	Our understanding of lysosomal biogenesis and general vesicular transport in animal cells has been greatly enhanced by studies of vacuolar biogenesis in yeast. Genetic screens have identified a number of proteins that play direct roles in the proper sorting of vacuolar hydrolases. These include t-SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins and Sec1p-like proteins, which have recently been implicated as key regulators of vesicle fusion. In this study we have extended these observations in yeast and have isolated and characterized a novel member of the Sec1p-like family of proteins from mammalian cells, mVps45. mVps45 shares a high level of identity with the Saccharomyces cerevisiae Sec1p-like protein Vps45p that is believed to function with the t-SNARE Pep12p in the fusion of Golgi-derived transport vesicles with a prevacuolar compartment. We found that mVps45 is a ubiquitously expressed peripheral membrane protein that localized to perinuclear Golgi-like and trans-Golgi network compartments in Chinese hamster every cells. We found that mVps45 could bind specifically to yeast Pep12p and to the mammalian Pep12p-like protein, syntaxin 6, in vitro.	UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA; UNIV QUEENSLAND, CTR BIOL MOL, BRISBANE, QLD 4072, AUSTRALIA	University of Oregon; University of Queensland				James, David/0000-0001-5946-5257; Stevens, Tom/0000-0001-6427-6848; Piper, Robert/0000-0001-9995-5699	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032448, F32GM016601, R01GM032448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32448, GM16601-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Burd CG, 1996, MOL CELL BIOL, V16, P2369; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWLES CR, 1994, J CELL SCI, V107, P3449; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; EGERTON M, 1993, YEAST, V9, P703, DOI 10.1002/yea.320090704; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HODEL A, 1994, J BIOL CHEM, V269, P8623; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JH, 1989, TRENDS BIOCHEM SCI, V14, P347, DOI 10.1016/0968-0004(89)90170-9; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOSHIDA S, 1995, GENE, V160, P117, DOI 10.1016/0378-1119(95)00214-Q	52	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6187	6193		10.1074/jbc.272.10.6187	http://dx.doi.org/10.1074/jbc.272.10.6187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045632	hybrid			2022-12-25	WOS:A1997WM64700016
J	Bliss, TM; Lane, DP				Bliss, TM; Lane, DP			Ku selectively transfers between DNA molecules with homologous ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; HUMAN AUTOANTIGEN KU; V(D)J RECOMBINATION; TRANSCRIPTION FACTOR; BINDING-ACTIVITY; PURIFICATION; GENE; ANTIGEN; SITE	Double strand break repair and V(D)J recombination in mammalian cells require the function of the Ku protein complex and the DNA-dependent protein kinase. The DNA-dependent protein kinase is targeted to DNA through its interaction with the Ku protein complex, and thus the specificity of template recognition in the repair and recombination reactions depend on Ku. We have studied Ku binding to DNA using competitive gel shift analysis. We find that Ku bound to one DNA molecule can transfer directly to another DNA molecule when the two DNA molecules have homologous ends containing a minimum of four matched bases. This remarkable reaction can give a false impression of sequence specificity of Ru DNA binding under certain assay conditions. A model is proposed for the DNA binding function of Ku on the basis of these results and the discovery of a novel type of DNA-Ku complex formed at high Ku/DNA ratios is discussed.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee				Lane, David/0000-0003-0551-3545				BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BRYANT PE, 1993, MUTAT RES, V299, P289, DOI 10.1016/0165-1218(93)90105-M; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1993, J BIOL CHEM, V268, P10440; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FALZON M, 1993, J BIOL CHEM, V268, P10546; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Higashiura M, 1993, CHROMOSOME RES, V1, P27, DOI 10.1007/BF00710604; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JACOBY DB, 1994, J BIOL CHEM, V269, P11484; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAY G, 1991, J BIOL CHEM, V266, P3052; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PORGES AJ, 1990, J IMMUNOL, V145, P4222; PRICE A, 1993, SEMIN CANCER BIOL, V4, P61; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROBERTS MR, 1994, P NATL ACAD SCI USA, V91, P6354, DOI 10.1073/pnas.91.14.6354; SIPLEY JD, 1995, P NATL ACAD SCI USA, V92, P7515, DOI 10.1073/pnas.92.16.7515; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TOTH EC, 1993, NUCLEIC ACIDS RES, V21, P3257, DOI 10.1093/nar/21.14.3257; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	46	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5765	5773		10.1074/jbc.272.9.5765	http://dx.doi.org/10.1074/jbc.272.9.5765			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038190	hybrid			2022-12-25	WOS:A1997WK74700058
J	Guillaume, G; Vanhove, M; LamotteBrasseur, J; Ledent, P; Jamin, M; Joris, B; Frere, JM				Guillaume, G; Vanhove, M; LamotteBrasseur, J; Ledent, P; Jamin, M; Joris, B; Frere, JM			Site-directed mutagenesis of glutamate 166 in two beta-lactamases - Kinetic and molecular modeling studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-ENZYME INTERMEDIATE; STREPTOMYCES-ALBUS-G; PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCUS-AUREUS PC1; REFINED CRYSTAL-STRUCTURE; ACTIVE-SITE; CATALYTIC MECHANISM; RESOLUTION; MUTANTS; CEPHALOSPORINS	The catalytic pathway of class A beta-lactamases involves an acyl-enzyme intermediate where the substrate is ester-linked to the Ser-70 residue, Glu-166 and Lys-73 have been proposed as candidates for the role of general base in the activation of the serine OH group, The replacement of Glu-166 by an asparagine in the TEM-1 and by a histidine in the Streptomyces albus G beta-lactamases yielded enzymes forming stable acyl-enzymes with beta-lactam antibiotics, Although acylation of the modified proteins by benzylpenicillin remained relatively fast, it was significantly impaired when compared to that observed with the wild-type enzyme. Moreover, the E166N substitution resulted in a spectacular modification of the substrate profile much larger than that described for other mutations of Omega-loop residues. Molecular modeling studies indicate that the displacement of the catalytic water molecule can be related to this observation, These results confirm the crucial roles of Glu-166 and of the ''catalytic'' mater molecule in both the acylation and the deacylation processes.	UNIV LIEGE,INST CHIM B6,CTR INGN PROT,B-4000 LIEGE,BELGIUM; UNIV LIEGE,INST CHIM B6,ENZYMOL LAB,B-4000 LIEGE,BELGIUM	University of Liege; University of Liege				Jamin, Marc/0000-0002-8677-2110				ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; [Anonymous], 1992, CHEM B LACTAMS; BRANNIGAN J, 1991, BIOCHEM J, V278, P673, DOI 10.1042/bj2780673; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; CLACKSON T, 1991, PCR PRACTICAL APPROA, P202; Damblon C, 1996, P NATL ACAD SCI USA, V93, P1747, DOI 10.1073/pnas.93.5.1747; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; DIDEBERG O, 1987, BIOCHEM J, V245, P911, DOI 10.1042/bj2450911; DUBUS A, 1994, BIOCHEM J, V301, P485, DOI 10.1042/bj3010485; ESCOBAR WA, 1994, BIOCHEMISTRY-US, V33, P7619, DOI 10.1021/bi00190a015; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; FISHER J, 1980, BIOCHEMISTRY-US, V19, P2895, DOI 10.1021/bi00554a012; FONZE E, 1995, ACTA CRYSTALLOGR D, V51, P682, DOI 10.1107/S0907444994014496; FRERE JM, 1985, CRC CR REV MICROBIOL, V11, P299; FRERE JM, 1974, EUR J BIOCHEM, V50, P203, DOI 10.1111/j.1432-1033.1974.tb03889.x; GALLENI M, 1993, BIOCHEM J, V291, P19, DOI 10.1042/bj2910019; GIBSON RM, 1990, BIOCHEM J, V272, P613, DOI 10.1042/bj2720613; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HERZBERG O, 1991, BIOCHEMISTRY-US, V30, P9503, DOI 10.1021/bi00103a017; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; JORIS B, 1991, ANTIMICROB AGENTS CH, V35, P2294, DOI 10.1128/AAC.35.11.2294; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KNOX JR, 1993, PROTEIN ENG, V6, P11, DOI 10.1093/protein/6.1.11; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; LAKAYE B, 1994, BIOCHEM J, V300, P141, DOI 10.1042/bj3000141; LAMOTTEBRASSEUR J, 1991, BIOCHEM J, V279, P213, DOI 10.1042/bj2790213; LAMOTTEBRASSEUR J, 1992, BIOCHEM J, V282, P189, DOI 10.1042/bj2820189; LEATHERBARROW RJ, 1987, ENZFITTER NON LINEAR; LEPAGE S, 1995, BIOCHEM J, V309, P49, DOI 10.1042/bj3090049; LEUNG YC, 1994, BIOCHEM J, V299, P671, DOI 10.1042/bj2990671; MARTIN M, 1988, BIOCHEM J, V254, P313; MATAGNE A, 1993, BIOCHEM J, V293, P607, DOI 10.1042/bj2930607; Maveyraud L, 1996, J BIOL CHEM, V271, P10482, DOI 10.1074/jbc.271.18.10482; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; PEARLMAN DA, 1995, AMBER 4 1; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; RAQUET X, 1995, PROTEINS, V23, P63, DOI 10.1002/prot.340230108; RAQUET X, 1996, THESIS U LIEGE LIEGE; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; Vanhove M, 1996, PROTEINS, V25, P104, DOI 10.1002/(SICI)1097-0134(199605)25:1<104::AID-PROT8>3.3.CO;2-H; VANHOVE M, 1996, BIOCHEM J, V321, P413	50	93	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5438	5444		10.1074/jbc.272.9.5438	http://dx.doi.org/10.1074/jbc.272.9.5438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038144	Green Published, hybrid			2022-12-25	WOS:A1997WK74700012
J	Okamoto, T; Akaike, T; Suga, M; Tanase, S; Horie, H; Miyajima, S; Ando, M; Ichinose, Y; Maeda, H				Okamoto, T; Akaike, T; Suga, M; Tanase, S; Horie, H; Miyajima, S; Ando, M; Ichinose, Y; Maeda, H			Activation of human matrix metalloproteinases by various bacterial proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA ELASTASE; HUMAN NEUTROPHIL COLLAGENASE; 92-KDA GELATINASE; HAGEMAN-FACTOR; PROTEOLYTIC INACTIVATION; INTERSTITIAL COLLAGENASE; MICROBIAL PROTEINASES; EVOLUTIONARY FAMILIES; TISSUE INHIBITOR; CYSTEINE SWITCH	Matrix metalloproteinases (MMPs) are zinc-containing proteinases that participate in tissue remodeling under physiological and pathological conditions. To test the involvement of bacterial proteinases in tissue injury during bacterial infections, we investigated the activation potential of various bacterial proteinases against precursors of MMPs (proMMPs) purified from human neutrophils (proMMP-8 and -9) and from human fibrosarcoma cells (proMMP-1). Each proMMP was subjected to treatment with a series of bacterial proteinases at molar ratios of 0.01-0.1 (bacterial proteinase to proMMP), and activities of MMPs generated were determined. Among six different bacterial proteinases, thermolysin family enzymes (family M4) such as Pseudomonas aeruginosa elastase, Vibrio cholerae proteinase, and thermolysin strongly activated all three proMMPs via limited proteolysis to generate active forms of the MMPs, N-terminal sequence analysis of the active MMPs revealed that cleavage occurred at the Val(82)-Leu(83) and Thr(90)-Phe(91) bonds of proMMP-1 and proMMP-9, respectively, which are located near the N terminus of the catalytic domain of MMPs. In contrast, Serratia 56-kDa proteinase and Pseudomonas alkaline proteinase, both of which are classified as members of the serralysin subfamily of zinc metalloproteinases (family M10), and Serratia 73-kDa thiol proteinase did mot evidence proteolytic processing or activation of proMMP-1, -8, and -9 under these experimental conditions. These results indicate that bacterial proteinases may play an important role in tissue destruction and disintegration of extracellular matrix at the site of infections.	KUMAMOTO UNIV,SCH MED,DEPT MICROBIOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM 2,KUMAMOTO 860,JAPAN; NAGASAKI UNIV,INST TROP MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN	Kumamoto University; Kumamoto University; Kumamoto University; Nagasaki University			Maeda, Hiroshi/N-4471-2016					BAICI A, 1980, ANAL BIOCHEM, V108, P230, DOI 10.1016/0003-2697(80)90574-6; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; Grant G A, 1992, Matrix Suppl, V1, P217; HARRIS ED, 1977, PROTEINASES MAMMALIA, P249; HASE CC, 1993, MICROBIOL REV, V57, P823; HASE CC, 1990, INFECT IMMUN, V58, P4011; HASTY KA, 1986, J BIOL CHEM, V261, P5645; HECK LW, 1986, INFECT IMMUN, V51, P115, DOI 10.1128/IAI.51.1.115-118.1986; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P486; ICHINOSE Y, 1992, EUR J EPIDEMIOL, V8, P743, DOI 10.1007/BF00145394; JACKSON RJ, 1994, INFECT IMMUN, V62, P5647, DOI 10.1128/IAI.62.12.5647-5651.1994; KAMINISHI H, 1994, FEMS MICROBIOL LETT, V121, P327, DOI 10.1016/0378-1097(94)90312-3; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES M, 1994, EUR J BIOCHEM, V223, P171, DOI 10.1111/j.1432-1033.1994.tb18980.x; MAEDA H, 1979, ANAL BIOCHEM, V92, P222, DOI 10.1016/0003-2697(79)90649-3; MAEDA H, 1989, CLIN CHIM ACTA, V185, P357, DOI 10.1016/0009-8981(89)90226-X; Maeda H, 1996, BIOL CHEM H-S, V377, P217; MAINARDI CL, 1985, ANN NY ACAD SCI, V460, P345, DOI 10.1111/j.1749-6632.1985.tb51181.x; MARUO K, 1993, J BIOL CHEM, V268, P17711; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUMOTO K, 1984, J BIOCHEM-TOKYO, V96, P739, DOI 10.1093/oxfordjournals.jbchem.a134892; MATSUMOTO K, 1992, CURR EYE RES, V11, P1105, DOI 10.3109/02713689209015082; MATSUMOTO K, 1984, J BACTERIOL, V157, P225, DOI 10.1128/JB.157.1.225-232.1984; MCCACHREN SS, 1989, ARTHRITIS RHEUM, V32, P1539, DOI 10.1002/anr.1780321207; MIYOSHI S, 1992, FEBS LETT, V308, P315, DOI 10.1016/0014-5793(92)81301-2; MOLLA A, 1989, J BIOL CHEM, V264, P10589; MOLLA A, 1986, INFECT IMMUN, V53, P522, DOI 10.1128/IAI.53.3.522-529.1986; MOOKHTIAR KA, 1990, BIOCHEMISTRY-US, V29, P10620, DOI 10.1021/bi00499a007; MORIHARA K, 1975, AGR BIOL CHEM TOKYO, V39, P1123, DOI 10.1080/00021369.1975.10861729; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; MULLIGAN MS, 1993, P NATL ACAD SCI USA, V90, P11523, DOI 10.1073/pnas.90.24.11523; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NISHINO N, 1980, J BIOL CHEM, V255, P3482; OKADA Y, 1992, J BIOL CHEM, V267, P21712; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; Sakata Y, 1996, MICROBIOL IMMUNOL, V40, P415, DOI 10.1111/j.1348-0421.1996.tb01088.x; SALO T, 1994, LAB INVEST, V70, P176; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHIBUYA Y, 1991, BIOCHIM BIOPHYS ACTA, V1077, P316, DOI 10.1016/0167-4838(91)90546-C; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SORSA T, 1992, INFECT IMMUN, V60, P4491, DOI 10.1128/IAI.60.11.4491-4495.1992; SORSA T, 1985, MED BIOL, V63, P66; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STARKEY PM, 1977, PROTEINASES MAMMALIA, P58; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; TANAKA H, 1992, BIOCHIM BIOPHYS ACTA, V1138, P243, DOI 10.1016/0925-4439(92)90044-N; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902	55	132	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6059	6066		10.1074/jbc.272.9.6059	http://dx.doi.org/10.1074/jbc.272.9.6059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038230	hybrid			2022-12-25	WOS:A1997WK74700098
J	Floto, RA; Somasundaram, B; Allen, JM; MahautSmith, MP				Floto, RA; Somasundaram, B; Allen, JM; MahautSmith, MP			Fc gamma receptor I activation triggers a novel Ca2+-activated current selective for monovalent cations in the human monocytic cell line, U937	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; IGG; CHANNELS; HETEROGENEITY; ACETYLCHOLINE; MACROPHAGES; EXPRESSION; GENERATION; CA-2+	Previous reports have suggested that receptors for immunoglobulin G (IgG), Fc gamma Rs, directly activate a nonselective cation channel (Young, J. D.-E., Unkeless, J. C., Young, T. M., Mauro, A., and Cohn, Z. A. (1983) Nature 306, 186-189; Nelson, D. J., Jacobs, E. R., Tang, J. M., Zeller, J. M., and Bone, R. C. (1985) J. Clin. Invest. 76, 500607). To investigate the mechanisms underlying membrane conductance changes following human high affinity (Fc gamma RI) receptor activation, we have used the human monocytic cell line U937 and combined conventional whole cell patch-clamp recordings with single cell fura-2 Ca2+ measurements. Using a K+-free internal solution, antibody cross-linking of IgG-occupied Fc gamma RI activated an inward current at negative potentials, whose amplitude and time course mirrored the concomitant rise in intracellular Ca2+. Current-voltage relationships, obtained under different ionic conditions, revealed a monovalent cation-selective conductance that, under physiological conditions, would result in Na+ influx. Noise analysis of current recordings indicated a single channel conductance of 18 picosiemens and a mean opening time of 4.5 ms. This current was also activated by rises in intracellular Ca2+ induced by ionomycin (3 mu M) or thapsigargin (1 mu M). Addition of the Ca2+ chelator 1,2-bis (2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid to the intracellular medium abolished any channel activation by ionomycin, Fc gamma RI, or the low affinity receptor, Fc gamma RII. These results demonstrate that Fc gamma RI activation triggers a novel Ca2+-activated channel selective for monovalent cations and that neither Fc gamma RI nor Fc gamma RII can directly activate a channel.	UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow	Floto, RA (corresponding author), PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.							ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; DART C, 1993, J PHYSIOL-LONDON, V471, P767, DOI 10.1113/jphysiol.1993.sp019927; FLOTO RA, 1995, CELL CALCIUM, V18, P377, DOI 10.1016/0143-4160(95)90053-5; FLOTO RA, 1995, J PHYSIOL-LONDON, V487, P190; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GIERSCHIK P, 1994, METHOD ENZYMOL, V237, P13; GRINSTEIN S, 1986, J BIOL CHEM, V261, P512; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; Haussinger D, 1996, BIOCHEM J, V313, P697; INCE C, 1988, J CELL BIOL, V106, P1873, DOI 10.1083/jcb.106.6.1873; KATZ B, 1970, NATURE, V226, P962, DOI 10.1038/226962a0; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIN CT, 1994, J CLIN IMMUNOL, V14, P1, DOI 10.1007/BF01541170; LIPTON SA, 1986, BIOCHIM BIOPHYS ACTA, V856, P59, DOI 10.1016/0005-2736(86)90010-6; MARTY A, 1983, PFLUG ARCH EUR J PHY, V396, P179, DOI 10.1007/BF00615524; MCCANN FV, 1983, SCIENCE, V219, P991, DOI 10.1126/science.6823563; NELSON DJ, 1985, J CLIN INVEST, V76, P500, DOI 10.1172/JCI111999; PARTRIDGE LD, 1988, TRENDS NEUROSCI, V11, P69, DOI 10.1016/0166-2236(88)90167-1; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SAGE SO, 1991, J PHYSIOL-LONDON, V441, P559, DOI 10.1113/jphysiol.1991.sp018767; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; YELLEN G, 1982, NATURE, V296, P357, DOI 10.1038/296357a0; YOUNG JDE, 1983, P NATL ACAD SCI-BIOL, V80, P1357, DOI 10.1073/pnas.80.5.1357; YOUNG JDE, 1983, NATURE, V306, P186, DOI 10.1038/306186a0	29	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4753	4758		10.1074/jbc.272.8.4753	http://dx.doi.org/10.1074/jbc.272.8.4753			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030528	hybrid			2022-12-25	WOS:A1997WJ85500016
J	Valenzano, KJ; HeathMonnig, E; Tollefsen, SE; Lake, M; Lobel, P				Valenzano, KJ; HeathMonnig, E; Tollefsen, SE; Lake, M; Lobel, P			Biophysical and biological properties of naturally occurring high molecular weight insulin-like growth factor II variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; IGF BINDING-PROTEINS; TUMOR HYPOGLYCEMIA; FACTOR RECEPTOR; SHORT STATURE; BOVINE SERUM; PURIFICATION; FETAL; SEQUENCE; SITES	A soluble form of the insulin-like growth factor IU mannose 6-phosphate receptor (sIGF-II/MPR) is present in fetal bovine serum and carries mature 7.5-kDa insulin-like growth factor II (IGF-II) and at least 12 different high molecular weight (M(r)) IGF-II isoforms (Valenzano, K. J., Remmler, J., and Lobel, P. (1995) J. Biol. Chem. 270, 16441-16448). In this study, we used gel filtration and anion exchange chromatographies to resolve the isoforms into eight fractions that were characterized with respect to their biochemical, biophysical, and biological properties. Each fraction contained one to three major protein species with apparent sizes ranging from 11 to 17 kDa by SDS-polyacrylamide gel electrophoresis. The 11-kDa species contains no post-translational modifications and consists of an extended IGF-II backbone terminating at Gly-87. The remaining high M(r) IGF-II isoforms are also composed of an 87-amino acid IGF-II peptide backbone but contain increasing amounts of sialated, O-linked sugars. Plasmon resonance spectroscopy experiments revealed that all the high M(r) isoforms and mature 7.5-kDa IGF-II bound to immobilized recombinant soluble human IGF-I receptor, recombinant human IGF-binding protein 1, and sIGF-II/MPR with similar kinetics. In addition, radiolabeled tracer experiments demonstrated that both mature and high M(r) IGF-II isoforms have similar binding profiles in fetal bovine serum and have similar affinities for IGF-II-binding proteins secreted from human fibroblasts. Finally, the biological activity of high M(r) IGF-II was shown to be similar to or slightly better than mature IGF-II in stimulating amino acid uptake in fibroblasts and in inducing myoblast differentiation.	UNIV MED & DENT NEW JERSEY,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,DEPT PHARMACOL,PISCATAWAY,NJ 08854; ST LOUIS CHILDRENS HOSP,DIV ENDOCRINOL & METAB,ST LOUIS,MO 63110; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; PHARMACIA UPJOHN AB,BIOPHARMACEUT R&D,S-11287 STOCKHOLM,SWEDEN	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Pfizer; Pharmacia Corporation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008339] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20805] Funding Source: Medline; NIGMS NIH HHS [GM08339] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH LA, 1994, CURRENT DIRECTION IN, P55; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLEMMONS DR, 1993, MOL REPROD DEV, V35, P368, DOI 10.1002/mrd.1080350409; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1989, P NATL ACAD SCI USA, V86, P6778, DOI 10.1073/pnas.86.17.6778; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; DAUGHADAY WH, 1987, METHOD ENZYMOL, V146, P248; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FILSON AJ, 1993, DEVELOPMENT, V118, P731; GELATO MC, 1989, ENDOCRINOLOGY, V124, P2935, DOI 10.1210/endo-124-6-2935; GELATO MC, 1988, J CLIN ENDOCR METAB, V67, P669, DOI 10.1210/jcem-67-4-669; GOWAN LK, 1987, ENDOCRINOLOGY, V121, P449, DOI 10.1210/endo-121-2-449; HAMMARBERG B, 1991, J BIOL CHEM, V266, P11058; HAMPTON B, 1989, J BIOL CHEM, V264, P19155; HASELBACHER G, 1982, ENDOCRINOLOGY, V110, P1822, DOI 10.1210/endo-110-5-1822; HEATHMONNIG E, 1987, J CLIN ENDOCR METAB, V64, P501, DOI 10.1210/jcem-64-3-501; HILL DJ, 1990, EARLY HUM DEV, V21, P49, DOI 10.1016/0378-3782(90)90110-5; HONEGGER A, 1986, J BIOL CHEM, V261, P569; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KIESS W, 1987, J BIOL CHEM, V262, P12745; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamson G, 1991, Growth Factors, V5, P19, DOI 10.3109/08977199109000268; LI M, 1991, GLYCOBIOLOGY, V1, P51; LIU JP, 1993, CELL, V75, P69; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OH Y, 1994, CURRENT DIRECTIONS I, P41; OKA Y, 1986, J BIOL CHEM, V261, P9090; PAGLINI S, 1975, ACTA PHYSIOL LAT AM, V25, P188; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; RECHLER MM, 1991, INSULIN LIKE GROWTH, P87; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; SAHAGIAN GG, 1982, METHOD ENZYMOL, V83, P392; SAIRAM MR, 1989, FASEB J, V3, P1915, DOI 10.1096/fasebj.3.8.2542111; SCHWARTZ GN, 1993, EXP HEMATOL, V21, P1447; SHAPIRO ET, 1990, J CLIN INVEST, V85, P1672, DOI 10.1172/JCI114619; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; TOLLEFSEN SE, 1987, J BIOL CHEM, V262, P16461; TOLLEFSEN SE, 1991, J CLIN INVEST, V87, P1241, DOI 10.1172/JCI115125; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; WADENSTEIN H, 1991, BIOTECHNOL APPL BIOC, V13, P412; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; ZUMSTEIN PP, 1985, P NATL ACAD SCI USA, V82, P3169, DOI 10.1073/pnas.82.10.3169	54	26	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4804	4813		10.1074/jbc.272.8.4804	http://dx.doi.org/10.1074/jbc.272.8.4804			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030536	hybrid			2022-12-25	WOS:A1997WJ85500024
J	Liu, Y; George, CX; Patterson, JB; Samuel, CE				Liu, Y; George, CX; Patterson, JB; Samuel, CE			Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; WILMS-TUMOR; HUMAN-CELLS; MODIFYING ACTIVITY; UNWINDING ACTIVITY; CANDIDATE ENZYME; MECHANISM; VIRUS; GENE; DNA	The double-stranded RNA-specific adenosine deaminase (ADAR) is an interferon-inducible RNA-editing enzyme implicated in the site-selective deamination of adenosine to inosine in viral RNAs and cellular pre-mRNAs. We have isolated and characterized human genomic clones of the ADAR gene and cDNA clones encoding splice site variants of the ADAR protein, Southern blot and sequence analyses revealed that the gene spans about 30 kilobase pairs and consists of 15 exons. The codon phasing of the splice site junctions of exons 3, 5, and 7 that encode the three copies of the highly conserved RNA-binding R-motif (R(I), R(II), and R(III)) was exactly conserved and identical to those R-motif exons of the interferon-inducible RNA-dependent protein kinase. Alternative splice site variants of the 1226-amino acid ADAR-a protein, designated b and c, were identified that differed in exons 6 and 7. ADAR-b was a 5'-splice site variant that possessed a 26-amino acid deletion within exon 7; ADAR-c was a 5'-splice site variant that possessed an additional 19-amino acid deletion within exon 6. The wild-type ADAR-a, -b, and -c proteins all possessed comparable double-stranded RNA-specific adenosine deaminase activity. However, mutational analysis of the R-motifs revealed that the exon 6 and 7 deletions of ADAR-b and -c variants altered the functional importance of each of the three R-motifs.	UNIV CALIF SANTA BARBARA, DEPT MOL CELLULAR & DEV BIOL, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, INTERDEPT GRAD PROGRAM BIOCHEM & MOL BIOL, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara					NIAID NIH HHS [AI-12520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012520, R37AI012520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASS BL, 1995, CURR BIOL, V5, P598, DOI 10.1016/S0960-9822(95)00119-9; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; CASEY JL, 1995, J VIROL, V69, P7593, DOI 10.1128/JVI.69.12.7593-7600.1995; CATTANEO R, 1994, CURR OPIN GENET DEV, V4, P895, DOI 10.1016/0959-437X(94)90076-0; CATTANEO R, 1992, CURR TOP MICROBIOL, V176, P63; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hurst SR, 1995, RNA, V1, P1051; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Long MY, 1995, P NATL ACAD SCI USA, V92, P12495, DOI 10.1073/pnas.92.26.12495; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Polson AG, 1996, NATURE, V380, P454; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WANG Y, 1995, J MOL BIOL, V254, P184, DOI 10.1006/jmbi.1995.0610; WEIER HUG, 1995, GENOMICS, V30, P372, DOI 10.1006/geno.1995.0034; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	56	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4419	4428		10.1074/jbc.272.7.4419	http://dx.doi.org/10.1074/jbc.272.7.4419			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020165	hybrid			2022-12-25	WOS:A1997WH01900081
J	Orlandi, PA				Orlandi, PA			Protein-disulfide isomerase-mediated reduction of the a subunit of cholera toxin in a human intestinal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-INSULIN TRANSHYDROGENASE; HEAT-LABILE ENTEROTOXIN; BREFELDIN-A; ENDOPLASMIC-RETICULUM; BACTERIAL ENTEROTOXINS; ADENYLATE-CYCLASE; CULTURED-CELLS; MEMBRANE; RECEPTOR; FUSION	A key step in the action of cholera toxin (CT) is the reduction of its A subunit to the A(1) peptide, The latter is an ADP-ribosyltransferase, which activates the alpha-subunit of the stimulatory G protein of adenylyl cyclase. In this study, the enzymatic reduction of membrane-bound CT in CaCo-2 human intestinal epithelial cells was characterized, Whereas diphtheria toxin was found to be reduced by a cell surface population of protein-disulfide isomerase (PDI) and its cytotoxicity was inhibited by p-chloromercuribenzenesulfonic acid, bacitracin, or anti-PDI antibodies, these inhibitors had no effect on CT reduction or activity in intact cells, In contrast, the reduction of CT in vitro by either postnuclear supernatants (PNS) or microsomal membranes in the presence of Triton X-100 was significantly inhibited by p-chloromercuribenzenesulfonic acid and bacitracin, Anti-PDI monoclonal antibodies likewise inhibited the in vitro reduction of CT and also were effective in depleting reductase activity from PNS, Since inhibition and depletion were not observed in the absence of detergent, these results suggested that the reductase activity was a soluble component localized to the lumen of microsomal vesicles and correlated with the presence of protein-disulfide isomerase, This was further confirmed by showing a corresponding depletion of reductase activity and PDI in alkali-treated microsomes, This activity was restored when purified bovine PDI was added back to alkali-treated microsomes in a redox buffer that reflected conditions found in the lumen of the endoplasmic reticulum (ER), When the CT-related reductase activity was assayed in subcellular fractions of PNS-derived membranes isolated on a 9-30% Iodixanol gradient, the activity, as measured by CT-A(1) peptide formation localized to those fractions containing PDI. Likewise CT-A(1) peptide formed in intact cells co-localized to those membrane fractions containing the majority of cellular PDI, Furthermore, the banding density corresponded to a region of the gradient containing ER-derived membranes, These results indicated that CT was a substrate for PDI-catalyzed reduction in intact cells and supported the hypothesis that CT reduction and activation occurs in the ER.			Orlandi, PA (corresponding author), NINCDS, MEMBRANE BIOCHEM SECT,MOL & CELLULAR NEUROBIOL LAB, NIH,BLDG 49, ROOM 2A28, BETHESDA, MD 20892 USA.							BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; DEWOLF MJS, 1987, BIOCHEMISTRY-US, V26, P3799, DOI 10.1021/bi00387a010; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONTA ST, 1993, INFECT IMMUN, V61, P3282, DOI 10.1128/IAI.61.8.3282-3286.1993; FEENER EP, 1990, J BIOL CHEM, V265, P18780; FISHMAN PH, 1993, ADV LIPID RES, V25, P165; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; FISHMAN PH, 1980, J MEMBRANE BIOL, V54, P61, DOI 10.1007/BF01875377; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1983, FUNCTIONS GLUTATHION, P271; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GHANI F, 1993, MOL BIOL CELL, V4, P434; GILL DM, 1988, METHOD ENZYMOL, V165, P235; GRAHAM J, 1994, ANAL BIOCHEM, V220, P367, DOI 10.1006/abio.1994.1351; GRIFFITHS SL, 1986, BIOCHEM J, V238, P313, DOI 10.1042/bj2380313; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JOBLING MG, 1992, INFECT IMMUN, V60, P4915, DOI 10.1128/IAI.60.11.4915-4924.1992; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KASSIS S, 1982, J BIOL CHEM, V257, P2148; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; MOSS J, 1980, J BIOL CHEM, V255, P1085; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; ORLANDI PA, 1993, J BIOL CHEM, V268, P17038; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; ROTH RA, 1981, BIOCHEM BIOPH RES CO, V98, P431, DOI 10.1016/0006-291X(81)90858-5; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; STREATFIELD SJ, 1992, P NATL ACAD SCI USA, V89, P12140, DOI 10.1073/pnas.89.24.12140; TAYLOR CA, 1985, EUR J CELL BIOL, V39, P97; THEUER CP, 1992, J BIOL CHEM, V267, P16872; THEUER CP, 1993, P NATL ACAD SCI USA, V90, P7774, DOI 10.1073/pnas.90.16.7774; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VARANDANI PT, 1978, BIOCHIM BIOPHYS ACTA, V538, P343, DOI 10.1016/0304-4165(78)90362-8; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; ZAREMBA TG, 1984, MOL PHARMACOL, V26, P206	50	101	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4591	4599						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020187				2022-12-25	WOS:A1997WH01900103
J	Ghosh, AK; Datta, PK; Jacob, ST				Ghosh, AK; Datta, PK; Jacob, ST			The dual role of helix-loop-helix-zipper protein USF in ribosomal RNA gene transcription in vivo	ONCOGENE			English	Article						ribosomal RNA gene; upstream stimulatory factor; repressor; activator; pol I transcription	POLYMERASE-I TRANSCRIPTION; UPSTREAM STIMULATORY FACTOR; KU-RELATED PROTEIN; WILD-TYPE P53; BINDING-FACTOR; MAMMALIAN-CELLS; CORE PROMOTER; FACTOR CPBF; FACTOR E1BF; E-BOX	We have previously demonstrated that the core promoter of rat ribosomal RNA gene (rDNA) contains an E-box-Like sequence to which the core promoter binding factor CPBF binds and that the 44 kDa subunit of this protein is immunologically related to USF1, the helix-loop-helix-zipper DNA binding protein. Further, we showed that RNA polymerase I (pol I) transcription in vitro is competed by oligonucleotides containing USF-binding site, which suggested a key role for USF in rDNA transcription. To prove the potential role of USF in pol I transcription in vivo, USF1 and USF2 homodimers and USF1/USF2 heterodimer were overexpressed in CHO cells by transfection of the respective cDNAs, Co-transfection of a plasmid containing rDNA followed by primer extension analysis showed that overexpression of USF1 and USF2 as homodimers resulted in inhibition of rDNA transcription by as much as 85-90% whereas overexpression of USF1/USF2 in the heterodimeric form activated transcription approximately 3.5-fold. Transfection of mutant USF2 cDNA that is devoid of the basic DNA-binding domain produced only minimal inhibition of rDNA transcription. These data show that USF can modulate transcription of rRNA gene in vivo by functioning as a repressor (homodimer) or activator (heterodimer) of pol I transcription in vivo and suggest that inhibition of rDNA transcription may be responsible for the antiproliferative action of USF homodimers.	FINCH UNIV HLTH SCI CHICAGO MED SCH, DEPT PHARMACOL & MOL BIOL, CHICAGO, IL 60064 USA	Chicago Medical School			Jacob, Samson/H-3135-2011	Datta, Prasun/0000-0001-5133-253X	NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DATTA PK, 1995, J BIOL CHEM, V270, P8637, DOI 10.1074/jbc.270.15.8637; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; Ghosh AK, 1996, BIOCHEM BIOPH RES CO, V225, P890, DOI 10.1006/bbrc.1996.1268; GHOSH AK, 1993, GENE, V125, P217, DOI 10.1016/0378-1119(93)90332-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1993, BIOCHEM BIOPH RES CO, V190, P747, DOI 10.1006/bbrc.1993.1112; ISHIKAWA Y, 1991, J MOL BIOL, V218, P55, DOI 10.1016/0022-2836(91)90873-5; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; JOOST CBM, 1994, SCIENCE, V266, P2015; JUVEN T, 1993, ONCOGENE, V8, P3411; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LI JM, 1994, MOL CELL BIOL, V14, P2191, DOI 10.1128/MCB.14.3.2191; LIN Q, 1994, J BIOL CHEM, V269, P23894; LIU ZJ, 1994, J BIOL CHEM, V269, P16618; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; Niu Huifeng, 1995, Gene Expression, V4, P111; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; Paule Marvin R., 1993, Gene Expression, V3, P1; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	44	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					589	594		10.1038/sj.onc.1200866	http://dx.doi.org/10.1038/sj.onc.1200866			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053857				2022-12-25	WOS:A1997WF52400010
J	Park, S; Sanchez, MP				Park, S; Sanchez, MP			The Eek receptor, a member of the Eph family of tyrosine protein kinases, can be activated by three different Eph family ligands	ONCOGENE			English	Article						receptor tyrosine kinase; Eph family; brain	GENE; EXPRESSION; BRAIN; IDENTIFICATION; CLONING; MOUSE; TRKB; ELK; OVEREXPRESSION; HINDBRAIN	The Eph family of receptors, the largest subgroup within the tyrosine protein kinase receptor family, are comprised of at least thirteen members, many of which are predominantly expressed in the developing and adult nervous system. In this study, we have isolated a full-length cDNA, encoding the mouse homologue of a previous partially characterized Eek protein, a member of Eph receptor tyrosine kinase family. In a comparison of the amino acid sequences of various Eph family members, Eek is most similar to Ehk-3/MDK1, Sek/Cek8, Ehk-2, Hek/Mek4/Cek4, and Bsk/Ehk1/Rek7/Cek7, which are predominantly expressed in the nervous system. Additionally, we have used a low-stringency PCR cloning technique to identify ligands, related to B61, that may interact with Eek. Three different GPI-linked ligands, namely Elf-1/Cek7-L, Ehk1-L/Efl-2/Lerk3 and AL-1/RAGS, were isolated from mouse brain. To study the functional interactions between these ligands and the Eek receptors, rye have constructed chimeric ligands consisting of the Fc portion of human IgG fused to their carboxyl-terminus. These chimeric ligands bound to, and activated both the Eek receptors and the Eek-TrkB chimeric receptors expressed in NIH3T3 cells. These findings suggest that Eek receptor can be activated by at least three different GPI-Linked ligands.			Park, S (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Sanchez, Marina P/A-2453-2011	Sanchez, Marina P/0000-0003-1905-3842; Park, Soochul/0000-0002-7029-3414				ANDRES AC, 1994, ONCOGENE, V9, P1461; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V9, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRIAN JP, 1991, MOL CELL BIOL, V11, P5016; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	50	21	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					533	542		10.1038/sj.onc.1200857	http://dx.doi.org/10.1038/sj.onc.1200857			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053851				2022-12-25	WOS:A1997WF52400004
J	Davydov, A; Davydov, R; Graslund, A; Lipscomb, JD; Andersson, KK				Davydov, A; Davydov, R; Graslund, A; Lipscomb, JD; Andersson, KK			Radiolytic reduction of methane monooxygenase dinuclear iron cluster at 77 K - EPR evidence for conformational change upon reduction or binding of component B to the diferric state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; 2 OXIDATION-STATES; X-RAY-ABSORPTION; HYDROXYLASE COMPONENT; DIIRON CENTER; MOSSBAUER; PROTEIN; HEMERYTHRIN; IDENTIFICATION; HYDROCARBONS	The soluble form of methane monooxygenase (MMO) consists of three components: reductase, hydroxylase (MMOH), and ''B'' (MMOB), Resting MMOH contains a diferric bis-mu-hydroxodinuclear iron ''diamond core'' cluster which is the site of oxygen activation chemistry after reduction, Here it is shown that gamma-irradiation of MMOH at 77 K results in reduction of the diiron cluster to an EPR active Fe(II) Fe(III) mixed valence state, At this temperature, the conformation of the enzyme remains essentially unchanged during reduction, so the EPR-spectrum becomes a probe of the conformation of the diferric state, The gamma-irradiated MMOH exhibits EPR spectra that differ in lineshape and saturation properties from those of the mixed valence MMOH generated by chemical reduction in solution; annealing the gamma-irradiated sample at 230 K yields the spectra of the chemically reduced sample, This demonstrates that the conformation of diferric MMOH in the vicinity of the diiron cluster changes during reduction to the mixed valence state, The analogous experiment for the MMOB MMOH complex gives a new mixed valence species following gamma-irradiation that differs from all previously reported mixed valence species, Thus, binding of MMOB also causes a change in the conformation of diferric MMOH, It is hypothesized that the structural changes observed for the first time here may involve conversion of the dihydroxo-bridged diamond core structure to one with more readily dissociable bridging oxygen ligands to facilitate reaction with O-2 following cluster reduction.	UNIV OSLO,DEPT BIOCHEM,N-0316 OSLO,NORWAY; UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOPHYS,S-10691 STOCKHOLM,SWEDEN; LUND UNIV,CTR CHEM,DEPT BIOCHEM,S-22100 LUND,SWEDEN; UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Oslo; Stockholm University; Lund University; University of Minnesota System; University of Minnesota Twin Cities			Andersson, K Kristoffer/F-9624-2010	Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [GM 40466, R01 GM040466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Andersson K. K., 1995, ADV INORG CHEM, V43, P359; ANDERSSON KK, 1991, NEW J CHEM, V15, P411; BOMINAAR EL, 1992, INORG CHEM, V31, P1845, DOI 10.1021/ic00036a023; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; Davydov R, 1996, BIOCHEMISTRY-US, V35, P5571, DOI 10.1021/bi952836y; DAVYDOV R, 1994, J AM CHEM SOC, V116, P11120, DOI 10.1021/ja00103a029; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DEWITT JG, 1995, INORG CHEM, V34, P2505, DOI 10.1021/ic00114a007; ELANGO N, 1997, IN PRESS PROTEIN SCI; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; HENDRICH MP, 1992, J BIOL CHEM, V267, P261; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; LIU KE, 1995, ADV INORG CHEM RAD, V42, P263; LIU Y, 1995, J BIOL CHEM, V270, P24662, DOI 10.1074/jbc.270.42.24662; MCCORMICK JM, 1991, J AM CHEM SOC, V113, P9066, DOI 10.1021/ja00024a007; PAULSEN KE, 1994, BIOCHEMISTRY-US, V33, P713, DOI 10.1021/bi00169a013; PULVER S, 1993, J AM CHEM SOC, V115, P12409, DOI 10.1021/ja00079a024; Que L, 1996, ACCOUNTS CHEM RES, V29, P190, DOI 10.1021/ar950146g; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Shu LJ, 1996, J BIOL INORG CHEM, V1, P297, DOI 10.1007/s007750050057; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489	31	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7022	7026		10.1074/jbc.272.11.7022	http://dx.doi.org/10.1074/jbc.272.11.7022			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054392	hybrid			2022-12-25	WOS:A1997WN14700031
J	Sobieszek, A; Borkowski, J; Bibiychuk, VS				Sobieszek, A; Borkowski, J; Bibiychuk, VS			Purification and characterization of a smooth muscle myosin light chain kinase-phosphatase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; COOPERATIVE ACTIVATION; PROTEIN PHOSPHATASES; REACTION-MECHANISM; CALMODULIN; BINDING; AUTOPHOSPHORYLATION; CONTRACTILE; SUBUNITS	We show that a myofibrillar form of smooth muscle myosin light chain phosphatase (MLCPase) forms a multienzyme complex with myosin light chain kinase (MLCKase), The stability of the complex was indicated by the copurification of MLCKase and MLCPase activities through multiple steps that included myofibril preparation, gel filtration chromatography, cation (SP-Sepharose BE) and anion (Q-Sepharose FF) exchange chromatography, and affinity purification on calmodulin and on thiophosphorylated regulatory light chain columns. In addition, the purified complex eluted as a single peak from a final gel filtration column in the presence of calmodulin (CaM). Because a similar MLCPase is present in varying amounts in standard preparations of both MLCKase and myosin filaments, we have named it a kinase- and myosin-associated protein phosphatase (KAMPPase), The KAMPPase multienzyme complex was composed of a 37-kDa catalytic (PC) subunit, a 67-kDa targeting (PT) subunit, and MLCKase with or without CaM, The approximate molar ratio of the PC and PT subunits was 1:2 with a variable and usually higher molar content of MLCKase, The targeting role of the PT subunit was directly demonstrated in binding experiments in which the PT subunit bound to both the kinase and to CaM, Its binding to CaM was, however, Ca2+-independent, MLCKase and the PT subunit potentiated activity of the PC subunit when intact myosin was used as the substrate. These data indicated that there is a Ca2+-independent interaction among the MLCPase, MLCKase, and CaM that are involved in the regulation of phosphatase activity.			Sobieszek, A (corresponding author), AUSTRIAN ACAD SCI,INST MOL BIOL,BILLROTHSTR 11,A-5020 SALZBURG,AUSTRIA.		Sobieszek, Apolinary/AAD-8985-2022	Sobieszek, Apolinary/0000-0003-4915-9621; Borkowski, Jacek/0000-0002-5535-5955				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BABIYCHUK EB, 1995, BIOCHEMISTRY-US, V34, P6366, DOI 10.1021/bi00019a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; FERSHT A, 1985, ENZYME STRUCTURE MEC, P39; FILENKO AM, 1997, IN PRESS BIOPHYS J; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; JOHNSON JD, 1995, ADV SEC MESS PHOSPH, V30, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MITSUI T, 1992, J BIOL CHEM, V267, P16727; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; Nieznanski K, 1997, BIOCHEM J, V322, P65, DOI 10.1042/bj3220065; OKUBO S, 1993, ADV PROTEIN PHOSPHAT, V7, P295; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOBIESZEK A, 1994, ELECTROPHORESIS, V15, P1014, DOI 10.1002/elps.11501501151; SOBIESZEK A, 1988, ANAL BIOCHEM, V172, P43, DOI 10.1016/0003-2697(88)90409-5; SOBIESZEK A, 1993, BIOCHEM J, V295, P405, DOI 10.1042/bj2950405; SOBIESZEK A, 1995, BIOCHEMISTRY-US, V34, P11855, DOI 10.1021/bi00037a025; Sobieszek A, 1997, J BIOL CHEM, V272, P7027, DOI 10.1074/jbc.272.11.7027; SOBIESZEK A, 1991, J MOL BIOL, V220, P947, DOI 10.1016/0022-2836(91)90365-D; SOBIESZEK A, 1990, J MUSCLE RES CELL M, V11, P114, DOI 10.1007/BF01766490; SOBIESZEK A, 1977, J MOL BIOL, V112, P559, DOI 10.1016/S0022-2836(77)80164-2; SOBIESZEK A, 1991, EUR J BIOCHEM, V199, P735, DOI 10.1111/j.1432-1033.1991.tb16178.x; Sobieszek A., 1994, AIRWAYS SMOOTH MUSCL, P1; SOBIESZEK A, 1984, SMOOTH MUSCLE CONTRA, P283; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	34	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7034	7041		10.1074/jbc.272.11.7034	http://dx.doi.org/10.1074/jbc.272.11.7034			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054394	hybrid			2022-12-25	WOS:A1997WN14700033
J	Cote, HCF; Bajzar, L; Stevens, WK; Samis, JA; Morser, J; MacGillivray, RTA; Nesheim, ME				Cote, HCF; Bajzar, L; Stevens, WK; Samis, JA; Morser, J; MacGillivray, RTA; Nesheim, ME			Functional characterization of recombinant human meizothrombin and meizothrombin(desF1) - Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTHROMBIN ACTIVATION; GAMMA-CARBOXYGLUTAMIC ACID; HUMAN ALPHA-THROMBIN; FACTOR-XA; FACTOR-V; PHOSPHOLIPID-BINDING; BOVINE PROTHROMBIN; HEPARIN; INTERMEDIATE; MECHANISM	Recombinant human prothrombin (rII) and two mutant forms (R155A,R271A,R284A (rMZ) and R271A,R284A (rMZdesF1)) were expressed in mammalian cells. Following activation and purification, recombinant thrombin (rIIa) and stable analogues of meizothrombin (rMZa) and meizothrombin(desF1) (rMZdesF1a) were obtained. Studies of the activation of protein C in the presence of recombinant soluble thrombomodulin (TM) show TM-dependent stimulation of protein C activation by all three enzymes and, in the presence of phosphatidylserine/phosphatidylcholine phospholipid vesicles, rMZa is 6-fold more potent than rIIa. In the presence of TM, rMZa was also shown to be an effective activator of TAFI (thrombin-activatable fibrinolysis inhibitor) (Bajzar, L., Manuel, R., and Nesheim, M. E. (1995) J. Biol. Chem. 270, 14477-14484). Ah three enzymes were capable of inducing platelet aggregation, but 60-fold higher concentrations of rMZa and rMZdesF1a were required to achieve the effects obtained with rIIa. Second order rate constants (M(-1). min(-1)) for inhibition by antithrombin III (AT-III) were 2.44 x 10(5) (rIIa), 6.10 x 10(4) (rMZa), and 1.05 x 10(5) (rMZdesF1a). The inhibition of rMZa and rMZdesF1a by AT-III is not affected by heparin. Ah three enzymes bound similarly to hirudin. The results of this and previous studies imply that full-length meizothrombin has marginal procoagulant properties compared to thrombin. However, meizothrombin has potent anticoagulant properties, expressed through TM-dependent activation of protein C, and can contribute to downregulation of fibrinolysis through the TM-dependent activation of TAFI.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOL BIOL,VANCOUVER,BC V6T 1Z3,CANADA; BERLEX BIOSCI,RICHMOND,CA 94804	Queens University - Canada; Queens University - Canada; University of British Columbia			Cote, Helene/K-7896-2012					Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; LIN JH, 1994, J BIOL CHEM, V269, P25021; LINDHOUT T, 1986, BIOCHEMISTRY-US, V25, P5962, DOI 10.1021/bi00368a019; LUI LW, 1994, J BIOL CHEM, V269, P11807; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; NI F, 1993, J BIOL CHEM, V268, P16899; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OWEN WG, 1974, J BIOL CHEM, V249, P594; PIETERS J, 1987, THROMB RES, V45, P573, DOI 10.1016/0049-3848(87)90320-3; ROSING J, 1986, J BIOL CHEM, V261, P4224; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Stevens WK, 1996, J BIOL CHEM, V271, P8062, DOI 10.1074/jbc.271.14.8062; TANS G, 1994, J BIOL CHEM, V269, P15969; THOMSPON LP, 1987, BLOOD, V70, pA410; TIJBURG PNM, 1991, J BIOL CHEM, V266, P4017; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; WU QY, 1994, J BIOL CHEM, V269, P3725; WU QY, 1992, J BIOL CHEM, V267, P7083	38	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6194	6200		10.1074/jbc.272.10.6194	http://dx.doi.org/10.1074/jbc.272.10.6194			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045633	hybrid			2022-12-25	WOS:A1997WM64700017
J	Elkeles, A; Breiman, A; Zizi, M				Elkeles, A; Breiman, A; Zizi, M			Functional differences among wheat voltage-dependent anion channel (VDAC) isoforms expressed in yeast - Indication for the presence of a novel VDAC-modulating protein?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; SELECTIVE CHANNEL; SACCHAROMYCES-CEREVISIAE; ION-CHANNEL; PORIN; PERMEABILITY; PURIFICATION; RECONSTITUTION; BILAYERS; RESIDUES	VDAC is a voltage gated anion channel located in the mitochondrial outer membrane, presumably participating in controlling aerobic metabolism, Three distinct wheat vdac cDNAs were expressed in a vdac minus yeast strain and successfully complemented its defective phenotype, The growth curves of these transformants were different. The wheat channel isoforms were functionally characterized following purification from yeast mitochondria and reconstitution into soybean phospholipid planar membranes, All three isoforms yielded voltage-dependent anion channels with electrophysiological parameters comparable to known VDACs. Isoform-related functional features (specific conductance levels, kinetics, and gating behaviors) are reported for the first time in VDACs. The presence (or absence) of protease inhibitors during the purification procedure, and the use of Pronase on reconstituted channels, strongly suggest that some of the unique wheat VDAC properties are due to co-purification of a yeast channel-modulating protein, Its effects, different from the reported functional interactions of the channel with hexo- or creatine kinases, could not be mimicked by the protein termed VDAC modulator, indicating the presence of a novel VDAC modulator, In addition to strengthening VDAC presumed role in metabolism, the functional diversity of the channels (as shown here in two different systems) implies a highly dynamic outer membrane permeability. Our results are consistent with VDAC functioning as a heteromer including one pore protein and other modulating subunits.	CATHOLIC UNIV LEUVEN, DEPT PHYSIOL, B-3000 LOUVAIN, BELGIUM; TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BOT, IL-69978 TEL AVIV, ISRAEL	KU Leuven; Tel Aviv University								BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1989, J BIOENERG BIOMEMBR, V21, P471, DOI 10.1007/BF00762519; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BLUMENTHAL A, 1993, PLANT PHYSIOL, V101, P579, DOI 10.1104/pp.101.2.579; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; ELKELES A, 1995, PLANT MOL BIOL, V29, P109, DOI 10.1007/BF00019123; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HEINS L, 1994, J BIOL CHEM, V269, P26402; HILLE B, 1992, IONIC CHANNELS EXCIT, P472; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Koppel D. A., 1996, Biophysical Journal, V70, pA2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AC, 1994, J BIOL CHEM, V269, P30974; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; LIU MY, 1994, BBA-BIOENERGETICS, V1185, P203, DOI 10.1016/0005-2728(94)90211-9; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; MIRZABEKOV T, 1993, J MEMBRANE BIOL, V133, P129; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Popp B, 1996, J BIOL CHEM, V271, P13593, DOI 10.1074/jbc.271.23.13593; Robinson R.A., 1965, ELECTROLYTE SOLUTION, V2nd; ROSTOVTSEVA T, 1996, BIOPHYS J, V70, pA1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SMITH MD, 1995, J BIOL CHEM, V270, P28331; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; THOMAS L, 1991, J STRUCT BIOL, V106, P161, DOI 10.1016/1047-8477(91)90085-B; WUNDER UR, 1991, J MEMBRANE BIOL, V123, P83, DOI 10.1007/BF01993966; ZIZI M, 1994, J BIOL CHEM, V269, P1614; ZIZI M, 1995, J MEMBRANE BIOL, V144, P121	38	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6252	6260		10.1074/jbc.272.10.6252	http://dx.doi.org/10.1074/jbc.272.10.6252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045642	hybrid			2022-12-25	WOS:A1997WM64700026
J	Yang, XM; Richardson, CC				Yang, XM; Richardson, CC			Amino acid changes in a unique sequence of bacteriophage T7 DNA polymerase alter the processivity of nucleotide polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; DEOXYRIBONUCLEIC-ACID; REPLICATION INVITRO; GENE-5 PROTEIN; DUPLEX DNA; MUTAGENESIS; REDUCTASE; SUBUNIT; DOMAIN; FORK	T7 gene 5 DNA polymerase forms a complex with Escherichia coli thioredoxin (its processivity factor), and a 76-amino acid sequence (residues 258-334), unique to gene 5 protein, has been implicated in this interaction. We have examined the effect of amino acid substitution(s) in this region on T7 phage growth and on the interaction of the polymerase with thioredoxin. Among the mutations in gene 5, we found that a substitution of either Glu or Ala for Lys-302 yielded a protein that could not complement T7 phage lacking gene 5 (T7 Delta 5) to grow on E. coli having reduced thioredoxin levels. One triple mutant (K300E,K302E,K304E) could not support the growth of T7 Delta 5 even in wild type cells. This altered polymerase is stimulated 4-fold less by thioredoxin than is the wild type enzyme and the polymerase thioredoxin complex has reduced processivity. The exonuclease activity of the altered polymerase is not stimulated to the same extent as that of the wild type enzyme by thioredoxin. The observed dissociation constant of the gene 5 protein K(300,302,304)E-thioredoxin complex is 7-fold higher than that of the wild type complex. The altered polymerase also has a lower binding affinity for double-stranded DNA.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDFORD E, 1997, IN PRESS P NATL ACAD, V94; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNARD A, 1991, GENE AMST, V100, P27; BLANCO L, 1989, J BIOL CHEM, V264, P8935; DAS SK, 1979, J BIOL CHEM, V254, P1227; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; FUJIMURA RK, 1976, J BIOL CHEM, V251, P2168; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1981, CURR TOP CELL REGUL, V19, P47; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HORI K, 1979, J BIOL CHEM, V254, P1598; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEMASTER DM, 1990, J MOL BIOL, V212, P167; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; OLLIS DL, 1985, NATURE, V313, P726; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; SAIKI R, 1985, SCIENCE, V242, P1350; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TABOR S, 1989, J BIOL CHEM, V264, P6447; Yang XM, 1996, J BIOL CHEM, V271, P24207, DOI 10.1074/jbc.271.39.24207	46	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6599	6606		10.1074/jbc.272.10.6599	http://dx.doi.org/10.1074/jbc.272.10.6599			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045689	Green Published, hybrid			2022-12-25	WOS:A1997WM64700073
J	Chin, D; Sloan, DJ; Quiocho, FA; Means, AR				Chin, D; Sloan, DJ; Quiocho, FA; Means, AR			Functional consequences of truncating amino acid side chains located at a calmodulin-peptide interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET ENZYMES; CENTRAL HELIX; ACTIVATION; BINDING; KINASE; RECOGNITION; MUTAGENESIS; PROTEINS; COMPLEX	To test the relevance of the calmodulin-peptide crystal structures to their respective calmodulin-enzyme interactions, amino acid side chains in calmodulin were altered at positions that interact with the calmodulin-binding peptide of smooth muscle myosin light chain kinase but not with the calmodulin kinase II alpha peptide, Since shortening the side chains of Trp-800, Arg-812, and Leu-813 in smooth muscle myosin light chain kinase abrogated calmodulin-dependent activation (Bagchi, I. C., Huang, Q., and Means, A, R. (1992) J. Biol. Chern. 267, 3024-3029), substitutions were introduced at positions in calmodulin which contact residues corresponding to Arg-812 and Leu-813 in the smooth muscle myosin light chain kinase peptide. Assays of smooth muscle myosin light chain kinase with the calmodulin mutants M51A, V55A, L32A,M51A,V55A, and L32A,M51A,V55A,F68L, M71A exhibited 60%, 25%, and less than 1% of maximal activity respectively, whereas the mutants fully activated calmodulin kinase II alpha. Alanine substitutions at positions on the smooth muscle myosin light chain kinase peptide, corresponding to Trp-800 and Arg-812 in the enzyme, produced an 8-fold increase in the enzyme inhibition constant in contrast with the abolition of calmodulin binding by similar mutations in the parent enzyme.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,HOUSTON,TX 77030	Duke University; Baylor College of Medicine; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; George SE, 1996, BIOCHEMISTRY-US, V35, P8307, DOI 10.1021/bi960495y; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P82; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1995, NAT STRUCT BIOL, V2, P943, DOI 10.1038/nsb1195-943; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Montigiani S, 1996, J MOL BIOL, V258, P6, DOI 10.1006/jmbi.1996.0229; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1984, FEBS LETT, V165, P269, DOI 10.1016/0014-5793(84)80183-0; ONEIL KT, 1987, SCIENCE, V236, P1454, DOI 10.1126/science.3589665; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; SU ZH, 1994, J BIOL CHEM, V269, P16761; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488	25	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5510	5513		10.1074/jbc.272.9.5510	http://dx.doi.org/10.1074/jbc.272.9.5510			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038155	hybrid			2022-12-25	WOS:A1997WK74700023
J	Gadda, G; Edmondson, RD; Russell, DH; Fitzpatrick, PF				Gadda, G; Edmondson, RD; Russell, DH; Fitzpatrick, PF			Identification of the naturally occurring flavin of nitroalkane oxidase from Fusarium oxysporum as a 5-nitrobutyl-FAD and conversion of the enzyme to the active FAD-containing form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; MONOAMINE-OXIDASE; LACTATE OXIDASE; MECHANISM; ADDUCTS; INACTIVATION; SUBSTRATE; OXIDATION	Nitroalkane oxidase from Fusarium oxysporum catalyzes the oxidation of nitroalkanes to aldehydes with production of nitrite and hydrogen peroxide, The UV-visible absorbance spectrum of the purified enzyme shows a single absorption peak at 336 nm with an extinction coefficient of 7.4 mM(-1) cm(-1). Upon denaturation of the enzyme at pH 7.0, a stoichiometric amount of FAD is released, The spectral properties of the enzyme as isolated are consistent with an N(5) adduct of the flavin, This is not due to a covalent linkage with the protein, since the free flavin adduct can be isolated from the enzyme at pH 2.1. The free flavin adduct shows an absorbance spectrum with a lambda(max) at 346 nm (10.7 mM(-1) cm(-1)) and is not fluorescent, Under alkaline conditions the free adduct decays, yielding FAD; the rate of this process is pH-dependent with a pK(a) of 7.4, Adduct decay is also observed with the native enzyme; in this case, however, the rate of decay is 160-fold slower (at pH 8.0) and not dependent on pH. During this process a large increase in enzymatic activity (similar to 26-fold at pH 7.0) is observed, the rate of which is equal to the rate of flavin adduct conversion to FAD, Thus, the native flavin adduct is not active but can be converted to FAD, the active form of the flavin, Maximal activation is pH- and FAD-dependent; two groups with pK(a) values of 5.65 +/- 0.25 and 8.75 +/- 0.05 must be unprotonated and protonated, respectively, The m/z(-) of the free flavin adduct is 103.0645 higher than that of FAD, as determined by matrix-assisted laser desorption ionization time-of-flight mass spectrometry This corresponds to a molecule of nitrobutane linked to FAD. A mechanism is proposed for the formation in vivo of the nitrobutyl-FAD of nitroalkane oxidase.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station			Russell, David H/C-3618-2015; Gadda, Giovanni/M-2354-2016	Russell, David H/0000-0003-0830-3914; Gadda, Giovanni/0000-0002-7508-4195				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; DENU JM, 1994, BIOCHEMISTRY-US, V33, P4001, DOI 10.1021/bi00179a029; EDMONDSO.DE, 1971, BIOCHEMISTRY-US, V10, P113; Edmondson RD, 1996, J AM SOC MASS SPECTR, V7, P995, DOI 10.1016/1044-0305(96)00027-X; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1980, J BIOL CHEM, V255, P5688; GHISLA S, 1979, J BIOL CHEM, V254, P662; GHISLA S, 1973, J LIEBIGS ANN CHEMIE, V8, P1388; Ghisla S., 1982, FLAVINS FLAVOPROTEIN, P133; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; Heasley CJ, 1996, BIOCHEM BIOPH RES CO, V225, P6, DOI 10.1006/bbrc.1996.1122; HEASLEY CJ, 1995, THESIS TEXAS A M U; Hemmerich P, 1971, FLAVINS FLAVOPROTEIN, P83; KIDO T, 1978, J BACTERIOL, V133, P53, DOI 10.1128/JB.133.1.53-58.1978; KNAPPE WR, 1971, FEBS LETT, V13, P293, DOI 10.1016/0014-5793(71)80244-2; Kurihara T, 1994, FLAVINS AND FLAVOPROTEINS 1993, P195; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; LIGHT DR, 1980, ANAL BIOCHEM, V109, P87, DOI 10.1016/0003-2697(80)90014-7; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; MARCOTTE P, 1976, BIOCHEMISTRY-US, V15, P3070, DOI 10.1021/bi00659a021; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MENON V, 1995, BIOORG CHEM, V23, P42, DOI 10.1006/bioo.1995.1004; Mullis K B, 1991, PCR Methods Appl, V1, P1; PORTER DJT, 1973, J BIOL CHEM, V248, P4400; PORTER DJT, 1977, J BIOL CHEM, V252, P4361; PORTER DJT, 1972, BIOCHEM BIOPH RES CO, V49, P257, DOI 10.1016/0006-291X(72)90038-1; SHERRY B, 1985, BIOCHEMISTRY-US, V24, P2594, DOI 10.1021/bi00332a002; SILVERMAN RB, 1985, BIOCHEMISTRY-US, V24, P2128, DOI 10.1021/bi00330a005; STEMBERG K, 1995, EUR J BIOCHEM, V228, P408; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011; WALSH CT, 1971, J BIOL CHEM, V246, P6855; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; YAMAJI K, 1968, FLAVINS FLAVOPROTEIN, P135	35	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5563	5570		10.1074/jbc.272.9.5563	http://dx.doi.org/10.1074/jbc.272.9.5563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038163	hybrid			2022-12-25	WOS:A1997WK74700031
J	Sun, H; Chen, ZT; Poppleton, H; Scholich, K; Mullenix, J; Weipz, GJ; Fulgham, DL; Bertics, PJ; Patel, TB				Sun, H; Chen, ZT; Poppleton, H; Scholich, K; Mullenix, J; Weipz, GJ; Fulgham, DL; Bertics, PJ; Patel, TB			The juxtamembrane, cytosolic region of the epidermal growth factor receptor is involved in association with alpha-subunit of G(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CARDIAC ADENYLATE-CYCLASE; TYROSINE KINASE; GS-ALPHA; BINDING; STIMULATION; DOMAIN; ACCUMULATION; SPECIFICITY; ACTIVATION	Previously, we have demonstrated that epidermal growth factor (EGF) can stimulate adenylyl cyclase activity via activation of G(s) in the heart. Moreover, we have recently shown that G(s alpha) is phosphorylated by the EGF receptor protein tyrosine kinase and that the juxtamembrane region of the EGF receptor can stimulate G(s) directly. Therefore, employing isolated cardiac membranes, the two-hybrid assay, and in vitro association studies with purified EGF receptor and G(s alpha) we have investigated G(s alpha) complex formation with the EGF receptor and elucidated the region in the receptor involved in this interaction. In isolated cardiac membranes, immunoprecipitation of EGF receptor was accompanied by co-immunoprecipitation of G(s alpha). In the yeast two-hybrid assay, the cytosolic domain of the EGF receptor and the N-terminal 64 amino acids of this region (Met(644)-Trp(707)) associated with G(s alpha). However, interactions of these regions of the EGF receptor with constitutively active G(s alpha) were diminished in the two-hybrid assay. Employing purified proteins, our studies demonstrate that the EGF receptor, directly and stoichiometrically, associates with G(s alpha) (1 mol of G(s alpha)/mol of EGF receptor). This association was not altered in the presence or absence of ATP and therefore, was independent of tyrosine phosphorylation of either of the proteins. Peptides corresponding to the juxtamembrane region of the receptor decreased association of the EGF receptor with G(s alpha). However, neither the C-terminally truncated EGF receptor (Delta 1022-1186) nor a peptide corresponding to residues 985-996 of the receptor altered association with G(s alpha), thus indicating the selectivity of the G protein interaction with the juxtamembrane region. Interestingly, peptides corresponding to N and C termini of G(s alpha) did not alter the association of G(s alpha) with the EGF receptor. Consistent with the findings from the two-hybrid assay where constitutively active G(s alpha) poorly associated with the EGF receptor, in vitro experiments with purified proteins also demonstrated that activation of G(s alpha) by guanosine 5'-3-O-(thio)triphosphate decreased the association of G protein with the EGF receptor. Thus we conclude that the juxtamembrane region of the EGF receptor, directly and stoichiometrically, associates with G(s alpha) and that upon activation of G(s alpha) this association is decreased.	UNIV TENNESSEE, CTR HLTH SCI, DEPT PHARMACOL, MEMPHIS, TN 38163 USA; UNIV WISCONSIN, DEPT BIOMOL CHEM, MADISON, WI 53706 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL 48308] Funding Source: Medline; NIGMS NIH HHS [GM 53271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CADENA DL, 1994, J BIOL CHEM, V269, P260; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COCHET C, 1991, J BIOL CHEM, V266, P637; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; MARENGERE LEM, 1994, J CELL SCI, P97; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1993, BIOCHEM PHARMACOL, V46, P1239, DOI 10.1016/0006-2952(93)90473-A; NAIR BG, 1993, GROWTH FACTORS, V8, P41, DOI 10.3109/08977199309029133; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PATEL TB, 1996, METHODS NEUROSCIENCE, P319; Poppleton H, 1996, J BIOL CHEM, V271, P6947, DOI 10.1074/jbc.271.12.6947; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; YANG LJ, 1993, J BIOL CHEM, V268, P3739; YU YM, 1992, J CELL PHYSIOL, V150, P559, DOI 10.1002/jcp.1041500317; Zhang JS, 1996, J BIOL CHEM, V271, P15026, DOI 10.1074/jbc.271.25.15026	36	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5413	5420		10.1074/jbc.272.9.5413	http://dx.doi.org/10.1074/jbc.272.9.5413			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038141	hybrid			2022-12-25	WOS:A1997WK74700009
J	Hollenberg, AN; Susulic, VS; Madura, JP; Zhang, B; Moller, DE; Tontonoz, P; Sarraf, P; Spiegelman, BM; Lowell, BB				Hollenberg, AN; Susulic, VS; Madura, JP; Zhang, B; Moller, DE; Tontonoz, P; Sarraf, P; Spiegelman, BM; Lowell, BB			Functional antagonism between CCAAT/enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; BETA-SUBUNIT GENE; MOUSE OBESE GENE; THYROID-HORMONE; ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; FATTY-ACIDS; TRANSCRIPTIONAL REPRESSION; NEGATIVE REGULATION; SIGNALING PATHWAYS	The ob gene product, leptin, is a major hormonal regulator of appetite and fat cell mass, Recent work has suggested that the antidiabetic agents, the thiazolidinediones (TZ), which are also high affinity ligands of peroxisome proliferator-activated receptor-gamma (PPAR gamma), inhibit leptin expression in rodents, To examine the effects of this class of drug on the leptin gene in adipocytes we performed Northern analysis on primary rat adipocytes cultured in the presence or absence of TZ, TZ reduced leptin mRNA levels by 75%, To determine whether this effect was mediated at the transcriptional level, we isolated 6510 base pairs of 5'-flanking sequence of the leptin promoter and studied reporter constructs in primary rat adipocytes and CV-1 cells, Sequence analysis demonstrated the presence of a consensus direct repeat with a 1-base-pair gap site between -3951 and -3939 as well as a consensus CCAAT/enhancer binding protein (C/EBP) site between -55 and -47, Our functional analysis in transfected primary rat adipocytes demonstrates that, despite the presence of a canonical direct repeat with a 1-base-pair gap site, TZ alone decreases reporter gene expression of leptin promoter constructs ranging from -6510 to +9 to -65 to +9, In CV-1 cells, which contain endogenous PPAR gamma, TZ treatment alone had little effect on these constructs, However, TZ treatment did inhibit C/EBP alpha-mediated transactivation of the leptin promoter, This down-regulation of leptin reporter constructs mapped to a -65 to +9 promoter fragment which binds C/EBP alpha in gel mobility shift assays but does not bind PPAR gamma 2 alone or as a heterodimer with 9-cis-retinoic acid receptor, Conversely, the promoter (-5400 to +24 base pairs) of the aP2 gene, another adipocyte-specific gene, was induced 7.3-fold by TZ, Co-transfection with C/EBP alpha minimally stimulated the aP2 promoter from basal levels but notably blocked activation by TZ, These data indicate that PPAR gamma and C/EBP alpha can functionally antagonize each other on at least two separate promoters and that this mechanism may explain the down-regulation of leptin expression by thiazolidinediones.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; MERCK RES LABS, DEPT MOL ENDOCRINOL, RAHWAY, NJ 07065 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Merck & Company; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049569, K08DK002119, K08DK002354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02354, DK49569, DK02119] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALROY I, 1995, MOL CELL BIOL, V15, P5789; AUWERX J, 1992, HORM RES, V38, P269, DOI 10.1159/000182557; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARR FE, 1994, J BIOL CHEM, V269, P4175; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; delaBrousse FC, 1996, P NATL ACAD SCI USA, V93, P4096, DOI 10.1073/pnas.93.9.4096; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MADISON LD, 1993, MOL CELL ENDOCRINOL, V94, P129, DOI 10.1016/0303-7207(93)90060-W; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	60	216	224	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5283	5290		10.1074/jbc.272.8.5283	http://dx.doi.org/10.1074/jbc.272.8.5283			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030601	Green Published, hybrid			2022-12-25	WOS:A1997WJ85500089
J	Jia, YL; Mathews, CJ; Hanrahan, JW				Jia, YL; Mathews, CJ; Hanrahan, JW			Phosphorylation by protein kinase C is required for acute activation of cystic fibrosis transmembrane conductance regulator by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE TRACHEAL EPITHELIUM; CFTR CHLORIDE CHANNEL; PHORBOL ESTER; ATP HYDROLYSIS; CELL-LINE; TRANSPORT; SECRETION; GENE; STIMULATION; HT-29CL.19A	Protein kinase A (PKA) stimulates Cl secretion by activating the cystic fibrosis transmembrane conductance regulator (CFTR), a tightly regulated Cl- channel in the apical membrane of many secretory epithelia. The CFTR channel is also modulated by protein kinase C (PKC), but the regulatory mechanisms are poorly understood, Here we present evidence that PKA-mediated phosphorylation alone is not a sufficient stimulus to open the CFTR chloride channel in the presence of MgATP; constitutive PKC phosphorylation is essential for acute activation of CFTR by PKA, When patches were excised from transfected Chinese hamster ovary cells, CFTR responses to PKA became progressively smaller with time and eventually disappeared. This decline in PKA responsiveness did not occur in the presence of exogenous PRC and was reversed by the addition of PKC to channels that had become refractory to PKA, PKC enhanced PKA stimulation of open probability without increasing the number of functional channels, Short-term pretreatment of cells with the PKC inhibitor chelerythrine (1 mu M) reduced the channel activity that could be elicited by forskolin in cell-attached patches. Moreover, in whole cell patches, acute stimulation of CFTR currents by chlorophenylthio-cAMP was abolished by two chemically unrelated PRC inhibitors, although an abrupt, partial activation was observed after a delay of >15 min. Modulation by PKC was most pronounced when basal PKC phosphorylation was reduced by briefly preincubating cells with chelerythrine, Constitutive PKC phosphorylation in unstimulated cells permits the maximum elevation of open probability by PKA to reach a level that is similar to 60% of that attained during in vitro exposure to both kinases. Differences in basal PI(C activity may contribute to the variable cAMP responsiveness of CFTR channels in different cell types.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				BAJNATH RB, 1993, PFLUG ARCH EUR J PHY, V425, P90, DOI 10.1007/BF00374508; BAJNATH RB, 1993, PFLUG ARCH EUR J PHY, V425, P100, DOI 10.1007/BF00374509; BARTHELSON RA, 1987, AM J PHYSIOL, V253, pC802, DOI 10.1152/ajpcell.1987.253.6.C802; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BREUER W, 1993, J BIOL CHEM, V268, P13935; CHANG EB, 1985, AM J PHYSIOL, V249, pC356, DOI 10.1152/ajpcell.1985.249.3.C356; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; DECHECCHI MC, 1992, FEBS LETT, V311, P25, DOI 10.1016/0014-5793(92)81358-S; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; DONOWITZ M, 1986, AM J PHYSIOL, V251, pG509, DOI 10.1152/ajpgi.1986.251.4.G509; FRIZZELL RA, 1979, AM J PHYSIOL, V236, pF1, DOI 10.1152/ajprenal.1979.236.1.F1; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanrahan JW, 1996, J EXP ZOOL, V275, P283; HAWS CM, 1993, PEDIAT PULMONOL S9, V18, P215; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P992; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; JARVIS WD, 1994, CANCER RES, V54, P1707; KLYCE SD, 1977, J PHYSIOL-LONDON, V266, P777, DOI 10.1113/jphysiol.1977.sp011793; Linsdell P, 1996, J PHYSIOL-LONDON, V496, P687, DOI 10.1113/jphysiol.1996.sp021719; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Marty Alain, 1995, P31; MATHEWS CJ, 1995, PEDIAT PULMONOL, V20, P424; MATHEWS CJ, 1996, PEDIAT PULMONOL S13, V21, P221; NAGEL W, 1980, J MEMBRANE BIOL, V56, P73, DOI 10.1007/BF01869354; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHOROFSKY SR, 1983, J MEMBRANE BIOL, V72, P105, DOI 10.1007/BF01870318; SULLIVAN SK, 1991, AM J PHYSIOL, V260, pC664, DOI 10.1152/ajpcell.1991.260.3.C664; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WELSH MJ, 1987, AM J PHYSIOL, V253, pC828, DOI 10.1152/ajpcell.1987.253.6.C828; WELSH MJ, 1983, J MEMBRANE BIOL, V71, P209, DOI 10.1007/BF01875462; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; WINPENNY JP, 1995, AM J PHYSIOL-CELL PH, V268, pC823, DOI 10.1152/ajpcell.1995.268.4.C823	42	162	164	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4978	4984		10.1074/jbc.272.8.4978	http://dx.doi.org/10.1074/jbc.272.8.4978			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030559	hybrid			2022-12-25	WOS:A1997WJ85500047
J	Oral, H; Dorn, GW; Mann, DL				Oral, H; Dorn, GW; Mann, DL			Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; SIGNAL TRANSDUCTION; CELLULAR PROLIFERATION; HUMAN MYOCARDIUM; PHOSPHOLIPASE-C; KAPPA-B; INDUCTION; EXPRESSION	To determine whether activation of the neutral sphingomyelinase pathway was responsible for the immediate (<30 min) negative inotropic effects of tumor necro sis factor-alpha (TNF-alpha), we examined sphingosine levels in diluent and TNF-alpha-stimulated cardiac myocytes. TNF-alpha stimulation of adult feline cardiac myocytes provoked a rapid (<15 min) increase in the hydrolysis of [C-14]sphingomyelin in cell-free extracts, as well as an increase in ceramide mass, consistent with cytokine-induced activation of the neutral sphingomyelinase pathway, High performance liquid chromatographic analysis of lipid extracts from TNF-alpha-stimulated cardiac myocytes showed that TNF-alpha stimulation produced a rapid (<30 min) increase in free sphingosine levels, Moreover, exogenous D-sphingosine mimicked the effects of TNF-alpha on intracellular calcium homeostasis, as well as the negative inotropic effects of TNF-alpha in isolated contracting myocytes; time course studies showed that exogenous D-sphingosine produced abnormalities in cell shortening that were maximal at 5 min, Finally, blocking sphingosine production using an inhibitor of ceramidase, n-oleoylethanolamine, completely abrogated the negative inotropic effects of TNF-alpha in isolated contracting cardiac myocytes, Additional studies employing biologically active ceramide analogs and sphingosine l-phosphate suggested that neither the immediate precursor of sphingosine nor the immediate metabolite of sphingosine, respectively, were likely to be responsible for the immediate negative inotropic effects of TNF-alpha. Thus, these studies suggest that sphingosine mediates the immediate negative inotropic effects of TNF-alpha in isolated cardiac myocytes.	BAYLOR COLL MED,VET ADM MED CTR,DEPT MED,CARDIOL SECT,HOUSTON,TX 77030; UNIV CINCINNATI,DEPT MED,DIV CARDIOL,CINCINNATI,OH 45267	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; University of Cincinnati			Mann, Douglas Lowell/AAQ-3524-2021	Mann, Douglas/0000-0002-2516-0145	NHLBI NIH HHS [P50 HL-O6H] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI S, 1994, CIRC RES, V75, P836, DOI 10.1161/01.RES.75.5.836; ARBUSTINI E, 1991, AM J PATHOL, V139, P709; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DETTBARN CA, 1994, J MOL CELL CARDIOL, V26, P229, DOI 10.1006/jmcc.1994.1026; DORN GW, 1992, AM J PHYSIOL, V263, pC864, DOI 10.1152/ajpcell.1992.263.4.C864; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GULICK T, 1989, P NATL ACAD SCI USA, V86, P6753, DOI 10.1073/pnas.86.17.6753; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; KOBAYASHI T, 1988, EUR J BIOCHEM, V172, P747, DOI 10.1111/j.1432-1033.1988.tb13952.x; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LEFER AM, 1990, SCIENCE, V249, P61, DOI 10.1126/science.2164258; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MCDONOUGH PM, 1994, CIRC RES, V75, P981, DOI 10.1161/01.RES.75.6.981; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SABBADINI R, 1993, BIOCHEM BIOPH RES CO, V193, P752, DOI 10.1006/bbrc.1993.1689; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SMITH SC, 1992, CIRC RES, V70, P856, DOI 10.1161/01.RES.70.4.856; TORREAMIONE G, 1995, CIRCULATION, V92, P1487, DOI 10.1161/01.CIR.92.6.1487; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WEBSTER RJ, 1994, J MOL CELL CARDIOL, V26, P1273, DOI 10.1006/jmcc.1994.1147; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	44	280	302	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4836	4842		10.1074/jbc.272.8.4836	http://dx.doi.org/10.1074/jbc.272.8.4836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030540	hybrid			2022-12-25	WOS:A1997WJ85500028
J	Schmidt, EE; Ohbayashi, T; Makino, Y; Tamura, TA; Schibler, U				Schmidt, EE; Ohbayashi, T; Makino, Y; Tamura, TA; Schibler, U			Spermatid-specific overexpression of the TATA-binding protein gene involves recruitment of two potent testis-specific promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GERM-CELLS; MOUSE; SPERMATOGENESIS; ACCUMULATION; TRANSLATION; TRANSCRIPTS; EXPRESSION; COMPLEXES	The gene encoding the TATA-binding protein, TBP, is highly overexpressed during the haploid stages of spermatogenesis in rodents, RNase protection analyses for mRNAs containing the previously identified first, second, and eighth exons suggested that most TBP mRNAs in testis did not initiate at the first exon used in somatic cells (here designated exon 1C), Using a sensitive ligation-mediated cDNA amplification method, 5' end variants of TBP mRNA were identified, and the corresponding cDNAs were cloned from liver and testis, In liver, a single promoter/first exon is used to generate a steady-state level of roughly five molecules of TBP mRNA per diploid cell equivalent. In testis, we detect modest up-regulation of the somatic promoter and recruitment of at least five other promoters, Three of the alternative promoter/first exons, including 1C and two of the testis-specific promoter/first exons, 1D and 1E, contribute roughly equivalent amounts of mRNA which, in sum, account for greater than 90% of all TBP mRNA in testis. As a result, round spermatids contain an estimated 1000 TBP mRNA molecules per haploid cell, Testis TBP mRNA also exhibits several low abundance 5' end splicing variants; however, all detected TBP mRNA leader sequences splice onto the common exon 2 and are expected to initiate translation at the same site within exon 2, The precise locations of the three major initiation exons are mapped on the gene, The identification of the strong testis specific promoter/first exons will be important for understanding spermatid-specific tbp gene regulation.	UNIV GENEVA, DEPT MOL BIOL, CH-1211 GENEVA 4, SWITZERLAND; CHIBA UNIV, FAC SCI, DEPT BIOL, INAGE KU, CHIBA 263, JAPAN	University of Geneva; Chiba University								BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; FOO NC, 1994, J BIOL CHEM, V269, P659; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GROSS MK, 1987, DEV BIOL, V122, P439, DOI 10.1016/0012-1606(87)90308-3; GU W, 1995, J BIOL CHEM, V270, P236, DOI 10.1074/jbc.270.1.236; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANS MS, 1994, J BIOL CHEM, V269, P14170; METTUS RV, 1994, ONCOGENE, V9, P3077; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; Ohbayashi T, 1996, BIOCHEM BIOPH RES CO, V225, P275, DOI 10.1006/bbrc.1996.1166; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Schmidt EE, 1996, CURR BIOL, V6, P768, DOI 10.1016/S0960-9822(02)00589-4; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; SUMITA K, 1993, NUCLEIC ACIDS RES, V21, P2769, DOI 10.1093/nar/21.11.2769; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; WEST AP, 1994, BIOL REPROD, V50, P869, DOI 10.1095/biolreprod50.4.869; ZAMBROWICZ BP, 1994, DEVELOPMENT, V120, P1549	25	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5326	5334		10.1074/jbc.272.8.5326	http://dx.doi.org/10.1074/jbc.272.8.5326			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030607	hybrid, Green Published			2022-12-25	WOS:A1997WJ85500095
J	Vitelli, R; Santillo, M; Lattero, D; Chiariello, M; Bifulco, M; Bruni, CB; Bucci, C				Vitelli, R; Santillo, M; Lattero, D; Chiariello, M; Bifulco, M; Bruni, CB; Bucci, C			Role of the small GTPase RAB7 in the late endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; TRANSPORT; FUSION; YPT7P; LOCALIZATION; COMPARTMENTS; INVOLVEMENT; POLYMERASE; LYSOSOMES; ENDOSOME	Rab7 is a small GTPase localized to the late endosomal compartment. Its function was investigated by overexpressing dominant negative or constitutively active mutants in BHK-21 cells. The effects of such overexpression on the internalization and/or degradation of different endocytic markers and on the morphology of the late endosomal compartment were analyzed. We observed a marked inhibition of the degradation of I-125-low density lipoproteins in cells transfected with the Rab7 dominant negative mutants while the rate of internalization was not affected. Moreover in these cells there was an accumulation of many small vesicles scattered throughout the cytoplasm. In contrast, overexpression of the activating mutants led to the appearance of atypically large endocytic structures and caused a dramatic change in the distribution of the cation-independent mannose 6-phosphate receptor. Our data indicate that the Rab7 protein in mammalian cells is present on a late endosomal compartment much larger than the compartment labeled by the cation-independent mannose 6-phosphate receptor, Rab7 also appears to play a fundamental role in controlling late endocytic membrane traffic.	UNIV NAPLES FEDERICO II,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL L CALIF,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO NEUROSCI & COMUNICAZONE INTERUMANA,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; Universita Mediterranea di Reggio Calabria			Bucci, Cecilia/F-6699-2012; Chiariello, Mario/O-3642-2014	Bucci, Cecilia/0000-0002-6232-6183; Chiariello, Mario/0000-0001-8434-5177; Bifulco, Maurizio/0000-0002-1771-4531				BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG Y, 1995, J CELL BIOL, V131, P1438; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MERESSE S, 1995, J CELL SCI, V108, P3349; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	29	244	248	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4391	4397		10.1074/jbc.272.7.4391	http://dx.doi.org/10.1074/jbc.272.7.4391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020161	hybrid			2022-12-25	WOS:A1997WH01900077
J	deJong, R; tenHoeve, J; Heisterkamp, N; Groffen, J				deJong, R; tenHoeve, J; Heisterkamp, N; Groffen, J			Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site	ONCOGENE			English	Article						SH2-SH3 adaptor protein; tyrosine-phosphorylation; BCR/ABL; leukemia; mutagenesis	CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; SH3 DOMAIN; C-CRK; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; KINASE-ACTIVITY; RAS ACTIVATION; ABL PROTEIN; FACTOR C3G	BCR/ABL has a causal role in Philadelphia (Ph)-chromosome positive leukemia. The SH2/SH3 adapter protein CRKL is a major substrate of the deregulated BCR/ABL tyrosine kinase and is aberrantly tyrosine-phosphorylated in Ph-positive leukemia cells. In this study, experiments were pursued to identify and analyse the CRKL phosphorylation site(s). In an in vitro kinase assay, CRKL phosphorylation by the abl kinase was limited to a small region between the two CRKL SH3 domains. Within this region, mutation of tyrosine residue 207 yielded a mutant CRKL which could not be phosphorylated by BCR/ABL. Stable overexpression of CRKL or CRKL-Y207F did not transform NIH3T3 cells, while the Y207F mutation eliminated tyrosine-phosphorylation of CRKL. These studies indicate that Y207 in CRKL represents the major in vivo phosphorylation site. Phosphorylation of Y207 provides a binding site for the CRKL SH2 domain and potentially for other SH2-containing proteins. The Y207F mutation in CRKL did not enhance or decrease association with various target signalling proteins, including SOS or C3G, which interact specifically with the CRKL N-SH3 domain. These findings suggest that complex formation with cellular targets is not modulated by CRKL tyrosine-phosphorylation.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, SECT MOL CARCINOGENESIS, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA 47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEJONG R, 1995, ONCOGENE, V11, P1469; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Harlow E., 1988, ANTIBODIES LAB MANUA; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LUGO TG, 1990, SCIENCE, V237, P532; MALY FE, 1994, J BIOL CHEM, V269, P18743; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sattler M, 1996, ONCOGENE, V12, P839; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1993, LEUKEMIA ADV RES TRE; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	76	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					507	513		10.1038/sj.onc.1200885	http://dx.doi.org/10.1038/sj.onc.1200885			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053848				2022-12-25	WOS:A1997WF52400001
J	Zinszner, H; Immanuel, D; Yin, Y; Liang, FX; Ron, D				Zinszner, H; Immanuel, D; Yin, Y; Liang, FX; Ron, D			A topogenic role for the oncogenic N-terminus of TLS: Nucleolar localization when transcription is inhibited	ONCOGENE			English	Article						hnRNP; gene expression; RNA-binding protein; immunofluorescence	RNA-BINDING PROTEIN; ACUTE MYELOID-LEUKEMIA; EWS/FLI-1 FUSION GENE; ROUND-CELL TUMOR; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MYXOID LIPOSARCOMA; COILED BODIES; SARCOMA; EWS	TLS (FUS) and the related gene EWS encode the N-terminal portion of many fusion oncoproteins involved in human sarcomas and leukemia. TLS is an RNA-binding nuclear protein that is identical to hnRNP P2 and may be implicated in mRNA metabolism. When RNA polymerase II is inhibited, TLS immunostaining in the nucleus is dramatically altered, from its normal diffuse nucleoplasmic pattern to accumulation in dense nuclease-resistant aggregates. Co-immunostaining with antibodies to fibrillarin or p80 coilin and immunoelectron microscopy revealed that the TLS associated with the nucleolus and are other known structures such as the coiled body or the interchromatin granule. Injection of cells with an oligodeoxynucleotide that disrupts splicing does not result in redistribution of TLS, indicating that the event is specific to inhibition of transcription. Oncoproteins that contain the N-terminal domain from either TLS, EWS or their Drosophila homologue, SARFH (CAZ), are also targeted to the same structure. These findings suggest a correlation between the topogenic and transforming activities of TLS and EWS N-termini and imply the existence of cellular targets that are shared by the germ-line encoded proteins and their oncogenic derivatives.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University; New York University; New York University; New York University				Ron, David/0000-0002-3014-5636; Liang, Fengxia/0000-0003-0037-4590	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; BRASCH K, 1992, EXP CELL RES, V202, P2211; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROWN AD, 1995, ONCOGENE, V10, P1749; CALVIO C, 1995, RNA, V1, P724; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Fujimura Y, 1996, ONCOGENE, V12, P159; HARDERS J, 1989, EMBO J, V8, P3941, DOI 10.1002/j.1460-2075.1989.tb08577.x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; KALLAND KH, 1991, NEW BIOL, V3, P389; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LESSNICK SL, 1995, ONCOGENE, V10, P423; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTH J, 1986, J MICROSC-OXFORD, V143, P125, DOI 10.1111/j.1365-2818.1986.tb02771.x; ROTH J, 1998, HISTOCHEMISTRY, V95, P132; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SPECTOR D, 1991, EMBO J, V10, P3476; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	52	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					451	461		10.1038/sj.onc.1200854	http://dx.doi.org/10.1038/sj.onc.1200854			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053842				2022-12-25	WOS:A1997WE36400008
J	Alves, AP; Mulloy, B; Diniz, JA; Mourao, PAS				Alves, AP; Mulloy, B; Diniz, JA; Mourao, PAS			Sulfated polysaccharides from the egg jelly layer are species-specific inducers of acrosomal reaction in sperms of sea urchins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITIES; L-GALACTOSE; COAT; GLYCOPROTEINS; SUBSTANCE; INDUCTION; TUNICATES; CUCUMBER; FUCAN	We have characterized the fine structure of sulfated polysaccharides from the egg jelly layer of three species of sea urchins and tested the ability of these purified polysaccharides to induce the acrosome reaction in spermatozoa. The sea urchin Echinometra lucunter contains a homopolymer of 2-sulfated, 3-linked alpha-L-galactan. The species Arbacia lixula and Lytechinus variegatus contain linear sulfated alpha-L-fucans with regular tetrasaccharide repeating units. Each of these sulfated polysaccharides induces the acrosome reaction in conspecific but not in heterospecific spermatozoa. These results demonstrate that species specificity of fertilization in sea urchins depends in part on the fine structure of egg jelly sulfated polysaccharide.	UNIV FED RIO DE JANEIRO,DEPT BIOQUIM,INST CIENCIAS BIOMED,BR-21941590 RIO JANEIRO,BRAZIL; NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,HERTS,ENGLAND; UNIV FED RIO DE JANEIRO,INST BIOFIS CARLOS CHAGAS FILHO,LAB ULTRAESTRUTURA CELULAR HERTHA MAYER,BR-21949900 RIO JANEIRO,BRAZIL	Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control; Universidade Federal do Rio de Janeiro			Mourao, Paulo/AAA-5386-2020					BARNES RD, 1980, INVERTEBRATE ZOOLOGY, P1001; BONNELL BS, 1994, DEV BIOL, V162, P313, DOI 10.1006/dbio.1994.1088; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CONTRERAS RR, 1988, CARBOHYD RES, V179, P411; DISCHE Z, 1948, J BIOL CHEM, V175, P595; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; KELLER SH, 1994, DEV BIOL, V162, P304, DOI 10.1006/dbio.1994.1087; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; LIPKIND GM, 1988, CARBOHYD RES, V181, P1, DOI 10.1016/0008-6215(88)84018-7; MIKAMITAKEI K, 1991, EXP CELL RES, V192, P82, DOI 10.1016/0014-4827(91)90160-V; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MULLOY B, 1994, J BIOL CHEM, V269, P22113; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; PAVAO MSG, 1989, CARBOHYD RES, V189, P374, DOI 10.1016/0008-6215(89)84115-1; RIBEIRO AC, 1994, CARBOHYD RES, V255, P225, DOI 10.1016/S0008-6215(00)90981-9; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCHACHTER H, 1969, J BIOL CHEM, V244, P4785; SEGALL GK, 1981, DEV BIOL, V86, P87, DOI 10.1016/0012-1606(81)90318-3; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; SHIMIZU T, 1990, DEV GROWTH DIFFER, V32, P473; STARR M, 1992, MAR ECOL PROG SER, V79, P275; SUZUKI N, 1990, ZOOL SCI, V7, P355; TRIMMER JS, 1986, ANNU REV CELL BIOL, V2, P1; Tyler A., 1966, P683; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; WERNER I, 1952, Acta Soc Med Ups, V57, P230	29	160	170	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6965	6971		10.1074/jbc.272.11.6965	http://dx.doi.org/10.1074/jbc.272.11.6965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054385	hybrid			2022-12-25	WOS:A1997WN14700024
J	Park, CS; Chang, CC; Kim, JY; Ogrydziak, DM; Ryu, DDY				Park, CS; Chang, CC; Kim, JY; Ogrydziak, DM; Ryu, DDY			Expression, secretion, and processing of rice alpha-amylase in the yeast Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE EXTRACELLULAR PROTEASE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; CLONING; PROTEINS	The gene encoding rice a-amylase in Oryza sativa was expressed in the yeast Yarrowia lipolytica, which is a potential host system for heterologous protein expression, For efficient secretion, the strong and inducible XPR2 promoter was used in the construction of four kinds of expression vectors with the following configurations between the XPR2 promoter and terminator: 1) XPR2 prepro-reson-rice alpha-amylase coding sequence, 2) rice cy-amylase signal peptide-rice alpha-amylase coding sequence, 3) XPR2 signal peptide-rice cu-amylase coding sequence, and 4) XPR2 signal peptide dipeptide stretchrice cu-amylase coding sequence, Secretion of active recombinant rice cu-amylase into the culture medium was achieved only in the first two cases, demonstrating that the XPR2 signal peptide is not sufficient to direct the secretion of heterologous protein, Furthermore, our study shows that the XPR2 prepro-region causes imprecise processing (after Pro(150)-Ala(151) or Val(135)-Leu(136) instead of Lys(156)-Arg(l57)) and leads to N-terminal amino acid sequences that differ from that of native rice cu-amylase. Secondary structure analysis proposed that the structural form in the vicinity of the KEX2-like endopeptidase processing site in the XPR2 pro-region might play a critical role in the processing of heterologous proteins, These results suggest that the XPR2 pro-region is dispensable for obtaining the precise N-terminal amino acid in heterologous protein secretion, In contrast, utilizing the rice Lu-amylase signal peptide was sufficient in directing secretion of recombinant protein with the expected N-terminal sequence, indicating that the signal peptide of rice cu-amylase was effectively recognized and processed by the Y. lipolytica secretory pathway.	UNIV CALIF DAVIS,DEPT CHEM ENGN & MAT SCI,BIOCHEM ENGN PROGRAM,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT FOOD SCI & TECHNOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis				Kim, Jeong-Yoon/0000-0001-5873-2069				BUCKHOLZ RG, 1991, BIO-TECHNOL, V9, P1067, DOI 10.1038/nbt1191-1067; Cregg J., 1988, DEV IND MICROBIOL, P33; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; De Zeeuw JR, 1973, United States Patent, Patent No. [3,756,917, 3756917]; De Zeeuw JR, 1973, United States Patent, Patent No. [3,736,229, 3736229]; DEZEEUW JR, 1983, Patent No. 4407953; ENDERLIN CS, 1994, YEAST, V10, P67, DOI 10.1002/yea.320100107; FABRE E, 1992, J BIOL CHEM, V267, P15049; FABRE E, 1991, J BIOL CHEM, V266, P3782; FLEER R, 1991, GENE, V107, P285, DOI 10.1016/0378-1119(91)90329-A; Franke A.E., 1988, DEV IND MICROBIOL, V29, P43; GAILLARDIN C, 1985, CURR GENET, V10, P49, DOI 10.1007/BF00418493; GAILLARDIN C, 1987, CURR GENET, V11, P369, DOI 10.1007/BF00378179; GAILLARDIN C, 1990, P 6 INT S GEN IND MI, V2, P509; GELLISSEN G, 1991, BIO-TECHNOL, V9, P291, DOI 10.1038/nbt0391-291; HARASHIMA S, 1994, RECOMBINANT MICROBES, P137; HESLOT H, 1990, P 2 SSM INT C MICR, P27; Heslot H, 1990, APPL MOL GENET SPRIN, P43; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INOUE H, 1990, GENE, V96, P22; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KUMAGAI MH, 1990, GENE, V94, P209, DOI 10.1016/0378-1119(90)90389-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDALL MT, 1994, CURR GENET, V26, P38, DOI 10.1007/BF00326302; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MATOBA S, 1989, J BIOL CHEM, V264, P6037; NICAUD JM, 1989, CURR GENET, V16, P253, DOI 10.1007/BF00422111; NICAUD JM, 1989, J BIOTECHNOL, V12, P285, DOI 10.1016/0168-1656(89)90048-5; ONEILL SD, 1990, MOL GEN GENET, V221, P235, DOI 10.1007/BF00261726; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Sambrook J., 2002, MOL CLONING LAB MANU; THARAUD C, 1992, GENE, V121, P111, DOI 10.1016/0378-1119(92)90168-O; TOKUNAGA M, 1992, BIOSCI BIOTECH BIOCH, V56, P155, DOI 10.1271/bbb.56.155; VALVERDE V, 1995, J BIOL CHEM, V270, P15821, DOI 10.1074/jbc.270.26.15821; VRETBLAD P, 1974, FEBS LETT, V47, P86, DOI 10.1016/0014-5793(74)80431-X; WEBER H, 1988, Critical Reviews in Biotechnology, V7, P281, DOI 10.3109/07388558809150535	37	47	52	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6876	6881		10.1074/jbc.272.11.6876	http://dx.doi.org/10.1074/jbc.272.11.6876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054373	hybrid			2022-12-25	WOS:A1997WN14700012
J	Nakamura, S; Suzuki, H; Kanazawa, T				Nakamura, S; Suzuki, H; Kanazawa, T			Stoichiometry of phosphorylation to fluorescein 8-isothiocyanate binding in the Ca2+-ATPase of sarcoplasmic reticulum vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; TIGHT-BINDING; ACTIVE-SITE; ISOTHIOCYANATE; CA-2+-ATPASE; CALCIUM; INHIBITION; REDUCTION; MAGNESIUM; MEMBRANE	In an attempt to establish the stoichiometry of phosphorylation in the Ca2+-ATPase of sarcoplasmic reticulum (SR) vesicles, phosphorylation by ATP (or P-i) or labeling by fluorescein 5-isothiocyanate (FITC) was performed with the SR vesicles under the conditions in which almost all the phosphorylation sites or FITC binding sites are phosphorylated or labeled. The resulting vesicles were solubilized in lithium dodecyl sulfate and then the Ca2+-ATPase was purified by size exclusion high performance liquid chromatography. Peptide mapping and sequencing of the tryptic digest of the purified enzyme showed that Lys-515 of the Ca2+-ATPase was exclusively labeled with FITC, in agreement with the previously reported findings. The content of the phosphoenzyme from ATP (4.57 nmol/mg of Ca2+-ATPase protein) or from P-i (4.94 nmol/mg of Ca2+-ATPase protein) in the purified enzyme was approximately half the content of the FITC binding site (8.17-8.25 nmol/mg of Ca2+-ATPase protein) and also half the content of the Ca2+-ATPase molecule (9.06 nmol/mg of Ca2+-ATPase protein) calculated from its molecular mass (110,331 Da). These results show that there is one specific FITC binding site per molecule of the Ca2+-ATPase (in agreement with the previously reported findings) and that the stoichiometry of phosphorylation to FITC binding is approximately 0.5:1.0, All the above findings lead to the conclusion that only half of the Ca2+-ATPase molecules present in the SR vesicles can be phosphorylated, FITC binding completely inhibited the ATP-induced phosphorylation before the binding reached its maximum level, This finding indicates that FITC preferentially binds to a part of the Ca2+-ATPase molecules and that this binding is primarily responsible for the inhibition of phosphorylation, suggesting an intermolecular ATPase ATPase interaction.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN; ASAHIKAWA MED COLL,DEPT DERMATOL,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College; Asahikawa Medical College								ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CSERMELY P, 1985, EUR J BIOCHEM, V150, P455, DOI 10.1111/j.1432-1033.1985.tb09043.x; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEGANI C, 1973, J BIOL CHEM, V248, P8222; GAFNI A, 1984, BIOCHEMISTRY-US, V23, P4362, DOI 10.1021/bi00314a018; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; Liu GQ, 1996, FEBS LETT, V390, P323, DOI 10.1016/0014-5793(96)00687-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1971, J BIOL CHEM, V246, P2702; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; Penefsky H S, 1979, Methods Enzymol, V56, P527; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; Post RL, 1967, METHOD ENZYMOL, V10, P773; SWOBODA G, 1985, Z NATURFORSCH C, V40, P863; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	25	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6232	6237		10.1074/jbc.272.10.6232	http://dx.doi.org/10.1074/jbc.272.10.6232			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045639	hybrid			2022-12-25	WOS:A1997WM64700023
J	Sone, M; Kishigami, S; Yoshihisa, T; Ito, K				Sone, M; Kishigami, S; Yoshihisa, T; Ito, K			Roles of disulfide bonds in bacterial alkaline phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FORMATION INVIVO; ACTIVE-SITE; PROTEIN; GENE; DSBA; CYTOPLASM; EXPORT; IDENTIFICATION; MUTATIONS	Alkaline phosphatase of Escherichia coli (a homodimeric protein found in the periplasmic space) contains two intramolecular disulfide bonds (Cys-168-Cys-178 and Cys-286-Cys-336) that are formed after export to the periplasmic space, The location-specific folding character of this enzyme allowed its wide usage as a reporter of protein localization in prokaryotic cells, To study the roles of disulfide bonds in alkaline phosphatase, we eliminated each of them by Cys to Ser mutations, Intracellular stability of alkaline phosphatase de creased in the absence of either one or both of the disulfide bonds, The mutant proteins were stabilized in a DegP protease-deficient strain, allowing accumulation at significant levels and subsequent characterization, A mutant protein that lacked the N-terminally located disulfide bond (Cys-168-Cys-178) was found to have Cys-286 and Cys-336 residues disulfide-bonded, to have a dimeric structure, and to have almost full enzymatic activity, Nevertheless, the mutant protein lost the trypsin-resistant conformation that is characteristically observed for the wild type enzyme, In contrast, mutants lacking Cys-286 and Cys-336 were monomeric and inactive, These results indicate that the Cys-286-Cys-336 disulfide bond is required and is sufficient for correctly positioning the active site region of this enzyme, but such an active conformation is still insufficient for the conformational stability of the enzyme, Thus, a fully active state of this enzyme can be formed without full protein stability, and the two disulfide bonds differentially contribute to these properties.	KYOTO UNIV,INST VIRUS RES,DEPT CELL BIOL,KYOTO 60601,JAPAN	Kyoto University			Yoshihisa, Tomoki/AFA-7466-2022	Kishigami, Satoshi/0000-0001-9447-5100				AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; [Anonymous], METHODS ENZYMOL B; APPLEBURY ML, 1969, J BIOL CHEM, V244, P308; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bollag D.M., 1991, PROTEIN METHODS, P143; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; CHAIDAROGLOU A, 1988, BIOCHEMISTRY-US, V27, P8338, DOI 10.1021/bi00422a008; CHANG CN, 1986, GENE, V44, P121; DERMAN AI, 1995, J BACTERIOL, V177, P3764, DOI 10.1128/jb.177.13.3764-3770.1995; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; FALK MC, 1982, BIOCHEMISTRY-US, V21, P1471, DOI 10.1021/bi00536a001; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MESSING J, 1987, METHOD ENZYMOL, V153, P3; Miller J. H., 1972, EXPT MOL GENETICS, P431; MURPHY JE, 1994, MOL MICROBIOL, V12, P351, DOI 10.1111/j.1365-2958.1994.tb01024.x; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P3552, DOI 10.1021/bi00863a029; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4284; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4293; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; SUBRAMANIAM V, 1995, BIOCHEMISTRY-US, V34, P1133, DOI 10.1021/bi00004a005; UEGUCHI C, 1990, J BACTERIOL, V172, P5643, DOI 10.1128/jb.172.10.5643-5649.1990; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025	40	89	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6174	6178		10.1074/jbc.272.10.6174	http://dx.doi.org/10.1074/jbc.272.10.6174			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045630	hybrid			2022-12-25	WOS:A1997WM64700014
J	Xiao, GH; Shoarinejad, F; Jin, F; Golemis, EA; Yeung, RS				Xiao, GH; Shoarinejad, F; Jin, F; Golemis, EA; Yeung, RS			The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANTLY INHERITED CANCER; TSC2 GENE; EKER RAT; MEMBRANE-FUSION; IDENTIFICATION; MUTATION; EFFECTOR; TISSUES; GROWTH; MODEL	The tuberous sclerosis complex 2 (TSC2) is a tumor suppressor gene that plays a causative role in the autosomal dominant syndrome of tuberous sclerosis, The latter is characterized by the development of hamartomas and occasional malignancies, Expression of the wild-type gene in TSC2 mutant tumor cells inhibits proliferation and tumorigenicity, This ''suppressor'' activity is encoded by functional domain(s) in the C terminus that contains homology to Rap1GAP. Using a yeast two-hybrid assay to identify proteins that interact with the C-terminal domain of tuberin, the product of TSC2, a cytosolic factor, rabaptin-5, was found to associate with a distinct domain lying adjacent to the TSC2 GAP homology region, Rabaptin-5 also binds the active form of GTPase Rab5, Immune complexes of native tuberin, as well as recombinant protein, possessed activity to stimulate GTP hydrolysis of Rab5. Tuberin GAP activity was specific for Rab5 and showed no cross-reactivity with Rab3a or Rab6, Cells lacking tuberin possessed minimal Rab5GAP activity and were associated with an increased uptake of horseradish peroxidase, Re-expression of tuberin in TSC2 mutant cells reduced the rate of fluid-phase endocytosis, These findings suggest that tuberin functions as a Rab5GAP in vivo to negatively regulate Rab5-GTP activity in endocytosis.	FOX CHASE CANC CTR, DIV MED SCI, PHILADELPHIA, PA 19111 USA; FOX CHASE CANC CTR, DIV BASIC SCI, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center				Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [CA61889] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061889, R29CA061889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNSTEIN J, 1991, ANN NY ACAD SCI, V615, P36; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Gomez MR, 1988, TUBEROUS SCLEROSIS; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; KHOSRAVIFAR R, 1995, METHOD ENZYMOL, V255, P46; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; NELLIST M, 1993, CELL, V75, P1305; PIZON V, 1994, J CELL SCI, V107, P1661; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; XIAO GH, 1995, CELL GROWTH DIFFER, V6, P1185; XU L, 1995, GENOMICS, V27, P475, DOI 10.1006/geno.1995.1079; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1995, MOL CARCINOGEN, V14, P28, DOI 10.1002/mc.2940140107	27	306	317	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6097	6100		10.1074/jbc.272.10.6097	http://dx.doi.org/10.1074/jbc.272.10.6097			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045618	hybrid			2022-12-25	WOS:A1997WM64700002
J	Fan, Z; Makielski, JC				Fan, Z; Makielski, JC			Anionic phospholipids activate ATP-sensitive potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG VENTRICULAR MYOCYTES; K+ CHANNELS; INWARD RECTIFIER; SULFONYLUREA RECEPTOR; CARDIAC MYOCYTES; FATTY-ACIDS; RUN-DOWN; CELLS; PROTEIN; MUSCLE	The ATP-sensitive potassium channel (KATP) controls insulin release in pancreatic beta-cells and also modulates important functions in other cell types. In this study we report that anionic phospholipids activated KATP in pancreatic beta-cells, cardiac myocytes, skeletal muscle cells, and a cloned KATP composed of two subunits (SUR/Kir6.2) stably expressed in a mammalian cell line. The effectiveness was proportional to the number of negative charges on the head group of the anionic phospholipid. Screening negative charges with polyvalent cations antagonized the effect. Enzymatic treatment with phospholipases that reduced charge on the lipids also reduced or eliminated the effect. These results suggest that intact phospholipids with negative charges are the critical requirement for activation of KATP, in distinction from the usual cell signaling pathway through phospholipids that requires cleavage. Mutations of two positively charged amino acid residues at the C terminus of Kir6.2 accelerated loss of channel activity and reduced the activating effects of phospholipids, suggesting involvement of this region in the activation. Metabolism of anionic phospholipids in plasmalemmal membrane may be a novel and general mechanism for regulation of KATP and perhaps other ion channels in the family of inward rectifiers.	UNIV WISCONSIN, DEPT MED, MADISON, WI 53792 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA	University of Wisconsin System; University of Wisconsin Madison; University of Chicago			Jahangir, Arshad/M-7916-2016					AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; DAVIES NW, 1991, J BIOENERG BIOMEMBR, V23, P509, DOI 10.1007/BF00785809; DEWEILLE JR, 1992, J BIOL CHEM, V267, P4557; EDDLESTONE GT, 1995, AM J PHYSIOL-CELL PH, V268, pC181, DOI 10.1152/ajpcell.1995.268.1.C181; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fakler B, 1996, CELL PHYSIOL BIOCHEM, V6, P195, DOI 10.1159/000154823; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FAN Z, 1994, AM J PHYSIOL-CELL PH, V267, pC1036; FAN Z, 1993, CIRC RES, V72, P715, DOI 10.1161/01.RES.72.3.715; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; FINDLAY I, 1985, J MEMBRANE BIOL, V88, P165, DOI 10.1007/BF01868430; FINDLAY I, 1988, BIOCHIM BIOPHYS ACTA, V943, P297, DOI 10.1016/0005-2736(88)90561-5; FURUKAWA T, 1994, J PHYSIOL-LONDON, V479, P95, DOI 10.1113/jphysiol.1994.sp020280; FURUKAWA T, 1993, J PHYSIOL-LONDON, V466, P707; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE M, 1995, J GEN PHYSIOL, V105, P249, DOI 10.1085/jgp.105.2.249; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KOZLOWSKI RZ, 1990, PROC R SOC SER B-BIO, V240, P397, DOI 10.1098/rspb.1990.0044; Light P, 1996, BBA-REV BIOMEMBRANES, V1286, P65, DOI 10.1016/0304-4157(96)00004-4; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MCKILLEN HC, 1994, J PHYSIOL-LONDON, V479, P341, DOI 10.1113/jphysiol.1994.sp020300; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; MULLER M, 1992, BIOCHEMISTRY-US, V31, P4656; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; OHNOSHOSAKU T, 1989, PFLUG ARCH EUR J PHY, V413, P562, DOI 10.1007/BF00594190; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; TAKANO M, 1993, PROG NEUROBIOL, V41, P21, DOI 10.1016/0301-0082(93)90039-U; TAKANO M, 1990, AM J PHYSIOL, V258, pH45, DOI 10.1152/ajpheart.1990.258.1.H45; Tokuyama Y, 1996, BIOCHEM BIOPH RES CO, V220, P532, DOI 10.1006/bbrc.1996.0439; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; YANG NB, 1994, P NATL ACAD SCI USA, V91, P12785, DOI 10.1073/pnas.91.26.12785; ZILBERTER Y, 1988, PFLUG ARCH EUR J PHY, V411, P584, DOI 10.1007/BF00582382	42	276	280	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5388	5395		10.1074/jbc.272.9.5388	http://dx.doi.org/10.1074/jbc.272.9.5388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038137	hybrid			2022-12-25	WOS:A1997WK74700005
J	Rassendren, F; Buell, GN; Virginio, C; Collo, G; North, RA; Surprenant, A				Rassendren, F; Buell, GN; Virginio, C; Collo, G; North, RA; Surprenant, A			The permeabilizing ATP receptor, P2X(7) - Cloning and expression of a human cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED LYSIS; ADENOSINE-TRIPHOSPHATE; HUMAN MACROPHAGES; CELLS	A cDNA was isolated from a human monocyte library that encodes the P2X(7) receptor; the predicted protein is 80% identical to the rat receptor, Whole cell recordings were made from human embryonic kidney cells transfected with the human cDNA and from human macrophages, Brief applications (1-3 s) of ATP and 2',3'-(4-benzoyl)-benzoyl-ATP elicited cation-selective currents, When compared with the rat P2X(7) receptor, these effects required higher concentrations of agonists, were more potentiated by removal of extracellular magnesium ions, and reversed more rapidly on agonist removal. Longer applications of agonists permeabilized the cells, as evidenced by uptake of the propidium dye YO-PRO1, but this was less marked than for cells expressing the rat P2X(7) receptor, Expression of chimeric molecules indicated that some of the differences between the rat and human receptor could be reversed by exchanging the intracellular C-terminal domain of the proteins.			Rassendren, F (corresponding author), GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 GENEVA,SWITZERLAND.		Rassendren, Francois/AAA-6190-2021; North, Richard/GQA-6156-2022	COLLO, Ginetta/0000-0003-1888-5049; Rassendren, Francois/0000-0003-3320-2461				Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; BLANCHARD DK, 1995, J CELL BIOCHEM, V57, P452, DOI 10.1002/jcb.240570311; BLANCHARD DK, 1991, J IMMUNOL, V147, P2579; BLANCHARD DK, 1995, BLOOD, V85, P3173, DOI 10.1182/blood.V85.11.3173.bloodjournal85113173; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; GARCIAGUZMAN M, 1997, IN PRESS MOL PHARM; HICKMAN SE, 1994, BLOOD, V84, P2452; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Valera S, 1995, RECEPTOR CHANNEL, V3, P283	15	427	453	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5482	5486		10.1074/jbc.272.9.5482	http://dx.doi.org/10.1074/jbc.272.9.5482			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038151	hybrid			2022-12-25	WOS:A1997WK74700019
J	Sato, K; Mori, H; Yoshida, M; Tagaya, M; Mizushima, S				Sato, K; Mori, H; Yoshida, M; Tagaya, M; Mizushima, S			Short hydrophobic segments in the mature domain of ProOmpA determine its stepwise movement during translocation across the cytoplasmic membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; PROTEIN TRANSLOCATION; PREPROTEIN TRANSLOCASE; SIGNAL PEPTIDE; SECA; ATP; RECONSTITUTION; MACHINERY; EXPORT; MUTAGENESIS	Based on the finding that a series of engineered proOmpAs containing disulfide-bridged loops of different sizes at different positions exhibits a discontinuous mode of polypeptide transit across the cytoplasmic membrane of Escherichia coli, we suggested previously that the translocation of preproteins takes place at every SO amino acid residues (Uchida, K., Mori, H., and Mizushima, S. (1995) J. Biol. Chem. 270, 30862-30868), In the present study, we investigated the molecular mechanism underlying this stepwise translocation, Deletion or relocation of hydrophobic segments of the mature domain of proOmpA (H1, residues 233-237; H2, residues 261-265) significantly altered the pattern of the stepwise translocation, The stepwise mode of polypeptide insertion was also observed with reconstituted proteoliposomes comprising purified SecA, SecY, and SecE. Crosslinking experiments involving a photoactivable crosslinker revealed that SecY and SecA are the components which interact with the hydrophobic segment of proOmpA. The present results indicate that the hydrophobic segments of the mature domains of preproteins interact with membrane embedded translocase during polypeptide transit across the membrane, which causes a discontinuous mode of polypeptide movement.	TOKYO UNIV PHARM & LIFE SCI,SCH LIFE SCI,TOKYO 19203,JAPAN	Tokyo University of Pharmacy & Life Sciences	Sato, K (corresponding author), TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,NAGATSUTA 4259,YOKOHAMA,KANAGAWA 226,JAPAN.							AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MIZUSHIMA S, 1986, ASSEMBLY MEMBRANE PR, P163; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; YAMADA H, 1989, J BIOL CHEM, V264, P1723	32	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5880	5886		10.1074/jbc.272.9.5880	http://dx.doi.org/10.1074/jbc.272.9.5880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038205	hybrid			2022-12-25	WOS:A1997WK74700073
J	Banno, Y; TamiyaKoizumi, K; Oshima, H; Morikawa, A; Yoshida, S; Nozawa, Y				Banno, Y; TamiyaKoizumi, K; Oshima, H; Morikawa, A; Yoshida, S; Nozawa, Y			Nuclear ADP-ribosylation factor (ARF)- and oleate-dependent phospholipase D (PLD) in rat liver cells - Increases of ARF-dependent PLD activity in regenerating liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CANINE KIDNEY-CELLS; GTP-BINDING PROTEIN; SWISS 3T3 CELLS; CHOLERA-TOXIN; HL-60 CELLS; TRANSLOCATION; ACTIVATION; DIACYLGLYCEROL; LOCALIZATION	Two forms of phospholipase D (PLD) have been found to be present in nuclei isolated from rat hepatocytes by measuring phosphatidylbutanol produced from exogenous radiolabeled phosphatidylcholine in the presence of butanol. In nuclear lysates from either rat liver or ascites hepatoma AH 7974 cells, the PLD activity was markedly stimulated by a recombinant ADP-ribosylation factor (rARF) in the presence of the guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) and phosphatidylinositol 4,5-bisphosphate. ATP and phorbol-12-myristate 13-acetate had no synergistic effect on this PLD activity. On the other hand, the nuclear PLD was stimulated by unsaturated fatty acids, especially by oleic acid. The ARF-dependent nuclear PLD activity was increased in the S-phase of the regenerating rat liver after partial hepatectomy and also was much higher in AH 7974 cells than in the resting rat liver. In contrast, the levels of the oleate-dependent PLD activity remained constant throughout the cell cycle in liver regeneration. The intranuclear levels of the stimulating proteins of the nuclear PLD activity, e.g. ARF, RhoA, and protein kinase C delta increased in the S-phase of the regenerating liver. These results suggested that the nuclear ARF-dependent PLD activity may be associated with cell proliferation.	NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,LAB CANC CELL BIOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University	Banno, Y (corresponding author), GIFU UNIV,SCH MED,DEPT BIOCHEM,TSUKASAMACHI 40,GIFU 500,JAPAN.							AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; ASANO M, 1994, J BIOL CHEM, V269, P12360; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; Csermely P, 1995, BBA-REV BIOMEMBRANES, V1241, P425, DOI 10.1016/0304-4157(95)00015-1; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HONG JX, 1994, J BIOL CHEM, V269, P9743; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; ISHIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1084, P53, DOI 10.1016/0005-2760(91)90055-M; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P525; Kanfer JN, 1996, FEBS LETT, V383, P6, DOI 10.1016/0014-5793(96)00205-0; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; Nakamura SI, 1996, P NATL ACAD SCI USA, V93, P4300, DOI 10.1073/pnas.93.9.4300; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Ojio K, 1996, BIOCHEM BIOPH RES CO, V224, P591, DOI 10.1006/bbrc.1996.1069; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; SMITH HC, 1982, BIOCHEMISTRY-US, V21, P6751, DOI 10.1021/bi00269a021; TAMIYAKOIZUMI K, 1989, BIOCHIM BIOPHYS ACTA, V1002, P182, DOI 10.1016/0005-2760(89)90285-3; TAMIYAKOIZUMI K, 1989, J BIOCHEM, V106, P593, DOI 10.1093/oxfordjournals.jbchem.a122901; YORK JD, 1994, J BIOL CHEM, V269, P7847	49	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5208	5213		10.1074/jbc.272.8.5208	http://dx.doi.org/10.1074/jbc.272.8.5208			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030590	hybrid			2022-12-25	WOS:A1997WJ85500078
J	Beckert, V; Bernhardt, R				Beckert, V; Bernhardt, R			Specific aspects of electron transfer from adrenodoxin to cytochromes P450scc and P45011 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENODOXIN; AFFECT BINDING; REDUCTASE; COMPLEXES; MUTATIONS; PROTEINS; IDENTIFICATION; MITOCHONDRIA; CHOLESTEROL; FERREDOXIN	An analysis of the electron transfer kinetics from the reduced [2Fe-2S] center of bovine adrenodoxin and its mutants to the natural electron accepters, cytochromes P450scc and P45011 beta, is the primary focus of this paper, A series of mutant proteins with distinctive structural parameters such as redox potential, microenvironment of the iron-sulfur cluster, electrostatic properties, and conformational stability was used to provide more detailed insight into the contribution of the electronic and conformational states of adrenodoxin to the driving forces of the complex formation of reduced adrenodoxin with cytochromes P450scc and P45011 beta and electron transfer. The apparent rate constants of P450scc reduction were generally proportional to the adrenodoxin redox potential under conditions in which the protein-protein interactions were not affected, However, the effect of redox potential differences was shown to be masked by structural and electrostatic effects, In contrast, no correlation of the reduction rates of P45011 beta with the redox potential of adrenodoxin mutants was found. Compared with the interaction with P450scc, however, the hydrophobic protein region between the iron sulfur cluster and the acidic site on the surface of adrenodoxin seems to play an important role for precise complementarity in the tightly associated complex with P45011 beta.	MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY; UNIV SAARLAND,FACHRICHTUNG BIOCHEM 124,D-66041 SAARBRUCKEN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Saarland University								AKHREM AA, 1979, ACTA BIOL MED GER, V38, P257; BECKERT V, 1995, EUR J BIOCHEM, V231, P226, DOI 10.1111/j.1432-1033.1995.tb20691.x; BECKERT V, 1994, J BIOL CHEM, V269, P2568; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BERNHARDT R, 1995, REV PHYSL BIOCH PHAR, V127, P137; Burova TV, 1996, PROTEIN SCI, V5, P1890, DOI 10.1002/pro.5560050915; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HANUKOGLU I, 1980, J BIOL CHEM, V255, P3057, DOI 10.1016/S0021-9258(19)85851-9; HARA T, 1994, CYTOCHROME P450, P417; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3082, DOI 10.1021/bi00659a023; HOLDEN HM, 1994, J BIOENERG BIOMEMBR, V26, P67, DOI 10.1007/BF00763220; KIDO T, 1979, J BIOL CHEM, V254, P1806; Kimura T., 1968, STRUCTURE BONDING, V5, P1; LAMBETH JD, 1980, J BIOL CHEM, V255, P4667; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1985, J BIOL CHEM, V260, P8810; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; LAMBETH JD, 1990, FRONTIERS BIOTRANSFO, V3, P58; LIM BT, 1980, J BIOL CHEM, V255, P2440; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEYER TE, 1983, P NATL ACAD SCI-BIOL, V80, P6740, DOI 10.1073/pnas.80.22.6740; MUKAI K, 1973, BIOCHIM BIOPHYS ACTA, V295, P49, DOI 10.1016/0005-2795(73)90072-X; OMURA T, 1964, J BIOL CHEM, V239, P2379; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SUGANO S, 1989, ANAL BIOCHEM, V182, P327, DOI 10.1016/0003-2697(89)90603-9; TUCKEY RC, 1983, J BIOL CHEM, V258, P4232; UHLMANN H, 1994, J BIOL CHEM, V269, P22557; UHLMANN H, 1995, J BIOL CHEM, V270, P29959; WADA A, 1992, J BIOL CHEM, V267, P22877; YAMAZAKI T, 1993, MOL CELL ENDOCRINOL, V95, P1, DOI 10.1016/0303-7207(93)90023-D	33	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4883	4888		10.1074/jbc.272.8.4883	http://dx.doi.org/10.1074/jbc.272.8.4883			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030546	hybrid			2022-12-25	WOS:A1997WJ85500034
J	Hirata, R; Graham, LA; Takatsuki, A; Stevens, TH; Anraku, Y				Hirata, R; Graham, LA; Takatsuki, A; Stevens, TH; Anraku, Y			VMA11 and VMA16 encode second and third proteolipid subunits of the Saccharomyces cerevisiae vacuolar membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; VESICLE PROTON PUMP; GENE ENCODES; V-ATPASE; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; CATALYTIC SUBUNIT; PLASMA-MEMBRANE; ENZYME COMPLEX; YEAST VACUOLE	The vacuolar membrane H+-ATPase (V-ATPase) of the yeast Saccharomyces cerevisiae is composed of peripheral catalytic (V-1) and integral membrane (V-0) domains. The 17-kDa proteolipid subunit (VMA3 gene product; Vma3p) is predicted to constitute at least part of the proton translocating pore of V-0. Recently, two VMA3 homologues, VMA11 and VMA16 (PPA1), have been identified in yeast, and VMA11 has been shown to be required for the V-ATPase activity. Cells disrupted for the VMA16 gene displayed the same phenotypes as those lacking either Vma3p or Vma11p; the mutant cells lost V-ATPase activity and failed to assemble V-ATPase subunits onto the vacuolar membrane. Epitope-tagged Vma11p and Vma16p were detected on the vacuolar membrane by immunofluorescence microscopy. Density gradient fractionation of the solubilized vacuolar proteins demonstrated that the tagged proteins copurified with the V-ATPase complex. We conclude that Vma11p and Vma16p are essential subunits of the V-ATPase. Vma3p contains a conserved glutamic acid residue (Glu(137)) whose carboxyl side chain is predicted to be important for proton transport activity. Mutational analysis of Vma11p and Vma16p revealed that both proteins contain a glutamic acid residue (Vma11p Glu(145) and Vma16p Glu(108)) functionally similar to Vma3p Glu(137). These residues could only be functionally substituted by an aspartic acid residue, because other mutations we examined inactivated the enzyme activity. Assembly and vacuolar targeting of the enzyme complex was not inhibited by these mutations. These results suggest that the three proteolipid subunits have similar but not redundant functions, each of which is most likely involved in proton transport activity of the enzyme complex. Yeast cells contain V-0 and V-1 subcomplexes in the vacuolar membrane and in the cytosol, respectively, that can be assembled into the active V0V1 complex in vivo. Surprisingly, loss-of-function mutations of either Vma11p Glu(145) or Vma16p Glu(108) resulted in a higher degree of assembly of the V-1 subunits onto the V-0 subcomplex in the vacuolar membrane.	UNIV TOKYO, GRAD SCH SCI, DEPT BIOL SCI, BUNKYO KU, TOKYO 113, JAPAN; RIKEN, INST PHYS & CHEM RES, WAKO, SAITAMA 35101, JAPAN; UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA	University of Tokyo; RIKEN; University of Oregon			Hirata, Ryogo/C-7424-2017	Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J EXP BIOL, V172, P67; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; APPERSON M, 1990, BIOCHEM BIOPH RES CO, V168, P574, DOI 10.1016/0006-291X(90)92359-8; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FORGAC M, 1992, J EXP BIOL, V172, P155; FOURY F, 1990, J BIOL CHEM, V265, P18554; GLUCK S, 1992, J EXP BIOL, V172, P29; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P164; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kaiser C., 1994, METHODS YEAST GENETI; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1992, J EXP BIOL, V172, P39; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS TH, 1992, J EXP BIOL, V172, P47; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	55	186	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4795	4803		10.1074/jbc.272.8.4795	http://dx.doi.org/10.1074/jbc.272.8.4795			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030535	hybrid			2022-12-25	WOS:A1997WJ85500023
J	Lai, HL; Yang, TH; Messing, RO; Ching, YH; Lin, SC; Chern, YJ				Lai, HL; Yang, TH; Messing, RO; Ching, YH; Lin, SC; Chern, YJ			Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA PC12 CELLS; PHORBOL-ESTER; RAT-BRAIN; STIMULATION; PHOSPHORYLATION; ADENOSINE; ACTIVATION	We have previously reported that phosphorylation of adenylyl cyclase type VI (AC6) may result in the suppression of adenylyl cyclase activity during desensitization of the A2a-adenosine receptor-mediated cAMP response (A2a desensitization) in rat pheochromocytoma PC12 cells. In the present study, we demonstrate that protein kinase C (PRC) is responsible for the phosphorylation and inhibition of AC6 during A2a desensitization. Inhibition of PKC by several independent methods markedly blocked the suppression of AC6 during A2a desensitization. Purified PKC from rat brain directly phosphorylated and inhibited recombinant AC6 expressed in Sf21 cells. Substantially lower AC6 activities were also observed in PC12 cells overexpressing PKC delta or PKC epsilon. Stimulation of A2a-R in PC12 cells under the same conditions as those required for A2a desensitization resulted in an increase in Ca2+-independent PKC activity. Most importantly, exogenous PKC did not further suppress AC6 activity in A2a-desensitized membranes. In vitro PKC phosphorylation of AC6 isolated from A2a-desensitized cells was also profoundly lower than that from control cells, suggesting a specific role for PKC in regulating AC6 during A2a desensitization in PC12 cells. Taken together, our data demonstrate that a calcium-independent, novel PKC inhibits AC6 activity during A2a desensitization in PC12 cells. Independent regulation of AC6 by calcium-independent PKC and by Ca2+ provides an exquisite mechanism for integrating signaling pathways to fine-tune cAMP synthesis.	ACAD SINICA, INST BIOMED SCI, TAIPEI, TAIWAN; NATL YANG MING MED COLL, INST NEUROSCI, TAIPEI 11221, TAIWAN; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, E GALLO CLIN & RES CTR, SAN FRANCISCO, CA 94110 USA	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center			Messing, Robert/D-3642-2015; chern, yijuang/S-7013-2018	Messing, Robert/0000-0002-5345-4431; chern, yijuang/0000-0002-5842-5429				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; CHERN YJ, 1995, MOL PHARMACOL, V48, P1; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; GINTY DD, 1991, J BIOL CHEM, V266, P15325; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Harlow E., 1988, ANTIBODIES LAB MANUA, P59; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOIZUMI S, 1994, BRIT J PHARMACOL, V112, P992, DOI 10.1111/j.1476-5381.1994.tb13179.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; SMITH MK, 1990, J BIOL CHEM, V265, P1837; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tsu RC, 1996, J NEUROSCI, V16, P1317; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; XENG L, 1995, BIOCHEM J, V312, P769; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	33	110	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4970	4977		10.1074/jbc.272.8.4970	http://dx.doi.org/10.1074/jbc.272.8.4970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030558	hybrid			2022-12-25	WOS:A1997WJ85500046
J	Li, R; Zheng, Y				Li, R; Zheng, Y			Residues of the Rho family GTPases Rho and Cdc42 that specify sensitivity to Dbl-like guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; H-RAS; FUNCTIONAL INTERACTION; ACTIVATING PROTEIN; IDENTIFICATION; EFFECTOR; DOMAIN; MECHANISM; FILOPODIA	The Dbl-like guanine nucleotide exchange factor (GEF) Lbc oncoprotein specifically activates the small GTP-binding protein Rho in mammalian fibroblasts to induce transformation and actin stress fiber formation, whereas another Dbl-related molecule, Cdc24, stimulates guanine nucleotide exchange of the Rho family GTPase Cdc42 to elicit effects on both gene induction and actin-based cytoskeleton change in Saccharomyces cerevisiae, To understand the mechanism of these functional interactions, we have taken a biochemical approach to probe the sites on Rho and Cdc42 that are involved in coupling to their respective GEFs, the Lbc and Cdc24 proteins, Point mutations in the switch II region of the small G-proteins, many of which would affect the interaction with GEF in the case of Pas, or a mutation in the switch I region that was identified as a contact site between Rab3A and Rab GEF had little effect on RhoA or Cdc42Hs with regard to the ability to interact with Lbc or Cdc24, suggesting that there exists a unique mechanism of regulation of the Rho family proteins by their GEFs, Analysis of a panel of chimeras made between RhoA and Cdc42Hs, which all maintained the ability to respond to Dbl, their mutual GEF, and to GTPase-activating protein, revealed that at least two distinct sites in each of the GTPases are required for activation by the respective GEFs, Further site-directed mutagenesis studies showed that the conserved residue Tyr(32) in the putative effector region of both GTPases (numbered by Cdc42Hs) is critical for binding of the GEFs and that specific recognition for Lbc or Cdc24 is achieved at least in part through residues Lys(27) of Rho and Gln(116) of Cdc42. Moreover, the loss of GEF responsiveness of a RhoA mutation (D76Q) was found to be caused by the impaired GEF catalysis, not by a change in the GEF binding affinity, Together, these results indicate that multiple sites of the Rho GTPases are involved in the regulation by GEFs, contributing to GEF binding or GEF catalysis, and raise the possibility that activation of each Rho family G-protein by a specific GEF may engage in a distinct mechanism.	UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MITSOU MY, 1992, EMBO J, V11, P2391; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SELF AJ, 1993, ONCOGENE, V8, P655; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	40	62	62	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4671	4679		10.1074/jbc.272.8.4671	http://dx.doi.org/10.1074/jbc.272.8.4671			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030518	hybrid			2022-12-25	WOS:A1997WJ85500006
J	Tulchinsky, E; Prokhortchouk, E; Georgiev, G; Lukanidin, E				Tulchinsky, E; Prokhortchouk, E; Georgiev, G; Lukanidin, E			A kappa B-related binding site is an integral part of the mts1 gene composite enhancer element located in the first intron of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NONMUSCLE MYOSIN; PROTEIN SUBUNITS; CHAIN PROMOTER; HEAVY-CHAIN; CELL-LINES; DNA; TRANSCRIPTION; FAMILY; SEQUENCE	The transcription of the mts1 gene correlates with the metastatic potential of mouse adenocarcinomas. Here we describe strong enhancer whose location coincides with the DNase I hypersensitivity area in the first intron of the mts1 gene. The investigation of the transcriptional activity of a series of plasmids bearing deletions in the first intron sequences revealed that the observed enhancer has a composite structure. The enhancer activity is partially formed by the kappa B-related element: GGGGTTTTTCCAC. This sequence element was able to form several sequence-specific complexes with nuclear proteins extracted from both Mts1-expressing CSML100 and Mts1-non-expressing CSML0 adenocarcinoma cells. Two of these complexes were identified as NF-kappa B/Rel-specific p50 . p50 home- and p50 . p65 heterodimers. The third complex was formed by the 200-kDa protein. Even though the synthetic kappa B-responsible promoter was active in mouse adenocarcinoma cells, a mutation preventing NF-kappa B binding had no effect on the mts1 natural enhancer activity. On the contrary, the mutation in the kappa B-related element, which abolished the binding of the 200-kDa protein, led to the functional inactivation of this site in the mts1 first intron. The mts1 kappa B-like element activated transcription from its own mts1 gene promoter, as well as from the heterologous promoter in both CSML0 and CSML100 cells. However, in vivo occupancy of this site was observed only in Mts1-expressing CSML100 cells, suggesting the involvement of the described element in positive control of mts1 transcription.	RUSSIAN ACAD SCI,INST GENE BIOL,MOSCOW,RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Tulchinsky, E (corresponding author), DANISH CANC SOC,DEPT MOL CANC BIOL,STRANDBOULEVARDEN 49,BLDG 43,DK-2100 COPENHAGEN,DENMARK.		Tulchinsky, Eugene/ABD-7070-2021; Prokhortchouk, Egor/I-9108-2014					AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLICK A, 1990, NUCLEIC ACIDS RES, V18, P625, DOI 10.1093/nar/18.3.625; DAVIES BR, 1993, ONCOGENE, V8, P999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FORD HL, 1995, ONCOGENE, V10, P1597; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAKINO R, 1994, NUCLEIC ACIDS RES, V22, P5679, DOI 10.1093/nar/22.25.5679; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NOMURA N, 1991, J BIOL CHEM, V266, P8590; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; RON D, 1991, MOL CELL BIOL, V11, P2887, DOI 10.1128/MCB.11.5.2887; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TULCHINSKY E, 1992, P NATL ACAD SCI USA, V89, P9146, DOI 10.1073/pnas.89.19.9146; TULCHINSKY E, 1993, ONCOGENE, V8, P79; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; VANVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971; WAHLS WP, 1991, NUCLEIC ACIDS RES, V19, P3269, DOI 10.1093/nar/19.12.3269; WILLIAMS M, 1992, NUCLEIC ACIDS RES, V20, P4935, DOI 10.1093/nar/20.18.4935	47	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4828	4835		10.1074/jbc.272.8.4828	http://dx.doi.org/10.1074/jbc.272.8.4828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030539	hybrid			2022-12-25	WOS:A1997WJ85500027
J	Stern, B; Denisova, G; Buyaner, D; Raviv, D; Gershoni, JM				Stern, B; Denisova, G; Buyaner, D; Raviv, D; Gershoni, JM			Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library	FASEB JOURNAL			English	Article						monoclonal antibodies; phage display libraries; protein secondary structure; AIDS; vaccine	HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-STRUCTURE DETERMINATION; GP120 SURFACE GLYCOPROTEIN; SECONDARY-STRUCTURE; GLOBULAR-PROTEINS; NMR-SPECTROSCOPY; TYPE-1; IDENTIFICATION; HIV; COMPLEMENT	Combinatorial phage display peptide libraries are routinely used to map epitopes of specific monoclonal antibodies. In this study we illustrate that these libraries can be used in the analysis of protein structure, By screening libraries at low stringency, a collection of phages can be obtained, These are characterized by the fact that they are recognized by a given monoclonal antibody yet with various affinities. Comparing the random peptides of these phages indicates the common essential residues necessary for antibody recognition. Aligning the inserts based on the detected homology has revealed structural motifs that correspond to secondary protein structures, The envelope protein of HIV-1 has been studied using this approach, A combinatorial phage display Library containing a 20 mer random peptide III protein III of the filamentous phage fd-tet has been used to analyze two different monoclonal antibodies directed against gp120. Our results provide experimental evidence that indicate that the C1 domain of gp120 contains an alpha helix.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University								BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DECROLY E, 1993, J VIROL, V67, P3552, DOI 10.1128/JVI.67.6.3552-3560.1993; DELORIMIER R, 1994, BIOCHEMISTRY-US, V33, P2055, DOI 10.1021/bi00174a011; Denisova G, 1996, AIDS RES HUM RETROV, V12, P901, DOI 10.1089/aid.1996.12.901; DIERICH MP, 1993, IMMUNOL TODAY, V14, P435, DOI 10.1016/0167-5699(93)90246-H; GALLAHER WR, 1995, AIDS RES HUM RETROV, V11, P191, DOI 10.1089/aid.1995.11.191; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GILBRAT JF, 1987, J MOL BIOL, V198, P425; Harlow E., 1988, ANTIBODIES LAB MANUA; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; KABSCH W, 1983, FEBS LETT, V155, P179, DOI 10.1016/0014-5793(82)80597-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVITT M, 1977, J MOL BIOL, V114, P181, DOI 10.1016/0022-2836(77)90207-8; MATTHEWS BW, 1976, ANNU REV PHYS CHEM, V27, P493, DOI 10.1146/annurev.pc.27.100176.002425; McPherson A, 1982, PREPARATION ANAL PRO; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1994, J VIROL, V68, P6836, DOI 10.1128/JVI.68.11.6836-6847.1994; NYGREN A, 1988, P NATL ACAD SCI USA, V85, P6543, DOI 10.1073/pnas.85.17.6543; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; OSCHKINAT H, 1994, ANGEW CHEM INT EDIT, V33, P277, DOI 10.1002/anie.199402771; PINTER C, 1995, AIDS RES HUM RETROV, V11, P577, DOI 10.1089/aid.1995.11.577; PRESTRELSKI SJ, 1992, PROTEINS, V14, P440, DOI 10.1002/prot.340140405; RAMAKRISHNAN C, 1982, INT J PEPT PROT RES, V20, P218; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; STERN B, 1997, IN PRESS METHODS MOL; UNGER R, 1989, PROTEINS, V5, P355, DOI 10.1002/prot.340050410; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719	35	18	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					147	153		10.1096/fasebj.11.2.9039957	http://dx.doi.org/10.1096/fasebj.11.2.9039957			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039957				2022-12-25	WOS:A1997WK50900007
J	Fasbender, A; Zabner, J; Chillon, M; Moninger, TO; Puga, AP; Davidson, BL; Welsh, MJ				Fasbender, A; Zabner, J; Chillon, M; Moninger, TO; Puga, AP; Davidson, BL; Welsh, MJ			Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYLYSINE DNA COMPLEXES; CYSTIC-FIBROSIS; PRIMARY HEPATOCYTES; NASAL EPITHELIUM; EXPRESSION; DELIVERY; CELLS; VECTOR; ENHANCEMENT; THERAPY	Improving the efficiency of gene transfer remains an important goal in developing new treatments for cystic fibrosis and other diseases, Adenovirus vectors and nonviral vectors each have specific advantages, but they also have limitations. Adenovirus vectors efficiently escape from the endosome and enter the nucleus, but the virus shows limited binding to airway epithelia, Nonviral cationic vectors bind efficiently to the negatively charged cell surface, but they do not catalyze subsequent steps in gene transfer, To take advantage of the unique features of the two different vector systems, we noncovalently complexed cationic molecules with recombinant adenovirus encoding a transgene, Complexes of cationic polymers and cationic lipids with adenovirus increased adenovirus uptake and transgene expression in cells that were inefficiently infected by adenovirus alone. Infection by both complexes was independent of adenovirus fiber and its receptor and occurred via a different cellular pathway than adenovirus alone. Complexes of cationic molecules and adenovirus also enhanced gene transfer to differentiated human airway epithelia in vitro and to the nasal epithelium of cystic fibrosis mice in vivo. These data show that complexes of adenovirus and cationic molecules increase the efficiency of gene transfer, which may enhance the development of gene therapy.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa			; Chillon, Miguel/A-2466-2009	Zabner, Joseph/0000-0002-9606-1339; Chillon, Miguel/0000-0003-0840-2111; Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385, P01HL051670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51670, HL42385] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P11548, DOI 10.1073/pnas.90.24.11548; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; FASBENDER AJ, 1995, AM J PHYSIOL-LUNG C, V269, pL45, DOI 10.1152/ajplung.1995.269.1.L45; FISHER KJ, 1994, BIOCHEM J, V299, P49, DOI 10.1042/bj2990049; GAO L, 1993, HUM GENE THER, V4, P17, DOI 10.1089/hum.1993.4.1-17; Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a; GOTTSCHALK S, 1994, GENE THER, V1, P185; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; HAY JG, 1995, HUM GENE THER, V6, P1487, DOI 10.1089/hum.1995.6.11-1487; HORWITZ MS, 1990, VIROLOGY, P01679; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; Kohout TA, 1996, CIRC RES, V78, P971, DOI 10.1161/01.RES.78.6.971; KUPFER JM, 1994, HUM GENE THER, V5, P1437, DOI 10.1089/hum.1994.5.12-1437; LOZIER JN, 1994, HUM GENE THER, V5, P313, DOI 10.1089/hum.1994.5.3-313; MILLER DK, 1981, P NATL ACAD SCI-BIOL, V78, P3605, DOI 10.1073/pnas.78.6.3605; OGIER G, 1994, ARCH VIROL, V135, P43, DOI 10.1007/BF01309764; PERSSON R, 1985, J VIROL, V54, P92, DOI 10.1128/JVI.54.1.92-97.1985; SETH P, 1994, BIOCHEM BIOPH RES CO, V203, P582, DOI 10.1006/bbrc.1994.2222; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WU GY, 1994, J BIOL CHEM, V269, P11542; YOSHIMURA K, 1993, J BIOL CHEM, V268, P2300; Zabner J, 1996, GENE THER, V3, P458; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253	38	227	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6479	6489		10.1074/jbc.272.10.6479	http://dx.doi.org/10.1074/jbc.272.10.6479			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045673	hybrid			2022-12-25	WOS:A1997WM64700057
J	ORourke, J; Yuan, R; DeWille, J				ORourke, J; Yuan, R; DeWille, J			CCAAT/enhancer-binding protein-delta (C/EBP-delta) is induced in growth-arrested mouse mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTION FACTORS; ADIPOCYTE DIFFERENTIATION; MESSENGER-RNA; DNA-BINDING; BETA; PARTICIPATION; INDUCTION; ISOFORMS; PROMOTER	CCAAT/enhancer binding proteins (C/EBPs) are a highly conserved family of DNA-binding proteins that regulate cell growth and differentiation in a highly tissue-specific manner, These experiments investigated the influence of the cell cycle on C/EBP isoform expression in mammary epithelial cells (COMMA D) and fibroblasts (NIH3T3). C/EBP-delta gene expression is induced in COMMA D cells arrested in G(0) by serum and growth factor withdrawal or contact inhibition. C/EBP-delta mRNA, nuclear protein content, and DNA binding activity increase during G(0) growth arrest and decrease after cell cycle induction in COMMA D cells. Growth arrest is markedly delayed in COMMA D cells expressing a C/EBP-delta antisense construct, C/EBP-beta is induced during G(1) of the cell cycle. In contrast to COMMA D cells, C/EBP-beta and C/EBP-delta mRNA levels remain relatively constant in growth-arrested and cell cycle induced NIH3T3 cells. However, C/EBP homologous protein (CHOP10) mRNA levels markedly increase in growth arrested NIH3T3 cells. Both COMMA D and NIH3T3 cells express growth arrest-specific (gas1) and JunD during G(0). These results demonstrate that COMMA D and NIH3T3 cells achieve a common growth arrest (G(0)) state by cell-specific strategies that involve the induction of different C/EBP isoforms.	OHIO STATE UNIV, DEPT VET BIOSCI, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; An MR, 1996, MOL CELL BIOL, V16, P2295; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DEWILLE JW, 1988, J BIOL CHEM, V263, P84; DEWILLE JW, 1993, BIOCHIM BIOPHYS ACTA, V1170, P291, DOI 10.1016/0005-2760(93)90012-X; DIEHL AM, 1994, HEPATOLOGY, V19, P447; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; GUENETTE RS, 1994, J MOL ENDOCRINOL, V12, P47, DOI 10.1677/jme.0.0120047; GUTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KALLIN B, 1991, MOL CELL BIOL, V11, P5338, DOI 10.1128/MCB.11.10.5338; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MEDINA D, 1986, J NATL CANCER I, V76, P1143; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISCHOULON D, 1991, MOL CELL BIOL, V251, P288; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NEVILLE M, 1989, MAMMARY GLAND, P563; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Rao VN, 1996, ONCOGENE, V12, P523; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCOTT LM, 1992, BLOOD, V80, P1725; SWANSON GM, 1993, J NATL CANCER I, V85, P848, DOI 10.1093/jnci/85.11.848; UHEDA M, 1996, MOL CELL BIOL, V16, P1479; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; WINSTON S, 1987, CURRENT PROTOCOLS MO; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	51	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6291	6296		10.1074/jbc.272.10.6291	http://dx.doi.org/10.1074/jbc.272.10.6291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045647	hybrid			2022-12-25	WOS:A1997WM64700031
J	Waldron, RT; Short, AD; Gill, DL				Waldron, RT; Short, AD; Gill, DL			Store-operated Ca2+ entry and coupling to Ca2+ pool depletion in thapsigargin-resistant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; INOSITOL PHOSPHATES; TRANSPORT ATPASE; NONMUSCLE CELLS; PROTEIN-KINASE; CALCIUM-ENTRY; GROWTH; EXPRESSION; INHIBITION; MECHANISM	The release of Ca2+ from intracellular Ca2+ pumping pools and the entry of extracellular Ca2+ are tightly coupled events. The potent and specific intracellular Ca2+ pump inhibitor, thapsigargin, blocks Ca2+ accumulation and allows Ca2+ release from pools within mammalian cells, inducing major changes in endoplasmic reticulum function and cell growth. Recent studies characterized the pools of Ca2+ within permeabilized DC-3F/ TG2 cells (a thapsigargin-resistant variant form of the DC-3F Chinese hamster lung fibroblast line, able to grow in 2 mu M thapsigargin), revealing highly thapsigargin-resistant intracellular Ca2+ pumping activity capable of accumulating Ca2+ within an inositol 1,4,5-trisphosphate-releasable Ca2+ pool (Waldron, R. T., Short, A. D., and Gill, D. L. (1995) J. Biol. Chem. 270, 11955-11961). Using intact fura-a-loaded thapsigargin-resistant DC-3F/TG2 cells, the present study investigated the role of this unusual Ca2+ pumping activity in maintaining cytosolic Ca2+, generating Ca2+ signals, and mediating Ca2+ entry. The thapsigargin-resistant Ca2+ pumping pool was capable of generating rapid cytosolic Ca2+ signals in response to the phospholipase C-coupled agonist, oleoyl lysophosphatidic acid. The resting level of cytosolic Ca2+ in DC-3F/TG2 cells was a-fold elevated compared with control cells (the parent DC-3F line), and transient extracellular Ca2+ removal induced a large ''overshoot'' in cytosolic Ca2+. The overshoot response was blocked by the Ca2+ influx inhibitor, SKF96365, and was kinetically identical to that induced in parent DC-SF cells after thapsigargin-induced Ca2+ pool emptying, indicating that the thapsigargin-resistant DC-3F/TG2 cells had ''constitutively'' opened Ca2+ entry channels coupled to an emptied or partially emptied thapsigargin-sensitive Ca2+ pumping pool. Even though oleoyl lysophosphatidic acid-mediated Ca2+ release induced little Ca2+ entry, complete ionomycin-activated emptying of the thapsigargin-resistant Ca2+ pool in DC-3F/TG2 cells induced a large, sustained entry of Ca2+ that was also completely blocked by SKF96365. The results revealed that the thapsigargin-resistant Ca2+ pump does maintain physiological Ca2+ levels, is able to fill an agonist-responsive Ca2+ pool in DC-3F/TG2 cells, and is likely responsible for the ability of these cells to function and grow in the presence of thapsigargin, In addition, Ca2+ influx in the resistant DC-3F/TG2 cells reflects emptying of pools that accumulate Ca2+ by both thapsigargin-sensitive and -resistant Ca2+ pumps; since these pumps accumulate Ca2+ in distinct pools in parent DC-3F cells, it is possible that more than one pool is coupled to Ca2+ influx in the resistant DC-3F/TG2 cells.	UNIV MARYLAND,SCH MED,DEPT BIOCHEM & MOL BIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NHLBI NIH HHS [HL55426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; FURUYA Y, 1994, CANCER RES, V54, P6167; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILL DL, 1996, BIOSCIENCE REP, V26, P1; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOUZAU CA, 1996, J BIOL CHEM, V271, P14807; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1992, ANN NY ACAD SCI, V371, P1; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	39	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6440	6447		10.1074/jbc.272.10.6440	http://dx.doi.org/10.1074/jbc.272.10.6440			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045668	hybrid			2022-12-25	WOS:A1997WM64700052
J	Barsony, J; Renyi, I; McKoy, W				Barsony, J; Renyi, I; McKoy, W			Subcellular distribution of normal and mutant vitamin D receptors in living cells - Studies with a novel fluorescent ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; 1,25-DIHYDROXYVITAMIN-D3; CALRETICULIN; BINDING; LOCALIZATION; FIBROBLASTS; ASSOCIATION; PROTEIN	To understand the subcellular localization of the vitamin D receptor (VDR) and to measure VDR content in single cells, we recently developed a fluorescent labeled ligand, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-calcitriol. This tagged hormone has intact biological activity, high affinity and specific binding to the receptor, and enhanced fluorescent emission upon receptor binding. Using BODIPY-calcitriol, here we monitored the subcellular distribution of VDR in Living cultured cells by microscopy, Time course studies showed that an equilibrium between the cytoplasmic and nuclear hormone binding developed within 5 min and was maintained thereafter, We found a substantial proportion of VDR residing in the cytoplasm, colocalized with endoplasmic reticulum, the Golgi complex, and microtubules. Confocal microscopy clarified the presence of VDR within discrete regions of the nucleus and along the nuclear envelope, There was no VDR in the plasma membrane, Low affinity BODIPY-calcitriol binding sites were in the mitochondria. Mutations in the VDR gene selectively and specifically altered BODIPY-calcitriol distribution, Defects in the hormone binding region of VDR prevented both nuclear and cytoplasmic hormone binding, Defects in the DNA binding region decreased the nuclear retention of VDR and prevented localization to nuclear foci, These results with BODIPY-calcitriol reveal cytoplasmic VDR localization in living cells and open the possibility of studying the three-dimensional architecture of intranuclear target sites.			Barsony, J (corresponding author), NIDDK,NIH,LAB CELL BIOCHEM & BIOL,BETHESDA,MD 20892, USA.							ADAMS JS, 1984, J STEROID BIOCHEM, V20, P857, DOI 10.1016/0022-4731(84)90396-0; AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; AMIZUKA N, 1992, ARCH HISTOL CYTOL, V55, P77, DOI 10.1679/aohc.55.77; BALMAIN N, 1993, CELL MOL BIOL, V39, P339; BARAN DT, 1994, J CELL BIOCHEM, V56, P510, DOI 10.1002/jcb.240560411; BARSONY J, 1990, J CELL BIOL, V111, P2385, DOI 10.1083/jcb.111.6.2385; BARSONY J, 1991, P NATL ACAD SCI USA, V88, P1436, DOI 10.1073/pnas.88.4.1436; BARSONY J, 1992, J BIOL CHEM, V267, P24457; BARSONY J, 1989, J CLIN INVEST, V83, P2093, DOI 10.1172/JCI114122; BARSONY J, 1995, ANAL BIOCHEM, V229, P68, DOI 10.1006/abio.1995.1380; BERDAL A, 1995, INT J DEV BIOL, V39, P257; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; BRONSON DD, 1991, PROG HISTOCHEM CYTOC, V22, P1; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURNS K, 1993, FEBS LETT, V318, P181, DOI 10.1016/0014-5793(93)80017-O; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DEDHAR S, 1994, NATURE, V367, P482; DENG YP, 1995, J HISTOCHEM CYTOCHEM, V43, P907, DOI 10.1177/43.9.7543914; GORSKI J, 1986, RECENT PROG HORM RES, V42, P297; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; JAKOB F, 1992, J STEROID BIOCHEM, V42, P11, DOI 10.1016/0960-0760(92)90005-4; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; JOHNSON JA, 1995, CURR EYE RES, V14, P101, DOI 10.3109/02713689508999921; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; LIU LT, 1994, J AM SOC NEPHROL, V5, P1251; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NEMERE I, 1987, J BONE MINER RES, V2, P99; PERROTAPPLANAT M, 1992, CANCER SURV, V14, P5; PIKE JW, 1983, J BIOL CHEM, V258, P8554; PRATT B, 1994, STEROID HORMONE RECE, P215; SANTISOMERE D, 1993, MOL ENDOCRINOL, V7, P833, DOI 10.1210/me.7.7.833; SCHERRER LC, 1992, J STEROID BIOCHEM, V41, P719, DOI 10.1016/0960-0760(92)90411-B; SIMPSON RU, 1980, P NATL ACAD SCI-BIOL, V77, P5822, DOI 10.1073/pnas.77.10.5822; SONE T, 1990, MOL ENDOCRINOL, V4, P623, DOI 10.1210/mend-4-4-623; STARNAUD R, 1995, J CELL BIOL, V131, P1351, DOI 10.1083/jcb.131.5.1351; TERASAKI M, 1992, J CELL SCI, V101, P315; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; WIESE RJ, 1993, MOL CELL ENDOCRINOL, V90, P197, DOI 10.1016/0303-7207(93)90152-A; WINROW CJ, 1995, MOL CELL ENDOCRINOL, V111, P175, DOI 10.1016/0303-7207(95)03563-M	45	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5774	5782		10.1074/jbc.272.9.5774	http://dx.doi.org/10.1074/jbc.272.9.5774			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038191	hybrid			2022-12-25	WOS:A1997WK74700059
J	Dusetti, NJ; Vasseur, S; Ortiz, EM; Romeo, H; Dagorn, JC; Burrone, O; Iovanna, JL				Dusetti, NJ; Vasseur, S; Ortiz, EM; Romeo, H; Dagorn, JC; Burrone, O; Iovanna, JL			The pancreatitis-associated protein I promoter allows targeting to the pancreas of a foreign gene, whose expression is up-regulated during pancreatic inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADENOVIRUS TYPE-5; MESSENGER-RNA CLONING; PAP-I; RAT; IDENTIFICATION; REGION; INTESTINE; SERUM	The pancreatitis-associated protein I (PAP I) is a pancreatic secretory protein expressed in pancreas during acute pancreatitis but not in the healthy pancreas, The promoter of the PAP I gene thus represents a potential candidate to drive expression of therapeutic molecules to the diseased pancreas, In this work, we have constructed recombinant adenoviruses harboring the chloramphenicol acetyltransferase (CAT) gene driven by several fragments of the PAP I promoter and have characterized their properties in vitro and in vivo. In vitro studies showed that the transduction of the pancreatic cell line AR-42J with these adenoviruses led to low levels of CAT activity in basal conditions. After stimulation with a combination of interleukin-6 and dexamethasone or after induction of oxidative stress, CAT activity was strongly induced, a characteristic of the endogenous PAP I gene, Stimulation was maximal when constructs comprised 1253 base pairs of the PAP I promoter, upstream from initiation of transcription, and decreased with shorter fragments of 317, 180, 118 or 61 base pairs. The recombinant adenovirus containing the CAT gene under the control of the PAP I promoter fragment (-1253/+10) was also tested in vivo. Following administration by intravenous injection into mice, CAT activity was measured in several tissues 96 h later, In healthy animals, low but significant CAT activity was detected in pancreas, compared with near background values observed ill the other tissues. When experimental acute pancreatitis was induced, CAT expression was strongly enhanced only in pancreas. In control experiments with adenoviruses in which the CAT gene was driven by the cytomegalovirus promoter, higher levels of expression were observed in all tissues, Expression was not modified after induction of acute pancreatitis. In conclusion, this study shows that (i) a recombinant adenovirus containing a fragment of the PAP I promoter allows specific targeting of a reporter gene to the mouse pancreas and (ii) expression of the reporter gene in pancreas is induced during acute pancreatitis. Adenovirus-mediated gene therapy of acute pancreatitis is therefore conceivable.	U315 INSERM,F-13009 MARSEILLE,FRANCE; INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); International Center for Genetic Engineering & Biotechnology (ICGEB)			Iovanna, Juan/M-9805-2017; Dusetti, Nelson/O-7919-2017; vasseur, sophie/O-9803-2017	Iovanna, Juan/0000-0003-1822-2237; Dusetti, Nelson/0000-0002-6161-8483; vasseur, sophie/0000-0002-2339-8854				Banks Peter A., 1993, P593; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUSETTI NJ, 1995, BIOCHEM J, V307, P9, DOI 10.1042/bj3070009; DUSETTI NJ, 1995, BIOCHEM J, V311, P643, DOI 10.1042/bj3110643; DUSETTI NJ, 1994, BIOCHEM BIOPH RES CO, V204, P238, DOI 10.1006/bbrc.1994.2450; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; DUSETTI NJ, 1993, J BIOL CHEM, V268, P14470; FRIGERIO JM, 1993, BIOCHEMISTRY-US, V32, P9236, DOI 10.1021/bi00086a032; GALLYAS F, 1988, J HISTOCHEM CYTOCHEM, V36, P807, DOI 10.1177/36.7.2898497; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GYR KE, 1984, PANCREATITIS CONCEPT, P23; HUCH K, 1995, SCAND J GASTROENTERO, V30, P812, DOI 10.3109/00365529509096333; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; IOVANNA JL, 1993, AM J PHYSIOL, V265, pG611, DOI 10.1152/ajpgi.1993.265.4.G611; IOVANNA JL, 1994, GASTROENTEROLOGY, V106, P728, DOI 10.1016/0016-5085(94)90708-0; IOVANNA JL, 1991, AM J PHYSIOL, V261, pG485, DOI 10.1152/ajpgi.1991.261.3.G485; ITHO T, 1993, BIOCHIM BIOPHYS ACTA, V1172, P184; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; LAMPEL M, 1977, VIRCHOWS ARCH A, V373, P107; LASSERRE C, 1992, CANCER RES, V52, P5089; MASCIOTRA L, 1995, DIGEST DIS SCI, V40, P519, DOI 10.1007/BF02064359; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; ORELLE B, 1992, J CLIN INVEST, V90, P2284, DOI 10.1172/JCI116115; SAINIO V, 1995, LANCET, V346, P663, DOI 10.1016/S0140-6736(95)92280-6; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Stephanova E, 1996, CYTOGENET CELL GENET, V72, P83, DOI 10.1159/000134168; TANYALCIN T, 1995, EUR J CLIN CHEM CLIN, V33, P195; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1917, DOI 10.1016/0016-5085(95)90158-2	32	22	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5800	5804		10.1074/jbc.272.9.5800	http://dx.doi.org/10.1074/jbc.272.9.5800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038194	hybrid			2022-12-25	WOS:A1997WK74700062
J	Mao, SF; Neale, GAM; Goorha, RM				Mao, SF; Neale, GAM; Goorha, RM			T-cell proto-oncogene rhombotin-2 is a complex transcription regulator containing multiple activation and repression domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING PROTEIN; LIM-DOMAIN; STIMULATE TRANSCRIPTION; TRANSGENIC MICE; MOTIF; RBTN2; EXPRESSION; GLUTAMINE; LEUKEMIA; PROMOTER	The LIM domain protein rhombotin-2 (RBTN-2/TTG-2/LMO2) is involved in many processes, including leukemogenesis and erythropoiesis, It is thought that the principle role of RBTN-2 in these processes is to regulate transcription. To examine the potential for RBTN-8 to modulate transcription, we constructed RBTN-2/GAL4 DNA-binding domain fusion proteins and measured their ability to activate transcription of a reporter gene construct, From these studies we identified a transcription activation domain within the NH, terminus of RBTN-2, This activation domain was further localized within a proline-rich 19-amino acid region, A second activation domain of 11 amino acids was also identified. This domain was located within the COOH terminus of RBTN-8, and functioned in mammalian cells but not in yeast, Furthermore, the two LIM domains of RBTN-2 were shown to function as transcription repression domains. Each individual LIM domain acted as an independent transcription repression domain on a heterologous activation domain. However, in context of full-length RBTN-8, the LIM domains selectively repressed the NH2-terminal activation domain, but had no effect on the COOH-terminal domain, Overall, these results demonstrate that the T-cell oncogene RBTN-2 is a complex transcription factor possessing multiple transcription regulatory modules, including two activation domains and two repression domains.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOL BIOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [CA 43277, P30 CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA043277, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; HARPER JW, 1993, CELL, V75, P805; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KINGSTON RE, 1993, CURRENT PROTOCOLS MO; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LARSON RC, 1995, ONCOGENE, V11, P853; LARSON RC, 1994, ONCOGENE, V9, P3676; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; NEALE GAM, 1995, CELL GROWTH DIFFER, V6, P587; NEALE GAM, 1995, BLOOD, V86, P3060; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RIBEIRO RC, 1991, BLOOD, V78, P466; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUBLER MA, 1994, ONCOGENE, V9, P1351; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, J MOL BIOL, V226, P747; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	44	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5594	5599		10.1074/jbc.272.9.5594	http://dx.doi.org/10.1074/jbc.272.9.5594			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038167	hybrid			2022-12-25	WOS:A1997WK74700035
J	Schlott, B; Guhrs, KH; Hartmann, M; Rocker, A; Collen, D				Schlott, B; Guhrs, KH; Hartmann, M; Rocker, A; Collen, D			Staphylokinase requires NH2-terminal proteolysis for plasminogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT STAPHYLOKINASE; ESCHERICHIA-COLI; HUMAN PLASMA; GENE; EXPRESSION; PROTEINS	Staphylokinase (Sak), a single-chain protein comprising 136 amino acids with NH2-terminal sequence, [GRAPHICS] forms a complex with plasmin, that is endowed with plasminogen activating properties, Plasmin is presumed to process mature (high molecular weight, HMW) Sak to low molecular weight derivatives (LMW-Sak), primarily by hydrolyzing the Lys(10)-Lys(11) peptide bond, but the kinetics of plasminogen activation by HMW-Sak and LMW-Sak are very similar. Here, the requirement of NH2-terminal proteolysis of Sak for the induction of plasminogen activating potential was studied by mutagenesis of Lys(10) and Lys(11) in combination with NH2-terminal microsequence analysis of equimolar mixtures of Sak and plasminogen and determination of kinetic parameters of plasminogen activation by catalytic amounts of Sak, Substitution of Lys(10) with Arg did not affect processing of the Arg(10)-Lys(11) site nor plasminogen activation, whereas substitution with His resulted in cleavage of the Lys(11)-Gly(12) peptide bond and abolished plasminogen activation. Substitution of Lys(11) with Arg did not affect Lys(10)-Arg(11) processing or plasminogen activation, whereas replacement with His did not prevent Lys(10)-His(11) hydrolysis but abolished plasminogen activation, Substitution of Lys(11) with Cys yielded ale inactive processed derivative which was fully activated by aminoethylation. Deletion of the 10 NH2-terminal amino acids did not affect plasminogen activation, but additional deletion of Lys(11) eliminated plasminogen activation. Thus generation of plasminogen activator potential in Sak proceeds via plasmin-mediated removal of the 10 NH2-terminal amino acids with exposure of Lys(11) as the new NH2 terminus, This provides a structural basis for the hypothesis, derived from kinetic measurements, that plasminogen activation by Sak needs to be primed by plasmin and a mechanism for the high fibrin selectivity of Sak in a plasma milieu.	CATHOLIC UNIV LEUVEN,CTR MOL & VASC BIOL,B-3000 LOUVAIN,BELGIUM	KU Leuven	Schlott, B (corresponding author), INST MOL BIOTECHNOL,D-07745 JENA,GERMANY.			Guehrs, Karl-Heinz/0000-0001-8847-1365				BEHNKE D, 1987, MOL GEN GENET, V210, P528, DOI 10.1007/BF00327208; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; Collen D, 1996, CIRCULATION, V93, P857, DOI 10.1161/01.CIR.93.5.857; COLLEN D, 1992, FIBRINOLYSIS, V6, P226, DOI 10.1016/0268-9499(92)90075-S; COLLEN D, 1994, BLOOD, V84, P680, DOI 10.1182/blood.V84.3.680.680; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Gase A, 1996, THROMB HAEMOSTASIS, V76, P755; HOFMANN T, 1964, BIOCHEMISTRY-US, V3, P356, DOI 10.1021/bi00891a010; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jonsson U., 1992, ADV BIOSENSOR, P291; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P214, DOI 10.1016/0268-9499(92)90074-R; Lijnen HR, 1996, FIBRINOLYSIS, V10, P119, DOI 10.1016/S0268-9499(96)80022-1; *PHARM BIOS AB, 1991, BIAC SYST MAN; SACHAROV DV, 1996, J BIOL CHEM, V271, P27912; SAKO T, 1985, EUR J BIOCHEM, V149, P557, DOI 10.1111/j.1432-1033.1985.tb08961.x; SAKO T, 1983, NUCLEIC ACIDS RES, V11, P7679, DOI 10.1093/nar/11.22.7679; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLOTT B, 1994, BIO-TECHNOL, V12, P185, DOI 10.1038/nbt0294-185; UESHIMA S, 1993, THROMB HAEMOSTASIS, V70, P495; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2050, DOI 10.1161/01.CIR.92.8.2050	25	41	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6067	6072		10.1074/jbc.272.9.6067	http://dx.doi.org/10.1074/jbc.272.9.6067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038231	hybrid			2022-12-25	WOS:A1997WK74700099
J	Silberman, S; Janulis, M; Schultz, RM				Silberman, S; Janulis, M; Schultz, RM			Characterization of downstream ras signals that induce alternative protease-dependent invasive phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR GENE; NIH 3T3 CELLS; HUMAN UROKINASE ENHANCER; EPIDERMAL GROWTH-FACTOR; MAP KINASE KINASE; C-JUN; CATHEPSIN-L; TRANSCRIPTION FACTORS; EXPERIMENTAL METASTASIS; IN-VITRO	Invasive and metastatic cells require protease expression for migration through the extracellular matrix. Metastatic NIH 3T3 fibroblasts transformed by different activated ras genes showed two different protease phenotypes, ras(UPA+/CL-) and ras(CL+/uPA-) (Zhang, J-Y,, and Schultz, R. M. (1992) Cancer Research 52, 6682-6689). Phenotype ras(uPA+/CL-) is dependent ras the serine-type protease urokinase plasminogen activator (uPA) and the phenotype ras(CL+/uPA-) on the cystine-type protease cathepsin L (CL) for lung colonization in experimental metastasis, The existence of multiple invasive phenotypes on ras-isoform transformation implied the activation of alternative pathways downstream from Ras. We now show that c-Raf-1, extracellular signal-regulated protein kinase (ERK)-1, and ERK-2 are hyperphosphorylated, and the ERK activity is high in both the uPA- and CL-dependent ras-transformed invasive phenotypes. Levels of c-Jun and c-Jun NH2-terminal kinase (JNK) activity are also high in the uPA-dependent phenotype, but they are almost undetectable in the CL-dependent phenotype, The uPA Ras-response element is a PEA3/URTF element, and mobility shift assays show a strong PEA3/URTF protein band in the uPA-dependent phenotype. This band is competed by a consensus AP-1 DNA sequence and by antibodies to PEA3 and c-Jun, Thus, the uPA-invasive phenotype appears to require the activation of Ets/PEA3 and c-Jun transcription factors activated by the ERK and JNK pathways, while the CL-invasive phenotype appears to require ERK activity with suppression of JNK and c-Jun activities. These postulates are supported by the introduction of a dominant negative c-Jun, TAM67, into cells of phenotype ras(uPA+/CL-), which down-regulated the high uPA mRNA levels characteristic of this phenotype to basal levels and up-regulated basal levels of CL mRNA to levels similar to those observed in cells of phenotype ras(CL+/uPA-). We conclude that the JNK pathway acts as ras a switch between two distinct protease phenotypes that are redundant in their abilities to grow tumors and metastasize.	LOYOLA UNIV, STRITCH SCH MED, DEPT MOL & CELLULAR BIOCHEM, MAYWOOD, IL 60153 USA; LOYOLA UNIV, STRITCH SCH MED, DEPT PATHOL, MAYWOOD, IL 60153 USA	Loyola University Chicago; Loyola University Chicago								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BLEI F, 1993, J CELL PHYSIOL, V155, P568, DOI 10.1002/jcp.1041550315; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHAUHAN SS, 1991, CANCER RES, V51, P1478; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, METHOD ENZYMOL, V238, P277; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DECESARE D, 1995, ONCOGENE, V11, P365; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; Dehrmann FM, 1995, ARCH BIOCHEM BIOPHYS, V324, P93, DOI 10.1006/abbi.1995.9924; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRAHAM CH, 1992, BIOCHEM CELL BIOL, V70, P867, DOI 10.1139/o92-135; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HEIDTMANN HH, 1993, ONCOL RES, V5, P441; HIGASHINO F, 1995, ONCOGENE, V10, P1461; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JS, 1994, J BIOL CHEM, V269, P2887; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Leonardsson G, 1995, P NATL ACAD SCI USA, V92, P12446, DOI 10.1073/pnas.92.26.12446; LISON D, 1993, INT J ANDROL, V16, P201, DOI 10.1111/j.1365-2605.1993.tb01180.x; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, METHOD ENZYMOL, V255, P273; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARSHALLHEYMAN H, 1994, ONCOGENE, V9, P3655; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MINATO T, 1994, J BIOL CHEM, V269, P20845; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NERLOV C, 1991, ONCOGENE, V6, P1583; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PARANJPE M, 1980, LIFE SCI, V26, P1223, DOI 10.1016/0024-3205(80)90067-3; REDDY GK, 1992, INT J BIOCHEM, V24, P1465; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROMANIC AM, 1994, BRAIN PATHOL, V4, P145, DOI 10.1111/j.1750-3639.1994.tb00825.x; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SETH A, 1992, J BIOL CHEM, V267, P24796; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU H, 1990, CANCER RES, V50, P7623; ZHANG JY, 1992, CANCER RES, V52, P6682	72	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5927	5935		10.1074/jbc.272.9.5927	http://dx.doi.org/10.1074/jbc.272.9.5927			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038212	hybrid			2022-12-25	WOS:A1997WK74700080
J	Stoops, JK; Cheng, RH; Yazdi, MA; Maeng, CY; Schroeter, JP; Klueppelberg, U; Kolodziej, SJ; Baker, TS; Reed, LJ				Stoops, JK; Cheng, RH; Yazdi, MA; Maeng, CY; Schroeter, JP; Klueppelberg, U; Kolodziej, SJ; Baker, TS; Reed, LJ			On the unique structural organization of the Saccharomyces cerevisiae pyruvate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYOELECTRON MICROSCOPY; ESCHERICHIA-COLI; X-RAY; LIPOAMIDE DEHYDROGENASE; PROTEIN-X; RESOLUTION; SUBUNIT; VIRUS; CORE	Dihydrolipoamide acyltransferase (E(2)), and structural component of the three classes of multienzyme complexes that catalyze the oxidative decarboxylation of alpha-keto acids, forms the central core to which the other components attach, We have determined the structures of the truncated 60-mer core dihydrolipoamide acetyltransferase (tE(2)) of the Saccharomyces cerevisiae pyruvate dehydrogenase complex and complexes of the tE(2) core associated with a truncated binding protein (tBP), intact binding protein (BP), and the BP associated with its dihydrolipoamide dehydrogenase (BP . E(3)). The tE(2) core is a pentagonal dodecahedron consisting of 20 cone-shaped trimers interconnected by 30 bridges, Previous studies have given rise to the generally accepted belief that the other components are bound on the outside of the E(2) scaffold, However, this investigation shows that the 12 large openings in the tE(2) core permit the entrance of tBP, BP, and BP . E(3) into a large central cavity where the BP component apparently binds near the tip of the tE(2) trimer, The bone-shaped E(3) molecule is anchored inside the central cavity through its interaction with BP, One end of E(3) as its catalytic site within the surface of the scaffold for interaction with other external catalytic domains, Though tE(2) has 60 potential binding sites, it binds only about 30 copies of tBP, 15 of BP, and 12 of BP . E(3). Thus, E(2) is unusual in that the stoichiometry and arrangement of the tBP, BP, and E(3) . BP components are determined by the geometric constraints of the underlying scaffold.	UNIV TEXAS, HLTH SCI CTR, LAB MED, HOUSTON, TX 77030 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV TEXAS, INST BIOCHEM, AUSTIN, TX 78712 USA; UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Health Science Center Houston; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Stoops, JK (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, HOUSTON, TX 77030 USA.		Cheng, Holland/A-8973-2008	, Timothy/0000-0001-6543-8968	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050, R01GM033050, R01GM046278, R01GM006590] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42866] Funding Source: Medline; NIGMS NIH HHS [GM 46278, R37 GM033050, GM 06590] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BEALE EML, 1988, INTRO OPTIMIZATION, P26; BELNAP DM, 1993, ULTRAMICROSCOPY, V48, P347, DOI 10.1016/0304-3991(93)90110-J; CHENG RH, 1995, CELL, V80, P621; CHENG RH, 1994, STRUCTURE, V2, P271; CHENG RH, 1992, P ELEC MICROSC SOC A, V50, P996; DEROSIER DJ, 1971, P NATL ACAD SCI USA, V68, P1135, DOI 10.1073/pnas.68.6.1135; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FULLER CC, 1979, BIOCHEM BIOPH RES CO, V90, P431, DOI 10.1016/0006-291X(79)91253-1; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; GONZALEZ RC, 1987, DIGITAL IMAGE PROCES, P425; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GUEST JR, 1989, ANN N Y ACAD SCI, V573, P76; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; KOETZLE TF, 1987, CRYSTALLOGRAPHIC DAT, P107; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Maeng CY, 1996, BIOCHEMISTRY-US, V35, P5879, DOI 10.1021/bi9600254; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; NEAGLE JC, 1991, BIOCHEM J, V278, P423, DOI 10.1042/bj2780423; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; TAKENAKA A, 1988, J BIOCHEM-TOKYO, V103, P463, DOI 10.1093/oxfordjournals.jbchem.a122293; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; WAGENKNECHT T, 1990, J BIOL CHEM, V265, P22402; YANG H, 1986, BIOPHYS J, V49, P56, DOI 10.1016/S0006-3495(86)83591-3; YANG H, 1985, J BIOL CHEM, V260, P6049	34	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5757	5764		10.1074/jbc.272.9.5757	http://dx.doi.org/10.1074/jbc.272.9.5757			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038189	Green Accepted, hybrid			2022-12-25	WOS:A1997WK74700057
J	Wasylyk, C; Bradford, AP; GutierrezHartmann, A; Wasylyk, B				Wasylyk, C; Bradford, AP; GutierrezHartmann, A; Wasylyk, B			Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2	ONCOGENE			English	Article						MAP kinase; auto-inhibition; DNA-binding; Drosophila; vertebrates	PROTEIN SECONDARY STRUCTURE; TERNARY COMPLEX FACTORS; DNA-BINDING ACTIVITY; GENE FAMILY; V-ETS; DOMAIN PROTEIN; C-FOS; ONCOGENIC CONVERSION; NEURAL NETWORKS; DROSOPHILA EYE	Cell transformation by the Pas oncogene is mediated by members of the ets gene family, To analyse the mechanisms of regulation, we have studied activation of several ets factors by Pas expression, We show that expression of Ha-Pas strongly activates the Ets1 p68 and p54 isoforms and Ets2 in F9 EC cells. We have mapped the Pas responsive elements of Ets1 p68 to two domains, RI+II and RIII. Mutation of threonine 82 to alanine in RI+II abolishes both Pas activation and phosphorylation by MAP kinase. Threonine 82 is part of a sequence that is conserved in Drosophila Pointed P2, an ets protein that has been shown both genetically and biochemically to mediate Pas signalling in Drosophila cells. We extend the comparison of these evolutionary related proteins by showing that Pointed P2 is activated by Pas in mammalian cells and mutation of the homologous threonine abolishes activation. Furthermore, we show that Pointed P2 resembles Ets1, in that it has conserved sequences in a similar position adjacent to the ets DNA binding domain that negatively auto-regulates DNA binding. These results go towards showing that the Drosophila Pointed and vertebrate Ets1 are evolutionary related proteins that have remarkably conserved Pas regulatory mechanisms downstream from MAP kinase.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wasylyk, C (corresponding author), UNIV LOUIS PASTEUR STRASBOURG 1, CNRS, INSERM, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.		Wasylyk, Bohdan/ABG-6778-2020; Gutierrez-Hartmann, Arthur/F-1295-2011	Wasylyk, Bohdan/0000-0002-1718-1237; 				ALBAGLI O, 1994, ONCOGENE, V9, P3259; ALBAGLI O, 1992, ONCOGENE, V7, P1435; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COFFER P, 1994, ONCOGENE, V9, P911; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GEGONNE A, 1992, NEW BIOL, V4, P512; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KIARIS H, 1995, INT J ONCOL, V7, P413; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QUEVA C, 1993, ONCOGENE, V8, P2511; RABAULT B, 1994, J BIOL CHEM, V269, P28143; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROSS IL, 1994, ONCOGENE, V9, P121; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VALENTINE MA, 1995, J EXP MED, V182, P1943, DOI 10.1084/jem.182.6.1943; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2	78	93	96	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					899	913		10.1038/sj.onc.1200914	http://dx.doi.org/10.1038/sj.onc.1200914			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050989				2022-12-25	WOS:A1997WK34400003
J	diRago, JP; Sohm, F; Boccia, C; Dujardin, G; Trumpower, BL; Slonimski, PP				diRago, JP; Sohm, F; Boccia, C; Dujardin, G; Trumpower, BL; Slonimski, PP			A point mutation in the mitochondrial cytochrome b gene obviates the requirement for the nuclear encoded core protein 2 subunit in the cytochrome bc(1) complex in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME QH2-CYTOCHROME-C REDUCTASE; C OXIDOREDUCTASE COMPLEX; RANGE CONTROL-CIRCUITS; PROTONMOTIVE Q-CYCLE; PROCESSING PEPTIDASE; ENERGY TRANSDUCTION; YEAST MITOCHONDRIA; DEFICIENT MUTANTS; ELECTRON-TRANSFER; MEMBRANE SYSTEM	A yeast mutant (cor2-45) in which approximately half of the C terminus of core protein 2 of the cytochrome bc(1) complex is lacking due to a frameshift mutation that introduces a stop at codon 197 in the COR2 gene fails to assemble the cytochrome bc(1) complex and does not grow on non-fermentable carbon sources that require respiration. The loss of respiration is more severe with this frameshift mutation than with the complete deletion of the COR2 gene, suggesting deleterious effects of the truncated core 2 protein. A search for extragenic suppressors of the nuclear cor2-45 mutation resulted (in addition to the expected nuclear suppressors) in the isolation of a suppressor mutation in the mitochondrial DNA that replaces serine 223 by proline in cytochrome b. Assembly of the cytochrome bc(1) complex and the respiratory deficient phenotype of the cor2-45 mutant are restored by the proline for serine replacement in cytochrome b. Surprisingly, this amino acid replacement in cytochrome b corrects not only the phenotype resulting from the cor2-45 frameshift mutation, but it also obviates the need for core protein 2 in the cytochrome bc(1) complex since it alleviates the respiratory deficiency resulting from the complete deletion of the COR2 gene. This is the first report of a homoplasmic missense point mutation of the mitochondrial DNA acting as a functional suppressor of a mutation located in a nuclear gene and the first demonstration that the supernumerary core protein 2 subunit is not essential for the electron transfer and energy transducing functions of the mitochondrial cytochrome bc(1) complex.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College	diRago, JP (corresponding author), UNIV PARIS 06,CTR GENET MOL,CNRS,AVE TERRASSE,F-91190 GIF SUR YVETTE,FRANCE.				NIGMS NIH HHS [GM20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUSQUET I, 1990, CURR GENET, V18, P117, DOI 10.1007/BF00312599; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; CLAISSE ML, 1974, EUR J BIOCHEM, V49, P49, DOI 10.1111/j.1432-1033.1974.tb03810.x; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COPPEE JY, 1994, FEBS LETT, V339, P1, DOI 10.1016/0014-5793(94)80373-0; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DIRAGO JP, 1995, J MOL BIOL, V248, P804, DOI 10.1006/jmbi.1995.0261; DIRAGO JP, 1990, FEBS LETT, V263, P93, DOI 10.1016/0014-5793(90)80713-S; DIRAGO JP, 1993, FEBS LETT, V328, P153, DOI 10.1016/0014-5793(93)80984-3; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; DUJARDIN G, 1980, MOL GEN GENET, V179, P469, DOI 10.1007/BF00271736; EMMERMANN M, 1994, MOL GEN GENET, V245, P237, DOI 10.1007/BF00283272; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GRAHAM LA, 1991, J BIOL CHEM, V266, P2248; GROUDINSKY O, 1981, MOL GEN GENET, V184, P493, DOI 10.1007/BF00352529; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; JANSCH L, 1995, EUR J BIOCHEM, V228, P878, DOI 10.1111/j.1432-1033.1995.tb20335.x; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1993, TRENDS BIOCHEM SCI, V18, P249, DOI 10.1016/0968-0004(93)90174-L; KARLSSON B, 1983, J MOL BIOL, V165, P287, DOI 10.1016/S0022-2836(83)80258-7; KOTYLAK Z, 1977, MITOCHONDRIA 1977, P161; KRUSZEWSKA A, 1980, CURR GENET, V2, P45, DOI 10.1007/BF00445693; KRUSZEWSKA A, 1984, CURR GENET, V9, P1, DOI 10.1007/BF00396198; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NETTER P, 1995, MOL GEN GENET, V246, P445, DOI 10.1007/BF00290448; OUDSHOORN P, 1987, EUR J BIOCHEM, V163, P97, DOI 10.1111/j.1432-1033.1987.tb10741.x; PUTRAMENT A, 1973, MOL GEN GENET, V126, P357, DOI 10.1007/BF00269445; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; SLONIMSKI PP, 1976, EUR J BIOCHEM, V73, P276; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; WYNN RM, 1986, PHOTOSYNTH RES, V9, P181, DOI 10.1007/BF00029743; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG XH, 1986, J BIOL CHEM, V261, P2282; YANG XH, 1988, J BIOL CHEM, V263, P11962; YUN CH, 1991, J BIOL CHEM, V266, P10967	52	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4699	4704		10.1074/jbc.272.8.4699	http://dx.doi.org/10.1074/jbc.272.8.4699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030521	hybrid			2022-12-25	WOS:A1997WJ85500009
J	Elsner, A; Engert, H; Saenger, W; Hamoen, L; Venema, G; Bernhard, F				Elsner, A; Engert, H; Saenger, W; Hamoen, L; Venema, G; Bernhard, F			Substrate specificity of hybrid modules from peptide synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; ATP-BINDING-SITE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TYROCIDINE SYNTHETASE-1; NUCLEOTIDE-BINDING; ACTIVATING DOMAIN; MOLECULAR CHARACTERIZATION; GENE; EXPRESSION	Homologous modules from two different peptide synthetases were analyzed for functionally equivalent regions. Hybrids between the coding regions of the phenylalanine-activating module of tyrocidine synthetase and the valine activating module of surfactin synthetase were constructed by combining the two reading frames at various highly conserved consensus sequences, The resulting DNA fragments were expressed in Escherichia coli as C-terminal fusions to the gene encoding for the maltose-binding protein, The fusion proteins were purified, and the amino acid specificities, the acceptance of different nucleotide analogues, and the substrate binding affinities were analyzed, We found evidence for a large N-terminal domain and a short C-terminal domain of about 19 kDa within the two modules, which are separated by the sequence motif GELCIGG, The two domains could be reciprocally transferred between the two modules, and the constructed hybrid proteins showed amino acid adenylating activity. Hybrid proteins fused at various consensus motifs within the two domains were inactive, indicating that the domains may fold independently and represent complex functional units, The N-terminal domain was found to be responsible for the amino acid specificity of the modules, and it is also involved in the recognition of the ribosyl and the phosphate moieties of the nucleotide substrate, For tyrocidine synthetase I, we could confine the sites for amino acid specificity to a region of 330 residues, The C-terminal domain is essential for the enzymatic activity and has a strong impact on the specific activity of the modules.	FREE UNIV BERLIN,INST KRISTALLOG,D-14195 BERLIN,GERMANY; UNIV GRONINGEN,DEPT GENET,NL-9751 NN HAREN,NETHERLANDS	Free University of Berlin; University of Groningen				Bernhard, Frank/0000-0002-4860-1783				BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BERNHARD F, 1996, DNA SEQUENCE, V6, P315; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; EGGEN RIL, 1991, J BACTERIOL, V173, P6383, DOI 10.1128/jb.173.20.6383-6389.1991; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FULDA M, 1994, MOL GEN GENET, V242, P241, DOI 10.1007/BF00280412; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HAMOEN LW, 1995, MOL MICROBIOL, V15, P55, DOI 10.1111/j.1365-2958.1995.tb02220.x; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KRAUSE M, 1985, J BACTERIOL, V162, P1120, DOI 10.1128/JB.162.3.1120-1125.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; MARAHIEL MA, 1985, MOL GEN GENET, V201, P231, DOI 10.1007/BF00425664; MENKHAUS M, 1993, J BIOL CHEM, V268, P7678; MITTENHUBER G, 1989, J BACTERIOL, V171, P4881, DOI 10.1128/jb.171.9.4881-4887.1989; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PAVELAVRANCIC M, 1994, EUR J BIOCHEM, V220, P535, DOI 10.1111/j.1432-1033.1994.tb18653.x; PAVELAVRANCIC M, 1994, J BIOL CHEM, V269, P14962; Sambrook J., 2002, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; TOKITA K, 1993, J BIOCHEM-TOKYO, V114, P522, DOI 10.1093/oxfordjournals.jbchem.a124210; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; ULLRICH C, 1991, BIOCHEMISTRY-US, V30, P6503, DOI 10.1021/bi00240a022; VANLIEMPT H, 1991, BIOMED BIOCHIM ACTA, V50, P256; VANSINDEREN D, 1993, MOL MICROBIOL, V8, P833; VOLLENBROICH D, 1993, FEBS LETT, V325, P220, DOI 10.1016/0014-5793(93)81077-D; VOLLENBROICH D, 1994, J BACTERIOL, V176, P395, DOI 10.1128/JB.176.2.395-400.1994; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841	43	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4814	4819		10.1074/jbc.272.8.4814	http://dx.doi.org/10.1074/jbc.272.8.4814			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030537	hybrid			2022-12-25	WOS:A1997WJ85500025
J	Garvey, EP; Oplinger, JA; Furfine, ES; Kiff, RJ; Laszlo, F; Whittle, BJR; Knowles, RG				Garvey, EP; Oplinger, JA; Furfine, ES; Kiff, RJ; Laszlo, F; Whittle, BJR; Knowles, RG			1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; POTENT; PURIFICATION; ISOFORM; AMINOGUANIDINE; ISOTHIOUREAS; ANTAGONISTS; ENDOTOXIN	N-(3-(Aminomethyl)benzyl)acetamidine (1400W) was a slow, tight binding inhibitor of human inducible nitric-oxide synthase (iNOS), The slow onset of inhibition by 1400W showed saturation kinetics with a maximal rate constant of 0.028 s(-1) and a binding constant of 2.0 mu M. Inhibition was dependent on the cofactor NADPH. L-Arginine was a competitive inhibitor of 1400W binding with a K-s value of 3.0 mu M Inhibited enzyme did not recover activity after 2 h. Thus, 1400W was either an irreversible inhibitor or an extremely slowly reversible inhibitor of human iNOS with a K-d value less than or equal to 7 nM. In contrast, inhibition of human neuronal NOS and endothelial NOS (eNOS) was relatively weaker, rapidly reversible, and competitive with L-arginine, with Ri values of 2 mu M and 50 mu M, respectively, Thus, 1400W was at least 5000-fold selective for MOS versus eNOS. This selectivity was similar to that observed in rat aortic rings, in which 1400W was greater than 1000-fold more potent against rat iNOS than eNOS. Finally, 1400W was greater than 50-fold more potent against iNOS than eNOS in a rat model of endotoxin-induced vascular injury. Thus, the potency and selectivity of 1400W inhibition of iNOS both in vitro and in vivo were far greater than of any previously described iNOS inhibitor.	GLAXO WELLCOME INC, DIV MED CHEM, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME RES & DEV LTD, DEPT PHARMACOL, BECKENHAM BR3 3BS, KENT, ENGLAND	GlaxoSmithKline; GlaxoSmithKline	Garvey, EP (corresponding author), GLAXO WELLCOME INC, DIV BIOCHEM, RES TRIANGLE PK, NC 27709 USA.							BAEK KJ, 1993, J BIOL CHEM, V268, P21120; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; DUSHAK VG, 1968, FARMAKOL TOKSIKOL, V4, P62; FASTIER FN, 1962, PHARMACOL REV, V14, P37; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GARVEY EP, 1994, ARCH BIOCHEM BIOPHYS, V311, P235, DOI 10.1006/abbi.1994.1232; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; Garvey EP, 1996, METHOD ENZYMOL, V268, P339; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HENERSHOT LC, 1958, J PHARMACOL EXP THER, V123, P1; HOVING S, 1995, J BIOL CHEM, V270, P29788; LASZLO F, 1994, BRIT J PHARMACOL, V111, P1309, DOI 10.1111/j.1476-5381.1994.tb14887.x; LASZLO F, 1995, EUR J PHARMACOL, V272, P169, DOI 10.1016/0014-2999(94)00637-M; Laubach VE, 1996, BIOCHEM BIOPH RES CO, V218, P802, DOI 10.1006/bbrc.1996.0143; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore WM, 1996, J MED CHEM, V39, P669, DOI 10.1021/jm950766n; NAKANE M, 1995, MOL PHARMACOL, V47, P831; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; OLKEN NM, 1992, J MED CHEM, V35, P1137, DOI 10.1021/jm00084a020; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P823; OR E, 1993, J BIOL CHEM, V268, P16929; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SOUTHAN GJ, 1995, BRIT J PHARMACOL, V114, P510, DOI 10.1111/j.1476-5381.1995.tb13256.x; STUEHR DJ, 1992, ADV ENZYMOL, V65, P287; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040	29	741	753	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4959	4963		10.1074/jbc.272.8.4959	http://dx.doi.org/10.1074/jbc.272.8.4959			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030556	hybrid			2022-12-25	WOS:A1997WJ85500044
J	Leventhal, PS; Shelden, EA; Kim, B; Feldman, EL				Leventhal, PS; Shelden, EA; Kim, B; Feldman, EL			Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR-MATRIX; TRANSFORMED-CELLS; FACTOR RECEPTOR; HUMAN TUMORS; CULTURE; FIBROBLASTS; EXPRESSION; CYTOSKELETAL	In the current studies, we examined whether focal adhesion kinase (FAK) and paxillin play a role in insulin-like growth factor-I (IGF-I)-stimulated morphological changes in neuronal cells, In SH-SY5Y human neuroblastoma cells, 10 nM IGF-I enhanced the extension of lamellipodia within 30 min, Scanning electron microscopy and staining with rhodamine-phalloidin showed that these lamellipodia displayed ruffles, filopodia, and a distinct meshwork of actin filaments, Immunofluorescent staining identified focal concentrations of FAK, paxillin, and phosphotyrosine within the lamellipodia, Immunoprecipitation experiments revealed that FAK and paxillin are tyrosine phosphorylated during IGF-I-stimulated lamellipodial extension, Maximal phosphorylation of FAK and paxillin was observed 15-30 min after the addition of 10 nM IGF-I, whereas maximal IGF-I receptor phosphorylation occurred within 5 min, FAK, paxillin, and IGF-I receptor tyrosine phosphorylation had similar concentration-response curves and were inhibited by the receptor blocking antibody alpha IR-3. These results indicate that FAK and paxillin are tyrosine-phosphorylated during IGF-I-stimulated lamellipodial advance and suggest that the tyrosine phosphorylation of these two proteins helps mediate IGF-I stimulated cell and growth cone motility, These responses contrast directly with recent reports showing insulin-stimulated dephosphorylation of FAK and paxillin.	UNIV MICHIGAN, DEPT NEUROL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			, Eric/GWC-7636-2022	Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [1F32NS09912-01, NS32843] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032843, F32NS009912] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4; ABERCROMBIE M, 1970, EXP CELL RES, V60, P437, DOI 10.1016/0014-4827(70)90537-9; ABERCROMBIE M, 1970, EXP CELL RES, V59, P393, DOI 10.1016/0014-4827(70)90646-4; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CHENG TPO, 1992, EXP CELL RES, V203, P25, DOI 10.1016/0014-4827(92)90035-7; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLEMMONS DR, 1994, INT CONGR SER, V1056, P183; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DAUGHADAY WH, 1992, INSULIN LIKE GROWTH, P5; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; GOLDBERG DJ, 1986, J CELL BIOL, V103, P1921, DOI 10.1083/jcb.103.5.1921; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; ISHII DN, 1987, INSULIN IGFS THEIR R, P315; IZZARD CS, 1980, J CELL SCI, V42, P81; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KLEITMAN N, 1989, CELL MOTIL CYTOSKEL, V13, P288, DOI 10.1002/cm.970130407; KOLEGA J, 1982, J CELL SCI, V54, P23; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; MARTIN DM, 1993, J CELL PHYSIOL, V155, P290, DOI 10.1002/jcp.1041550210; MARTIN DM, 1993, REGUL PEPTIDES, V48, P255; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OWENS LV, 1995, CANCER RES, V55, P2752; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; SANKAR S, 1995, AM J PATHOL, V147, P601; SIDDLE K, 1994, HORM RES, V41, pS56; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; Tobe K, 1996, MOL CELL BIOL, V16, P4765; VanderZon GCM, 1996, BIOCHEMISTRY-US, V35, P10377, DOI 10.1021/bi960350r; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wu DY, 1996, J NEUROSCI, V16, P1470	50	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5214	5218		10.1074/jbc.272.8.5214	http://dx.doi.org/10.1074/jbc.272.8.5214			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030591	hybrid			2022-12-25	WOS:A1997WJ85500079
J	Wu, LNY; Genge, BR; Dunkelberger, DG; LeGeros, RZ; Concannon, B; Wuthier, RE				Wu, LNY; Genge, BR; Dunkelberger, DG; LeGeros, RZ; Concannon, B; Wuthier, RE			Physicochemical characterization of the nucleational core of matrix vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-PLATE CARTILAGE; EPIPHYSEAL CARTILAGE; CALCIUM PHOSPHATES; ALKALINE-PHOSPHATASE; MINERAL PHASES; BONE; CALCIFICATION; SPECTROSCOPY; MEMBRANE; COMPLEX	While previous studies revealed that matrix vesicles (MV) contain a nucleational core (NC) that converts to apatite when incubated with synthetic cartilage lymph, the initial mineral phase present in MV is not well characterized. This study explored the physicochemical nature of this Ca2+ and P-i-rich NC. MV, isolated from growth plate cartilage, were analyzed directly by solid-state P-31 NMR, or incubated with hydrazine or NaOCl to remove organic constituents. Other samples of MV were subjected to sequential treatments with enzymes, salt solutions, and detergents to expose the NC. We examined the NC using transmission electron microscopy, energy-dispersive analysis with x-rays, and electron and x-ray diffraction, Fourier transform-infrared spectroscopy, high performance thin-layer chromatographic analysis, and SDS-polyacrylamide gel electrophoresis, We found that most of the MV proteins and lipids could be removed without destroying the NC; however, NaOCl treatment annihilated its activity. SDS-polyacrylamide gel electrophoresis showed that annexin V, a phosphatidylserine (PS)-dependent Ca2+-binding protein, was the major protein in the NC; high performance thin-layer chromatographic analysis revealed that the detergents removed the majority of the polar lipids, but left significant free cholesterol and fatty acids, and small but critical amounts of PS. Transmission electron microscopy showed that the NC was composed of clusters of similar to 1.0 nm subunits, which energy-dispersive analysis with x-rays revealed contained Ca and P-i with a Ca/P ratio of 1.06 +/- 0.01, Electron diffraction, x-ray diffraction, and Fourier transform-infrared analysis all indicated that the NC was noncrystalline. H-1-Cross-polarization P-31 MMR indicated that the solid phase of MV was an HPO42--rich mixture of amorphous calcium phosphate and a complex of PS, Ca2+, and P-i, Taken together, our findings indicate that the NC of MV is composed of an acid-phosphate-rich amorphous calcium phosphate intermixed with PS-Ca2+-P-i, annexin V, and other proteins and lipids.	UNIV S CAROLINA, PHYS SCI CTR 424A, DEPT CHEM & BIOCHEM, LAB BIOMINERALIZAT RES, COLUMBIA, SC 29208 USA; UNIV S CAROLINA, SCH MED, COLUMBIA, SC 29208 USA; UNIV S CAROLINA, COLL SCI & MATH, CTR ELECTRON MICROSCOPY, COLUMBIA, SC 29208 USA; NYU, COLL DENT, CALCIUM PHOSPHATE RES LAB, NEW YORK, NY 10010 USA; PACIFIC NW LAB, ENVIRONM & MOL SCI LAB, RICHLAND, WA 99352 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; New York University; United States Department of Energy (DOE); Pacific Northwest National Laboratory					NIAMS NIH HHS [AR18983] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81; ARSENAULT AL, 1988, CALCIFIED TISSUE INT, V42, P119, DOI 10.1007/BF02556344; ARSENAULT AL, 1985, CHEM BIOL MINERALIZE, P364; BAGINSKI ES, 1973, CLIN CHIM ACTA, V46, P46; BANERJEE P, 1990, BIOCHIM BIOPHYS ACTA, V1044, P305, DOI 10.1016/0005-2760(90)90074-8; BETTS F, 1975, P NATL ACAD SCI USA, V72, P2088, DOI 10.1073/pnas.72.6.2088; Betts F., 1974, T AM CRYST ASS, V10, P73; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; BOSKEY AL, 1976, CALC TISS RES, V19, P273; BOSKEY AL, 1980, ARCH BIOCHEM BIOPHYS, V199, P305, DOI 10.1016/0003-9861(80)90285-4; BOSKEY AL, 1976, CALCIF TISSUE RES S, V22, P197; BOYDE A, 1978, CALC TISS RES, V26, P47, DOI 10.1007/BF02013233; BRECEVIC L, 1972, CALC TISS RES, V10, P82, DOI 10.1007/BF02012538; BUCKWALTER JA, 1993, COLLAGEN REL RES, V3, P489; CONCANNON B, 1996, THESIS U S CAROLINA, P1; COTMORE JM, 1971, SCIENCE, V172, P1339, DOI 10.1126/science.172.3990.1339; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAWSON RMC, 1960, BIOCHEM J, V75, P45, DOI 10.1042/bj0750045; DLUHY RA, 1983, BIOCHEMISTRY-US, V22, P6318, DOI 10.1021/bi00295a043; EANES ED, 1973, CALC TISS RES, V12, P143, DOI 10.1007/BF02013730; EANES ED, 1985, CHEM BIOL MINERALIZE, P213; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1991, J BIOL CHEM, V266, P10678; Hohling H J, 1995, Connect Tissue Res, V33, P171, DOI 10.3109/03008209509016998; IANNOTTI JP, 1994, CLIN ORTHOP RELAT R, P222; IRVING JT, 1958, NATURE, V181, P704, DOI 10.1038/181704a0; KIRSCH T, 1994, J BIOL CHEM, V269, P20103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGEROS RZ, 1981, PROG CRYST GROWTH CH, V4, P1; LEGEROS RZ, 1983, SCANNING ELECT MICRO, V114, P407; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; REY C, 1990, CALCIFIED TISSUE INT, V46, P384, DOI 10.1007/BF02554969; ROUFOSSE AH, 1984, BIOCHEMISTRY-US, V23, P6115, DOI 10.1021/bi00320a033; SARIG S, 1994, LAB INVEST, V71, P782; SAUER GR, 1988, J BIOL CHEM, V263, P13718; SAUER GR, 1994, CALCIFIED TISSUE INT, V54, P414, DOI 10.1007/BF00305529; TERMINE JD, 1973, CALC TISS RES, V13, P73, DOI 10.1007/BF02013723; TOMAZIC BB, 1993, J BIOMED MATER RES, V27, P217, DOI 10.1002/jbm.820270211; TROTTER PJ, 1995, BIOCHEM J, V308, P591, DOI 10.1042/bj3080591; VALHMU WB, 1990, BONE MINER, V8, P195, DOI 10.1016/0169-6009(90)90105-O; WARNER GP, 1983, CALCIFIED TISSUE INT, V35, P327, DOI 10.1007/BF02405054; WATKINS EL, 1980, BIOCHIM BIOPHYS ACTA, V631, P289, DOI 10.1016/0304-4165(80)90303-7; WU LNY, 1993, J BIOL CHEM, V268, P25084; WU YT, 1994, J MOL BIOL, V244, P423, DOI 10.1006/jmbi.1994.1740; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1977, CALC TISS RES, V23, P125, DOI 10.1007/BF02012777; WUTHIER RE, 1966, J LIPID RES, V7, P558; WUTHIER RE, 1968, J LIPID RES, V9, P68; WUTHIER RE, 1993, J NUTR, V123, P301, DOI 10.1093/jn/123.suppl_2.301; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311; WUTHIER RE, 1982, CALCIUM NORMAL PATHO, P41	56	106	109	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4404	4411		10.1074/jbc.272.7.4404	http://dx.doi.org/10.1074/jbc.272.7.4404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020163	hybrid			2022-12-25	WOS:A1997WH01900079
J	Chung, SM; Eckrich, M; PerroneBizzozero, N; Kohn, DT; Furneaux, H				Chung, SM; Eckrich, M; PerroneBizzozero, N; Kohn, DT; Furneaux, H			The Elav-like proteins bind to a conserved regulatory element in the 3'-untranslated region of GAP-43 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; NEURONAL GROWTH; INDUCED STABILIZATION; GENE-EXPRESSION; PC12 CELLS; PLASTICITY; REGENERATION; SPECIFICITY	Previous studies have identified three brain proteins (40, 65 and 95 kDa, respectively) that specifically bind to the 5'-untranslated region of GAP-43 mRNA. In this study, using a specific monoclonal antibody, we now show that the 40-kDa proteins are members of the Elav-like protein family. This family of specific RNA-binding proteins comprise three neural specific members called HuD, HuC, and Hel-N1. We have shown that purified recombinant HuD can bind with high affinity to GAP 43 mRNA. In addition, we have mapped the binding site to a highly conserved 26-nucleotide sequence within the regulatory element, The binding of HuD to this site is readily displaced by RNA oligonucleotides encoding other HuD binding sites, We also show that only the first and second RNA binding domains of HuD are required for selective binding to GAP 43 mRNA.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOL PHARMACOL & THERAPEUT, LAB MOL NEUROONCOL, NEW YORK, NY 10021 USA; UNIV NEW MEXICO, SCH MED, DEPT BIOCHEM, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, HLTH SCI CTR, CTR CANC, ALBUQUERQUE, NM 87131 USA	Memorial Sloan Kettering Cancer Center; University of New Mexico; University of New Mexico; University of New Mexico's Health Sciences Center				furneaux, henry/0000-0003-2212-1017	NCI NIH HHS [P30-CA08748] Funding Source: Medline; NINDS NIH HHS [NS29682, NS30255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030255, R29NS030255, R01NS029682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS LG, 1996, OVEREXPRESSION RNA B; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1991, PROG BRAIN RES, V89, P69; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; DALMAU J, 1992, AM J PATHOL, V141, P1; DANI JW, 1991, NEUROSCIENCE, V40, P277, DOI 10.1016/0306-4522(91)90190-Y; DEGRAAN PNE, 1989, J NEUROCHEM, V52, P17; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GISPEN WE, BRAIN RES, V328, P381; HOMYK T, 1985, J NEUROGENET, V2, P309, DOI 10.3109/01677068509102326; JACOBSON RD, 1986, J NEUROSCI, V6, P1843; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KING PH, 1994, J NEUROSCI, V14, P1943; Kohn DT, 1996, MOL BRAIN RES, V36, P240, DOI 10.1016/0169-328X(95)00239-O; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIEBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MA WJ, 1996, IN PRESS HUM GENET; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MCGUIRE CB, 1988, DEV BRAIN RES, V41, P277, DOI 10.1016/0165-3806(88)90189-7; NELSON RB, 1985, EXP NEUROL, V89, P213, DOI 10.1016/0014-4886(85)90277-8; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V200, P789, DOI 10.1006/bbrc.1994.1520; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V205, P1380, DOI 10.1006/bbrc.1994.2818; PERRONE-BIZZOZERO N I, 1991, Molecular and Cellular Neuroscience, V2, P402; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TSAI KC, 1997, IN PRESS J NEUROSCI; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	44	132	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6593	6598		10.1074/jbc.272.10.6593	http://dx.doi.org/10.1074/jbc.272.10.6593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045688	hybrid			2022-12-25	WOS:A1997WM64700072
J	Fraser, PD; Miura, Y; Misawa, N				Fraser, PD; Miura, Y; Misawa, N			In vitro characterization of astaxanthin biosynthetic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-AURANTIACUM; HAEMATOCOCCUS-PLUVIALIS; CAROTENOID BIOSYNTHESIS; INVITRO BIOSYNTHESIS; FUNCTIONAL-ANALYSIS; PHAFFIA-RHODOZYMA; ESCHERICHIA-COLI; BETA-CAROTENE; BACTERIUM; PATHWAY	Escherichia coli strains expressing the marine bacteria (Agrobacterium aurantiacum and Alcaligenes sp. strain PC-1) astaxanthin biosynthetic genes (crtZ and W), Haenatococcus pluvialis bht, and Erwinia uredovora crtZ genes were used for in, vitro characterization of the respective enzymes. Specific enzyme assays indicated that all of the enzymes are bifunctional, in that the CrtZ enzymes formed zeaxanthin from beta-carotene via beta-cryptoxanthin, as well as astaxanthin from canthaxanthin via phoenicoxanthin (adonirubin). The BKT/CrtW enzymes synthesized canthaxanthin via echinenone from beta-carotene and 4-ketozeaxanthin (adonixanthin) with trace amounts of astaxanthin from zeaxanthin. Comparison of maximum catalytic activities as well. as selectivity experiments carried out in the presence of both utilizable substrates indicated that the CrtZ enzymes from marine bacteria converted canthaxanthin to astaxanthin preferentially, whereas the Erwirnia CrtZ possessed a favorability to the formation of zeaxanthin from beta-carotene. The CrtW/BKT enzymes were not so defined in their substrate preference, responding readily to fluctuations in substrate levels. Other properties obtained indicated that the enzymes were strictly oxygen-requiring; and a cofactor mixture of a oxoglutarate, ascorbic acid, and Fe2+ was beneficial to activity. Based on enzymological data, a predicted pathway for astaxanthin biosynthesis is described, and it is proposed that CrtZ-like enzymes be termed carotenoid 3,(3')-beta-ionone ring hydroxylase and CrtW/BKT carotenoid 4,(4')-beta-ionone ring oxygenase.			Fraser, PD (corresponding author), KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,1-13-5 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.			Misawa, Norihiko/0000-0003-1373-0769				ANDREWES AG, 1976, PHYTOCHEMISTRY, V15, P1003, DOI 10.1016/S0031-9422(00)84390-3; BOUSSIBA S, 1991, PLANT CELL PHYSIOL, V32, P1077, DOI 10.1093/oxfordjournals.pcp.a078171; BRAMLEY PM, 1985, ADV LIPID RES, V21, P243; BRITTON G, 1985, METHOD ENZYMOL, V111, P113, DOI 10.1016/S0076-6879(85)11007-4; DAWSON GW, 1993, J BIOL CHEM, V268, P27154; Fan L, 1995, PLANT CELL PHYSIOL, V36, P1519; FRASER PD, 1991, PHYTOCHEMISTRY, V22, P441; FUJITA T, 1983, B JPN SOC SCI FISH, V49, P1855; FUNK C, 1993, PLANT PHYSIOL, V101, P1231, DOI 10.1104/pp.101.4.1231; FUNK C, 1994, ARCH BIOCHEM BIOPHYS, V308, P258, DOI 10.1006/abbi.1994.1036; Heinz Ernst, 1993, P33; HUNDLE BS, 1993, FEBS LETT, V315, P329, DOI 10.1016/0014-5793(93)81188-6; JOHNSON EA, 1991, CRIT REV BIOTECHNOL, V11, P297, DOI 10.3109/07388559109040622; JYONOUCHI H, 1993, NUTR CANCER, V19, P269, DOI 10.1080/01635589309514258; KAJIWARA S, 1995, PLANT MOL BIOL, V29, P343, DOI 10.1007/BF00043657; LANGE T, 1994, PLANTA, V195, P98; MATSUNO T, 1989, CAROTENOIDS, P59; MATSUNO T, 1991, PURE APPL CHEM, V63, P81, DOI 10.1351/pac199163010081; MCDERMOTT JC, 1974, BIOCHEM J, V144, P231, DOI 10.1042/bj1440231; MIKI W, 1991, PURE APPL CHEM, V63, P141, DOI 10.1351/pac199163010141; MIKI W, 1994, EXPERIENTIA, V50, P684, DOI 10.1007/BF01952874; Miki Wataru, 1994, Journal of Marine Biotechnology, V2, P35; MISAWA N, 1995, BIOCHEM BIOPH RES CO, V209, P867, DOI 10.1006/bbrc.1995.1579; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; RENSTROM B, 1981, HELV CHIM ACTA, V64, P449; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SANDMANN G, 1985, BIOCHIM BIOPHYS ACTA, V843, P73, DOI 10.1016/0304-4165(85)90051-0; SANDMANN G, 1992, TARGET ASSAYS MODERN, P9; SCHROEDER WA, 1995, J BIOL CHEM, V270, P18374, DOI 10.1074/jbc.270.31.18374; TANAKA T, 1994, CARCINOGENESIS, V15, P15, DOI 10.1093/carcin/15.1.15; TORRISSEN O J, 1989, Reviews in Aquatic Sciences, V1, P209; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V96, P645, DOI 10.1016/0003-9861(62)90350-8; YOKOYAMA A, 1994, BIOSCI BIOTECH BIOCH, V58, P1842, DOI 10.1271/bbb.58.1842; YOKOYAMA A, 1995, FEMS MICROBIOL LETT, V128, P139, DOI 10.1016/0378-1097(95)00097-O	35	129	150	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6128	6135		10.1074/jbc.272.10.6128	http://dx.doi.org/10.1074/jbc.272.10.6128			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045623	hybrid			2022-12-25	WOS:A1997WM64700007
J	Meerovitch, K; Wing, S; Goltzman, D				Meerovitch, K; Wing, S; Goltzman, D			Preproparathyroid hormone-related protein, a secreted peptide, is a substrate for the ubiquitin proteolytic system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; PARATHYROID-HORMONE; CELL-LINE; C-JUN; DEGRADATION; PROTEASOME; GROWTH; EXPRESSION; GENE; VIVO	Parathyroid hormone-related protein (PTHrP) is an important causal factor of hypercalcemia associated with malignancy. PTHrP also modulates cell growth and differentiation of normal cells through mechanisms that include binding to cell surface-specific receptors as well as by possible intracellular routes. To understand the regulation of intracellular PTHrP expression, posttranslational processing of PTHrP was investigated. Using cell-free translations it was shown that PTHrP can be ligated efficiently to multiple ubiquitin moieties. Both conjugation to ubiquitin and degradation of pre pro-PTHrP synthesized in vitro were ATP dependent. Translation in vitro in the presence of the proteasome inhibitor MG-132 abolished the degradation of PTHrP. Treatment of cells, cotransfected with hemagglutinin-tagged ubiquitin and histidine-tagged prepro-PTHrP, with MG 132, led to the accumulation of ubiquitinated prepro-PTHrP, Deletion mutagenesis experiments indicated that both the prepro secretory domain and a PEST (amino acid residues Pro (P), Glu (E), and/or Asp (D), Ser (S), and Thr (T)) motif in the COOH-terminal region of the protein were not required as cis-acting determinants for ubiquitination. This is the first report of a wild-type secretory polypeptide serving as a substrate of the ubiquitin proteolytic pathway. These results suggest that the ubiquitin dependent proteolytic pathway is involved in regulating the metabolic stability of intracellular PTHrP, and this regulation may be an important mechanism for modulating its effects on cell growth and differentiation.	ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3A 1A1,CANADA; ROYAL VICTORIA HOSP,POLYPEPTIDE LAB,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University								ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BORN W, 1987, MOL ENDOCRINOL, V1, P5, DOI 10.1210/mend-1-1-5; Broadus Arthur E., 1994, P259; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806; HENDERSON J, 1991, CANCER RES, V51, P6521; HENDERSON JE, 1992, ENDOCRINOLOGY, V130, P449, DOI 10.1210/en.130.1.449; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; HENDY GN, 1992, PARATHYROID HORMONE, P25; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KAISER SM, 1994, MOL ENDOCRINOL, V8, P139, DOI 10.1210/me.8.2.139; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LI X, 1993, CANCER RES, V53, P2980; LIU B, 1995, INT J CANCER, V63, P276, DOI 10.1002/ijc.2910630222; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; Oda K, 1996, BIOCHEM BIOPH RES CO, V219, P800, DOI 10.1006/bbrc.1996.0314; OKANO K, 1995, ENDOCRINOLOGY, V136, P1782, DOI 10.1210/en.136.4.1782; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RABBANI SA, 1993, BIOCHEMISTRY-US, V32, P4931, DOI 10.1021/bi00069a030; RABBANI SA, 1995, ENDOCRINOLOGY, V136, P5416, DOI 10.1210/en.136.12.5416; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SADIS S, 1995, MOL CELL BIOL, V15, P4086; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YASUDA T, 1989, J BIOL CHEM, V264, P7720	47	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6706	6713		10.1074/jbc.272.10.6706	http://dx.doi.org/10.1074/jbc.272.10.6706			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045703	hybrid			2022-12-25	WOS:A1997WM64700087
J	Bonen, DK; Hausman, AML; Hadjiagapiou, C; Skarosi, SF; Davidson, NO				Bonen, DK; Hausman, AML; Hadjiagapiou, C; Skarosi, SF; Davidson, NO			Expression of a recombinant apolipoprotein(a) in HepG2 cells - Evidence for intracellular assembly of lipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; B-CONTAINING LIPOPROTEINS; MESSENGER-RNA; BABOON HEPATOCYTES; MAMMALIAN-CELLS; APO(A) GENE; HUMAN LIVER; PLASMA; LP(A); SIZE	Apolipoprotein(a) (apo(a)), a large glycoprotein with extensive homology to plasminogen, forms a complex with apolipoprotein B100 (apoB100), which circulates in human plasma in the form of lipoprotein(a) (Lp(a)), Evidence indicates that the association of apo(a) with apoB100 occurs in the extracellular environment, We have reevaluated the possibility that apo(a)-B100 association can also occur as an intracellular event through studies with HepG2 cells stably transfected with an apo(a) minigene. Several lines of evidence support this possibility, First, continued Lp(a) production was demonstrated following incubation of transfected HepG2 cells with anti-apo(a) antisera, conditions that effectively block the fluid-phase association of apo(a) and apoB100 in vitro, Second, an apo(a)-B100 complex was detectable in Western blot analyses of transfected HepG2 lysates following immunoprecipitation with anti-apo(a) antisera, These studies incorporated precautions to eliminate cell-surface attachment of preformed apo(a)-B100 complexes to the low density lipoprotein receptor and were conducted in the presence of the lysine analog E-aminocaproic acid, which precludes apo(a)-B100 association occurring during the isolation and analyses, Third, the presence of an intracellular apo(a)-B100 complex was demonstrated in lipoproteins isolated from microsomal contents, Of particular significance was the observation that this complex contained the precursor form of apo(a), which is not secreted, in addition to the mature, recombinant form, Finally, direct evidence was provided for the synthesis of a precursor form of apo(a) in a nascent intracellular complex with apoB100 following treatment of transfected HepG2 cells with brefeldin A plus N-acetyl-leucyl-leucyl-norleucinal, Taken together, these data suggest that apo(a)B100 association can occur as an intracellular event in a human hepatoma-derived cell line, raising important implications for the regulation of Lp(a) secretion from human liver.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago					NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albers JJ, 1996, J LIPID RES, V37, P192; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; BYRNE CD, 1994, ARTERIOSCLER THROMB, V14, P534, DOI 10.1161/01.ATV.14.4.534; CHAPMAN MJ, 1994, ATHEROSCLEROSIS, V110, pS69, DOI 10.1016/0021-9150(94)05385-V; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIESA G, 1992, J BIOL CHEM, V267, P24369; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EDELSTEIN C, 1994, CHEM PHYS LIPIDS, V67-8, P135, DOI 10.1016/0009-3084(94)90132-5; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; FLESS GM, 1989, J LIPID RES, V30, P651; FRANK S, 1994, BIOCHEM J, V304, P27, DOI 10.1042/bj3040027; Frank S, 1996, EUR J CLIN INVEST, V26, P109, DOI 10.1046/j.1365-2362.1996.112255.x; FRANK S, 1994, BIOCHEMISTRY-US, V33, P12329, DOI 10.1021/bi00206a041; GAW A, 1994, J CLIN INVEST, V93, P2526, DOI 10.1172/JCI117263; Gaw Allan, 1994, Current Opinion in Lipidology, V5, P149, DOI 10.1097/00041433-199404000-00012; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KOSTNER GM, 1993, ARTERIOSCLER THROMB, V13, P1101, DOI 10.1161/01.ATV.13.7.1101; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; LANTZ LM, 1995, BIOTECHNIQUES, V1, P58; LASCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MOOSER V, 1995, HUM MOL GENET, V4, P173, DOI 10.1093/hmg/4.2.173; MORRISETT JD, 1990, LIPOPROTEIN A, P53; NILSSON J, 1981, ANAL BIOCHEM, V110, P342, DOI 10.1016/0003-2697(81)90201-3; Park JW, 1996, BIOCHEM J, V317, P125, DOI 10.1042/bj3170125; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SCANU AM, 1990, J LAB CLIN MED, V116, P142; Tam SP, 1996, J LIPID RES, V37, P518; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; WADE DP, 1991, ATHEROSCLEROSIS, V91, P63, DOI 10.1016/0021-9150(91)90187-8; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, J BIOL CHEM, V269, P28716; WHITE AL, 1992, J BIOL CHEM, V267, P15657; White Ann L., 1995, Current Opinion in Lipidology, V6, P75, DOI 10.1097/00041433-199504000-00003; WILKINSON J, 1994, J LIPID RES, V35, P1896	46	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5659	5667		10.1074/jbc.272.9.5659	http://dx.doi.org/10.1074/jbc.272.9.5659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038176	hybrid			2022-12-25	WOS:A1997WK74700044
J	Feyzi, E; Lustig, F; Fager, G; Spillmann, D; Lindahl, U; Salmivirta, M				Feyzi, E; Lustig, F; Fager, G; Spillmann, D; Lindahl, U; Salmivirta, M			Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; FIBROBLAST GROWTH; CELL-SURFACE; PROTEOGLYCANS; SEQUENCES; PDGF; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; IDENTIFICATION; DEGRADATION	Platelet-derived growth factors (PDGFs) are homo- or heterodimers of two related polypeptides, known as A and B chains, The A chain exists as two splice variants due to the alternative usage of exons 6 (PDGF-A(L), longer) and 7 (PDGF-A(S), shorter). Exon 6 encodes an 18-amino acid sequence rich in basic amino acid residues, which has been implicated as a cell retention signal, Several lines of evidence indicate that the retention is due to binding of PDGF-A(L) to glycosaminoglycans, especially to heparan sulfate. We have analyzed the saccharide domains of smooth muscle cell-derived heparan sulfate involved in this interaction, Furthermore, we have employed selectively modified heparin oligosaccharides to elucidate the dependence of the binding on different sulfate groups and on fragment length, The shortest PDGF-A(L) binding domain consists of 6-8 monosaccharide units. Studies using selectively desulfated heparins and heparin fragments suggest that N-, 2-O-, and 6-O-sulfate groups all contribute to the interaction Structural comparison of heparan sulfate oligosaccharides separated by affinity chromatography on immobilized PDGF-A(L) showed that the bound pool was enriched in -IdceA(2-OSO3)-GleNSO(3)(6-OSO3)- disaccharide units. Furthermore, analogous separation of a partially O-desulfated heparin decamer preparation, using a highly selective nitrocellulose filter-trapping system, yielded a PDGF-A(L)-bound fraction in which more than half of the disaccharide units had the structure -IdceA(2-OSO3)-GIcNSO(3)(6-OSO3)-. Our results suggest that the interaction between PDGF-A(L) and heparin/heparan sulfate is mediated via N-sulfated saccharide domains containing both 2-O- and 6-O-sulfate groups.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; GOTHENBURG UNIV,SAHLGRENS HOSP,WALLENBERG LAB CARDIOVASC RES,S-41345 GOTHENBURG,SWEDEN	Uppsala University; Sahlgrenska University Hospital; University of Gothenburg								ANDERSSON M, 1994, J BIOL CHEM, V269, P926; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; FAGER G, 1988, EXP CELL RES, V176, P319, DOI 10.1016/0014-4827(88)90334-5; FAGER G, 1995, J CELL PHYSIOL, V163, P380, DOI 10.1002/jcp.1041630218; GALLAGHER JT, 1992, ADV EXP MED BIOL, V313, P49; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lustig F, 1996, BIOCHEMISTRY-US, V35, P12077, DOI 10.1021/bi960118l; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; NAGASAWA K, 1986, CARBOHYD RES, V158, P183, DOI 10.1016/0008-6215(86)84016-2; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1988, J BIOL CHEM, V263, P5197; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	43	114	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5518	5524		10.1074/jbc.272.9.5518	http://dx.doi.org/10.1074/jbc.272.9.5518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038157	hybrid			2022-12-25	WOS:A1997WK74700025
J	Kenny, JJ; Knobloch, TJ; Augustus, M; Carter, KC; Rosen, CA; Lang, JC				Kenny, JJ; Knobloch, TJ; Augustus, M; Carter, KC; Rosen, CA; Lang, JC			GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes	ONCOGENE			English	Article						apoptosis; Bcl-2 homologue; leukemia; melanoma; FISH analysis	FOLLICULAR LYMPHOMA; SEQUENCE SIMILARITY; HUMAN MELANOCYTES; HOMOLOG BAK; APOPTOSIS; INDUCTION; ANTIGENS; MEMBRANE; PROTEIN; DEATH	Our laboratory previously described the independent isolation of the fibroblast growth factor 4 (FGF-4) gene by NIH3T3 transformation assay using DNA from a patient with CML leukemia (Lucas et al., 1994). The FGF-4 gene was truncated by DNA rearrangement with a novel gene named GRS. In this manuscript we describe isolation of GRS cDNA and show by sequence comparison that GRS is a novel member of the Bcl-2 gene family. Northern analysis shows expression of the gene in normal human tissue to be largely restricted to the hematopoietic compartment. Analysis of the pattern of gene expression in cancer cell lines demonstrates GRS is expressed in hematopoietic malignancies and in melanoma. The chromosomal location of GRS has also been determined. The gene is positioned on chromosome 15 within bands q24-25.	OHIO STATE UNIV HOSP,ARTHUR G JAMES CANC HOSP & RES INST 1248,COLUMBUS,OH 43210; HUMAN GENOME SCI,ROCKVILLE,MD 20850	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; GlaxoSmithKline; Human Genome Sciences Inc					NCI NIH HHS [CA 63134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKHSHI A, 1985, CELL, V41, P889; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FRASER JK, 1987, EXP HEMATOL, V15, P406; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOKALJVOKAC N, 1991, CYTOGENET CELL GENET, V57, P11, DOI 10.1159/000133103; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LIN EY, 1993, J IMMUNOL, V151, P1979; LUCAS JM, 1994, ONCOL RES, V6, P139; Morris C, 1996, ONCOGENE, V12, P677; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OTLVAI ZN, 1993, CELL, V74, P609; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M	28	27	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					997	1001		10.1038/sj.onc.1200898	http://dx.doi.org/10.1038/sj.onc.1200898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050999				2022-12-25	WOS:A1997WK34400013
J	Brandt, ME; Vickery, LE				Brandt, ME; Vickery, LE			Cooperativity and dimerization of recombinant human estrogen receptor hormone-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CRYSTAL-STRUCTURE; EXTINCTION COEFFICIENTS; SECONDARY STRUCTURE; ESCHERICHIA-COLI; FULL-LENGTH; DNA; PROTEINS; MUTAGENESIS; MECHANISM	The estrogen receptor dimerizes and exhibits cooperative ligand binding as part of its normal functioning. Interaction of the estrogen receptor with its ligands is mediated by a C-terminal hormone-binding domain (HBD), and residues within the HED are thought to contribute to dimerization, To examine dimer interactions in the isolated HBD, a human estrogen receptor HBD fragment was expressed in high yield as a cleavable fusion protein in Escherichia coli, The isolated HBD peptide exhibited affinity for estradiol, ligand discrimination, and cooperative estradiol binding (Hill coefficient similar to 1.6) similar to the full-length protein. Circular dichroism spectroscopy suggests that the HBD contains significant amounts of alpha-helix (similar to 60%) and some beta-strand (similar to 7%) and that ligand binding induces little change in secondary structure. HBD dimer dissociation, measured using size exclusion chromatography, exhibited a half-life of similar to 1.2 h, which ligand binding increased similar to 3-fold (estradiol) to similar to 4-fold (4-hydroxytamoxifen). These results suggest that the isolated estrogen receptor HBD dimerizes and undergoes conformational changes associated with cooperative ligand binding in a manner comparable to the full-length protein, and that one effect of ligand binding is to alter the receptor dimer dissociation kinetics.			Brandt, ME (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,346-D MED SCI 1,IRVINE,CA 92697, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30109] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS H, 1992, RECEPTOR, V2, P77; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bornstein P, 1977, Methods Enzymol, V47, P132; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; OBOURN JD, 1993, BIOCHEMISTRY-US, V32, P6229, DOI 10.1021/bi00075a016; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sambrook J., 2002, MOL CLONING LAB MANU; SASSON S, 1988, MOL ENDOCRINOL, V2, P307, DOI 10.1210/mend-2-4-307; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWARTZ JA, 1994, BIOCHEMISTRY-US, V33, P13267, DOI 10.1021/bi00249a013; SEIELSTAD DA, 1995, MOL ENDOCRINOL, V9, P647, DOI 10.1210/me.9.6.647; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WOOGE CH, 1992, MOL ENDOCRINOL, V6, P861, DOI 10.1210/me.6.6.861; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	34	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4843	4849		10.1074/jbc.272.8.4843	http://dx.doi.org/10.1074/jbc.272.8.4843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030541	hybrid, Green Submitted			2022-12-25	WOS:A1997WJ85500029
J	Arighi, E; Alberti, L; Torriti, F; Ghizzoni, S; Rizzetti, MG; Pelicci, G; Pasini, B; Bongarzone, I; Piutti, C; Pierotti, MA; Borrello, MG				Arighi, E; Alberti, L; Torriti, F; Ghizzoni, S; Rizzetti, MG; Pelicci, G; Pasini, B; Bongarzone, I; Piutti, C; Pierotti, MA; Borrello, MG			Identification of Shc docking site on Ret tyrosine kinase	ONCOGENE			English	Article						Ret; Shc; receptor tyrosine kinase; oncogene	PAPILLARY THYROID CARCINOMAS; SIGNAL-TRANSDUCTION; PROTO-ONCOGENE; INSULIN-RECEPTOR; DOMAIN; PROTEINS; PHOSPHOTYROSINE; PHOSPHORYLATION; PROTOONCOGENE; BINDING	The RET proto-oncogene encodes two isoforms of a receptor type tyrosine kinase which plays a role in neural crest and kidney development, Distinct germ-line mutations of RET have been associated inherited cancer syndromes MEN2A, MEN2B FMTC as well as with the congenital disorder Hirschsprung disease (HSCR), whereas somatic rearrangements (RET/PTCs) have been frequently detected in the papillary thyroid carcinoma, Despite these findings, suggesting a relevant role for RET product in development and neoplastic processes, little is known about the signalling triggered by this receptor, In this study, we have demonstrated that the transducing adaptor molecule She is recruited and activated by both Ret isoforms and by the rearranged cytoplasmatic Ret/ptc2 oncoproteins as well as by the membrane bound receptor activated by MEN2A or by MEN2B associated mutations, Moreover, our analysis has identified the Ret tyrosine residue and the She domains involved in the interaction, In fact, here we show that both the phosphotyrosine binding domains of She, PTB and SH2, interact with Ret/ptc2 in vitro, However, PTB domain binds 20 folds higher amount of Ret/ptc2 than SH2, The putative binding site for either SH2 and PTB domains has been identified as Tyr586 of Ret/ptc2 (Tyr1062 on proto-Ret). In keeping with this finding, by using RET/PTC2-Y586F mutant, we have demonstrated that this tyrosine residue, the last amino acid but one before the divergence of the two Ret isoforms, is the docking site for She.	IST NAZL TUMORI,DIV EXPT ONCOL A,I-20133 MILAN,ITALY; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY; IST NAZL TUMORI,SCI DIRECT,I-20133 MILAN,ITALY; PHARMACIA & UPJOHN RES,ONCOL & IMMUNOL PRECLIN RES,I-20014 NERVIANO,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS European Institute of Oncology (IEO); Fondazione IRCCS Istituto Nazionale Tumori Milan			Bongarzone, Italia/B-9544-2017; Pasini, Barbara/AHI-2004-2022; Pierotti, Marco Alessandro/AAC-4728-2022; Pelicci, Giuliana/AAA-8921-2022; Borrello, Maria Grazia/C-3161-2017	Bongarzone, Italia/0000-0003-2530-9170; Pasini, Barbara/0000-0002-4373-1212; Pierotti, Marco Alessandro/0000-0002-7431-8332; Pelicci, Giuliana/0000-0003-0986-8255; Borrello, Maria Grazia/0000-0002-6854-2848				BALDARI CT, 1995, ONCOGENE, V10, P1141; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH S, 1993, NATURE, V367, P87; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANZI C, 1992, ONCOGENE, V7, P2189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PONDER PAJ, 1995, CANCER SURV, V25, P195; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TRUB T, 1995, J BIOL CHEM, V270, P18205; TRUPP E, 1996, NATURE, V381, P785; TURCK CW, 1994, PEPTIDE RES, V7, P140; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1996, J BIOL CHEM, V271, P31119	46	104	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					773	782		10.1038/sj.onc.1200896	http://dx.doi.org/10.1038/sj.onc.1200896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047384				2022-12-25	WOS:A1997WJ11200003
J	Fasshauer, D; Bruns, D; Shen, B; Jahn, R; Brunger, AT				Fasshauer, D; Bruns, D; Shen, B; Jahn, R; Brunger, AT			A structural change occurs upon binding of syntaxin to SNAP-25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SYNAPTIC VESICLE DOCKING; MEMBRANE-FUSION COMPLEX; PREDICTING COILED COILS; CLOSTRIDIAL NEUROTOXINS; LEUCINE ZIPPER; SNARE COMPLEX; IN-VITRO; SPECIFICITY; ACTIVATION	The highly conserved proteins syntaxin and SNAP-25 are part of a protein complex that is thought to play a key role in exocytosis of synaptic vesicles, Previous work demonstrated that syntaxin and SNAP-25 bind to each other with high affinity and that their binding regions are predicted to form coiled coils, Circular dichroism spectroscopy was used here to study the alpha-helicity of the individual proteins and to gain insight into structural changes associated with complex formation, Syntaxin displayed approximately 43% alpha-helical content, In contrast, the alpha-helical content of SNAP-25 was low under physiological conditions, Formation of the SNAP-25-syntaxin complex was associated with a dramatic increase in alpha-helicity. Interaction of a 90-residue NH2-terminal fragment of SNAP-25 comprising the minimal syntaxin binding domain lead to a similar but less pronounced increase in alpha-helicity, Single amino acid replacements in the putative hydrophobic core of this fragment with hydrophilic amino acids abolished the induced structural change and disrupted the interaction monitored by binding assays, Replacements with hydrophobic residues had no effect. Our findings are consistent with induced coiled coil formation upon binding of syntaxin and SNAP-25.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Fasshauer, Dirk/B-1563-2013	Fasshauer, Dirk/0000-0002-1040-4282; Brunger, Axel/0000-0001-5121-2036; Jahn, Reinhard/0000-0003-1542-3498	NIGMS NIH HHS [GM54160-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Calakos N, 1996, PHYSIOL REV, V76, P1; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250	28	161	164	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4582	4590		10.1074/jbc.272.7.4582	http://dx.doi.org/10.1074/jbc.272.7.4582			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020186	hybrid			2022-12-25	WOS:A1997WH01900102
J	Zable, AC; Favero, TG; Abramson, JJ				Zable, AC; Favero, TG; Abramson, JJ			Glutathione modulates ryanodine receptor from skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID CALCIUM RELEASE; TRIGGER CA-2+ RELEASE; CA2+ RELEASE; OXIDIZED GLUTATHIONE; OXIDATION; CHANNEL; BINDING; RESPONSES; INTENSITY; VESICLES	In this report, we demonstrate the ability of the cellular thiol glutathione to modulate the ryanodine receptor hom skeletal muscle sarcoplasmic reticulum. Reduced glutathione (GSH) inhibited Ca2+-stimulated [H-3]ryanodine binding to the sarcoplasmic reticulum and inhibited the single-channel gating activity of the reconstituted Ca2+ release channel. The effects of GSH on both the [H-3]ryanodine binding and single-channel measurements were dose-dependent, exhibiting an IC50 of similar to 2.4 mM in binding experiments. Scatchard analysis demonstrated that GSH decreased the binding affinity of ryanodine for its receptor (increased K-d) and lowered the maximal binding occupancy (B-max). In addition, GSH did not modify the Ca2+ dependence of [H-3]ryanodine binding. In single-channel experiments, GSH (5-10 mM), added to the cis side of the bilayer lipid membrane, lowered the open probability (P-o) of a Ca2+ (50 mu M)-stimulated Ca2+ channel without modifying the single-channel conductance. Subsequent perfusion of the cis chamber with an identical buffer, containing 50 mu M Ca2+ without GSH, re-established Ca2+-stimulated channel gating. GSH did not inhibit channel activity when added to the trans side of the bilayer lipid membrane. Similar to GSH, the thiol-reducing agents dithiothreitol and beta-mercaptoethanol also inhibited high affinity [H-3]ryanodine binding to sarcoplasmic reticulum membranes. In contrast to GSH, glutathione disulfide (GSSG) was a potent stimulator of high affinity [H-3]ryanodine binding and it also stimulated the activity of the reconstituted single Ca2+ release channel. These results provide direct evidence that glutathione interacts with reactive thiols associated with the Ca2+ release channel/ryanodine receptor complex, which are located on the cytoplasmic face of the SR, and support previous observations (Liu, G,Abramson, J. J., Zable, A. C., and Pessah, I. N. (1994) Alol. Pharmacol. 45, 189-200) that reactive thiols may be involved in the gating of the Ca2+ release channel.	PORTLAND STATE UNIV,DEPT PHYS,PORTLAND,OR 97201; UNIV PORTLAND,DEPT BIOL,PORTLAND,OR 97203	Portland State University; University of Portland								ABRAMSON JJ, 1993, ARCH BIOCHEM BIOPHYS, V301, P396, DOI 10.1006/abbi.1993.1162; ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; ABRAMSON JJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P245, DOI 10.1016/0003-9861(88)90633-9; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; FAVERO TG, 1995, J APPL PHYSIOL, V78, P1665, DOI 10.1152/jappl.1995.78.5.1665; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GILBERT KR, 1991, NEUROSCI LETT, V133, P11, DOI 10.1016/0304-3940(91)90045-U; HALLIWELL B, 1985, FREE RADICAL BIO MED, P73; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JI LL, 1992, J APPL PHYSIOL, V73, P1854, DOI 10.1152/jappl.1992.73.5.1854; KALCKAR HM, 1947, J BIOL CHEM, V167, P461; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; PARK MK, 1995, EXP PHYSIOL, V80, P835, DOI 10.1113/expphysiol.1995.sp003891; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; RENARDROONEY DC, 1995, BIOCHEM J, V310, P185, DOI 10.1042/bj3100185; SALAMA G, 1984, J BIOL CHEM, V259, P3363; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SEN CK, 1995, J APPL PHYSIOL, V79, P675, DOI 10.1152/jappl.1995.79.3.675; STUART J, 1992, ARCH BIOCHEM BIOPHYS, V292, P512, DOI 10.1016/0003-9861(92)90024-Q; TORCHINSKI YM, 1981, SULFUR PROTEINS, P72; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725	36	122	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7069	7077		10.1074/jbc.272.11.7069	http://dx.doi.org/10.1074/jbc.272.11.7069			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054399	hybrid			2022-12-25	WOS:A1997WN14700038
J	Hieshima, K; Imai, T; Opdenakker, G; VanDamme, J; Kusuda, J; Tei, H; Sakaki, Y; Takatsuki, K; Miura, R; Yoshie, O; Nomiyama, H				Hieshima, K; Imai, T; Opdenakker, G; VanDamme, J; Kusuda, J; Tei, H; Sakaki, Y; Takatsuki, K; Miura, R; Yoshie, O; Nomiyama, H			Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver - Chemotactic activity for lymphocytes and gene localization on chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; RECEPTOR-BINDING; INTERLEUKIN-8; SEQUENCE; MCP-3; CYTOKINE; FAMILY; CDNA; IDENTIFICATION; LYMPHOTACTIN	Partial overlapping cDNA sequences likely to encode a novel human CC chemokine were identified from the GenBank Expressed Sequence Tag data base. Using these sequences, we isolated full-length cDNA encoding a protein of 96 amino acid residues with 20-28% identity to other CC chemokines. By Northern blot, this chemokine was mainly expressed in liver among various tissues and strongly induced in several human cell Lines by phorbol myristate acetate. We thus designated this chemokine as LARC from Liver and Activation-Regulated Chemokine. We mapped the LARC gene close to the chromosomal marker D2S159 at chromosome 2q33-q37 by somatic cell and radiation hybrid mappings and isolated two yeast artificial chromosome clones containing the LARC gene from this region. To prepare LARC, we subcloned the cDNA into a baculovirus vector and expressed it in insect cells. The secreted protein started at Ala-27 and was significantly chemotactic for lymphocytes. At a concentration of 1 mu g/ml, it also showed a weak chemotactic activity for granulocytes. Unlike other CC chemokines, however, LARC was not chemotactic for monocytic THP-I cells or blood monocytes. LARC tagged with secreted alkaline phosphatase-(His)(6) bound specifically to lymphocytes, the binding being competed only by LARC and not by other CC or CXC chemokines. Scatchard analysis revealed a single class of receptors for LARC on lymphocytes with a K-d of 0.4 nM and 2100 sites/cell. Collectively, LARC is a novel CC chemokine, which may represent a new group of CC chemokines localized on chromosome 2.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED,KUMAMOTO 860,JAPAN; SHIONOGI INST MED SCI,OSAKA 566,JAPAN; UNIV LOUVAIN,REGA INST MED RES,LAB MOL IMMUNOL,B-3000 LOUVAIN,BELGIUM; NATL INST HLTH,LAB GENET RESOURCES,SHINJUKU KU,TOKYO 162,JAPAN; UNIV TOKYO,INST MED SCI,CTR HUMAN GENOME,MINATO KU,TOKYO 108,JAPAN	Kumamoto University; Kumamoto University; Shionogi & Company Limited; KU Leuven; University of Tokyo			Opdenakker, Ghislain/V-8562-2019; Hieshima, Kunio/AAF-7040-2019; Opdenakker, Ghislain/Q-3130-2017; Nomiyama, Hisayuki/F-2840-2013	Opdenakker, Ghislain/0000-0003-1714-2294; Hieshima, Kunio/0000-0002-7786-4646; Opdenakker, Ghislain/0000-0003-1714-2294; Nomiyama, Hisayuki/0000-0002-2716-4043; Yoshie, Osamu/0000-0003-4353-5809				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARYWARD P, 1996, GENOMICS, V32, P1; BEALL CJ, 1992, J BIOL CHEM, V267, P3455; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BROXMEYER HE, 1995, ANN HEMATOL, V71, P235, DOI 10.1007/s002770050112; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cook DN, 1996, J LEUKOCYTE BIOL, V59, P61, DOI 10.1002/jlb.59.1.61; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; MASURE S, 1995, J INTERF CYTOK RES, V15, P955, DOI 10.1089/jir.1995.15.955; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MILLER MD, 1989, J IMMUNOL, V143, P2907; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MURAKAMI K, 1996, IN PRESS DNA CELL BI; NAKAO M, 1990, MOL CELL BIOL, V10, P3646, DOI 10.1128/MCB.10.7.3646; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1988, J IMMUNOL, V141, P1081; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SHULZKNAPPE P, 1996, J EXP MED, V183, P295; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; Strieter RM, 1996, J IMMUNOL, V156, P3583; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANDAMME J, 1994, CYTOKINES PRACTICAL, P215; VANHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VanSnick J, 1996, J IMMUNOL, V157, P2570; Weber M, 1996, J EXP MED, V183, P681, DOI 10.1084/jem.183.2.681; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; YOSHIDA T, 1996, GENOMICS, V395, P82; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; 1994, CYTOGENET CELL GENET, V67, P216	54	296	326	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5846	5853		10.1074/jbc.272.9.5846	http://dx.doi.org/10.1074/jbc.272.9.5846			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038201	hybrid			2022-12-25	WOS:A1997WK74700069
J	Zou, J; Presky, DH; Wu, CY; Gubler, U				Zou, J; Presky, DH; Wu, CY; Gubler, U			Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta 1 and beta 2 and JAK kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; IL-12 RECEPTOR; CELLS; ACTIVATION; CYTOKINE; LYMPHOCYTES; EXPRESSION; PURIFICATION; ANTIGEN; TYPE-1	The role of the cytoplasmic regions of interleukin-12 receptors (IL-12R) beta 1 and beta 2 in stimulating proliferation was examined, The transmembrane and cytoplasmic regions of IL-12R beta 1 or IL-12R beta 2 were fused to the extracellular domain of the epidermal growth factor (EGF) receptor, yielding chimeric receptors E12R1 and E12R2, respectively, These chimeras were stably transfected into BaF3 cells, a factor-dependent murine pro-B cell line, Only E12R2 or E12R1+E12R2 transfectants were capable of EGF-dependent proliferation, EGF-dependent phosphorylation of E12R2, JAK2, Tyk2, and STAT3 was observed, JAK2 was phosphorylated in E12R1-, E12R2-, and E12R1 +E12R2-expressing cells, However, direct associations were detectable only between E12R2 and JAK2. Tyk2 phosphorylation was observed only in cells expressing E12R1 or E12R1+E12R2. In parallel with this activation pattern, direct interactions only between Tyk2 and E12R1 were demonstrable. Phosphorylation of STAT3 was observed in cells expressing E12R1, E12R2, and E12R1+E12R2. The expression levels of STAT4 protein in BaF3 cells are undetectable by the methods employed here; therefore, STAT4 phosphorylation was not observed. Taken together, the data indicate that differential interactions take place between the cytoplasmic regions of the two IL-12R subunits and JAK2/Tyk2 and that the cytoplasmic region of IL-12R beta 2 alone is capable of delivering a proliferative signal.	HOFFMANN LA ROCHE INC,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110	Roche Holding								BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; CHIZZONITE R, 1992, J IMMUNOL, V148, P3117; CHUA AO, 1994, J IMMUNOL, V153, P128; DELALUNA S, 1988, GENE, V62, P121; DESAI BB, 1992, J IMMUNOL, V148, P3125; FENDLY BM, 1990, CANCER RES, V50, P1550; GATELY MK, 1995, CURRENT PROTOCOLS IM, V1; Harlow E., 1988, ANTIBODIES LAB MANUA; INNIS MA, 1995, PCR STRATEGIES, P179; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PIGNATA C, 1995, CELL IMMUNOL, V165, P211, DOI 10.1006/cimm.1995.1207; PIGNATA C, 1994, BLOOD, V83, P184; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; THIERFELDER WE, 1996, THIE, V382, P171; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Wu CY, 1996, EUR J IMMUNOL, V26, P345, DOI 10.1002/eji.1830260212; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZOU JJ, 1995, J BIOL CHEM, V270, P5864, DOI 10.1074/jbc.270.11.5864	28	105	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6073	6077		10.1074/jbc.272.9.6073	http://dx.doi.org/10.1074/jbc.272.9.6073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038232	hybrid			2022-12-25	WOS:A1997WK74700100
J	Tortora, G; Damiano, V; Bianco, C; Baldassarre, G; Bianco, AR; Lanfrancone, L; Pelicci, PG; Ciardiello, F				Tortora, G; Damiano, V; Bianco, C; Baldassarre, G; Bianco, AR; Lanfrancone, L; Pelicci, PG; Ciardiello, F			The RI alpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor	ONCOGENE			English	Article						growth factors; signal transduction; breast cells	MAMMARY EPITHELIAL-CELLS; C-HA-RAS; REGULATORY SUBUNIT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DEPENDENT ACTIVATION; NUCLEOTIDE EXCHANGE; HL-60 LEUKEMIA; MESSENGER-RNA; CAMP; DIFFERENTIATION	Functional interactions between protein kinase A (PKA) and epidermal growth factor receptor (EGF-R) signalling pathways have been suggested. Unlike the type II isoform of PKA (PKAII), the type I (PKAI) and/or its regulatory submit RI alpha are generally overexpressed in cancer cells and are induced following transforming growth factor alpha (TGF alpha)/EGF-R-dependent transformation. Downregulation of RI alpha/PKAI inhibits TGF alpha expression and EGF-R-dependent signalling. We have previously shown that addition of EGF to quiescent human normal epithelial MCF-10A cells determines PKAI expression and cell membrane translocation before cells enter S phase, while PKAI inhibition prevents S phase entry. Constitutive overexpression of PKAI confers the ability to grow in serum free medium, bypassing EGF requirement. Here we demonstrate a direct interaction of PKAI, but not of PKAII, with the activated EGF-R, that occurs within 5 min following EGF treatment of MCF-10A cells, Moreover, induction of mitogen-activated protein kinase (MAPK) activity following EGF-R activation is mimicked by PKAI overexpression and inhibited by downregulators of PKAI. Finally, the PKAI-EGF-R association occurs through the binding of RI alpha to the SH3 domain(s) of Grb2 adaptor protein, thus allowing the recruitment of the PKAI holoenzyme to the activated EGF-R. This is the first demonstration of a direct interaction of PKAI with the activated EGF-R macromolecular signalling complex.	EUROPEAN INST ONCOL,DEPT EXPT ONCOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO)	Tortora, G (corresponding author), UNIV NAPLES,DIPARTIMENTO ENDOCRINOL & ONCOL MOL & CLIN,CATTEDRA ONCOL MED,VIA PANSINI 5,I-80131 NAPLES,ITALY.		Baldassarre, Gustavo/K-1350-2016; Tortora, Giampaolo/HGB-6261-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Baldassarre, Gustavo/0000-0002-9750-8825; Lanfrancone, Luisa/0000-0002-4523-3815; Ciardiello, Fortunato/0000-0002-3369-4841; Tortora, Giampaolo/0000-0002-1378-4962				BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOCHUNG YS, 1993, PHARMACOL THERAPEUT, V60, P265, DOI 10.1016/0163-7258(93)90010-B; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1993, INT J CANCER, V53, P438, DOI 10.1002/ijc.2910530315; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GRIFFITHS G, 1990, J CELL SCI, V96, P691; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LAXMINARAYANA D, 1993, J CLIN INVEST, V92, P2207, DOI 10.1172/JCI116823; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; TORTORA G, 1994, ONCOGENE, V9, P3233; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	24	94	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					923	928		10.1038/sj.onc.1200906	http://dx.doi.org/10.1038/sj.onc.1200906			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050991				2022-12-25	WOS:A1997WK34400005
J	Adams, M; Reginato, MJ; Shao, DL; Lazar, MA; Chatterjee, VK				Adams, M; Reginato, MJ; Shao, DL; Lazar, MA; Chatterjee, VK			Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; ADIPOSE CONVERSION; HORMONE RECEPTORS; FACTOR-ALPHA; MAP KINASE; CELLS; EXPRESSION; PATHWAY; CAMP; TYROSINE	The nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) regulates transcription in response to prostanoid and thiazolidinedione ligands and promotes adipocyte differentiation. The amino-terminal A/B domain of this receptor contains a consensus mitogen-activated protein kinase site in a region common to PPAR gamma 1 and -gamma 2 isoforms. The A/B domain of human PPAR gamma 1 was phosphorylated in vivo, and this was abolished either by mutation of serine 84 to alanine (S84A) or coexpression of a phosphoprotein phosphatase. In vitro, this domain was phosphorylated by ERK2 and JNK, and this was markedly reduced in the S84A mutant. A wild type Gal4-PPAR gamma(A/B) chimera exhibited weak constitutive transcriptional activity. Remarkably, this was significantly enhanced in the S84A mutant fusion. Ligand-dependent activation by full-length mouse PPAR gamma 2 was also augmented by mutation of the homologous serine in the A/B domain to alanine. The nonphosphorylatable form of PPAR gamma was also more adipogenic. Thus, phosphorylation of a mitogen-activated protein kinase site in the A/B region of PPAR gamma inhibits both ligand-independent and ligand-dependent transactivation functions. This observation provides a potential mechanism whereby transcriptional activation by PPAR gamma may be modulated by growth factor or cytokine-stimulated signal transduction pathways involved in adipogenesis.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Reginato, Mauricio/I-6155-2013; Lazar, Mitchell A/AAF-3738-2019	Reginato, Mauricio/0000-0002-7541-4094; Chatterjee, Vengalil Krishna/0000-0002-2654-8854	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015677] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49780] Funding Source: Medline; NIGMS NIH HHS [5F31 GM15677] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Greene M. E., 1995, Gene Expression, V4, P281; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LUETTEKE NC, 1993, CELL GROWTH DIFFER, V4, P203; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PETRUSCHKE T, 1993, J CLIN ENDOCR METAB, V76, P742, DOI 10.1210/jc.76.3.742; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; TOMURA H, 1995, P NATL ACAD SCI USA, V92, P5600, DOI 10.1073/pnas.92.12.5600; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WU GD, 1992, J BIOL CHEM, V267, P7863; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xue JC, 1996, MOL CELL BIOL, V16, P1567; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU Y, 1993, J BIOL CHEM, V286, P26817	46	491	509	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5128	5132		10.1074/jbc.272.8.5128	http://dx.doi.org/10.1074/jbc.272.8.5128			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030579	hybrid			2022-12-25	WOS:A1997WJ85500067
J	Collombet, JM; Wheeler, VC; Vogel, F; Coutelle, C				Collombet, JM; Wheeler, VC; Vogel, F; Coutelle, C			Introduction of plasmid DNA into isolated mitochondria by electroporation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; TRANSFORMATION; DISEASES; MTDNA; MOUSE; GENE	Mitochondrial disorders are a large group of phenotypically heterogeneous diseases. An understanding of their molecular basis would benefit greatly from the ability to manipulate the mitochondrial genome and/or to introduce functional exogenous DNA into mitochondria. As a first step toward this approach, we have used electroporation to introduce a 7.2-kilobase plasmid DNA into isolated functional mitochondria. Transfer of the DNA at field strengths between 8 and 20 kV/cm was investigated by Southern blot analysis. Maximal plasmid internalization was achieved at a field strength of 14 kV/cm. The functional integrity of the mitochondria after electroporation was verified by enzymatic assays of specific mitochondrial marker enzymes and by measuring respiratory control. At field strengths above 12 kV/cm, an increasing mitochondrial destruction was observed. 12 kV/cm was found to be optimal for the most efficient plasmid internalization while still retaining the functional integrity of the mitochondria. At this field strength, about half of the internalized plasmid was found in the inner membrane or mitochondrial matrix, as determined by immunoelectron microscopy and Southern blot analysis of electroporated mitochondria treated with digitonin. We estimate that on average one plasmid molecule/mitochondrion reaches the matrix or inner membrane.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,DEPT BIOCHEM & MOL GENET,LONDON W2 1PG,ENGLAND; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	Imperial College London; Helmholtz Association; Max Delbruck Center for Molecular Medicine								ANZANIO PQ, 1991, P NATL ACAD SCI USA, V88, P5592; BUTOW RA, 1990, TRENDS BIOCHEM SCI, V15, P465, DOI 10.1016/0968-0004(90)90299-Q; CLARK MA, 1982, NATURE, V295, P605, DOI 10.1038/295605a0; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CORBISIER P, 1990, EUR J CELL BIOL, V51, P173; CUDD A, 1986, BIOCHIM BIOPHYS ACTA, V860, P201, DOI 10.1016/0005-2736(86)90516-X; DEMARS R, 1976, P NATL ACAD SCI USA, V73, P1693, DOI 10.1073/pnas.73.5.1693; DOOLITTLE DP, 1974, J HERED, V65, P194, DOI 10.1093/oxfordjournals.jhered.a108500; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P137; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLEIN TM, 1987, NATURE, V327, P70, DOI 10.1038/327070a0; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MCLEAN JR, 1958, J BIOL CHEM, V233, P657; Meaking WS, 1995, BBA-GENE STRUCT EXPR, V1264, P357, DOI 10.1016/0167-4781(95)00177-8; Sambrook J., 2002, MOL CLONING LAB MANU; SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1993, TRENDS GENET, V9, P128, DOI 10.1016/0168-9525(93)90207-X; Wheeler VC, 1996, GENE, V169, P251, DOI 10.1016/0378-1119(95)00812-8; WHEELER VC, 1995, ANAL BIOCHEM, V225, P374, DOI 10.1006/abio.1995.1175; ZEVIANI M, 1992, J INHERIT METAB DIS, V15, P456, DOI 10.1007/BF01799604	25	70	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5342	5347		10.1074/jbc.272.8.5342	http://dx.doi.org/10.1074/jbc.272.8.5342			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030609	hybrid			2022-12-25	WOS:A1997WJ85500097
J	Gachet, C; Payrastre, B; Guinebault, C; Trumel, C; Ohlmann, P; Mauco, G; Cazenave, JP; Plantavid, M; Chap, H				Gachet, C; Payrastre, B; Guinebault, C; Trumel, C; Ohlmann, P; Mauco, G; Cazenave, JP; Plantavid, M; Chap, H			Reversible translocation of phosphoinositide 3-kinase to the cytoskeleton of ADP-aggregated human platelets occurs independently of Rho A and without synthesis of phosphatidylinositol (3,4)-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-STIMULATED PLATELETS; HUMAN BLOOD-PLATELETS; BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; IIB-IIIA; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; TYROSINE PHOSPHORYLATION; ADENOSINE-DIPHOSPHATE	The aim of our study was to evaluate the effect of ADP and the role of cytoskeleton reorganization during re versible and irreversible platelet aggregation induced by ADP and thrombin, respectively, on the heterodimeric (p85 alpha-p110) phosphoinositide 3-kinase translocation to the cytoskeleton and its activation. Reversible ADP-induced aggregation was accompanied by a reversible reorganization of the cytoskeleton and an increase in levels of the regulatory subunit p85 alpha in this cytoskeleton similar to the increase observed in thrombin-activated platelets. This translocation followed a course parallel to the amplitude of aggregation. No increase in levels of both phosphatidylinositol (3,4)-bisphosphate (PtdIns(3,4)P-2) and phosphatidylinositol-(3,4,5)P-3 could, however, be detected even at the maximum aggregation and PI3-kinase alpha translocation. Moreover, in contrast to the situation for thrombin stimulation, the GTP-binding protein RhoA was hardly translocated to the cytoskeleton when platelets were stimulated with ADP, whereas translocation of pp60(c-scr) and focal adhesion kinase did occur. These results suggest (i) translocation of signaling enzymes does not necessarily imply their activation, (ii) the reversibility of ADP induced platelet aggregation may be the cause or the result of a lack of PI 3-kinase activation and hence of PtdIns(3,4)P-2 production, and (iii) RhoA does not seem to be involved in the ADP activation pathway of platelets. Whether PtdIns(3,4)P-2 or RhoA may contribute to the stabilization of platelet aggregates remains to be established.	HOP PURPAN,INSERM U326,F-31059 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gachet, C (corresponding author), ETAB TRANSFUS SANGUINE,INSERM U311,BP 36,10 RUE SPIELMANN,F-67065 STRASBOURG,FRANCE.		Gachet, Christian/H-9156-2016; Mauco, Gerard/A-3164-2016; Cazenave, Jean-Pierre/AAE-2935-2019	Mauco, Gerard/0000-0003-2998-2397; trumel, cathy/0000-0001-9717-5808; , Bernard/0000-0002-8693-0190				BORN GVR, 1985, CIRCULATION, V72, P741, DOI 10.1161/01.CIR.72.4.741; BRAY PF, 1994, THROMB HAEMOSTASIS, V72, P492; CATTANEO M, 1992, BLOOD, V80, P2787; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; DASH D, 1995, FEBS LETT, V363, P231, DOI 10.1016/0014-5793(95)00320-9; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; DELASALLE C, 1995, THROMB HAEMOSTASIS, V74, P990; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GACHET C, 1995, BRIT J HAEMATOL, V91, P434, DOI 10.1111/j.1365-2141.1995.tb05319.x; GACHET C, 1992, EUR J BIOCHEM, V207, P259, DOI 10.1111/j.1432-1033.1992.tb17046.x; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NURDEN P, 1995, J CLIN INVEST, V95, P1612, DOI 10.1172/JCI117835; ODA A, 1992, J BIOL CHEM, V267, P20075; Ohlmann P, 1995, BIOCHEM J, V312, P775, DOI 10.1042/bj3120775; PACKHAM MA, 1993, BIOCHEM J, V290, P849, DOI 10.1042/bj2900849; PULCINELLI FM, 1995, FEBS LETT, V364, P87, DOI 10.1016/0014-5793(95)00352-A; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHROR K, 1993, PLATELETS, V4, P252, DOI 10.3109/09537109309013225; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SULTAN C, 1991, J BIOL CHEM, V266, P23554; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TORTI M, 1995, J BIOL CHEM, V270, P13179, DOI 10.1074/jbc.270.22.13179; WENNSTROM S, 1994, ONCOGENE, V9, P651; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1995, BIOCHEM BIOPH RES CO, V211, P484, DOI 10.1006/bbrc.1995.1839; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	51	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4850	4854		10.1074/jbc.272.8.4850	http://dx.doi.org/10.1074/jbc.272.8.4850			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030542	hybrid			2022-12-25	WOS:A1997WJ85500030
J	Gite, S; RajBhandary, UL				Gite, S; RajBhandary, UL			Lysine 207 as the site of cross-linking between the 3'-end of Escherichia coli initiator tRNA and methionyl-tRNA formyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; FORMYLMETHIONINE TRANSFER-RNA; GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; ACCEPTOR STEM; PROTEIN-SYNTHESIS; CRYSTAL-STRUCTURE; ANTICODON STEM; SEQUENCE; RECOGNITION; SPECIFICITY	The specific formylation of initiator methionyl-tRNA by methionyl-tRNA formyltransferase (MTF) is important for initiation of protein synthesis in Escherichia coli. In attempts to identify regions of MTF that come close to the 3'-end of the tRNA, we oxidized P-32-3'-end-labeled E. coli initiator methionine tRNA with sodium metaperiodate and cross-linked it to MTF. The cross-linked MTF was separated from uncross-linked MTF by DEAE-celulose chromatography, and the tRNA in the cross-linked MTF was hydrolyzed with nuclease P1 and RNase T1, leaving behind an oxidized fragment of [P-32]AMP attached to MTF. Trypsin digestion of the cross-linked MTF followed by high pressure liquid chromatography of the digest yielded two peaks of radioactive peptides, I* and II*. These peptides were characterized by N- and/or C-terminal sequencing and by matrix-assisted laser desorption ionization mass spectroscopy. Peptide I* contained amino acids Gln(186)-Lys(210) with Lys(207) as the site of the cross-link. Peptide II*, a partial digestion product, contained amino acids Gln(186)-Arg(214) also with Lys(207) as the site of the cross-link, The molecular masses of peptides I* and II* indicate that the final product of the cross-linking reaction between the periodate-oxidized AMP moiety of the tRNA and Lys(207) is most likely a morpholino derivative rather than a reduced Schiffs base.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM17151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017151, R56GM017151, R01GM017151, R37GM017151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; ANDERSSON SGE, 1995, J BACTERIOL, V177, P4171, DOI 10.1128/jb.177.14.4171-4175.1995; BAZAES S, 1987, CHEM MODIFICATION EN, P35; BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; BLOMBACK B, 1967, METHOD ENZYMOL, V11, P398; BROWN DM, 1965, J CHEM SOC, P5072, DOI 10.1039/jr9650005072; BUCHANAN JM, 1982, AMINO ACIDS FERMENTA, P57; BURLINGAME AL, 1994, ANAL CHEM, V66, pR634; CUDNY H, 1986, J BIOL CHEM, V261, P6450; DAVIS MW, 1994, BIOCHEMISTRY-US, V33, P9904, DOI 10.1021/bi00199a012; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; FAYAT G, 1979, EUR J BIOCHEM, V96, P87, DOI 10.1111/j.1432-1033.1979.tb13016.x; FERANDON D, 1994, CELL, V79, P1221; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HOUNTONDJI C, 1980, EUR J BIOCHEM, V107, P403; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; JONES BN, 1986, METHODS PROTEIN MICR, P337; KHYM JX, 1963, BIOCHEMISTRY-US, V2, P344, DOI 10.1021/bi00902a029; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CP, 1993, P NATL ACAD SCI USA, V90, P7149, DOI 10.1073/pnas.90.15.7149; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; MAJUMDAR A, 1976, J BIOL CHEM, V251, P137; MATSUDAIRA P, 1993, PRACTICAL GUIDE PROT, P1; MECHULAM Y, 1991, J MOL BIOL, V217, P467; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; Meinnel Thierry, 1995, P251; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NI LY, 1991, GENE, V106, P197, DOI 10.1016/0378-1119(91)90199-L; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; RAJBHANDARY UL, 1980, FED PROC, V39, P2815; Rajbhandary Uttam L., 1995, P1; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SINDONA G, 1992, NATO ADV SCI I C-MAT, V353, P383; SKALA J, 1992, YEAST, V8, P777, DOI 10.1002/yea.320080911; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; Voorma H. O., 1996, TRANSLATIONAL CONTRO, p[759, 759]; WALLIS NG, 1995, BIOCHEMISTRY-US, V34, P7668, DOI 10.1021/bi00023a013; WARREN L, 1957, J BIOL CHEM, V229, P613; WHITFELD PR, 1954, BIOCHEM J, V58, P390, DOI 10.1042/bj0580390; ZIMMERN D, 1983, EMBO J, V2, P1901, DOI 10.1002/j.1460-2075.1983.tb01677.x	53	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5305	5312		10.1074/jbc.272.8.5305	http://dx.doi.org/10.1074/jbc.272.8.5305			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030604	hybrid			2022-12-25	WOS:A1997WJ85500092
J	Naik, UP; Patel, PM; Parise, LV				Naik, UP; Patel, PM; Parise, LV			Identification of a novel calcium-binding protein that interacts with the integrin alpha(IIb) cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT; CALRETICULIN; POLYPEPTIDE; ACTIVATION; ADHESION; MUTATION; INVITRO; SYSTEM; IIIA	The mechanism by which platelets regulate the function of integrin alpha(IIb)beta(3) (or GPIIb/IIIa), the platelet fibrinogen receptor, is unknown but may involve the binding of proteins or other factors to integrin cytoplasmic domains, To identify candidate cytoplasmic domain binding proteins, we screened a human fetal liver cDNA library in the yeast two-hybrid system, using the alpha(IIb) cytoplasmic domain as ''bait,'' and isolated a novel 855-base pair clone, The open reading frame encodes a novel 191-amino acid polypeptide (termed CIB for calcium- and integrin-binding protein) that appears to be specific for the cytoplasmic domain of alpha(IIb), since it does not interact with the alpha(v), alpha(2), alpha(5), beta(1), or beta(3) integrin cytoplasmic domains in the yeast two-hybrid system, This protein has sequence homology to two known Ca2+-binding regulatory proteins, calcineurin B (58% similarity) and calmodulin (56% similarity), and has two EF-hand motifs corresponding to the two C-terminal Ca2+ binding domains of these proteins, Moreover, recombinant CIB specifically binds Ca-45(2+) in blot overlay assays, Using reverse transcriptase-polymerase chain reaction and Western blot analysis, we detected CIB mRNA and protein (similar to 25 kDa), respectively, in human platelets, An enzyme-linked immunosorbent assay performed using either immobilized recombinant CIB or monoclonal antibody-captured alpha(IIb)beta(3) indicates a specific interaction between CIB and intact alpha(IIb)beta(3). These results suggest that CIB is a candidate regulatory molecule for integrin alpha(IIb)beta(3).	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	Naik, UP (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CTR THROMBOSIS & HEMOSTASIS,CB 7365,CHAPEL HILL,NC 27599, USA.				NHLBI NIH HHS [1-P01-HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barreuther MF, 1996, EXP CELL RES, V222, P10, DOI 10.1006/excr.1996.0002; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hendey B, 1996, BLOOD, V87, P2038; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; OTOOLE TE, 1991, SCIENCE, V254, P854; POMIES P, 1995, BIOCHEMISTRY-US, V34, P5104, DOI 10.1021/bi00015a022; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SMYTH SS, 1993, BLOOD, V81, P2827; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; WencelDrake JD, 1996, BLOOD, V87, P602, DOI 10.1182/blood.V87.2.602.bloodjournal872602; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	27	223	236	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4651	4654		10.1074/jbc.272.8.4651	http://dx.doi.org/10.1074/jbc.272.8.4651			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030514	hybrid			2022-12-25	WOS:A1997WJ85500002
J	Quijada, L; Soto, M; Alonso, C; Requena, JM				Quijada, L; Soto, M; Alonso, C; Requena, JM			Analysis of post-transcriptional regulation operating on transcription products of the tandemly linked Leishmania infantum hsp70 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TRYPANOSOMA-BRUCEI; MESSENGER-RNAS; DIFFERENTIAL EXPRESSION; GENOMIC ORGANIZATION; MEXICANA-AMAZONENSIS; CRUZI; PARASITES; SEQUENCES; CLUSTER	The genomic organization and expression of the hsp70 genes of Leishmania infantum were examined. In the cluster there are at least six copies of the hsp70 genes arranged in a head-to-tail tandem of 3.8-kilobase repetition units. The hsp70 gene copy (gene 6) located at the 3' end of the tandem has a 3'-untranslated region highly divergent in sequence relative to the 3'-untranslated region of the rest of hsp70 gene copies (genes 1-5). Nuclease S1 protection assays indicated that the steady-state level of the mRNAs derived from gene 6 is about SO-fold more abundant than the transcript level derived from genes 1-5. Nuclear run-on assays showed, however, that all hsp70 genes are transcribed at similar rates. Thus, it is likely that the differences in the steady-state levels of the transcripts from the hsp70 genes should be associated with variations in their processing or maturation rates. While the abundance of the mRNAs derived from hsp70 genes 1-5 is increased by heat shock, the hsp70 gene 6 mRNA level remains unaffected. Our data showed that ongoing protein synthesis is required for the maintenance of the heat inducement, depicting, thus, a post-transcriptional mechanism of positive regulation involving a labile protein factor that would be either induced or activated during heat shock.	UNIV AUTONOMA MADRID,CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Requena, Jose M/I-2022-2019; Álvarez, Manuel Soto/Q-5234-2018	Requena, Jose M/0000-0001-7550-0198; Álvarez, Manuel Soto/0000-0001-6825-841X				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ALY R, 1993, GENE, V127, P155, DOI 10.1016/0378-1119(93)90714-E; ALY R, 1995, EXP PARASITOL, V80, P159; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BLATTNER J, 1995, GENE, V162, P153, DOI 10.1016/0378-1119(95)00366-E; BOCK JH, 1993, MOL BIOCHEM PARASIT, V62, P187, DOI 10.1016/0166-6851(93)90108-A; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; GIBSON WC, 1988, J MOL BIOL, V201, P315, DOI 10.1016/0022-2836(88)90140-4; GLASS DJ, 1986, MOL CELL BIOL, V6, P4657, DOI 10.1128/MCB.6.12.4657; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; Hausler T, 1996, MOL BIOCHEM PARASIT, V76, P57, DOI 10.1016/0166-6851(95)02538-3; Hotz HR, 1995, MOL BIOCHEM PARASIT, V75, P1, DOI 10.1016/0166-6851(95)02503-0; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; HUG M, 1994, MOL CELL BIOL, V14, P7428, DOI 10.1128/MCB.14.11.7428; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LEE MGS, 1990, MOL BIOCHEM PARASIT, V41, P221, DOI 10.1016/0166-6851(90)90185-O; Lee MGS, 1996, MOL CELL BIOL, V16, P1220; LEE MGS, 1988, NUCLEIC ACIDS RES, V16, P9567, DOI 10.1093/nar/16.20.9567; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MACFARLANE J, 1990, EUR J BIOCHEM, V190, P377, DOI 10.1111/j.1432-1033.1990.tb15586.x; Maniatis T., 1982, MOL CLONING; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOTTRAM JC, 1989, MOL BIOCHEM PARASIT, V37, P115, DOI 10.1016/0166-6851(89)90108-4; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; PETERSEN R, 1988, GENE, V72, P161, DOI 10.1016/0378-1119(88)90138-2; Quijada L, 1996, PARASITOLOGY, V112, P277, DOI 10.1017/S0031182000065793; REQUENA JM, 1988, NUCLEIC ACIDS RES, V16, P1393, DOI 10.1093/nar/16.4.1393; REQUENA JM, 1992, MOL BIOCHEM PARASIT, V53, P201, DOI 10.1016/0166-6851(92)90022-C; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARLE S, 1989, NUCLEIC ACIDS RES, V17, P5081, DOI 10.1093/nar/17.13.5081; SHAPIRA M, 1989, EUR J BIOCHEM, V185, P231, DOI 10.1111/j.1432-1033.1989.tb15107.x; SOARES CMA, 1989, FEBS LETT, V250, P497, DOI 10.1016/0014-5793(89)80784-7; SOTO M, 1993, J BIOL CHEM, V268, P21835; SOTO M, 1992, EUR J BIOCHEM, V205, P211, DOI 10.1111/j.1432-1033.1992.tb16770.x; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; VANDERPLOEG LHT, 1985, SCIENCE, V228, P1443, DOI 10.1126/science.4012301; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; WILSON ME, 1993, J BIOL CHEM, V268, P15731; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	48	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4493	4499		10.1074/jbc.272.7.4493	http://dx.doi.org/10.1074/jbc.272.7.4493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020174	hybrid			2022-12-25	WOS:A1997WH01900090
J	Okazaki, M; Kishida, S; Hinoi, T; Hasegawa, T; Tamada, M; Kataoka, T; Kikuchi, A				Okazaki, M; Kishida, S; Hinoi, T; Hasegawa, T; Tamada, M; Kataoka, T; Kikuchi, A			Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator	ONCOGENE			English	Article						RalGDS; Raf; Ras; Ral; c-fos promoter	PLASMA-MEMBRANE; PROTEIN-KINASE; EFFECTOR; TRANSFORMATION; GTPASES; RAC1; IDENTIFICATION; PATHWAY; CDC42HS; RHOA	Ral, a member of small GTP-binding protein (G protein) superfamily, has been suggested to act downstream of Ras, since Ral GDP dissociation stimulator (RalGDS) has been found to be an effector protein of Ras. In this study, we examined the effects of RalGDS and Ral on gene expression using c-fos promoter linked to the luciferase reporter gene (c-fos-luciferase). RalGDS interacted with Ras(G12V/E37G) (in which Gly-12 and Glu-37 were changed to Val and Gly, respectively) which failed to bind to Raf in COS cells, RafCAAX is an active Raf kinase targeted to the plasma membranes by virtue of the addition of a C-terminal localization signal from K-Ras. Transfection of either RalGDS or RafCAAX into NIH3T3 cells slightly stimulated c-fos-luciferase expression and cotransfection of both proteins greatly enhanced the expression. RalGDS and an activated Rac (Rac(G12V)) did not act synergistically to stimulate c-fos-luciferase expression. Transfection of an activated Ral (Ral(G23V)) stimulated c-fos-luciferase expression. Furthermore, cotransfection of Ral(G23V) and an activated Ras (Ras(G12V)) enhanced Ras(G12V)-dependent c-fos-luciferase expression. However, Ral(G23V) did not synergize with RafCAAX, Rac(G12V) or RalGDS to stimulate the expression. These results show that RalGDS and Ral regulate c-fos promoter activity and suggest that RalGDS may activate c-fas promoter synergistically with the signal from Raf by transmitting the signal to a target other than Ral.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Hiroshima University; Kobe University			Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177; kishida, shosei/0000-0003-0405-851X				ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GORMAN CM, 1985, HIGH EFFICIENCY GENE; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lee T, 1996, DEVELOPMENT, V122, P409; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Okazaki M, 1996, CANCER RES, V56, P2387; Park SH, 1995, ONCOGENE, V11, P2349; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wolthuis RMF, 1996, ONCOGENE, V13, P353; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	43	57	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					515	521		10.1038/sj.onc.1200860	http://dx.doi.org/10.1038/sj.onc.1200860			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053849				2022-12-25	WOS:A1997WF52400002
J	Wolf, G; Elez, R; Doermer, A; Holtrich, U; Ackermann, H; Stutte, HJ; Altmannsberger, HM; RubsamenWaigmann, H; Strebhardt, K				Wolf, G; Elez, R; Doermer, A; Holtrich, U; Ackermann, H; Stutte, HJ; Altmannsberger, HM; RubsamenWaigmann, H; Strebhardt, K			Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer	ONCOGENE			English	Article						serine/threonine kinase; mRNA expression; prognosis; non-small cell lung cancer; polo-like kinase	PROTEIN-TYROSINE KINASES; K-RAS ONCOGENE; NUCLEAR ANTIGEN; PARAFFIN SECTIONS; DROSOPHILA POLO; CYCLE ANALYSIS; ADENOCARCINOMA; TUMORS; INDEX; GENE	Our previous data indicate that the expression of the PLK gene which codes for a serine/threonine kinase is restricted to proliferating cells. In Northern blot experiments PLK mRNA expression was at the limit of detection in normal lung tissue but elevated in most samples of non-small cell lung cancer (NSCLC). A very low frequency of PLK transcripts was only found in bronchiolo-alveolar carcinomas. NSCLC patients whose tumors showed moderate PLK expression survived significantly longer (5 year survival rate=51.8%) than those with high levels of PLK transcripts (24.2%, P=0.001). No statistically significant correlation was found between PLK mRNA expression and age, sex, TNM status, histological type or degree of differentiation, Interestingly, the prognosis of patients in postsurgical stages I and II was correlated with PLK expression (5 year survival rates in stage I: 69.1% (moderate PLK) - 43.5% (high PLK), P=0.03 or in stage II: 51.9% (moderate PLK) - 9.9% (high PLK), P=0.006). These results suggest that PLK mRNA expression provides a new independent prognostic indicator for patients with NSCLC.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY; KRANKENHAUS NORDSTADT,DEPT THORAC & VASC SURG,FRANKFURT,GERMANY; KRANKENHAUS NW FRANKFURT,DEPT PATHOL,FRANKFURT,GERMANY; UNIV FRANKFURT,SCH MED,DEPT PATHOL,D-60596 FRANKFURT,GERMANY; UNIV FRANKFURT,SCH MED,DEPT BIOMATH,D-60596 FRANKFURT,GERMANY; BAYER AG,PHARMA RES CTR,INST VIROL,D-42096 WUPPERTAL,GERMANY	Krankenhaus Nordwest; Goethe University Frankfurt; Goethe University Frankfurt; Bayer AG			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHME B, 1993, ONCOGENE, V8, P2857; BONGIORNO PF, 1994, J THORAC CARDIOV SUR, V107, P590, DOI 10.1016/S0022-5223(94)70107-5; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYTON F, 1991, CANCER, V68, P1309, DOI 10.1002/1097-0142(19910915)68:6<1309::AID-CNCR2820680621>3.0.CO;2-I; DEAN PN, 1984, CELL TISSUE KINET, V17, P427, DOI 10.1111/j.1365-2184.1984.tb00601.x; FONTANINI G, 1992, CANCER-AM CANCER SOC, V70, P1520, DOI 10.1002/1097-0142(19920915)70:6<1520::AID-CNCR2820700613>3.0.CO;2-K; FUJII M, 1993, ACTA MED OKAYAMA, V47, P103; GERDES J, 1984, J IMMUNOL, V133, P1710; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GOULD VE, 1989, THORACIC ONCOLOGY, P77; Haldane JBS, 1940, BIOMETRIKA, V31, P346, DOI 10.2307/2332614; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS EK, 1991, SURVIVORSHIP ANAL CL; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; KARN T, 1993, ONCOGENE, V8, P3433; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Miller R.G., 1981, SIMULTANEOUS STAT IN, Ved 2nd, DOI DOI 10.1007/s11263-015-0816-y; MOORE DF, 1995, LUNG CANC STAGING PR, P481; PENCE JC, 1993, ARCH SURG-CHICAGO, V128, P1382; QUIRKE P, 1986, J PATHOL, V149, P79, DOI 10.1002/path.1711490202; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5737; Sambrook J., 2002, MOL CLONING LAB MANU; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STREBHARDT K, 1994, ONCOL REP, V1, P195; SUNKEL CE, 1988, J CELL SCI, V89, P25; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOLM M, 1993, J CANCER RES CLIN, V119, P507, DOI 10.1007/BF01686458	39	286	305	1	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					543	549		10.1038/sj.onc.1200862	http://dx.doi.org/10.1038/sj.onc.1200862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053852				2022-12-25	WOS:A1997WF52400005
J	Cai, ZZ; Bettaieb, A; ElMahdani, N; Legres, LG; Stancou, R; Masliah, J; Chouaib, S				Cai, ZZ; Bettaieb, A; ElMahdani, N; Legres, LG; Stancou, R; Masliah, J; Chouaib, S			Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; TNF RECEPTOR; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; DEATH DOMAIN; HL-60 CELLS; CERAMIDE; APOPTOSIS; DNA	The interference of tumor necrosis factor-alpha (TNF) signaling processes with the acquisition of tumor resistance to TNF was investigated using the TNF-sensitive human breast carcinoma MCF7 cell line and its established TNF-resistant variant (R-A1). The resistance of R-A1 cells to TNF correlated with a low level of p55 TNF receptor expression and an absence of TNF signaling through TNF receptors. Stable transfection of wild-type p55 receptor in R-A1 resulted in enhancement of p55 expression and in partial restoration of TNF signaling, including nuclear factor-kappa B (NF-kappa B) activation, However, the transfected cells remained resistant to TNF-induced apoptosis, Northern blot analysis revealed a comparable induction of manganous superoxide dis mutase and A20 mRNA expression in p55-transfected cells and in sensitive MCF7 cells, making it unlikely that these genes are involved in the resistance to TNF-mediated cytotoxicity. While TNF significantly stimulated both neutral and acidic sphingomyelinase (SMase) activities with concomitant sphingomyelin (SM) hydrolysis and ceramide generation in MCF7, it failed to trigger these events in TNF-resistant p55-transfected cells, In addition, the basal SM content was significantly higher in sensitive MCF7 as compared to the resistant counterparts, Furthermore, the TNF-resistant cells tested could be induced to undergo cell death after exposure to exogenous SMase or cell-permeable C-6-ceramide. This study also shows that TNF failed to induce arachidonic acid release in p55-transfected resistant cells, suggesting that an alteration of phospholipase A(2) activation may be associated with MCF7 cell resistance to TNF. Our findings strongly suggest a role of ceramide in the mechanism of cell resistance to TNF-mediated cell death and may be relevant in elucidating the biochemical nature of intracellular messengers leading to such resistance.	INST GUSTAVE ROUSSY,INSERM,CONTRAT JEUNE FORMAT CYTOKINES & IMMUN ANTITUMORA,F-94805 VILLEJUIF,FRANCE; CTR CLAUDIUS REGAUD,INSERM CJF 9503,F-31052 TOULOUSE,FRANCE; CTR HOSP & UNIV ST ANTOINE,CNRS URS 1283,F-75012 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite			LEGRES, Luc/A-7650-2012; Luc, LEGRES/R-4956-2019; Chouaib, Salem/F-7939-2016	Bettaieb, Ali/0000-0002-6018-9592				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUAIB S, 1992, B CANCER, V79, P935; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FEUILLARD J, 1991, CYTOKINE, V3, P1; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FOLCH J, 1957, J BIOL CHEM, V226, P497; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jaattela M, 1996, J IMMUNOL, V156, P1166; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JOHNS LD, 1994, J IMMUNOL, V152, P5877; JOSEPH CK, 1993, J BIOL CHEM, V268, P2002; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU J, 1994, J BIOL CHEM, V269, P3047; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MUTCH DG, 1992, CANCER RES, V52, P866; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; RAINES MA, 1993, J BIOL CHEM, V268, P14572; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SPENCE MW, 1993, ADV LIPID RES, V26, P3; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; WALLACH D, 1984, J IMMUNOL, V132, P2464; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YANG ZH, 1993, J BIOL CHEM, V268, P20520; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; ZYAD A, 1992, INT J CANCER, V52, P953, DOI 10.1002/ijc.2910520621	62	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6918	6926		10.1074/jbc.272.11.6918	http://dx.doi.org/10.1074/jbc.272.11.6918			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054379	hybrid			2022-12-25	WOS:A1997WN14700018
J	Nakhla, AM; Romas, NA; Rosner, W				Nakhla, AM; Romas, NA; Rosner, W			Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE LNCAP; GROWTH-FACTOR-I; MEDIATED TRANSCRIPTION; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; LIGAND-BINDING; CANCER CELLS; PHOSPHORYLATION; ACCUMULATION; STIMULATION	These experiments were designed to examine the relationship between the effects of steroid hormones mediated by classic intracellular steroid hormone receptors and those mediated by a signaling system subserved at the plasma membrane by a receptor for sex hormone-binding globulin, It is known that unliganded sex hormone-binding globulin (SHBG) binds to a receptor (R(SHBG)) on prostate membranes, The R,,, SHBG complex is rapidly activated by estradiol to stimulate adenylate cyclase, with a resultant increase in intracellular cAMP. In this paper we examine the effect of this system on a prostate gene product known to be activated by androgens, prostate-specific antigen, In serum-free organ culture of human prostates, dihydrotestosterone caused an increase in prostate specific antigen secretion, This event was blocked by the anti-androgens cyproterone acetate and hydroxyflutamide, In the absence of androgens, estradiol added to prostate tissue, whose R(SHBG) was occupied by SHBG, reproduced the results seen with dihydrotestosterone. Neither estradiol alone nor SHBG alone duplicated these effects. The estradiol SHBG-induced increase in prostate-specific antigen was not blocked by anti-estrogens, but was blocked both by anti-androgens and a steroid (2-methoxyestradiol) that prevents the binding of estradiol to SHBG, Furthermore, an inhibitor of protein kinase A prevented the estradiol SHBG-induced increase in prostate-specific antigen but not that which followed dihydrotestosterone. These data indicate that there is a signaling system that amalgamates steroid-initiated intracellular events with steroid dependent occurrences generated at the cell membrane and that the latter signaling system proceeds by a pathway that involves protein kinase A.	COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,DEPT MED,NEW YORK,NY 10019; COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,DEPT UROL,NEW YORK,NY 10019; COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10019	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036714] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36714] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BERNS EMJJ, 1986, PROSTATE, V9, P247, DOI 10.1002/pros.2990090305; BRANN DW, 1995, J STEROID BIOCHEM, V52, P113, DOI 10.1016/0960-0760(94)00160-N; CULIG Z, 1994, CANCER RES, V54, P5474; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DUNN JF, 1980, J CLIN ENDOCR METAB, V51, P404, DOI 10.1210/jcem-51-2-404; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISSORE F, 1994, STEROIDS, V59, P661, DOI 10.1016/0039-128X(94)90023-X; FONG CJ, 1992, PROSTATE, V21, P121, DOI 10.1002/pros.2990210205; Fortunati N, 1996, ENDOCRINOLOGY, V137, P686, DOI 10.1210/en.137.2.686; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HENTTU P, 1993, CANCER RES, V53, P1051; HEYNS W, 1967, CLIN CHIM ACTA, V18, P361, DOI 10.1016/0009-8981(67)90032-0; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; LEPOR H, 1990, UROL CLIN N AM, V17, P461; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Nakhla AM, 1996, ENDOCRINOLOGY, V137, P4126, DOI 10.1210/en.137.10.4126; NAKHLA AM, 1995, J CLIN ENDOCR METAB, V80, P2259, DOI 10.1210/jc.80.7.2259; NAKHLA AM, 1994, P NATL ACAD SCI USA, V91, P5402, DOI 10.1073/pnas.91.12.5402; NAKHLA AM, 1990, J CLIN ENDOCR METAB, V71, P398, DOI 10.1210/jcem-71-2-398; NAKHLA AM, 1994, STEROIDS, V59, P586, DOI 10.1016/0039-128X(94)90052-3; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PEEHL DM, 1995, CANCER-AM CANCER SOC, V75, P2021, DOI 10.1002/1097-0142(19950401)75:7+<2021::AID-CNCR2820751644>3.0.CO;2-R; PORTO CS, 1995, J STEROID BIOCHEM, V53, P561, DOI 10.1016/0960-0760(95)00111-C; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROSNER W, 1992, J ANDROL, V13, P101; ROSNER W, 1996, REPROD ENDOCRINOLOGY, P605; Smith CL, 1995, BIOCHEM SOC T, V23, P935, DOI 10.1042/bst0230935; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WARRIAR N, 1994, PROSTATE, V24, P176, DOI 10.1002/pros.2990240403; WEHLING M, 1994, TRENDS ENDOCRIN MET, V5, P347, DOI 10.1016/1043-2760(94)90165-1; YOUNG CYF, 1991, CANCER RES, V51, P3748	39	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6838	6841		10.1074/jbc.272.11.6838	http://dx.doi.org/10.1074/jbc.272.11.6838			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054366	hybrid			2022-12-25	WOS:A1997WN14700005
J	Hao, WH; Tan, Z; Prasad, K; Reddy, KK; Chen, J; Prestwich, GD; Falck, JR; Shears, SB; Lafer, EM				Hao, WH; Tan, Z; Prasad, K; Reddy, KK; Chen, J; Prestwich, GD; Falck, JR; Shears, SB; Lafer, EM			Regulation of AP-3 function by inositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY PROTEIN AP-3; SYNAPSE-SPECIFIC PROTEIN; CLATHRIN BINDING; CA2+-ACTIVATED SECRETION; MONOCLONAL-ANTIBODIES; F1-20 PROTEIN; C2B DOMAIN; SYNAPTOTAGMIN; RECEPTOR; NP185	As part of the growing effort to understand the role inositol phosphates and inositol lipids play in the regulation of vesicle traffic within nerve terminals, we determined whether or not the synapse-specific clathrin assembly protein AP-3 can interact with inositol lipids. We found that soluble dioctanoyl-phosphatidylinositol 3,4,5-trisphosphate (DiC(8)-PtdIns(3,4,5)P-3) was only 7.5-fold weaker a ligand than D-myo-inositol hexakisphosphate in assays that measured the displacement of D-myo-[H-3]inositol hexakisphosphate. In functional as says we found that both of these ligands inhibited clathrin assembly, but DiC(8)-PtdIns(3,4,5)P-3 was more potent and exhibited a larger maximal effect. We also examined the structural features of DiC(8)-PtdIns(3,4,5)P-3 that establish specificity. Dioctanoyl-phosphatidylinositol 3,4-bisphosphate, which does not have a 5-phosphate, and 4,5-O-bisphosphoryl D-myo-inosityl 1-O-(1,2-O-diundecyl)-sn-3-glycerylphosphate, which does not have a 3-phosphate, were, respectively, a-fold and 4 fold less potent than DiC(8)-PtdIns(3,4,5)P-3 as inhibitors of clathrin assembly. Deacylation of DiC(8)-PtdIns(3,4,5)P-3 reduced its affinity for AP 3 almost 20-fold, and also dramatically lowered its ability to inhibit clathrin assembly. The deacylated products of the soluble derivatives of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 4,5-bisphosphate were both not significant inhibitors of clathrin assembly. It therefore appears that the interactions of inositides with AP-3 should not be considered simply in terms of electrostatic effects of the highly charged phosphate groups. Ligand specificity appears also to be mediated by hydrophobic interactions with the fatty-acyl chains of the inositol lipids.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,DEPT MOL MED,SAN ANTONIO,TX 78245; NIEHS,LAB SIGNAL TRANSDUCT,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Utah System of Higher Education; University of Utah			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916; Falck, John/0000-0002-9219-7845; Lafer, Eileen/0000-0002-0493-6522	NIGMS NIH HHS [GM31278] Funding Source: Medline; NINDS NIH HHS [R01 NS029051, NS29632, NS29051] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS029051, R01NS029632, R01NS029051] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECK KA, 1991, J BIOL CHEM, V266, P4442; CHEN J, 1996, IN PRESS J LABELLED; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; PERRY DG, 1991, J HISTOCHEM CYTOCHEM, V39, P1461, DOI 10.1177/39.11.1918924; PERRY DG, 1992, J NEUROSCI RES, V33, P408, DOI 10.1002/jnr.490330307; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shears S B, 1996, Subcell Biochem, V26, P187; SOUSA R, 1992, J NEUROSCI, V12, P2130; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; TOKER A, 1994, J BIOL CHEM, V269, P32358; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; ZHOU SB, 1992, J NEUROSCI, V12, P2144; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	44	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6393	6398		10.1074/jbc.272.10.6393	http://dx.doi.org/10.1074/jbc.272.10.6393			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045662	hybrid			2022-12-25	WOS:A1997WM64700046
J	Krantz, DE; Peter, D; Liu, YJ; Edwards, RH				Krantz, DE; Peter, D; Liu, YJ; Edwards, RH			Phosphorylation of a vesicular monoamine transporter by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIERARCHICAL PROTEIN-PHOSPHORYLATION; RABBIT SKELETAL-MUSCLE; GLYCOGEN-SYNTHASE; NEUROTRANSMITTER TRANSPORTERS; SUBSTRATE RECOGNITION; CHROMAFFIN GRANULES; SEROTONIN TRANSPORT; NEUROBLASTOMA-CELLS; CELLULAR-REGULATION; CYTOPLASMIC DOMAIN	The vesicular monoamine transporters (VMATs) package monoamine neurotransmitters into secretory vesicles for regulated exocytotic release. One isoform occurs in the adrenal gland (VMAT1) and another in the brain (VMAT2). To assess their potential for regulation, we have investigated the phosphorylation of the VMATs, Using heterologous expression in Chinese hamster ovary, PC12, and COS cells, we find that rat VMAT2, but not VMAT1, is constitutively phosphorylated, Phosphoamino acid analysis indicates that this phosphorylation occurs on serine residues, and the analysis of VMAT1-VMAT2 chimeras and site-directed mutagenesis localize the phosphorylation sites to serines 512 and 514 at the carboxyl terminus of VMAT2, Since these residues occur in an acidic region, we tested the ability of the acidotropic kinases casein kinase I (CKI) and casein kinase II (CKII) to phosphorylate bacterial fusion proteins containing the carboxyl terminus of VMAT2. Purified CKI and CKII phosphorylate the wild-type carboxyl terminus of VMAT2, but not a double mutant with both serines 512 and 514 replaced by alanine, The protein kinase inhibitor CKI-7 and unlabeled GTP both block in vitro phosphorylation by cell homogenates, indicating a role for CKII and possibly CKI in vitro, Both kinases phosphorylate the VMAT2 fusion protein to a much greater extent than a similar fusion protein containing the carboxyl terminus of VMAT1, consistent with differential phosphorylation of the two transporters observed in intact cells, These results provide the first demonstration of phosphorylation of a vesicular neurotransmitter transporter and a potential mechanism for differential regulation of the two VMATs.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Liu, Yongjian/J-7852-2018					ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; BOURBON HM, 1995, J BIOL CHEM, V270, P11130, DOI 10.1074/jbc.270.19.11130; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; DIAZNIDO J, 1992, J NEUROCHEM, V58, P1820, DOI 10.1111/j.1471-4159.1992.tb10058.x; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Frize E.D., 1954, NEW ENGL J MED, V251, P1006; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GIRAULT JA, 1990, J NEUROCHEM, V55, P1772, DOI 10.1111/j.1471-4159.1990.tb04968.x; Hardie G., 1995, PROTEIN KINASE FACTS; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; Kaufman S, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P103; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; NAKANISHI N, 1995, J BIOCHEM, V118, P291, DOI 10.1093/oxfordjournals.jbchem.a124905; NAKANISHI N, 1995, FEBS LETT, V368, P411; NAKANISHI N, 1995, J NEUROCHEM, V64, P600; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1994, J BIOL CHEM, V269, P7231; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REINHARD JF, 1987, P NATL ACAD SCI USA, V84, P8160, DOI 10.1073/pnas.84.22.8160; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	60	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6752	6759		10.1074/jbc.272.10.6752	http://dx.doi.org/10.1074/jbc.272.10.6752			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045708	hybrid			2022-12-25	WOS:A1997WM64700092
J	Shao, XP; Tarnasky, HA; Schalles, U; Oko, R; vanderHoorn, FA				Shao, XP; Tarnasky, HA; Schalles, U; Oko, R; vanderHoorn, FA			Interactional cloning of the 84-kDa major outer dense fiber protein Odf84 - Leucine zippers mediate associations of Odf84 and Odf27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM FIBROUS SHEATH; RAT SPERM; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; HUMAN-SPERMATOZOA; DEVELOPMENTAL EXPRESSION; TRANSLATIONAL REGULATION; MAMMALIAN SPERM; TRANSGENIC MICE; MOUSE SPERM	The study of mammalian sperm tail outer dense fibers (ODF), a structure of unknown function, is hampered by the insoluble nature of ODF proteins and the availability of only one cloned component, Odf27. We report here the first use of the Odf27 leucine zipper as bait in a yeast two-hybrid screen to isolate a novel testis-specific protein whose interaction with Odf27 depends critically on the Odf27 leucine zipper. We find that the novel gene, 111-450, encodes a product that localizes to ODF as determined by fluorescence microscopy and immunoelectron microscopy and that the gene 111-450 product is identical to the major ODF protein, Odf84. Interestingly, Odf84 contains two C-terminal leucine zippers, and we demonstrate that all leucine residues in the upstream leucine zipper are required for interaction with Odf27, demonstrating the strategic validity of our approach. The use of the yeast screening approach to isolate leucine zipper containing proteins should be useful in other systems, and our findings have implications for ODF structural models.	UNIV CALGARY, DEPT MED BIOCHEM, CALGARY, AB T2N 4N1, CANADA; QUEENS UNIV, DEPT ANAT & CELL BIOL, KINGSTON, ON K7L 3N6, CANADA	University of Calgary; Queens University - Canada								AFZELIUS BA, 1975, J CELL BIOL, V66, P225, DOI 10.1083/jcb.66.2.225; BACCETTI B, 1973, J SUBMICR CYTOL PATH, V5, P237; BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; Barth A. D., 1989, ABNORMAL MORPHOLOGY; BEDFORD JM, 1974, J EXP ZOOL, V187, P181, DOI 10.1002/jez.1401870202; BRAUN RE, 1990, ENZYME, V44, P120, DOI 10.1159/000468752; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BRITO M, 1989, GAMETE RES, V22, P205, DOI 10.1002/mrd.1120220208; BURFEIND P, 1991, DEV BIOL, V148, P195, DOI 10.1016/0012-1606(91)90329-2; Calvin H. I, 1971, Journal Reprod Fertil, VNo. 13, P65; CALVIN HI, 1979, BIOL REPROD, V21, P873, DOI 10.1095/biolreprod21.4.873; CALVIN HI, 1974, EXP CELL RES, V86, P280, DOI 10.1016/0014-4827(74)90714-9; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CHEMES HE, 1987, FERTIL STERIL, V48, P664; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERMONT Y, 1990, ANAT RECORD, V227, P447, DOI 10.1002/ar.1092270408; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DELMAS V, 1994, MOL CELL ENDOCRINOL, V100, P121, DOI 10.1016/0303-7207(94)90290-9; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FAJARDO MA, 1994, DEV BIOL, V166, P643, DOI 10.1006/dbio.1994.1344; Fawcett D. W., 1970, Biol Reprod, V2, P90, DOI 10.1095/biolreprod2.Supplement_2.90; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FULCHER KD, 1995, BIOL REPROD, V52, P41, DOI 10.1095/biolreprod52.1.41; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; GROOTEGOED JA, 1977, BIOCHEM J, V168, P23, DOI 10.1042/bj1680023; Gu W, 1996, MOL CELL BIOL, V16, P4535; HENKEL R, 1992, BIOL CHEM H-S, V373, P685, DOI 10.1515/bchm3.1992.373.2.685; HIGGY NA, 1994, BIOL REPROD, V50, P1357, DOI 10.1095/biolreprod50.6.1357; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IRONS MJ, 1982, ANAT RECORD, V202, P463, DOI 10.1002/ar.1092020405; IRONS MJ, 1982, AM J ANAT, V165, P121, DOI 10.1002/aja.1001650204; KUHN R, 1991, MECH DEVELOP, V35, P143, DOI 10.1016/0925-4773(91)90064-D; KUHN R, 1988, EMBO J, V7, P447, DOI 10.1002/j.1460-2075.1988.tb02832.x; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; Lee K, 1996, MOL CELL BIOL, V16, P3023; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; MCGADEY J, 1970, HISTOCHEMISTRY, V23, P180, DOI 10.1007/BF00305851; MORALES CR, 1994, MOL REPROD DEV, V37, P229, DOI 10.1002/mrd.1080370215; OKO R, 1994, BIOL REPROD, V50, P1000, DOI 10.1095/biolreprod50.5.1000; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; OKO R, 1989, ANAT REC, V225, P46, DOI 10.1002/ar.1092250108; OKO R, 1996, CELLULAR MOL REGULAT, P135; OKO RJ, 1991, ANN NY ACAD SCI, V637, P203, DOI 10.1111/j.1749-6632.1991.tb27311.x; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; OLSON GE, 1976, BIOL REPROD, V14, P517, DOI 10.1095/biolreprod14.5.517; OLSON GE, 1980, BIOL REPROD, V22, P319, DOI 10.1095/biolreprod22.2.319; PAPAVASSILIOU AG, 1994, ANTICANCER RES, V14, P1801; PHILLIPS DM, 1972, J CELL BIOL, V53, P561, DOI 10.1083/jcb.53.2.561; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFER M, 1993, MOL CELL BIOL, V13, P1708, DOI 10.1128/MCB.13.3.1708; SCHAFER U, 1986, MOL GEN GENET, V202, P219, DOI 10.1007/BF00331640; Shao XP, 1996, BIOL REPROD, V55, P1343, DOI 10.1095/biolreprod55.6.1343; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; VERA JC, 1984, J BIOL CHEM, V259, P5970; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; YUAN L, 1995, BIOL REPROD, V52, P131, DOI 10.1095/biolreprod52.1.131	63	82	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6105	6113		10.1074/jbc.272.10.6105	http://dx.doi.org/10.1074/jbc.272.10.6105			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045620	hybrid			2022-12-25	WOS:A1997WM64700004
J	Bai, G; Kusiak, JW				Bai, G; Kusiak, JW			Nerve growth factor up-regulates the N-methyl-D-aspartate receptor subunit 1 promoter in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; CEREBELLAR GRANULE CELLS; NMDA RECEPTOR; NEUROTROPHIC FACTOR; GENE-EXPRESSION; RAT-BRAIN; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL REGULATION; FOREBRAIN ISCHEMIA; MOLECULAR-CLONING	The N-methyl-D-aspartate (NMDA) subtype of glutamate receptor plays important roles in synaptic plasticity, the induction of long term potentiation, and excitotoxicity. Mechanisms governing the regulation of expression of its subunit genes remain largely unknown. The promoter of the essential subunit of the NMDA receptor heteromer, NMDAR1, contains DNA binding elements recognized by the nerve growth factor-inducible/early growth reaction factor (NGFI/Egr) family of transcription factors that are rapidly induced by neurotrophins, such as nerve growth factor (NGF), This study examined the effect of NGF on the activity of the N-methyl-D-aspartate receptor subunit 1 (NMDAR1) promoter/luciferase reporter constructs in PC12 cells, which contain the high affinity TrkA receptor for NGF and the low affinity p75(NTR) receptor for neurotrophins. NGF up-regulated the activity of the NMDAR1 promoter by 3-4-fold in a time- and dose-dependent manner. 5' deletional analysis of the promoter indicated that the responsive element(s) resides in the proximal region containing GSG and Spl sites. Mutational analysis of these sites revealed that both were important for NGF regulation. Transient expression of Egr-1 increased activity of the wild type promoter but failed to increase activity of a GSG mutant promoter. Other neurotrophins did not activate the promoter, while K-252a inhibited the action of NGF, These results suggest that the NGF effect is mediated by the high affinity NGF receptor, Trk A and that neurotrophin binding to the low affinity neurotrophin receptor, p75(NTR), alone does not affect the promoter activity. Our results suggest that NGF is able to up-regulate the activity of the NMDAR1 promoter and may play a role in controlling the expression levels of NMDA receptors.			Bai, G (corresponding author), NIA, GERONTOL RES CTR, MOL NEUROBIOL UNIT, NIH, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA.							Awobuluyi M., 1994, Society for Neuroscience Abstracts, V20, P237; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRANN DW, 1993, NEUROENDOCRINOLOGY, V58, P666, DOI 10.1159/000126607; Casado M., 1994, Society for Neuroscience Abstracts, V20, P495; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DAY ML, 1990, J BIOL CHEM, V265, P15253; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FITZGERALD LW, 1995, J NEUROSCI, V15, P2453, DOI 10.1523/JNEUROSCI.15-03-02453.1995; FRANKLIN SO, 1993, MOL BRAIN RES, V19, P93, DOI 10.1016/0169-328X(93)90153-G; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GASS P, 1993, J CEREBR BLOOD F MET, V13, P337, DOI 10.1038/jcbfm.1993.42; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEURTEAUX C, 1994, BRAIN RES, V659, P67, DOI 10.1016/0006-8993(94)90864-8; HOFER M, 1994, J NEUROCHEM, V62, P2300; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; ISHIDA N, 1994, NEUROSCI LETT, V166, P211, DOI 10.1016/0304-3940(94)90488-X; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOKAIA Z, 1995, EXP NEUROL, V136, P73, DOI 10.1006/exnr.1995.1085; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KUSIAK JW, 1993, MOL BRAIN RES, V20, P64, DOI 10.1016/0169-328X(93)90110-B; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LESCH KP, 1992, EUR J PHARM-MOLEC PH, V227, P109, DOI 10.1016/0922-4106(92)90151-K; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORAN J, 1989, BRAIN RES, V486, P15, DOI 10.1016/0006-8993(89)91272-9; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; Muzet M, 1996, NEUROREPORT, V7, P548, DOI 10.1097/00001756-199601310-00041; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PEARCE IA, 1987, FEBS LETT, V223, P143, DOI 10.1016/0014-5793(87)80525-2; PRATT GD, 1993, NEUROSCIENCE, V57, P307, DOI 10.1016/0306-4522(93)90064-M; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SUGIMOTO A, 1994, NEUROSCI LETT, V170, P39, DOI 10.1016/0304-3940(94)90233-X; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TREMBLAY M, 1995, NEUROREPORT, V6, P2225, DOI 10.1097/00001756-199511000-00030; VACCARINO FM, 1992, MOL BRAIN RES, V12, P233, DOI 10.1016/0169-328X(92)90089-T; WOODBURN VL, 1993, NEUROPHARMACOLOGY, V32, P1047, DOI 10.1016/0028-3908(93)90070-J; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	64	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5936	5942		10.1074/jbc.272.9.5936	http://dx.doi.org/10.1074/jbc.272.9.5936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038213	hybrid			2022-12-25	WOS:A1997WK74700081
J	Kusakabe, T; Richardson, CC				Kusakabe, T; Richardson, CC			Template recognition and ribonucleotide specificity of the DNA primase of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIMASE; LAGGING-STRAND SYNTHESIS; COORDINATED LEADING-STRAND; NUCLEOTIDE-BINDING SITE; 63-KDA GENE-4 PROTEIN; RNA PRIMER SYNTHESIS; REPLICATION FORK; DEOXYRIBONUCLEIC-ACID; HELICASE-PRIMASE; INITIATION SITES	The 63-kDa gene 4 DNA primase of phage T7 catalyzes the synthesis of oligoribonucleotides on single-stranded DNA templates. At the sequence, 5'-GTC-3', the primase synthesizes the dinucleotide pppAC; the cytidine residue of the recognition sequence is cryptic. Only tetraribonucleotides function as primers, but the specificity for the third and fourth position is not as stringent with a preference of CMP > AMP much greater than UMP > GMP. The predominant recognition sites on M13 DNA are 5'-(G/T)GGTC-3' and 5'-GTGTC-3'. Synthesis is usually limited to tetranucleotides, but T7 primase can synthesize longer oligoribonucleotides on templates containing long stretches of guanosine residues 5' to the recognition sequence. The specificity beyond the first two positions of the primer increases as the length of the template on the 3'-side of 5'-GTC-3' increases. On an oligonucleotide having 20 3'-flanking cytidine residues GIMP is incorporated at the third position; incorporation is reduced 4-fold when the flanking sequence reaches 65 residues, and little is incorporated on M13 templates. The presence of the 56-kDa gene 4 helicase decreases the incorporation of GMP on long templates. We propose that pausing is required for the incorporation of less preferred nucleotides and that pausing is decreased by the ability of the primase to translocate 5' to 3' on templates having long 3'-flanking sequences.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN S, 1983, NUCLEIC ACIDS RES, V11, P6041, DOI 10.1093/nar/11.17.6041; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5267; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHA TA, 1986, J BIOL CHEM, V261, P7001; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FUJIYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P903, DOI 10.1073/pnas.78.2.903; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HINE AV, 1994, P NATL ACAD SCI USA, V91, P12327, DOI 10.1073/pnas.91.25.12327; HINTON DM, 1987, J BIOL CHEM, V262, P10873; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KIM YT, 1992, J BIOL CHEM, V267, P15022; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KORNBERG A, 1992, DNA REPLICATION, P275; KORNBERG AH, 1992, J BIOL CHEM, P275; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V257, P2821; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV AA, 1995, J BIOL CHEM, V270, P15711, DOI 10.1074/jbc.270.26.15711; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SPRINGGATE CF, 1975, J MOL BIOL, V97, P577, DOI 10.1016/S0022-2836(75)80060-X; Swart JR, 1995, BIOCHEMISTRY-US, V34, P16097, DOI 10.1021/bi00049a025; SWART JR, 1993, J BIOL CHEM, V268, P12970; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TOUGU K, 1994, J BIOL CHEM, V269, P4675; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	55	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5943	5951		10.1074/jbc.272.9.5943	http://dx.doi.org/10.1074/jbc.272.9.5943			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038214	hybrid, Green Published			2022-12-25	WOS:A1997WK74700082
J	Giannini, G; DiMarcotullio, L; Zazzeroni, F; Alesse, E; Zani, M; TAng, A; Sorrentino, V; Screpanti, I; Frati, L; Gulino, A				Giannini, G; DiMarcotullio, L; Zazzeroni, F; Alesse, E; Zani, M; TAng, A; Sorrentino, V; Screpanti, I; Frati, L; Gulino, A			2-aminopurine unravels a role for pRB in the regulation of gene expression by transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TGF-BETA; RETINOBLASTOMA GENE; DEPENDENT KINASE; PROTEIN-KINASE; OKADAIC ACID; HETEROOLIGOMERIC COMPLEXES; TRANSCRIPTIONAL ACTIVATION; SP1-MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION	Transforming growth factor type beta (TGF beta) is a pleiotropic factor that regulates different cellular activities including cell growth, differentiation, and extracellular matrix deposition. All the known effects of TGF beta appear to be mediated by its interaction with cell surface receptors that possess a serine/threonine kinase activity. However, the intracellular signals that follow receptor activation and lead to the different cellular responses to TGF beta are still largely unknown. On the basis of the different sensitivity to the protein kinase inhibitor 2-aminopurine and the phosphatase inhibitor okadaic acid, we identified two distinct pathways through which TGF beta activates a genomic response. Consistently, a-aminopurine prevented and okadaic acid potentiated the induction of JE by TGF beta. The induction of PAI-1 and junB was instead potentiated by 2-aminopurine, after a transient inhibition and was unaffected by okadaic acid. The superinducing effect of 2-aminopurine required the presence of a functional RE protein since it was abolished in SV40 large T antigen-transfected cells, absent in the BT549 and Saos-2 RB-defective cell lines, and restored in BT549 and Saos-2 cells after reintroduction of pRB. The effects of 2-aminopurine on the TGF beta inducible junB expression occur in all the cell lines examined suggesting that junB, and possibly other genes, can be regulated by TGF beta through a distinct pRB-dependent pathway.	UNIV AQUILA,DEPT EXPT MED,I-67100 LAQUILA,ITALY; NEUROL MEDITERRANEAN INST,POZZILLI,ITALY; CHILDRENS HOSP LOS ANGELES,SCH MED,DEPT PEDIAT & MICROBIOL,LOS ANGELES,CA 90027; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY; UNIV SIENA,SCH MED,INST HISTOL,I-53100 SIENA,ITALY	University of L'Aquila; Children's Hospital Los Angeles; University of Siena	Giannini, G (corresponding author), UNIV ROMA LA SAPIENZA,DEPT EXPT MED & PATHOL,VIALE REGINA ELENA 324,I-00161 ROME,ITALY.		Frati, Luigi/ABI-7437-2020; Giannini, Giuseppe/B-5672-2013; Sorrentino, Vincenzo/A-4793-2014	Giannini, Giuseppe/0000-0003-0299-4056; Sorrentino, Vincenzo/0000-0002-8573-8631; Zazzeroni, Francesca/0000-0002-4474-3274; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178				Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COUSSENS LM, 1994, J CELL PHYSIOL, V160, P435, DOI 10.1002/jcp.1041600306; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FUNG YKT, 1993, ONCOGENE, V8, P2659; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GJETTING T, 1995, BIOL CHEM H-S, V376, P441; GREENWEL P, 1995, MOL CELL BIOL, V15, P6813; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KRAMER IM, 1994, J CELL SCI, V107, P3469; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUND LR, 1992, FEBS LETT, V298, P177, DOI 10.1016/0014-5793(92)80050-Q; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MAIO JJ, 1995, EXP CELL RES, V219, P442, DOI 10.1006/excr.1995.1250; METHENY LJ, 1995, EXP CELL RES, V218, P151, DOI 10.1006/excr.1995.1142; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; ONG G, 1991, ONCOGENE, V6, P761; PIENTENPOL JA, 1990, CELL, V61, P777; PIENTEPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SCREPANTI I, 1995, J CELL BIOL, V130, P183, DOI 10.1083/jcb.130.1.183; SEGARINI PR, 1993, BIOCHIM BIOPHYS ACTA, V1155, P269, DOI 10.1016/0304-419X(93)90009-2; SERRA R, 1995, DEVELOPMENT, V121, P3057; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; TAKESHITA A, 1995, J IMMUNOL, V155, P419; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	51	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5313	5319		10.1074/jbc.272.8.5313	http://dx.doi.org/10.1074/jbc.272.8.5313			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030605	hybrid			2022-12-25	WOS:A1997WJ85500093
J	Higazi, AAR; Mazar, A; Wang, JY; Quan, N; Griffin, R; Reilly, R; Henkin, J; Cines, DB				Higazi, AAR; Mazar, A; Wang, JY; Quan, N; Griffin, R; Reilly, R; Henkin, J; Cines, DB			Soluble human urokinase receptor is composed of two active units	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PLASMINOGEN-ACTIVATOR; LIGAND INTERACTION; BINDING; DOMAIN; PROTEIN	The mechanism by which single-chain urokinase (scuPA) binds to its receptor (uPAR) is incompletely understood, We report that a fragment comprising the first domain of recombinant soluble uPAR (sDI) as well as a fragment comprising the remaining domains (sDII-DIII) competes with the binding of recombinant full-length soluble uPAR (suPAR) to scuPA with an IC50 = 253 nM and an IC50 = 1569, respectively, sDII-III binds directly to scuPA with K-d = 238 nM. Binding of scuPA to each fragment also induces the expression of plasminogen activator activity. sDI and sDII-DIII (200 nM each) induced activity equal to 66 and 36% of the maximum activity induced by full-length suPAR (5 nM), respectively, Each fragment also stimulates the binding of scuPA to cells lacking endogenous uPAR, Although scuPA binds to sDI and to sDII-DIII through its amino-terminal fragment, the fragments act synergistically to inhibit the binding of suPAR and to stimulate plasminogen activator activity, Furthermore, sDII-DIII retards the velocity and alters the pattern of cleavage of sDI by chymotrypsin, These results suggest that binding of scuPA to more than one epitope in suPAR is required for its optimal activation and association with cell membranes.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; ABBOTT LABS,ABBOTT PK,IL 60064	University of Pennsylvania; Abbott Laboratories					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049517] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50970, HL49517, HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; Higazi AAR, 1996, BIOCHEMISTRY-US, V35, P6884, DOI 10.1021/bi9514774; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Kost C, 1996, EUR J BIOCHEM, V236, P682, DOI 10.1111/j.1432-1033.1996.0682d.x; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MAZAR AP, 1995, FIBRINOLYSIS S1, V6, P49; NELLES L, 1987, J BIOL CHEM, V262, P5682; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006; PLOUG M, 1991, J BIOL CHEM, V266, P1926; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; STRATTONTHOMAS JR, 1995, PROTEIN ENG, V8, P463, DOI 10.1093/protein/8.5.463; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; WALTZ DA, 1994, J BIOL CHEM, V269, P14746	25	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5348	5353		10.1074/jbc.272.8.5348	http://dx.doi.org/10.1074/jbc.272.8.5348			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030610	hybrid			2022-12-25	WOS:A1997WJ85500098
J	Zou, Y; Walker, R; Bassett, H; Geacintov, NE; VanHouten, B				Zou, Y; Walker, R; Bassett, H; Geacintov, NE; VanHouten, B			Formation of DNA repair intermediates and incision by the ATP-dependent UvrB-UvrC endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; (A)BC EXCINUCLEASE; UVRABC NUCLEASE; PROTEIN; COMPLEX; CLEAVAGE; BINDING; MECHANISM; DAMAGE	The Escherichia coli UvrB and UvrC proteins play key roles in DNA damage processing and incisions during nucleotide excision repair. To study the DNA structural requirements and protein DNA intermediates formed during these processes, benzo[a]pyrene diol epoxide-damaged and structure-specific 50-base pair substrates were constructed, DNA fragments containing a preexisting 3' incision were rapidly and efficiently incised 5' to the adduct, Gel mobility shift assays indicated that this substrate supported UvrA dissociation from the UvrB-DNA complex, which led to efficient incision, Experiments with a DNA fragment containing an internal noncomplementary 11-base region surrounding the benzo[a]pyrene diol epoxide adduct indicated that UVrABC nuclease does not require fully duplexed DNA for binding and incision, In the absence of UvrA, UvrB (UvrC) bound to an 11-base noncomplementary region containing a 3' nick (Y substrate), forming a stable protein-DNA complex (K-d similar to 5-10 nM). Formation of this complex was absolutely dependent upon UvrC, Addition to this complex of ATP, but not adenosine 5'-(beta,gamma-iminotriphosphate) or adenosine 5'-(beta,gamma-methylene)triphosphate, caused incision three or four nucleotides 5' to the double strand-single strand junction, The ATPase activity of native UvrB is activated upon interaction with UvrC and enhanced further by the addition of Y substrate, Incision of this Y structure occurs even without DNA damage, Thus the UvrBC complex is a structure-specific, ATP dependent endonuclease.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; NYU,DEPT CHEM,NEW YORK,NY 10003	University of Texas System; University of Texas Medical Branch Galveston; New York University			Zou, Yue/ABA-8429-2020; Van Houten, Bennett/K-2284-2019		NATIONAL CANCER INSTITUTE [R01CA020851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES007955] Funding Source: NIH RePORTER; NCI NIH HHS [CA20851] Funding Source: Medline; NIEHS NIH HHS [ES07955, ES06676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; CARON PR, 1988, NUCLEIC ACIDS RES, V20, P9641; COSMAN M, 1991, P 13 INT S POL AR HY, P1151; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; Maxam A M, 1980, Methods Enzymol, V65, P499; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; SNOWDEN A, 1993, THESIS U VERMONT BUR; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANHOUTEN B, 1994, DNA DAMAGE EFFECTS D, P236; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038	23	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4820	4827		10.1074/jbc.272.8.4820	http://dx.doi.org/10.1074/jbc.272.8.4820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030538	hybrid			2022-12-25	WOS:A1997WJ85500026
J	Columbano, A; LeddaColumbano, GM; Pibiri, M; Piga, R; Shinozuka, H; DeLuca, V; Cerignoli, F; Tripodi, M				Columbano, A; LeddaColumbano, GM; Pibiri, M; Piga, R; Shinozuka, H; DeLuca, V; Cerignoli, F; Tripodi, M			Increased expression of c-fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP	ONCOGENE			English	Article						immediate early genes; liver; priming; cell proliferation; TCPOBOP; CCl4	MYC MESSENGER-RNA; FACTOR KAPPA-B; REGENERATING LIVER; RAT-LIVER; CELL-PROLIFERATION; GROWTH-FACTORS; GENE; 1,4-BIS<2-(3,5-DICHLOROPYRIDYLOXY)>BENZENE; INDUCTION; IDENTIFICATION	The notion that an increased expression of immediate early genes such as c-fos and c-jun is an absolute requirement for the G(0)-G(1) transition of the hepatocytes has recently been challenged by the finding that rat liver cell proliferation induced by primary mitogens may occur in the absence of such changes (Columbano and Shinozuka, 1996). To further investigate the relationship between immediate early genes and hepatocyte proliferation, we have compared the hepatic levels of c-fos, c-jun and LRF-1 transcripts during mouse liver cell proliferation in two conditions: (i) direct hyperplasia induced by the non-genotoxic hepatocarcinogen 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene, and (ii) compensatory regeneration caused by a necrogenic dose of carbon tetrachloride. The results show striking differences in the activation of early genes. In spite of a rapid stimulation of S phase by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (approximately 8% of hepatocytes were BrdU-positive as early as 24 h after mitogen treatment versus 1% of labelled hepatocytes after 2/3 partial hepatectomy), no changes in the expression of c-fos, c-jun and LRF-1 could be observed. Moreover, no change in steady state mRNA hepatic levels of IGFBP-1 (a gene highly expressed in rat liver following partial hepatectomy), and only a slight increase in c-myc and PRL-1, was found after mitogen administration. On the contrary, a rapid, massive and transient increase in the hepatic mRNA levels of all these genes was observed during carbon tetrachloride induced regeneration. The results indicate that increased expression of immediate early genes may be dependent upon the nature of the proliferative stimulus, and it may not be a prerequisite in certain in vivo conditions such as proliferation induced in the absence of liver tissue damage.	UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15260; UNIV ROMA LA SAPIENZA,DIP BIOPATOL UMANA,SEZ BIOL CELLULARE,FDN IST PASTEUR CENCI BOLOGNETTI,ROME,ITALY	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fondazione Cenci Bolognetti; Sapienza University Rome	Columbano, A (corresponding author), UNIV CAGLIARI,IST PATOL SPERIMENTALE,I-09124 CAGLIARI,ITALY.		Tripodi, Marco/F-1143-2011; Tripodi, Marco/ABO-1160-2022; Columbano, Amedeo/C-7463-2011	Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X; Columbano, Amedeo/0000-0002-6956-9030; PIBIRI, MONICA/0000-0002-9660-9616	NCI NIH HHS [CA53453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; COLUMBANO A, 1996, P AM ASSOC CANC RES, V37, P1466; CONI P, 1990, CARCINOGENESIS, V11, P835, DOI 10.1093/carcin/11.5.835; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIWAN BA, 1992, CARCINOGENESIS, V13, P1893, DOI 10.1093/carcin/13.10.1893; DRAGANI TA, 1985, CARCINOGENESIS, V6, P225, DOI 10.1093/carcin/6.2.225; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; GARIBOLDI M, 1995, MOL CARCINOGEN, V14, P71, DOI 10.1002/mc.2940140202; GOLDSWORTHY TL, 1994, CELL PROLIFERAT, V27, P269, DOI 10.1111/j.1365-2184.1994.tb01424.x; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; MENEGAZZI M, 1996, IN PRESS HEPATOLOGY; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Ohmura T, 1996, LIFE SCI, V58, pPL211, DOI 10.1016/0024-3205(96)00039-2; Ohmura T, 1996, AM J PATHOL, V148, P815; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCEARCE LM, 1996, CELL DEATH DIFFER, V3, P51; SHINOZUKA H, 1994, LAB INVEST, V71, P35; SHORT J, 1972, J BIOL CHEM, V247, P1757; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0	33	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					857	863		10.1038/sj.onc.1200891	http://dx.doi.org/10.1038/sj.onc.1200891			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047393				2022-12-25	WOS:A1997WJ11200012
J	Wells, JM; Illenye, S; Magae, J; Wu, CL; Heintz, NH				Wells, JM; Illenye, S; Magae, J; Wu, CL; Heintz, NH			Accumulation of E2F-4 center dot DP-1 DNA binding complexes correlates with induction of dhfr gene expression during the G(1) to S phase transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GROWTH-REGULATION; IN-VIVO; MOUSE FIBROBLASTS; MOLECULAR-CLONING; FACTOR DRTF1/E2F; FAMILY MEMBERS	Previously genomic DNase I footprinting showed changes in protein binding to two overlapping E2F sites correlates with activation of dhfr gene expression at the G(1)/S boundary of the Chinese hamster cell cycle (Wells, J., Held, P., Illenye, S., and Heintz, N. H. (1996) Mol. Cell. Biol. 16, 634-647). Here gel mobility and antibody supershift assays were used to relate changes in the components of E2F DNA binding complexes in cell extracts to repression and induction of dhfr gene expression. In extracts from log phase cells, E2F complexes contained predominantly E2F-4 and E2F-2 in association with DP-1, and DNA binding assays showed complexes containing E2F-2 preferentially interact with only one of the two overlapping E2F sites. In serum starvation-stimulation experiments, arrest in G(1) by low serum was accompanied by decreased levels of dhfr mRNA and the appearance of an E2F-4 . DP-1 . p130 complex. After serum stimulation, induction of dhfr gene expression was preceded by loss of the p130 complex in mid G, and coincided with marked increases in two free E2F . DP-1 complexes in late G(1), one of which contained E2F-4 and a second which contained an unidentified E2F. We suggest activation of dhfr gene expression after serum stimulation requires at least two temporally distinct processes, relief of p130-mediated repression and subsequent activation of transcription by free E2F.	UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,CELL & MOL BIOL PROGRAM,BURLINGTON,VT 05405; MASSACHUSETTS GEN HOSP,CTR CANC,MOL ONCOL LAB,CHARLESTOWN,MA 02129	University of Vermont; University of Vermont; Harvard University; Massachusetts General Hospital								Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRESSLER LG, 1989, SEMIN DIAGN PATHOL, V6, P55; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOLDSMITH ME, 1988, MOL PHARMACOL, V33, P378; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON LF, 1978, J CELL PHYSIOL, V97, P397, DOI 10.1002/jcp.1040970314; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; Magae J, 1996, J CELL SCI, V109, P1717; MASTERS JN, 1985, MOL CELL BIOL, V5, P493, DOI 10.1128/MCB.5.3.493; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PIERCE AJ, 1992, NUCLEIC ACIDS RES, V20, P6583, DOI 10.1093/nar/20.24.6583; SANTIAGO C, 1984, J CELL PHYSIOL, V118, P79, DOI 10.1002/jcp.1041180114; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SHULL S, 1991, J BIOL CHEM, V266, P24398; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Wells J, 1996, MOL CELL BIOL, V16, P634; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	66	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4483	4492		10.1074/jbc.272.7.4483	http://dx.doi.org/10.1074/jbc.272.7.4483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020173	hybrid			2022-12-25	WOS:A1997WH01900089
J	Menon, AG; Rutter, JL; vonSattel, JP; Synder, H; Murdoch, C; Blumenfeld, A; Martuza, RL; vonDeimling, A; Gusella, JF; Houseal, TW				Menon, AG; Rutter, JL; vonSattel, JP; Synder, H; Murdoch, C; Blumenfeld, A; Martuza, RL; vonDeimling, A; Gusella, JF; Houseal, TW			Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative 'tumor progression' locus	ONCOGENE			English	Article						loss of heterozygosity; chromosome 14; meningioma	CYTOGENETIC ANALYSIS; BRAIN TUMORS; GENES; EVOLUTION; AMPLIFICATION; TUMORIGENESIS; RECOMBINATION; METAPHASE; FRAGMENTS; PROBES	Formation of meningiomas has been associated with the loss of genetic material on chromosome 22. To approach the additional chromosomal events that underlie progression of these tumors to malignancy, we have examined several other chromosomal regions for loss of heterozygosity (LOH) in these tumors. Fifty-eight tumors, comprising 43 benign meningiomas, 11 atypical meningiomas and four malignant meningiomas, were examined. While the loss of chromosome 22 was seen in approximately half of all these tumors, regardless of their malignancy, the most frequent chromosomal losses observed in the malignant and atypical tumors were on the long arm of chromosome 14. Thirty-nine tumors were informative for at least one of the three markers on chromosome 14 that we tested. Of these, 7/14 malignant and atypical tumors showed LOH in contrast to only 1/25 benign tumors. Other loci that showed LOH in malignant tumors, although at a much lower frequency, were on chromosomes 17p and 1p, The high frequency of LOH for loci on chromosome 14q in atypical and malignant tumors suggests the presence of a tumor progression gene at this locus. In one of the malignant meningiomas heterozygosity was lost at D14S13 and D14S16 but retained at the proximal marker D14S43 as well as the more distal marker D14S23. This suggests that an interstitial deletion occurred in this tumor which should be useful for further refining the position of the putative tumor progression locus.	MASSACHUSETTS GEN HOSP,MOL NEUROGENET LAB,CHARLESTOWN,MA 02129; GEORGETOWN UNIV,DEPT NEUROSURG,WASHINGTON,DC 20007; UNIV BONN,INST NEUROPATHOL,D-5300 BONN,GERMANY; GENZYME GENET,FRAMINGHAM,MA 01701	Harvard University; Massachusetts General Hospital; Georgetown University; University of Bonn; Sanofi-Aventis; Genzyme Corporation	Menon, AG (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267, USA.		von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; Rutter, Joni/0000-0002-6502-2361	NINDS NIH HHS [NS31145-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031145] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALSAADI A, 1987, CANCER GENET CYTOGEN, V26, P127, DOI 10.1016/0165-4608(87)90140-3; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; BELLO MJ, 1989, NEOPLASMA, V36, P71; BIGNER SH, 1986, CANCER GENET CYTOGEN, V22, P121, DOI 10.1016/0165-4608(86)90172-X; BOGHOSIAN L, 1989, CANCER GENET CYTOGEN, V43, P39, DOI 10.1016/0165-4608(89)90125-8; CASALONE R, 1990, CANCER GENET CYTOGEN, V45, P237, DOI 10.1016/0165-4608(90)90088-R; CASARTELLI C, 1989, CANCER GENET CYTOGEN, V40, P33, DOI 10.1016/0165-4608(89)90143-X; CHALLA VR, 1992, NEUROSURGERY, V1, P613; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBHART E, 1986, BREAST CANCER RES TR, V8, P125, DOI 10.1007/BF01807701; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KATSUYAMA J, 1986, CANCER GENET CYTOGEN, V22, P63, DOI 10.1016/0165-4608(86)90138-X; KLINGER K, 1992, AM J HUM GENET, V51, P55; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NAKAMURA Y, 1989, GENOMICS, V4, P76, DOI 10.1016/0888-7543(89)90317-0; *NIH CEPH COLL MAP, 1992, SCIENCE, V258, P67; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RUSSELL DS, 1990, PATHOLOGY TUMORS NER; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1722, DOI 10.1093/nar/19.7.1722; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; SUZUKI T, 1989, CANCER RES, V49, P1095; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; ZANKL H, 1972, HUMANGENETIK, V14, P167, DOI 10.1007/BF00273305	34	99	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					611	616		10.1038/sj.onc.1200853	http://dx.doi.org/10.1038/sj.onc.1200853			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053860				2022-12-25	WOS:A1997WF52400013
J	Hack, V; Schmid, D; Breitkreutz, R; StahlHenning, C; Drings, P; Kinscherf, R; Taut, F; Holm, E; Droge, W				Hack, V; Schmid, D; Breitkreutz, R; StahlHenning, C; Drings, P; Kinscherf, R; Taut, F; Holm, E; Droge, W			Cystine levels, cystine flux, and protein catabolism in cancer cachexia, HIV/SIV infection, and senescence	FASEB JOURNAL			English	Article						skeletal muscle catabolism; HIV infection; cancer; plasma cystine level; glutamine exchange rate; controlled constructive metabolism	ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO-ACID-CONCENTRATIONS; VIRUS-INFECTION; METABOLISM; EXERCISE; CYSTEINE; ALANINE; GLUCOSE; UREA	Patients with skeletal muscle catabolism (cachexia) fail to conserve the skeletal muscle protein and release lar re amounts of nitrogen as urea. Previous studies suggest that the threshold for the conversion of amino acids into other forms of chemical energy and the concomitant production of urea are regulated by the plasma cystine level and hepatic cysteine catabolism. Studies of plasma amino acid exchange rates in the lower extremities now show that healthy young subjects regulate their plasma cystine level in a process that may be described as controlled constructive catabolism. The term controlled describes the fact that the release of cystine and other amino acids from the peripheral tissue is negatively correlated with (certain) plasma amino acid levels. The term constructive describes the fact that the release of cystine is correlated with an increase of the plasma cystine level. The regulation of the plasma cystine level is disturbed in conditions with progressive skeletal muscle catabolism including cancer, HIV infection, and old age. These conditions show also a low plasma glutamine:cystine ratio indicative of an impaired hepatic cystine catabolism. In HIV (+) patients and SIV-infected macaques, a decrease of the plasma cystine level was found to coincide with the decrease of CD4(+) T cells.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV IMMUNOCHEM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,MED CLIN MANNHEIM 1,DEPT PATHOPHYSIOL,D-68167 MANNHEIM,GERMANY; GERMAN PRIMATE CTR,DEPT VIROL & IMMUNOL,D-37077 GOTTINGEN,GERMANY; HOSP THORAX DIS,D-69126 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT ANESTHESIOL,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Deutsches Primatenzentrum (DPZ); Ruprecht Karls University Heidelberg			Kinscherf, Ralf/AAV-7164-2021					AOKI T, 1993, CLIN IMMUNOL IMMUNOP, V69, P253, DOI 10.1006/clin.1993.1178; Aoki T T, 1972, Adv Enzyme Regul, V10, P145, DOI 10.1016/0065-2571(72)90011-8; BARBEY K, 1963, Z KREISLAUFFORSCH, V52, P1129; BELLA DL, 1995, AM J PHYSIOL-ENDOC M, V269, pE910, DOI 10.1152/ajpendo.1995.269.5.E910; BRENNAN MF, 1977, CANCER RES, V37, P2359; BRENNAN MF, 1986, DIGEST DIS SCI, V31, pS77, DOI 10.1007/BF01295991; CHAWLA RK, 1984, GASTROENTEROLOGY, V87, P770; CHEN MK, 1993, ANN SURG, V217, P655, DOI 10.1097/00000658-199306000-00007; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; DIAMOND JM, 1992, NATURE, V357, P362, DOI 10.1038/357362a0; DOHM GL, 1986, EXERCISE SPORT SCI R, V14, P143; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1996, ANTIOXIDANTS DIS MEC, V28, P581; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; FEIN R, 1985, CANCER, V56, P2512, DOI 10.1002/1097-0142(19851115)56:10<2512::AID-CNCR2820561032>3.0.CO;2-9; FONTANA L, 1986, IMMUNOBIOLOGY, V171, P425, DOI 10.1016/S0171-2985(86)80074-2; FRIEDMAN PJ, 1987, NUTR RES, V7, P707, DOI 10.1016/S0271-5317(87)80101-X; Gross A, 1996, AIDS RES HUM RETROV, V12, P1639, DOI 10.1089/aid.1996.12.1639; GRUNFELD C, 1991, GASTROINTESTINAL NUT, P207; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; HORTIN GL, 1994, CLIN CHEM, V40, P785; Kinscherf R, 1996, J MOL MED-JMM, V74, P393, DOI 10.1007/s001090050040; KOHASHI N, 1978, J BIOCHEM-TOKYO, V84, P159, DOI 10.1093/oxfordjournals.jbchem.a132104; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; LONG CL, 1976, AM J CLIN NUTR, V29, P380, DOI 10.1093/ajcn/29.4.380; OWEN OE, 1969, J CLIN INVEST, V48, P584; PISTERS PWT, 1993, CRIT REV CL LAB SCI, V30, P223, DOI 10.3109/10408369309084669; POLI G, 1985, CLIN EXP IMMUNOL, V62, P128; SHAW JHF, 1987, SURGERY, V101, P181; SHAW JHF, 1985, SURGERY, V97, P557; STIPANUK MH, 1986, ANNU REV NUTR, V6, P179, DOI 10.1146/annurev.nu.06.070186.001143; STRAIN AJ, 1979, INVEST CELL PATHOL, V2, P181; UBUKA T, 1992, Amino Acids (Vienna), V2, P143, DOI 10.1007/BF00806085; ULLUM H, 1995, J EXP MED, V182, P789, DOI 10.1084/jem.182.3.789; VIRU A, 1987, SPORTS MED, V4, P95, DOI 10.2165/00007256-198704020-00003; Warren S, 1932, AM J MED SCI, V184, P610, DOI 10.1097/00000441-193211000-00002; WATERHOUSE C, 1979, CANCER RES, V39, P1968	38	51	52	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					84	92		10.1096/fasebj.11.1.9034170	http://dx.doi.org/10.1096/fasebj.11.1.9034170			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034170				2022-12-25	WOS:A1997WK14700012
J	Pappan, K; Zheng, SQ; Wang, XM				Pappan, K; Zheng, SQ; Wang, XM			Identification and characterization of a novel plant phospholipase D that requires polyphosphoinositides and submicromolar calcium for activity in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; NEOMYCIN; PURIFICATION	Phospholipase D (PLD; EC 3.1.4.4) has been proposed to be involved in a number of cellular processes including transmembrane signaling and membrane deterioration. PLD previously described from various plant sources generally requires millimolar ranges of calcium for optimal activity. in this study, we genetically suppressed the expression of this conventional PLD in Arabidopsis by introducing an antisense PLD cDNA. However, both the antisense transgenic and wild-type plants showed comparable PLD activity in the presence of submicromolar concentrations of calcium and phosphatidylinositol 4,5-bisphosphate using phosphatidylcholine as a substrate, This new PLD activity was partially stimulated by phosphatidylinositol 4-phosphate, but not by other phospholipids, including phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, or phosphatidylcholine. Its requirement for polyphosphoinositides was further supported by its ability to be inhibited by neomycin. The polyphosphoinositide-dependent PLD requires calcium for activity, but no magnesium. The calcium stimulation was observed in the nanomolar range and reached a plateau at 5 mu m calcium. The findings of this study demonstrate the presence of different PLDs that are regulated in a distinct manner in plants. The potential significance of a PLD that is regulated by polyphosphoinositides and physiological concentrations of Ca2+ is discussed.	KANSAS STATE UNIV, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Kansas State University			Wang, Xuemin/M-2853-2013; Pappan, Kirk/AAV-5946-2021	wang, xuemin/0000-0002-6251-6745; Pappan, Kirk/0000-0002-2341-8798				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHEN Q, 1991, MOL BIOL PLANT DEV; CHEN QY, 1991, PLANT PHYSIOL, V96, P340, DOI 10.1104/pp.96.1.340; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DROBAK BK, 1993, PLANT PHYSIOL, V102, P705, DOI 10.1104/pp.102.3.705; DYER JH, 1994, PLANT PHYSIOL, V105, P715, DOI 10.1104/pp.105.2.715; Dyer JH, 1995, PLANT PHYSIOL, V109, P1497; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HANAHAN DJ, 1947, J BIOL CHEM, V169, P699; Heller M, 1978, Adv Lipid Res, V16, P267; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; PALIYATH G, 1987, PHYSIOL PLANTARUM, V71, P503, DOI 10.1111/j.1399-3054.1987.tb02891.x; PAPPAN K, 1997, J BIOL CHEM, V272, P6861; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Ryu SB, 1996, BBA-LIPID LIPID MET, V1303, P243, DOI 10.1016/0005-2760(96)00096-3; RYU SB, 1995, PLANT PHYSIOL, V108, P713, DOI 10.1104/pp.108.2.713; SCHACHT J, 1978, J LIPID RES, V19, P1063; SHARDL CL, 1987, GENE, V61, P1; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; UEKI J, 1995, PLANT CELL PHYSIOL, V36, P903, DOI 10.1093/oxfordjournals.pcp.a078837; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WANG X, 1993, ARCH BIOCHEM BIOPHYS, V306, P496; WANG X, 1993, LIPID METABOLISM PLA, P499; WANG XM, 1994, J BIOL CHEM, V269, P20312; Young SA, 1996, PLANT CELL, V8, P1079, DOI 10.1105/tpc.8.6.1079	32	106	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7048	7054		10.1074/jbc.272.11.7048	http://dx.doi.org/10.1074/jbc.272.11.7048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054396	hybrid			2022-12-25	WOS:A1997WN14700035
J	Chen, H; Hung, MC				Chen, H; Hung, MC			Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU PROMOTER; EXPRESSION; CLONING; PROTEIN; IDENTIFICATION; ENHANCER; BINDING; CELLS; E1A	Overexpression of HER-2/neu is frequently found in human cancer and has been shown to enhance the metastatic potential of tumors and to induce the chemoresistance of cancer cells. The molecular mechanism(s) by which HER-2/neu expression is deregulated in cancer is not clear. We reported previously that adenovirus 5 E1A is capable of transcriptionally repressing the HER-2/neu promoter. We report here that the E1A-associated p300 protein can derepress the E1A-mediated repression of HER-2/neu in a dose-dependent manner. A p300 mutant, which lost its ability to bind to E1A, also effectively rescued the repressed HER-2/neu promoter in the presence of excess E1A inside the cells. A protein complex can bind to the p300 consensus sequences in HER-2/neu promoter. The intensity of the retarded band of the protein complex decreased significantly after preincubation of the nuclear extracts with beads that has been conjugated with anti-p300 antibody. The binding of E1A to p300 and the p300 consensus sequence in HER-2/neu promoter were crucial for the ability of E1A to repress HER-2/neu promoter, demonstrating that p300 is involved in the transcriptional regulation of HER-2/neu and serves as a target for E1A repression.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA58880, R01-CA60858] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EDKNER R, 1996, MOL CELL BIOL, V16, P3454; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; MILLER SJ, 1995, ONCOL REP, V2, P497; Miller SJ, 1996, DNA CELL BIOL, V15, P749, DOI 10.1089/dna.1996.15.749; MILLER SJ, 1994, INT J ONCOL, V4, P599; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE MRA, 1992, ONCOGENE, V7, P677; YAN DH, 1993, MOL CARCINOGEN, V7, P44, DOI 10.1002/mc.2940070108; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	22	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6101	6104		10.1074/jbc.272.10.6101	http://dx.doi.org/10.1074/jbc.272.10.6101			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045619	hybrid			2022-12-25	WOS:A1997WM64700003
J	Coolican, SA; Samuel, DS; Ewton, DZ; McWade, FJ; Florini, JR				Coolican, SA; Samuel, DS; Ewton, DZ; McWade, FJ; Florini, JR			The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; MYOBLAST DIFFERENTIATION; TERMINAL DIFFERENTIATION; S6 KINASE; MUSCLE DIFFERENTIATION; SKELETAL MYOBLASTS; TYROSINE KINASE; DNA-SYNTHESIS; SH2 DOMAIN	It is well established that mitogens inhibit differentiation of skeletal muscle cells, but the insulin-like growth factors (IGFs), acting through a single receptor, stimulate both proliferation and differentiation of myoblasts, Although the IGF-I mitogenic signaling pathway has been extensively studied in other cell types, little is known about the signaling pathway leading to differentiation in skeletal muscle, Ey using specific inhibitors of the IGF signal transduction pathway, we have begun to define the signaling intermediates mediating the two responses to IGFs, We found that PD098059, an inhibitor of mitogen-activated protein (MAP) kinase kinase activation, inhibited IGF-stimulated proliferation of L6A1 myoblasts and the events associated with it, such as phosphorylation of the MAP kinases and elevation of c-fos mRNA and cyclin D protein, Surprisingly, PD098059 caused a dramatic enhancement of differentiation, evident both at a morphological (fusion of myoblasts into myotubes) and biochemical level (elevation of myogenin and p21 cyclin-dependent kinase inhibitor expression, as well as creatine kinase activity), In sharp contrast, LY294002, an inhibitor of phosphatidylinositol 3-kinase, and rapamycin, an inhibitor of the activation of p70 S6 kinase (p70(S6k)), completely abolished IGF stimulation of L6A1 differentiation. We found that p70(S6k) activity increased substantially during differentiation, and this increase was further enhanced by PD098059, Our results demonstrate that the MAP kinase pathway plays a primary role in the mitogenic response and is inhibitory to the myogenic response in L6A1 myoblasts, while activation of the phosphatidylinositol 3-kinase/ p70(S6k) pathway is essential for IGF stimulated differentiation. Thus, it appears that signaling from the IGF-I receptor utilizes two distinct pathways leading either to proliferation or differentiation.			Coolican, SA (corresponding author), SYRACUSE UNIV,DEPT BIOL,130 COLL PL,SYRACUSE,NY 13244, USA.				NHLBI NIH HHS [R37HL11551] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL011551] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACH LA, 1995, ENDOCRINOLOGY, V136, P5061, DOI 10.1210/en.136.11.5061; BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; DOUMIT ME, 1993, J CELL PHYSIOL, V157, P326, DOI 10.1002/jcp.1041570216; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; EWTON DZ, 1995, J ENDOCRINOL, V144, P539, DOI 10.1677/joe.0.1440539; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; EWTON DZ, 1981, DEV BIOL, V86, P31, DOI 10.1016/0012-1606(81)90312-2; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FLORINI JR, 1989, ANAL BIOCHEM, V182, P399, DOI 10.1016/0003-2697(89)90614-3; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GUO K, 1995, MOL CELL BIOL, V15, P3823; HASHIMOTO N, 1995, EUR J BIOCHEM, V227, P379, DOI 10.1111/j.1432-1033.1995.tb20400.x; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JIN P, 1991, J BIOL CHEM, V266, P1245; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIGSBERG IR, 1971, DEV BIOL, V26, P133, DOI 10.1016/0012-1606(71)90113-8; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LINKHART T, 1978, J CELL BIOL, V79, P25; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; LINKHART TA, 1980, J SUPRAMOL STR CELL, V14, P483, DOI 10.1002/jss.400140407; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; ONG J, 1987, ENDOCRINOLOGY, V120, P353, DOI 10.1210/endo-120-1-353; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUINN LS, 1994, J CELL PHYSIOL, V159, P387, DOI 10.1002/jcp.1041590302; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Stewart CEH, 1996, J CELL PHYSIOL, V169, P23, DOI 10.1002/(SICI)1097-4652(199610)169:1<23::AID-JCP3>3.0.CO;2-G; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; TURO KA, 1982, AM J PHYSIOL, V243, pC278, DOI 10.1152/ajpcell.1982.243.5.C278; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; YABLONKAREUVENI Z, 1993, DEV BIOL, V156, P307, DOI 10.1006/dbio.1993.1079; YEN A, 1994, EUR J CELL BIOL, V65, P103	64	530	548	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6653	6662		10.1074/jbc.272.10.6653	http://dx.doi.org/10.1074/jbc.272.10.6653			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045696	hybrid			2022-12-25	WOS:A1997WM64700080
J	Gafvelin, G; Sakaguchi, M; Andersson, H; vonHeijne, G				Gafvelin, G; Sakaguchi, M; Andersson, H; vonHeijne, G			Topological rules for membrane protein assembly in eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; SEMLIKI FOREST VIRUS; COLI INNER MEMBRANE; ESCHERICHIA-COLI; SIGNAL SEQUENCE; AMINO-ACIDS; TRANSMEMBRANE SEGMENTS; MICROSOMAL MEMBRANE; INVITRO MUTAGENESIS; LEADER PEPTIDASE	Insertion into the endoplasmic reticulum membrane of model proteins with one, two, and four transmembrane segments and different distributions of positively charged residues in the N-terminal tail and the polar loops has been studied both in vitro and in vivo, Membrane insertion of these same constructs has previously been analyzed in Escherichia coli, thus making possible a detailed comparison between the topological rules for membrane protein assembly in prokaryotic and eukaryotic cells, In general, we find that positively charged residues have similar effects on the membrane topology in both systems when they are placed in the N-terminal tail but that the effects of charged residues in internal loops clearly differ, Our results rule out a sequential start-stop transfer model where successive hydrophobic segments insert with alternating orientations starting from the most N terminal one as the only mechanism for membrane protein insertion in eukaryotic cells.	UNIV STOCKHOLM, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN; KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOL BIOL, FUKUOKA 812, JAPAN; KAROLINSKA INST, NOVUM, CTR BIOTECHNOL, DEPT BIOL MOL, S-14157 HUDDINGE, SWEDEN	Stockholm University; Kyushu University; Karolinska Institutet			von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Gafvelin, Guro/0000-0003-1618-4011				ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; ANDERSSON H, 1994, FEBS LETT, V347, P169, DOI 10.1016/0014-5793(94)00530-3; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CAO GQ, 1994, J BIOL CHEM, V269, P26898; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Erickson B. W., 1976, PROTEINS, VII, P255; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; Geller D, 1996, J BIOL CHEM, V271, P13746, DOI 10.1074/jbc.271.23.13746; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENNESSEY ES, 1993, FEBS LETT, V331, P159, DOI 10.1016/0014-5793(93)80317-N; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kiefer H, 1996, BIOCHEMISTRY-US, V35, P16077, DOI 10.1021/bi9612069; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, J VIROL, V65, P147; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; VONHEIJNE G, 1994, FEBS LETT, V346, P69, DOI 10.1016/0014-5793(94)00296-7; WAHLBERG JM, 1989, J VIROL, V63, P4991, DOI 10.1128/JVI.63.12.4991-4997.1989; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742	51	122	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6119	6127		10.1074/jbc.272.10.6119	http://dx.doi.org/10.1074/jbc.272.10.6119			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045622	hybrid			2022-12-25	WOS:A1997WM64700006
J	Gerhardt, CC; Lodder, HC; Vincent, M; Bakker, RA; Planta, RJ; Vreugdenhil, E; Kits, KS; vanHeerikhuizen, H				Gerhardt, CC; Lodder, HC; Vincent, M; Bakker, RA; Planta, RJ; Vreugdenhil, E; Kits, KS; vanHeerikhuizen, H			Cloning and expression of a complementary DNA encoding a molluscan octopamine receptor that couples to chloride channels in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYRAMINE RECEPTOR; SERINE RESIDUES; APLYSIA; IDENTIFICATION; ACTIVATION; PROTEIN; NEURONS	A cDNA encoding a G-protein coupled receptor was cloned from the central nervous system of the pond snail Lymnaea stagnalis. The predicted amino acid sequence of this cDNA most closely resembles the Drosophila tyramine/octopamine receptor, the Locusta tyramine receptor, and an octopamine receptor (Lym oa(1)) that we recently cloned from Lymnaea. After stable expression of the cDNA in HEK293 cells, we found that [H-3]rauwolscine binds with high affinity to the receptor (K-D = 6.2 . 10(-4) M). Octopamine appears to be the most potent naturally occurring agonist to displace the [H-3]rauwolscine binding (K-i = 3.0 . 10(-7) m). Therefore, the receptor is considered to be an octopamine receptor and is consequently designated Lym oa(2). The novel receptor shares little pharmacological resemblance with Lym oa(1), indicating that the two receptors represent different octopamine receptor subfamilies. Octopaminergic stimulation of Lym oa(2) does not induce changes in intracellular concentrations of cAMP or inositol phosphates. However, electrophysiological experiments indicate that octopamine is able to activate a voltage-independent Cl- current in HEK293 cells stably expressing Lym oa(2). Although opening of this chloride channel most probably does not require the activation of either protein kinase A or C, it can be blocked by inhibition of protein phosphorylation.	FREE UNIV AMSTERDAM,DEPT BIOCHEM & MOL BIOL,NL-1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM,DEPT MOL & CELLULAR NEUROBIOL,MEMBRANE PHYSIOL SECT,NL-1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam								ARAKAWA S, 1990, NEURON, V2, P343; BAHLS FH, 1990, NEUROSCI LETT, V120, P131, DOI 10.1016/0304-3940(90)90186-D; BROWNSTEIN MJ, 1974, P NATL ACAD SCI USA, V71, P4662, DOI 10.1073/pnas.71.12.4662; CARPENTER DO, 1974, NATURE, V252, P483, DOI 10.1038/252483a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX BA, 1992, J NEUROCHEM, V59, P627, DOI 10.1111/j.1471-4159.1992.tb09416.x; COX RTL, 1988, COMP BIOCHEM PHYS C, V91, P541, DOI 10.1016/0742-8413(88)90074-6; DAVID JC, 1985, PROG NEUROBIOL, V24, P141, DOI 10.1016/0301-0082(85)90009-7; ELEKES K, 1993, BRAIN RES, V16, P191; EVANS PD, 1993, NEUROCHEM RES, V18, P869, DOI 10.1007/BF00998270; Gerhardt CC, 1997, MOL PHARMACOL, V51, P293, DOI 10.1124/mol.51.2.293; Gerhardt CC, 1996, EUR J PHARMACOL, V311, P249, DOI 10.1016/0014-2999(96)00410-4; GUTHRIE PB, 1975, COMP BIOCHEM PHYS C, V52, P109, DOI 10.1016/0306-4492(75)90023-4; HIRIPI L, 1994, BRAIN RES, V633, P119, DOI 10.1016/0006-8993(94)91530-X; LEURS R, 1994, BRIT J PHARMACOL, V112, P847, DOI 10.1111/j.1476-5381.1994.tb13157.x; LEVITAN IB, 1974, P NATL ACAD SCI USA, V71, P1145, DOI 10.1073/pnas.71.4.1145; MCCAMAN MW, 1980, NONCATECHOLIC PHENYL, P193; NATHANSON JA, 1973, SCIENCE, V180, P308, DOI 10.1126/science.180.4083.308; PELLMAR TC, 1981, BRAIN RES, V223, P448, DOI 10.1016/0006-8993(81)91163-X; Postma FR, 1996, EMBO J, V15, P63, DOI 10.1002/j.1460-2075.1996.tb00334.x; SAAVEDRA JM, 1974, SCIENCE, V185, P364, DOI 10.1126/science.185.4148.364; SAUDOU F, 1990, EMBO J, V9, P3611, DOI 10.1002/j.1460-2075.1990.tb07572.x; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Van Der Steen W. J., 1969, NETH J ZOOL, V19, P131, DOI DOI 10.1163/002829669X00170; VANDENBROECK J, 1995, J NEUROCHEM, V64, P2387; WALKER RJ, 1972, EXPERIENTIA, V28, P1173, DOI 10.1007/BF01946151; WANG CD, 1991, MOL PHARMACOL, V40, P168	28	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6201	6207		10.1074/jbc.272.10.6201	http://dx.doi.org/10.1074/jbc.272.10.6201			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045634	hybrid, Green Published			2022-12-25	WOS:A1997WM64700018
J	Gupta, D; Dam, TK; Oscarson, S; Brewer, CF				Gupta, D; Dam, TK; Oscarson, S; Brewer, CF			Thermodynamics of lectin-carbohydrate interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOPEPTIDES; CONCANAVALIN-A; BINDING-SITE; LIGAND-BINDING; SPECIFICITY; OLIGOSACCHARIDES; MUTAGENESIS; ANTIBODY	The trisaccharide 3,6-di-O-(alpha-D-mannopyranosyl)-D-mannose, which is present in all asparagine-linked carbohydrates, was previously shown by titration microcalorimetry to bind to the lectin concanavalin A (ConA) with nearly -6 kcal mol(-1) greater enthalpy change and 60-fold higher affinity than methyl-alpha-D-mannopyranoside (Mandal, D. K., Kishore, N., and Brewer, C. F. (1994) Biochemistry 33, 1149-1156). Similar studies of the binding of a series of monodeoxy derivatives of the alpha(1-3) residue of the trimannoside showed that this arm was required for high affinity binding (Mandal, D. K., Bhattacharyya, L., Koenig, S. H., Brown, R., D., III, Oscarson, S., and Brewer, C. F. (1994) Biochemistry 33, 1157-1162). In the present paper, a series of monodeoxy derivatives of the alpha(1-6) arm and ''core'' Man residue of the trimannoside as well as dideoxy and trideoxy analogs were synthesized. Isothermal titration microcalorimetry experiments establish that the 3-, 4-, and 6-hydroxyl groups of the alpha(1-6)Man residue of the trimannoside binds to the lectin, along with the 2- and 4-hydroxyl groups of the core Man residue and the 3- and 4-hydroxyl groups of the alpha(1-3)Man residue. Dideoxy analogs and trideoxy analogs showed losses of affinities and enthalpy values consistent with losses in binding of specific hydroxyl groups of the trimannoside. The free energy and enthalpy contributions to binding of individual hydroxyl groups of the trimannoside determined from the corresponding monodeoxy analogs are observed to be nonlinear, indicating differential contributions of the solvent and protein to the thermodynamics of binding of the analogs. The thermodynamic solution data agree well with the recent x-ray crystal structure of ConA complexed with the trimannoside (Naismith, J. H., and Field, R. A. (1996) J. Biol. Chem. 271, 972-976).	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; UNIV STOCKHOLM,DEPT ORGAN CHEM,STOCKHOLM,SWEDEN	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stockholm University				Oscarson, Stefan/0000-0002-8273-4918	NCI NIH HHS [P30 CA-13330, CA-16054] Funding Source: Medline; NCRR NIH HHS [I-S10-RR02309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA016054] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; BHATTACHARYYA L, 1989, EUR J BIOCHEM, V178, P721, DOI 10.1111/j.1432-1033.1989.tb14503.x; BITTIGER H, 1976, CONCANAVALIN TOOL; BREWER CF, 1986, J BIOL CHEM, V261, P7306; BREWER CF, 1983, J BIOMOL STRUCT DYN, V1, P961, DOI 10.1080/07391102.1983.10507497; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; KALB AJ, 1968, BIOCHEM J, V109, P669, DOI 10.1042/bj1090669; LEMIEUX RU, 1991, CIBA F SYMP, V158, P231; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; Lis H., 1981, The biochemistry of plants. A comprehensive treatise. Volume 6. Proteins and nucleic acids., P371; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MUNSKE GR, 1984, ARCH BIOCHEM BIOPHYS, V233, P582, DOI 10.1016/0003-9861(84)90482-X; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Oscarson S, 1995, CARBOHYD RES, V278, P271, DOI 10.1016/0008-6215(95)00268-5; SAHA SK, 1994, CARBOHYD RES, V254, P157; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YARIV J, 1968, BIOCHIM BIOPHYS ACTA, V165, P303, DOI 10.1016/0304-4165(68)90063-9	28	67	70	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6388	6392		10.1074/jbc.272.10.6388	http://dx.doi.org/10.1074/jbc.272.10.6388			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045661	hybrid			2022-12-25	WOS:A1997WM64700045
J	Tao, Y; Guermah, M; Martinez, E; Oelgeschlager, T; Hasegawa, S; Takada, R; Yamamoto, T; Horikoshi, M; Roeder, RG				Tao, Y; Guermah, M; Martinez, E; Oelgeschlager, T; Hasegawa, S; Takada, R; Yamamoto, T; Horikoshi, M; Roeder, RG			Specific interactions and potential functions of human TAF(II)100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BOX-BINDING; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; TFIID SUBUNIT; PROMOTER; IDENTIFICATION; POLYPEPTIDE; EXPRESSION; PROTEINS; REPEATS	Human transcription initiation factor TFIID contains the TATA-binding protein (TBP) and several TBP-associated factors (TAFs), To investigate the structural organization and function of TFIID, we have cloned and expressed a cDNA encoding the third largest human TFIID subunit, hTAF(II)100, Immunoprecipitation studies demonstrate that hTAF(II)100 is an integral subunit that is associated with all transcriptionally-competent forms of TFIID, They further suggest that at least part of the N-terminal region lies on the surface of TFIID, while a C-terminal region containing conserved WD-40 repeats appears inaccessible, Both in vivo and in vitro assays indicate that hTAF,100 interacts strongly with the histone H4-related hTAF(II)80 and the histone H3-related hTAF(II)31, as well as a stable complex comprised of both hTAF(II)80 and hTAF(II)31, Apparently weaker interactions of hTAF(II)100 with TBP, hTAF(II)250, hTAF(II)28, and hTAF(II)20, but not hTAF(II)55, also have been observed. These results suggest a role for hTAF,100 in stabilizing interactions of TAFs, especially the histone-like TAFs, in TFIID, In addition, functional studies show that anti-hTAF(II)100 antibodies selectively inhibit basal transcription from a TATA-less initiator-containing promoter, relative to a TATA containing promoter, suggesting a possible core promoter-specific function for hTAF(II)100.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST MOL & CELLULAR BIOSCI,DEV BIOL LAB,BUNKYO KU,TOKYO 113,JAPAN	Rockefeller University; University of Tokyo			Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233; Takada, Ritsuko/0000-0002-1615-056X; Oelgeschlager, Thomas/0000-0002-4086-719X	NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045258] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI37327] Funding Source: Medline; NIGMS NIH HHS [GM45258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Harlow E., 1988, ANTIBODIES LAB MANUA; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAMBROOKK J, 1989, MOL CLONING LAB MANU; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	36	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6714	6721		10.1074/jbc.272.10.6714	http://dx.doi.org/10.1074/jbc.272.10.6714			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045704	hybrid			2022-12-25	WOS:A1997WM64700088
J	Jiang, W; Hackney, DD				Jiang, W; Hackney, DD			Monomeric kinesin head domains hydrolyze multiple ATP molecules before release from a microtubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RATE-LIMITING STEP; ADENOSINE-TRIPHOSPHATASE; MOTOR DOMAIN; MECHANISM; MOVEMENT; KINETICS; BINDING	Transient kinetic analysis of microtubule-stimulated ATP hydrolysis by the monomeric kinesin motor domain DKH357 was performed to investigate the kinetic pattern of a monomer. Both ATP and ADP produced dissociation of the complex, microtubule (MT). E, of microtubules with DKH357 at a maximum rate of similar to 45 s(-1) as determined by decrease in turbidity, The maximum dissociation rate was independent of the KCl concentration between 25 and 200 mM. At subsaturating levels of nucleotide, ATP was more effective than ADP in dissociating DKH357 from MT . E (1.6 and 0.4 mu M(-1) s(-1) for ATP and ADP, respectively, at 50 mM KCl), Addition of ATP to MT . E results in a burst of product formation with a maximum initial rate of similar to 100 s(-1) at saturating levels of ATP, This maximum hydrolysis rate of 100 s(-1) is similar to the maximum steady state ATPase rate at saturating microtubules of similar to 70 s(-1), and thus hydrolysis is at least partially rate-limiting, When the MT lattice was highly occupied with bound DKH357, the amplitude of the burst was similar to 2 per DKH357 active site (superstoichiometric), The rate constant for the burst transient was similar to 45 s(-1), which is the same as the rate for dissociation of DKB357 from the microtubule and this suggests that dissociation and termination of the burst phase are coupled, The size of the burst increased with decreasing initial occupancy of the MT lattice with bound DKH357 and approached the value of similar to 4 ATP molecules predicted by previous steady state measurements (Jiang, W,, Stock, M., Li, X,, and Hackney, D, D., submitted for publication).	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HACKNEY DD, 1996, ANNU REV PHYSIOL, V58, P732; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P63214; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Jiang W., 1996, Biophysical Journal, V70, pA43; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020	22	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5616	5621		10.1074/jbc.272.9.5616	http://dx.doi.org/10.1074/jbc.272.9.5616			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038170	hybrid			2022-12-25	WOS:A1997WK74700038
J	Price, DJ; Rivnay, B; Fu, YG; Jiang, SX; Avraham, S; Avraham, H				Price, DJ; Rivnay, B; Fu, YG; Jiang, SX; Avraham, S; Avraham, H			Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr(568/570) of the activated c-KIT in megakaryocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MOLECULAR-CLONING; BETA-RECEPTOR; GENE; SRC; FAMILY; IDENTIFICATION; ENCODES; LACKING; BINDING	The Csk homologous kinase (CHK), formerly MATK, has previously been shown to bind to activated c-KIT, In this report, we characterize the binding of SH2(CHK) to specific phosphotyrosine sites on the c-KIT protein sequence, Phosphopeptide inhibition of the in vitro interaction of SH2(CHK)-glutathione S-transferase fusion protein/c-KIT from SCF/KL-treated Mo7e megakaryocytic cells indicated that two sites on c-KIT were able to bind SH2(CHK), These sites were the Tyr(568/570) diphosphorylated sequence and the monophosphorylated Tyr(721) sequence. To confirm this, we precipitated native CHK from cellular extracts using phosphorylated peptides linked to Affi-Gel 15. In addition, purified SH2(CHK)-glutathione S-transferase fusion protein was precipitated with the same peptide beads, All of the peptide bead-binding studies were consistent with the direct binding of SH2(CHK) to phosphorylated Tyr(568/570) and Tyr(721) sites, Binding of FYN and SHC to the diphosphorylated Tyr(568/570) Site was observed, while binding of Csk to this site was not observed, The SH2(CHK) binding to the two sites is direct and not through phosphorylated intermediates such as FYN or SHC. Site-directed mutagenesis of the full-length c-KIT cDNA followed by transient transfection indicated that only the Tyr(568/570) and not the Tyr(721), is able to bind SH2(CHK), This indicates that CHK binds to the same site on c-KIT to which FYN binds, possibly bringing the two into proximity on associated c-KIT subunits and leading to the down-regulation of FYN by CHK.	HARVARD UNIV,BETH ISRAEL DEACONESS MED CTR,INST MED,DIV EXPT MED,SCH MED,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL DEACONESS MED CTR,SCH MED,DIV HEMATOL ONCOL,DEPT MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Price, Daniel/0000-0002-4083-9113; Avraham, Hava/0000-0002-7545-3640	NHLBI NIH HHS [HL51456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERMAN M, 1995, MOL CELL BIOL, V15, P711; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; JHUN BH, 1995, J BIOL CHEM, V270, P9661, DOI 10.1074/jbc.270.16.9661; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARTANEN J, 1991, ONCOGENE, V6, P2013; REITH AD, 1991, GENOME ANAL, V3, P105; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKANO S, 1994, ONCOGENE, V9, P1155; SERVE H, 1994, J BIOL CHEM, V269, P6026; ULICH TR, 1991, BLOOD, V78, P1954; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	22	81	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5915	5920		10.1074/jbc.272.9.5915	http://dx.doi.org/10.1074/jbc.272.9.5915			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038210	hybrid			2022-12-25	WOS:A1997WK74700078
J	Solecki, D; Schwarz, S; Wimmer, E; Lipp, M; Bernhardt, G				Solecki, D; Schwarz, S; Wimmer, E; Lipp, M; Bernhardt, G			The promoters for human and monkey poliovirus receptors - Requirements for basic and cell type-specific activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; MOLECULAR-CLONING; VIRUS BINDING; GENE; EXPRESSION; SITE; MOUSE; LINES; IDENTIFICATION; TRANSCRIPTION	The cellular receptors for poliovirus (PVR) are glycoproteins belonging to the immunoglobulin superfamily, Functional receptors for poliovirus are only expressed by primates; known rodent homologues lack the ability to bind virus due to amino acid differences, Human poliovirus infections are targeted to the gastrointestinal tract and, rarely, to motor neurons in the central nervous system, Available evidence suggests that poliovirus uses only one cellular receptor, implying that the tissue tropism of poliovirus is likely to be related to the expression of the human PVR (hPVR), However, low levels of expression of hPVR-specific mRNAs can be detected in many human tissues other than the apparent target cells, The nonpathogenic function of hPVR is unknown, For a study of the transcriptional control of hPVR expression, we have isolated and characterized the promoter of the hPVR gene, Deletion analysis defined an approximately 280 base pair minimal promoter fragment that: 1) lacks TATA- and CAAT-like elements, 2) is distinguished by a high GC content, and 3) promotes transcription at multiple start sites, The pattern of activity caused by transfection of serial 5'- and 3'-promoter deletions is almost identical in HEp2, HeLa, COS-l, and mouse L929 cells, indicating a similar transcriptional regulation of the hPVR promoter in these cell lines, However, on transfection of Raji cells, a Burkitt's lymphoma cell line harboring a transcriptionally inactive hPVR gene, all promoter reporter constructs tested exerted only residual activity, These results suggest that the cis-element(s) governing cell type-specific hPVR expression resides in the minimal promoter region. We also report the sequences of the promoters of two monkey homologues to hPVR (AGM(YI and AGM alpha 2), Transcripts encoding the monkey poliovirus receptors originate from a region analogous to that identified for hPVR transcripts.	MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY; SUNY STONY BROOK, SCH MED, DEPT MOL GENET & MICROBIOL, STONY BROOK, NY 11794 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Bernhardt, Günter/F-6946-2012; Lipp, Martin/G-2235-2010; Solecki, David/N-8080-2018	Bernhardt, Günter/0000-0002-0510-2853; Lipp, Martin/0000-0002-0087-2672	NCI NIH HHS [CA28146] Funding Source: Medline; NIAID NIH HHS [AI32100, AI1522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032100] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P129, DOI 10.1016/0167-4781(94)90255-0; AOKI J, 1994, J BIOL CHEM, V269, P8431; BERNHARDT G, 1994, VIROLOGY, V203, P344, DOI 10.1006/viro.1994.1493; BERNHARDT G, 1994, VIROLOGY, V199, P105, DOI 10.1006/viro.1994.1102; BIBB JA, 1994, J GEN VIROL, V75, P1875, DOI 10.1099/0022-1317-75-8-1875; BIBB JA, 1994, J VIROL, V68, P6111, DOI 10.1128/JVI.68.9.6111-6115.1994; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHAMBERLIN ME, 1994, J BIOL CHEM, V269, P17152; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; FAGRAEUS A, 1981, ARCH VIROL, V69, P229, DOI 10.1007/BF01317338; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FREISTADT M, 1994, COLD SPRING HARBOR M, P445; FREISTADT MS, 1993, VIROLOGY, V195, P798, DOI 10.1006/viro.1993.1433; FROHMAN M, 1995, PCR METH APPL, V4, pS40; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370; GROMEIER M, 1995, ANN NY ACAD SCI, V753, P19, DOI 10.1111/j.1749-6632.1995.tb27528.x; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; HOLLAND JJ, 1961, VIROLOGY, V15, P312, DOI 10.1016/0042-6822(61)90363-4; HOLMES KV, 1994, COLD SPRING HARBOR M, P403; ITOH F, 1992, ONCOGENE, V7, P1201; KOIKE S, 1994, COLD SPRING HARBOR M, P463; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P951, DOI 10.1073/pnas.88.3.951; KOIKE S, 1992, J VIROL, V66, P7059, DOI 10.1128/JVI.66.12.7059-7066.1992; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; LANS MS, 1994, J BIOL CHEM, V269, P14170; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MEDRANO L, 1973, VIROLOGY, V54, P515, DOI 10.1016/0042-6822(73)90161-X; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MIYAGOE Y, 1994, J BIOL CHEM, V269, P8268; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; MORRISON ME, 1994, J VIROL, V68, P2578, DOI 10.1128/JVI.68.4.2578-2588.1994; OKADA Y, 1987, VIROLOGY, V156, P238, DOI 10.1016/0042-6822(87)90403-X; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; SCHONK D, 1990, CYTOGENET CELL GENET, V54, P15; SELINKA HC, 1991, P NATL ACAD SCI USA, V88, P3598, DOI 10.1073/pnas.88.9.3598; SHEPLEY MP, 1994, J VIROL, V68, P1301, DOI 10.1128/JVI.68.3.1301-1308.1994; SIDDIQUE T, 1988, Genomics, V3, P156, DOI 10.1016/0888-7543(88)90147-4; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WANG YB, 1994, J BIOL CHEM, V269, P9137; WIMMER E, 1994, COLD SPRING HARBOR M, P101; XU Y, 1995, BIOCHEM BIOPH RES CO, V206, P935, DOI 10.1006/bbrc.1995.1132; ZIBERT A, 1991, VIROLOGY, V182, P250, DOI 10.1016/0042-6822(91)90668-2	47	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5579	5586		10.1074/jbc.272.9.5579	http://dx.doi.org/10.1074/jbc.272.9.5579			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038165	hybrid			2022-12-25	WOS:A1997WK74700033
J	Wang, J; Tu, YP; Woodson, J; Song, XL; Ross, EM				Wang, J; Tu, YP; Woodson, J; Song, XL; Ross, EM			A GTPase-activating protein for the G protein G alpha(z) - Identification, purification, and mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; ALPHA-SUBUNIT; COUPLED RECEPTORS; CELLS; ACCUMULATION; EXPRESSION; INHIBITION; TRANSDUCIN	A GTPase-activating protein (GAP) specific for G alpha(2) was identified in brain, spleen, retina, platelet, C6 glioma cells, and several other tissues and cells. G(z) GAP from bovine brain is a membrane protein that is refractory to solubilization with most deter-gents but was solubilized with warm Triton X-100 and purified up to 50,000-fold. Activity is associated with at least two separate proteins of M(r) similar to 22,000 and 28,000, both of which have similar specific activities. In an assay that measures the rate of hydrolysis of GTP pre-bound to detergent-soluble G alpha(2), the GAP accelerates hydrolysis over 200-fold, from 0.014 to 3 min(-1) at 15 degrees C, or to greater than or equal to 20 min(-1) at 30 degrees C. It does not alter rates of nucleotide association or dissociation. When co-reconstituted into phospholipid vesicles with trimeric G(z) and m2 muscarinic receptor, G(z) GAP accelerates agonist-stimulated steady-state GTP hydrolysis as predicted by its effect on the hydrolytic reaction. In the single turnover assay, the K-m of the GAP for G alpha(z)-GTP is 2 nM. Its activity is inhibited by G alpha(z)-guanosine 5'-O-thiotriphosphate (G alpha(z)-GTP gamma S) or by G alpha(z)-GDP/AlF4 with K-i similar to 1.5 nM for both species; Ga alpha(z)-GDP does not inhibit. G protein beta gamma subunits inhibit G(z) GAP activity, apparently by forming a GTP-G alpha(z) beta gamma complex that is a poor CAP substrate. G(z) CAP displays little GAP activity toward G alpha(i1) or G alpha(o), but its activity with G alpha(z) is competitively inhibited by both G alpha(i1) and G alpha(o) at nanomolar concentrations when they are bound to GTP gamma S but not to GDP. Neither phospholipase C-beta 1 (a G(q) GAP) nor several adenylyl cyclase isoforms display G(alpha) GAP activity.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HINTON DR, 1990, J NEUROSCI, V10, P2763; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Huskens J, 1996, J AM CHEM SOC, V118, P4396, DOI 10.1021/ja953771p; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCCORMICK F, 1993, HDB EXP PHARM, V108, P345; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PARKER EM, 1991, J BIOL CHEM, V266, P519; Ross E M, 1978, Methods Enzymol, V53, P222; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TSU RC, 1995, BIOCHEM J, V309, P331, DOI 10.1042/bj3090331; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	48	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5732	5740		10.1074/jbc.272.9.5732	http://dx.doi.org/10.1074/jbc.272.9.5732			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038185	hybrid			2022-12-25	WOS:A1997WK74700053
J	AlShamkhani, A; Mallett, S; Brown, MH; James, W; Barclay, AN				AlShamkhani, A; Mallett, S; Brown, MH; James, W; Barclay, AN			Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CROSS-LINKING; EXPRESSION; PROTEINS; CD4; LYMPHOCYTES; ANTIGEN; COMPLEX; BINDING	OX40 ligand (OX40L) and OX40 are members of the tumor necrosis factor and tumor necrosis factor receptor superfamilies, respectively. OX40L is expressed on activated B and T cells and endothelial cell lines, whereas OX40 is expressed on activated T cells, A construct for mouse OX40L was expressed as a soluble protein with domains 3 and 4 of rat CD4 as a tag (sCD4-OX40L). It formed a homotrimer as assessed by chemical cross-linking and gel filtration chromatography, Radio labeled sCD4-OX40L bound to activated mouse T cells with a high affinity (K-D = 0.2-0.4 nM) and dissociated slowly (k(off) = 4 x 10(-5) s(-1)), The affinity and kinetics of the OX40L/OX40 interactions were studied using the BIAcore(TM) biosensor, which measures macromolecular interactions in real time, The extracellular part of the OX40 antigen was expressed as a soluble monomeric protein and immobilized on the BIAcore sensor chip. sCD4-OX40L bound the OX40 with a high affinity (K-D = 3.8 nM), although this was lower than that determined on the surface of activated T cells (K-D = 0.2-0.4 nM), where there is likely to be less restriction in mobility of the receptor. In the reverse orientation, sOX40 bound to immobilized sCD4-OX40L with a stoichiometry of 3.1 receptors to one ligand, with low affinity (K-D = 190 nM) and had a relatively fast dissociation rate constant (k(off) = 2 x 10(-2) s(-1)). Thus if the OX40 receptor is cleaved by proteolysis, it will release any bound ligand and is unlikely to block re-binding of ligand to cell surface OX40 because of the low monomeric affinity.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND	University of Oxford			james, william/H-4289-2013; Mallett, Sue/GPS-9933-2022	james, william/0000-0002-2506-1198; Mallett, Sue/0000-0002-0596-8200				ADAM D, 1995, J BIOL CHEM, V270, P17482; AlShamkhani A, 1996, EUR J IMMUNOL, V26, P1695, DOI 10.1002/eji.1830260805; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARCLAY AN, 1993, LEUCOCYTE ANTIGENS F; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BAZZONI F, 1995, P NATL ACAD SCI USA, V92, P5376, DOI 10.1073/pnas.92.12.5376; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BROWN MH, 1994, PROTEIN ENG, V7, P515, DOI 10.1093/protein/7.4.515; CALDERHEAD DM, 1993, J IMMUNOL, V151, P5261; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DELPRETE G, 1995, IMMUNOL TODAY, V16, P76, DOI 10.1016/0167-5699(95)80092-1; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HINTZEN RQ, 1991, J IMMUNOL, V147, P29; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MASON DW, 1980, BIOCHEM J, V187, P1; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; MOHLER KM, 1993, J IMMUNOL, V151, P1548; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1987, J BIOL CHEM, V262, P6951; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Stuber E, 1996, J EXP MED, V183, P979, DOI 10.1084/jem.183.3.979; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	38	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5275	5282		10.1074/jbc.272.8.5275	http://dx.doi.org/10.1074/jbc.272.8.5275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030600	hybrid			2022-12-25	WOS:A1997WJ85500088
J	Cartwright, P; Beilharz, T; Hansen, P; Garrett, J; Lithgow, T				Cartwright, P; Beilharz, T; Hansen, P; Garrett, J; Lithgow, T			Mft52, an acid-bristle protein in the cytosol that delivers precursor proteins to yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND CYTOPLASMIC POLYSOMES; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; IMPORT RECEPTOR; TRANSLOCATION; RECOGNITION; MEMBRANE; SIGNAL; PREPROTEINS; VIABILITY	We have identified a novel protein, Mft52, in the cytosol of yeast cells, Mft52 has a two-domain structure that includes a receptor-like carboxyl-terminal ''acid-bristle'' domain, which binds basic, amphipathic mitochondrial targeting sequences, Native Mft52, purified from the cytosol of yeast cells, is found as a large particle eluting in the void volume of a Superose 6 gel filtration column, Fusion proteins, consisting of mitochondrial targeting sequences fused to nonmitochondrial passenger proteins, are targeted to mitochondria in wild type yeast cells, but defects in the gene encoding Mft52 drastically reduce the delivery of these proteins to the mitochondria, We propose that Mft52 is a subunit of a particle that is part of a system of targeting factors and molecular chaperones mediating the earliest stages of protein targeting to the mitochondria.	LA TROBE UNIV,SCH BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA; HAMILTON COLL,DEPT BIOL,CLINTON,NY 13323	La Trobe University; Hamilton College			Beilharz, Traude/I-1438-2014; Beilharz, Traude/O-5457-2019; Lithgow, Trevor J/H-5925-2017	Beilharz, Traude/0000-0002-8942-9502; Beilharz, Traude/0000-0002-8942-9502; Lithgow, Trevor J/0000-0002-0102-7884				ADES IZ, 1980, J BIOL CHEM, V255, P9918; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GARRETT JM, 1991, MOL GEN GENET, V225, P483, DOI 10.1007/BF00261691; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; ITO M, 1993, FEBS LETT, V320, P125, DOI 10.1016/0014-5793(93)80076-7; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KOMIYA T, 1994, J BIOL CHEM, V269, P30893; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KUMAMOTO T, 1987, J BIOCHEM-TOKYO, V102, P833, DOI 10.1093/oxfordjournals.jbchem.a122122; LAIN B, 1994, J BIOL CHEM, V269, P15588; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; Martoglio B, 1996, TRENDS CELL BIOL, V6, P142, DOI 10.1016/0962-8924(96)10001-5; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SUISSA M, 1982, J BIOL CHEM, V257, P3048; Tang HY, 1996, MOL CELL BIOL, V16, P4897; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WETTENHALL REH, 1989, BIOCHEMISTRY-US, V27, P170; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; ZOLADEK T, 1995, MOL CELL BIOL, V15, P6884	46	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5320	5325		10.1074/jbc.272.8.5320	http://dx.doi.org/10.1074/jbc.272.8.5320			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030606	hybrid			2022-12-25	WOS:A1997WJ85500094
J	Tingley, WG; Ehlers, MD; Kameyama, K; Doherty, C; Ptak, JB; Riley, CT; Huganir, RL				Tingley, WG; Ehlers, MD; Kameyama, K; Doherty, C; Ptak, JB; Riley, CT; Huganir, RL			Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMERIC NMDA RECEPTORS; LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; SPLICE VARIANTS; ACTIVATION; MODULATION; RESPONSES; CLONING; CHANNEL	Modulation of N-methyl-D-aspartate receptors in the brain by protein phosphorylation may play a central role in the regulation of synaptic plasticity, To examine the phosphorylation of the NR1 subunit of N-methyl-D-aspartate receptors in situ, we have generated several polyclonal antibodies that recognize the NR1 subunit only when specific serine residues are phosphorylated. Using these antibodies, we demonstrate that protein kinase C (PKC) phosphorylates serine residues 890 and 896 and cAMP-dependent protein kinase (PKA) phosphorylates serine residue 897 of the NR1 subunit. Activation of PKC and PKA together lead to the simultaneous phosphorylation of neighboring serine residues 896 and 897, Phosphorylation of serine 890 by PKC results in the dispersion of surface associated clusters of the NR1 subunit expressed in fibroblasts, while phosphorylation of serine 896 and 897 has no effect on the subcellular distribution of NR1. The PKC-induced redistribution of the NR1 subunit in cells occurs within minutes of serine 890 phosphorylation and reverses upon dephosphorylation. These results demonstrate that PKA and PKC phosphorylate distinct residues within a small region of the NR1 subunit and differentially affect the subcellular distribution of the NR1 subunit.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BIOPOLYMER LAB, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University								ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COURTNEY MJ, 1992, J NEUROCHEM, V59, P983, DOI 10.1111/j.1471-4159.1992.tb08339.x; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; Ehlers MD, 1996, CURR OPIN CELL BIOL, V8, P484, DOI 10.1016/S0955-0674(96)80024-X; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; GERBER G, 1989, J NEUROSCI, V9, P3606; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; MARKRAM H, 1992, J PHYSIOL-LONDON, V457, P491, DOI 10.1113/jphysiol.1992.sp019389; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKAZAWA K, 1995, NEURON, V15, P697, DOI 10.1016/0896-6273(95)90157-4; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; Sambrook J, 1989, MOL CLONING LAB MANU; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	49	428	442	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5157	5166		10.1074/jbc.272.8.5157	http://dx.doi.org/10.1074/jbc.272.8.5157			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030583	hybrid			2022-12-25	WOS:A1997WJ85500071
J	Besser, D; Bardelli, A; Didichenko, S; Thelen, M; Comoglio, PM; Ponzetto, C; Nagamine, Y				Besser, D; Bardelli, A; Didichenko, S; Thelen, M; Comoglio, PM; Ponzetto, C; Nagamine, Y			Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2	ONCOGENE			English	Article						GRB2; hepatocyte growth factor; plasminogen activator; signal transduction; Tpr-Met	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; DEPENDENT PROTEIN-KINASE; DOMINANT-NEGATIVE MUTANT; PHOSPHATIDYLINOSITOL 3-KINASE; HGF RECEPTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; SH2 DOMAINS	The oncogene Tpr-Met is a constitutively active form of the hepatocyte growth factor/scatter factor (HGF/SF) receptor Met. It comprises the intracellular moiety of Met linked to the dimerization domain of the nuclear envelope protein Tpr, thus functioning as a constitutively activated Met, HGF/SF is responsible for various biological processes including angiogenesis and wound healing, in which secreted serine protease urokinase-type plasminogen activator (uPA) is implicated, The action of HGF/SF on cells is mediated by the autophosphorylation of Met on two carboxyterminal tyrosine Y(1349)VHVNATVY(1356)VNV. The two tyrosine provide docking sites for various effector molecules, suggesting that multiple signaling pathways are activated to exert biological effects of HGF/SF [Ponzetto et al., Cell (1994) 77: 261], We found that Tpr-Met efficiently activates the uPA gene via a SOS/Ras/extracellular signal regulated kinase (ERK)-dependent signaling pathway, Mutation of Y-1356, which abrogates GRB2 binding, reduced the induction to half of the control level, while mutation of Y-1349 showed little effect on uPA induction, suggesting an important but partly replaceable role for GRB2 in Met-dependent uPA gene induction, Mutation of both (YVHV)-V-1349 and (YVNV)-V-1356 into optimal PI 3-kinase sites resulted in a residual induction of about one quarter of the control level, suggesting a potential role for PI 3-kinase, Dose-response analysis of the Tpr-Met showed a biphasic curve, These results suggest that the interplay among different signaling molecules on the receptor is important for full induction of the pathway leading to the activation of the uPA gene.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; UNIV BERN,THEODOR KOCHER INST,CH-3012 BERN,SWITZERLAND; UNIV TURIN,SCH MED,CANC RES INST,I-10126 TURIN,ITALY	Friedrich Miescher Institute for Biomedical Research; University of Turin; University of Bern; University of Turin			Besser, Daniel/A-8304-2012; BARDELLI, Alberto/J-9721-2018	Besser, Daniel/0000-0002-4958-9624; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				BARDELLI A, 1992, ONCOGENE, V7, P1973; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Blasi F, 1990, Semin Cancer Biol, V1, P117; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE JS, 1994, NUCLEIC ACIDS RES, V22, P569, DOI 10.1093/nar/22.4.569; LONGATI P, 1994, ONCOGENE, V9, P49; MENOUD PA, 1993, NUCLEIC ACIDS RES, V21, P1845, DOI 10.1093/nar/21.8.1845; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1995, FIBRINOLYSIS DIS; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RUSCIANO D, 1995, ONCOGENE, V11, P1979; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1993, CELL, V72, P1; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TIENARI J, 1991, CELL REGUL, V2, P285, DOI 10.1091/mbc.2.4.285; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VONDERAHE D, 1990, NUCLEIC ACIDS RES, V18, P1991, DOI 10.1093/nar/18.8.1991	54	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					705	711		10.1038/sj.onc.1200879	http://dx.doi.org/10.1038/sj.onc.1200879			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038378				2022-12-25	WOS:A1997WG43000009
J	Griffiths, SD; Clarke, AR; Healy, LE; Ross, G; Ford, AM; Hooper, ML; Wyllie, AH; Greaves, M				Griffiths, SD; Clarke, AR; Healy, LE; Ross, G; Ford, AM; Hooper, ML; Wyllie, AH; Greaves, M			Absence of p53 permits propagation of mutant cells following genotoxic damage	ONCOGENE			English	Article						ionizing radiation; mutation; p53; apoptosis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR GENE; IONIZING-RADIATION; P53-DEFICIENT MICE; HEMATOPOIETIC-CELLS; ANTICANCER AGENTS; GAMMA-IRRADIATION; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS	Much evidence has been gathered in support of a critical role for p53 in the cellular response to DNA damage. p53 dysfunction is associated with progression and poor prognosis of many human cancers and with a high incidence of tumours in p53 knockout mice. The absence of a p53-dependent G(1) arrest that facilitates DNA repair or apoptosis might impact critically on clinical cancer in two ways. First, by abrogating the impact on therapy that operates via genotoxic damage and apoptosis; and second, by encouraging progression either by inducing genomic instability and DNA mis-repair or by permitting survival of mutants. However, experiments examining the relationship between p53 deficiency and mutation frequency have so far failed to confirm these predictions. The precise role played by p53 is therefore unclear. We now report use of a short term in vitro approach to assess the influence of p53 on radiation-induced mutations at the hprt locus in murine B cell precursors that are normally radiation ultrasensitive, We find a high number of hprt mutants among X-irradiated p53 null cells, which results from preferential survival as clonogenic mutants rather than from a p53-dependent increase in mutation rate. This result has important implications for genotoxic cancer therapy.	INST CANC RES, LEUKAEMIA RES FUND CTR, LONDON SW3 6JB, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JB, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, SECT RADIOTHERAPY, LONDON SW3 6JB, ENGLAND; UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Edinburgh			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Healy, Lyn/0000-0002-7044-8789				BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BLANDINO G, 1995, ONCOGENE, V10, P731; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BREIMER LH, 1988, BRIT J CANCER, V57, P6, DOI 10.1038/bjc.1988.2; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX R, 1977, NATURE, V267, P425, DOI 10.1038/267425a0; DERUIJTER YCEM, 1980, MUTAT RES, V69, P325, DOI 10.1016/0027-5107(80)90097-4; DIVE C, 1993, FRONTIERS PHARM CANC, P21; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FAN SJ, 1994, CANCER RES, V54, P5824; FURUNOFUKUSHI I, 1993, RADIAT RES, V136, P97, DOI 10.2307/3578645; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; GRIFFITHS SD, 1994, INT J RADIAT BIOL, V66, P197, DOI 10.1080/09553009414551101; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENT, 1994, INT J RADIAT BIOL, V65, P125; KODAMA H, 1984, J CELL PHYSIOL, V118, P233, DOI 10.1002/jcp.1041180303; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE G, 1989, J IMMUNOL, V142, P3875; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARUYAMA Y, 1987, ADV RADIAT BIOL, V12, P1; MERRITT AJ, 1994, CANCER RES, V54, P614; MORLEY AA, 1983, NATURE, V302, P155, DOI 10.1038/302155a0; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; NICKLAS JA, 1989, MUTAT RES, V215, P147, DOI 10.1016/0027-5107(89)90178-4; NISHINO H, 1995, ONCOGENE, V11, P263; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; PURDIE CA, 1994, ONCOGENE, V9, P603; ROSS GM, 1995, CANCER RES, V55, P1235; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SELLINS KS, 1987, J IMMUNOL, V139, P3199; THACKER J, 1992, ADV RADIAT BIOL, V16, P77; THACKER J, 1979, RAD RES; VIJAYALAXMI, 1984, MUTAT RES, V125, P87, DOI 10.1016/0027-5107(84)90035-6; WALTON MI, 1993, CANCER RES, V53, P1853; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	58	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					523	531		10.1038/sj.onc.1200871	http://dx.doi.org/10.1038/sj.onc.1200871			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053850				2022-12-25	WOS:A1997WF52400003
J	Garner, B; vanReyk, D; Dean, RT; Jessup, W				Garner, B; vanReyk, D; Dean, RT; Jessup, W			Direct copper reduction by macrophages - Its role in low density lipoprotein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SMOOTH-MUSCLE CELLS; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; ALPHA-TOCOPHEROL; SUPEROXIDE PRODUCTION; MEDIATED OXIDATION; PLASMA-MEMBRANE; METAL-IONS; LDL	Oxidation of low density lipoprotein (LDL) results in changes to the lipoprotein that are potentially atherogenic. Numerous studies have shown that macrophages cultured in vitro can promote LDL oxidation via a transition metal-dependent process, yet the exact mechanisms that are responsible for macrophage-mediated LDL oxidation are not understood, One contributing mechanism may be the ability of macrophages to reduce transition metals. Reduced metals (such as Fe(II) or Cu(I)) rapidly react with lipid hydroperoxides, leading to the formation of reactive lipid radicals and conversion of the reduced metal to its oxidized form. We demonstrate here the ability of macrophages to reduce extracellular iron and copper and identify a contributing mechanism, Evidence is provided that a proportion of cell-mediated metal reduction is due to direct transplasma membrane electron transport, Glucagon suppressed both macrophage-mediated metal reduction and LDL oxidation, Although metal reduction was augmented when cells were provided with a substrate for thiol production, thiol export was not a strict requirement for cell-mediated metal reduction, Similarly, while the metal-dependent acceleration of LDL oxidation by macrophages was augmented by thiol production, macrophages could still promote LDL oxidation when thiol export was minimized (by substrate limitation). This study identifies a novel mechanism that may contribute to macrophage-mediated LDL oxidation and may also reveal potential new strategies for the inhibition of this process.	HEART RES INST,CELL BIOL UNIT,SYDNEY,NSW 2050,AUSTRALIA	University of Sydney; Heart Research Institute				Dean, Roger Thornton/0000-0002-8859-8902				ALCAIN FJ, 1992, BIOCHEM BIOPH RES CO, V186, P951, DOI 10.1016/0006-291X(92)90838-C; ALCAIN FJ, 1994, P NATL ACAD SCI USA, V91, P7903, DOI 10.1073/pnas.91.17.7903; ANDERSON WL, 1975, ANAL BIOCHEM, V67, P493, DOI 10.1016/0003-2697(75)90323-1; AVIRAM M, 1994, J LIPID RES, V35, P385; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; BEHRENS WA, 1987, ANAL BIOCHEM, V165, P102, DOI 10.1016/0003-2697(87)90206-5; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; CHENG KL, 1986, CRC HDB ORGANIC ANAL, P309; CHRISTEN S, 1994, J CLIN INVEST, V93, P2149, DOI 10.1172/JCI117211; CLARK MG, 1981, BIOCHEM J, V200, P565, DOI 10.1042/bj2000565; CLARK MG, 1982, BIOCHEM J, V204, P795, DOI 10.1042/bj2040795; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DORMANDY TL, 1965, J PHYSIOL-LONDON, V180, P684, DOI 10.1113/jphysiol.1965.sp007724; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FUKUZAWA K, 1988, ARCH BIOCHEM BIOPHYS, V260, P153, DOI 10.1016/0003-9861(88)90436-5; GARNER B, 1994, BIOCHEM J, V301, P421, DOI 10.1042/bj3010421; Garner B, 1996, REDOX REP, V2, P97, DOI 10.1080/13510002.1996.11747035; GOLDENBERG H, 1979, J BIOL CHEM, V254, P2491; GRAHAM A, 1994, FREE RADICAL RES, V21, P295, DOI 10.3109/10715769409056582; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HUNTER GC, 1991, P SOC EXP BIOL MED, V196, P273; IHEANACHO EN, 1993, BIOCHIM BIOPHYS ACTA, V1182, P15, DOI 10.1016/0925-4439(93)90147-S; ITABASHI H, 1990, ANAL SCI, V6, P721, DOI 10.2116/analsci.6.721; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; JESSUP W, 1993, ATHEROSCLEROSIS, V99, P107, DOI 10.1016/0021-9150(93)90056-Z; JESSUP W, 1995, OXIDATIVE STRESS LIP, P99; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KRITHARIDES L, 1995, ARCH BIOCHEM BIOPHYS, V323, P127, DOI 10.1006/abbi.1995.0018; LAMB DJ, 1992, ATHEROSCLEROSIS, V92, P187, DOI 10.1016/0021-9150(92)90277-N; Lentner C., 1984, GEIGY SCI TABLES, V3, P92; LOW H, 1991, J BIOENERG BIOMEMBR, V23, P903, DOI 10.1007/BF00786008; LYNCH SM, 1995, J BIOL CHEM, V270, P5158, DOI 10.1074/jbc.270.10.5158; MILLER DM, 1989, ARCH BIOCHEM BIOPHYS, V271, P113, DOI 10.1016/0003-9861(89)90261-0; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARTHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337, DOI 10.1016/0005-2760(87)90139-1; RIFICI VA, 1994, ATHEROSCLEROSIS, V107, P99, DOI 10.1016/0021-9150(94)90145-7; ROSENFELD ME, 1990, TOXICOL PATHOL, V18, P560; ROUZER CA, 1982, J BIOL CHEM, V257, P2002; SANTANAM N, 1995, J LIPID RES, V36, P2203; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; SPARROW CP, 1993, J LIPID RES, V34, P1219; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; SUN IL, 1984, J BIOENERG BIOMEMBR, V16, P583, DOI 10.1007/BF00743247; SUN IL, 1984, BIOCHEM BIOPH RES CO, V125, P649, DOI 10.1016/0006-291X(84)90588-6; SUN IL, 1981, BIOCHEM BIOPH RES CO, V101, P68, DOI 10.1016/S0006-291X(81)80011-3; SUN IL, 1985, EXP CELL RES, V156, P528, DOI 10.1016/0014-4827(85)90559-2; TIEN M, 1982, BIOCHEM BIOPH RES CO, V107, P279, DOI 10.1016/0006-291X(82)91701-6; VanReyk DM, 1996, FREE RADICAL RES, V24, P55, DOI 10.3109/10715769609087999; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; YOSHIDA Y, 1994, BBA-GEN SUBJECTS, V1200, P85, DOI 10.1016/0304-4165(94)90121-X	65	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6927	6935		10.1074/jbc.272.11.6927	http://dx.doi.org/10.1074/jbc.272.11.6927			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054380	hybrid			2022-12-25	WOS:A1997WN14700019
J	Demeule, M; Wenger, RM; Beliveau, R				Demeule, M; Wenger, RM; Beliveau, R			Molecular interactions of cyclosporin A with P-glycoprotein - Photolabeling with cyclosporin derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; HAMSTER OVARY CELLS; MONOCLONAL-ANTIBODIES; BINDING; IDENTIFICATION; VINBLASTINE; CYCLOPHILIN; TRANSPORT; VESICLES; PSC-833	The interaction between P-glycoprotein (140-180 kDa) from the multidrug-resistant Chinese hamster ovary cell line CH(R)C5 and cyclosporin A was characterized using three different photoactivable cyclosporin A analogs. Two monoclonal antibodies, which are able to discriminate between two major domains of cyclosporin A (the cyclophilin and calcineurin binding domains), were used to detect the photolabeled proteins. A protein of 155 kDa corresponding to P-glycoprotein was much more strongly photolabeled in membranes of CH(R)C5 cells than in membranes of their drug-sensitive parent cell line AuxB1. The antitumor drug vinblastine and the reversal agents verapamil and cyclosporin A inhibited the photolabeling, and the nonimmunosuppressive derivative PSC-833 caused a stronger inhibition than cyclosporin A. P-glycoprotein photolabeled with cyclosporin A analogs was only detected with the monoclonal antibody that recognizes cyclosporin A and its metabolites, indicating that the calcineurin binding domain recognized specifically by the other antibody is not exposed. These results suggest that the portion of cyclosporin A that binds to calcineurin plays a role in the interaction of cyclosporin A with P-glycoprotein.	UNIV QUEBEC,HOP ST JUSTINE,MOL ONCOL LAB,DEPT CHIM BIOCHIM,MONTREAL,PQ H3C 3P8,CANADA; SANDOZ PHARMA LTD,CH-4002 BASEL,SWITZERLAND	Universite de Montreal; University of Quebec; University of Quebec Montreal; Novartis; Sandoz								BOESCH D, 1991, CANCER RES, V51, P4226; BOREL JF, 1991, TRANSPL P, V23, P1867; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; Georges E, 1990, Adv Pharmacol, V21, P185, DOI 10.1016/S1054-3589(08)60343-9; GOLDBERG H, 1988, BIOCHEM BIOPH RES CO, V152, P552, DOI 10.1016/S0006-291X(88)80073-1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JETTE L, 1995, BIOCHEM PHARMACOL, V50, P1701, DOI 10.1016/0006-2952(95)02073-X; Jette L, 1996, AM J PHYSIOL-RENAL, V270, pF756, DOI 10.1152/ajprenal.1996.270.5.F756; KAJIJI S, 1994, BIOCHEMISTRY-US, V33, P5041, DOI 10.1021/bi00183a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING V, 1983, CANCER TREAT REP, V67, P869; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; NASSAL M, 1983, LIEBIGS ANN CHEM, V9, P1510; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; NIELSEN D, 1992, BIOCHIM BIOPHYS ACTA, V1139, P169, DOI 10.1016/0925-4439(92)90131-6; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PATEL NH, 1994, INVEST NEW DRUG, V12, P1, DOI 10.1007/BF00873229; QUESNIAUX V, 1987, CLIN CHEM, V33, P32; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; QUESNIAUX VFJ, 1987, MOL IMMUNOL, V24, P1159, DOI 10.1016/0161-5890(87)90162-3; SAFA AR, 1992, CANCER INVEST, V10, P295, DOI 10.3109/07357909209032754; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029	31	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6647	6652		10.1074/jbc.272.10.6647	http://dx.doi.org/10.1074/jbc.272.10.6647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045695	hybrid			2022-12-25	WOS:A1997WM64700079
J	Duguay, SJ; Milewski, WM; Young, BD; Nakayama, K; Steiner, DF				Duguay, SJ; Milewski, WM; Young, BD; Nakayama, K; Steiner, DF			Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPROTEASE; FURIN; PACE4; SITE; IDENTIFICATION; MUTATIONS; PROTEINS; VIRUSES; CELLS; TOXIN	Insulin-like growth factor I (IGF-I) is required for normal embryonic development and postnatal growth. Like most hormones and growth factors, IGF-I is synthesized as a proprotein that is converted to the mature form by endoproteolysis. Processing of pro-IGF-I to mature IGF-I occurs by cleavage within the unique pentabasic processing motif Lys-X-X-Lys-X-X-Arg(71)-X-X-Arg-X-X-Arg(77). We have previously shown that human embryonic kidney 293 cells process pro-IGF-IA at Arg(71) to generate IGF-I-(1-70) and at Arg(77) to produce IGF-I-(1-76). Cleavage at each of these sites requires upstream basic residues, indicating that subtilisin-related proprotein convertases (SPCs) may be involved, In order to investigate the identity of the endogenous enzymes involved in maturation of pro-IGF-IA, we have expressed wild-type and mutant pro-IGF-IA in 293 cells and in the furin-deficient Chinese hamster ovary cell line, RPE.40. We have also co-expressed these constructs with SPCs that are thought to play a role in processing precursor proteins in the constitutive pathway: furin, PACE4, PC6A, PC6B, and LPC, The results show that furin is most active at cleaving wild type and mutant pro-IGF-IA and can cleave these precursors at multiple sites within the pentabasic motif. PC6A and LPC are less active than furin but cleave only at Arg(71). PACE4 and PC6B have very little activity on pro IGF-IA precursors, Wild-type pro-IGF-IA was correctly processed to mature IGF-I in 10 of 10 cell lines that were tested. Since furin, PC6A, and LPC are known to have a broad pattern of tissue distribution and we have demonstrated expression of LPC in RPE.40 cells, our results suggest that these SPCs may be responsible for the endogenous pro-IGF-IA processing activity observed in a wide variety of cell lines.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1M 6BQ,ENGLAND; UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Chicago; Cancer Research UK; University of London; Queen Mary University London; University of Tsukuba	Duguay, SJ (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,5841 S MARYLAND AVE,MC 1028,CHICAGO,IL 60637, USA.		Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, R37DK013914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13914] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Campan M, 1996, BIOCHEMISTRY-US, V35, P3797, DOI 10.1021/bi952552d; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUGUAY SJ, 1995, J BIOL CHEM, V270, P17566, DOI 10.1074/jbc.270.29.17566; HALBAN PA, 1994, BIOCHEM J, V299, P1; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Meerabux J, 1996, CANCER RES, V56, P448; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11596; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; STEINER DF, 1990, HDB EXPT PHARM, V92, P67; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521	30	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6663	6670		10.1074/jbc.272.10.6663	http://dx.doi.org/10.1074/jbc.272.10.6663			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045697	hybrid			2022-12-25	WOS:A1997WM64700081
J	Loo, DT; Chalupny, NJ; Bajorath, J; Shuford, WW; Mittler, RS; Aruffo, A				Loo, DT; Chalupny, NJ; Bajorath, J; Shuford, WW; Mittler, RS; Aruffo, A			Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; CRYSTAL-STRUCTURE; ANTIGEN 4-1BB; LIGAND; PROTEIN; EXPRESSION; GROWTH; FAMILY; CD2; FIBRONECTIN	The T cell activation antigen 4-1BB (CDw137) is a distantly related member of the tumor necrosis factor receptor family of cell surface receptors, We previously reported that murine 4-1BB (m4-1BB) bound to extracellular matrix (ECM) proteins, Recently, a tumor necrosis factor-like ligand of m4-1BB, m4-1BBL, as well as the human counterparts of 4-1BB (ILA) and 4-1BBL (h4-1BB and h4-1BBL, respectively) have been cloned, No information is currently available on how binding of m4-1BB to ECM proteins affects its binding to m4-1BBL and vice versa and if the ability of m4-1BB to bind ECM proteins is conserved across species, We report that binding of m4-1BBL to m4-1BB blocked its ability to bind laminin (LN), while binding of m4-1BB to LN did not block its ability to bind m4-1BBL, Furthermore, binding of m4-1BBL to the m4-1BB LN complex did not displace LN, These findings suggest the two ligands bind to proximal but distinct sites on m4-1BB, This is supported by the observation that six of eight anti-m4-1BB monoclonal antibodies blocked the interaction between 4-1BB and 4-1BBL, while seven blocked LN binding, Ligand and monoclonal antibody binding studies with a truncated protein lacking the amino-terminal LN-homologous domain of m4-1BB demonstrated that regions downstream of the LN-homologous domain participate in LN binding and that the intact protein is required for m4-1BBL binding, Studies with h4-1BB showed that h4-1BB only bound h4-1BBL, indicating that the ECM binding activity of 4-1BB is not conserved across species, This finding allowed the construction of murine/human 4-1BB chimeras, which permitted further dissection of the regions of 4-1BB involved in LN and 4-1BBL binding and suggests that sequence differences in the LN-homologous domain of h4-1BB in part account for the inability of h4-1BB to bind ECM proteins.			Loo, DT (corresponding author), BMS,PRI,3005 1ST AVE,SEATTLE,WA 98121, USA.		Bajorath, Jürgen/F-7493-2014					ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA, P270; CHALUPNY NJ, 1992, P NATL ACAD SCI USA, V89, P10360, DOI 10.1073/pnas.89.21.10360; DEBENEDETTE MA, 1995, J EXP MED, V181, P985, DOI 10.1084/jem.181.3.985; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FUREY WF, 1986, SCIENCE, V231, P704, DOI 10.1126/science.3945804; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HOLLENBAUGH D, 1994, CURRENT PROTOCOLS IM; HURTADO JC, 1995, J IMMUNOL, V155, P3360; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KIM YJ, 1993, J IMMUNOL, V151, P1255; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MOSMANN TR, 1987, J IMMUNOL, V138, P1813; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; POLLOK KE, 1995, EUR J IMMUNOL, V25, P488, DOI 10.1002/eji.1830250227; POLLOK KE, 1993, J IMMUNOL, V150, P771; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHWARZ H, 1993, GENE, V134, P295, DOI 10.1016/0378-1119(93)90110-O; SCHWARZ H, 1995, BLOOD, V85, P1043, DOI 10.1182/blood.V85.4.1043.bloodjournal8541043; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321	28	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6448	6456		10.1074/jbc.272.10.6448	http://dx.doi.org/10.1074/jbc.272.10.6448			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045669	hybrid			2022-12-25	WOS:A1997WM64700053
J	Maples, CJ; Ruiz, WG; Apodaca, G				Maples, CJ; Ruiz, WG; Apodaca, G			Both microtubules and actin filaments are required for efficient postendocytotic traffic of the polymeric immunoglobulin receptor in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PLASMA-MEMBRANE PROTEINS; MDCK CELLS; CYTOCHALASIN-D; BRUSH-BORDER; FUSION INVITRO; ORGANIZATION; VESICLES; TRANSCYTOSIS; MYOSIN	It has been postulated that membrane traffic in polarized epithelial cells requires both actin filaments and microtubules. We have tested this hypothesis by analysing the effect of cytochalasin D (cytoD; an actin-disrupting agent), by itself or in combination with nocodazole (a microtubule depolymerizing agent), on postendocytic traffic in Madin-Darby canine kidney cells. CytoD treatment inhibited basolateral to apical transcytosis of IgA in polymeric immunoglobulin receptor expressing cells by approximately 45%, but had little effect on basolateral recycling of transferrin. Apical recycling of IgA was also inhibited by approximately 20%. Like nocodazole, cytoD acted at an early step in transcytosis, and inhibited translocation of IgA between the basolateral early endosomes and the apical recycling endosome. There was little inhibition of the subsequent release of IgA from the apical recycling endosome of cytoD- or nocoda zole-treated cells, Order-of-addition experiments suggest that the cytoD-sensitive step preceded the nocodazole-sensitive step. Treatment with both cytoD and nocodazole inhibited transcytosis 95%. These results suggest that in addition to microtubules, efficient postendocytic traffic in polarized epithelial cells also requires actin filaments.	UNIV PITTSBURGH, LAB EPITHELIAL CELL BIOL, RENAL ELECTROLYTE DIV, DEPT MED, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT CELL BIOL & PHYSIOL, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Apodaca, Gerard/HCJ-0048-2022					ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BRETSCHER A, 1994, J CELL BIOL, V126, P821, DOI 10.1083/jcb.126.4.821; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COUDRIER E, 1992, FEBS LETT, V307, P87, DOI 10.1016/0014-5793(92)80907-X; DRENCKHAHN D, 1988, J CELL BIOL, V107, P1037, DOI 10.1083/jcb.107.3.1037; Durrbach A, 1996, J CELL SCI, V109, P457; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; FATH KR, 1994, CURR OPIN CELL BIOL, V6, P131, DOI 10.1016/0955-0674(94)90126-0; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HAYS RM, 1994, AM J PHYSIOL-CELL PH, V267, pC1507, DOI 10.1152/ajpcell.1994.267.6.C1507; HAYS RM, 1993, PEDIATR NEPHROL, V7, P672, DOI 10.1007/BF00852577; HIROKAWA N, 1982, J CELL BIOL, V95, P249, DOI 10.1083/jcb.95.1.249; HIROKAWA N, 1982, J CELL BIOL, V94, P425, DOI 10.1083/jcb.94.2.425; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; JACKMAN MR, 1994, J CELL SCI, V107, P2547; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; LAFONT F, 1994, NATURE, V372, P801; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; MADARA JL, 1987, AM J PHYSIOL, V253, pC171, DOI 10.1152/ajpcell.1987.253.1.C171; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; MILLS JW, 1992, TOXICOL APPL PHARM, V116, P92, DOI 10.1016/0041-008X(92)90149-M; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MORRIS A, 1980, NATURE, V287, P637, DOI 10.1038/287637a0; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; NAIM HY, 1995, J CELL BIOL, V129, P1241, DOI 10.1083/jcb.129.5.1241; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; SANDOZ D, 1986, EUR J CELL BIOL, V39, P481; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SONG WX, 1994, J BIOL CHEM, V269, P29474; STEVENSON BR, 1994, J CELL SCI, V107, P367; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; YAHARA I, 1982, J CELL BIOL, V92, P69, DOI 10.1083/jcb.92.1.69	55	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6741	6751		10.1074/jbc.272.10.6741	http://dx.doi.org/10.1074/jbc.272.10.6741			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045707	hybrid			2022-12-25	WOS:A1997WM64700091
J	Juin, P; Thieffry, M; Henry, JP; Vallette, FM				Juin, P; Thieffry, M; Henry, JP; Vallette, FM			Relationship between the peptide-sensitive channel and the mitochondrial outer membrane protein translocation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC CHANNEL; BASIC PEPTIDES; CROSS-LINKING; IMPORT; PRESEQUENCE; RECEPTOR; RECONSTITUTION; IDENTIFICATION; INVOLVEMENT; RECOGNITION	The peptide-sensitive channel (PSC), a cationic channel of the mitochondrial outer membrane, is blocked by synthetic mitochondrial presequences and by nonmitochondrial basic peptides such as dynorphin B(1-13), Both types of peptides are imported into mitochondria. However, the import of dynorphin B(1-13) had to be further characterized since its properties differed from those of the general import pathway used by mitochondrial peptides. Cross-linking experiments with iodinated dynorphin B(1-13) led to the labeling of TOM 40/ISP 42, a component of the protein import machinery of the outer membrane. Accordingly, dynorphin B(1-13) could also be used as a presequence to direct the import of a cytosolic protein into the mitochondria, Pretreatment of intact mitochondria by trypsin removed components capable of discriminating between true mitochondrial presequences and other basic peptides active on the PSC. After proteolysis, both types of peptides appeared to cross the outer membrane through the same pathway, Involvement of the PSC in the translocation complex was shown by immunoprecipitation of the PSC activity by anti-ISP 42 antibodies. Taken together, the present data reinforce the hypothesis that the PSC is the pore responsible for the translocation of protein through the outer membrane.	INST BIOL PHYSICOCHIM,CNRS UNITE PROPRE RECH 9071,SERV NEUROBIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; CNRS,NEUROBIOL CELLULAIRE & MOL LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018; JUIN, Philippe P/H-3636-2014; JUIN, Philippe/Q-1338-2019	Vallette, Francois M/0000-0002-3296-8572; JUIN, Philippe P/0000-0002-4997-3888; JUIN, Philippe/0000-0002-4997-3888; Vallette, Francois/0000-0003-0802-0519				ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; CHICH JF, 1991, EUR J BIOCHEM, V196, P29, DOI 10.1111/j.1432-1033.1991.tb15781.x; FEVRE F, 1993, J BIOENERG BIOMEMBR, V25, P55, DOI 10.1007/BF00768068; FEVRE F, 1994, BIOPHYS J, V66, P1887, DOI 10.1016/S0006-3495(94)80982-8; FONT B, 1991, FEBS LETT, V279, P105, DOI 10.1016/0014-5793(91)80262-2; GAIKWAD AS, 1994, J BIOL CHEM, V269, P6437; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry JP, 1996, J BIOENERG BIOMEMBR, V28, P101, DOI 10.1007/BF02110639; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; JUIN P, 1995, BIOCHEM BIOPH RES CO, V211, P92, DOI 10.1006/bbrc.1995.1782; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFALLER R, 1989, J BIOL CHEM, V264, P34; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, TRENDS BIOCHEM SCI, V15, P369, DOI 10.1016/0968-0004(90)90230-9; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; THIEFFRY M, 1992, BIOPHYS J, V63, P333, DOI 10.1016/S0006-3495(92)81626-0; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VALLETTE FM, 1994, J BIOL CHEM, V269, P13367; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	30	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					6044	6050		10.1074/jbc.272.9.6044	http://dx.doi.org/10.1074/jbc.272.9.6044			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038228	hybrid			2022-12-25	WOS:A1997WK74700096
J	Lamb, DC; Kelly, DE; Schunck, WH; Shyadehi, AZ; Akhtar, M; Lowe, DJ; Baldwin, BC; Kelly, SL				Lamb, DC; Kelly, DE; Schunck, WH; Shyadehi, AZ; Akhtar, M; Lowe, DJ; Baldwin, BC; Kelly, SL			The mutation T315A in Candida albicans sterol 14 alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOLE RESISTANCE; AIDS PATIENTS	Sterol 14 alpha-demethylase (P45051) is the target for azole antifungal compounds, and resistance to these drugs and agrochemicals is of significant practical importance, We undertook site-directed mutagenesis of the Candida albicans P45051 heterologously expressed in Saccharomyces cerevisiae 60 probe a model structure for the enzyme, The change T315A reduced enzyme activity 2-fold as predicted for the removal of the residue that formed a hydrogen bond with the 3-OH of the sterol substrate and helped to locate it in the active site, This alteration perturbed the heme environment, causing an altered reduced carbon monoxide difference spectrum with a maximum at 445 mn. The changes also reduced the affinity of the enzyme for the azole antifungals ketoconazole and fluconazole and after expression induced by galactose caused 45-fold azole resistance in transformants of S, cerevisiae. This is the first example of a single base change in the target enzyme conferring resistance to azoles through reduced azole affinity.	UNIV SHEFFIELD, DEPT MOL BIOL & BIOTECHNOL, KREBS INST BIOMOLEC RES, SHEFFIELD S10 2UH, S YORKSHIRE, ENGLAND; MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY; UNIV SOUTHAMPTON, DEPT BIOCHEM, SOUTHAMPTON SO16 7PX, HANTS, ENGLAND; JOHN INNES CTR PLANT SCI RES, NITROGEN FIXAT LAB, NORWICH NR4 7UH, NORFOLK, ENGLAND; ZENECA AGROCHEM, JEALOTTS HILL RES STN, BRACKNELL RG42 6ET, BERKS, ENGLAND	University of Sheffield; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Southampton; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center								AOYAMA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1320, DOI 10.1006/bbrc.1994.1848; BAILY GG, 1994, AIDS, V8, P787, DOI 10.1097/00002030-199406000-00010; BOSCOTT PE, 1994, J MOL GRAPH MODEL, V12, P185, DOI 10.1016/0263-7855(94)80086-3; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HITCHCOCK CA, 1990, BIOCHEM J, V266, P475, DOI 10.1042/bj2660475; JEFCOATE CR, 1969, BIOCHEMISTRY-US, V8, P3455, DOI 10.1021/bi00836a049; JOSEPHHORNE T, 1995, FEBS LETT, V374, P174, DOI 10.1016/0014-5793(95)01102-K; JOSEPHHORNE T, 1995, FEMS MICROBIOL LETT, V127, P29; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; Kelly SL, 1995, FEBS LETT, V377, P217, DOI 10.1016/0014-5793(95)01342-3; KELLY SL, 1993, BIOCHEM SOC T, V21, P1034, DOI 10.1042/bst0211034; KIRSCH DR, 1988, GENE, V68, P229, DOI 10.1016/0378-1119(88)90025-X; LAMB DC, 1995, FEBS LETT, V368, P326, DOI 10.1016/0014-5793(95)00684-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OMURA T, 1964, J BIOL CHEM, V239, P2370; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; SANTOS MAS, 1993, EMBO J, V12, P607, DOI 10.1002/j.1460-2075.1993.tb05693.x; Shyadehi AZ, 1996, J BIOL CHEM, V271, P12445, DOI 10.1074/jbc.271.21.12445; Stromstedt M, 1996, ARCH BIOCHEM BIOPHYS, V329, P73, DOI 10.1006/abbi.1996.0193; VENKATESWARLU K, 1995, FEMS MICROBIOL LETT, V131, P337, DOI 10.1111/j.1574-6968.1995.tb07797.x; WATSON PF, 1989, BIOCHEM BIOPH RES CO, V164, P1170, DOI 10.1016/0006-291X(89)91792-0; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655	23	162	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5682	5688		10.1074/jbc.272.9.5682	http://dx.doi.org/10.1074/jbc.272.9.5682			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038178	hybrid			2022-12-25	WOS:A1997WK74700046
J	Lugli, SM; Feng, NP; Heim, MH; Adam, M; Schnyder, B; Etter, H; Yamage, M; Eugster, HP; Lutz, RA; Zurawski, G; Moser, R				Lugli, SM; Feng, NP; Heim, MH; Adam, M; Schnyder, B; Etter, H; Yamage, M; Eugster, HP; Lutz, RA; Zurawski, G; Moser, R			Tumor necrosis factor alpha enhances the expression of the interleukin (IL)-4 receptor alpha-chain on endothelial cells increasing IL-4 or IL-13-induced Stat6 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; ADHESION MOLECULE-1; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; TNF-ALPHA; TRANSCRIPTION FACTOR; GAMMA-CHAIN; PROTEINS; COMPONENT; CYTOKINE	Functional receptors for interleukin (IL)-4 and IL-13 on endothelial cells consist of the 130-kDa IL-4 receptor alpha-chain (IL-4R alpha) and a 65-75-kDa IL-13 binding subunit that are expressed in a ratio of about 1:3, respectively. The restricted number of IL-4R alpha limits subunit heterodimerization and in turn receptor-mediated signaling, We report here, the effects of tumor necrosis factor alpha (TNF-alpha) on the expression of the receptor subunits for IL-4 and IL-13. By flow cytofluorometry and receptor-binding analysis of iodinated IL-4 and IL-13, stimulation with TNF-alpha-induced a 23-fold increase of the IL-4R alpha expression, The up-regulation was also confirmed at the transcriptional level by reverse transcription-polymerase chain reaction, Radioligand cross-linking experiments revealed no change in the subunit composition of the TNF-alpha-induced receptor complex, Nevertheless, TNF-alpha stimulation led to increased activation of the IL-4-specific signal transducers and activators of transcription protein (Stat6) by IL-4 and IL-13. Thus, TNF-alpha corrects the subunit imbalance of the endothelial IL-4 IL-13 receptor complex thereby increasing receptor heterodimerization and in turn the signaling capability by IL-4 and IL-13.	SWISS FED INST TECHNOL, INST TOXICOL, CH-8057 ZURICH, SWITZERLAND; UNIV ZURICH HOSP, INST CLIN CHEM, CH-8091 ZURICH, SWITZERLAND; UNIV BASEL HOSP, DEPT RES, CH-4031 BASEL, SWITZERLAND; DUPONT CO INC, STINE HASKELL RES CTR, NEWARK, DE 19714 USA; DNAX RES INST MOL & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; University of Basel; DuPont; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Heim, Markus/A-7526-2008	Heim, Markus/0000-0002-7523-4894				BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CARLOS TM, 1994, BLOOD, V84, P2068; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWIT H, 1994, BLOOD, V84, P608; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MATSUBARA N, 1990, PATHOBIOLOGY, V58, P168, DOI 10.1159/000163578; MCCARTY JM, 1995, FEBS LETT, V372, P194, DOI 10.1016/0014-5793(95)00976-G; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; MOSER R, 1992, J IMMUNOL, V149, P1432; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; NILSSON G, 1995, EUR J IMMUNOL, V25, P870, DOI 10.1002/eji.1830250337; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PALEOLOG EM, 1992, CYTOKINE, V4, P470, DOI 10.1016/1043-4666(92)90007-E; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; PURI RK, 1993, BIOCHEM BIOPH RES CO, V197, P1424, DOI 10.1006/bbrc.1993.2636; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Schnyder B, 1996, BLOOD, V87, P4286, DOI 10.1182/blood.V87.10.4286.bloodjournal87104286; SIRONI M, 1994, BLOOD, V84, P1913; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	49	38	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5487	5494		10.1074/jbc.272.9.5487	http://dx.doi.org/10.1074/jbc.272.9.5487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038152	hybrid			2022-12-25	WOS:A1997WK74700020
J	Polte, TR; Hanks, SK				Polte, TR; Hanks, SK			Complexes of focal adhesion kinase (FAK) and Crk-associated substrate (p130(Cas)) are elevated in cytoskeleton-associated fractions following adhesion and Src transformation - Requirements for Src kinase activity and FAK proline-rich motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-TYROSINE KINASE; PHOSPHOTYROSINE-CONTAINING PROTEINS; GROWTH-FACTOR; SH2 DOMAIN; LYSOPHOSPHATIDIC ACID; V-CRK; SUBCELLULAR-LOCALIZATION; EXTRACELLULAR-MATRIX; STABLE ASSOCIATION	The focal adhesion kinase (FAK) and Crk-associated substrate, p130(Cas) (Gas), have been implicated in diverse signaling pathways including those mediated by integrins, G-protein-coupled receptors, tyrosine kinase receptors, and the v-src and v-crk oncogenes. The recent identification of a direct interaction between FAK and Cas prompted the examination of potential regulation of FAX . Cas complexes by factors that result in concomitant increase in their phosphotyrosine content, namely cell adhesion and transformation by Src. Both conditions resulted in elevated FAK . Cas complex levels in nonionic detergent-insoluble fractions, indicating increased association with the cytoskeleton. For activated Src, this effect requires an active Src catalytic domain but not its Src homology 2 (SH2) or Src homology 3 (SH3) domains. FAK kinase domain tyrosines 576 and 577 are also required, suggesting that direct phosphorylation of these sites by Src may influence the solubility and/or stability of the complex. FAK-Cas association was only observed in the context of Cas binding to at least one of two distinct proline-rich sites on FAK. These findings firmly establish a direct interaction between FAK and Cas and demonstrate that Src can influence the subcellular localization of the complex by a tyrosine phosphorylation-dependent mechanism.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NIGMS NIH HHS [GM49882] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; ILLC D, 1995, NATURE, V377, P539; Ishino M, 1995, ONCOGENE, V11, P2331; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROECKEL D, 1994, EXP CELL RES, V211, P42, DOI 10.1006/excr.1994.1056; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	66	151	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5501	5509		10.1074/jbc.272.9.5501	http://dx.doi.org/10.1074/jbc.272.9.5501			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038154	hybrid			2022-12-25	WOS:A1997WK74700022
J	Ranson, H; Cornel, AJ; Fournier, D; Vaughan, A; Collins, FH; Hemingway, J				Ranson, H; Cornel, AJ; Fournier, D; Vaughan, A; Collins, FH; Hemingway, J			Cloning and localization of a glutathione S-transferase class I gene from Anopheles gambiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DDT-DEHYDROCHLORINASE; MOLECULAR-CLONING; SEQUENCE; MOSQUITO; THETA; PURIFICATION; RESISTANCE; FAMILY; FORMS; RAT	1,1,1-Trichloro-2,2-bis(p-chlorophenyl)ethane (DDT) resistance in both adults and larvae of Anopheles gambiae is mediated by stage-specific glutathione S-transferases (GSTs). On the basis of their biochemical characteristics the larval resistance-associated GSTs are likely to be insect class I GSTs, Aggst1-2, a class I GST gene, which is expressed in larvae, has been cloned from the malaria vector A, gambiae. The gene was inserted into a bacterial expression system, and the detection of 1-chloro-2,4-dinitrobenzene (CDNB) conjupating activity in Eschericia coli expressing the recombinant enzyme confirmed that aggst1-2 encodes a catalytically active GST, The gene encodes a 209 amino acid protein with 46% sequence similarity to a Drosophila melanogaster class I GST (GST-DI), 44% similarity with a Musca domestica class I GST (MdGST-1), but only low levels of homology with class II insect GSTs, including the adult specific AgGST2-1 from A, gambiae. Southern analysis of genomic DNA indicated that A. gambiae has multiple class I GSTs, In situ hybridization of class I, genomic and cDNA clones to polytene chromosomes identified a single region of complementarity on chromosome 2R division 18B, suggesting that these class I GSTs in A, gambiae are arranged sequentially in the genome, Three positive overlapping recombinant clones were identified from an A, gambiae genomic library, Mapping and partial sequencing of these clones suggests that there are several GSTs and truncated GST pseudogenes within the 30kb of DNA that these clones span.	UNIV WALES COLL CARDIFF, DEPT PURE & APPL BIOL, CARDIFF CF1 3TL, S GLAM, WALES; CTR DIS CONTROL & PREVENT, DIV PARASIT DIS, ENTOMOL BRANCH, CHAMBLEE, GA 30341 USA; UNIV TOULOUSE 3, LAB ENTOMOL APPL, F-31062 TOULOUSE, FRANCE	Cardiff University; Centers for Disease Control & Prevention - USA; Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Ranson, Hilary/0000-0003-2332-8247; Hemingway, Janet/0000-0002-3200-7173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTLING D, 1993, EUR J BIOCHEM, V216, P579, DOI 10.1111/j.1432-1033.1993.tb18177.x; BEALL C, 1992, BIOCHEM GENET, V30, P515, DOI 10.1007/BF01037590; BOARD P, 1994, BIOCHEM J, V299, P425, DOI 10.1042/bj2990425; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG PK, 1994, J BIOTECHNOL, V36, P247, DOI 10.1016/0168-1656(94)90156-2; CHIEN C, 1991, INSECT BIOCHEM, V21, P857, DOI 10.1016/0020-1790(91)90092-S; CLARK AG, 1984, PESTIC BIOCHEM PHYS, V22, P249, DOI 10.1016/0048-3575(84)90018-X; CLARK AG, 1985, INSECT BIOCHEM, V15, P35, DOI 10.1016/0020-1790(85)90041-1; FAVIA G, 1994, P NATL ACAD SCI USA, V91, P10315, DOI 10.1073/pnas.91.22.10315; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HEMINGWAY J, 1985, PESTIC BIOCHEM PHYS, V24, P68, DOI 10.1016/0048-3575(85)90115-4; Kumar V., 1994, Insect Molecular Biology, V3, P41, DOI 10.1111/j.1365-2583.1994.tb00149.x; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MIGNOGNA G, 1993, EUR J BIOCHEM, V211, P421, DOI 10.1111/j.1432-1033.1993.tb17566.x; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; PRAPANTHADARA L, 1995, B ENTOMOL RES, V85, P267, DOI 10.1017/S0007485300034350; PRAPANTHADARA LA, 1993, PESTIC BIOCHEM PHYS, V47, P119, DOI 10.1006/pest.1993.1070; Reiss R.A., 1993, Insect Molecular Biology, V2, P25, DOI 10.1111/j.1365-2583.1993.tb00122.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SNYDER MJ, 1995, INSECT BIOCHEM MOLEC, V25, P455, DOI 10.1016/0965-1748(94)00083-B; SYVANEN M, 1994, MOL GEN GENET, V245, P25, DOI 10.1007/BF00279747; TANG AH, 1994, J BIOL CHEM, V269, P27876; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; VAUGHAN A, 1995, BIOCHEM J, V305, P651, DOI 10.1042/bj3050651; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; WOOD E, 1986, COMP BIOCHEM PHYS B, V84, P607, DOI 10.1016/0305-0491(86)90130-6	30	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5464	5468		10.1074/jbc.272.9.5464	http://dx.doi.org/10.1074/jbc.272.9.5464			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038148	hybrid			2022-12-25	WOS:A1997WK74700016
J	RodriguezLopez, JN; HernandezRuiz, J; GarciaCanovas, F; Thorneley, RNF; Acosta, M; Arnao, MB				RodriguezLopez, JN; HernandezRuiz, J; GarciaCanovas, F; Thorneley, RNF; Acosta, M; Arnao, MB			The inactivation and catalytic pathways of horseradish peroxidase with m-chloroperoxybenzoic acid - A spectrophotometric and transient kinetic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CALCIUM-ION; HYDROGEN-PEROXIDE; MECHANISM; COMPOUND; ENZYME; RECOMBINANT; STATE; HEME	The kinetics of the catalytic cycle and irreversible inactivation of horseradish peroxidase C (HRP-C) reacting with m-chloroperoxybenzoic acid (mCPBA) have been studied by conventional and stopped-flow spectrophotometry, mCPBA oxidized HRP-C to compound I with a second order-rate constant k(1) = 3.6 x 10(7) M(-1) s(-1) at pH 7.0, 25 degrees C. Excess mCPBA subsequently acted as a one-electron reducing substrate, converting compound I to compound II and compound II to resting, ferric enzyme. In both of these reactions, spectrally distinct, transient forms of the enzyme were observed (lambda(max) = 411 nm, epsilon = 45 mM(-1) cm(-1) for compound I with mCPB-4, and lambda(max) = 408 nm, epsilon = 77 mM(-1) cm(-1) for compound II with mCPBA), The compound I-mCPBA intermediate (shown by near infrared spectroscopy to be identical to P965) decayed either to compound II in a catalytic cycle (k(3) = 6.4 x 10(-3) s(-1)) or, in a competing inactivation reaction, to verdohemoprotein (k(i) = 3.3 x 10(-3) s(-1)). Thus, a partition ratio of r = 2 is obtained for the inactivation of ferric HRP-C by mCPBA, The intermediate formed from compound II with mCPBA is not part of the inactivation pathway and only decays via the catalytic cycle to give resting, ferric enzyme (k(5) = 1.0 x 10(-3) s(-1)). The data are compared with those from earlier steady-state kinetic studies and demonstrate the importance of single turnover experiments, The results are discussed in terms of the physiologically relevant reactions of plant peroxidases with hydrogen peroxide.	UNIV MURCIA,FAC BIOL,DEPT BIOL VEGETAL FISIOL VEGETAL,E-30100 MURCIA,SPAIN; UNIV MURCIA,DEPT BIOQUIM & BIOL MOL A,E-30100 MURCIA,SPAIN; JOHN INNES INST,NITROGEN FIXAT LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	University of Murcia; University of Murcia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Acosta, Manuel/A-2127-2008; Garcia-Canovas, Francisco/M-1290-2014; Josefa, Hernandez-Ruiz/R-5424-2018; Neptuno, Jose/F-5012-2016; Arnao, Marino B./ABE-9146-2020	Acosta, Manuel/0000-0003-0611-6672; Garcia-Canovas, Francisco/0000-0002-8869-067X; Josefa, Hernandez-Ruiz/0000-0002-1847-8809; Arnao, Marino B./0000-0001-8517-6889; Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173				ACOSTA M, 1988, BIOCHIM BIOPHYS ACTA, V955, P194, DOI 10.1016/0167-4838(88)90193-8; ACOSTA M, 1993, PLANT PEROXIDASES BI, P201; ADEDIRAN SA, 1989, EUR J BIOCHEM, V186, P571, DOI 10.1111/j.1432-1033.1989.tb15246.x; Arnao MB, 1995, J MOL CATAL A-CHEM, V104, P179, DOI 10.1016/1381-1169(95)00114-X; Arnao MB, 1996, BIOCHEM MOL BIOL INT, V39, P97; ARNAO MB, 1990, BIOCHIM BIOPHYS ACTA, V1038, P85, DOI 10.1016/0167-4838(90)90014-7; ARNAO MB, 1990, BIOCHIM BIOPHYS ACTA, V1041, P43, DOI 10.1016/0167-4838(90)90120-5; BAECK HK, 1992, J AM CHEM SOC, V114, P718; BAGGER S, 1971, ACTA CHEM SCAND, V25, P976, DOI 10.3891/acta.chem.scand.25-0976; BERNASCONI CF, 1976, RELAXATION KINETICS, P31; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; Cano A, 1996, J PLANT PHYSIOL, V147, P721, DOI 10.1016/S0176-1617(11)81484-7; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P7889; CHANCE B, 1949, ARCH BIOCHEM, V21, P416; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; DAVIES DM, 1976, BIOCHEM J, V157, P247, DOI 10.1042/bj1570247; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1977, BIOCHEMISTRY-US, V16, P2949, DOI 10.1021/bi00632a023; GARRIDODELSOLO C, 1993, BIOCHEM J, V294, P459, DOI 10.1042/bj2940459; Gazaryan IG, 1996, BIOCHEM J, V313, P841, DOI 10.1042/bj3130841; Gilfoyle DJ, 1996, EUR J BIOCHEM, V236, P714, DOI 10.1111/j.1432-1033.1996.00714.x; Hiner ANP, 1996, BIOTECHNOL BIOENG, V50, P655, DOI 10.1002/(SICI)1097-0290(19960620)50:6<655::AID-BIT6>3.3.CO;2-U; HINER ANP, 1995, EUR J BIOCHEM, V234, P506, DOI 10.1111/j.1432-1033.1995.506_b.x; HIROMI K, 1979, KINETICS FAST ENZYME, P244; JOB D, 1978, EUR J BIOCHEM, V86, P565, DOI 10.1111/j.1432-1033.1978.tb12340.x; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MARANON MJR, 1994, PHYTOCHEMISTRY, V37, P1217, DOI 10.1016/S0031-9422(00)90388-1; MARKLUND S, 1973, ARCH BIOCHEM BIOPHYS, V154, P614, DOI 10.1016/0003-9861(73)90016-7; Mehlhorn H, 1996, FEBS LETT, V378, P203, DOI 10.1016/0014-5793(95)01448-9; MILLER VP, 1992, J BIOL CHEM, V267, P8936; MORISHIMA I, 1986, J BIOL CHEM, V261, P9391; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; NAKAJIMA R, 1980, J BIOL CHEM, V255, P2067; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; NICHOLLS P, 1963, ENZYMES, V8, P47; PENEL C, 1992, PLANT PEROXIDASES 19; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SMITH AT, 1990, J BIOL CHEM, V265, P13335; TAKAHAMA U, 1993, PHYSIOL PLANTARUM, V89, P791, DOI 10.1111/j.1399-3054.1993.tb05286.x; YAMAZAKI I, 1981, MOL CELL BIOCHEM, V40, P143	46	86	86	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5469	5476		10.1074/jbc.272.9.5469	http://dx.doi.org/10.1074/jbc.272.9.5469			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038149	hybrid			2022-12-25	WOS:A1997WK74700017
J	Tailor, P; Gilman, J; Williams, S; Couture, C; Mustelin, T				Tailor, P; Gilman, J; Williams, S; Couture, C; Mustelin, T			Regulation of the low molecular weight phosphotyrosine phosphatase by phosphorylation at tyrosines 131 and 132	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN PHOSPHATASE; ACTIVATION; CD45; OVEREXPRESSION; INHIBITION; P56(LCK); KINASE; GROWTH	Activation of resting T lymphocytes is initiated by rapid but transient tyrosine phosphorylation of a number of cellular proteins, Several protein tyrosine kinases and protein tyrosine phosphatases are known to be important for this response, Here we report that normal T lymphocytes express the B isoform of low molecular weight protein tyrosine phosphatase B (LMPTP-B), The cDNA was cloned from Jurkat T cells, and an antiserum was raised against it, LMPTP immunoprecipitated from resting Jurkat T cells was found to be tyrosine phosphorylated. On stimulation of the cells through their T cell antigen receptor, the phosphotyrosine content of LMPTP-B declined rapidly. In co-transfected COS cells, Lck and Fyn caused phosphorylation of LMPTP, whereas Csk, Zap, and Jak2 did not. Most of the phosphate was located at Tyr-131, and some was also located at Tyr-132. Incubation of wild-type LMPTP with Lck and adenosine 5'-O-(thiotriphosphate) caused a 2-fold increase in the activity of LMPTP, Site-directed mutagenesis showed that Tyr-131 is important for the catalytic activity of LMPTP, and that thiophosphorylation of Tyr-131, and to a lesser degree Tyr-132, is responsible for the activation.	LA JOLLA INST ALLERGY & IMMUNOL,DIV CELL BIOL,SAN DIEGO,CA 92121	La Jolla Institute for Immunology				Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN A, 1990, ADV IMMUNOL, V48, P277; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; HSI ED, 1989, J BIOL CHEM, V264, P10836; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WO YYP, 1992, J BIOL CHEM, V267, P10856; ZHANG M, 1995, ADV PROTEIN PHOSPHAT, V9, P1	25	91	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5371	5374		10.1074/jbc.272.9.5371	http://dx.doi.org/10.1074/jbc.272.9.5371			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038134	hybrid			2022-12-25	WOS:A1997WK74700002
J	Black, PN; Zhang, Q; Weimar, JD; DiRusso, CC				Black, PN; Zhang, Q; Weimar, JD; DiRusso, CC			Mutational analysis of a fatty acyl-coenzyme A synthetase signature motif identifies seven amino acid residues that modulate fatty acid substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLATION; ESCHERICHIA-COLI; COA SYNTHETASE; OUTER-MEMBRANE; A SYNTHETASE; FADL GENE; TRANSPORT PROTEIN; BINDING; EXPRESSION; CLONING	Fatty acyl-CoA synthetase (fatty acid:CoA ligase, AMP-forming; EC 6.2.1.3) catalyzes the formation of fatty acyl-CoA by a two-step process that proceeds through the hydrolysis of pyrophosphate. In Escherichia coli this enzyme plays a pivotal role in the uptake of long chain fatty acids (C12-C18) and in the regulation of the global transcriptional regulator FadR, The E. coli fatty acyl-CoA synthetase has remarkable amino acid similarities and identities to the family of both prokaryotic and eukaryotic fatty acyl-CoA synthetases, indicating a common ancestry, Most notable in this regard is a 26-amino acid consensus sequence, DGWLHTGDIGXWX-PXGXLKIIDRKEE, common to all fatty acyl-CoA synthetases for which sequence information is available, Within this consensus are 8 invariant and 13 highly conserved amino acid residues in the 12 fatty acyl-CoA synthetases compared, We propose that this sequence represents the fatty acyl-CoA synthetase signature motif (FAGS signature motif). This region of fatty acyl-CoA synthetase from E. coli, (431)NGWLHTGDIAVMDEEGFL-RIVDRKK(455), contains 17 amino acid residues that are either identical or highly conserved to the FAGS signature motif. Eighteen site directed mutations within the fatty acyl-CoA synthetase structural gene (fadD) corresponding to this motif were constructed to evaluate the contribution of this region of the enzyme to catalytic activity, Three distinct classes of mutations were identified on the basis of growth characteristics on fatty acids, enzymatic activities using cell extracts, and studies using purified wild-type and mutant forms of the enzyme: 1) those that resulted in either wild-type or nearly wild-type fatty acyl-CoA synthetase activity profiles; 2) those that had little or no enzyme activity; and 3) those that resulted in lowering and altering fatty acid chain length specificity, Among the 18 mutants characterized, 7 fall in the third class, We propose that the FAGS signature motif is essential for catalytic activity and functions in part to promote fatty acid chain length specificity and thus may compose part of the fatty acid binding site within the enzyme.			Black, PN (corresponding author), ALBANY MED COLL, DEPT BIOCHEM & MOL BIOL, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.		DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881; DiRusso, Concetta/0000-0001-7388-9152				ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; AZIZAN A, 1994, J BACTERIOL, V176, P6653, DOI 10.1128/JB.176.21.6653-6662.1994; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1995, BIOCHEM J, V310, P389, DOI 10.1042/bj3100389; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROFMAN M, 1989, BIOCHEM BIOPH RES CO, V159, P1026; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; FULDA M, 1994, MOL GEN GENET, V242, P241, DOI 10.1007/BF00280412; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Groot P H, 1976, Adv Lipid Res, V14, P75; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMEDA K, 1987, BIOCHEM INT, V14, P227; KAMEDA K, 1986, BIOCHEM INT, V13, P343; KAMEDA K, 1985, BIOCHIM BIOPHYS ACTA, V840, P29, DOI 10.1016/0304-4165(85)90158-8; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; KORCHAK HM, 1994, J BIOL CHEM, V269, P30281; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; KUMAR GB, 1993, J BIOL CHEM, V268, P15469; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JCK, 1993, RES COMMUN CHEM PATH, V82, P331; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; NUNN WD, 1978, P NATL ACAD SCI USA, V75, P3377, DOI 10.1073/pnas.75.7.3377; NUNN WD, 1986, J BIOL CHEM, V261, P167; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Sambrook J, 1987, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Singh RK, 1996, COMPUT APPL BIOSCI, V12, P191; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	49	131	147	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4896	4903		10.1074/jbc.272.8.4896	http://dx.doi.org/10.1074/jbc.272.8.4896			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030548	hybrid			2022-12-25	WOS:A1997WJ85500036
J	Iozzo, RV; Pillarisetti, J; Sharma, B; Murdoch, AD; Danielson, KG; Uitto, J; Mauviel, A				Iozzo, RV; Pillarisetti, J; Sharma, B; Murdoch, AD; Danielson, KG; Uitto, J; Mauviel, A			Structural and functional characterization of the human perlecan gene promoter - Transcriptional activation by transforming growth factor-beta via a nuclear factor 1-binding element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; COLON-CARCINOMA-CELLS; DENSITY-LIPOPROTEIN-RECEPTOR; BASEMENT-MEMBRANES; FACTOR-I; RESPONSIVE ELEMENT; COLLAGEN PROMOTER; BINDING PROTEINS; DNA-BINDING; DOMAIN-III	Perlecan, a modular heparan sulfate proteoglycan of basement membranes and cell surfaces, plays a crucial role in regulating the assembly of extracellular matrices and the binding of nutrients and growth factors to target cells. To achieve a molecular understanding of perlecan gene regulation, we isolated the 5'-flanking region and investigated its functional promoter activity and its response to cytokines. Transient cell transfection assays, using plasmid constructs harboring the perlecan promoter linked to the chloramphenicol acetyltransferase reporter gene, demonstrated that the largest similar to 2.5-kilobase construct contained maximal promoter activity. This promoter region was functionally active in a variety of cells of diverse histogenetic origin, thus corroborating the widespread expression of this gene product. Stepwise 5' deletion analyses demonstrated that the -461-base pair (bp) proximal promoter retained similar to 90% of the total activity, and internal deletions confirmed that the most proximal sequence was essential for proper promoter activity, Nanomolar amounts of transforming growth factor-beta induced 2-3-fold perlecan mRNA and protein core levels in normal human skin fibroblasts, and this induction was transcriptionally regulated; in contrast, tumor necrosis factor-alpha had no effect and was incapable of counteracting the effects of TGF-beta, Using additional 5' deletions and DNase footprinting analyses, we mapped the TGF-beta responsive region to a sequence of 177 bp contained between -461 and -285. This region harbored a 14-bp element similar to a TGF-beta-responsive element present in the promoters of collagen alpha 1(I), alpha 2(I), elastin, and growth hormone. Electrophoretic mobility shift assays and mutational analyses demonstrated that the perlecan TGF-beta-responsive element bound specifically to TGF-beta-inducible nuclear proteins with high affinity for NF-1 member(s) of transcription factors.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOL MED,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107, USA.		MAUVIEL, Alain/F-6251-2013; Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112; Mauviel, Alain/0000-0002-0438-2793	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NIAMS NIH HHS [P01 AR38923] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Austria M. R., 1993, Molecular Biology of the Cell, V4, p184A; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COHEN IR, 1994, CANCER RES, V54, P5771; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; CVEKL A, 1995, MOL CELL BIOL, V15, P653; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DODGE GR, 1990, J BIOL CHEM, V265, P18023; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GRASSEL S, 1995, MOL CELL BIOCHEM, V145, P61, DOI 10.1007/BF00925714; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; IOZZO RV, 1989, ARCH BIOCHEM BIOPHYS, V269, P239, DOI 10.1016/0003-9861(89)90105-7; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; IOZZO RV, 1990, J BIOL CHEM, V265, P19980; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; ISEMURA M, 1987, J BIOL CHEM, V262, P8926; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KLEIN G, 1995, MATRIX BIOL, V14, P457, DOI 10.1016/0945-053X(95)90003-9; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; MARIGO V, 1994, BIOCHEM BIOPH RES CO, V199, P1049, DOI 10.1006/bbrc.1994.1335; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MCBAIN JA, 1990, CELL GROWTH DIFFER, V1, P281; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JE, 1994, CELL DEV BIOL A, V30, P120; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NASO MF, 1994, J BIOL CHEM, V269, P32999; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PIEDAGNEL R, 1994, J BIOL CHEM, V269, P17469; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; SANTRA M, 1994, J BIOL CHEM, V269, P579; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SUNDARRAJ N, 1995, J CELL SCI, V108, P2601; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Vihinen T, 1996, J BIOL CHEM, V271, P12532, DOI 10.1074/jbc.271.21.12532; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZUTTER MM, 1994, J BIOL CHEM, V269, P463; [No title captured]	58	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5219	5228		10.1074/jbc.272.8.5219	http://dx.doi.org/10.1074/jbc.272.8.5219			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030592	hybrid			2022-12-25	WOS:A1997WJ85500080
J	Richter, M; Schleithoff, L; Deufel, T; LehmannHorn, F; HerrmannFrank, A				Richter, M; Schleithoff, L; Deufel, T; LehmannHorn, F; HerrmannFrank, A			Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM RELEASE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CALMODULIN; CHANNEL; CA2+; BINDING; GENE; IDENTIFICATION; LOCALIZATION	Malignant hyperthermia is an inherited autosomal disorder of skeletal muscle in which certain volatile anesthetics and depolarizing muscle relaxants trigger an abnormally high release of Ca2+ from the intracellular Ca2+ store, the sarcoplasmic reticulum, In about 50% of cases, malignant hyperthermia susceptibility is linked to the gene encoding the skeletal muscle ryanodine receptor/Ca2+ release channel (RYR1). To date, eight point mutations have been identified in human RYR1, Although these mutations are thought to lead to an increased caffeine and halothane sensitivity in the contractile response of skeletal muscle, their functional consequences have not been investigated on the molecular level, In the present study, we provide the first functional characterization of a point mutation located in the central part of RYR1, Gly(2434) --> Arg. Using high affinity [H-3]ryanodine binding as the experimental approach, we show that this mutation enhances the sensitivity of RYR1 to activating concentrations of Ca2+ and to the exogenous and diagnostically used ligands caffeine and 4-chloro-m-cresol. In parallel, the sensitivity to inhibiting concentrations of Ca2+ and calmodulin was reduced, transferring the mutant Ca2+ release channel into a hyperexcitable state.	UNIV ULM, DEPT APPL PHYSIOL, D-89069 ULM, GERMANY; UNIV HOSP, INST CLIN CHEM & LAB DIAGNOST, D-07740 JENA, GERMANY	Ulm University; Friedrich Schiller University of Jena				Deufel, Thomas/0000-0003-4839-3117				BURATTI R, 1995, BIOCHEM BIOPH RES CO, V213, P1082, DOI 10.1006/bbrc.1995.2238; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ELLIS FR, 1984, BRIT J ANAESTH, V56, P1267; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FLETCHER JE, 1993, BIOCHEM MOL BIOL INT, V29, P763; FLETCHER JE, 1991, LIFE SCI, V49, P1651, DOI 10.1016/0024-3205(91)90060-O; FLETCHER JE, 1990, BIOCHEM CELL BIOL, V68, P1195, DOI 10.1139/o90-177; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; HerrmannFrank A, 1996, BIOCHEM PHARMACOL, V52, P149, DOI 10.1016/0006-2952(96)00175-X; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; HERRMANNFRANK A, 1997, IN PRESS AM J ANESTH; ILES DE, 1994, HUM MOL GENET, V3, P969, DOI 10.1093/hmg/3.6.969; KEATING KE, 1994, HUM MOL GENET, V3, P1855, DOI 10.1093/hmg/3.10.1855; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MACLENNAN DH, 1995, CURR OPIN NEUROL, V8, P397, DOI 10.1097/00019052-199510000-00013; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; NELSON TE, 1992, ANESTHESIOLOGY, V76, P588, DOI 10.1097/00000542-199204000-00016; ODriscoll S, 1996, BIOCHEM J, V319, P421, DOI 10.1042/bj3190421; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Phillips MS, 1996, GENOMICS, V34, P24, DOI 10.1006/geno.1996.0238; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; PLANK B, 1988, BIOCHIM BIOPHYS ACTA, V938, P79, DOI 10.1016/0005-2736(88)90124-1; QUANE KA, 1994, GENOMICS, V23, P236, DOI 10.1006/geno.1994.1483; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SHOMER NH, 1995, MUSCLE NERVE, V18, P1167, DOI 10.1002/mus.880181013; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SUDBRAK R, 1995, AM J HUM GENET, V56, P684; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tegazzin V, 1996, ANESTHESIOLOGY, V84, P1380, DOI 10.1097/00000542-199606000-00014; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VALDIVIA HH, 1991, AM J PHYSIOL, V261, pC237, DOI 10.1152/ajpcell.1991.261.2.C237; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	45	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5256	5260		10.1074/jbc.272.8.5256	http://dx.doi.org/10.1074/jbc.272.8.5256			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030597	hybrid			2022-12-25	WOS:A1997WJ85500085
J	Vijayaraghavan, S; Goueli, SA; Davey, MP; Carr, DW				Vijayaraghavan, S; Goueli, SA; Davey, MP; Carr, DW			Protein kinase A-anchoring inhibitor peptides arrest mammalian sperm motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; BOVINE EPIDIDYMAL SPERMATOZOA; FLAGELLAR MOTILITY; SUBCELLULAR-LOCALIZATION; MOUSE SPERM; PHOSPHORYLATION; ADENOSINE; CLONING; CALCIUM; PHOSPHOPROTEIN	Cyclic AMP-dependent protein kinase (PKA) is anchored at specific subcellular sites through the interaction of the regulatory subunit (R) with protein kinase A-anchoring proteins (AKAPs) via an amphipathic helix binding motif, Synthetic peptides containing this amphipathic helix domain competitively disrupt PKA binding to AKAPs and cause a loss of PKA modulation of cellular responses, In this report we use S-Ht31, a cell-permeant anchoring inhibitor peptide, to study the role of PKA anchoring in sperm, Our analysis of three species of mammalian sperm detected three isoforms of PKA (RII alpha, RII beta, and RI beta) and one 110-kDa AKAP, The addition of S-Ht31 to bovine caudal epididymal sperm inhibits motility in a time- and concentration dependent manner, A control peptide, S-Ht31-P, identical to S-Ht31 except for a proline for isoleucine substitution to prevent amphipathic helix formation, had no effect on motility, The inhibition of motility by S-Ht31 is reversible but only if calcium is present in the suspension buffer, suggesting a role for PKA anchoring in regulating cellular calcium homeostasis. Surprisingly, inhibition of PKA catalytic activity had little effect on basal motility or motility stimulated by agents previously thought to work via PKA activation, These data suggest that the interaction of the regulatory subunit of PKA with sperm AKAPs, independent of PKA catalytic activity, is a key regulator of sperm motility and that disruption of this interaction using cell permeable anchoring inhibitor peptides may form the basis of a sperm targeted contraceptive.	VET AFFAIRS MED CTR,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,PORTLAND,OR 97201; OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006; PROMEGA CORP,MADISON,WI 53711; UNIV WISCONSIN,SCH MED,DEPT PATHOL & LAB MED,MADISON,WI 53711	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; Promega Corporation; University of Wisconsin System; University of Wisconsin Madison					NICHD NIH HHS [HD30908, HD32508] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD032508, R01HD030908] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BABCOCK DF, 1976, J BIOL CHEM, V251, P3881; Bedford JM, 1990, MARSHALLS PHYSL REPR, V2, P379; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR DW, 1993, J BIOL CHEM, V268, P20729; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GARBERS D, 1973, BIOL REPROD, V8, P589, DOI 10.1093/biolreprod/8.5.589; Garbers D L, 1978, Adv Cyclic Nucleotide Res, V9, P583; GARBERS DL, 1980, ADV CYCLIC NUCLEOTID, V13, P252; GLASS DB, 1989, J BIOL CHEM, V264, P14579; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HOROWITZ JA, 1988, J BIOL CHEM, V263, P2098; HOSKINS DD, 1973, J BIOL CHEM, V248, P1135; HOSKINS DD, 1974, J REPROD FERTIL, V37, P131, DOI 10.1530/jrf.0.0370131; HOSKINS DD, 1975, BIOL REPROD, V18, P168; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KHATRA BS, 1985, BIOCHEM BIOPH RES CO, V130, P567, DOI 10.1016/0006-291X(85)90454-1; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kopf GS, 1991, ELEMENTS MAMMALIAN F, P153; LEE MA, 1986, BIOL REPROD, V34, P349, DOI 10.1095/biolreprod34.2.349; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LINDEMANN CB, 1989, ARCH ANDROLOGY, V23, P1, DOI 10.3109/01485018908986783; LIOTTA AS, 1994, J BIOL CHEM, V269, P22996; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NOLAND TD, 1987, BIOL REPROD, V37, P171, DOI 10.1095/biolreprod37.1.171; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; PARISET C, 1994, MOL REPROD DEV, V39, P415, DOI 10.1002/mrd.1080390410; PAUPARD MC, 1988, J CELL BIOCHEM, V37, P161, DOI 10.1002/jcb.240370204; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Satir P., 1985, Modern Cell Biology, V4, P1; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; Smith GD, 1996, BIOL REPROD, V54, P719, DOI 10.1095/biolreprod54.3.719; STEPHENS DT, 1988, BIOL REPROD, V38, P577, DOI 10.1095/biolreprod38.3.577; Tash J.S., 1988, Progress in Clinical and Biological Research, V267, P335; TASH JS, 1984, CELL, V38, P551, DOI 10.1016/0092-8674(84)90509-9; TASH JS, 1986, J CELL BIOL, V103, P649, DOI 10.1083/jcb.103.2.649; TASH JS, 1989, CELL MOTIL CYTOSKEL, V14, P332, DOI 10.1002/cm.970140303; TASH JS, 1994, J ANDROL, V15, P505; VIJAYARAGHAVAN S, 1994, MOL REPROD DEV, V38, P326, DOI 10.1002/mrd.1080380314; Vijayaraghavan S, 1996, BIOL REPROD, V54, P709, DOI 10.1095/biolreprod54.3.709; VIJAYARAGHAVAN S, 1986, BIOL REPROD, V34, P468, DOI 10.1095/biolreprod34.3.468; VIJAYARAGHAVAN S, 1989, BIOL REPROD, V40, P744, DOI 10.1095/biolreprod40.4.744; VIJAYARAGHAVAN S, 1990, MOL REPROD DEV, V25, P186, DOI 10.1002/mrd.1080250212; VIJAYARAGHAVAN S, 1985, J CYCLIC NUCL PROT, V10, P499; VIJAYARAGHAVAN S, 1985, BIOL REPROD, V32, P489, DOI 10.1095/biolreprod32.3.489; VIJAYARAGHAVAN S, 1989, CELL CALCIUM, V10, P241, DOI 10.1016/0143-4160(89)90007-9	59	206	211	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4747	4752		10.1074/jbc.272.8.4747	http://dx.doi.org/10.1074/jbc.272.8.4747			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030527	hybrid			2022-12-25	WOS:A1997WJ85500015
J	Fabianek, RA; HuberWunderlich, M; Glockshuber, R; Kunzler, P; Hennecke, H; ThonyMeyer, L				Fabianek, RA; HuberWunderlich, M; Glockshuber, R; Kunzler, P; Hennecke, H; ThonyMeyer, L			Characterization of the Bradyrhizobium japonicum CycY protein, a membrane-anchored periplasmic thioredoxin that may play a role as a reductant in the biogenesis of c-type cytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; SYMBIOTIC NITROGEN-FIXATION; BOND FORMATION INVIVO; DISULFIDE-ISOMERASE; RHIZOBIUM-JAPONICUM; REDOX PROPERTIES; SEQUENCE-ANALYSIS; RNA-POLYMERASE; GENE-CLUSTER; DSBA	A new member of membrane-anchored periplasmic thioredoxin-like proteins was identified in Bradyrhizobium japonicum. It is the product of cycY, the last gene in a cluster of cytochrome c biogenesis genes. Mutational analysis revealed that cycY is essential for the biosynthesis of all c-type cytochromes in this bacterium. The CycY protein was shown to be exported to the periplasm by its N-terminal signal sequence-like domain. Results from Western blot analyses of membrane and soluble fractions indicated that the CycY protein remains bound to the membrane. A soluble version of the protein devoid of its N-terminal membrane anchor (CycY*) was expressed in Escherichia coli and purified to homogeneity from the periplasmic fraction. The protein showed redox reactivity and properties similar to other thioredoxins such as fluorescence quenching in the oxidized form. Its equilibrium constant with glutathione was determined to be 168 mM, from which a standard redox potential of -0.217 V was calculated, suggesting that CycY might act as a reductant in the otherwise oxidative environment of the periplasm. This is in agreement with our hypothesis that CycY is required, directly or indirectly, for the reduction of the heme-binding site cysteines in the CXXCH motif of c-type apocytochromes before heme attachment occurs.	ETH ZENTRUM,INST MIKROBIOL,CH-8092 ZURICH,SWITZERLAND; ETH ZENTRUM,INST MOL BIOL & BIOPHYS,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich								ALVAREZMORALES A, 1986, NUCLEIC ACIDS RES, V14, P4207; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; BECKMAN DL, 1993, P NATL ACAD SCI USA, V90, P2179, DOI 10.1073/pnas.90.6.2179; BERGLUND O, 1970, J BIOL CHEM, V245, P6030; BOTT M, 1995, J BACTERIOL, V177, P2214, DOI 10.1128/jb.177.8.2214-2217.1995; CROOKE H, 1995, MOL MICROBIOL, V15, P1139, DOI 10.1111/j.1365-2958.1995.tb02287.x; DANIEL RM, 1972, BIOCHIM BIOPHYS ACTA, V275, P347, DOI 10.1016/0005-2728(72)90215-0; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; HAHN M, 1984, MOL GEN GENET, V193, P46, DOI 10.1007/BF00327412; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; KERESZT A, 1995, MOL GEN GENET, V247, P39, DOI 10.1007/BF00425819; KRANZ RG, 1995, ANOXYGENIC PHOTOSYNT, P709; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LOFERER H, 1993, EMBO J, V12, P3373, DOI 10.1002/j.1460-2075.1993.tb06011.x; LOFERER H, 1995, J BIOL CHEM, V270, P26178, DOI 10.1074/jbc.270.44.26178; LOFERER H, 1994, EUR J BIOCHEM, V223, P339, DOI 10.1111/j.1432-1033.1994.tb18999.x; METHERINGHAM R, 1995, ARCH MICROBIOL, V164, P301, DOI 10.1007/BF02529965; Miller J.H., 1972, EXPT MOL GENETICS; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; PAGE MD, 1995, MOL MICROBIOL, V15, P307, DOI 10.1111/j.1365-2958.1995.tb02245.x; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; RAMSEIER TM, 1991, J BIOL CHEM, V266, P7793; REGENSBURGER B, 1983, ARCH MICROBIOL, V135, P103, DOI 10.1007/BF00408017; RITZ D, 1995, MOL GEN GENET, V247, P27, DOI 10.1007/BF00425818; RITZ D, 1993, MOL MICROBIOL, V9, P729, DOI 10.1111/j.1365-2958.1993.tb01733.x; ROST N, 1964, NATURE, V201, P185; SAMBONGI Y, 1994, FEBS LETT, V344, P207, DOI 10.1016/0014-5793(94)00399-8; Sambrook J., 2002, MOL CLONING LAB MANU; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURPIN MA, 1994, GENE, V143, P73, DOI 10.1016/0378-1119(94)90607-6; ThonyMeyer L, 1996, J BACTERIOL, V178, P6166; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1996, EUR J BIOCHEM, V235, P754, DOI 10.1111/j.1432-1033.1996.00754.x; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; Turner G. L., 1980, Methods for evaluating biological nitrogen fixation., P111; VARGAS C, 1994, J BACTERIOL, V176, P4117, DOI 10.1128/JB.176.13.4117-4123.1994; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	52	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4467	4473		10.1074/jbc.272.7.4467	http://dx.doi.org/10.1074/jbc.272.7.4467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020171	hybrid			2022-12-25	WOS:A1997WH01900087
J	Hirsch, DD; Stork, PJS				Hirsch, DD; Stork, PJS			Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TYROSINE-PHOSPHATASE; MAP KINASE; C-JUN; SIGNAL-TRANSDUCTION; HEAT-SHOCK; CELL-LINES; RAS	The c-Jun N-terminal protein kinases (JNKs), also called stress-activated protein kinases, are members of the growing family of serine/threonine kinases in the mitogen-activated protein (MAP) kinase superfamily. Like other MAP kinases, JNKs are activated via phosphorylation on adjacent threonine and tyrosine residues and can be inactivated by a unique family of dual specificity phosphatases, called MAP kinase phosphatases (MKPs). MKPs are encoded by immediate early genes and induced in response to environmental stressors and growth factor stimulation. Two prevalent isoforms of MKP, MKP1 and MKP2, are co-expressed in a wide variety of cell types. In this study, we examined the actions of MKP1 and MKP2 on JNK1 and JNK2. JNK1 phosphorylation and activation was inhibited by expression of both MKP1 and MKP2, although MKP1 selectivity toward JNK1 appeared significantly higher than that of MKP2. In contrast, JNK2 activity was inhibited by either phosphatase to similar degrees. Both MKP1 and MKP2 were highly effective at blocking the activation of the physiological target of JNK activation, the transcription factor c-Jun. In PC12 cells, MKP1 and MKP2 are transcriptionally induced following stimulation by nerve growth factor. In these cells, UV light-evoked JNK activation was reduced by pretreatment with nerve growth factor. Therefore, JNKs may be selective targets of MKP action in certain cells.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DIV CARDIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008947] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08947-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	51	108	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4568	4575		10.1074/jbc.272.7.4568	http://dx.doi.org/10.1074/jbc.272.7.4568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020184				2022-12-25	WOS:A1997WH01900100
J	Kuang, B; Rubenstein, PA				Kuang, B; Rubenstein, PA			The effects of severely decreased hydrophobicity in a subdomain 3/4 loop on the dynamics and stability of yeast G-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MUTATION; BINDING; MODEL; POLYMERIZATION; CONFORMATION; REFINEMENT; OLIGOMERS; FILAMENT; PROTEINS	The hydrophobicity of the subdomain 3/4 hydrophobic loop (262-274) has been implicated to be essential for actin's function. We previously showed (Kuang, B., and Rubenstein, P. A. (1997) J. Biol. Chem. 272, 1237-1247) that a mutant yeast actin (V266G/L267G) with markedly decreased hydrophobicity in this loop conferred severe cold sensitivity to its polymerization. Here we further tested the mutational effect on the conformation and function of G-actin. This GG mutation caused no significant changes in overall secondary structure or in the microenvironment around actin's tryptophan residues, nor did it alter the dissociation constant of G-actin for ATP. However, it lowers the intrinsic ATPase activity and the melting temperature for Mg-GG actin from 51 to 33 degrees C and transforms the conformation of subdomain 2 and the central cleft of G-actin into an F-monomer-like structure. The results suggest that the hydrophobic plug may not only play a role in actin filament stabilization but also may be important for controlling the stability of G-actin and for promoting the conformational change of the monomer needed for addition to a growing actin filament.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NIGMS NIH HHS [GM33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN X, 1995, J BIOL CHEM, V270, P11415, DOI 10.1074/jbc.270.19.11415; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; CROSBIE RH, 1994, BIOPHYS J, V67, P1954; EGELMAN EH, 1995, CURR OPIN STRUC BIOL, V5, P172, DOI 10.1016/0959-440X(95)80072-7; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; Heintz D, 1996, BIOCHEMISTRY-US, V35, P258, DOI 10.1021/bi950765x; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KARPOVA TS, 1995, J CELL BIOL, V131, P1483, DOI 10.1083/jcb.131.6.1483; Kim E, 1995, BIOPHYS J, V69, P2024, DOI 10.1016/S0006-3495(95)80072-X; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; KONNO K, 1987, BIOCHEMISTRY-US, V26, P3582, DOI 10.1021/bi00386a050; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; MOSSAKOWSKA M, 1993, BIOCHEM J, V289, P897, DOI 10.1042/bj2890897; MOZOVILLARIAS A, 1985, BIOCHEMISTRY-US, V24, P1544, DOI 10.1021/bi00327a038; NEWMAN J, 1985, BIOCHEMISTRY-US, V24, P1538, DOI 10.1021/bi00327a037; Oosawa F, 1971, SUBUNITS BIOL SYST A, P261; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHUTT CE, 1995, J STRUCT BIOL, V115, P186, DOI 10.1006/jsbi.1995.1043; SPUDICH JA, 1974, J BIOL CHEM, V249, P6013; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; WRIGGERS W, 1996, BIOPHYS J, V68, pA34	30	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4412	4418		10.1074/jbc.272.7.4412	http://dx.doi.org/10.1074/jbc.272.7.4412			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020164	hybrid			2022-12-25	WOS:A1997WH01900080
J	Moretti, F; Farsetti, A; Soddu, S; Misiti, S; Crescenzi, M; Filetti, S; Andreoli, M; Sacchi, A; Pontecorvi, A				Moretti, F; Farsetti, A; Soddu, S; Misiti, S; Crescenzi, M; Filetti, S; Andreoli, M; Sacchi, A; Pontecorvi, A			p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells	ONCOGENE			English	Article						p53; tumor suppressor gene; differentiation; thyroid carcinoma	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; G(1) ARREST; MUTANT P53; MUTATIONS; GROWTH; PROTEIN; TRANSFORMATION; THYROTROPIN; INDUCTION	Alterations of the tumor suppressor gene p53 are uncommon in differentiated thyroid neoplasia but are detected at high frequency in anaplastic thyroid carcinoma suggesting that impaired p53 function may contribute to the undifferentiated and highly aggressive phenotype of these tumors, Effects of wild type p53 (wt-p53) re-expression were investigated in a human anaplastic thyroid carcinoma cell line (ARO) expressing a mutated p53, ARO cells were stably transfected with the temperature-sensitive p53 Val(135) gene (ts-p53) which exhibits wild type-like activity at 32 degrees C, Exogenous wt-p53 function in ARO-tsp53 clones was assessed by evaluating its transcriptional activity on a CAT reporter vector containing p53 binding sites, At 32 degrees C, a significant reduction in the proliferation rate (congruent to 50%) was observed, with accumulation of cells in the G(0)/G(1) phase of the cell cycle, This effect was accompanied by induction of the expression of the growth inhibitor p21/Waf1 gene, At 32 degrees C, ARO-tsp53 clones also showed a marked impairment of their tumorigenic potential, Furthermore, transfected clones re-acquired the ability to respond to thyrotropin (TSH) stimulation showing an increased expression of thyroid-specific genes (thyroglobulin, thyroperoxidase and TSH receptor), In conclusion, re-expression of wt-p53 activity in ARO cells, inhibits cell proliferation and restores responsiveness to physiological stimuli.	REGINA ELENA INST CANC RES,MOL ONCOGENESIS LAB,ROME,ITALY; CNR,INST EXPT MED,ROME,ITALY; UNIV ROMA LA SAPIENZA,CHAIR ENDOCRINOL 2,ROME,ITALY; UNIV CATANZARO,CHAIR ENDOCRINOL,CATANZARO,ITALY; CATHOLIC UNIV ROME,INST MED PATHOL,ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Magna Graecia University of Catanzaro; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			Crescenzi, Marco/J-3603-2018; Soddu, Silvia/K-2467-2018; Farsetti, Antonella/I-8710-2018; Soddu, Silvia/ABH-6774-2020; Moretti, Fabiola/I-5647-2013	Crescenzi, Marco/0000-0003-0156-1494; Soddu, Silvia/0000-0001-8526-0044; Farsetti, Antonella/0000-0002-8603-7925; Soddu, Silvia/0000-0001-8526-0044; Moretti, Fabiola/0000-0002-2691-1254				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BATTISTA S, 1995, ONCOGENE, V11, P2029; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Fagin JA, 1996, CANCER RES, V56, P765; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FAGIN JA, 1994, THYROID TODAY, V17, P1; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUBER GK, 1992, ENDOCRINOLOGY, V130, P2858, DOI 10.1210/en.130.5.2858; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; INGBAR S H, 1985, P682; ITO T, 1992, CANCER RES, V52, P1369; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIMURA H, 1992, EXP CELL RES, V203, P402, DOI 10.1016/0014-4827(92)90014-Y; LAMPARIELLO F, 1991, CYTOMETRY, V12, P343, DOI 10.1002/cyto.990120409; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; NAMBA H, 1992, ENDOCRINOLOGY, V132, P839; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PROKOCIMER M, 1994, BLOOD, V84, P2391; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WRIGHT PA, 1991, ONCOGENE, V6, P1693; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; [No title captured]	51	112	115	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					729	740		10.1038/sj.onc.1200887	http://dx.doi.org/10.1038/sj.onc.1200887			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038381	Green Published, Bronze			2022-12-25	WOS:A1997WG43000012
J	Jiang, H; StUlme, D; Dickens, G; Chabuk, A; Lavarreda, M; Lazarovici, P; Guroff, G				Jiang, H; StUlme, D; Dickens, G; Chabuk, A; Lavarreda, M; Lazarovici, P; Guroff, G			Both p140(trk) and p75(NGFR) nerve growth factor receptors mediate nerve growth factor-stimulated calcium uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; FACTOR-INDUCED INCREASE; PC12 CELLS; NEURITE OUTGROWTH; CHROMAFFIN CELLS; FIBER OUTGROWTH; K-252A; RAT; NEURONS; PHOSPHORYLATION	Human p140(trk) and p75(NGFR) were transfected separately into 3T3 cells. Nerve growth factor stimulates calcium uptake into both transfectants but not into untransfected 3T3 cells. p140(trk) cells were stimulated maximally by 25 ng/ml; 100 ng/ml was submaximal for p75(NGFR) cells. K-252a inhibits the effect of NGF on p140(trk) cells but not on p75(NGFR) cells; brain-derived neurotrophic factor stimulates calcium uptake in p75(NGFR) cells but not in p140(trk) cells. The data suggest that both nerve growth factor receptors could be involved in the nerve growth factor-mediated actions of calcium on its target cells: neuronal survival, neuronal protection, and synaptic plasticity.	NICHHD,GROWTH FACTORS SECT,NIH,BETHESDA,MD 20892; HEBREW UNIV JERUSALEM,FAC MED,SCH PHARM,DEPT PHARMACOL,IL-91010 JERUSALEM,ISRAEL	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Hebrew University of Jerusalem								ALOE L, 1979, P NATL ACAD SCI USA, V76, P1246, DOI 10.1073/pnas.76.3.1246; ALONSO AP, 1986, FEBS LETT, V208, P48; BERG MM, 1992, J BIOL CHEM, V267, P13; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Blochl A, 1996, J BIOL CHEM, V271, P21100; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; COLLINS F, 1991, J NEUROSCI, V11, P2582; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; DEGEORGE JJ, 1988, J NEUROSCI RES, V21, P323, DOI 10.1002/jnr.490210225; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; FINK DW, 1990, J NEUROCHEM, V55, P1716, DOI 10.1111/j.1471-4159.1990.tb04961.x; Frade JM, 1996, NATURE, V383, P166; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOZAK A, 1992, J NEUROSCI RES, V33, P30, DOI 10.1002/jnr.490330105; LAASBERG T, 1988, FEBS LETT, V239, P367, DOI 10.1016/0014-5793(88)80953-0; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MARTINEZ HJ, 1985, P NATL ACAD SCI USA, V82, P7777, DOI 10.1073/pnas.82.22.7777; MOBLEY WC, 1985, SCIENCE, V229, P282; NAKANISHI S, 1988, J BIOL CHEM, V263, P6215; NIKODIJEVIC B, 1975, P NATL ACAD SCI USA, V72, P4769, DOI 10.1073/pnas.72.12.4769; NIKODIJEVIC B, 1992, J NEUROSCI RES, V31, P591, DOI 10.1002/jnr.490310402; NIKODIJEVIC B, 1990, J NEUROSCI RES, V26, P288, DOI 10.1002/jnr.490260304; NIKODIJEVIC B, 1995, J NEUROSCI RES, V40, P494, DOI 10.1002/jnr.490400408; NIKODIJEVIC B, 1991, J NEUROSCI RES, V28, P192, DOI 10.1002/jnr.490280206; REYNOLDS CP, 1981, J NEUROSCI RES, V6, P319, DOI 10.1002/jnr.490060307; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; Stoop R, 1996, J NEUROSCI, V16, P3256; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; VINORES SA, 1980, CANCER LETT, V10, P309, DOI 10.1016/0304-3835(80)90047-6	41	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6835	6837		10.1074/jbc.272.11.6835	http://dx.doi.org/10.1074/jbc.272.11.6835			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054365	hybrid			2022-12-25	WOS:A1997WN14700004
J	Morales, J; Russell, JE; Liebhaber, SA				Morales, J; Russell, JE; Liebhaber, SA			Destabilization of human alpha-globin mRNA by translation anti-termination is controlled during erythroid differentiation and is paralleled by phased shortening of the Poly(A) tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; ENDONUCLEOLYTIC CLEAVAGE; ERYTHROLEUKEMIA-CELLS; DEGRADATION; REGION; DEADENYLATION; TRANSCRIPT; ELEMENTS; PATHWAY; COMPLEX	The extraordinary stability of globin mRNAs permits their accumulation to over 95% of total cellular mRNA during erythroid differentiation. The stability of human alpha-globin mRNA correlates with assembly of a sequence-specific ribonucleoprotein complex at its 3'-untranslated region, A naturally occurring anti-termination mutation, Constant Spring (CS), which permits ribosomes to enter the 3'-untranslated region of the alpha-globin mRNA, results in accelerated mRNA decay, To study the mechanism of this destabilization in vivo, we established transgenic mouse lines carrying the human alpha(CS) gene, Relative to wild type human alpha-globin mRNA (alpha(wt)), alpha(CS) mRNA is destabilized in marrow erythroid cells, The poly(A) tails of both the alpha(CS) and alpha(wt) mRNAs show a periodicity of 20-25 nucleotides consistent with phased binding of poly(A) binding proteins, However, the mean size of poly(A) tails of the unstable alpha(CS) mRNA is significantly shorter than that of the alpha(wt) mRNA, Unexpectedly, the alpha(wt) and alpha(CS) mRNAs are of equal stability in peripheral reticulocytes, where their respective poly(A) tails shorten coordinately, These findings demonstrate a characteristic organization of the poly(A) tail on alpha-globin mRNA which is maintained during normal and accelerated decay, a correlation between poly(A) metabolism and anti-termination-mediated accelerated mRNA turnover, and a switch in the mechanism of mRNA decay during erythroid terminal differentiation.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania				Morales, Julia/0000-0003-1632-5419	NHLBI NIH HHS [K11-HL02623, HL38632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002623, P60HL038632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; Baker EJ, 1993, CONTROL MESSENGER RN, P367; BASTOS RN, 1977, J MOL BIOL, V110, P205, DOI 10.1016/S0022-2836(77)80069-7; BASTOS RN, 1977, J MOL BIOL, V110, P191, DOI 10.1016/S0022-2836(77)80068-5; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG JB, 1971, NATURE, V234, P337, DOI 10.1038/234337a0; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; GORSKI J, 1975, NATURE, V253, P749, DOI 10.1038/253749a0; GORSKI J, 1974, J MOL BIOL, V86, P363, DOI 10.1016/0022-2836(74)90025-4; HUNT DM, 1982, BRIT J HAEMATOL, V51, P405, DOI 10.1111/j.1365-2141.1982.tb02796.x; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jacobson A., 1995, TRANSLATIONAL CONTRO, P451; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LIEBHABER SA, 1981, J CLIN INVEST, V68, P439, DOI 10.1172/JCI110273; Liebhaber SA, 1996, MOL CELL BIOL, V16, P2637; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; LODISH HF, 1976, CELL, V7, P59, DOI 10.1016/0092-8674(76)90255-5; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUSSELL JE, 1997, PROG NUCL ACID RES M, V57, pCH8; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SURDEJ P, 1994, ANNU REV GENET, V28, P263; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; VOLLOCH V, 1981, CELL, V23, P509, DOI 10.1016/0092-8674(81)90146-X; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; WEISS IM, 1995, MOL CELL BIOL, V15, P2457	39	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6607	6613		10.1074/jbc.272.10.6607	http://dx.doi.org/10.1074/jbc.272.10.6607			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045690	hybrid			2022-12-25	WOS:A1997WM64700074
J	Shimomura, T; Denda, K; Kitamura, A; Kawaguchi, T; Kito, M; Kondo, J; Kagaya, S; Qin, L; Takata, H; Miyazawa, K; Kitamura, N				Shimomura, T; Denda, K; Kitamura, A; Kawaguchi, T; Kito, M; Kondo, J; Kagaya, S; Qin, L; Takata, H; Miyazawa, K; Kitamura, N			Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DENSITY-LIPOPROTEIN RECEPTOR; ALPHA-TRYPSIN INHIBITOR; MESSENGER-RNA; ALZHEIMERS-DISEASE; LDL-RECEPTOR; COAGULATION INHIBITOR; MOLECULAR-CLONING; NEXIN-II; DOMAINS	Hepatocyte growth factor (HGF) activator is a serine protease that is produced and secreted by the liver and circulates in the blood as an inactive zymogen. In response to tissue injury, the HGF activator zymogen is converted to the active form by limited proteolysis. The activated HGF activator converts an inactive single chain precursor of HGF to a biologically active heterodimer in injured tissue, The activated HGF may be involved in the regeneration of the injured tissue, In this study, we purified an inhibitor of HGF activator from the conditioned medium of a human MKN45 stomach carcinoma cell line and molecularly cloned its cDNA. The sequence of the cDNA revealed that the inhibitor has two well defined Kunitz domains, suggesting that the inhibitor is a member of the Kunitz family of serine protease inhibitors. The sequence also showed that the primary translation product of the inhibitor has a hydrophobic sequence at the COOH-terminal region, Inhibitory activity toward HGF activator was detected in the membrane fraction as well as in the conditioned medium of MKN45 cells. These results suggest that the inhibitor may be produced as a membrane-associated form and secreted by the producing cells as a proteolytically truncated form.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; MITSUBISHI CHEM CORP,RES CTR,AOBA KU,YOKOHAMA,KANAGAWA 227,JAPAN; KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN	Tokyo Institute of Technology; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical; Kansai Medical University			MIYAZAWA, KEIJI/I-9713-2014					CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; ITOH H, 1994, J BIOL CHEM, V269, P3818; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KIDO H, 1988, J BIOL CHEM, V263, P18104; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARS WM, 1993, AM J PATHOL, V143, P949; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAILER JP, 1990, TRENDS BIOCHEM SCI, V15, P435; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SINHA S, 1990, J BIOL CHEM, V265, P8983; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; STONE KL, 1986, J CHROMATOGR, V359, P203, DOI 10.1016/0021-9673(86)80074-7; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WUN TC, 1988, J BIOL CHEM, V263, P6001; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YANAGITA K, 1993, J BIOL CHEM, V268, P21212	41	235	262	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6370	6376		10.1074/jbc.272.10.6370	http://dx.doi.org/10.1074/jbc.272.10.6370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045658	hybrid			2022-12-25	WOS:A1997WM64700042
J	Vincenz, C; Dixit, VM				Vincenz, C; Dixit, VM			Fas-associated-death domain protein interleukin-1 beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING-ENZYME; INHIBITION; ACTIVATION; APOPTOSIS; CED-3; P35	The pivotal discovery that Pas-associated death do main protein (FADD) interleukin-lp converting enzyme (FLICE)/MACH was recruited to the CD95 signaling complex by virtue of its ability to bind the adapter molecule FADD established that this protease has a role in initiating the death pathway (Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815; Muzio, M., Chinnaiyan, A. M., Kischkel, K. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827). In this report, we describe the cloning and characterization of a new member of the caspase family, a homologue of FLICE/MACH, and Mch4. Since the overall architecture and function of this molecule is similar to that of FLICE, it has been designated FLICE2. Importantly, the carboxyl-terminal half of the small catalytic subunit that includes amino acids predicted to be involved in substrate binding is distinct. We show that the pro-domain of FLICE2 encodes a functional death effector do main that binds to the corresponding domain in the adapter molecule FADD. Consistent with this finding, FLICE2 is recruited to both the CD95 and p55 tumor necrosis factor receptor signaling complexes in a FADD-dependent manner. A functional role for FLICE2 is suggested by the finding that an active site mutant of FLICE2 inhibits CD95 and tumor necrosis factor receptor-mediated apoptosis. FLICE2 is therefore involved in CD95 and p55 signal transduction.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIEHS NIH HHS [ES08111] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GU I, 1996, J BIOL CHEM, V271, P10816; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SARMA V, 1992, J IMMUNOL, V148, P3302; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHOU Q, 1997, IN PRESS J BIOL CHEM, V272	28	240	254	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6578	6583		10.1074/jbc.272.10.6578	http://dx.doi.org/10.1074/jbc.272.10.6578			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045686	hybrid			2022-12-25	WOS:A1997WM64700070
J	Chary, P; Harris, CM; Harris, TM; Lloyd, RS				Chary, P; Harris, CM; Harris, TM; Lloyd, RS			Differential tolerance to DNA polymerization by HIV-1 reverse transcriptase on N-6 adenine C(10)R and C10S benzo[a]pyrene-7,8-dihydrodiol 9,10-epoxide-adducted templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO REPLICATION; POLYCYCLIC AROMATIC-HYDROCARBONS; DEOXYADENOSINE N-6-AMINO GROUP; BENZO<A>PYRENE 7,8-DIOL-9,10-EPOXIDES; MODIFIED OLIGONUCLEOTIDE; TRANSLESION SYNTHESIS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; THUMB SUBDOMAIN; TRANS ADDITION	To determine the effect of various stereoisomers of benzo[a]pyrene-7,8-dihydrodiol 9,10-epoxide (BPDE) on translesion bypass by human immunodeficiency virus-1 reverse transcriptase and its alpha-helix H mutants, six 33-mer templates were constructed bearing site- and stereospecific adducts. This in vitro model system was chosen to understand the structure-function relationships between the polymerase and damaged DNA during replication. Comparison of the replication pattern between wild type human immunodeficiency virus-1 reverse transcriptase and its mutants, using primers which were 3' to the lesion, revealed essentially similar patterns, While these primers terminated with all three of the C(10)R and two of the C10S BPDE-adducted templates 1 base 5' and 1 base 3' to the damaged site respectively, (+)-anti-trans-(C10S) BPDE-adducted DNA alone permitted the formation of full-length products. Utilization of a primer with its 3'-hydroxyl 1 base beyond the lesion resulted in full-length products with all the C10S BPDE-adducted templates and the (-)-syn-trans-(C(10)R)-BPDE-adducted template, following replication with either the wild type or mutant enzymes, However, the other two C(10)R BPDE-adducted templates failed to allow any primer extension, even with the wild type enzyme, Although T . P depletion studies further confirmed the differential primer extension abilities using the C(10)R and C10S adducted templates, their binding affinities were similar, yet distinct from the unadducted template.	UNIV TEXAS,MED BRANCH,CTR MOL SCI,GALVESTON,TX 77555; VANDERBILT UNIV,DEPT CHEM,NASHVILLE,TN 37235	University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P01ES005355] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES06676, P20 ES05355] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT RE, 1977, ORIGINS HUMAN CANCER, P289; AMIN S, 1993, CARCINOGENESIS, V14, P2033, DOI 10.1093/carcin/14.10.2033; ANDERSON MW, 1990, BIOL REACT INTERMED, V4, P235; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11708; BELGUISEVALLADIER P, 1994, J MOL BIOL, V236, P151, DOI 10.1006/jmbi.1994.1125; BISHOP JM, 1987, SCIENCE, V235, P302; BROOKES P, 1982, CARCINOGENESIS, V3, P1223, DOI 10.1093/carcin/3.10.1223; Chary P, 1996, CHEM RES TOXICOL, V9, P409, DOI 10.1021/tx950012b; CHARY P, 1995, J BIOL CHEM, V270, P4990, DOI 10.1074/jbc.270.10.4990; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; CHRISTNER DF, 1994, BIOCHEMISTRY-US, V33, P14297, DOI 10.1021/bi00251a043; CONNEY AH, 1982, CANCER RES, V42, P4875; COOPER GM, 1982, SCIENCE, V218, P801; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; FORGACS E, IN PRESS J BIOL CHEM, V272; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; HRUSZKEWYCZ AM, 1991, CARCINOGENESIS, V12, P2185, DOI 10.1093/carcin/12.11.2185; HRUSZKEWYCZ AM, 1991, CARCINOGENESIS, V12, P1659, DOI 10.1093/carcin/12.9.1659; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JEFFREY AM, 1976, J AM CHEM SOC, V98, P5714, DOI 10.1021/ja00434a060; JENNETTE KW, 1977, BIOCHEMISTRY-US, V16, P932, DOI 10.1021/bi00624a019; KIM SJ, 1992, J AM CHEM SOC, V114, P5480, DOI 10.1021/ja00039a101; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOREEDA M, 1978, SCIENCE, V199, P778, DOI 10.1126/science.622566; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; LEVIN W, 1980, J BIOL CHEM, V255, P9067; MAO B, 1993, BIOCHEMISTRY-US, V32, P11785, DOI 10.1021/bi00095a006; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MICHAELS ML, 1991, CARCINOGENESIS, V12, P1641, DOI 10.1093/carcin/12.9.1641; MOORE PD, 1982, P NATL ACAD SCI-BIOL, V79, P7166, DOI 10.1073/pnas.79.23.7166; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAID B, 1991, NUCLEIC ACIDS RES, V19, P1311, DOI 10.1093/nar/19.6.1311; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P9009, DOI 10.1021/bi00028a009; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P1364, DOI 10.1021/bi00004a031; SELKIRK JK, 1982, MECHANISMS CHEM CARC, P331; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; Strauss B S, 1989, Ann Ist Super Sanita, V25, P177; SUN D, 1992, BIOCHEMISTRY-US, V31, P2822, DOI 10.1021/bi00125a025; THRALL BD, 1992, CARCINOGENESIS, V13, P1529, DOI 10.1093/carcin/13.9.1529; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WOOD AW, 1977, BIOCHEM BIOPH RES CO, V77, P1389, DOI 10.1016/S0006-291X(77)80133-2; YANG SK, 1988, BIOCHEM PHARMACOL, V37, P61, DOI 10.1016/0006-2952(88)90755-1; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070	57	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5805	5813		10.1074/jbc.272.9.5805	http://dx.doi.org/10.1074/jbc.272.9.5805			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038195	hybrid			2022-12-25	WOS:A1997WK74700063
J	Chen, QR; Miyaura, C; Higashi, S; Murakami, M; Kudo, I; Saito, S; Hiraide, T; Shibasaki, Y; Suda, T				Chen, QR; Miyaura, C; Higashi, S; Murakami, M; Kudo, I; Saito, S; Hiraide, T; Shibasaki, Y; Suda, T			Activation of cytosolic phospholipase A(2) by platelet-derived growth factor is essential for cyclooxygenase-2-dependent prostaglandin E(2) synthesis in mouse osteoblasts cultured with interleukin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A(2); BONE-RESORPTION; ENDOPEROXIDE SYNTHASE; ARACHIDONIC-ACID; MC3T3-E1 CELLS; MESSENGER-RNA; MAST-CELLS; EXPRESSION; PHOSPHORYLATION; PROTEIN	The synthesis of prostaglandins (PGs) is regulated by the arachidonic acid release by phospholipase A(2) (PLA(2)) and its conversion to PGs by cyclooxygenase (COX). In the present study, we examined the regulation of PG synthesis by interleukin (IL)-1 alpha in primary mouse osteoblastic cells isolated from mouse calvaria. Although IL-1 alpha greatly enhanced cox-2 mRNA expression and its protein levels, PGE(2) was not produced until 24 h. When arachidonic acid was added to osteoblastic cells precultured with IL-1 alpha for 24 h, PGE(2) was produced within 10 min, Of several growth factors tested, platelet-derived growth factor (PDGF) specifically initiated the rapid synthesis of PGE(2), which was markedly suppressed by a selective inhibitor of cox-2 (NS-398), In mouse osteoblastic cells, cytosolic PLA(2) (cPLA(2)) mRNA and its protein were constitutively expressed and increased approximately 2-fold by IL-1 alpha, but secretory PLA(2) mRNA was not detected, PDGF rapidly stimulated PLA(2) activity, which was blocked completely by a cPLA(2) inhibitor (arachidonyltrifluoromethyl ketone). The PDGF-induced cPLA(2) activation was accompanied by phosphorylation of its protein, These results indicate that cox-2 induction by IL-1 alpha is not sufficient, but cPLA(2) activation by PDGF is crucial for IL-1 alpha-induced PGE(2) synthesis in mouse osteoblasts.	SHOWA UNIV,SCH DENT,DEPT BIOCHEM,SHINAGAWA KU,TOKYO 142,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,DEPT HLTH CHEM,SHINAGAWA KU,TOKYO 142,JAPAN; SHOWA UNIV,SCH DENT,DEPT ORTHODONT,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University; Showa University; Showa University			miyaura, chisato/D-1864-2013	miyaura, chisato/0000-0002-2548-8191				ABBOUD SL, 1993, BLOOD, V81, P2547; AKATSU T, 1991, J BONE MINER RES, V6, P183; ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CANALIS E, 1989, J CELL PHYSIOL, V140, P530, DOI 10.1002/jcp.1041400319; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCHRAN DL, 1993, BONE, V14, P53, DOI 10.1016/8756-3282(93)90256-A; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HARRISON JR, 1994, J BONE MINER RES, V9, P817; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Kawaguchi H, 1996, J BONE MINER RES, V11, P358; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P1157, DOI 10.1210/en.135.3.1157; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KOZAWA O, 1995, ENDOCRINOLOGY, V136, P4473, DOI 10.1210/en.136.10.4473; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MIYAURA C, 1995, J BONE MINER RES, V10, P1365; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Onoe Y, 1996, J IMMUNOL, V156, P758; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1654, DOI 10.1210/endo-126-3-1654; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SATO K, 1986, BIOCHEM BIOPH RES CO, V138, P618, DOI 10.1016/S0006-291X(86)80541-1; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TASHJIAN AH, 1982, ENDOCRINOLOGY, V111, P118, DOI 10.1210/endo-111-1-118; XU XX, 1994, J BIOL CHEM, V269, P31693; ZHANG L, 1991, AM J PHYSIOL, V261, pC348, DOI 10.1152/ajpcell.1991.261.2.C348	50	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5952	5958		10.1074/jbc.272.9.5952	http://dx.doi.org/10.1074/jbc.272.9.5952			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038215	hybrid			2022-12-25	WOS:A1997WK74700083
J	Mieda, M; Haga, T; Saffen, DW				Mieda, M; Haga, T; Saffen, DW			Expression of the rat m4 muscarinic acetylcholine receptor gene is regulated by the neuron-restrictive silencer element/repressor element 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE-ACETYLTRANSFERASE GENE; SODIUM-CHANNEL GENE; TRANSGENIC MICE; MESSENGER-RNAS; BRAIN; LOCALIZATION; IDENTIFICATION; SUBTYPE; REGION; CELLS	Neuronal cell-specific expression of the rat m4 muscarinic acetylcholine receptor (mAChR) is regulated by a silencer element, A likely mediator of this silencing is the neuron-restrictive silencer element/repressor element 1 (NRSE/RE1), which is present 837 base pairs (bp) upstream from the transcription initiation site of the m4 mAChR gene (Wood, I. C., Roopra, A., Harrington, C., and Buckley, N. J. (1995) J. Biol. Chem. 270, 30933-30940; Mieda, M., Haga, T., and Saffen, D. W. (1996) J. Biol. Chem. 271, 5177-5182), In the present study, we examined whether this putative NRSE/RE1 functions as a silencer, Transient expression assays using m4 mAChR promoter/luciferase expression vectors showed that the m4 NRSE/RE1 is necessary and sufficient to repress m4 promoter activity in non-neuronal L6 cells. m4 promoter activity was only partially repressed, however, in neuronal NG108-15 cells exogenously expressing the neuronal-restrictive silencer factor/RE1-silencing transcription factor (NRSF/REST). By contrast, the promoter activity of the type II sodium channel (NaII) gene was nearly completely repressed in NRSF/REST-expressing NG108-15 cells. Experiments with expression vectors containing chimeric promoters revealed that the NRSE/RE1 elements derived from both the m4 and NaII genes are independently sufficient to silence NaII gene promoter activity, but only partially repress m4 mAChR gene promoter activity in NRSF/REST-expressing; NG108-15 cells, Thus, the repression activity of NRSF/REST depends upon the species of promoter to which it is linked, Gel-shift assays showed that the NRSF/REST is the only protein that binds to a 92-bp segment from the m4 mAChR promoter containing NRSE/RE1. This and the fact that m4 promoter activity was completely repressed in 1,6 cells suggest that the proteins that bind to the m4 constitutive promoter may be different from those in NG108-15 cells. Deletion analysis of the m4 constitutive promoter revealed that a 90-bp segment immediately upstream from the transcription initiation site contains significant promoter activity. Gel-shift assays revealed that several proteins in nuclear extracts prepared from L6 and NG108-15 cells bind to this 90-bp segment and that some of these proteins are L6 or NG108-15 cell-specific. These data support the idea that the repression activity of NRSF/REST depends upon the species of promoter to which it is linked and upon the proteins that bind to those promoters.			Mieda, M (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.			Mieda, Michihiro/0000-0002-2451-7034				BONNER TI, 1989, TRENDS PHARMACOL SCI, P11; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HADDAD EB, 1994, AM J PHYSIOL, V266, pL642, DOI 10.1152/ajplung.1994.266.6.L642; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LI YP, 1993, J NEUROCHEM, V61, P748; LI YP, 1995, MOL BRAIN RES, V30, P106, DOI 10.1016/0169-328X(94)00285-M; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; MAK JCW, 1993, LIFE SCI, V53, P1501, DOI 10.1016/0024-3205(93)90624-C; MAK JCW, 1992, AM J RESP CELL MOL, V7, P344, DOI 10.1165/ajrcmb/7.3.344; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; Mieda M, 1996, J BIOL CHEM, V271, P5177; MISAWA H, 1992, J BIOL CHEM, V267, P20392; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; TILLMAN JB, 1993, MOL CELL ENDOCRINOL, V95, P101, DOI 10.1016/0303-7207(93)90034-H; Wood IC, 1995, J BIOL CHEM, V270, P30933, DOI 10.1074/jbc.270.52.30933; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221	26	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5854	5860		10.1074/jbc.272.9.5854	http://dx.doi.org/10.1074/jbc.272.9.5854			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038202	hybrid			2022-12-25	WOS:A1997WK74700070
J	Hiratsuka, A; Yamane, H; Yamazaki, S; Ozawa, N; Watabe, T				Hiratsuka, A; Yamane, H; Yamazaki, S; Ozawa, N; Watabe, T			Subunit Ya-specific glutathione peroxidase activity toward cholesterol 7-hydroperoxides of glutathione S-transferases in cytosols from rat liver and skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL LIPID HYDROPEROXIDES; LOW-DENSITY-LIPOPROTEIN; STEROL METABOLISM; ALPHA-OXIDE; BINDING; LIGANDIN; PROTEIN; CARCINOGEN; EXPRESSION; 7-HYDROPEROXYCHOLEST-5-EN-3-BETA-OL	Dermal 7 alpha- and 7 beta-hydroperoxycholest-5-en-3 beta-ols (cholesterol 7 alpha- and 7 beta-hydroperoxides), regarded as good aging markers in the rat (Ozawa, N., Yamazaki, S., Chiba, K., Aoyama, H., Tomisawa, H., Tateishi, M., and Watabe, T. (1991) Biochem. Biophys. Res. Commun. 178, 242-247), were reduced in the presence of glutathione (GSH) with concomitant formation of GSSG by cytosol from rat liver in which no detectable level of the hy droperoxides had been demonstrated to occur. The GSH peroxidase (GSH Pr) activity toward the toxic steroid hydroperoxides was exerted to almost the same extent by both Alpha-class GSH S-transferases (GSTs), Ya-Ya and Ya-Yc, and by selenium-containing GSH Pr (Se-GSH Pr) in rat liver cytosol. None of three Mu class GSTs, Yb1-Yb1, Yb1-Yb2, and Yb2-Yb2, and a Theta-class GST, Yrs-Yrs, from rat liver and a Pi-class GST, Yp-Yp, from rat kidney showed any appreciable GSH Pr activity toward the hydroperoxides. The subunit Ya-bearing GSTs and Se GSH Pr purified from rat liver cytosol showed marked differences in apparent specific activity toward the cholesterol hydroperoxides (GSTs Ya-Ya > Ya-Yc much greater than Se-GSH Pr). However, a kinetic study indicated that Se-GSH Pr had a higher affinity for steroid hydroperoxides than did the GSTs, so that Se GSH Pr could catalyze the reduction of lower concentrations of cholesterol 7-hydroperoxides with approximately equal V-max/K-m values to those by the GSTs. Rat skin had no GST bearing the subunit Ya but contained only a very low concentration of Se GSH Pr, possibly resulting in the accumulation of cholesterol 7-hydroperoxides in the skin but not in the liver. From rat skin cytosol, GSTs Yc-Yc, Yb1-Yb1, Yb1-Yb2, Yb2-Yb2, and Yp-Yp were isolated, purified to homogeneity, and identified with the corresponding GSTs from liver and kidney. The GSTs accounted for 0.23% of total skin cytosolic protein, and the most abundant isoform of skin GSTs was Yb2-Yb2, followed by Yc-Yc, Yp-Yp, Yb1-Yb1, and Yb1-Yb2 in decreasing order.	TOKYO UNIV PHARM & LIFE SCI,SCH PHARM,DEPT DRUG METAB & MOL TOXICOL,HACHIOJI,TOKYO 19203,JAPAN; PHARMACIA & UPJOHN INC,TSUKUBA RES LABS,TOXICOL & EFFICACY RES,TSUKUBA,IBARAKI 30042,JAPAN	Tokyo University of Pharmacy & Life Sciences; Eisai Co Ltd; Pfizer								AGARWAL R, 1992, BIOCHEM PHARMACOL, V44, P2047, DOI 10.1016/0006-2952(92)90108-U; [Anonymous], 1980, ENZYMATIC BASIS DETO; BLACHE D, 1995, FEBS LETT, V357, P135, DOI 10.1016/0014-5793(94)01348-5; BLACK HS, 1971, NATURE, V234, P306, DOI 10.1038/234306a0; BLACK HS, 1972, CANCER RES, V32, P2630; BLACKBURN GM, 1979, J CHEM SOC CHEM COMM, P420, DOI 10.1039/c39790000420; CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433; Chang M, 1987, Arch Biochem Biophys, V259, P536, DOI 10.1016/0003-9861(87)90520-0; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; DELBOCCIO G, 1987, BIOCHEM J, V244, P21, DOI 10.1042/bj2440021; FARRANTS AKO, 1987, BIOCHEM J, V245, P423, DOI 10.1042/bj2450423; FLOHE L, 1976, GLUTATHIONE METABOLI, P115; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; GUTHENBERG C, 1985, BIOCHEM J, V230, P609, DOI 10.1042/bj2300609; HABIG WH, 1974, P NATL ACAD SCI USA, V71, P3879, DOI 10.1073/pnas.71.10.3879; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAYES JD, 1981, BIOCHEM J, V197, P491, DOI 10.1042/bj1970491; HIRATSUKA A, 1990, J BIOL CHEM, V265, P11973; HIRATSUKA A, 1994, BIOCHEM BIOPH RES CO, V202, P278, DOI 10.1006/bbrc.1994.1924; HIRATSUKA A, 1995, BIOCHEM BIOPH RES CO, V212, P74; KETLEY JN, 1975, J BIOL CHEM, V250, P8670; KETTERER B, 1986, XENOBIOTICA, V16, P957, DOI 10.3109/00498258609038976; Ketterer B, 1986, Basic Life Sci, V39, P103; KETTERER B, 1988, GLUTATHIONE CONJUGAT, P74; KULIG MJ, 1973, J ORG CHEM, V38, P3639, DOI 10.1021/jo00960a050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LITTLE C, 1972, BIOCHIM BIOPHYS ACTA, V284, P375, DOI 10.1016/0005-2744(72)90133-7; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALAVASI B, 1992, CHEM PHYS LIPIDS, V62, P209, DOI 10.1016/0009-3084(92)90057-V; MANNERVIK B, 1982, J BIOL CHEM, V257, P9909; MANNERVIK B, 1984, FEBS LETT, V174, P289; MEYER DJ, 1982, FEBS LETT, V150, P499, DOI 10.1016/0014-5793(82)80798-9; MUKHTAR H, 1995, INT J ONCOL, V6, P37; OKUDA H, 1986, BIOCHEM PHARMACOL, V35, P535, DOI 10.1016/0006-2952(86)90232-7; OZAWA N, 1991, BIOCHEM BIOPH RES CO, V178, P242, DOI 10.1016/0006-291X(91)91805-M; RAZA H, 1991, J INVEST DERMATOL, V96, P463, DOI 10.1111/1523-1747.ep12470150; RAZA H, 1992, PHARM SKIN, P131; REDDY AP, 1988, NUCLEIC ACIDS RES, V16, P5557, DOI 10.1093/nar/16.12.5557; Sakamaki R, 1994, J Atheroscler Thromb, V1, P80; SINGHAL SS, 1993, BIOCHIM BIOPHYS ACTA, V1163, P266, DOI 10.1016/0167-4838(93)90161-J; SMITH LL, 1986, MUTAT RES, V161, P39, DOI 10.1016/0027-5107(86)90098-9; SUN FF, 1986, J BIOL CHEM, V261, P8540; TENG JI, 1973, J ORG CHEM, V38, P119, DOI 10.1021/jo00941a024; TIPPING E, 1976, EUR J BIOCHEM, V67, P583, DOI 10.1111/j.1432-1033.1976.tb10724.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1987, EUR J BIOCHEM, V170, P159, DOI 10.1111/j.1432-1033.1987.tb13681.x; WATABE T, 1979, BIOCHEM BIOPH RES CO, V87, P469, DOI 10.1016/0006-291X(79)91819-9; WATABE T, 1984, BIOCHIM BIOPHYS ACTA, V795, P60; WATABE T, 1981, J BIOL CHEM, V256, P2900; WATABE T, 1982, BIOCHEM BIOPH RES CO, V108, P724, DOI 10.1016/0006-291X(82)90889-0; YOSHIDA M, 1982, AGR BIOL CHEM TOKYO, V46, P41, DOI 10.1080/00021369.1982.10865023; YOSHIMURA S, 1980, BIOCHIM BIOPHYS ACTA, V621, P130, DOI 10.1016/0005-2795(80)90068-9	55	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4763	4769		10.1074/jbc.272.8.4763	http://dx.doi.org/10.1074/jbc.272.8.4763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030530	hybrid			2022-12-25	WOS:A1997WJ85500018
J	Zaheer, A; Lim, R				Zaheer, A; Lim, R			Protein kinase A (PKA)- and protein kinase C-phosphorylated glia maturation factor promotes the catalytic activity of PKA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; ASSOCIATION; EXPRESSION; ACTIVATION; SEQUENCES; RAF-1	We observed previously that glia maturation factor (GMF), a 17-kDa brain protein, is rapidly phosphorylated in astrocytes following stimulation by phorbol ester, and that protein kinase A (PKA)-phosphorylated GMF is a potent inhibitor of extracellular signal-regulated kinase (ERK) and enhancer of p38; both are subfamilies of mitogen-activated protein (MAP) kinase, suggesting GMF as a bifunctional regulator of the MAP kinase cascades, In the current report, we present evidence that PKA-phosphorylated GMF also promotes (11-fold) the catalytic activity of PKA itself, resulting in a positive feedback loop. Furthermore, GMF phosphorylated by protein kinase C (PKC), but not by casein kinase II or p90 ribosomal S6 kinase, also activates PKA (7-fold). It appears that the mutual augmentation of GMF and PKA, and the stimulating effect of PKC, both serve to maximize the influence of PKA on the regulation of MAP kinase cascades by GMF. Using synthetic peptide fragments containing putative phosphorylation sites of GMF, we demonstrate that PKA is capable of phosphorylating threonine 26 and serine 82, whereas PKC, p90 ribosomal S6 kinase, and casein kinase II, can phosphorylate serine 71, threonine 26, and serine 52, respectively, The generation of various phospho-isoforms of GMF may explain its modulation of signal transduction at multiple locations.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV NEUROCHEM & NEUROBIOL, IOWA CITY, IA 52242 USA; VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Darnell JE, 1996, P NATL ACAD SCI USA, V93, P6221, DOI 10.1073/pnas.93.13.6221; David M, 1996, J BIOL CHEM, V271, P4585; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAPLAN R, 1991, J NEUROCHEM, V57, P483, DOI 10.1111/j.1471-4159.1991.tb03777.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM R, 1995, BIOCHEM BIOPH RES CO, V211, P928, DOI 10.1006/bbrc.1995.1901; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; LIM R, 1990, P NATL ACAD SCI USA, V87, P5233, DOI 10.1073/pnas.87.14.5233; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Zaheer A, 1996, BIOCHEMISTRY-US, V35, P6283, DOI 10.1021/bi960034c	20	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5183	5186		10.1074/jbc.272.8.5183	http://dx.doi.org/10.1074/jbc.272.8.5183			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030586	hybrid			2022-12-25	WOS:A1997WJ85500074
J	Mechta, F; Lallemand, D; Pfarr, CM; Yaniv, M				Mechta, F; Lallemand, D; Pfarr, CM; Yaniv, M			Transformation by ras modifies AP1 composition and activity	ONCOGENE			English	Article						AP1; cJun; Fra1; Ras; serum inducibility; transformation	SERUM RESPONSE ELEMENT; NIH 3T3 CELLS; TERNARY COMPLEX-FORMATION; JUN ACTIVATION DOMAIN; IMMEDIATE EARLY GENES; C-FOS EXPRESSION; PROTEIN-KINASE; GROWTH-FACTORS; TRANSCRIPTION FACTOR; CYCLIN D1	The Ras proteins play a central role in regulating cell growth and their mutation can lead to abnormal proliferation. To analyse the potential link betwen AP1 activity, encoded by members of the jun and fos gene families, and Ras-mediated cellular transformation, we have studied several NIH3T3 clones which overexpress the Ha-Ras or Ki-Ras oncogenes. These transformed fibroblasts accumulated higher levels of cJun, JunB, Fra1 and Fra2 proteins relative to their normal counterparts. They also displayed increased AP1 DNA binding activity which was predominantly composed of cJun and Fra1 containing diners. Following serum stimulation of Ras clones, the elevated levels of cJun and Fra1 remained steady,,while the induction of JunB and Fra2 was partially attenuated. Moreover, deregulated Ras signaling resulted in a complete loss of the serum inducibility of cFos and FosB. Ectopic co-expression of cJun and Fra1 in NIH3T3 fibroblasts led to a transformed phenotype, attenuation of cFos serum inducibility, increased AP1 activity and Cyclin D1 accumulation, all characteristics of oncogenic Ras expressing cells. These results demonstrate that cJun and Fra1 are crucial mediators of the Ras-transformation process.	INST PASTEUR, UNITE VIRUS ONCOGENES, URA 1644 CNRS, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			lallemand, dominique/O-7445-2017; Pfarr, Curt/HHD-1410-2022; MECHTA-GRIGORIOU, Fatima/C-5253-2017	lallemand, dominique/0000-0002-0212-7342; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSSLINGER M, 1994, INC, V10, P133; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILMUS J, 1994, ONCOGENE, V9, P3627; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERBER, 1994, ONCOGENE, V9, P2105; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MECHTA F, 1989, New Biologist, V1, P297; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHONTHAL A, 1988, NATURE, V354, P325; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SEWING A, 1993, J CELL SCI, V104, P545; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	86	187	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					837	847		10.1038/sj.onc.1200900	http://dx.doi.org/10.1038/sj.onc.1200900			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047391				2022-12-25	WOS:A1997WJ11200010
J	Bluyssen, HAR; Levy, DE				Bluyssen, HAR; Levy, DE			Stat2 is a transcriptional activator that requires sequence-specific contacts provided by Stat1 and p48 for stable interaction with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; STIMULATED-GENE FACTOR-3; PROTEIN-TYROSINE KINASE; INTERFERON REGULATORY FACTOR; MUTANT-CELL LINE; ALPHA-INTERFERON; BINDING PROTEINS; GROWTH-FACTOR; PROMOTER; PATHWAY	Transcriptional responses to interferon (IFN) are mediated by tyrosine phosphorylation and nuclear translocation of transcription factors of the signal transducer and activator of transcription (Stat) family, The Stat1 protein is required for all transcriptional responses to IFN (both type I and type II), Responses to type I IFN (alpha and beta) also require Stat2 and the IFN regulatory factor family protein p48, which form a heterotrimeric transcription complex with Stat1 termed ISGF3, Stat1 homodimers formed in response to IFN-gamma treatment can also interact with p48 and function as transcriptional activators. We now show that Stat2 is capable of forming a stable homodimer that interacts with p48, can be recruited to DNA, and can activate transcription, raising a question of why Stat1 is required, Analysis of the transcriptional competence, affinity, and specificity of Stat2-p48 complexes compared with other Stat protein-containing transcription factor complexes suggests distinct roles for each component, Although Stat2 is a potent transactivator, it does not interact stably with DNA in complex with p48 alone. Adding Stat1 increases the affinity and alters the sequence selectivity of p48-DNA interactions by contacting a half-site of its palindromic recognition motif adjacent to a p48 interaction sequence. Thus, ISGF3 assembly involves p48 functioning as an adaptor protein to recruit Stat1 and Stat2 to an IFN-alpha-stimulated response element, Stat2 contributes a potent transactivation domain but is unable to directly contact DNA, while Stat1 stabilizes the heteromeric complex by contacting DNA directly.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788; Bluyssen, Hans/0000-0002-4568-6259	NIAID NIH HHS [AI28900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; BLUYSSEN HAR, 1994, EUR J BIOCHEM, V220, P395, DOI 10.1111/j.1432-1033.1994.tb18636.x; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RAZ R, 1994, J BIOL CHEM, V269, P24391; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; [No title captured]	53	107	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4600	4605		10.1074/jbc.272.7.4600	http://dx.doi.org/10.1074/jbc.272.7.4600			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020188	hybrid			2022-12-25	WOS:A1997WH01900104
J	Meyers, R; Cantley, LC				Meyers, R; Cantley, LC			Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; SWISS 3T3 CELLS; SACCHAROMYCES-CEREVISIAE; CELLULAR-REGULATION; MAMMALIAN PROTEIN; PHOSPHOLIPASE-D; KINASE; 3-KINASE; YEAST; 4,5-BISPHOSPHATE	Phosphatidylinositol (PtdIns) 4-kinases catalyze the synthesis of PtdIns-4-P, the immediate precursor of PtdIns-4,5-P-2. Here we report the cloning of a novel, ubiquitously expressed PtdIns 4-kinase (PI4K beta), The 2.4-kilobase pair cDNA encodes a putative translation product of 801 amino acids which shows greatest homology to the yeast PIK1 gene. The recombinant protein exhibits lipid kinase activity when expressed in Escherichia coli, and specific antibodies recognize a 110-kDa PtdIns 4-kinase in cell lysates, The biochemical properties of PI4K beta are characteristic of a type III enzyme, Interestingly, both recombinant PI4K beta and the endogenous protein are inhibited by 150 nM wortmannin, suggesting that we have cloned the previously described PtdIns 4-kinase that is responsible for regulating the synthesis of agonist-sensitive pools of polyphosphoinositides (Nakanishi, S., Catt, J. K., and Balla, T. (1995) Proc. Natl. Acad. Sci, U. S. A. 92, 5317-5321).	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36624] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1990, METHODS INOSITIDE RE, P155; Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MANIATIS T, 1982, MOL CLONING LABORATO, P320; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; YANO H, 1993, J BIOL CHEM, V268, P25846; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	51	144	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4384	4390		10.1074/jbc.272.7.4384	http://dx.doi.org/10.1074/jbc.272.7.4384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020160	hybrid			2022-12-25	WOS:A1997WH01900076
J	Herren, B; Raines, EW; Ross, R				Herren, B; Raines, EW; Ross, R			Expression of a disintegrin-like protein in cultured human vascular cells and in vivo	FASEB JOURNAL			English	Article						RGD; endothelium; smooth muscle; atherosclerosis; integrins; metargidin; metalloproteinase	SPERM-EGG FUSION; MATRIX METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; NONHUMAN PRIMATE; FAMILY; SEQUENCES; HYPERCHOLESTEROLEMIA; IDENTIFICATION; PROLIFERATION; INHIBITORS	Metalloproteinase-like, disintegrin-like, and cysteine-rich. proteins (MDCs) are potential novel regulators of cell-cell and cell-matrix interactions, as well as of matrix degradation, We have asked whether MDCs are expressed in cultured diploid vascular cells, and have identified MDC 15 in human aortic smooth muscle (SMC) and umbilical vein endothelium (HUVEC), MDC 15 mRNA is expressed at higher levels in HUVECs than in SMCs. In cultured SMCs, MDC 15 mRNA levels are not regulated by PDGF or IGF-I or by adherence to different extracellular matrices, Nor is regulation of MDC 15 mRNA levels observed in HUVEC monolayers at different cell densities, after multi-scratch wounding, or after treatment with TNF-alpha, LPS, or thrombin, However, differences in proteolytic processing of MDC 15 are observed in different HUVEC strains, In contrast to cultured arterial cells, MDC 15 protein is not expressed in vivo in normal vessels, but is up-regulated in lesions of atherosclerosis, These findings suggest that MDC 15 may be a potential regulator of vascular cell function and may be involved in the development of lesions of atherosclerosis.	UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL47151, HL18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BARAMOVA EN, 1989, ARCH BIOCHEM BIOPHYS, V275, P63, DOI 10.1016/0003-9861(89)90350-0; BARAMOVA EN, 1991, BIOMED BIOCHIM ACTA, V50, P762; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CHANG MY, 1995, ARTERIOSCL THROM VAS, V15, P1631, DOI 10.1161/01.ATV.15.10.1631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINI RM, 1992, TOXICON, V30, P265, DOI 10.1016/0041-0101(92)90869-7; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; LINDER B, 1995, EXP CELL RES, V221, P66, DOI 10.1006/excr.1995.1353; MARUYAMA M, 1992, TOXICON, V30, P1387, DOI 10.1016/0041-0101(92)90514-6; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VANDERWAL AC, 1994, CARDIOVASC PATHOL, V3, P81, DOI 10.1016/1054-8807(94)90037-X; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, J CELL BIOL, V131, P175; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	39	101	110	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					173	180		10.1096/fasebj.11.2.9039960	http://dx.doi.org/10.1096/fasebj.11.2.9039960			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039960				2022-12-25	WOS:A1997WK50900010
J	Farzan, M; Choe, H; Martin, KA; Sun, Y; Sidelko, M; Mackay, CR; Gerard, NP; Sodroski, J; Gerard, C				Farzan, M; Choe, H; Martin, KA; Sun, Y; Sidelko, M; Mackay, CR; Gerard, NP; Sodroski, J; Gerard, C			HIV-1 entry and macrophage inflammatory protein-1 beta-mediated signaling are independent functions of the chemokine receptor CCR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; T-CELLS; MUTAGENESIS; INTERLEUKIN-8; GLYCOPROTEIN; TRANSDUCTION; EXPRESSION; BINDING; AIDS	The human immunodeficiency virus type 1 (HIV-1) requires the presence of specific chemokine receptors in addition to CD4 to enter its target cell. The chemokine receptor CCR5 is used by macrophage-tropic strains of HIV-1, which predominate during the asymptomatic stages of infection. Here we investigate whether the ability of CCR5 to signal in response to its beta-chemokine ligands is necessary or sufficient for viral entry. Three CCR5 mutants with little or no ability to mobilize calcium in response to macrophage inflammatory protein-lp could nonetheless support HIV-1 entry and the early steps in the virus life cycle with efficiencies comparable with those of wild-type CCR5. Conversely, a chimeric receptor with the N terminus of CCR2 replacing that of CCRB responded to macrophage inflammatory protein-l beta and MCP-1 but did not efficiently support viral entry. These results demonstrate that chemokine signaling and HIV-1 entry are separable functions of CCR5 and that only viral entry requires the N-terminal domain of CCR5.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PEDIAT,PERLMUTTER LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DIV HUMAN RETROVIROL,DANA FARBER CANC INST,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; LEUKOSITE INC,CAMBRIDGE,MA 02142	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340; Martin, Kathleen/0000-0002-1748-0034; Farzan, Michael/0000-0002-2990-5319	NHLBI NIH HHS [HL39759] Funding Source: Medline; NIAID NIH HHS [AI28691, AI24755] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024755, P30AI028691, R01AI024755] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BRAND D, 1995, J VIROL, V69, P166, DOI 10.1128/JVI.69.1.166-171.1995; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CULLEN BR, 1989, METHOD ENZYMOL, V152, P64; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MORO O, 1993, J BIOL CHEM, V268, P22273; Oravecz T, 1996, J IMMUNOL, V157, P1329; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU L, 1996, NATURE, V184, P179; ZHU SZ, 1994, MOL PHARMACOL, V45, P517	42	161	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6854	6857		10.1074/jbc.272.11.6854	http://dx.doi.org/10.1074/jbc.272.11.6854			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054370	hybrid			2022-12-25	WOS:A1997WN14700009
J	Zhuang, P; Chen, AI; Peterson, CB				Zhuang, P; Chen, AI; Peterson, CB			Native and multimeric vitronectin exhibit similar affinity for heparin - Differences in heparin binding properties induced upon denaturation are due to self-association into a multivalent form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM SPREADING FACTOR; S-PROTEIN VITRONECTIN; MOLECULAR-WEIGHT KININOGEN; THROMBIN-ANTITHROMBIN-III; BLOOD-COAGULATION; CONTACT ACTIVATION; ALPHA-THROMBIN; LIGHT CHAIN; COMPLEX; DOMAIN	For many years, the concept that the heparin-binding sequence is sequestered within vitronectin and exposed upon denaturation of the protein has guided experimental design and interpretation of related structure-function studies on the protein, To evaluate binding of heparin to both native and denatured/renatured vitronectin, methods for monitoring binding in solution have been developed. A fluorescence method based on changes in an extrinsic probe attached to heparin has been used to evaluate heparin binding to native and denatured/renatured vitronectin. This approach indicates that there are not major differences in intrinsic heparin-binding affinities between native and renatured protein and invalidate the currently accepted model for a cryptic heparin-binding sequence in the protein, Denaturation and renaturation oligomer, On the basis of the binding data from solution studies and interaction of the native monomer and the denatured multimeric form of vitronectin with a heparin column, along with evaluation of the ionic strength dependence of heparin binding to these vitronectin forms in solution, an alternative model is favored to account for the altered heparin binding properties of vitronectin associated with denaturation of the protein. This model proposes that multivalent interactions between heparin and multimeric vitronectin are responsible for differences in heparin affinity chromatography and ionic strength dependence compared with the native protein.	UNIV TENNESSEE, DEPT BIOCHEM & CELLULAR & MOL BIOL, KNOXVILLE, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville					NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAMA T, 1986, J BIOCHEM-TOKYO, V100, P1343, DOI 10.1093/oxfordjournals.jbchem.a121840; BARNES DW, 1983, J BIOL CHEM, V258, P2548; BARNES DW, 1985, J BIOL CHEM, V260, P9117; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BOCK PE, 1983, J BIOL CHEM, V258, P5079; BOCK PE, 1985, J BIOL CHEM, V260, P2434; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; EVINGTON JRN, 1986, BIOCHIM BIOPHYS ACTA, V871, P85, DOI 10.1016/0167-4838(86)90136-6; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; ISHIKAWA M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P173, DOI 10.1016/0167-4838(92)90351-D; Jaques L B, 1977, Methods Biochem Anal, V24, P203, DOI 10.1002/9780470110447.ch4; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; LANE DA, 1987, J BIOL CHEM, V262, P16343; LASKER SE, 1966, ARCH BIOCHEM BIOPHYS, V115, P360, DOI 10.1016/0003-9861(66)90286-4; LIANG OD, 1994, J BIOCHEM-TOKYO, V116, P457, DOI 10.1093/oxfordjournals.jbchem.a124546; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; PIEPKORN MW, 1980, ARCH BIOCHEM BIOPHYS, V205, P315, DOI 10.1016/0003-9861(80)90113-7; PIEPKORN MW, 1981, BIOCHEM J, V196, P649, DOI 10.1042/bj1960649; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; PREISSNER KT, 1988, THROMB HAEMOSTASIS, V60, P399; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; ROVELLI G, 1990, EUR J BIOCHEM, V192, P797, DOI 10.1111/j.1432-1033.1990.tb19293.x; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1992, THROMB HAEMOSTASIS, V68, P657; SHEEHAN M, 1995, CLIN EXP IMMUNOL, V101, P136; SILNUTZER J, 1984, BIOCHEM BIOPH RES CO, V118, P339, DOI 10.1016/0006-291X(84)91106-9; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; WISNIOWSKI P, 1995, J LAB CLIN MED, V125, P38; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	52	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					6858	6867		10.1074/jbc.272.11.6858	http://dx.doi.org/10.1074/jbc.272.11.6858			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054371	hybrid			2022-12-25	WOS:A1997WN14700010
J	Gray, PC; Tibbs, VC; Catterall, WA; Murphy, BJ				Gray, PC; Tibbs, VC; Catterall, WA; Murphy, BJ			Identification of a 15-kDa cAMP-dependent protein kinase-anchoring protein associated with skeletal muscle L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; A-KINASE; ANTAGONIST RECEPTOR; CA2+ CHANNELS; CYCLIC-AMP; II-BETA; PHOSPHORYLATION; LOCALIZATION; BINDING; CELLS	Voltage-dependent potentiation of skeletal muscle L-type calcium channels requires phosphorylation by cAMP-dependent protein kinase (PKA) that is localized by binding to a cAMP-dependent protein kinase-anchoring protein (AKAP), L-type calcium channels purified from rabbit skeletal muscle contain an endogenous co-purifying protein kinase activity that phosphorylates the alpha 1 and beta subunits of the channel, The co-purifying kinase also phosphorylates a known PKA peptide substrate, is stimulated by cAMP, and is inhibited by PKA inhibitor peptide-(5-24), indicating that it is PKA, PKA activity co-immunoprecipitates with the calcium channel, suggesting that the channel and the kinase are physically associated, Using biotinylated type II regulatory subunit of PKA (RII) as a probe, we have identified a 15-kDa RII binding protein in purified calcium channel preparations, which we have designated AKAP-15. Anti-peptide antibodies directed against the alpha 1 subunit of the calcium channel co-immunoprecipitate AKAP-15. Together, these findings demonstrate a physical link between PKA and the calcium channel and suggest that AKAP-15 may mediate their interaction.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM07750] Funding Source: Medline; NINDS NIH HHS [NS07332] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; HARPER JF, 1985, VITAM HORM, V42, P197; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JOACHIM S, 1990, EUR J CELL BIOL, V51, P76; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; JOLY JC, 1989, J CELL BIOL, V109, P2288; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAI Y, 1990, J BIOL CHEM, V265, P20839; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MURPHY BJ, 1989, ANN NY ACAD SCI, V560, P391, DOI 10.1111/j.1749-6632.1989.tb24118.x; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OCALLAHAN CM, 1988, J BIOL CHEM, V263, P17342; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	40	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	1997	272	10					6297	6302		10.1074/jbc.272.10.6297	http://dx.doi.org/10.1074/jbc.272.10.6297			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WM647	9045648	hybrid			2022-12-25	WOS:A1997WM64700032
J	Giffin, W; KwastWelfeld, J; Rodda, DJ; Prefontaine, GG; TraykovaAndonova, M; Zhang, YX; Weigel, NL; Lefebvre, YA; Hache, RJG				Giffin, W; KwastWelfeld, J; Rodda, DJ; Prefontaine, GG; TraykovaAndonova, M; Zhang, YX; Weigel, NL; Lefebvre, YA; Hache, RJG			Sequence-specific DNA binding and transcription factor phosphorylation by Ku autoantigen/DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; CHICKEN PROGESTERONE-RECEPTOR; MOUSE GLUCOCORTICOID RECEPTOR; RNA-POLYMERASE-I; V(D)J RECOMBINATION; MMTV PROMOTER; ATAXIA-TELANGIECTASIA; RESPONSE ELEMENT; END BINDING; C-MYC	NRE1 is a DNA sequence element through which Ku antigen/DNA-dependent protein kinase (DNA-PK) catalytic subunit represses the induction of mouse mammary tumor virus transcription by glucocorticoids. Although Ru is an avid binder of DNA ends and has the ability to translocate along DNA, we report that direct sequence-specific Ku binding occurs with higher affinity (K-d = 0.84 +/- 0.24 nM) than DNA end binding. Comparison of Ku binding to several sequences over which Ku can accumulate revealed two classes of sequence. Sequences with similarity to NRE1 competed efficiently for NRE1 binding. Conversely, sequences lacking similarity to NRE1 competed poorly for Ku and were not recognized in the absence of DNA ends. Phosphorylation of glucocorticoid receptor (GR) fusion proteins by DNA-PK reflected Ku DNA-binding preferences and demonstrated that co-localization of GR with DNA-PK on DNA in cis was critical for efficient phosphorylation. Phosphorylation of the GR fusion protein by DNA-PK mapped to a single site, Ser-527. This site occurs adjacent the GR nuclear localization sequence between the DNA and ligand binding domains of GR, and thus its phosphorylation, if confirmed, has the potential to affect receptor function in vivo.	OTTAWA CIVIC HOSP,LOEB MED RES INST,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Baylor College of Medicine				Zhang, Yixian/0000-0002-6429-3127				Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BHARGAVA AK, 1993, P NATL ACAD SCI USA, V90, P10260, DOI 10.1073/pnas.90.21.10260; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BODWELL JE, 1995, J STEROID BIOCHEM, V52, P135, DOI 10.1016/0960-0760(94)00157-H; BORROR KC, 1995, STEROIDS, V60, P375, DOI 10.1016/0039-128X(94)00068-N; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; FALZON M, 1990, J BIOL CHEM, V265, P13084; FALZON M, 1993, J BIOL CHEM, V268, P10546; FALZON M, 1989, J BIOL CHEM, V264, P21915; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; FUERNKRANZ HA, 1994, NUCLEIC ACIDS RES, V22, P5665, DOI 10.1093/nar/22.25.5665; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HSU SC, 1995, J BIOL CHEM, V270, P3359, DOI 10.1074/jbc.270.7.3359; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MAY G, 1991, J BIOL CHEM, V266, P3052; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; POLETTI A, 1993, BIOCHEMISTRY-US, V32, P9563, DOI 10.1021/bi00088a007; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WEIGEL NL, 1995, J STEROID BIOCHEM, V53, P509, DOI 10.1016/0960-0760(95)00098-K; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	82	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5647	5658		10.1074/jbc.272.9.5647	http://dx.doi.org/10.1074/jbc.272.9.5647			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038175	hybrid			2022-12-25	WOS:A1997WK74700043
J	Jefferson, AB; Auethavekiat, V; Pot, DA; Williams, LT; Majerus, PW				Jefferson, AB; Auethavekiat, V; Pot, DA; Williams, LT; Majerus, PW			Signaling inositol polyphosphate-5-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEINS; GUANINE-NUCLEOTIDE EXCHANGE; HUMAN-PLATELETS; PHOSPHATIDYLINOSITOL 3-KINASE; POLYPHOSPHATE 5-PHOSPHATASE; 1,4,5-TRISPHOSPHATE 5-PHOSPHATASE; PHOSPHOLIPASE-C; SH2 DOMAINS; KINASE-C; GRB2	An inositol polyphosphate-5-phosphatase (SIP-110) that binds the SH3 domains of the adaptor protein GRB2 was produced in Sf9 cells and characterized. SIP-110 binds to GRB2 in vitro with a stoichiometry of 1 mol of GRB2/0.7 mol of SIP-110. GRB2 binding does not affect enzyme activity implying that GRB2 serves mainly to localize SIP-110 within cells. SIP-110 hydrolyses inositol (Ins)(1,3,4,5)P-4 to Ins(1,3,4)P-3. The enzyme does not hydrolyze Ins(1,4,5)P-3 that is a substrate for previously described 5-phosphatases nor does it hydrolyze phosphatidylinositol (PtdIns)(4,5)P-2. SIP-110 also hydrolyzed PtdIns(3,4,5)P-3 to PtdIns(3,4)P-2 as did recombinant forms of two other 5-phosphatases designated as inositol polyphosphate-5- phosphatase II, and OCRL (the protein that is mutated in oculocerebrorenal syndrome), The inositol polyphosphate-5-phosphatase enzyme family now is represented by at least 9 distinct genes and includes enzymes that fall into 4 subfamilies based on their activities toward various 5-phosphatase substrates.	WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; CHIRON CORP,EMERYVILLE,CA 94608	Washington University (WUSTL); Novartis				Pot, David/0000-0002-1480-9826	NHLBI NIH HHS [HL14147, HL16634, HL32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, R01HL016634, P50HL014147, R37HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DREYER AL, 1996, BIOCHEM BIOPH RES CO, V225, P243; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JACKSON SP, 1995, EMBO J, V14, P4400; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1996, J BIOL CHEM, V271, P29729, DOI 10.1074/jbc.271.47.29729; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIERUS PW, 1992, ANN REV BIOCH, V61, P225; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; NORRIS FA, 1995, J BIOL CHEM, V270, pS1612; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSS TS, 1991, J BIOL CHEM, V266, P20283; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; VERJANS B, 1990, CELL SIGNAL, V2, P595, DOI 10.1016/0898-6568(90)90082-L; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WOSCHOLSKI R, 1931, J BIOL CHEM, V7, P270; YORK JD, 1994, J MOL BIOL, V236, P584, DOI 10.1006/jmbi.1994.1167; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; ZHANG S, 1995, P NATL ACAD SCI USA, V92, P4853; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	69	29	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5983	5988		10.1074/jbc.272.9.5983	http://dx.doi.org/10.1074/jbc.272.9.5983			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038219	hybrid			2022-12-25	WOS:A1997WK74700087
J	vanderKaay, J; Batty, IH; Cross, DAE; Watt, PW; Downes, CP				vanderKaay, J; Batty, IH; Cross, DAE; Watt, PW; Downes, CP			A novel, rapid, and highly sensitive mass assay for phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) and its application to measure insulin-stimulated PtdIns(3,4,5)P-3 production in rat skeletal muscle in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; MOLECULAR-CLONING; 3-KINASE; RECEPTOR; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; 1,4,5-TRISPHOSPHATE; 4,5-BISPHOSPHATE; NEUTROPHILS; ACTIVATION	The pivotal role of phosphatidylinositol S-kinase (PI 3-kinase) in signal transduction has been well established in recent years. Receptor-regulated forms of PI 3-kinase are thought to phosphorylate phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) at the 3-position of the inositol ring to give the putative lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3). Cellular levels of PtdIns(5,4,5)P-3 are currently measured by time-consuming procedures involving radiolabeling with high levels of (PO4)-P-32, extraction, and multiple chromatography steps. To avoid these lengthy and hazardous procedures, many laboratories prefer to assay PI 3-kinase activity in cell extracts and/or appropriate immunoprecipitates. Such approaches are not readily applied to measurements of PtdIns(3,4,5)P-3 in extracts of animal tissues. Moreover, they can be misleading since the association of PI 3-kinases in molecular complexes is not necessarily correlated with the enzyme's activity state, Direct measurements of PtdIns(3,4,5)P-3 would also be desirable since its concentration may be subject to additional control mechanisms such as activation or inhibition of the phosphatases responsible for PtdIns(3,4,5)P-3 metabolism. We now report a simple, reproducible isotope dilution assay which detects PtdIns(3,4,5)P-3 at subpicomole sensitivity, suitable for measurements of both basal and stimulated levels of PtdIns(3,4,5)P-3 obtained from samples containing approximately 1 mg of cellular protein. Total lipid extracts, containing PtdIns(3,4,5)P-3, are first subjected to alkaline hydrolysis which results ill the release of the polar head group Ins(1,3,4,5)P-4. The latter is measured by its ability to displace [P-32]Ins(1,3,4,5)P-4 from a highly specific binding protein present in cerebellar membrane preparations. We show that this assay solely detects PtdIns(3,4,5)P-3 and does not suffer from interference by other compounds generated after alkaline hydrolysis of total cellular lipids, Measurements on a wide range of cells, including rat-1 fibroblasts, 1321N1 astrocytoma cells, HEK 293 cells, and rat adipocytes, show wortmannin-sensitive increased levels of PtdIns(3,4,5)P-3 upon stimulation with appropriate agonists. The enhanced utility of this procedure is further demonstrated by measurements of PtdIns(3,4,5)P-3 levels in tissue derived from whole animals. Specifically, we show that stimulation with insulin increases PtdIns(3,4,5)P-3 levels in rat skeletal muscle in vivo with a time course which parallels the activation of protein kinase B in the same samples.	UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	vanderKaay, J (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.							Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; BATTY IH, 1994, BIOCHEM J, V297, P529, DOI 10.1042/bj2970529; BELLACOSA A, 1991, SCIENCE, V254, P244; BROCKERHOFF H, 1961, J BIOL CHEM, V236, P1907; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; CHALLISS RAJ, 1990, J NEUROCHEM, V54, P2138, DOI 10.1111/j.1471-4159.1990.tb04920.x; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CULLEN PJ, 1994, BIOCHEM J, V298, P739, DOI 10.1042/bj2980739; DONIE F, 1989, FEBS LETT, V254, P155, DOI 10.1016/0014-5793(89)81029-4; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANDERKAAY J, 1995, ANAL BIOCHEM, V225, P183, DOI 10.1006/abio.1995.1135; WARD SG, 1992, J BIOL CHEM, V267, P23862; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	36	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5477	5481		10.1074/jbc.272.9.5477	http://dx.doi.org/10.1074/jbc.272.9.5477			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9038150	hybrid			2022-12-25	WOS:A1997WK74700018
J	Russo, G; Ricciardelli, G; Pietropaolo, C				Russo, G; Ricciardelli, G; Pietropaolo, C			Different domains cooperate to target the human ribosomal L7a protein to the nucleus and to the nucleoli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE REQUIREMENTS; XENOPUS-LAEVIS; LOCALIZATION SEQUENCES; T-ANTIGEN; SIGNAL; IDENTIFICATION; LOCATION; TRANSLOCATION; ACCUMULATION; GENE	The human ribosomal protein L7a is a component of the major ribosomal subunit, We transiently expressed in HeLa cells L7a-beta-galactosidase fusion proteins and studied their subcellular localization by indirect immunofluorescence staining with anti-p-galactosidase antibodies, We have identified three distinct domains responsible for the nuclear targeting of the protein: domain I, amino acids 23-51; domain II, amino acids 52-100; domain III, amino acids 101-220, each of which contains at least one nuclear localization signal (NLS), Through subcellular localization analysis of deletion mutants of L7a-beta-galactosidase chimeras, we demonstrate that domain II plays a special role because it is necessary, although not sufficient, to target the chimeric beta-galactosidase to the nucleoli, In fact, we demonstrate that the nucleolar targeting process requires the presence of domain II plus an additional basic domain that can be represented by an NLS or a basic stretch of amino acids without NLS activity. Thus, when multiple NLS are present, each NLS exerts distinct functions, Domain II drives nucleolar accumulation of a reporter protein with the cooperative action of a short basic amino acid sequence, suggesting a mechanism requiring protein-protein or protein-nucleic acid interactions.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	University of Naples Federico II								BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFALCO S, 1993, GENE, V126, P227, DOI 10.1016/0378-1119(93)90371-9; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; GIRARD JP, 1994, J BIOL CHEM, V269, P18499; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOONIN EV, 1994, NUCLEIC ACIDS RES, V22, P2166, DOI 10.1093/nar/22.11.2166; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MEIER UT, 1992, CELL, V70, P127; MESSMER B, 1993, EUR J CELL BIOL, V61, P369; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RIKKONEN M, 1992, VIROLOGY, V189, P462, DOI 10.1016/0042-6822(92)90570-F; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081	40	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					5229	5235		10.1074/jbc.272.8.5229	http://dx.doi.org/10.1074/jbc.272.8.5229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9030593	hybrid			2022-12-25	WOS:A1997WJ85500081
J	Beauchemin, N; Kunath, T; Robitaille, J; Chow, B; Turbide, C; Daniels, E; Veillette, A				Beauchemin, N; Kunath, T; Robitaille, J; Chow, B; Turbide, C; Daniels, E; Veillette, A			Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells	ONCOGENE			English	Article						biliary glycoprotein; Bgp; C-CAM; colon carcinoma; SHP-1; PTP1C; HCP	ANTIGEN-RELATED GENE; CARCINOEMBRYONIC ANTIGEN; ADHESION MOLECULE; ECTO-ATPASE; C-CAM; PHOSPHOTYROSINE PHOSPHATASE; COLORECTAL CARCINOMAS; ENDOGENOUS SUBSTRATE; MONOCLONAL-ANTIBODY; MURINE CORONAVIRUS	Biliary glycoprotein (Bgp) is a member of the immunoglobulin superfamily and the carcinoembryonic antigen family. Previous studies have shown that Bgp functions as an intercellular adhesion molecule and a canalicular bile salt transporter. Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. In this study, we have examined the possibility that the cytoplasmic domain of Bgp can interact with signal transduction molecules. We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. Mutation of either of two tyrosine residues present in the cytoplasmic domain of Bgp abrogated SHP-1 binding, suggesting that this association was mediated by both tyrosine residues. Similarly, we noted that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp in vitro. It is therefore conceivable that some of the functions of Bgp are mediated through its ability to induce intracellular protein tyrosine dephosphorylation.	MCGILL UNIV,CTR CANC,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), MCGILL UNIV,CTR CANC,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA.			Kunath, Tilo/0000-0002-8805-7356				Adachi M, 1996, CELL, V85, P15; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRUMMER J, 1995, ONCOGENE, V11, P1649; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.3.CO;2-U; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; HSIEH JT, 1995, CANCER RES, V55, P190; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kunath T, 1995, ONCOGENE, V11, P2375; KUPRINA NI, 1990, HISTOCHEMISTRY, V94, P179, DOI 10.1007/BF02440185; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1989, J BIOL CHEM, V264, P14408; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	53	122	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					783	790		10.1038/sj.onc.1200888	http://dx.doi.org/10.1038/sj.onc.1200888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047385				2022-12-25	WOS:A1997WJ11200004
J	Sarig, G; WeismanShomer, P; Erlitzki, R; Fry, M				Sarig, G; WeismanShomer, P; Erlitzki, R; Fry, M			Purification and characterization of qTBP42 a new single-stranded and quadruplex telomeric DNA-binding protein from rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GENE-PRODUCT; SPECIFICALLY BINDS; QUARTET STRUCTURES; HUMAN FIBROBLASTS; EPITHELIAL-CELLS; NUCLEIC-ACIDS; BETA-SUBUNIT; SEQUENCE; HAIRPIN; REPEATS	Telomeres of vertebrate chromosomes terminate with a short 5'-d(TTAGGG)-3' single stranded overhang that can form in vitro tetrahelical structures, Here we describe a new protein from rat hepatocyte nuclei designated quadruplex telomere-binding protein 42 (qTBP42) that tightly binds 5'-d(TTAGGG)(n)-3' and 5'-d(CCCTAA)(n)-3' single-stranded and tetraplex forms of 5'-d(TTAGGG)(n)-3', The thermostable qTBP42 was isolated from boiled nuclear extracts and purified to near homogeneity by successive steps of column chromatography on DEAE-cellulose, phosphocellulose, and phenyl-Sepharose, A subunit molecular size of 42.0 +/- 2.0 kDa was determined for qTBP42 by Southwestern blotting and SDS-polyacrylamide gel electrophoresis of the protein and its UV cross-linked complex with labeled telomeric DNA. A native size of 53.5 +/- 0.9 kDa, estimated by Superdexo(C) 200 gel filtration, suggests that qTBP42 is a monomeric protein, Sequences of five tryptic peptides of qTBP42 contained motifs shared by a mammalian CArG box-binding protein, hnRNP A/B, hnRNP C, and a human sing le-stranded telomeric DNA-binding protein, Complexes of qTBP42 with each complementary strand of telomeric DNA and with quadruplex forms of the guanine-rich strand had 3.7-14.6 nM dissociation constants, K-d, whereas complexes with double-stranded telomeric DNA had up to 100-fold higher K-d values, By associating with tetraplex and single-stranded telomeric DNA, qTBP42 increased their heat stability and resistance to digestion by micrococcal nuclease.	TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine								ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; GUPTA G, 1993, BIOCHEMISTRY-US, V32, P7098, DOI 10.1021/bi00079a005; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KHAN FA, 1991, FEBS LETT, V290, P159, DOI 10.1016/0014-5793(91)81249-8; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; LIU ZP, 1995, P NATL ACAD SCI USA, V92, P6002, DOI 10.1073/pnas.92.13.6002; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1992, BIOCHEMISTRY-US, V31, P10835, DOI 10.1021/bi00159a026; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHARF R, 1988, BIOCHEMISTRY-US, V27, P2990, DOI 10.1021/bi00408a049; SHARP ZD, 1990, BIOCHIM BIOPHYS ACTA, V1048, P306, DOI 10.1016/0167-4781(90)90073-B; SHAY JW, 1993, ONCOGENE, V8, P1407; SMITH FW, 1993, BIOCHEMISTRY-US, V32, P8682, DOI 10.1021/bi00084a040; SUNDQUIST WI, 1989, NATURE, V344, P410; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WEISMANSHOMER P, 1994, BIOCHEM BIOPH RES CO, V205, P305, DOI 10.1006/bbrc.1994.2665; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	64	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					4474	4482		10.1074/jbc.272.7.4474	http://dx.doi.org/10.1074/jbc.272.7.4474			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9020172	hybrid			2022-12-25	WOS:A1997WH01900088
J	Jouanneau, J; Plouet, J; Moens, G; Thiery, JP				Jouanneau, J; Plouet, J; Moens, G; Thiery, JP			FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo	ONCOGENE			English	Article						FGF-2; angiogenesis; tumor proliferation	FIBROBLAST GROWTH-FACTOR; DNA-SYNTHESIS; FACTOR CDNA; 3T3 CELLS; PROGRESSION; SECRETION; FAMILY; FORMS; LINE; TRANSFORMATION	The comparative biological properties of NET-II cells, a rat bladder carcinoma cell line constitutively expressing FGF-1 and FGF-2 were analysed in nude mice, FGF-1 is not secreted by the transfected cells unless the cDNA contains a signal sequence; conversely, NET-II cells transfected with FGF-2 coding sequence produce and secrete the factor in a biologically active form, Bovine brain capillary endothelial cells are stimulated to proliferate upon addition of medium conditioned by the FGF-2-producing cells and this activity can be abrogated by the addition of anti-FGF-2 blocking antibodies, In addition, the FGF-2-containing medium, which cannot stimulate NET-II cells due to absence of appropriate receptors, is able to induce scattering of NET-II cells expressing the FGFR1, It has been reported previously that FGF-1-producing cells are highly tumorigenic in nude mice and induce carcinoma with a period of latency reduced from 6 to 5 weeks when compared to parental NET-II cells, In contrast, NET-II cells producing FGF-2 are no more tumorigenic than parental cells, indicating are no more tumorigenic than parental cells, indicating that FGF-1 and FGF-2 have different oncogenic properties in carcinoma, FGF-1 and FGF-2 are potent antiogenic factors that trigger the host endothelial cells, VEGF, another potent angiogen was found to be expressed in small amounts by NET-II cells and to be expressed in reduced amount in the FGF-producing cells, In the NET-II system in vivo FGF-1 and FGF-2 are highly and comparatively angiogenic in the resultant carcinoma and this occurs in the absence of production of significant amounts of VEGF by the carcinoma cells, Taken together, our results indicate that activated angiogenesis is not sufficient for rapid tumor expansion, FGF-1 behaves as a tumorigenic factor in the NET-II bladder carcinoma cell model, whereas expression and secretion of large amounts of FGF-2 are not sufficient for increasing tumor growth.	UPR 9006 CNRS,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	Jouanneau, J (corresponding author), INST CURIE,UMR 144 CNRS,26 RUE ULM,F-75248 PARIS 05,FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [(NIH, 2RO1 CA 49417-06)] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUSCI S, 1994, J CELL SCI, V107, P1277; BELLUSCI S, 1995, INVAS METAST, V14, P319; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CARUELLE D, 1989, J CELL BIOCHEM, V39, P117, DOI 10.1002/jcb.240390204; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; COLBEREGARAPIN F, 1982, J MOL BIOL, V105, P1; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; TAKAHASHI JB, 1992, BIOCHEM BIOPH RES CO, V189, P398, DOI 10.1016/0006-291X(92)91572-8; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; YAYON A, 1990, CANC METASTASIS REV, V9, P192	40	37	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					671	676		10.1038/sj.onc.1200883	http://dx.doi.org/10.1038/sj.onc.1200883			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038374				2022-12-25	WOS:A1997WG43000005
J	Horton, LE; Templeton, DJ				Horton, LE; Templeton, DJ			The cyclin box and C-terminus of cyclins A and E specify CDK activation and substrate specificity	ONCOGENE			English	Article						cell cycle; cyclins; cyclin dependent kinase; lamin B	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE; CELL-CYCLE; DEPENDENT KINASE-2; CRYSTAL-STRUCTURE; S-PHASE; BINDING; CDC2; PHOSPHORYLATION; EXPRESSION	The cyclins and their catalytic partners, the Cyclin Dependent Kinases (CDKs), are essential for progression through the cell cycle. Cyclin/kinase complexes containing cyclins A or E are active primarily in Late G(1) to S phase and both have been shown to phosphorylate histone H1 and the retinoblastoma gene product (pRb) in vitro. Despite these similarities, cyclins A and E display differences in CDK activation and substrate specificity. We find that in vitro, cyclin E/CDK2 and cyclin A/CDK2 phosphorylate histone H1 similarly but only cyclin A/CDK2 phosphorylates lamin B. While both cyclin A and cyclin E bind CDK1 efficiently, only cyclin A activates CDK1 kinase activity. Using chimeric proteins between cyclins A and E we find that both the cyclin box and C-terminus of cyclins A and E are required for CDK binding, activation and targeting of substrate specificity.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CELL BIOL PROGRAM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Templeton, Dennis J/F-7695-2011		NCI NIH HHS [CA-55719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; Hunt T, 1991, Semin Cell Biol, V2, P213; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; MARSHALL CJ, 1994, NATURE, V367, P24; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAYSMITH K, 1993, CURR OPIN CELL BIOL, V5, P166; NUGENT JHA, 1991, J CELL SCI, V99, P669; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; TSAI LH, 1993, ONCOGENE, V8, P1593; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	47	32	33	2	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					491	498		10.1038/sj.onc.1200851	http://dx.doi.org/10.1038/sj.onc.1200851			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053846				2022-12-25	WOS:A1997WE36400012
